
<html lang="en"     class="pb-page"  data-request-id="c54e0a8c-5195-468b-b254-aa229c642b6e"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2021.64.issue-7;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.1c00208;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Synthetic Approaches to the New Drugs Approved during 2019" /></meta><meta name="dc.Creator" content="Andrew C.  Flick" /></meta><meta name="dc.Creator" content="Carolyn A.  Leverett" /></meta><meta name="dc.Creator" content="Hong X.  Ding" /></meta><meta name="dc.Creator" content="Emma  McInturff" /></meta><meta name="dc.Creator" content="Sarah J.  Fink" /></meta><meta name="dc.Creator" content="Subham  Mahapatra" /></meta><meta name="dc.Creator" content="Daniel W.  Carney" /></meta><meta name="dc.Creator" content="Erick A.  Lindsey" /></meta><meta name="dc.Creator" content="Jacob C.  DeForest" /></meta><meta name="dc.Creator" content="Scott P.  France" /></meta><meta name="dc.Creator" content="Simon  Berritt" /></meta><meta name="dc.Creator" content="Simone V.  Bigi-Botterill" /></meta><meta name="dc.Creator" content="Tony S.  Gibson" /></meta><meta name="dc.Creator" content="Yiyang  Liu" /></meta><meta name="dc.Creator" content="Christopher J.  O’Donnell" /></meta><meta name="dc.Description" content="New drugs introduced to the market are privileged structures having affinities for biological targets implicated in human diseases and conditions. These new chemical entities (NCEs), particularly s..." /></meta><meta name="Description" content="New drugs introduced to the market are privileged structures having affinities for biological targets implicated in human diseases and conditions. These new chemical entities (NCEs), particularly s..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="March 30, 2021" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.1c00208" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00208" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.1c00208" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00208" /></link>
        
    
    

<title>Synthetic Approaches to the New Drugs Approved during 2019 | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.1c00208" /></meta><meta property="og:title" content="Synthetic Approaches to the New Drugs Approved during 2019" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0067.jpeg" /></meta><meta property="og:description" content="New drugs introduced to the market are privileged structures having affinities for biological targets implicated in human diseases and conditions. These new chemical entities (NCEs), particularly small molecules and antibody–drug conjugates, provide insight into molecular recognition and simultaneously function as leads for the design of future medicines. This review is part of a continuing series presenting the most likely process-scale synthetic approaches to 40 NCEs approved for the first time anywhere in the world in 2019." /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta><meta name="twitter:description" content="New drugs introduced to the market are privileged structures having affinities for biological targets implicated in human diseases and conditions. These new chemical entities (NCEs), particularly small molecules and antibody–drug conjugates, provide insight into molecular recognition and simultaneously function as leads for the design of future medicines. This review is part of a continuing series presenting the most likely process-scale synthetic approaches to 40 NCEs approved for the first time anywhere in the world in 2019." /></meta><meta name="twitter:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0067.jpeg" /></meta><meta name="twitter:title" content="Synthetic Approaches to the New Drugs Approved during 2019" /></meta>
        
            <meta property="og:type" content="Article" /></meta>
        

        
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.1c00208"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/ke1q~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-6ee29527b3d8ff00a106.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00208">
            
        





































    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-12/achre4.2021.54.issue-12/20210615/achre4.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-25/aamick.2021.13.issue-25/20210630/aamick.2021.13.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-6/aapmcd.2021.3.issue-6/20210611/aapmcd.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-6/abseba.2021.7.issue-6/20210614/abseba.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-12/accacs.2021.11.issue-12/20210618/accacs.2021.11.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-12/acncdm.2021.12.issue-12/20210616/acncdm.2021.12.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-6/aelccp.2021.6.issue-6/20210611/aelccp.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-6/aeecco.2021.1.issue-6/20210611/aeecco.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-6/aewcaa.2021.1.issue-6/20210611/aewcaa.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-6/aidcbc.2021.7.issue-6/20210611/aidcbc.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-6/amlcef.2021.3.issue-6/20210607/amlcef.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-6/amclct.2021.12.issue-6/20210610/amclct.2021.12.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-25/acsodf.2021.6.issue-25/20210629/acsodf.2021.6.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-25/ascecg.2021.9.issue-25/20210628/ascecg.2021.9.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-25/ancham.2021.93.issue-25/20210629/ancham.2021.93.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-25/bichaw.2021.60.issue-25/20210629/bichaw.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-6/bomaf6.2021.22.issue-6/20210614/bomaf6.2021.22.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-12/cmatex.2021.33.issue-12/20210622/cmatex.2021.33.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-6/cgdefu.2021.21.issue-6/20210602/cgdefu.2021.21.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-12/enfuem.2021.35.issue-12/20210617/enfuem.2021.35.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-12/esthag.2021.55.issue-12/20210615/esthag.2021.55.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-6/estlcu.2021.8.issue-6/20210608/estlcu.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-25/iecred.2021.60.issue-25/20210630/iecred.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-12/inocaj.2021.60.issue-12/20210621/inocaj.2021.60.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-25/jafcau.2021.69.issue-25/20210630/jafcau.2021.69.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-6/jceaax.2021.66.issue-6/20210610/jceaax.2021.66.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-6/jceda8.2021.98.issue-6/20210608/jceda8.2021.98.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-6/jctcce.2021.17.issue-6/20210608/jctcce.2021.17.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-12/joceah.2021.86.issue-12/20210618/joceah.2021.86.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-24/jpcafh.2021.125.issue-24/20210624/jpcafh.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-24/jpcbfk.2021.125.issue-24/20210624/jpcbfk.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-24/jpccck.2021.125.issue-24/20210624/jpccck.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-24/jpclcd.2021.12.issue-24/20210624/jpclcd.2021.12.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-6/jprobs.2021.20.issue-6/20210604/jprobs.2021.20.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-25/jacsat.2021.143.issue-25/20210630/jacsat.2021.143.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-6/jamsef.2021.32.issue-6/20210602/jamsef.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-25/langd5.2021.37.issue-25/20210629/langd5.2021.37.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-12/mamobx.2021.54.issue-12/20210622/mamobx.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-6/mpohbp.2021.18.issue-6/20210607/mpohbp.2021.18.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-12/orlef7.2021.23.issue-12/20210618/orlef7.2021.23.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-12/orgnd7.2021.40.issue-12/20210628/orgnd7.2021.40.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.1c00208&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.1c00208&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.1c00208&amp;href=/doi/10.1021/acs.jmedchem.1c00208" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 7</span><span class="cit-fg-pageRange">, 3604-3657</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/7" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.1c00125" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.0c01882" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Synthetic Approaches to the New Drugs Approved during 2019</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Andrew C. Flick</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Andrew C. Flick</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Takeda Pharmaceuticals, 9625 Towne Centre Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Andrew+C.++Flick">Andrew C. Flick</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Carolyn A. Leverett</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Carolyn A. Leverett</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Worldwide Research and Development, 445 Eastern Point Road, Groton, Connecticut 06340, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Carolyn+A.++Leverett">Carolyn A. Leverett</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hong X. Ding</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hong X. Ding</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmacodia (Beijing) Co., Ltd., Beijing 100085, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hong+X.++Ding">Hong X. Ding</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Emma McInturff</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Emma McInturff</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Worldwide Research and Development, 445 Eastern Point Road, Groton, Connecticut 06340, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Emma++McInturff">Emma McInturff</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0426-3089" title="Orcid link">http://orcid.org/0000-0003-0426-3089</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sarah J. Fink</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sarah J. Fink</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Takeda Pharmaceuticals, 125 Binney Street, Cambridge, Massachusetts 02142, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sarah+J.++Fink">Sarah J. Fink</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath5">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Subham Mahapatra</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Subham Mahapatra</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Worldwide Research and Development, 445 Eastern Point Road, Groton, Connecticut 06340, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Subham++Mahapatra">Subham Mahapatra</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath6">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Daniel W. Carney</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Daniel W. Carney</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Takeda Pharmaceuticals, 9625 Towne Centre Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Daniel+W.++Carney">Daniel W. Carney</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath7">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Erick A. Lindsey</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Erick A. Lindsey</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Takeda Pharmaceuticals, 9625 Towne Centre Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Erick+A.++Lindsey">Erick A. Lindsey</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath8">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jacob C. DeForest</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jacob C. DeForest</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Worldwide Research and Development, 10777 Science Center Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jacob+C.++DeForest">Jacob C. DeForest</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath9">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0316-6685" title="Orcid link">http://orcid.org/0000-0002-0316-6685</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Scott P. France</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Scott P. France</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Worldwide Research and Development, 445 Eastern Point Road, Groton, Connecticut 06340, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Scott+P.++France">Scott P. France</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath10">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1679-6165" title="Orcid link">http://orcid.org/0000-0003-1679-6165</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Simon Berritt</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Simon Berritt</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Worldwide Research and Development, 445 Eastern Point Road, Groton, Connecticut 06340, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Simon++Berritt">Simon Berritt</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath11">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5572-6771" title="Orcid link">http://orcid.org/0000-0001-5572-6771</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Simone V. Bigi-Botterill</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Simone V. Bigi-Botterill</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Takeda Pharmaceuticals, 9625 Towne Centre Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Simone+V.++Bigi-Botterill">Simone V. Bigi-Botterill</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath12">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1309-2314" title="Orcid link">http://orcid.org/0000-0003-1309-2314</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tony S. Gibson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tony S. Gibson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Takeda Pharmaceuticals, 9625 Towne Centre Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tony+S.++Gibson">Tony S. Gibson</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath13">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yiyang Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yiyang Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Worldwide Research and Development, 445 Eastern Point Road, Groton, Connecticut 06340, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yiyang++Liu">Yiyang Liu</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath14">View Biography</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Christopher J. O’Donnell</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christopher J. O’Donnell</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pfizer Worldwide Research and Development, 445 Eastern Point Road, Groton, Connecticut 06340, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#187b706a716b6c7768707d6a367236777c7776767d747458687e71627d6a367b7775"><span class="__cf_email__" data-cfemail="ed8e859f849e99829d85889fc387c38289828383888181ad9d8b8497889fc38e8280">[email protected]</span></a>. Tel: 860-405-4976.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christopher+J.++O%E2%80%99Donnell">Christopher J. O’Donnell</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath15">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1004-7139" title="Orcid link">http://orcid.org/0000-0003-1004-7139</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00208&amp;href=/doi/10.1021%2Facs.jmedchem.1c00208" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 7</span><span class="cit-pageRange">, 3604–3657</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 30, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>3 February 2021</li><li><span class="item_label"><b>Published</b> online</span>30 March 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 8 April 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.1c00208" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00208</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D3604%26pageCount%3D54%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DAndrew%2BC.%2BFlick%252C%2BCarolyn%2BA.%2BLeverett%252C%2BHong%2BX.%2BDing%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D7%26contentID%3Dacs.jmedchem.1c00208%26title%3DSynthetic%2BApproaches%2Bto%2Bthe%2BNew%2BDrugs%2BApproved%2Bduring%2B2019%26numPages%3D54%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D3657%26publicationDate%3DApril%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.1c00208"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">6791</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.1c00208" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Synthetic Approaches to the New Drugs Approved during 2019&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Andrew&quot;,&quot;last_name&quot;:&quot;C. Flick&quot;},{&quot;first_name&quot;:&quot;Carolyn&quot;,&quot;last_name&quot;:&quot;A. Leverett&quot;},{&quot;first_name&quot;:&quot;Hong&quot;,&quot;last_name&quot;:&quot;X. Ding&quot;},{&quot;first_name&quot;:&quot;Emma&quot;,&quot;last_name&quot;:&quot;McInturff&quot;},{&quot;first_name&quot;:&quot;Sarah&quot;,&quot;last_name&quot;:&quot;J. Fink&quot;},{&quot;first_name&quot;:&quot;Subham&quot;,&quot;last_name&quot;:&quot;Mahapatra&quot;},{&quot;first_name&quot;:&quot;Daniel&quot;,&quot;last_name&quot;:&quot;W. Carney&quot;},{&quot;first_name&quot;:&quot;Erick&quot;,&quot;last_name&quot;:&quot;A. Lindsey&quot;},{&quot;first_name&quot;:&quot;Jacob&quot;,&quot;last_name&quot;:&quot;C. DeForest&quot;},{&quot;first_name&quot;:&quot;Scott&quot;,&quot;last_name&quot;:&quot;P. France&quot;},{&quot;first_name&quot;:&quot;Simon&quot;,&quot;last_name&quot;:&quot;Berritt&quot;},{&quot;first_name&quot;:&quot;Simone&quot;,&quot;last_name&quot;:&quot;V. Bigi-Botterill&quot;},{&quot;first_name&quot;:&quot;Tony&quot;,&quot;last_name&quot;:&quot;S. Gibson&quot;},{&quot;first_name&quot;:&quot;Yiyang&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Christopher&quot;,&quot;last_name&quot;:&quot;J. O’Donnell&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;30&quot;,&quot;issue&quot;:&quot;7&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;3604-3657&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.1c00208&quot;},&quot;abstract&quot;:&quot;New drugs introduced to the market are privileged structures having affinities for biological targets implicated in human diseases and conditions. These new chemical entities (NCEs), particularly small molecules and antibody–drug conjugates, provide insight into molecular recognition and simultaneously function as leads for the design of future medicines. This review is part of a continuing series presenting the most likely process-scale synthetic approaches to 40 NCEs approved for the first time anywhere in the world in 2019.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00208&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00208" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00208&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00208" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00208&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00208" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00208&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00208&amp;href=/doi/10.1021/acs.jmedchem.1c00208" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.1c00208" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.1c00208" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (9 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.1c00208%26sid%3Dliteratum%253Aachs%26pmid%3D33783211%26genre%3Darticle%26aulast%3DFlick%26date%3D2021%26atitle%3DSynthetic%2BApproaches%2Bto%2Bthe%2BNew%2BDrugs%2BApproved%2Bduring%2B2019%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D7%26spage%3D3604%26epage%3D3657%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291301" title="Salts">Salts</a>,</li><li><a href="/action/doSearch?ConceptID=291650" title="Alcohols">Alcohols</a>,</li><li><a href="/action/doSearch?ConceptID=292178" title="Organic compounds">Organic compounds</a>,</li><li><a href="/action/doSearch?ConceptID=291651" title="Anions">Anions</a>,</li><li><a href="/action/doSearch?ConceptID=291070" title="Pharmaceuticals">Pharmaceuticals</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/7" title="Go to Volume 64, Issue 7"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/jmcmar.2021.64.issue-7/20210408/jmcmar.2021.64.issue-7.largecover.jpg" alt="Go to Volume 64, Issue 7"/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0067.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0067.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">New drugs introduced to the market are privileged structures having affinities for biological targets implicated in human diseases and conditions. These new chemical entities (NCEs), particularly small molecules and antibody–drug conjugates, provide insight into molecular recognition and simultaneously function as leads for the design of future medicines. This review is part of a continuing series presenting the most likely process-scale synthetic approaches to 40 NCEs approved for the first time anywhere in the world in 2019.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61164" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61164" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="quote"><p class="first">The most fruitful basis for the discovery of a new drug is to start with an old drug.</p><div class="attrib">—Sir James Whyte Black, Recipient of the 1988 Nobel Prize in Medicine</div></div><div class="NLM_p">As structures of small-molecule medicines increase in complexity, the importance of synthetic capability comes into sharp focus. An increased understanding of ligand–receptor interactions within target classes and continuous improvement in predictive tools culminate in a high degree of specificity within molecular design. Careful arrangement of structural features about a molecule therefore necessitates efficient, practical synthetic approaches to these privileged structures. Knowledge of the synthetic approaches to newly approved drugs raises the awareness of the methods available to the medicinal chemist, further enabling researchers in the field to discover new drugs more efficiently. This annual review, which is now in its 18th installment,<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> presents synthetic routes to the 40 molecular new chemical entities (NCEs) that were approved for the first time by a governing body anywhere in the world during 2019 (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). Biologics, existing drugs approved for expanded indications, and new formulations of existing drugs have been excluded from this review. For organizational purposes, drugs presented in this review are categorized into the following 11 therapeutic areas: anti-infective/antibiotic, cardiovascular and hematologic, neurological (central nervous system (CNS)), dermatologic, gastrointestinal, inflammation and immunologic, metabolic, musculoskeletal, oncologic, reproductive, and respiratory drugs. Within each of these therapeutic areas, drugs are ordered alphabetically by generic name, and for each a brief overview of the relevant pharmacology or differentiating feature of the medicine<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> and the discovery and development of the drug is provided, followed by a detailed review of the most scalable synthesis reported. Unless otherwise noted, each starting material within each scheme can be obtained from a commercial source. It is important to note that a drug’s process-scale synthetic approach is often not explicitly disclosed at the time of this review’s publication. In some cases, only a discovery-scale or general synthetic approach capable of delivering the active pharmaceutical ingredient (API) has been made available. Nonetheless, the synthetic sequences presented in this review have all been previously reported either in patent or public chemical literature and, to the best of our assessment, represent scalable routes originating from commercially available starting materials. It should also be noted that a very similar review entitled “New Drug Approvals for 2019: Synthesis and Clinical Applications” covering the synthesis of drugs approved by the U.S. Food and Drug Administration (USFDA) appeared in the <i>European Journal of Medicinal Chemistry</i> (<i>EJMC</i>)<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> and preceded this 18th installment of our review. We were honored that the authors of that review chose to present the information in an almost identical fashion—including language, phrases, and organization replicated from our previous reviews—despite their conspicuous failure to reference any of our installments within this series. Regardless, this annual <i>Journal of Medicinal Chemistry</i> review provides more holistic, accurate, and comprehensive coverage of the drugs approved, details of their synthesis, and supporting references. Given the volume of critical information omitted by the <i>EJMC</i> article, we believe that this review is a necessary contribution to the chemical literature that corrects numerous factual, typographical, and structural inaccuracies.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0002.jpeg" id="GRAPHIC-d7e374-autogenerated" class="inline-fig internalNav" /></img><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0003.jpeg" id="GRAPHIC-d7e375-autogenerated" class="inline-fig internalNav" /></img><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0004.jpeg" id="GRAPHIC-d7e376-autogenerated" class="inline-fig internalNav" /></img><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0005.jpeg" id="GRAPHIC-d7e377-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of the 40 NCEs approved in 2019.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0001.jpeg jm1c00208_0002.jpeg jm1c00208_0003.jpeg jm1c00208_0004.jpeg jm1c00208_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">2.  Antibiotic and Antifungal Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33010" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33010" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4">2.1.  Cefiderocol (Fetroja)</h3><div class="NLM_p">Cefiderocol is an injectable cephalosporin antibiotic developed by Shionogi & Co. and approved by the USFDA for the treatment of complicated urinary tract infections (cUTIs) when there is limited or no alternative treatment. Like other β-lactam antibiotics, cefiderocol inhibits Gram-negative bacterial cell wall synthesis. However, its enhanced stability toward β-lactamases and siderophore properties enable uptake into the bacterial periplasmic space.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> The drug exhibits significant antimicrobial activity across a variety of Gram-negative multidrug-resistant bacteria,<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> received the USFDA’s Qualified Infectious Disease Product (QIDP) designation, and was granted “Priority Review”.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a></div><div class="NLM_p">Although syntheses of cefiderocol and its analogues that are suitable for medicinal chemistry purposes have been reported,<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> a convergent approach involving linkage of a catechol-containing fragment linked through a quaternary pyrrolidinium salt to a β-lactam on a multikilogram scale was reported by Shionogi & Co. in a series of patents<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> and is depicted in <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a> and <a class="ref internalNav" href="#sch2" aria-label="2">2</a>. Preparation of the catechol fragment <b>7</b> began with chlorination of benzaldehyde <b>1</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). Demethylation of <b>2</b> with AlCl<sub>3</sub> afforded catechol <b>3</b>, which was then bisprotected as <i>p</i>-methoxybenzyl (PMB) ether <b>4</b> prior to oxidation to give benzoic acid <b>5</b>. Finally, activation of the acid with mesyl chloride prior to coupling with amine <b>6</b> gave the protected fragment <b>7</b> in 62% overall yield over five steps from <b>1</b>.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0009.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Cefiderocol Protected Catechol Fragment <b>7</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0010.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Cefiderocol (<b>I</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The construction of the β-lactam subunit and its linkage to catechol fragment <b>7</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>) began with aminothiazole <b>8</b>,<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> whose substructure is also incorporated into other β-lactam antibiotics such as ceftazidime (Fortaz) and aztreonam (Azactam). The acid was activated with mesyl chloride prior to reaction with the cephalosporin core <b>9</b>, which is obtained semisynthetically from a fermentation precursor.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Sulfide <b>10</b> was then carefully oxidized to sulfoxide <b>11</b> to minimize competing reactions during the subsequent quaternization step. Exposure of chloride <b>11</b> to pyrrolidine <b>7</b> in the presence of boric acid and sodium iodide afforded <b>12</b> as the tetraalkylammonium iodide salt. The sulfoxide was then converted back to the sulfide <b>13</b> upon treatment with phosphorus trichloride. Acidic removal of the PMB groups on a multikilogram scale followed by crystallization with sulfuric acid and <i>p</i>-toluenesulfonic acid gave cefidicerol (<b>I</b>).<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Although the yields and conditions outlined in <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a> and <a class="ref internalNav" href="#sch2" aria-label="2">2</a> reflect those exemplified in the patent, the authors noted that alternative reagents are capable of performing the same transformations for this sequence.<a onclick="showRef(event, 'cit7b'); return false;" href="javascript:void(0);" class="ref cit7b">(7b)</a></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7">2.2.  Lascufloxacin Hydrochloride (Lasvic)</h3><div class="NLM_p">Lascufloxacin hydrochloride is a novel fluoroquinolone antibacterial agent developed by Kyorin Pharmaceuticals in Japan to treat bacterial respiratory infections.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> The compound exhibits potent activity against a broad spectrum of pathogens, including both aerobic and anaerobic classes.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Enzymatic analysis indicated the compound inhibits both wild-type and mutated targets, which renders it active against quinolone-resistant strains of bacteria. Kyorin Pharmaceuticals received marketing approval for oral lascufloxacin tablets by Japan’s Ministry of Health, Labor and Welfare.</div><div class="NLM_p">Researchers at Kyorin Pharmaceuticals devised a kilogram-scale synthesis of the drug. The molecular structure consists of a fluoroquinoline core appended with a syn-disubstituted fluoropyrrolidine fragment. To prepare the fluoropyrrolidine fragment, the authors employed a linear route starting from amino ester <b>14</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>).<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Cbz protection of <b>14</b> followed by Claisen condensation afforded pyrrolidone <b>15</b> in 75% yield. Asymmetric hydrogenation using a ruthenium catalyst with (<i>S</i>)-BINAP as the ligand provided <i>trans</i>-pyrrolidine <b>16</b>. Saponification of the ester followed by coupling with cyclopropylamine furnished crystalline amide <b>18</b>, which was isolated in 60% yield from <b>15</b>. The amide was then reduced to the corresponding amine with borane THF and isolated as its hydrochloride salt. Benzyl protection gave trialkylamine <b>20</b>, which was treated with perfluoro-1-octanesulfonyl fluoride (POSF) to deliver chiral fluoride <b>21</b> with inversion of stereochemistry. Benzyl deprotection and salt formation produced fluoropyrrolidine fragment <b>22</b> as a crystalline solid.</div><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0011.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Lascufloxacin Fluoropyrrolidine Fragment <b>22</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The fluoroquinolone core was constructed from acetoacetate <b>23</b> (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>).<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Condensation of <b>23</b> with triethyl orthoformate (<b>24</b>) followed by treatment with 2-fluoroethylamine hydrochloride (<b>25</b>) afforded quinolone <b>26</b>. Interestingly, the ethyl ester was converted to borate complex <b>27</b> via treatment with boric acid and acetic anhydride, which was noted to provide improved solubility and enhanced reactivity in the subsequent S<sub>N</sub>Ar reaction.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Finally, substitution of <b>27</b> with fluoropyrrolidine <b>22</b> provided lascufloxacin (<b>II</b>).</div><figure id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0012.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Final Assembly of Lascufloxacin Hydrochloride (<b>II</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10">2.3.  Lefamulin (Xenleta)</h3><div class="NLM_p">Lefamulin, developed by Nabriva Therapeutics, is a semisynthetic pleuromutilin antibiotic approved for the treatment of community-acquired bacterial pneumonia.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Pleuromutilin antibiotics have been in use since the 1950s.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> However, lefamulin is the first to be approved for systemic use in humans. Intravenous and oral formulations of lefamulin were approved by the USFDA. This novel antibiotic inhibits translocation and bacterial protein synthesis by selectively binding to the peptidyl transferase center of the prokaryotic 50S ribosome.<a onclick="showRef(event, 'ref14 ref16'); return false;" href="javascript:void(0);" class="ref ref14 ref16">(14,16)</a></div><div class="NLM_p">A large-scale process approach to lefamulin has been performed on a kilogram scale as described in a patent by Nabriva, and this sequence is described in <a class="ref internalNav" href="#sch5" aria-label="Schemes 5">Schemes 5</a> and <a class="ref internalNav" href="#sch6" aria-label="6">6</a>.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Advantageously, the pleuromutilin cyclooctanol core is a natural product produced by fermentation, reducing the synthetic task to the union of advanced tricyclic fragment <b>36</b> with thiocyclohexanol <b>34</b>. This trisubstituted cyclohexane was produced by first resolving racemic acid <b>28</b> with (<i>S</i>)-α-methylbenzylamine (<b>29</b>) (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>). Multiple recrystallizations were performed until the desired optical rotation was achieved, followed by salt breaking with HCl to deliver chiral acid <b>30</b>. The authors noted that an enzymatic resolution was also a viable option, but specific details were not described. Curtius rearrangement introduced the amine functionality with complete stereoretention to give Boc-protected amine <b>31</b> in 81% yield after chromatography. Exposure of the olefin to <i>m</i>CPBA resulted in syn epoxidation of the carbamate. Ring opening with thiobenzoic acid gave <b>33</b> with the regiocontrolled trans arrangement of the S and O substituents as the major product. The minor regioisomer was removed through crystallization and trituration with toluene/heptane and likely accounts for the mediocre 32% yield of <b>33</b> for this step. Hydrazine monohydrate in the presence of dithiothreitol (DTT) converted the thioester to sulfide <b>34</b> while minimizing disulfide formation. Although this sequence represents the largest-scale approach exemplified, a smaller-scale alternative procedure that avoids chromatography was described in which the steps from acid <b>30</b> onward were telescoped, with the amine protected as a trifluoromethyl amide in place of Boc.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div><figure id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0013.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Lefamulin Cyclohexyl Fragment <b>34</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0070.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0070.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Lefamulin (<b>III</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0070.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The pleuromutilin core <b>35</b>, which was obtained by fermentation processes,<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> was tosylated to provide <b>36</b>, which was then treated with thiol <b>34</b> to give mercaptan <b>37</b> (<a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>). Removal of Boc followed by recrystallization gave lefamulin (<b>III</b>).</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13">2.4.  Pretomanid</h3><div class="NLM_p">Pretomanid is an orally bioavailable antimycobacterial treatment recently approved under the Limited Population Pathway for Antibacterial and Antifungal Drug (LPAD) pathway in the USA.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> The nitroimidazole drug was developed by the Global Alliance for Tuberculosis (TB) Drug Development under license from Novartis for the treatment of TB. Pretomanid is administered as part of the BPaL (bedaquiline, pretomanid, and linezolid) and BPaMZ (bedaquiline, pretomanid, moxifloxacin, and pyrazinamide) regimens.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Pretomanid, which undergoes partial nitro reduction in anaerobic environments within bacteria or protozoa and not within human tissues, inhibits mycolic acid biosynthesis—a process critical for bacterial cell wall production, survival, and pathogenesis of <i>Mycobacterium tuberculosis</i>.<a onclick="showRef(event, 'cit19b ref21'); return false;" href="javascript:void(0);" class="ref cit19b ref21">(19b,21)</a></div><div class="NLM_p">The synthesis of pretomanid has attracted considerable attention within the synthetic community. Several academic laboratories have published various methods to prepare the drug candidate.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Early patents discussing the preparation of pretomanid incorporated 2,4-dinitro-1<i>H</i>-imidazole as the starting material, which exhibits explosive characteristics detrimental to safe, large-scale procedures.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Although several methods to prepare the drug have been published in several patents,<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> a route to pretomanid that avoids the use of dinitroimidazole is shown in <a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></div><figure id="sch7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0014.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of Pretomanid (<b>IV</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Chloroimidazole <b>38</b> was reacted with silyl-protected epoxide <b>39</b> under basic conditions. Following crystallization from cyclohexane, alcohol <b>40</b> was isolated in 67% yield over two steps. Exposure of alcohol <b>40</b> to benzyl bromide <b>41</b> in DMF under cryogenic conditions formed benzyl ether <b>42</b> in 61% yield. Silyl deprotection with TBAF liberated the primary alcohol, which underwent cyclization upon treatment with methanolic potassium hydroxide. Recrystallization from isopropanol and cyclohexane afforded pretomanid (<b>IV</b>) in 57% yield over three steps.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15">2.5.  Relebactam (Recarbrio)</h3><div class="NLM_p">Discovered and developed by Merck, relebactam (MK-7655) is a novel β-lactamase inhibitor exhibiting activity against a broad range of β-lactamase enzymes. This cyclic urea, coformulated with imipenem and cilastatin, was approved by the USFDA for the treatment of complicated intra-abdominal infections (cIAIs).<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> In recent decades, infections due to multidrug-resistant Gram-negative pathogens have increased in prevalence, posing a significant challenge to this class of therapeutics. Relebactam binds covalently to an active-site serine within Ambler class A, C, and D β-lactamases, thereby increasing the concentrations of drug available for binding to penicillin-binding proteins (PBP), resulting in bactericidal activity.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Mechanistically, opening of the relebactam five-membered urea ring occurs during an acylation reaction between the C-7 carbonyl and a serine residue within the β-lactamase active site. Modeling studies have suggested that the <i>N</i>,<i>O</i>-oxysulfate group further stabilizes the ring-opened acyl-β-lactamase intermediate via hydrogen-bond formation with neighboring conserved catalytic site residues.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></div><div class="NLM_p">Several publications and patents pertaining to the preparation of relebactam on scale have been disclosed.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Strategically, a late-stage establishment of the bridged urea structure was adopted, necessitating stereocontrolled construction of an appropriately substituted piperidine subunit. Researchers at Merck developed a scalable synthesis that was initially reported in 2011,<a onclick="showRef(event, 'cit28e'); return false;" href="javascript:void(0);" class="ref cit28e">(28e)</a> and since then they have made several improvements that are described in <a class="ref internalNav" href="#sch8" aria-label="Schemes 8">Schemes 8</a> and <a class="ref internalNav" href="#sch9" aria-label="9">9</a>.<a onclick="showRef(event, 'cit28b'); return false;" href="javascript:void(0);" class="ref cit28b">(28b)</a> (<i>S</i>)-<i>N</i>-Boc-pyroglutamic acid (<b>43</b>) underwent a ring-opening reaction upon treatment with trimethylsulfoxonium iodide (<b>44</b>) and potassium <i>tert</i>-butoxide, resulting in intermediate <b>45</b>, which could be carried forward without workup. Condensation of <b>45</b> with (benzyloxy)ammonium chloride in the presence of lithium chloride and cyanoacetic acid resulted in α-chlorooxime <b>46</b>. Critical to the reaction’s efficiency, DMSO suppressed unintended displacement of the chloride within <b>46</b> by residual iodide from the previous ylide reaction. Subjection of <b>46</b> to potassium <i>tert</i>-butoxide in chilled DMF secured piperidine <b>47</b>. Trimethylsilyl bromide and <i>N</i>,<i>O</i>-bis(trimethylsilyl)acetamide (BSA) removed the Boc group to furnish piperidine <b>48</b>, which existed as a rapidly equilibrating mixture of (<i>E</i>)- and (<i>Z</i>)-oximes. Studies were conducted to optimize the conditions for reduction of oxime <b>48</b>. Ultimately, a mixture of sodium borohydride and triglyme delivered the desired product, which was further resolved by recrystallization from 0.05 M sulfuric acid to allow for isolation of hydroxylamine <b>49</b> as the H<sub>2</sub>SO<sub>4</sub> salt in excellent yield and diastereomeric purity. Salt metathesis was required to convert the poorly soluble salt <b>49</b> to its trifluoroacetate counterpart prior to amidation with nucleophile <b>50</b>. Subsequent tosylate salt formation provided piperidine <b>51</b>.</div><figure id="sch8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0015.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Preparation of Relebactam Piperidine <b>51</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0016.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Synthesis of Relebactam (<b>V</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Exposure of <b>51</b> to triphosgene followed by acidic workup and ethereal recrystallization resulted in an intramolecular cyclization to secure bridged urea <b>52</b> (<a class="ref internalNav" href="#sch9" aria-label="Scheme 9">Scheme 9</a>). Reduction, sulfonylation, and buffering conditions then facilitated arrival at <b>53</b>, which underwent careful fit-for-purpose Boc removal using conditions involving trimethylsilyl iodide to afford relebactam (<b>V</b>) as a zwitterionic monohydrate.<a onclick="showRef(event, 'cit28d cit28f'); return false;" href="javascript:void(0);" class="ref cit28d cit28f">(28d,f)</a></div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18">2.6.  Triclabendazole (Egaten)</h3><div class="NLM_p">Triclabendazole, also known as CGA 89317 or CGP 23030, is an orally bioavailable anthelmintic against infections caused by <i>Fasciola</i> species.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Developed by Novartis, triclabendazole received USFDA approval and is the only approved treatment for fascioliasis, a neglected tropical disease impacting 2.4 million patients six years of age and older worldwide.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Listed as an Essential Medicine by the World Health Organization (WHO), the drug’s mechanism of action against immature and mature worms of <i>Fasciola hepatica</i> and <i>Fasciola gigantica</i> has not yet been fully elucidated. However, in vitro and in vivo studies in infected animals have suggested that triclabendazole and its two primary metabolites, the sulfoxide and sulfone derivatives, inhibit tubulin polymerization as well as protein and enzyme synthesis.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></div><div class="NLM_p">Although the preparation of triclabendazole was published earlier by Ciba Geigy AG,<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> a more recent process disclosed by SeQuent Scientific Limited is more commercially scalable, environmentally friendly, and cost-effective.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> As shown in <a class="ref internalNav" href="#sch10" aria-label="Scheme 10">Scheme 10</a>, substitution of aryl chloride <b>54</b> with phenol <b>55</b> proceeded in 87% yield to generate diaryl ether <b>56</b>. Nitro reduction followed by deacetylation furnished diamine <b>57</b>, which was treated with carbon disulfide in methanolic sodium hydroxide to secure thiobenzimidazolone <b>58</b> in excellent yield from <b>56</b>. Methylation with dimethyl sulfate (<b>59</b>) followed by subsequent treatment with base and palladium on carbon in warm toluene furnished triclabendazole (<b>VI</b>). Recrystallization from isopropanol furnished the final product in 82% yield over the final four operations. Although the role of Pd/C in this final sequence is not explicitly stated in the patent,<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> presumably the Pd/C is used in the third step to avoid any oxidation products prior to the recrystallization. The published routes by Ciba Geigy AG also furnish triclabendazole via methylation of thiobenzimidazolone <b>58</b> using <b>59</b> followed by treatment with Pd/C under refluxing conditions<a onclick="showRef(event, 'cit31a ref32'); return false;" href="javascript:void(0);" class="ref cit31a ref32">(31a,32)</a></div><figure id="sch10" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0017.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Synthesis of Triclabendazole (<b>VI</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">3.  Cardiovascular and Hematologic Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33471" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33471" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21">3.1.  Esaxerenone (Minnebro)</h3><div class="NLM_p">Esaxerenone, a novel, nonsteroidal, selective mineralocorticoid receptor antagonist (MRA) discovered by Exelixis and developed by Daiichi Sankyo, was approved in Japan for the treatment of hypertension.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Excessive mineralocorticoid receptor activation by endogenous ligands (e.g., aldosterone) has been found to be involved in hypertension. Esaxerenone exerts an antihypertensive effect by blocking activation of this receptor.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> The drug has at least a 1000-fold higher selectivity for the mineralocorticoid receptor than other steroid hormone receptors, a long half-life, high oral bioavailability, and a more pronounced antihypertensive effect than spironolactone or eplerenone.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a></div><div class="NLM_p">While a kilogram-scale synthesis of esaxerenone has not yet been published, researchers at Daiichi Sankyo reported a method to generate the esaxerenone atropisomer without column chromatography, as depicted in <a class="ref internalNav" href="#sch11" aria-label="Scheme 11">Scheme 11</a>.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Ketone <b>60</b> underwent α-bromination followed by reaction with the enolate of ethyl cyanoacetate to give cyanoketone <b>61</b>, which was carried forward in toluene. Pyrrole formation took place under modified Knorr conditions to give mixtures of <b>62</b> and its 2-chlorinated counterpart, which was dechlorinated under transfer hydrogenation conditions to give pyrrole <b>62</b> in 82% yield from ketone <b>60</b>. N-Alkylation of the pyrrole with ethylene carbonate and subsequent ester hydrolysis then generated acid <b>63</b> as a mixture of atropisomers. A variety of amines, solvents, and temperatures were screened to identify resolution conditions. Ultimately, heating a solution of <b>63</b> and quinine in dimethylacetamide, ethyl acetate, and water followed by gradual cooling provided the desired <i>S</i> atropisomer quinine salt <b>64</b> in 43% yield with 98% de. Interestingly, the identity of the desired atopisomer was initially confirmed by X-ray crystallography, and subsequently an HPLC method was disclosed by Daichi Sankyo that described differentiating characterization of the atropisomers within their 2016 patent.<a onclick="showRef(event, 'cit36c'); return false;" href="javascript:void(0);" class="ref cit36c">(36c)</a> The corresponding free base, which was carried forward as a solution in ethyl acetate, was converted to the acid chloride using oxalyl chloride and reacted with 4-(methylsulfonyl)aniline (<b>65</b>). The free alcohol in intermediate <b>64</b> was concomitantly reacted with oxalyl chloride and aniline <b>65</b> to form the corresponding oxamate intermediate. Hydrolysis of the oxamate with potassium hydroxide and crystallization of the product from ethanol and water cleanly provided esaxerenone (<b>VII</b>) in 89% yield from <b>64</b>.</div><figure id="sch11" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0018.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 11. Synthesis of Esaxerenone (<b>VII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23">3.2.  Voxelotor (Oxbryta)</h3><div class="NLM_p">Voxelotor, also known as GBT440, is a relaxed-state (R-state) stabilizer of hemoglobin developed by Global Blood Therapeutics and approved by the USFDA for the treatment of sickle cell disease.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Sickle cell disease is a genetic disorder characterized by the mutation of a single amino acid (glutamic acid 6 to valine) in the hemoglobin β-chain.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> This simple mutation results in the polymerization of hemoglobin under low-oxygen conditions, which is responsible for the dysfunctional red blood cell phenotype associated with sickle cell disease.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Voxelotor forms a Schiff base with the N-terminal valine of the hemoglobin α-chain, which increases the affinity of sickle cell hemoglobin for oxygen and prevents polymerization.<a onclick="showRef(event, 'cit37b ref40'); return false;" href="javascript:void(0);" class="ref cit37b ref40">(37b,40)</a> The recommended dose of voxelotor is a 1500 mg tablet administered orally twice daily.<a onclick="showRef(event, 'cit37a'); return false;" href="javascript:void(0);" class="ref cit37a">(37a)</a></div><div class="NLM_p">A concise, convergent approach to the construction of voxelotor is described in the patent literature and is depicted in <a class="ref internalNav" href="#sch12" aria-label="Scheme 12">Scheme 12</a>.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Resorcinol (<b>66</b>) was protected as the corresponding bis(ethoxyethyl ether) by treatment with ethyl vinyl ether (<b>67</b>) and pyridinium <i>p</i>-tosylate (PPTS) in THF. The resulting arene underwent directed ortho metalation with <i>n</i>-butyllithum followed by a DMF quench to install the aldehyde. Removal of the ethoxyethyl groups with aqueous HCl furnished benzaldehyde <b>68</b>. Separately, (2-chloropyridin-3-yl)methanol (<b>69</b>) underwent Suzuki coupling with pyrazoloboronate <b>70</b>, and subsequent treatment with thionyl chloride in dichloromethane provided pyridinyl chloride <b>71</b>. Finally, O-alkylation of <b>68</b> with <b>71</b> mediated by sodium iodide and sodium bicarbonate in warm NMP delivered voxelotor (<b>VIII</b>). No yields were reported for the conversion of <b>69</b> to the drug product.</div><figure id="sch12" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0019.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 12. Synthesis of Voxelotor (<b>VIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch12"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i25">4.  CNS Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38431" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38431" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26">4.1.  Brexanolone (Zulresso)</h3><div class="NLM_p">Developed by Sage Therapeutics, brexanolone was approved by the USFDA as a first-in-class treatment for postpartum depression (PPD) in adult women.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> PPD affects 10–20% of women worldwide and is one of the primary contributors to maternal morbidity.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Additionally, PPD poses serious risks to the emotional, cognitive, behavioral, and physical development of the infant and siblings. Brexanolone is administered as a continuous intravenous infusion over 60 h at variable doses under active supervision of a healthcare provider. Brexanolone is a formulation of the naturally occurring neuroactive steroid allopregnanolone, which despite extensive study had not been approved for use as a therapeutic prior to 2019. Allopregnanolone has low aqueous solubility, poor oral bioavailability, and low metabolic stability. Brexanolone is a β-cyclodextrin-based formulation of allopregnanolone that helps to maintain stable physiological serum concentration. The drug is a positive allosteric modulator (PAM) of synaptic and extrasynaptic γ-aminobutyric acid type A (GABA<sub>A</sub>) receptors.<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43,44)</a> The plasma concentration of allopregnanolone increases in concert with progesterone during pregnancy and reaches its highest level in the third trimester. However, its concentration falls abruptly after childbirth. Failure of GABA<sub>A</sub> receptors to adapt to these sudden changes triggers postpartum depression.</div><div class="NLM_p">Brexanolone was prepared on scale via the semisynthetic pathway depicted in <a class="ref internalNav" href="#sch13" aria-label="Scheme 13">Scheme 13</a>.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> The synthesis began from pregnenolone (<b>72</b>), another naturally occurring steroid. Catalytic hydrogenation of <b>72</b> produced isopregnanolone (<b>73</b>), which is an epimer of allopregnanolone.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Stereoinversion at the 3β-hydroxy center was accomplished via Mitsunobu reaction.<a onclick="showRef(event, 'ref45 ref46 ref47'); return false;" href="javascript:void(0);" class="ref ref45 ref46 ref47">(45−47)</a> Alcohol <b>73</b> was treated with trifluoroacetic acid in the presence of diethyl azodicarboxylate (DEAD) and triphenylphosphine to generate stereoinverted trifluoroacetate <b>74</b>. In this case, the Mitsunobu reaction byproduct, triphenylphosphine oxide, was precipitated from diisopropyl ether prior to concentration of the filtrate. Recrystallization of the product furnished trifluoroacetate <b>74</b> in high purity without the need for column chromatography.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Finally, saponification furnished brexanolone (<b>IX</b>), which was purified by recrystallization from hot acetonitrile.</div><figure id="sch13" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0020.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 13. Synthesis of Brexanolone (<b>IX</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch13"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28">4.2.  Cenobamate (Xcopri)</h3><div class="NLM_p">Cenobamate, also known as YKP3089, was developed by SK Life Sciences and approved by the USFDA for treatment of adults with partial-onset seizures.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Like many antiepileptic drugs, the exact mechanism of cenobamate remains unknown.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> However, the drug’s mechanism of action is believed to involve blockade of a voltage-gated sodium channel, thereby interrupting repetitive neuronal firing.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Cenobamate has also been shown to be a positive allosteric modulator of the GABA<sub>A</sub> receptor. Although the field of antiepileptic drugs has seen a number of approvals over the past decade, recent data indicate that cenobamate has the potential to become a new standard of care for patients suffering from uncontrolled focal seizures.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a></div><div class="NLM_p">To date, a large-scale synthesis of cenobamate has not been explicitly reported. Patent literature from SK Life Sciences indicated that the drug was accessible in three steps from α-bromo ketone <b>75</b> (<a class="ref internalNav" href="#sch14" aria-label="Scheme 14">Scheme 14</a>).<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> Treatment of <b>75</b> with 1<i>H</i>-tetrazole (<b>76</b>) in DMF in the presence of K<sub>2</sub>CO<sub>3</sub> at room temperature resulted in a 1:1 mixture of tetrazole regioisomers <b>77</b> and <b>78</b>. Subsequent crystallization of the mixture from chilled heptane gave a 43% yield of the desired tetrazole regioisomer <b>78</b>, while a 41% yield of the undesired tetrazole regioisomer <b>77</b> was recovered. Although an asymmetric catalytic hydrogenation to access chiral alcohol <b>79</b> could be envisaged, SK Life Sciences described an elegant enantioselective enzymatic reduction.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> Tetrazole <b>78</b> was treated with RB791 cells that were transfected with the expression constructs pET21-MIX coding for the oxidoreductase from <i>Candida magnoliae</i> for 48 h at room temperature. Exposure to the oxidoreductase resulted in 99% conversion of ketone <b>78</b> to chiral alcohol <b>79</b> with >99% ee on a 50 g scale. After aqueous workup, crude chiral alcohol <b>79</b> was treated with chlorosulfonyl isocyanate (<b>80</b>) in THF. Following a water quench and crystallization, cenobamate (<b>X</b>) was obtained in 86% yield from tetrazole <b>78</b>.</div><figure id="sch14" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0021.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 14. Synthesis of Cenobamate (<b>X</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch14"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30">4.3.  Lasmiditan (Reyvow)</h3><div class="NLM_p">Lasmiditan, also known as COL-144, is an orally bioavailable selective serotonin receptor agonist (SSRA) discovered by Eli Lilly and Company and licensed to CoLucid Pharmaceuticals prior to Eli Lilly’s acquisition of CoLucid.<a onclick="showRef(event, 'ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref54 ref55">(54,55)</a> Approved by the USFDA for the acute treatment of migraine with or without aura in adults,<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> the once-daily-dosed drug is the first in a novel class of drugs called “ditans”. Differing in chemical structure from the “triptans” that selectively agonize the (5-HT)<sub>1B/1D</sub> receptors, lasmiditan selectively targets the (5-HT)<sub>1F</sub> receptor. This first-in-class neutrally acting antimigraine agent (NAAMA) resulted in a lowered risk of vasoconstriction by sparing activation of the (5-HT)<sub>1B</sub> receptor, which is particularly advantageous for the treatment of migraine in patients having cardiovascular disease. In two pivotal Phase III clinical trials (SAMURAI and SPARTAN), lasmiditan significantly improved the proportion of patients freed from moderate to severe headache pain relative to placebo.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a></div><div class="NLM_p">A robust synthesis of the drug was first described by researchers at Eli Lilly and is depicted in <a class="ref internalNav" href="#sch15" aria-label="Scheme 15">Scheme 15</a>.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> Lithiation of 2-chloropyridine and subjection to Weinreb amide <b>81</b> delivered methylpiperidine <b>82</b> in 38% yield. A Buchwald–Hartwig reaction employing benzophenone imine (<b>83</b>) followed by acidic deprotection provided primary aryl amine <b>84</b> in 82% yield over two steps. Amidation of <b>84</b> with benzoyl chloride <b>85</b> followed by subjection to succinic acid furnished lasmiditan (<b>XI</b>) as the hemisuccinate salt in excellent yield over two steps. Although Eli Lilly’s patent exemplified this sequence on scales of less than 1 g,<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> it should be noted that a patent from CoLucid exemplified this procedure on much larger scales.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a></div><figure id="sch15" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0022.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 15. Eli Lilly Synthesis of Lasmiditan (<b>XI</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch15"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32">4.4.  Lemborexant (Dayvigo)</h3><div class="NLM_p">Lemborexant is an orally administered dual orexin receptor (OXR) antagonist developed by Eisai for the treatment of adults with insomnia.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> Lemborexant received its first approval from the USFDA, with subsequent approval in Japan during January 2020. Insomnia is an increasingly prevalent disorder that is estimated to impact 30% of the general population,<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> and it affects women twice as frequently as men, particularly within the elderly population.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> Unlike many other pharmaceutical treatments for insomnia involving γ-aminobutyric acid or monoamine agonists, lemborexant exhibits reversible competitive antagonism of OXR1 and OXR2.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> Orexin peptides help regulate the sleep–wake cycle such that the orexin neurons are active during waking hours and inactive during sleep.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a></div><div class="NLM_p">Lemborexant analogues and their synthetic approaches were first reported in 2015.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> However, a synthesis of lemborexant on a 200 g scale was disclosed in a 2013 patent, and this approach is depicted in <a class="ref internalNav" href="#sch16" aria-label="Scheme 16">Scheme 16</a>.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> Deprotonation of aryl acetonitrile <b>86</b> with NaHMDS and subsequent exposure to (<i>R</i>)-epichlorohydrin (<b>87</b>) afforded cyclopropane <b>88</b>, which was immediately converted in situ to the carboxylic acid in the presence of base. Upon acidification, the acid intermediate underwent lactonization to produce <b>89</b> in 70% yield with 91% ee. Reduction of lactone <b>89</b> to the corresponding diol with LiBH<sub>4</sub> followed by selective enzymatic acetylation of the less hindered alcohol furnished alcohol <b>90</b> in essentially quantitative yield. Tosylation followed by S<sub>N</sub>2 displacement with pyrimidinol <b>91</b> was accompanied by in situ cleavage of the acetate group during workup, providing alcohol <b>92</b> in 70% yield over two steps. Next, a one-pot, two-step oxidation of the primary alcohol within <b>92</b> to the carboxylic acid was facilitated by TEMPO and NaOCl, followed by treatment with NaClO<sub>2</sub>, and finally a pH adjustment. Recrystallization from acetonitrile took place before T3P-mediated amidation with aminopyridine <b>93</b> to provide lemborexant (<b>XII</b>) in 61% yield over three steps.</div><figure id="sch16" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0023.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 16. Synthesis of Lemborexant (<b>XII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch16"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34">4.5.  Lumateperone (Caplyta)</h3><div class="NLM_p">Lumateperone, also known as ITI-007, is a first-in-class potent 5-HT<sub>2A</sub> antagonist, postsynaptic D<sub>2</sub> antagonist, and inhibitor of serotonin transport developed by Intra-Cellular Therapies<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> under a license from Bristol-Myers Squibb.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> Lumateperone was granted fast-track status in 2017 and received first global approval from the USFDA for the once-daily oral administration treatment of schizophrenia in adults. Upon approval, lumateperone received a boxed warning indicating increased mortality risk in elderly patients with dementia-related psychosis treatments. The tetracyclic quinoxaline-type compound shows a remarkable dose-dependent selectivity for the 5-HT<sub>2A</sub>, D<sub>2</sub>, D<sub>1</sub>/GluN2B, and SERT receptors.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> Only after full saturation of 5-HT<sub>2A</sub> is incremental occupancy of the remaining receptors observed, allowing for treatment of different CNS diseases at clinically separable doses. This potent selectivity for 5-HT<sub>2A</sub> over D<sub>2</sub> also reduces the side effects observed with other antipsychotics such as clozapine<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> and olanzapine.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a></div><div class="NLM_p">A concise scalable route to lumateperone (<b>XIII</b>) and structurally related analogues has been described.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> Starting with hydrazine <b>94</b>, a Fischer indole synthesis with ketone <b>95</b> gave tricyclic indole <b>96</b> (<a class="ref internalNav" href="#sch17" aria-label="Scheme 17">Scheme 17</a>).<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> Reduction with triethylsilyl hydride, treatment of the resulting product with (<i>R</i>)-mandelic acid in MeOH, subsequent formation of the (<i>S</i>)-mandelic acid diastereomeric salt, and free-basing with aqueous NaOH afforded chirally pure <i>cis</i>-indoline <b>97</b>. Protection of the amine and subsequent Buchwald–Hartwig reaction<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> with <b>83</b> furnished cyclization precursor <b>100</b>. N-Alkylation with ethyl bromoacetate (<b>101</b>) followed by hydrolysis of the diphenylamine gave tetracycle <b>102</b> via spontaneous ring closure. A second N-alkylation followed by reduction of the carbonyl with borane in THF gave piperazine <b>103</b>. Carbamate hydrolysis and a final N-alkylation with 4-chloro-1-(4-fluorophenyl)butan-1-one (<b>105</b>) provided the fully elaborated cis tetracycle <b>106</b>. The free base of <b>106</b> was dissolved in isopropanol and treated with a solution of <i>p</i>-toluenesulfonic acid to provide lumateperone tosylate (<b>XIII</b>).</div><figure id="sch17" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Scheme 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0024.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 17. Synthesis of Lumateperone (<b>XIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch17"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36">4.6.  Mirogabalin Besylate (Tarlige)</h3><div class="NLM_p">Mirogabalin besylate is a member of the gabapentinoid drug class,<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> which includes gabapentin (Neurotin) and pregabalin (Lyrica). The drug was developed by Daiichi Sankyo and was first approved in Japan for the treatment of peripheral neuropathic pain (PNP), including diabetic PNP and postherpetic neuralgia.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> Mirogabalin was also clinically developed for treatment of fibromyalgia pain in the USA and the EU but was discontinued after it failed to meet primary end points in Phase III trials.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a></div><div class="NLM_p">The analgesic properties of mirogabalin and related gabapentinoids derive from inhibition of calcium-mediated neurotransmitter release at voltage-gated calcium channels (VGCCs) within the dorsal horn. Gabapentinoids elicit their response by binding to the α<sub>2</sub>δ-1 subunit. Mirogabalin has high affinity for the α<sub>2</sub>δ-1 and α<sub>2</sub>δ-2 subunits, which have been associated with analgesic effects (α<sub>2</sub>δ-1) and CNS side effects (α<sub>2</sub>δ-2).<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> Mirogabalin has a remarkable dissociation half-life (>11 h at α<sub>2</sub>δ-1), which is substantially longer in duration than the half-life for pregabalin (∼1.5 h for both α<sub>2</sub>δ-1 and α<sub>2</sub>δ-2). This increase in half-life has been postulated to contribute to its potent, long-lasting analgesic effects while reducing side effects associated with gabapentinoids.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a></div><div class="NLM_p">A number of synthetic approaches to the drug have been disclosed within several patents,<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> each improving on the previous disclosure. The synthetic sequence in <a class="ref internalNav" href="#sch18" aria-label="Scheme 18">Scheme 18</a> reflects a likely scalable route to mirogabalin as the besylate salt. Condensation of allyl alcohol (<b>107</b>) and butyraldehyde (<b>108</b>) provided acetal <b>109</b>. Acid-mediated Claisen rearrangement through the use of maleic acid (<b>110</b>) gave rise to aldehyde <b>111</b> upon exposure to warm DMA.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> Knoevenagel–Doebner condensation with malonic acid (<b>112</b>) afforded α,β-unsaturated acid <b>113</b>,<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> which was then treated with Ac<sub>2</sub>O under basic conditions to affect an intramolecular [2 + 2] cycloaddition reaction. This transformation, which presumably proceeded through a ketene intermediate, delivered cyclobutanone <b>114</b> in 62% yield over the two-step sequence from <b>111</b>.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> Horner–Wadsworth–Emmons olefination with phosphonate <b>115</b> delivered a mixture of <i>E</i> and <i>Z</i> alkenes, which underwent conjugate addition with nitromethane to arrive at nitroalkane <b>117</b>. Reduction with Fe and subsequent chiral chromatographic separation of the resultant amine afforded optically pure <b>118</b>. Acidic removal of the <i>tert</i>-butyl ester with 4 N HCl in dioxane, subjection to triethylamine, and finally treatment with a 1 M aqueous solution of phenylsulfonic acid provided mirogabalin besylate (<b>XIV</b>) in good yield across the two-step sequence.</div><figure id="sch18" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Scheme 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0025.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 18. Synthesis of Mirogabalin Besylate (<b>XIV</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch18"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38">4.7.  Remimazolam Tosylate (Ruibeining)</h3><div class="NLM_p">Remimazolam is a benzodiazepine derivative drug initially developed by PAION as an anesthetic and sedative. As a GABA<sub>A</sub> receptor agonist, remimazolam acts faster than existing anesthetics such as midazolam.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> The drug has been administered to patients undergoing colonoscopy and allows faster recovery of neuropsychiatric functions than midazolam.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> More recently, Hengrui Pharma received approval for marketing of the drug from China’s National Medical Products Administration (CNMPA).<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a></div><div class="NLM_p">Among the several routes that have been published,<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> researchers at Hengrui Pharma disclosed a concise kilogram-scale synthesis of remimazolam tosylate that is described in <a class="ref internalNav" href="#sch19" aria-label="Scheme 19">Scheme 19</a>.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> Lithium–halogen exchange of 2-bromopyridine (<b>120</b>) followed by exposure to carboxylic acid <b>119</b> produced diaryl ketone <b>121</b> in 51% yield. DCC-mediated amidation of methyl ester <b>122</b> with <b>121</b> produced amide <b>123</b>, which was deprotected and cyclized to form benzodiazepine <b>124</b> in 48% yield from aniline <b>121</b>. Conversion of amide <b>124</b> to the corresponding chloroiminium ion preceded iminoyl chloride substitution with 2-aminopropanol (<b>126</b>) to afford amidine <b>127</b>, which was further cyclized to remimazolam (<b>128</b>) upon treatment with thionyl chloride. Finally, salt formation with <i>p</i>-TsOH followed by recrystallization from water produced remimazolam tosylate (<b>XV</b>) in 50% yield. It should be noted that the authors reported chromatographic isolation of intermediates <b>121</b>, <b>127</b>, and <b>128</b>.</div><figure id="sch19" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Scheme 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0026.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 19. Synthesis of Remimazolam Tosylate (<b>XV</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch19"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40">4.8.  Solriamfetol (Sunosi)</h3><div class="NLM_p">Solriamfetol was approved by the USFDA for excessive daytime sleepiness for patients with narcolepsy or obstructive sleep apnea. Solriamfetol is a phenylalanine derivative that is proposed to act as a dopamine and norepinephrine reuptake inhibitor.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> The dual activity of solriamfetol is unique compared with other wake-promoting agents, and this drug presents a significant advantage compared with the current standard of care (modafinil or armodafinil), to which nearly half of patients with obstructive sleep apnea do not respond.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> Additional treatments include methylphenidate and amphetamines, though these options carry risks that include cardiovascular issues and potential risk of abuse. Solriamfetol was initially developed by SK Group and then licensed to Aerial BioPharma in 2011. It was purchased by Jazz Pharmaceuticals for development, manufacturing, and worldwide commercial rights with the exception of select Asian countries.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a></div><div class="NLM_p">A patent from SK Biopharmaceuticals originally described a synthesis of solriamfetol using phosgene and an amine to install the carbamate functionality.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> Glenmark recently disclosed a route that is likely more suitable for large-scale preparation of the API, which is outlined in <a class="ref internalNav" href="#sch20" aria-label="Scheme 20">Scheme 20</a>, although the experimental procedures exemplified the synthesis on a gram scale using solvents that are likely to be replaced in a manufacturing setting (e.g., dichloromethane).<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> The relatively simple structure of solriamfetol was accessed from <span class="smallcaps smallerCapital">d</span>-phenylalanine methyl ester (<b>129</b>). Dissociation of the HCl salt followed by reduction of the ester provided amino alcohol <b>130</b>. Carbamate formation to access <b>131</b> was achieved through the use of sodium cyanate under acidic conditions. The HCl salt of solriamfetol (<b>XVI</b>) was made by exposing the free base to HCl in a mixture of dichloromethane and ethyl acetate.</div><figure id="sch20" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Scheme 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0027.jpeg" id="gr23" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 20. Synthesis of Solriamfetol (<b>XVI</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch20"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42">4.9.  Ubrogepant (Ubrelvy)</h3><div class="NLM_p">Ubrogepant is an orally administered small-molecule drug that was approved by the USFDA for the treatment of acute migraine in adults with or without aura.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> Migraine is a chronic neurological disease that affects more than 10% of the world population.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> Ubrogepant is a first-in-class oral calcitonin gene-related peptide (CGRP) receptor antagonist that was developed by Allergen under license from Merck & Co. CGRP is a neurotransmitter present in peripheral sensory trigeminal neurons that innervates the pain-sensitive dura and meningeal blood vessels.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> During a migraine attack, elevated levels of CGRP induce potent vasodilatory effects on cerebral arteries. This modulates the sensitivity of the nociceptive trigeminal neurons, which are pivotal for the pathogenesis of migraine. Significant efforts industry-wide targeting both CGRP and its receptor for migraine therapies have resulted in the discovery of a second CGRP receptor antagonist, rimegepant, which earned USFDA approval in February 2020.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a></div><div class="NLM_p">Multiple patent applications have been filed by researchers at Merck describing the preparation of ubrogepant, all of which utilized similar reaction sequences.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> The route depicted herein has been demonstrated on the process scale and features fewer synthetic steps than the original discovery route.<a onclick="showRef(event, 'cit96d'); return false;" href="javascript:void(0);" class="ref cit96d">(96d)</a> The convergent synthetic strategy employed a late-stage amide bond formation to unite two key fragments, <b>140</b> and <b>153</b>. The preparation of aminopiperidinone fragment <b>140</b> commenced with <span class="smallcaps smallerCapital">l</span>-serine isopropyl ester <b>132</b>, which was converted to iodide <b>133</b> via a Finkelstein reaction (<a class="ref internalNav" href="#sch21" aria-label="Scheme 21">Scheme 21</a>). This compound was then subjected to an alkylation reaction with 4-bromophenylacetone (<b>134</b>) and subsequent hydrogenative debromination to furnish keto ester <b>135</b> as an undisclosed mixture of isomers. Next, the key step utilized a transaminase-induced dynamic kinetic resolution to produce piperidinone <b>136</b> in high yield with high diastereoselectivity at C-4 and C-5 (dr > 60:1). The diastereomeric ratio at C-2 was approximately 1.2:1. N-Trifluoroethylation was effected under strongly basic conditions to obtain the desired monoalkylated intermediate <b>138</b> along with an undisclosed proportion of bisalkylated product <b>139</b>. The crude mixture of <b>138</b> and <b>139</b> was subsequently converted to 4-nitrobenzoic acid salt <b>140</b> after Boc deprotection. Crystalline <b>140</b> was isolated as a single diastereomer in high yield after 5-nitro-2-hydroxybenzaldehyde-mediated epimerization at C-2.</div><figure id="sch21" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Scheme 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0028.jpeg" id="gr24" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 21. Synthesis of Ubrogepant Aminopiperidinone Fragment <b>140</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Pyrrolidinone <b>143</b> was prepared from <i>N</i>-(<i>tert</i>-butyl)-3-methylpyridin-2-amine (<b>141</b>) in two steps (<a class="ref internalNav" href="#sch22" aria-label="Scheme 22">Scheme 22</a>). First, aminopyridine <b>141</b> was converted to methyl carbamate <b>142</b>. Subsequent intramolecular cyclization furnished pyrrolidinone <b>143</b>, which was used as described in <a class="ref internalNav" href="#sch23" aria-label="Scheme 23">Scheme 23</a>.</div><figure id="sch22" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Scheme 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0029.jpeg" id="gr25" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 22. Synthesis of Ubrogepant Pyrrolidinone <b>143</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch23" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Scheme 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0030.jpeg" id="gr26" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 23. Synthesis of Ubrogepant Acid Fragment <b>153</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The preparation of acid fragment <b>153</b> is described in <a class="ref internalNav" href="#sch23" aria-label="Scheme 23">Scheme 23</a>. First, 2,3-dibromo-5-chloropyridine (<b>144</b>) was treated with <i>i-</i>PrMgCl·LiCl to promote halogen–metal exchange. The arylmagnesium species was then quenched with DMF and subsequently reduced to provide alcohol <b>145</b>. The hydroxyl moiety in <b>145</b> was protected as the TIPS ether <b>146</b>, and the methyl ester was reduced and converted to benzyl chloride <b>147</b>. Pyrrolidinone <b>143</b> was then alkylated with freshly prepared chloride <b>147</b>. Subsequent subjection to TBAF generated free alcohol <b>148</b>. This hydroxyl compound was converted to chloride <b>149</b> by treatment with thionyl chloride, setting the stage for the key intramolecular cyclization reaction. The enantioselective cyclization was accomplished using chiral phase-transfer catalyst <b>150</b> to deliver the key spiroazaindole <b>151</b> in high yield and enantiomeric ratio. Chloropyridine <b>151</b> was converted to carboxylic acid <b>152</b> via palladium-catalyzed carbonylation, and subsequent removal of the <i>tert</i>-butyl group under strongly acidic conditions revealed the key coupling partner <b>153</b>. To unite subunits <b>140</b> and <b>153</b>, 4-nitrobenzoic acid salt <b>140</b> was treated with aqueous tripotassium phosphate to generate the free-base amine (<a class="ref internalNav" href="#sch24" aria-label="Scheme 24">Scheme 24</a>). EDC-mediated amide coupling with carboxylic acid <b>153</b> then delivered ubrogepant (<b>XVII</b>) in 97% yield over two steps.</div><figure id="sch24" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Scheme 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0031.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0031.jpeg" id="gr27" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 24. Final Assembly of Ubrogepant (<b>XVII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch24"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i47">5.  Dermatologic Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36681" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36681" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48">5.1.  Benvitimod (Symbiox)</h3><div class="NLM_p">Benvitimod is a stilbenoid natural product isolated from <i>Photorhabdus</i> bacterial symbionts of <i>Heterorhabditis</i> nematodes.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> The compound possesses anti-inflammatory and immune-modulating activities through interaction with cytokines involved in Th1- and Th17-type autoimmune inflammatory and Th2-type allergic diseases.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> Beijing Wenfeng Tianji Pharma has owned the development of this small-molecule drug since the late 1990s. In 2019, benvitimod was approved by the Chinese Food and Drug Administration (CFDA) for the treatment of psoriasis in China.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a></div><div class="NLM_p">A multikilogram-scale synthetic route was originally developed by researchers at Chongqing Science Technology Academy.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> The patent was later licensed to Beijing Wenfeng Tianji Pharma, whose authors described significant changes and improvements to the laboratory-scale process, including elimination of hazardous reagents, increased yields, and reduced levels of impurities (<a class="ref internalNav" href="#sch25" aria-label="Scheme 25">Scheme 25</a>). Friedel–Crafts alkylation of ester <b>154</b> with isopropanol afforded benzoic acid <b>155</b>. The authors noted that increasing the volumetric ratio of 80% sulfuric acid solution from 2 to 2.5 L/kg relative to ester <b>154</b> allowed rapid precipitation of carboxylic acid <b>155</b> from the reaction mixture, thereby preventing side reactions. Next, carboxylic acid <b>155</b> was reduced to benzyl alcohol <b>156</b> with KBH<sub>4</sub> in 90% yield. The reduction was carried out at 25 °C instead of 0 °C to avoid accumulation of reactants at low temperature. Benzyl alcohol <b>156</b> was then treated with thionyl chloride in DMF to deliver benzyl chloride <b>157</b> in 91% yield. The incorporation of DMF as the solvent mitigated the acidity of the reaction mixture, improving both the yield and quality of <b>157</b>. Condensation of benzyl chloride <b>157</b> with triethyl phosphite furnished phosphonate ester <b>158</b>. Horner–Wadsworth–Emmons reaction of <b>158</b> with benzaldehyde (<b>159</b>) provided stilbene derivative <b>160</b>. The authors noted that potassium <i>tert</i>-butoxide was particularly effective in this reaction for the minimization of side products. Finally, demethylation of <b>160</b> with pyridine hydrochloride afforded benvitimod (<b>XVIII</b>) in 83% yield. The API was recrystallized from toluene in 90% yield.</div><figure id="sch25" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Scheme 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0032.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0032.jpeg" id="gr28" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 25. Synthesis of Benvitimod (<b>XVIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch25"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50">5.2.  Trifarotene (Aklief)</h3><div class="NLM_p">Trifarotene, also known as CD5789, is a first-in-class retinoid treatment for acne vulgaris in patients nine years of age and older.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> Although the exact mechanism of action is unknown, the drug is a selective agonist of retinoic acid receptor (RAR)-γ, the most common RAR found in the skin. Upon stimulation, RAR-γ modulates gene expression related to inflammation and epidermal proliferation and differentiation. Developed by Galderma Research and Development LLC for acne vulgaris treatment, it previously was granted Orphan Drug Designation by the USFDA for lamellar ichthyosis, a rare genetic condition that affects the skin, and is under license to Mayne Pharma International for that indication.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> Trifarotene received USFDA approval and is the first topical treatment for both facial and truncal acne.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> In two pivotal Phase III clinical trials (PERFECT1 and PERFECT2), trifarotene significantly reduced inflammatory facial lesions as early as 2 weeks and truncal lesions as early as 4 weeks relative to placebo.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a></div><div class="NLM_p">The preparation of trifarotene followed a general procedure published previously by Galderma, as depicted in <a class="ref internalNav" href="#sch26" aria-label="Scheme 26">Scheme 26</a>.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> This general procedure was incorporated for the production of structural analogues of the drug. Aniline <b>161</b> was brominated to provide arene <b>162</b> in excellent yield. Bisalkylation of the aniline furnished pyrrolidine <b>163</b> in 52% yield. This was followed by lithium–halogen exchange and a triisopropylborate quench to yield boronic acid <b>164</b> in 66% yield. Suzuki coupling of boronic acid <b>164</b> with bromophenol <b>165</b> delivered triarene <b>166</b>. Lastly, an alkylation employing 2-bromoethyl acetate installed the acetylated ethylene glycol side chain within <b>167</b>. Subsequent saponification afforded trifarotene (<b>XIX</b>) in 55% yield.</div><figure id="sch26" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Scheme 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0033.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0033.jpeg" id="gr29" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 26. Synthesis of Trifarotene (<b>XIX</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0033.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch26"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i52">6.  Gastrointestinal Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44754" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44754" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec6_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53">6.1.  Tenapanor Hydrochloride (Ibsrela)</h3><div class="NLM_p">Tenapanor hydrochloride, also known as AZD-1722 and RDX5791, is a selective sodium hydrogen exchanger 3 (NHE3) inhibitor developed by Ardelyx and approved by the USFDA for the treatment of constipation-predominant irritable bowel syndrome (IBS-C).<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> Inhibition of NHE3 on enterocytes in the gut epithelium reduces absorption of sodium ions and increases water secretion, which accelerates gut transit time.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> The recommended dose of tenapanor hydrochloride is 50 mg administered orally twice daily.<a onclick="showRef(event, 'cit105b ref107'); return false;" href="javascript:void(0);" class="ref cit105b ref107">(105b,107)</a> The high molecular weight and two basic amines within the lengthy dimeric structure of tenapanor likely contribute to its absorption profile, rendering it a gut-restricted GI-targeted drug.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a></div><div class="NLM_p">Different synthetic approaches to tenapanor have been reported, typically exemplifying the preparation of the compound on a gram scale.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> A multigram synthesis and details of the isolation of the API and its crystalline forms were described by Teva Pharmaceuticals, and this approach is outlined in <a class="ref internalNav" href="#sch27" aria-label="Scheme 27">Scheme 27</a>. Bromoacetophenone <b>168</b> was reacted with amine <b>169</b>, and the resulting ketone was reduced with sodium borohydride to furnish racemic alcohol <b>170</b> in 65% yield over two steps. Compound <b>170</b> then underwent an intramolecular cyclization under acidic conditions, and the resulting tetrahydroisoquinoline was resolved using <span class="smallcaps smallerCapital">d</span>-dibenzoyltartaric acid (<span class="smallcaps smallerCapital">d</span>-(+)-DBTA) to afford enantiomerically pure azacycle <b>171</b> in 31% yield over three steps. Buchwald–Hartwig introduction of benzenethiol gave rise to mercaptan <b>173</b>, albeit in modest yield. Gaseous chlorination in the presence of acetic acid converted the benzyl thioether to sulfonyl chloride <b>174</b>, setting the stage for the dimerization sequence. A variety of dimerization strategies have been studied, as evidenced by patent literature.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> Teva’s approach employed the reaction of sulfonyl chloride <b>174</b> with diamine <b>175</b> under mildly basic conditions followed by Boc deprotection to prepare amine <b>176</b>. This compound was then reacted with bis(isocyanate) <b>177</b> and base followed by methanolic HCl. The protocol produced tenapanor (<b>XX</b>) as the bis(hydrochloride) salt in 50% yield.</div><figure id="sch27" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Scheme 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0034.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0034.jpeg" id="gr30" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 27. Synthesis of Tenapanor Hydrochloride (<b>XX</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0034.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch27"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i55">7.  Inflammation/Immunologic Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47680" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47680" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec7_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56">7.1.  Peficitinib Hydrobromide (Smyraf)</h3><div class="NLM_p">Peficitinib hydrobromide is an orally active Janus kinase (JAK) inhibitor developed by Astellas Pharma for the treatment of rheumatoid arthritis (RA) in patients with inadequate response to conventional therapies.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> The drug received its first global approval in Japan as a once-daily therapy at doses of 100 and 150 mg/day.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> The drug inhibits JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2) enzymes with moderate selectivity for JAK3.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> Inhibition of JAK enzymes suppresses the activation of cytokine-mediated signal transduction pathways that are responsible for inflammation and joint destruction and contribute to RA. Peficitinib hydrobromide inhibits signal inducer and activator of transcription 5 (STAT5) phosphorylation, which is a marker of JAK inhibition in human whole blood.</div><div class="NLM_p">Although a process-scale preparation of peficitinib has yet to be described in the literature, a multigram synthesis of the molecule was reported by Astellas.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> The seven-step longest linear synthetic sequence commenced with 4-chloro-7-azaindole (<b>178</b>), which was initially N-protected with triisopropylsilyl chloride (TIPSCl) to give <b>179</b> (<a class="ref internalNav" href="#sch28" aria-label="Scheme 28">Scheme 28</a>). When <b>179</b> was treated with <i>sec</i>-BuLi, the TIPS group was critical to block C-2, directing lithiation to C-5. An ethyl chloroformate quench yielded the desired C-5-substituted ethyl ester, which was deprotected with TBAF to provide 7-azaindole <b>180</b>. Basic hydrolysis of the ester in <b>180</b> and subsequent treatment with CDI/aqueous NH<sub>4</sub>OH provided amide <b>181</b> in 82% yield over the two-step sequence.</div><figure id="sch28" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Scheme 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0035.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0035.jpeg" id="gr31" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 28. Synthesis of Peficitinib Chloropyridine Derivative <b>181</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0035.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch28"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Completion of the synthesis of the drug took place as depicted in <a class="ref internalNav" href="#sch29" aria-label="Scheme 29">Scheme 29</a>. The desired <i>trans</i>-4-aminoadamantan-1-ol (<b>185</b>) was obtained from a diastereomeric mixture of 4-aminoadamantan-1-ol (<b>182</b>) (1:1 dr) in two steps. First, the amine moiety in <b>182</b> was protected with benzyl chloroformate, and the resulting diastereomers (<b>183</b> and <b>184</b>) were chromatographically separated. The desired trans isomer <b>184</b> was subsequently treated with palladium on carbon in the presence of hydrogen gas to afford <b>185</b>. Subjection of <b>185</b> to chloropyridine <b>181</b> at forcing temperatures (200 °C) furnished the peficitinib free base, which was converted to the HBr salt of peficitinib (<b>XXI</b>), enabling isolation of the drug in crystalline form.</div><figure id="sch29" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Scheme 29</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0036.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0036.jpeg" id="gr32" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 29. Synthesis of Peficitinib Hydrobromide (<b>XXI</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0036.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch29"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec7_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59">7.2.  Upadacitinib (Rinvoq)</h3><div class="NLM_p">Upadacitinib, a once-daily orally administered selective JAK1 inhibitor developed by AbbVie,<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> was approved for treatment of moderate to severe RA.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> Similar to tofacitinib and baricitinib, upadacitinib received a USFDA boxed safety warning due to increased risks of thrombosis.<a onclick="showRef(event, 'ref116 ref117'); return false;" href="javascript:void(0);" class="ref ref116 ref117">(116,117)</a> The selective inhibition of cytokine JAK1-dependent inflammatory pathways associated with RA (e.g., interleukin-6 and interferon-γ) minimize off-target physiological side effects associated with JAK2 and JAK3 engagement.<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a></div><div class="NLM_p">AbbVie disclosed an updated comprehensive synthetic route to the API<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> that moved away from hazardous reagents such as diazomethane and long reaction times and focused on a convergent synthesis coupling fragments <b>191</b> (<a class="ref internalNav" href="#sch30" aria-label="Scheme 30">Scheme 30</a>) and <b>198</b> (<a class="ref internalNav" href="#sch31" aria-label="Scheme 31">Scheme 31</a>). The synthesis of fragment <b>191</b> began with a Larock indole synthesis<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> employing dibromopyrazine <b>186</b> (<a class="ref internalNav" href="#sch30" aria-label="Scheme 30">Scheme 30</a>). This facile reaction afforded indole <b>188</b> in good yield. Tosylate protection followed by palladium-catalyzed Buchwald–Hartwig amination provided ethyl carbamate <b>191</b>.<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> The authors noted that using the methyl or ethyl carbamate gave rise to downstream intermediates as crystalline solids, greatly aiding in purification.</div><figure id="sch30" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Scheme 30</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0037.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0037.jpeg" id="gr33" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 30. Synthesis of Upadacitinib Ethyl Carbamate <b>191</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0037.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch30"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The chiral pyrrolidine fragment <b>198</b> was rapidly synthesized starting from an in situ Michael addition–Dieckmann condensation<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> of Cbz-protected glycine ethyl ester <b>192</b> and ethyl acrylate (<b>193</b>) in the presence of NaO<i>t</i>-Bu to afford <b>194</b> (<a class="ref internalNav" href="#sch31" aria-label="Scheme 31">Scheme 31</a>). Reaction with trflic anhydride gave enol triflate <b>195</b>, which underwent a Suzuki–Miyaura reaction with ethylboronic acid to provide 4-ethylpyrrolidine <b>196</b> in good yield. Acid hydrolysis set the stage for a ruthenium-catalyzed asymmetric hydrogenation using (<i>S</i>)-Segphos as a chiral phosphine ligand.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> The synthetic sequence to the sulfoxonium ylide<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> was carried out sequentially without isolation of intermediates. This sequence began with saponification of ethyl ester <b>196</b>, setting the stage for a ruthenium-catalyzed asymmetric hydrogenation using ruthenium diacetate and (<i>S</i>)-Segphos as a chiral phosphine ligand.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> With the chiral acid in hand, activation with CDI and displacement with the methylide (formed from deprotonation of dimethylsulfonyl chloride) afforded sulfoxonium <b>198</b>. Treatment of the sulfoxonium with lithium bromide under acidic conditions gave the α-bromo ketone, which was carried on to the next step. Displacement of the bromide with carbamate <b>191</b> furnished intermediate <b>199</b>, the ring-closure precursor, in good yield. Cyclization/dehydration under mild conditions followed by basic detosylation afforded tricycle <b>200</b> in 92% yield. Removal of the carboxybenzoyl group with 10% palladium hydroxide on carbon gave the free amine, which was isolated as bis(hydrochloride) salt <b>201</b>. Reaction of 2,2,2-trifluoroethylamine with CDI and slow addition of imidazolide <b>201</b> provided upadacitinib hemihydrate (<b>XXII</b>) in 87% yield.</div><figure id="sch31" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Scheme 31</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0038.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0038.jpeg" id="gr34" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 31. Synthesis of Upadacitinib (<b>XXII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0038.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch31"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i62">8.  Metabolic Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23334" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23334" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec8_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63">8.1.  Remogliflozin Etabonate (Remo, Remozen)</h3><div class="NLM_p">Remogliflozin etabonate is the prodrug of remogliflozin, a selective sodium–glucose cotransporter subtype 2 (SGLT2) inhibitor discovered by Kissei Pharmaceutical. Remogliflozin etabonate was approved in India for the treatment of type 2 diabetes mellitus.<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> Inhibition of SGLT2 lowers blood glucose concentrations by meditating reabsorption of glucose from glomerular filtrate.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> Several SGLT2 inhibitors have been approved globally or are currently under development, including canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> The ester prodrug exhibited good absorption and was shown to be rapidly hydrolyzed to the active compound in the gastrointestinal mucosa.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> The drug has good selectivity for SGLT2 over SGLT1 (<i>K</i><sub>i</sub> = 12.4 and 4520 nM, respectively) but a short half-life (<i>t</i><sub>1/2</sub> = 2–4 h) compared with other SGLT2 inhibitors.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> In a Phase III clinical trial in India, remogliflozin etabonate (100 mg or 250 mg administered twice daily) demonstrated noninferiority to dapagliflozin (10 mg once daily).<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a></div><div class="NLM_p">A patent disclosed by Glenmark Pharmaceuticals reported a synthesis of remogliflozin etabonate originating from 4-(hydroxymethyl)phenol, and this approach is depicted in <a class="ref internalNav" href="#sch32" aria-label="Scheme 32">Scheme 32</a>.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> Phenol <b>202</b> was converted to 1,2-dihydro-3<i>H</i>-pyrazol-3-one <b>204</b> using a four-step sequence without purification of intermediates. Alkylation of the phenol with isopropyl bromide was followed by chlorination of the benzyl alcohol moiety. Reaction of the resultant benzyl chloride with methyl acetoacetate in the presence of lithium chloride, sodium iodide, and DIPEA gave β-keto ester <b>203</b>. This intermediate was further treated with hydrazine monohydrate to produce pyrazolone <b>204</b>, which was recrystallized from water. In an interesting series of operations, regioselective N-isopropylation of the pyrazolone group was achieved via initial O-mesylation of <b>204</b> followed by subjection to isopropyl bromide and finally desulfonation with aqueous base to generate isopropyl pyrazolone <b>205</b>. Stirring <b>205</b> with <i>O</i>-acetyl-<span class="smallcaps smallerCapital">d</span>-glucopyranosyl bromide (<b>206</b>) and lithium hydroxide monohydrate in <i>tert</i>-butanol introduced the necessary glucose ring system in high yield. Deacetylation of the crude product with aqueous hydroxide afforded remogliflozin free base (<b>207</b>), which was then purified by crystallization from <i>tert</i>-butanol, ethyl acetate, and <i>n</i>-hexane. Reaction with ethyl chloroformate provided remogliflozin etabonate (<b>XXIII</b>), which was isolated by filtration and crystallized from isopropanol first to give the isopropanol solvate of remogliflozin etabonate. This form was further crystallized from water and acetonitrile to provide remogliflozin etabonate hemihydrate in 62% yield. It should be noted that an alternate synthesis of remogliflozin etabonate hemihydrate from <b>207</b> in 92% yield using diethyl pyrocarbonate and catalytic scandium triflate has been reported.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> While this route is higher-yielding than the approach outlined in <a class="ref internalNav" href="#sch32" aria-label="Scheme 32">Scheme 32</a>, use of the scandium triflate catalyst is unlikely to be economically viable on industrial scale.</div><figure id="sch32" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Scheme 32</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0039.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0039.jpeg" id="gr35" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 32. Synthesis of Remogliflozin Etabonate (<b>XXIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0039.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch32"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec8_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65">8.2.  Sotagliflozin (Zynquista)</h3><div class="NLM_p">Sotagliflozin is a dual SGLT1–SGLT2 inhibitor indicated for adults with type-1 diabetes to be used with insulin, particularly for patients with a body mass index >27 kg/m<sup>2</sup> and who have been unable to adequately control their glycemic index by optimized insulin therapy alone.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> The drug, which was codeveloped by Sanofi and Lexicon Pharmaceuticals, was approved by the European Medicines Agency (EMA) for use in the European Union. Interestingly, sotagliflozin is the first approved dual sodium–glucose cotransporter and was found during clinical trials to offer benefits for patients with heart failure with preserved ejection fraction (HfpEF).<a onclick="showRef(event, 'ref132 ref133'); return false;" href="javascript:void(0);" class="ref ref132 ref133">(132,133)</a></div><div class="NLM_p">A process reportedly capable of delivering thousands of kilograms of sotagliflozin for clinical studies was reported by Lexicon Pharmaceuticals in their 2010 patent.<a onclick="showRef(event, 'ref134 ref135'); return false;" href="javascript:void(0);" class="ref ref134 ref135">(134,135)</a> The convergent route hinged upon the union of aryl iodide fragment <b>211</b> (<a class="ref internalNav" href="#sch33" aria-label="Scheme 33">Scheme 33</a>) with furanose subunit <b>216</b> (<a class="ref internalNav" href="#sch34" aria-label="Scheme 34">Scheme 34</a>) through a ketone synthesis strategy. Fragment <b>211</b> was accessed starting from benzoic acid <b>208</b> (<a class="ref internalNav" href="#sch33" aria-label="Scheme 33">Scheme 33</a>). Activation of the carboxylic acid to give acid chloride <b>209</b> followed by Friedel–Crafts acylation with ethyl phenyl ether furnished arene <b>210</b> in good yield. The regioselectivity of the Friedel–Crafts acylation was high (∼100:1) provided that the water content of the DCM was low (0.01% w/w). Although the largest-scale report (450 kg scale) of the triethylsilyl hydride reduction of ketone <b>211</b> was conducted in high yield and purity, alternative conditions were also developed using NaBH<sub>4</sub> and AlCl<sub>3</sub> (250 kg scale) in attempts reduce the cost of the process.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a></div><figure id="sch33" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Scheme 33</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0040.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0040.jpeg" id="gr36" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 33. Synthesis of Aryl Iodide Fragment <b>211</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0040.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch33"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch34" data-index="35" class="article__inlineFigure"><h2 class="fig-label">Scheme 34</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0041.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0041.jpeg" id="gr37" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 34. Synthesis of Sotagliflozin (<b>XXIV</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0041.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch34"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The core sugar moiety of the API was ultimately derived from <span class="smallcaps smallerCapital">l</span>-(−)-xylose (<b>212</b>) (<a class="ref internalNav" href="#sch34" aria-label="Scheme 34">Scheme 34</a>). Global acetonide protection of <b>212</b>, involving rearrangement of the pyranose to the furanose, gave bis(acetonide) <b>213</b>. Selective deprotection to give <b>214</b> took place under acidic conditions with careful control of the pH (1.5–2.0), temperature, and duration to minimize overhydrolysis. Subsequent selective oxidation of the primary alcohol of <b>214</b> was performed using NaClO<sub>2</sub> with catalytic TEMPO and NaClO and controlled by slow addition of reagents. The resulting carboxylic acid was then isolated as morpholine salt <b>215</b> as a crystalline intermediate in 73% overall yield from <b>212</b>. This was particularly advantageous because morpholine was required in the subsequent amidation step and the formation of the salt avoided isolation of the free acid, which was prone to self-deprotection. The formation of morpholine amide <b>216</b> was performed with catalytic B(OH)<sub>3</sub> under Dean–Stark conditions. Treatment of amide <b>216</b> with <i>tert</i>-butylmagnesium chloride led to deprotonation of the secondary alcohol, providing an intermediate that could be reacted with the Grignard reagent of fragment <b>211</b> (generated by treatment with isopropylmagnesium chloride) to afford ketone <b>217</b> without any loss of stereointegrity. Diastereoselective reduction of the carbonyl using Luche conditions gave <b>218</b> with a high diastereomeric ratio, and the crude product solution could be taken forward without further workup. Acetonide deprotection and concomitant ring expansion of <b>218</b> by subjection to acidic conditions in warm acetonitrile gave <b>219</b> as a 1:1 mixture of anomers. Subsequent dynamic kinetic resolution (DKR) via stereoselective acetylation gave <b>220</b> with high dr in good overall yield from <b>217</b>. This compound was then reacted with thiourea and boron trifluoride diethyl etherate to install the thiol, which was subsequently methylated with iodomethane to give <b>221</b> with excellent diastereomeric excess in high yield. Finally, global deprotection of the acetate groups was achieved with sodium methoxide to furnish sotagliflozin (<b>XXIV</b>).</div></div></div><div id="sec9" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i68">9.  Musculoskeletal Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71161" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71161" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec9_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69">9.1.  Siponimod (Mayzent)</h3><div class="NLM_p">Siponimod, also known as BAF312, is a potent and selective sphingosine-1-phosphate (S1P) agonist that was discovered and developed by Novartis. It was approved by the USFDA for the treatment of relapsing forms of multiple sclerosis (MS), making it the first treatment to be approved for the condition in 15 years.<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> The relapsing form of MS includes clinically isolated syndrome, relapsing–remitting disease, and active secondary progressive disease in adults.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> S1P regulates a diverse range of physiological processes such as lymphocyte trafficking, cardiac function, vascular development, and inflammation.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> Siponimod binds with nanomolar potency to S1P, which is located on the extracellular region of immune cells, blocking its normal action. The therapeutic mode of action involves downmodulation of S1P receptors on T-lymphocytes, which are then sequestered within secondary lymphoid tissues, preventing recirculation into the central nervous system. This results in reduced immune attack on nerve cells in the brain and spinal cord.</div><div class="NLM_p">The most likely process-scale synthesis of siponimod, illustrated in <a class="ref internalNav" href="#sch35" aria-label="Scheme 35">Scheme 35</a>, was described by Novartis in a 2013 patent, although no yields were reported.<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> Aryl bromide <b>222</b> was converted to olefin <b>223</b> by means of Grignard addition followed by acid-mediated elimination. Hydrogenation of this olefin and subsequent bromination afforded bromoarene <b>224</b>. Conversion of this arene to the corresponding benzyl bromide was facilitated through a carbonylation reaction, which was followed by oxidation state adjustment and subjection to HBr to furnish benzyl bromide <b>226</b>. Subjection to oxime <b>227</b> followed by a substitution reaction with ketone <b>229</b> led to the formation of oxime ether <b>230</b>. Oxidation of the benzyl alcohol to the corresponding benzaldehyde preceded reductive amination with azetidine <b>232</b> to complete the synthesis of siponimod (<b>XXV</b>), which was then treated with ethanolic fumaric acid to provide the target product as the bis(fumarate) salt.</div><figure id="sch35" data-index="36" class="article__inlineFigure"><h2 class="fig-label">Scheme 35</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0042.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0042.jpeg" id="gr38" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 35. Synthesis of Siponimod (<b>XXV</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0042.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch35"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec10" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i71">10.  Oncology Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12617" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12617" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec10_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72">10.1.  Alpelisib (Piqray)</h3><div class="NLM_p">Alpelisib, developed and launched by Novartis, is a selective and orally bioavailable phosphatidylinositol-3-kinase α (PI3K-α) inhibitor approved by the USFDA.<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a> The drug was approved for the treatment of postmenopausal women and men with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-negative advanced and metastatic breast cancer that presents a catalytic subunit (PIK3CA)-mutated gene and is used in combination with fulvestrant (Faslodex).<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> PIK3CA is the most commonly mutated gene in HR+/HER2– breast cancer.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a></div><div class="NLM_p">To date, multiple syntheses of alpelisib have been reported, but no explicit process-scale approach has been disclosed.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> Novartis reported a linear route that appears to be adaptable toward scale, and this approach is outlined in <a class="ref internalNav" href="#sch36" aria-label="Scheme 36">Scheme 36</a>. However, reaction yields were not reported for many key transformations.<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> Subjection of picoline analogue <b>233</b> to Ruppert’s reagent (TMSCF<sub>3</sub>) in the presence of sodium acetate followed by hydrolytic silyl group removal provided tertiary alcohol <b>234</b> in quantitative yield. Mesylation of the tertiary alcohol proceeded in 85% yield by treatment with NaH and mild heating. Subsequent exposure to AlMe<sub>3</sub> in cyclohexane provided intermediate <b>235</b>, the picoline core of alpelisib, in 28% yield. Lithiation of the benzylic methyl group at the 4-position and subsequent quench with Weinreb amide <b>236</b> provided 4-pyridylacetone <b>237</b> after acidic workup. Treatment of <b>237</b> with thiourea in the presence of NBS produced 2-aminothiazole <b>238</b> as the HBr salt, which was precipitated from solution by the addition of isopropanol. Neutralization of <b>238</b> with pyridine followed by reaction with phenyl chloroformate (<b>239</b>) yielded 2-aminothiazole carbamate <b>240</b>. The phenoxy group was displaced upon installation of <span class="smallcaps smallerCapital">l</span>-prolineamide (<b>241</b>), ultimately providing alpelisib (<b>XXVI</b>).</div><figure id="sch36" data-index="37" class="article__inlineFigure"><h2 class="fig-label">Scheme 36</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0043.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0043.jpeg" id="gr39" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 36. Synthesis of Alpelisib (<b>XXVI</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0043.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch36"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec10_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74">10.2.  Darolutamide (Nubeqa)</h3><div class="NLM_p">Darolutamide, also known as ODM-201, is a second-generation androgen receptor (AR) antagonist that was codeveloped by Orion and Bayer Healthcare and approved by the USFDA for the treatment of nonmetastatic castration-resistant prostate cancer.<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a> AR is a ligand-dependent transcription factor that controls the expression of various genes involved in cell growth and survival.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> Aberrant activation of AR is a well-known driver of prostate cancer.<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a> Second-generation AR antagonists, such as darolutamide, inhibit many of the AR variants that cause resistance to first-generation antagonists.<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> Interestingly, darolutamide is a mixture of two diastereomers that interconvert in vivo via oxidation to a ketone metabolite (keto-darolutamide, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) followed by reduction. The two alcohol diastereomers and the ketone metabolite have similar pharmacological activities.<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> For the purposes of this review, darolutamide will be represented as a mixture of diastereomers at the carbon center bearing the secondary alcohol (e.g., <b>XXVII</b> in <a class="ref internalNav" href="#sch37" aria-label="Scheme 37">Scheme 37</a>).</div><figure id="fig2" data-index="38" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0007.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Equilibrium of darolutamide (<b>XXVII</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch37" data-index="39" class="article__inlineFigure"><h2 class="fig-label">Scheme 37</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0044.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0044.jpeg" id="gr40" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 37. Synthesis of Darolutamide (<b>XXVII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0044.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch37"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">An optimized process-scale synthesis of darolutamide was reported by Orion in the patent literature and was recently reviewed by Hughes.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> Pyrazole <b>242</b> was lithiated at C-5 and quenched with bromine to yield bromopyrazole <b>243</b>, making way for coupling with pinacol borane <b>244</b> to afford nitrile <b>245</b>. Removal of the THP protecting group from <b>245</b> with methanolic HCl gave rise to pyrazole <b>246</b> in 88% yield over two steps. Next, a Mitsunobu reaction between pyrazole <b>246</b> and alcohol <b>247</b> and subsequent Boc removal afforded amine <b>248</b> in 82% yield. As noted by Hughes,<a onclick="showRef(event, 'cit149b'); return false;" href="javascript:void(0);" class="ref cit149b">(149b)</a> Mitsunobu reactions are rare in process chemistry because of the challenge of separating the reaction byproducts from the desired product. However, because protonated amine <b>248</b> was water-soluble, this product could be partitioned into the aqueous phase upon acidic workup, allowing the reaction byproducts to be retained in the organic phase and removed. The desired product was isolated in 82% yield after adjustment of the aqueous-phase pH and extraction. Amine <b>248</b> was then coupled with carboxylic acid <b>249</b> using T3P. Finally, the ketone was reduced with sodium borohydride in ethanol to produce the final product <b>XXVII</b> as a mixture of diastereomers in 67% yield over two steps.</div></div><div id="sec10_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76">10.3.  Enfortumab Vedotin (Padcev)</h3><div class="NLM_p">Enfortumab vedotin is an antibody–drug conjugate (ADC) consisting of a fully humanized monoclonal antibody targeting nectin-4 linked to the microtubule-disrupting agent monomethyl auristatin E (MMAE). These two entities are connected via a linker consisting of a maleimide conjugation handle that includes an enzyme-cleavable valine–citrulline–<i>p</i>-aminobenzyl alcohol group that releases MMAE after the conjugate has been internalized by the cancer cell recognizing the antibody. Enfortumab vedotin was approved by the USFDA for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced, or metastatic setting.<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a> Enfortumab vedotin was discovered at Agensys prior to the acquisition of Agensys by Astellas Pharma. The drug was codeveloped by Astellas Pharma and Seattle Genetics.</div><div class="NLM_p">Enfortumab vedotin was synthesized according to the methods described in <a class="ref internalNav" href="#sch38" aria-label="Scheme 38">Scheme 38</a>. The nectin-4 monoclonal antibody Ha22-2(2,4)6.1 (<b>250</b>) was dissolved in a buffer consisting of 10 mM acetate (pH 5.0), 1% sorbitol, 3% arginine, 20 vol % 0.1 M TrisCl (pH 8.4), 25 mM EDTA, and 750 mM NaCl that was adjusted to pH 7.5.<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a> This solution was treated with tris(2-carboxyethyl)phosphine (TCEP) to reduce the intrachain disulfide bonds to give intermediate <b>251</b>. Reaction of the free thiol groups with 4.4 equiv of the linker–payload mc-ValCitPABC-MMAE (<b>252</b>) followed by reoxidation of the remaining disulfide bonds and quenching of the remaining linker–payload with <i>N</i>-acetylcysteine provided enfortumab vedotin (<b>XXVIII</b>) with a drug to antibody ratio (DAR) of 3.8. Linker–payload <b>252</b> is commercially available and was first used in the synthesis of brentuximab vedotin (Adcetris). The synthesis of this linker–payload was described in a previous review.<a onclick="showRef(event, 'cit1j'); return false;" href="javascript:void(0);" class="ref cit1j">(1j)</a></div><figure id="sch38" data-index="40" class="article__inlineFigure"><h2 class="fig-label">Scheme 38</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0045.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0045.jpeg" id="gr41" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 38. Synthesis of Enfortumab Vedotin (<b>XVIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0045.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch38"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec10_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78">10.4.  Entrectinib (Rozlytrek)</h3><div class="NLM_p">Entrectinib is an orally available, CNS-active, selective inhibitor of the tyrosine kinases tropomyosin receptor kinase (Trk) A/B/C, anaplastic lymphoma kinase (ALK), and c-ros oncogene 1 (ROS1). These gene fusions are all known to be involved in a wide variety of solid tumors, with some further complicated by brain metastases.<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a> Entrectinib received its first approval in Japan for the treatment of adult and pediatric patients with neurotrophin receptor tyrosine kinase (NTRK) fusion-positive, advanced, or recurring solid tumors. The drug is one of a variety of next-generation tyrosine kinase inhibitors (TKIs) and received accelerated approval by the USFDA for adults with this same indication and for ROS1-positive metastatic non-small cell lung cancer (NSCLC).<a onclick="showRef(event, 'cit152a ref153 ref154'); return false;" href="javascript:void(0);" class="ref cit152a ref153 ref154">(152a,153,154)</a> Approval of the drug was based on several clinical trials of entrectinib in adults, one of which showed an overall response rate (ORR) of 57% in dosed patients possessing a variety of NTRK fusion-positive solid tumors.<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> Additionally, clinical trials of adults with ROS1-rearranged NSCLC showed a 78% ORR after treatment with entrectinib.<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> The drug was initially developed by Nerviano Medical Sciences and Ignyta before being acquired by Roche, which currently markets the drug worldwide except in Japan, where the drug is licensed to Chugai Pharmaceutical Company.<a onclick="showRef(event, 'cit152a'); return false;" href="javascript:void(0);" class="ref cit152a">(152a)</a></div><div class="NLM_p">A route for the preparation of entrectinib has been reported by Nerviano that relies upon joining functionalized carboxylic acid fragment <b>258</b> with 5-(3,5-difluorobenzyl)-1<i>H</i>-indazol-3-amine (<b>259</b>) (<a class="ref internalNav" href="#sch39" aria-label="Schemes 39">Schemes 39</a> and <a class="ref internalNav" href="#sch40" aria-label="40">40</a>).<a onclick="showRef(event, 'ref156 ref157'); return false;" href="javascript:void(0);" class="ref ref156 ref157">(156,157)</a> Acid fragment <b>258</b> was prepared on a gram scale by a five-step process starting from <i>tert</i>-butyl 4-fluoro-2-nitrobenzoate (<b>253</b>) (<a class="ref internalNav" href="#sch39" aria-label="Scheme 39">Scheme 39</a>). Reaction with <i>N</i>-methylpiperazine (<b>254</b>) at room temperature provided the expected substitution product in high yield.<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a> Reduction of the nitro group followed by reductive amination with pyranone <b>256</b> provided <b>257</b> in good yield. Trifluoroacetylation followed by removal of the <i>tert</i>-butyl ester delivered acid <b>258</b> as the trifluoroacetate salt, which was isolated by trituration from diethyl ether.<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a></div><figure id="sch39" data-index="41" class="article__inlineFigure"><h2 class="fig-label">Scheme 39</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0046.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0046.jpeg" id="gr42" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 39. Synthesis of Entrectinib Benzoic Acid Intermediate <b>258</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0046.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch39"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Synthesis of the final drug product on a kilogram scale started with <b>258</b> which was converted to the corresponding acyl chloride by treatment with oxalyl chloride in DCM (<a class="ref internalNav" href="#sch40" aria-label="Scheme 40">Scheme 40</a>).<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a> Subjection of the crude acyl chloride to <b>259</b><a onclick="showRef(event, 'cit152d'); return false;" href="javascript:void(0);" class="ref cit152d">(152d)</a> and pyridine at −30 to −40 °C provided the core structure of entrectinib, which was obtained with >95% purity after trituration from a mixture of solvents. Cleavage of the trifluoroacetate with K<sub>2</sub>CO<sub>3</sub> in aqueous MeOH at 10 °C, filtration, and precipitation provided amorphous entrectinib. Recrystallization of amorphous entrectinib (<b>XXIX</b>) from EtOH/water provided the desired crystal form of the drug in 66% overall yield for the three-step process.<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a></div><figure id="sch40" data-index="42" class="article__inlineFigure"><h2 class="fig-label">Scheme 40</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0047.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0047.jpeg" id="gr43" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 40. Synthesis of Entrectinib (<b>XXIX</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0047.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch40"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec10_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81">10.5.  Erdafitinib (Balversa)</h3><div class="NLM_p">Erdafitinib, also known as JNJ-42756493, is a first-in-class pan-fibroblast growth factor receptor (FGFR) kinase inhibitor discovered by Astex Pharmaceuticals and Janssen.<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a> The drug was approved by the USFDA for the treatment of metastatic urothelial carcinoma with specific FGFR2 and FGFR3 genetic mutations.<a onclick="showRef(event, 'ref159 ref160'); return false;" href="javascript:void(0);" class="ref ref159 ref160">(159,160)</a> Urothelial cancer, particularly of the bladder, is the sixth most common cancer, representing 4.5% of all new cancer cases with an estimated 81 000 new cases and 17 980 deaths in 2020.<a onclick="showRef(event, 'ref158 ref161'); return false;" href="javascript:void(0);" class="ref ref158 ref161">(158,161)</a> FGFR genetic mutations play a significant role in the pathogenesis of certain cancers, including urothelial cancer. Erdafitinib binds to and inhibits the enzymatic activity of FGFR1–4, inhibiting phosphorylation and cell signaling. In addition, erdafitinib also binds to Fms-related tyrosine kinase 4 (FLT4), the tyrosine–protein kinase c-KIT, and vascular endothelial growth factor receptor 2 (VEGFR-2).<a onclick="showRef(event, 'ref159 ref162 ref163'); return false;" href="javascript:void(0);" class="ref ref159 ref162 ref163">(159,162,163)</a></div><div class="NLM_p">A gram-scale synthesis of erdafitinib has been described that starts with chlorination of 6-bromoquinoxaline (<b>260</b>) (<a class="ref internalNav" href="#sch41" aria-label="Scheme 41">Scheme 41</a>).<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a> Suzuki coupling of chloride <b>261</b> and pyrazole <b>262</b> provided bromide <b>263</b>, which underwent Buchwald–Hartwig coupling with aniline <b>264</b>. Alkylation of the secondary amine with bromide <b>266</b> followed by removal of the silyl ether, mesylation, and recrystallization with DIPE provided <b>268</b>. Displacement of the mesylate with isopropylamine and subsequent recrystallization from diethyl ether and acetonitrile furnished erdafitinib (<b>XXX</b>) as the free base in 83% yield from mesylate <b>268</b>.</div><figure id="sch41" data-index="43" class="article__inlineFigure"><h2 class="fig-label">Scheme 41</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0048.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0048.jpeg" id="gr44" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 41. Synthesis of Erdafitinib (<b>XXX</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0048.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch41"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec10_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83">10.6.  Fedratinib (Inrebic)</h3><div class="NLM_p">Fedratinib is a JAK2 inhibitor that was approved for the treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis.<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a> The current standard of care is ruxolitinib; patients who have not had success with this treatment or have become intolerant to ruxolitinib currently have a generally poor prognosis.<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a> Fedratinib is an ATP-mimetic molecule that binds to both the ATP binding site and the substrate binding site of the target kinase. The drug is not specific to the Janus kinase family and likely affects a broad array of other kinases, resulting in toxicity concerns. Fedratinib was approved as an orphan drug with priority review designation, but it contains a black box warning for encephalopathy, proposed to be due to inhibition of neuronal thiamine uptake.<a onclick="showRef(event, 'ref167 ref168'); return false;" href="javascript:void(0);" class="ref ref167 ref168">(167,168)</a> Fedratinib was initially discovered at TargeGen, which was acquired by Sanofi-Aventis in 2010. In 2016, fedratinib was acquired by Impact Biomedicines, which is now a subsidiary of Bristol Myers Squibb.<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a></div><div class="NLM_p">Although no explicitly described large-scale synthesis of the drug has been reported to date, a TargeGen patent disclosed a discovery route to fedratinib.<a onclick="showRef(event, 'ref170 ref171'); return false;" href="javascript:void(0);" class="ref ref170 ref171">(170,171)</a> While the bond disconnections in <a class="ref internalNav" href="#sch42" aria-label="Scheme 42">Scheme 42</a> constitute a viable strategy for large-scale synthesis, the conditions for each step render this approach more amenable for smaller quantities of API production. The two-step assembly of fedratinib involved a Pd-catalyzed amination of aryl bromide <b>269</b> with aminopyrimidine <b>270</b>. Alternatively, a substitution reaction between aniline <b>271</b> and chloropyrimidine <b>272</b> allows for production of the identical aryl chloride <b>273</b>. Subjection of aryl chloride <b>273</b> to aniline <b>274</b> in the presence of base followed by treatment with acidic isopropanol furnished fedratinib (<b>XXXI</b>) as the bis(HCl) salt hydrate.</div><figure id="sch42" data-index="44" class="article__inlineFigure"><h2 class="fig-label">Scheme 42</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0049.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0049.jpeg" id="gr45" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 42. Synthesis of Fedratinib (<b>XXXI</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0049.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch42"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A preparation of aniline <b>274</b> was not described by TargeGen, but construction of this intermediate has been described in the literature previously (<a class="ref internalNav" href="#sch43" aria-label="Scheme 43">Scheme 43</a>). Alkylation of phenol <b>275</b> with alkyl chloride <b>276</b> followed by hydrogenation of <b>277</b> furnishes aniline <b>274</b> in good yield.<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a></div><figure id="sch43" data-index="45" class="article__inlineFigure"><h2 class="fig-label">Scheme 43</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0071.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0071.jpeg" id="gr46" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 43. Synthesis of Fedratinib Aniline <b>274</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0071.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch43"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec10_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i86" class="anchor-spacer"></div><h3 class="article-section__title" id="_i86">10.7.  Flumatinib Mesylate (Haosenxifu)</h3><div class="NLM_p">Flumatinib mesylate, also known as HHGV-678, is a selective inhibitor of the tyrosine kinase BCR-ABL1. The drug was discovered and developed by Jiangsu Hengrui Pharmaceutical Group and was approved by the CNMPA for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase (CML-CP).<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a> Structurally, flumatinib is similar to imatinib: the central phenyl ring was modified to a pyridine, and a CF<sub>3</sub> group was appended to the benzamide group. With these changes, flumatinib demonstrated superior efficacy and a similar safety profile at 3, 6, and 12 months in comparison with imatinib during a Phase III clinical trial conducted in China.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a></div><div class="NLM_p">Although several strategies for the synthesis of flumatinib have been reported,<a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a> researchers at Hansoh Pharma recently published a patent describing a process route to the drug (<a class="ref internalNav" href="#sch44" aria-label="Scheme 44">Scheme 44</a>).<a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a> Sulfonyl pyrimidine <b>278</b> and nitropyridine <b>279</b> underwent a substitution reaction to produce the aminopyrimidine core structure <b>280</b> in 83% yield.<a onclick="showRef(event, 'cit175g'); return false;" href="javascript:void(0);" class="ref cit175g">(175g)</a> As an interesting alternative to Sandmeyer conditions, nitropyridine <b>280</b> was reacted with tri(<i>p</i>-chlorophenyl)phosphine and PhPOCl<sub>2</sub> at elevated temperature to give chloride <b>281</b> in 97% yield. Flumatinib was then obtained in 94% yield from the copper-catalyzed coupling of <b>281</b> with amide <b>282</b> in the presence of base and <i>tert</i>-butyl hydroquinone (TBHQ).<a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a> The final salt formation with methanesulfonic acid gave flumatinib mesylate (<b>XXXII</b>) in 98% yield.<a onclick="showRef(event, 'cit175a'); return false;" href="javascript:void(0);" class="ref cit175a">(175a)</a></div><figure id="sch44" data-index="46" class="article__inlineFigure"><h2 class="fig-label">Scheme 44</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0050.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0050.jpeg" id="gr47" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 44. Synthesis of Flumatinib Mesylate (<b>XXXII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0050.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch44"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Amide <b>282</b> originated from benzonitrile <b>283</b> (<a class="ref internalNav" href="#sch45" aria-label="Scheme 45">Scheme 45</a>). Bromination of this tolyl derivative followed by substitution with <i>N</i>-methylpiperazine (<b>254</b>) and subsequent palladium-catalyzed conversion of the nitrile to the primary amide proceeded in excellent yield across the two-step sequence.<a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a></div><figure id="sch45" data-index="47" class="article__inlineFigure"><h2 class="fig-label">Scheme 45</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0051.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0051.jpeg" id="gr48" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 45. Synthesis of Flumatinib Amide <b>282</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0051.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch45"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec10_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i89" class="anchor-spacer"></div><h3 class="article-section__title" id="_i89">10.8.  Pexidartinib (Turalio)</h3><div class="NLM_p">Pexidartinib, also known as PLX3397, is a tyrosine kinase inhibitor discovered by Plexxikon and developed by Daiichi-Sankyo. The drug was approved by the USFDA for the treatment of symptomatic tenosynovial giant cell tumors (TGCTs) associated with severe morbidity or functional limitations and not amenable to improvement with surgery.<a onclick="showRef(event, 'ref177 ref178'); return false;" href="javascript:void(0);" class="ref ref177 ref178">(177,178)</a> TGCTs are a group of rare tumors that arise from the fibrous tissue surrounding the joints, mucosal bursas, and tendon sheaths. Pexidartinib exhibits potent, selective tyrosine kinase activity against colony-stimulating factor 1 receptor (CSF-1R), c-KIT, and FLT3 harboring an internal tandem duplication mutation (FLT3-ITD).<a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(179)</a></div><div class="NLM_p">The preparation of pexidartinib and its derivatives has been described previously.<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a> However, a relatively short kilogram-scale synthesis of the drug was disseminated by researchers at Daiichi-Sankyo, and this sequence is depicted in <a class="ref internalNav" href="#sch46" aria-label="Scheme 46">Scheme 46</a>.<a onclick="showRef(event, 'ref181'); return false;" href="javascript:void(0);" class="ref ref181">(181)</a> Nucleophilic attack of chloroazaindole <b>285</b> on pyridine aldehyde <b>284</b> in the presence of tetrabutylammonium hydrogen sulfate resulted in alcohol <b>286</b>, which was reduced with triethylsilane. Subsequent treatment with TFA removed both Boc groups to afford aminopyridine <b>287</b> in good yield. Introduction of the side chain by reductive amination with aldehyde <b>288</b> and subsequent exposure to TFA delivered pexidartinib. After neutralization, the free-base form of the drug was obtained and thereafter converted into the HCl salt in 90% yield using concentrated HCl and ethanol.</div><figure id="sch46" data-index="48" class="article__inlineFigure"><h2 class="fig-label">Scheme 46</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0052.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0052.jpeg" id="gr49" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 46. Synthesis of Pexidartinib (<b>XXXIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0052.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch46"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec10_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i91" class="anchor-spacer"></div><h3 class="article-section__title" id="_i91">10.9.  Polatuzumab Vedotin (Polivy)</h3><div class="NLM_p">Polatuzumab vedotin is an ADC consisting of an anti-CD79b monoclonal antibody conjugated to MMAE. These two entities are connected via a linker consisting of a maleimide conjugation handle that includes an enzyme-cleavable valine–citrulline–<i>p</i>-aminobenzyl alcohol group. MMAE is released after the conjugate has been internalized by the cancer cell that recognizes the antibody. Polatuzumab vedotin was approved by the USFDA for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in combination with bendamustine plus rituximab.<a onclick="showRef(event, 'ref182'); return false;" href="javascript:void(0);" class="ref ref182">(182)</a> Polatuzumab vedotin was developed by Genentech (a division of Roche) using the ADC linker–payload technology licensed from and developed by Senter and co-workers at Seagen (formerly Seattle Genetics).<a onclick="showRef(event, 'ref183'); return false;" href="javascript:void(0);" class="ref ref183">(183)</a> This same linker–payload and conjugation strategy was incorporated into brentuximab vedotin (approved in 2011) and enfortumab vedotin (approved in 2019).</div><div class="NLM_p">Although an explicit preparation of polatuzumab vedotin was not found in the primary or patent literature, the drug was prepared using Seagen technology.<a onclick="showRef(event, 'ref184'); return false;" href="javascript:void(0);" class="ref ref184">(184)</a> Thus, the synthesis is described generally in <a class="ref internalNav" href="#sch47" aria-label="Scheme 47">Scheme 47</a> and is very similar to that described for brentuximab vedotin. It is also analogous to the preparation of enfortumab vedotin reviewed in <a class="ref internalNav" href="#sch38" aria-label="Scheme 38">Scheme 38</a> but uses slightly different reagents.<a onclick="showRef(event, 'ref183'); return false;" href="javascript:void(0);" class="ref ref183">(183)</a> Anti-CD79b antibody <b>289</b> was dissolved in PBS, and 50 mM borate was added. After the pH was adjusted to 8, dithiothreitol (DTT) was added to reduce the intrachain disulfide bonds to reveal approximately eight free sulfhydryl groups (<b>290</b>). Reaction of these free thiol groups with 4 equiv of <b>252</b> (<a class="ref internalNav" href="#sch38" aria-label="Scheme 38">Scheme 38</a>) in acetonitrile followed by reoxidation of the unreacted sulfhydryl groups and quenching of excess vcMMAE with cysteine provided polatuzumab vedotin (<b>XXXIV</b>) with a DAR of approximately 3.7. Indicative of the growth of this technology, the linker–payload construct <b>252</b> is now commercially available, and its synthesis has been reviewed previously.<a onclick="showRef(event, 'cit1j'); return false;" href="javascript:void(0);" class="ref cit1j">(1j)</a></div><figure id="sch47" data-index="49" class="article__inlineFigure"><h2 class="fig-label">Scheme 47</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0053.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0053.jpeg" id="gr50" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 47. Synthesis of Polatuzumab Vedotin (<b>XXXIV</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0053.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch47"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec10_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i93" class="anchor-spacer"></div><h3 class="article-section__title" id="_i93">10.10.  Quizartinib Dihydrochloride (Vanflyta)</h3><div class="NLM_p">Quizartinib dihydrochloride, also known as AC220, is a highly potent oral FLT3 receptor tyrosine kinase inhibitor approved in Japan for the treatment of patients with relapsed/refractory FLT3-ITD-positive AML.<a onclick="showRef(event, 'ref185'); return false;" href="javascript:void(0);" class="ref ref185">(185)</a> As a second-generation inhibitor of FLT3, quizartinib has demonstrated a number of advantages over first-generation FLT3 inhibitors, which display less optimal tolerability, potency, and oral pharmacokinetic properties.<a onclick="showRef(event, 'ref186'); return false;" href="javascript:void(0);" class="ref ref186">(186)</a> The drug was discovered by Ambit Biosciences and licensed to Astellas in 2009. However, after the termination of the collaboration in 2013, Daiichi Sankyo obtained the rights to develop the drug through acquisition of Ambit Biosciences in 2014.<a onclick="showRef(event, 'ref187'); return false;" href="javascript:void(0);" class="ref ref187">(187)</a></div><div class="NLM_p">The synthetic route to quizartinib dihydrochloride has been described in several published reports by Ambit Biosciences, and this linear route is outlined in <a class="ref internalNav" href="#sch48" aria-label="Scheme 48">Scheme 48</a>.<a onclick="showRef(event, 'ref186 ref188'); return false;" href="javascript:void(0);" class="ref ref186 ref188">(186,188)</a> Aminobenzothiazole <b>291</b> was demethylated using HBr to liberate phenol <b>292</b>, which participated in a cyclization reaction upon subjection to α-bromo ketone <b>293</b> and base to give tricyclic phenol <b>294</b>. Alkylation of <b>294</b> with chloromorpholine <b>295</b> furnished <b>296</b>, making way for reduction of the nitro group to generate aniline <b>297</b>. Reaction of this intermediate with carbamate <b>298</b> provided quizartinib as the free base, which was subjected to methanolic HCl to provide the bis(HCl) salt of quizartinib (<b>XXXV</b>) in 89% yield.<a onclick="showRef(event, 'ref189'); return false;" href="javascript:void(0);" class="ref ref189">(189)</a></div><figure id="sch48" data-index="50" class="article__inlineFigure"><h2 class="fig-label">Scheme 48</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0054.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0054.jpeg" id="gr51" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 48. Synthesis of Quizartinib Dihydrochloride (<b>XXXV</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0054.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch48"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec10_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i95" class="anchor-spacer"></div><h3 class="article-section__title" id="_i95">10.11.  Selinexor (Xpovio)</h3><div class="NLM_p">Selinexor, an oral medication developed by Karyopharm, was approved for treatment of multiple myeloma after receiving an orphan drug fast-track designation from the USFDA.<a onclick="showRef(event, 'ref190'); return false;" href="javascript:void(0);" class="ref ref190">(190)</a> The drug inhibits chromosome region maintenance 1 protein/exportin 1 (CRM1/XPO1), which leads to increased retention of major tumor suppressor proteins and can result in selective apoptosis in cancer cells.<a onclick="showRef(event, 'ref191'); return false;" href="javascript:void(0);" class="ref ref191">(191)</a> Increased expression of XPO1 has been identified in a number of cancers, giving selinexor potential application for multiple indications. Thus, over 40 clinical trials examining selinexor as a single therapy or in combination with other chemotherapeutic agents are currently underway.<a onclick="showRef(event, 'ref190'); return false;" href="javascript:void(0);" class="ref ref190">(190)</a> Furthermore, the drug inhibits the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway and induces expression of nerve growth factor receptor (NGFR), which is thought to act as a tumor suppressor.<a onclick="showRef(event, 'ref192'); return false;" href="javascript:void(0);" class="ref ref192">(192)</a> Selinexor is a first-in-class therapeutic and has also received fast-track designation from the USFDA for diffuse large B-cell lymphoma.<a onclick="showRef(event, 'ref191'); return false;" href="javascript:void(0);" class="ref ref191">(191)</a> Even more interestingly, selinexor has been identified as a potential treatment for SARS-CoV-2 (COVID-19). Phase II clinical trials to evaluate selinexor as a treatment for infected patients were initiated in April 2020.<a onclick="showRef(event, 'ref193'); return false;" href="javascript:void(0);" class="ref ref193">(193)</a></div><div class="NLM_p">In a synthetic route to selinexor disclosed in an early patent from Karyopharm, many reactions within the sequence were exemplified on a 100 g scale, and this route is depicted in <a class="ref internalNav" href="#sch49" aria-label="Scheme 49">Scheme 49</a>.<a onclick="showRef(event, 'ref194'); return false;" href="javascript:void(0);" class="ref ref194">(194)</a> The route began with the reaction of 3,5-bis(trifluoromethyl)benzonitrile (<b>299</b>) with sodium hydrosulfide and magnesium chloride in DMF to generate thioamide <b>300</b>, which upon subjection to hydrazine hydrate in DMF underwent a cyclization reaction to furnish 1,2,4-triazole <b>301</b>. Next, addition to vinyl iodide <b>302</b> and subsequent elimination gave rise to <b>303</b>, which was reported to exist as a 9:1 ratio of the desired <i>Z</i> isomer to the <i>E</i> isomer impurity. It is unclear from reports whether the <i>E</i> isomer was removed by purification methods or if this isopropyl ester is prone to isomerization. Ester <b>303</b> was saponified under basic conditions, and after pH adjustment, T3P-mediated coupling with hydrazine <b>305</b> generated selinexor (<b>XXXVI</b>). No yield was reported for this final step, although Karyopharm exemplified this step on a 13 kg scale.<a onclick="showRef(event, 'ref195'); return false;" href="javascript:void(0);" class="ref ref195">(195)</a></div><figure id="sch49" data-index="51" class="article__inlineFigure"><h2 class="fig-label">Scheme 49</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0055.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0055.jpeg" id="gr52" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 49. Synthesis of Selinexor (<b>XXXVI</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0055.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch49"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec10_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i97" class="anchor-spacer"></div><h3 class="article-section__title" id="_i97">10.12.  Trastuzumab Deruxtecan (Enhertu)</h3><div class="NLM_p">Trastuzumab deruxtecan, an ADC developed by Daiichi Sankyo in collaboration with AstraZeneca, was approved by the USFDA after being granted accelerated approval, fast-track designation, and breakthrough therapy designation.<a onclick="showRef(event, 'ref196 ref197'); return false;" href="javascript:void(0);" class="ref ref196 ref197">(196,197)</a> Trastuzumab deruxtecan was approved for the treatment of adults with unresectable or metastatic HER2-positive breast cancer who have previously undergone at least two prior HER2-based treatments.<a onclick="showRef(event, 'ref197'); return false;" href="javascript:void(0);" class="ref ref197">(197)</a> The drug, which incorporates the same antibody as trastuzumab emtansine (Kadcyla), contains a HER2-directed antibody, trastuzumab, conjugated to topisomerase I inhibitor DXd (<b>306</b>) via an enzymatically cleavable maleimide glycine-glycine-phenylalanine-glycine (GGFG) peptidic linker (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).<a onclick="showRef(event, 'ref198'); return false;" href="javascript:void(0);" class="ref ref198">(198)</a> The linker–DXd intermediate, known as deruxtecan (<b>307</b>), is conjugated to trastuzumab via interchain cysteine residues present on the antibody, with an average of eight deruxtecan units attached to each trastuzumab antibody (DAR ≈ 8). The observed therapeutic effect of trastuzumab deruxtecan relies on overexpression of HER2 in many cancer types, facilitating antibody-driven binding of the ADC with HER2 receptors present in cancer cells.<a onclick="showRef(event, 'ref199'); return false;" href="javascript:void(0);" class="ref ref199">(199)</a> After binding of the ADC to the surface of the targeted cell, internalization and subsequent protease-mediated cleavage of the linker portion of deruxtecan takes place, releasing DXd as the active species.<a onclick="showRef(event, 'cit198a'); return false;" href="javascript:void(0);" class="ref cit198a">(198a)</a> A camptothecin derivative of the known topisomerase I inhibitor exatecan (<b>308</b>), DXd inhibits DNA replication, tumor cell apoptosis, and cell cycle arrest by binding with and inhibiting topoisomerase I-DNA complexes.<a onclick="showRef(event, 'ref196 ref200'); return false;" href="javascript:void(0);" class="ref ref196 ref200">(196,200)</a> Interestingly, the linker technology used in trastuzumab deruxtecan varies from that in many other ADCs currently approved for human use, enabling a significantly higher DAR and the maximum theoretical DAR possible for conventional interchain cysteine conjugation.<a onclick="showRef(event, 'cit198a'); return false;" href="javascript:void(0);" class="ref cit198a">(198a)</a> The increased drug loading enables a substantially higher delivery of payload to tumor cells, even cells with low HER2 expression. This high DAR is possible because of a favorable stability and clearance profile, which is often a liability with other ADC types.<a onclick="showRef(event, 'cit198a cit200b'); return false;" href="javascript:void(0);" class="ref cit198a cit200b">(198a,200b)</a> In clinical trials of 184 patients treated with the drug, 60% of patients dosed with trastuzumab deruxtecan observed tumor shrinkage, leading to a median response duration of 14.8 months.<a onclick="showRef(event, 'ref201 ref196'); return false;" href="javascript:void(0);" class="ref ref201 ref196">(201,196)</a></div><figure id="fig3" data-index="52" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0008.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Approach to payload–linker assembly for trastuzumab deruxtecan (<b>XXXVII</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A new synthesis of exatecan was recently reported by Daiichi Sankyo<a onclick="showRef(event, 'ref202'); return false;" href="javascript:void(0);" class="ref ref202">(202)</a> and was developed with the goal of identifying a shorter and improved route to enable industrial production of exatecan,<a onclick="showRef(event, 'ref202'); return false;" href="javascript:void(0);" class="ref ref202">(202)</a> deruxtecan,<a onclick="showRef(event, 'ref203'); return false;" href="javascript:void(0);" class="ref ref203">(203)</a> and the antibody-conjugated form of deruxtecan, trastuzumab deruxtecan.<a onclick="showRef(event, 'ref204'); return false;" href="javascript:void(0);" class="ref ref204">(204)</a> The synthesis of deruxtecan makes use of a late-stage coupling of exatecan and advanced linker intermediate <b>325</b> (see <a class="ref internalNav" href="#sch53" aria-label="Scheme 53">Scheme 53</a>).<a onclick="showRef(event, 'ref203'); return false;" href="javascript:void(0);" class="ref ref203">(203)</a> The synthesis of exatecan began with bromination of 2-fluoro-1-methyl-4-nitrobenzene (<b>309</b>) with NBS/sulfuric acid in heptane, making way for subsequent nitro reduction and acetylation of the resulting aniline to provide compound <b>310</b> (<a class="ref internalNav" href="#sch50" aria-label="Scheme 50">Scheme 50</a>).<a onclick="showRef(event, 'ref202'); return false;" href="javascript:void(0);" class="ref ref202">(202)</a> The three-step sequence was completed in 37% overall yield, providing <b>310</b> as a white solid after a series of aqueous workup events and crystallization.<a onclick="showRef(event, 'ref202'); return false;" href="javascript:void(0);" class="ref ref202">(202)</a> Coupling of this bromide with 3-butenoic acid (<b>311</b>) under Heck conditions (Pd(OAc)<sub>2</sub>/P(<i>o</i>-tol)<sub>3</sub>) and subsequent hydrogenation of the resulting mixture of alkene isomers resulted in intermediate <b>312</b> in 91% overall yield for the two-step process after precipitation from heptane. Activation of the resulting carboxylic acid in <b>312</b> with TFA/TFAA initiated an intramolecular cyclization to provide tetrahydronapthalenone <b>313</b> in 92% yield after precipitation from a cold solution of acetonitrile/water.<a onclick="showRef(event, 'ref202'); return false;" href="javascript:void(0);" class="ref ref202">(202)</a> A THF solution of this carbocycle was sequentially subjected to nitration conditions followed by heterogeneous reduction, ultimately providing bis(amino acetate) <b>314</b> in 52% yield after workup and isolation. Selective aniline deacetylation with hot aqueous HCl provided intermediate <b>315</b> in 80% yield after precipitation and recrystallization from acetone.<a onclick="showRef(event, 'ref202'); return false;" href="javascript:void(0);" class="ref ref202">(202)</a></div><figure id="sch50" data-index="53" class="article__inlineFigure"><h2 class="fig-label">Scheme 50</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0056.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0056.jpeg" id="gr53" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 50. Synthesis of Exatecan Precursor <b>315</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0056.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch50"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The remaining synthetic steps to exatecan are shown in <a class="ref internalNav" href="#sch51" aria-label="Scheme 51">Scheme 51</a>.<a onclick="showRef(event, 'ref202'); return false;" href="javascript:void(0);" class="ref ref202">(202)</a> Subjection of <b>315</b> to advanced intermediate <b>316</b>, which is commercially available and also has been previously described in the literature,<a onclick="showRef(event, 'ref205'); return false;" href="javascript:void(0);" class="ref ref205">(205)</a> provided the core structure of exatecan via a PPTS-mediated Friedlaender-type reaction. This reaction took place under refluxing conditions in <i>o</i>-cresol and toluene and relied first on condensation of the ketone within <b>316</b> and the aniline within <b>315</b>.<a onclick="showRef(event, 'ref202'); return false;" href="javascript:void(0);" class="ref ref202">(202)</a> Reaction of these two intermediates gave rise to intermediate enamine <b>317</b>, which then underwent dehydrative intramolecular cyclization to generate quinoline <b>318</b> in high yield (96%) as a mixture of diastereomers (ratio not reported) on a 170 g scale. Among several published reports detailing the conversion of the mixture of <b>318</b> to exatecan, one process proceeds via isolation of exatecan in modest yields on a 300 g scale involving an extensively studied amine deprotection/crystallization/isomerization sequence.<a onclick="showRef(event, 'ref202 ref206'); return false;" href="javascript:void(0);" class="ref ref202 ref206">(202,206)</a> In this regard, treatment of the mixture of <b>318</b> with aqueous methanesulfonic acid under refluxing conditions in ethylcyclohexene and 2-methoxyethanol resulted in the formation of the dihydromesylate amine salt of exatecan as a mixture with <i>epi</i>-exatecan salt <b>319</b>, which can be separated by recrystallization. After separation of the isomers, the undesired isomer <b>319</b> could also be recycled and converted to exatecan via an amine reprotection and deprotection sequence, which was made possible by isomerization of <b>319</b> under the deprotection reaction conditions. By the use of this overall process, the desired mesylate salt dihydrate of exatecan (<b>308</b>) was isolated in 43% yield after a series of aqueous washes and recrystallization events.<a onclick="showRef(event, 'ref202 ref206'); return false;" href="javascript:void(0);" class="ref ref202 ref206">(202,206)</a></div><figure id="sch51" data-index="54" class="article__inlineFigure"><h2 class="fig-label">Scheme 51</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0057.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0057.jpeg" id="gr54" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 51. Synthesis of Exatecan (<b>308</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0057.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch51"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">An improved synthetic route to linker intermediate <b>325</b> on a multikilogram scale that enabled isolation of deruxtecan in crystal form without the need for chiral chromatography was also recently reported by Daiichi Sankyo.<a onclick="showRef(event, 'ref203'); return false;" href="javascript:void(0);" class="ref ref203">(203)</a> This route is outlined in <a class="ref internalNav" href="#sch52" aria-label="Scheme 52">Scheme 52</a>. Subjection of glycine acid <b>320</b> to a previously developed oxidative decarboxylation process<a onclick="showRef(event, 'ref207'); return false;" href="javascript:void(0);" class="ref ref207">(207)</a> with Pb(OAc)<sub>4</sub> and acetic acid in refluxing THF provided aminal <b>321</b> in 68% yield after precipitation from cyclopentyl methyl ether.<a onclick="showRef(event, 'ref203'); return false;" href="javascript:void(0);" class="ref ref203">(203)</a> One-pot acetyl cleavage and subsequent two-carbon homologation with benzyl glycolate under Lewis acid conditions provided benzyl ester <b>322</b> in 88% yield. Removal of Fmoc within <b>322</b> followed by coupling with dipeptide <b>323</b> (prepared by coupling of <span class="smallcaps smallerCapital">l</span>-phenylalanine and <i>N</i>-9-fluorenylmethoxycarbonylglycylglycine<a onclick="showRef(event, 'ref208'); return false;" href="javascript:void(0);" class="ref ref208">(208)</a>) enabled the formation of compound <b>324</b> in 94% yield over the one-pot, two-step sequence after crystallization of the product from 2-propanol.<a onclick="showRef(event, 'ref203'); return false;" href="javascript:void(0);" class="ref ref203">(203)</a> Cleavage of the benzyl ester from <b>324</b> was performed under heterogeneous conditions with H<sub>2</sub> catalyzed by a palladium/carbon–ethylenediamine complex, providing <b>325</b> in 89% yield following filtration and precipitation from ethyl acetate.<a onclick="showRef(event, 'ref203'); return false;" href="javascript:void(0);" class="ref ref203">(203)</a></div><figure id="sch52" data-index="55" class="article__inlineFigure"><h2 class="fig-label">Scheme 52</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0058.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0058.jpeg" id="gr55" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 52. Synthesis of Advanced Deruxtecan Linker Intermediate <b>325</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0058.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch52"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">With both exatecan <b>308</b> and linker <b>325</b> in hand, the final steps to deruxtecan were conducted by joining these two fragments under peptide coupling conditions with EDCI and HOBt·H<sub>2</sub>O at room temperature, providing intermediate <b>326</b> in 84% yield (<a class="ref internalNav" href="#sch53" aria-label="Scheme 53">Scheme 53</a>).<a onclick="showRef(event, 'ref203'); return false;" href="javascript:void(0);" class="ref ref203">(203)</a> Isolation of the product in acceptable purity was possible via treatment of the organic layer from the reaction with activated carbon and MgSO<sub>4</sub> and subsequent crystallization from THF. Finally, Fmoc deprotection of <b>326</b> with DBU in THF and reaction of the resulting amine with 6-maleimidocaproic acid (<b>327</b>) generated deruxtecan (<b>307</b>) on a 400 g scale. By the use of this method, precipitation of the product from acetone and 1-propanol yielded 191 g of <b>307</b>, which could also be prepared in a variety of other crystal forms suitable for conjugation to the trastuzumab antibody.<a onclick="showRef(event, 'ref203'); return false;" href="javascript:void(0);" class="ref ref203">(203)</a></div><figure id="sch53" data-index="56" class="article__inlineFigure"><h2 class="fig-label">Scheme 53</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0059.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0059.jpeg" id="gr56" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 53. Synthesis of Deruxtecan (<b>307</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0059.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch53"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Preparation of the final drug product, trastuzumab deruxtecan, necessitated conjugation of deruxtecan to the anti-HER2 monoclonal antibody trastuzumab, generating the ADC with a loading of approximately eight deruxtecan units per antibody (<a class="ref internalNav" href="#sch54" aria-label="Scheme 54">Scheme 54</a>).<a onclick="showRef(event, 'ref196 ref203'); return false;" href="javascript:void(0);" class="ref ref196 ref203">(196,203)</a> This conjugation process proceeded through treatment of a PBS/EDTA buffer solution of the trastuzumab antibody with TCEP and 1 M dipotassium hydrogen phosphate, providing a final pH of 7.4. Incubation at 37 °C led to reduction of the intrachain disulfide bonds, giving rise to intermediate <b>328</b>. Subjection of this mixture to excess deruxtecan (9.2 equiv per antibody) followed by reoxidation and quenching of any nonreacted sulfide bonds with aqueous <i>N</i>-acetylcysteine provided trastuzumab deruxtecan (<b>XXXVII</b>) in ∼8:1 DAR after purification by gel filtration.<a onclick="showRef(event, 'ref196 cit198b ref203 ref209'); return false;" href="javascript:void(0);" class="ref ref196 cit198b ref203 ref209">(196,198b,203,209)</a></div><figure id="sch54" data-index="57" class="article__inlineFigure"><h2 class="fig-label">Scheme 54</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0060.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0060.jpeg" id="gr57" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 54. Conjugative Endgame for Trastuzumab Deruxtecan (<b>XXXVII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0060.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch54"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec10_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i103" class="anchor-spacer"></div><h3 class="article-section__title" id="_i103">10.13.  Zanubrutinib (Brukinsa)</h3><div class="NLM_p">Zanubrutinib, also known as BGB-3111, was discovered by BeiGene and approved by the USFDA for the treatment of adult patients with mantle cell lymphoma (MCL) who have previously received at least one prior therapy.<a onclick="showRef(event, 'ref210'); return false;" href="javascript:void(0);" class="ref ref210">(210)</a> The drug also received approval from CNMPA in June 2020 for the same indication.<a onclick="showRef(event, 'ref211'); return false;" href="javascript:void(0);" class="ref ref211">(211)</a> As a next-generation oral irreversible Bruton’s tyrosine kinase (BTK) inhibitor, zanubrutinib was designed to minimize off-target kinase inhibition while achieving maximal exposure.<a onclick="showRef(event, 'ref212'); return false;" href="javascript:void(0);" class="ref ref212">(212)</a> In kinase inhibition and cell-based assays, zanubrutinib exhibited superior selective BTK inhibition compared with ibrutinib, particularly against EGFR.<a onclick="showRef(event, 'ref213'); return false;" href="javascript:void(0);" class="ref ref213">(213)</a></div><div class="NLM_p">Researchers at BeiGene have reported multiple synthetic routes to zanubrutinib.<a onclick="showRef(event, 'ref214'); return false;" href="javascript:void(0);" class="ref ref214">(214)</a> The most likely process synthesis, depicted in <a class="ref internalNav" href="#sch55" aria-label="Scheme 55">Scheme 55</a>, began with benzoic acid <b>329</b>.<a onclick="showRef(event, 'cit214b'); return false;" href="javascript:void(0);" class="ref cit214b">(214b)</a> Reaction with malononitrile in refluxing ethyl acetate generated vinyl dinitrile <b>330</b>, which was subsequently methylated using trimethyl orthoformate in warm acetonitrile to generate ether <b>331</b>. Formation of the corresponding 2-aminopyrazole followed, and this product was immediately reacted with a piperidine-containing keto aldehyde equivalent (in this case vinylogous amide <b>333</b>, whose synthesis is described in <a class="ref internalNav" href="#sch56" aria-label="Scheme 56">Scheme 56</a>), giving rise to zanubrutinib heterocyclic subunit <b>334</b>. Next, hydrogenative saturation of the fused pyrimidine ring followed by acidic removal of the Boc group provided piperidine <b>335</b> as the bis(HCl) salt. Chiral salt resolution next allowed for isolation of the desired piperidine geometry. To this effect, exposure of <b>335</b> to potassium hydroxide followed by pH adjustment with MsOH and subsequent treatment with <span class="smallcaps smallerCapital">l</span>-dibenzoyltartaric acid (L-DBTA) resulted in hydrolysis of the nitrile and isolation of the desired enantiomer as the tartaric acid salt. Reaction of tartrate <b>336</b> with acryloyl chloride under Schotten–Baumann conditions furnished zanubrutinib (<b>XXXVIII</b>) in 70% yield from <b>336</b>.</div><figure id="sch55" data-index="58" class="article__inlineFigure"><h2 class="fig-label">Scheme 55</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0061.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0061.jpeg" id="gr58" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 55. Synthesis of Zanubrutinib (<b>XXXVIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0061.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch55"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch56" data-index="59" class="article__inlineFigure"><h2 class="fig-label">Scheme 56</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0062.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0062.jpeg" id="gr59" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 56. Synthesis of Zanubrutinib Vinylogous Amide <b>333</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0062.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch56"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The synthesis of vinylogous amide <b>333</b> was achieved in a three-step process starting from carboxylic acid <b>337</b> (<a class="ref internalNav" href="#sch56" aria-label="Scheme 56">Scheme 56</a>). Subjection of <b>337</b> to <i>N</i>,<i>O</i>-dimethylhydroxylamine hydrochloride (<b>338</b>) in the presence of EDCI/HOBt led to Weinreb amide <b>339</b>, which was converted to ketone <b>340</b> via reaction with methylmagnesium bromide. Exposure of methyl ketone <b>340</b> to <i>N</i>,<i>N</i>-dimethylformamide dimethyl acetal (DMF-DMA) at elevated temperature provided the desired product <b>333</b> in 83% overall yield across the three-step sequence.<a onclick="showRef(event, 'cit214b'); return false;" href="javascript:void(0);" class="ref cit214b">(214b)</a></div></div></div><div id="sec11" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i106">11.  Reproductive Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85558" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85558" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec11_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i107" class="anchor-spacer"></div><h3 class="article-section__title" id="_i107">11.1.  Relugolix (Relumina)</h3><div class="NLM_p">Relugolix is a nonpeptide gonadotropin-releasing hormone (GnRH) receptor antagonist that was discovered by Takeda Pharmaceuticals and developed by Myovant Sciences. Relugolix has recently been approved in Japan for the treatment of uterine fibroids<a onclick="showRef(event, 'ref215'); return false;" href="javascript:void(0);" class="ref ref215">(215)</a> and is also currently in Phase III studies for the treatment of endometriosis and prostate cancer.<a onclick="showRef(event, 'ref216'); return false;" href="javascript:void(0);" class="ref ref216">(216)</a></div><div class="NLM_p">Although no explicit large-scale synthesis of the drug has been reported to date,<a onclick="showRef(event, 'ref217'); return false;" href="javascript:void(0);" class="ref ref217">(217)</a> researchers at Takeda disclosed a discovery chemistry route to relugolix that is described in <a class="ref internalNav" href="#sch57" aria-label="Scheme 57">Scheme 57</a>.<a onclick="showRef(event, 'ref218'); return false;" href="javascript:void(0);" class="ref ref218">(218)</a> Reaction of ketone <b>341</b> and ethyl cyanoacetate (<b>342</b>) in the presence of triethylamine and sulfur resulted in the formation of an aminothiophene, a process known as the Gewald aminothiophene synthesis.<a onclick="showRef(event, 'ref219'); return false;" href="javascript:void(0);" class="ref ref219">(219)</a> The corresponding amino group was protected as the ethyl carbamate in 94% yield to generate thiophene <b>343</b>. This intermediate underwent substitution with benzyl chloride <b>344</b> and was then subjected to radical bromination conditions (NBS, AIBN) to give rise to benzyl bromide <b>345</b> in 93% yield over two steps. Displacement of the bromide with amine <b>346</b> followed by reduction of the nitroarene gave aniline <b>347</b> in 96% yield over two steps. This aniline was reacted with CDI, and the resulting imidazolide was further treated with <i>N</i>-methoxyamine to arrive at urea <b>348</b>. At this stage, a cyclization reaction mediated by diethyl pyrocarbonate (DEPC) in the presence of aminopyridazine <b>349</b> followed by exposure to sodium methoxide generated thymine derivative <b>350</b>. Hoffman conditions using chloroformate <b>351</b> were employed to quaternize the basic center within <b>350</b>, which was then displaced by dimethylamine to give relugolix (<b>XXXIX</b>) in 44% yield over two steps.<a onclick="showRef(event, 'ref218'); return false;" href="javascript:void(0);" class="ref ref218">(218)</a></div><figure id="sch57" data-index="60" class="article__inlineFigure"><h2 class="fig-label">Scheme 57</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0063.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0063.jpeg" id="gr60" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 57. Synthesis of Relugolix (<b>XXXIX</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0063.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch57"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec12" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i109">12.  Respiratory Drugs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05446" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05446" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec12_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i110" class="anchor-spacer"></div><h3 class="article-section__title" id="_i110">12.1.  Elexacaftor (Trikafta)</h3><div class="NLM_p">Elexacaftor is part of a fixed-dose combination tablet along with tezacaftor and ivacaftor that was developed by Vertex Pharmaceuticals and approved by the USFDA to treat patients with the most common cystic fibrosis mutation (<i>F508del</i>).<a onclick="showRef(event, 'ref220'); return false;" href="javascript:void(0);" class="ref ref220">(220)</a> Ivacaftor is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator,<a onclick="showRef(event, 'ref221'); return false;" href="javascript:void(0);" class="ref ref221">(221)</a> while elexacaftor and tezacaftor are CFTR correctors.<a onclick="showRef(event, 'ref222'); return false;" href="javascript:void(0);" class="ref ref222">(222)</a> Mutations in the genes encoding CFTR proteins affect the transport of chloride and bicarbonate across the apical membranes of epithelial cells, leading to mucosal buildup and ultimately chronic infections and organ dysfunction. Utilizing the two classes of CFTR modulators in combination serves to simultaneously increase defective CFTR protein processing and trafficking and improve CFTR protein activity at the cell surface.<a onclick="showRef(event, 'ref222'); return false;" href="javascript:void(0);" class="ref ref222">(222)</a></div><div class="NLM_p">Two synthetic routes to elexacaftor were disclosed by Vertex in 2018 and 2019.<a onclick="showRef(event, 'ref223'); return false;" href="javascript:void(0);" class="ref ref223">(223)</a> A review summarizing these routes was also recently published.<a onclick="showRef(event, 'ref224'); return false;" href="javascript:void(0);" class="ref ref224">(224)</a> In their first-generation strategy, Vertex prepared elexacaftor through a convergent approach, with the synthesis of three fragments coupled sequentially about a lynchpin dichloronicotinic acid core. Pyrazole fragment <b>354</b> originated from methyl (<i>E</i>)-3-methoxyacrylate (<b>351</b>) (<a class="ref internalNav" href="#sch58" aria-label="Scheme 58">Scheme 58</a>). This Michael acceptor underwent an addition–elimination reaction when treated with hydrazine monohydrate, followed by cyclization and Boc protection to afford pyrazolone <b>352</b> in 71% yield. A Mitsunobu reaction involving trifluoroalcohol <b>353</b> and subsequent Boc deprotection with HCl provided pyrazole <b>354</b>.</div><figure id="sch58" data-index="61" class="article__inlineFigure"><h2 class="fig-label">Scheme 58</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0064.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0064.jpeg" id="gr61" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 58. Synthesis of Elexacaftor Pyrazole Fragment <b>354</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0064.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch58"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Two methods were disclosed to synthesize chiral pyrrolidine <b>358</b>, a five-step enzymatic resolution procedure and a four-step ring-contraction route. The contraction approach was described on 257 kg scale and was originally published by BF Goodrich in 1980.<a onclick="showRef(event, 'ref225'); return false;" href="javascript:void(0);" class="ref ref225">(225)</a> Piperidone <b>355</b> was treated with base in chloroform in the presence of a phase-transfer reagent (<a class="ref internalNav" href="#sch59" aria-label="Scheme 59">Scheme 59</a>), which triggered a fascinating mechanistic sequence. This sequence is described in detail in the literature<a onclick="showRef(event, 'ref224'); return false;" href="javascript:void(0);" class="ref ref224">(224)</a> and relies on epoxidation, piperidine ring cleavage via nitrogen-assisted opening of the dichloroepoxide intermediate, subsequent imine hydrolysis, and recyclization to furnish the ring-contracted product. Following this, the chiral methyl stereocenter could be installed through asymmetric hydrogenation using rhodium or ruthenium catalysis, both providing high yield and enantioselectivity. A final LiAlH<sub>4</sub> reduction and salt formation afforded pyrrolidine <b>358</b> in 75% yield over two steps.</div><figure id="sch59" data-index="62" class="article__inlineFigure"><h2 class="fig-label">Scheme 59</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0065.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0065.jpeg" id="gr62" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 59. Preparation of Elexacaftor Pyrrolidine Salt <b>358</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0065.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch59"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To complete the synthesis of elexacaftor, carboxylic acid <b>359</b> was protected as the <i>tert</i>-butyl ester (<a class="ref internalNav" href="#sch60" aria-label="Scheme 60">Scheme 60</a>). This was followed by a substitution reaction with pyrazole <b>354</b> to give <b>366</b> in 95% yield over the two steps. Ester <b>366</b> was hydrolyzed under acidic conditions in 91% yield. Activation of the acid with CDI and exposure to sulfonamide <b>368</b> afforded the penultimate chloropyridine <b>369</b> in 93% yield. A final substitution of the remaining pyridyl chloride with hindered pyrrolidine <b>358</b> afforded elexacaftor (<b>XL</b>) in 90% yield.</div><figure id="sch60" data-index="63" class="article__inlineFigure"><h2 class="fig-label">Scheme 60</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0066.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0066.jpeg" id="gr63" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 60. Synthesis of Elexacaftor (<b>XL</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0066.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch60"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec13" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i114">13.  Summary</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01060" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01060" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">The pharmaceutical industry worldwide enjoyed another year of excellent productivity during 2019. These 40 new medicines reviewed herein include many structures of considerable complexity and address a broad variety of diseases. The full array of synthetic transformations required for their assembly collectively spans chemistry discovered over a century ago to the latest enzymatic resolution capabilities. The increasing number of transition-metal-catalyzed reactions occurring within this review emphasizes the importance of this technology toward an expanded scope of bonds capable of being secured by this technology as well as the ability to conduct these transformations with attention to “green chemistry”. As the demand for access to increasingly complex chemical space grows, so will the demand for innovative synthetic technologies that will drive creative, artistic, and efficient approaches to these challenging, therapeutically important molecules.</div></div><div class="NLM_back"><div class="NLM_notes" id="notes1"><p class="first last">The authors declare no competing financial interest.</p></div><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.1c00208" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15344" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15344" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christopher J. O’Donnell</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Worldwide Research and Development, 445 Eastern Point Road, Groton, Connecticut 06340, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1004-7139" title="Orcid link">http://orcid.org/0000-0003-1004-7139</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#33505b415a40475c435b56411d591d5c575c5d5d565f5f7343555a4956411d505c5e"><span class="__cf_email__" data-cfemail="64070c160d17100b140c01164a0e4a0b000b0a0a0108082414020d1e01164a070b09">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrew C. Flick</span> - <span class="hlFld-Affiliation affiliation">Takeda
Pharmaceuticals, 9625 Towne Centre Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carolyn A. Leverett</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Worldwide Research and Development, 445 Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hong X. Ding</span> - <span class="hlFld-Affiliation affiliation">Pharmacodia
(Beijing) Co., Ltd., Beijing 100085, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Emma McInturff</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Worldwide Research and Development, 445 Eastern Point Road, Groton, Connecticut 06340, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0426-3089" title="Orcid link">http://orcid.org/0000-0003-0426-3089</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sarah J. Fink</span> - <span class="hlFld-Affiliation affiliation">Takeda
Pharmaceuticals, 125 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Subham Mahapatra</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Worldwide Research and Development, 445 Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniel W. Carney</span> - <span class="hlFld-Affiliation affiliation">Takeda
Pharmaceuticals, 9625 Towne Centre Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Erick A. Lindsey</span> - <span class="hlFld-Affiliation affiliation">Takeda
Pharmaceuticals, 9625 Towne Centre Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jacob C. DeForest</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Worldwide Research and Development, 10777 Science Center Drive, San Diego, California 92121, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0316-6685" title="Orcid link">http://orcid.org/0000-0002-0316-6685</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Scott P. France</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Worldwide Research and Development, 445 Eastern Point Road, Groton, Connecticut 06340, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1679-6165" title="Orcid link">http://orcid.org/0000-0003-1679-6165</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Simon Berritt</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Worldwide Research and Development, 445 Eastern Point Road, Groton, Connecticut 06340, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5572-6771" title="Orcid link">http://orcid.org/0000-0001-5572-6771</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Simone V. Bigi-Botterill</span> - <span class="hlFld-Affiliation affiliation">Takeda
Pharmaceuticals, 9625 Towne Centre Drive, San Diego, California 92121, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1309-2314" title="Orcid link">http://orcid.org/0000-0003-1309-2314</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tony S. Gibson</span> - <span class="hlFld-Affiliation affiliation">Takeda
Pharmaceuticals, 9625 Towne Centre Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yiyang Liu</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Worldwide Research and Development, 445 Eastern Point Road, Groton, Connecticut 06340, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><p>The authors declare no competing financial interest.<br /></br></p></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23608" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23608" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="64" class="article__inlineFigure"><h2 class="fig-label">Andrew C. Flick</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=BIO-d7e4564-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Andrew C. Flick</b> earned a B.A. in Chemistry from Lake Forest College. After brief appointments at Abbott Laboratories and Array BioPharma, he joined Professor Albert Padwa’s laboratory at Emory University in Atlanta, GA. After obtaining his Ph.D. in organic chemistry in 2008, he joined Pfizer, where he was involved with numerous medicinal chemistry projects within the Neurosciences, Rare Diseases, and Inflammation & Immunology therapeutic areas. As a team leader, his contributions led to the discovery of the transcription factor inhibitor PF-06763809, which is currently undergoing Phase I trials for the treatment of psoriasis. He recently joined Takeda’s Gastroenterology Drug Discovery Unit and has authored over 40 peer-reviewed publications and patents.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="65" class="article__inlineFigure"><h2 class="fig-label">Carolyn A. Leverett</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=BIO-d7e4569-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Carolyn A. Leverett</b> began her career at Pfizer in 2012, focusing on the development of microtubule-inhibitor-based payloads for use as antibody–drug conjugates. After working for several years in the area of targeted protein degradation, she currently works in the Applied Synthesis Technology group at Pfizer, where she leads the miniaturized Parallel Medicinal Chemistry (PMC) group, supporting all of the major medicinal chemistry therapeutic areas in the Pfizer portfolio. She is a native of North Carolina and obtained her B.S. in Chemistry from North Carolina State University. She completed her doctoral studies with Professor Albert Padwa at Emory University, working on total syntheses of several piperidine-based natural products and the alkaloid minfiensine. Prior to joining Pfizer, she was a postdoctoral fellow working with Professor Daniel Romo at Texas A&M University, exploring new applications of nucleophile-catalyzed aldol lactonization reactions.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="66" class="article__inlineFigure"><h2 class="fig-label">Hong X. Ding</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=BIO-d7e4574-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Hong X. Ding</b> obtained a B.S. in Pharmaceutics in 2001 and a Ph.D. in Medicinal Chemistry in 2006 from Zhejiang University in Hangzhou, China. She is the cofounder and Chief Executive Officer of Pharmacodia, a company founded in 2013 that is an online platform providing data and information service in the pharmaceutical R&D field. In 2010–2013, she worked with Shenogen Pharma Group, a China-based biotech company. As senior director of the R&D department, she was responsible for the CMC development of a novel ER-α-36-targeted Phase II candidate drug named icaritin (SNG162) and the discovery and development of second-generation small molecules based on the structure optimization of SNG162. Before joining Shenogen, she worked at BioDuro starting in 2006 as a senior group leader and senior research scientist.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="67" class="article__inlineFigure"><h2 class="fig-label">Emma McInturff</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=BIO-d7e4579-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Emma McInturff</b> obtained a B.S. in Chemistry from Boise State University and a Ph.D. from the University of Texas at Austin, working in the laboratory of Professor Michael Krische on ruthenium-catalyzed carbonyl addition methodology development. She joined the Pfizer Process Chemistry group in Groton, CT, in 2014.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="68" class="article__inlineFigure"><h2 class="fig-label">Sarah J. Fink</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=BIO-d7e4584-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Sarah J. Fink</b> obtained a B.A. in Chemistry and English Literature from Williams College followed by a Ph.D. in Organic Chemistry from the University of Cambridge with Professor Ian Paterson. Her thesis work focused on the total synthesis of aplyronine C. After a fellowship for young international scientists at Shanghai Institute of Materia Medica, she joined BioDuro in Shanghai in 2014, where she was a chemistry group leader for integrated drug discovery projects in multiple therapeutic areas. She relocated to Boston with BioDuro in 2017, where she was an associate director for integrated programs. She joined Takeda’s Rare Disease Drug Discovery Unit as an NCE program lead in early 2020.</p></figure></div><div class="bio" rid="ath6"><figure id="ath6" data-index="69" class="article__inlineFigure"><h2 class="fig-label">Subham Mahapatra</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=BIO-d7e4589-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Subham Mahapatra</b> received his M.Sc. in Chemistry from Indian Institute of Technology in Mumbai and earned his Ph.D. from Oregon State University in Corvallis, OR, where he completed the first total syntheses of the natural products amphidinolide C and F. Subsequently, his postdoctoral research with Professor Barry Trost at Stanford University was focused on the development of a new C–H activation method for the generation of aza π-allyl intermediates. Later, he joined the laboratory of Professor Seth Herzon at Yale University, where he worked on the total synthesis of lomaiviticin A. He joined Pfizer in 2017 and currently is a Senior Scientist (medicinal chemistry) in the Internal Medicine Department, where his research focuses on cardiovascular and metabolic disease areas.</p></figure></div><div class="bio" rid="ath7"><figure id="ath7" data-index="70" class="article__inlineFigure"><h2 class="fig-label">Daniel W. Carney</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=BIO-d7e4594-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Daniel W. Carney</b> earned a B.S. in Chemistry from Worcester Polytechnic Institute in 2009 and a Ph.D. in Chemistry from Brown University in 2014, working in the laboratory of Jason Sello on acyldepsipeptide (ADEP) antibiotics and other anti-infective small molecules. He worked as a postdoctoral researcher in the laboratory of Dale Boger at Scripps Research in La Jolla, CA, on the synthesis of vinca alkaloids before joining Ferring Pharmaceuticals in 2016, where he worked on peptide-based antibiotics. He joined Takeda Pharmaceuticals in 2018, where he is currently a senior scientist on the GI chemistry team.</p></figure></div><div class="bio" rid="ath8"><figure id="ath8" data-index="71" class="article__inlineFigure"><h2 class="fig-label">Erick A. Lindsey</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=BIO-d7e4599-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Erick A. Lindsey</b> obtained his B.S. in Chemistry from Grand Valley State University and a Ph.D. in Chemistry from North Carolina State University under the guidance of Christian Melander. Following postdoctoral studies in Dale Boger’s lab, he joined Arcus Biosciences and contributed to the discovery of AB680, a small-molecule CD73 inhibitor currently in Phase I studies. He joined Takeda in 2019 and is currently involved with multiple medicinal chemistry projects within the Gastroenterology Drug Discovery Unit.</p></figure></div><div class="bio" rid="ath9"><figure id="ath9" data-index="72" class="article__inlineFigure"><h2 class="fig-label">Jacob C. DeForest</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=BIO-d7e4604-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Jacob C. DeForest</b> received his B.A. in Chemistry from Pepperdine University under the supervision of Professor Matt Joyner in 2012. He completed his Ph.D. in Chemistry at the University of California, Irvine, in 2017, working with Professor Scott Rychnovsky on the total synthesis of alkaloid natural products. He joined the Pfizer Process Chemistry group in Groton, CT, in 2017 and then transitioned to the Oncology Medicinal Chemistry team in La Jolla, CA, in 2020.</p></figure></div><div class="bio" rid="ath10"><figure id="ath10" data-index="73" class="article__inlineFigure"><h2 class="fig-label">Scott P. France</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=BIO-d7e4609-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Scott P. France</b> obtained his M.Chem. in Chemistry at the University of Manchester and then earned his Ph.D. working with Professor Nicholas J. Turner at the Manchester Institute of Biotechnology. His thesis focused on the development and application of the imine reductase enzyme platform for chiral amine synthesis and biocatalytic cascades. He joined Pfizer in 2017, working in the Applied Synthesis Technologies group, enabling biocatalytic synthetic processes to accelerate the delivery of Pfizer’s medicinal chemistry portfolio.</p></figure></div><div class="bio" rid="ath11"><figure id="ath11" data-index="74" class="article__inlineFigure"><h2 class="fig-label">Simon Berritt</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=BIO-d7e4614-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Simon Berritt</b> attended the University of Sussex in the U.K., where he received his B.Sc. in 2004 and his Ph.D. in Chemistry in 2007 under the supervision of Prof. Philip J. Parsons and Dr. Clive S. Penkett. He then moved to the U.S. and served as a postdoctoral fellow at the University of Pennsylvania after a brief stint as a collaborative GOALI Postdoctoral Fellow with Merck & Co. and the University of Pennsylvania. He spent the next 8 years working as Director of the Center for High Throughput Experimentation at the University of Pennsylvania. He recently joined the Applied Synthesis Technologies group at Pfizer in Groton, CT.</p></figure></div><div class="bio" rid="ath12"><figure id="ath12" data-index="75" class="article__inlineFigure"><h2 class="fig-label">Simone V. Bigi-Botterill</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=BIO-d7e4620-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Simone V. Bigi-Botterill</b> obtained a B.S. in Biochemistry from the University of Notre Dame and a M.A.S. in Clinical Research with a concentration in Translational Sciences from the University of California, San Diego. Research for her thesis focused on identification of a gene signature specific to TBK1-driven pathways in patients that did not respond to the anti-TNFα therapeutics etanercept and adalimumab. After a brief stint at Scripps Institution of Oceanography working under Professor William Gerwick in natural product isolation and total synthesis, she joined Takeda in 2012 as a medicinal chemist. Currently she works within the Gastroenterology Drug Discovery Unit, focusing on structure-based drug design of small-molecule therapeutics for a variety of gastrointestinal-related disease pathologies.</p></figure></div><div class="bio" rid="ath13"><figure id="ath13" data-index="76" class="article__inlineFigure"><h2 class="fig-label">Tony S. Gibson</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=BIO-d7e4625-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Tony S. Gibson</b> received his B.S. in Chemistry from the University of California, San Diego in 1997, and after working briefly in the biotech industry, he earned an M.S. in Organic Chemistry from Kansas State University in 2002 and later an M.P.H. in Biostatistics from San Diego State University in 2017. He joined Takeda in 2009, working as a medicinal chemist first in the Inflammation Drug Discovery Unit and currently in the Gastroenterology Drug Discovery Unit as a Senior Scientist.</p></figure></div><div class="bio" rid="ath14"><figure id="ath14" data-index="77" class="article__inlineFigure"><h2 class="fig-label">Yiyang Liu</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=BIO-d7e4630-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Yiyang Liu</b> was born in Hefei, China. He obtained his Ph.D. in Chemistry at Caltech under the supervision of Prof. Brian Stoltz. After postdoctoral studies with Prof. Adam Matzger at the University of Michigan, he joined Pfizer in May 2017 as a Senior Scientist in Process Chemistry, where he was recently promoted to Principal Scientist.</p></figure></div><div class="bio" rid="ath15"><figure id="ath15" data-index="78" class="article__inlineFigure"><h2 class="fig-label">Christopher J. O’Donnell</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=BIO-d7e4635-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Christopher J. O’Donnell</b> obtained a B.S. in Chemistry from the University of Illinois at Urbana–Champaign and a Ph.D. in Organic Chemistry from the University of Wisconsin, Madison. After postdoctoral research at the University of California, Irvine, he joined Pfizer in 1999 in the Neuroscience Medicinal Chemistry group. As a scientist, project leader, and manager in these areas, he has led project teams to the nomination of over 10 clinical candidates. In 2010, he moved to the Oncology Medicinal Chemistry group to build the Antibody–Drug Conjugate Chemistry group, and his team has nominated 11 conjugates for clinical development. In 2018, he moved to the Pfizer Ventures team, where he makes and manages equity investments for Pfizer. He is an author/inventor of 75 peer-reviewed journal articles and patent applications.</p></figure></div><div class="ack" id="ACK-d7e4640-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i130">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00200" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00200" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors thank Steve Woodhead for helpful discussions on erdafitinib and Elizabeth Tanner for assistance in preparing the manuscript.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">Ac</td><td class="NLM_def"><p class="first last">acetyl</p></td></tr><tr><td class="NLM_term">ADDP</td><td class="NLM_def"><p class="first last">1,1′-(azodicarbonyl)dipiperidine</p></td></tr><tr><td class="NLM_term">AIBN</td><td class="NLM_def"><p class="first last">2,2-azobis(isobutyronitrile)</p></td></tr><tr><td class="NLM_term">aq</td><td class="NLM_def"><p class="first last">aqueous</p></td></tr><tr><td class="NLM_term">BHT</td><td class="NLM_def"><p class="first last">butylated hydroxytoluene</p></td></tr><tr><td class="NLM_term">BINAP</td><td class="NLM_def"><p class="first last">2,2-bis(diphenylphosphino)-1,1-dinaphthalene</p></td></tr><tr><td class="NLM_term">Bn</td><td class="NLM_def"><p class="first last">benzyl</p></td></tr><tr><td class="NLM_term">Boc</td><td class="NLM_def"><p class="first last"><i>N</i>-<i>tert</i>-butoxycarbonyl</p></td></tr><tr><td class="NLM_term">2,2-bpy</td><td class="NLM_def"><p class="first last">2,2-bipyridyl</p></td></tr><tr><td class="NLM_term">BSA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>O</i>-bis(trimethylsilyl)acetamide</p></td></tr><tr><td class="NLM_term">BTBAC</td><td class="NLM_def"><p class="first last">benzyltributylammonium chloride</p></td></tr><tr><td class="NLM_term">Bu</td><td class="NLM_def"><p class="first last">butyl</p></td></tr><tr><td class="NLM_term"><i>n</i>-Bu</td><td class="NLM_def"><p class="first last"><i>n</i>-butyl</p></td></tr><tr><td class="NLM_term">TTBP·HBF<sub>4</sub></td><td class="NLM_def"><p class="first last">tri-<i>tert</i>-butylphosphonium tetrafluoroborate</p></td></tr><tr><td class="NLM_term">cat.</td><td class="NLM_def"><p class="first last">catalytic</p></td></tr><tr><td class="NLM_term">Cbz</td><td class="NLM_def"><p class="first last">benzyloxycarbonyl</p></td></tr><tr><td class="NLM_term">CDI</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-carbonyldiimidazole</p></td></tr><tr><td class="NLM_term">COD</td><td class="NLM_def"><p class="first last">1,5-cyclooctadiene</p></td></tr><tr><td class="NLM_term">conc</td><td class="NLM_def"><p class="first last">concentrated</p></td></tr><tr><td class="NLM_term">CPME</td><td class="NLM_def"><p class="first last">cyclopentyl methyl ether</p></td></tr><tr><td class="NLM_term">CSA</td><td class="NLM_def"><p class="first last">camphorsulfonic acid</p></td></tr><tr><td class="NLM_term">Cy</td><td class="NLM_def"><p class="first last">cyclohexyl</p></td></tr><tr><td class="NLM_term">dba</td><td class="NLM_def"><p class="first last">dibenzylideneacetone</p></td></tr><tr><td class="NLM_term">DBDMH</td><td class="NLM_def"><p class="first last">1,3-dibromo-5,5-dimethylhydantoin</p></td></tr><tr><td class="NLM_term">DBTA</td><td class="NLM_def"><p class="first last">dibenzoyltartaric acid</p></td></tr><tr><td class="NLM_term">DBU</td><td class="NLM_def"><p class="first last">1,8-diazabicyclo[5.4.0]undec-7-ene</p></td></tr><tr><td class="NLM_term">DCC</td><td class="NLM_def"><p class="first last">1,3-dicyclohexylcarbodiimide</p></td></tr><tr><td class="NLM_term">DCE</td><td class="NLM_def"><p class="first last">dichloroethane</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DCPP</td><td class="NLM_def"><p class="first last">2,3-dichlorophenylpiperazine</p></td></tr><tr><td class="NLM_term">de</td><td class="NLM_def"><p class="first last">diastereomeric excess</p></td></tr><tr><td class="NLM_term">DEPC</td><td class="NLM_def"><p class="first last">diethylpyrocarbonate</p></td></tr><tr><td class="NLM_term">dr</td><td class="NLM_def"><p class="first last">diastereomeric ratio</p></td></tr><tr><td class="NLM_term">DIBAL</td><td class="NLM_def"><p class="first last">diisobutylaluminum hydride</p></td></tr><tr><td class="NLM_term">DIC</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylcarbodiimide</p></td></tr><tr><td class="NLM_term">DIPE</td><td class="NLM_def"><p class="first last">diisopropyl ether</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last">diisopropylethylamine</p></td></tr><tr><td class="NLM_term">DIP-Cl</td><td class="NLM_def"><p class="first last">2,6-bis(bis(2-chloroethyl)amino)-4,8-dipiperidinopyrimido(5,4-<i>d</i>)pyrimidine</p></td></tr><tr><td class="NLM_term">DMA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylacetamide</p></td></tr><tr><td class="NLM_term">DMAP</td><td class="NLM_def"><p class="first last">4-(dimethylamino)pyridine</p></td></tr><tr><td class="NLM_term">DME</td><td class="NLM_def"><p class="first last">1,2-dimethoxyethane</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">DMF–DMA</td><td class="NLM_def"><p class="first last">dimethylformamide–dimethylacetal</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">DPPA</td><td class="NLM_def"><p class="first last">diphenylphosphoryl azide</p></td></tr><tr><td class="NLM_term">dppb</td><td class="NLM_def"><p class="first last">1,4-bis(diphenylphosphino)butane</p></td></tr><tr><td class="NLM_term">dppf</td><td class="NLM_def"><p class="first last">1,1′-ferrocenediylbis(diphenylphosphine)</p></td></tr><tr><td class="NLM_term">dtbpf</td><td class="NLM_def"><p class="first last">1,1′-bis(di-<i>tert</i>-butylphosphino)ferrocene</p></td></tr><tr><td class="NLM_term">DTT</td><td class="NLM_def"><p class="first last">dithiothreitol</p></td></tr><tr><td class="NLM_term">EDCI</td><td class="NLM_def"><p class="first last"><i>N</i>-(3-dimethylaminopropal)-<i>N</i>-ethylcarbodiimide</p></td></tr><tr><td class="NLM_term">ee</td><td class="NLM_def"><p class="first last">enantiomeric excess</p></td></tr><tr><td class="NLM_term">EEDQ</td><td class="NLM_def"><p class="first last">2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline</p></td></tr><tr><td class="NLM_term">Et</td><td class="NLM_def"><p class="first last">ethyl</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last">1-[bis(dimethylamino)methylene]-1<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]pyridinium 3-oxide hexafluorophosphate</p></td></tr><tr><td class="NLM_term">HBTU</td><td class="NLM_def"><p class="first last">(2-(1<i>H</i>-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate</p></td></tr><tr><td class="NLM_term">Hex</td><td class="NLM_def"><p class="first last">hexyl</p></td></tr><tr><td class="NLM_term">nHex</td><td class="NLM_def"><p class="first last"><i>n</i>-hexyl</p></td></tr><tr><td class="NLM_term">HMDS</td><td class="NLM_def"><p class="first last">hexamethyldisilazane</p></td></tr><tr><td class="NLM_term">HOAc</td><td class="NLM_def"><p class="first last">acetic acid</p></td></tr><tr><td class="NLM_term">HOAt</td><td class="NLM_def"><p class="first last">1-hydroxy-7-azabenzotriazole</p></td></tr><tr><td class="NLM_term">HOBt</td><td class="NLM_def"><p class="first last">1-hydroxybenzotriazole hydrate</p></td></tr><tr><td class="NLM_term">HOPO</td><td class="NLM_def"><p class="first last">2-hydroxypyridine 1-oxide</p></td></tr><tr><td class="NLM_term"><i>i</i>-Pr</td><td class="NLM_def"><p class="first last">isopropyl</p></td></tr><tr><td class="NLM_term">IPA</td><td class="NLM_def"><p class="first last">isopropyl acetate</p></td></tr><tr><td class="NLM_term"><i>i</i>-PrOH</td><td class="NLM_def"><p class="first last">isopropyl alcohol</p></td></tr><tr><td class="NLM_term">KOTMS</td><td class="NLM_def"><p class="first last">potassium trimethylsilanolate</p></td></tr><tr><td class="NLM_term">LAH</td><td class="NLM_def"><p class="first last">lithium aluminum hydride</p></td></tr><tr><td class="NLM_term">LHMDS</td><td class="NLM_def"><p class="first last">lithium bis(trimethylsilyl)amide</p></td></tr><tr><td class="NLM_term">LDA</td><td class="NLM_def"><p class="first last">lithium diisopropylamide</p></td></tr><tr><td class="NLM_term">mCPBA</td><td class="NLM_def"><p class="first last">3-chloroperoxybenzoic acid</p></td></tr><tr><td class="NLM_term">Me</td><td class="NLM_def"><p class="first last">methyl</p></td></tr><tr><td class="NLM_term">MeCN</td><td class="NLM_def"><p class="first last">acetonitrile</p></td></tr><tr><td class="NLM_term">MEK</td><td class="NLM_def"><p class="first last">methyl ethyl ketone</p></td></tr><tr><td class="NLM_term">MeTHF</td><td class="NLM_def"><p class="first last">2-methyltetrahydrofuran</p></td></tr><tr><td class="NLM_term">MIBK</td><td class="NLM_def"><p class="first last">methyl isobutyl ketone</p></td></tr><tr><td class="NLM_term">MMAE</td><td class="NLM_def"><p class="first last">monomethyl auristatin E</p></td></tr><tr><td class="NLM_term">Ms</td><td class="NLM_def"><p class="first last">methylsulfonyl, mesyl</p></td></tr><tr><td class="NLM_term">MS</td><td class="NLM_def"><p class="first last">molecular sieves</p></td></tr><tr><td class="NLM_term">MTBE</td><td class="NLM_def"><p class="first last">methyl <i>tert</i>-butyl ether</p></td></tr><tr><td class="NLM_term"><i>n</i>-Pr</td><td class="NLM_def"><p class="first last"><i>n</i>-propyl</p></td></tr><tr><td class="NLM_term">NADP</td><td class="NLM_def"><p class="first last">nicotinamide adenine dinucleotide phosphate</p></td></tr><tr><td class="NLM_term">NADPNa</td><td class="NLM_def"><p class="first last">sodium nicotinamide adenine dinucleotide phosphate</p></td></tr><tr><td class="NLM_term">NBS</td><td class="NLM_def"><p class="first last"><i>N</i>-bromosuccinimide</p></td></tr><tr><td class="NLM_term">NIS</td><td class="NLM_def"><p class="first last"><i>N</i>-iodosuccinimide</p></td></tr><tr><td class="NLM_term">NMM</td><td class="NLM_def"><p class="first last"><i>N</i>-methylmorpholine</p></td></tr><tr><td class="NLM_term">NMO</td><td class="NLM_def"><p class="first last"><i>N</i>-methylmorpholine <i>N</i>-oxide</p></td></tr><tr><td class="NLM_term">NMP</td><td class="NLM_def"><p class="first last"><i>N</i>-methyl-2-pyrrolidone</p></td></tr><tr><td class="NLM_term">PBS</td><td class="NLM_def"><p class="first last">phosphate-buffered saline</p></td></tr><tr><td class="NLM_term">PCC</td><td class="NLM_def"><p class="first last">pyridinium chlorochromate</p></td></tr><tr><td class="NLM_term">Ph</td><td class="NLM_def"><p class="first last">phenyl</p></td></tr><tr><td class="NLM_term">PhCH<sub>3</sub></td><td class="NLM_def"><p class="first last">toluene</p></td></tr><tr><td class="NLM_term">Pin</td><td class="NLM_def"><p class="first last">pinacolato</p></td></tr><tr><td class="NLM_term">PLP</td><td class="NLM_def"><p class="first last">pyridoxal 5′-phosphate hydrate</p></td></tr><tr><td class="NLM_term">POSF</td><td class="NLM_def"><p class="first last">perfluoro-1-octanesulfonyl fluoride</p></td></tr><tr><td class="NLM_term">PPA</td><td class="NLM_def"><p class="first last">polyphosphoric acid</p></td></tr><tr><td class="NLM_term">PPTS</td><td class="NLM_def"><p class="first last">pyridinium <i>p</i>-toluenesulfonate</p></td></tr><tr><td class="NLM_term"><i>p</i>-TsOH</td><td class="NLM_def"><p class="first last"><i>p</i>-toluenesulfonic acid</p></td></tr><tr><td class="NLM_term">py</td><td class="NLM_def"><p class="first last">pyridine</p></td></tr><tr><td class="NLM_term">rt</td><td class="NLM_def"><p class="first last">room temperature</p></td></tr><tr><td class="NLM_term">Su</td><td class="NLM_def"><p class="first last">succinimide</p></td></tr><tr><td class="NLM_term">SFC</td><td class="NLM_def"><p class="first last">supercritical fluid chromatography</p></td></tr><tr><td class="NLM_term">T3P</td><td class="NLM_def"><p class="first last">1-propanephosphonic acid cyclic</p></td></tr><tr><td class="NLM_term">TBA</td><td class="NLM_def"><p class="first last">tributylamine</p></td></tr><tr><td class="NLM_term">TBAB</td><td class="NLM_def"><p class="first last">tetrabutylammonium bromide</p></td></tr><tr><td class="NLM_term">TBAC</td><td class="NLM_def"><p class="first last">tetrabutylammonium chloride</p></td></tr><tr><td class="NLM_term">TBAF</td><td class="NLM_def"><p class="first last">tetrabutylammonium fluoride</p></td></tr><tr><td class="NLM_term">TBHQ</td><td class="NLM_def"><p class="first last"><i>tert</i>-butyl hydroquinone</p></td></tr><tr><td class="NLM_term">TBAHS</td><td class="NLM_def"><p class="first last">tetrabutylammonium hydrogen sulfate</p></td></tr><tr><td class="NLM_term">TBAI</td><td class="NLM_def"><p class="first last">tetrabutylammonium iodide</p></td></tr><tr><td class="NLM_term">TBS</td><td class="NLM_def"><p class="first last"><i>tert</i>-butyldimethylsilyl</p></td></tr><tr><td class="NLM_term">TBTU</td><td class="NLM_def"><p class="first last"><i>O</i>-(benzotriazol-1-yl)-<i>N</i>,<i>N</i>,<i>N</i>,<i>N</i>-tetramethyluronium tetrafluoroborate</p></td></tr><tr><td class="NLM_term"><i>t</i>-Bu</td><td class="NLM_def"><p class="first last"><i>tert</i>-butyl</p></td></tr><tr><td class="NLM_term">TEA</td><td class="NLM_def"><p class="first last">triethylamine</p></td></tr><tr><td class="NLM_term">TEMPO</td><td class="NLM_def"><p class="first last">2,2,6,6-tetramethylpiperidin-1-oxyl</p></td></tr><tr><td class="NLM_term">Tf</td><td class="NLM_def"><p class="first last">triflic, trifluoromethanesulfonyl</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">TFAA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid anhydride</p></td></tr><tr><td class="NLM_term">TFE</td><td class="NLM_def"><p class="first last">2,2,2-trifluoroethanol</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">THP</td><td class="NLM_def"><p class="first last">tetrahydropyranyl</p></td></tr><tr><td class="NLM_term">TMA</td><td class="NLM_def"><p class="first last">trimethylamine</p></td></tr><tr><td class="NLM_term">TMEDA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>,<i>N</i>,<i>N</i>-tetramethylethylenediamine</p></td></tr><tr><td class="NLM_term">TMP</td><td class="NLM_def"><p class="first last">tetramethylpiperidine</p></td></tr><tr><td class="NLM_term">TMS</td><td class="NLM_def"><p class="first last">trimethylsilyl</p></td></tr><tr><td class="NLM_term">Tr</td><td class="NLM_def"><p class="first last">trityl, triphenylmethyl</p></td></tr><tr><td class="NLM_term">Ts</td><td class="NLM_def"><p class="first last"><i>p</i>-toluenesulfonyl</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i132">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78602" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78602" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 225 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K. C.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2002 New Drugs</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">233</span>, <span class="refDoi"> DOI: 10.2174/1389557043487457</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.2174%2F1389557043487457" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=14965293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhvVWgu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=207-233&author=J.+Liauthor=K.+K.+C.+Liu&title=Synthetic+Approaches+to+the+2002+New+Drugs&doi=10.2174%2F1389557043487457"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2002 new drugs</span></div><div class="casAuthors">Li, Jin; Liu, Kevin K.-C.</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">207-233</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  In addn., these new chem. entities (NCEs) not only provide insights into mol. recognition, but also serve as drug-like leads for designing future new drugs.  Therefore, it is important to be acquainted with these new structures as well as their syntheses.  To these ends, this review covers the syntheses of 28 NCEs marketed in 2002.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGx8Y2c3smk7Vg90H21EOLACvtfcHk0ljTJ-u4ELzdeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhvVWgu7c%253D&md5=d93f443a242964b39e822ecb12ddacad</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.2174%2F1389557043487457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389557043487457%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DK.%2BK.%2BC.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202002%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2004%26volume%3D4%26spage%3D207%26epage%3D233%26doi%3D10.2174%2F1389557043487457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit1b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2004 New Drugs</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1133</span>– <span class="NLM_lpage">1144</span>, <span class="refDoi"> DOI: 10.2174/138955705774933329</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.2174%2F138955705774933329" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=16375759" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Gru77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=1133-1144&author=J.+Liauthor=K.+K.+C.+Liuauthor=S.+Sakya&title=Synthetic+Approaches+to+the+2004+New+Drugs&doi=10.2174%2F138955705774933329"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2004 new drugs</span></div><div class="casAuthors">Li, Jin; Liu, Kevin K.-C.; Sakya, Subas</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1133-1144</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  In addn., these new chem. entities (NCEs) not only provide insights into mol. recognition, but also serve as leads for designing future drugs.  To this end, this review covers the syntheses of 12 NCEs marketed in 2004, such as azacitidine, duloxetine hydrochloride, etc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbXh0-pEnN47Vg90H21EOLACvtfcHk0liod-OcAgV_0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Gru77P&md5=9593b6bfb38f08160e1b198f53b70a53</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.2174%2F138955705774933329&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955705774933329%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DK.%2BK.%2BC.%26aulast%3DSakya%26aufirst%3DS.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202004%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2005%26volume%3D5%26spage%3D1133%26epage%3D1144%26doi%3D10.2174%2F138955705774933329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit1c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2003 New Drugs</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1105</span>– <span class="NLM_lpage">1125</span>, <span class="refDoi"> DOI: 10.2174/1389557043402900</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.2174%2F1389557043402900" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=15579116" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVWitbfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=1105-1125&author=K.+K.-C.+Liuauthor=J.+Liauthor=S.+Sakya&title=Synthetic+Approaches+to+the+2003+New+Drugs&doi=10.2174%2F1389557043402900"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1cR"><div class="casContent"><span class="casTitleNuber">1c</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2003 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Li, Jin; Sakya, Subas</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1105-1125</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  In addn., these new chem. entities (NCEs) not only provide insights into mol. recognition, but also serve as drug-like leads for designing new future drugs.  To these ends, this review covers the syntheses of 23 NCEs marketed in 2003.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLauPqC1hEzbVg90H21EOLACvtfcHk0liod-OcAgV_0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVWitbfO&md5=f3f6acd4fefd93ede895369105d1cefb</span></div><a href="/servlet/linkout?suffix=cit1c&amp;dbid=16384&amp;doi=10.2174%2F1389557043402900&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389557043402900%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DSakya%26aufirst%3DS.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202003%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2004%26volume%3D4%26spage%3D1105%26epage%3D1125%26doi%3D10.2174%2F1389557043402900" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit1d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K. C.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2005 New Drugs</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">429</span>– <span class="NLM_lpage">450</span>, <span class="refDoi"> DOI: 10.2174/138955707780363800</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.2174%2F138955707780363800" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=17430228" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BD2sXivV2hu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=429-450&author=S.+M.+Sakyaauthor=J.+Liauthor=K.+K.+C.+Liu&title=Synthetic+Approaches+to+the+2005+New+Drugs&doi=10.2174%2F138955707780363800"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1dR"><div class="casContent"><span class="casTitleNuber">1d</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2005 new drugs</span></div><div class="casAuthors">Sakya, Subas M.; Li, Jin; Liu, Kevin K.-C.</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">429-450</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  In addn., these new chem. entities (NCEs) not only provide insights into mol. recognition, but also serve as drug-like leads for designing future new drugs.  To these ends, this review covers the syntheses of 22 NCEs marketed in 2005.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpk_TvNK-ZG2LVg90H21EOLACvtfcHk0liod-OcAgV_0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXivV2hu7g%253D&md5=cdbab18a11647fe6089fc6c6ded6ede9</span></div><a href="/servlet/linkout?suffix=cit1d&amp;dbid=16384&amp;doi=10.2174%2F138955707780363800&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955707780363800%26sid%3Dliteratum%253Aachs%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DK.%2BK.%2BC.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202005%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2007%26volume%3D7%26spage%3D429%26epage%3D450%26doi%3D10.2174%2F138955707780363800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit1e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2006 New Drugs</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1255</span>– <span class="NLM_lpage">1269</span>, <span class="refDoi"> DOI: 10.2174/138955707782795629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.2174%2F138955707782795629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=18220978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlKktr7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=1255-1269&author=K.+K.+C.+Liuauthor=S.+M.+Sakyaauthor=J.+Li&title=Synthetic+Approaches+to+the+2006+New+Drugs&doi=10.2174%2F138955707782795629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1eR"><div class="casContent"><span class="casTitleNuber">1e</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2006 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Sakya, Subas M.; Li, Jin</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1255-1269</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  In addn., these new chem. entities (NCEs) not only provide insights into mol. recognition, but also serve as drug-like leads for designing future new drugs.  To these ends, this review covers the syntheses of 16 NCEs marketed in 2006.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpX9HJKV9Z-pLVg90H21EOLACvtfcHk0liod-OcAgV_0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlKktr7K&md5=4d0a4be2d4e258c11f73792380a40078</span></div><a href="/servlet/linkout?suffix=cit1e&amp;dbid=16384&amp;doi=10.2174%2F138955707782795629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955707782795629%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.%2BC.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202006%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2007%26volume%3D7%26spage%3D1255%26epage%3D1269%26doi%3D10.2174%2F138955707782795629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit1f"><span><span class="NLM_label">(f) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2007 New Drugs</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1526</span>– <span class="NLM_lpage">1548</span>, <span class="refDoi"> DOI: 10.2174/138955708786786435</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.2174%2F138955708786786435" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=19075810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptFagtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=1526-1548&author=K.+K.+C.+Liuauthor=S.+M.+Sakyaauthor=C.+J.+O%E2%80%99Donnellauthor=J.+Li&title=Synthetic+Approaches+to+the+2007+New+Drugs&doi=10.2174%2F138955708786786435"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1fR"><div class="casContent"><span class="casTitleNuber">1f</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2007 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Sakya, Subas M.; O'Donnell, Christopher J.; Li, Jin</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1526-1548</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">This review covers the syntheses of 19 new chem. entities (NCEs) marketed in 2007.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  These NCEs provide insights into mol. recognition and also serve as leads for designing future new drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb2ujHwEzjb7Vg90H21EOLACvtfcHk0li8qmdrsPtvBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptFagtw%253D%253D&md5=b2e378b89f153b6374a4aa375cf65fd7</span></div><a href="/servlet/linkout?suffix=cit1f&amp;dbid=16384&amp;doi=10.2174%2F138955708786786435&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955708786786435%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.%2BC.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202007%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2008%26volume%3D8%26spage%3D1526%26epage%3D1548%26doi%3D10.2174%2F138955708786786435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit1g"><span><span class="NLM_label">(g) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2008 New Drugs</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1655</span>– <span class="NLM_lpage">1675</span>, <span class="refDoi"> DOI: 10.2174/138955709791012201</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.2174%2F138955709791012201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1g&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=20088782" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1g&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmtVygtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=1655-1675&author=K.+K.-C.+Liuauthor=S.+M.+Sakyaauthor=C.+J.+O%E2%80%99Donnellauthor=J.+Li&title=Synthetic+Approaches+to+the+2008+New+Drugs&doi=10.2174%2F138955709791012201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1gR"><div class="casContent"><span class="casTitleNuber">1g</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2008 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Sakya, Subas M.; O'Donnell, Christopher J.; Li, Jin</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1655-1675</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  These new chem. entities (NCEs) provide insights into mol. recognition and also serve as leads for designing future new drugs.  This review covers the syntheses of 18 NCEs marketed in 2008.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozyNqyXXeUK7Vg90H21EOLACvtfcHk0li8qmdrsPtvBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmtVygtL8%253D&md5=7c21b476dd957ab5b90c98502ee0ec2a</span></div><a href="/servlet/linkout?suffix=cit1g&amp;dbid=16384&amp;doi=10.2174%2F138955709791012201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955709791012201%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202008%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2009%26volume%3D9%26spage%3D1655%26epage%3D1675%26doi%3D10.2174%2F138955709791012201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit1h"><span><span class="NLM_label">(h) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2009 New Drugs</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1136</span>– <span class="NLM_lpage">1154</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2010.12.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1h&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2Fj.bmc.2010.12.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1h&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=21256756" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1h&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlKlu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=1136-1154&author=K.+K.+C.+Liuauthor=S.+M.+Sakyaauthor=C.+J.+O%E2%80%99Donnellauthor=A.+C.+Flickauthor=J.+Li&title=Synthetic+Approaches+to+the+2009+New+Drugs&doi=10.1016%2Fj.bmc.2010.12.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1hR"><div class="casContent"><span class="casTitleNuber">1h</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2009 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Sakya, Subas M.; O'Donnell, Christopher J.; Flick, Andrew C.; Li, Jin</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1136-1154</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  These new chem. entities (NCEs) provide insights into mol. recognition and also serve as leads for designing future new drugs.  This review covers the syntheses of 21 NCEs marketed in 2009.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhM07bPdVyP7Vg90H21EOLACvtfcHk0li8qmdrsPtvBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlKlu7Y%253D&md5=132426fbdd026496e573cb26110b559b</span></div><a href="/servlet/linkout?suffix=cit1h&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2010.12.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2010.12.038%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.%2BC.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202009%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2011%26volume%3D19%26spage%3D1136%26epage%3D1154%26doi%3D10.1016%2Fj.bmc.2010.12.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit1i"><span><span class="NLM_label">(i) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2010 New Drugs</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1155</span>– <span class="NLM_lpage">1174</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2011.12.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1i&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2Fj.bmc.2011.12.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1i&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=22261026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1i&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFSnsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=1155-1174&author=K.+K.+C.+Liuauthor=S.+M.+Sakyaauthor=C.+J.+O%E2%80%99Donnellauthor=A.+C.+Flickauthor=H.+X.+Ding&title=Synthetic+Approaches+to+the+2010+New+Drugs&doi=10.1016%2Fj.bmc.2011.12.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1iR"><div class="casContent"><span class="casTitleNuber">1i</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2010 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Sakya, Subas M.; O'Donnell, Christopher J.; Flick, Andrew C.; Ding, Hong X.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1155-1174</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each represents a privileged structure for its biol. target.  These new chem. entities (NCEs) provide insights into mol. recognition and also serve as leads for designing future new drugs.  This review covers the synthesis of 15 NCEs that were launched anywhere in the world in 2010.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpn4x86l05yfrVg90H21EOLACvtfcHk0lhxbH9eSuNCsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFSnsLc%253D&md5=e4a5130168e87de1a00a090241a54412</span></div><a href="/servlet/linkout?suffix=cit1i&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2011.12.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2011.12.049%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.%2BC.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DDing%26aufirst%3DH.%2BX.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202010%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26spage%3D1155%26epage%3D1174%26doi%3D10.1016%2Fj.bmc.2011.12.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit1j"><span><span class="NLM_label">(j) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2011 New Drugs</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2795</span>– <span class="NLM_lpage">2825</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2013.02.061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1j&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2Fj.bmc.2013.02.061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1j&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=23623674" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1j&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmsVCksbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=2795-2825&author=H.+X.+Dingauthor=K.+K.+C.+Liuauthor=S.+M.+Sakyaauthor=A.+C.+Flickauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+the+2011+New+Drugs&doi=10.1016%2Fj.bmc.2013.02.061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1jR"><div class="casContent"><span class="casTitleNuber">1j</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2011 new drugs</span></div><div class="casAuthors">Ding, Hong X.; Liu, Kevin K.-C.; Sakya, Subas M.; Flick, Andrew C.; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2795-2825</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each represents a privileged structure for its biol. target.  These new chem. entities (NCEs) provide insights into mol. recognition and also serve as leads for designing future new drugs.  This review covers the synthesis of 26 NCEs that were launched in the world in 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4leMAGdR_wLVg90H21EOLACvtfcHk0lhxbH9eSuNCsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmsVCksbs%253D&md5=07079afb3ea7459e73455de425e5d756</span></div><a href="/servlet/linkout?suffix=cit1j&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.02.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.02.061%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DLiu%26aufirst%3DK.%2BK.%2BC.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202011%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D2795%26epage%3D2825%26doi%3D10.1016%2Fj.bmc.2013.02.061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit1k"><span><span class="NLM_label">(k) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leverett, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyne, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2012 New Drugs</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">2005</span>– <span class="NLM_lpage">2032</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2014.02.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1k&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2Fj.bmc.2014.02.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1k&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=24629448" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1k&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkt1WhsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=2005-2032&author=H.+X.+Dingauthor=C.+A.+Leverettauthor=R.+E.+Kyneauthor=K.+K.+C.+Liuauthor=S.+M.+Sakyaauthor=A.+C.+Flickauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+the+2012+New+Drugs&doi=10.1016%2Fj.bmc.2014.02.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1kR"><div class="casContent"><span class="casTitleNuber">1k</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2012 new drugs</span></div><div class="casAuthors">Ding, Hong X.; Leverett, Carolyn A.; Kyne, Robert E.; Liu, Kevin K.-C.; Sakya, Subas M.; Flick, Andrew C.; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2005-2032</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs introduced to the market every year represent a privileged structure for a particular biol. target.  These new chem. entities (NCEs) provide insights into mol. recognition and also serve as leads for designing future new drugs.  This review covers the synthesis of twenty-six NCEs that were launched or approved worldwide in 2012 and two addnl. drugs which were launched at the end of 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5C7y-_vIFErVg90H21EOLACvtfcHk0lhxbH9eSuNCsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkt1WhsL0%253D&md5=bb629a07ee4cfa5efe4f8b2ca0003410</span></div><a href="/servlet/linkout?suffix=cit1k&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.02.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.02.017%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DLeverett%26aufirst%3DC.%2BA.%26aulast%3DKyne%26aufirst%3DR.%2BE.%26aulast%3DLiu%26aufirst%3DK.%2BK.%2BC.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202012%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D2005%26epage%3D2032%26doi%3D10.1016%2Fj.bmc.2014.02.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit1l"><span><span class="NLM_label">(l) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leverett, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyne, R. E.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2013 New Drugs</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1895</span>– <span class="NLM_lpage">1922</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2015.02.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1l&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2Fj.bmc.2015.02.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1l&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=25797159" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1l&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC2MXktFKnt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=1895-1922&author=H.+X.+Dingauthor=C.+A.+Leverettauthor=R.+E.+Kyneauthor=K.+K.+C.+Liuauthor=S.+J.+Finkauthor=A.+C.+Flickauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+the+2013+New+Drugs&doi=10.1016%2Fj.bmc.2015.02.056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1lR"><div class="casContent"><span class="casTitleNuber">1l</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2013 new drugs</span></div><div class="casAuthors">Ding, Hong X.; Leverett, Carolyn A.; Kyne, Robert E., Jr.; Liu, Kevin K.-C.; Fink, Sarah J.; Flick, Andrew C.; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1895-1922</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs introduced to the market every year represent privileged structures for particular biol. targets.  These new chem. entities (NCEs) provide insight into mol. recognition and also serve as leads for designing future new drugs.  This annual review covers the synthesis of twenty-four NCEs that were approved for the first time in 2013 and two 2012 drugs which were not covered during the previous edition of this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr83u4l4iyn9LVg90H21EOLACvtfcHk0lhxbH9eSuNCsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXktFKnt7k%253D&md5=b64a1ec20260b828d7f6de0e0a1319b0</span></div><a href="/servlet/linkout?suffix=cit1l&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.02.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.02.056%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DLeverett%26aufirst%3DC.%2BA.%26aulast%3DKyne%26aufirst%3DR.%2BE.%26aulast%3DLiu%26aufirst%3DK.%2BK.%2BC.%26aulast%3DFink%26aufirst%3DS.%2BJ.%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202013%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D1895%26epage%3D1922%26doi%3D10.1016%2Fj.bmc.2015.02.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit1m"><span><span class="NLM_label">(m) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leverett, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyne, R. E.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2014 New Drugs</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1937</span>– <span class="NLM_lpage">1980</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.03.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1m&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2Fj.bmc.2016.03.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1m&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=27020685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1m&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC28Xks1yktr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=1937-1980&author=A.+C.+Flickauthor=H.+X.+Dingauthor=C.+A.+Leverettauthor=R.+E.+Kyneauthor=K.+K.+C.+Liuauthor=S.+J.+Finkauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+the+2014+New+Drugs&doi=10.1016%2Fj.bmc.2016.03.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1mR"><div class="casContent"><span class="casTitleNuber">1m</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2014 new drugs</span></div><div class="casAuthors">Flick, Andrew C.; Ding, Hong X.; Leverett, Carolyn A.; Kyne, Robert E., Jr.; Liu, Kevin K.-C.; Fink, Sarah J.; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1937-1980</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs introduced to the market every year represent privileged structures for particular biol. targets.  These new chem. entities (NCEs) provide insight into mol. recognition and also serve as leads for designing future new drugs.  This annual review covers the synthesis of thirty-seven NCEs that were approved for the first time in 2014 and one drug which was approved in 2013 and was not covered in a previous edition of this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlkq2WCDEAgbVg90H21EOLACvtfcHk0lg0qLVxQW2dhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xks1yktr0%253D&md5=a5ce03081110edb2b616006c73d14650</span></div><a href="/servlet/linkout?suffix=cit1m&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.03.004%26sid%3Dliteratum%253Aachs%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DLeverett%26aufirst%3DC.%2BA.%26aulast%3DKyne%26aufirst%3DR.%2BE.%26aulast%3DLiu%26aufirst%3DK.%2BK.%2BC.%26aulast%3DFink%26aufirst%3DS.%2BJ.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202014%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26spage%3D1937%26epage%3D1980%26doi%3D10.1016%2Fj.bmc.2016.03.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit1n"><span><span class="NLM_label">(n) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leverett, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyne, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the New Drugs Approved During 2015</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">6480</span>– <span class="NLM_lpage">6515</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00010</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00010" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1n&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmt1amsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=6480-6515&author=A.+C.+Flickauthor=H.+X.+Dingauthor=C.+A.+Leverettauthor=R.+E.+Kyneauthor=K.+K.+C.+Liuauthor=S.+J.+Finkauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+the+New+Drugs+Approved+During+2015&doi=10.1021%2Facs.jmedchem.7b00010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1nR"><div class="casContent"><span class="casTitleNuber">1n</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic Approaches to the New Drugs Approved During 2015</span></div><div class="casAuthors">Flick, Andrew C.; Ding, Hong X.; Leverett, Carolyn A.; Kyne, Robert E.; Liu, Kevin K. -C.; Fink, Sarah J.; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6480-6515</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">New drugs introduced to the market every year represent privileged structures for particular biol. targets.  These new chem. entities (NCEs) provide insight into mol. recognition while serving as leads for designing future new drugs.  This annual review describes the most likely process-scale synthetic approaches to 29 new chem. entities (NCEs) that were approved for the first time in 2015.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5OCn9h-Lu07Vg90H21EOLACvtfcHk0lg0qLVxQW2dhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmt1amsrw%253D&md5=b10c1f677c2f4a216b11a4c89e8b3683</span></div><a href="/servlet/linkout?suffix=cit1n&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00010%26sid%3Dliteratum%253Aachs%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DLeverett%26aufirst%3DC.%2BA.%26aulast%3DKyne%26aufirst%3DR.%2BE.%26aulast%3DLiu%26aufirst%3DK.%2BK.%2BC.%26aulast%3DFink%26aufirst%3DS.%2BJ.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%2520New%2520Drugs%2520Approved%2520During%25202015%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D6480%26epage%3D6515%26doi%3D10.1021%2Facs.jmedchem.7b00010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit1o"><span><span class="NLM_label">(o) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leverett, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to New Drugs Approved During 2016</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">7004</span>– <span class="NLM_lpage">7031</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00260</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00260" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1o&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntVCmsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=7004-7031&author=A.+C.+Flickauthor=H.+X.+Dingauthor=C.+A.+Leverettauthor=S.+J.+Finkauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+New+Drugs+Approved+During+2016&doi=10.1021%2Facs.jmedchem.8b00260"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1oR"><div class="casContent"><span class="casTitleNuber">1o</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic Approaches to New Drugs Approved During 2016</span></div><div class="casAuthors">Flick, Andrew C.; Ding, Hong X.; Leverett, Carolyn A.; Fink, Sarah J.; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7004-7031</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review discusses the published syntheses of the nineteen new chem. entities approved for the first time by a governing body anywhere in the world in 2016.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr16l1kfs1KlbVg90H21EOLACvtfcHk0ljWmej2dzfZHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntVCmsbc%253D&md5=183bbabe40dbfd7b7cfbcd94fd55f0d0</span></div><a href="/servlet/linkout?suffix=cit1o&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00260%26sid%3Dliteratum%253Aachs%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DLeverett%26aufirst%3DC.%2BA.%26aulast%3DFink%26aufirst%3DS.%2BJ.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520New%2520Drugs%2520Approved%2520During%25202016%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D7004%26epage%3D7031%26doi%3D10.1021%2Facs.jmedchem.8b00260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit1p"><span><span class="NLM_label">(p) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leverett, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McInturff, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helal, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the New Drugs Approved During 2017</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">7340</span>– <span class="NLM_lpage">7382</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00196</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00196" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1p&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXms1Wqt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=7340-7382&author=A.+C.+Flickauthor=C.+A.+Leverettauthor=H.+X.+Dingauthor=E.+McInturffauthor=S.+J.+Finkauthor=C.+J.+Helalauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+the+New+Drugs+Approved+During+2017&doi=10.1021%2Facs.jmedchem.9b00196"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1pR"><div class="casContent"><span class="casTitleNuber">1p</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic Approaches to the New Drugs Approved During 2017</span></div><div class="casAuthors">Flick, Andrew C.; Leverett, Carolyn A.; Ding, Hong X.; McInturff, Emma; Fink, Sarah J.; Helal, Christopher J.; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7340-7382</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  New drugs introduced to the market every year represent privileged structures for particular biol. targets.  These new chem. entities (NCEs) provide insight into mol. recognition while serving as leads for designing future new drugs.  This annual review describes the most likely process-scale synthetic approaches to 31 new chem. entities approved for the first time globally in 2017.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozpSoktvArg7Vg90H21EOLACvtfcHk0ljWmej2dzfZHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXms1Wqt7g%253D&md5=83863eeaaadfcaab14c45e0ace932455</span></div><a href="/servlet/linkout?suffix=cit1p&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00196%26sid%3Dliteratum%253Aachs%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DLeverett%26aufirst%3DC.%2BA.%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DMcInturff%26aufirst%3DE.%26aulast%3DFink%26aufirst%3DS.%2BJ.%26aulast%3DHelal%26aufirst%3DC.%2BJ.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%2520New%2520Drugs%2520Approved%2520During%25202017%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D7340%26epage%3D7382%26doi%3D10.1021%2Facs.jmedchem.9b00196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit1q"><span><span class="NLM_label">(q) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leverett, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McInturff, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helal, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeForest, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morse, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahapatra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to New Drugs Approved During 2018</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">10652</span>– <span class="NLM_lpage">10704</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00345</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00345" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1q&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BB3cXot1WmsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=10652-10704&author=A.+C.+Flickauthor=C.+A.+Leverettauthor=H.+X.+Dingauthor=E.+McInturffauthor=S.+J.+Finkauthor=C.+J.+Helalauthor=J.+C.+DeForestauthor=P.+D.+Morseauthor=S.+Mahapatraauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+New+Drugs+Approved+During+2018&doi=10.1021%2Facs.jmedchem.0c00345"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1qR"><div class="casContent"><span class="casTitleNuber">1q</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic Approaches to New Drugs Approved during 2018</span></div><div class="casAuthors">Flick, Andrew C.; Leverett, Carolyn A.; Ding, Hong X.; McInturff, Emma; Fink, Sarah J.; Helal, Christopher J.; DeForest, Jacob C.; Morse, Peter D.; Mahapatra, Subham; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">10652-10704</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This annual review described the most likely process-scale synthetic approaches to thirty-nine new chem. entities approved for the first time globally in 2018.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp81HH6nQfU5bVg90H21EOLACvtfcHk0ljWmej2dzfZHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXot1WmsrY%253D&md5=9abe3e119215f96408e4a3448b36ce96</span></div><a href="/servlet/linkout?suffix=cit1q&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00345%26sid%3Dliteratum%253Aachs%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DLeverett%26aufirst%3DC.%2BA.%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DMcInturff%26aufirst%3DE.%26aulast%3DFink%26aufirst%3DS.%2BJ.%26aulast%3DHelal%26aufirst%3DC.%2BJ.%26aulast%3DDeForest%26aufirst%3DJ.%2BC.%26aulast%3DMorse%26aufirst%3DP.%2BD.%26aulast%3DMahapatra%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520New%2520Drugs%2520Approved%2520During%25202018%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D10652%26epage%3D10704%26doi%3D10.1021%2Facs.jmedchem.0c00345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="note"><p class="first last">For a more detailed description of the medicinal chemistry strategy and preclinical and clinical pharmacology of these drugs, see:</p></div><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Agard, N. J.</span>; <span class="NLM_string-name">Dragovich, P. S.</span>; <span class="NLM_string-name">Beal, A. M.</span>; <span class="NLM_string-name">Bolger, C. A.</span>; <span class="NLM_string-name">Kahn, S. A.</span>; <span class="NLM_string-name">Hubbard, B.</span>; <span class="NLM_string-name">Lipovšec, D.</span></span> <span> </span><span class="NLM_article-title">To Market, To Market—2019: Macromolecular Therapeutics</span>. In  <i>2020 Medicinal Chemistry Reviews</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronson, J. J.</span></span>, Ed.; <span class="NLM_publisher-name">Division of Medicinal Chemistry, American Chemical Society</span>: <span class="NLM_publisher-loc">Washington, DC</span>, <span class="NLM_year">2020</span>; Vol.  <span class="NLM_volume">55</span>, Chapter 28.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.29200%2Facsmedchemrev-v55.ch28" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=N.+J.+Agard&author=P.+S.+Dragovich&author=A.+M.+Beal&author=C.+A.+Bolger&author=S.+A.+Kahn&author=B.+Hubbard&author=D.+Lipov%C5%A1ecauthor=J.+J.+Bronson&title=2020+Medicinal+Chemistry+Reviews"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.29200%2Facsmedchemrev-v55.ch28&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.29200%252Facsmedchemrev-v55.ch28%26sid%3Dliteratum%253Aachs%26aulast%3DAgard%26aufirst%3DN.%2BJ.%26atitle%3DTo%2520Market%252C%2520To%2520Market%25E2%2580%25942019%253A%2520Macromolecular%2520Therapeutics%26btitle%3D2020%2520Medicinal%2520Chemistry%2520Reviews%26aulast%3DBronson%26aufirst%3DJ.%2BJ.%26pub%3DDivision%2520of%2520Medicinal%2520Chemistry%252C%2520American%2520Chemical%2520Society%26date%3D2020%26volume%3D55" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.-M.</span></span> <span> </span><span class="NLM_article-title">New Drug Approvals for 2019: Synthesis and Clinical Applications</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>205</i></span>,  <span class="NLM_fpage">112667</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112667</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2Fj.ejmech.2020.112667" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=32911308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslyjtr3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=205&publication_year=2020&pages=112667&author=S.+Yuanauthor=B.+Yuauthor=H.-M.+Liu&title=New+Drug+Approvals+for+2019%3A+Synthesis+and+Clinical+Applications&doi=10.1016%2Fj.ejmech.2020.112667"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">New drug approvals for 2019: Synthesis and clinical applications</span></div><div class="casAuthors">Yuan, Shuo; Yu, Bin; Liu, Hong-Min</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">205</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112667</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">48 new drugs including 38 chem. entities (33 new chem. entities, 3 new diagnostic agents, and 2 payloads of antibody drug conjugates) and 10 biologics were approved by the U.  S. Food and Drug Administration (FDA) during 2019.  These marketed new drugs represent privileged structures and novel action of mechanism, and thus can be served as leads to discover new drugs with the similar biol. targets and improved therapeutic efficacy.  This review aims to provide an overview regarding the synthetic approaches of 33 new chem. entities approved by the FDA in 2019 and their clin. applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5SG-B5Zmuf7Vg90H21EOLACvtfcHk0lg6firrCnjbMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslyjtr3N&md5=4cd45aa9a308b65500be483d394d7a96</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112667&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112667%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DH.-M.%26atitle%3DNew%2520Drug%2520Approvals%2520for%25202019%253A%2520Synthesis%2520and%2520Clinical%2520Applications%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D205%26spage%3D112667%26doi%3D10.1016%2Fj.ejmech.2020.112667" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Zhanel, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golden, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zelenitsky, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiebe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adam, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Idowu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domalaon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweizer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhanel, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagace-Wiens, P. R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walkty, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noreddin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, J. P.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlowsky, J. A.</span></span> <span> </span><span class="NLM_article-title">Cefiderocol: A Siderophore Cephalosporin with Activity against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">271</span>– <span class="NLM_lpage">289</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-1055-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs40265-019-1055-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=30712199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFyjtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=271-289&author=G.+G.+Zhanelauthor=A.+R.+Goldenauthor=S.+Zelenitskyauthor=K.+Wiebeauthor=C.+K.+Lawrenceauthor=H.+J.+Adamauthor=T.+Idowuauthor=R.+Domalaonauthor=F.+Schweizerauthor=M.+A.+Zhanelauthor=P.+R.+S.+Lagace-Wiensauthor=A.+J.+Walktyauthor=A.+Noreddinauthor=J.+P.+Lynchauthor=J.+A.+Karlowsky&title=Cefiderocol%3A+A+Siderophore+Cephalosporin+with+Activity+against+Carbapenem-Resistant+and+Multidrug-Resistant+Gram-Negative+Bacilli&doi=10.1007%2Fs40265-019-1055-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli</span></div><div class="casAuthors">Zhanel, George G.; Golden, Alyssa R.; Zelenitsky, Sheryl; Wiebe, Karyn; Lawrence, Courtney K.; Adam, Heather J.; Idowu, Temilolu; Domalaon, Ronald; Schweizer, Frank; Zhanel, Michael A.; Lagace-Wiens, Philippe R. S.; Walkty, Andrew J.; Noreddin, Ayman; Lynch III, Joseph P.; Karlowsky, James A.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">271-289</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Cefiderocol is an injectable siderophore cephalosporin discovered and being developed by Shionogi & Co., Ltd., Japan.  As with other β-lactam antibiotics, the principal antibacterial/bactericidal activity of cefiderocol occurs by inhibition of Gram-neg. bacterial cell wall synthesis by binding to penicillin binding proteins; however, it is unique in that it enters the bacterial periplasmic space as a result of its siderophore-like property and has enhanced stability to β-lactamases.  The chem. structure of cefiderocol is similar to both ceftazidime and cefepime, which are third- and fourth-generation cephalosporins, resp., but with high stability to a variety of β-lactamases, including AmpC and extended-spectrum β-lactamases (ESBLs).  Cefiderocol has a pyrrolidinium group in the side chain at position 3 like cefepime and a carboxypropanoxyimino group in the side chain at position 7 of the cephem nucleus like ceftazidime.  The major difference in the chem. structures of cefiderocol, ceftazidime and cefepime is the presence of a catechol group on the side chain at position 3.  Together with the high stability to β-lactamases, including ESBLs, AmpC and carbapenemases, the microbiol. activity of cefiderocol against aerobic Gram-neg. bacilli is equal to or superior to that of ceftazidime-avibactam and meropenem, and it is active against a variety of Ambler class A, B, C and D β-lactamases.  Cefiderocol is also more potent than both ceftazidime-avibactam and meropenem vs. Acinetobacter baumannii, including meropenem non-susceptible and multidrug-resistant (MDR) isolates.  Cefiderocol's activity against meropenem-non-susceptible and Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriales is comparable or superior to ceftazidime-avibactam.  Cefiderocol is also more potent than both ceftazidime-avibactam and meropenem against all resistance phenotypes of Pseudomonas aeruginosa and against Stenotrophomonas maltophilia.  The current dosing regimen being used in phase III studies is 2 g administered i.v. every 8 h (q8 h) using a 3-h infusion.  The pharmacokinetics of cefiderocol are best described by a three-compartment linear model.  The mean plasma half-life (t1/2) was ∼ 2.3 h, protein binding is 58%, and total drug clearance ranged from 4.6-6.0 L/h for both single- and multi-dose infusions and was primarily renally excreted unchanged (61-71%).  Cefiderocol is primarily renally excreted unchanged and clearance correlates with creatinine clearance.  Dosage adjustment is thus required for both augmented renal clearance and in patients with moderate to severe renal impairment.  In vitro and in vivo pharmacodynamic studies have reported that as with other cephalosporins the pharmacodynamic index that best predicts clin. outcome is the percentage of time that free drug concns. exceed the min. inhibitory concn. (%fT > MIC).  In vivo efficacy of cefiderocol has been studied in a variety of humanized drug exposure murine and rat models of infection utilizing a variety of MDR and extremely drug resistant strains.  Cefiderocol has performed similarly to or has been superior to comparator agents, including ceftazidime and cefepime.  A phase II prospective, multicenter, double-blind, randomized clin. trial assessed the safety and efficacy of cefiderocol 2000 mg q8 h vs. imipenem/cilastatin 1000 mg q8 h, both administered i.v. for 7-14 days over 1 h, in the treatment of complicated urinary tract infection (cUTI, including pyelonephritis) or acute uncomplicated pyelonephritis in hospitalized adults.  A total of 452 patients were initially enrolled in the study, with 303 in the cefiderocol arm and 149 in the imipenem/cilastatin arm.  The primary outcome measure was a composite of clin. cure and microbiol. eradication at the test-of-cure (TOC) visit, i.e., 7 days after the end of treatment in the microbiol. intent-to-treat (MITT) population.  Secondary outcome measures included microbiol. response per pathogen and per patient at early assessment (EA), end of treatment (EOT), TOC, and follow-up (FUP); clin. response per pathogen and per patient at EA, EOT, TOC, and FUP; plasma, urine and concns. of cefiderocol; and the no. of participants with adverse events.  The composite of clin. and microbiol. response rates was 72.6% (183/252) for cefiderocol and 54.6% (65/119) for imipenem/cilastatin in the MITT population.  Clin. response rates per patient at the TOC visit were 89.7% (226/252) for cefiderocol and 87.4% (104/119) for imipenem/cilastatin in the MITT population.  Microbiol. eradication rates were 73.0% (184/252) for cefiderocol and 56.3% (67/119) for imipenem/cilastatin in the MITT population.  Addnl., two phase III clin. trials are currently being conducted by Shionogi & Co., Ltd., Japan.  The two trials are evaluating the efficacy of cefiderocol in the treatment of serious infections in adult patients caused by carbapenem-resistant Gram-neg. pathogens and evaluating the efficacy of cefiderocol in the treatment of adults with hospital-acquired bacterial pneumonia, ventilator-assocd. pneumonia or healthcare-assocd. pneumonia caused by Gram-neg. pathogens.  Cefiderocol appears to be well tolerated (minor reported adverse effects were gastrointestinal and phlebitis related), with a side effect profile that is comparable to other cephalosporin antimicrobials.  Cefiderocol appears to be well positioned to help address the increasing no. of infections caused by carbapenem-resistant and MDR Gram-neg. bacilli, including ESBL- and carbapenemase-producing strains (including metallo-β-lactamase producers).  A distinguishing feature of cefiderocol is its activity against resistant P. aeruginosa, A. baumannii, S. maltophilia and Burkholderia cepacia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj__AYoJTP8rVg90H21EOLACvtfcHk0lg6firrCnjbMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFyjtLo%253D&md5=47bef7c5e2c7231f9a38e5e524efd0b2</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-1055-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-1055-2%26sid%3Dliteratum%253Aachs%26aulast%3DZhanel%26aufirst%3DG.%2BG.%26aulast%3DGolden%26aufirst%3DA.%2BR.%26aulast%3DZelenitsky%26aufirst%3DS.%26aulast%3DWiebe%26aufirst%3DK.%26aulast%3DLawrence%26aufirst%3DC.%2BK.%26aulast%3DAdam%26aufirst%3DH.%2BJ.%26aulast%3DIdowu%26aufirst%3DT.%26aulast%3DDomalaon%26aufirst%3DR.%26aulast%3DSchweizer%26aufirst%3DF.%26aulast%3DZhanel%26aufirst%3DM.%2BA.%26aulast%3DLagace-Wiens%26aufirst%3DP.%2BR.%2BS.%26aulast%3DWalkty%26aufirst%3DA.%2BJ.%26aulast%3DNoreddin%26aufirst%3DA.%26aulast%3DLynch%26aufirst%3DJ.%2BP.%26aulast%3DKarlowsky%26aufirst%3DJ.%2BA.%26atitle%3DCefiderocol%253A%2520A%2520Siderophore%2520Cephalosporin%2520with%2520Activity%2520against%2520Carbapenem-Resistant%2520and%2520Multidrug-Resistant%2520Gram-Negative%2520Bacilli%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D271%26epage%3D289%26doi%3D10.1007%2Fs40265-019-1055-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit4b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamawaki, K.</span></span> <span> </span><span class="NLM_article-title">Cefiderocol: Discovery, Chemistry, and in Vivo Profiles of a Novel Siderophore Cephalosporin</span>. <i>Clin. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">S538</span>– <span class="NLM_lpage">S543</span>, <span class="refDoi"> DOI: 10.1093/cid/ciz826</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1093%2Fcid%2Fciz826" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31724047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnsVKqt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2019&pages=S538-S543&author=T.+Satoauthor=K.+Yamawaki&title=Cefiderocol%3A+Discovery%2C+Chemistry%2C+and+in+Vivo+Profiles+of+a+Novel+Siderophore+Cephalosporin&doi=10.1093%2Fcid%2Fciz826"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4b</span><div class="casTitle"><span class="NLM_cas:atitle">Cefiderocol: discovery, chemistry, and in vivo profiles of a novel siderophore cephalosporin</span></div><div class="casAuthors">Sato, Takafumi; Yamawaki, Kenji</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Infectious Diseases</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">Suppl._7</span>),
    <span class="NLM_cas:pages">S538-S543</span>CODEN:
                <span class="NLM_cas:coden">CIDIEL</span>;
        ISSN:<span class="NLM_cas:issn">1537-6591</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The emergence of antimicrobial resistance is a significant public health issue worldwide, particularly for healthcare-assocd. infections caused by carbapenem-resistant gram-neg. pathogens.  Cefiderocol is a novel siderophore cephalosporin targeting gram-neg. bacteria, including strains with carbapenem resistance.  The structural characteristics of cefiderocol show similarity to both ceftazidime and cefepime, which enable cefiderocol to withstand hydrolysis by β-lactamases.  The unique chem. component is the addn. of a catechol moiety on the C-3 side chain, which chelates iron and mimics naturally occurring siderophore mols.  Following the chelation of iron, cefiderocol is actively transported across the outer membrane of the bacterial cell to the periplasmic space via specialized iron transporter channels.  Furthermore, cefiderocol has demonstrated structural stability against hydrolysis by both serine- and metallo-β-lactamases, including clin. relevant carbapenemases such as Klebsiella pneumoniae carbapenemase, oxacillin carbapenemase-48, and New Delhi metallo-β-lactamase.  Cefiderocol has demonstrated promising in vitro antibacterial and bactericidal activity, which correlates with its in vivo efficacy in several animal models.  This article reviews the discovery and chem. of cefiderocol, as well as some of the key microbiol. and in vivo findings on cefiderocol from recently conducted investigations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyXYWehTmFjbVg90H21EOLACvtfcHk0lg6firrCnjbMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnsVKqt7g%253D&md5=2088f7219b245b209f0ebc0b59151eae</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1093%2Fcid%2Fciz826&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcid%252Fciz826%26sid%3Dliteratum%253Aachs%26aulast%3DSato%26aufirst%3DT.%26aulast%3DYamawaki%26aufirst%3DK.%26atitle%3DCefiderocol%253A%2520Discovery%252C%2520Chemistry%252C%2520and%2520in%2520Vivo%2520Profiles%2520of%2520a%2520Novel%2520Siderophore%2520Cephalosporin%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2019%26volume%3D69%26spage%3DS538%26epage%3DS543%26doi%3D10.1093%2Fcid%2Fciz826" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><a href="https://www.fda.gov/news-events/press-announcements/fda-approves-new-antibacterial-drug-treat-complicated-urinary-tract-infections-part-ongoing-efforts" class="extLink">https://www.fda.gov/news-events/press-announcements/fda-approves-new-antibacterial-drug-treat-complicated-urinary-tract-infections-part-ongoing-efforts</a> (accessed 2020-12-18).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-approves-new-antibacterial-drug-treat-complicated-urinary-tract-infections-part-ongoing-efforts+%28accessed+2020-12-18%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aoki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshizawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamawaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hisakawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasegawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusano, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugimoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishitani, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuji, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishikawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamano, Y.</span></span> <span> </span><span class="NLM_article-title">Cefiderocol (S-649266), A New Siderophore Cephalosporin Exhibiting Potent Activities against Pseudomonas Aeruginosa and Other Gram-Negative Pathogens Including Multi-Drug Resistant Bacteria: Structure Activity Relationship</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>155</i></span>,  <span class="NLM_fpage">847</span>– <span class="NLM_lpage">868</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.06.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2Fj.ejmech.2018.06.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=29960205" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1aktLzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=2018&pages=847-868&author=T.+Aokiauthor=H.+Yoshizawaauthor=K.+Yamawakiauthor=K.+Yokooauthor=J.+Satoauthor=S.+Hisakawaauthor=Y.+Hasegawaauthor=H.+Kusanoauthor=M.+Sanoauthor=H.+Sugimotoauthor=Y.+Nishitaniauthor=T.+Satoauthor=M.+Tsujiauthor=R.+Nakamuraauthor=T.+Nishikawaauthor=Y.+Yamano&title=Cefiderocol+%28S-649266%29%2C+A+New+Siderophore+Cephalosporin+Exhibiting+Potent+Activities+against+Pseudomonas+Aeruginosa+and+Other+Gram-Negative+Pathogens+Including+Multi-Drug+Resistant+Bacteria%3A+Structure+Activity+Relationship&doi=10.1016%2Fj.ejmech.2018.06.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship</span></div><div class="casAuthors">Aoki, Toshiaki; Yoshizawa, Hidenori; Yamawaki, Kenji; Yokoo, Katsuki; Sato, Jun; Hisakawa, Shinya; Hasegawa, Yasushi; Kusano, Hiroki; Sano, Masayuki; Sugimoto, Hideki; Nishitani, Yasuhiro; Sato, Takafumi; Tsuji, Masakatsu; Nakamura, Rio; Nishikawa, Toru; Yamano, Yoshinori</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">155</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">847-868</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The structure-activity relationship (SAR) for a novel series of catechol conjugated siderophore cephalosporins is described with their in vitro activities against multi-drug resistant Gram-neg. pathogens including Pseudomonas aeruginosa, Acinetobacter baumannii, Stenotrophomonas maltophilia and Enterobacteriaceae.  Cefiderocol (3) was one of the best mols. which displayed well-balanced and potent activities against multi-drug resistant Gram-neg. pathogens including carbapenem resistant bacteria among the prepd. compds. with the modified C-7 side chain and the modified C-3 side chain.  Cefiderocol (3) is a highly promising parenteral cephalosporin for the treatment of multi-drug resistant Gram-neg. infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZtNQuAziKHbVg90H21EOLACvtfcHk0liFBbBTadT4FA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1aktLzL&md5=8dbb57fbf55c68d788ffba60f4b5b597</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.06.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.06.014%26sid%3Dliteratum%253Aachs%26aulast%3DAoki%26aufirst%3DT.%26aulast%3DYoshizawa%26aufirst%3DH.%26aulast%3DYamawaki%26aufirst%3DK.%26aulast%3DYokoo%26aufirst%3DK.%26aulast%3DSato%26aufirst%3DJ.%26aulast%3DHisakawa%26aufirst%3DS.%26aulast%3DHasegawa%26aufirst%3DY.%26aulast%3DKusano%26aufirst%3DH.%26aulast%3DSano%26aufirst%3DM.%26aulast%3DSugimoto%26aufirst%3DH.%26aulast%3DNishitani%26aufirst%3DY.%26aulast%3DSato%26aufirst%3DT.%26aulast%3DTsuji%26aufirst%3DM.%26aulast%3DNakamura%26aufirst%3DR.%26aulast%3DNishikawa%26aufirst%3DT.%26aulast%3DYamano%26aufirst%3DY.%26atitle%3DCefiderocol%2520%2528S-649266%2529%252C%2520A%2520New%2520Siderophore%2520Cephalosporin%2520Exhibiting%2520Potent%2520Activities%2520against%2520Pseudomonas%2520Aeruginosa%2520and%2520Other%2520Gram-Negative%2520Pathogens%2520Including%2520Multi-Drug%2520Resistant%2520Bacteria%253A%2520Structure%2520Activity%2520Relationship%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D155%26spage%3D847%26epage%3D868%26doi%3D10.1016%2Fj.ejmech.2018.06.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsubara, F.</span>; <span class="NLM_string-name">Kurita, T.</span>; <span class="NLM_string-name">Nagamatsu, D.</span></span> <span> </span><span class="NLM_article-title">Salt of Cephalosporin Derivative, Crystalline Solid Form of Same and Method for Producing Same</span>. <span class="NLM_patent">WO 2016035845 A1</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=F.+Matsubara&author=T.+Kurita&author=D.+Nagamatsu&title=Salt+of+Cephalosporin+Derivative%2C+Crystalline+Solid+Form+of+Same+and+Method+for+Producing+Same"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMatsubara%26aufirst%3DF.%26atitle%3DSalt%2520of%2520Cephalosporin%2520Derivative%252C%2520Crystalline%2520Solid%2520Form%2520of%2520Same%2520and%2520Method%2520for%2520Producing%2520Same%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Fukuda, M.</span>; <span class="NLM_string-name">Watanabe, T.</span>; <span class="NLM_string-name">Kurita, T.</span>; <span class="NLM_string-name">Yokota, Y.</span>; <span class="NLM_string-name">Takeo, M.</span>; <span class="NLM_string-name">Noguchi, K.</span></span> <span> </span><span class="NLM_article-title">Preparation of Intermediate of Cephalosporin Derivatives</span>. <span class="NLM_patent">WO 2016035847 A1</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=M.+Fukuda&author=T.+Watanabe&author=T.+Kurita&author=Y.+Yokota&author=M.+Takeo&author=K.+Noguchi&title=Preparation+of+Intermediate+of+Cephalosporin+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFukuda%26aufirst%3DM.%26atitle%3DPreparation%2520of%2520Intermediate%2520of%2520Cephalosporin%2520Derivatives%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Kawasaki, H.</span>; <span class="NLM_string-name">Kojima, N.</span>; <span class="NLM_string-name">Fujihira, A.</span>; <span class="NLM_string-name">Takahashi, K.</span>; <span class="NLM_string-name">Matsubara, F.</span>; <span class="NLM_string-name">Matsuoka, N.</span></span> <span> </span><span class="NLM_article-title">Pharmaceutical Preparation Comprising Cephalosporin Having Catechol Groups with Improved Stability, and Manufacture Thereof</span>. <span class="NLM_patent">WO 2016035846 A1</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=H.+Kawasaki&author=N.+Kojima&author=A.+Fujihira&author=K.+Takahashi&author=F.+Matsubara&author=N.+Matsuoka&title=Pharmaceutical+Preparation+Comprising+Cephalosporin+Having+Catechol+Groups+with+Improved+Stability%2C+and+Manufacture+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKawasaki%26aufirst%3DH.%26atitle%3DPharmaceutical%2520Preparation%2520Comprising%2520Cephalosporin%2520Having%2520Catechol%2520Groups%2520with%2520Improved%2520Stability%252C%2520and%2520Manufacture%2520Thereof%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><a href="https://www.kegg.jp/dbget-bin/www_bget?dr:D11013" class="extLink">https://www.kegg.jp/dbget-bin/www_bget?dr:D11013</a> (accessed 2020-12-18).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.kegg.jp%2Fdbget-bin%2Fwww_bget%3Fdr%3AD11013+%28accessed+2020-12-18%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kishii, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takei, M.</span></span> <span> </span><span class="NLM_article-title">In Vitro Activities and Spectrum of the Novel Fluoroquinolone Lascufloxacin (KRP-AM1977)</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">e00120-17</span>, <span class="refDoi"> DOI: 10.1128/AAC.00120-17</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1128%2FAAC.00120-17" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=28320717" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2017&pages=e00120-17&author=R.+Kishiiauthor=Y.+Yamaguchiauthor=M.+Takei&title=In+Vitro+Activities+and+Spectrum+of+the+Novel+Fluoroquinolone+Lascufloxacin+%28KRP-AM1977%29&doi=10.1128%2FAAC.00120-17"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1128%2FAAC.00120-17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00120-17%26sid%3Dliteratum%253Aachs%26aulast%3DKishii%26aufirst%3DR.%26aulast%3DYamaguchi%26aufirst%3DY.%26aulast%3DTakei%26aufirst%3DM.%26atitle%3DIn%2520Vitro%2520Activities%2520and%2520Spectrum%2520of%2520the%2520Novel%2520Fluoroquinolone%2520Lascufloxacin%2520%2528KRP-AM1977%2529%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2017%26volume%3D61%26spage%3De00120-17%26doi%3D10.1128%2FAAC.00120-17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamagishi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsukawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suematsu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikamo, H.</span></span> <span> </span><span class="NLM_article-title">In vitro Activity of Lascufloxacin, a Novel Fluoroquinolone Antibacterial Agent, against Various Clinical Isolates of Anaerobes and <i>Streptococcus Anginosus</i> Group</span>. <i>Anaerobe</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">61</span>– <span class="NLM_lpage">64</span>, <span class="refDoi"> DOI: 10.1016/j.anaerobe.2018.08.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2Fj.anaerobe.2018.08.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=30114441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFequr3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2018&pages=61-64&author=Y.+Yamagishiauthor=Y.+Matsukawaauthor=H.+Suematsuauthor=H.+Mikamo&title=In+vitro+Activity+of+Lascufloxacin%2C+a+Novel+Fluoroquinolone+Antibacterial+Agent%2C+against+Various+Clinical+Isolates+of+Anaerobes+and+Streptococcus+Anginosus+Group&doi=10.1016%2Fj.anaerobe.2018.08.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro activity of lascufloxacin, a novel fluoroquinolone antibacterial agent, against various clinical isolates of anaerobes and Streptococcus anginosus group</span></div><div class="casAuthors">Yamagishi, Yuka; Matsukawa, Yoko; Suematsu, Hiroyuki; Mikamo, Hiroshige</div><div class="citationInfo"><span class="NLM_cas:title">Anaerobe</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">61-64</span>CODEN:
                <span class="NLM_cas:coden">ANAEF8</span>;
        ISSN:<span class="NLM_cas:issn">1075-9964</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The in vitro activities of lascufloxacin were evaluated by comparison with seven ref. compds. using 412 clin. isolates of anaerobes and Streptococcus anginosus group.  Lascufloxacin showed potent and broad antibacterial activities greater than those of existing quinolones against the clin. isolates used in this study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsjc-PBP_vRrVg90H21EOLACvtfcHk0liL_Nbq287-4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFequr3O&md5=2393853dd981dfd38baaec4fe4b77604</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.anaerobe.2018.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.anaerobe.2018.08.002%26sid%3Dliteratum%253Aachs%26aulast%3DYamagishi%26aufirst%3DY.%26aulast%3DMatsukawa%26aufirst%3DY.%26aulast%3DSuematsu%26aufirst%3DH.%26aulast%3DMikamo%26aufirst%3DH.%26atitle%3DIn%2520vitro%2520Activity%2520of%2520Lascufloxacin%252C%2520a%2520Novel%2520Fluoroquinolone%2520Antibacterial%2520Agent%252C%2520against%2520Various%2520Clinical%2520Isolates%2520of%2520Anaerobes%2520and%2520Streptococcus%2520Anginosus%2520Group%26jtitle%3DAnaerobe%26date%3D2018%26volume%3D54%26spage%3D61%26epage%3D64%26doi%3D10.1016%2Fj.anaerobe.2018.08.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gotoh, T.</span>; <span class="NLM_string-name">Araya, I.</span></span> <span> </span><span class="NLM_article-title">Process for Production of 3,4-Disubstituted Pyrrolidine Derivative and Intermediate for the Production</span>. <span class="NLM_patent">EP 1992613 A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=T.+Gotoh&author=I.+Araya&title=Process+for+Production+of+3%2C4-Disubstituted+Pyrrolidine+Derivative+and+Intermediate+for+the+Production"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGotoh%26aufirst%3DT.%26atitle%3DProcess%2520for%2520Production%2520of%25203%252C4-Disubstituted%2520Pyrrolidine%2520Derivative%2520and%2520Intermediate%2520for%2520the%2520Production%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uchida, H.</span>; <span class="NLM_string-name">Hanada, M.</span></span> <span> </span><span class="NLM_article-title">Solid Pharmaceutical Composition</span>. <span class="NLM_patent">US 20160067185 A1</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=H.+Uchida&author=M.+Hanada&title=Solid+Pharmaceutical+Composition"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DUchida%26aufirst%3DH.%26atitle%3DSolid%2520Pharmaceutical%2520Composition%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Guruswamy, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arul, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaitanya, M. V. S. R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darsi, S. S. P. K.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis and Antimicrobial Evaluation of Novel Tricyclic Benzoxazine Fluoroquinolones under Conventional and Microwave Methods</span>. <i>J. Heterocycl. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">532</span>– <span class="NLM_lpage">538</span>, <span class="refDoi"> DOI: 10.1002/jhet.2093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1002%2Fjhet.2093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC2MXltFSltLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2015&pages=532-538&author=B.+Guruswamyauthor=R.+Arulauthor=M.+V.+S.+R.+K.+Chaitanyaauthor=S.+S.+P.+K.+Darsi&title=Design%2C+Synthesis+and+Antimicrobial+Evaluation+of+Novel+Tricyclic+Benzoxazine+Fluoroquinolones+under+Conventional+and+Microwave+Methods&doi=10.1002%2Fjhet.2093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis and Antimicrobial Evaluation of Novel Tricyclic Benzoxazine Fluoroquinolones under Conventional and Microwave Methods</span></div><div class="casAuthors">Guruswamy, B.; Arul, R.; Chaitanya, M. V. S. R. K.; Darsi, S. S. Praveen Kumar</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Heterocyclic Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">532-538</span>CODEN:
                <span class="NLM_cas:coden">JHTCAD</span>;
        ISSN:<span class="NLM_cas:issn">1943-5193</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The synthesis of novel fluoroquinolones bearing 2-(piperidin-4-yl)-1H-benzo[d]imidazole I (R = Et, CH2CH2OEt, benzyl, etc.) was described.  Alternatively, synthesis of these products was also demonstrated using microwave irradn. technique.  The antimicrobial activity of newly synthesized compds. was evaluated against no. of microorganisms and the activity is compared with highly active levofloxacin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZo8c7SPxzu7Vg90H21EOLACvtfcHk0liL_Nbq287-4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXltFSltLw%253D&md5=c8281e70883aa5d95fcc7c7d811b2fdb</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1002%2Fjhet.2093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjhet.2093%26sid%3Dliteratum%253Aachs%26aulast%3DGuruswamy%26aufirst%3DB.%26aulast%3DArul%26aufirst%3DR.%26aulast%3DChaitanya%26aufirst%3DM.%2BV.%2BS.%2BR.%2BK.%26aulast%3DDarsi%26aufirst%3DS.%2BS.%2BP.%2BK.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Antimicrobial%2520Evaluation%2520of%2520Novel%2520Tricyclic%2520Benzoxazine%2520Fluoroquinolones%2520under%2520Conventional%2520and%2520Microwave%2520Methods%26jtitle%3DJ.%2520Heterocycl.%2520Chem.%26date%3D2015%26volume%3D52%26spage%3D532%26epage%3D538%26doi%3D10.1002%2Fjhet.2093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Takagi, N.</span>; <span class="NLM_string-name">Fubasami, H.</span>; <span class="NLM_string-name">Matsukubo, H.</span></span> <span> </span><span class="NLM_article-title">(6,7-Substituted-8-alkoxy-1-cyclopropyl-1,4-dihydro-4-oxo-3-quinolinecarboxylic Acid O3,O4)bis(acyloxy-O)borates and the Salts Thereof, and Methods for Their Manufacture</span>. <span class="NLM_patent">EP 464823 A1</span>, <span class="NLM_year">1992</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1992&author=N.+Takagi&author=H.+Fubasami&author=H.+Matsukubo&title=%286%2C7-Substituted-8-alkoxy-1-cyclopropyl-1%2C4-dihydro-4-oxo-3-quinolinecarboxylic+Acid+O3%2CO4%29bis%28acyloxy-O%29borates+and+the+Salts+Thereof%2C+and+Methods+for+Their+Manufacture"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTakagi%26aufirst%3DN.%26atitle%3D%25286%252C7-Substituted-8-alkoxy-1-cyclopropyl-1%252C4-dihydro-4-oxo-3-quinolinecarboxylic%2520Acid%2520O3%252CO4%2529bis%2528acyloxy-O%2529borates%2520and%2520the%2520Salts%2520Thereof%252C%2520and%2520Methods%2520for%2520Their%2520Manufacture%26date%3D1992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, K. L.</span></span> <span> </span><span class="NLM_article-title">Leave It to Lefamulin: A Pleuromutilin Treatment Option in Community-Acquired Bacterial Pneumonia</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">1867</span>– <span class="NLM_lpage">1876</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01219-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs40265-019-01219-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31705486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFemtb7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=1867-1876&author=Y.+R.+Leeauthor=K.+L.+Jacobs&title=Leave+It+to+Lefamulin%3A+A+Pleuromutilin+Treatment+Option+in+Community-Acquired+Bacterial+Pneumonia&doi=10.1007%2Fs40265-019-01219-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Leave it to Lefamulin: A Pleuromutilin Treatment Option in Community-Acquired Bacterial Pneumonia</span></div><div class="casAuthors">Lee, Young Ran; Jacobs, Katy Louise</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1867-1876</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Lefamulin (BC-3781) is the first systemic pleuromutilin antibiotic found to be safe and effective in the treatment of community-acquired bacterial pneumonia (CABP) in humans.  This novel antibiotic was developed to combat the increasing incidence of bacterial resistance to current therapies.  As the first semisynthetic pleuromutilin for systemic use in humans, lefamulin has demonstrated efficacy against the most common bacteria responsible for CABP, including strains exhibiting resistance to macrolides, fluoroquinolones, tetracyclines, vancomycin, and beta-lactams.  In vitro studies have demonstrated efficacy against Staphylococcus aureus, beta-hemolytic and viridans group streptococci, coagulase-neg. staphylococci, Enterococcus faecium, Streptococcus pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, Chlamydophila pneumoniae, Legionella pneumophilia, and Moraxella catarrhalis at MIC values lower than those of currently available therapies.  Two phase III trials (LEAP-1 and LEAP-2) have demonstrated similar findings, meeting non-inferiority criteria for CABP with a minimal side-effect profile.  Pharmacokinetic and pharmacodynamic evaluations have shown sufficient drug levels in plasma, s.c. adipose tissue, skeletal muscle, and epithelial lining fluid, warranting further investigation for other clin. uses.  Lefamulin was approved by the United States Food and Drug Administration (FDA) on 19 August 2019 for the treatment of CABP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHUgKKAfSTYrVg90H21EOLACvtfcHk0liL_Nbq287-4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFemtb7O&md5=6f7dccf9ec6e4b657b587bf7d92183a5</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01219-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01219-5%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DY.%2BR.%26aulast%3DJacobs%26aufirst%3DK.%2BL.%26atitle%3DLeave%2520It%2520to%2520Lefamulin%253A%2520A%2520Pleuromutilin%2520Treatment%2520Option%2520in%2520Community-Acquired%2520Bacterial%2520Pneumonia%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D1867%26epage%3D1876%26doi%3D10.1007%2Fs40265-019-01219-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Veve, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, J. L.</span></span> <span> </span><span class="NLM_article-title">Lefamulin: Review of a Promising Novel Pleuromutilin Antibiotic</span>. <i>Pharmacotherapy</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">935</span>– <span class="NLM_lpage">946</span>, <span class="refDoi"> DOI: 10.1002/phar.2166</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1002%2Fphar.2166" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=30019769" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs12is7zE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2018&pages=935-946&author=M.+P.+Veveauthor=J.+L.+Wagner&title=Lefamulin%3A+Review+of+a+Promising+Novel+Pleuromutilin+Antibiotic&doi=10.1002%2Fphar.2166"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Lefamulin: Review of a Promising Novel Pleuromutilin Antibiotic</span></div><div class="casAuthors">Veve, Michael P.; Wagner, Jamie L.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacotherapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">935-946</span>CODEN:
                <span class="NLM_cas:coden">PHPYDQ</span>;
        ISSN:<span class="NLM_cas:issn">1875-9114</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The emergence and spread of antimicrobial resistance have led to a global public health emergency requiring development of new antimicrobial classes.  Lefamulin (formally BC-3781) is a novel pleuromutilin antibiotic currently undergoing Food and Drug Administration review for community-acquired bacterial pneumonia (CABP) as i.v. (IV) and oral (PO) formulations.  Although pleuromutilin antibiotics were first developed in the 1950s, lefamulin is the first to be used for systemic treatment of bacterial infections in humans.  Lefamulin exhibits a unique mechanism of action through inhibition of protein synthesis by binding to the peptidyl transferase center of the 50S bacterial ribosome, thus preventing the binding of tRNA for peptide transfer.  Lefamulin displays activity against gram-pos. and atypical organisms assocd. with CABP (i.e., Streptococcus pneumoniae,Haemophilus influenzae, Mycoplasma pneumoniae,Legionella pneumophila, and Chlamydophila pneumoniae), with an expanded gram-pos. spectrum including Staphylococcus aureus (i.e., methicillin-resistant, vancomycin-intermediate, and heterogeneous strains) and vancomycin-resistant Enterococcus faecium.  Lefamulin was also shown to retain activity against multidrug-resistant Neisseria gonorrhoeae and Mycoplasma genitalium.  Lefamulin exhibits time-dependent killing, and the pharmacodynamic target best assocd. with antibacterial activity is fAUC0-24/MIC (min. inhibitory concn. [MIC]).  Preclin. and phase II trials indicate that lefamulin concs. in lung tissue are well tolerated at an IV dose of 150 mg twice/day over 1 h or a PO dose of 600 mg twice/day, and preliminary phase III data suggest similar efficacy when compared with moxifloxacin with or without linezolid in CABP.  Documented resistance and cross-resistance with other gram-pos. antibacterials remains low.  Addnl. published in vitro, in vivo, and preclin. trial data suggest further exploration of lefamulin in various infectious disease states (e.g., acute bacterial skin and skin structure infections, and sexually transmitted infections).  This review discusses the pertinent bacterial spectrum of activity, preclin. and ongoing clin. data, and potential roles in therapy for lefamulin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrai5MjdMSCqLVg90H21EOLACvtfcHk0lizV5k7pfzBvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs12is7zE&md5=1d12eb7df78105bde865e23af4e9c636</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1002%2Fphar.2166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fphar.2166%26sid%3Dliteratum%253Aachs%26aulast%3DVeve%26aufirst%3DM.%2BP.%26aulast%3DWagner%26aufirst%3DJ.%2BL.%26atitle%3DLefamulin%253A%2520Review%2520of%2520a%2520Promising%2520Novel%2520Pleuromutilin%2520Antibiotic%26jtitle%3DPharmacotherapy%26date%3D2018%26volume%3D38%26spage%3D935%26epage%3D946%26doi%3D10.1002%2Fphar.2166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Falco, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almirante, B.</span></span> <span> </span><span class="NLM_article-title">An Overview of Lefamulin for the Treatment of Community Acquired Bacterial Pneumonia</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">629</span>– <span class="NLM_lpage">636</span>, <span class="refDoi"> DOI: 10.1080/14656566.2020.1714592</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1080%2F14656566.2020.1714592" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31958020" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1Kjuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2020&pages=629-636&author=V.+Falcoauthor=J.+Burgosauthor=B.+Almirante&title=An+Overview+of+Lefamulin+for+the+Treatment+of+Community+Acquired+Bacterial+Pneumonia&doi=10.1080%2F14656566.2020.1714592"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16aR"><div class="casContent"><span class="casTitleNuber">16a</span><div class="casTitle"><span class="NLM_cas:atitle">An overview of lefamulin for the treatment of community acquired bacterial pneumonia</span></div><div class="casAuthors">Falco, Vicenc; Burgos, Joaquin; Almirante, Benito</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">629-636</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  : Lefamulin is a novel antibiotic that belongs to the pleuromutilin class with excellent activity against all microorganisms, including atypical pathogens, that cause community-acquired pneumonia (CAP).: This article reviews the spectrum of activity, the main pharmacokinetic and pharmacodynamic characteristics of lefamulin as well as its clin. efficacy and safety in the treatment of CAP in adult patients.: The clin. efficacy of lefamulin in patients with non severe CAP has been demonstrated in 2 randomized clin. trials.  Precisely one of the limitations of the phase 3 trials is that the proportion of severe CAP cases is very low.  Its particular mechanism of action, affecting ribosomal protein synthesis, provides a low probability of cross-resistance to other commonly used antibiotics in CAP.  These findings, together with the antimicrobial activity of lefamulin, its pharmacokinetic parameters and safety profile make it a good alternative for outpatient treatment of CAP.  In patients hospitalized with CAP, lefamulin can be used as a potential oral step-down agent after an i.v. regimen with beta-lactams, or as a therapeutic alternative in patients with β-lactam allergies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHwxGEKPDywbVg90H21EOLACvtfcHk0lizV5k7pfzBvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1Kjuro%253D&md5=12538028d3ecebd5f0b14e720ec47690</span></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=10.1080%2F14656566.2020.1714592&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14656566.2020.1714592%26sid%3Dliteratum%253Aachs%26aulast%3DFalco%26aufirst%3DV.%26aulast%3DBurgos%26aufirst%3DJ.%26aulast%3DAlmirante%26aufirst%3DB.%26atitle%3DAn%2520Overview%2520of%2520Lefamulin%2520for%2520the%2520Treatment%2520of%2520Community%2520Acquired%2520Bacterial%2520Pneumonia%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2020%26volume%3D21%26spage%3D629%26epage%3D636%26doi%3D10.1080%2F14656566.2020.1714592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit16b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">File, T. M.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saviski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelone, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seltzer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paukner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wicha, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talbot, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasink, L. B.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety of Intravenous-to-Oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-Acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation against Pneumonia (LEAP 1) Trial</span>. <i>Clin. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">1856</span>– <span class="NLM_lpage">1867</span>, <span class="refDoi"> DOI: 10.1093/cid/ciz090</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1093%2Fcid%2Fciz090" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=30722059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnsVKlurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2019&pages=1856-1867&author=T.+M.+Fileauthor=L.+Goldbergauthor=A.+Dasauthor=C.+Sweeneyauthor=J.+Saviskiauthor=S.+P.+Geloneauthor=E.+Seltzerauthor=S.+Pauknerauthor=W.+W.+Wichaauthor=G.+H.+Talbotauthor=L.+B.+Gasink&title=Efficacy+and+Safety+of+Intravenous-to-Oral+Lefamulin%2C+a+Pleuromutilin+Antibiotic%2C+for+the+Treatment+of+Community-Acquired+Bacterial+Pneumonia%3A+The+Phase+III+Lefamulin+Evaluation+against+Pneumonia+%28LEAP+1%29+Trial&doi=10.1093%2Fcid%2Fciz090"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16bR"><div class="casContent"><span class="casTitleNuber">16b</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of intravenous-to-oral lefamulin, a pleuromutilin antibiotic, for the treatment of community-acquired bacterial pneumonia: the phase III lefamulin evaluation against pneumonia (LEAP 1) trial</span></div><div class="casAuthors">File, Thomas M., Jr.; Goldberg, Lisa; Das, Anita; Sweeney, Carolyn; Saviski, John; Gelone, Steven P.; Seltzer, Elyse; Paukner, Susanne; Wicha, Wolfgang W.; Talbot, George H.; Gasink, Leanne B.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Infectious Diseases</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1856-1867</span>CODEN:
                <span class="NLM_cas:coden">CIDIEL</span>;
        ISSN:<span class="NLM_cas:issn">1537-6591</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background.  Lefamulin, a pleuromutilin antibiotic, is active against pathogens commonly causing community-acquired bacterial pneumonia (CABP).  The Lefamulin Evaluation Against Pneumonia (LEAP 1) study was a global noninferiority trial to evaluate the efficacy and safety of lefamulin for the treatment of CABP.  In this double-blind study, adults with CABP of Pneumonia Outcomes Research Team risk class ≥III were randomized 1:1 to receive lefamulin at 150 mg i.v. (IV) every 12 h or moxifloxacin at 400 mg IV every 24 h.  After 6 doses, patients could be switched to an oral study drug if prespecified improvement criteria were met.  If methicillin-resistant Staphylococcus aureus was suspected, either linezolid or placebo was added to moxifloxacin or lefamulin, resp.  The US Food and Drug Administration primary endpoint was an early clin. response (ECR) 96 ± 24 h after the first dose of the study drug in the intent-to-treat (ITT) population (noninferiority margin, 12.5%).  The European Medicines Agency co-primary endpoints were an investigator assessment of clin. response (IACR) 5-10 days after the last dose of the study drug in the modified ITT (mITT) and clin. evaluable (CE) populations (noninferiority margin, 10%).  There were 551 patients randomized (n = 276 lefamulin; n = 275 moxifloxacin).  Lefamulin was noninferior to moxifloxacin for ECR (87.3% vs 90.2%, resp.; difference -2.9%, 95% confidence interval [CI] g -8.5 to 2.8) and IACR (mITT, 81.7% vs 84.2%, resp.; difference -2.6%, 95% CI -8.9 to 3.9; CE, 86.9% vs 89.4%, resp.; difference -2.5%, 95% CI -8.4 to 3.4).  Rates of study drug discontinuation due to treatment-emergent adverse events were 2.9% for lefamulin and 4.4% for moxifloxacin.  Conclusions.  Lefamulin was noninferior to moxifloxacin for the primary efficacy endpoints and was generally safe and well tolerated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAygfQ2PIOZLVg90H21EOLACvtfcHk0lizV5k7pfzBvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnsVKlurY%253D&md5=8f51288366ed79a4a793c07e66076187</span></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=10.1093%2Fcid%2Fciz090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcid%252Fciz090%26sid%3Dliteratum%253Aachs%26aulast%3DFile%26aufirst%3DT.%2BM.%26aulast%3DGoldberg%26aufirst%3DL.%26aulast%3DDas%26aufirst%3DA.%26aulast%3DSweeney%26aufirst%3DC.%26aulast%3DSaviski%26aufirst%3DJ.%26aulast%3DGelone%26aufirst%3DS.%2BP.%26aulast%3DSeltzer%26aufirst%3DE.%26aulast%3DPaukner%26aufirst%3DS.%26aulast%3DWicha%26aufirst%3DW.%2BW.%26aulast%3DTalbot%26aufirst%3DG.%2BH.%26aulast%3DGasink%26aufirst%3DL.%2BB.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Intravenous-to-Oral%2520Lefamulin%252C%2520a%2520Pleuromutilin%2520Antibiotic%252C%2520for%2520the%2520Treatment%2520of%2520Community-Acquired%2520Bacterial%2520Pneumonia%253A%2520The%2520Phase%2520III%2520Lefamulin%2520Evaluation%2520against%2520Pneumonia%2520%2528LEAP%25201%2529%2520Trial%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2019%26volume%3D69%26spage%3D1856%26epage%3D1867%26doi%3D10.1093%2Fcid%2Fciz090" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Riedl, R.</span>; <span class="NLM_string-name">Heilmayer, W.</span>; <span class="NLM_string-name">Spence, L.</span></span> <span> </span><span class="NLM_article-title">Process for the Preparation of Pleuromutilins</span>. <span class="NLM_patent">US 9120727 B2</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=R.+Riedl&author=W.+Heilmayer&author=L.+Spence&title=Process+for+the+Preparation+of+Pleuromutilins"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRiedl%26aufirst%3DR.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%2520Pleuromutilins%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heilmayer, W.</span>; <span class="NLM_string-name">Spence, L.</span>; <span class="NLM_string-name">Hinsmann, P.</span></span> <span> </span><span class="NLM_article-title">Purification of Pleuromutilin</span>. <span class="NLM_patent">WO 2018146264 A1</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=W.+Heilmayer&author=L.+Spence&author=P.+Hinsmann&title=Purification+of+Pleuromutilin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHeilmayer%26aufirst%3DW.%26atitle%3DPurification%2520of%2520Pleuromutilin%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Keam, S. J.</span></span> <span> </span><span class="NLM_article-title">Pretomanid: First Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">1797</span>– <span class="NLM_lpage">1803</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01207-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs40265-019-01207-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31583606" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A280%3ADC%252BB3MnkvF2gsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=1797-1803&author=S.+J.+Keam&title=Pretomanid%3A+First+Approval&doi=10.1007%2Fs40265-019-01207-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19aR"><div class="casContent"><span class="casTitleNuber">19a</span><div class="casTitle"><span class="NLM_cas:atitle">Pretomanid: First Approval</span></div><div class="casAuthors">Keam Susan J</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1797-1803</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Pretomanid, an oral nitroimidazooxazine antimycobacterial agent administered as part of the BPaL (bedaquiline, pretomanid and linezolid) and BPaMZ (bedaquiline, pretomanid, moxifloxacin and pyrazinamide) regimens, has been developed by the Global Alliance for TB Drug Development (TB Alliance) under license from Novartis, for the treatment for tuberculosis (TB).  TB Alliance has licensed Mylan to manufacture and commercialize pretomanid for use as part of the BPaMZ and BPaL regimens.  The license is non-exclusive in low- and middle-income countries and exclusive in high-income markets.  Pretomanid, as part of the BPaL regimen, was recently approved in the USA under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) pathway for the treatment of adults with pulmonary extensively drug-resistant (XDR) or treatment-intolerant or non-responsive multidrug-resistant (MDR) TB.  Pretomanid is also under regulatory review in the EU.  This article summarizes the milestones in the development of pretomanid leading to this first regulatory approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ32shufXmAyUNoizSOkG_FfW6udTcc2eZ3MItsoddP1rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MnkvF2gsA%253D%253D&md5=5c28b82e658d5ce4aa0f1187cf2e7736</span></div><a href="/servlet/linkout?suffix=cit19a&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01207-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01207-9%26sid%3Dliteratum%253Aachs%26aulast%3DKeam%26aufirst%3DS.%2BJ.%26atitle%3DPretomanid%253A%2520First%2520Approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D1797%26epage%3D1803%26doi%3D10.1007%2Fs40265-019-01207-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit19b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Stover, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warrener, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VanDevanter, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherman, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arain, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langhorne, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Towell, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMurray, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreiswirth, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, W. R.</span></span> <span> </span><span class="NLM_article-title">A Small-Molecule Nitroimidazopyran Drug Candidate for the Treatment of Tuberculosis</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>405</i></span>,  <span class="NLM_fpage">962</span>– <span class="NLM_lpage">966</span>, <span class="refDoi"> DOI: 10.1038/35016103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1038%2F35016103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10879539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BD3cXks1Wksb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=405&publication_year=2000&pages=962-966&author=C.+K.+Stoverauthor=P.+Warrenerauthor=D.+R.+VanDevanterauthor=D.+R.+Shermanauthor=T.+M.+Arainauthor=M.+H.+Langhorneauthor=S.+W.+Andersonauthor=J.+A.+Towellauthor=Y.+Yuanauthor=D.+N.+McMurrayauthor=B.+N.+Kreiswirthauthor=C.+E.+Barryauthor=W.+R.+Baker&title=A+Small-Molecule+Nitroimidazopyran+Drug+Candidate+for+the+Treatment+of+Tuberculosis&doi=10.1038%2F35016103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19bR"><div class="casContent"><span class="casTitleNuber">19b</span><div class="casTitle"><span class="NLM_cas:atitle">A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis</span></div><div class="casAuthors">Stover, C. Kendall; Warrener, Paul; VanDevanter, Donald R.; Sherman, David R.; Arain, Taraq M.; Langhorne, Michael H.; Anderson, Scott W.; Towell, J. Andrew; Yuan, Ying; McMurray, David N.; Krelswirth, Barry N.; Barry, Clifton E.; Baker, William R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">405</span>
        (<span class="NLM_cas:issue">6789</span>),
    <span class="NLM_cas:pages">962-966</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Mycobacterium tuberculosis, which causes tuberculosis, is the greatest single infectious cause of mortality worldwide, killing roughly; two million people annually.  Ests. indicate that one-third of the world population is infected with latent M. tuberculosis.  The synergy between tuberculosis and the AIDS epidemic, and the surge of multidrug-resistant clin. isolates of M. tuberculosis have reaffirmed tuberculosis as a primary public health threat.  However, new antitubercular drugs with new mechanisms of action have not been developed in over thirty years.  Here we report a series of compds. contg. a nitroimidazopyran nucleus that possess antitubercular activity.  After activation by a mechanism dependent on M. tuberculosis F420 cofactor, nitroimidazopyrans inhibited the synthesis of protein and cell wall lipid.  In contrast to current antitubercular drugs, nitroimidazopyrans exhibited bactericidal activity against both replicating and static M. tuberculosis.  Lead compd. PA-824 showed potent bactericidal activity against multidrug-resistant M. tuberculosis and promising oral activity in animal infection models.  We conclude that nitroimidazopyrans offer the practical qualities of a small mol. with the potential for the treatment of tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrw41eD4TtVwbVg90H21EOLACvtfcHk0lgPH2TyImxLag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXks1Wksb0%253D&md5=f5f6e2935928da72e328bddd4995515f</span></div><a href="/servlet/linkout?suffix=cit19b&amp;dbid=16384&amp;doi=10.1038%2F35016103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35016103%26sid%3Dliteratum%253Aachs%26aulast%3DStover%26aufirst%3DC.%2BK.%26aulast%3DWarrener%26aufirst%3DP.%26aulast%3DVanDevanter%26aufirst%3DD.%2BR.%26aulast%3DSherman%26aufirst%3DD.%2BR.%26aulast%3DArain%26aufirst%3DT.%2BM.%26aulast%3DLanghorne%26aufirst%3DM.%2BH.%26aulast%3DAnderson%26aufirst%3DS.%2BW.%26aulast%3DTowell%26aufirst%3DJ.%2BA.%26aulast%3DYuan%26aufirst%3DY.%26aulast%3DMcMurray%26aufirst%3DD.%2BN.%26aulast%3DKreiswirth%26aufirst%3DB.%2BN.%26aulast%3DBarry%26aufirst%3DC.%2BE.%26aulast%3DBaker%26aufirst%3DW.%2BR.%26atitle%3DA%2520Small-Molecule%2520Nitroimidazopyran%2520Drug%2520Candidate%2520for%2520the%2520Treatment%2520of%2520Tuberculosis%26jtitle%3DNature%26date%3D2000%26volume%3D405%26spage%3D962%26epage%3D966%26doi%3D10.1038%2F35016103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><a href="https://www.tballiance.org/why-new-tb-drugs/global-pandemic" class="extLink">https://www.tballiance.org/why-new-tb-drugs/global-pandemic</a> (accessed 2021-01-14).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.tballiance.org%2Fwhy-new-tb-drugs%2Fglobal-pandemic+%28accessed+2021-01-14%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Manjunatha, U. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boshoff, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowd, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albert, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norton, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniels, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. E.,  3rd</span></span> <span> </span><span class="NLM_article-title">Identification of a Nitroimidazo-Oxazine-Specific Protein Involved in PA-824 Resistance in Mycobacterium Tuberculosis</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">431</span>– <span class="NLM_lpage">436</span>, <span class="refDoi"> DOI: 10.1073/pnas.0508392103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1073%2Fpnas.0508392103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=16387854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BD28XpsVSltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=431-436&author=U.+H.+Manjunathaauthor=H.+Boshoffauthor=C.+S.+Dowdauthor=L.+Zhangauthor=T.+J.+Albertauthor=J.+E.+Nortonauthor=L.+Danielsauthor=T.+Dickauthor=S.+S.+Pangauthor=C.+E.+Barry&title=Identification+of+a+Nitroimidazo-Oxazine-Specific+Protein+Involved+in+PA-824+Resistance+in+Mycobacterium+Tuberculosis&doi=10.1073%2Fpnas.0508392103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21aR"><div class="casContent"><span class="casTitleNuber">21a</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis</span></div><div class="casAuthors">Manjunatha, Ujjini H.; Boshoff, Helena; Dowd, Cynthia S.; Zhang, Liang; Albert, Thomas J.; Norton, Jason E.; Daniels, Lacy; Dick, Thomas; Pang, Siew Siew; Barry, Clifton E., III</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">431-436</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">PA-824 is a promising new compd. for the treatment of tuberculosis that is currently undergoing human trials.  Like its progenitors metronidazole and CGI-17341, PA-824 is a prodrug of the nitroimidazole class, requiring bioreductive activation of an arom. nitro group to exert an antitubercular effect.  The authors have confirmed that resistance to PA-824 (a nitroimidazo-oxazine) and CGI-17341 (a nitroimidazo-oxazole) is most commonly mediated by loss of a specific glucose-6-phosphate dehydrogenase (FGD1) or its deazaflavin cofactor F420, which together provide electrons for the reductive activation of this class of mols.  Although FGD1 and F420 are necessary for sensitivity to these compds., they are not sufficient and require addnl. accessory proteins that directly interact with the nitroimidazole.  To understand more proximal events in the reductive activation of PA-824, the authors examd. mutants that were wild-type for both FGD1 and F420 and found that, although these mutants had acquired high-level resistance to PA-824 (and another nitroimidazo-oxazine), they retained sensitivity to CGI-17341 (and a related nitroimidazo-oxazole).  Microarray-based comparative genome sequencing of these mutants identified lesions in Rv3547, a conserved hypothetical protein with no known function.  Complementation with intact Rv3547 fully restored sensitivity to nitroimidazo-oxazines and restored the ability of Mtb to metabolize PA-824.  These results suggest that the sensitivity of Mtb to PA-824 and related compds. is mediated by a protein that is highly specific for subtle structural variations in these bicyclic nitroimidazoles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX0bL9yx6FB7Vg90H21EOLACvtfcHk0lgPlVwkysTTmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpsVSltQ%253D%253D&md5=66a247925f28a6d254c75a543bb52e74</span></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0508392103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0508392103%26sid%3Dliteratum%253Aachs%26aulast%3DManjunatha%26aufirst%3DU.%2BH.%26aulast%3DBoshoff%26aufirst%3DH.%26aulast%3DDowd%26aufirst%3DC.%2BS.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DAlbert%26aufirst%3DT.%2BJ.%26aulast%3DNorton%26aufirst%3DJ.%2BE.%26aulast%3DDaniels%26aufirst%3DL.%26aulast%3DDick%26aufirst%3DT.%26aulast%3DPang%26aufirst%3DS.%2BS.%26aulast%3DBarry%26aufirst%3DC.%2BE.%26atitle%3DIdentification%2520of%2520a%2520Nitroimidazo-Oxazine-Specific%2520Protein%2520Involved%2520in%2520PA-824%2520Resistance%2520in%2520Mycobacterium%2520Tuberculosis%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2006%26volume%3D103%26spage%3D431%26epage%3D436%26doi%3D10.1073%2Fpnas.0508392103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit21b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manjunatha, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boshoff, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ha, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niyomrattanakit, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ledwidge, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowd, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, I. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiricek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. E.,  3rd</span></span> <span> </span><span class="NLM_article-title">PA-824 Kills Nonreplicating Mycobacterium Tuberculosis by Intracellular No Release</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>322</i></span>,  <span class="NLM_fpage">1392</span>– <span class="NLM_lpage">1395</span>, <span class="refDoi"> DOI: 10.1126/science.1164571</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1126%2Fscience.1164571" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=19039139" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVagt7jN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=322&publication_year=2008&pages=1392-1395&author=R.+Singhauthor=U.+Manjunathaauthor=H.+I.+Boshoffauthor=Y.+H.+Haauthor=P.+Niyomrattanakitauthor=R.+Ledwidgeauthor=C.+S.+Dowdauthor=I.+Y.+Leeauthor=P.+Kimauthor=L.+Zhangauthor=S.+Kangauthor=T.+H.+Kellerauthor=J.+Jiricekauthor=C.+E.+Barry&title=PA-824+Kills+Nonreplicating+Mycobacterium+Tuberculosis+by+Intracellular+No+Release&doi=10.1126%2Fscience.1164571"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21bR"><div class="casContent"><span class="casTitleNuber">21b</span><div class="casTitle"><span class="NLM_cas:atitle">PA-824 Kills Nonreplicating Mycobacterium tuberculosis by Intracellular NO Release</span></div><div class="casAuthors">Singh, Ramandeep; Manjunatha, Ujjini; Boshoff, Helena I. M.; Ha, Young Hwan; Niyomrattanakit, Pornwaratt; Ledwidge, Richard; Dowd, Cynthia S.; Lee, Ill Young; Kim, Pilho; Zhang, Liang; Kang, Sunhee; Keller, Thomas H.; Jiricek, Jan; Barry, Clifton E., III</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">322</span>
        (<span class="NLM_cas:issue">5906</span>),
    <span class="NLM_cas:pages">1392-1395</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Bicyclic nitroimidazoles, including PA-824, are exciting candidates for the treatment of tuberculosis.  These prodrugs require intracellular activation for their biol. function.  We found that Rv3547 is a deazaflavin-dependent nitroreductase (Ddn) that converts PA-824 into three primary metabolites; the major one is the corresponding des-nitroimidazole (des-nitro).  When derivs. of PA-824 were used, the amt. of des-nitro metabolite formed was highly correlated with anaerobic killing of Mycobacterium tuberculosis (Mtb).  Des-nitro metabolite formation generated reactive nitrogen species, including nitric oxide (NO), which are the major effectors of the anaerobic activity of these compds.  Furthermore, NO scavengers protected the bacilli from the lethal effects of the drug.  Thus, these compds. may act as intracellular NO donors and could augment a killing mechanism intrinsic to the innate immune system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdOQ6XyUn59bVg90H21EOLACvtfcHk0lgPlVwkysTTmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVagt7jN&md5=5d7d8715b5565938b3ffd9fd35a723da</span></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=10.1126%2Fscience.1164571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1164571%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DManjunatha%26aufirst%3DU.%26aulast%3DBoshoff%26aufirst%3DH.%2BI.%26aulast%3DHa%26aufirst%3DY.%2BH.%26aulast%3DNiyomrattanakit%26aufirst%3DP.%26aulast%3DLedwidge%26aufirst%3DR.%26aulast%3DDowd%26aufirst%3DC.%2BS.%26aulast%3DLee%26aufirst%3DI.%2BY.%26aulast%3DKim%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DKang%26aufirst%3DS.%26aulast%3DKeller%26aufirst%3DT.%2BH.%26aulast%3DJiricek%26aufirst%3DJ.%26aulast%3DBarry%26aufirst%3DC.%2BE.%26atitle%3DPA-824%2520Kills%2520Nonreplicating%2520Mycobacterium%2520Tuberculosis%2520by%2520Intracellular%2520No%2520Release%26jtitle%3DScience%26date%3D2008%26volume%3D322%26spage%3D1392%26epage%3D1395%26doi%3D10.1126%2Fscience.1164571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit21c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Manjunatha, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boshoff, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. E.</span></span> <span> </span><span class="NLM_article-title">The Mechanism of Action of PA-824: Novel Insights from Transcriptional Profiling</span>. <i>Commun. Integr. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">215</span>– <span class="NLM_lpage">218</span>, <span class="refDoi"> DOI: 10.4161/cib.2.3.7926</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.4161%2Fcib.2.3.7926" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=19641733" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1yru7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2009&pages=215-218&author=U.+Manjunathaauthor=H.+I.+Boshoffauthor=C.+E.+Barry&title=The+Mechanism+of+Action+of+PA-824%3A+Novel+Insights+from+Transcriptional+Profiling&doi=10.4161%2Fcib.2.3.7926"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21cR"><div class="casContent"><span class="casTitleNuber">21c</span><div class="casTitle"><span class="NLM_cas:atitle">The mechanism of action of PA-824: novel insights from transcriptional profiling</span></div><div class="casAuthors">Manjunatha, Ujjini; Boshoff, Helena I. M.; Barry, Clifton E., III</div><div class="citationInfo"><span class="NLM_cas:title">Communicative & Integrative Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">215-218</span>CODEN:
                <span class="NLM_cas:coden">CIBOBQ</span>;
        ISSN:<span class="NLM_cas:issn">1942-0889</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">The bicyclic nitroimidazole PA-824 is a pro-drug with a very complex mechanism of action active against both replicating and hypoxic, non-replicating Mycobacterium tuberculosis.  Microarray anal. of the mode of action of PA-824 showed a puzzling mixed effect both on genes responsive to both cell wall inhibition (like isoniazid) and respiratory poisoning (like cyanide).  The aerobic killing mechanism of this drug appears to involve inhibition of cell wall mycolic acid biosynthesis through an as yet unknown mol. mechanism.  However, the structure-activity relationships governing aerobic activity do not parallel the relationships detg. anaerobic activity.  Based on the metabolite profiling of PA-824 and various derivs. by Ddn-mediated activation, we have shown that PA-824 acts directly as an NO donor.  This respiratory poisoning through nitric oxide release seemed to be a crucial element of anaerobic activity by PA-824.  The effect of PA-824 on the respiratory complex under hypoxic non-replicating conditions was also manifested in a rapid drop in intracellular ATP levels, again similar to that obsd. by cyanide treatment.  Thus, transcriptional profiling provided valuable clues to elucidating the mol. mechanism of mycobacterial killing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRIjCfr9dB9bVg90H21EOLACvtfcHk0lgPlVwkysTTmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1yru7bF&md5=b7b25a9c2c9b39ff446571c9a2d6d297</span></div><a href="/servlet/linkout?suffix=cit21c&amp;dbid=16384&amp;doi=10.4161%2Fcib.2.3.7926&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcib.2.3.7926%26sid%3Dliteratum%253Aachs%26aulast%3DManjunatha%26aufirst%3DU.%26aulast%3DBoshoff%26aufirst%3DH.%2BI.%26aulast%3DBarry%26aufirst%3DC.%2BE.%26atitle%3DThe%2520Mechanism%2520of%2520Action%2520of%2520PA-824%253A%2520Novel%2520Insights%2520from%2520Transcriptional%2520Profiling%26jtitle%3DCommun.%2520Integr.%2520Biol.%26date%3D2009%26volume%3D2%26spage%3D215%26epage%3D218%26doi%3D10.4161%2Fcib.2.3.7926" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Marsini, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reider, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorensen, E. J.</span></span> <span> </span><span class="NLM_article-title">A Concise and Convergent Synthesis of PA-824</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">7479</span>– <span class="NLM_lpage">7482</span>, <span class="refDoi"> DOI: 10.1021/jo1015807</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo1015807" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1GqsbrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2010&pages=7479-7482&author=M.+A.+Marsiniauthor=P.+J.+Reiderauthor=E.+J.+Sorensen&title=A+Concise+and+Convergent+Synthesis+of+PA-824&doi=10.1021%2Fjo1015807"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22aR"><div class="casContent"><span class="casTitleNuber">22a</span><div class="casTitle"><span class="NLM_cas:atitle">A concise and convergent synthesis of PA-824</span></div><div class="casAuthors">Marsini, Maurice A.; Reider, Paul J.; Sorensen, Erik J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7479-7482</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An efficient four-step synthesis of PA-824 (I), a promising antituberculosis drug candidate, has been developed.  This concise approach offers significant improvements over the synthetic route currently used for large-scale prodn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0pd6Qc_jnNLVg90H21EOLACvtfcHk0lgpyI-3WyoWCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1GqsbrE&md5=6d2dba5d47e3efb9743efecd36e77cb3</span></div><a href="/servlet/linkout?suffix=cit22a&amp;dbid=16384&amp;doi=10.1021%2Fjo1015807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo1015807%26sid%3Dliteratum%253Aachs%26aulast%3DMarsini%26aufirst%3DM.%2BA.%26aulast%3DReider%26aufirst%3DP.%2BJ.%26aulast%3DSorensen%26aufirst%3DE.%2BJ.%26atitle%3DA%2520Concise%2520and%2520Convergent%2520Synthesis%2520of%2520PA-824%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2010%26volume%3D75%26spage%3D7479%26epage%3D7482%26doi%3D10.1021%2Fjo1015807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit22b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutherland, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kmentova, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franzblau, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denny, W. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Structure-Activity Studies of Biphenyl Analogues of the Tuberculosis Drug (6<i>S</i>)-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5<i>H</i>-imidazo[2,1-<i>b</i>][1,3]oxazine (PA-824)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">282</span>– <span class="NLM_lpage">294</span>, <span class="refDoi"> DOI: 10.1021/jm901207n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901207n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVKhs7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=282-294&author=B.+D.+Palmerauthor=A.+M.+Thompsonauthor=H.+S.+Sutherlandauthor=A.+Blaserauthor=I.+Kmentovaauthor=S.+G.+Franzblauauthor=B.+Wanauthor=Y.+Wangauthor=Z.+Maauthor=W.+A.+Denny&title=Synthesis+and+Structure-Activity+Studies+of+Biphenyl+Analogues+of+the+Tuberculosis+Drug+%286S%29-2-Nitro-6-%7B%5B4-%28trifluoromethoxy%29benzyl%5Doxy%7D-6%2C7-dihydro-5H-imidazo%5B2%2C1-b%5D%5B1%2C3%5Doxazine+%28PA-824%29&doi=10.1021%2Fjm901207n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22bR"><div class="casContent"><span class="casTitleNuber">22b</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and structure-activity studies of biphenyl analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)</span></div><div class="casAuthors">Palmer, Brian D.; Thompson, Andrew M.; Sutherland, Hamish S.; Blaser, Adrian; Kmentova, Iveta; Franzblau, Scott G.; Wan, Baojie; Wang, Yuehong; Ma, Zhenkun; Denny, William A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">282-294</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of biphenyl analogs of the new tuberculosis drug PA-824 e. g. , I was prepd., primarily by coupling the known (6S)-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-6-ol with iodobenzyl halides, followed by Suzuki coupling of these iodides with appropriate arylboronic acids or by assembly of the complete biaryl side chain prior to coupling with the above alc.  Antitubercular activity was detd. under both replicating (MABA) and nonreplicating (LORA) conditions.  Para-Linked biaryls were the most active, followed by meta-linked and then ortho-linked analogs.  A more detailed study of a larger group of para-linked analogs showed a significant correlation between potency (MABA) and both lipophilicity (CLOGP) and the electron-withdrawing properties of terminal ring substituents (.sum.σ).  Selected compds. were evaluated for their efficacy in a mouse model of acute Mycobacterium tuberculosis infection.  In vivo activity correlated well with the stability of compds. to microsomal metab.  Three compds. bearing combinations of lipophilic, electron-withdrawing groups achieved >200-fold higher efficacies than the parent drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5IcLLHAUDWbVg90H21EOLACvtfcHk0lgpyI-3WyoWCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVKhs7rL&md5=1ff5a8bd11f095f428898ec13f884259</span></div><a href="/servlet/linkout?suffix=cit22b&amp;dbid=16384&amp;doi=10.1021%2Fjm901207n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901207n%26sid%3Dliteratum%253Aachs%26aulast%3DPalmer%26aufirst%3DB.%2BD.%26aulast%3DThompson%26aufirst%3DA.%2BM.%26aulast%3DSutherland%26aufirst%3DH.%2BS.%26aulast%3DBlaser%26aufirst%3DA.%26aulast%3DKmentova%26aufirst%3DI.%26aulast%3DFranzblau%26aufirst%3DS.%2BG.%26aulast%3DWan%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DZ.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26atitle%3DSynthesis%2520and%2520Structure-Activity%2520Studies%2520of%2520Biphenyl%2520Analogues%2520of%2520the%2520Tuberculosis%2520Drug%2520%25286S%2529-2-Nitro-6-%257B%255B4-%2528trifluoromethoxy%2529benzyl%255Doxy%257D-6%252C7-dihydro-5H-imidazo%255B2%252C1-b%255D%255B1%252C3%255Doxazine%2520%2528PA-824%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D282%26epage%3D294%26doi%3D10.1021%2Fjm901207n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit22c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Strassfeld, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wickens, Z. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picazo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobsen, E. N.</span></span> <span> </span><span class="NLM_article-title">Highly Enantioselective, Hydrogen-Bond-Donor Catalyzed Additions to Oxetanes</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>142</i></span>,  <span class="NLM_fpage">9175</span>– <span class="NLM_lpage">9180</span>, <span class="refDoi"> DOI: 10.1021/jacs.0c03991</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.0c03991" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BB3cXosVKqsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2020&pages=9175-9180&author=D.+A.+Strassfeldauthor=Z.+K.+Wickensauthor=E.+Picazoauthor=E.+N.+Jacobsen&title=Highly+Enantioselective%2C+Hydrogen-Bond-Donor+Catalyzed+Additions+to+Oxetanes&doi=10.1021%2Fjacs.0c03991"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22cR"><div class="casContent"><span class="casTitleNuber">22c</span><div class="casTitle"><span class="NLM_cas:atitle">Highly Enantioselective, Hydrogen-Bond-Donor Catalyzed Additions to Oxetanes</span></div><div class="casAuthors">Strassfeld, Daniel A.; Wickens, Zachary K.; Picazo, Elias; Jacobsen, Eric N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">9175-9180</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A precisely designed chiral squaramide deriv. is shown to promote the highly enantioselective addn. of trimethylsilyl bromide (TMSBr) to a broad variety of 3-substituted and 3,3-disubstituted oxetanes.  The reaction provides direct and general access to synthetically valuable 1,3-bromohydrin building blocks from easily accessed achiral precursors.  The products are readily elaborated both by nucleophilic substitution and through transition-metal-catalyzed cross-coupling reactions.  The enantioselective catalytic oxetane ring opening was employed as part of a three-step, gram-scale synthesis of pretomanid, a recently approved medication for the treatment of multidrug-resistant tuberculosis.  Heavy-atom kinetic isotope effect (KIE) studies are consistent with enantiodetermining delivery of bromide from the H-bond-donor (HBD) catalyst to the activated oxetane.  While the nucleophilicity of the bromide ion is expected to be attenuated by assocn. to the HBD, overall rate acceleration is achieved by enhancement of Lewis acidity of the TMSBr reagent through anion abstraction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoU1lCPb-jtirVg90H21EOLACvtfcHk0lgpyI-3WyoWCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXosVKqsbY%253D&md5=ccc51be70e5455ce0da0a75a6eb2c871</span></div><a href="/servlet/linkout?suffix=cit22c&amp;dbid=16384&amp;doi=10.1021%2Fjacs.0c03991&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.0c03991%26sid%3Dliteratum%253Aachs%26aulast%3DStrassfeld%26aufirst%3DD.%2BA.%26aulast%3DWickens%26aufirst%3DZ.%2BK.%26aulast%3DPicazo%26aufirst%3DE.%26aulast%3DJacobsen%26aufirst%3DE.%2BN.%26atitle%3DHighly%2520Enantioselective%252C%2520Hydrogen-Bond-Donor%2520Catalyzed%2520Additions%2520to%2520Oxetanes%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2020%26volume%3D142%26spage%3D9175%26epage%3D9180%26doi%3D10.1021%2Fjacs.0c03991" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit22d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinde, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franzblau, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denny, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, B. D.</span></span> <span> </span><span class="NLM_article-title">Synthesis, Reduction Potentials, and Antitubercular Activity of Ring A/B Analogues of the Bioreductive Drug (6<i>S</i>)-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5<i>H</i>-imidazo[2,1-<i>b</i>][1,3]oxazine (PA-824)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">637</span>– <span class="NLM_lpage">645</span>, <span class="refDoi"> DOI: 10.1021/jm801087e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801087e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFais7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=637-645&author=A.+M.+Thompsonauthor=A.+Blaserauthor=R.+F.+Andersonauthor=S.+S.+Shindeauthor=S.+G.+Franzblauauthor=Z.+Maauthor=W.+A.+Dennyauthor=B.+D.+Palmer&title=Synthesis%2C+Reduction+Potentials%2C+and+Antitubercular+Activity+of+Ring+A%2FB+Analogues+of+the+Bioreductive+Drug+%286S%29-2-Nitro-6-%7B%5B4-%28trifluoromethoxy%29benzyl%5Doxy%7D-6%2C7-dihydro-5H-imidazo%5B2%2C1-b%5D%5B1%2C3%5Doxazine+%28PA-824%29&doi=10.1021%2Fjm801087e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22dR"><div class="casContent"><span class="casTitleNuber">22d</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Reduction Potentials, and Antitubercular Activity of Ring A/B Analogues of the Bioreductive Drug (6S)-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)</span></div><div class="casAuthors">Thompson, Andrew M.; Blaser, Adrian; Anderson, Robert F.; Shinde, Sujata S.; Franzblau, Scott G.; Ma, Zhenkun; Denny, William A.; Palmer, Brian D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">637-645</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The nitroimidazooxazine I (PA-824) is a new class of bioreductive drug for tuberculosis.  A series of related bicyclic nitroheterocycles was synthesized, designed to have a wide range of one-electron redn. potentials E(1) (from -570 to -338 mV, compared with -534 mV for I).  The obsd. E(1) values closely correlated with the σm values of the heteroatom at the 4/8-position of the adjacent six-membered ring.  Although the compds. spanned a range of E(1) values around that of I, only the nitroimidazothiazines showed significant antitubercular activity (at a similar level of potency), suggesting that E(1) is not the main driver of efficacy.  Furthermore, there was a correlation between activity and the formation of imidazole ring-reduced products at the two-electron level, pointing to the potential importance of this redn. pathway, which is detd. by the nature of the substituent at the 2-position of the 4-nitroimidazole ring.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoalNzH_DuAirVg90H21EOLACvtfcHk0lg6M6PrXZaiQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFais7%252FK&md5=a9fe7edce4c538f14ddec49942a1e9a0</span></div><a href="/servlet/linkout?suffix=cit22d&amp;dbid=16384&amp;doi=10.1021%2Fjm801087e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801087e%26sid%3Dliteratum%253Aachs%26aulast%3DThompson%26aufirst%3DA.%2BM.%26aulast%3DBlaser%26aufirst%3DA.%26aulast%3DAnderson%26aufirst%3DR.%2BF.%26aulast%3DShinde%26aufirst%3DS.%2BS.%26aulast%3DFranzblau%26aufirst%3DS.%2BG.%26aulast%3DMa%26aufirst%3DZ.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DPalmer%26aufirst%3DB.%2BD.%26atitle%3DSynthesis%252C%2520Reduction%2520Potentials%252C%2520and%2520Antitubercular%2520Activity%2520of%2520Ring%2520A%252FB%2520Analogues%2520of%2520the%2520Bioreductive%2520Drug%2520%25286S%2529-2-Nitro-6-%257B%255B4-%2528trifluoromethoxy%2529benzyl%255Doxy%257D-6%252C7-dihydro-5H-imidazo%255B2%252C1-b%255D%255B1%252C3%255Doxazine%2520%2528PA-824%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D637%26epage%3D645%26doi%3D10.1021%2Fjm801087e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit22e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Orita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miwa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uehara, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otera, J.</span></span> <span> </span><span class="NLM_article-title">Integration of Solventless Reaction in a Multi-Step Process: Application to an Efficient Synthesis of PA-824</span>. <i>Adv. Synth. Catal.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>349</i></span>,  <span class="NLM_fpage">2136</span>– <span class="NLM_lpage">2144</span>, <span class="refDoi"> DOI: 10.1002/adsc.200700119</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1002%2Fadsc.200700119" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFCnt7bO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=349&publication_year=2007&pages=2136-2144&author=A.+Oritaauthor=K.+Miwaauthor=G.+Ueharaauthor=J.+Otera&title=Integration+of+Solventless+Reaction+in+a+Multi-Step+Process%3A+Application+to+an+Efficient+Synthesis+of+PA-824&doi=10.1002%2Fadsc.200700119"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22eR"><div class="casContent"><span class="casTitleNuber">22e</span><div class="casTitle"><span class="NLM_cas:atitle">Integration of solventless reaction in a multi-step process: application to an efficient synthesis of PA-824</span></div><div class="casAuthors">Orita, Akihiro; Miwa, Kai; Uehara, Genta; Otera, Junzo</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Synthesis & Catalysis</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">349</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2136-2144</span>CODEN:
                <span class="NLM_cas:coden">ASCAF7</span>;
        ISSN:<span class="NLM_cas:issn">1615-4150</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">In order to improve redundant synthetic processes, the integration of a solventless reaction has proved to be useful for gaining high reaction mass efficiency (RME) as well as reducing the amt. of solvents.  This concept was applied to synthesis of PA-824, a potential antituberculosis drug.  Thus, the solventless ring-opening reaction of glycidyl silyl ether with 2,4-dinitroimidazole was connected to succeeding soln. reactions.  The ring-opening of glycidol followed by selective silylation of the primary hydroxy group under solventless conditions was also feasible.  As a consequence, the overall yield of the target compd. was nearly tripled, and thus the RME values were increased more than 2.5 times while the amt. of necessary solvents was decreased to less than 1/3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcpf25EF_EW7Vg90H21EOLACvtfcHk0lg6M6PrXZaiQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFCnt7bO&md5=869a7057a842e377f50972650e8a4802</span></div><a href="/servlet/linkout?suffix=cit22e&amp;dbid=16384&amp;doi=10.1002%2Fadsc.200700119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fadsc.200700119%26sid%3Dliteratum%253Aachs%26aulast%3DOrita%26aufirst%3DA.%26aulast%3DMiwa%26aufirst%3DK.%26aulast%3DUehara%26aufirst%3DG.%26aulast%3DOtera%26aufirst%3DJ.%26atitle%3DIntegration%2520of%2520Solventless%2520Reaction%2520in%2520a%2520Multi-Step%2520Process%253A%2520Application%2520to%2520an%2520Efficient%2520Synthesis%2520of%2520PA-824%26jtitle%3DAdv.%2520Synth.%2520Catal.%26date%3D2007%26volume%3D349%26spage%3D2136%26epage%3D2144%26doi%3D10.1002%2Fadsc.200700119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Baker, W. R.</span>; <span class="NLM_string-name">Cai, S.</span>; <span class="NLM_string-name">Keeler, E. L.</span></span> <span> </span><span class="NLM_article-title">Preparation of Bicyclic Nitroimidazole Antibacterial Compounds</span>. <span class="NLM_patent">WO 9701562 A1</span>, <span class="NLM_year">1997</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1997&author=W.+R.+Baker&author=S.+Cai&author=E.+L.+Keeler&title=Preparation+of+Bicyclic+Nitroimidazole+Antibacterial+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBaker%26aufirst%3DW.%2BR.%26atitle%3DPreparation%2520of%2520Bicyclic%2520Nitroimidazole%2520Antibacterial%2520Compounds%26date%3D1997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit23b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Baker, W. R.</span>; <span class="NLM_string-name">Cai, S.</span>; <span class="NLM_string-name">Keeler, E. L.</span></span> <span> </span><span class="NLM_article-title">Nitro-[2,1-<i>b</i>]imidazopyran Compounds and Antibacterial Uses Thereof</span>. <span class="NLM_patent">US 6087358 A</span>, <span class="NLM_year">2000</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2000&author=W.+R.+Baker&author=S.+Cai&author=E.+L.+Keeler&title=Nitro-%5B2%2C1-b%5Dimidazopyran+Compounds+and+Antibacterial+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBaker%26aufirst%3DW.%2BR.%26atitle%3DNitro-%255B2%252C1-b%255Dimidazopyran%2520Compounds%2520and%2520Antibacterial%2520Uses%2520Thereof%26date%3D2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Miao, D.</span>; <span class="NLM_string-name">Hu, Q.</span>; <span class="NLM_string-name">Li, Y.</span>; <span class="NLM_string-name">Yu, Z.</span>; <span class="NLM_string-name">Wang, H.</span>; <span class="NLM_string-name">Zhu, X.</span></span> <span> </span><span class="NLM_article-title">Synthesis Method of PA-824 (Pretomanid) for Treating Tuberculosis</span>. <span class="NLM_patent">CN 107915747 A</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=D.+Miao&author=Q.+Hu&author=Y.+Li&author=Z.+Yu&author=H.+Wang&author=X.+Zhu&title=Synthesis+Method+of+PA-824+%28Pretomanid%29+for+Treating+Tuberculosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMiao%26aufirst%3DD.%26atitle%3DSynthesis%2520Method%2520of%2520PA-824%2520%2528Pretomanid%2529%2520for%2520Treating%2520Tuberculosis%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit24b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Miao, D.</span>; <span class="NLM_string-name">Hu, Q.</span>; <span class="NLM_string-name">Zhang, X.</span>; <span class="NLM_string-name">Zhao, L.</span>; <span class="NLM_string-name">Cao, Y.</span>; <span class="NLM_string-name">Wang, H.</span></span> <span> </span><span class="NLM_article-title">Crystal Form of PA-824 and Preparation Method, and Its Application for Treating Tuberculosis (TB)</span>. <span class="NLM_patent">CN 106565744 A</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=D.+Miao&author=Q.+Hu&author=X.+Zhang&author=L.+Zhao&author=Y.+Cao&author=H.+Wang&title=Crystal+Form+of+PA-824+and+Preparation+Method%2C+and+Its+Application+for+Treating+Tuberculosis+%28TB%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMiao%26aufirst%3DD.%26atitle%3DCrystal%2520Form%2520of%2520PA-824%2520and%2520Preparation%2520Method%252C%2520and%2520Its%2520Application%2520for%2520Treating%2520Tuberculosis%2520%2528TB%2529%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit24c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.</span></span> <span> </span><span class="NLM_article-title">Synthesis Research of PA-824 as Antituberculosis Candidate</span>. <i>Huagong Shikan</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">51</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtV2rsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2010&pages=32-51&author=T.+Wangauthor=H.+Zhangauthor=H.+Fan&title=Synthesis+Research+of+PA-824+as+Antituberculosis+Candidate"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24cR"><div class="casContent"><span class="casTitleNuber">24c</span><div class="casTitle"><span class="NLM_cas:atitle">Microwave-assisted extraction method of Cuphea hookeriana Walp pigment</span></div><div class="casAuthors">Sun, Qianhong; Wang, Ying; Zhang, Lei; Wang, Binyu</div><div class="citationInfo"><span class="NLM_cas:title">Huagong Shikan</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">32-35</span>CODEN:
                <span class="NLM_cas:coden">HUSHFT</span>;
        ISSN:<span class="NLM_cas:issn">1002-154X</span>.
    
            (<span class="NLM_cas:orgname">Huagong Shikan Zazhishe</span>)
        </div><div class="casAbstract">The aim of this paper is to construct a microwave-assisted extn. method for extg. pigment of Cuphea hookeriana Walp.  Process parameters for different extn. process conditions were optimized.  The correlation of parameters to the extn. yield followed a order: liq. materials>power>ethanol concn.>microwave processing time.  The optimal technique was obtained as follows: solvent 80% of acidic aq. alc., microwave power 800 W, the solid/liq. proportion 1g:30mL, extg. time 60s.  Compared with traditional methods, the microwave extn. method has advantages of high efficiency, quick extn. rate and lower energy consumption, and it has a bright prospects for application in pigment extn. of plant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUhJM_AnDOkrVg90H21EOLACvtfcHk0lg6M6PrXZaiQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtV2rsw%253D%253D&md5=a8c9d249c0bb259eec0b063a6ce4cd38</span></div><a href="/servlet/linkout?suffix=cit24c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DFan%26aufirst%3DH.%26atitle%3DSynthesis%2520Research%2520of%2520PA-824%2520as%2520Antituberculosis%2520Candidate%26jtitle%3DHuagong%2520Shikan%26date%3D2010%26volume%3D24%26spage%3D32%26epage%3D51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit24d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, M.</span>; <span class="NLM_string-name">Yang, C.</span>; <span class="NLM_string-name">Li, L.</span>; <span class="NLM_string-name">Liu, E.</span>; <span class="NLM_string-name">Li, L.</span>; <span class="NLM_string-name">Zhan, H.</span>; <span class="NLM_string-name">Fan, W.</span>; <span class="NLM_string-name">Tian, J.</span>; <span class="NLM_string-name">Sang, D.</span>; <span class="NLM_string-name">Mao, X.</span></span> <span> </span><span class="NLM_article-title">A Method for Synthesizing Antituberculosis Drug Candidate PA-824</span>. <span class="NLM_patent">CN 106632393 A</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=M.+Yao&author=C.+Yang&author=L.+Li&author=E.+Liu&author=L.+Li&author=H.+Zhan&author=W.+Fan&author=J.+Tian&author=D.+Sang&author=X.+Mao&title=A+Method+for+Synthesizing+Antituberculosis+Drug+Candidate+PA-824"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DM.%26atitle%3DA%2520Method%2520for%2520Synthesizing%2520Antituberculosis%2520Drug%2520Candidate%2520PA-824%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit24e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, X.</span>; <span class="NLM_string-name">Miao, X.</span>; <span class="NLM_string-name">Guo, M.</span>; <span class="NLM_string-name">Gong, P.</span>; <span class="NLM_string-name">Jiang, N.</span>; <span class="NLM_string-name">Chen, G.</span></span> <span> </span><span class="NLM_article-title">Preparation Method of Nitroimidazolopyran Compound, and Its Application in Treating Tuberculosis</span>. <span class="NLM_patent">CN 110483549 A</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=X.+Zhai&author=X.+Miao&author=M.+Guo&author=P.+Gong&author=N.+Jiang&author=G.+Chen&title=Preparation+Method+of+Nitroimidazolopyran+Compound%2C+and+Its+Application+in+Treating+Tuberculosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZhai%26aufirst%3DX.%26atitle%3DPreparation%2520Method%2520of%2520Nitroimidazolopyran%2520Compound%252C%2520and%2520Its%2520Application%2520in%2520Treating%2520Tuberculosis%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, B. P.</span>; <span class="NLM_string-name">Reddy, K. R.</span>; <span class="NLM_string-name">Reddy, A. V. N.</span>; <span class="NLM_string-name">Krishna, B. V.</span></span> <span> </span><span class="NLM_article-title">An Improved Process for Preparing Pretomanid</span>. <span class="NLM_patent">IN 201641030408 A</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=B.+P.+Reddy&author=K.+R.+Reddy&author=A.+V.+N.+Reddy&author=B.+V.+Krishna&title=An+Improved+Process+for+Preparing+Pretomanid"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DReddy%26aufirst%3DB.%2BP.%26atitle%3DAn%2520Improved%2520Process%2520for%2520Preparing%2520Pretomanid%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rybak, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claeys, K. C.</span></span> <span> </span><span class="NLM_article-title">Imipenem-Cilastatin-Relebactam: A Novel B-Lactam-B-Lactamase Inhibitor Combination for the Treatment of Multidrug-Resistant Gram-Negative Infections</span>. <i>Pharmacotherapy</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">343</span>– <span class="NLM_lpage">356</span>, <span class="refDoi"> DOI: 10.1002/phar.2378</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1002%2Fphar.2378" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=32060929" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BB3cXntFSmt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2020&pages=343-356&author=J.+R.+Smithauthor=J.+M.+Rybakauthor=K.+C.+Claeys&title=Imipenem-Cilastatin-Relebactam%3A+A+Novel+B-Lactam-B-Lactamase+Inhibitor+Combination+for+the+Treatment+of+Multidrug-Resistant+Gram-Negative+Infections&doi=10.1002%2Fphar.2378"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Imipenem-Cilastatin-Relebactam: A Novel β-Lactam-β-Lactamase Inhibitor Combination for the Treatment of Multidrug-Resistant Gram-Negative Infections</span></div><div class="casAuthors">Smith, Jordan R.; Rybak, Jeffrey M.; Claeys, Kimberly C.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacotherapy</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">343-356</span>CODEN:
                <span class="NLM_cas:coden">PHPYDQ</span>;
        ISSN:<span class="NLM_cas:issn">1875-9114</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Imipenem-cilastatin-relebactam (IMI-REL) is a novel β-lactam-β-lactamase inhibitor combination recently approved for the treatment of complicated urinary tract infections (cUTIs) and complicated intraabdominal infections (cIAIs).  Relebactam is a β-lactamase inhibitor with the ability to inhibit a broad spectrum of β-lactamases such as class A and class C β-lactamases, including carbapenemases.  The addn. of relebactam to imipenem restores imipenem activity against several imipenem-resistant bacteria, including Enterobacteriaceae and Pseudomonas aeruginosa.  Clin. data demonstrate that IMI-REL is well tolerated and effective in the treatment of cUTIs and cIAIs due to imipenem-resistant bacteria.  In a phase III trial comparing IMI-REL with imipenem plus colistin, favorable clin. response was achieved in 71% and 70% of patients, resp.  Available clin. and pharmacokinetic data support the approved dosage of a 30-min infusion of imipenem 500 mg-cilastatin 500 mg-relebactam 250 mg every 6 h, along with dosage adjustments based on renal function.  In this review, we describe the chem., mechanism of action, spectrum of activity, pharmacokinetics and pharmacodynamics, and clin. efficacy, and safety and tolerability of this new agent.  The approval of IMI-REL represents another important step in the ongoing fight against multidrug-resistant gram-neg. pathogens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGph2Rjs531UWbVg90H21EOLACvtfcHk0lg8s2NV3Mfy6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXntFSmt7s%253D&md5=6e670b780d6b80a00075df2de6ae4d9b</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1002%2Fphar.2378&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fphar.2378%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DJ.%2BR.%26aulast%3DRybak%26aufirst%3DJ.%2BM.%26aulast%3DClaeys%26aufirst%3DK.%2BC.%26atitle%3DImipenem-Cilastatin-Relebactam%253A%2520A%2520Novel%2520B-Lactam-B-Lactamase%2520Inhibitor%2520Combination%2520for%2520the%2520Treatment%2520of%2520Multidrug-Resistant%2520Gram-Negative%2520Infections%26jtitle%3DPharmacotherapy%26date%3D2020%26volume%3D40%26spage%3D343%26epage%3D356%26doi%3D10.1002%2Fphar.2378" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Bhagunde, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Racine, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizk, M. L.</span></span> <span> </span><span class="NLM_article-title">A Translational Pharmacokinetic/Pharmacodynamic Model to Characterize Bacterial Kill in the Presence of Imipenem-Relebactam</span>. <i>Int. J. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">55</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1016/j.ijid.2019.08.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2Fj.ijid.2019.08.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31479762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVOmtr%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2019&pages=55-61&author=P.+Bhagundeauthor=Z.+Zhangauthor=F.+Racineauthor=D.+Carrauthor=J.+Wuauthor=K.+Youngauthor=M.+L.+Rizk&title=A+Translational+Pharmacokinetic%2FPharmacodynamic+Model+to+Characterize+Bacterial+Kill+in+the+Presence+of+Imipenem-Relebactam&doi=10.1016%2Fj.ijid.2019.08.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27aR"><div class="casContent"><span class="casTitleNuber">27a</span><div class="casTitle"><span class="NLM_cas:atitle">A translational pharmacokinetic/pharmacodynamic model to characterize bacterial kill in the presence of imipenem-relebactam</span></div><div class="casAuthors">Bhagunde, Pratik; Zhang, Zufei; Racine, Fred; Carr, Donna; Wu, Jin; Young, Katherine; Rizk, Matthew L.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Infectious Diseases</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">55-61</span>CODEN:
                <span class="NLM_cas:coden">IJIDF3</span>;
        ISSN:<span class="NLM_cas:issn">1201-9712</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Relebactam is a small mol. β-lactamase inhibitor under clin. investigation for use as a fixed-dose combination with imipenem/cilastatin.  Here we present a translational pharmacokinetic/pharmacodynamic math. model to support optimal dose selection of relebactam.  Data derived from in vitro checkerboard and hollow fiber infection studies of imipenem-resistant strains of Pseudomonas aeruginosa were incorporated into the model.  The model integrates the effect of relebactam concn. on imipenem susceptibility in a semi-mechanistic manner using the checkerboard data and characterizes the bacterial time-kill profiles from the hollow fiber infection model data.  Simulations demonstrated that the ratio of the area under the concn.-time curve for free drug to the min. inhibitory concn. (fAUC/MIC) was the pharmacokinetic driver for relebactam, with a target fAUC/MIC = 7.5 assocd. with 2-log kill.  At a clin. dose of 250 mg relebactam, greater than 2-log redns. in bacterial load are projected for imipenem-resistant strains with an imipenem/relebactam MIC ≤ 4μg/mL.  The study confirms that the pharmacokinetic/pharmacodynamic driver for relebactam is fAUC/MIC, that an fAUC/MIC ratio of 7.5 is assocd. with 2-log kill in vitro, and that a 250 mg clin. dose of relebactam achieves this target value when delivered in combination with imipenem/cilastatin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbxW9s5LhnNbVg90H21EOLACvtfcHk0lg8s2NV3Mfy6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVOmtr%252FP&md5=6652628dd0f67ca153408a9b338ac6ff</span></div><a href="/servlet/linkout?suffix=cit27a&amp;dbid=16384&amp;doi=10.1016%2Fj.ijid.2019.08.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijid.2019.08.026%26sid%3Dliteratum%253Aachs%26aulast%3DBhagunde%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DRacine%26aufirst%3DF.%26aulast%3DCarr%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DYoung%26aufirst%3DK.%26aulast%3DRizk%26aufirst%3DM.%2BL.%26atitle%3DA%2520Translational%2520Pharmacokinetic%252FPharmacodynamic%2520Model%2520to%2520Characterize%2520Bacterial%2520Kill%2520in%2520the%2520Presence%2520of%2520Imipenem-Relebactam%26jtitle%3DInt.%2520J.%2520Infect.%2520Dis.%26date%3D2019%26volume%3D89%26spage%3D55%26epage%3D61%26doi%3D10.1016%2Fj.ijid.2019.08.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit27b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kaushik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ammerman, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martins, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreiswirth, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamichhane, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parrish, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuermberger, E. L.</span></span> <span> </span><span class="NLM_article-title"><i>In vitro</i> Activity of the New β-Lactamase Inhibitors Relebactam and Vaborbactam in Combination with β-Lactams against Mycobacterium Abscessus Complex Clinical Isolates</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">e02623-18</span>, <span class="refDoi"> DOI: 10.1128/AAC.02623-18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1128%2FAAC.02623-18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=30642943" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2019&pages=e02623-18&author=A.+Kaushikauthor=N.+C.+Ammermanauthor=J.+Leeauthor=O.+Martinsauthor=B.+N.+Kreiswirthauthor=G.+Lamichhaneauthor=N.+M.+Parrishauthor=E.+L.+Nuermberger&title=In+vitro+Activity+of+the+New+%CE%B2-Lactamase+Inhibitors+Relebactam+and+Vaborbactam+in+Combination+with+%CE%B2-Lactams+against+Mycobacterium+Abscessus+Complex+Clinical+Isolates&doi=10.1128%2FAAC.02623-18"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27b&amp;dbid=16384&amp;doi=10.1128%2FAAC.02623-18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.02623-18%26sid%3Dliteratum%253Aachs%26aulast%3DKaushik%26aufirst%3DA.%26aulast%3DAmmerman%26aufirst%3DN.%2BC.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DMartins%26aufirst%3DO.%26aulast%3DKreiswirth%26aufirst%3DB.%2BN.%26aulast%3DLamichhane%26aufirst%3DG.%26aulast%3DParrish%26aufirst%3DN.%2BM.%26aulast%3DNuermberger%26aufirst%3DE.%2BL.%26atitle%3DIn%2520vitro%2520Activity%2520of%2520the%2520New%2520%25CE%25B2-Lactamase%2520Inhibitors%2520Relebactam%2520and%2520Vaborbactam%2520in%2520Combination%2520with%2520%25CE%25B2-Lactams%2520against%2520Mycobacterium%2520Abscessus%2520Complex%2520Clinical%2520Isolates%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2019%26volume%3D63%26spage%3De02623-18%26doi%3D10.1128%2FAAC.02623-18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit27c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, M. W.</span></span> <span> </span><span class="NLM_article-title">Clinical Pharmacokinetics and Pharmacodynamics of Imipenem-Cilastatin/Relebactam Combination Therapy</span>. <i>Clin. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">567</span>– <span class="NLM_lpage">573</span>, <span class="refDoi"> DOI: 10.1007/s40262-020-00865-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs40262-020-00865-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=32009210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BB3cXls1ynurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2020&pages=567-573&author=M.+W.+McCarthy&title=Clinical+Pharmacokinetics+and+Pharmacodynamics+of+Imipenem-Cilastatin%2FRelebactam+Combination+Therapy&doi=10.1007%2Fs40262-020-00865-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27cR"><div class="casContent"><span class="casTitleNuber">27c</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical Pharmacokinetics and Pharmacodynamics of Imipenem-Cilastatin/Relebactam Combination Therapy</span></div><div class="casAuthors">McCarthy, Matthew W.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">567-573</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Abstr.: On 16 July, 2019, the US Food and Drug Administration approved imipenem-cilastatin/relebactam (Recarbrio) for the treatment of adults with complicated urinary tract infections and complicated intra-abdominal infections.  This decision was based on substantial clin. and pre-clin. data, including rigorous pharmacokinetic and pharmacodynamic work, and is an important step forward in the management of these debilitating conditions.  This article provides an overview of the body of research assocd. with imipenem-cilastatin/relebactam, beginning with an examn. of the fundamental underpinnings of the pharmacokinetic/pharmacodynamic index.  This is followed by the pharmacokinetic/pharmacodynamic work that led to the approval of this novel drug combination, including data derived from checkerboard and hollow fiber infection studies, as well as large, multi-center, phase III clin. trials known as RESTORE-IMI 1 and RESTORE-IMI 2.  The article also explores how this important new antibiotic may be used to treat other infections in the years to come, including hospital-acquired bacterial pneumonia and ventilator-assocd. pneumonia attributed to imipenem-non-susceptible pathogens and certain atypical mycobacterial infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqx8mmN0IZvKrVg90H21EOLACvtfcHk0lhF7obIZnXYPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXls1ynurg%253D&md5=03311683cc74d3be2dc4dc4d2538fb55</span></div><a href="/servlet/linkout?suffix=cit27c&amp;dbid=16384&amp;doi=10.1007%2Fs40262-020-00865-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40262-020-00865-3%26sid%3Dliteratum%253Aachs%26aulast%3DMcCarthy%26aufirst%3DM.%2BW.%26atitle%3DClinical%2520Pharmacokinetics%2520and%2520Pharmacodynamics%2520of%2520Imipenem-Cilastatin%252FRelebactam%2520Combination%2520Therapy%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2020%26volume%3D59%26spage%3D567%26epage%3D573%26doi%3D10.1007%2Fs40262-020-00865-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Blizzard, T. A.</span>; <span class="NLM_string-name">Chen, H.</span>; <span class="NLM_string-name">Gude, C.</span>; <span class="NLM_string-name">Hermes, J. D.</span>; <span class="NLM_string-name">Imbriglio, J. E.</span>; <span class="NLM_string-name">Kim, S.</span>; <span class="NLM_string-name">Wu, J. Y.</span>; <span class="NLM_string-name">Ha, S.</span>; <span class="NLM_string-name">Mortko, C. J.</span>; <span class="NLM_string-name">Mangion, I.</span>; <span class="NLM_string-name">Rivera, N.</span>; <span class="NLM_string-name">Ruck, R. T.</span>; <span class="NLM_string-name">Shevlin, M.</span></span> <span> </span><span class="NLM_article-title">Preparation of Sulfooxydiazabicyclooctanecarboxamide Derivatives and Analogues for Use as β-Lactamase Inhibitors</span>. <span class="NLM_patent">WO 2009091856 A2</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=T.+A.+Blizzard&author=H.+Chen&author=C.+Gude&author=J.+D.+Hermes&author=J.+E.+Imbriglio&author=S.+Kim&author=J.+Y.+Wu&author=S.+Ha&author=C.+J.+Mortko&author=I.+Mangion&author=N.+Rivera&author=R.+T.+Ruck&author=M.+Shevlin&title=Preparation+of+Sulfooxydiazabicyclooctanecarboxamide+Derivatives+and+Analogues+for+Use+as+%CE%B2-Lactamase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBlizzard%26aufirst%3DT.%2BA.%26atitle%3DPreparation%2520of%2520Sulfooxydiazabicyclooctanecarboxamide%2520Derivatives%2520and%2520Analogues%2520for%2520Use%2520as%2520%25CE%25B2-Lactamase%2520Inhibitors%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit28b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, J. Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shevlin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gudipati, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, Y.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, F.</span></span> <span> </span><span class="NLM_article-title">Diastereoselective FeCl3·6H2O/NaBH4 Reduction of Oxime Ether for the Synthesis of β-Lactamase Inhibitor Relebactam</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">994</span>– <span class="NLM_lpage">1000</span>, <span class="refDoi"> DOI: 10.1021/acs.joc.9b02948</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.joc.9b02948" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVWqsLbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2020&pages=994-1000&author=J.+Y.+L.+Chungauthor=D.+Mengauthor=M.+Shevlinauthor=V.+Gudipatiauthor=Q.+Chenauthor=Y.+Liuauthor=Y.-H.+Lamauthor=A.+Dumasauthor=J.+Scottauthor=Q.+Tuauthor=F.+Xu&title=Diastereoselective+FeCl3%C2%B76H2O%2FNaBH4+Reduction+of+Oxime+Ether+for+the+Synthesis+of+%CE%B2-Lactamase+Inhibitor+Relebactam&doi=10.1021%2Facs.joc.9b02948"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28bR"><div class="casContent"><span class="casTitleNuber">28b</span><div class="casTitle"><span class="NLM_cas:atitle">Diastereoselective FeCl3·6H2O/NaBH4 Reduction of Oxime Ether for the Synthesis of β-Lactamase Inhibitor Relebactam</span></div><div class="casAuthors">Chung, John Y. L.; Meng, Dongfang; Shevlin, Michael; Gudipati, Venugopal; Chen, Qinghao; Liu, Yizhou; Lam, Yu-hong; Dumas, Aaron; Scott, Jeremy; Tu, Qiang; Xu, Feng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">994-1000</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Relebactam, a potent β-lactamase inhibitor, in combination with Primaxin is an FDA-approved (Recarbrio) treatment for serious and antibiotic-resistant bacterial infections.  An efficient synthesis of key chiral piperidine intermediate I suitable for large-scale prepn. of relebactam is described.  The key steps include a unique highly diastereoselective FeCl3·6H2O/NaBH4 redn. of a chiral oxime ether and chemoselective amidation of the resulting unprotected pipecolic acid.  NMR studies and d. functional theory calcns. were carried out on the substrate-Fe(III) complexes, which shed light on diastereoselective redn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokHfs8PHiCoLVg90H21EOLACvtfcHk0lhF7obIZnXYPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVWqsLbJ&md5=2974d820ed9f3a93879c057494cf25e9</span></div><a href="/servlet/linkout?suffix=cit28b&amp;dbid=16384&amp;doi=10.1021%2Facs.joc.9b02948&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.joc.9b02948%26sid%3Dliteratum%253Aachs%26aulast%3DChung%26aufirst%3DJ.%2BY.%2BL.%26aulast%3DMeng%26aufirst%3DD.%26aulast%3DShevlin%26aufirst%3DM.%26aulast%3DGudipati%26aufirst%3DV.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLam%26aufirst%3DY.-H.%26aulast%3DDumas%26aufirst%3DA.%26aulast%3DScott%26aufirst%3DJ.%26aulast%3DTu%26aufirst%3DQ.%26aulast%3DXu%26aufirst%3DF.%26atitle%3DDiastereoselective%2520FeCl3%25C2%25B76H2O%252FNaBH4%2520Reduction%2520of%2520Oxime%2520Ether%2520for%2520the%2520Synthesis%2520of%2520%25CE%25B2-Lactamase%2520Inhibitor%2520Relebactam%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2020%26volume%3D85%26spage%3D994%26epage%3D1000%26doi%3D10.1021%2Facs.joc.9b02948" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit28c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, E. M.</span>; <span class="NLM_string-name">Freund, J.</span>; <span class="NLM_string-name">Gallop, M. A.</span>; <span class="NLM_string-name">Duncton, M. A. J.</span></span> <span> </span><span class="NLM_article-title">β-Lactamase Inhibitors and Uses Thereof</span>. <span class="NLM_patent">WO 2018208557 A1</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=E.+M.+Gordon&author=J.+Freund&author=M.+A.+Gallop&author=M.+A.+J.+Duncton&title=%CE%B2-Lactamase+Inhibitors+and+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGordon%26aufirst%3DE.%2BM.%26atitle%3D%25CE%25B2-Lactamase%2520Inhibitors%2520and%2520Uses%2520Thereof%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit28d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasuda, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reamer, R. A.</span></span> <span> </span><span class="NLM_article-title">N-Boc Deprotection and Isolation Method for Water-Soluble Zwitterionic Compounds</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">11792</span>– <span class="NLM_lpage">11796</span>, <span class="refDoi"> DOI: 10.1021/jo502319z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo502319z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVyjtLfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2014&pages=11792-11796&author=Z.+Liuauthor=N.+Yasudaauthor=M.+Simeoneauthor=R.+A.+Reamer&title=N-Boc+Deprotection+and+Isolation+Method+for+Water-Soluble+Zwitterionic+Compounds&doi=10.1021%2Fjo502319z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28dR"><div class="casContent"><span class="casTitleNuber">28d</span><div class="casTitle"><span class="NLM_cas:atitle">N-Boc Deprotection and Isolation Method for Water-Soluble Zwitterionic Compounds</span></div><div class="casAuthors">Liu, Zhijian; Yasuda, Nobuyoshi; Simeone, Michael; Reamer, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">11792-11796</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A highly efficient TMSI-mediated deprotection and direct isolation method to obtain zwitterionic compds. from the corresponding N-Boc derivs. has been developed.  This method has been demonstrated in the final deprotection/isolation of the β-lactamase inhibitor MK-7655 as a part of its manufg. process.  Further application of this process toward other zwitterionic compds., such as dipeptides and tripeptides, has been successfully developed.  Furthermore, a catalytic version of this transformation has been demonstrated in the presence of BSA or BSTFA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqk_bYF7atVrVg90H21EOLACvtfcHk0lgYKS2g99esFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVyjtLfP&md5=9b486f313ca22a0cbca5a7be880b0c17</span></div><a href="/servlet/linkout?suffix=cit28d&amp;dbid=16384&amp;doi=10.1021%2Fjo502319z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo502319z%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DYasuda%26aufirst%3DN.%26aulast%3DSimeone%26aufirst%3DM.%26aulast%3DReamer%26aufirst%3DR.%2BA.%26atitle%3DN-Boc%2520Deprotection%2520and%2520Isolation%2520Method%2520for%2520Water-Soluble%2520Zwitterionic%2520Compounds%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2014%26volume%3D79%26spage%3D11792%26epage%3D11796%26doi%3D10.1021%2Fjo502319z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit28e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Mangion, I. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruck, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huffman, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shevlin, M.</span></span> <span> </span><span class="NLM_article-title">A Concise Synthesis of a β-Lactamase Inhibitor</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">5480</span>– <span class="NLM_lpage">5483</span>, <span class="refDoi"> DOI: 10.1021/ol202195n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol202195n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFOqu7%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=5480-5483&author=I.+K.+Mangionauthor=R.+T.+Ruckauthor=N.+Riveraauthor=M.+A.+Huffmanauthor=M.+Shevlin&title=A+Concise+Synthesis+of+a+%CE%B2-Lactamase+Inhibitor&doi=10.1021%2Fol202195n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28eR"><div class="casContent"><span class="casTitleNuber">28e</span><div class="casTitle"><span class="NLM_cas:atitle">A concise synthesis of a β-lactamase inhibitor</span></div><div class="casAuthors">Mangion, Ian K.; Ruck, Rebecca T.; Rivera, Nelo; Huffman, Mark A.; Shevlin, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5480-5483</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">MK-7655 (I) is a β-lactamase inhibitor in clin. trials as a combination therapy for the treatment of bacterial infection resistant to β-lactam antibiotics.  Its unusual structural challenges have inspired a rapid synthesis featuring an iridium-catalyzed N-H insertion and a series of late stage transformations designed around the reactivity of the labile bicyclo[3.2.1]urea at the core of the target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOWYLM3Irur7Vg90H21EOLACvtfcHk0lgYKS2g99esFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFOqu7%252FF&md5=65c566fa7bb43e063c0e1dce89759c20</span></div><a href="/servlet/linkout?suffix=cit28e&amp;dbid=16384&amp;doi=10.1021%2Fol202195n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol202195n%26sid%3Dliteratum%253Aachs%26aulast%3DMangion%26aufirst%3DI.%2BK.%26aulast%3DRuck%26aufirst%3DR.%2BT.%26aulast%3DRivera%26aufirst%3DN.%26aulast%3DHuffman%26aufirst%3DM.%2BA.%26aulast%3DShevlin%26aufirst%3DM.%26atitle%3DA%2520Concise%2520Synthesis%2520of%2520a%2520%25CE%25B2-Lactamase%2520Inhibitor%26jtitle%3DOrg.%2520Lett.%26date%3D2011%26volume%3D13%26spage%3D5480%26epage%3D5483%26doi%3D10.1021%2Fol202195n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit28f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, S. P.</span>; <span class="NLM_string-name">Limanto, J.</span>; <span class="NLM_string-name">Zhong, Y.-L.</span>; <span class="NLM_string-name">Yasuda, N.</span>; <span class="NLM_string-name">Liu, Z.</span></span> <span> </span><span class="NLM_article-title">Preparation of <i>tert</i>-Butyl 4-((1<i>R</i>,2<i>S</i>,5<i>R</i>)-6-(Benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamido)piperidine-1-carboxylate</span>. <span class="NLM_patent">WO 2014200786 A1</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=S.+P.+Miller&author=J.+Limanto&author=Y.-L.+Zhong&author=N.+Yasuda&author=Z.+Liu&title=Preparation+of+tert-Butyl+4-%28%281R%2C2S%2C5R%29-6-%28Benzyloxy%29-7-oxo-1%2C6-diazabicyclo%5B3.2.1%5Doctane-2-carboxamido%29piperidine-1-carboxylate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28f&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DS.%2BP.%26atitle%3DPreparation%2520of%2520tert-Butyl%25204-%2528%25281R%252C2S%252C5R%2529-6-%2528Benzyloxy%2529-7-oxo-1%252C6-diazabicyclo%255B3.2.1%255Doctane-2-carboxamido%2529piperidine-1-carboxylate%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit28g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Pawar, S. S.</span>; <span class="NLM_string-name">Dond, B. D.</span>; <span class="NLM_string-name">Bhavsar, S.</span>; <span class="NLM_string-name">Jadhav, A. S.</span>; <span class="NLM_string-name">Ahirrao, V. K.</span>; <span class="NLM_string-name">Patil, K. R.</span>; <span class="NLM_string-name">Yeole, R. D.</span>; <span class="NLM_string-name">Deshpande, P. K.</span>; <span class="NLM_string-name">Patel, M. V.</span></span> <span> </span><span class="NLM_article-title">Process for O-Sulfonation of 1,6-Diazabicyclo[3.2.1]octane Compounds</span>. <span class="NLM_patent">WO 2018234962 A</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=S.+S.+Pawar&author=B.+D.+Dond&author=S.+Bhavsar&author=A.+S.+Jadhav&author=V.+K.+Ahirrao&author=K.+R.+Patil&author=R.+D.+Yeole&author=P.+K.+Deshpande&author=M.+V.+Patel&title=Process+for+O-Sulfonation+of+1%2C6-Diazabicyclo%5B3.2.1%5Doctane+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28g&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPawar%26aufirst%3DS.%2BS.%26atitle%3DProcess%2520for%2520O-Sulfonation%2520of%25201%252C6-Diazabicyclo%255B3.2.1%255Doctane%2520Compounds%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit28h"><span><span class="NLM_label">(h) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Wankhede, K. S.</span>; <span class="NLM_string-name">Surwase, M. M.</span>; <span class="NLM_string-name">Bhawsar, S.</span>; <span class="NLM_string-name">Deshpande, P. K.</span>; <span class="NLM_string-name">Yeole, R. D.</span>; <span class="NLM_string-name">Patel, M. V.</span></span> <span> </span><span class="NLM_article-title">Process for Preparation of (2<i>S</i>,5<i>R</i>)-Sulfuric Acid Mono-{[(4-aminopiperidin-4-yl)carbonyl]-7-oxo-1,6-diazabicyclo[3.2.1]-oct-6-yl}ester</span> <span class="NLM_patent">WO 2015033191 A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=K.+S.+Wankhede&author=M.+M.+Surwase&author=S.+Bhawsar&author=P.+K.+Deshpande&author=R.+D.+Yeole&author=M.+V.+Patel&title=Process+for+Preparation+of+%282S%2C5R%29-Sulfuric+Acid+Mono-%7B%5B%284-aminopiperidin-4-yl%29carbonyl%5D-7-oxo-1%2C6-diazabicyclo%5B3.2.1%5D-oct-6-yl%7Dester"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28h&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWankhede%26aufirst%3DK.%2BS.%26atitle%3DProcess%2520for%2520Preparation%2520of%2520%25282S%252C5R%2529-Sulfuric%2520Acid%2520Mono-%257B%255B%25284-aminopiperidin-4-yl%2529carbonyl%255D-7-oxo-1%252C6-diazabicyclo%255B3.2.1%255D-oct-6-yl%257Dester%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf" class="extLink">https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf</a> (accessed 2020-09-18).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2019%2F208711s000lbl.pdf+%28accessed+2020-09-18%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><a href="https://www.who.int/foodborne_trematode_infections/fascioliasis/en/" class="extLink">https://www.who.int/foodborne_trematode_infections/fascioliasis/en/</a> (accessed 2020-09-15).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.who.int%2Ffoodborne_trematode_infections%2Ffascioliasis%2Fen%2F+%28accessed+2020-09-15%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Gallay, J.-J.</span>; <span class="NLM_string-name">Kuhne, M.</span>; <span class="NLM_string-name">Meyer, A.</span>; <span class="NLM_string-name">Rechsteiner, O.</span>; <span class="NLM_string-name">Schellenbaum, M.</span></span> <span> </span><span class="NLM_article-title">2-Alkylthio-2-Alkylsulphinyl- and 2-Alkylsulfonyl-6-Phenylbenzimidazoles as Antihelmintic Agents</span>. <span class="NLM_patent">US 4197307 A</span>, <span class="NLM_year">1980</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1980&author=J.-J.+Gallay&author=M.+Kuhne&author=A.+Meyer&author=O.+Rechsteiner&author=M.+Schellenbaum&title=2-Alkylthio-2-Alkylsulphinyl-+and+2-Alkylsulfonyl-6-Phenylbenzimidazoles+as+Antihelmintic+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGallay%26aufirst%3DJ.-J.%26atitle%3D2-Alkylthio-2-Alkylsulphinyl-%2520and%25202-Alkylsulfonyl-6-Phenylbenzimidazoles%2520as%2520Antihelmintic%2520Agents%26date%3D1980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit31b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span>; <span class="NLM_string-name">Zhou, Q.</span></span> <span> </span><span class="NLM_article-title">Method for Preparing Triclabendazole</span>. <span class="NLM_patent">CN 101555231 A</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=X.+Li&author=Q.+Zhou&title=Method+for+Preparing+Triclabendazole"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26atitle%3DMethod%2520for%2520Preparing%2520Triclabendazole%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rane, R. A.</span>; <span class="NLM_string-name">Verma, S.</span>; <span class="NLM_string-name">Arulmoli, T.</span></span> <span> </span><span class="NLM_article-title">Process for Preparation of Triclabendazole</span>. <span class="NLM_patent">US 20130303781 A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=R.+A.+Rane&author=S.+Verma&author=T.+Arulmoli&title=Process+for+Preparation+of+Triclabendazole"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRane%26aufirst%3DR.%2BA.%26atitle%3DProcess%2520for%2520Preparation%2520of%2520Triclabendazole%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duggan, S.</span></span> <span> </span><span class="NLM_article-title">Esaxerenone: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">477</span>– <span class="NLM_lpage">481</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01073-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs40265-019-01073-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=30806972" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFyitLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=477-481&author=S.+Duggan&title=Esaxerenone%3A+First+Global+Approval&doi=10.1007%2Fs40265-019-01073-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Esaxerenone: First Global Approval</span></div><div class="casAuthors">Duggan, Sean</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">477-481</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Esaxerenone (MINNEBRO)-a novel oral, non-steroidal, selective mineralocorticoid receptor blocker-is being developed by Daiichi Sankyo for the treatment of hypertension and diabetic nephropathies.  In Jan. 2019, based on pos. results from a phase III trial conducted in Japan in patients with essential hypertension, esaxerenone received marketing approval in Japan for the treatment of hypertension.  This article summarizes the milestones in the development of esaxerenone leading to this first global approval for the treatment of hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2L1-zk-v857Vg90H21EOLACvtfcHk0lhFHEM3agtnOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFyitLk%253D&md5=5cc6a7b8dbdd3a58eaf1e3ceb2a15937</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01073-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01073-5%26sid%3Dliteratum%253Aachs%26aulast%3DDuggan%26aufirst%3DS.%26atitle%3DEsaxerenone%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D477%26epage%3D481%26doi%3D10.1007%2Fs40265-019-01073-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kolkhof, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bärfacker, L.</span></span> <span> </span><span class="NLM_article-title">Mineralocorticoid Receptor Antagonists: 60 Years of Research and Development</span>. <i>J. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>234</i></span>,  <span class="NLM_fpage">T125</span>– <span class="NLM_lpage">T140</span>, <span class="refDoi"> DOI: 10.1530/JOE-16-0600</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1530%2FJOE-16-0600" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=28634268" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1cXovVeisrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=234&publication_year=2017&pages=T125-T140&author=P.+Kolkhofauthor=L.+B%C3%A4rfacker&title=Mineralocorticoid+Receptor+Antagonists%3A+60+Years+of+Research+and+Development&doi=10.1530%2FJOE-16-0600"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Mineralocorticoid receptor antagonists: 60 years of research and development</span></div><div class="casAuthors">Kolkhof, Peter; Baerfacker, Lars</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Endocrinology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">234</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">T125-T140</span>CODEN:
                <span class="NLM_cas:coden">JOENAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-0795</span>.
    
            (<span class="NLM_cas:orgname">BioScientifica Ltd.</span>)
        </div><div class="casAbstract">A review.  The cDNA of the mineralocorticoid receptor (MR) was cloned 30 years ago, in 1987.  At that time, spirolactone, the first generation of synthetic steroid-based MR antagonists (MRAs), which was identified in preclin. in vivo models, had already been in clin. use for 30 years.  Subsequent decades of research and development by Searle & Co., Ciba-Geigy, Roussel Uclaf and Schering AG toward identifying a second generation of much more specific steroidal MRAs were all based on the initial 17-spirolactone construct.  The salient example is eplerenone, first described in 1987, coincidentally with the cloning of MR cDNA.  Its launch on the market in 2003 paralleled intensive drug discovery programs for a new generation of non-steroidal MRAs.  Now, 30 years after the cDNA cloning of MR and 60 years of clin. use of steroidal MRAs, novel non-steroidal MRAs such as apararenone, esaxerenone and finerenone are in late-stage clin. trials in patients with heart failure, chronic kidney disease (CKD), hypertension and liver disease.  Finerenone has already been studied in over 2000 patients with heart failure plus chronic kidney disease and/or diabetes, and in patients with diabetic kidney disease, in five phase II clin. trials.  Here, we reflect on the history of the various generations of MRAs and review characteristics of the most important steroidal and non-steroidal MRAs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQHEittdmQ4LVg90H21EOLACvtfcHk0lhFHEM3agtnOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXovVeisrg%253D&md5=e046bcbc7630871c4b62c8c754762d8c</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1530%2FJOE-16-0600&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1530%252FJOE-16-0600%26sid%3Dliteratum%253Aachs%26aulast%3DKolkhof%26aufirst%3DP.%26aulast%3DB%25C3%25A4rfacker%26aufirst%3DL.%26atitle%3DMineralocorticoid%2520Receptor%2520Antagonists%253A%252060%2520Years%2520of%2520Research%2520and%2520Development%26jtitle%3DJ.%2520Endocrinol.%26date%3D2017%26volume%3D234%26spage%3DT125%26epage%3DT140%26doi%3D10.1530%2FJOE-16-0600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Arai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Homma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morikawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ubukata, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuruoka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizuno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sada, T.</span></span> <span> </span><span class="NLM_article-title">Pharmacological Profile of CS-3150, a Novel, Highly Potent and Selective Non-Steroidal Mineralocorticoid Receptor Antagonist</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>761</i></span>,  <span class="NLM_fpage">226</span>– <span class="NLM_lpage">234</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2015.06.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2Fj.ejphar.2015.06.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=26073023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtV2iur%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=761&publication_year=2015&pages=226-234&author=K.+Araiauthor=T.+Hommaauthor=Y.+Morikawaauthor=N.+Ubukataauthor=H.+Tsuruokaauthor=K.+Aokiauthor=H.+Ishikawaauthor=M.+Mizunoauthor=T.+Sada&title=Pharmacological+Profile+of+CS-3150%2C+a+Novel%2C+Highly+Potent+and+Selective+Non-Steroidal+Mineralocorticoid+Receptor+Antagonist&doi=10.1016%2Fj.ejphar.2015.06.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35aR"><div class="casContent"><span class="casTitleNuber">35a</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist</span></div><div class="casAuthors">Arai, Kiyoshi; Homma, Tsuyoshi; Morikawa, Yuka; Ubukata, Naoko; Tsuruoka, Hiyoyuki; Aoki, Kazumasa; Ishikawa, Hirokazu; Mizuno, Makoto; Sada, Toshio</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">761</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">226-234</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The present study was designed to characterize the pharmacol. profile of CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist.  In the radioligand-binding assay, CS-3150 inhibited 3H-aldosterone binding to mineralocorticoid receptor with an IC50 value of 9.4 nM, and its potency was superior to that of spironolactone and eplerenone, whose IC50s were 36 and 713 nM, resp.  CS-3150 also showed at least 1000-fold higher selectivity for mineralocorticoid receptor over other steroid hormone receptors, glucocorticoid receptor, androgen receptor and progesterone receptor.  In the reporter gene assay, CS-3150 inhibited aldosterone-induced transcriptional activation of human mineralocorticoid receptor with an IC50 value of 3.7 nM, and its potency was superior to that of spironolactone and eplerenone, whose IC50s were 66 and 970 nM, resp.  CS-3150 had no agonistic effect on mineralocorticoid receptor and did not show any antagonistic or agonistic effect on glucocorticoid receptor, androgen receptor and progesterone receptor even at the high concn. of 5 μM.  In adrenalectomized rats, single oral administration of CS-3150 suppressed aldosterone-induced decrease in urinary Na+/K+ ratio, an index of in vivo mineralocorticoid receptor activation, and this suppressive effect was more potent and longer-lasting than that of spironolactone and eplerenone.  Chronic treatment with CS-3150 inhibited blood pressure elevation induced by deoxycorticosterone acetate (DOCA)/salt-loading to rats, and this antihypertensive effect was more potent than that of spironolactone and eplerenone.  These findings indicate that CS-3150 is a selective and highly potent mineralocorticoid receptor antagonist with long-lasting oral activity.  This agent could be useful for the treatment of hypertension, cardiovascular and renal disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrD6nBWXLrrQLVg90H21EOLACvtfcHk0liQo5hsm7oA-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtV2iur%252FK&md5=89919d8637cc9cc23d1915e987b086d5</span></div><a href="/servlet/linkout?suffix=cit35a&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2015.06.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2015.06.015%26sid%3Dliteratum%253Aachs%26aulast%3DArai%26aufirst%3DK.%26aulast%3DHomma%26aufirst%3DT.%26aulast%3DMorikawa%26aufirst%3DY.%26aulast%3DUbukata%26aufirst%3DN.%26aulast%3DTsuruoka%26aufirst%3DH.%26aulast%3DAoki%26aufirst%3DK.%26aulast%3DIshikawa%26aufirst%3DH.%26aulast%3DMizuno%26aufirst%3DM.%26aulast%3DSada%26aufirst%3DT.%26atitle%3DPharmacological%2520Profile%2520of%2520CS-3150%252C%2520a%2520Novel%252C%2520Highly%2520Potent%2520and%2520Selective%2520Non-Steroidal%2520Mineralocorticoid%2520Receptor%2520Antagonist%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2015%26volume%3D761%26spage%3D226%26epage%3D234%26doi%3D10.1016%2Fj.ejphar.2015.06.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit35b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itoh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rakugi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshimura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamakawa, S.</span></span> <span> </span><span class="NLM_article-title">Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients with Essential Hypertension (ESAX-HTN Study)</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">58</span>, <span class="refDoi"> DOI: 10.1161/HYPERTENSIONAHA.119.13569</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1161%2FHYPERTENSIONAHA.119.13569" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31786983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlKiurzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2020&pages=51-58&author=S.+Itoauthor=H.+Itohauthor=H.+Rakugiauthor=Y.+Okudaauthor=M.+Yoshimuraauthor=S.+Yamakawa&title=Double-Blind+Randomized+Phase+3+Study+Comparing+Esaxerenone+%28CS-3150%29+and+Eplerenone+in+Patients+with+Essential+Hypertension+%28ESAX-HTN+Study%29&doi=10.1161%2FHYPERTENSIONAHA.119.13569"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35bR"><div class="casContent"><span class="casTitleNuber">35b</span><div class="casTitle"><span class="NLM_cas:atitle">Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study)</span></div><div class="casAuthors">Ito, Sadayoshi; Itoh, Hiroshi; Rakugi, Hiromi; Okuda, Yasuyuki; Yoshimura, Motonobu; Yamakawa, Satoru</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">51-58</span>CODEN:
                <span class="NLM_cas:coden">HPRTDN</span>;
        ISSN:<span class="NLM_cas:issn">0194-911X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Mineralocorticoid receptors (MRs) are implicated in the pathol. of hypertension.  MR blockers are recommended for the treatment of salt-sensitive or resistant hypertension.  This phase 3 multicenter, randomized, double-blind study compared the efficacy and safety of esaxerenone, a new selective nonsteroidal MR blocker, at 2.5 and 5 mg/day and eplerenone 50 mg/day in Japanese patients with essential hypertension.  After a 4-wk washout period, 1001 eligible adults with hypertension were randomized evenly to esaxerenone 2.5 or 5 mg/day or eplerenone 50 mg/day treatments, taken orally once daily for 12 wk.  Primary end points were changes in sitting systolic or diastolic blood pressure (BP) from baseline at the end of treatment.  Esaxerenone 2.5 mg/day was noninferior to eplerenone for redns. in sitting and 24-h BP.  Redns. in BP with esaxerenone 5 mg/day were significantly greater than those with esaxerenone 2.5 mg/day.  Changes in diurnal BP showed persistent 24-h antihypertensive effects in all treatment groups.  The proportions of patients achieving target sitting BP (<140/90 mm Hg) were 31.5%, 41.2%, and 27.5% with esaxerenone 2.5 and 5 mg/day and eplerenone 50 mg/day, resp.  Incidences of adverse events (all mild or moderate) were similar across treatment groups.  These results indicate that esaxerenone is an effective and well-tolerated MR blocker in Japanese patients with essential hypertension, with BP-lowering activity at least equiv. to eplerenone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwMdV4JvQNhrVg90H21EOLACvtfcHk0liQo5hsm7oA-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlKiurzE&md5=5b931b85f7068e10ca7eb093a25c8585</span></div><a href="/servlet/linkout?suffix=cit35b&amp;dbid=16384&amp;doi=10.1161%2FHYPERTENSIONAHA.119.13569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FHYPERTENSIONAHA.119.13569%26sid%3Dliteratum%253Aachs%26aulast%3DIto%26aufirst%3DS.%26aulast%3DItoh%26aufirst%3DH.%26aulast%3DRakugi%26aufirst%3DH.%26aulast%3DOkuda%26aufirst%3DY.%26aulast%3DYoshimura%26aufirst%3DM.%26aulast%3DYamakawa%26aufirst%3DS.%26atitle%3DDouble-Blind%2520Randomized%2520Phase%25203%2520Study%2520Comparing%2520Esaxerenone%2520%2528CS-3150%2529%2520and%2520Eplerenone%2520in%2520Patients%2520with%2520Essential%2520Hypertension%2520%2528ESAX-HTN%2520Study%2529%26jtitle%3DHypertension%26date%3D2020%26volume%3D75%26spage%3D51%26epage%3D58%26doi%3D10.1161%2FHYPERTENSIONAHA.119.13569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, M.</span>; <span class="NLM_string-name">Nagasawa, H.</span>; <span class="NLM_string-name">Sato, N.</span></span> <span> </span><span class="NLM_article-title">Method for Producing Pyrrole Derivative, and Intermediate Thereof</span>. <span class="NLM_patent">WO 2015030010</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=M.+Watanabe&author=H.+Nagasawa&author=N.+Sato&title=Method+for+Producing+Pyrrole+Derivative%2C+and+Intermediate+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWatanabe%26aufirst%3DM.%26atitle%3DMethod%2520for%2520Producing%2520Pyrrole%2520Derivative%252C%2520and%2520Intermediate%2520Thereof%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit36b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, M.</span>; <span class="NLM_string-name">Okachi, T.</span>; <span class="NLM_string-name">Kawahara, M.</span>; <span class="NLM_string-name">Nagasawa, H.</span>; <span class="NLM_string-name">Sato, N.</span>; <span class="NLM_string-name">Takita, T.</span>; <span class="NLM_string-name">Hasegawa, G.</span></span> <span> </span><span class="NLM_article-title">Pyrrole Derivative Crystal and Method for Manufacturing Same</span>. <span class="NLM_patent">WO 2014168103</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=M.+Watanabe&author=T.+Okachi&author=M.+Kawahara&author=H.+Nagasawa&author=N.+Sato&author=T.+Takita&author=G.+Hasegawa&title=Pyrrole+Derivative+Crystal+and+Method+for+Manufacturing+Same"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWatanabe%26aufirst%3DM.%26atitle%3DPyrrole%2520Derivative%2520Crystal%2520and%2520Method%2520for%2520Manufacturing%2520Same%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit36c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, M.</span>; <span class="NLM_string-name">Okachi, T.</span>; <span class="NLM_string-name">Kawahara, M.</span>; <span class="NLM_string-name">Nagasawa, H.</span>; <span class="NLM_string-name">Sato, N.</span>; <span class="NLM_string-name">Takita, T.</span>; <span class="NLM_string-name">Hasegawa, G.</span></span> <span> </span><span class="NLM_article-title">Crystal of Pyrrole Derivative and Method for Producing the Same</span>. <span class="NLM_patent">US 20160096803</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=M.+Watanabe&author=T.+Okachi&author=M.+Kawahara&author=H.+Nagasawa&author=N.+Sato&author=T.+Takita&author=G.+Hasegawa&title=Crystal+of+Pyrrole+Derivative+and+Method+for+Producing+the+Same"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWatanabe%26aufirst%3DM.%26atitle%3DCrystal%2520of%2520Pyrrole%2520Derivative%2520and%2520Method%2520for%2520Producing%2520the%2520Same%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, H. A.</span></span> <span> </span><span class="NLM_article-title">Voxelotor: First Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">209</span>– <span class="NLM_lpage">215</span>, <span class="refDoi"> DOI: 10.1007/s40265-020-01262-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs40265-020-01262-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=32020554" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A280%3ADC%252BB38%252FotlKmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2020&pages=209-215&author=H.+A.+Blair&title=Voxelotor%3A+First+Approval&doi=10.1007%2Fs40265-020-01262-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37aR"><div class="casContent"><span class="casTitleNuber">37a</span><div class="casTitle"><span class="NLM_cas:atitle">Voxelotor: First Approval</span></div><div class="casAuthors">Blair Hannah A</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">209-215</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Voxelotor (Oxbryta®) is a haemoglobin S polymerization inhibitor that has been developed for the treatment of sickle cell disease.  In November 2019, voxelotor received its first global approval in the USA for the treatment of sickle cell disease in adults and paediatric patients aged ≥ 12 years.  The drug was granted accelerated approval based on the results of the phase III HOPE trial.  Phase III clinical development of voxelotor for sickle cell disease is ongoing worldwide.  Voxelotor also has Orphan Drug designation and Priority Medicine status in Europe for the treatment of sickle cell disease.  This article summarizes the milestones in the development of voxelotor leading to this first approval as a disease-modifying agent for sickle cell disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTbpElibNSrFHwOGIfWJ7-GfW6udTcc2eZW-zTQ_Hwqsbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38%252FotlKmuw%253D%253D&md5=3c3d29ad328a435555bdd0fc54f24494</span></div><a href="/servlet/linkout?suffix=cit37a&amp;dbid=16384&amp;doi=10.1007%2Fs40265-020-01262-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-020-01262-7%26sid%3Dliteratum%253Aachs%26aulast%3DBlair%26aufirst%3DH.%2BA.%26atitle%3DVoxelotor%253A%2520First%2520Approval%26jtitle%3DDrugs%26date%3D2020%26volume%3D80%26spage%3D209%26epage%3D215%26doi%3D10.1007%2Fs40265-020-01262-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit37b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Metcalf, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dufu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva-Garcia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Partridge, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patskovska, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patskovsky, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almo, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gwaltney, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchaleelaha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulvannan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oksenberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span> <span> </span><span class="NLM_article-title">Discovery of GBT440, an Orally Bioavailable R-State Stabilizer of Sickle Cell Hemoglobin</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">321</span>– <span class="NLM_lpage">326</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00491</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00491" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFWqur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=321-326&author=B.+Metcalfauthor=C.+Chuangauthor=K.+Dufuauthor=M.+P.+Patelauthor=A.+Silva-Garciaauthor=C.+Johnsonauthor=Q.+Luauthor=J.+R.+Partridgeauthor=L.+Patskovskaauthor=Y.+Patskovskyauthor=S.+C.+Almoauthor=M.+P.+Jacobsonauthor=L.+Huaauthor=Q.+Xuauthor=S.+L.+Gwaltneyauthor=C.+Yeeauthor=J.+Harrisauthor=B.+P.+Morganauthor=J.+Jamesauthor=D.+Xuauthor=A.+Hutchaleelahaauthor=K.+Paulvannanauthor=D.+Oksenbergauthor=Z.+Li&title=Discovery+of+GBT440%2C+an+Orally+Bioavailable+R-State+Stabilizer+of+Sickle+Cell+Hemoglobin&doi=10.1021%2Facsmedchemlett.6b00491"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37bR"><div class="casContent"><span class="casTitleNuber">37b</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of GBT440, an Orally Bioavailable R-State Stabilizer of Sickle Cell Hemoglobin</span></div><div class="casAuthors">Metcalf, Brian; Chuang, Chihyuan; Dufu, Kobina; Patel, Mira P.; Silva-Garcia, Abel; Johnson, Carl; Lu, Qing; Partridge, James R.; Patskovska, Larysa; Patskovsky, Yury; Almo, Steven C.; Jacobson, Matthew P.; Hua, Lan; Xu, Qing; Gwaltney, Stephen L.; Yee, Calvin; Harris, Jason; Morgan, Bradley P.; James, Joyce; Xu, Donghong; Hutchaleelaha, Athiwat; Paulvannan, Kumar; Oksenberg, Donna; Li, Zhe</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">321-326</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors report the discovery of a new potent allosteric effector of sickle cell Hb, GBT440 I, that increases the affinity of Hb for oxygen and consequently inhibits its polymn. when subjected to hypoxic conditions.  Unlike earlier allosteric activators that bind covalently to Hb in a 2:1 stoichiometry, I binds with a 1:1 stoichiometry.  Compd. I is orally bioavailable and partitions highly and favorably into the red blood cell with a RBC/plasma ratio of ∼150.  This partitioning onto the target protein is anticipated to allow therapeutic concns. to be achieved in the red blood cell at low plasma concns.  I is in Phase 2 clin. trials for the treatment of sickle cell disease (NCT02285088).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6HR9j4wMylbVg90H21EOLACvtfcHk0liUgwYAt5WjgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFWqur0%253D&md5=63766931fdf731c68fd284cf86cc77d0</span></div><a href="/servlet/linkout?suffix=cit37b&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00491%26sid%3Dliteratum%253Aachs%26aulast%3DMetcalf%26aufirst%3DB.%26aulast%3DChuang%26aufirst%3DC.%26aulast%3DDufu%26aufirst%3DK.%26aulast%3DPatel%26aufirst%3DM.%2BP.%26aulast%3DSilva-Garcia%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DC.%26aulast%3DLu%26aufirst%3DQ.%26aulast%3DPartridge%26aufirst%3DJ.%2BR.%26aulast%3DPatskovska%26aufirst%3DL.%26aulast%3DPatskovsky%26aufirst%3DY.%26aulast%3DAlmo%26aufirst%3DS.%2BC.%26aulast%3DJacobson%26aufirst%3DM.%2BP.%26aulast%3DHua%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DGwaltney%26aufirst%3DS.%2BL.%26aulast%3DYee%26aufirst%3DC.%26aulast%3DHarris%26aufirst%3DJ.%26aulast%3DMorgan%26aufirst%3DB.%2BP.%26aulast%3DJames%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DD.%26aulast%3DHutchaleelaha%26aufirst%3DA.%26aulast%3DPaulvannan%26aufirst%3DK.%26aulast%3DOksenberg%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DZ.%26atitle%3DDiscovery%2520of%2520GBT440%252C%2520an%2520Orally%2520Bioavailable%2520R-State%2520Stabilizer%2520of%2520Sickle%2520Cell%2520Hemoglobin%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D321%26epage%3D326%26doi%3D10.1021%2Facsmedchemlett.6b00491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kato, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piel, F. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaston, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohene-Frempong, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnamurti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panepinto, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weatherall, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vichinsky, E. P.</span></span> <span> </span><span class="NLM_article-title">Sickle Cell Disease</span>. <i>Nat. Rev. Dis. Primers</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">18010</span>, <span class="refDoi"> DOI: 10.1038/nrdp.2018.10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1038%2Fnrdp.2018.10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=29542687" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A280%3ADC%252BC1MnhsVOnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2018&pages=18010&author=G.+J.+Katoauthor=F.+B.+Pielauthor=C.+D.+Reidauthor=M.+H.+Gastonauthor=K.+Ohene-Frempongauthor=L.+Krishnamurtiauthor=W.+R.+Smithauthor=J.+A.+Panepintoauthor=D.+J.+Weatherallauthor=F.+F.+Costaauthor=E.+P.+Vichinsky&title=Sickle+Cell+Disease&doi=10.1038%2Fnrdp.2018.10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Sickle cell disease</span></div><div class="casAuthors">Kato Gregory J; Piel Frederic B; Reid Clarice D; Gaston Marilyn H; Ohene-Frempong Kwaku; Krishnamurti Lakshmanan; Smith Wally R; Panepinto Julie A; Weatherall David J; Costa Fernando F; Vichinsky Elliott P</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Disease primers</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">18010</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Sickle cell disease (SCD) is a group of inherited disorders caused by mutations in HBB, which encodes haemoglobin subunit β.  The incidence is estimated to be between 300,000 and 400,000 neonates globally each year, the majority in sub-Saharan Africa.  Haemoglobin molecules that include mutant sickle β-globin subunits can polymerize; erythrocytes that contain mostly haemoglobin polymers assume a sickled form and are prone to haemolysis.  Other pathophysiological mechanisms that contribute to the SCD phenotype are vaso-occlusion and activation of the immune system.  SCD is characterized by a remarkable phenotypic complexity.  Common acute complications are acute pain events, acute chest syndrome and stroke; chronic complications (including chronic kidney disease) can damage all organs.  Hydroxycarbamide, blood transfusions and haematopoietic stem cell transplantation can reduce the severity of the disease.  Early diagnosis is crucial to improve survival, and universal newborn screening programmes have been implemented in some countries but are challenging in low-income, high-burden settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRfr1rFc0-x0Rjv2lLSLOxFfW6udTcc2eZW-zTQ_Hwqsbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MnhsVOnsg%253D%253D&md5=983b343f1afd547e34a7836b06320373</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fnrdp.2018.10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrdp.2018.10%26sid%3Dliteratum%253Aachs%26aulast%3DKato%26aufirst%3DG.%2BJ.%26aulast%3DPiel%26aufirst%3DF.%2BB.%26aulast%3DReid%26aufirst%3DC.%2BD.%26aulast%3DGaston%26aufirst%3DM.%2BH.%26aulast%3DOhene-Frempong%26aufirst%3DK.%26aulast%3DKrishnamurti%26aufirst%3DL.%26aulast%3DSmith%26aufirst%3DW.%2BR.%26aulast%3DPanepinto%26aufirst%3DJ.%2BA.%26aulast%3DWeatherall%26aufirst%3DD.%2BJ.%26aulast%3DCosta%26aufirst%3DF.%2BF.%26aulast%3DVichinsky%26aufirst%3DE.%2BP.%26atitle%3DSickle%2520Cell%2520Disease%26jtitle%3DNat.%2520Rev.%2520Dis.%2520Primers%26date%3D2018%26volume%3D4%26spage%3D18010%26doi%3D10.1038%2Fnrdp.2018.10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eaton, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofrichter, J.</span></span> <span> </span><span class="NLM_article-title">Sickle Cell Hemoglobin Polymerization</span>. <i>Adv. Protein Chem.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">279</span>, <span class="refDoi"> DOI: 10.1016/S0065-3233(08)60287-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2FS0065-3233%2808%2960287-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=2195851" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADyaK3MXktVGqtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1990&pages=63-279&author=W.+A.+Eatonauthor=J.+Hofrichter&title=Sickle+Cell+Hemoglobin+Polymerization&doi=10.1016%2FS0065-3233%2808%2960287-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Sickle cell hemoglobin polymerization</span></div><div class="casAuthors">Eaton, William A.; Hofrichter, James</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Protein Chemistry</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">63-279</span>CODEN:
                <span class="NLM_cas:coden">APCHA2</span>;
        ISSN:<span class="NLM_cas:issn">0065-3233</span>.
    </div><div class="casAbstract">A review with ∼300 refs. discussing the structure and thermodn., kinetics, and rheol. of HbS polymer in relation to the pathophysiol. and therapy of sickle cell anemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRiXAF3c3PS7Vg90H21EOLACvtfcHk0ljtFicd8RmgMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXktVGqtLs%253D&md5=4bf3caa0d638422cabe899c8f71162d6</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2FS0065-3233%2808%2960287-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0065-3233%252808%252960287-9%26sid%3Dliteratum%253Aachs%26aulast%3DEaton%26aufirst%3DW.%2BA.%26aulast%3DHofrichter%26aufirst%3DJ.%26atitle%3DSickle%2520Cell%2520Hemoglobin%2520Polymerization%26jtitle%3DAdv.%2520Protein%2520Chem.%26date%3D1990%26volume%3D40%26spage%3D63%26epage%3D279%26doi%3D10.1016%2FS0065-3233%2808%2960287-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oksenberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dufu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva-Garcia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchaleelaha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patskovska, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patskovsky, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almo, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metcalf, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Archer, D. R.</span></span> <span> </span><span class="NLM_article-title">GBT440 Increases Haemoglobin Oxygen Affinity, Reduces Sickling and Prolongs RBC Half-Life in a Murine Model of Sickle Cell Disease</span>. <i>Br. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>175</i></span>,  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">153</span>, <span class="refDoi"> DOI: 10.1111/bjh.14214</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1111%2Fbjh.14214" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=27378309" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFCkurfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2016&pages=141-153&author=D.+Oksenbergauthor=K.+Dufuauthor=M.+P.+Patelauthor=C.+Chuangauthor=Z.+Liauthor=Q.+Xuauthor=A.+Silva-Garciaauthor=C.+Zhouauthor=A.+Hutchaleelahaauthor=L.+Patskovskaauthor=Y.+Patskovskyauthor=S.+C.+Almoauthor=U.+Sinhaauthor=B.+W.+Metcalfauthor=D.+R.+Archer&title=GBT440+Increases+Haemoglobin+Oxygen+Affinity%2C+Reduces+Sickling+and+Prolongs+RBC+Half-Life+in+a+Murine+Model+of+Sickle+Cell+Disease&doi=10.1111%2Fbjh.14214"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease</span></div><div class="casAuthors">Oksenberg, Donna; Dufu, Kobina; Patel, Mira P.; Chuang, Chihyuan; Li, Zhe; Xu, Qing; Silva-Garcia, Abel; Zhou, Chengjing; Hutchaleelaha, Athiwat; Patskovska, Larysa; Patskovsky, Yury; Almo, Steven C.; Sinha, Uma; Metcalf, Brian W.; Archer, David R.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">141-153</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : A major driver of the pathophysiol. of sickle cell disease (SCD) is polymn. of deoxygenated Hb S (HbS), which leads to sickling and destruction of red blood cells (RBCs) and end-organ damage.  Pharmacol. increasing the proportion of oxygenated HbS in RBCs may inhibit polymn., prevent sickling and provide long term disease modification.  We report that GBT440, a small mol. which binds to the N-terminal α chain of Hb, increases HbS affinity for oxygen, delays in vitro HbS polymn. and prevents sickling of RBCs.  Moreover, in a murine model of SCD, GBT440 extends the half-life of RBCs, reduces reticulocyte counts and prevents ex vivoRBC sickling.  Importantly, oral dosing of GBT440 in animals demonstrates suitability for once daily dosing in humans and a highly selective partitioning into RBCs, which is a key therapeutic safety attribute.  Thus, GBT440 has the potential for clin. use as a disease-modifying agent in sickle cell patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9twqbw0I4ELVg90H21EOLACvtfcHk0ljtFicd8RmgMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFCkurfP&md5=07276e0b19eac3cb2baef00c872c9197</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1111%2Fbjh.14214&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjh.14214%26sid%3Dliteratum%253Aachs%26aulast%3DOksenberg%26aufirst%3DD.%26aulast%3DDufu%26aufirst%3DK.%26aulast%3DPatel%26aufirst%3DM.%2BP.%26aulast%3DChuang%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DSilva-Garcia%26aufirst%3DA.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DHutchaleelaha%26aufirst%3DA.%26aulast%3DPatskovska%26aufirst%3DL.%26aulast%3DPatskovsky%26aufirst%3DY.%26aulast%3DAlmo%26aufirst%3DS.%2BC.%26aulast%3DSinha%26aufirst%3DU.%26aulast%3DMetcalf%26aufirst%3DB.%2BW.%26aulast%3DArcher%26aufirst%3DD.%2BR.%26atitle%3DGBT440%2520Increases%2520Haemoglobin%2520Oxygen%2520Affinity%252C%2520Reduces%2520Sickling%2520and%2520Prolongs%2520RBC%2520Half-Life%2520in%2520a%2520Murine%2520Model%2520of%2520Sickle%2520Cell%2520Disease%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2016%26volume%3D175%26spage%3D141%26epage%3D153%26doi%3D10.1111%2Fbjh.14214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span>; <span class="NLM_string-name">Guz, N.</span>; <span class="NLM_string-name">Shao, Y.</span>; <span class="NLM_string-name">Cocuz, J.</span>; <span class="NLM_string-name">Frieser, M.</span>; <span class="NLM_string-name">Yiannikouros, G. P.</span>; <span class="NLM_string-name">Liao, L.</span></span> <span> </span><span class="NLM_article-title">Process for Synthesizing 2-Hydroxy-6-((2-(1-isopropyl-1<i>H</i>-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde</span>. <span class="NLM_patent">WO 2017197083</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=Z.+Li&author=N.+Guz&author=Y.+Shao&author=J.+Cocuz&author=M.+Frieser&author=G.+P.+Yiannikouros&author=L.+Liao&title=Process+for+Synthesizing+2-Hydroxy-6-%28%282-%281-isopropyl-1H-pyrazol-5-yl%29-pyridin-3-yl%29methoxy%29benzaldehyde"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DZ.%26atitle%3DProcess%2520for%2520Synthesizing%25202-Hydroxy-6-%2528%25282-%25281-isopropyl-1H-pyrazol-5-yl%2529-pyridin-3-yl%2529methoxy%2529benzaldehyde%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><a href="https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-post-partum-depression#::̃text=The%20U.S.%20Food%20and%20Drug,the%20FDA%20specifically%20for%20PPD" class="extLink">https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-post-partum-depression#::̃text=The%20U.S.%20Food%20and%20Drug,the%20FDA%20specifically%20for%20PPD</a> (accessed Sept 18, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-approves-first-treatment-post-partum-depression%23%3A%3A%CC%83text%3DThe%2520U.S.%2520Food%2520and%2520Drug%2Cthe%2520FDA%2520specifically%2520for%2520PPD+%28accessed+Sept+18%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kanes, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colquhoun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunduz-Bruce, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schacterle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doherty, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paul, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raines, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epperson, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deligiannidis, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riesenberg, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubinow, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meltzer-Brody, S.</span></span> <span> </span><span class="NLM_article-title">Brexanolone (SAGE-547 Injection) in Post-Partum Depression: A Randomised Controlled Trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>390</i></span>,  <span class="NLM_fpage">480</span>– <span class="NLM_lpage">489</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(17)31264-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2FS0140-6736%2817%2931264-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=28619476" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVWrtLfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=390&publication_year=2017&pages=480-489&author=S.+Kanesauthor=H.+Colquhounauthor=H.+Gunduz-Bruceauthor=R.+Arnoldauthor=A.+Schacterleauthor=J.+Dohertyauthor=E.+Hoffmannauthor=J.+Jonasauthor=S.+Paulauthor=S.+Rainesauthor=C.+N.+Eppersonauthor=K.+M.+Deligiannidisauthor=R.+Riesenbergauthor=D.+Rubinowauthor=S.+Meltzer-Brody&title=Brexanolone+%28SAGE-547+Injection%29+in+Post-Partum+Depression%3A+A+Randomised+Controlled+Trial&doi=10.1016%2FS0140-6736%2817%2931264-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Brexanolone (SAGE-547 injection) in post-partum depression: a randomized controlled trial</span></div><div class="casAuthors">Kanes, Stephen; Colquhoun, Helen; Gunduz-Bruce, Handan; Raines, Shane; Arnold, Ryan; Schacterle, Amy; Doherty, James; Epperson, C. Neill; Deligiannidis, Kristina M.; Riesenberg, Robert; Hoffmann, Ethan; Rubinow, David; Jonas, Jeffrey; Paul, Steven; Meltzer-Brody, Samantha</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">390</span>
        (<span class="NLM_cas:issue">10093</span>),
    <span class="NLM_cas:pages">480-489</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Post-partum depression is a serious mood disorder in women that might be triggered by peripartum fluctuations in reproductive hormones.  This phase 2 study investigated brexanolone (USAN; formerly SAGE-547 injection), an i.v. formulation of allopregnanolone, a pos. allosteric modulator of γ-aminobutyric acid (GABAA) receptors, for the treatment of post-partum depression.  For this double-blind, randomized, placebo-controlled trial, we enrolled self-referred or physician-referred female inpatients (≤6 mo post partum) with severe post-partum depression (Hamilton Rating Scale for Depression [HAM-D] total score ≥26) in four hospitals in the USA.  Eligible women were randomly assigned (1:1), via a computer-generated randomization program, to receive either a single, continuous i.v. dose of brexanolone or placebo for 60 h.  Patients and investigators were masked to treatment assignments.  The primary efficacy endpoint was the change from baseline in the 17-item HAM-D total score at 60 h, assessed in all randomized patients who started infusion of study drug or placebo and who had a completed baseline HAM-D assessment and at least one post-baseline HAM-D assessment.  Patients were followed up until day 30.  This trial is registered with ClinicalTrials.gov, no. NCT02614547.  This trial was done between Dec 15, 2015 (first enrollment), and May 19, 2016 (final visit of the last enrolled patient). 21 women were randomly assigned to the brexanolone (n=10) and placebo (n=11) groups.  At 60 h, mean redn. in HAM-D total score from baseline was 21·0 points (SE 2·9) in the brexanolone group compared with 8·8 points (SE 2·8) in the placebo group (difference -12·2, 95% CI -20·77 to -3·67; p=0·0075; effect size 1·2).  No deaths, serious adverse events, or discontinuations because of adverse events were reported in either group.  Four of ten patients in the brexanolone group had adverse events compared with eight of 11 in the placebo group.  The most frequently reported adverse events in the brexanolone group were dizziness (two patients in the brexanolone group vs three patients in the placebo group) and somnolence (two vs none).  Moderate treatment-emergent adverse events were reported in two patients in the brexanolone group (sinus tachycardia, n=1; somnolence, n=1) and in two patients in the placebo group (infusion site pain, n=1; tension headache, n=1); one patient in the placebo group had a severe treatment-emergent adverse event (insomnia).  In women with severe post-partum depression, infusion of brexanolone resulted in a significant and clin. meaningful redn. in HAM-D total score, compared with placebo.  Our results support the rationale for targeting synaptic and extrasynaptic GABAA receptors in the development of therapies for patients with post-partum depression.  A pivotal clin. program for the investigation of brexanolone in patients with post-partum depression is in progress.Sage Therapeutics, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrD2zxS90OOibVg90H21EOLACvtfcHk0ljtFicd8RmgMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVWrtLfO&md5=26d790135111213994d47e3e887f8908</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2817%2931264-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252817%252931264-3%26sid%3Dliteratum%253Aachs%26aulast%3DKanes%26aufirst%3DS.%26aulast%3DColquhoun%26aufirst%3DH.%26aulast%3DGunduz-Bruce%26aufirst%3DH.%26aulast%3DArnold%26aufirst%3DR.%26aulast%3DSchacterle%26aufirst%3DA.%26aulast%3DDoherty%26aufirst%3DJ.%26aulast%3DHoffmann%26aufirst%3DE.%26aulast%3DJonas%26aufirst%3DJ.%26aulast%3DPaul%26aufirst%3DS.%26aulast%3DRaines%26aufirst%3DS.%26aulast%3DEpperson%26aufirst%3DC.%2BN.%26aulast%3DDeligiannidis%26aufirst%3DK.%2BM.%26aulast%3DRiesenberg%26aufirst%3DR.%26aulast%3DRubinow%26aufirst%3DD.%26aulast%3DMeltzer-Brody%26aufirst%3DS.%26atitle%3DBrexanolone%2520%2528SAGE-547%2520Injection%2529%2520in%2520Post-Partum%2520Depression%253A%2520A%2520Randomised%2520Controlled%2520Trial%26jtitle%3DLancet%26date%3D2017%26volume%3D390%26spage%3D480%26epage%3D489%26doi%3D10.1016%2FS0140-6736%2817%2931264-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Meltzer-Brody, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colquhoun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riesenberg, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epperson, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deligiannidis, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubinow, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sankoh, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clemson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schacterle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanes, S.</span></span> <span> </span><span class="NLM_article-title">Brexanolone Injection in Post-Partum Depression: Two Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trials</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>392</i></span>,  <span class="NLM_fpage">1058</span>– <span class="NLM_lpage">1070</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(18)31551-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2FS0140-6736%2818%2931551-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=30177236" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1eit7fO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=392&publication_year=2018&pages=1058-1070&author=S.+Meltzer-Brodyauthor=H.+Colquhounauthor=R.+Riesenbergauthor=C.+N.+Eppersonauthor=K.+M.+Deligiannidisauthor=D.+R.+Rubinowauthor=H.+Liauthor=A.+J.+Sankohauthor=C.+Clemsonauthor=A.+Schacterleauthor=J.+Jonasauthor=S.+Kanes&title=Brexanolone+Injection+in+Post-Partum+Depression%3A+Two+Multicentre%2C+Double-Blind%2C+Randomised%2C+Placebo-Controlled%2C+Phase+3+Trials&doi=10.1016%2FS0140-6736%2818%2931551-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44aR"><div class="casContent"><span class="casTitleNuber">44a</span><div class="casTitle"><span class="NLM_cas:atitle">Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials</span></div><div class="casAuthors">Meltzer-Brody, Samantha; Colquhoun, Helen; Riesenberg, Robert; Epperson, C. Neill; Deligiannidis, Kristina M.; Rubinow, David R.; Li, Haihong; Sankoh, Abdul J.; Clemson, Christine; Schacterle, Amy; Jonas, Jeffrey; Kanes, Stephen</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">392</span>
        (<span class="NLM_cas:issue">10152</span>),
    <span class="NLM_cas:pages">1058-1070</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">We assessed brexanolone injection, a pos. allosteric modulator of GABAA receptors, for the treatment of moderate to severe post-partum depression.  We screened 375 women simultaneously across both studies, of whom 138 were randomly assigned to receive either BRX90, BRX60, or placebo in study 1, and 108 were randomly assigned to receive BRX90 or placebo in study 2.  In study 1, at 60 h, the LS mean redn. in HAM-D total score from baseline was 19·5 points in the BRX60 group and 17·7 points in the BRX90 group compared with 14·0 points in the placebo group.  In study 2, at 60 h, the LS mean redn. in HAM-D total score from baseline was 14·6 points in the BRX90 group.  In study 1, 19 patients in the BRX60 group and 22 patients in the BRX90 group had adverse events.  In study 2, 25 patients in the BRX90 group had adverse events.  The most common treatment-emergent AE were headache, dizziness, and somnolence.  In study 1, 1 patient had suicidal ideation and intentional overdose attempt during follow-up.  In study 2, 1 patient had altered state of consciousness and syncope.  Administration of brexanolone injection for post-partum depression resulted in significant and clin. meaningful redns. in HAM-D total score at 60 h compared with placebo, with rapid onset of action and durable treatment response during the study period.  Brexanolone injection is a novel therapeutic drug for post-partum depression that has the potential to improve treatment options for women with this disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpj--PbsOaXZbVg90H21EOLACvtfcHk0lh_PkiCnWfP_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1eit7fO&md5=5072e7aff1bec96fa11f63b7cb41deea</span></div><a href="/servlet/linkout?suffix=cit44a&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2818%2931551-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252818%252931551-4%26sid%3Dliteratum%253Aachs%26aulast%3DMeltzer-Brody%26aufirst%3DS.%26aulast%3DColquhoun%26aufirst%3DH.%26aulast%3DRiesenberg%26aufirst%3DR.%26aulast%3DEpperson%26aufirst%3DC.%2BN.%26aulast%3DDeligiannidis%26aufirst%3DK.%2BM.%26aulast%3DRubinow%26aufirst%3DD.%2BR.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DSankoh%26aufirst%3DA.%2BJ.%26aulast%3DClemson%26aufirst%3DC.%26aulast%3DSchacterle%26aufirst%3DA.%26aulast%3DJonas%26aufirst%3DJ.%26aulast%3DKanes%26aufirst%3DS.%26atitle%3DBrexanolone%2520Injection%2520in%2520Post-Partum%2520Depression%253A%2520Two%2520Multicentre%252C%2520Double-Blind%252C%2520Randomised%252C%2520Placebo-Controlled%252C%2520Phase%25203%2520Trials%26jtitle%3DLancet%26date%3D2018%26volume%3D392%26spage%3D1058%26epage%3D1070%26doi%3D10.1016%2FS0140-6736%2818%2931551-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit44b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez Botella, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salituro, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beresis, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanco, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belfort, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loya, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ackley, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Althaus, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossman, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doherty, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robichaud, A. J.</span></span> <span> </span><span class="NLM_article-title">Neuroactive Steroids. 2. 3α-Hydroxy-3β-methyl-21-(4-cyano-1H-pyrazol-1′-yl)-19-nor-5β-pregnan-20-one (SAGE-217): A Clinical Next Generation Neuroactive Steroid Positive Allosteric Modulator of the (γ-Aminobutyric Acid)A Receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">7810</span>– <span class="NLM_lpage">7819</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00846</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00846" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A280%3ADC%252BC1cfitFSgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=7810-7819&author=G.+Martinez+Botellaauthor=F.+G.+Salituroauthor=B.+L.+Harrisonauthor=R.+T.+Beresisauthor=Z.+Baiauthor=M.-J.+Blancoauthor=G.+M.+Belfortauthor=J.+Daiauthor=C.+M.+Loyaauthor=M.+A.+Ackleyauthor=A.+L.+Althausauthor=S.+J.+Grossmanauthor=E.+Hoffmannauthor=J.+J.+Dohertyauthor=A.+J.+Robichaud&title=Neuroactive+Steroids.+2.+3%CE%B1-Hydroxy-3%CE%B2-methyl-21-%284-cyano-1H-pyrazol-1%E2%80%B2-yl%29-19-nor-5%CE%B2-pregnan-20-one+%28SAGE-217%29%3A+A+Clinical+Next+Generation+Neuroactive+Steroid+Positive+Allosteric+Modulator+of+the+%28%CE%B3-Aminobutyric+Acid%29A+Receptor&doi=10.1021%2Facs.jmedchem.7b00846"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44bR"><div class="casContent"><span class="casTitleNuber">44b</span><div class="casTitle"><span class="NLM_cas:atitle">Neuroactive Steroids. 2. 3α-Hydroxy-3β-methyl-21-(4-cyano-1H-pyrazol-1'-yl)-19-nor-5β-pregnan-20-one (SAGE-217): A Clinical Next Generation Neuroactive Steroid Positive Allosteric Modulator of the (γ-Aminobutyric Acid)A Receptor</span></div><div class="casAuthors">Martinez Botella Gabriel; Salituro Francesco G; Harrison Boyd L; Blanco Maria-Jesus; Belfort Gabriel M; Dai Jing; Loya Carlos M; Ackley Michael A; Althaus Alison L; Grossman Scott J; Hoffmann Ethan; Doherty James J; Robichaud Albert J; Beresis Richard T; Bai Zhu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7810-7819</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Certain classes of neuroactive steroids (NASs) are positive allosteric modulators (PAM) of synaptic and extrasynaptic GABAA receptors.  Herein, we report new SAR insights in a series of 5β-nor-19-pregnan-20-one analogues bearing substituted pyrazoles and triazoles at C-21, culminating in the discovery of 3α-hydroxy-3β-methyl-21-(4-cyano-1H-pyrazol-1'-yl)-19-nor-5β-pregnan-20-one (SAGE-217, 3), a potent GABAA receptor modulator at both synaptic and extrasynaptic receptor subtypes, with excellent oral DMPK properties.  Compound 3 has completed a phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial and is currently being studied in parallel phase 2 clinical trials for the treatment of postpartum depression (PPD), major depressive disorder (MDD), and essential tremor (ET).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTiySZLUBmmmoUSrryheKE6fW6udTcc2ebseOx7KqjFvrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cfitFSgsg%253D%253D&md5=d9cb22ed2087152aa0e67d0906faa583</span></div><a href="/servlet/linkout?suffix=cit44b&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00846&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00846%26sid%3Dliteratum%253Aachs%26aulast%3DMartinez%2BBotella%26aufirst%3DG.%26aulast%3DSalituro%26aufirst%3DF.%2BG.%26aulast%3DHarrison%26aufirst%3DB.%2BL.%26aulast%3DBeresis%26aufirst%3DR.%2BT.%26aulast%3DBai%26aufirst%3DZ.%26aulast%3DBlanco%26aufirst%3DM.-J.%26aulast%3DBelfort%26aufirst%3DG.%2BM.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DLoya%26aufirst%3DC.%2BM.%26aulast%3DAckley%26aufirst%3DM.%2BA.%26aulast%3DAlthaus%26aufirst%3DA.%2BL.%26aulast%3DGrossman%26aufirst%3DS.%2BJ.%26aulast%3DHoffmann%26aufirst%3DE.%26aulast%3DDoherty%26aufirst%3DJ.%2BJ.%26aulast%3DRobichaud%26aufirst%3DA.%2BJ.%26atitle%3DNeuroactive%2520Steroids.%25202.%25203%25CE%25B1-Hydroxy-3%25CE%25B2-methyl-21-%25284-cyano-1H-pyrazol-1%25E2%2580%25B2-yl%2529-19-nor-5%25CE%25B2-pregnan-20-one%2520%2528SAGE-217%2529%253A%2520A%2520Clinical%2520Next%2520Generation%2520Neuroactive%2520Steroid%2520Positive%2520Allosteric%2520Modulator%2520of%2520the%2520%2528%25CE%25B3-Aminobutyric%2520Acid%2529A%2520Receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D7810%26epage%3D7819%26doi%3D10.1021%2Facs.jmedchem.7b00846" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Torregrossa, E.</span>; <span class="NLM_string-name">Brusasca, M.</span>; <span class="NLM_string-name">Manfrotto, C.</span></span> <span> </span><span class="NLM_article-title">Process for the Preparation of Allopregnanolone</span>. <span class="NLM_patent">US 20200087341 A1</span>, <span class="NLM_year">2020</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=E.+Torregrossa&author=M.+Brusasca&author=C.+Manfrotto&title=Process+for+the+Preparation+of+Allopregnanolone"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTorregrossa%26aufirst%3DE.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%2520Allopregnanolone%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">MacNevin, C.</span>; <span class="NLM_string-name">Stein, D. G.</span>; <span class="NLM_string-name">Liotta, D. C.</span>; <span class="NLM_string-name">Sayeed, I.</span>; <span class="NLM_string-name">Guthrie, D. B.</span>; <span class="NLM_string-name">Lockwood, M. A.</span>; <span class="NLM_string-name">Natchus, M. G.</span></span> <span> </span><span class="NLM_article-title">Preparation of Steroid Analogues for Neuroprotection</span>. <span class="NLM_patent">WO 2009108804 A2</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=C.+MacNevin&author=D.+G.+Stein&author=D.+C.+Liotta&author=I.+Sayeed&author=D.+B.+Guthrie&author=M.+A.+Lockwood&author=M.+G.+Natchus&title=Preparation+of+Steroid+Analogues+for+Neuroprotection"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMacNevin%26aufirst%3DC.%26atitle%3DPreparation%2520of%2520Steroid%2520Analogues%2520for%2520Neuroprotection%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Purdy, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrow, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blinn, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paul, S. M.</span></span> <span> </span><span class="NLM_article-title">Synthesis, Metabolism, and Pharmacological Activity of 3α-Hydroxy Steroids Which Potentiate GABA-Receptor-Mediated Chloride Ion Uptake in Rat Cerebral Cortical Synaptoneurosomes</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">1572</span>– <span class="NLM_lpage">1581</span>, <span class="refDoi"> DOI: 10.1021/jm00168a008</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00168a008" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADyaK3cXitlGltb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=1990&pages=1572-1581&author=R.+H.+Purdyauthor=A.+L.+Morrowauthor=J.+R.+Blinnauthor=S.+M.+Paul&title=Synthesis%2C+Metabolism%2C+and+Pharmacological+Activity+of+3%CE%B1-Hydroxy+Steroids+Which+Potentiate+GABA-Receptor-Mediated+Chloride+Ion+Uptake+in+Rat+Cerebral+Cortical+Synaptoneurosomes&doi=10.1021%2Fjm00168a008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47aR"><div class="casContent"><span class="casTitleNuber">47a</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, metabolism, and pharmacological activity of 3α-hydroxy steroids which potentiate GABA-receptor-mediated chloride ion uptake in rat cerebral cortical synaptoneurosomes</span></div><div class="casAuthors">Purdy, Robert H.; Morrow, A. Leslie; Blinn, James R.; Paul, Steven M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1572-81</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">A series of natural and synthetic 3α-hydroxy steroids were tested for their ability to potentiate GABA-receptor-mediated Cl- uptake into cerebral cortical synaptoneurosomes.  The naturally occurring metabolites 3α-hydroxy-5α-pregnan-20-one (I) and 3α,21-dihydroxy-5α-pregnan-20-one (II) were the most active in augmenting GABAA-receptor-mediated Cl- uptake.  Pharmacol. activity was reduced in the 5β-pregnane isomers and by some, but not all, modifications of the side chain.  The ability of these steroids to potentiate muscimol-stimulated Cl- uptake is lost by acetylation at C-3, introduction of unsatn. at C-9(11), inversion to the 3β-hydroxy isomer, or inversion of configuration at C-17.  A facile procedure is reported for the synthesis of unlabeled and tritium-labeled I and II.  The 9α,11α,12α-3H-labeled derivs. of I and II were used to identify the distribution and metabolic products of these active steroids.  Uptake of the more hydrophobic [3H]-I into brain was significantly greater than that of [3H]-II.  The principal 3H-labeled metabolites recovered from brain were the 3-oxo derivs., which are both inactive on GABA receptor-mediated Cl- flux.  Mol. modeling of the active steroids based on quant. structure-activity relationships provides evidence to support the stereospecificity of the binding interactions and suggests that there may be more than one type of steroid binding site assocd. with the GABAA-receptor-mediated Cl- ionophore.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopDFFJx0W6_LVg90H21EOLACvtfcHk0ljPcmuWIsOxOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXitlGltb4%253D&md5=702b2efda65742a8959dfd0328ef12c6</span></div><a href="/servlet/linkout?suffix=cit47a&amp;dbid=16384&amp;doi=10.1021%2Fjm00168a008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00168a008%26sid%3Dliteratum%253Aachs%26aulast%3DPurdy%26aufirst%3DR.%2BH.%26aulast%3DMorrow%26aufirst%3DA.%2BL.%26aulast%3DBlinn%26aufirst%3DJ.%2BR.%26aulast%3DPaul%26aufirst%3DS.%2BM.%26atitle%3DSynthesis%252C%2520Metabolism%252C%2520and%2520Pharmacological%2520Activity%2520of%25203%25CE%25B1-Hydroxy%2520Steroids%2520Which%2520Potentiate%2520GABA-Receptor-Mediated%2520Chloride%2520Ion%2520Uptake%2520in%2520Rat%2520Cerebral%2520Cortical%2520Synaptoneurosomes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1990%26volume%3D33%26spage%3D1572%26epage%3D1581%26doi%3D10.1021%2Fjm00168a008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit47b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kapras, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stastna, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chodounska, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pouzar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kristofikova, Z.</span></span> <span> </span><span class="NLM_article-title">Preparation of Steroid Sulfamates and Their Interaction with GABA<sub>A</sub> Receptor</span>. <i>Collect. Czech. Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">643</span>– <span class="NLM_lpage">650</span>, <span class="refDoi"> DOI: 10.1135/cccc2008187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1135%2Fcccc2008187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkvVSht7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2009&pages=643-650&author=V.+Kaprasauthor=E.+Stastnaauthor=H.+Chodounskaauthor=V.+Pouzarauthor=Z.+Kristofikova&title=Preparation+of+Steroid+Sulfamates+and+Their+Interaction+with+GABAA+Receptor&doi=10.1135%2Fcccc2008187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47bR"><div class="casContent"><span class="casTitleNuber">47b</span><div class="casTitle"><span class="NLM_cas:atitle">Preparation of steroid sulfamates and their interaction with GABAA receptor</span></div><div class="casAuthors">Kapras, Vojtech; Stastna, Eva; Chodounska, Hana; Pouzar, Vladimir; Kristofikova, Zdena</div><div class="citationInfo"><span class="NLM_cas:title">Collection of Czechoslovak Chemical Communications</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">643-650</span>CODEN:
                <span class="NLM_cas:coden">CCCCAK</span>;
        ISSN:<span class="NLM_cas:issn">0010-0765</span>.
    
            (<span class="NLM_cas:orgname">Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic</span>)
        </div><div class="casAbstract">Sulfamoyl chloride was used for the prepn. of 3α-sulfamate and 3β-sulfamate derivs. of steroids.  The target compds. thus prepd. included 20-oxo-5α-pregnan-3α-yl sulfamate, 20-oxo-5α-pregnan-3β-yl sulfamate, 20-oxo-5β-pregnan-3α-yl sulfamate and 20-oxo-5β-pregnan-3β-yl sulfamate from the corresponding 3α- and 3β-alcs.  Sulfur trioxide-pyridine complex was employed for the prepn. of 20-oxo-5α-pregnan-3α-yl pyridinium sulfate.  Specific steroid binding properties were detected by the decrease of the specific [35S]-tert-butylbicyclo[2.2.2]phosphorothionate binding after application of the tested compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEkSF-5-n6K7Vg90H21EOLACvtfcHk0ljPcmuWIsOxOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkvVSht7Y%253D&md5=19f95028012ef528015536ae0469e896</span></div><a href="/servlet/linkout?suffix=cit47b&amp;dbid=16384&amp;doi=10.1135%2Fcccc2008187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1135%252Fcccc2008187%26sid%3Dliteratum%253Aachs%26aulast%3DKapras%26aufirst%3DV.%26aulast%3DStastna%26aufirst%3DE.%26aulast%3DChodounska%26aufirst%3DH.%26aulast%3DPouzar%26aufirst%3DV.%26aulast%3DKristofikova%26aufirst%3DZ.%26atitle%3DPreparation%2520of%2520Steroid%2520Sulfamates%2520and%2520Their%2520Interaction%2520with%2520GABAA%2520Receptor%26jtitle%3DCollect.%2520Czech.%2520Chem.%2520Commun.%26date%3D2009%26volume%3D74%26spage%3D643%26epage%3D650%26doi%3D10.1135%2Fcccc2008187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><a href="https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-adults-partial-onset-seizures" class="extLink">https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-adults-partial-onset-seizures</a> (accessed 2020-09-15).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-approves-new-treatment-adults-partial-onset-seizures+%28accessed+2020-09-15%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Dougherty, M. L.</span></span> <span> </span><span class="NLM_article-title">Epilepsy Essentials: Cenobamate</span>. <i>Pract. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>, (<span class="NLM_issue">November/December</span>),  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">30</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&pages=29-30&issue=November%2FDecember&author=M.+L.+Dougherty&title=Epilepsy+Essentials%3A+Cenobamate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDougherty%26aufirst%3DM.%2BL.%26atitle%3DEpilepsy%2520Essentials%253A%2520Cenobamate%26jtitle%3DPract.%2520Neurol.%26date%3D2019%26issue%3DNovember%252FDecember%26spage%3D29%26epage%3D30" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit49b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, I.-S.</span></span> <span> </span><span class="NLM_article-title">Effects of Cenobamate (YKP3089), a Newly Developed Anti-Epileptic Drug, on Voltage-Gated Sodium Channels in Rat Hippocampal CA3 Neurons</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>855</i></span>,  <span class="NLM_fpage">175</span>– <span class="NLM_lpage">182</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2019.05.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2Fj.ejphar.2019.05.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31063770" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpsVajs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=855&publication_year=2019&pages=175-182&author=M.+Nakamuraauthor=J.-H.+Choauthor=H.+Shinauthor=I.-S.+Jang&title=Effects+of+Cenobamate+%28YKP3089%29%2C+a+Newly+Developed+Anti-Epileptic+Drug%2C+on+Voltage-Gated+Sodium+Channels+in+Rat+Hippocampal+CA3+Neurons&doi=10.1016%2Fj.ejphar.2019.05.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49bR"><div class="casContent"><span class="casTitleNuber">49b</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of cenobamate (YKP3089), a newly developed anti-epileptic drug, on voltage-gated sodium channels in rat hippocampal CA3 neurons</span></div><div class="casAuthors">Nakamura, Michiko; Cho, Jin-Hwa; Shin, Hyewon; Jang, Il-Sung</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">855</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">175-182</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">New, more effective pharmacol. treatments for epilepsy are needed, as a substantial portion of patients (>30%) are refractory to currently available anti-epileptic drugs.  Cenobamate (YKP3089) is an investigational anti-epileptic drug in clin. development.  Two completed adequate and well-controlled studies demonstrated a significant redn. in focal seizures with cenobamate in patients with epilepsy.  In this study, we characterized the effects of cenobamate on voltage-gated Na+ channels in acutely isolated rat hippocampal CA3 neurons using a whole-cell patch-clamp technique.  While cenobamate had little effect on the peak component of transient Na+ current (INaT) induced by brief depolarizing step pulses, it potently inhibited the non-inactivating persistent component of INa (INaP).  In addn., cenobamate potently inhibited the current by slow voltage-ramp stimuli.  Cenobamate significantly shifted the steady-state fast inactivation relationship toward a hyperpolarizing range, indicating that cenobamate binds to voltage-gated Na+ channels at the inactivated state with a higher affinity.  Cenobamate also accelerated the development of inactivation and retarded recovery from inactivation of voltage-gated Na+ channels.  In current clamp expts., cenobamate hyperpolarized membrane potentials in a concn.-dependent manner, and these effects were mediated by inhibiting the INaP.  Cenobamate also increased the threshold for generation of action potentials, and decreased the no. of action potentials elicited by depolarizing current injection.  Given that the INaP plays a pivotal role in the repetitive and/or burst generation of action potentials, the cenobamate-mediated preferential blockade of INaP might contribute to anti-epileptic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVK5NrddBugrVg90H21EOLACvtfcHk0li2eDgSoHP9SQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpsVajs70%253D&md5=ca9e3a5135f82c479661e7d9bcb25295</span></div><a href="/servlet/linkout?suffix=cit49b&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2019.05.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2019.05.007%26sid%3Dliteratum%253Aachs%26aulast%3DNakamura%26aufirst%3DM.%26aulast%3DCho%26aufirst%3DJ.-H.%26aulast%3DShin%26aufirst%3DH.%26aulast%3DJang%26aufirst%3DI.-S.%26atitle%3DEffects%2520of%2520Cenobamate%2520%2528YKP3089%2529%252C%2520a%2520Newly%2520Developed%2520Anti-Epileptic%2520Drug%252C%2520on%2520Voltage-Gated%2520Sodium%2520Channels%2520in%2520Rat%2520Hippocampal%2520CA3%2520Neurons%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2019%26volume%3D855%26spage%3D175%26epage%3D182%26doi%3D10.1016%2Fj.ejphar.2019.05.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, I.-S.</span></span> <span> </span><span class="NLM_article-title">Mechanism of Action of Cenobamate: Preferential Inhibition of the Persistent Sodium Current (P5.278)</span>. <i>Neurology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>90</i></span> (<span class="NLM_issue">15 Suppl.</span>),  <span class="NLM_fpage">P5.278</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2018&pages=P5.278&issue=15+Suppl.&author=M.+Nakamuraauthor=H.+Shinauthor=I.-S.+Jang&title=Mechanism+of+Action+of+Cenobamate%3A+Preferential+Inhibition+of+the+Persistent+Sodium+Current+%28P5.278%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNakamura%26aufirst%3DM.%26aulast%3DShin%26aufirst%3DH.%26aulast%3DJang%26aufirst%3DI.-S.%26atitle%3DMechanism%2520of%2520Action%2520of%2520Cenobamate%253A%2520Preferential%2520Inhibition%2520of%2520the%2520Persistent%2520Sodium%2520Current%2520%2528P5.278%2529%26jtitle%3DNeurology%26date%3D2018%26volume%3D90%26issue%3D15%2520Suppl%26spage%3DP5.278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit50b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Bialer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johannessen, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perucca, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, H. S.</span></span> <span> </span><span class="NLM_article-title">Progress Report on New Antiepileptic Drugs: A Summary of the Twelfth Eilat Conference (EILAT XII)</span>. <i>Epilepsy Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">141</span>, <span class="refDoi"> DOI: 10.1016/j.eplepsyres.2015.01.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2Fj.eplepsyres.2015.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=25769377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A280%3ADC%252BC2MjptFOhug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2015&pages=85-141&author=M.+Bialerauthor=S.+I.+Johannessenauthor=R.+H.+Levyauthor=E.+Peruccaauthor=T.+Tomsonauthor=H.+S.+White&title=Progress+Report+on+New+Antiepileptic+Drugs%3A+A+Summary+of+the+Twelfth+Eilat+Conference+%28EILAT+XII%29&doi=10.1016%2Fj.eplepsyres.2015.01.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50bR"><div class="casContent"><span class="casTitleNuber">50b</span><div class="casTitle"><span class="NLM_cas:atitle">Progress report on new antiepileptic drugs: A summary of the Twelfth Eilat Conference (EILAT XII)</span></div><div class="casAuthors">Bialer Meir; Johannessen Svein I; Levy Rene H; Perucca Emilio; Tomson Torbjorn; White H Steve</div><div class="citationInfo"><span class="NLM_cas:title">Epilepsy research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">85-141</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The Twelfth Eilat Conference on New Antiepileptic Drugs (AEDs) - EILAT XII, took place in Madrid, Spain from August 31st to September 3rd 2014.  About 130 basic scientists, clinical pharmacologists and neurologists from 22 countries attended the conference, whose main themes included "Conquering pharmacoresistant epilepsy", "Innovative emergency treatments", "Progress report on second-generation treatment" and "New methods and formulations".  Consistent with previous formats of this conference, a large part of the program was devoted to a review of AEDs in development, as well as updates on AEDs introduced since 2004.  Like the EILAT X and EILAT XI reports, the current article focuses on the preclinical and clinical pharmacology of AEDs that are currently in development.  These include adenosine-releasing silk, allopregnanolone (SAGE-547), AMP-X-0079, brivaracetam, bumetanide, cannabidiol, cannabidivarin, 2-deoxy-glucose, everolimus, ganaxolone, huperzine A, imepitoin, minocycline, NAX 801-2, pitolisant, PRX 0023, SAGE-217, valnoctamide and its homologue sec-butyl-propylacetamide (SPD), and VLB-01.  Since the previous Eilat conference, perampanel has been introduced into the market and twelve novel potential epilepsy treatments are presented for the first time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSxQNGd8mA3bUodMGTatQ7LfW6udTcc2eYX1PJIG8ec2Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MjptFOhug%253D%253D&md5=52293a4db7a5eb4e017b1c6f6b986950</span></div><a href="/servlet/linkout?suffix=cit50b&amp;dbid=16384&amp;doi=10.1016%2Fj.eplepsyres.2015.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.eplepsyres.2015.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DBialer%26aufirst%3DM.%26aulast%3DJohannessen%26aufirst%3DS.%2BI.%26aulast%3DLevy%26aufirst%3DR.%2BH.%26aulast%3DPerucca%26aufirst%3DE.%26aulast%3DTomson%26aufirst%3DT.%26aulast%3DWhite%26aufirst%3DH.%2BS.%26atitle%3DProgress%2520Report%2520on%2520New%2520Antiepileptic%2520Drugs%253A%2520A%2520Summary%2520of%2520the%2520Twelfth%2520Eilat%2520Conference%2520%2528EILAT%2520XII%2529%26jtitle%3DEpilepsy%2520Res.%26date%3D2015%26volume%3D111%26spage%3D85%26epage%3D141%26doi%3D10.1016%2Fj.eplepsyres.2015.01.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Krauss, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milanov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milovanovic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinhoff, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamin, M.</span></span> <span> </span><span class="NLM_article-title">Safety and Efficacy of Adjunctive Cenobamate (YKP3089) in Patients with Uncontrolled Focal Seizures: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Dose-Response Trial</span>. <i>Lancet Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">38</span>– <span class="NLM_lpage">48</span>, <span class="refDoi"> DOI: 10.1016/S1474-4422(19)30399-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2FS1474-4422%2819%2930399-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31734103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFKitbfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2020&pages=38-48&author=G.+L.+Kraussauthor=P.+Kleinauthor=C.+Brandtauthor=S.+K.+Leeauthor=I.+Milanovauthor=M.+Milovanovicauthor=B.+J.+Steinhoffauthor=M.+Kamin&title=Safety+and+Efficacy+of+Adjunctive+Cenobamate+%28YKP3089%29+in+Patients+with+Uncontrolled+Focal+Seizures%3A+A+Multicentre%2C+Double-Blind%2C+Randomised%2C+Placebo-Controlled%2C+Dose-Response+Trial&doi=10.1016%2FS1474-4422%2819%2930399-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51aR"><div class="casContent"><span class="casTitleNuber">51a</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial</span></div><div class="casAuthors">Krauss, Gregory L.; Klein, Pavel; Brandt, Christian; Lee, Sang Kun; Milanov, Ivan; Milovanovic, Maja; Steinhoff, Bernhard J.; Kamin, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Neurology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">38-48</span>CODEN:
                <span class="NLM_cas:coden">LNAEAM</span>;
        ISSN:<span class="NLM_cas:issn">1474-4422</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">We aimed to evaluate the safety, efficacy, and tolerability of adjunctive cenobamate in patients with uncontrolled focal-onset epilepsy.  Median percentage changes in seizure frequency were -24·0% (IQR -45·0 to -7·0%) for the placebo group compared with -35·5% (-62·5 to -15·0%; p=0·0071) for the 100 mg dose group, -55·0% (-73·0 to -23·0%; p<0·0001) for the 200 mg dose group, and -55·0% (-85·0 to -28·0%; p<0·0001) for the 400 mg dose group.  Responder rates during the maintenance phase were 25% (26 of 102 patients) for the placebo group compared with 40% (41 of 102; odds ratio 1·97, 95% CI 1·08-3·56; p=0·0365) for the 100 mg dose group, 56% (55 of 98; 3·74, 2·06-6·80; p<0·0001) for the 200 mg dose group, and 64% (61 of 95; 5·24, 2·84-9·67; p<0·0001) for the 400 mg dose group.  Treatment-emergent adverse events occurred in 76 (70%) of 108 patients in the placebo group, 70 (65%) of 108 in the 100 mg group, 84 (76%) of 110 in the 200 mg group, and 100 (90%) of 111 in the 400 mg group.  Treatment-emergent adverse events led to discontinuation in five (5%) patients in the placebo group, 11 (10%) in the 100 mg dose group, 15 (14%) in the 200 mg dose group, and 22 (20%) in the 400 mg dose group.  Adjunctive cenobamate reduced focal (partial)-onset seizure frequency, in a dose-related fashion.  Treatment-emergent adverse events were most frequent in the highest dose group.  Cenobamate appears to effective treatment option in patients with uncontrolled focal seizures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXjn-4gvNxabVg90H21EOLACvtfcHk0li2eDgSoHP9SQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFKitbfF&md5=cb2451d4f97c64948f4fe9bfe55d1e0a</span></div><a href="/servlet/linkout?suffix=cit51a&amp;dbid=16384&amp;doi=10.1016%2FS1474-4422%2819%2930399-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1474-4422%252819%252930399-0%26sid%3Dliteratum%253Aachs%26aulast%3DKrauss%26aufirst%3DG.%2BL.%26aulast%3DKlein%26aufirst%3DP.%26aulast%3DBrandt%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DS.%2BK.%26aulast%3DMilanov%26aufirst%3DI.%26aulast%3DMilovanovic%26aufirst%3DM.%26aulast%3DSteinhoff%26aufirst%3DB.%2BJ.%26aulast%3DKamin%26aufirst%3DM.%26atitle%3DSafety%2520and%2520Efficacy%2520of%2520Adjunctive%2520Cenobamate%2520%2528YKP3089%2529%2520in%2520Patients%2520with%2520Uncontrolled%2520Focal%2520Seizures%253A%2520A%2520Multicentre%252C%2520Double-Blind%252C%2520Randomised%252C%2520Placebo-Controlled%252C%2520Dose-Response%2520Trial%26jtitle%3DLancet%2520Neurol.%26date%3D2020%26volume%3D19%26spage%3D38%26epage%3D48%26doi%3D10.1016%2FS1474-4422%2819%2930399-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit51b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">French, J. A.</span></span> <span> </span><span class="NLM_article-title">Cenobamate for Focal Seizures—A Game Changer?</span>. <i>Nat. Rev. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">134</span>, <span class="refDoi"> DOI: 10.1038/s41582-019-0309-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1038%2Fs41582-019-0309-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31915370" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlsVCmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2020&pages=133-134&author=J.+A.+French&title=Cenobamate+for+Focal+Seizures%E2%80%94A+Game+Changer%3F&doi=10.1038%2Fs41582-019-0309-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51bR"><div class="casContent"><span class="casTitleNuber">51b</span><div class="casTitle"><span class="NLM_cas:atitle">Cenobamate for focal seizures - a game changer?</span></div><div class="casAuthors">French, Jacqueline A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neurology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">133-134</span>CODEN:
                <span class="NLM_cas:coden">NRNACP</span>;
        ISSN:<span class="NLM_cas:issn">1759-4758</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">In the first published efficacy study of cenobamate for treatment-resistant focal seizures, high doses produced high seizure-free rates, suggesting cenobamate can outperform existing options.  A risk of serious rash and low tolerability at higher doses means further safety studies and clin. experience are needed to det. its clin. value.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsAAE9bcAkjrVg90H21EOLACvtfcHk0lgQea927UF-gQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlsVCmuw%253D%253D&md5=2796aefd91a86ecf269bb7cda3f43add</span></div><a href="/servlet/linkout?suffix=cit51b&amp;dbid=16384&amp;doi=10.1038%2Fs41582-019-0309-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41582-019-0309-7%26sid%3Dliteratum%253Aachs%26aulast%3DFrench%26aufirst%3DJ.%2BA.%26atitle%3DCenobamate%2520for%2520Focal%2520Seizures%25E2%2580%2594A%2520Game%2520Changer%253F%26jtitle%3DNat.%2520Rev.%2520Neurol.%26date%3D2020%26volume%3D16%26spage%3D133%26epage%3D134%26doi%3D10.1038%2Fs41582-019-0309-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y.-M.</span>; <span class="NLM_string-name">Kim, C.-G.</span>; <span class="NLM_string-name">Kang, Y.-S.</span>; <span class="NLM_string-name">Yi, H.-J.</span>; <span class="NLM_string-name">Lee, H.-S.</span>; <span class="NLM_string-name">Ku, B.-C.</span>; <span class="NLM_string-name">Lee, E.-H.</span>; <span class="NLM_string-name">Im, D.-J.</span>; <span class="NLM_string-name">Shin, Y.-J.</span></span> <span> </span><span class="NLM_article-title">Preparation of Triazoles and Tetrazoles Containing Carbamoyl Group as Anticonvulsants</span>. <span class="NLM_patent">WO 2006112685 A1</span>, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=Y.-M.+Choi&author=C.-G.+Kim&author=Y.-S.+Kang&author=H.-J.+Yi&author=H.-S.+Lee&author=B.-C.+Ku&author=E.-H.+Lee&author=D.-J.+Im&author=Y.-J.+Shin&title=Preparation+of+Triazoles+and+Tetrazoles+Containing+Carbamoyl+Group+as+Anticonvulsants"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DY.-M.%26atitle%3DPreparation%2520of%2520Triazoles%2520and%2520Tetrazoles%2520Containing%2520Carbamoyl%2520Group%2520as%2520Anticonvulsants%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit52b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S. C.</span>; <span class="NLM_string-name">Uhm, M. Y.</span>; <span class="NLM_string-name">Lee, D. W.</span>; <span class="NLM_string-name">Kim, H. H.</span>; <span class="NLM_string-name">Lee, D. H.</span>; <span class="NLM_string-name">Lee, H. S.</span></span> <span> </span><span class="NLM_article-title">Process for Preparation of Carbamic Acid (<i>R</i>)-1-Aryl-2-tetrazolyl-ethyl Esters</span>. <span class="NLM_patent">WO 2011046380 A2</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=S.+C.+Lim&author=M.+Y.+Uhm&author=D.+W.+Lee&author=H.+H.+Kim&author=D.+H.+Lee&author=H.+S.+Lee&title=Process+for+Preparation+of+Carbamic+Acid+%28R%29-1-Aryl-2-tetrazolyl-ethyl+Esters"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DS.%2BC.%26atitle%3DProcess%2520for%2520Preparation%2520of%2520Carbamic%2520Acid%2520%2528R%2529-1-Aryl-2-tetrazolyl-ethyl%2520Esters%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit52c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S. C.</span>; <span class="NLM_string-name">Uhm, M. Y.</span>; <span class="NLM_string-name">Cho, N. R.</span>; <span class="NLM_string-name">Lee, D. W.</span>; <span class="NLM_string-name">Lee, J. Y.</span>; <span class="NLM_string-name">Kim, H. H.</span>; <span class="NLM_string-name">Lee, D. H.</span></span> <span> </span><span class="NLM_article-title">Preparation of Carbamic Acid (<i>R</i>)-1-Aryl-2-tetrazolyl-ethyl Esters</span>. <span class="NLM_patent">US 20100323410 A1</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=S.+C.+Lim&author=M.+Y.+Uhm&author=N.+R.+Cho&author=D.+W.+Lee&author=J.+Y.+Lee&author=H.+H.+Kim&author=D.+H.+Lee&title=Preparation+of+Carbamic+Acid+%28R%29-1-Aryl-2-tetrazolyl-ethyl+Esters"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DS.%2BC.%26atitle%3DPreparation%2520of%2520Carbamic%2520Acid%2520%2528R%2529-1-Aryl-2-tetrazolyl-ethyl%2520Esters%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Magano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunetz, J. R.</span></span> <span> </span><span class="NLM_article-title">Large-Scale Carbonyl Reductions in the Pharmaceutical Industry</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1156</span>– <span class="NLM_lpage">1184</span>, <span class="refDoi"> DOI: 10.1021/op2003826</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op2003826" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC38XitF2ntb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2012&pages=1156-1184&author=J.+Maganoauthor=J.+R.+Dunetz&title=Large-Scale+Carbonyl+Reductions+in+the+Pharmaceutical+Industry&doi=10.1021%2Fop2003826"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Large-Scale Carbonyl Reductions in the Pharmaceutical Industry</span></div><div class="casAuthors">Magano, Javier; Dunetz, Joshua R.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1156-1184</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Herein we present a review on methods for carbonyl redns. on large scale (≥100 mmol) applied to the synthesis of drug candidates in the pharmaceutical industry.  We discuss the most common and reliable methods for the redn. of aldehydes, ketones, carboxylic acids, esters, amides, imides, and acid chlorides.  Representative examples illustrate detailed reaction and workup conditions and highlight the advantages and limitations of each reducing agent with special emphasis on safety, cost, and amenability to scale-up.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxMDFgyL6o4bVg90H21EOLACvtfcHk0lgQea927UF-gQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitF2ntb4%253D&md5=3eeacc054ae4dd0dfeb3422237418573</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Fop2003826&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop2003826%26sid%3Dliteratum%253Aachs%26aulast%3DMagano%26aufirst%3DJ.%26aulast%3DDunetz%26aufirst%3DJ.%2BR.%26atitle%3DLarge-Scale%2520Carbonyl%2520Reductions%2520in%2520the%2520Pharmaceutical%2520Industry%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2012%26volume%3D16%26spage%3D1156%26epage%3D1184%26doi%3D10.1021%2Fop2003826" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, Y. N.</span></span> <span> </span><span class="NLM_article-title">Lasmiditan: First Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">1989</span>– <span class="NLM_lpage">1996</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01225-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs40265-019-01225-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31749059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A280%3ADC%252BB3MfhtlGgtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=1989-1996&author=Y.+N.+Lamb&title=Lasmiditan%3A+First+Approval&doi=10.1007%2Fs40265-019-01225-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Lasmiditan: First Approval</span></div><div class="casAuthors">Lamb Yvette N</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1989-1996</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Lasmiditan (REYVOW®; Eli Lilly and Company) is an orally available serotonin (5-HT)1F receptor agonist.  In October 2019, the US FDA approved lasmiditan 50 mg and 100 mg tablets for the acute treatment of migraine with or without aura in adults.  Approval was based on positive results from two pivotal phase III trials, in which lasmiditan significantly improved the proportions of patients achieving freedom from headache pain and freedom from the most bothersome symptom (photophobia, phonophobia or nausea), relative to placebo, when used to treat a migraine with moderate to severe pain.  Lasmiditan is not for use in the preventive treatment of migraine.  This article summarizes the milestones in the development of lasmiditan leading to its first approval for the acute treatment of migraine in adults.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQrg8vE0Fvv8VvAgqb2vdc5fW6udTcc2ebOMvCUpgS9q7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MfhtlGgtg%253D%253D&md5=54ba4498e8b1a3f567f0e56b56e04322</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01225-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01225-7%26sid%3Dliteratum%253Aachs%26aulast%3DLamb%26aufirst%3DY.%2BN.%26atitle%3DLasmiditan%253A%2520First%2520Approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D1989%26epage%3D1996%26doi%3D10.1007%2Fs40265-019-01225-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><a href="https://investor.lilly.com/news-releases/news-release-details/lilly-completes-acquisition-colucid-pharmaceuticals" class="extLink">https://investor.lilly.com/news-releases/news-release-details/lilly-completes-acquisition-colucid-pharmaceuticals</a> (accessed 2020-12-18).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Finvestor.lilly.com%2Fnews-releases%2Fnews-release-details%2Flilly-completes-acquisition-colucid-pharmaceuticals+%28accessed+2020-12-18%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><a href="https://uspl.lilly.com/reyvow/reyvow.html#pi" class="extLink">https://uspl.lilly.com/reyvow/reyvow.html#pi</a> (accessed 2020-09-17).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fuspl.lilly.com%2Freyvow%2Freyvow.html%23pi+%28accessed+2020-09-17%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Loo, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ailani, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baygani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hundemer, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Port, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krege, J. H.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety of Lasmiditan in Patients Using Concomitant Migraine Preventive Medications: Findings from SAMURAI and SPARTAN, Two Randomized Phase 3 Trials</span>. <i>J. Headache Pain</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">84</span>, <span class="refDoi"> DOI: 10.1186/s10194-019-1032-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1186%2Fs10194-019-1032-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31340760" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A280%3ADC%252BB3MvgvVaitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=84&author=L.+S.+Looauthor=J.+Ailaniauthor=J.+Schimauthor=S.+Bayganiauthor=H.+P.+Hundemerauthor=M.+Portauthor=J.+H.+Krege&title=Efficacy+and+Safety+of+Lasmiditan+in+Patients+Using+Concomitant+Migraine+Preventive+Medications%3A+Findings+from+SAMURAI+and+SPARTAN%2C+Two+Randomized+Phase+3+Trials&doi=10.1186%2Fs10194-019-1032-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials</span></div><div class="casAuthors">Loo Li Shen; Baygani Simin; Port Martha; Krege John H; Ailani Jessica; Schim Jack; Hundemer Hans-Peter</div><div class="citationInfo"><span class="NLM_cas:title">The journal of headache and pain</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">84</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  To study the efficacy and safety of lasmiditan for acute treatment of migraine in patients using migraine preventive medications.  BACKGROUND:  While lasmiditan has been proven to be an effective acute treatment for migraine, its effectiveness has not been examined when used concurrently with migraine preventives.  METHODS:  SAMURAI and SPARTAN were similarly designed, double-blind, phase 3, placebo-controlled studies of patients 18 years or older with 3 to 8 migraine attacks per month.  Patients were randomized to treat a migraine attack with oral lasmiditan 50 mg (SPARTAN only), 100 mg, 200 mg, or placebo.  Migraine preventives were allowed as long as doses were stable for 3 months prior to screening and were unchanged during the study.  Preventive medications with established or probable efficacy, as recommended by the American Academy of Neurology, the American Headache Society, and the European Headache Federation, plus botulinum toxin type A and candesartan, were included.  Within the subgroups of patients using and not using preventive therapies, lasmiditan and placebo groups were analyzed for the outcome of pain-free at 2 h and other efficacy outcomes.  The subgroups of patients using and not using preventive therapies were compared and interaction p-values were calculated for safety and efficacy outcomes.  RESULTS:  In these trials, 698 of 3981 patients (17.5%) used migraine preventive treatments.  Among patients using preventives, all lasmiditan doses resulted in significantly more patients being pain-free at 2 h, compared to placebo (p < 0.05).  Primary efficacy outcome (pain-free at 2 h), key secondary outcome (most bothersome symptom-free at 2 h) and all other efficacy outcomes were not significantly different between patients using or not using migraine preventives (all interaction p-values ≥0.1).  Rates of adverse events were similar for patients using and not using preventive medications.  CONCLUSIONS:  Lasmiditan was more effective than placebo for the acute treatment of migraine in patients concurrently using migraine preventive medications.  Lasmiditan efficacy and safety measures were similar for patients using and not using preventive medications.  TRIAL REGISTRATION:  SAMURAI (NCT02439320) and SPARTAN (NCT02605174).  Registered 18 March 2015.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTAZ7GLHZKdm-WhZTslLrfffW6udTcc2eZurK_JA84nsrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MvgvVaitA%253D%253D&md5=5501acda0fff8f2009e4eea1ce69f0d3</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1186%2Fs10194-019-1032-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs10194-019-1032-x%26sid%3Dliteratum%253Aachs%26aulast%3DLoo%26aufirst%3DL.%2BS.%26aulast%3DAilani%26aufirst%3DJ.%26aulast%3DSchim%26aufirst%3DJ.%26aulast%3DBaygani%26aufirst%3DS.%26aulast%3DHundemer%26aufirst%3DH.%2BP.%26aulast%3DPort%26aufirst%3DM.%26aulast%3DKrege%26aufirst%3DJ.%2BH.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Lasmiditan%2520in%2520Patients%2520Using%2520Concomitant%2520Migraine%2520Preventive%2520Medications%253A%2520Findings%2520from%2520SAMURAI%2520and%2520SPARTAN%252C%2520Two%2520Randomized%2520Phase%25203%2520Trials%26jtitle%3DJ.%2520Headache%2520Pain%26date%3D2019%26volume%3D20%26spage%3D84%26doi%3D10.1186%2Fs10194-019-1032-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, M. P.</span>; <span class="NLM_string-name">Kohlman, D. T.</span>; <span class="NLM_string-name">Liang, S. X.</span>; <span class="NLM_string-name">Mancuso, V.</span>; <span class="NLM_string-name">Victor, F.</span>; <span class="NLM_string-name">Xu, Y.-C.</span>; <span class="NLM_string-name">Ying, B.-P.</span>; <span class="NLM_string-name">Zacherl, D. P.</span>; <span class="NLM_string-name">Zhang, D.</span></span> <span> </span><span class="NLM_article-title">Pyridinoylpiperidines as 5-HT1F Agonists</span>. <span class="NLM_patent">WO 2003084949 A1</span>, <span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=M.+P.+Cohen&author=D.+T.+Kohlman&author=S.+X.+Liang&author=V.+Mancuso&author=F.+Victor&author=Y.-C.+Xu&author=B.-P.+Ying&author=D.+P.+Zacherl&author=D.+Zhang&title=Pyridinoylpiperidines+as+5-HT1F+Agonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DM.%2BP.%26atitle%3DPyridinoylpiperidines%2520as%25205-HT1F%2520Agonists%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deore, D.</span>; <span class="NLM_string-name">Bhirud, S. B.</span>; <span class="NLM_string-name">Chand, P.</span>; <span class="NLM_string-name">Naik, S.</span>; <span class="NLM_string-name">Badgujar, S.</span>; <span class="NLM_string-name">Baviskar, D.</span></span> <span> </span><span class="NLM_article-title">Process for Preparation of Lasmiditan</span>. <span class="NLM_patent">WO 2020095171 A1</span>, <span class="NLM_year">2020</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=D.+Deore&author=S.+B.+Bhirud&author=P.+Chand&author=S.+Naik&author=S.+Badgujar&author=D.+Baviskar&title=Process+for+Preparation+of+Lasmiditan"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDeore%26aufirst%3DD.%26atitle%3DProcess%2520for%2520Preparation%2520of%2520Lasmiditan%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, L. J.</span></span> <span> </span><span class="NLM_article-title">Lemborexant: First Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">425</span>– <span class="NLM_lpage">432</span>, <span class="refDoi"> DOI: 10.1007/s40265-020-01276-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs40265-020-01276-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=32096020" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlslCltro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2020&pages=425-432&author=L.+J.+Scott&title=Lemborexant%3A+First+Approval&doi=10.1007%2Fs40265-020-01276-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Lemborexant: First Approval</span></div><div class="casAuthors">Scott, Lesley J.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">425-432</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Abstr.: Lemborexant (DAYVIGO) is an orally administered, dual orexin receptor (OXR) antagonist that exhibits reversible competitive antagonism at OXR1 and OXR2 (> affinity at OXR2) that was discovered and developed by Eisai Inc. for the treatment of adult patients with insomnia.  In Dec. 2019, lemborexant received its first approval (with final interim scheduling) in the USA for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.  In Jan. 2020, lemborexant also received approval in Japan for the treatment of insomnia.  It is also being investigated for the treatment of irregular sleep-wake rhythm disorder (ISWRD) assocd. with mild to moderate Alzheimer's disease.  This article summarizes the milestones in the development of lemborexant leading to its first global approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9xrf3D4Hk4rVg90H21EOLACvtfcHk0liNbj1DPTdRMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlslCltro%253D&md5=3d7e881e7ca2d223682081871963761c</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1007%2Fs40265-020-01276-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-020-01276-1%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DL.%2BJ.%26atitle%3DLemborexant%253A%2520First%2520Approval%26jtitle%3DDrugs%26date%3D2020%26volume%3D80%26spage%3D425%26epage%3D432%26doi%3D10.1007%2Fs40265-020-01276-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roth, T.</span></span> <span> </span><span class="NLM_article-title">Insomnia: Definition, Prevalence, Etiology, and Consequences</span>. <i>J. Clin. Sleep Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">5 Suppl.</span>),  <span class="NLM_fpage">S7</span>– <span class="NLM_lpage">S10</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.5664%2Fjcsm.26929" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=17824495" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2007&pages=S7-S10&issue=5+Suppl.&author=T.+Roth&title=Insomnia%3A+Definition%2C+Prevalence%2C+Etiology%2C+and+Consequences"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.5664%2Fjcsm.26929&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5664%252Fjcsm.26929%26sid%3Dliteratum%253Aachs%26aulast%3DRoth%26aufirst%3DT.%26atitle%3DInsomnia%253A%2520Definition%252C%2520Prevalence%252C%2520Etiology%252C%2520and%2520Consequences%26jtitle%3DJ.%2520Clin.%2520Sleep%2520Med.%26date%3D2007%26volume%3D3%26issue%3D5%2520Suppl%26spage%3DS7%26epage%3DS10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Morin, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drake, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harvey, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystal, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manber, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riemann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiegelhalder, K.</span></span> <span> </span><span class="NLM_article-title">Insomnia Disorder</span>. <i>Nat. Rev. Dis. Primers</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">15026</span>, <span class="refDoi"> DOI: 10.1038/nrdp.2015.26</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1038%2Fnrdp.2015.26" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=27189779" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A280%3ADC%252BC2s%252Fgs1aqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2015&pages=15026&author=C.+M.+Morinauthor=C.+L.+Drakeauthor=A.+G.+Harveyauthor=A.+D.+Krystalauthor=R.+Manberauthor=D.+Riemannauthor=K.+Spiegelhalder&title=Insomnia+Disorder&doi=10.1038%2Fnrdp.2015.26"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62aR"><div class="casContent"><span class="casTitleNuber">62a</span><div class="casTitle"><span class="NLM_cas:atitle">Insomnia disorder</span></div><div class="casAuthors">Morin Charles M; Drake Christopher L; Harvey Allison G; Krystal Andrew D; Manber Rachel; Riemann Dieter; Spiegelhalder Kai</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Disease primers</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">15026</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Insomnia disorder affects a large proportion of the population on a situational, recurrent or chronic basis and is among the most common complaints in medical practice.  The disorder is predominantly characterized by dissatisfaction with sleep duration or quality and difficulties initiating or maintaining sleep, along with substantial distress and impairments of daytime functioning.  It can present as the chief complaint or, more often, co-occurs with other medical or psychiatric disorders, such as pain and depression.  Persistent insomnia has been linked with adverse long-term health outcomes, including diminished quality of life and physical and psychological morbidity.  Despite its high prevalence and burden, the aetiology and pathophysiology of insomnia is poorly understood.  In the past decade, important changes in classification and diagnostic paradigms have instigated a move from a purely symptom-based conceptualization to the recognition of insomnia as a disorder in its own right.  These changes have been paralleled by key advances in therapy, with generic pharmacological and psychological interventions being increasingly replaced by approaches that have sleep-specific and insomnia-specific therapeutic targets.  Psychological and pharmacological therapies effectively reduce the time it takes to fall asleep and the time spent awake after sleep onset, and produce a modest increase in total sleep time; these are outcomes that correlate with improvements in daytime functioning.  Despite this progress, several challenges remain, including the need to improve our knowledge of the mechanisms that underlie insomnia and to develop more cost-effective, efficient and accessible therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQcrna7Vp9c5HRxY89Cm6SyfW6udTcc2eYnkHemZAz7sLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s%252Fgs1aqug%253D%253D&md5=3bae6793183afcb0c89f4b11ffca776f</span></div><a href="/servlet/linkout?suffix=cit62a&amp;dbid=16384&amp;doi=10.1038%2Fnrdp.2015.26&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrdp.2015.26%26sid%3Dliteratum%253Aachs%26aulast%3DMorin%26aufirst%3DC.%2BM.%26aulast%3DDrake%26aufirst%3DC.%2BL.%26aulast%3DHarvey%26aufirst%3DA.%2BG.%26aulast%3DKrystal%26aufirst%3DA.%2BD.%26aulast%3DManber%26aufirst%3DR.%26aulast%3DRiemann%26aufirst%3DD.%26aulast%3DSpiegelhalder%26aufirst%3DK.%26atitle%3DInsomnia%2520Disorder%26jtitle%3DNat.%2520Rev.%2520Dis.%2520Primers%26date%3D2015%26volume%3D1%26spage%3D15026%26doi%3D10.1038%2Fnrdp.2015.26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit62b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Abad, V. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guilleminault, C.</span></span> <span> </span><span class="NLM_article-title">Insomnia in Elderly Patients: Recommendations for Pharmacological Management</span>. <i>Drugs Aging</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">791</span>– <span class="NLM_lpage">817</span>, <span class="refDoi"> DOI: 10.1007/s40266-018-0569-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs40266-018-0569-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=30058034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVShtb%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2018&pages=791-817&author=V.+C.+Abadauthor=C.+Guilleminault&title=Insomnia+in+Elderly+Patients%3A+Recommendations+for+Pharmacological+Management&doi=10.1007%2Fs40266-018-0569-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62bR"><div class="casContent"><span class="casTitleNuber">62b</span><div class="casTitle"><span class="NLM_cas:atitle">Insomnia in Elderly Patients: Recommendations for Pharmacological Management</span></div><div class="casAuthors">Abad, Vivien C.; Guilleminault, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Drugs & Aging</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">791-817</span>CODEN:
                <span class="NLM_cas:coden">DRAGE6</span>;
        ISSN:<span class="NLM_cas:issn">1170-229X</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Chronic insomnia affects 57% of the elderly in the United States, with impairment of quality of life, function, and health.  Chronic insomnia burdens society with billions of dollars in direct and indirect costs of care.  The main modalities in the treatment of insomnia in the elderly are psychol./behavioral therapies, pharmacol. treatment, or a combination of both.  Various specialty societies view psychol./behavioral therapies as the initial treatment intervention.  Pharmacotherapy plays an adjunctive role when insomnia symptoms persist or when patients are unable to pursue cognitive behavioral therapies.  Current drugs for insomnia fall into different classes: orexin agonists, histamine receptor antagonists, non-benzodiazepine gamma aminobutyric acid receptor agonists, and benzodiazepines.  This review focuses on Food and Drug Administration (FDA)-approved drugs for insomnia, including suvorexant, low-dose doxepin, Z-drugs (eszopiclone, zolpidem, zaleplon), benzodiazepines (triazolam, temazepam), and ramelteon.  We review the indications, dosing, efficacy, benefits, and harms of these drugs in the elderly, and discuss data on drugs that are commonly used off-label to treat insomnia, and those that are in clin. development.  The choice of a hypnotic agent in the elderly is symptom-based.  Ramelteon or short-acting Z-drugs can treat sleep-onset insomnia.  Suvorexant or low-dose doxepin can improve sleep maintenance.  Eszopiclone or zolpidem extended release can be utilized for both sleep onset and sleep maintenance.  Low-dose zolpidem sublingual tablets or zaleplon can alleviate middle-of-the-night awakenings.  Benzodiazepines should not be used routinely.  Trazodone, a commonly used off-label drug for insomnia, improves sleep quality and sleep continuity but carries significant risks.  Tiagabine, sometimes used off-label for insomnia, is not effective and should not be utilized.  Non-FDA-approved hypnotic agents that are commonly used include melatonin, diphenhydramine, tryptophan, and valerian, despite limited data on benefits and harms.  Melatonin slightly improves sleep onset and sleep duration, but product quality and efficacy may vary.  Tryptophan decreases sleep onset in adults, but data in the elderly are not available.  Valerian is relatively safe but has equivocal benefits on sleep quality.  Phase II studies of dual orexin receptor antagonists (almorexant, lemborexant, and filorexant) have shown some improvement in sleep maintenance and sleep continuity.  Piromelatine may improve sleep maintenance.  Histamine receptor inverse agonists (APD-125, eplivanserin, and LY2624803) improve slow-wave sleep but, for various reasons, the drug companies withdrew their products.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoL09It5208Y7Vg90H21EOLACvtfcHk0lgJWUGjnpjn_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVShtb%252FL&md5=609f59e3556523ff8c81a02aee785664</span></div><a href="/servlet/linkout?suffix=cit62b&amp;dbid=16384&amp;doi=10.1007%2Fs40266-018-0569-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40266-018-0569-8%26sid%3Dliteratum%253Aachs%26aulast%3DAbad%26aufirst%3DV.%2BC.%26aulast%3DGuilleminault%26aufirst%3DC.%26atitle%3DInsomnia%2520in%2520Elderly%2520Patients%253A%2520Recommendations%2520for%2520Pharmacological%2520Management%26jtitle%3DDrugs%2520Aging%26date%3D2018%26volume%3D35%26spage%3D791%26epage%3D817%26doi%3D10.1007%2Fs40266-018-0569-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Scammell, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winrow, C. J.</span></span> <span> </span><span class="NLM_article-title">Orexin Receptors: Pharmacology and Therapeutic Opportunities</span>. <i>Annu. Rev. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">243</span>– <span class="NLM_lpage">66</span>, <span class="refDoi"> DOI: 10.1146/annurev-pharmtox-010510-100528</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1146%2Fannurev-pharmtox-010510-100528" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=21034217" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisFOju74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2011&pages=243-66&author=T.+E.+Scammellauthor=C.+J.+Winrow&title=Orexin+Receptors%3A+Pharmacology+and+Therapeutic+Opportunities&doi=10.1146%2Fannurev-pharmtox-010510-100528"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63aR"><div class="casContent"><span class="casTitleNuber">63a</span><div class="casTitle"><span class="NLM_cas:atitle">Orexin receptors: pharmacology and therapeutic opportunities</span></div><div class="casAuthors">Scammell, Thoams E.; Winrow, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">243-266</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Orexin-A and -B (also known as hypocretin-1 and -2) are neuropeptides produced in the lateral hypothalamus that promote many aspects of arousal through the OX1 and OX2 receptors.  In fact, they are necessary for normal wakefulness, as loss of the orexin-producing neurons causes narcolepsy in humans and rodents.  This has generated considerable interest in developing small-mol. orexin receptor antagonists as a novel therapy for the treatment of insomnia.  Orexin antagonists, esp. those that block OX2 or both OX1 and OX2 receptors, clearly promote sleep in animals, and clin. results are encouraging: Several compds. are in Phase III trials.  As the orexin system mainly promotes arousal, these new compds. will likely improve insomnia without incurring many of the side effects encountered with current medications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5EYJ1Vu6n0bVg90H21EOLACvtfcHk0lgJWUGjnpjn_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisFOju74%253D&md5=2fe03aa1eda09d266ab0d93426740f60</span></div><a href="/servlet/linkout?suffix=cit63a&amp;dbid=16384&amp;doi=10.1146%2Fannurev-pharmtox-010510-100528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-pharmtox-010510-100528%26sid%3Dliteratum%253Aachs%26aulast%3DScammell%26aufirst%3DT.%2BE.%26aulast%3DWinrow%26aufirst%3DC.%2BJ.%26atitle%3DOrexin%2520Receptors%253A%2520Pharmacology%2520and%2520Therapeutic%2520Opportunities%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2011%26volume%3D51%26spage%3D243%26epage%3D66%26doi%3D10.1146%2Fannurev-pharmtox-010510-100528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit63b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Grandner, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perlis, M. L.</span></span> <span> </span><span class="NLM_article-title">Pharmacotherapy for Insomnia Disorder in Older Adults</span>. <i>JAMA Netw. Open</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>2</i></span>, <span class="NLM_elocation-id">e1918214</span> <span class="refDoi"> DOI: 10.1001/jamanetworkopen.2019.18214</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1001%2Fjamanetworkopen.2019.18214" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31880788" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2019&author=M.+A.+Grandnerauthor=M.+L.+Perlis&title=Pharmacotherapy+for+Insomnia+Disorder+in+Older+Adults&doi=10.1001%2Fjamanetworkopen.2019.18214"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63b&amp;dbid=16384&amp;doi=10.1001%2Fjamanetworkopen.2019.18214&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamanetworkopen.2019.18214%26sid%3Dliteratum%253Aachs%26aulast%3DGrandner%26aufirst%3DM.%2BA.%26aulast%3DPerlis%26aufirst%3DM.%2BL.%26atitle%3DPharmacotherapy%2520for%2520Insomnia%2520Disorder%2520in%2520Older%2520Adults%26jtitle%3DJAMA%2520Netw.%2520Open%26date%3D2019%26volume%3D2%26doi%3D10.1001%2Fjamanetworkopen.2019.18214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span> <span> </span><span class="NLM_article-title">The Orexin/Receptor System: Molecular Mechanism and Therapeutic Potential for Neurological Diseases</span>. <i>Front. Mol. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">220</span>, <span class="refDoi"> DOI: 10.3389/fnmol.2018.00220</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.3389%2Ffnmol.2018.00220" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=30002617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFGmt7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=220&author=C.+Wangauthor=Q.+Wangauthor=B.+Jiauthor=Y.+Panauthor=C.+Xuauthor=B.+Chengauthor=B.+Baiauthor=J.+Chen&title=The+Orexin%2FReceptor+System%3A+Molecular+Mechanism+and+Therapeutic+Potential+for+Neurological+Diseases&doi=10.3389%2Ffnmol.2018.00220"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">The orexin/receptor system: molecular mechanism and therapeutic potential for neurological diseases</span></div><div class="casAuthors">Wang, Chunmei; Wang, Qinqin; Ji, Bingyuan; Pan, Yanyou; Xu, Chao; Cheng, Baohua; Bai, Bo; Chen, Jing</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Molecular Neuroscience</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">220/1-220/16</span>CODEN:
                <span class="NLM_cas:coden">FMNRAJ</span>;
        ISSN:<span class="NLM_cas:issn">1662-5099</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Orexins, also known as hypocretins, are two neuropeptides secreted from orexin-contg. neurons, mainly in the lateral hypothalamus (LH).  Orexins orchestrate their effects by binding and activating two G-protein-coupled receptors (GPCRs), orexin receptor type 1 (OX1R) and type 2 (OX2R).  Orexin/receptor pathways play vital regulatory roles in many physiol. processes, esp. feeding behavior, sleep-wake rhythm, reward and addiction and energy balance.  Furthermore several reports showed that orexin/receptor pathways are involved in pathol. processes of neurol. diseases such as narcolepsy, depression, ischemic stroke, drug addiction and Alzheimer's disease (AD).  This review article summarizes the expression patterns, physiol. functions and potential mol. mechanisms of the orexin/receptor system in neurol. diseases, providing an overall framework for considering these pathways from the standpoints of basic research and clin. treatment of neurol. diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGre2X2KfcbVS7Vg90H21EOLACvtfcHk0lg9vsRluI53-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFGmt7fK&md5=d6e7659df8c3ac08fa58cd7958a449b3</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.3389%2Ffnmol.2018.00220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnmol.2018.00220%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DJi%26aufirst%3DB.%26aulast%3DPan%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DC.%26aulast%3DCheng%26aufirst%3DB.%26aulast%3DBai%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DJ.%26atitle%3DThe%2520Orexin%252FReceptor%2520System%253A%2520Molecular%2520Mechanism%2520and%2520Therapeutic%2520Potential%2520for%2520Neurological%2520Diseases%26jtitle%3DFront.%2520Mol.%2520Neurosci.%26date%3D2018%26volume%3D11%26spage%3D220%26doi%3D10.3389%2Ffnmol.2018.00220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naoe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terauchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozaki, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doko, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takemura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorimachi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beuckmann, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yonaga, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of (1<i>R</i>,2<i>S</i>)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-<i>N</i>-(5-fluoropyridin-2-yl)cyclopropanecarboxamide (E2006): A Potent and Efficacious Oral Orexin Receptor Antagonist</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">4648</span>– <span class="NLM_lpage">4664</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00217</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00217" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotVSntbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4648-4664&author=Y.+Yoshidaauthor=Y.+Naoeauthor=T.+Terauchiauthor=F.+Ozakiauthor=T.+Dokoauthor=A.+Takemuraauthor=T.+Tanakaauthor=K.+Sorimachiauthor=C.+T.+Beuckmannauthor=M.+Suzukiauthor=T.+Uenoauthor=S.+Ozakiauthor=M.+Yonaga&title=Discovery+of+%281R%2C2S%29-2-%7B%5B%282%2C4-Dimethylpyrimidin-5-yl%29oxy%5Dmethyl%7D-2-%283-fluorophenyl%29-N-%285-fluoropyridin-2-yl%29cyclopropanecarboxamide+%28E2006%29%3A+A+Potent+and+Efficacious+Oral+Orexin+Receptor+Antagonist&doi=10.1021%2Facs.jmedchem.5b00217"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (1R,2S)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide (E2006): A Potent and Efficacious Oral Orexin Receptor Antagonist</span></div><div class="casAuthors">Yoshida, Yu; Naoe, Yoshimitsu; Terauchi, Taro; Ozaki, Fumihiro; Doko, Takashi; Takemura, Ayumi; Tanaka, Toshiaki; Sorimachi, Keiichi; Beuckmann, Carsten T.; Suzuki, Michiyuki; Ueno, Takashi; Ozaki, Shunsuke; Yonaga, Masahiro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4648-4664</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The orexin/hypocretin receptors are a family of G protein-coupled receptors and consist of orexin-1 (OX1) and orexin-2 (OX2) receptor subtypes.  Orexin receptors are expressed throughout the central nervous system and are involved in the regulation of the sleep/wake cycle.  Because modulation of these receptors constitutes a promising target for novel treatments of disorders assocd. with the control of sleep and wakefulness, such as insomnia, the development of orexin receptor antagonists has emerged as an important focus in drug discovery research.  Here, we report the design, synthesis, characterization, and structure-activity relationships (SARs) of novel orexin receptor antagonists.  Various modifications made to the core structure of a previously developed compd. (-)-5 (I), the lead mol., resulted in compds. with improved chem. and pharmacol. profiles.  The investigation afforded a potential therapeutic agent, (1R,2S)-2-{[(2,4-dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide (E2006, II), an orally active, potent orexin antagonist.  The efficacy was demonstrated in mice in an in vivo study by using sleep parameter measurements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzsPb-jXQr4bVg90H21EOLACvtfcHk0lg9vsRluI53-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotVSntbk%253D&md5=939b30c00a05039e911484ef1f6800ad</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00217%26sid%3Dliteratum%253Aachs%26aulast%3DYoshida%26aufirst%3DY.%26aulast%3DNaoe%26aufirst%3DY.%26aulast%3DTerauchi%26aufirst%3DT.%26aulast%3DOzaki%26aufirst%3DF.%26aulast%3DDoko%26aufirst%3DT.%26aulast%3DTakemura%26aufirst%3DA.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DSorimachi%26aufirst%3DK.%26aulast%3DBeuckmann%26aufirst%3DC.%2BT.%26aulast%3DSuzuki%26aufirst%3DM.%26aulast%3DUeno%26aufirst%3DT.%26aulast%3DOzaki%26aufirst%3DS.%26aulast%3DYonaga%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520%25281R%252C2S%2529-2-%257B%255B%25282%252C4-Dimethylpyrimidin-5-yl%2529oxy%255Dmethyl%257D-2-%25283-fluorophenyl%2529-N-%25285-fluoropyridin-2-yl%2529cyclopropanecarboxamide%2520%2528E2006%2529%253A%2520A%2520Potent%2520and%2520Efficacious%2520Oral%2520Orexin%2520Receptor%2520Antagonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4648%26epage%3D4664%26doi%3D10.1021%2Facs.jmedchem.5b00217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moniz, G. A.</span>; <span class="NLM_string-name">Wilcoxen, A. Z.</span>; <span class="NLM_string-name">Benayoud, F.</span>; <span class="NLM_string-name">Lee, J.</span>; <span class="NLM_string-name">Zhang, H.</span>; <span class="NLM_string-name">Terauchi, T.</span>; <span class="NLM_string-name">Takemura, A.</span>; <span class="NLM_string-name">Yoshida, Y.</span>; <span class="NLM_string-name">Tanaka, T.</span>; <span class="NLM_string-name">Sorimachi, K.</span>; <span class="NLM_string-name">Naoe, Y.</span>; <span class="NLM_string-name">Kazuta, Y.</span></span> <span> </span><span class="NLM_article-title">Methods and Compounds Useful in the Synthesis of Orexin-2 Receptor Antagonists</span>. <span class="NLM_patent">WO 2013123240 A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=G.+A.+Moniz&author=A.+Z.+Wilcoxen&author=F.+Benayoud&author=J.+Lee&author=H.+Zhang&author=T.+Terauchi&author=A.+Takemura&author=Y.+Yoshida&author=T.+Tanaka&author=K.+Sorimachi&author=Y.+Naoe&author=Y.+Kazuta&title=Methods+and+Compounds+Useful+in+the+Synthesis+of+Orexin-2+Receptor+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMoniz%26aufirst%3DG.%2BA.%26atitle%3DMethods%2520and%2520Compounds%2520Useful%2520in%2520the%2520Synthesis%2520of%2520Orexin-2%2520Receptor%2520Antagonists%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Wennogle, L. P.</span>; <span class="NLM_string-name">Li, P.</span></span> <span> </span><span class="NLM_article-title">Organic Compounds, Substituted Fluorinated Heterocycle Fused Gamma-Carbolines for Use in Treatment of Diseases Involving 5-HT2A Receptor, Serotonin Transporter, and/or Pathways Involving Dopamine Receptor Signaling</span>. <span class="NLM_patent">WO 2017165755 A1</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=L.+P.+Wennogle&author=P.+Li&title=Organic+Compounds%2C+Substituted+Fluorinated+Heterocycle+Fused+Gamma-Carbolines+for+Use+in+Treatment+of+Diseases+Involving+5-HT2A+Receptor%2C+Serotonin+Transporter%2C+and%2For+Pathways+Involving+Dopamine+Receptor+Signaling"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWennogle%26aufirst%3DL.%2BP.%26atitle%3DOrganic%2520Compounds%252C%2520Substituted%2520Fluorinated%2520Heterocycle%2520Fused%2520Gamma-Carbolines%2520for%2520Use%2520in%2520Treatment%2520of%2520Diseases%2520Involving%25205-HT2A%2520Receptor%252C%2520Serotonin%2520Transporter%252C%2520and%252For%2520Pathways%2520Involving%2520Dopamine%2520Receptor%2520Signaling%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit67b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, G.</span>; <span class="NLM_string-name">Davis, R.</span>; <span class="NLM_string-name">Wennogle, L. P.</span></span> <span> </span><span class="NLM_article-title">Novel Methods for Acute Treatment of Depression and/or Anxiety</span>. <span class="NLM_patent">WO 2019178484 A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=G.+Snyder&author=R.+Davis&author=L.+P.+Wennogle&title=Novel+Methods+for+Acute+Treatment+of+Depression+and%2For+Anxiety"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSnyder%26aufirst%3DG.%26atitle%3DNovel%2520Methods%2520for%2520Acute%2520Treatment%2520of%2520Depression%2520and%252For%2520Anxiety%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blair, H. A.</span></span> <span> </span><span class="NLM_article-title">Lumateperone: First Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">417</span>– <span class="NLM_lpage">423</span>, <span class="refDoi"> DOI: 10.1007/s40265-020-01271-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs40265-020-01271-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=32060882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A280%3ADC%252BB387itl2iuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2020&pages=417-423&author=H.+A.+Blair&title=Lumateperone%3A+First+Approval&doi=10.1007%2Fs40265-020-01271-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Lumateperone: First Approval</span></div><div class="casAuthors">Blair Hannah A</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">417-423</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Lumateperone (Caplyta(®)) is a novel, orally available agent developed by Intra-Cellular Therapies (under a license from Bristol-Myers Squibb) for the treatment of schizophrenia and other neuropsychiatric and neurological disorders.  Lumateperone is a first-in-class selective and simultaneous modulator of serotonin, dopamine and glutamate.  In December 2019, lumateperone received its first global approval in the USA for the treatment of schizophrenia in adults.  The drug is also under clinical development for bipolar depression, behavioural disorders associated with dementia and Alzheimer's disease, sleep maintenance insomnia and major depressive disorders.  This article summarizes the milestones in the development of lumateperone leading to this first approval for the treatment of schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSA-ZQG6zODSPEeosoOnpOLfW6udTcc2ebl3rsd_-uttrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB387itl2iuw%253D%253D&md5=26b1f35c1ec74f78be3b37b984f5bffa</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1007%2Fs40265-020-01271-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-020-01271-6%26sid%3Dliteratum%253Aachs%26aulast%3DBlair%26aufirst%3DH.%2BA.%26atitle%3DLumateperone%253A%2520First%2520Approval%26jtitle%3DDrugs%26date%3D2020%26volume%3D80%26spage%3D417%26epage%3D423%26doi%3D10.1007%2Fs40265-020-01271-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davis, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correll, C. U.</span></span> <span> </span><span class="NLM_article-title">ITI-007 in the Treatment of Schizophrenia: From Novel Pharmacology to Clinical Outcomes</span>. <i>Expert Rev. Neurother.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">601</span>– <span class="NLM_lpage">614</span>, <span class="refDoi"> DOI: 10.1080/14737175.2016.1174577</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1080%2F14737175.2016.1174577" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=27042868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC28XmslOjsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=601-614&author=R.+E.+Davisauthor=C.+U.+Correll&title=ITI-007+in+the+Treatment+of+Schizophrenia%3A+From+Novel+Pharmacology+to+Clinical+Outcomes&doi=10.1080%2F14737175.2016.1174577"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes</span></div><div class="casAuthors">Davis, Robert E.; Correll, Christoph U.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Neurotherapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">601-614</span>CODEN:
                <span class="NLM_cas:coden">ERNXAR</span>;
        ISSN:<span class="NLM_cas:issn">1473-7175</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">ITI-007 is an investigational drug being developed for schizophrenia and other neuropsychiatric/neurodegenerative diseases.  ITI-007 has a unique pharmacol. profile, combining potent 5-HT2a receptor antagonism with cell-type-specific dopamine and glutamate receptor modulation, plus serotonin reuptake inhibition.  At dopamine-D2 receptors, ITI-007 acts as a post-synaptic antagonist and pre-synaptic partial agonist.  Addnl., ITI-007 stimulates phosphorylation of glutamatergic NMDA-NR2B receptors, downstream of dopamine-D1 receptor intracellular signaling.  Based on a large, placebo and risperidone controlled, Phase-II trial, ITI-007 60 mg was shown to be effective in reducing symptoms in patients with acutely exacerbated schizophrenia.  The antipsychotic efficacy of ITI-007 60 mg in this patient population was confirmed in a recently completed Phase III study.  ITI-007 was assocd. with minimal safety risk compared to risperidone (Phase II study) or placebo (both studies) for neuromotor disturbances, prolactin changes, wt. gain and metabolic abnormalities.  A second 6-wk, placebo and risperidone-controlled Phase-III trial in acutely exacerbated schizophrenia is ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVCRMQthqMa7Vg90H21EOLACvtfcHk0ljG7aDvcvU9kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmslOjsrs%253D&md5=8781454405edda6e05bb7d384606ddc0</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1080%2F14737175.2016.1174577&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14737175.2016.1174577%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DR.%2BE.%26aulast%3DCorrell%26aufirst%3DC.%2BU.%26atitle%3DITI-007%2520in%2520the%2520Treatment%2520of%2520Schizophrenia%253A%2520From%2520Novel%2520Pharmacology%2520to%2520Clinical%2520Outcomes%26jtitle%3DExpert%2520Rev.%2520Neurother.%26date%3D2016%26volume%3D16%26spage%3D601%26epage%3D614%26doi%3D10.1080%2F14737175.2016.1174577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ellison, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dufresne, R. L.</span></span> <span> </span><span class="NLM_article-title">A Review of the Clinical Utility of Serum Clozapine and Norclozapine Levels</span>. <i>Ment. Health Clin.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">68</span>– <span class="NLM_lpage">73</span>, <span class="refDoi"> DOI: 10.9740/mhc.2015.03.068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.9740%2Fmhc.2015.03.068" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=68-73&author=J.+C.+Ellisonauthor=R.+L.+Dufresne&title=A+Review+of+the+Clinical+Utility+of+Serum+Clozapine+and+Norclozapine+Levels&doi=10.9740%2Fmhc.2015.03.068"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.9740%2Fmhc.2015.03.068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.9740%252Fmhc.2015.03.068%26sid%3Dliteratum%253Aachs%26aulast%3DEllison%26aufirst%3DJ.%2BC.%26aulast%3DDufresne%26aufirst%3DR.%2BL.%26atitle%3DA%2520Review%2520of%2520the%2520Clinical%2520Utility%2520of%2520Serum%2520Clozapine%2520and%2520Norclozapine%2520Levels%26jtitle%3DMent.%2520Health%2520Clin.%26date%3D2015%26volume%3D5%26spage%3D68%26epage%3D73%26doi%3D10.9740%2Fmhc.2015.03.068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buckley, P. F.</span></span> <span> </span><span class="NLM_article-title">Olanzapine: A Critical Review of Recent Literature</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">2077</span>– <span class="NLM_lpage">2089</span>, <span class="refDoi"> DOI: 10.1517/14656566.6.12.2077</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1517%2F14656566.6.12.2077" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=16197360" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFCjsbjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=2077-2089&author=P.+F.+Buckley&title=Olanzapine%3A+A+Critical+Review+of+Recent+Literature&doi=10.1517%2F14656566.6.12.2077"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Olanzapine: a critical review of recent literature</span></div><div class="casAuthors">Buckley, Peter F.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2077-2089</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">The purpose of this review is to critically review the current literature on olanzapine with an emphasis on emergent themes and key findings in the use of this agent for the treatment of mood disorders and schizophrenia.  New information continues to emerge on the impact of olanzapine on schizo-phrenia and on aspects of the course of mood disorders.  There are also continued efforts to understand, predict and manage the side-effect risk with olanzapine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquFaBBxEa2sbVg90H21EOLACvtfcHk0ljG7aDvcvU9kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFCjsbjL&md5=7a8d254ff01b11854b8af9e93acb80a5</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1517%2F14656566.6.12.2077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.6.12.2077%26sid%3Dliteratum%253Aachs%26aulast%3DBuckley%26aufirst%3DP.%2BF.%26atitle%3DOlanzapine%253A%2520A%2520Critical%2520Review%2520of%2520Recent%2520Literature%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2005%26volume%3D6%26spage%3D2077%26epage%3D2089%26doi%3D10.1517%2F14656566.6.12.2077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robichaud, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomesch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beard, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrick, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanover, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mates, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wennogle, L. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Tetracyclic Quinoxaline Derivative as a Potent and Orally Active Multifunctional Drug Candidate for the Treatment of Neuropsychiatric and Neurological Disorders</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">2670</span>– <span class="NLM_lpage">2682</span>, <span class="refDoi"> DOI: 10.1021/jm401958n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401958n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC2cXivFOhu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=2670-2682&author=P.+Liauthor=Q.+Zhangauthor=A.+J.+Robichaudauthor=T.+Leeauthor=J.+Tomeschauthor=W.+Yaoauthor=J.+D.+Beardauthor=G.+L.+Snyderauthor=H.+Zhuauthor=Y.+Pengauthor=J.+P.+Hendrickauthor=K.+E.+Vanoverauthor=R.+E.+Davisauthor=S.+Matesauthor=L.+P.+Wennogle&title=Discovery+of+a+Tetracyclic+Quinoxaline+Derivative+as+a+Potent+and+Orally+Active+Multifunctional+Drug+Candidate+for+the+Treatment+of+Neuropsychiatric+and+Neurological+Disorders&doi=10.1021%2Fjm401958n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Tetracyclic Quinoxaline Derivative as a Potent and Orally Active Multifunctional Drug Candidate for the Treatment of Neuropsychiatric and Neurological Disorders</span></div><div class="casAuthors">Li, Peng; Zhang, Qiang; Robichaud, Albert J.; Lee, Taekyu; Tomesch, John; Yao, Wei; Beard, J. David; Snyder, Gretchen L.; Zhu, Hongwen; Peng, Youyi; Hendrick, Joseph P.; Vanover, Kimberly E.; Davis, Robert E.; Mates, Sharon; Wennogle, Lawrence P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2670-2682</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report the synthesis and structure-activity relationships of a class of tetracyclic butyrophenones that exhibit potent binding affinities to serotonin 5-HT2A and dopamine D2 receptors.  This work has led to the discovery of 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluorophenyl)-butan-1-one 4-methylbenzenesulfonate (ITI-007, I.TsOH), which is a potent 5-HT2A antagonist, postsynaptic D2 antagonist, and inhibitor of serotonin transporter.  This multifunctional drug candidate is orally bioavailable and exhibits good antipsychotic efficacy in vivo.  Currently, this investigational new drug is under clin. development for the treatment of neuropsychiatric and neurol. disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozLklhmBkFo7Vg90H21EOLACvtfcHk0livfueYVK2dpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXivFOhu7o%253D&md5=318c9a3df9d79a2ac593c40015021015</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1021%2Fjm401958n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401958n%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DRobichaud%26aufirst%3DA.%2BJ.%26aulast%3DLee%26aufirst%3DT.%26aulast%3DTomesch%26aufirst%3DJ.%26aulast%3DYao%26aufirst%3DW.%26aulast%3DBeard%26aufirst%3DJ.%2BD.%26aulast%3DSnyder%26aufirst%3DG.%2BL.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DPeng%26aufirst%3DY.%26aulast%3DHendrick%26aufirst%3DJ.%2BP.%26aulast%3DVanover%26aufirst%3DK.%2BE.%26aulast%3DDavis%26aufirst%3DR.%2BE.%26aulast%3DMates%26aufirst%3DS.%26aulast%3DWennogle%26aufirst%3DL.%2BP.%26atitle%3DDiscovery%2520of%2520a%2520Tetracyclic%2520Quinoxaline%2520Derivative%2520as%2520a%2520Potent%2520and%2520Orally%2520Active%2520Multifunctional%2520Drug%2520Candidate%2520for%2520the%2520Treatment%2520of%2520Neuropsychiatric%2520and%2520Neurological%2520Disorders%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D2670%26epage%3D2682%26doi%3D10.1021%2Fjm401958n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, B.</span></span> <span> </span><span class="NLM_article-title">The Fischer Indole Synthesis</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1963</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">373</span>– <span class="NLM_lpage">401</span>, <span class="refDoi"> DOI: 10.1021/cr60224a003</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr60224a003" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=1963&pages=373-401&author=B.+Robinson&title=The+Fischer+Indole+Synthesis&doi=10.1021%2Fcr60224a003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1021%2Fcr60224a003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr60224a003%26sid%3Dliteratum%253Aachs%26aulast%3DRobinson%26aufirst%3DB.%26atitle%3DThe%2520Fischer%2520Indole%2520Synthesis%26jtitle%3DChem.%2520Rev.%26date%3D1963%26volume%3D63%26spage%3D373%26epage%3D401%26doi%3D10.1021%2Fcr60224a003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartwig, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driver, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernández-Rivas, C.</span></span> <span> </span><span class="NLM_article-title">Palladium-Catalyzed C-N(sp<sup>2</sup>) Bond Formation: N-Arylation of Aromatic and Unsaturated Nitrogen and the Reductive Elimination Chemistry of Palladium Azolyl and Methyleneamido Complexes</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">827</span>– <span class="NLM_lpage">828</span>, <span class="refDoi"> DOI: 10.1021/ja973524g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja973524g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref74/cit74a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADyaK1cXmvFWmtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=1998&pages=827-828&author=G.+Mannauthor=J.+F.+Hartwigauthor=M.+S.+Driverauthor=C.+Fern%C3%A1ndez-Rivas&title=Palladium-Catalyzed+C-N%28sp2%29+Bond+Formation%3A+N-Arylation+of+Aromatic+and+Unsaturated+Nitrogen+and+the+Reductive+Elimination+Chemistry+of+Palladium+Azolyl+and+Methyleneamido+Complexes&doi=10.1021%2Fja973524g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74aR"><div class="casContent"><span class="casTitleNuber">74a</span><div class="casTitle"><span class="NLM_cas:atitle">Palladium-Catalyzed C-N(sp2) Bond Formation: N-Arylation of Aromatic and Unsaturated Nitrogen and the Reductive Elimination Chemistry of Palladium Azolyl and Methyleneamido Complexes</span></div><div class="casAuthors">Mann, Grace; Hartwig, John F.; Driver, ftref Michael S.; Fernandez-Rivas, Carolina</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">827-828</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Studies on palladium-catalyzed arylation of unsatd. or arom. nitrogen centers, along with direct observation of the key C-N bond-forming reductive elimination of N-aryl pyrrole and N-aryl imines are reported.  Reaction of aryl halides with pyrrole, indole, carbazole, or benzophenone imine, in the presence of a base and a catalytic amt. of Pd(OAc)2 and DPPF gave N-aryl azoles and N-aryl imines in high yields.  N-aryl azoles are biol. important and N-aryl imines serve as protected anilines.  These new C-N bond-forming reactions are suitable for electron poor or electron rich aryl halides.  The step in the catalytic cycle that forms the C-N bond is likely to be a reductive elimination.  C-N bond-forming reductive eliminations involving unsatd. or arom. nitrogens have not been obsd. previously, but are important for understanding how the relative C-N reductive elimination rates relate to the well-known C-C bond-forming reductive eliminations involving alkyl, aryl, and vinyl groups.  Reductive eliminations to form N-aryl azoles were slow, but occurred in high yields with DPPF as the ligand on palladium.  Yields were lower for analogous PPh3 complexes.  In contrast to the elimination of N-aryl azoles, reductive eliminations to form N-aryl imines from palladium methyleneamido complexes were fast and were more akin to C-N reductive eliminations of arylamines or C-C reductive elimination of styrenes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq8P9QzvuwS7Vg90H21EOLACvtfcHk0livfueYVK2dpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmvFWmtQ%253D%253D&md5=1bbea02bae760fbc209e03ff279475c7</span></div><a href="/servlet/linkout?suffix=cit74a&amp;dbid=16384&amp;doi=10.1021%2Fja973524g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja973524g%26sid%3Dliteratum%253Aachs%26aulast%3DMann%26aufirst%3DG.%26aulast%3DHartwig%26aufirst%3DJ.%2BF.%26aulast%3DDriver%26aufirst%3DM.%2BS.%26aulast%3DFern%25C3%25A1ndez-Rivas%26aufirst%3DC.%26atitle%3DPalladium-Catalyzed%2520C-N%2528sp2%2529%2520Bond%2520Formation%253A%2520N-Arylation%2520of%2520Aromatic%2520and%2520Unsaturated%2520Nitrogen%2520and%2520the%2520Reductive%2520Elimination%2520Chemistry%2520of%2520Palladium%2520Azolyl%2520and%2520Methyleneamido%2520Complexes%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1998%26volume%3D120%26spage%3D827%26epage%3D828%26doi%3D10.1021%2Fja973524g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit74b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wolfe, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Åhman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadighi, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchwald, S. L.</span></span> <span> </span><span class="NLM_article-title">An Ammonia Equivalent for the Palladium-Catalyzed Amination of Aryl Halides and Triflates</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">6367</span>– <span class="NLM_lpage">6370</span>, <span class="refDoi"> DOI: 10.1016/S0040-4039(97)01465-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2FS0040-4039%2897%2901465-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADyaK2sXlvFGns7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1997&pages=6367-6370&author=J.+P.+Wolfeauthor=J.+%C3%85hmanauthor=J.+P.+Sadighiauthor=R.+A.+Singerauthor=S.+L.+Buchwald&title=An+Ammonia+Equivalent+for+the+Palladium-Catalyzed+Amination+of+Aryl+Halides+and+Triflates&doi=10.1016%2FS0040-4039%2897%2901465-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74bR"><div class="casContent"><span class="casTitleNuber">74b</span><div class="casTitle"><span class="NLM_cas:atitle">An ammonia equivalent for the palladium-catalyzed amination of aryl halides and triflates</span></div><div class="casAuthors">Wolfe, John P.; Ahman, Jens; Sadighi, Joseph P.; Singer, Robert A.; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">6367-6370</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Com. available benzophenone imine serves as a convenient NH3 equiv. in the Pd-catalyzed amination of aryl halides and triflates.  The benzophenone imine adducts can be cleaved directly to the corresponding primary anilines by catalytic hydrogenation or treatment with hydroxylamine hydrochloride or a catalytic amt. of HCl in wet THF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXMgy_yfX_ubVg90H21EOLACvtfcHk0lhQEUQU_K2WeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXlvFGns7k%253D&md5=a460a4291911fcf3da1c7f6f61a1c38b</span></div><a href="/servlet/linkout?suffix=cit74b&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2897%2901465-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252897%252901465-2%26sid%3Dliteratum%253Aachs%26aulast%3DWolfe%26aufirst%3DJ.%2BP.%26aulast%3D%25C3%2585hman%26aufirst%3DJ.%26aulast%3DSadighi%26aufirst%3DJ.%2BP.%26aulast%3DSinger%26aufirst%3DR.%2BA.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DAn%2520Ammonia%2520Equivalent%2520for%2520the%2520Palladium-Catalyzed%2520Amination%2520of%2520Aryl%2520Halides%2520and%2520Triflates%26jtitle%3DTetrahedron%2520Lett.%26date%3D1997%26volume%3D38%26spage%3D6367%26epage%3D6370%26doi%3D10.1016%2FS0040-4039%2897%2901465-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chincholkar, M.</span></span> <span> </span><span class="NLM_article-title">Analgesic Mechanisms of Gabapentinoids and Effects in Experimental Pain Models: A Narrative Review</span>. <i>Br. J. Anaesth.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">1315</span>– <span class="NLM_lpage">1334</span>, <span class="refDoi"> DOI: 10.1016/j.bja.2018.02.066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2Fj.bja.2018.02.066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=29793598" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXkvVCrsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2018&pages=1315-1334&author=M.+Chincholkar&title=Analgesic+Mechanisms+of+Gabapentinoids+and+Effects+in+Experimental+Pain+Models%3A+A+Narrative+Review&doi=10.1016%2Fj.bja.2018.02.066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Analgesic mechanisms of gabapentinoids and effects in experimental pain models: a narrative review</span></div><div class="casAuthors">Chincholkar, M.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Anaesthesia</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1315-1334</span>CODEN:
                <span class="NLM_cas:coden">BJANAD</span>;
        ISSN:<span class="NLM_cas:issn">1471-6771</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The focus of perioperative pain management should be to attempt to minimise the nociceptive input and reduce the risk of transition to central sensitization.  Gabapentinoids are being increasingly used as adjuncts for management of perioperative pain.  Although gabapentinoids are classed as calcium channel blockers, their mechanisms of action are poorly understood.  The analgesic effect in neuropathic pain is well evidenced but the role in postoperative pain is less certain.  Medline and EMBASE database searches were conducted to identify studies relating to mechanisms of action and effects in exptl. animal models of inflammatory and postoperative pain and human models of exptl. pain.  The effects of gabapentinoids may be attributed to depression of dorsal horn sensitivity through a multitude of mechanisms.  They inhibit calcium mediated neurotransmitter release through effects on α2δ-1 subunits.  They inhibit forward trafficking of α2δ-1 from the dorsal root ganglion, their recycling from endosomal compartments, thrombospondin mediated processes and stimulate glutamate uptake by excitatory amino acid transporters.  Mechanisms not directly related to neurotransmitter release at dorsal horn include inhibition of descending serotonergic facilitation, stimulation of descending inhibition, anti-inflammatory actions, and influence on the affective component of pain.  Gabapentinoids are effective analgesics in most animal models of inflammation and postoperative pain but effects in human models are variable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcjsuFSpt4K7Vg90H21EOLACvtfcHk0lhQEUQU_K2WeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXkvVCrsg%253D%253D&md5=a7f36db7a18eb0a7d0701d773a1562de</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2Fj.bja.2018.02.066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bja.2018.02.066%26sid%3Dliteratum%253Aachs%26aulast%3DChincholkar%26aufirst%3DM.%26atitle%3DAnalgesic%2520Mechanisms%2520of%2520Gabapentinoids%2520and%2520Effects%2520in%2520Experimental%2520Pain%2520Models%253A%2520A%2520Narrative%2520Review%26jtitle%3DBr.%2520J.%2520Anaesth.%26date%3D2018%26volume%3D120%26spage%3D1315%26epage%3D1334%26doi%3D10.1016%2Fj.bja.2018.02.066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deeks, E. D.</span></span> <span> </span><span class="NLM_article-title">Mirogabalin: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">463</span>– <span class="NLM_lpage">468</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01070-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs40265-019-01070-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=30778848" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFyitrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=463-468&author=E.+D.+Deeks&title=Mirogabalin%3A+First+Global+Approval&doi=10.1007%2Fs40265-019-01070-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Mirogabalin: First Global Approval</span></div><div class="casAuthors">Deeks, Emma D.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">463-468</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Mirogabalin besylate (hereafter mirogabalin) [Tarlige] is an orally administered gabapentinoid developed by Daiichi Sankyo for the treatment of peripheral neuropathic pain (PNP), including diabetic PNP and post-herpetic neuralgia.  The drug binds to and modulates the α2δ-1 subunit of the voltage-gated calcium channels widely found in the nervous system in areas that mediate pain transmission and processing.  Mirogabalin has a unique binding profile and long duration of action.  The drug is approved in Japan for the treatment of PNP and is in clin. development for this indication elsewhere in Asia.  Clin. development of the drug for fibromyalgia pain was discontinued in the USA and EU after the primary endpoint was not met in phase 3 trials.  No recent reports of development have been identified for PNP in the USA or India or for fibromyalgia pain in Australia, India, New Zealand, Russia, Argentina, Belarus, Chile, Colombia, Israel, Mexico, Switzerland, Canada, Serbia or South Africa.  This article summarizes the milestones in the development of mirogabalin leading to this first approval for PNP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoA8cUiDvLmPbVg90H21EOLACvtfcHk0lhQEUQU_K2WeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFyitrg%253D&md5=9a9b9f14f0190da528f3bc9b8cf277a7</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01070-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01070-8%26sid%3Dliteratum%253Aachs%26aulast%3DDeeks%26aufirst%3DE.%2BD.%26atitle%3DMirogabalin%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D463%26epage%3D468%26doi%3D10.1007%2Fs40265-019-01070-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Domon, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arakawa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuda, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitano, Y.</span></span> <span> </span><span class="NLM_article-title">Binding Characteristics and Analgesic Effects of Mirogabalin, a Novel Ligand for the α2δ Subunit of Voltage-Gated Calcium Channels</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>365</i></span>,  <span class="NLM_fpage">573</span>– <span class="NLM_lpage">582</span>, <span class="refDoi"> DOI: 10.1124/jpet.117.247551</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1124%2Fjpet.117.247551" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=29563324" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVCntbrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=365&publication_year=2018&pages=573-582&author=Y.+Domonauthor=N.+Arakawaauthor=T.+Inoueauthor=F.+Matsudaauthor=M.+Takahashiauthor=N.+Yamamuraauthor=K.+Kaiauthor=Y.+Kitano&title=Binding+Characteristics+and+Analgesic+Effects+of+Mirogabalin%2C+a+Novel+Ligand+for+the+%CE%B12%CE%B4+Subunit+of+Voltage-Gated+Calcium+Channels&doi=10.1124%2Fjpet.117.247551"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Binding characteristics and analgesic effects of mirogabalin, a novel ligand for the a2d subunit of voltage-gated calcium channels</span></div><div class="casAuthors">Domon, Yuki; Arakawa, Naohisa; Inoue, Tatsuya; Matsuda, Fumihiko; Takahashi, Makoto; Yamamura, Naotoshi; Kai, Kiyonori; Kitano, Yutaka</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">365</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">573-582</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">In the present study, we investigated the in vitro binding characteristics and in vivo analgesic effects of mirogabalin compared with those of pregabalin, a std. a2d ligand.  Mirogabalin showed potent and selective binding affinities for the a2d subunits, while having no effects on 186 off-target proteins.  Similar to pregabalin, mirogabalin did not show clear subtype selectivity (a2d-1 vs. a2d-2) or species differences (human vs. rat).  However, in contrast to pregabalin, mirogabalin showed greater binding affinities for human a2d-1, human a2d-2, rat a2d-1, and rat a2d-2 subunits; further, it had a slower dissocn. rate for the a2d-1 subunit than the a2d-2 subunit.  In safety pharmacol. evaluations, mirogabalin and pregabalin inhibited rota-rod performance and locomotor activity in rats; however, the safety indexes of mirogabalin were superior to those of pregabalin.  In conclusion, mirogabalin shows potent and selective binding affinities for the human and rat a2d subunits, and slower dissocn. rates for the a2d-1 subunit than the a2d-2 subunit.  It shows potent and long-lasting analgesic effects in rat models of neuropathic pain, and wider safety margins for side effects of the central nervous system.  These properties of mirogabalin can be assocd. with its unique binding characteristics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHpJ0JBnhkh7Vg90H21EOLACvtfcHk0lhQEUQU_K2WeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVCntbrP&md5=e0c0b3f89de15327211551395f4db648</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1124%2Fjpet.117.247551&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.117.247551%26sid%3Dliteratum%253Aachs%26aulast%3DDomon%26aufirst%3DY.%26aulast%3DArakawa%26aufirst%3DN.%26aulast%3DInoue%26aufirst%3DT.%26aulast%3DMatsuda%26aufirst%3DF.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DYamamura%26aufirst%3DN.%26aulast%3DKai%26aufirst%3DK.%26aulast%3DKitano%26aufirst%3DY.%26atitle%3DBinding%2520Characteristics%2520and%2520Analgesic%2520Effects%2520of%2520Mirogabalin%252C%2520a%2520Novel%2520Ligand%2520for%2520the%2520%25CE%25B12%25CE%25B4%2520Subunit%2520of%2520Voltage-Gated%2520Calcium%2520Channels%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2018%26volume%3D365%26spage%3D573%26epage%3D582%26doi%3D10.1124%2Fjpet.117.247551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, K.</span>; <span class="NLM_string-name">Kawamura, A.</span>; <span class="NLM_string-name">Arakawa, N.</span>; <span class="NLM_string-name">Domon, Y.</span></span> <span> </span><span class="NLM_article-title">Preparation of Bicyclic γ-Amino Acid Derivatives as Potential-Dependent Calcium Channel A2δ Subunit Ligands</span>. <span class="NLM_patent">WO 2009041453 A1</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=K.+Shimada&author=A.+Kawamura&author=N.+Arakawa&author=Y.+Domon&title=Preparation+of+Bicyclic+%CE%B3-Amino+Acid+Derivatives+as+Potential-Dependent+Calcium+Channel+A2%CE%B4+Subunit+Ligands"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DShimada%26aufirst%3DK.%26atitle%3DPreparation%2520of%2520Bicyclic%2520%25CE%25B3-Amino%2520Acid%2520Derivatives%2520as%2520Potential-Dependent%2520Calcium%2520Channel%2520A2%25CE%25B4%2520Subunit%2520Ligands%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit78b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, Y.</span>; <span class="NLM_string-name">Ukai, K.</span>; <span class="NLM_string-name">Kitawaki, T.</span>; <span class="NLM_string-name">Nakajima, T.</span>; <span class="NLM_string-name">Kitagawa, Y.</span>; <span class="NLM_string-name">Furuya, Y.</span>; <span class="NLM_string-name">Imai, M.</span>; <span class="NLM_string-name">Numagami, E.</span>; <span class="NLM_string-name">Wakayama, M.</span>; <span class="NLM_string-name">Saito, A.</span></span> <span> </span><span class="NLM_article-title">Preparation of High-Purity Optically Active Bicyclic γ-Amino Acid Derivative</span>. <span class="NLM_patent">WO 2015005298 A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=Y.+Nakamura&author=K.+Ukai&author=T.+Kitawaki&author=T.+Nakajima&author=Y.+Kitagawa&author=Y.+Furuya&author=M.+Imai&author=E.+Numagami&author=M.+Wakayama&author=A.+Saito&title=Preparation+of+High-Purity+Optically+Active+Bicyclic+%CE%B3-Amino+Acid+Derivative"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNakamura%26aufirst%3DY.%26atitle%3DPreparation%2520of%2520High-Purity%2520Optically%2520Active%2520Bicyclic%2520%25CE%25B3-Amino%2520Acid%2520Derivative%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit78c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, Y.</span>; <span class="NLM_string-name">Kimura, K.</span></span> <span> </span><span class="NLM_article-title">Method for the Preparation of Bicyclic Compound Via Iminium Salt</span>. <span class="NLM_patent">WO 2012169474 A1</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=Y.+Nakamura&author=K.+Kimura&title=Method+for+the+Preparation+of+Bicyclic+Compound+Via+Iminium+Salt"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNakamura%26aufirst%3DY.%26atitle%3DMethod%2520for%2520the%2520Preparation%2520of%2520Bicyclic%2520Compound%2520Via%2520Iminium%2520Salt%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit78d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, Y.</span>; <span class="NLM_string-name">Furuya, Y.</span>; <span class="NLM_string-name">Shimada, K.</span>; <span class="NLM_string-name">Onishi, Y.</span></span> <span> </span><span class="NLM_article-title">Optical Resolution of Bicyclic Compound Using Enzyme</span>. <span class="NLM_patent">WO 2013154066 A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=Y.+Nakamura&author=Y.+Furuya&author=K.+Shimada&author=Y.+Onishi&title=Optical+Resolution+of+Bicyclic+Compound+Using+Enzyme"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNakamura%26aufirst%3DY.%26atitle%3DOptical%2520Resolution%2520of%2520Bicyclic%2520Compound%2520Using%2520Enzyme%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martín
Castro, A. M.</span></span> <span> </span><span class="NLM_article-title">Claisen Rearrangement over the Past Nine Decades</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">2939</span>– <span class="NLM_lpage">3002</span>, <span class="refDoi"> DOI: 10.1021/cr020703u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr020703u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A280%3ADC%252BD2c3os1GjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2004&pages=2939-3002&author=A.+M.+Mart%C3%ADn%0ACastro&title=Claisen+Rearrangement+over+the+Past+Nine+Decades&doi=10.1021%2Fcr020703u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Claisen rearrangement over the past nine decades</span></div><div class="casAuthors">Martin Castro Ana M</div><div class="citationInfo"><span class="NLM_cas:title">Chemical reviews</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2939-3002</span>
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQd_KT9-T-OQ4xhnOQkIHOxfW6udTcc2eY-rZ_9zH8JO7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c3os1GjsQ%253D%253D&md5=ca5ca8c432c74dcc346d1f7447a39f31</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1021%2Fcr020703u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr020703u%26sid%3Dliteratum%253Aachs%26aulast%3DMart%25C3%25ADn%2BCastro%26aufirst%3DA.%2BM.%26atitle%3DClaisen%2520Rearrangement%2520over%2520the%2520Past%2520Nine%2520Decades%26jtitle%3DChem.%2520Rev.%26date%3D2004%26volume%3D104%26spage%3D2939%26epage%3D3002%26doi%3D10.1021%2Fcr020703u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, G.</span></span> <span> </span><span class="NLM_article-title">The Knoevenagel Condensation</span>. <i>In Organic Reactions</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_fpage">204</span>– <span class="NLM_lpage">599</span>, <span class="refDoi"> DOI: 10.1002/0471264180.or015.02</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1002%2F0471264180.or015.02" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&pages=204-599&author=G.+Jones&title=The+Knoevenagel+Condensation&doi=10.1002%2F0471264180.or015.02"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1002%2F0471264180.or015.02&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F0471264180.or015.02%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DG.%26atitle%3DThe%2520Knoevenagel%2520Condensation%26jtitle%3DIn%2520Organic%2520Reactions%26date%3D2011%26spage%3D204%26epage%3D599%26doi%3D10.1002%2F0471264180.or015.02" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Snider, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allentoff, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, Y. S.</span></span> <span> </span><span class="NLM_article-title">Type III Intramolecular [2 + 2] Cycloadditions of Vinylketenes</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">5320</span>– <span class="NLM_lpage">5328</span>, <span class="refDoi"> DOI: 10.1021/jo00257a022</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo00257a022" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADyaL1cXlvV2rtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1988&pages=5320-5328&author=B.+B.+Sniderauthor=A.+J.+Allentoffauthor=Y.+S.+Kulkarni&title=Type+III+Intramolecular+%5B2+%2B+2%5D+Cycloadditions+of+Vinylketenes&doi=10.1021%2Fjo00257a022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Type III intramolecular [2 + 2] cycloadditions of vinylketenes</span></div><div class="casAuthors">Snider, Barry B.; Allentoff, Alban J.; Kulkarni, Yashwant S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5320-8</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    </div><div class="casAbstract">Treatment of trans-α,β-unsatd. acid chlorides with Et3N in C6H6 at reflux gives a ca. 1:1 mixt. of cis- and trans-α,β-unsatd. ketenes in excellent yield.  If there is a second double bond in the side chain, the cis isomer undergoes a type III intramol. cycloaddn. to produce a bicyclo[3.2.0]hept-3-en-6-one and/or a bicyclo[3.1.1]hept-2-en-6-one in 30-50% yield from the acid chloride.  The effect of substituents on the stereochem. and regiochem. of the cycloaddn. is described.  Thus, intramol. cycloaddn reaction of (E)-6-methyl-2,6-heptadienoic acid gave 43% 1-methylbicyclo[3.2.0]hept-3-en-6-one.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrm6-p6p4Yl57Vg90H21EOLACvtfcHk0lh3fg6Tf4U-1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXlvV2rtb0%253D&md5=38766f3170999fc74f2df7e220f20afa</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1021%2Fjo00257a022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00257a022%26sid%3Dliteratum%253Aachs%26aulast%3DSnider%26aufirst%3DB.%2BB.%26aulast%3DAllentoff%26aufirst%3DA.%2BJ.%26aulast%3DKulkarni%26aufirst%3DY.%2BS.%26atitle%3DType%2520III%2520Intramolecular%2520%255B2%2520%252B%25202%255D%2520Cycloadditions%2520of%2520Vinylketenes%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1988%26volume%3D53%26spage%3D5320%26epage%3D5328%26doi%3D10.1021%2Fjo00257a022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDowell, T. S.</span></span> <span> </span><span class="NLM_article-title">Remimazolam, a Short-Acting GABA(A) Receptor Agonist for Intravenous Sedation and/or Anesthesia in Day-Case Surgical and Non-Surgical Procedures</span>. <i>IDrugs</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">929</span>– <span class="NLM_lpage">937</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=21154153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvVeltb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2010&pages=929-937&author=W.+K.+Rogersauthor=T.+S.+McDowell&title=Remimazolam%2C+a+Short-Acting+GABA%28A%29+Receptor+Agonist+for+Intravenous+Sedation+and%2For+Anesthesia+in+Day-Case+Surgical+and+Non-Surgical+Procedures"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82aR"><div class="casContent"><span class="casTitleNuber">82a</span><div class="casTitle"><span class="NLM_cas:atitle">Remimazolam, a short-acting GABAA receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures</span></div><div class="casAuthors">Rogers, William Kirke; McDowell, Thomas S.</div><div class="citationInfo"><span class="NLM_cas:title">IDrugs</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">929-937</span>CODEN:
                <span class="NLM_cas:coden">IDRUFN</span>;
        ISSN:<span class="NLM_cas:issn">2040-3410</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Remimazolam (CNS-7056) is a short-acting GABAA receptor agonist, under development by PAION, in collaboration with Japanese licensee Ono Pharmaceutical, as an i.v. sedative agent for potential use in day-case procedures, and the induction and maintenance of anesthesia.  A member of the benzodiazapene class of drugs, the structure of remimazolam was modified to produce a drug that displays organ-independent metab.  The incorporation of a carboxylic ester moiety into the benzodiazapene core of remimazolam renders it susceptible to non-specific tissue esterases and it is rapidly metabolized into its pharmacol. inactive metabolite CNS-7054.  Preclin. studies in sheep demonstrated that remimazolam produced a more rapid onset of action, and a shorter duration of action, compared with midazolam.  In a phase IIa clin. trial evaluating remimazolam as a procedural sedative for upper gastrointestinal endoscopy in patients, the time to recovery from sedation was shorter and more consistent with remimazolam, relative to midazolam.  Because of its organ-independent metab. and rapid and predictable onset and recovery, remimazolam appears to have potential advantages over other currently available short-acting sedatives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrU4KS2bq2azrVg90H21EOLACvtfcHk0lh3fg6Tf4U-1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvVeltb4%253D&md5=d5b3fd32ceb0dceb0794bb12da622978</span></div><a href="/servlet/linkout?suffix=cit82a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRogers%26aufirst%3DW.%2BK.%26aulast%3DMcDowell%26aufirst%3DT.%2BS.%26atitle%3DRemimazolam%252C%2520a%2520Short-Acting%2520GABA%2528A%2529%2520Receptor%2520Agonist%2520for%2520Intravenous%2520Sedation%2520and%252For%2520Anesthesia%2520in%2520Day-Case%2520Surgical%2520and%2520Non-Surgical%2520Procedures%26jtitle%3DIDrugs%26date%3D2010%26volume%3D13%26spage%3D929%26epage%3D937" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit82b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Saari, T. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uusi-Oukari, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahonen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olkkola, K. T.</span></span> <span> </span><span class="NLM_article-title">Enhancement of GABAergic Activity: Neuropharmacological Effects of Benzodiazepines and Therapeutic Use in Anesthesiology</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">243</span>– <span class="NLM_lpage">267</span>, <span class="refDoi"> DOI: 10.1124/pr.110.002717</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1124%2Fpr.110.002717" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=21245208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjslGis7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2011&pages=243-267&author=T.+I.+Saariauthor=M.+Uusi-Oukariauthor=J.+Ahonenauthor=K.+T.+Olkkola&title=Enhancement+of+GABAergic+Activity%3A+Neuropharmacological+Effects+of+Benzodiazepines+and+Therapeutic+Use+in+Anesthesiology&doi=10.1124%2Fpr.110.002717"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82bR"><div class="casContent"><span class="casTitleNuber">82b</span><div class="casTitle"><span class="NLM_cas:atitle">Enhancement of GABAergic activity: neuropharmacological effects of benzodiazepines and therapeutic use in anesthesiology</span></div><div class="casAuthors">Saari, Teijo I.; Uusi-Oukari, Mikko; Ahonen, Jouni; Olkkola, Klaus T.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">243-267</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  GABA is the major inhibitory neurotransmitter in the central nervous system (CNS).  The type A GABA receptor (GABAAR) system is the primary pharmacol. target for many drugs used in clin. anesthesia.  The α1, β2, and γ2 subunit-contg. GABAARs located in the various parts of CNS are thought to be involved in versatile effects caused by inhaled anesthetics and classic benzodiazepines (BZD), both of which are widely used in clin. anesthesiol.  During the past decade, the emergence of tonic inhibitory conductance in extrasynaptic GABAARs has coincided with evidence showing that these receptors are highly sensitive to the sedatives and hypnotics used in anesthesia.  Anesthetic enhancement of tonic GABAergic inhibition seems to be preferentially increased in regions shown to be important in controlling memory, awareness, and sleep.  This review focuses on the physiol. of the GABAARs and the pharmacol. properties of clin. used BZDs.  Although classic BZDs are widely used in anesthesiol. practice, there is a const. need for new drugs with more favorable pharmacokinetic and pharmacodynamic effects and fewer side effects.  New hypnotics are currently developed, and promising results for one of these, the GABAAR agonist remimazolam, have recently been published.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkr0H2ObeOh7Vg90H21EOLACvtfcHk0lh3fg6Tf4U-1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjslGis7s%253D&md5=226f9e78eac12ce20ec0c6f41a667785</span></div><a href="/servlet/linkout?suffix=cit82b&amp;dbid=16384&amp;doi=10.1124%2Fpr.110.002717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.110.002717%26sid%3Dliteratum%253Aachs%26aulast%3DSaari%26aufirst%3DT.%2BI.%26aulast%3DUusi-Oukari%26aufirst%3DM.%26aulast%3DAhonen%26aufirst%3DJ.%26aulast%3DOlkkola%26aufirst%3DK.%2BT.%26atitle%3DEnhancement%2520of%2520GABAergic%2520Activity%253A%2520Neuropharmacological%2520Effects%2520of%2520Benzodiazepines%2520and%2520Therapeutic%2520Use%2520in%2520Anesthesiology%26jtitle%3DPharmacol.%2520Rev.%26date%3D2011%26volume%3D63%26spage%3D243%26epage%3D267%26doi%3D10.1124%2Fpr.110.002717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rex, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhandari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desta, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMicco, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaeffer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Etzkorn, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barish, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pruitt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cash, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quirk, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiongco, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernstein, D.</span></span> <span> </span><span class="NLM_article-title">A Phase III Study Evaluating the Efficacy and Safety of Remimazolam (CNS 7056) Compared with Placebo and Midazolam in Patients Undergoing Colonoscopy</span>. <i>Gastrointest. Endosc.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">427</span>– <span class="NLM_lpage">437</span>, <span class="refDoi"> DOI: 10.1016/j.gie.2018.04.2351</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2Fj.gie.2018.04.2351" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=29723512" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A280%3ADC%252BC1MjpsFSiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2018&pages=427-437&author=D.+K.+Rexauthor=R.+Bhandariauthor=T.+Destaauthor=M.+P.+DeMiccoauthor=C.+Schaefferauthor=K.+Etzkornauthor=C.+F.+Barishauthor=R.+Pruittauthor=B.+D.+Cashauthor=D.+Quirkauthor=F.+Tiongcoauthor=S.+Sullivanauthor=D.+Bernstein&title=A+Phase+III+Study+Evaluating+the+Efficacy+and+Safety+of+Remimazolam+%28CNS+7056%29+Compared+with+Placebo+and+Midazolam+in+Patients+Undergoing+Colonoscopy&doi=10.1016%2Fj.gie.2018.04.2351"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">A phase III study evaluating the efficacy and safety of remimazolam (CNS 7056) compared with placebo and midazolam in patients undergoing colonoscopy</span></div><div class="casAuthors">Rex Douglas K; Bhandari Raj; Desta Taddese; DeMicco Michael P; Schaeffer Cynthia; Etzkorn Kyle; Barish Charles F; Pruitt Ronald; Cash Brooks D; Quirk Daniel; Tiongco Felix; Sullivan Shelby; Bernstein David</div><div class="citationInfo"><span class="NLM_cas:title">Gastrointestinal endoscopy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">427-437.e6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND AND AIMS:  Remimazolam is an ultrashort-acting benzodiazepine.  METHODS:  We performed a randomized double-blind comparison of remimazolam to placebo for outpatient colonoscopy.  This study design was a requirement of the U.S.  Food and Drug Administration.  An additional group was randomized to open-label midazolam administered according to its package insert instructions (the randomization ratio for remimazolam:placebo:midazolam was 30:6:10).  Study medications were administered under the supervision of the endoscopist, without any involvement of an anesthesia specialist.  Patients were given 50 to 75 μg of fentanyl before receiving study medications.  Patients who failed to achieve adequate sedation in any arm were rescued with midazolam dosed at the investigator's discretion.  The primary endpoint was a composite that required 3 criteria be met: completion of the colonoscopy, no need for rescue medication, and ≤5 doses of remimazolam or placebo in any 15-minute interval (≤3 doses of midazolam in any 12-minute interval in the open-label midazolam arm).  RESULTS:  There were 461 randomized patients in 12 U.S. sites.  The primary endpoint was met for remimazolam, placebo, and midazolam in 91.3%, 1.7%, and 25.2% of patients, respectively (P < .0001 for remimazolam vs placebo).  Patients administered remimazolam received less fentanyl, had faster recovery of neuropsychiatric function, were ready for discharge earlier, and felt back to normal sooner than patients with both placebo and midazolam.  Hypotension was less frequent with remimazolam, and hypoxia occurred in 1% of patients with remimazolam or midazolam.  There were no treatment-emergent serious adverse events.  CONCLUSION:  Remimazolam can be administered safely under the supervision of endoscopists for outpatient colonoscopy, and it allows faster recovery of neuropsychiatric function compared with placebo (midazolam rescue) and midazolam. (Clinical trial registration number: NCT02290873.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSFZEybBPieYXwOGIfWJ7-GfW6udTcc2ea-BFqGEsx3Drntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MjpsFSiuw%253D%253D&md5=49006518b16bd1a25863950791c5fbcf</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2Fj.gie.2018.04.2351&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.gie.2018.04.2351%26sid%3Dliteratum%253Aachs%26aulast%3DRex%26aufirst%3DD.%2BK.%26aulast%3DBhandari%26aufirst%3DR.%26aulast%3DDesta%26aufirst%3DT.%26aulast%3DDeMicco%26aufirst%3DM.%2BP.%26aulast%3DSchaeffer%26aufirst%3DC.%26aulast%3DEtzkorn%26aufirst%3DK.%26aulast%3DBarish%26aufirst%3DC.%2BF.%26aulast%3DPruitt%26aufirst%3DR.%26aulast%3DCash%26aufirst%3DB.%2BD.%26aulast%3DQuirk%26aufirst%3DD.%26aulast%3DTiongco%26aufirst%3DF.%26aulast%3DSullivan%26aufirst%3DS.%26aulast%3DBernstein%26aufirst%3DD.%26atitle%3DA%2520Phase%2520III%2520Study%2520Evaluating%2520the%2520Efficacy%2520and%2520Safety%2520of%2520Remimazolam%2520%2528CNS%25207056%2529%2520Compared%2520with%2520Placebo%2520and%2520Midazolam%2520in%2520Patients%2520Undergoing%2520Colonoscopy%26jtitle%3DGastrointest.%2520Endosc.%26date%3D2018%26volume%3D88%26spage%3D427%26epage%3D437%26doi%3D10.1016%2Fj.gie.2018.04.2351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><a href="https://www.paion.com/fileadmin/user_upload/Annual_financial_report_2019.pdf" class="extLink">https://www.paion.com/fileadmin/user_upload/Annual_financial_report_2019.pdf</a> (accessed March 24, 2021)<a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__m.en-2Dcphi.cn_news_show-2D60667.html&amp;d=DwMGaQ&amp;c=UE1eNsedaKncO0Yl_u8bfw&amp;r=MKA0UqpxRyImwzO_tEhpkCczC9cjy5h9oz_Ouk5Cc5s&amp;m=-4LALaCF2r5FJfAZhrY6lNCusszVReTqiDE0k0hDI6k&amp;s=zNgbs2gPWpvdaZZ8tj_wxZnPfKORLU7i7OJ6Pq3axXY&amp;e=" class="extLink">https://urldefense.proofpoint.com/v2/url?u=https-3A__m.en-2Dcphi.cn_news_show-2D60667.html&d=DwMGaQ&c=UE1eNsedaKncO0Yl_u8bfw&r=MKA0UqpxRyImwzO_tEhpkCczC9cjy5h9oz_Ouk5Cc5s&m=-4LALaCF2r5FJfAZhrY6lNCusszVReTqiDE0k0hDI6k&s=zNgbs2gPWpvdaZZ8tj_wxZnPfKORLU7i7OJ6Pq3axXY&e=</a> (accessed 2021-01-12).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.paion.com%2Ffileadmin%2Fuser_upload%2FAnnual_financial_report_2019.pdf+%28accessed+March+24%2C+2021%29https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__m.en-2Dcphi.cn_news_show-2D60667.html%26d%3DDwMGaQ%26c%3DUE1eNsedaKncO0Yl_u8bfw%26r%3DMKA0UqpxRyImwzO_tEhpkCczC9cjy5h9oz_Ouk5Cc5s%26m%3D-4LALaCF2r5FJfAZhrY6lNCusszVReTqiDE0k0hDI6k%26s%3DzNgbs2gPWpvdaZZ8tj_wxZnPfKORLU7i7OJ6Pq3axXY%26e%3D+%28accessed+2021-01-12%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, P. L.</span>; <span class="NLM_string-name">Jung, D. K.</span>; <span class="NLM_string-name">Kaldor, I.</span>; <span class="NLM_string-name">Pacofsky, G. J.</span>; <span class="NLM_string-name">Stafford, J. A.</span>; <span class="NLM_string-name">Tidwell, J. H.</span></span> <span> </span><span class="NLM_article-title">Short-Acting Benzodiazepines</span>. <span class="NLM_patent">WO 0069836 A1</span>, <span class="NLM_year">2000</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2000&author=P.+L.+Feldman&author=D.+K.+Jung&author=I.+Kaldor&author=G.+J.+Pacofsky&author=J.+A.+Stafford&author=J.+H.+Tidwell&title=Short-Acting+Benzodiazepines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFeldman%26aufirst%3DP.%2BL.%26atitle%3DShort-Acting%2520Benzodiazepines%26date%3D2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit85b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, P.</span>; <span class="NLM_string-name">Wu, G.</span>; <span class="NLM_string-name">Gao, X.</span>; <span class="NLM_string-name">Zhang, Q.</span>; <span class="NLM_string-name">Chen, Y.</span></span> <span> </span><span class="NLM_article-title">Benzodiazepine Derivatives Tosylate Salts, Their Polymorphic Forms, Preparation Methods and Uses Thereof</span>. <span class="NLM_patent">WO 2013029431 A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=P.+Sun&author=G.+Wu&author=X.+Gao&author=Q.+Zhang&author=Y.+Chen&title=Benzodiazepine+Derivatives+Tosylate+Salts%2C+Their+Polymorphic+Forms%2C+Preparation+Methods+and+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DP.%26atitle%3DBenzodiazepine%2520Derivatives%2520Tosylate%2520Salts%252C%2520Their%2520Polymorphic%2520Forms%252C%2520Preparation%2520Methods%2520and%2520Uses%2520Thereof%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span>; <span class="NLM_string-name">Gao, X.</span>; <span class="NLM_string-name">Bian, L.</span></span> <span> </span><span class="NLM_article-title">A Kind of Preparation Method of Benzodiazepine * Derivatives</span>. <span class="NLM_patent">CN 108264499 A</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=H.+Xu&author=X.+Gao&author=L.+Bian&title=A+Kind+of+Preparation+Method+of+Benzodiazepine+*+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DH.%26atitle%3DA%2520Kind%2520of%2520Preparation%2520Method%2520of%2520Benzodiazepine%2520%252A%2520Derivatives%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noriaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishino, S.</span></span> <span> </span><span class="NLM_article-title">Advances in Pharmaceutical Treatment Options for Narcolepsy</span>. <i>Expert Opin. Orphan Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">597</span>– <span class="NLM_lpage">610</span>, <span class="refDoi"> DOI: 10.1080/21678707.2018.1521267</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1080%2F21678707.2018.1521267" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslOksrfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2018&pages=597-610&author=T.+Takahashiauthor=S.+Noriakiauthor=M.+Matsumuraauthor=C.+Liauthor=K.+Takahashiauthor=S.+Nishino&title=Advances+in+Pharmaceutical+Treatment+Options+for+Narcolepsy&doi=10.1080%2F21678707.2018.1521267"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in pharmaceutical treatment options for narcolepsy</span></div><div class="casAuthors">Takahashi, Tatsunori; Noriaki, Sakai; Matsumura, Mari; Li, Chenyu; Takahashi, Kayo; Nishino, Seiji</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Orphan Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">597-610</span>CODEN:
                <span class="NLM_cas:coden">EOODAJ</span>;
        ISSN:<span class="NLM_cas:issn">2167-8707</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: Narcolepsy is a syndrome characterized by excessive daytime sleepiness (EDS), cataplexy, and other abnormal manifestations of rapid eye movement sleep phenomena.  Since hypocretin deficiency is presumed to be the main pathophysiol. of narcoleptic symptoms, hypocretin replacement therapy would be promising; small mol. hypocretin receptor agonists and intranasal administration of hypocretin peptides are recognized as potential pharmaceutical treatments.  Pitolisant, a histaminergic inverse agonist, recently became available in European countries for the treatment of EDS.  Addnl., other emerging treatments such as immunotherapies, TRH analogs, and solriamfetol have been under investigation.: The pathophysiol. of narcolepsy is summarized, along with the current and emerging pharmaceutical treatments for narcolepsy.: Hypocretin replacement therapy might be the most straightforward and effective treatment to address both cataplexy and EDS.  Although small mol. synthetic hypocretin receptor agonists and intranasal hypocretin administration have been developed, for hypocretin receptor agonists, only preliminary data are available, and the efficacy data for intranasal delivery in human subjects are also lacking.  Recently, the U.  S. FDA has accepted the New Drug Application of solriamfetol for excessive sleepiness.  It is likely that other emerging treatments will also become available in the clin. setting in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcT2IROEHRdLVg90H21EOLACvtfcHk0lhk_KU6QssxSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslOksrfF&md5=0a49a2f5d9dad8cd06333a35e60ed3ee</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1080%2F21678707.2018.1521267&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F21678707.2018.1521267%26sid%3Dliteratum%253Aachs%26aulast%3DTakahashi%26aufirst%3DT.%26aulast%3DNoriaki%26aufirst%3DS.%26aulast%3DMatsumura%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DTakahashi%26aufirst%3DK.%26aulast%3DNishino%26aufirst%3DS.%26atitle%3DAdvances%2520in%2520Pharmaceutical%2520Treatment%2520Options%2520for%2520Narcolepsy%26jtitle%3DExpert%2520Opin.%2520Orphan%2520Drugs%26date%3D2018%26volume%3D6%26spage%3D597%26epage%3D610%26doi%3D10.1080%2F21678707.2018.1521267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, J.</span></span> <span> </span><span class="NLM_article-title">Solriamfetol for the Treatment of Excessive Daytime Sleepiness Associated with Narcolepsy</span>. <i>Expert Rev. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">723</span>– <span class="NLM_lpage">728</span>, <span class="refDoi"> DOI: 10.1080/17512433.2019.1632705</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1080%2F17512433.2019.1632705" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31215815" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtF2ntL%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2019&pages=723-728&author=J.+Yangauthor=J.+Gao&title=Solriamfetol+for+the+Treatment+of+Excessive+Daytime+Sleepiness+Associated+with+Narcolepsy&doi=10.1080%2F17512433.2019.1632705"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Solriamfetol for the treatment of excessive daytime sleepiness associated with narcolepsy</span></div><div class="casAuthors">Yang, Junyi; Gao, Junfa</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">723-728</span>CODEN:
                <span class="NLM_cas:coden">ERCPAG</span>;
        ISSN:<span class="NLM_cas:issn">1751-2433</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Narcolepsy is a chronic disabling condition, excessive daytime somnolence is the main symptoms of it.  There is currently no cure for narcolepsy, and hence there is a great need for new treatment options.  Solriamfetol is a new selective dopamine and norepinephrine reuptake inhibitor with robust wake-promoting effects.  The purpose of this paper is to review solriamfetol.: The chem. property, mechanism of action, pharmacokinetics, clin. efficacy, and safety of solriamfetol are introduced in this paper.: Solriamfetol can bind to dopamine and norepinephrine transporters and inhibit reuptake of dopamine and norepinephrine.  Clin. trials showed that solriamfetol could significantly improve the ability to stay awake and subjective symptoms of excessive sleepiness in adults with narcolepsy.  Solriamfetol was well tolerated.  Very common adverse reactions were headache, nausea, decreased appetite, insomnia, and anxiety.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrd4WAi6hUSZrVg90H21EOLACvtfcHk0lhk_KU6QssxSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtF2ntL%252FM&md5=ec3732b4ecedaa5eb02bc79b552ebc2c</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1080%2F17512433.2019.1632705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17512433.2019.1632705%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DJ.%26atitle%3DSolriamfetol%2520for%2520the%2520Treatment%2520of%2520Excessive%2520Daytime%2520Sleepiness%2520Associated%2520with%2520Narcolepsy%26jtitle%3DExpert%2520Rev.%2520Clin.%2520Pharmacol.%26date%3D2019%26volume%3D12%26spage%3D723%26epage%3D728%26doi%3D10.1080%2F17512433.2019.1632705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abad, V. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guilleminault, C.</span></span> <span> </span><span class="NLM_article-title">Solriamfetol for the Treatment of Daytime Sleepiness in Obstructive Sleep Apnea</span>. <i>Expert Rev. Respir. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1007</span>– <span class="NLM_lpage">1019</span>, <span class="refDoi"> DOI: 10.1080/17476348.2018.1541742</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1080%2F17476348.2018.1541742" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=30365900" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVyhsb3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2018&pages=1007-1019&author=V.+C.+Abadauthor=C.+Guilleminault&title=Solriamfetol+for+the+Treatment+of+Daytime+Sleepiness+in+Obstructive+Sleep+Apnea&doi=10.1080%2F17476348.2018.1541742"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Solriamfetol for the treatment of daytime sleepiness in obstructive sleep apnea</span></div><div class="casAuthors">Abad, Vivien C.; Guilleminault, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Respiratory Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1007-1019</span>CODEN:
                <span class="NLM_cas:coden">ERRMBF</span>;
        ISSN:<span class="NLM_cas:issn">1747-6348</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  : Obstructive sleep apnea (OSA) is highly prevalent and constitutes a major health hazard.  Current pharmacotherapy is ineffective in correcting sleep-disordered breathing and is used adjunctively to address residual sleepiness.  A new drug, solriamfetol, a selective norepinephrine-dopamine reuptake inhibitor, is the first drug of its class that is being considered by the US Food and Drug Administration (FDA) to treat excessive sleepiness in OSA and narcolepsy patients.: This review covers drug chem., pharmacodynamics, pharmacokinetics, and metab. of solriamfetol.  Results of three Phase 3 trials, Treatment of OSA and Narcolepsy Excessive Sleepiness (TONES 3, 4, 5), relevant to OSA patients are summarized.  Published abstrs./articles and a 2017 Jazz Investor Presentation provided data.  Databases searched included PubMed, Google Scholar, Lexi-Comp, Scopus, Science, and Ovid.: Solriamfetol shows promise as adjunctive therapy in OSA.  It is well tolerated and effective in reducing sleepiness and is an alternative to modafinil or armodafinil.  Unlike stimulants like methylphenidate or dextroamphetamine, it does not have cardiac effects, rebound hypersomnia, or withdrawal effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXNDKKRG2fPbVg90H21EOLACvtfcHk0lidoiXStdZ10Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVyhsb3F&md5=0c4026642ed1eecc0ea64d013e19e5ca</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1080%2F17476348.2018.1541742&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17476348.2018.1541742%26sid%3Dliteratum%253Aachs%26aulast%3DAbad%26aufirst%3DV.%2BC.%26aulast%3DGuilleminault%26aufirst%3DC.%26atitle%3DSolriamfetol%2520for%2520the%2520Treatment%2520of%2520Daytime%2520Sleepiness%2520in%2520Obstructive%2520Sleep%2520Apnea%26jtitle%3DExpert%2520Rev.%2520Respir.%2520Med.%26date%3D2018%26volume%3D12%26spage%3D1007%26epage%3D1019%26doi%3D10.1080%2F17476348.2018.1541742" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y. M.</span>; <span class="NLM_string-name">Byun, J. K.</span></span> <span> </span><span class="NLM_article-title">Preparation of <i>O</i>-(Carbamoyl)Phenylalaninol Antidepressants</span>. <span class="NLM_patent">WO 9607637 A1</span>, <span class="NLM_year">1996</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1996&author=Y.+M.+Choi&author=J.+K.+Byun&title=Preparation+of+O-%28Carbamoyl%29Phenylalaninol+Antidepressants"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DY.%2BM.%26atitle%3DPreparation%2520of%2520O-%2528Carbamoyl%2529Phenylalaninol%2520Antidepressants%26date%3D1996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhirud, S. B.</span>; <span class="NLM_string-name">Naik, S.</span>; <span class="NLM_string-name">Mishra, S. K.</span>; <span class="NLM_string-name">Kawthekar, R. B.</span>; <span class="NLM_string-name">Patekar, D. S.</span>; <span class="NLM_string-name">Patil, N.</span></span> <span> </span><span class="NLM_article-title">Process for the Preparation of Solriamfetol and Its Salts, Particularly Its Dibenzoyl-<span class="smallcaps smallerCapital">d</span>-Tartrate and Di-<i>p</i>-Toluoyl-<span class="smallcaps smallerCapital">d</span>-Tartrate Used as Precursors for Solriamfetol Hydrochloride</span>. <span class="NLM_patent">WO 2020035769 A1</span>, <span class="NLM_year">2020</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=S.+B.+Bhirud&author=S.+Naik&author=S.+K.+Mishra&author=R.+B.+Kawthekar&author=D.+S.+Patekar&author=N.+Patil&title=Process+for+the+Preparation+of+Solriamfetol+and+Its+Salts%2C+Particularly+Its+Dibenzoyl-d-Tartrate+and+Di-p-Toluoyl-d-Tartrate+Used+as+Precursors+for+Solriamfetol+Hydrochloride"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBhirud%26aufirst%3DS.%2BB.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%2520Solriamfetol%2520and%2520Its%2520Salts%252C%2520Particularly%2520Its%2520Dibenzoyl-d-Tartrate%2520and%2520Di-p-Toluoyl-d-Tartrate%2520Used%2520as%2520Precursors%2520for%2520Solriamfetol%2520Hydrochloride%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, L. J.</span></span> <span> </span><span class="NLM_article-title">Ubrogepant: First Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">323</span>– <span class="NLM_lpage">328</span>, <span class="refDoi"> DOI: 10.1007/s40265-020-01264-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs40265-020-01264-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=32020557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A280%3ADC%252BB38%252FotlKlsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2020&pages=323-328&author=L.+J.+Scott&title=Ubrogepant%3A+First+Approval&doi=10.1007%2Fs40265-020-01264-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Ubrogepant: First Approval</span></div><div class="casAuthors">Scott Lesley J</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">323-328</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Ubrogepant (Ubrelvy®) is an orally administered, small molecule, highly-selective, calcitonin gene-related peptide (CGRP) antagonist that was developed by Allergan under license to Merck & Co. as an acute treatment for migraine.  In December 2019, ubrogepant received its first global approval in the USA for the acute treatment of migraine (± aura) in adults.  This article summarizes the milestones in the development of ubrogepant leading to its first global approval for the acute treatment of migraine (± aura) in adults.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTbpElibNSrFMvLc4ARHEmzfW6udTcc2eZYZMVryzNg-7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38%252FotlKlsA%253D%253D&md5=dee277e0c6d6835ea105dbb4024f8a92</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1007%2Fs40265-020-01264-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-020-01264-5%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DL.%2BJ.%26atitle%3DUbrogepant%253A%2520First%2520Approval%26jtitle%3DDrugs%26date%3D2020%26volume%3D80%26spage%3D323%26epage%3D328%26doi%3D10.1007%2Fs40265-020-01264-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">Safety and Efficacy of Ubrogepant for the Acute Treatment of Episodic Migraine: A Meta-Analysis of Randomized Clinical Trials</span>. <i>CNS Drugs</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">463</span>– <span class="NLM_lpage">471</span>, <span class="refDoi"> DOI: 10.1007/s40263-020-00715-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs40263-020-00715-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=32193827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlvFOmtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2020&pages=463-471&author=Y.+Yangauthor=M.+Chenauthor=Y.+Sunauthor=B.+Gaoauthor=Z.+Chenauthor=Z.+Wang&title=Safety+and+Efficacy+of+Ubrogepant+for+the+Acute+Treatment+of+Episodic+Migraine%3A+A+Meta-Analysis+of+Randomized+Clinical+Trials&doi=10.1007%2Fs40263-020-00715-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and Efficacy of Ubrogepant for the Acute Treatment of Episodic Migraine: A Meta-Analysis of Randomized Clinical Trials</span></div><div class="casAuthors">Yang, Yanbo; Chen, Mingjia; Sun, Yue; Gao, Bixi; Chen, Zhouqing; Wang, Zhong</div><div class="citationInfo"><span class="NLM_cas:title">CNS Drugs</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">463-471</span>CODEN:
                <span class="NLM_cas:coden">CNDREF</span>;
        ISSN:<span class="NLM_cas:issn">1172-7047</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Abstr.: Background: Ubrogepant is a small mol. calcitonin gene-related peptide receptor antagonist that is used for the acute treatment of migraine.  Objective: The aim was to conduct a meta-anal. to systematically evaluate the efficacy and safety of ubrogepant for the treatment of episodic migraine compared with placebo in the adult population.  Methods: We systematically searched PubMed, EMBASE, and the Cochrane Library Central Register of Controlled Trials for relevant randomized clin. trials, from the earliest available date to Nov. 10, 2019, to evaluate the efficacy and safety of short-term ubrogepant use.  Inclusion criteria were (1) randomized clin. trial; (2) enrolled adult participants diagnosed with episodic migraine; (3) compared ubrogepant with placebo at doses that were evaluated in phase III clin. trials; (4) enrolled more than 100 patients in each group; and (5) provided any information on primary or secondary outcomes.  Trials were excluded if their participants were diagnosed with chronic migraine.  Results: A total of three multicenter, randomized clin. trials with 3326 patients were included.  Ubrogepant use was assocd. with a significantly higher percentage of patients with pain freedom (ubrogepant 20.8%; placebo 12.6%; relative risk [RR] 1.65, 95% confidence interval [CI] 1.38-1.98) and absence of the most bothersome migraine-assocd. symptoms (ubrogepant 37.3%; placebo 27.6%; RR 1.35, 95% CI 1.20-1.53) at 2 h post-dose compared with placebo.  Ubrogepant increased the rate of absence of migraine-assocd. symptoms at 2 h post-dose compared with placebo (photophobia: RR 1.30 [95% CI 1.18-1.44], I2 = 49%; phonophobia: RR 1.20 [95% CI 1.11-1.29]; nausea: RR 1.07 [95% CI 1.02-1.13]), and patients were more likely to function normally at 2 h post-dose compared with placebo (RR 1.30 [95% CI 1.16-1.45]).  No significant difference was found for treatment-related adverse events within 48 h or 30 days for ubrogepant compared with placebo (48 h: RR 1.07 [95% CI 0.85-1.35]; 30 days: RR 1.03 [95% CI 0.79-1.34]).  Subgroup anal. demonstrated that compared to placebo, ubrogepant led to greater rates of freedom from pain at 2 h with 25-mg, 50-mg, and 100-mg doses and absence of the most bothersome symptoms with 50-mg and 100-mg doses.  Conclusions: The use of ubrogepant as an acute treatment of episodic migraine in adults led to a greater percentage of freedom from pain and absence of the most bothersome symptoms at 2 h post-dose.  Short-term use of ubrogepant was not related to an increased risk for adverse events.  Further studies are needed to evaluate efficacy and safety for long-term use and in specific subgroups of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLwAEfqfxC0bVg90H21EOLACvtfcHk0lidoiXStdZ10Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlvFOmtLc%253D&md5=717a479cce7f32fc41d95616dd0b1e6d</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1007%2Fs40263-020-00715-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40263-020-00715-7%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DGao%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DZ.%26atitle%3DSafety%2520and%2520Efficacy%2520of%2520Ubrogepant%2520for%2520the%2520Acute%2520Treatment%2520of%2520Episodic%2520Migraine%253A%2520A%2520Meta-Analysis%2520of%2520Randomized%2520Clinical%2520Trials%26jtitle%3DCNS%2520Drugs%26date%3D2020%26volume%3D34%26spage%3D463%26epage%3D471%26doi%3D10.1007%2Fs40263-020-00715-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Dodick, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipton, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ailani, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finnegan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trugman, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szegedi, A.</span></span> <span> </span><span class="NLM_article-title">Ubrogepant for the Treatment of Migraine</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>381</i></span>,  <span class="NLM_fpage">2230</span>– <span class="NLM_lpage">2241</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1813049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1056%2FNEJMoa1813049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31800988" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVylsL3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=381&publication_year=2019&pages=2230-2241&author=D.+W.+Dodickauthor=R.+B.+Liptonauthor=J.+Ailaniauthor=K.+Luauthor=M.+Finneganauthor=J.+M.+Trugmanauthor=A.+Szegedi&title=Ubrogepant+for+the+Treatment+of+Migraine&doi=10.1056%2FNEJMoa1813049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94aR"><div class="casContent"><span class="casTitleNuber">94a</span><div class="casTitle"><span class="NLM_cas:atitle">Ubrogepant for the treatment of migraine</span></div><div class="casAuthors">Dodick, David W.; Lipton, Richard B.; Ailani, Jessica; Lu, Kaifeng; Finnegan, Michelle; Trugman, Joel M.; Szegedi, Armin</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">381</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2230-2241</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Ubrogepant is an oral, small-mol. calcitonin gene-related peptide receptor antagonist for acute migraine treatment. methods We conducted a randomized trial to evaluate the efficacy, safety, and side-effect profile of ubrogepant.  We assigned adults with migraine, with or without aura, in a 1:1:1 ratio to receive an initial dose of placebo, ubrogepant at a dose of 50 mg, or ubrogepant at a dose of 100 mg for treatment of a single migraine attack, with the option to take a second dose.  The coprimary efficacy end points were freedom from pain at 2 h after the initial dose and absence of the most bothersome migraine-assocd. symptom at 2 h.  Secondary end points included pain relief (at 2 h), sustained pain relief (from 2 to 24 h), sustained freedom from pain (from 2 to 24 h), and absence of symptoms assocd. with migraine (photophobia, phonophobia, and nausea) at 2 h. results A total of 1672 participants were enrolled; 559 were assigned to receive placebo, 556 to receive 50 mg of ubrogepant, and 557 to receive 100 mg of ubrogepant.  The percentage of participants who had freedom from pain at 2 h was 11.8% in the placebo group, 19.2% in the 50-mg ubrogepant group (P = 0.002, adjusted for multiplicity, for the comparison with placebo), and 21.2% in the 100-mg ubrogepant group (P<0.001).  The percentage of participants who had freedom from the most bothersome symptom at 2 h was 27.8% in the placebo group, 38.6% in the 50-mg ubrogepant group (P = 0.002), and 37.7% in the 100-mg ubrogepant group (P = 0.002).  Adverse events within 48 h after the initial or optional second dose were reported in 12.8% of participants in the placebo group, in 9.4% in the 50-mg ubrogepant group, and in 16.3% in the 100-mg ubrogepant group.  The most common adverse events were nausea, somnolence, and dry mouth (reported in 0.4 to 4.1%); these events were more frequent in the 100-mg ubrogepant group (reported in 2.1 to 4.1%).  Serious adverse events reported within 30 days in the ubrogepant groups included appendicitis, spontaneous abortion, pericardial effusion, and seizure; none of the events occurred within 48 h after the dose. conclusions A higher percentage of participants who received ubrogepant than of those who received placebo had freedom from pain and absence of the most bothersome symptom at 2 h after the dose.  The most commonly reported adverse events were nausea, somnolence, and dry mouth.  Further trials are needed to det. the durability and safety of ubrogepant for acute migraine treatment and to compare it with other drugs for migraine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozl_vTLCa_ALVg90H21EOLACvtfcHk0liO57i0tEBgcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVylsL3K&md5=3ac0c00c8b4d6216e24fb20ec4ce75dc</span></div><a href="/servlet/linkout?suffix=cit94a&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1813049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1813049%26sid%3Dliteratum%253Aachs%26aulast%3DDodick%26aufirst%3DD.%2BW.%26aulast%3DLipton%26aufirst%3DR.%2BB.%26aulast%3DAilani%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DK.%26aulast%3DFinnegan%26aufirst%3DM.%26aulast%3DTrugman%26aufirst%3DJ.%2BM.%26aulast%3DSzegedi%26aufirst%3DA.%26atitle%3DUbrogepant%2520for%2520the%2520Treatment%2520of%2520Migraine%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2019%26volume%3D381%26spage%3D2230%26epage%3D2241%26doi%3D10.1056%2FNEJMoa1813049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit94b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraley, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgey, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regan, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danziger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michener, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hostetler, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvatore, C.</span></span> <span> </span><span class="NLM_article-title">Characterization of Ubrogepant: A Potent and Selective Antagonist of the Human Calcitonin Gene-Related Peptide Receptor</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>373</i></span>,  <span class="NLM_fpage">160</span>– <span class="NLM_lpage">166</span>, <span class="refDoi"> DOI: 10.1124/jpet.119.261065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1124%2Fjpet.119.261065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BB3cXovV2rsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2020&pages=160-166&author=E.+Mooreauthor=M.+E.+Fraleyauthor=I.+M.+Bellauthor=C.+S.+Burgeyauthor=R.+B.+Whiteauthor=C.-C.+Liauthor=C.+P.+Reganauthor=A.+Danzigerauthor=M.+S.+Michenerauthor=E.+Hostetlerauthor=P.+Banerjeeauthor=C.+Salvatore&title=Characterization+of+Ubrogepant%3A+A+Potent+and+Selective+Antagonist+of+the+Human+Calcitonin+Gene-Related+Peptide+Receptor&doi=10.1124%2Fjpet.119.261065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94bR"><div class="casContent"><span class="casTitleNuber">94b</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of ubrogepant: a potent and selective antagonist of the human calcitonin gene-related peptide receptor</span></div><div class="casAuthors">Moore, Eric; Fraley, Mark E.; Bell, Ian M.; Burgey, Christopher S.; White, Rebecca B.; Li, Chi-Chung; Regan, Christopher P.; Danziger, Andrew; Michener, Maria Stranieri; Hostetler, Eric; Banerjee, Pradeep; Salvatore, Christopher</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">160-166</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A growing body of evidence has implicated the calcitonin gene-related peptide (CGRP) receptors in migraine pathophysiol.  With the approval of monoclonal antibodies targeting CGRP or the CGRP receptor, the inhibition of CGRP-mediated signaling emerged as a promising approach for preventive treatments of migraine in adults.  Recently, small-mol. anti-CGRP treatments have shown efficacy for treating migraine.  The current studies aimed to characterize the pharmacol. properties of ubrogepant, an orally bioavailable CGRP receptor antagonist for the acute treatment of migraine.  In a series of ligand-binding assays, ubrogepant exhibited a high binding affinity for native (Ki = 0.067 nM) and cloned human (Ki = 0.070 nM) and rhesus CGRP receptors (Ki = 0.079 nM), with relatively lower affinities for CGRP receptors from rat, mouse, rabbit, and dog.  In functional assays, ubrogepant potently blocked human a-CGRP2-stimulated cAMP response (IC50 of 0.08 nM) and exhibited highly selective antagonist activity for the CGRP receptor compared with other members of the human calcitonin receptor family.  Results demonstrated that ubrogepant produced concn.-dependent inhibition of CIDV with a mean EC50 of 3.2 and 2.6 nM in rhesus monkeys and humans, resp.  Brain penetration studies with ubrogepant in monkeys showed a cerebrospinal fluid:plasma ratio of 0.03 and low CGRP receptor occupancy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCwthjgvD5tLVg90H21EOLACvtfcHk0liO57i0tEBgcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXovV2rsLw%253D&md5=1a6ac185d26ebae7e5c0c16f34bf2c3c</span></div><a href="/servlet/linkout?suffix=cit94b&amp;dbid=16384&amp;doi=10.1124%2Fjpet.119.261065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.119.261065%26sid%3Dliteratum%253Aachs%26aulast%3DMoore%26aufirst%3DE.%26aulast%3DFraley%26aufirst%3DM.%2BE.%26aulast%3DBell%26aufirst%3DI.%2BM.%26aulast%3DBurgey%26aufirst%3DC.%2BS.%26aulast%3DWhite%26aufirst%3DR.%2BB.%26aulast%3DLi%26aufirst%3DC.-C.%26aulast%3DRegan%26aufirst%3DC.%2BP.%26aulast%3DDanziger%26aufirst%3DA.%26aulast%3DMichener%26aufirst%3DM.%2BS.%26aulast%3DHostetler%26aufirst%3DE.%26aulast%3DBanerjee%26aufirst%3DP.%26aulast%3DSalvatore%26aufirst%3DC.%26atitle%3DCharacterization%2520of%2520Ubrogepant%253A%2520A%2520Potent%2520and%2520Selective%2520Antagonist%2520of%2520the%2520Human%2520Calcitonin%2520Gene-Related%2520Peptide%2520Receptor%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2020%26volume%3D373%26spage%3D160%26epage%3D166%26doi%3D10.1124%2Fjpet.119.261065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holland, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goadsby, P. J.</span></span> <span> </span><span class="NLM_article-title">Targeted CGRP Small Molecule Antagonists for Acute Migraine Therapy</span>. <i>Neurotherapeutics</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">304</span>– <span class="NLM_lpage">312</span>, <span class="refDoi"> DOI: 10.1007/s13311-018-0617-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs13311-018-0617-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=29556965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltFWltLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=304-312&author=P.+R.+Hollandauthor=P.+J.+Goadsby&title=Targeted+CGRP+Small+Molecule+Antagonists+for+Acute+Migraine+Therapy&doi=10.1007%2Fs13311-018-0617-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted CGRP Small Molecule Antagonists for Acute Migraine Therapy</span></div><div class="casAuthors">Holland, Philip R.; Goadsby, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Neurotherapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">304-312</span>CODEN:
                <span class="NLM_cas:coden">NEURNV</span>;
        ISSN:<span class="NLM_cas:issn">1878-7479</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Migraine is a highly prevalent, severe, and disabling neurol. condition with a significant unmet need for effective acute therapies.  Patients (∼50%) are dissatisfied with their currently available therapies.  Calcitonin gene-related peptide (CGRP) has emerged as a key neuropeptide involved in the pathophysiol. of migraines.  As reviewed in this manuscript, a no. of small mol. antagonists of the CGRP receptor have been developed for migraine therapy.  Incredibly, the majority of the clin. trials conducted have proven pos., demonstrating the importance of this signalling pathway in migraine.  Unfortunately, a no. of these mols. raised liver toxicity concerns when used daily for as little as 7 days resulting in their discontinuation.  Despite the clear safety concerns, clin. trial data suggests that their intermittent use remains a viable and safe alternative, with 2 mols. remaining in clin. development (ubrogepant and rimegepant).  Further, these proofs of principle studies identifying CGRP as a viable clin. target have led to the development of several CGRP or CGRP receptor-targeted monoclonal antibodies that continue to show good clin. efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohm5utSthexrVg90H21EOLACvtfcHk0limXgo-b1IMng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltFWltLs%253D&md5=3ea00aa7553e9134c86509b02ecb5d58</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1007%2Fs13311-018-0617-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13311-018-0617-4%26sid%3Dliteratum%253Aachs%26aulast%3DHolland%26aufirst%3DP.%2BR.%26aulast%3DGoadsby%26aufirst%3DP.%2BJ.%26atitle%3DTargeted%2520CGRP%2520Small%2520Molecule%2520Antagonists%2520for%2520Acute%2520Migraine%2520Therapy%26jtitle%3DNeurotherapeutics%26date%3D2018%26volume%3D15%26spage%3D304%26epage%3D312%26doi%3D10.1007%2Fs13311-018-0617-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Bell, I. M.</span>; <span class="NLM_string-name">Fraley, M. E.</span>; <span class="NLM_string-name">Gallicchio, S. N.</span>; <span class="NLM_string-name">Ginnetti, A.</span>; <span class="NLM_string-name">Mitchell, H. J.</span>; <span class="NLM_string-name">Paone, D. V.</span>; <span class="NLM_string-name">Staas, D. D.</span>; <span class="NLM_string-name">Wang, C.</span>; <span class="NLM_string-name">Zartman, C. B.</span>; <span class="NLM_string-name">Stevenson, H. E.</span></span> <span> </span><span class="NLM_article-title">Preparation of Piperidinonylcarboxamideazaindane Derivatives for Use as CGRP Receptor Antagonists</span>. <span class="NLM_patent">WO 2012064910 A1</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=I.+M.+Bell&author=M.+E.+Fraley&author=S.+N.+Gallicchio&author=A.+Ginnetti&author=H.+J.+Mitchell&author=D.+V.+Paone&author=D.+D.+Staas&author=C.+Wang&author=C.+B.+Zartman&author=H.+E.+Stevenson&title=Preparation+of+Piperidinonylcarboxamideazaindane+Derivatives+for+Use+as+CGRP+Receptor+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBell%26aufirst%3DI.%2BM.%26atitle%3DPreparation%2520of%2520Piperidinonylcarboxamideazaindane%2520Derivatives%2520for%2520Use%2520as%2520CGRP%2520Receptor%2520Antagonists%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit96b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Belyk, K. M.</span>; <span class="NLM_string-name">Cleator, E.</span>; <span class="NLM_string-name">Kuo, S.-C.</span>; <span class="NLM_string-name">Maligres, P. E.</span>; <span class="NLM_string-name">Xiang, B.</span>; <span class="NLM_string-name">Yasuda, N.</span>; <span class="NLM_string-name">Yin, J.</span></span> <span> </span><span class="NLM_article-title">Process for Preparing Pyrrolo[2,3-<i>b</i>]Pyridine Derivatives as CGRP Receptor Antagonists</span>. <span class="NLM_patent">WO2013138418 A2</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=K.+M.+Belyk&author=E.+Cleator&author=S.-C.+Kuo&author=P.+E.+Maligres&author=B.+Xiang&author=N.+Yasuda&author=J.+Yin&title=Process+for+Preparing+Pyrrolo%5B2%2C3-b%5DPyridine+Derivatives+as+CGRP+Receptor+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBelyk%26aufirst%3DK.%2BM.%26atitle%3DProcess%2520for%2520Preparing%2520Pyrrolo%255B2%252C3-b%255DPyridine%2520Derivatives%2520as%2520CGRP%2520Receptor%2520Antagonists%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit96c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span>; <span class="NLM_string-name">Molinaro, C.</span>; <span class="NLM_string-name">Wuelfing, W. P.</span>; <span class="NLM_string-name">Yasuda, N.</span>; <span class="NLM_string-name">Yin, J.</span>; <span class="NLM_string-name">Zhong, Y.-L.</span>; <span class="NLM_string-name">Lynch, J.</span>; <span class="NLM_string-name">Andreani, T.</span></span> <span> </span><span class="NLM_article-title">Process for Preparing Spirolactams as CGRP Receptor Antagonists</span>. <span class="NLM_patent">WO2013169348 A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=F.+Chen&author=C.+Molinaro&author=W.+P.+Wuelfing&author=N.+Yasuda&author=J.+Yin&author=Y.-L.+Zhong&author=J.+Lynch&author=T.+Andreani&title=Process+for+Preparing+Spirolactams+as+CGRP+Receptor+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DF.%26atitle%3DProcess%2520for%2520Preparing%2520Spirolactams%2520as%2520CGRP%2520Receptor%2520Antagonists%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit96d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span>; <span class="NLM_string-name">Molinaro, C.</span>; <span class="NLM_string-name">Wuelfing, W. P.</span>; <span class="NLM_string-name">Yasuda, N.</span>; <span class="NLM_string-name">Yin, J.</span>; <span class="NLM_string-name">Zhong, Y.-L.</span>; <span class="NLM_string-name">Lynch, J.</span>; <span class="NLM_string-name">Andreani, T.</span></span> <span> </span><span class="NLM_article-title">Process for Making CGRP Receptor Antagonists</span>. <span class="NLM_patent">US 9174989 B2</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=F.+Chen&author=C.+Molinaro&author=W.+P.+Wuelfing&author=N.+Yasuda&author=J.+Yin&author=Y.-L.+Zhong&author=J.+Lynch&author=T.+Andreani&title=Process+for+Making+CGRP+Receptor+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DF.%26atitle%3DProcess%2520for%2520Making%2520CGRP%2520Receptor%2520Antagonists%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joyce, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brachmann, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glazer, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lango, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwär, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bode, H. B.</span></span> <span> </span><span class="NLM_article-title">Bacterial Biosynthesis of a Multipotent Stilbene</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">1942</span>– <span class="NLM_lpage">1945</span>, <span class="refDoi"> DOI: 10.1002/anie.200705148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1002%2Fanie.200705148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjtFGns7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2008&pages=1942-1945&author=S.+A.+Joyceauthor=A.+O.+Brachmannauthor=I.+Glazerauthor=L.+Langoauthor=G.+Schw%C3%A4rauthor=D.+J.+Clarkeauthor=H.+B.+Bode&title=Bacterial+Biosynthesis+of+a+Multipotent+Stilbene&doi=10.1002%2Fanie.200705148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Bacterial biosynthesis of a multipotent stilbene</span></div><div class="casAuthors">Joyce, Susan A.; Brachmann, Alexander O.; Glazer, Itamar; Lango, Lea; Schwaer, Gertrud; Clarke, David J.; Bode, Helge B.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1942-1945</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The biosynthesis of the only nonplant stilbene (I) by Photorhabdus has been solved by identification of all the genes involved in its biosynthesis and by feeding expts.  I is derived from the condensation of two β-ketoacyl thioesters and is required for the normal development of Heterorhabditis nematodes, the natural host of Photorhabdus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7rDKVf76R1bVg90H21EOLACvtfcHk0lg_AXJPWCL7Eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjtFGns7Y%253D&md5=e522231c97fd095cf533196cc2f85a85</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1002%2Fanie.200705148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200705148%26sid%3Dliteratum%253Aachs%26aulast%3DJoyce%26aufirst%3DS.%2BA.%26aulast%3DBrachmann%26aufirst%3DA.%2BO.%26aulast%3DGlazer%26aufirst%3DI.%26aulast%3DLango%26aufirst%3DL.%26aulast%3DSchw%25C3%25A4r%26aufirst%3DG.%26aulast%3DClarke%26aufirst%3DD.%2BJ.%26aulast%3DBode%26aufirst%3DH.%2BB.%26atitle%3DBacterial%2520Biosynthesis%2520of%2520a%2520Multipotent%2520Stilbene%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2008%26volume%3D47%26spage%3D1942%26epage%3D1945%26doi%3D10.1002%2Fanie.200705148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Furue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto-Hachiya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuji, G.</span></span> <span> </span><span class="NLM_article-title">Aryl Hydrocarbon Receptor in Atopic Dermatitis and Psoriasis</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">5424</span>, <span class="refDoi"> DOI: 10.3390/ijms20215424</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.3390%2Fijms20215424" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BB3cXptFSisbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=5424&author=M.+Furueauthor=A.+Hashimoto-Hachiyaauthor=G.+Tsuji&title=Aryl+Hydrocarbon+Receptor+in+Atopic+Dermatitis+and+Psoriasis&doi=10.3390%2Fijms20215424"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Aryl hydrocarbon receptor in atopic dermatitis and psoriasis</span></div><div class="casAuthors">Furue, Masutaka; Hashimoto-Hachiya, Akiko; Tsuji, Gaku</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5424</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  The aryl hydrocarbon receptor (AHR)/AHR-nuclear translocator (ARNT) system is a sensitive sensor for small mol., xenobiotic chems. of exogenous and endogenous origin, including dioxins, phytochems., microbial bioproducts, and tryptophan photoproducts.  AHR/ARNT are abundantly expressed in the skin.  Once activated, the AHR/ARNT axis strengthens skin barrier functions and accelerates epidermal terminal differentiation by upregulating filaggrin expression.  In addn., AHR activation induces oxidative stress.  However, some AHR ligands simultaneously activate the nuclear factor-erythroid 2-related factor-2 (NRF2) transcription factor, which is a master switch of antioxidative enzymes that neutralizes oxidative stress.  The immunoregulatory system governing T-helper 17/22 (Th17/22) and T regulatory cells (Treg) is also regulated by the AHR system.  Notably, AHR agonists, such as tapinarof, are currently used as therapeutic agents in psoriasis and atopic dermatitis.  In this review, we summarize recent topics on AHR related to atopic dermatitis and psoriasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFGUR1M-E3XrVg90H21EOLACvtfcHk0lg_AXJPWCL7Eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXptFSisbg%253D&md5=86eae79a17386d7bb00630feaa97415c</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.3390%2Fijms20215424&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20215424%26sid%3Dliteratum%253Aachs%26aulast%3DFurue%26aufirst%3DM.%26aulast%3DHashimoto-Hachiya%26aufirst%3DA.%26aulast%3DTsuji%26aufirst%3DG.%26atitle%3DAryl%2520Hydrocarbon%2520Receptor%2520in%2520Atopic%2520Dermatitis%2520and%2520Psoriasis%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26spage%3D5424%26doi%3D10.3390%2Fijms20215424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zang, Y.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, D.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Z.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, W.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Y.</span></span> <span> </span><span class="NLM_article-title">Use of a Dose-Response Model to Guide Future Clinical Trial of Benvitimod Cream to Treat Mild and Moderate Psoriasis</span>. <i>Int. J. Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">95</span>, <span class="refDoi"> DOI: 10.5414/CP202486</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.5414%2FCP202486" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=26709597" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC28XmvV2gtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2016&pages=87-95&author=Y.-N.+Zangauthor=D.-L.+Jiangauthor=L.+Caiauthor=X.+Chenauthor=Q.+Wangauthor=Z.-W.+Xieauthor=Y.+Liuauthor=C.-Y.+Zhangauthor=S.+Jingauthor=G.-H.+Chenauthor=J.-Z.+Zhangauthor=L.+Xuauthor=W.-Y.+Fengauthor=L.-B.+Zhaoauthor=Y.+Fang&title=Use+of+a+Dose-Response+Model+to+Guide+Future+Clinical+Trial+of+Benvitimod+Cream+to+Treat+Mild+and+Moderate+Psoriasis&doi=10.5414%2FCP202486"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Use of a dose-response model to guide future clinical trials of benvitimod cream to treat mild and moderate psoriasis</span></div><div class="casAuthors">Zang, Yan-Nan; Jiang, Dao-Li; Cai, Lin; Chen, Xin; Wang, Qian; Xie, Zhen-Wei; Liu, Yang; Zhang, Chun-Yan; Jing, Shan; Chen, Gen-Hui; Zhang, Jian-Zhong; Xu, Ling; Feng, Wan-Yu; Zhao, Li-Bo; Fang, Yi</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Clinical Pharmacology and Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">87-95</span>CODEN:
                <span class="NLM_cas:coden">ICTHEK</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Dustri-Verlag Dr. Karl Feistle</span>)
        </div><div class="casAbstract">Objective: To investigate the time-dose-response relationship of benvitimod cream after topical administration in patients with mild and moderate psoriasis vulgaris for dosage regimen exploring.  Methods: 36 patients with mild and moderate psoriasis vulgaris were randomly assigned to receive 0.5%, 1.0%, 1.5%, and 0% (placebo) benvitimod cream of 30 g/1.7 m2 twice daily for 6 wk.  The primary efficacy outcome was the proportion of patients achieving more than 75% change of the psoriasis area and severity index (PASI 75) from baseline.  A longitudinal Emax model was established using the NONMEM method, and then applied to try to find an appropriate dose for following trials.  Results: In the final time-dose-response model, the primary outcome at week 6 of PASI 75 of the 0.5%, 1.0%, and 1.5% benvitimod cream was 31%, 63%, and 75%, resp., demonstrating that the 1.0% benvitimod cream was an appropriate dose for the next trial.  The time parameters of ET50 and ET90 were 15 and 69 days for 1.0% benvitimod cream, indicating that the max. efficacy of PASI change rate was obtained at approx. week 10.  The accuracy of PASI change rate by extrapolation prediction was limited at week 10, so the treatment period should be longer in future trials.  Conclusions: The established dose-response model could well describe the relationship between PASI change rate and doses of benvitimod cream in patients with mild and moderate psoriasis vulgaris.  This modeling approach may help choose 1.0% benvitimod cream twice daily as a dosage regimen in following clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqkSagXwYp8bVg90H21EOLACvtfcHk0lg_AXJPWCL7Eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmvV2gtLY%253D&md5=5ed5633b5e741e183c219533fa2d6635</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.5414%2FCP202486&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5414%252FCP202486%26sid%3Dliteratum%253Aachs%26aulast%3DZang%26aufirst%3DY.-N.%26aulast%3DJiang%26aufirst%3DD.-L.%26aulast%3DCai%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DXie%26aufirst%3DZ.-W.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DC.-Y.%26aulast%3DJing%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DG.-H.%26aulast%3DZhang%26aufirst%3DJ.-Z.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DFeng%26aufirst%3DW.-Y.%26aulast%3DZhao%26aufirst%3DL.-B.%26aulast%3DFang%26aufirst%3DY.%26atitle%3DUse%2520of%2520a%2520Dose-Response%2520Model%2520to%2520Guide%2520Future%2520Clinical%2520Trial%2520of%2520Benvitimod%2520Cream%2520to%2520Treat%2520Mild%2520and%2520Moderate%2520Psoriasis%26jtitle%3DInt.%2520J.%2520Clin.%2520Pharmacol.%2520Ther.%26date%3D2016%26volume%3D54%26spage%3D87%26epage%3D95%26doi%3D10.5414%2FCP202486" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span> <span> </span><span class="NLM_article-title">Industrialized Production Process of New Medicament Benvitimod for Treating Psoriasis</span>. <span class="NLM_patent">CN 103172497 A</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=B.+Li&title=Industrialized+Production+Process+of+New+Medicament+Benvitimod+for+Treating+Psoriasis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DB.%26atitle%3DIndustrialized%2520Production%2520Process%2520of%2520New%2520Medicament%2520Benvitimod%2520for%2520Treating%2520Psoriasis%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf" class="extLink">https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf</a> (accessed 2020-09-17).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2019%2F211527s000lbl.pdf+%28accessed+2020-09-17%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, L. J.</span></span> <span> </span><span class="NLM_article-title">Trifarotene: First Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">1905</span>– <span class="NLM_lpage">1909</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01218-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs40265-019-01218-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31713811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFCjtrfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=1905-1909&author=L.+J.+Scott&title=Trifarotene%3A+First+Approval&doi=10.1007%2Fs40265-019-01218-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Trifarotene: First Approval</span></div><div class="casAuthors">Scott, Lesley J.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1905-1909</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Topical trifarotene (Aklief) is a first-in-class, fourth-generation retinoid [selective retinoic acid receptor (RAR)-γ agonist] being developed by Galderma Research and Development LLC for the treatment of acne vulgaris.  In Oct. 2019 trifarotene received its first global approval in the USA for the topical treatment of acne vulgaris in patients 9 years of age and older.  This article summarizes the milestones in the development of trifarotene leading to its first global approval for acne vulgaris.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpE9jRMJrjPS7Vg90H21EOLACvtfcHk0lhPNH7kB3ta9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFCjtrfM&md5=9c811e694067c8bfe303e1d27d0b6d40</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01218-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01218-6%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DL.%2BJ.%26atitle%3DTrifarotene%253A%2520First%2520Approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D1905%26epage%3D1909%26doi%3D10.1007%2Fs40265-019-01218-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiboutot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popp, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gooderham, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynde, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Rosso, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blume-Peytavi, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weglovska, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parish, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witkowska, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez Colon, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alió Saenz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graeber, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein Gold, L.</span></span> <span> </span><span class="NLM_article-title">Randomized Phase 3 Evaluation of Trifarotene 50 μg/g Cream Treatment of Moderate Facial and Truncal Acne</span>. <i>J. Am. Acad. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">1691</span>– <span class="NLM_lpage">1699</span>, <span class="refDoi"> DOI: 10.1016/j.jaad.2019.02.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2Fj.jaad.2019.02.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=30802558" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVWqtbfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2019&pages=1691-1699&author=J.+Tanauthor=D.+Thiboutotauthor=G.+Poppauthor=M.+Gooderhamauthor=C.+Lyndeauthor=J.+Del+Rossoauthor=J.+Weissauthor=U.+Blume-Peytaviauthor=J.+Weglovskaauthor=S.+Johnsonauthor=L.+Parishauthor=D.+Witkowskaauthor=N.+Sanchez+Colonauthor=A.+Ali%C3%B3+Saenzauthor=F.+Ahmadauthor=M.+Graeberauthor=L.+Stein+Gold&title=Randomized+Phase+3+Evaluation+of+Trifarotene+50+%CE%BCg%2Fg+Cream+Treatment+of+Moderate+Facial+and+Truncal+Acne&doi=10.1016%2Fj.jaad.2019.02.044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized phase 3 evaluation of trifarotene 50μg/g cream treatment of moderate facial and truncal acne</span></div><div class="casAuthors">Tan, Jerry; Thiboutot, Diane; Popp, Georg; Gooderham, Melinda; Lynde, Charles; Del Rosso, James; Weiss, Jonathan; Blume-Peytavi, Ulrike; Weglovska, Jolanta; Johnson, Sandra; Parish, Lawrence; Witkowska, Dagmara; Sanchez Colon, Nestor; Alio Saenz, Alessandra; Ahmad, Faiz; Graeber, Michael; Stein Gold, Linda</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Academy of Dermatology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1691-1699</span>CODEN:
                <span class="NLM_cas:coden">JAADDB</span>;
        ISSN:<span class="NLM_cas:issn">0190-9622</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Acne vulgaris often affects the face, shoulders, chest, and back, but treatment of nonfacial acne has not been rigorously studied.  Assess the safety and efficacy of trifarotene 50μg/g cream, a novel topical retinoid, in moderate facial and truncal acne.  Two phase III double-blind, randomized, vehicle-controlled, 12-wk studies of once-daily trifarotene cream vs. vehicle in subjects aged 9 years or older.  The primary end points were rate of success on the face, as detd. by the Investigator's Global Assessment (clear or almost clear and ≥2-grade improvement), and abs. change from baseline in inflammatory and noninflammatory counts from baseline to week 12.  The secondary end points were rate of success on the trunk (clear or almost clear and ≥2-grade improvement) and abs. change in truncal inflammatory and noninflammatory counts from baseline to week 12.  Safety was assessed through adverse events, local tolerability, vital signs, and routine lab. testing results.  In both studies, at week 12 the facial success rates according to the Investigator's Global Assessment and truncal Physician's Global Assessment and change in inflammatory and noninflammatory lesion counts (both abs. and percentage) were all highly significant in favor of trifarotene when compared with the vehicle.  Adjunctive topical or systemic treatments were not studied.  These studies demonstrate that trifarotene appears to be safe, effective, and well tolerated in treatment of both facial and truncal acne.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1FR_eONWv6LVg90H21EOLACvtfcHk0lhPNH7kB3ta9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVWqtbfL&md5=9e524bd5f9089c957704ac5e9fcb70ac</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1016%2Fj.jaad.2019.02.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaad.2019.02.044%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DThiboutot%26aufirst%3DD.%26aulast%3DPopp%26aufirst%3DG.%26aulast%3DGooderham%26aufirst%3DM.%26aulast%3DLynde%26aufirst%3DC.%26aulast%3DDel%2BRosso%26aufirst%3DJ.%26aulast%3DWeiss%26aufirst%3DJ.%26aulast%3DBlume-Peytavi%26aufirst%3DU.%26aulast%3DWeglovska%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DS.%26aulast%3DParish%26aufirst%3DL.%26aulast%3DWitkowska%26aufirst%3DD.%26aulast%3DSanchez%2BColon%26aufirst%3DN.%26aulast%3DAli%25C3%25B3%2BSaenz%26aufirst%3DA.%26aulast%3DAhmad%26aufirst%3DF.%26aulast%3DGraeber%26aufirst%3DM.%26aulast%3DStein%2BGold%26aufirst%3DL.%26atitle%3DRandomized%2520Phase%25203%2520Evaluation%2520of%2520Trifarotene%252050%2520%25CE%25BCg%252Fg%2520Cream%2520Treatment%2520of%2520Moderate%2520Facial%2520and%2520Truncal%2520Acne%26jtitle%3DJ.%2520Am.%2520Acad.%2520Dermatol.%26date%3D2019%26volume%3D80%26spage%3D1691%26epage%3D1699%26doi%3D10.1016%2Fj.jaad.2019.02.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Biadatti, T.</span>; <span class="NLM_string-name">Dumais, L.</span>; <span class="NLM_string-name">Soulet, C.</span>; <span class="NLM_string-name">Talano, S.</span>; <span class="NLM_string-name">Daver, S.</span></span> <span> </span><span class="NLM_article-title">Novel Ligands That Modulate RAR Receptors, and Use Thereof in Human Medicine and in Cosmetics</span>. <span class="NLM_patent">WO 2006066978 A1</span>, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=T.+Biadatti&author=L.+Dumais&author=C.+Soulet&author=S.+Talano&author=S.+Daver&title=Novel+Ligands+That+Modulate+RAR+Receptors%2C+and+Use+Thereof+in+Human+Medicine+and+in+Cosmetics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBiadatti%26aufirst%3DT.%26atitle%3DNovel%2520Ligands%2520That%2520Modulate%2520RAR%2520Receptors%252C%2520and%2520Use%2520Thereof%2520in%2520Human%2520Medicine%2520and%2520in%2520Cosmetics%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Zielińska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasilewski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fichna, J.</span></span> <span> </span><span class="NLM_article-title">Tenapanor Hydrochloride for the Treatment of Constipation-Predominant Irritable Bowel Syndrome</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1093</span>– <span class="NLM_lpage">1099</span>, <span class="refDoi"> DOI: 10.1517/13543784.2015.1054480</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1517%2F13543784.2015.1054480" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=26065434" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFCksb3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2015&pages=1093-1099&author=M.+Zieli%C5%84skaauthor=A.+Wasilewskiauthor=J.+Fichna&title=Tenapanor+Hydrochloride+for+the+Treatment+of+Constipation-Predominant+Irritable+Bowel+Syndrome&doi=10.1517%2F13543784.2015.1054480"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105aR"><div class="casContent"><span class="casTitleNuber">105a</span><div class="casTitle"><span class="NLM_cas:atitle">Tenapanor hydrochloride for the treatment of constipation-predominant irritable bowel syndrome</span></div><div class="casAuthors">Zielinska, Marta; Wasilewski, Andrzej; Fichna, Jakub</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1093-1099</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Introduction: Constipation-predominant irritable bowel syndrome (IBS-C) is a common functional gastrointestinal (GI) disorder characterized by recurrent abdominal pain and prolonged GI transit.  The pathogenesis of IBS-C has still not been established; therefore, drugs currently in use in IBS-C act mainly symptomatically, whereas novel pharmacol. targets are urgently needed.  Tenapanor is a potent inhibitor of Na+/H+ exchanger 3 [NHE3], localized in the apical membrane of intestinal epithelial cells.  NHE3 participates in the uptake of sodium ions and water from the intestinal lumen.  Areas covered: In this review, the authors discuss pharmacodynamics and pharmacokinetics of tenapanor, focusing on animal models and in vitro studies.  They also summarize clin. trials on tenapanor's safety and efficacy in view of its potential role in IBS-C therapy.  Expert opinion: Tenapanor possesses an excellent preclin. safety profile and, as of now, there are no serious concerns about its side effects.  The non-systemic action of tenapanor constitutes a significant advantage, as it minimizes possible adverse effects or drug-drug interactions.  However, Phase III clin. trials are still needed to confirm results obtained in earlier phases and optimize the dose-response for tenapanor, whereas limiting diarrhea, its major adverse effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR0UxJixVSu7Vg90H21EOLACvtfcHk0liwOxBNgsl5LQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFCksb3P&md5=8dc37d7e06076fd906964ff774f48fea</span></div><a href="/servlet/linkout?suffix=cit105a&amp;dbid=16384&amp;doi=10.1517%2F13543784.2015.1054480&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2015.1054480%26sid%3Dliteratum%253Aachs%26aulast%3DZieli%25C5%2584ska%26aufirst%3DM.%26aulast%3DWasilewski%26aufirst%3DA.%26aulast%3DFichna%26aufirst%3DJ.%26atitle%3DTenapanor%2520Hydrochloride%2520for%2520the%2520Treatment%2520of%2520Constipation-Predominant%2520Irritable%2520Bowel%2520Syndrome%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2015%26volume%3D24%26spage%3D1093%26epage%3D1099%26doi%3D10.1517%2F13543784.2015.1054480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit105b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span> <span> </span><span class="NLM_article-title">Tenapanor: First Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">1897</span>– <span class="NLM_lpage">1903</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01215-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs40265-019-01215-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31677150" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFemsLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=1897-1903&author=A.+Markham&title=Tenapanor%3A+First+Approval&doi=10.1007%2Fs40265-019-01215-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105bR"><div class="casContent"><span class="casTitleNuber">105b</span><div class="casTitle"><span class="NLM_cas:atitle">Tenapanor: First Approval</span></div><div class="casAuthors">Markham, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1897-1903</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">The selective sodium hydrogen exchanger 3 (NHE3) inhibitor tenapanor is being developed by Ardelyx Inc. for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) [under the tradename IBSRELA] and for hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis or with end stage renal disease (ESRD).  Based on pos. results from the phase III T3MPO trial program, tenapanor was recently approved in the USA for the treatment of IBS-C in adults.  This article summarises the milestones in the development of tenapanor leading to this first approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpE-doTb0dW1bVg90H21EOLACvtfcHk0liwOxBNgsl5LQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFemsLjP&md5=7d27d0d461b6b153e15097e54d9a67fa</span></div><a href="/servlet/linkout?suffix=cit105b&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01215-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01215-9%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26atitle%3DTenapanor%253A%2520First%2520Approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D1897%26epage%3D1903%26doi%3D10.1007%2Fs40265-019-01215-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leadbetter, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carreras, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koo-McCoy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohler, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labonte, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenbaum, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navre, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charmot, D.</span></span> <span> </span><span class="NLM_article-title">RDX5791, a First-in-Class Minimally Systemic NHE3 Inhibitor in Clinical Development for CIC and IBS-C, Increases Intestinal Sodium Leading to Enhanced Intestinal Fluid Volume and Transit</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>140</i></span>,  <span class="NLM_fpage">S-99</span>, <span class="refDoi"> DOI: 10.1016/S0016-5085(11)60405-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2FS0016-5085%2811%2960405-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2011&pages=S-99&author=A.+G.+Spencerauthor=J.+W.+Jacobsauthor=M.+R.+Leadbetterauthor=C.+W.+Carrerasauthor=X.+Duauthor=N.+Bellauthor=S.+Koo-McCoyauthor=J.+N.+Kohlerauthor=E.+Labonteauthor=D.+P.+Rosenbaumauthor=M.+Navreauthor=D.+Charmot&title=RDX5791%2C+a+First-in-Class+Minimally+Systemic+NHE3+Inhibitor+in+Clinical+Development+for+CIC+and+IBS-C%2C+Increases+Intestinal+Sodium+Leading+to+Enhanced+Intestinal+Fluid+Volume+and+Transit&doi=10.1016%2FS0016-5085%2811%2960405-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1016%2FS0016-5085%2811%2960405-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0016-5085%252811%252960405-8%26sid%3Dliteratum%253Aachs%26aulast%3DSpencer%26aufirst%3DA.%2BG.%26aulast%3DJacobs%26aufirst%3DJ.%2BW.%26aulast%3DLeadbetter%26aufirst%3DM.%2BR.%26aulast%3DCarreras%26aufirst%3DC.%2BW.%26aulast%3DDu%26aufirst%3DX.%26aulast%3DBell%26aufirst%3DN.%26aulast%3DKoo-McCoy%26aufirst%3DS.%26aulast%3DKohler%26aufirst%3DJ.%2BN.%26aulast%3DLabonte%26aufirst%3DE.%26aulast%3DRosenbaum%26aufirst%3DD.%2BP.%26aulast%3DNavre%26aufirst%3DM.%26aulast%3DCharmot%26aufirst%3DD.%26atitle%3DRDX5791%252C%2520a%2520First-in-Class%2520Minimally%2520Systemic%2520NHE3%2520Inhibitor%2520in%2520Clinical%2520Development%2520for%2520CIC%2520and%2520IBS-C%252C%2520Increases%2520Intestinal%2520Sodium%2520Leading%2520to%2520Enhanced%2520Intestinal%2520Fluid%2520Volume%2520and%2520Transit%26jtitle%3DGastroenterology%26date%3D2011%26volume%3D140%26spage%3DS-99%26doi%3D10.1016%2FS0016-5085%2811%2960405-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211801s000lbl.pdf" class="extLink">https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211801s000lbl.pdf</a> (accessed 2020-09-18).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2019%2F211801s000lbl.pdf+%28accessed+2020-09-18%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Charmot, D.</span></span> <span> </span><span class="NLM_article-title">Non-Systemic Drugs: A Critical Review</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1434</span>– <span class="NLM_lpage">1445</span>, <span class="refDoi"> DOI: 10.2174/138161212799504858</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.2174%2F138161212799504858" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=22300258" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvVKku7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=1434-1445&author=D.+Charmot&title=Non-Systemic+Drugs%3A+A+Critical+Review&doi=10.2174%2F138161212799504858"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Non-systemic drugs: a critical review</span></div><div class="casAuthors">Charmot, Dominique</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1434-1445</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Non-systemic drugs act within the intestinal lumen without reaching the systemic circulation.  The first generation included polymeric resins that sequester phosphate ions, potassium ions, or bile acids for the treatment of electrolyte imbalances or hypercholesteremia.  The field has evolved towards non-absorbable small mols. or peptides targeting luminal enzymes or transporters for the treatment of mineral metab. disorders, diabetes, gastrointestinal (GI) disorders, and enteric infections.  From a drug design and development perspective, non-systemic agents offer novel opportunities to address unmet medical needs while minimizing toxicity risks, but also present new challenges, including developing a better understanding and control of non-transcellular leakage pathways into the systemic circulation.  The pharmacokinetic-pharmacodynamic relationship of drugs acting in the GI tract can be complex due to the variability of intestinal transit, interaction with chyme, and the complex environment of the surface epithelia.  We review the main classes of nonabsorbable agents at various stages of development, and their therapeutic potential and limitations.  The rapid progress in the identification of intestinal receptors and transporters, their functional characterization and role in metabolic and inflammatory disorders, will undoubtedly renew interest in the development of novel, safe, non-systemic therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKdEQRhLF7irVg90H21EOLACvtfcHk0liwOxBNgsl5LQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvVKku7g%253D&md5=7a391aa741bb1a4bba9516b0f39acee1</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.2174%2F138161212799504858&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161212799504858%26sid%3Dliteratum%253Aachs%26aulast%3DCharmot%26aufirst%3DD.%26atitle%3DNon-Systemic%2520Drugs%253A%2520A%2520Critical%2520Review%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2012%26volume%3D18%26spage%3D1434%26epage%3D1445%26doi%3D10.2174%2F138161212799504858" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Charmot, D.</span>; <span class="NLM_string-name">Jacobs, J. W.</span>; <span class="NLM_string-name">Leadbetter, M. R.</span>; <span class="NLM_string-name">Navre, M.</span>; <span class="NLM_string-name">Carreras, C.</span>; <span class="NLM_string-name">Bell, N.</span></span> <span> </span><span class="NLM_article-title">Preparation of Isoquinolines and Related Compounds as Inhibitors of NHE-Mediated Antiport Useful in the Treatment of Disorders Associated with Fluid Retention or Salt Overload and Gastrointestinal Tract Disorders</span>. <span class="NLM_patent">WO 2010078449 A2</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=D.+Charmot&author=J.+W.+Jacobs&author=M.+R.+Leadbetter&author=M.+Navre&author=C.+Carreras&author=N.+Bell&title=Preparation+of+Isoquinolines+and+Related+Compounds+as+Inhibitors+of+NHE-Mediated+Antiport+Useful+in+the+Treatment+of+Disorders+Associated+with+Fluid+Retention+or+Salt+Overload+and+Gastrointestinal+Tract+Disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCharmot%26aufirst%3DD.%26atitle%3DPreparation%2520of%2520Isoquinolines%2520and%2520Related%2520Compounds%2520as%2520Inhibitors%2520of%2520NHE-Mediated%2520Antiport%2520Useful%2520in%2520the%2520Treatment%2520of%2520Disorders%2520Associated%2520with%2520Fluid%2520Retention%2520or%2520Salt%2520Overload%2520and%2520Gastrointestinal%2520Tract%2520Disorders%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit109b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Bell, N.</span>; <span class="NLM_string-name">Carreras, C.</span>; <span class="NLM_string-name">Charmot, D.</span>; <span class="NLM_string-name">Chen, T.</span>; <span class="NLM_string-name">Leadbetter, M.</span>; <span class="NLM_string-name">Jacobs, J.</span>; <span class="NLM_string-name">Lewis, J.</span></span> <span> </span><span class="NLM_article-title">Compounds and Methods for Inhibiting NHE-Mediated Antiport in the Treatment of Disorders Associated with Fluid Retention or Salt Overload and Gastrointestinal Tract Disorders</span>. <span class="NLM_patent">WO 2010078449</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=N.+Bell&author=C.+Carreras&author=D.+Charmot&author=T.+Chen&author=M.+Leadbetter&author=J.+Jacobs&author=J.+Lewis&title=Compounds+and+Methods+for+Inhibiting+NHE-Mediated+Antiport+in+the+Treatment+of+Disorders+Associated+with+Fluid+Retention+or+Salt+Overload+and+Gastrointestinal+Tract+Disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBell%26aufirst%3DN.%26atitle%3DCompounds%2520and%2520Methods%2520for%2520Inhibiting%2520NHE-Mediated%2520Antiport%2520in%2520the%2520Treatment%2520of%2520Disorders%2520Associated%2520with%2520Fluid%2520Retention%2520or%2520Salt%2520Overload%2520and%2520Gastrointestinal%2520Tract%2520Disorders%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit109c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Luthra, P. K.</span>; <span class="NLM_string-name">Ahmad, S.</span>; <span class="NLM_string-name">Das, D.</span>; <span class="NLM_string-name">Singh, S.</span>; <span class="NLM_string-name">Singh, A.</span></span> <span> </span><span class="NLM_article-title">Processes for the Preparation of Tenapanor, Its Crystalline Dihydrochloride Form and Intermediates Thereof</span>. <span class="NLM_patent">WO 2020051014 A1</span>, <span class="NLM_year">2020</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=P.+K.+Luthra&author=S.+Ahmad&author=D.+Das&author=S.+Singh&author=A.+Singh&title=Processes+for+the+Preparation+of+Tenapanor%2C+Its+Crystalline+Dihydrochloride+Form+and+Intermediates+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLuthra%26aufirst%3DP.%2BK.%26atitle%3DProcesses%2520for%2520the%2520Preparation%2520of%2520Tenapanor%252C%2520Its%2520Crystalline%2520Dihydrochloride%2520Form%2520and%2520Intermediates%2520Thereof%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keam, S. J.</span></span> <span> </span><span class="NLM_article-title">Peficitinib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">887</span>– <span class="NLM_lpage">891</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01131-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs40265-019-01131-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31093950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFWmtLzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=887-891&author=A.+Markhamauthor=S.+J.+Keam&title=Peficitinib%3A+First+Global+Approval&doi=10.1007%2Fs40265-019-01131-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Peficitinib: First Global Approval</span></div><div class="casAuthors">Markham, Anthony; Keam, Susan J.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">887-891</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Peficitinib [Smyraf (Astellas Pharma)] is a Janus kinase (JAK)1, JAK2, JAK3 and tyrosine kinase (Tyk)2 (pan-JAK) inhibitor recently approved in Japan for the treatment of rheumatoid arthritis.  Inhibition of JAK suppresses the activation of cytokine signalling pathways involved in inflammation and joint destruction in rheumatoid arthritis.  Peficitinib has been shown to significantly improve ACR20 and other measures of disease severity and to reduce the mean modified total Sharp score change from baseline in clin. trials.  This article summarizes the milestones in the development of peficitinib leading to this first approval as a treatment for rheumatoid arthritis in patients who have an inadequate response to conventional therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0H33aqSsFn7Vg90H21EOLACvtfcHk0lhdhpGQgsYklQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFWmtLzI&md5=eb2d2061829fc515854130050139871c</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01131-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01131-y%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26aulast%3DKeam%26aufirst%3DS.%2BJ.%26atitle%3DPeficitinib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D887%26epage%3D891%26doi%3D10.1007%2Fs40265-019-01131-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawakami, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwasaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, J. C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rokuda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izutsu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ushijima, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaneko, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akazawa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiomi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, E.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety of Peficitinib (ASP015K) in Patients with Rheumatoid Arthritis and an Inadequate Response to Conventional DMARDs: A Randomised, Double-Blind, Placebo-Controlled Phase III Trial (RAJ3)</span>. <i>Ann. Rheum. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">1320</span>– <span class="NLM_lpage">1332</span>, <span class="refDoi"> DOI: 10.1136/annrheumdis-2019-215163</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1136%2Fannrheumdis-2019-215163" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31350270" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BB3cXktVSqu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2019&pages=1320-1332&author=Y.+Tanakaauthor=T.+Takeuchiauthor=S.+Tanakaauthor=A.+Kawakamiauthor=M.+Iwasakiauthor=Y.+W.+Songauthor=Y.-H.+Chenauthor=J.+C.-C.+Weiauthor=S.-H.+Leeauthor=M.+Rokudaauthor=H.+Izutsuauthor=S.+Ushijimaauthor=Y.+Kanekoauthor=R.+Akazawaauthor=T.+Shiomiauthor=E.+Yamada&title=Efficacy+and+Safety+of+Peficitinib+%28ASP015K%29+in+Patients+with+Rheumatoid+Arthritis+and+an+Inadequate+Response+to+Conventional+DMARDs%3A+A+Randomised%2C+Double-Blind%2C+Placebo-Controlled+Phase+III+Trial+%28RAJ3%29&doi=10.1136%2Fannrheumdis-2019-215163"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111aR"><div class="casContent"><span class="casTitleNuber">111a</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3)</span></div><div class="casAuthors">Tanaka, Yoshiya; Takeuchi, Tsutomu; Tanaka, Sakae; Kawakami, Atsushi; Iwasaki, Manabu; Song, Yeong Wook; Chen, Yi-Hsing; Wei, James Cheng-Chung; Lee, Sang-Heon; Rokuda, Mitsuhiro; Izutsu, Hiroyuki; Ushijima, Satoshi; Kaneko, Yuichiro; Akazawa, Rio; Shiomi, Teruaki; Yamada, Emi</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the Rheumatic Diseases</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1320-1332</span>CODEN:
                <span class="NLM_cas:coden">ARDIAO</span>;
        ISSN:<span class="NLM_cas:issn">0003-4967</span>.
    
            (<span class="NLM_cas:orgname">BMJ</span>)
        </div><div class="casAbstract">Objectives To investigate the efficacy and safety of peficitinib, an oral Janus kinase inhibitor, in patients with rheumatoid arthritis (RA).  Methods In this double-blind phase III study, patients with RA and an inadequate response to prior diseasemodifying anti-rheumatic drugs (DMARDs) were randomised to peficitinib 100 mg once daily, peficitinib 150 mg once daily, placebo or open-label etanercept for 52 wk' treatment; placebo-treated patients were switched at week 12 to peficitinib 100 or 150 mg once daily.  The primary endpoint was American College of Rheumatol. (ACR)20 response at week 12/ early termination (ET).  Secondary endpoints (assessed throughout) included ACR20, ACR50 and ACR70 response, changes from baseline in disease activity scores (DAS)28 and ACR core parameters, adverse events (AEs) and changes in clin. or lab. measurements.  Results In total, 507 patients received treatment.  ACR20 response rates at week 12/ET were significantly higher in the peficitinib 100 mg (57.7%) and 150 mg (74.5%) groups vs. placebo (30.7%) (p<0.001).  ACR50/70 response rates were also higher for both peficitinib doses vs. placebo.  Improvements in ACR response were maintained until week 52.  Changes from baseline in DAS28-C-reactive protein/ erythrocyte sedimentation rate and the ACR core set were significantly greater for both peficitinib doses vs. placebo at week 12/ET (p<0.001).  AE incidence was similar across treatment arms.  Incidence of serious infection and herpes zoster-related disease was higher with peficitinib vs. placebo, but with no clear dosedependent increase.  Conclusions In patients with RA and inadequate response to DMARDs, peficitinib 100 mg once daily or 150 mg once daily was efficacious in reducing RA symptoms and was well tolerated compared with placebo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDAebqPwKbebVg90H21EOLACvtfcHk0lhdhpGQgsYklQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXktVSqu7k%253D&md5=c4ccdebb71ae698e654b57fee74c0ce5</span></div><a href="/servlet/linkout?suffix=cit111a&amp;dbid=16384&amp;doi=10.1136%2Fannrheumdis-2019-215163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fannrheumdis-2019-215163%26sid%3Dliteratum%253Aachs%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DTakeuchi%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DS.%26aulast%3DKawakami%26aufirst%3DA.%26aulast%3DIwasaki%26aufirst%3DM.%26aulast%3DSong%26aufirst%3DY.%2BW.%26aulast%3DChen%26aufirst%3DY.-H.%26aulast%3DWei%26aufirst%3DJ.%2BC.-C.%26aulast%3DLee%26aufirst%3DS.-H.%26aulast%3DRokuda%26aufirst%3DM.%26aulast%3DIzutsu%26aufirst%3DH.%26aulast%3DUshijima%26aufirst%3DS.%26aulast%3DKaneko%26aufirst%3DY.%26aulast%3DAkazawa%26aufirst%3DR.%26aulast%3DShiomi%26aufirst%3DT.%26aulast%3DYamada%26aufirst%3DE.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Peficitinib%2520%2528ASP015K%2529%2520in%2520Patients%2520with%2520Rheumatoid%2520Arthritis%2520and%2520an%2520Inadequate%2520Response%2520to%2520Conventional%2520DMARDs%253A%2520A%2520Randomised%252C%2520Double-Blind%252C%2520Placebo-Controlled%2520Phase%2520III%2520Trial%2520%2528RAJ3%2529%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2019%26volume%3D78%26spage%3D1320%26epage%3D1332%26doi%3D10.1136%2Fannrheumdis-2019-215163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit111b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawakami, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwasaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rokuda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izutsu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ushijima, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaneko, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiomi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Der Heijde, D.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety of Peficitinib (ASP015K) in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III Randomised, Double-Blind, Placebo-Controlled Trial (RAJ4) in Japan</span>. <i>Ann. Rheum. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">1305</span>– <span class="NLM_lpage">1319</span>, <span class="refDoi"> DOI: 10.1136/annrheumdis-2019-215164</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1136%2Fannrheumdis-2019-215164" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31350269" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BB3cXktVSqu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2019&pages=1305-1319&author=T.+Takeuchiauthor=Y.+Tanakaauthor=S.+Tanakaauthor=A.+Kawakamiauthor=M.+Iwasakiauthor=K.+Katayamaauthor=M.+Rokudaauthor=H.+Izutsuauthor=S.+Ushijimaauthor=Y.+Kanekoauthor=T.+Shiomiauthor=E.+Yamadaauthor=D.+Van+Der+Heijde&title=Efficacy+and+Safety+of+Peficitinib+%28ASP015K%29+in+Patients+with+Rheumatoid+Arthritis+and+an+Inadequate+Response+to+Methotrexate%3A+Results+of+a+Phase+III+Randomised%2C+Double-Blind%2C+Placebo-Controlled+Trial+%28RAJ4%29+in+Japan&doi=10.1136%2Fannrheumdis-2019-215164"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111bR"><div class="casContent"><span class="casTitleNuber">111b</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomized, double-blind, placebo-controlled trial (RAJ4) in Japan</span></div><div class="casAuthors">Takeuchi, Tsutomu; Tanaka, Yoshiya; Tanaka, Sakae; Kawakami, Atsushi; Iwasaki, Manabu; Katayama, Kou; Rokuda, Mitsuhiro; Izutsu, Hiroyuki; Ushijima, Satoshi; Kaneko, Yuichiro; Shiomi, Teruaki; Yamada, Emi; Van Der Heijde, Desiree</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the Rheumatic Diseases</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1305-1319</span>CODEN:
                <span class="NLM_cas:coden">ARDIAO</span>;
        ISSN:<span class="NLM_cas:issn">0003-4967</span>.
    
            (<span class="NLM_cas:orgname">BMJ</span>)
        </div><div class="casAbstract">To evaluate the efficacy and safety of the oral Janus kinase (JAK) inhibitor peficitinib vs. placebo in Japanese patients with rheumatoid arthritis (RA).  In this multicentre, double-blind, parallel group, placebo-controlled phase III study, patients with RA and inadequate response to methotrexate (MTX) were randomized 1:1:1 to placebo, peficitinib 100 mg once daily or peficitinib 150 mg once daily with MTX for 52 wk.  Based on baseline randomization, at week 12, non-responders receiving placebo were switched to peficitinib until the end of treatment; the remaining patients were switched to peficitinib at week 28.  Primary efficacy variables were American College of Rheumatol. (ACR)20 response rate at week 12/early termination (ET) and change from baseline in van der Heijde-modified total Sharp score (mTSS) at week 28/ET.  The 519 patients were randomized and treated.  Significantly more (p<0.001) peficitinib (58.6%, 100 mg; 64.4%, 150 mg) than placebo (21.8%) recipients achieved ACR20 response at week 12/ ET.  Significantly lower (p<0.001) mean changes from baseline in mTSS at week 28/ET occurred in peficitinib (1.62, 100 mg; 1.03, 150 mg) than placebo (3.37) recipients.  Peficitinib was assocd. with haematol. and biochem. parameter changes, and increased incidence of serious infections and herpes zoster-related disease.  One death from suicide occurred in a patient in the placebo group after switching to peficitinib 100 mg.  In Japanese patients with RA and inadequate response to MTX, peficitinib demonstrated significant superiority vs. placebo in reducing RA symptoms and suppressing joint destruction.  Peficitinib had an acceptable safety and tolerability profile, with no new safety signals compared with other JAK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomsauLdMHNw7Vg90H21EOLACvtfcHk0liQUmyEhlXjfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXktVSqu7Y%253D&md5=1e3d6da357f25c0cb2be7220f4d77ba5</span></div><a href="/servlet/linkout?suffix=cit111b&amp;dbid=16384&amp;doi=10.1136%2Fannrheumdis-2019-215164&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fannrheumdis-2019-215164%26sid%3Dliteratum%253Aachs%26aulast%3DTakeuchi%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DTanaka%26aufirst%3DS.%26aulast%3DKawakami%26aufirst%3DA.%26aulast%3DIwasaki%26aufirst%3DM.%26aulast%3DKatayama%26aufirst%3DK.%26aulast%3DRokuda%26aufirst%3DM.%26aulast%3DIzutsu%26aufirst%3DH.%26aulast%3DUshijima%26aufirst%3DS.%26aulast%3DKaneko%26aufirst%3DY.%26aulast%3DShiomi%26aufirst%3DT.%26aulast%3DYamada%26aufirst%3DE.%26aulast%3DVan%2BDer%2BHeijde%26aufirst%3DD.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Peficitinib%2520%2528ASP015K%2529%2520in%2520Patients%2520with%2520Rheumatoid%2520Arthritis%2520and%2520an%2520Inadequate%2520Response%2520to%2520Methotrexate%253A%2520Results%2520of%2520a%2520Phase%2520III%2520Randomised%252C%2520Double-Blind%252C%2520Placebo-Controlled%2520Trial%2520%2528RAJ4%2529%2520in%2520Japan%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2019%26volume%3D78%26spage%3D1305%26epage%3D1319%26doi%3D10.1136%2Fannrheumdis-2019-215164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, G. G.</span></span> <span> </span><span class="NLM_article-title">Comparative Efficacy and Safety of Peficitinib 25, 50, 100, and 150 mg in Patients with Active Rheumatoid Arthritis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials</span>. <i>Clin. Drug Invest.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">72</span>, <span class="refDoi"> DOI: 10.1007/s40261-019-00863-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs40261-019-00863-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31602572" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFCkt7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2020&pages=65-72&author=Y.+H.+Leeauthor=G.+G.+Song&title=Comparative+Efficacy+and+Safety+of+Peficitinib+25%2C+50%2C+100%2C+and+150+mg+in+Patients+with+Active+Rheumatoid+Arthritis%3A+A+Bayesian+Network+Meta-Analysis+of+Randomized+Controlled+Trials&doi=10.1007%2Fs40261-019-00863-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative Efficacy and Safety of Peficitinib 25, 50, 100, and 150 mg in Patients with Active Rheumatoid Arthritis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials</span></div><div class="casAuthors">Lee, Young Ho; Song, Gwan Gyu</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Drug Investigation</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">65-72</span>CODEN:
                <span class="NLM_cas:coden">CDINFR</span>;
        ISSN:<span class="NLM_cas:issn">1173-2563</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Background and Objective: Peficitinib, a JAK3-selective inhibitor that blocks the signal transduction and then suppresses immune responses, has been developed for the treatment of patients with moderate to severe active rheumatoid arthritis (RA).  We assessed the relative efficacy and safety of once-daily administration of peficitinib (a JAK3-selective inhibitor) 25 mg, 50 mg, 100 mg, and 150 mg in patients with active RA.  Methods: A Bayesian network meta-anal. was conducted to combine direct and indirect evidence from eligible randomized controlled trials (RCTs).  The literature search was performed up to May 2019 using MEDLINE, Embase, and the Cochrane Controlled Trials Register.  Results: Three RCTs involving 948 patients met the inclusion criteria.  There were ten pairwise comparisons, including five direct comparisons and five interventions.  The American College of Rheumatol. 20% (ACR20) response rate was significantly higher in the peficitinib 150-mg group than in the placebo group (odds ratio (OR): 3.61; 95% credible interval (CrI): 2.35-5.57).  Similarly, the ACR20 response rate was significantly higher in the peficitinib 100-mg group than in the placebo group (OR: 2.33, 95% CrI: 1.51-3.56).  The peficitinib 50-mg group had a significantly higher ACR20 response rate than the placebo group.  However, the ACR20 response rate was not significantly higher in the peficitinib 25-mg group than in the placebo group.  The ranking probability based on the surface under the cumulative ranking curve (SUCRA) indicated that peficitinib 150 mg was likely to achieve the best ACR20 response rate (SUCRA = 0.995), followed by peficitinib 100 mg (SUCRA = 0.696), peficitinib 50 mg (SUCRA = 0.558), peficitinib 25 mg (SUCRA = 0.153), and placebo (SUCRA = 0.098).  The ACR50 and ACR70 response rates showed a similar distribution pattern to the ACR20 response rate.  The difference in the no. of patients with adverse events (AEs) among the intervention groups was not statistically significant.  Conclusions: Peficitinib 50, 100, and 150 mg once daily was effective in treating active RA, without causing a significant risk for AEs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozk8cPRSzjSrVg90H21EOLACvtfcHk0liQUmyEhlXjfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFCkt7bK&md5=44afac47286da7a1a8c31313ab7f3151</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1007%2Fs40261-019-00863-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40261-019-00863-9%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DY.%2BH.%26aulast%3DSong%26aufirst%3DG.%2BG.%26atitle%3DComparative%2520Efficacy%2520and%2520Safety%2520of%2520Peficitinib%252025%252C%252050%252C%2520100%252C%2520and%2520150%2520mg%2520in%2520Patients%2520with%2520Active%2520Rheumatoid%2520Arthritis%253A%2520A%2520Bayesian%2520Network%2520Meta-Analysis%2520of%2520Randomized%2520Controlled%2520Trials%26jtitle%3DClin.%2520Drug%2520Invest.%26date%3D2020%26volume%3D40%26spage%3D65%26epage%3D72%26doi%3D10.1007%2Fs40261-019-00863-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, T.</span>; <span class="NLM_string-name">Tanaka, A.</span>; <span class="NLM_string-name">Nakai, K.</span>; <span class="NLM_string-name">Sasaki, H.</span>; <span class="NLM_string-name">Takahashi, F.</span>; <span class="NLM_string-name">Shirakami, S.</span>; <span class="NLM_string-name">Hatanaka, K.</span>; <span class="NLM_string-name">Nakajima, Y.</span>; <span class="NLM_string-name">Mukoyoshi, K.</span>; <span class="NLM_string-name">Hamaguchi, H.</span>; <span class="NLM_string-name">Kunikawa, S.</span>; <span class="NLM_string-name">Higashi, Y.</span></span> <span> </span><span class="NLM_article-title">Preparation of Heterocyclic Compounds as Janus Kinase 3 Inhibitors</span>. <span class="NLM_patent">WO 2007077949 A1</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=T.+Inoue&author=A.+Tanaka&author=K.+Nakai&author=H.+Sasaki&author=F.+Takahashi&author=S.+Shirakami&author=K.+Hatanaka&author=Y.+Nakajima&author=K.+Mukoyoshi&author=H.+Hamaguchi&author=S.+Kunikawa&author=Y.+Higashi&title=Preparation+of+Heterocyclic+Compounds+as+Janus+Kinase+3+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit113a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DInoue%26aufirst%3DT.%26atitle%3DPreparation%2520of%2520Heterocyclic%2520Compounds%2520as%2520Janus%2520Kinase%25203%2520Inhibitors%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit113b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Nakajima, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tojo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatanaka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirakami, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukoyoshi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamaguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moritomo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, T.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Evaluation of 1<i>H</i>-Pyrrolo[2,3-<i>b</i>]Pyridine Derivatives as Novel Immunomodulators Targeting Janus Kinase 3</span>. <i>Chem. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">341</span>– <span class="NLM_lpage">353</span>, <span class="refDoi"> DOI: 10.1248/cpb.c15-00036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1248%2Fcpb.c15-00036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=25786493" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlCns7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2015&pages=341-353&author=Y.+Nakajimaauthor=T.+Tojoauthor=M.+Moritaauthor=K.+Hatanakaauthor=S.+Shirakamiauthor=A.+Tanakaauthor=H.+Sasakiauthor=K.+Nakaiauthor=K.+Mukoyoshiauthor=H.+Hamaguchiauthor=F.+Takahashiauthor=A.+Moritomoauthor=Y.+Higashiauthor=T.+Inoue&title=Synthesis+and+Evaluation+of+1H-Pyrrolo%5B2%2C3-b%5DPyridine+Derivatives+as+Novel+Immunomodulators+Targeting+Janus+Kinase+3&doi=10.1248%2Fcpb.c15-00036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113bR"><div class="casContent"><span class="casTitleNuber">113b</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of 1H-pyrrolo[2,3-b]pyridine derivatives as novel immunomodulators targeting Janus kinase 3</span></div><div class="casAuthors">Nakajima, Yutaka; Tojo, Takashi; Morita, Masataka; Hatanaka, Keiko; Shirakami, Shohei; Tanaka, Akira; Sasaki, Hiroshi; Nakai, Kazuo; Mukoyoshi, Koichiro; Hamaguchi, Hisao; Takahashi, Fumie; Moritomo, Ayako; Higashi, Yasuyuki; Inoue, Takayuki</div><div class="citationInfo"><span class="NLM_cas:title">Chemical & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">341-353</span>CODEN:
                <span class="NLM_cas:coden">CPBTAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-2363</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">A series of 1H-pyrrolo[2,3-b]pyridine derivs. I [R = H, Me, c-Hex, Ph; R1 = NHCH(CH2CH3)2, piperidin-1-yl, ((1S,2R)-2-methylcyclohexyl)aminyl, cyclohexylaminyl, etc.] as novel immunomodulators targeting JAK3 for use in treating immune diseases such as organ transplantation has been described.  In the chem. modification of N-cyclohexyl-N-methyl-1H-pyrrolo[2,3-b]pyridin-4-amine, the introduction of a carbamoyl group to the C5-position and substitution of a cyclohexylamino group at the C4-position of the 1H-pyrrolo[2,3-b]pyridine ring led to a large increase in JAK3 inhibitory activity.  Compd. I [R = H, R1 = ((1S,2R)-2-methylcyclohexyl)aminyl] was identified as a potent, moderately selective JAK3 inhibitor, and the immunomodulating effect of I [R = H, R1 = ((1S,2R)-2-methylcyclohexyl)aminyl] on interleukin-2-stimulated T cell proliferation was shown.  Docking calcns. and WaterMap anal. of the 1H-pyrrolo[2,3-b]pyridine-5-carboxamide derivs. I were conducted to confirm the substituent effects on JAK3 inhibitory activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqu2gjDw0D-L7Vg90H21EOLACvtfcHk0liQUmyEhlXjfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlCns7rF&md5=63a1e935c4507ce9e679c94eaed58b3c</span></div><a href="/servlet/linkout?suffix=cit113b&amp;dbid=16384&amp;doi=10.1248%2Fcpb.c15-00036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fcpb.c15-00036%26sid%3Dliteratum%253Aachs%26aulast%3DNakajima%26aufirst%3DY.%26aulast%3DTojo%26aufirst%3DT.%26aulast%3DMorita%26aufirst%3DM.%26aulast%3DHatanaka%26aufirst%3DK.%26aulast%3DShirakami%26aufirst%3DS.%26aulast%3DTanaka%26aufirst%3DA.%26aulast%3DSasaki%26aufirst%3DH.%26aulast%3DNakai%26aufirst%3DK.%26aulast%3DMukoyoshi%26aufirst%3DK.%26aulast%3DHamaguchi%26aufirst%3DH.%26aulast%3DTakahashi%26aufirst%3DF.%26aulast%3DMoritomo%26aufirst%3DA.%26aulast%3DHigashi%26aufirst%3DY.%26aulast%3DInoue%26aufirst%3DT.%26atitle%3DSynthesis%2520and%2520Evaluation%2520of%25201H-Pyrrolo%255B2%252C3-b%255DPyridine%2520Derivatives%2520as%2520Novel%2520Immunomodulators%2520Targeting%2520Janus%2520Kinase%25203%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D2015%26volume%3D63%26spage%3D341%26epage%3D353%26doi%3D10.1248%2Fcpb.c15-00036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit113c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hamaguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amano, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moritomo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirakami, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakajima, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, T.</span></span> <span> </span><span class="NLM_article-title">Discovery and Structural Characterization of Peficitinib (ASP015K) as a Novel and Potent JAK Inhibitor</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">4971</span>– <span class="NLM_lpage">4983</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2018.08.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2Fj.bmc.2018.08.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=30145050" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFyktrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=4971-4983&author=H.+Hamaguchiauthor=Y.+Amanoauthor=A.+Moritomoauthor=S.+Shirakamiauthor=Y.+Nakajimaauthor=K.+Nakaiauthor=N.+Nomuraauthor=M.+Itoauthor=Y.+Higashiauthor=T.+Inoue&title=Discovery+and+Structural+Characterization+of+Peficitinib+%28ASP015K%29+as+a+Novel+and+Potent+JAK+Inhibitor&doi=10.1016%2Fj.bmc.2018.08.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113cR"><div class="casContent"><span class="casTitleNuber">113c</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and structural characterization of peficitinib (ASP015K) as a novel and potent JAK inhibitor</span></div><div class="casAuthors">Hamaguchi, Hisao; Amano, Yasushi; Moritomo, Ayako; Shirakami, Shohei; Nakajima, Yutaka; Nakai, Kazuo; Nomura, Naoko; Ito, Misato; Higashi, Yasuyuki; Inoue, Takayuki</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4971-4983</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Janus kinases (JAKs) are considered promising targets for the treatment of autoimmune diseases including rheumatoid arthritis (RA) due to their important role in multiple cytokine receptor signaling pathways.  Recently, several JAK inhibitors have been developed for the treatment of RA.  Here, the authors describe the identification of the novel orally bioavailable JAK inhibitor 18, peficitinib (also known as ASP015K), which showed moderate selectivity for JAK3 over JAK1, JAK2, and TYK2 in enzyme assays.  Chem. modification at the C4-position of lead compd. 5 led to a large increase in JAK inhibitory activity and metabolic stability in liver microsomes.  Furthermore, the authors detd. the crystal structures of JAK1, JAK2, JAK3, and TYK2 in a complex with peficitinib, and revealed that the 1H-pyrrolo[2,3-b]pyridine-5-carboxamide scaffold of peficitinib forms triple hydrogen bonds with the hinge region.  Interestingly, the binding modes of peficitinib in the ATP-binding pockets differed among JAK1, JAK2, JAK3, and TYK2.  WaterMap anal. of the crystal structures suggests that unfavorable water mols. are the likely reason for the difference in orientation of the 1H-pyrrolo[2,3-b]pyridine-5-carboxamide scaffold to the hinge region among JAKs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXmtQr-zPJgbVg90H21EOLACvtfcHk0ljZ7bkXb4eS8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFyktrnO&md5=ee50230760e7ab2300f9ccb6a42f62a8</span></div><a href="/servlet/linkout?suffix=cit113c&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2018.08.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2018.08.005%26sid%3Dliteratum%253Aachs%26aulast%3DHamaguchi%26aufirst%3DH.%26aulast%3DAmano%26aufirst%3DY.%26aulast%3DMoritomo%26aufirst%3DA.%26aulast%3DShirakami%26aufirst%3DS.%26aulast%3DNakajima%26aufirst%3DY.%26aulast%3DNakai%26aufirst%3DK.%26aulast%3DNomura%26aufirst%3DN.%26aulast%3DIto%26aufirst%3DM.%26aulast%3DHigashi%26aufirst%3DY.%26aulast%3DInoue%26aufirst%3DT.%26atitle%3DDiscovery%2520and%2520Structural%2520Characterization%2520of%2520Peficitinib%2520%2528ASP015K%2529%2520as%2520a%2520Novel%2520and%2520Potent%2520JAK%2520Inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26spage%3D4971%26epage%3D4983%26doi%3D10.1016%2Fj.bmc.2018.08.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bryan, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajapaksa, N. S.</span></span> <span> </span><span class="NLM_article-title">Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">9030</span>– <span class="NLM_lpage">9058</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00667</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00667" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVOmsLzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9030-9058&author=M.+C.+Bryanauthor=N.+S.+Rajapaksa&title=Kinase+Inhibitors+for+the+Treatment+of+Immunological+Disorders%3A+Recent+Advances&doi=10.1021%2Facs.jmedchem.8b00667"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances</span></div><div class="casAuthors">Bryan, Marian C.; Rajapaksa, Naomi S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">9030-9058</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Small mol. inhibitors targeting autoimmune and inflammatory processes have been an area of intense focus within academia and industry.  Much of this work has been aimed at key kinases operating as central nodes in inflammatory signaling pathways.  While this focus has led to over 30 FDA-approved small mol. kinase inhibitors, only one is currently approved for autoimmune and inflammatory diseases.  Despite this lack of success, there remains tremendous reason for excitement.  Our growing understanding of the biol. involved in the inflammatory response, the factors that lead to safer small mol. kinase inhibitors, and the availability of selective tool mols. for interrogating specific nodes and pathways are all pushing the field forward.  This article focuses on recent developments requiring novel approaches to create safe and effective small mol. kinase inhibitors and where further work is needed to realize the promise of small mol. kinase inhibitors for patient benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVucOE4LCJALVg90H21EOLACvtfcHk0ljZ7bkXb4eS8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVOmsLzI&md5=aff62adff54c9152d2b2156b05d67400</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00667%26sid%3Dliteratum%253Aachs%26aulast%3DBryan%26aufirst%3DM.%2BC.%26aulast%3DRajapaksa%26aufirst%3DN.%2BS.%26atitle%3DKinase%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520Immunological%2520Disorders%253A%2520Recent%2520Advances%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D9030%26epage%3D9058%26doi%3D10.1021%2Facs.jmedchem.8b00667" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duggan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keam, S. J.</span></span> <span> </span><span class="NLM_article-title">Upadacitinib: First Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">1819</span>– <span class="NLM_lpage">1828</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01211-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs40265-019-01211-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31642025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A280%3ADC%252BB3MjgvVSrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=1819-1828&author=S.+Dugganauthor=S.+J.+Keam&title=Upadacitinib%3A+First+Approval&doi=10.1007%2Fs40265-019-01211-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Upadacitinib: First Approval</span></div><div class="casAuthors">Duggan Sean; Keam Susan J</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1819-1828</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Upadacitinib (Rinvoq®), an orally-administered Janus kinase 1 (JAK-1) inhibitor, is being developed by AbbVie for the treatment of rheumatoid arthritis.  In August 2019, based on positive results from multinational phase III trials conducted in patients with rheumatoid arthritis, upadacitinib received marketing approval in the USA for the treatment of moderately to severely active rheumatoid arthritis and an inadequate response or intolerance to methotrexate.  This article summarizes the milestones in the development of upadacitinib leading to this first approval for the treatment of rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRfxtr5CsQWZxWfpMXQLRstfW6udTcc2eZDvd4QXKOD87ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MjgvVSrtg%253D%253D&md5=3ef93907bbec16e744d0fb2b6dae65e0</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01211-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01211-z%26sid%3Dliteratum%253Aachs%26aulast%3DDuggan%26aufirst%3DS.%26aulast%3DKeam%26aufirst%3DS.%2BJ.%26atitle%3DUpadacitinib%253A%2520First%2520Approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D1819%26epage%3D1828%26doi%3D10.1007%2Fs40265-019-01211-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matteson, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murad, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vassallo, R.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety of Tofacitinib, Baricitinib, and Upadacitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis</span>. <i>Mayo Clin. Proc.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">P1404</span>– <span class="NLM_lpage">P1419</span>, <span class="refDoi"> DOI: 10.1016/j.mayocp.2020.01.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2Fj.mayocp.2020.01.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=32499126" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BB3cXksVyhur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2020&pages=P1404-P1419&author=F.+Wangauthor=L.+Sunauthor=S.+Wangauthor=J.+M.+Davisauthor=E.+L.+Mattesonauthor=M.+H.+Muradauthor=F.+Luoauthor=R.+Vassallo&title=Efficacy+and+Safety+of+Tofacitinib%2C+Baricitinib%2C+and+Upadacitinib+for+Rheumatoid+Arthritis%3A+A+Systematic+Review+and+Meta-Analysis&doi=10.1016%2Fj.mayocp.2020.01.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and Safety of Tofacitinib, Baricitinib, and Upadacitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis</span></div><div class="casAuthors">Wang, Faping; Sun, Ling; Wang, Shaohua; Davis, John M., III; Matteson, Eric L.; Murad, M. Hassan; Luo, Fengming; Vassallo, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Mayo Clinic Proceedings</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1404-1419</span>CODEN:
                <span class="NLM_cas:coden">MACPAJ</span>;
        ISSN:<span class="NLM_cas:issn">0025-6196</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Meta-Anal.  To assess the efficacy and safety profiles of different dosing regimens of tofacitinib, baricitinib, and upadacitinib, novel selective oral Janus activated kinase inhibitors, in rheumatoid arthritis (RA).Randomized controlled trials of tofacitinib (5 and 10 mg twice daily) baricitinib (2 and 4 mg daily), and upadacitinib (15 and 30 mg daily) in RA were identified from MEDLINE, EMBASE, and Cochrane databases through Dec. 11, 2019.  Random-effects models were used to est. pooled mean differences and relative risks (RRs).  American College of Rheumatol. 20%, Health Assessment Questionnaire-Disability Index, adverse events, risk for infection, venous thromboembolic events, and malignancy were calcd.Twenty trials with an overall low risk of bias involving 8982 patients were identified.  Tofacitinib, baricitinib, and upadacitinib improved RA control as detd. by American College of Rheumatol. 20% (RR, 2.03; 95% CI, 1.87 to 2.20) and Health Assessment Questionnaire-Disability Index scores (mean differences, -0.31; 95% CI, -0.34 to -0.28) compared with placebo.  Data for venous thromboembolic events were not available for tofacitinib or baricitinib, but there was no increase in risk with upadacitinib (15 mg daily: RR, 2.34; 95% CI, 0.34 to 15.92).Tofacitinib, baricitinib, and upadacitinib significantly improve RA control.  Head-to-head Janus activated kinase inhibitor clin. trials are needed to further inform decision making.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPUHOp3UYN_7Vg90H21EOLACvtfcHk0lic7QpN-NMHVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXksVyhur4%253D&md5=6c9a72b336492abe2fb16e80384b3a66</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1016%2Fj.mayocp.2020.01.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mayocp.2020.01.039%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DF.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DDavis%26aufirst%3DJ.%2BM.%26aulast%3DMatteson%26aufirst%3DE.%2BL.%26aulast%3DMurad%26aufirst%3DM.%2BH.%26aulast%3DLuo%26aufirst%3DF.%26aulast%3DVassallo%26aufirst%3DR.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Tofacitinib%252C%2520Baricitinib%252C%2520and%2520Upadacitinib%2520for%2520Rheumatoid%2520Arthritis%253A%2520A%2520Systematic%2520Review%2520and%2520Meta-Analysis%26jtitle%3DMayo%2520Clin.%2520Proc.%26date%3D2020%26volume%3D95%26spage%3DP1404%26epage%3DP1419%26doi%3D10.1016%2Fj.mayocp.2020.01.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211675s000lbl.pdf" class="extLink">https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211675s000lbl.pdf</a> (accessed 2020-09-15).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2019%2F211675s000lbl.pdf+%28accessed+2020-09-15%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parmentier, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graff, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argiriadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camp, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padley, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyland, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosebraugh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wishart, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, A. J.</span></span> <span> </span><span class="NLM_article-title">In Vitro and in Vivo Characterization of the JAK1 Selectivity of Upadacitinib (ABT-494)</span>. <i>BMC Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">23</span>, <span class="refDoi"> DOI: 10.1186/s41927-018-0031-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1186%2Fs41927-018-0031-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=30886973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A280%3ADC%252BB3cbls1ymuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2018&pages=23&author=J.+M.+Parmentierauthor=J.+Vossauthor=C.+Graffauthor=A.+Schwartzauthor=M.+Argiriadiauthor=M.+Friedmanauthor=H.+S.+Campauthor=R.+J.+Padleyauthor=J.+S.+Georgeauthor=D.+Hylandauthor=M.+Rosebraughauthor=N.+Wishartauthor=L.+Olsonauthor=A.+J.+Long&title=In+Vitro+and+in+Vivo+Characterization+of+the+JAK1+Selectivity+of+Upadacitinib+%28ABT-494%29&doi=10.1186%2Fs41927-018-0031-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)</span></div><div class="casAuthors">Parmentier Julie M; Voss Jeff; Graff Candace; Schwartz Annette; Argiriadi Maria; Friedman Michael; George Jonathan S; Hyland Deborah; Wishart Neil; Olson Lisa; Long Andrew J; Camp Heidi S; Padley Robert J; Rosebraugh Matthew</div><div class="citationInfo"><span class="NLM_cas:title">BMC rheumatology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">23</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Background:  Anti-cytokine therapies such as adalimumab, tocilizumab, and the small molecule JAK inhibitor tofacitinib have proven that cytokines and their subsequent downstream signaling processes are important in the pathogenesis of rheumatoid arthritis.  Tofacitinib, a pan-JAK inhibitor, is the first approved JAK inhibitor for the treatment of RA and has been shown to be effective in managing disease.  However, in phase 2 dose-ranging studies tofacitinib was associated with dose-limiting tolerability and safety issues such as anemia.  Upadacitinib (ABT-494) is a selective JAK1 inhibitor that was engineered to address the hypothesis that greater JAK1 selectivity over other JAK family members will translate into a more favorable benefit:risk profile.  Upadacitinib selectively targets JAK1 dependent disease drivers such as IL-6 and IFNγ, while reducing effects on reticulocytes and natural killer (NK) cells, which potentially contributed to the tolerability issues of tofacitinib.  Methods:  Structure-based hypotheses were used to design the JAK1 selective inhibitor upadacitinib.  JAK family selectivity was defined with in vitro assays including biochemical assessments, engineered cell lines, and cytokine stimulation.  In vivo selectivity was defined by the efficacy of upadacitinib and tofacitinib in a rat adjuvant induced arthritis model, activity on reticulocyte deployment, and effect on circulating NK cells.  The translation of the preclinical JAK1 selectivity was assessed in healthy volunteers using ex vivo stimulation with JAK-dependent cytokines.  Results:  Here, we show the structural basis for the JAK1 selectivity of upadacitinib, along with the in vitro JAK family selectivity profile and subsequent in vivo physiological consequences.  Upadacitinib is ~ 60 fold selective for JAK1 over JAK2, and > 100 fold selective over JAK3 in cellular assays.  While both upadacitinib and tofacitinib demonstrated efficacy in a rat model of arthritis, the increased selectivity of upadacitinib for JAK1 resulted in a reduced effect on reticulocyte deployment and NK cell depletion relative to efficacy.  Ex vivo pharmacodynamic data obtained from Phase I healthy volunteers confirmed the JAK1 selectivity of upadactinib in a clinical setting.  Conclusions:  The data presented here highlight the JAK1 selectivity of upadacinitinib and supports its use as an effective therapy for the treatment of RA with the potential for an improved benefit:risk profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRTVFFxllNWaxfKb6ELK8t0fW6udTcc2eYDSW3heUDJ87ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbls1ymuw%253D%253D&md5=5ca2dcb18a98362567d2193e858cc800</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1186%2Fs41927-018-0031-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs41927-018-0031-x%26sid%3Dliteratum%253Aachs%26aulast%3DParmentier%26aufirst%3DJ.%2BM.%26aulast%3DVoss%26aufirst%3DJ.%26aulast%3DGraff%26aufirst%3DC.%26aulast%3DSchwartz%26aufirst%3DA.%26aulast%3DArgiriadi%26aufirst%3DM.%26aulast%3DFriedman%26aufirst%3DM.%26aulast%3DCamp%26aufirst%3DH.%2BS.%26aulast%3DPadley%26aufirst%3DR.%2BJ.%26aulast%3DGeorge%26aufirst%3DJ.%2BS.%26aulast%3DHyland%26aufirst%3DD.%26aulast%3DRosebraugh%26aufirst%3DM.%26aulast%3DWishart%26aufirst%3DN.%26aulast%3DOlson%26aufirst%3DL.%26aulast%3DLong%26aufirst%3DA.%2BJ.%26atitle%3DIn%2520Vitro%2520and%2520in%2520Vivo%2520Characterization%2520of%2520the%2520JAK1%2520Selectivity%2520of%2520Upadacitinib%2520%2528ABT-494%2529%26jtitle%3DBMC%2520Rheumatol.%26date%3D2018%26volume%3D2%26spage%3D23%26doi%3D10.1186%2Fs41927-018-0031-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Allian, A.</span>; <span class="NLM_string-name">Jayanth, J.</span>; <span class="NLM_string-name">Mohamed, M.-E.</span>; <span class="NLM_string-name">Mulhern, M.</span>; <span class="NLM_string-name">Nordstroem, L. F.</span>; <span class="NLM_string-name">Othman, A.</span>; <span class="NLM_string-name">Rozema, M.</span>; <span class="NLM_string-name">Bhagavatula, L.</span>; <span class="NLM_string-name">Marroum, P. J.</span>; <span class="NLM_string-name">Mayer, P. T.</span></span> <span> </span><span class="NLM_article-title">Processes for the preparation of (3<i>S</i>,4<i>R</i>)-3-ethyl-4-(3<i>H</i>-imidazo[1,2-<i>a</i>]pyrrolo[2,3-<i>e</i>]-pyrazin-8-yl)-<i>N</i>-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof</span>. <span class="NLM_patent">WO 2017066775 A1</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=A.+Allian&author=J.+Jayanth&author=M.-E.+Mohamed&author=M.+Mulhern&author=L.+F.+Nordstroem&author=A.+Othman&author=M.+Rozema&author=L.+Bhagavatula&author=P.+J.+Marroum&author=P.+T.+Mayer&title=Processes+for+the+preparation+of+%283S%2C4R%29-3-ethyl-4-%283H-imidazo%5B1%2C2-a%5Dpyrrolo%5B2%2C3-e%5D-pyrazin-8-yl%29-N-%282%2C2%2C2-trifluoroethyl%29pyrrolidine-1-carboxamide+and+solid+state+forms+thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAllian%26aufirst%3DA.%26atitle%3DProcesses%2520for%2520the%2520preparation%2520of%2520%25283S%252C4R%2529-3-ethyl-4-%25283H-imidazo%255B1%252C2-a%255Dpyrrolo%255B2%252C3-e%255D-pyrazin-8-yl%2529-N-%25282%252C2%252C2-trifluoroethyl%2529pyrrolidine-1-carboxamide%2520and%2520solid%2520state%2520forms%2520thereof%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Larock, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yum, E. K.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Indoles Via Palladium-Catalyzed Heteroannulation of Internal Alkynes</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">6689</span>– <span class="NLM_lpage">6690</span>, <span class="refDoi"> DOI: 10.1021/ja00017a059</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja00017a059" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADyaK3MXkvFajsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=1991&pages=6689-6690&author=R.+C.+Larockauthor=E.+K.+Yum&title=Synthesis+of+Indoles+Via+Palladium-Catalyzed+Heteroannulation+of+Internal+Alkynes&doi=10.1021%2Fja00017a059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of indoles via palladium-catalyzed heteroannulation of internal alkynes</span></div><div class="casAuthors">Larock, Richard C.; Yum, Eul Kgun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6689-90</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">2,3-Disubstituted indoles are formed in high yields by the Pd-catalyzed annulation of internal alkynes by o-IC6H4NH2 and its derivs.  The reaction is highly regioselective and tolerates alkynes bearing aryl, alc. and silyl groups, as well as C:C bonds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJ_hHxDmTHKLVg90H21EOLACvtfcHk0lhlozyTWx74hQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXkvFajsrs%253D&md5=498dd4febb8eba7e5903cd02b9258a16</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1021%2Fja00017a059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00017a059%26sid%3Dliteratum%253Aachs%26aulast%3DLarock%26aufirst%3DR.%2BC.%26aulast%3DYum%26aufirst%3DE.%2BK.%26atitle%3DSynthesis%2520of%2520Indoles%2520Via%2520Palladium-Catalyzed%2520Heteroannulation%2520of%2520Internal%2520Alkynes%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1991%26volume%3D113%26spage%3D6689%26epage%3D6690%26doi%3D10.1021%2Fja00017a059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van Epps, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiamengo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edmunds, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ericsson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frank, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goedken, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotecki, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morytko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shekhar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skinner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wishart, N.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Tricyclic Cores for Kinase Inhibition</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">693</span>– <span class="NLM_lpage">698</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.11.108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2Fj.bmcl.2012.11.108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=23265875" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVyiurbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=693-698&author=S.+Van+Eppsauthor=B.+Fiamengoauthor=J.+Edmundsauthor=A.+Ericssonauthor=K.+Frankauthor=M.+Friedmanauthor=D.+Georgeauthor=J.+Georgeauthor=E.+Goedkenauthor=B.+Koteckiauthor=G.+Martinezauthor=P.+Mertaauthor=M.+Morytkoauthor=S.+Shekharauthor=B.+Skinnerauthor=K.+Stewartauthor=J.+Vossauthor=G.+Wallaceauthor=L.+Wangauthor=L.+Wangauthor=N.+Wishart&title=Design+and+Synthesis+of+Tricyclic+Cores+for+Kinase+Inhibition&doi=10.1016%2Fj.bmcl.2012.11.108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of tricyclic cores for kinase inhibition</span></div><div class="casAuthors">Van Epps, Stacy; Fiamengo, Bryan; Edmunds, Jeremy; Ericsson, Anna; Frank, Kristine; Friedman, Michael; George, Dawn; George, Jonathan; Goedken, Eric; Kotecki, Brian; Martinez, Gloria; Merta, Philip; Morytko, Michael; Shekhar, Shashank; Skinner, Barbara; Stewart, Kent; Voss, Jeffrey; Wallace, Grier; Wang, Lu; Wishart, Neil</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">693-698</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Interest in therapeutic kinase inhibitors continues to grow beyond success in oncol.  To date, ATP-mimetic kinase inhibitors have focused primarily on monocyclic and bicyclic heterocyclic cores.  We sought to expand on the repertoire of potential cores for kinase inhibition by exploring tricyclic variants of classical bicyclic hinge binding motifs such as pyrrolopyridine and pyrrolopyrazine.  Herein we describe the syntheses of eight alternative tricyclic cores as well as in vitro screening results for representative kinases of potential therapeutic interest.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpw43t_VvXMbbVg90H21EOLACvtfcHk0lhlozyTWx74hQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVyiurbJ&md5=59cb993b841a73569309f0fca703b4c4</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.11.108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.11.108%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BEpps%26aufirst%3DS.%26aulast%3DFiamengo%26aufirst%3DB.%26aulast%3DEdmunds%26aufirst%3DJ.%26aulast%3DEricsson%26aufirst%3DA.%26aulast%3DFrank%26aufirst%3DK.%26aulast%3DFriedman%26aufirst%3DM.%26aulast%3DGeorge%26aufirst%3DD.%26aulast%3DGeorge%26aufirst%3DJ.%26aulast%3DGoedken%26aufirst%3DE.%26aulast%3DKotecki%26aufirst%3DB.%26aulast%3DMartinez%26aufirst%3DG.%26aulast%3DMerta%26aufirst%3DP.%26aulast%3DMorytko%26aufirst%3DM.%26aulast%3DShekhar%26aufirst%3DS.%26aulast%3DSkinner%26aufirst%3DB.%26aulast%3DStewart%26aufirst%3DK.%26aulast%3DVoss%26aufirst%3DJ.%26aulast%3DWallace%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWishart%26aufirst%3DN.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Tricyclic%2520Cores%2520for%2520Kinase%2520Inhibition%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D693%26epage%3D698%26doi%3D10.1016%2Fj.bmcl.2012.11.108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schaefer, J. P.</span>; <span class="NLM_string-name">Bloomfield, J. J.</span></span> <span> </span><span class="NLM_article-title">The Dieckmann Condensation (Including the Thorpe-Ziegler Condensation)</span>. In  <i>Organic Reactions</i>; <span class="NLM_publisher-name">John Wiley & Sons</span>: <span class="NLM_publisher-loc">Somerset, NJ</span>, <span class="NLM_year">2011</span>; pp  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">203</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1002%2F0471264180.or015.01" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&pages=1-203&author=J.+P.+Schaefer&author=J.+J.+Bloomfield&title=Organic+Reactions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1002%2F0471264180.or015.01&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F0471264180.or015.01%26sid%3Dliteratum%253Aachs%26aulast%3DSchaefer%26aufirst%3DJ.%2BP.%26atitle%3DThe%2520Dieckmann%2520Condensation%2520%2528Including%2520the%2520Thorpe-Ziegler%2520Condensation%2529%26btitle%3DOrganic%2520Reactions%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%26date%3D2011%26spage%3D1%26epage%3D203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tellers, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McWilliams, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphrey, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Journet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMichele, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinksmon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKeown, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tillyer, R. D.</span></span> <span> </span><span class="NLM_article-title">On the Mechanism of an Asymmetric α,β-Unsaturated Carboxylic Acid Hydrogenation: Application to the Synthesis of a PGD2 Receptor Antagonist</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">17063</span>– <span class="NLM_lpage">17073</span>, <span class="refDoi"> DOI: 10.1021/ja0623358</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja0623358" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht12ls7nF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2006&pages=17063-17073&author=D.+M.+Tellersauthor=J.+C.+McWilliamsauthor=G.+Humphreyauthor=M.+Journetauthor=L.+DiMicheleauthor=J.+Hinksmonauthor=A.+E.+McKeownauthor=T.+Rosnerauthor=Y.+Sunauthor=R.+D.+Tillyer&title=On+the+Mechanism+of+an+Asymmetric+%CE%B1%2C%CE%B2-Unsaturated+Carboxylic+Acid+Hydrogenation%3A+Application+to+the+Synthesis+of+a+PGD2+Receptor+Antagonist&doi=10.1021%2Fja0623358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">On the Mechanism of an Asymmetric α,β-Unsaturated Carboxylic Acid Hydrogenation: Application to the Synthesis of a PGD2 Receptor Antagonist</span></div><div class="casAuthors">Tellers, David M.; McWilliams, J. Christopher; Humphrey, Guy; Journet, Michel; DiMichele, Lisa; Hinksmon, Joseph; McKeown, Arlene E.; Rosner, Thorsten; Sun, Yongkui; Tillyer, Richard D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">17063-17073</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Ruthenium complexes employing axially chiral ligands were found to be effective asym. hydrogenation catalysts for the redn. of α,β-unsatd. ene acid I to give II, a prostaglandin D2 (PGD2) receptor antagonist.  With [(S-BINAP)Ru(p-cymene)Cl2]2 (III, S-BINAP = (S)-(+)-2,2'-bis(diphenylphospino)-1,1'-binaphthyl), it was discovered that low hydrogen pressures (<30 psi) were essential to achieve high enantioselectivities (92% ee).  A detailed mechanistic study was undertaken to elucidate this pressure dependence.  It was detd. that compd. I is in a ruthenium-catalyzed equil. with endocyclic isomer IV and in photochem. equil. with the Z isomer.  Each isomer could be hydrogenated to give II, albeit with different rates and enantioselectivities.  Hydrogenation of IV with III was found to give II in high enantiomeric excess, regardless of pressure and at a rate substantially faster than that of hydrogenation of I and its Z-isomer.  In contrast, isomers I and the Z-isomer exhibited pressure-dependent enantioselectivities, with higher enantiomeric excesses obtained at lower pressures.  A rationale for this pressure dependence is described.  Deuterium labeling studies with IV and tiglic acid were used to elucidate the mechanism of hydride insertion and product release from ruthenium.  Under neutral conditions, protonolysis was the major pathway for metal-carbon cleavage, while under basic conditions, hydrogenolysis of the metal-carbon bond was predominant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoK672H_nH_e7Vg90H21EOLACvtfcHk0lhlozyTWx74hQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht12ls7nF&md5=772b115c9de846aa8b33bebe0c70d6da</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1021%2Fja0623358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja0623358%26sid%3Dliteratum%253Aachs%26aulast%3DTellers%26aufirst%3DD.%2BM.%26aulast%3DMcWilliams%26aufirst%3DJ.%2BC.%26aulast%3DHumphrey%26aufirst%3DG.%26aulast%3DJournet%26aufirst%3DM.%26aulast%3DDiMichele%26aufirst%3DL.%26aulast%3DHinksmon%26aufirst%3DJ.%26aulast%3DMcKeown%26aufirst%3DA.%2BE.%26aulast%3DRosner%26aufirst%3DT.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DTillyer%26aufirst%3DR.%2BD.%26atitle%3DOn%2520the%2520Mechanism%2520of%2520an%2520Asymmetric%2520%25CE%25B1%252C%25CE%25B2-Unsaturated%2520Carboxylic%2520Acid%2520Hydrogenation%253A%2520Application%2520to%2520the%2520Synthesis%2520of%2520a%2520PGD2%2520Receptor%2520Antagonist%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2006%26volume%3D128%26spage%3D17063%26epage%3D17073%26doi%3D10.1021%2Fja0623358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Corey, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaykovsky, M.</span></span> <span> </span><span class="NLM_article-title">Dimethylsulfoxonium Methylide</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1962</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">867</span>– <span class="NLM_lpage">868</span>, <span class="refDoi"> DOI: 10.1021/ja00864a040</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja00864a040" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADyaF38XktVelt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=1962&pages=867-868&author=E.+J.+Coreyauthor=M.+Chaykovsky&title=Dimethylsulfoxonium+Methylide&doi=10.1021%2Fja00864a040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Dimethylsulfoxonium methylide</span></div><div class="casAuthors">Corey, E. J.; Chaykovsky, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1962</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">867-8</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">Solns. of the title compd., Me2S(O)CH2 (I), were prepd. by adding 1 equiv. of powd. NaH to Me3SOCl in Me2SO at room temp.  I reacts with Ph2CO, BzH, 4-phenylcyclohexanone, and cycloheptanone to produce the corresponding methylene epoxide in 90, 56, 72, and 71% yield, resp.  PhCH2COPh and 4-cholestenone are not attacked by I.  PhCH:CHBz and I react to form 95% 2-phenyl-2-benzoylcyclopropane.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKJ5faQzZazLVg90H21EOLACvtfcHk0lhialzBrgUfGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF38XktVelt7w%253D&md5=a0a1b8481c8c59335084926338965f50</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1021%2Fja00864a040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00864a040%26sid%3Dliteratum%253Aachs%26aulast%3DCorey%26aufirst%3DE.%2BJ.%26aulast%3DChaykovsky%26aufirst%3DM.%26atitle%3DDimethylsulfoxonium%2520Methylide%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1962%26volume%3D84%26spage%3D867%26epage%3D868%26doi%3D10.1021%2Fja00864a040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span> <span> </span><span class="NLM_article-title">Remogliflozin Etabonate: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">1157</span>– <span class="NLM_lpage">1161</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01150-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs40265-019-01150-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31201711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFyisrjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=1157-1161&author=A.+Markham&title=Remogliflozin+Etabonate%3A+First+Global+Approval&doi=10.1007%2Fs40265-019-01150-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Remogliflozin Etabonate: First Global Approval</span></div><div class="casAuthors">Markham, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1157-1161</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Remogliflozin, a selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor, which is to be administered as remogliflozin etabonate (Remo, Remozen), the prodrug for remogliflozin, recently received its first approval as a treatment for type 2 diabetes mellitus (T2DM) in India.  This article summarizes the milestones in the development of remogliflozin etabonate leading to this first approval for T2DM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0u5UfapE0prVg90H21EOLACvtfcHk0lhialzBrgUfGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFyisrjP&md5=d599b50ff2c1d3131e7d3dbbc2ce663f</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01150-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01150-9%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26atitle%3DRemogliflozin%2520Etabonate%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D1157%26epage%3D1161%26doi%3D10.1007%2Fs40265-019-01150-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mikhail, N.</span></span> <span> </span><span class="NLM_article-title">Remogliflozin Etabonate: A Novel SGLT2 Inhibitor for Treatment of Diabetes Mellitus</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1381</span>– <span class="NLM_lpage">1387</span>, <span class="refDoi"> DOI: 10.1517/13543784.2015.1061501</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1517%2F13543784.2015.1061501" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=26288025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslWgsrrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2015&pages=1381-1387&author=N.+Mikhail&title=Remogliflozin+Etabonate%3A+A+Novel+SGLT2+Inhibitor+for+Treatment+of+Diabetes+Mellitus&doi=10.1517%2F13543784.2015.1061501"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Remogliflozin etabonate: a novel SGLT2 inhibitor for treatment of diabetes mellitus</span></div><div class="casAuthors">Mikhail, Nasser</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1381-1387</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Inhibitors of sodium-glucose co-transporter type 2 (SGLT2) represent a new class of anti-hyperglycemic agents with a unique mechanism of action.  These drugs lower blood glucose by increasing urinary glucose excretion.  Remogliflozin etabonate (RE) is a prodrug of remogliflozin, an SGLT2 inhibitor under development.  The following article reviews all of the clin. studies published regarding metab., drug interaction, safety and efficacy of RE in healthy subjects, patients with type 1 and type 2 diabetes.  Available data suggest low potential for RE to interact with other drugs affecting the P 450 system.  Compared with placebo, RE reduces Hb A1c (HbA1c) levels by an av. of 0.5 - 1.0% after 12 wk of therapy in drug-naive patients with type 2 diabetes.  Because of its relatively short half-life, RE may be slightly more effective when used twice daily than once daily.  One preliminary study also showed that RE decreased plasma glucose levels in type 1 diabetes.  Advantages of RE include modest wt. loss of ∼ 2 kg, low risk of hypoglycemia, and a trend toward decrease in blood pressure.  The commonest adverse effects of RE are genital mycotic infections, urinary tract infections, and dizziness.  However, further studies are needed to establish its long-term safety and efficacy, and to det. whether it has specific advantages over currently approved SGLT2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXbRYZ1I__ILVg90H21EOLACvtfcHk0lhialzBrgUfGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslWgsrrJ&md5=f32c67db6d483a6328b1828fc35d0c7b</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1517%2F13543784.2015.1061501&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2015.1061501%26sid%3Dliteratum%253Aachs%26aulast%3DMikhail%26aufirst%3DN.%26atitle%3DRemogliflozin%2520Etabonate%253A%2520A%2520Novel%2520SGLT2%2520Inhibitor%2520for%2520Treatment%2520of%2520Diabetes%2520Mellitus%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2015%26volume%3D24%26spage%3D1381%26epage%3D1387%26doi%3D10.1517%2F13543784.2015.1061501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dash, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babu, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivas, N. R.</span></span> <span> </span><span class="NLM_article-title">Comparative Pharmacokinetics of Three SGLT-2 Inhibitors Sergliflozin, Remogliflozin and Ertugliflozin: An Overview</span>. <i>Xenobiotica</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">1015</span>– <span class="NLM_lpage">1026</span>, <span class="refDoi"> DOI: 10.1080/00498254.2016.1247219</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1080%2F00498254.2016.1247219" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=27718782" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslGqsL3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2017&pages=1015-1026&author=R.+P.+Dashauthor=R.+J.+Babuauthor=N.+R.+Srinivas&title=Comparative+Pharmacokinetics+of+Three+SGLT-2+Inhibitors+Sergliflozin%2C+Remogliflozin+and+Ertugliflozin%3A+An+Overview&doi=10.1080%2F00498254.2016.1247219"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative pharmacokinetics of three SGLT-2 inhibitors sergliflozin, remogliflozin and ertugliflozin: an overview</span></div><div class="casAuthors">Dash, Ranjeet Prasad; Babu, R. Jayachandra; Srinivas, Nuggehally R.</div><div class="citationInfo"><span class="NLM_cas:title">Xenobiotica</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1015-1026</span>CODEN:
                <span class="NLM_cas:coden">XENOBH</span>;
        ISSN:<span class="NLM_cas:issn">0049-8254</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">1. Several sodium-glucose cotransporter-2 (SGLT-2) inhibitors are in clin. use for the management of type 2 diabetes.  The objectives of the current review were: (a) to provide a comparative pharmacokinetics including absorption, distribution, metab. and excretory (ADME) profiles of three SGLT-2 inhibitors namely: sergliflozin, remogliflozin and ertugliflozin; (b) to provide some perspectives on possible developmental issues.2.  Based on the half-life (t1/2) values obsd. in humans, the rank order of the three SGLT-2 inhibitors was ertugliflozin (16 h) > remogliflozin (2-4 h) > sergliflozin (1-1.5 h).  Therefore, while once a day dosing of ertugliflozin is possible, the other two drugs need to be dosed more frequently.  Perhaps, the short t1/2 of sergliflozin may have contributed for its discontinuation.3.  Although there was paucity of published data on the metab., transporter related and excretory aspects for sergliflozin, the other two drugs provided a differentiating profile.  However, the compiled data suggested that there may be a minimal or no risk of pharmacokinetic drug interaction issues assocd. with any of the reviewed drugs.4.  Because of the crowded development pipeline and approved SGLT-2 inhibitors, the safety and efficacy of sergliflozin, remogliflozin and ertugliflozin appear to be a key from differentiation perspective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxS-KdVFfEk7Vg90H21EOLACvtfcHk0lheJsP651Yvyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslGqsL3M&md5=5e2b9d9c4505757ebf79ab6328982091</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1080%2F00498254.2016.1247219&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00498254.2016.1247219%26sid%3Dliteratum%253Aachs%26aulast%3DDash%26aufirst%3DR.%2BP.%26aulast%3DBabu%26aufirst%3DR.%2BJ.%26aulast%3DSrinivas%26aufirst%3DN.%2BR.%26atitle%3DComparative%2520Pharmacokinetics%2520of%2520Three%2520SGLT-2%2520Inhibitors%2520Sergliflozin%252C%2520Remogliflozin%2520and%2520Ertugliflozin%253A%2520An%2520Overview%26jtitle%3DXenobiotica%26date%3D2017%26volume%3D47%26spage%3D1015%26epage%3D1026%26doi%3D10.1080%2F00498254.2016.1247219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sigafoos, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowers, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castellino, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Culp, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reese, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphreys, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussey, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor Semmes, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobbins, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polli, J. W.</span></span> <span> </span><span class="NLM_article-title">Assessment of the Drug Interaction Risk for Remogliflozin Etabonate, a Sodium-Dependent Glucose Cotransporter-2 Inhibitor: Evidence from <i>in Vitro</i>, Human Mass Balance, and Ketoconazole Interaction Studies</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">2090</span>– <span class="NLM_lpage">2101</span>, <span class="refDoi"> DOI: 10.1124/dmd.112.047258</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1124%2Fdmd.112.047258" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=22851617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFKkt73L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=2090-2101&author=J.+F.+Sigafoosauthor=G.+D.+Bowersauthor=S.+Castellinoauthor=A.+G.+Culpauthor=D.+S.+Wagnerauthor=M.+J.+Reeseauthor=J.+E.+Humphreysauthor=E.+K.+Husseyauthor=R.+L.+O%E2%80%99Connor+Semmesauthor=A.+Kapurauthor=W.+Taoauthor=R.+L.+Dobbinsauthor=J.+W.+Polli&title=Assessment+of+the+Drug+Interaction+Risk+for+Remogliflozin+Etabonate%2C+a+Sodium-Dependent+Glucose+Cotransporter-2+Inhibitor%3A+Evidence+from+in+Vitro%2C+Human+Mass+Balance%2C+and+Ketoconazole+Interaction+Studies&doi=10.1124%2Fdmd.112.047258"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Assessment of the drug interaction risk for remogliflozin etabonate, a sodium-dependent glucose cotransporter-2 inhibitor: evidence from in vitro, human mass balance, and ketoconazole interaction studies</span></div><div class="casAuthors">Sigafoos, James F.; Bowers, Gary D.; Castellino, Stephen; Culp, Amanda G.; Wagner, David S.; Reese, Melinda J.; Humphreys, Joan E.; Hussey, Elizabeth K.; Semmes, Robin L. O'Connor; Kapur, Anita; Tao, Wenli; Dobbins, Robert L.; Polli, Joseph W.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2090-2101</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Remogliflozin etabonate is the ester prodrug of remogliflozin, a selective sodium-dependent glucose cotransporter-2 inhibitor.  This work investigated the absorption, metab., and excretion of [14C]remogliflozin etabonate in humans, as well as the influence of P-glycoprotein (Pgp) and cytochrome P 450 (P 450) enzymes on the disposition of remogliflozin etabonate and its metabolites to understand the risks for drug interactions.  After a single oral 402 ± 1.0 mg (106 ± 0.3 μCi) dose, [14C]remogliflozin etabonate is rapidly absorbed and extensively metabolized.  The area under the concn.-time curve from 0 to infinity [AUC(0-∞)] of plasma radioactivity was approx. 14-fold higher than the sum of the AUC(0-∞) of remogliflozin etabonate, remogliflozin, and 5-methyl-4-({4-[(1-methylethyl)oxy]phenyl}methyl)-1H-pyrazol-3-yl-β-D-glucopyranoside (GSK279782), a pharmacol. active N-dealkylated metabolite.  Elimination half-lives of total radioactivity, remogliflozin etabonate, and remogliflozin were 6.57, 0.39, and 1.57 h, resp.  Products of remogliflozin etabonate metab. are eliminated primarily via renal excretion, with 92.8% of the dose recovered in the urine.  Three glucuronide metabolites made up the majority of the radioactivity in plasma and represent 67.1% of the dose in urine, with 5-methyl-1-(1-methylethyl)-4-({4-[(1-methylethyl)oxy]phenyl}methyl)-1H-pyrazol-3-yl-β-D-glucopyranosiduronic acid (GSK1997711) representing 47.8% of the dose.  In vitro studies demonstrated that remogliflozin etabonate and remogliflozin are Pgp substrates, and that CYP3A4 can form GSK279782 directly from remogliflozin.  A ketoconazole clin. drug interaction study, along with the human mass balance findings, confirmed that CYP3A4 contributes less than 50% to remogliflozin metab., demonstrating that other enzyme pathways (e.g., P450s, UDP-glucuronosyltransferases, and glucosidases) make significant contributions to the drug's clearance.  Overall, these studies support a low clin. drug interaction risk for remogliflozin etabonate due to the availability of multiple biotransformation pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoCS5ji1GnebVg90H21EOLACvtfcHk0lheJsP651Yvyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFKkt73L&md5=e416fe362dec69d516bc6dee55988d92</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1124%2Fdmd.112.047258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.112.047258%26sid%3Dliteratum%253Aachs%26aulast%3DSigafoos%26aufirst%3DJ.%2BF.%26aulast%3DBowers%26aufirst%3DG.%2BD.%26aulast%3DCastellino%26aufirst%3DS.%26aulast%3DCulp%26aufirst%3DA.%2BG.%26aulast%3DWagner%26aufirst%3DD.%2BS.%26aulast%3DReese%26aufirst%3DM.%2BJ.%26aulast%3DHumphreys%26aufirst%3DJ.%2BE.%26aulast%3DHussey%26aufirst%3DE.%2BK.%26aulast%3DO%25E2%2580%2599Connor%2BSemmes%26aufirst%3DR.%2BL.%26aulast%3DKapur%26aufirst%3DA.%26aulast%3DTao%26aufirst%3DW.%26aulast%3DDobbins%26aufirst%3DR.%2BL.%26aulast%3DPolli%26aufirst%3DJ.%2BW.%26atitle%3DAssessment%2520of%2520the%2520Drug%2520Interaction%2520Risk%2520for%2520Remogliflozin%2520Etabonate%252C%2520a%2520Sodium-Dependent%2520Glucose%2520Cotransporter-2%2520Inhibitor%253A%2520Evidence%2520from%2520in%2520Vitro%252C%2520Human%2520Mass%2520Balance%252C%2520and%2520Ketoconazole%2520Interaction%2520Studies%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2012%26volume%3D40%26spage%3D2090%26epage%3D2101%26doi%3D10.1124%2Fdmd.112.047258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dharmalingam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aravind, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thacker, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paramesh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chawla, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asirvatham, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goyal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shembalkar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balamurugan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadam, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alva, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kodgule, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tandon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaidyanathan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pendse, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaikwad, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katare, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suryawanshi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barkate, H.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">587</span>– <span class="NLM_lpage">600</span>, <span class="refDoi"> DOI: 10.1007/s40265-020-01285-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs40265-020-01285-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=32162274" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlslGjurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2020&pages=587-600&author=M.+Dharmalingamauthor=S.+R.+Aravindauthor=H.+Thackerauthor=S.+Parameshauthor=B.+Mohanauthor=M.+Chawlaauthor=A.+Asirvathamauthor=R.+Goyalauthor=J.+Shembalkarauthor=R.+Balamuruganauthor=P.+Kadamauthor=H.+Alvaauthor=R.+Kodguleauthor=M.+Tandonauthor=S.+Vaidyanathanauthor=A.+Pendseauthor=R.+Gaikwadauthor=S.+Katareauthor=S.+Suryawanshiauthor=H.+Barkate&title=Efficacy+and+Safety+of+Remogliflozin+Etabonate%2C+a+New+Sodium+Glucose+Co-Transporter-2+Inhibitor%2C+in+Patients+with+Type+2+Diabetes+Mellitus%3A+A+24-Week%2C+Randomized%2C+Double-Blind%2C+Active-Controlled+Trial&doi=10.1007%2Fs40265-020-01285-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial</span></div><div class="casAuthors">Dharmalingam, Mala; Aravind, S. R.; Thacker, Hemant; Paramesh, S.; Mohan, Brij; Chawla, Manoj; Asirvatham, Arthur; Goyal, Ramesh; Shembalkar, Jayashri; Balamurugan, R.; Kadam, Pradnya; Alva, Hansraj; Kodgule, Rahul; Tandon, Monika; Vaidyanathan, Sivakumar; Pendse, Amol; Gaikwad, Rajesh; Katare, Sagar; Suryawanshi, Sachin; Barkate, Hanmant</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">587-600</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Abstr.: Background: Metformin is the first-line treatment for type 2 diabetes mellitus (T2DM), but many patients either cannot tolerate it or cannot achieve glycemic control with metformin alone, so treatment with other glucose-lowering agents in combination with metformin is frequently required.  Remogliflozin etabonate, a novel agent, is an orally bioavailable prodrug of remogliflozin, which is a potent and selective sodium-glucose co-transporter-2 inhibitor.  Objective: Our objective was to evaluate the efficacy and safety of remogliflozin etabonate compared with dapagliflozin in subjects with T2DM in whom a stable dose of metformin as monotherapy was providing inadequate glycemic control.  Methods: A 24-wk randomized, double-blind, double-dummy, active-controlled, three-arm, parallel-group, multicenter, phase III study was conducted in India.  Patients aged ≥ 18 and ≤ 65 years diagnosed with T2DM, receiving metformin ≥ 1500 mg/day, and with glycated Hb (HbA1c) levels ≥ 7 to ≤ 10% at screening were randomized into three groups.  Every patient received metformin ≥ 1500 mg and either remogliflozin etabonate 100 mg twice daily (BID) (group 1, n = 225) or remogliflozin etabonate 250 mg BID (group 2, n = 241) or dapagliflozin 10 mg once daily (QD) in the morning and placebo QD in the evening (group 3, n = 146).  The patients were followed-up at weeks 1 and 4 and at 4-wk intervals thereafter until week 24.  The endpoints included mean change in HbA1c (primary endpoint, noninferiority margin = 0.35), fasting plasma glucose (FPG), postprandial plasma glucose (PPG), bodyweight, blood pressure, and fasting lipids.  Treatment-emergent adverse events (TEAEs), safety lab. values, ECG, and vital signs were evaluated.  Results: Of 612 randomized patients, 167 (group 1), 175 (group 2), and 103 (group 3) patients with comparable baseline characteristics completed the study.  Mean change ± std. error (SE) in HbA1c from baseline to week 24 was - 0.72 ± 0.09, - 0.77 ± 0.09, and - 0.58 ± 0.12% in groups 1, 2, and 3, resp.  The difference in mean HbA1c of group 1 vs. group 3 (- 0.14%, 90% confidence interval [CI] - 0.38 to 0.10) and group 2 vs. group 3 (- 0.19%; 90% CI - 0.42 to 0.05) was noninferior to that in group 3 (p < 0.001).  No significant difference was found between group 1 or group 2 and group 3 in change in FPG, PPG, and bodyweight.  The overall incidence of TEAEs was comparable across study groups (group 1 = 32.6%, group 2 = 34.4%, group 3 = 29.5%), including adverse events (AEs) of special interest (hypoglycemic events, urinary tract infection, genital fungal infection).  Most TEAEs were mild to moderate in intensity, and no severe AEs were reported.  Conclusion: This study demonstrated the noninferiority of remogliflozin etabonate 100 and 250 mg compared with dapagliflozin, from the first anal. of an initial 612 patients.  Remogliflozin etabonate therefore may be considered an effective and well-tolerated alternative treatment option for glycemic control in T2DM.  Trial Registration: CTRI/2017/07/009121.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoer0K7fLdXvrVg90H21EOLACvtfcHk0lh4CmQcqao5tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlslGjurs%253D&md5=f95767947ac543a6155c276375a583fa</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1007%2Fs40265-020-01285-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-020-01285-0%26sid%3Dliteratum%253Aachs%26aulast%3DDharmalingam%26aufirst%3DM.%26aulast%3DAravind%26aufirst%3DS.%2BR.%26aulast%3DThacker%26aufirst%3DH.%26aulast%3DParamesh%26aufirst%3DS.%26aulast%3DMohan%26aufirst%3DB.%26aulast%3DChawla%26aufirst%3DM.%26aulast%3DAsirvatham%26aufirst%3DA.%26aulast%3DGoyal%26aufirst%3DR.%26aulast%3DShembalkar%26aufirst%3DJ.%26aulast%3DBalamurugan%26aufirst%3DR.%26aulast%3DKadam%26aufirst%3DP.%26aulast%3DAlva%26aufirst%3DH.%26aulast%3DKodgule%26aufirst%3DR.%26aulast%3DTandon%26aufirst%3DM.%26aulast%3DVaidyanathan%26aufirst%3DS.%26aulast%3DPendse%26aufirst%3DA.%26aulast%3DGaikwad%26aufirst%3DR.%26aulast%3DKatare%26aufirst%3DS.%26aulast%3DSuryawanshi%26aufirst%3DS.%26aulast%3DBarkate%26aufirst%3DH.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Remogliflozin%2520Etabonate%252C%2520a%2520New%2520Sodium%2520Glucose%2520Co-Transporter-2%2520Inhibitor%252C%2520in%2520Patients%2520with%2520Type%25202%2520Diabetes%2520Mellitus%253A%2520A%252024-Week%252C%2520Randomized%252C%2520Double-Blind%252C%2520Active-Controlled%2520Trial%26jtitle%3DDrugs%26date%3D2020%26volume%3D80%26spage%3D587%26epage%3D600%26doi%3D10.1007%2Fs40265-020-01285-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Swamy, V.</span>; <span class="NLM_string-name">Bhirud, S. B.</span>; <span class="NLM_string-name">Nair, R.</span>; <span class="NLM_string-name">Khemnar, E.</span>; <span class="NLM_string-name">Kadam, S.</span>; <span class="NLM_string-name">Thorat, J.</span></span> <span> </span><span class="NLM_article-title">An Improved Process for the Preparation Remogliflozin Etabonate or Pharmaceutically Acceptable Salt, Solvate, Hydrate Thereof</span>. <span class="NLM_patent">WO 2019193572</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=V.+Swamy&author=S.+B.+Bhirud&author=R.+Nair&author=E.+Khemnar&author=S.+Kadam&author=J.+Thorat&title=An+Improved+Process+for+the+Preparation+Remogliflozin+Etabonate+or+Pharmaceutically+Acceptable+Salt%2C+Solvate%2C+Hydrate+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSwamy%26aufirst%3DV.%26atitle%3DAn%2520Improved%2520Process%2520for%2520the%2520Preparation%2520Remogliflozin%2520Etabonate%2520or%2520Pharmaceutically%2520Acceptable%2520Salt%252C%2520Solvate%252C%2520Hydrate%2520Thereof%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, D. E.</span>; <span class="NLM_string-name">McClure, M. S.</span>; <span class="NLM_string-name">Powers, J. D.</span>; <span class="NLM_string-name">Crawford, C. F.</span>; <span class="NLM_string-name">Berry, M. B.</span></span> <span> </span><span class="NLM_article-title">Process for the Preparation of Glucopyranosyloxypyrazoles</span>. <span class="NLM_patent">WO 2010127067</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=D.+E.+Patterson&author=M.+S.+McClure&author=J.+D.+Powers&author=C.+F.+Crawford&author=M.+B.+Berry&title=Process+for+the+Preparation+of+Glucopyranosyloxypyrazoles"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPatterson%26aufirst%3DD.%2BE.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%2520Glucopyranosyloxypyrazoles%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit131b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, D. E.</span>; <span class="NLM_string-name">McClure, M. S.</span>; <span class="NLM_string-name">Powers, J. D.</span>; <span class="NLM_string-name">Crawford, C. F.</span>; <span class="NLM_string-name">Berry, M. B.</span></span> <span> </span><span class="NLM_article-title">Chemical Process</span>. <span class="NLM_patent">US 20120053330</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=D.+E.+Patterson&author=M.+S.+McClure&author=J.+D.+Powers&author=C.+F.+Crawford&author=M.+B.+Berry&title=Chemical+Process"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPatterson%26aufirst%3DD.%2BE.%26atitle%3DChemical%2520Process%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit131c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">McClure, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caine, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crump, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glover, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kedia, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, J.</span></span> <span> </span><span class="NLM_article-title">Highly Selective Primary Alkoxycarboxylation and Esterification of Unprotected Pyranose Derivatives Mediated by Scandium(III) Triflate Catalysis</span>. <i>Eur. J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2012</i></span>,  <span class="NLM_fpage">3561</span>– <span class="NLM_lpage">3565</span>, <span class="refDoi"> DOI: 10.1002/ejoc.201200261</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1002%2Fejoc.201200261" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC38Xms1eru7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2012&publication_year=2012&pages=3561-3565&author=M.+S.+McClureauthor=M.+B.+Berryauthor=D.+Caineauthor=C.+Crawfordauthor=B.+C.+Crumpauthor=B.+N.+Gloverauthor=S.+B.+Kediaauthor=A.+Millarauthor=M.+B.+Mitchellauthor=C.+J.+Nicholsauthor=D.+E.+Pattersonauthor=J.+Powers&title=Highly+Selective+Primary+Alkoxycarboxylation+and+Esterification+of+Unprotected+Pyranose+Derivatives+Mediated+by+Scandium%28III%29+Triflate+Catalysis&doi=10.1002%2Fejoc.201200261"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131cR"><div class="casContent"><span class="casTitleNuber">131c</span><div class="casTitle"><span class="NLM_cas:atitle">Highly Selective Primary Alkoxycarboxylation and Esterification of Unprotected Pyranose Derivatives Mediated by Scandium(III) Triflate Catalysis</span></div><div class="casAuthors">McClure, Michael S.; Berry, Malcolm B.; Caine, Darren; Crawford, Claire; Crump, Brian C.; Glover, Bobby N.; Kedia, Sandeep B.; Millar, Alan; Mitchell, Mark B.; Nichols, Christopher J.; Patterson, Daniel E.; Powers, Jeremiah</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2012</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">3561-3565, S3561/1-S3561/35</span>CODEN:
                <span class="NLM_cas:coden">EJOCFK</span>;
        ISSN:<span class="NLM_cas:issn">1099-0690</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A highly scandium(III) triflate-catalyzed regioselective alkoxycarboxylation and acylation of primary alcs. of pyranose derivs., e.g. I (R = H) gave the corresponding glycosides, e.g. I [R = C(O)OEt] in good yields, is described.  The reaction is high yielding and proceeds under mild conditions with 0.15-1 mol-% Sc(OTf)3 used in combination with anhydrides or pyro-carbonates at 40-50 °C.  Selectivities obsd. for alkoxycarboxylation of unprotected pyranose derivs. are > 95 %, and this constitutes a significant advantage over existing methods.  Mechanistic implications, including the role of steric demand and metal-heteroatom coordination are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVrN6YUmN2YLVg90H21EOLACvtfcHk0lh9F4YanIdb2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xms1eru7c%253D&md5=31a64de6d81599581699e9ef2759b5e7</span></div><a href="/servlet/linkout?suffix=cit131c&amp;dbid=16384&amp;doi=10.1002%2Fejoc.201200261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejoc.201200261%26sid%3Dliteratum%253Aachs%26aulast%3DMcClure%26aufirst%3DM.%2BS.%26aulast%3DBerry%26aufirst%3DM.%2BB.%26aulast%3DCaine%26aufirst%3DD.%26aulast%3DCrawford%26aufirst%3DC.%26aulast%3DCrump%26aufirst%3DB.%2BC.%26aulast%3DGlover%26aufirst%3DB.%2BN.%26aulast%3DKedia%26aufirst%3DS.%2BB.%26aulast%3DMillar%26aufirst%3DA.%26aulast%3DMitchell%26aufirst%3DM.%2BB.%26aulast%3DNichols%26aufirst%3DC.%2BJ.%26aulast%3DPatterson%26aufirst%3DD.%2BE.%26aulast%3DPowers%26aufirst%3DJ.%26atitle%3DHighly%2520Selective%2520Primary%2520Alkoxycarboxylation%2520and%2520Esterification%2520of%2520Unprotected%2520Pyranose%2520Derivatives%2520Mediated%2520by%2520Scandium%2528III%2529%2520Triflate%2520Catalysis%26jtitle%3DEur.%2520J.%2520Org.%2520Chem.%26date%3D2012%26volume%3D2012%26spage%3D3561%26epage%3D3565%26doi%3D10.1002%2Fejoc.201200261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Deeks, E. D.</span></span> <span> </span><span class="NLM_article-title">Sotagliflozin: A Review in Type 1 Diabetes</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">1977</span>– <span class="NLM_lpage">1987</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01230-w</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs40265-019-01230-w" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31761990" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A280%3ADC%252BB3Mfis1elsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=1977-1987&author=E.+D.+Deeks&title=Sotagliflozin%3A+A+Review+in+Type+1+Diabetes&doi=10.1007%2Fs40265-019-01230-w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132aR"><div class="casContent"><span class="casTitleNuber">132a</span><div class="casTitle"><span class="NLM_cas:atitle">Sotagliflozin: A Review in Type 1 Diabetes</span></div><div class="casAuthors">Deeks Emma D</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1977-1987</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Sotagliflozin (Zynquista®) is the first dual inhibitor of sodium-glucose co-transporter-1 and -2 (SGLT1 and 2).  In the phase 3, inTANDEM 1-3 trials, adjunctive use of oral sotagliflozin (200 mg or 400 mg once daily) improved glycaemic control and reduced bodyweight and insulin requirements relative to placebo over 24 weeks of treatment in adults whose type 1 diabetes (T1D) was inadequately controlled by insulin therapy.  Similar benefits were seen with the drug in patients who were overweight/obese [i.e. body mass index (BMI) ≥ 27 kg/m(2)] in inTANDEM 1 and 2 (pooled).  The benefits of sotagliflozin were largely maintained over 52 weeks of treatment.  Overall, use of sotagliflozin in this setting is generally well tolerated and reduces, or at least does not increase, the likelihood of hypoglycaemia; however, as with other SGLT inhibitors, sotagliflozin carries a risk of diabetic ketoacidosis (DKA).  On the basis of its risk/benefit profile, sotagliflozin is indicated in the EU as an adjunct to insulin in adults with T1D with a BMI ≥ 27 kg/m(2) who have failed to achieve adequate glycaemic control despite optimal insulin therapy, thus expanding the currently limited adjunctive oral treatment options available for use in this population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT73gPAhxy4lK2q3xNe7a7QfW6udTcc2eaa0-u4Xt5aibntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3Mfis1elsA%253D%253D&md5=df376424720fa574b7c5f8c21e210fba</span></div><a href="/servlet/linkout?suffix=cit132a&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01230-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01230-w%26sid%3Dliteratum%253Aachs%26aulast%3DDeeks%26aufirst%3DE.%2BD.%26atitle%3DSotagliflozin%253A%2520A%2520Review%2520in%2520Type%25201%2520Diabetes%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D1977%26epage%3D1987%26doi%3D10.1007%2Fs40265-019-01230-w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit132b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Nuffer, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trujillo, J. M.</span></span> <span> </span><span class="NLM_article-title">A Review of Sotagliflozin for Use in Type 1 Diabetes</span>. <i>Ther. Adv. Endocrinol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1177/2042018819890527</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1177%2F2042018819890527" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1-12&author=W.+Nufferauthor=B.+Williamsauthor=J.+M.+Trujillo&title=A+Review+of+Sotagliflozin+for+Use+in+Type+1+Diabetes&doi=10.1177%2F2042018819890527"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit132b&amp;dbid=16384&amp;doi=10.1177%2F2042018819890527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F2042018819890527%26sid%3Dliteratum%253Aachs%26aulast%3DNuffer%26aufirst%3DW.%26aulast%3DWilliams%26aufirst%3DB.%26aulast%3DTrujillo%26aufirst%3DJ.%2BM.%26atitle%3DA%2520Review%2520of%2520Sotagliflozin%2520for%2520Use%2520in%2520Type%25201%2520Diabetes%26jtitle%3DTher.%2520Adv.%2520Endocrinol.%2520Metab.%26date%3D2019%26volume%3D10%26spage%3D1%26epage%3D12%26doi%3D10.1177%2F2042018819890527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Rendell, M. S.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety of Sotagliflozin in Treating Diabetes Type 1</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">307</span>– <span class="NLM_lpage">315</span>, <span class="refDoi"> DOI: 10.1080/14656566.2017.1414801</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1080%2F14656566.2017.1414801" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=29212386" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlOnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=307-315&author=M.+S.+Rendell&title=Efficacy+and+Safety+of+Sotagliflozin+in+Treating+Diabetes+Type+1&doi=10.1080%2F14656566.2017.1414801"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133aR"><div class="casContent"><span class="casTitleNuber">133a</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of sotagliflozin in treating diabetes type 1</span></div><div class="casAuthors">Rendell, Marc S.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">307-315</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Introduction: Sotagliflozin is the first dual SGLT1/SGLT2 inhibitor developed for use in diabetes.  Sotagliflozin blocks SGLT2 in the kidneys and SGLT1 in the intestines resulting in reduced early phase glucose absorption and increased blood levels of GLP-1 and PYY.  Urinary glucose excretion is lower than with other agents as a result of decreased glucose absorption.  The primary development effort to date has been in Type 1 diabetes.  Areas covered: The published information on sotagliflozin is reviewed, along with the recent results of several pivotal Type 1 diabetes trials.  Expert opinion: Sotagliflozin treatment lowers HbA1c and reduces glucose variability, with a trend to less hypoglycemic events.  In the Type 1 trials, sotagliflozin treated individuals experienced DKA at a higher rate than placebo treated patients.  An addnl. safety issue arises from the as yet unknown potential risks in women of child bearing potential in whom DKA is of utmost concern.  The sotagliflozin development program has now been extended to trials in Type 2 diabetes, and long term studies will be needed to assess the benefits and risks of the agent in comparison to other currently marketed SGLT2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZ8NVz2zZpYrVg90H21EOLACvtfcHk0lgFa2av6XLA8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlOnsw%253D%253D&md5=ca54a2b039a79b31639e8f28a8762fe7</span></div><a href="/servlet/linkout?suffix=cit133a&amp;dbid=16384&amp;doi=10.1080%2F14656566.2017.1414801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14656566.2017.1414801%26sid%3Dliteratum%253Aachs%26aulast%3DRendell%26aufirst%3DM.%2BS.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Sotagliflozin%2520in%2520Treating%2520Diabetes%2520Type%25201%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2018%26volume%3D19%26spage%3D307%26epage%3D315%26doi%3D10.1080%2F14656566.2017.1414801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit133b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Cefalo, C. M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cinti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moffa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Impronta, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorice, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mezza, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pontecorvi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giaccari, A.</span></span> <span> </span><span class="NLM_article-title">Sotagliflozin, the First Dual SGLT Inhibitor: Current Outlook and Perspectives</span>. <i>Cardiovasc. Diabetol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">20</span>, <span class="refDoi"> DOI: 10.1186/s12933-019-0828-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1186%2Fs12933-019-0828-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=30819210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A280%3ADC%252BB3cfovFGqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=20&author=C.+M.+A.+Cefaloauthor=F.+Cintiauthor=S.+Moffaauthor=F.+Improntaauthor=G.+P.+Soriceauthor=T.+Mezzaauthor=A.+Pontecorviauthor=A.+Giaccari&title=Sotagliflozin%2C+the+First+Dual+SGLT+Inhibitor%3A+Current+Outlook+and+Perspectives&doi=10.1186%2Fs12933-019-0828-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133bR"><div class="casContent"><span class="casTitleNuber">133b</span><div class="casTitle"><span class="NLM_cas:atitle">Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives</span></div><div class="casAuthors">Cefalo Chiara Maria Assunta; Cinti Francesca; Moffa Simona; Impronta Flavia; Sorice Gian Pio; Mezza Teresa; Pontecorvi Alfredo; Giaccari Andrea; Cefalo Chiara Maria Assunta; Cinti Francesca; Moffa Simona; Impronta Flavia; Sorice Gian Pio; Mezza Teresa; Pontecorvi Alfredo; Giaccari Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular diabetology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">20</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Sotagliflozin is a dual sodium-glucose co-transporter-2 and 1 (SGLT2/1) inhibitor for the treatment of both type 1 (T1D) and type 2 diabetes (T2D).  Sotagliflozin inhibits renal sodium-glucose co-transporter 2 (determining significant excretion of glucose in the urine, in the same way as other, already available SGLT-2 selective inhibitors) and intestinal SGLT-1, delaying glucose absorption and therefore reducing post prandial glucose.  Well-designed clinical trials, have shown that sotagliflozin (as monotherapy or add-on therapy to other anti-hyperglycemic agents) improves glycated hemoglobin in adults with T2D, with beneficial effects on bodyweight and blood pressure.  Similar results have been obtained in adults with T1D treated with either continuous subcutaneous insulin infusion or multiple daily insulin injections, even after insulin optimization.  A still ongoing phase 3 study is currently evaluating the effect of sotagliflozin on cardiovascular outcomes (ClinicalTrials.gov NCT03315143).  In this review we illustrate the advantages and disadvantages of dual SGLT 2/1 inhibition, in order to better characterize and investigate its mechanisms of action and potentialities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT0aUujJc8o0dK0qsdY6Nc1fW6udTcc2ea-1zws-7-ss7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cfovFGqsA%253D%253D&md5=1ab51883200e473784a2ef9a79287ed7</span></div><a href="/servlet/linkout?suffix=cit133b&amp;dbid=16384&amp;doi=10.1186%2Fs12933-019-0828-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12933-019-0828-y%26sid%3Dliteratum%253Aachs%26aulast%3DCefalo%26aufirst%3DC.%2BM.%2BA.%26aulast%3DCinti%26aufirst%3DF.%26aulast%3DMoffa%26aufirst%3DS.%26aulast%3DImpronta%26aufirst%3DF.%26aulast%3DSorice%26aufirst%3DG.%2BP.%26aulast%3DMezza%26aufirst%3DT.%26aulast%3DPontecorvi%26aufirst%3DA.%26aulast%3DGiaccari%26aufirst%3DA.%26atitle%3DSotagliflozin%252C%2520the%2520First%2520Dual%2520SGLT%2520Inhibitor%253A%2520Current%2520Outlook%2520and%2520Perspectives%26jtitle%3DCardiovasc.%2520Diabetol.%26date%3D2019%26volume%3D18%26spage%3D20%26doi%3D10.1186%2Fs12933-019-0828-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit133c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Rendell, M. S.</span></span> <span> </span><span class="NLM_article-title">The Journey from Gene Knockout to Clinical Medicine: Telotristat and Sotagliflozin</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">817</span>– <span class="NLM_lpage">824</span>, <span class="refDoi"> DOI: 10.2147/DDDT.S144556</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.2147%2FDDDT.S144556" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=30880915" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlCgt7nL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2019&pages=817-824&author=M.+S.+Rendell&title=The+Journey+from+Gene+Knockout+to+Clinical+Medicine%3A+Telotristat+and+Sotagliflozin&doi=10.2147%2FDDDT.S144556"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133cR"><div class="casContent"><span class="casTitleNuber">133c</span><div class="casTitle"><span class="NLM_cas:atitle">The journey from gene knockout to clinical medicine: telotristat and sotagliflozin</span></div><div class="casAuthors">Rendell, Marc S.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">817-824</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Gene knockout has been a powerful technique to evaluate the physiol. role of selected gene products.  Lexicon pioneered high-throughput gene knockout technol. and went further in designing agents to inhibit products of gene expression.  Two agents have entered late-stage development.  Telotristat is an inhibitor of tryptophan hydroxylase (TPH), preventing the prodn. of serotonin.  Although this agent blocks the two isoforms of TPH, it does not cross the blood-brain barrier, thus avoiding central neurol. manifestations.  It inhibits the peripheral prodn. of serotonin, and in particular prevents serotonin action in the intestines, resulting in decreased peristaltic action.  Lexicon successfully developed telotristat to treat carcinoid syndrome not responding adequately to somatostatin inhibitors.  Sotagliflozin development proceeded from the observation that dual inhibition of SGLT2 in the kidneys and SGLT1 in the intestines resulted in increased renal glucose excretion, reduced early-phase glucose absorption, as well as increased blood levels of GLP-1 and PYY.  Initial development efforts focused on type 1 diabetes and have shown reduced postprandial glucose levels, less tendency to hypoglycemia, and lower HbA1c.  Several other SGLT2 inhibitors have been assocd. with increased frequency of diabetic ketoacidosis (DKA).  In the type 1 trials, sotagliflozin-treated individuals experienced DKA at a higher rate than placebo-treated patients.  The sotagliflozin development program has now been extended to trials on type 2 diabetes.  Long-term clin. trials will det. the benefits and risks of the agent in comparison to other currently marketed SGLT2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-Fc7sxo4CkLVg90H21EOLACvtfcHk0lgFa2av6XLA8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlCgt7nL&md5=1dd88aa094e8a816c7617a07dd2ae21e</span></div><a href="/servlet/linkout?suffix=cit133c&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S144556&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S144556%26sid%3Dliteratum%253Aachs%26aulast%3DRendell%26aufirst%3DM.%2BS.%26atitle%3DThe%2520Journey%2520from%2520Gene%2520Knockout%2520to%2520Clinical%2520Medicine%253A%2520Telotristat%2520and%2520Sotagliflozin%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2019%26volume%3D13%26spage%3D817%26epage%3D824%26doi%3D10.2147%2FDDDT.S144556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iimura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bednarz, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Q.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, N.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span> <span> </span><span class="NLM_article-title">Process Development of Sotagliflozin, a Dual Inhibitor of Sodium-Glucose Cotransporter-1/2 for the Treatment of Diabetes</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">2689</span>– <span class="NLM_lpage">2701</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.0c00359</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.0c00359" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFyqsrnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2020&pages=2689-2701&author=M.+M.+Zhaoauthor=H.+Zhangauthor=S.+Iimuraauthor=M.+S.+Bednarzauthor=Q.-L.+Songauthor=N.-K.+Limauthor=J.+Yanauthor=W.+Wuauthor=K.+Daiauthor=X.+Guauthor=Y.+Wang&title=Process+Development+of+Sotagliflozin%2C+a+Dual+Inhibitor+of+Sodium-Glucose+Cotransporter-1%2F2+for+the+Treatment+of+Diabetes&doi=10.1021%2Facs.oprd.0c00359"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Process Development of Sotagliflozin, a Dual Inhibitor of Sodium-Glucose Cotransporter-1/2 for the Treatment of Diabetes</span></div><div class="casAuthors">Zhao, Matthew M.; Zhang, Haiming; Iimura, Shinya; Bednarz, Mark S.; Song, Qiu-Ling; Lim, Ngiap-Kie; Yan, Jie; Wu, Wenxue; Dai, Kuangchu; Gu, Xiaodong; Wang, Youchu</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2689-2701</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The development of an efficient manufg. process for sotagliflozin (LX4211), a dual inhibitor of sodium-glucose cotransporter-1/2 (SGLT-1/2) for the treatment of diabetes, is described.  Sotagliflozin features five contiguous chiral centers on the carbohydrate core flanked by a thioether group and a biaryl moiety.  Three chiral centers are obtained from the starting material L-xylose, while the other two were established (or modified) via three highly stereoselective transformations: Luche redn. (dr: 97/3), dynamic kinetic resoln. of anomeric hemiacetal (dr: 95/5), and Lewis acid-promoted thiolation (dr: 1000/1).  Global deprotection of the resulting penultimate intermediate with catalytic sodium methoxide followed by recrystn. furnishes sotagliflozin.  The longest linear sequence consists of 10 steps from L-xylose with an overall yield of 40%.  This process has been performed on multi-hundred kilogram batches to satisfy the drug substance development demands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomlSCt_ZR7BbVg90H21EOLACvtfcHk0lgFa2av6XLA8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFyqsrnP&md5=691f8d1beca1ce2f0069c6830baa0a0a</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.0c00359&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.0c00359%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DM.%2BM.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DIimura%26aufirst%3DS.%26aulast%3DBednarz%26aufirst%3DM.%2BS.%26aulast%3DSong%26aufirst%3DQ.-L.%26aulast%3DLim%26aufirst%3DN.-K.%26aulast%3DYan%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DDai%26aufirst%3DK.%26aulast%3DGu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DY.%26atitle%3DProcess%2520Development%2520of%2520Sotagliflozin%252C%2520a%2520Dual%2520Inhibitor%2520of%2520Sodium-Glucose%2520Cotransporter-1%252F2%2520for%2520the%2520Treatment%2520of%2520Diabetes%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2020%26volume%3D24%26spage%3D2689%26epage%3D2701%26doi%3D10.1021%2Facs.oprd.0c00359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Paul, S. M.</span>; <span class="NLM_string-name">Perlberg, A.</span>; <span class="NLM_string-name">Zhao, M. M.</span></span> <span> </span><span class="NLM_article-title">Preparation of Solid Forms of (2<i>S</i>,3<i>R</i>,4<i>R</i>,5<i>S</i>,6<i>R</i>)-2-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2<i>H</i>-pyran-3,4,5-triol for Use in Treating Disorders Related to the Inhibition of Sodium Glucose Co-Transporter 2</span>. <span class="NLM_patent">WO 2010009197 A1</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=S.+M.+De+Paul&author=A.+Perlberg&author=M.+M.+Zhao&title=Preparation+of+Solid+Forms+of+%282S%2C3R%2C4R%2C5S%2C6R%29-2-%284-Chloro-3-%284-ethoxybenzyl%29phenyl%29-6-%28methylthio%29tetrahydro-2H-pyran-3%2C4%2C5-triol+for+Use+in+Treating+Disorders+Related+to+the+Inhibition+of+Sodium+Glucose+Co-Transporter+2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BPaul%26aufirst%3DS.%2BM.%26atitle%3DPreparation%2520of%2520Solid%2520Forms%2520of%2520%25282S%252C3R%252C4R%252C5S%252C6R%2529-2-%25284-Chloro-3-%25284-ethoxybenzyl%2529phenyl%2529-6-%2528methylthio%2529tetrahydro-2H-pyran-3%252C4%252C5-triol%2520for%2520Use%2520in%2520Treating%2520Disorders%2520Related%2520to%2520the%2520Inhibition%2520of%2520Sodium%2520Glucose%2520Co-Transporter%25202%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><a href="https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-mayzent-siponimod-first-oral-drug-treat-secondary-progressive-ms-active-disease" class="extLink">https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-mayzent-siponimod-first-oral-drug-treat-secondary-progressive-ms-active-disease</a> (accessed 2020-09-15).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.novartis.com%2Fnews%2Fmedia-releases%2Fnovartis-receives-fda-approval-mayzent-siponimod-first-oral-drug-treat-secondary-progressive-ms-active-disease+%28accessed+2020-09-15%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209884s000lbl.pdf" class="extLink">https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209884s000lbl.pdf</a> (accessed 2021-01-14).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2019%2F209884s000lbl.pdf+%28accessed+2021-01-14%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuntland, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefebvre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinterding, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">End, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heining, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruns, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuesslein-Hildesheim, B.</span></span> <span> </span><span class="NLM_article-title">Discovery of BAF312 (Siponimod), a Potent and Selective S1P Receptor Modulator</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">333</span>– <span class="NLM_lpage">337</span>, <span class="refDoi"> DOI: 10.1021/ml300396r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300396r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktVynug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=333-337&author=S.+Panauthor=N.+S.+Grayauthor=W.+Gaoauthor=Y.+Miauthor=Y.+Fanauthor=X.+Wangauthor=T.+Tuntlandauthor=J.+Cheauthor=S.+Lefebvreauthor=Y.+Chenauthor=A.+Chuauthor=K.+Hinterdingauthor=A.+Gardinauthor=P.+Endauthor=P.+Heiningauthor=C.+Brunsauthor=N.+G.+Cookeauthor=B.+Nuesslein-Hildesheim&title=Discovery+of+BAF312+%28Siponimod%29%2C+a+Potent+and+Selective+S1P+Receptor+Modulator&doi=10.1021%2Fml300396r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of BAF312 (Siponimod), a Potent and Selective S1P Receptor Modulator</span></div><div class="casAuthors">Pan, Shifeng; Gray, Nathanael S.; Gao, Wenqi; Mi, Yuan; Fan, Yi; Wang, Xing; Tuntland, Tove; Che, Jianwei; Lefebvre, Sophie; Chen, Yu; Chu, Alan; Hinterding, Klaus; Gardin, Anne; End, Peter; Heining, Peter; Bruns, Christian; Cooke, Nigel G.; Nuesslein-Hildesheim, Barbara</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">333-337</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of alkoxyimino derivs. as S1P1 agonists were discovered through de novo design using FTY720 as the chem. starting point.  Extensive structure-activity relationship studies led to the discovery of (E)-1-(4-(1-(((4-cyclohexyl-3-(trifluoromethyl)benzyl)oxy)imino)ethyl)-2-ethylbenzyl)azetidine-3-carboxylic acid (I, BAF312, Siponimod), which has recently completed phase 2 clin. trials in patients with relapsing-remitting multiple sclerosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoV0CukK1Qn3bVg90H21EOLACvtfcHk0li_8jXUWdhJkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktVynug%253D%253D&md5=a410b8b34f28380a51b3ffb63ae23161</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1021%2Fml300396r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300396r%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DS.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DGao%26aufirst%3DW.%26aulast%3DMi%26aufirst%3DY.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DChe%26aufirst%3DJ.%26aulast%3DLefebvre%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DChu%26aufirst%3DA.%26aulast%3DHinterding%26aufirst%3DK.%26aulast%3DGardin%26aufirst%3DA.%26aulast%3DEnd%26aufirst%3DP.%26aulast%3DHeining%26aufirst%3DP.%26aulast%3DBruns%26aufirst%3DC.%26aulast%3DCooke%26aufirst%3DN.%2BG.%26aulast%3DNuesslein-Hildesheim%26aufirst%3DB.%26atitle%3DDiscovery%2520of%2520BAF312%2520%2528Siponimod%2529%252C%2520a%2520Potent%2520and%2520Selective%2520S1P%2520Receptor%2520Modulator%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D333%26epage%3D337%26doi%3D10.1021%2Fml300396r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gallou, F.</span>; <span class="NLM_string-name">Sedelmeier, J. M.</span>; <span class="NLM_string-name">Vogel, C.</span></span> <span> </span><span class="NLM_article-title">Process for Preparing <i>N</i>-(4-Cyclohexyl-3-Trifluoromethyl-Benzyloxy)-Acetimidic Acid Ethyl Ester</span>. <span class="NLM_patent">WO 2013113915 A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=F.+Gallou&author=J.+M.+Sedelmeier&author=C.+Vogel&title=Process+for+Preparing+N-%284-Cyclohexyl-3-Trifluoromethyl-Benzyloxy%29-Acetimidic+Acid+Ethyl+Ester"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGallou%26aufirst%3DF.%26atitle%3DProcess%2520for%2520Preparing%2520N-%25284-Cyclohexyl-3-Trifluoromethyl-Benzyloxy%2529-Acetimidic%2520Acid%2520Ethyl%2520Ester%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Juric, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabernero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janku, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burris, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schellens, J. H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middleton, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berlin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gil-Martin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rugo, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seggewiss-Bernhardt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bootle, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demanse, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenstein, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coughlin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quadt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span> <span> </span><span class="NLM_article-title">Phosphatidylinositol 3-Kinase A-Selective Inhibition with Alpelisib (BYL719) in Pik3ca-Altered Solid Tumors: Results from the First-in-Human Study</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">1291</span>– <span class="NLM_lpage">1299</span>, <span class="refDoi"> DOI: 10.1200/JCO.2017.72.7107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1200%2FJCO.2017.72.7107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=29401002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlynurbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2018&pages=1291-1299&author=D.+Juricauthor=J.+Rodonauthor=J.+Taberneroauthor=F.+Jankuauthor=H.+A.+Burrisauthor=J.+H.+M.+Schellensauthor=M.+R.+Middletonauthor=J.+Berlinauthor=M.+Schulerauthor=M.+Gil-Martinauthor=H.+S.+Rugoauthor=R.+Seggewiss-Bernhardtauthor=A.+Huangauthor=D.+Bootleauthor=D.+Demanseauthor=L.+Blumensteinauthor=C.+Coughlinauthor=C.+Quadtauthor=J.+Baselga&title=Phosphatidylinositol+3-Kinase+A-Selective+Inhibition+with+Alpelisib+%28BYL719%29+in+Pik3ca-Altered+Solid+Tumors%3A+Results+from+the+First-in-Human+Study&doi=10.1200%2FJCO.2017.72.7107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140aR"><div class="casContent"><span class="casTitleNuber">140a</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphatidylinositol 3-Kinase α-selective inhibition with alpelisib (BYL719) in PIK3CA-altered solid tumors: results from the first-in-human study</span></div><div class="casAuthors">Juric, Dejan; Rodon, Jordi; Tabernero, Josep; Janku, Filip; Burris, Howard A.; Schellens, Jan H. M.; Middleton, Mark R.; Berlin, Jordan; Schuler, Martin; Gil-Martin, Marta; Rugo, Hope S.; Seggewiss-Bernhardt, Ruth; Huang, Alan; Bootle, Douglas; Demanse, David; Blumenstein, Lars; Coughlin, Christina; Quadt, Cornelia; Baselga, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1291-1299</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose We report the first-in-human phase Ia study to our knowledge (ClinicalTrials.gov identifier: NCT01219699) identifying the max. tolerated dose and assessing safety and preliminary efficacy of single-agent alpelisib (BYL719), an oral phosphatidylinositol 3-kinase α (PI3Kα)-selective inhibitor.  Patients and Methods In the dose-escalation phase, patients with PIK3CA-altered advanced solid tumors received once-daily or twice-daily oral alpelisib on a continuous schedule.  In the dose-expansion phase, patients with PIK3CA-altered solid tumors and PIK3CA-wild-type, estrogen receptor-pos./human epidermal growth factor receptor 2-neg. breast cancer received alpelisib 400 mg once daily.  Results One hundred thirty-four patients received treatment.  Alpelisib max. tolerated doses were established as 400mg once daily and 150mg twice daily.  Nine patients (13.2%) in the dose-escalation phase had dose-limiting toxicities of hyperglycemia (n = 6), nausea (n = 2), and both hyperglycemia and hypophosphatemia (n = 1).  Frequent all-grade, treatment-related adverse events included hyperglycemia (51.5%), nausea (50.0%), decreased appetite (41.8%), diarrhea (40.3%), and vomiting (31.3%).  Alpelisib was rapidly absorbed; half-life was 7.6 h at 400 mg once daily with minimal accumulation.  Objective tumor responses were obsd. at doses ≥ 270 mg once daily; overall response ratewas 6.0% (n = 8; one patient with endometrial cancer had a complete response, and seven patients with cervical, breast, endometrial, colon, and rectal cancers had partial responses).  Stable disease was achieved in 70 (52.2%) patients and was maintained . 24 wk in 13 (9.7%) patients; disease control rate (complete and partial responses and stable disease) was 58.2%.  In patients with estrogen receptor-pos./human epidermal growth factor receptor 2-neg. breast cancer, median progression-free survival was 5.5 mo.  Frequently mutated genes (≥ 10% tumors) included TP53 (51.3%), APC (23.7%), KRAS (22.4%), ARID1A (13.2%), and FBXW7 (10.5%).  Conclusion Alpelisib demonstrated a tolerable safety profile and encouraging preliminary activity in patients with PIK3CA-altered solid tumors, supporting the rationale for selective PI3Kα inhibition in combination with other agents for the treatment of PIK3CA-mutant tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGps0P3SQLaDT7Vg90H21EOLACvtfcHk0li7x3bsy1Nz-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlynurbO&md5=e95593fa4359b0ae552c92f909387f5b</span></div><a href="/servlet/linkout?suffix=cit140a&amp;dbid=16384&amp;doi=10.1200%2FJCO.2017.72.7107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2017.72.7107%26sid%3Dliteratum%253Aachs%26aulast%3DJuric%26aufirst%3DD.%26aulast%3DRodon%26aufirst%3DJ.%26aulast%3DTabernero%26aufirst%3DJ.%26aulast%3DJanku%26aufirst%3DF.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%2BM.%26aulast%3DMiddleton%26aufirst%3DM.%2BR.%26aulast%3DBerlin%26aufirst%3DJ.%26aulast%3DSchuler%26aufirst%3DM.%26aulast%3DGil-Martin%26aufirst%3DM.%26aulast%3DRugo%26aufirst%3DH.%2BS.%26aulast%3DSeggewiss-Bernhardt%26aufirst%3DR.%26aulast%3DHuang%26aufirst%3DA.%26aulast%3DBootle%26aufirst%3DD.%26aulast%3DDemanse%26aufirst%3DD.%26aulast%3DBlumenstein%26aufirst%3DL.%26aulast%3DCoughlin%26aufirst%3DC.%26aulast%3DQuadt%26aufirst%3DC.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DPhosphatidylinositol%25203-Kinase%2520A-Selective%2520Inhibition%2520with%2520Alpelisib%2520%2528BYL719%2529%2520in%2520Pik3ca-Altered%2520Solid%2520Tumors%253A%2520Results%2520from%2520the%2520First-in-Human%2520Study%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D36%26spage%3D1291%26epage%3D1299%26doi%3D10.1200%2FJCO.2017.72.7107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit140b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span> <span> </span><span class="NLM_article-title">Alpelisib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">1249</span>– <span class="NLM_lpage">1253</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01161-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs40265-019-01161-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31256368" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlCiur%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=1249-1253&author=A.+Markham&title=Alpelisib%3A+First+Global+Approval&doi=10.1007%2Fs40265-019-01161-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140bR"><div class="casContent"><span class="casTitleNuber">140b</span><div class="casTitle"><span class="NLM_cas:atitle">Alpelisib: First Global Approval</span></div><div class="casAuthors">Markham, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1249-1253</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Alpelisib (Piqray)-an orally available phosphatidylinositol 3-kinase (PI3K) inhibitor with specific activity against PI3K alpha (PI3Kα)-is being developed by Novartis for the treatment of breast cancer.  Alpelisib has demonstrated efficacy in combination with fulvestrant as treatment for hormone receptor (HR)-pos., human epidermal growth factor receptor-2 (HER2)-neg. breast cancer in patients with a PIK3CA mutation and was recently approved for this indication in the USA.  This article summarizes the milestones in the development of alpelisib leading to this first approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqX1sEhr0QGHrVg90H21EOLACvtfcHk0li7x3bsy1Nz-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlCiur%252FN&md5=4d9e9d1e3742a9bce160ca2c7987ce6c</span></div><a href="/servlet/linkout?suffix=cit140b&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01161-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01161-6%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26atitle%3DAlpelisib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D1249%26epage%3D1253%26doi%3D10.1007%2Fs40265-019-01161-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><a href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-alpelisib-metastatic-breast-cancer" class="extLink">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-alpelisib-metastatic-breast-cancer</a> (accessed 2020-06-02).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fresources-information-approved-drugs%2Ffda-approves-alpelisib-metastatic-breast-cancer+%28accessed+2020-06-02%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Koboldt, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulton, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLellan, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalicki-Veizer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMichael, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulton, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dooling, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mardis, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ally, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasundaram, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butterfield, Y. S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlsen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuah, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, H.-J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coope, R. J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhalla, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirst, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirst, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holt, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mungall, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pleasance, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon Robertson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schein, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shafiei, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sipahimalani, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slobodan, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoll, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiessen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varhol, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wye, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birol, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marra, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherniack, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saksena, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onofrio, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pho, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schumacher, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gentry, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crenshaw, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ardlie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beroukhim, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winckler, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Getz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabriel, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kucherlapati, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoadley, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Todd Auman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turman, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Topal, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, H.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva, G. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iglesia, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Usary, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Booker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulabani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bodenheimer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoyle, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simons, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soloway, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mose, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jefferys, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neil Hayes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perou, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malik, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahurkar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisenberger, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Triche, T.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bootwalla, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maglinte, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berman, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Den Berg, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baylin, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laird, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creighton, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donehower, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Getz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voet, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saksena, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gehlenborg, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiCara, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yingchun Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivachenko, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stojanov, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nazaire, M.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorvaldsdottir, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesirov, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreisberg, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernard, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bressler, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erkkila, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorsson, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shmulevich, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciriello, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinhold, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerami, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arman Aksoy, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antipin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reva, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladanyi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sander, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anur, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spellman, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhaak, R. R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akbani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broom, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casasent, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakefield, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unruh, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baggerly, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coombes, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haussler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benz, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benz, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szeto, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paull, E. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sokolov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thusberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mooney, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellrott, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grifford, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilks, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craft, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meerzaman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gastier-Foster, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramirez, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pyatt, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zmuda, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtenberg, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brookens, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerken, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harper, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leraas, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wise, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabler, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAllister, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barr, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart-Kothari, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarvin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandusky, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacocca, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabeno, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czerwinski, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrelli, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolzhansky, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abramov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voronina, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potapova, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suchorska, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murawa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kycler, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibbs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spychała, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murawa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brzeziński, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Łaźniak, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teresiak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leporowska, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogusz-Czerniewicz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malicki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackiewicz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiznerowicz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Le, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohl, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viet Tien, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorp, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Bang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sussman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duc Phu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hajek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phi Hung, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viet The Phuong, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quyet Thang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaki Khan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penny, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallery, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curley, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shelton, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yena, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingle, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Couch, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lingle, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maria
Gonzalez-Angulo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyer, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, X.</span></span> <span> </span><span class="NLM_article-title">Comprehensive Molecular Portraits of Human Breast Tumours</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>490</i></span>,  <span class="NLM_fpage">61</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.1038/nature11412</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1038%2Fnature11412" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=23000897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlyltrvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=490&publication_year=2012&pages=61-70&author=D.+C.+Koboldtauthor=R.+S.+Fultonauthor=M.+D.+McLellanauthor=H.+Schmidtauthor=J.+Kalicki-Veizerauthor=J.+F.+McMichaelauthor=L.+L.+Fultonauthor=D.+J.+Doolingauthor=L.+Dingauthor=E.+R.+Mardisauthor=R.+K.+Wilsonauthor=A.+Allyauthor=M.+Balasundaramauthor=Y.+S.+N.+Butterfieldauthor=R.+Carlsenauthor=C.+Carterauthor=A.+Chuauthor=E.+Chuahauthor=H.-J.+E.+Chunauthor=R.+J.+N.+Coopeauthor=N.+Dhallaauthor=R.+Guinauthor=C.+Hirstauthor=M.+Hirstauthor=R.+A.+Holtauthor=D.+Leeauthor=H.+I.+Liauthor=M.+Mayoauthor=R.+A.+Mooreauthor=A.+J.+Mungallauthor=E.+Pleasanceauthor=A.+Gordon+Robertsonauthor=J.+E.+Scheinauthor=A.+Shafieiauthor=P.+Sipahimalaniauthor=J.+R.+Slobodanauthor=D.+Stollauthor=A.+Tamauthor=N.+Thiessenauthor=R.+J.+Varholauthor=N.+Wyeauthor=T.+Zengauthor=Y.+Zhaoauthor=I.+Birolauthor=S.+J.+M.+Jonesauthor=M.+A.+Marraauthor=A.+D.+Cherniackauthor=G.+Saksenaauthor=R.+C.+Onofrioauthor=N.+H.+Phoauthor=S.+L.+Carterauthor=S.+E.+Schumacherauthor=B.+Tabakauthor=B.+Hernandezauthor=J.+Gentryauthor=H.+Nguyenauthor=A.+Crenshawauthor=K.+Ardlieauthor=R.+Beroukhimauthor=W.+Wincklerauthor=G.+Getzauthor=S.+B.+Gabrielauthor=M.+Meyersonauthor=L.+Chinauthor=P.+J.+Parkauthor=R.+Kucherlapatiauthor=K.+A.+Hoadleyauthor=J.+Todd+Aumanauthor=C.+Fanauthor=Y.+J.+Turmanauthor=Y.+Shiauthor=L.+Liauthor=M.+D.+Topalauthor=X.+Heauthor=H.-H.+Chaoauthor=A.+Pratauthor=G.+O.+Silvaauthor=M.+D.+Iglesiaauthor=W.+Zhaoauthor=J.+Usaryauthor=J.+S.+Bergauthor=M.+Adamsauthor=J.+Bookerauthor=J.+Wuauthor=A.+Gulabaniauthor=T.+Bodenheimerauthor=A.+P.+Hoyleauthor=J.+V.+Simonsauthor=M.+G.+Solowayauthor=L.+E.+Moseauthor=S.+R.+Jefferysauthor=S.+Baluauthor=J.+S.+Parkerauthor=D.+Neil+Hayesauthor=C.+M.+Perouauthor=S.+Malikauthor=S.+Mahurkarauthor=H.+Shenauthor=D.+J.+Weisenbergerauthor=T.+Tricheauthor=P.+H.+Laiauthor=M.+S.+Bootwallaauthor=D.+T.+Maglinteauthor=B.+P.+Bermanauthor=D.+J.+Van+Den+Bergauthor=S.+B.+Baylinauthor=P.+W.+Lairdauthor=C.+J.+Creightonauthor=L.+A.+Donehowerauthor=G.+Getzauthor=M.+Nobleauthor=D.+Voetauthor=G.+Saksenaauthor=N.+Gehlenborgauthor=D.+DiCaraauthor=J.+Zhangauthor=H.+Zhangauthor=C.-J.+Wuauthor=S.+Yingchun+Liuauthor=M.+S.+Lawrenceauthor=L.+Zouauthor=A.+Sivachenkoauthor=P.+Linauthor=P.+Stojanovauthor=R.+Jingauthor=J.+Choauthor=R.+Sinhaauthor=R.+W.+Parkauthor=M.-D.+Nazaireauthor=J.+Robinsonauthor=H.+Thorvaldsdottirauthor=J.+Mesirovauthor=P.+J.+Parkauthor=L.+Chinauthor=S.+Reynoldsauthor=R.+B.+Kreisbergauthor=B.+Bernardauthor=R.+Bresslerauthor=T.+Erkkilaauthor=J.+Linauthor=V.+Thorssonauthor=W.+Zhangauthor=I.+Shmulevichauthor=G.+Cirielloauthor=N.+Weinholdauthor=N.+Schultzauthor=J.+Gaoauthor=E.+Ceramiauthor=B.+Grossauthor=A.+Jacobsenauthor=R.+Sinhaauthor=B.+Arman+Aksoyauthor=Y.+Antipinauthor=B.+Revaauthor=R.+Shenauthor=B.+S.+Taylorauthor=M.+Ladanyiauthor=C.+Sanderauthor=P.+Anurauthor=P.+T.+Spellmanauthor=Y.+Luauthor=W.+Liuauthor=R.+R.+G.+Verhaakauthor=G.+B.+Millsauthor=R.+Akbaniauthor=N.+Zhangauthor=B.+M.+Broomauthor=T.+D.+Casasentauthor=C.+Wakefieldauthor=A.+K.+Unruhauthor=K.+Baggerlyauthor=K.+Coombesauthor=J.+N.+Weinsteinauthor=D.+Hausslerauthor=C.+C.+Benzauthor=J.+M.+Stuartauthor=S.+C.+Benzauthor=J.+Zhuauthor=C.+C.+Szetoauthor=G.+K.+Scottauthor=C.+Yauauthor=E.+O.+Paullauthor=D.+Carlinauthor=C.+Wongauthor=A.+Sokolovauthor=J.+Thusbergauthor=S.+Mooneyauthor=S.+Ngauthor=T.+C.+Goldsteinauthor=K.+Ellrottauthor=M.+Griffordauthor=C.+Wilksauthor=S.+Maauthor=B.+Craftauthor=C.+Yanauthor=Y.+Huauthor=D.+Meerzamanauthor=J.+M.+Gastier-Fosterauthor=J.+Bowenauthor=N.+C.+Ramirezauthor=A.+D.+Blackauthor=R.+E.+Pyattauthor=P.+Whiteauthor=E.+J.+Zmudaauthor=J.+Frickauthor=T.+M.+Lichtenbergauthor=R.+Brookensauthor=M.+M.+Georgeauthor=M.+A.+Gerkenauthor=H.+A.+Harperauthor=K.+M.+Leraasauthor=L.+J.+Wiseauthor=T.+R.+Tablerauthor=C.+McAllisterauthor=T.+Barrauthor=M.+Hart-Kothariauthor=K.+Tarvinauthor=C.+Sallerauthor=G.+Sanduskyauthor=C.+Mitchellauthor=M.+V.+Iacoccaauthor=J.+Brownauthor=B.+Rabenoauthor=C.+Czerwinskiauthor=N.+Petrelliauthor=O.+Dolzhanskyauthor=M.+Abramovauthor=O.+Voroninaauthor=O.+Potapovaauthor=J.+R.+Marksauthor=W.+M.+Suchorskaauthor=D.+Murawaauthor=W.+Kyclerauthor=M.+Ibbsauthor=K.+Korskiauthor=A.+Spycha%C5%82aauthor=P.+Murawaauthor=J.+J.+Brzezi%C5%84skiauthor=H.+Perzauthor=R.+%C5%81a%C5%BAniakauthor=M.+Teresiakauthor=H.+Tatkaauthor=E.+Leporowskaauthor=M.+Bogusz-Czerniewiczauthor=J.+Malickiauthor=A.+Mackiewiczauthor=M.+Wiznerowiczauthor=X.+Van+Leauthor=B.+Kohlauthor=N.+Viet+Tienauthor=R.+Thorpauthor=N.+Van+Bangauthor=H.+Sussmanauthor=B.+Duc+Phuauthor=R.+Hajekauthor=N.+Phi+Hungauthor=T.+Viet+The+Phuongauthor=H.+Quyet+Thangauthor=K.+Zaki+Khanauthor=R.+Pennyauthor=D.+Malleryauthor=E.+Curleyauthor=C.+Sheltonauthor=P.+Yenaauthor=J.+N.+Ingleauthor=F.+J.+Couchauthor=W.+L.+Lingleauthor=T.+A.+Kingauthor=A.+Maria%0AGonzalez-Anguloauthor=G.+B.+Millsauthor=M.+D.+Dyerauthor=S.+Liuauthor=X.+Meng&title=Comprehensive+Molecular+Portraits+of+Human+Breast+Tumours&doi=10.1038%2Fnature11412"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142aR"><div class="casContent"><span class="casTitleNuber">142a</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive molecular portraits of human breast tumors</span></div><div class="casAuthors">Koboldt, Daniel C.; Fulton, Robert S.; McLellan, Michael D.; Schmidt, Heather; Kalicki-Veizer, Joelle; McMichael, Joshua F.; Fulton, Lucinda L.; Dooling, David J.; Ding, Li; Mardis, Elaine R.; Wilson, Richard K.; Ally, Adrian; Balasundaram, Miruna; Butterfield, Yaron S. N.; Carlsen, Rebecca; Carter, Candace; Chu, Andy; Chuah, Eric; Chun, Hye-Jung E.; Coope, Robin J. N.; Dhalla, Noreen; Guin, Ranabir; Hirst, Carrie; Hirst, Martin; Holt, Robert A.; Lee, Darlene; Li, Haiyan I.; Mayo, Michael; Moore, Richard A.; Mungall, Andrew J.; Pleasance, Erin; Gordon Robertson, A.; Schein, Jacqueline E.; Shafiei, Arash; Sipahimalani, Payal; Slobodan, Jared R.; Stoll, Dominik; Tam, Angela; Thiessen, Nina; Varhol, Richard J.; Wye, Natasja; Zeng, Thomas; Zhao, Yongjun; Birol, Inanc; Jones, Steven J. M.; Marra, Marco A.; Cherniack, Andrew D.; Saksena, Gordon; Onofrio, Robert C.; Pho, Nam H.; Carter, Scott L.; Schumacher, Steven E.; Tabak, Barbara; Hernandez, Bryan; Gentry, Jeff; Nguyen, Huy; Crenshaw, Andrew; Ardlie, Kristin; Beroukhim, Rameen; Winckler, Wendy; Getz, Gad; Gabriel, Stacey B.; Meyerson, Matthew; Chin, Lynda; Park, Peter J.; Kucherlapati, Raju; Hoadley, Katherine A.; Todd Auman, J.; Fan, Cheng; Turman, Yidi J.; Shi, Yan; Li, Ling; Topal, Michael D.; He, Xiaping; Chao, Hann-Hsiang; Prat, Aleix; Silva, Grace O.; Iglesia, Michael D.; Zhao, Wei; Usary, Jerry; Berg, Jonathan S.; Adams, Michael; Brooker, Jessica; Wu, Junyuan; Gulabani, Anisha; Bodenheimer, Tom; Hoyle, Alan P.; Simons, Janae V.; Soloway, Matthew G.; Mose, Lisle E.; Jefferys, Stuart R.; Balu, Saianand; Parker, Joel S.; Hayes, D. Neil; Perou, Charles M.; Malik, Simeen; Mahurkar, Swapna; Shen, Hui; Weisenberger, Daniel J.; Triche, Timothy, Jr.; Lai, Phillip H.; Bootwalla, Moiz S.; Maglinte, Dennis T.; Berman, Benjamin P.; Van Den Berg, David J.; Baylin, Stephen B.; Laird, Peter W.; Creighton, Chad J.; Donehower, Lawrence A.; Getz, Gad; Noble, Michael; Voet, Doug; Saksena, Gordon; Gehlenborg, Nils; DiCara, Daniel; Zhang, Juinhua; Zhang, Hailei; Wu, Chang-Jiun; Liu, Spring Yingchun; Lawrence, Michael S.; Zou, Lihua; Sivachenko, Andrey; Lin, Pei; Stojanov, Petar; Jing, Rui; Cho, Juok; Sinha, Raktim; Park, Richard W.; Nazaire, Marc-Danie; Robinson, Jim; Thorvaldsdottir, Helga; Mesirov, Jill; Park, Peter J.; Chin, Lynda; Reynolds, Sheila; Kreisberg, Richard B.; Bernard, Brady; Bressler, Ryan; Erkkila, Timo; Lin, Jake; Thorsson, Vesteinn; Zhang, Wei; Shmulevich, Ilya; Ciriello, Giovanni; Weinhold, Nils; Schultz, Nikolaus; Gao, Jianjiong; Cerami, Ethan; Gross, Benjamin; Jacobsen, Anders; Sinha, Rileen; Arman Aksoy, B.; Antipin, Yevgeniy; Reva, Boris; Shen, Ronglai; Taylor, Barry S.; Ladanyi, Marc; Sander, Chris; Anur, Pavana; Spellman, Paul T.; Lu, Yiling; Liu, Wenbin; Verhaak, Roel R. G.; Mills, Gordon B.; Akbani, Rehan; Zhang, Nianxiang; Broom, Bradley M.; Casasent, Tod D.; Wakefield, Chris; Unruh, Anna K.; Baggerly, Keith; Coombes, Kevin; Weinstein, John N.; Haussler, David; Benz, Christopher C.; Stuart, Joshua M.; Benz, Stephen C.; Zhu, Jingchun; Szeto, Christopher C.; Scott, Gary K.; Yau, Christina; Paull, Evan O.; Carlin, Daniel; Wong, Christopher; Sokolov, Artem; Thusberg, Janita; Mooney, Sean; Ng, Sam; Goldstein, Theodore C.; Ellrott, Kyle; Grifford, Mia; Wilks, Christopher; Ma, Singer; Craft, Brian; Yan, Chunhua; Hu, Ying; Meerzaman, Daoud; Gastier-Foster, Julie M.; Bowen, Jay; Ramirez, Nilsa C.; Black, Aaron D.; White, Peter; Zmuda, Erik J.; Frick, Jessica; Lichtenberg, Tara M.; Brookens, Robin; George, Myra M.; Gerken, Mark A.; Harper, Hollie A.; Leraas, Kristen M.; Wise, Lisa J.; Tabler, Teresa R.; McAllister, Cynthia; Barr, Thomas; Hart-Kothari, Melissa; Tarvin, Katie; Saller, Charles; Sandusky, George; Mitchell, Colleen; Iacocca, Mary V.; Brown, Jennifer; Rabeno, Brenda; Czerwinski, Christine; Petrelli, Nicholas; Dolzhansky, Oleg; Abramov, Mikhail; Voronina, Olga; Potapova, Olga; Marks, Jeffrey R.; Suchorska, Wiktoria M.; Murawa, Dawid; Kycler, Witold; Ibbs, Matthew; Korski, Konstanty; Spychala, Arkadiusz; Murawa, Pawel; Brzezinski, Jacek J.; Perz, Hanna; Lazniak, Radoslaw; Teresiak, Marek; Tatka, Honorata; Leporowska, Ewa; Bogusz-Czerniewicz, Marta; Malicki, Julian; Mackiewicz, Andrzej; Wiznerowicz, Maciej; Le, Xuan Van; Kohl, Bernard; Nguyen, Viet Tien; Thorp, Richard; Nguyen, Van Bang; Sussman, Howard; Phu, Bui Duc; Hajek, Richard; Nguyen, Phi Hung; Phuong, Tran Viet The; Thang, Huynh Quyet; Khan, Khurram Zaki; Penny, Robert; Mallery, David; Curley, Erin; Shelton, Candace; Yena, Peggy; Ingle, James N.; Couch, Fergus J.; Lingle, Wilma L.; King, Tari A.; Gonzalez-Angulo, Ana Maria; Mills, Gordon B.; Dyer, Mary D.; Liu, Shuying; Meng, Xiaolong; Patangan, Modesto; Waldman, Frederic; Stoeppler, Hubert; Rathmell, W. Kimryn; Thorne, Leigh; Huang, Mei; Boice, Lori; Hill, Ashley; Morrison, Carl; Gaudioso, Carmelo; Bshara, Wiam; Daily, Kelly; Egea, Sophie C.; Pegram, Mark D.; Gomez-Fernandez, Carmen; Dhir, Rajiv; Bhargava, Rohit; Brufsky, Adam; Shriver, Craig D.; Hooke, Jeffrey A.; Leigh Campbell, Jamie; Mural, Richard J.; Hu, Hai; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">490</span>
        (<span class="NLM_cas:issue">7418</span>),
    <span class="NLM_cas:pages">61-70</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We analyzed primary breast cancers by genomic DNA copy no. arrays, DNA methylation, exome sequencing, mRNA arrays, microRNA sequencing and reverse-phase protein arrays.  Our ability to integrate information across platforms provided key insights into previously defined gene expression subtypes and demonstrated the existence of four main breast cancer classes when combining data from five platforms, each of which shows significant mol. heterogeneity.  Somatic mutations in only three genes (TP53, PIK3CA and GATA3) occurred at >10% incidence across all breast cancers; however, there were numerous subtype-assocd. and novel gene mutations including the enrichment of specific mutations in GATA3, PIK3CA and MAP3K1 with the luminal A subtype.  We identified two novel protein-expression-defined subgroups, possibly produced by stromal/microenvironmental elements, and integrated analyses identified specific signaling pathways dominant in each mol. subtype including a HER2/phosphorylated HER2/EGFR/phosphorylated EGFR signature within the HER2-enriched expression subtype.  Comparison of basal-like breast tumors with high-grade serous ovarian tumors showed many mol. commonalities, indicating a related etiol. and similar therapeutic opportunities.  The biol. finding of the four main breast cancer subtypes caused by different subsets of genetic and epigenetic abnormalities raises the hypothesis that much of the clin. observable plasticity and heterogeneity occurs within, and not across, these major biol. subtypes of breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo931CeJ0ZZBrVg90H21EOLACvtfcHk0lispUInHOgI6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlyltrvN&md5=0836d0dd2c87f61c82fc0c5f33859407</span></div><a href="/servlet/linkout?suffix=cit142a&amp;dbid=16384&amp;doi=10.1038%2Fnature11412&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11412%26sid%3Dliteratum%253Aachs%26aulast%3DKoboldt%26aufirst%3DD.%2BC.%26aulast%3DFulton%26aufirst%3DR.%2BS.%26aulast%3DMcLellan%26aufirst%3DM.%2BD.%26aulast%3DSchmidt%26aufirst%3DH.%26aulast%3DKalicki-Veizer%26aufirst%3DJ.%26aulast%3DMcMichael%26aufirst%3DJ.%2BF.%26aulast%3DFulton%26aufirst%3DL.%2BL.%26aulast%3DDooling%26aufirst%3DD.%2BJ.%26aulast%3DDing%26aufirst%3DL.%26aulast%3DMardis%26aufirst%3DE.%2BR.%26aulast%3DWilson%26aufirst%3DR.%2BK.%26aulast%3DAlly%26aufirst%3DA.%26aulast%3DBalasundaram%26aufirst%3DM.%26aulast%3DButterfield%26aufirst%3DY.%2BS.%2BN.%26aulast%3DCarlsen%26aufirst%3DR.%26aulast%3DCarter%26aufirst%3DC.%26aulast%3DChu%26aufirst%3DA.%26aulast%3DChuah%26aufirst%3DE.%26aulast%3DChun%26aufirst%3DH.-J.%2BE.%26aulast%3DCoope%26aufirst%3DR.%2BJ.%2BN.%26aulast%3DDhalla%26aufirst%3DN.%26aulast%3DGuin%26aufirst%3DR.%26aulast%3DHirst%26aufirst%3DC.%26aulast%3DHirst%26aufirst%3DM.%26aulast%3DHolt%26aufirst%3DR.%2BA.%26aulast%3DLee%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DH.%2BI.%26aulast%3DMayo%26aufirst%3DM.%26aulast%3DMoore%26aufirst%3DR.%2BA.%26aulast%3DMungall%26aufirst%3DA.%2BJ.%26aulast%3DPleasance%26aufirst%3DE.%26aulast%3DGordon%2BRobertson%26aufirst%3DA.%26aulast%3DSchein%26aufirst%3DJ.%2BE.%26aulast%3DShafiei%26aufirst%3DA.%26aulast%3DSipahimalani%26aufirst%3DP.%26aulast%3DSlobodan%26aufirst%3DJ.%2BR.%26aulast%3DStoll%26aufirst%3DD.%26aulast%3DTam%26aufirst%3DA.%26aulast%3DThiessen%26aufirst%3DN.%26aulast%3DVarhol%26aufirst%3DR.%2BJ.%26aulast%3DWye%26aufirst%3DN.%26aulast%3DZeng%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DBirol%26aufirst%3DI.%26aulast%3DJones%26aufirst%3DS.%2BJ.%2BM.%26aulast%3DMarra%26aufirst%3DM.%2BA.%26aulast%3DCherniack%26aufirst%3DA.%2BD.%26aulast%3DSaksena%26aufirst%3DG.%26aulast%3DOnofrio%26aufirst%3DR.%2BC.%26aulast%3DPho%26aufirst%3DN.%2BH.%26aulast%3DCarter%26aufirst%3DS.%2BL.%26aulast%3DSchumacher%26aufirst%3DS.%2BE.%26aulast%3DTabak%26aufirst%3DB.%26aulast%3DHernandez%26aufirst%3DB.%26aulast%3DGentry%26aufirst%3DJ.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DCrenshaw%26aufirst%3DA.%26aulast%3DArdlie%26aufirst%3DK.%26aulast%3DBeroukhim%26aufirst%3DR.%26aulast%3DWinckler%26aufirst%3DW.%26aulast%3DGetz%26aufirst%3DG.%26aulast%3DGabriel%26aufirst%3DS.%2BB.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DChin%26aufirst%3DL.%26aulast%3DPark%26aufirst%3DP.%2BJ.%26aulast%3DKucherlapati%26aufirst%3DR.%26aulast%3DHoadley%26aufirst%3DK.%2BA.%26aulast%3DTodd%2BAuman%26aufirst%3DJ.%26aulast%3DFan%26aufirst%3DC.%26aulast%3DTurman%26aufirst%3DY.%2BJ.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DTopal%26aufirst%3DM.%2BD.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DChao%26aufirst%3DH.-H.%26aulast%3DPrat%26aufirst%3DA.%26aulast%3DSilva%26aufirst%3DG.%2BO.%26aulast%3DIglesia%26aufirst%3DM.%2BD.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DUsary%26aufirst%3DJ.%26aulast%3DBerg%26aufirst%3DJ.%2BS.%26aulast%3DAdams%26aufirst%3DM.%26aulast%3DBooker%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DGulabani%26aufirst%3DA.%26aulast%3DBodenheimer%26aufirst%3DT.%26aulast%3DHoyle%26aufirst%3DA.%2BP.%26aulast%3DSimons%26aufirst%3DJ.%2BV.%26aulast%3DSoloway%26aufirst%3DM.%2BG.%26aulast%3DMose%26aufirst%3DL.%2BE.%26aulast%3DJefferys%26aufirst%3DS.%2BR.%26aulast%3DBalu%26aufirst%3DS.%26aulast%3DParker%26aufirst%3DJ.%2BS.%26aulast%3DNeil%2BHayes%26aufirst%3DD.%26aulast%3DPerou%26aufirst%3DC.%2BM.%26aulast%3DMalik%26aufirst%3DS.%26aulast%3DMahurkar%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DWeisenberger%26aufirst%3DD.%2BJ.%26aulast%3DTriche%26aufirst%3DT.%26aulast%3DLai%26aufirst%3DP.%2BH.%26aulast%3DBootwalla%26aufirst%3DM.%2BS.%26aulast%3DMaglinte%26aufirst%3DD.%2BT.%26aulast%3DBerman%26aufirst%3DB.%2BP.%26aulast%3DVan%2BDen%2BBerg%26aufirst%3DD.%2BJ.%26aulast%3DBaylin%26aufirst%3DS.%2BB.%26aulast%3DLaird%26aufirst%3DP.%2BW.%26aulast%3DCreighton%26aufirst%3DC.%2BJ.%26aulast%3DDonehower%26aufirst%3DL.%2BA.%26aulast%3DGetz%26aufirst%3DG.%26aulast%3DNoble%26aufirst%3DM.%26aulast%3DVoet%26aufirst%3DD.%26aulast%3DSaksena%26aufirst%3DG.%26aulast%3DGehlenborg%26aufirst%3DN.%26aulast%3DDiCara%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DC.-J.%26aulast%3DYingchun%2BLiu%26aufirst%3DS.%26aulast%3DLawrence%26aufirst%3DM.%2BS.%26aulast%3DZou%26aufirst%3DL.%26aulast%3DSivachenko%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DP.%26aulast%3DStojanov%26aufirst%3DP.%26aulast%3DJing%26aufirst%3DR.%26aulast%3DCho%26aufirst%3DJ.%26aulast%3DSinha%26aufirst%3DR.%26aulast%3DPark%26aufirst%3DR.%2BW.%26aulast%3DNazaire%26aufirst%3DM.-D.%26aulast%3DRobinson%26aufirst%3DJ.%26aulast%3DThorvaldsdottir%26aufirst%3DH.%26aulast%3DMesirov%26aufirst%3DJ.%26aulast%3DPark%26aufirst%3DP.%2BJ.%26aulast%3DChin%26aufirst%3DL.%26aulast%3DReynolds%26aufirst%3DS.%26aulast%3DKreisberg%26aufirst%3DR.%2BB.%26aulast%3DBernard%26aufirst%3DB.%26aulast%3DBressler%26aufirst%3DR.%26aulast%3DErkkila%26aufirst%3DT.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DThorsson%26aufirst%3DV.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DShmulevich%26aufirst%3DI.%26aulast%3DCiriello%26aufirst%3DG.%26aulast%3DWeinhold%26aufirst%3DN.%26aulast%3DSchultz%26aufirst%3DN.%26aulast%3DGao%26aufirst%3DJ.%26aulast%3DCerami%26aufirst%3DE.%26aulast%3DGross%26aufirst%3DB.%26aulast%3DJacobsen%26aufirst%3DA.%26aulast%3DSinha%26aufirst%3DR.%26aulast%3DArman%2BAksoy%26aufirst%3DB.%26aulast%3DAntipin%26aufirst%3DY.%26aulast%3DReva%26aufirst%3DB.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DTaylor%26aufirst%3DB.%2BS.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DSander%26aufirst%3DC.%26aulast%3DAnur%26aufirst%3DP.%26aulast%3DSpellman%26aufirst%3DP.%2BT.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DVerhaak%26aufirst%3DR.%2BR.%2BG.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DAkbani%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DBroom%26aufirst%3DB.%2BM.%26aulast%3DCasasent%26aufirst%3DT.%2BD.%26aulast%3DWakefield%26aufirst%3DC.%26aulast%3DUnruh%26aufirst%3DA.%2BK.%26aulast%3DBaggerly%26aufirst%3DK.%26aulast%3DCoombes%26aufirst%3DK.%26aulast%3DWeinstein%26aufirst%3DJ.%2BN.%26aulast%3DHaussler%26aufirst%3DD.%26aulast%3DBenz%26aufirst%3DC.%2BC.%26aulast%3DStuart%26aufirst%3DJ.%2BM.%26aulast%3DBenz%26aufirst%3DS.%2BC.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DSzeto%26aufirst%3DC.%2BC.%26aulast%3DScott%26aufirst%3DG.%2BK.%26aulast%3DYau%26aufirst%3DC.%26aulast%3DPaull%26aufirst%3DE.%2BO.%26aulast%3DCarlin%26aufirst%3DD.%26aulast%3DWong%26aufirst%3DC.%26aulast%3DSokolov%26aufirst%3DA.%26aulast%3DThusberg%26aufirst%3DJ.%26aulast%3DMooney%26aufirst%3DS.%26aulast%3DNg%26aufirst%3DS.%26aulast%3DGoldstein%26aufirst%3DT.%2BC.%26aulast%3DEllrott%26aufirst%3DK.%26aulast%3DGrifford%26aufirst%3DM.%26aulast%3DWilks%26aufirst%3DC.%26aulast%3DMa%26aufirst%3DS.%26aulast%3DCraft%26aufirst%3DB.%26aulast%3DYan%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DMeerzaman%26aufirst%3DD.%26aulast%3DGastier-Foster%26aufirst%3DJ.%2BM.%26aulast%3DBowen%26aufirst%3DJ.%26aulast%3DRamirez%26aufirst%3DN.%2BC.%26aulast%3DBlack%26aufirst%3DA.%2BD.%26aulast%3DPyatt%26aufirst%3DR.%2BE.%26aulast%3DWhite%26aufirst%3DP.%26aulast%3DZmuda%26aufirst%3DE.%2BJ.%26aulast%3DFrick%26aufirst%3DJ.%26aulast%3DLichtenberg%26aufirst%3DT.%2BM.%26aulast%3DBrookens%26aufirst%3DR.%26aulast%3DGeorge%26aufirst%3DM.%2BM.%26aulast%3DGerken%26aufirst%3DM.%2BA.%26aulast%3DHarper%26aufirst%3DH.%2BA.%26aulast%3DLeraas%26aufirst%3DK.%2BM.%26aulast%3DWise%26aufirst%3DL.%2BJ.%26aulast%3DTabler%26aufirst%3DT.%2BR.%26aulast%3DMcAllister%26aufirst%3DC.%26aulast%3DBarr%26aufirst%3DT.%26aulast%3DHart-Kothari%26aufirst%3DM.%26aulast%3DTarvin%26aufirst%3DK.%26aulast%3DSaller%26aufirst%3DC.%26aulast%3DSandusky%26aufirst%3DG.%26aulast%3DMitchell%26aufirst%3DC.%26aulast%3DIacocca%26aufirst%3DM.%2BV.%26aulast%3DBrown%26aufirst%3DJ.%26aulast%3DRabeno%26aufirst%3DB.%26aulast%3DCzerwinski%26aufirst%3DC.%26aulast%3DPetrelli%26aufirst%3DN.%26aulast%3DDolzhansky%26aufirst%3DO.%26aulast%3DAbramov%26aufirst%3DM.%26aulast%3DVoronina%26aufirst%3DO.%26aulast%3DPotapova%26aufirst%3DO.%26aulast%3DMarks%26aufirst%3DJ.%2BR.%26aulast%3DSuchorska%26aufirst%3DW.%2BM.%26aulast%3DMurawa%26aufirst%3DD.%26aulast%3DKycler%26aufirst%3DW.%26aulast%3DIbbs%26aufirst%3DM.%26aulast%3DKorski%26aufirst%3DK.%26aulast%3DSpycha%25C5%2582a%26aufirst%3DA.%26aulast%3DMurawa%26aufirst%3DP.%26aulast%3DBrzezi%25C5%2584ski%26aufirst%3DJ.%2BJ.%26aulast%3DPerz%26aufirst%3DH.%26aulast%3D%25C5%2581a%25C5%25BAniak%26aufirst%3DR.%26aulast%3DTeresiak%26aufirst%3DM.%26aulast%3DTatka%26aufirst%3DH.%26aulast%3DLeporowska%26aufirst%3DE.%26aulast%3DBogusz-Czerniewicz%26aufirst%3DM.%26aulast%3DMalicki%26aufirst%3DJ.%26aulast%3DMackiewicz%26aufirst%3DA.%26aulast%3DWiznerowicz%26aufirst%3DM.%26aulast%3DVan%2BLe%26aufirst%3DX.%26aulast%3DKohl%26aufirst%3DB.%26aulast%3DViet%2BTien%26aufirst%3DN.%26aulast%3DThorp%26aufirst%3DR.%26aulast%3DVan%2BBang%26aufirst%3DN.%26aulast%3DSussman%26aufirst%3DH.%26aulast%3DDuc%2BPhu%26aufirst%3DB.%26aulast%3DHajek%26aufirst%3DR.%26aulast%3DPhi%2BHung%26aufirst%3DN.%26aulast%3DViet%2BThe%2BPhuong%26aufirst%3DT.%26aulast%3DQuyet%2BThang%26aufirst%3DH.%26aulast%3DZaki%2BKhan%26aufirst%3DK.%26aulast%3DPenny%26aufirst%3DR.%26aulast%3DMallery%26aufirst%3DD.%26aulast%3DCurley%26aufirst%3DE.%26aulast%3DShelton%26aufirst%3DC.%26aulast%3DYena%26aufirst%3DP.%26aulast%3DIngle%26aufirst%3DJ.%2BN.%26aulast%3DCouch%26aufirst%3DF.%2BJ.%26aulast%3DLingle%26aufirst%3DW.%2BL.%26aulast%3DKing%26aufirst%3DT.%2BA.%26aulast%3DMaria%2BGonzalez-Angulo%26aufirst%3DA.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DDyer%26aufirst%3DM.%2BD.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DMeng%26aufirst%3DX.%26atitle%3DComprehensive%2520Molecular%2520Portraits%2520of%2520Human%2520Breast%2520Tumours%26jtitle%3DNature%26date%3D2012%26volume%3D490%26spage%3D61%26epage%3D70%26doi%3D10.1038%2Fnature11412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit142b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sabine, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crozier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brookes, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drake, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piper, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Velde, C. J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasenburg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kieback, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markopoulos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dirix, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seynaeve, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rea, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartlett, J. M. S.</span></span> <span> </span><span class="NLM_article-title">Mutational Analysis of PI3K/AKT Signaling Pathway in Tamoxifen Exemestane Adjuvant Multinational Pathology Study</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">2951</span>– <span class="NLM_lpage">2958</span>, <span class="refDoi"> DOI: 10.1200/JCO.2013.53.8272</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1200%2FJCO.2013.53.8272" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=25071141" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVClt7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=2951-2958&author=V.+S.+Sabineauthor=C.+Crozierauthor=C.+L.+Brookesauthor=C.+Drakeauthor=T.+Piperauthor=C.+J.+H.+van+de+Veldeauthor=A.+Hasenburgauthor=D.+G.+Kiebackauthor=C.+Markopoulosauthor=L.+Dirixauthor=C.+Seynaeveauthor=D.+W.+Reaauthor=J.+M.+S.+Bartlett&title=Mutational+Analysis+of+PI3K%2FAKT+Signaling+Pathway+in+Tamoxifen+Exemestane+Adjuvant+Multinational+Pathology+Study&doi=10.1200%2FJCO.2013.53.8272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142bR"><div class="casContent"><span class="casTitleNuber">142b</span><div class="casTitle"><span class="NLM_cas:atitle">Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study</span></div><div class="casAuthors">Sabine, Vicky S.; Crozier, Cheryl; Brookes, Cassandra L.; Drake, Camilla; Piper, Tammy; van de Velde, Cornelis J. H.; Hasenburg, Annette; Kieback, Dirk G.; Markopoulos, Christos; Dirix, Luc; Seynaeve, Caroline; Rea, Daniel W.; Bartlett, John M. S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">2951-2958</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Deregulation of key PI3K/AKT pathway genes may contribute to endocrine resistance in breast cancer (BC).  PIK3CA is the most frequently mutated gene in luminal BC (∼ 35%); however, the effect of mutations in helical vs. kinase domains remains controversial.  We hypothesize that improved outcomes occur in patients with estrogen receptor-pos. (ER pos.) BC receiving endocrine therapy and possessing PIK3CA mutations.  Materials and Methods: DNA was extd. from 4,540 formalin-fixed paraffin-embedded BC samples from the Exemestane Vs. Tamoxifen-Exemestane pathol. study.  Mutational analyses were performed for 25 mutations (PIK3CA×10, AKT1×1, KRAS×5, HRAS×3, NRAS×2 and BRAF×4).  Results: PIK3CA mutations were frequent (39.8%), whereas RAS/RAF mutations were rare (< 1%).  In univariable analyses PIK3CA mutations were assocd. with significantly improved 5-yr distant relapse-free survival (DRFS; HR, 0.76; 95% CI, 0.63 to 0.91; P = .003).  However, a multivariable anal. correcting for known clin. and biol. prognostic factors failed to demonstrate that PIK3CA mutation status is an independent prognostic marker for DRFS (HR, 0.92; 95% CI, 0.75 to 1.12; P = .4012).  PIK3CA mutations were more frequent in low-risk luminal BCs (eg, grade 1 node v 3, node-neg. v -pos.), confounding the relationship between mutations and outcome.  Conclusion PIK3CA mutations are present in approx. 40% of luminal BCs but are not an independent predictor of outcome in the context of endocrine therapy, whereas RAS/RAF mutations are rare in luminal BC.  A complex relationship between low-risk cancers and PIK3CA mutations was identified.  Although the PI3K/AKT pathway remains a viable therapeutic target as the result of a high mutation frequency, PIK3CA mutations do not seem to affect residual risk following treatment with endocrine therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopC9qdV5seeLVg90H21EOLACvtfcHk0li3nOPnLoyt5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVClt7%252FI&md5=37cab79073c6cc4df51807e53f456c81</span></div><a href="/servlet/linkout?suffix=cit142b&amp;dbid=16384&amp;doi=10.1200%2FJCO.2013.53.8272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2013.53.8272%26sid%3Dliteratum%253Aachs%26aulast%3DSabine%26aufirst%3DV.%2BS.%26aulast%3DCrozier%26aufirst%3DC.%26aulast%3DBrookes%26aufirst%3DC.%2BL.%26aulast%3DDrake%26aufirst%3DC.%26aulast%3DPiper%26aufirst%3DT.%26aulast%3Dvan%2Bde%2BVelde%26aufirst%3DC.%2BJ.%2BH.%26aulast%3DHasenburg%26aufirst%3DA.%26aulast%3DKieback%26aufirst%3DD.%2BG.%26aulast%3DMarkopoulos%26aufirst%3DC.%26aulast%3DDirix%26aufirst%3DL.%26aulast%3DSeynaeve%26aufirst%3DC.%26aulast%3DRea%26aufirst%3DD.%2BW.%26aulast%3DBartlett%26aufirst%3DJ.%2BM.%2BS.%26atitle%3DMutational%2520Analysis%2520of%2520PI3K%252FAKT%2520Signaling%2520Pathway%2520in%2520Tamoxifen%2520Exemestane%2520Adjuvant%2520Multinational%2520Pathology%2520Study%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D32%26spage%3D2951%26epage%3D2958%26doi%3D10.1200%2FJCO.2013.53.8272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Furet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guagnano, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairhurst, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imbach-Weese, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruce, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritsch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blasco, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aichholz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caravatti, G.</span></span> <span> </span><span class="NLM_article-title">Discovery of NVP-BYL719 a Potent and Selective Phosphatidylinositol-3 Kinase Alpha Inhibitor Selected for Clinical Evaluation</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3741</span>– <span class="NLM_lpage">3748</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.05.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2Fj.bmcl.2013.05.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=23726034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC3sXosFaisrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=3741-3748&author=P.+Furetauthor=V.+Guagnanoauthor=R.+A.+Fairhurstauthor=P.+Imbach-Weeseauthor=I.+Bruceauthor=M.+Knappauthor=C.+Fritschauthor=F.+Blascoauthor=J.+Blanzauthor=R.+Aichholzauthor=J.+Hamonauthor=D.+Fabbroauthor=G.+Caravatti&title=Discovery+of+NVP-BYL719+a+Potent+and+Selective+Phosphatidylinositol-3+Kinase+Alpha+Inhibitor+Selected+for+Clinical+Evaluation&doi=10.1016%2Fj.bmcl.2013.05.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143aR"><div class="casContent"><span class="casTitleNuber">143a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation</span></div><div class="casAuthors">Furet, Pascal; Guagnano, Vito; Fairhurst, Robin A.; Imbach-Weese, Patricia; Bruce, Ian; Knapp, Mark; Fritsch, Christine; Blasco, Francesca; Blanz, Joachim; Aichholz, Reiner; Hamon, Jacques; Fabbro, Doriano; Caravatti, Giorgio</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3741-3748</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Phosphatidylinositol-3-kinase α (PI3Kα) is a therapeutic target of high interest in anticancer drug research.  On the basis of a binding model rationalizing the high selectivity and potency of a particular series of 2-aminothiazole compds. in inhibiting PI3Kα, a medicinal chem. program has led to the discovery of the clin. candidate NVP-BYL719 I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraN93Vwrfb4bVg90H21EOLACvtfcHk0li3nOPnLoyt5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXosFaisrY%253D&md5=a0d2d69e01e7a82a5fed04114105925e</span></div><a href="/servlet/linkout?suffix=cit143a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.05.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.05.007%26sid%3Dliteratum%253Aachs%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DGuagnano%26aufirst%3DV.%26aulast%3DFairhurst%26aufirst%3DR.%2BA.%26aulast%3DImbach-Weese%26aufirst%3DP.%26aulast%3DBruce%26aufirst%3DI.%26aulast%3DKnapp%26aufirst%3DM.%26aulast%3DFritsch%26aufirst%3DC.%26aulast%3DBlasco%26aufirst%3DF.%26aulast%3DBlanz%26aufirst%3DJ.%26aulast%3DAichholz%26aufirst%3DR.%26aulast%3DHamon%26aufirst%3DJ.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DCaravatti%26aufirst%3DG.%26atitle%3DDiscovery%2520of%2520NVP-BYL719%2520a%2520Potent%2520and%2520Selective%2520Phosphatidylinositol-3%2520Kinase%2520Alpha%2520Inhibitor%2520Selected%2520for%2520Clinical%2520Evaluation%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D3741%26epage%3D3748%26doi%3D10.1016%2Fj.bmcl.2013.05.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit143b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Gallou, I. S.</span>; <span class="NLM_string-name">Gauer, C.</span>; <span class="NLM_string-name">Stowasser, F.</span></span> <span> </span><span class="NLM_article-title">Preparation of Crystalline Form of (<i>S</i>)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-(4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)pyridin-4-yl]thiazol-2-yl)Amide and Its Use as PI3K Inhibitor</span>. <span class="NLM_patent">WO 2012016970 A1</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=I.+S.+Gallou&author=C.+Gauer&author=F.+Stowasser&title=Preparation+of+Crystalline+Form+of+%28S%29-Pyrrolidine-1%2C2-dicarboxylic+acid+2-amide+1-%284-methyl-5-%5B2-%282%2C2%2C2-trifluoro-1%2C1-dimethylethyl%29pyridin-4-yl%5Dthiazol-2-yl%29Amide+and+Its+Use+as+PI3K+Inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit143b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGallou%26aufirst%3DI.%2BS.%26atitle%3DPreparation%2520of%2520Crystalline%2520Form%2520of%2520%2528S%2529-Pyrrolidine-1%252C2-dicarboxylic%2520acid%25202-amide%25201-%25284-methyl-5-%255B2-%25282%252C2%252C2-trifluoro-1%252C1-dimethylethyl%2529pyridin-4-yl%255Dthiazol-2-yl%2529Amide%2520and%2520Its%2520Use%2520as%2520PI3K%2520Inhibitor%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit143c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Caponigro, G.</span>; <span class="NLM_string-name">Horn-Spirohn, T.</span>; <span class="NLM_string-name">Lehar, J.</span></span> <span> </span><span class="NLM_article-title">Pharmaceutical Combination Comprising the PI3K Inhibitor Alpelisib and the B-Raf Inhibitor Dabrafenib; the Use of Such Combination in the Treatment or Prevention of Cancer</span>. <span class="NLM_patent">WO 2017037573 A1</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=G.+Caponigro&author=T.+Horn-Spirohn&author=J.+Lehar&title=Pharmaceutical+Combination+Comprising+the+PI3K+Inhibitor+Alpelisib+and+the+B-Raf+Inhibitor+Dabrafenib%3B+the+Use+of+Such+Combination+in+the+Treatment+or+Prevention+of+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit143c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCaponigro%26aufirst%3DG.%26atitle%3DPharmaceutical%2520Combination%2520Comprising%2520the%2520PI3K%2520Inhibitor%2520Alpelisib%2520and%2520the%2520B-Raf%2520Inhibitor%2520Dabrafenib%253B%2520the%2520Use%2520of%2520Such%2520Combination%2520in%2520the%2520Treatment%2520or%2520Prevention%2520of%2520Cancer%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit143d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, R.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuo, Z.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y.-P.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, Antitumor Activity and Theoretical Calculation of Novel PI3Ka Inhibitors</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">103737</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2020.103737</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2Fj.bioorg.2020.103737" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=32193031" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlt1eltL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2020&pages=103737&author=R.-Y.+Jinauthor=T.+Tangauthor=S.+Zhouauthor=X.+Longauthor=H.+Guoauthor=J.+Zhouauthor=H.+Yanauthor=Z.+Liauthor=Z.-Y.+Zuoauthor=H.-L.+Xieauthor=Y.-P.+Tang&title=Design%2C+Synthesis%2C+Antitumor+Activity+and+Theoretical+Calculation+of+Novel+PI3Ka+Inhibitors&doi=10.1016%2Fj.bioorg.2020.103737"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143dR"><div class="casContent"><span class="casTitleNuber">143d</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, antitumor activity and theoretical calculation of novel PI3Ka inhibitors</span></div><div class="casAuthors">Jin, Ru-Yi; Tang, Tian; Zhou, Sha; Long, Xu; Guo, Hui; Zhou, Jing; Yan, Hao; Li, Zhi; Zuo, Zheng-Yu; Xie, Hong-Lei; Tang, Yu-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">103737</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">PI3Kα has been identified as an ideal target to treat with PIK3CA gene mutation disease, including drugs such as Alpelisib and Copanlisib.  Five purine analogs and four thiazole analogs were designed and synthesized.  Their enzymic activity against PI3Ka/β/γ/δ were tested, resp.  All compds. showed excellent selectivity in modulating PI3Ka activity, and parts of the compds. showed good inhibition.  Meanwhile, Autodock 4.2 was used to explore the binding mode of I (X = CH2), the most potent compd., with the target protein.  In addn., DFT was used to calc. the HOMO-LUMO maps of the compds. I (X = CH2, O)and pos. control.  This paper will provide some useful information for further drug design of PI3Kα inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpV3yML-gA7ZrVg90H21EOLACvtfcHk0lg-WxQAlrfdCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlt1eltL0%253D&md5=a37c7739138ee57a14c6a91688e3821e</span></div><a href="/servlet/linkout?suffix=cit143d&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2020.103737&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2020.103737%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DR.-Y.%26aulast%3DTang%26aufirst%3DT.%26aulast%3DZhou%26aufirst%3DS.%26aulast%3DLong%26aufirst%3DX.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DYan%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DZuo%26aufirst%3DZ.-Y.%26aulast%3DXie%26aufirst%3DH.-L.%26aulast%3DTang%26aufirst%3DY.-P.%26atitle%3DDesign%252C%2520Synthesis%252C%2520Antitumor%2520Activity%2520and%2520Theoretical%2520Calculation%2520of%2520Novel%2520PI3Ka%2520Inhibitors%26jtitle%3DBioorg.%2520Chem.%26date%3D2020%26volume%3D98%26spage%3D103737%26doi%3D10.1016%2Fj.bioorg.2020.103737" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Erb, B.</span>; <span class="NLM_string-name">Gallou, I. S.</span>; <span class="NLM_string-name">Kleinbeck, F. K.</span></span> <span> </span><span class="NLM_article-title">Process for the Preparation of <i>N</i>1-(Pyridinylthiazolyl)pyrrolidine-1,2-dicarboxamide Derivatives</span>. <span class="NLM_patent">WO 2012117071 A1</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=B.+Erb&author=I.+S.+Gallou&author=F.+K.+Kleinbeck&title=Process+for+the+Preparation+of+N1-%28Pyridinylthiazolyl%29pyrrolidine-1%2C2-dicarboxamide+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DErb%26aufirst%3DB.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%2520N1-%2528Pyridinylthiazolyl%2529pyrrolidine-1%252C2-dicarboxamide%2520Derivatives%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duggan, S.</span></span> <span> </span><span class="NLM_article-title">Darolutamide: First Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">1813</span>– <span class="NLM_lpage">1818</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01212-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs40265-019-01212-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31605368" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFGmsLzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=1813-1818&author=A.+Markhamauthor=S.+Duggan&title=Darolutamide%3A+First+Approval&doi=10.1007%2Fs40265-019-01212-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Darolutamide: First Approval</span></div><div class="casAuthors">Markham, Anthony; Duggan, Sean</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1813-1818</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Darolutamide (NUBEQA) is a structurally distinct non-steroidal androgen receptor antagonist being developed by Orion and Bayer as a treatment for prostate cancer.  Based on pos. results in the phase III ARAMIS trial, darolutamide was recently approved in the USA for the treatment of men with non-metastatic castration-resistant prostate cancer.  This article summarizes the milestones in the development of darolutamide leading to this first approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-yVESrmxlELVg90H21EOLACvtfcHk0lg-WxQAlrfdCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFGmsLzE&md5=1d5a9ca159a713d87f87ee4945e03c62</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01212-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01212-y%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26aulast%3DDuggan%26aufirst%3DS.%26atitle%3DDarolutamide%253A%2520First%2520Approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D1813%26epage%3D1818%26doi%3D10.1007%2Fs40265-019-01212-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gelmann, E. P.</span></span> <span> </span><span class="NLM_article-title">Molecular Biology of the Androgen Receptor</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">3001</span>– <span class="NLM_lpage">3015</span>, <span class="refDoi"> DOI: 10.1200/JCO.2002.10.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1200%2FJCO.2002.10.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=12089231" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BD38Xlslyrt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2002&pages=3001-3015&author=E.+P.+Gelmann&title=Molecular+Biology+of+the+Androgen+Receptor&doi=10.1200%2FJCO.2002.10.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular biology of the androgen receptor</span></div><div class="casAuthors">Gelmann, Edward P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3001-3015</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Androgen receptor (AR) is a member of the steroid hormone receptor family of mols.  AR primarily is responsible for mediating the physiol. effects of androgens by binding to specific DNA sequences that influence transcription of androgen-responsive genes.  The three-dimensional structure of the AR ligand-binding domain has shown it is similar to other steroid hormone receptors and that ligand binding alters the protein conformation to allow binding of coactivator mols. that amplify the hormone signal and mediate transcriptional initiation.  However, AR also undergoes intramol. interactions that regulate its interactions with coactivators and influence its activity.  A large no. of naturally occurring mutations of the human AR gene have provided important information about AR mol. structure and intermol. interactions.  AR is also a crit. mediator of prostate cancer promotion, conferring growth signals to prostate cancer cells throughout the natural history of the disease.  Late-stage prostate cancer, unresponsive to hormonal deprivation, sustains AR signaling through a diverse array of mol. strategies.  Variations in the AR gene may also confer genetic predisposition to prostate cancer development and severity.  Further understanding of AR action and new strategies to interfere with AR signaling hold promise for improving prostate cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGow1FLAt0Xj67Vg90H21EOLACvtfcHk0lg-WxQAlrfdCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xlslyrt7c%253D&md5=9bb664012a4ef9cdc841e56abddb5231</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1200%2FJCO.2002.10.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2002.10.018%26sid%3Dliteratum%253Aachs%26aulast%3DGelmann%26aufirst%3DE.%2BP.%26atitle%3DMolecular%2520Biology%2520of%2520the%2520Androgen%2520Receptor%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2002%26volume%3D20%26spage%3D3001%26epage%3D3015%26doi%3D10.1200%2FJCO.2002.10.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Taplin, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balk, S. P.</span></span> <span> </span><span class="NLM_article-title">Androgen Receptor: A Key Molecule in the Progression of Prostate Cancer to Hormone Independence</span>. <i>J. Cell. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">483</span>– <span class="NLM_lpage">190</span>, <span class="refDoi"> DOI: 10.1002/jcb.10653</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1002%2Fjcb.10653" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=14755679" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsVWjsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2004&pages=483-190&author=M.+E.+Taplinauthor=S.+P.+Balk&title=Androgen+Receptor%3A+A+Key+Molecule+in+the+Progression+of+Prostate+Cancer+to+Hormone+Independence&doi=10.1002%2Fjcb.10653"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147aR"><div class="casContent"><span class="casTitleNuber">147a</span><div class="casTitle"><span class="NLM_cas:atitle">Androgen receptor: A key molecule in the progression of prostate cancer to hormone independence</span></div><div class="casAuthors">Taplin, Mary-Ellen; Balk, Steven P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Biochemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">483-490</span>CODEN:
                <span class="NLM_cas:coden">JCEBD5</span>;
        ISSN:<span class="NLM_cas:issn">0730-2312</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">A review.  Despite earlier detection and recent advances in surgery and radiation, prostate cancer is second only to lung cancer in male cancer deaths in the United States.  Hormone therapy in the form of medical or surgical castration remains the mainstay of systemic treatment in prostate cancer.  Over the last 15 yr with the clin. use of prostate specific antigen (PSA), there has been a shift to using hormone therapy earlier in the disease course and for longer duration.  Despite initial favorable response to hormone therapy, over a period of time these tumors will develop androgen-independence that results in death.  The androgen receptor (AR) is central to the initiation and growth of prostate cancer and to its response to hormone therapy.  Analyses have shown that AR continues to be expressed in androgen-independent tumors and AR signaling remains intact as demonstrated by the expression of the AR regulated gene, PSA.  Androgen-independent prostate cancers have demonstrated a variety of AR alterations that are either not found in hormone naive tumors or found at lower frequency.  These changes include AR amplification, AR point mutation, and changes in expression of AR co-regulatory proteins.  These AR changes result in a "super AR" that can respond to lower concns. of androgens or to a wider variety of agonistic ligands.  There is also mounting evidence that AR can be activated in a ligand independent fashion by compds. such as growth factors or cytokines working independently or in combination.  These growth factors working through receptor tyrosine kinase pathways may promote AR activation and growth in low androgen environments.  The clin. significance of these AR alterations in the development and progression of androgen-independent prostate cancer remains to be detd.  Understanding the changes in AR signaling in the evolution of androgen-independent prostate cancer will be key to the development of more effective hormone therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcsjFuYf-yBrVg90H21EOLACvtfcHk0ljWF18mJ6bENw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsVWjsrc%253D&md5=2a61b4f669124bf5aba64a6b724dd7d4</span></div><a href="/servlet/linkout?suffix=cit147a&amp;dbid=16384&amp;doi=10.1002%2Fjcb.10653&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcb.10653%26sid%3Dliteratum%253Aachs%26aulast%3DTaplin%26aufirst%3DM.%2BE.%26aulast%3DBalk%26aufirst%3DS.%2BP.%26atitle%3DAndrogen%2520Receptor%253A%2520A%2520Key%2520Molecule%2520in%2520the%2520Progression%2520of%2520Prostate%2520Cancer%2520to%2520Hormone%2520Independence%26jtitle%3DJ.%2520Cell.%2520Biochem.%26date%3D2004%26volume%3D91%26spage%3D483%26epage%3D190%26doi%3D10.1002%2Fjcb.10653" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit147b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Heinlein, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span> <span> </span><span class="NLM_article-title">Androgen Receptor in Prostate Cancer</span>. <i>Endocr. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">276</span>– <span class="NLM_lpage">308</span>, <span class="refDoi"> DOI: 10.1210/er.2002-0032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1210%2Fer.2002-0032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=15082523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktFSqtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2004&pages=276-308&author=C.+A.+Heinleinauthor=C.+Chang&title=Androgen+Receptor+in+Prostate+Cancer&doi=10.1210%2Fer.2002-0032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147bR"><div class="casContent"><span class="casTitleNuber">147b</span><div class="casTitle"><span class="NLM_cas:atitle">Androgen receptor in prostate cancer</span></div><div class="casAuthors">Heinlein, Cynthia A.; Chang, Chawnshang</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine Reviews</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">276-308</span>CODEN:
                <span class="NLM_cas:coden">ERVIDP</span>;
        ISSN:<span class="NLM_cas:issn">0163-769X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">A review.  The normal development and maintenance of the prostate is dependent on androgen acting through the androgen receptor (AR).  AR remains important in the development and progression of prostate cancer.  AR expression is maintained throughout prostate cancer progression, and the majority of androgen-independent or hormone refractory prostate cancers express AR.  Mutation of AR, esp. mutations that result in a relaxation of AR ligand specificity, may contribute to the progression of prostate cancer and the failure of endocrine therapy by allowing AR transcriptional activation in response to antiandrogens or other endogenous hormones.  Similarly, alterations in the relative expression of AR coregulators have been found to occur with prostate cancer progression and may contribute to differences in AR ligand specificity or transcriptional activity.  Prostate cancer progression is also assocd. with increased growth factor prodn. and an altered response to growth factors by prostate cancer cells.  The kinase signal transduction cascades initiated by mitogenic growth factors modulate the transcriptional activity of AR and the interaction between AR and AR coactivators.  The inhibition of AR activity through mechanisms in addn. to androgen ablation, such as modulation of signal transduction pathways, may delay prostate cancer progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohu1DBHGGcpLVg90H21EOLACvtfcHk0ljWF18mJ6bENw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktFSqtLY%253D&md5=26055b1c7af99c71c9c9f6143b97a5ef</span></div><a href="/servlet/linkout?suffix=cit147b&amp;dbid=16384&amp;doi=10.1210%2Fer.2002-0032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fer.2002-0032%26sid%3Dliteratum%253Aachs%26aulast%3DHeinlein%26aufirst%3DC.%2BA.%26aulast%3DChang%26aufirst%3DC.%26atitle%3DAndrogen%2520Receptor%2520in%2520Prostate%2520Cancer%26jtitle%3DEndocr.%2520Rev.%26date%3D2004%26volume%3D25%26spage%3D276%26epage%3D308%26doi%3D10.1210%2Fer.2002-0032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moilanen, A.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riikonen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oksala, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravanti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aho, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wohlfahrt, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nykänen, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Törmäkangas, O. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palvimo, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kallio, P. J.</span></span> <span> </span><span class="NLM_article-title">Discovery of ODM-201, a New-Generation Androgen Receptor Inhibitor Targeting Resistance Mechanisms to Androgen Signaling-Directed Prostate Cancer Therapies</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">12007</span>, <span class="refDoi"> DOI: 10.1038/srep12007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1038%2Fsrep12007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=26137992" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A280%3ADC%252BC28%252Fgs1Grtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=12007&author=A.-M.+Moilanenauthor=R.+Riikonenauthor=R.+Oksalaauthor=L.+Ravantiauthor=E.+Ahoauthor=G.+Wohlfahrtauthor=P.+S.+Nyk%C3%A4nenauthor=O.+P.+T%C3%B6rm%C3%A4kangasauthor=J.+J.+Palvimoauthor=P.+J.+Kallio&title=Discovery+of+ODM-201%2C+a+New-Generation+Androgen+Receptor+Inhibitor+Targeting+Resistance+Mechanisms+to+Androgen+Signaling-Directed+Prostate+Cancer+Therapies&doi=10.1038%2Fsrep12007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies</span></div><div class="casAuthors">Moilanen Anu-Maarit; Riikonen Reetta; Oksala Riikka; Ravanti Laura; Aho Eija; Wohlfahrt Gerd; Nykanen Pirjo S; Tormakangas Olli P; Kallio Pekka J; Palvimo Jorma J</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">12007</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Activation of androgen receptor (AR) is crucial for prostate cancer growth.  Remarkably, also castration-resistant prostate cancer (CRPC) is dependent on functional AR, and several mechanisms have been proposed to explain the addiction.  Known causes of CRPC include gene amplification and overexpression as well as point mutations of AR.  We report here the pharmacological profile of ODM-201, a novel AR inhibitor that showed significant antitumor activity and a favorable safety profile in phase 1/2 studies in men with CRPC.  ODM-201 is a full and high-affinity AR antagonist that, similar to second-generation antiandrogens enzalutamide and ARN-509, inhibits testosterone-induced nuclear translocation of AR.  Importantly, ODM-201 also blocks the activity of the tested mutant ARs arising in response to antiandrogen therapies, including the F876L mutation that confers resistance to enzalutamide and ARN-509.  In addition, ODM-201 reduces the growth of AR-overexpressing VCaP prostate cancer cells both in vitro and in a castration-resistant VCaP xenograft model.  In contrast to other antiandrogens, ODM-201 shows negligible brain penetrance and does not increase serum testosterone levels in mice.  In conclusion, ODM-201 is a potent AR inhibitor that overcomes resistance to AR-targeted therapies by antagonizing both overexpressed and mutated ARs.  ODM-201 is currently in a phase 3 trial in CRPC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRGSs0XLGfdrZHZzFRCXxVKfW6udTcc2eYxNlhAjTbWr7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252Fgs1Grtg%253D%253D&md5=b7dddd064bec0bf7c3b828028820cdc9</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1038%2Fsrep12007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep12007%26sid%3Dliteratum%253Aachs%26aulast%3DMoilanen%26aufirst%3DA.-M.%26aulast%3DRiikonen%26aufirst%3DR.%26aulast%3DOksala%26aufirst%3DR.%26aulast%3DRavanti%26aufirst%3DL.%26aulast%3DAho%26aufirst%3DE.%26aulast%3DWohlfahrt%26aufirst%3DG.%26aulast%3DNyk%25C3%25A4nen%26aufirst%3DP.%2BS.%26aulast%3DT%25C3%25B6rm%25C3%25A4kangas%26aufirst%3DO.%2BP.%26aulast%3DPalvimo%26aufirst%3DJ.%2BJ.%26aulast%3DKallio%26aufirst%3DP.%2BJ.%26atitle%3DDiscovery%2520of%2520ODM-201%252C%2520a%2520New-Generation%2520Androgen%2520Receptor%2520Inhibitor%2520Targeting%2520Resistance%2520Mechanisms%2520to%2520Androgen%2520Signaling-Directed%2520Prostate%2520Cancer%2520Therapies%26jtitle%3DSci.%2520Rep.%26date%3D2015%26volume%3D5%26spage%3D12007%26doi%3D10.1038%2Fsrep12007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Laitinen, I.</span>; <span class="NLM_string-name">Karjalainen, O.</span></span> <span> </span><span class="NLM_article-title">Process for the Preparation of Androgen Receptor Antagonists and Intermediates Thereof</span>. <span class="NLM_patent">WO 2016162604</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=I.+Laitinen&author=O.+Karjalainen&title=Process+for+the+Preparation+of+Androgen+Receptor+Antagonists+and+Intermediates+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit149a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLaitinen%26aufirst%3DI.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%2520Androgen%2520Receptor%2520Antagonists%2520and%2520Intermediates%2520Thereof%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit149b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, D. L.</span></span> <span> </span><span class="NLM_article-title">Review of Synthetic Routes and Crystalline Forms of the Antiandrogen Oncology Drugs Enzalutamide, Apalutamide, and Darolutamide</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">347</span>– <span class="NLM_lpage">362</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.0c00005</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.0c00005" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref149/cit149b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjtl2ku7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2020&pages=347-362&author=D.+L.+Hughes&title=Review+of+Synthetic+Routes+and+Crystalline+Forms+of+the+Antiandrogen+Oncology+Drugs+Enzalutamide%2C+Apalutamide%2C+and+Darolutamide&doi=10.1021%2Facs.oprd.0c00005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149bR"><div class="casContent"><span class="casTitleNuber">149b</span><div class="casTitle"><span class="NLM_cas:atitle">Review of Synthetic Routes and Crystalline Forms of the Anti-Androgen Oncology Drugs Enzalutamide, Apalutamide, and Darolutamide</span></div><div class="casAuthors">Hughes, David L.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">347-362</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This article reviewed the synthetic routes and final cryst. forms of recently approved anti-androgen drugs enzalutamide, apalutamide, and darolutamide, used for treatment of prostate cancer.  The patent literature was the primary source of information.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJxg3gDFfY3bVg90H21EOLACvtfcHk0lgY4rExL_eAYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjtl2ku7k%253D&md5=4e5ef1b009701200500f5ea16744b1fa</span></div><a href="/servlet/linkout?suffix=cit149b&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.0c00005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.0c00005%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DD.%2BL.%26atitle%3DReview%2520of%2520Synthetic%2520Routes%2520and%2520Crystalline%2520Forms%2520of%2520the%2520Antiandrogen%2520Oncology%2520Drugs%2520Enzalutamide%252C%2520Apalutamide%252C%2520and%2520Darolutamide%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2020%26volume%3D24%26spage%3D347%26epage%3D362%26doi%3D10.1021%2Facs.oprd.0c00005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanna, K. S.</span></span> <span> </span><span class="NLM_article-title">Enfortumab Vedotin to Treat Urothelial Carcinoma</span>. <i>Drugs Today</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">335</span>, <span class="refDoi"> DOI: 10.1358/dot.2020.56.5.3127027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1358%2Fdot.2020.56.5.3127027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A280%3ADC%252BB38vmvVahtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2020&pages=329-335&author=K.+S.+Hanna&title=Enfortumab+Vedotin+to+Treat+Urothelial+Carcinoma&doi=10.1358%2Fdot.2020.56.5.3127027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Enfortumab vedotin to treat urothelial carcinoma</span></div><div class="casAuthors">Hanna K S</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of today (Barcelona, Spain : 1998)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">329-335</span>
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    </div><div class="casAbstract">The antibody-drug conjugate enfortumab vedotin is a fully humanized monoclonal antibody targeting Nectin-4 linked to a microtubule-disrupting agent, monomethyl auristatin E, via a protease-cleavable maleimidocaproyl valine-citrulline linker.  In this article, we provide a comprehensive review of the preclinical and clinical activity of enfortumab vedotin, which has been recently approved in the U.S. for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who have previously received a programmed cell death protein 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) inhibitor as well as platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting.  Enfortumab vedotin is the first antibody-drug conjugate approved for patients with urothelial carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQJU-wjw_aULU2yPDyEFiigfW6udTcc2eYIpLD5o-u5trntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38vmvVahtQ%253D%253D&md5=cf5fecfaae37104c4a9218f741b0117f</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1358%2Fdot.2020.56.5.3127027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2020.56.5.3127027%26sid%3Dliteratum%253Aachs%26aulast%3DHanna%26aufirst%3DK.%2BS.%26atitle%3DEnfortumab%2520Vedotin%2520to%2520Treat%2520Urothelial%2520Carcinoma%26jtitle%3DDrugs%2520Today%26date%3D2020%26volume%3D56%26spage%3D329%26epage%3D335%26doi%3D10.1358%2Fdot.2020.56.5.3127027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Satpayev, D.</span>; <span class="NLM_string-name">Morrison, R. K.</span>; <span class="NLM_string-name">Morrison, K. J. M.</span>; <span class="NLM_string-name">Gudas, J.</span>; <span class="NLM_string-name">Jakobovits, A.</span>; <span class="NLM_string-name">Torgov, M.</span>; <span class="NLM_string-name">An, Z.</span></span> <span> </span><span class="NLM_article-title">Antibody–Drug Conjugates That Bind to 191P4D12 Proteins and Their Use in Treatment of Cancer</span>. <span class="NLM_patent">US 20120078028 A1</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=D.+Satpayev&author=R.+K.+Morrison&author=K.+J.+M.+Morrison&author=J.+Gudas&author=A.+Jakobovits&author=M.+Torgov&author=Z.+An&title=Antibody%E2%80%93Drug+Conjugates+That+Bind+to+191P4D12+Proteins+and+Their+Use+in+Treatment+of+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSatpayev%26aufirst%3DD.%26atitle%3DAntibody%25E2%2580%2593Drug%2520Conjugates%2520That%2520Bind%2520to%2520191P4D12%2520Proteins%2520and%2520Their%2520Use%2520in%2520Treatment%2520of%2520Cancer%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Salama, Z. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keam, S. J.</span></span> <span> </span><span class="NLM_article-title">Entrectinib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">1477</span>– <span class="NLM_lpage">1483</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01177-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs40265-019-01177-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31372957" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A280%3ADC%252BB3MvktVemsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=1477-1483&author=Z.+T.+Al-Salamaauthor=S.+J.+Keam&title=Entrectinib%3A+First+Global+Approval&doi=10.1007%2Fs40265-019-01177-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152aR"><div class="casContent"><span class="casTitleNuber">152a</span><div class="casTitle"><span class="NLM_cas:atitle">Entrectinib: First Global Approval</span></div><div class="casAuthors">Al-Salama Zaina T; Keam Susan J</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1477-1483</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Entrectinib (Rozlytrek(®)) is an oral selective inhibitor of the tyrosine kinases tropomyosin receptor kinases (Trk)A/B/C [encoded by the genes neurotrophic tyrosine receptor kinase (NTRK) 1, 2 and 3, respectively], c-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK) with central nervous system (CNS) activity developed by Roche for the treatment of various solid tumours harbouring NTRK1/2/3 or ROS1 gene fusions.  In June 2019, entrectinib received its first global approval in Japan, for the treatment of adult and paediatric patients with NTRK fusion-positive, advanced or recurrent solid tumours and is under regulatory review for the treatment of adult patients with ROS1-positive non-small cell lung cancer (NSCLC).  Entrectinib is also under regulatory review in the USA (PDUFA date 18 August 2019) and EU [Priority Medicines (PRIME) designation] for NTRK-positive solid tumours and ROS1-positive NSCLC.  This article summarizes the milestones in the development of entrectinib leading to this first global approval for solid tumours in Japan.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRqIyGZmvQlpEkUaC_kzhvyfW6udTcc2eYIpLD5o-u5trntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MvktVemsg%253D%253D&md5=750c86d20c43273cf07f505988ac8dbd</span></div><a href="/servlet/linkout?suffix=cit152a&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01177-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01177-y%26sid%3Dliteratum%253Aachs%26aulast%3DAl-Salama%26aufirst%3DZ.%2BT.%26aulast%3DKeam%26aufirst%3DS.%2BJ.%26atitle%3DEntrectinib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D1477%26epage%3D1483%26doi%3D10.1007%2Fs40265-019-01177-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit152b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wehrmann, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golden, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naraparaju, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croucher, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacFarland, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolla, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cam, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornby, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodeur, G. M.</span></span> <span> </span><span class="NLM_article-title">Entrectinib Is a Potent Inhibitor of TRK-Driven Neuroblastomas in a Xenograft Mouse Model</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>372</i></span>,  <span class="NLM_fpage">179</span>– <span class="NLM_lpage">186</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2016.01.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2Fj.canlet.2016.01.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=26797418" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtF2nsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2016&pages=179-186&author=R.+Iyerauthor=L.+Wehrmannauthor=R.+L.+Goldenauthor=K.+Naraparajuauthor=J.+L.+Croucherauthor=S.+P.+MacFarlandauthor=P.+Guanauthor=V.+Kollaauthor=G.+Weiauthor=N.+Camauthor=G.+Liauthor=Z.+Hornbyauthor=G.+M.+Brodeur&title=Entrectinib+Is+a+Potent+Inhibitor+of+TRK-Driven+Neuroblastomas+in+a+Xenograft+Mouse+Model&doi=10.1016%2Fj.canlet.2016.01.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152bR"><div class="casContent"><span class="casTitleNuber">152b</span><div class="casTitle"><span class="NLM_cas:atitle">Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model</span></div><div class="casAuthors">Iyer, Radhika; Wehrmann, Lea; Golden, Rebecca L.; Naraparaju, Koumudi; Croucher, Jamie L.; MacFarland, Suzanne P.; Guan, Peng; Kolla, Venkatadri; Wei, Ge; Cam, Nicholas; Li, Gang; Hornby, Zachary; Brodeur, Garrett M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">179-186</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Neuroblastoma (NB) is one of the most common and deadly childhood solid tumors.  These tumors are characterized by clin. heterogeneity, from spontaneous regression to relentless progression, and the Trk family of neurotrophin receptors plays an important role in this heterogeneous behavior.  We wanted to det. if entrectinib (RXDX-101, Ignyta, Inc.), an oral Pan-Trk, Alk and Ros1 inhibitor, was effective in our NB model.  In vitro effects of entrectinib, either as a single agent or in combination with the chemotherapeutic agents Irinotecan (Irino) and Temozolomide (TMZ), were studied on an SH-SY5Y cell line stably transfected with TrkB.  In vivo growth inhibition activity was studied in NB xenografts, again as a single agent or in combination with Irino-TMZ.  Entrectinib significantly inhibited the growth of TrkB-expressing NB cells in vitro, and it significantly enhanced the growth inhibition of Irino-TMZ when used in combination.  Single agent therapy resulted in significant tumor growth inhibition in animals treated with entrectinib compared to control animals [p < 0.0001 for event-free survival (EFS)].  Addn. of entrectinib to Irino-TMZ also significantly improved the EFS of animals compared to vehicle or Irino-TMZ treated animals [p < 0.0001 for combination vs. control, p = 0.0012 for combination vs. Irino-TMZ].  We show that entrectinib inhibits growth of TrkB expressing NB cells in vitro and in vivo, and that it enhances the efficacy of conventional chemotherapy in in vivo models.  Our data suggest that entrectinib is a potent Trk inhibitor and should be tested in clin. trials for NBs and other Trk-expressing tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbMHXOlRcgw7Vg90H21EOLACvtfcHk0lgppPvycoPrSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtF2nsrs%253D&md5=61009162e126baedb2eb91d37c305fe9</span></div><a href="/servlet/linkout?suffix=cit152b&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2016.01.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2016.01.018%26sid%3Dliteratum%253Aachs%26aulast%3DIyer%26aufirst%3DR.%26aulast%3DWehrmann%26aufirst%3DL.%26aulast%3DGolden%26aufirst%3DR.%2BL.%26aulast%3DNaraparaju%26aufirst%3DK.%26aulast%3DCroucher%26aufirst%3DJ.%2BL.%26aulast%3DMacFarland%26aufirst%3DS.%2BP.%26aulast%3DGuan%26aufirst%3DP.%26aulast%3DKolla%26aufirst%3DV.%26aulast%3DWei%26aufirst%3DG.%26aulast%3DCam%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DHornby%26aufirst%3DZ.%26aulast%3DBrodeur%26aufirst%3DG.%2BM.%26atitle%3DEntrectinib%2520Is%2520a%2520Potent%2520Inhibitor%2520of%2520TRK-Driven%2520Neuroblastomas%2520in%2520a%2520Xenograft%2520Mouse%2520Model%26jtitle%3DCancer%2520Lett.%26date%3D2016%26volume%3D372%26spage%3D179%26epage%3D186%26doi%3D10.1016%2Fj.canlet.2016.01.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit152c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ricciuti, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brambilla, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baglivo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matocci, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiari, R.</span></span> <span> </span><span class="NLM_article-title">Targeting NTRK Fusion in Non-Small Cell Lung Cancer: Rationale and Clinical Evidence</span>. <i>Med. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">105</span>, <span class="refDoi"> DOI: 10.1007/s12032-017-0967-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs12032-017-0967-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=28444624" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A280%3ADC%252BC1crhtlartw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2017&pages=105&author=B.+Ricciutiauthor=M.+Brambillaauthor=G.+Metroauthor=S.+Baglivoauthor=R.+Matocciauthor=M.+Pirroauthor=R.+Chiari&title=Targeting+NTRK+Fusion+in+Non-Small+Cell+Lung+Cancer%3A+Rationale+and+Clinical+Evidence&doi=10.1007%2Fs12032-017-0967-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152cR"><div class="casContent"><span class="casTitleNuber">152c</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence</span></div><div class="casAuthors">Ricciuti Biagio; Brambilla Marta; Metro Giulio; Baglivo Sara; Matocci Roberta; Chiari Rita; Pirro Matteo</div><div class="citationInfo"><span class="NLM_cas:title">Medical oncology (Northwood, London, England)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">105</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">In the era of personalized medicine, the identification of targetable genetic alterations represented a major step forward in anticancer therapy.  NTRK rearrangements represent the molecular driver of a subset of solid tumors, including 3% of non-small-cell lung cancers (NSCLCs).  Preliminary data indicate that molecularly selected NSCLC patients harboring NTRK fusions derive an unprecedented clinical benefit from Trk-directed targeted therapies.  The aim of this review is to describe the molecular biology of NTRK signaling pathway and to summarize the preclinical data on novel Trk inhibitors, touching upon the clinical development of these inhibitors for the treatment of advanced NSCLC, which have already shown encouraging anticancer activity and acceptable safety profile in early phase I clinical trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQTnwSnq62_edHxxy173TfNfW6udTcc2eb0DyXGQhPElbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1crhtlartw%253D%253D&md5=5bda2359279c7a766d92663ce761b50f</span></div><a href="/servlet/linkout?suffix=cit152c&amp;dbid=16384&amp;doi=10.1007%2Fs12032-017-0967-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12032-017-0967-5%26sid%3Dliteratum%253Aachs%26aulast%3DRicciuti%26aufirst%3DB.%26aulast%3DBrambilla%26aufirst%3DM.%26aulast%3DMetro%26aufirst%3DG.%26aulast%3DBaglivo%26aufirst%3DS.%26aulast%3DMatocci%26aufirst%3DR.%26aulast%3DPirro%26aufirst%3DM.%26aulast%3DChiari%26aufirst%3DR.%26atitle%3DTargeting%2520NTRK%2520Fusion%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%253A%2520Rationale%2520and%2520Clinical%2520Evidence%26jtitle%3DMed.%2520Oncol.%26date%3D2017%26volume%3D34%26spage%3D105%26doi%3D10.1007%2Fs12032-017-0967-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit152d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Menichincheri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ardini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnaghi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avanzi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banfi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bossi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buffa, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canevari, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ceriani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colombo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donati, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fasolini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felder, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiorelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiorentini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isacchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgia, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchionni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nesi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orrenius, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panzeri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesenti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusconi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saccardo, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanotti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orsini, P.</span></span> <span> </span><span class="NLM_article-title">Discovery of Entrectinib: A New 3-Aminoindazole as a Potent Anaplastic Lymphoma Kinase (ALK), C-Ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) Inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">3392</span>– <span class="NLM_lpage">3408</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00064</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00064" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref152/cit152d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC28Xks1eitL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=3392-3408&author=M.+Menichincheriauthor=E.+Ardiniauthor=P.+Magnaghiauthor=N.+Avanziauthor=P.+Banfiauthor=R.+Bossiauthor=L.+Buffaauthor=G.+Canevariauthor=L.+Cerianiauthor=M.+Colomboauthor=L.+Cortiauthor=D.+Donatiauthor=M.+Fasoliniauthor=E.+Felderauthor=C.+Fiorelliauthor=F.+Fiorentiniauthor=A.+Galvaniauthor=A.+Isacchiauthor=A.+L.+Borgiaauthor=C.+Marchionniauthor=M.+Nesiauthor=C.+Orreniusauthor=A.+Panzeriauthor=E.+Pesentiauthor=L.+Rusconiauthor=M.+B.+Saccardoauthor=E.+Vanottiauthor=E.+Perroneauthor=P.+Orsini&title=Discovery+of+Entrectinib%3A+A+New+3-Aminoindazole+as+a+Potent+Anaplastic+Lymphoma+Kinase+%28ALK%29%2C+C-Ros+Oncogene+1+Kinase+%28ROS1%29%2C+and+Pan-Tropomyosin+Receptor+Kinases+%28Pan-TRKs%29+Inhibitor&doi=10.1021%2Facs.jmedchem.6b00064"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152dR"><div class="casContent"><span class="casTitleNuber">152d</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor</span></div><div class="casAuthors">Menichincheri, Maria; Ardini, Elena; Magnaghi, Paola; Avanzi, Nilla; Banfi, Patrizia; Bossi, Roberto; Buffa, Laura; Canevari, Giulia; Ceriani, Lucio; Colombo, Maristella; Corti, Luca; Donati, Daniele; Fasolini, Marina; Felder, Eduard; Fiorelli, Claudio; Fiorentini, Francesco; Galvani, Arturo; Isacchi, Antonella; Borgia, Andrea Lombardi; Marchionni, Chiara; Nesi, Marcella; Orrenius, Christian; Panzeri, Achille; Pesenti, Enrico; Rusconi, Luisa; Saccardo, Maria Beatrice; Vanotti, Ermes; Perrone, Ettore; Orsini, Paolo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3392-3408</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase responsible for the development of different tumor types.  Despite the remarkable clin. activity of crizotinib (Xalkori), the first ALK inhibitor approved in 2011, the emergence of resistance mutations and of brain metastases frequently causes relapse in patients.  Within the ALK drug discovery program, the authors identified compd. I, a novel 3-aminoindazole active on ALK in biochem. and in cellular assays.  Its optimization led to compd. II (entrectinib), a potent orally available ALK inhibitor active on ALK-dependent cell lines, efficiently penetrant the blood-brain barrier (BBB) in different animal species and highly efficacious in in vivo xenograft models.  Moreover, entrectinib resulted to be strictly potent on the closely related tyrosine kinases ROS1 and TRKs recently found constitutively activated in several tumor types.  Entrectinib is currently undergoing phase I/II clin. trial for the treatment of patients affected by ALK-, ROS1-, and TRK-pos. tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpU_xyLC5-GabVg90H21EOLACvtfcHk0lgppPvycoPrSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xks1eitL8%253D&md5=140217fba2ac81d71600f7344f2d8a3e</span></div><a href="/servlet/linkout?suffix=cit152d&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00064%26sid%3Dliteratum%253Aachs%26aulast%3DMenichincheri%26aufirst%3DM.%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DMagnaghi%26aufirst%3DP.%26aulast%3DAvanzi%26aufirst%3DN.%26aulast%3DBanfi%26aufirst%3DP.%26aulast%3DBossi%26aufirst%3DR.%26aulast%3DBuffa%26aufirst%3DL.%26aulast%3DCanevari%26aufirst%3DG.%26aulast%3DCeriani%26aufirst%3DL.%26aulast%3DColombo%26aufirst%3DM.%26aulast%3DCorti%26aufirst%3DL.%26aulast%3DDonati%26aufirst%3DD.%26aulast%3DFasolini%26aufirst%3DM.%26aulast%3DFelder%26aufirst%3DE.%26aulast%3DFiorelli%26aufirst%3DC.%26aulast%3DFiorentini%26aufirst%3DF.%26aulast%3DGalvani%26aufirst%3DA.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DBorgia%26aufirst%3DA.%2BL.%26aulast%3DMarchionni%26aufirst%3DC.%26aulast%3DNesi%26aufirst%3DM.%26aulast%3DOrrenius%26aufirst%3DC.%26aulast%3DPanzeri%26aufirst%3DA.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DRusconi%26aufirst%3DL.%26aulast%3DSaccardo%26aufirst%3DM.%2BB.%26aulast%3DVanotti%26aufirst%3DE.%26aulast%3DPerrone%26aufirst%3DE.%26aulast%3DOrsini%26aufirst%3DP.%26atitle%3DDiscovery%2520of%2520Entrectinib%253A%2520A%2520New%25203-Aminoindazole%2520as%2520a%2520Potent%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%252C%2520C-Ros%2520Oncogene%25201%2520Kinase%2520%2528ROS1%2529%252C%2520and%2520Pan-Tropomyosin%2520Receptor%2520Kinases%2520%2528Pan-TRKs%2529%2520Inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D3392%26epage%3D3408%26doi%3D10.1021%2Facs.jmedchem.6b00064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit152e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Rolfo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giovannetti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gil-Bazo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Passiglia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giallombardo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peeters, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raez, L.</span></span> <span> </span><span class="NLM_article-title">Entrectinib: A Potent New TRK, ROS1, and ALK Inhibitor</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1493</span>– <span class="NLM_lpage">1500</span>, <span class="refDoi"> DOI: 10.1517/13543784.2015.1096344</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1517%2F13543784.2015.1096344" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=26457764" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslGiurfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2015&pages=1493-1500&author=C.+Rolfoauthor=R.+Ruizauthor=E.+Giovannettiauthor=I.+Gil-Bazoauthor=A.+Russoauthor=F.+Passigliaauthor=M.+Giallombardoauthor=M.+Peetersauthor=L.+Raez&title=Entrectinib%3A+A+Potent+New+TRK%2C+ROS1%2C+and+ALK+Inhibitor&doi=10.1517%2F13543784.2015.1096344"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152eR"><div class="casContent"><span class="casTitleNuber">152e</span><div class="casTitle"><span class="NLM_cas:atitle">Entrectinib: a potent new TRK, ROS1, and ALK inhibitor</span></div><div class="casAuthors">Rolfo, Christian; Ruiz, Rossana; Giovannetti, Elisa; Gil-Bazo, Ignacio; Russo, Antonio; Passiglia, Francesco; Giallombardo, Marco; Peeters, Marc; Raez, Luis</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1493-1500</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Entrectinib: Receptor tyrosine kinases (RTKs) and their signaling pathways, control normal cellular processes; however, their deregulation play important roles in malignant transformation.  In advanced non-small cell lung cancer (NSCLC), the recognition of oncogenic activation of specific RTKs, has led to the development of molecularly targeted agents that only benefit roughly 20% of patients.  Entrectinib is a pan-TRK, ROS1 and ALK inhibitor that has shown potent anti-neoplastic activity and tolerability in various neoplastic conditions, particularly NSCLC.  This review outlines the pharmacokinetics, pharmacodynamics, mechanism of action, safety, tolerability, pre-clin. studies and clin. trials of entrectinib, a promising novel agent for the treatment of advanced solid tumors with mol. alterations of Trk-A, B and C, ROS1 or ALK.: Among the several exptl. drugs under clin. development, entrectinib is emerging as an innovative and promising targeted agent.  The encouraging antitumor activity reported in the Phase 1 studies, together with the acceptable toxicity profile, suggest that entrectinib, thanks to its peculiar mechanism of action, could play an important role in the treatment-strategies of multiple TRK-A, B, C, ROS1, and ALK- dependent solid tumors, including NSCLC and colorectal cancer.  That being said, further evidence for its clin. use is still needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1dnNvbW7UarVg90H21EOLACvtfcHk0lgSiFaYbDfyuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslGiurfN&md5=0affa310c3da8996f49cc1b7b931fa68</span></div><a href="/servlet/linkout?suffix=cit152e&amp;dbid=16384&amp;doi=10.1517%2F13543784.2015.1096344&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2015.1096344%26sid%3Dliteratum%253Aachs%26aulast%3DRolfo%26aufirst%3DC.%26aulast%3DRuiz%26aufirst%3DR.%26aulast%3DGiovannetti%26aufirst%3DE.%26aulast%3DGil-Bazo%26aufirst%3DI.%26aulast%3DRusso%26aufirst%3DA.%26aulast%3DPassiglia%26aufirst%3DF.%26aulast%3DGiallombardo%26aufirst%3DM.%26aulast%3DPeeters%26aufirst%3DM.%26aulast%3DRaez%26aufirst%3DL.%26atitle%3DEntrectinib%253A%2520A%2520Potent%2520New%2520TRK%252C%2520ROS1%252C%2520and%2520ALK%2520Inhibitor%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2015%26volume%3D24%26spage%3D1493%26epage%3D1500%26doi%3D10.1517%2F13543784.2015.1096344" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><a href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc" class="extLink">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc</a> (accessed 2020-12-18).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fresources-information-approved-drugs%2Ffda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc+%28accessed+2020-12-18%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><a href="https://cancerdiscovery.aacrjournals.org/content/9/10/OF2" class="extLink">https://cancerdiscovery.aacrjournals.org/content/9/10/OF2</a> (accessed 2020-06-11).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fcancerdiscovery.aacrjournals.org%2Fcontent%2F9%2F10%2FOF2+%28accessed+2020-06-11%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drilon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siena, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dziadziuszko, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlesi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krebs, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Braud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolfo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karapetis, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arkenau, H.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chae, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otterson, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murakami, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, D. S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prenen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riehl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow-Maneval, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmons, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doebele, R. C.</span></span> <span> </span><span class="NLM_article-title">Entrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer: Integrated Analysis of Three Phase 1–2 Trials</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">261</span>– <span class="NLM_lpage">270</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(19)30690-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2FS1470-2045%2819%2930690-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31838015" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlyht7nM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2020&pages=261-270&author=A.+Drilonauthor=S.+Sienaauthor=R.+Dziadziuszkoauthor=F.+Barlesiauthor=M.+G.+Krebsauthor=A.+T.+Shawauthor=F.+de+Braudauthor=C.+Rolfoauthor=M.-J.+Ahnauthor=J.+Wolfauthor=T.+Setoauthor=B.+C.+Choauthor=M.+R.+Patelauthor=C.-H.+Chiuauthor=T.+Johnauthor=K.+Gotoauthor=C.+S.+Karapetisauthor=H.-T.+Arkenauauthor=S.-W.+Kimauthor=Y.+Oheauthor=Y.-C.+Liauthor=Y.+K.+Chaeauthor=C.+H.+Chungauthor=G.+A.+Ottersonauthor=H.+Murakamiauthor=C.-C.+Linauthor=D.+S.+W.+Tanauthor=H.+Prenenauthor=T.+Riehlauthor=E.+Chow-Manevalauthor=B.+Simmonsauthor=N.+Cuiauthor=A.+Johnsonauthor=S.+Engauthor=T.+R.+Wilsonauthor=R.+C.+Doebele&title=Entrectinib+in+ROS1+Fusion-Positive+Non-Small-Cell+Lung+Cancer%3A+Integrated+Analysis+of+Three+Phase+1%E2%80%932+Trials&doi=10.1016%2FS1470-2045%2819%2930690-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials</span></div><div class="casAuthors">Drilon, Alexander; Siena, Salvatore; Dziadziuszko, Rafal; Barlesi, Fabrice; Krebs, Matthew G.; Shaw, Alice T.; de Braud, Filippo; Rolfo, Christian; Ahn, Myung-Ju; Wolf, Jurgen; Seto, Takashi; Cho, Byoung Chul; Patel, Manish R.; Chiu, Chao-Hua; John, Thomas; Goto, Koichi; Karapetis, Christos S.; Arkenau, Hendrick-Tobias; Kim, Sang-We; Ohe, Yuichiro; Li, Yu-Chung; Chae, Young K.; Chung, Christine H.; Otterson, Gregory A.; Murakami, Haruyasu; Lin, Chia-Chi; Tan, Daniel S. W.; Prenen, Hans; Riehl, Todd; Chow-Maneval, Edna; Simmons, Brian; Cui, Na; Johnson, Ann; Eng, Susan; Wilson, Timothy R.; Doebele, Robert C.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">261-270</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Recurrent gene fusions, such as ROS1 fusions, are oncogenic drivers of various cancers, including non-small-cell lung cancer (NSCLC).  Up to 36% of patients with ROS1 fusion-pos. NSCLC have brain metastases at the diagnosis of advanced disease.  Entrectinib is a ROS1 inhibitor that has been designed to effectively penetrate and remain in the CNS.  We explored the use of entrectinib in patients with locally advanced or metastatic ROS1 fusion-pos. NSCLC.  We did an integrated anal. of three ongoing phase 1 or 2 trials of entrectinib (ALKA-372-001, STARTRK-1, and STARTRK-2).  The efficacy-evaluable population included adult patients (aged ≥18 years) with locally advanced or metastatic ROS1 fusion-pos. NSCLC who received entrectinib at a dose of at least 600 mg orally once per day, with at least 12 mo' follow-up.  All patients had an Eastern Cooperative Oncol. Group performance status of 0-2, and previous cancer treatment (except for ROS1 inhibitors) was allowed.  The primary endpoints were the proportion of patients with an objective response (complete or partial response according to Response Evaluation Criteria in Solid Tumors version 1.1) and duration of response, and were evaluated by blinded independent central review.  The safety-evaluable population for the safety anal. included all patients with ROS1 fusion-pos. NSCLC in the three trials who received at least one dose of entrectinib (irresp. of dose or duration of follow-up).  These ongoing studies are registered with ClinicalTrials.gov, NCT02097810 (STARTRK-1) and NCT02568267 (STARTRK-2), and EudraCT, 2012-000148-88 (ALKA-372-001).  Patients were enrolled in ALKA-372-001 from Oct 26, 2012, to March 27, 2018; in STARTRK-1 from Aug 7, 2014, to May 10, 2018; and in STARTRK-2 from Nov 19, 2015 (enrolment is ongoing).  At the data cutoff date for this anal. (May 31, 2018), 41 (77%; 95% CI 64-88) of 53 patients in the efficacy-evaluable population had an objective response.  Median follow-up was 15·5 monhts (IQR 13·4-20·2).  Median duration of response was 24·6 mo (95% CI 11·4-34·8).  In the safety-evaluable population, 79 (59%) of 134 patients had grade 1 or 2 treatment-related adverse events. 46 (34%) of 134 patients had grade 3 or 4 treatment-related adverse events, with the most common being wt. increase (ten [8%]) and neutropenia (five [4%]). 15 (11%) patients had serious treatment-related adverse events, the most common of which were nervous system disorders (four [3%]) and cardiac disorders (three [2%]).  No treatment-related deaths occurred.  Entrectinib is active with durable disease control in patients with ROS1 fusion-pos. NSCLC, and is well tolerated with a manageable safety profile, making it amenable to long-term dosing in these patients.  These data highlight the need to routinely test for ROS1 fusions to broaden therapeutic options for patients with ROS1 fusion-pos. NSCLC.Ignyta/F Hoffmann-La Roche.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWfS5hEFDF4rVg90H21EOLACvtfcHk0lgSiFaYbDfyuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlyht7nM&md5=8c451f65061d0ad0ac6bd8f6730ab51c</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2819%2930690-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252819%252930690-4%26sid%3Dliteratum%253Aachs%26aulast%3DDrilon%26aufirst%3DA.%26aulast%3DSiena%26aufirst%3DS.%26aulast%3DDziadziuszko%26aufirst%3DR.%26aulast%3DBarlesi%26aufirst%3DF.%26aulast%3DKrebs%26aufirst%3DM.%2BG.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3Dde%2BBraud%26aufirst%3DF.%26aulast%3DRolfo%26aufirst%3DC.%26aulast%3DAhn%26aufirst%3DM.-J.%26aulast%3DWolf%26aufirst%3DJ.%26aulast%3DSeto%26aufirst%3DT.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DPatel%26aufirst%3DM.%2BR.%26aulast%3DChiu%26aufirst%3DC.-H.%26aulast%3DJohn%26aufirst%3DT.%26aulast%3DGoto%26aufirst%3DK.%26aulast%3DKarapetis%26aufirst%3DC.%2BS.%26aulast%3DArkenau%26aufirst%3DH.-T.%26aulast%3DKim%26aufirst%3DS.-W.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DY.-C.%26aulast%3DChae%26aufirst%3DY.%2BK.%26aulast%3DChung%26aufirst%3DC.%2BH.%26aulast%3DOtterson%26aufirst%3DG.%2BA.%26aulast%3DMurakami%26aufirst%3DH.%26aulast%3DLin%26aufirst%3DC.-C.%26aulast%3DTan%26aufirst%3DD.%2BS.%2BW.%26aulast%3DPrenen%26aufirst%3DH.%26aulast%3DRiehl%26aufirst%3DT.%26aulast%3DChow-Maneval%26aufirst%3DE.%26aulast%3DSimmons%26aufirst%3DB.%26aulast%3DCui%26aufirst%3DN.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DEng%26aufirst%3DS.%26aulast%3DWilson%26aufirst%3DT.%2BR.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26atitle%3DEntrectinib%2520in%2520ROS1%2520Fusion-Positive%2520Non-Small-Cell%2520Lung%2520Cancer%253A%2520Integrated%2520Analysis%2520of%2520Three%2520Phase%25201%25E2%2580%25932%2520Trials%26jtitle%3DLancet%2520Oncol.%26date%3D2020%26volume%3D21%26spage%3D261%26epage%3D270%26doi%3D10.1016%2FS1470-2045%2819%2930690-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Lombardi Borgia, A.</span>; <span class="NLM_string-name">Menichincheri, M.</span>; <span class="NLM_string-name">Orsini, P.</span>; <span class="NLM_string-name">Panzeri, A.</span>; <span class="NLM_string-name">Perrone, E.</span>; <span class="NLM_string-name">Vanotti, E.</span>; <span class="NLM_string-name">Nesi, M.</span>; <span class="NLM_string-name">Marchionni, C.</span></span> <span> </span><span class="NLM_article-title">Preparation of Substituted Indazole Derivatives for Use as Kinase Inhibitors</span>. <span class="NLM_patent">WO 2009013126 A1</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=A.+Lombardi+Borgia&author=M.+Menichincheri&author=P.+Orsini&author=A.+Panzeri&author=E.+Perrone&author=E.+Vanotti&author=M.+Nesi&author=C.+Marchionni&title=Preparation+of+Substituted+Indazole+Derivatives+for+Use+as+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit156a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLombardi%2BBorgia%26aufirst%3DA.%26atitle%3DPreparation%2520of%2520Substituted%2520Indazole%2520Derivatives%2520for%2520Use%2520as%2520Kinase%2520Inhibitors%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit156b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Menichincheri, M.</span>; <span class="NLM_string-name">Bertrand, J. A.</span>; <span class="NLM_string-name">Marchionni, C.</span>; <span class="NLM_string-name">Nesi, M.</span>; <span class="NLM_string-name">Orsini, P.</span>; <span class="NLM_string-name">Panzeri, A.</span></span> <span> </span><span class="NLM_article-title">Preparation of Substituted Indazole Derivatives Active as Kinase Inhibitors for Treating Cancer, Cell Proliferative Disorders, and Other Diseases</span>. <span class="NLM_patent">WO 2010069966 A1</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=M.+Menichincheri&author=J.+A.+Bertrand&author=C.+Marchionni&author=M.+Nesi&author=P.+Orsini&author=A.+Panzeri&title=Preparation+of+Substituted+Indazole+Derivatives+Active+as+Kinase+Inhibitors+for+Treating+Cancer%2C+Cell+Proliferative+Disorders%2C+and+Other+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit156b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMenichincheri%26aufirst%3DM.%26atitle%3DPreparation%2520of%2520Substituted%2520Indazole%2520Derivatives%2520Active%2520as%2520Kinase%2520Inhibitors%2520for%2520Treating%2520Cancer%252C%2520Cell%2520Proliferative%2520Disorders%252C%2520and%2520Other%2520Diseases%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barbugian, N. A.</span>; <span class="NLM_string-name">Forino, R.</span>; <span class="NLM_string-name">Fumagalli, T.</span>; <span class="NLM_string-name">Orsini, P.</span></span> <span> </span><span class="NLM_article-title">Process for the Preparation of <i>N</i>-[5-(3,5-Difluorobenzyl)-1<i>H</i>-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(tetrahydropyran-4-ylamino)-benzamide</span>. <span class="NLM_patent">WO 2013174876 A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=N.+A.+Barbugian&author=R.+Forino&author=T.+Fumagalli&author=P.+Orsini&title=Process+for+the+Preparation+of+N-%5B5-%283%2C5-Difluorobenzyl%29-1H-indazol-3-yl%5D-4-%284-methylpiperazin-1-yl%29-2-%28tetrahydropyran-4-ylamino%29-benzamide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBarbugian%26aufirst%3DN.%2BA.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%2520N-%255B5-%25283%252C5-Difluorobenzyl%2529-1H-indazol-3-yl%255D-4-%25284-methylpiperazin-1-yl%2529-2-%2528tetrahydropyran-4-ylamino%2529-benzamide%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murray, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newell, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angibaud, P.</span></span> <span> </span><span class="NLM_article-title">A Successful Collaboration between Academia, Biotech and Pharma Led to Discovery of Erdafitinib, a Selective FGFR Inhibitor Recently Approved by the FDA</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1509</span>– <span class="NLM_lpage">1511</span>, <span class="refDoi"> DOI: 10.1039/C9MD90044F</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1039%2FC9MD90044F" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1Oms73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1509-1511&author=C.+W.+Murrayauthor=D.+R.+Newellauthor=P.+Angibaud&title=A+Successful+Collaboration+between+Academia%2C+Biotech+and+Pharma+Led+to+Discovery+of+Erdafitinib%2C+a+Selective+FGFR+Inhibitor+Recently+Approved+by+the+FDA&doi=10.1039%2FC9MD90044F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">A successful collaboration between academia, biotech and pharma led to discovery of erdafitinib, a selective FGFR inhibitor recently approved by the FDA</span></div><div class="casAuthors">Murray, Christopher W.; Newell, David R.; Angibaud, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1509-1511</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPXodFayPaObVg90H21EOLACvtfcHk0lgtylK4WqsWJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1Oms73P&md5=dab27c44172ffb251ad03a53ffa2176b</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1039%2FC9MD90044F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC9MD90044F%26sid%3Dliteratum%253Aachs%26aulast%3DMurray%26aufirst%3DC.%2BW.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DAngibaud%26aufirst%3DP.%26atitle%3DA%2520Successful%2520Collaboration%2520between%2520Academia%252C%2520Biotech%2520and%2520Pharma%2520Led%2520to%2520Discovery%2520of%2520Erdafitinib%252C%2520a%2520Selective%2520FGFR%2520Inhibitor%2520Recently%2520Approved%2520by%2520the%2520FDA%26jtitle%3DMedChemComm%26date%3D2019%26volume%3D10%26spage%3D1509%26epage%3D1511%26doi%3D10.1039%2FC9MD90044F" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><a href="http://www.janssen.com/balversa-erdafitinib-receives-us-fda-approval-treatment-patients-locally-advanced-or-metastatic" class="extLink">www.janssen.com/balversa-erdafitinib-receives-us-fda-approval-treatment-patients-locally-advanced-or-metastatic</a> (accessed 2020-12-18).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=www.janssen.com%2Fbalversa-erdafitinib-receives-us-fda-approval-treatment-patients-locally-advanced-or-metastatic+%28accessed+2020-12-18%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><a href="https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-metastatic-bladder-cancer" class="extLink">https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-metastatic-bladder-cancer</a> (accessed 2020-12-18).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-approves-first-targeted-therapy-metastatic-bladder-cancer+%28accessed+2020-12-18%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><a href="https://seer.cancer.gov/statfacts/html/urinb.html" class="extLink">https://seer.cancer.gov/statfacts/html/urinb.html</a> (accessed 2020-09-15).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fseer.cancer.gov%2Fstatfacts%2Fhtml%2Furinb.html+%28accessed+2020-09-15%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212018s000lbl.pdf" class="extLink">https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212018s000lbl.pdf</a> (accessed 2021-01-14).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2019%2F212018s000lbl.pdf+%28accessed+2021-01-14%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perera, T. P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jovcheva, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mevellec, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vialard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Lange, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhulst, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulussen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van De Ven, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freyne, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squires, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saxty, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilissen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newell, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Platero, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karkera, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angibaud, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laquerre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenzi, M. V.</span></span> <span> </span><span class="NLM_article-title">Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1010</span>– <span class="NLM_lpage">1020</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-16-0589</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1158%2F1535-7163.MCT-16-0589" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=28341788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpt1Sht7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=1010-1020&author=T.+P.+S.+Pereraauthor=E.+Jovchevaauthor=L.+Mevellecauthor=J.+Vialardauthor=D.+De+Langeauthor=T.+Verhulstauthor=C.+Paulussenauthor=K.+Van+De+Venauthor=P.+Kingauthor=E.+Freyneauthor=D.+C.+Reesauthor=M.+Squiresauthor=G.+Saxtyauthor=M.+Pageauthor=C.+W.+Murrayauthor=R.+Gilissenauthor=G.+Wardauthor=N.+T.+Thompsonauthor=D.+R.+Newellauthor=N.+Chengauthor=L.+Xieauthor=J.+Yangauthor=S.+J.+Plateroauthor=J.+D.+Karkeraauthor=C.+Moyauthor=P.+Angibaudauthor=S.+Laquerreauthor=M.+V.+Lorenzi&title=Discovery+and+Pharmacological+Characterization+of+JNJ-42756493+%28Erdafitinib%29%2C+a+Functionally+Selective+Small-Molecule+FGFR+Family+Inhibitor&doi=10.1158%2F1535-7163.MCT-16-0589"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor</span></div><div class="casAuthors">Perera, Timothy P. S.; Jovcheva, Eleonora; Mevellec, Laurence; Vialard, Jorge; De Lange, Desiree; Verhulst, Tinne; Paulussen, Caroline; Van De Ven, Kelly; King, Peter; Freyne, Eddy; Rees, David C.; Squires, Matthew; Saxty, Gordon; Page, Martin; Murray, Christopher W.; Gilissen, Ron; Ward, George; Thompson, Neil T.; Newell, David R.; Cheng, Na; Xie, Liang; Yang, Jennifer; Platero, Suso J.; Karkera, Jayaprakash D.; Moy, Christopher; Angibaud, Patrick; Laquerre, Sylvie; Lorenzi, Matthew V.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1010-1020</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Fibroblast growth factor (FGF) signaling plays crit. roles in key biol. processes ranging from embryogenesis to wound healing and has strong links to several hallmarks of cancer.  Genetic alterations in FGF receptor (FGFR) family members are assocd. with increased tumor growth, metastasis, angiogenesis, and decreased survival.  JNJ-42756493, erdafitinib, is an orally active small mol. with potent tyrosine kinase inhibitory activity against all four FGFR family members and selectivity vs. other highly related kinases.  JNJ-42756493 shows rapid uptake into the lysosomal compartment of cells in culture, which is assocd. with prolonged inhibition of FGFR signaling, possibly due to sustained release of the inhibitor.  In xenografts from human tumor cell lines or patient-derived tumor tissue with activating FGFR alterations, JNJ-42756493 administration results in potent and dose-dependent antitumor activity accompanied by pharmacodynamic modulation of phospho-FGFR and phospho-ERK in tumors.  The results of the current study provide a strong rationale for the clin. investigation of JNJ-42756493 in patients with tumors harboring FGFR pathway alterations.  Mol Cancer Ther; 16(6); 1010-20. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhJZ2AgFcI6LVg90H21EOLACvtfcHk0liJ3q1TOHjKrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpt1Sht7g%253D&md5=2cae21f09ad519925ab2a3c760284b02</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0589%26sid%3Dliteratum%253Aachs%26aulast%3DPerera%26aufirst%3DT.%2BP.%2BS.%26aulast%3DJovcheva%26aufirst%3DE.%26aulast%3DMevellec%26aufirst%3DL.%26aulast%3DVialard%26aufirst%3DJ.%26aulast%3DDe%2BLange%26aufirst%3DD.%26aulast%3DVerhulst%26aufirst%3DT.%26aulast%3DPaulussen%26aufirst%3DC.%26aulast%3DVan%2BDe%2BVen%26aufirst%3DK.%26aulast%3DKing%26aufirst%3DP.%26aulast%3DFreyne%26aufirst%3DE.%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DSquires%26aufirst%3DM.%26aulast%3DSaxty%26aufirst%3DG.%26aulast%3DPage%26aufirst%3DM.%26aulast%3DMurray%26aufirst%3DC.%2BW.%26aulast%3DGilissen%26aufirst%3DR.%26aulast%3DWard%26aufirst%3DG.%26aulast%3DThompson%26aufirst%3DN.%2BT.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DCheng%26aufirst%3DN.%26aulast%3DXie%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DPlatero%26aufirst%3DS.%2BJ.%26aulast%3DKarkera%26aufirst%3DJ.%2BD.%26aulast%3DMoy%26aufirst%3DC.%26aulast%3DAngibaud%26aufirst%3DP.%26aulast%3DLaquerre%26aufirst%3DS.%26aulast%3DLorenzi%26aufirst%3DM.%2BV.%26atitle%3DDiscovery%2520and%2520Pharmacological%2520Characterization%2520of%2520JNJ-42756493%2520%2528Erdafitinib%2529%252C%2520a%2520Functionally%2520Selective%2520Small-Molecule%2520FGFR%2520Family%2520Inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2017%26volume%3D16%26spage%3D1010%26epage%3D1020%26doi%3D10.1158%2F1535-7163.MCT-16-0589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saxty, G. M. C. W.</span>; <span class="NLM_string-name">Berdini, V.</span>; <span class="NLM_string-name">Besong, G. E.</span>; <span class="NLM_string-name">Hamlett, C. C. F.</span>; <span class="NLM_string-name">Johnson, C. N.</span>; <span class="NLM_string-name">Woodhead, S. J.</span>; <span class="NLM_string-name">Reader, M.</span>; <span class="NLM_string-name">Rees, D. C.</span>; <span class="NLM_string-name">Mevellec, L. A.</span>; <span class="NLM_string-name">Angibaud, P. R.</span>; <span class="NLM_string-name">Freyne, E. J. E.</span>; <span class="NLM_string-name">Govaerts, T. C. H.</span>; <span class="NLM_string-name">Weerts, J. E. E.</span>; <span class="NLM_string-name">Perera, T. P. S.</span>; <span class="NLM_string-name">Gilissen, R. A. H. J.</span>; <span class="NLM_string-name">Wroblowski, B.</span>; <span class="NLM_string-name">Lacrampe, J. F. A.</span>; <span class="NLM_string-name">Papanikos, A.</span>; <span class="NLM_string-name">Querolle, O. A. G.</span>; <span class="NLM_string-name">Pasquier, E. T. J.</span>; <span class="NLM_string-name">Pilatte, I. N. C.</span>; <span class="NLM_string-name">Bonnet, P. G. A.</span>; <span class="NLM_string-name">Embrechts, W. C. J.</span>; <span class="NLM_string-name">Akkari, R.</span>; <span class="NLM_string-name">Meerpoel, L.</span></span> <span> </span><span class="NLM_article-title">Pyrazolyl Quinazoline Kinase Inhibitors</span>. <span class="NLM_patent">WO 2011135376 A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=G.+M.+C.+W.+Saxty&author=V.+Berdini&author=G.+E.+Besong&author=C.+C.+F.+Hamlett&author=C.+N.+Johnson&author=S.+J.+Woodhead&author=M.+Reader&author=D.+C.+Rees&author=L.+A.+Mevellec&author=P.+R.+Angibaud&author=E.+J.+E.+Freyne&author=T.+C.+H.+Govaerts&author=J.+E.+E.+Weerts&author=T.+P.+S.+Perera&author=R.+A.+H.+J.+Gilissen&author=B.+Wroblowski&author=J.+F.+A.+Lacrampe&author=A.+Papanikos&author=O.+A.+G.+Querolle&author=E.+T.+J.+Pasquier&author=I.+N.+C.+Pilatte&author=P.+G.+A.+Bonnet&author=W.+C.+J.+Embrechts&author=R.+Akkari&author=L.+Meerpoel&title=Pyrazolyl+Quinazoline+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSaxty%26aufirst%3DG.%2BM.%2BC.%2BW.%26atitle%3DPyrazolyl%2520Quinazoline%2520Kinase%2520Inhibitors%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ragheb, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLornan, D. P.</span></span> <span> </span><span class="NLM_article-title">Current and Future Role of Fedratinib in the Treatment of Myelofibrosis</span>. <i>Future Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">175</span>– <span class="NLM_lpage">186</span>, <span class="refDoi"> DOI: 10.2217/fon-2019-0612</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.2217%2Ffon-2019-0612" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31971457" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitlGmt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2020&pages=175-186&author=M.+Raghebauthor=C.+N.+Harrisonauthor=D.+P.+McLornan&title=Current+and+Future+Role+of+Fedratinib+in+the+Treatment+of+Myelofibrosis&doi=10.2217%2Ffon-2019-0612"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Current and future role of fedratinib in the treatment of myelofibrosis</span></div><div class="casAuthors">Ragheb, Monica; Harrison, Claire N.; McLornan, Donal P.</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">175-186</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1744-8301</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Fedratinib (INREBIC [fedratinib] capsules, Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation), is a potent JAK2 inhibitor that has been approved for use in myelofibrosis, both as a first-line agent and also in second line following ruxolitinib (Novartis Pharmaceuticals, Basel, Switzerland) failure or intolerance.  Within this article, we will review relevant preclin. and early/late clin. trial data concerning the use of fedratinib to treat myeloproliferative neoplasms.  Moreover, we will review in detail the assumed safety issues that led to temporary cessation of all programs with the agent in 2013 which subsequently re-entered the clin. arena in 2017.  We will discuss how physicians may safely transition a patient across from ruxolitinib to fedratinib following intolerance or lack of efficacy.  At last, we will discuss potential future applications of this agent within the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpj3DAteR97M7Vg90H21EOLACvtfcHk0liJ3q1TOHjKrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitlGmt7k%253D&md5=0b0e682e3318cefd59a964c332b3aba8</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.2217%2Ffon-2019-0612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon-2019-0612%26sid%3Dliteratum%253Aachs%26aulast%3DRagheb%26aufirst%3DM.%26aulast%3DHarrison%26aufirst%3DC.%2BN.%26aulast%3DMcLornan%26aufirst%3DD.%2BP.%26atitle%3DCurrent%2520and%2520Future%2520Role%2520of%2520Fedratinib%2520in%2520the%2520Treatment%2520of%2520Myelofibrosis%26jtitle%3DFuture%2520Oncol.%26date%3D2020%26volume%3D16%26spage%3D175%26epage%3D186%26doi%3D10.2217%2Ffon-2019-0612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bose, P.</span></span> <span> </span><span class="NLM_article-title">Advances in Potential Treatment Options for Myeloproliferative Neoplasm Associated Myelofibrosis</span>. <i>Expert Opin. Orphan Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">415</span>– <span class="NLM_lpage">425</span>, <span class="refDoi"> DOI: 10.1080/21678707.2019.1664900</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1080%2F21678707.2019.1664900" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=33094033" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVemsLbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2019&pages=415-425&author=P.+Bose&title=Advances+in+Potential+Treatment+Options+for+Myeloproliferative+Neoplasm+Associated+Myelofibrosis&doi=10.1080%2F21678707.2019.1664900"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in potential treatment options for myeloproliferative neoplasm associated myelofibrosis</span></div><div class="casAuthors">Bose, Prithviraj</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Orphan Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">415-425</span>CODEN:
                <span class="NLM_cas:coden">EOODAJ</span>;
        ISSN:<span class="NLM_cas:issn">2167-8707</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  : The Janus kinase (JAK)1/2 inhibitor ruxolitinib provides rapid, sustained and often dramatic benefits to patients with myelofibrosis, inducing spleen shrinkage and ameliorating symptoms, and improves survival.  However, the drug has little effect on the underlying bone marrow fibrosis or on mutant allele burden, and clin. resistance eventually develops.  Furthermore, ruxolitinib-induced cytopenias can be challenging in everyday practice.: The developmental therapeutics landscape in MF is discussed.  This includes potential partners for ruxolitinib being developed with an aim to improve cytopenias, or to enhance its disease-modifying effects.  The development of other JAK inhibitors with efficacy post-ruxolitinib or other unique attributes is being pursued in earnest.  Agents with novel mechanisms of action are being studied in patients whose disease responds sub-optimally to, is refractory to or progresses after ruxolitinib.: The JAK inhibitors fedratinib, pacritinib and momelotinib are clearly active, and it is expected that one or more of these will become licensed in the future.  The activin receptor ligand traps are promising as treatments for anemia.  Imetelstat has shown interesting activity post-ruxolitinib, and azactidine may be a useful partner for ruxolitinib in some patients.  Appropriately, multiple pre-clin. and clin. leads are being pursued in this difficult therapeutic area.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnB43vheV7dLVg90H21EOLACvtfcHk0li1LSSbXJZx0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVemsLbN&md5=80653a777dd5eeca110d8b8463656fe9</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1080%2F21678707.2019.1664900&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F21678707.2019.1664900%26sid%3Dliteratum%253Aachs%26aulast%3DBose%26aufirst%3DP.%26atitle%3DAdvances%2520in%2520Potential%2520Treatment%2520Options%2520for%2520Myeloproliferative%2520Neoplasm%2520Associated%2520Myelofibrosis%26jtitle%3DExpert%2520Opin.%2520Orphan%2520Drugs%26date%3D2019%26volume%3D7%26spage%3D415%26epage%3D425%26doi%3D10.1080%2F21678707.2019.1664900" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diamond, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rupar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behshad, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardiner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wynn, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeleswaram, S.</span></span> <span> </span><span class="NLM_article-title">The Janus Kinase 2 Inhibitor Fedratinib Inhibits Thiamine Uptake: A Putative Mechanism for the Onset of Wernicke’s Encephalopathy</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">1656</span>– <span class="NLM_lpage">1662</span>, <span class="refDoi"> DOI: 10.1124/dmd.114.058883</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1124%2Fdmd.114.058883" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=25063672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1yqurzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2014&pages=1656-1662&author=Q.+Zhangauthor=Y.+Zhangauthor=S.+Diamondauthor=J.+Boerauthor=J.+J.+Harrisauthor=Y.+Liauthor=M.+Ruparauthor=E.+Behshadauthor=C.+Gardinerauthor=P.+Collierauthor=P.+Liuauthor=T.+Burnauthor=R.+Wynnauthor=G.+Hollisauthor=S.+Yeleswaram&title=The+Janus+Kinase+2+Inhibitor+Fedratinib+Inhibits+Thiamine+Uptake%3A+A+Putative+Mechanism+for+the+Onset+of+Wernicke%E2%80%99s+Encephalopathy&doi=10.1124%2Fdmd.114.058883"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">The janus kinase 2 inhibitor fedratinib inhibits thiamine uptake: a putative mechanism for the onset of Wernicke's encephalopathy</span></div><div class="casAuthors">Zhang, Qiang; Zhang, Yan; Diamond, Sharon; Boer, Jason; Harris, Jennifer J.; Li, Yu; Rupar, Mark; Behshad, Elham; Gardiner, Christine; Collier, Paul; Liu, Phillip; Burn, Timothy; Wynn, Richard; Hollis, Gregory; Yeleswaram, Swamy</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1656-1662, 7 pp.</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The clin. development of fedratinib, a Janus kinase (JAK2) inhibitor, was terminated after reports of Wernicke's encephalopathy in myelofibrosis patients.  Since Wernicke's encephalopathy is induced by thiamine deficiency, investigations were conducted to probe possible mechanisms through which fedratinib may lead to a thiamine-deficient state.  In vitro studies indicate that fedratinib potently inhibits the carrier-mediated uptake and transcellular flux of thiamine in Caco-2 cells, suggesting that oral absorption of dietary thiamine is significantly compromised by fedratinib dosing.  Transport studies with recombinant human thiamine transporters identified the individual human thiamine transporter (hTHTR2) that is inhibited by fedratinib.  Inhibition of thiamine uptake appears unique to fedratinib and is not shared by marketed JAK inhibitors, and this observation is consistent with the known structure-activity relationship for the binding of thiamine to its transporters.  The results from these studies provide a mol. basis for the development of Wernicke's encephalopathy upon fedratinib treatment and highlight the need to evaluate interactions of investigational drugs with nutrient transporters in addn. to classic xenobiotic transporters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3h6hu-138srVg90H21EOLACvtfcHk0li1LSSbXJZx0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1yqurzJ&md5=0e840cc3953ddcdf2f0864450f6f5c6e</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1124%2Fdmd.114.058883&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.114.058883%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DDiamond%26aufirst%3DS.%26aulast%3DBoer%26aufirst%3DJ.%26aulast%3DHarris%26aufirst%3DJ.%2BJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DRupar%26aufirst%3DM.%26aulast%3DBehshad%26aufirst%3DE.%26aulast%3DGardiner%26aufirst%3DC.%26aulast%3DCollier%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DBurn%26aufirst%3DT.%26aulast%3DWynn%26aufirst%3DR.%26aulast%3DHollis%26aufirst%3DG.%26aulast%3DYeleswaram%26aufirst%3DS.%26atitle%3DThe%2520Janus%2520Kinase%25202%2520Inhibitor%2520Fedratinib%2520Inhibits%2520Thiamine%2520Uptake%253A%2520A%2520Putative%2520Mechanism%2520for%2520the%2520Onset%2520of%2520Wernicke%25E2%2580%2599s%2520Encephalopathy%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2014%26volume%3D42%26spage%3D1656%26epage%3D1662%26doi%3D10.1124%2Fdmd.114.058883" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><a href="https://www.fda.gov/news-events/press-announcements/fda-approves-treatment-patients-rare-bone-marrow-disorder" class="extLink">https://www.fda.gov/news-events/press-announcements/fda-approves-treatment-patients-rare-bone-marrow-disorder</a> (accessed 2020-12-18).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-approves-treatment-patients-rare-bone-marrow-disorder+%28accessed+2020-12-18%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blair, H. A.</span></span> <span> </span><span class="NLM_article-title">Fedratinib: First Approval for Treating Myelofibrosis</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">1719</span>– <span class="NLM_lpage">1725</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01205-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs40265-019-01205-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31571162" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVOlu7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=1719-1725&author=H.+A.+Blair&title=Fedratinib%3A+First+Approval+for+Treating+Myelofibrosis&doi=10.1007%2Fs40265-019-01205-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Fedratinib: First approval for treating myelofibrosis</span></div><div class="casAuthors">Blair, Hannah A.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1719-1725</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Fedratinib (INREBIC) is a JAK2-selective inhibitor that has been developed as an oral treatment for myelofibrosis.  In August 2019, fedratinib received its first global approval in the USA for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.  Phase III clin. development for myelofibrosis is ongoing worldwide.  This article summarizes the milestones in the development of fedratinib leading to this first approval for myelofibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0phtMTwbye7Vg90H21EOLACvtfcHk0li1LSSbXJZx0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVOlu7rP&md5=36fa843febf45050d5dd2d1044b715c8</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01205-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01205-x%26sid%3Dliteratum%253Aachs%26aulast%3DBlair%26aufirst%3DH.%2BA.%26atitle%3DFedratinib%253A%2520First%2520Approval%2520for%2520Treating%2520Myelofibrosis%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D1719%26epage%3D1725%26doi%3D10.1007%2Fs40265-019-01205-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Noronha, G.</span>; <span class="NLM_string-name">Mak, C. C.</span>; <span class="NLM_string-name">Cao, J.</span>; <span class="NLM_string-name">Renick, J.</span>; <span class="NLM_string-name">McPherson, A.</span>; <span class="NLM_string-name">Zeng, B.</span>; <span class="NLM_string-name">Pathak, V. P.</span>; <span class="NLM_string-name">Lohse, D. L.</span>; <span class="NLM_string-name">Hood, J. D.</span>; <span class="NLM_string-name">Soll, R. M.</span></span> <span> </span><span class="NLM_article-title">Preparation of Pyrimidine Derivatives as JAK Kinases Inhibitors</span>. <span class="NLM_patent">US 20110212077 A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=G.+Noronha&author=C.+C.+Mak&author=J.+Cao&author=J.+Renick&author=A.+McPherson&author=B.+Zeng&author=V.+P.+Pathak&author=D.+L.+Lohse&author=J.+D.+Hood&author=R.+M.+Soll&title=Preparation+of+Pyrimidine+Derivatives+as+JAK+Kinases+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNoronha%26aufirst%3DG.%26atitle%3DPreparation%2520of%2520Pyrimidine%2520Derivatives%2520as%2520JAK%2520Kinases%2520Inhibitors%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tefferi, A.</span></span> <span> </span><span class="NLM_article-title"><i>N</i>-<i>tert</i>-Butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino]benzenesulfonamide for Treating Myelofibrosis</span>. <span class="NLM_patent">WO 2012060847 A1</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=A.+Tefferi&title=N-tert-Butyl-3-%5B%285-methyl-2-%7B%5B4-%282-pyrrolidin-1-ylethoxy%29phenyl%5Damino%7Dpyrimidin-4-yl%29amino%5Dbenzenesulfonamide+for+Treating+Myelofibrosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTefferi%26aufirst%3DA.%26atitle%3DN-tert-Butyl-3-%255B%25285-methyl-2-%257B%255B4-%25282-pyrrolidin-1-ylethoxy%2529phenyl%255Damino%257Dpyrimidin-4-yl%2529amino%255Dbenzenesulfonamide%2520for%2520Treating%2520Myelofibrosis%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span>; <span class="NLM_string-name">Li, H.</span></span> <span> </span><span class="NLM_article-title">Preparation of Diphenyl Aminopyrimidine Compounds as JAK2 Kinase Inhibitors</span>. <span class="NLM_patent">CN 109232440 A</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=Y.+Wang&author=H.+Li&title=Preparation+of+Diphenyl+Aminopyrimidine+Compounds+as+JAK2+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26atitle%3DPreparation%2520of%2520Diphenyl%2520Aminopyrimidine%2520Compounds%2520as%2520JAK2%2520Kinase%2520Inhibitors%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><a href="http://www.nmpa.gov.cn/WS04/CL2056/371524.html" class="extLink">http://www.nmpa.gov.cn/WS04/CL2056/371524.html</a> (accessed 2021-01-14).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=http%3A%2F%2Fwww.nmpa.gov.cn%2FWS04%2FCL2056%2F371524.html+%28accessed+2021-01-14%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span> <span> </span><span class="NLM_article-title">Frontline Flumatinib Versus Imatinib in Patients with Chronic Myeloid Leukemia in Chronic Phase: Results from the China Randomized Phase III Study</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">7004</span>, <span class="refDoi"> DOI: 10.1200/JCO.2019.37.15_suppl.7004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1200%2FJCO.2019.37.15_suppl.7004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2019&pages=7004&author=Z.+Liauthor=L.+Mengauthor=Y.+Zhangauthor=H.+Zhuauthor=J.+Cuiauthor=A.+Sunauthor=Y.+Huauthor=J.+Jinauthor=H.+Jiangauthor=X.+Zhangauthor=Y.+Liauthor=Q.+Liuauthor=L.+Liuauthor=W.+Zhangauthor=J.+Guauthor=J.-H.+Qiaoauthor=B.+Liuauthor=F.+Zhangauthor=Y.+Guoauthor=J.+Wang&title=Frontline+Flumatinib+Versus+Imatinib+in+Patients+with+Chronic+Myeloid+Leukemia+in+Chronic+Phase%3A+Results+from+the+China+Randomized+Phase+III+Study&doi=10.1200%2FJCO.2019.37.15_suppl.7004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1200%2FJCO.2019.37.15_suppl.7004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2019.37.15_suppl.7004%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DMeng%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DSun%26aufirst%3DA.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DGu%26aufirst%3DJ.%26aulast%3DQiao%26aufirst%3DJ.-H.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26atitle%3DFrontline%2520Flumatinib%2520Versus%2520Imatinib%2520in%2520Patients%2520with%2520Chronic%2520Myeloid%2520Leukemia%2520in%2520Chronic%2520Phase%253A%2520Results%2520from%2520the%2520China%2520Randomized%2520Phase%2520III%2520Study%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2019%26volume%3D37%26spage%3D7004%26doi%3D10.1200%2FJCO.2019.37.15_suppl.7004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, P.</span>; <span class="NLM_string-name">Lv, A.</span>; <span class="NLM_string-name">Yang, B.</span>; <span class="NLM_string-name">Hu, C.</span>; <span class="NLM_string-name">Wang, W.</span></span> <span> </span><span class="NLM_article-title">Aminopyrimidine Compounds and Their Salts, Process for Preparation and Pharmaceutical Use Thereof</span>. <span class="NLM_patent">WO 2006069525 A1</span>, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=P.+Sun&author=A.+Lv&author=B.+Yang&author=C.+Hu&author=W.+Wang&title=Aminopyrimidine+Compounds+and+Their+Salts%2C+Process+for+Preparation+and+Pharmaceutical+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit175a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DP.%26atitle%3DAminopyrimidine%2520Compounds%2520and%2520Their%2520Salts%252C%2520Process%2520for%2520Preparation%2520and%2520Pharmaceutical%2520Use%2520Thereof%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit175b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Q.</span>; <span class="NLM_string-name">Du, Z.</span>; <span class="NLM_string-name">Kang, X.</span></span> <span> </span><span class="NLM_article-title">Method for Preparing Flumatinib Mesylate</span>. <span class="NLM_patent">CN 102796079 A</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=Q.+Zhu&author=Z.+Du&author=X.+Kang&title=Method+for+Preparing+Flumatinib+Mesylate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit175b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DQ.%26atitle%3DMethod%2520for%2520Preparing%2520Flumatinib%2520Mesylate%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit175c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J.</span>; <span class="NLM_string-name">Chen, Y.</span>; <span class="NLM_string-name">Yang, W.</span>; <span class="NLM_string-name">Jin, A.</span></span> <span> </span><span class="NLM_article-title">Method for Refining Flumatinib</span>. <span class="NLM_patent">CN 105777714 A</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=J.+Cui&author=Y.+Chen&author=W.+Yang&author=A.+Jin&title=Method+for+Refining+Flumatinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit175c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%26atitle%3DMethod%2520for%2520Refining%2520Flumatinib%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit175d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, L.</span>; <span class="NLM_string-name">Jin, A.</span></span> <span> </span><span class="NLM_article-title">Synthesizing Method of Flumatinib</span>. <span class="NLM_patent">CN 105884746 A</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=L.+Jin&author=A.+Jin&title=Synthesizing+Method+of+Flumatinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit175d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DL.%26atitle%3DSynthesizing%2520Method%2520of%2520Flumatinib%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit175e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Lv, H.</span>; <span class="NLM_string-name">Wu, D.</span>; <span class="NLM_string-name">Jiang, C.</span>; <span class="NLM_string-name">Zhang, Y.</span>; <span class="NLM_string-name">Cao, J.</span></span> <span> </span><span class="NLM_article-title">Flumatinib Mesylate Intermediate Purification Method</span>. <span class="NLM_patent">CN 107652269 A</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=H.+Lv&author=D.+Wu&author=C.+Jiang&author=Y.+Zhang&author=J.+Cao&title=Flumatinib+Mesylate+Intermediate+Purification+Method"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit175e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLv%26aufirst%3DH.%26atitle%3DFlumatinib%2520Mesylate%2520Intermediate%2520Purification%2520Method%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit175f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span>; <span class="NLM_string-name">Liu, L.</span>; <span class="NLM_string-name">Wu, D.</span>; <span class="NLM_string-name">Sun, Y.</span>; <span class="NLM_string-name">Cao, J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Method of Intermediate of Flumatinib Mesylate</span>. <span class="NLM_patent">CN 107663151 A</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=M.+Chen&author=L.+Liu&author=D.+Wu&author=Y.+Sun&author=J.+Cao&title=Synthetic+Method+of+Intermediate+of+Flumatinib+Mesylate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit175f&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DM.%26atitle%3DSynthetic%2520Method%2520of%2520Intermediate%2520of%2520Flumatinib%2520Mesylate%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit175g"><span><span class="NLM_label">(g) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gou, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis, Crystal Structure, and Spectral Characterization of Flumatinib Mesylate</span>. <i>Synth. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">2564</span>– <span class="NLM_lpage">2570</span>, <span class="refDoi"> DOI: 10.1080/00397910903289248</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1080%2F00397910903289248" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175g&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpslOju7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2010&pages=2564-2570&author=G.+Xuauthor=H.+Shenauthor=T.+Tongauthor=A.+Luauthor=S.+Gou&title=Synthesis%2C+Crystal+Structure%2C+and+Spectral+Characterization+of+Flumatinib+Mesylate&doi=10.1080%2F00397910903289248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit175gR"><div class="casContent"><span class="casTitleNuber">175g</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Crystal Structure, and Spectral Characterization of Flumatinib Mesylate</span></div><div class="casAuthors">Xu, Gang; Shen, Hong; Tong, Taifeng; Lu, Aifeng; Gou, Shaohua</div><div class="citationInfo"><span class="NLM_cas:title">Synthetic Communications</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2564-2570</span>CODEN:
                <span class="NLM_cas:coden">SYNCAV</span>;
        ISSN:<span class="NLM_cas:issn">0039-7911</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">Flumatinib mesylate (I), a 3-substituted picolinamide deriv. structurally similar to imatinib mesylate, was prepd.  The compd. was characterized by IR, UV, NMR, and electrospray ionization-mass spectra together with x-ray crystal structure anal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1olx-bKQ3MrVg90H21EOLACvtfcHk0lgxwz3QblXmwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpslOju7Y%253D&md5=4203b742f57f7743000f437c0f408d43</span></div><a href="/servlet/linkout?suffix=cit175g&amp;dbid=16384&amp;doi=10.1080%2F00397910903289248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00397910903289248%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DG.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DTong%26aufirst%3DT.%26aulast%3DLu%26aufirst%3DA.%26aulast%3DGou%26aufirst%3DS.%26atitle%3DSynthesis%252C%2520Crystal%2520Structure%252C%2520and%2520Spectral%2520Characterization%2520of%2520Flumatinib%2520Mesylate%26jtitle%3DSynth.%2520Commun.%26date%3D2010%26volume%3D40%26spage%3D2564%26epage%3D2570%26doi%3D10.1080%2F00397910903289248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span>; <span class="NLM_string-name">Zhao, J.</span>; <span class="NLM_string-name">Ji, H.</span>; <span class="NLM_string-name">Zong, S.</span></span> <span> </span><span class="NLM_article-title">The Preparation Method of Flumatinib</span>. <span class="NLM_patent">CN 111072636 A</span>, <span class="NLM_year">2020</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=G.+Chen&author=J.+Zhao&author=H.+Ji&author=S.+Zong&title=The+Preparation+Method+of+Flumatinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DG.%26atitle%3DThe%2520Preparation%2520Method%2520of%2520Flumatinib%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tap, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelderblom, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmerini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blay, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcindor, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganjoo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Broto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterfy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Healey, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Sande, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelhorn, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuster, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yver, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong-Starksen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stacchiotti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, A. J.</span></span> <span> </span><span class="NLM_article-title">Pexidartinib Versus Placebo for Advanced Tenosynovial Giant Cell Tumour (Enliven): A Randomised Phase 3 Trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>394</i></span>,  <span class="NLM_fpage">478</span>– <span class="NLM_lpage">487</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(19)30764-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2FS0140-6736%2819%2930764-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31229240" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1Wqt7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=394&publication_year=2019&pages=478-487&author=W.+D.+Tapauthor=H.+Gelderblomauthor=E.+Palmeriniauthor=J.+Desaiauthor=S.+Bauerauthor=J.+Y.+Blayauthor=T.+Alcindorauthor=K.+Ganjooauthor=J.+Martin-Brotoauthor=C.+W.+Ryanauthor=D.+M.+Thomasauthor=C.+Peterfyauthor=J.+H.+Healeyauthor=M.+van+de+Sandeauthor=H.+L.+Gelhornauthor=D.+E.+Shusterauthor=Q.+Wangauthor=A.+Yverauthor=H.+H.+Hsuauthor=P.+S.+Linauthor=S.+Tong-Starksenauthor=S.+Stacchiottiauthor=A.+J.+Wagner&title=Pexidartinib+Versus+Placebo+for+Advanced+Tenosynovial+Giant+Cell+Tumour+%28Enliven%29%3A+A+Randomised+Phase+3+Trial&doi=10.1016%2FS0140-6736%2819%2930764-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial</span></div><div class="casAuthors">Tap, William D.; Gelderblom, Hans; Palmerini, Emanuela; Desai, Jayesh; Bauer, Sebastian; Blay, Jean-Yves; Alcindor, Thierry; Ganjoo, Kristen; Martin-Broto, Javier; Ryan, Christopher W.; Thomas, David M.; Peterfy, Charles; Healey, John H.; van de Sande, Michiel; Gelhorn, Heather L.; Shuster, Dale E.; Wang, Qiang; Yver, Antoine; Hsu, Henry H.; Lin, Paul S.; Tong-Starksen, Sandra; Stacchiotti, Silvia; Wagner, Andrew J.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">394</span>
        (<span class="NLM_cas:issue">10197</span>),
    <span class="NLM_cas:pages">478-487</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">We aimed to evaluate pexidartinib, a CSF1 receptor inhibitor, in patients with TGCT to provide them with a viable systemic treatment option, esp. in cases that are not amenable to surgical resection.  This phase 3 randomised trial had two parts.  Part one was a double-blind study in which patients with symptomatic, advanced TGCT for whom surgery was not recommended were randomly assigned via an integrated web response system (1:1) to the pexidartinib or placebo group.  Individuals in the pexidartinib group received a loading dose of 1000 mg pexidartinib per day orally (400 mg morning; 600 mg evening) for the first 2 wk, followed by 800 mg per day (400 mg twice a day) for 22 wk.  Safety was analyzed in all patients who received at least one dose of the study drug.  The proportion of patients who achieved overall response was higher for pexidartinib than placebo at week 25 by RECIST (24 [39%] of 61 vs none of 59; abs. difference 39% [95% CI 27-53]; p<0.0001).  Hair color changes (67%), fatigue (54%), aspartate aminotransferase increase (39%), nausea (38%), alanine aminotransferase increase (28%), and dysgeusia (25%) were the most frequent pexidartinib-assocd. adverse events. Three patients given pexidartinib had aminotransferase elevations three or more times the upper limit of normal with total bilirubin and alk. phosphatase two or more times the upper limit of normal indicative of mixed or cholestatic hepatotoxicity, one lasting 7 mo and confirmed by biopsy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2mP33487nP7Vg90H21EOLACvtfcHk0lgxwz3QblXmwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1Wqt7jI&md5=0f59ec1b2387ce7d238c28cc9d727aa5</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2819%2930764-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252819%252930764-0%26sid%3Dliteratum%253Aachs%26aulast%3DTap%26aufirst%3DW.%2BD.%26aulast%3DGelderblom%26aufirst%3DH.%26aulast%3DPalmerini%26aufirst%3DE.%26aulast%3DDesai%26aufirst%3DJ.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DBlay%26aufirst%3DJ.%2BY.%26aulast%3DAlcindor%26aufirst%3DT.%26aulast%3DGanjoo%26aufirst%3DK.%26aulast%3DMartin-Broto%26aufirst%3DJ.%26aulast%3DRyan%26aufirst%3DC.%2BW.%26aulast%3DThomas%26aufirst%3DD.%2BM.%26aulast%3DPeterfy%26aufirst%3DC.%26aulast%3DHealey%26aufirst%3DJ.%2BH.%26aulast%3Dvan%2Bde%2BSande%26aufirst%3DM.%26aulast%3DGelhorn%26aufirst%3DH.%2BL.%26aulast%3DShuster%26aufirst%3DD.%2BE.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DYver%26aufirst%3DA.%26aulast%3DHsu%26aufirst%3DH.%2BH.%26aulast%3DLin%26aufirst%3DP.%2BS.%26aulast%3DTong-Starksen%26aufirst%3DS.%26aulast%3DStacchiotti%26aufirst%3DS.%26aulast%3DWagner%26aufirst%3DA.%2BJ.%26atitle%3DPexidartinib%2520Versus%2520Placebo%2520for%2520Advanced%2520Tenosynovial%2520Giant%2520Cell%2520Tumour%2520%2528Enliven%2529%253A%2520A%2520Randomised%2520Phase%25203%2520Trial%26jtitle%3DLancet%26date%3D2019%26volume%3D394%26spage%3D478%26epage%3D487%26doi%3D10.1016%2FS0140-6736%2819%2930764-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178"><span><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211810s000lbl.pdf" class="extLink">https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211810s000lbl.pdf</a> (accessed 2021-01-14).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2019%2F211810s000lbl.pdf+%28accessed+2021-01-14%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref179"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref179'); return false;" data-citation="" class="refNumLink">179</a></strong><div class="NLM_citation" id="cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, Y. N.</span></span> <span> </span><span class="NLM_article-title">Pexidartinib: First Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">1805</span>– <span class="NLM_lpage">1812</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01210-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs40265-019-01210-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31602563" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFCkt7bI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=1805-1812&author=Y.+N.+Lamb&title=Pexidartinib%3A+First+Approval&doi=10.1007%2Fs40265-019-01210-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Pexidartinib: First Approval</span></div><div class="casAuthors">Lamb, Yvette N.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1805-1812</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Pexidartinib (TURALIO) is an orally administered small mol. tyrosine kinase inhibitor with selective activity against the colony-stimulating factor 1 (CSF1) receptor, KIT proto-oncogene receptor tyrosine kinase (KIT) and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation (FLT3-ITD).  In August 2019, the US FDA approved pexidartinib capsules for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) assocd. with severe morbidity or functional limitations and not amenable to improvement with surgery.  This approval was based on pos. results from the phase III ENLIVEN trial.  Pexidartinib is being investigated in various malignancies as monotherapy or combination therapy.  This article summarizes the milestones in the development of pexidartinib leading to its first approval for TGCT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozyYjPD6iP87Vg90H21EOLACvtfcHk0lgxwz3QblXmwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFCkt7bI&md5=749eeadc87c3d34db97ee6aaa7837cac</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01210-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01210-0%26sid%3Dliteratum%253Aachs%26aulast%3DLamb%26aufirst%3DY.%2BN.%26atitle%3DPexidartinib%253A%2520First%2520Approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D1805%26epage%3D1812%26doi%3D10.1007%2Fs40265-019-01210-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref180"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref180'); return false;" data-citation="" class="refNumLink">180</a></strong><div class="NLM_citation" id="cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spangenberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohsfield, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crapser, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phan, N. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Severson, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burton, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spevak, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habets, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rymar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walters, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nespi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broome, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, B. L.</span></span> <span> </span><span class="NLM_article-title">Sustained Microglial Depletion with CSF1R Inhibitor Impairs Parenchymal Plaque Development in an Alzheimer’s Disease Model</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">3758</span>, <span class="refDoi"> DOI: 10.1038/s41467-019-11674-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1038%2Fs41467-019-11674-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31434879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A280%3ADC%252BB3MrgtFOruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=3758&author=E.+Spangenbergauthor=L.+A.+Hohsfieldauthor=J.+Crapserauthor=N.+Y.+Phanauthor=K.+N.+Greenauthor=P.+L.+Seversonauthor=J.+Zhangauthor=E.+A.+Burtonauthor=Y.+Zhangauthor=W.+Spevakauthor=J.+Linauthor=G.+Habetsauthor=A.+Rymarauthor=G.+Tsangauthor=J.+Waltersauthor=M.+Nespiauthor=P.+Singhauthor=S.+Broomeauthor=P.+Ibrahimauthor=C.+Zhangauthor=G.+Bollagauthor=B.+L.+West&title=Sustained+Microglial+Depletion+with+CSF1R+Inhibitor+Impairs+Parenchymal+Plaque+Development+in+an+Alzheimer%E2%80%99s+Disease+Model&doi=10.1038%2Fs41467-019-11674-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer's disease model</span></div><div class="casAuthors">Spangenberg Elizabeth; Hohsfield Lindsay A; Crapser Joshua; Phan Nicole Y; Green Kim N; Severson Paul L; Zhang Jiazhong; Burton Elizabeth A; Zhang Ying; Spevak Wayne; Lin Jack; Habets Gaston; Rymar Andrey; Tsang Garson; Walters Jason; Nespi Marika; Singh Parmveer; Broome Stephanie; Ibrahim Prabha; Zhang Chao; Bollag Gideon; West Brian L</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3758</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Many risk genes for the development of Alzheimer's disease (AD) are exclusively or highly expressed in myeloid cells.  Microglia are dependent on colony-stimulating factor 1 receptor (CSF1R) signaling for their survival.  We designed and synthesized a highly selective brain-penetrant CSF1R inhibitor (PLX5622) allowing for extended and specific microglial elimination, preceding and during pathology development.  We find that in the 5xFAD mouse model of AD, plaques fail to form in the parenchymal space following microglial depletion, except in areas containing surviving microglia.  Instead, Aβ deposits in cortical blood vessels reminiscent of cerebral amyloid angiopathy.  Altered gene expression in the 5xFAD hippocampus is also reversed by the absence of microglia.  Transcriptional analyses of the residual plaque-forming microglia show they exhibit a disease-associated microglia profile.  Collectively, we describe the structure, formulation, and efficacy of PLX5622, which allows for sustained microglial depletion and identify roles of microglia in initiating plaque pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSZsPEWZPmRRMNIRw0GKUoEfW6udTcc2ebMTDMi9nCigLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MrgtFOruw%253D%253D&md5=ec6089949cf49ffec6faefe983cb3beb</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1038%2Fs41467-019-11674-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-019-11674-z%26sid%3Dliteratum%253Aachs%26aulast%3DSpangenberg%26aufirst%3DE.%26aulast%3DHohsfield%26aufirst%3DL.%2BA.%26aulast%3DCrapser%26aufirst%3DJ.%26aulast%3DPhan%26aufirst%3DN.%2BY.%26aulast%3DGreen%26aufirst%3DK.%2BN.%26aulast%3DSeverson%26aufirst%3DP.%2BL.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DBurton%26aufirst%3DE.%2BA.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DSpevak%26aufirst%3DW.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DHabets%26aufirst%3DG.%26aulast%3DRymar%26aufirst%3DA.%26aulast%3DTsang%26aufirst%3DG.%26aulast%3DWalters%26aufirst%3DJ.%26aulast%3DNespi%26aufirst%3DM.%26aulast%3DSingh%26aufirst%3DP.%26aulast%3DBroome%26aufirst%3DS.%26aulast%3DIbrahim%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DWest%26aufirst%3DB.%2BL.%26atitle%3DSustained%2520Microglial%2520Depletion%2520with%2520CSF1R%2520Inhibitor%2520Impairs%2520Parenchymal%2520Plaque%2520Development%2520in%2520an%2520Alzheimer%25E2%2580%2599s%2520Disease%2520Model%26jtitle%3DNat.%2520Commun.%26date%3D2019%26volume%3D10%26spage%3D3758%26doi%3D10.1038%2Fs41467-019-11674-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref181"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref181'); return false;" data-citation="" class="refNumLink">181</a></strong><div class="NLM_citation" id="cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, P. N. J. M.</span>; <span class="NLM_string-name">Matsuura, S.</span></span>; <span> </span><span class="NLM_article-title">Synthesis of 1<i>H</i>-Pyrrolo[2,3-<i>b</i>]pyridin Derivatives That Modulate Kinases</span>. <span class="NLM_patent">WO 2016179412 A1</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=P.+N.+J.+M.+Ibrahim&author=S.+Matsuura&title=Synthesis+of+1H-Pyrrolo%5B2%2C3-b%5Dpyridin+Derivatives+That+Modulate+Kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%2BJ.%2BM.%26atitle%3DSynthesis%2520of%25201H-Pyrrolo%255B2%252C3-b%255Dpyridin%2520Derivatives%2520That%2520Modulate%2520Kinases%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref182"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref182'); return false;" data-citation="" class="refNumLink">182</a></strong><div class="NLM_citation" id="cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Amaya, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimeno, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamdar, M.</span></span> <span> </span><span class="NLM_article-title">Polatuzumab Vedotin to Treat Relapsed or Refractory Diffuse Large B-Cell Lymphoma, in Combination with Bendamustine Plus Rituximab</span>. <i>Drugs Today</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">287</span>– <span class="NLM_lpage">294</span>, <span class="refDoi"> DOI: 10.1358/dot.2020.56.4.3127026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1358%2Fdot.2020.56.4.3127026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A280%3ADC%252BB38zntFOjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2020&pages=287-294&author=M.+L.+Amayaauthor=A.+Jimenoauthor=M.+Kamdar&title=Polatuzumab+Vedotin+to+Treat+Relapsed+or+Refractory+Diffuse+Large+B-Cell+Lymphoma%2C+in+Combination+with+Bendamustine+Plus+Rituximab&doi=10.1358%2Fdot.2020.56.4.3127026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximab</span></div><div class="casAuthors">Amaya M L; Jimeno A; Kamdar M</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of today (Barcelona, Spain : 1998)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">287-294</span>
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    </div><div class="casAbstract">Diffuse large B-cell lymphoma (DLBCL) is the most common non Hodgkin lymphoma (NHL) in adults, and it accounts for about 30% of adult NHL cases.  Newly diagnosed patients are treated with rituximab in combination with anthracycline-containing chemotherapy, but a significant number of patients relapse after initial treatment.  New strategies for relapsed lymphomas are in development among which antibody-drug conjugates (ADCs) are currently in clinical trials.  Polatuzumab vedotin is a novel ADC which binds to the commonly expressed B-cell antigen CD79b, and it delivers monomethyl auristatin E, a small molecule with anti-tubulin activity.  Polatuzumab vedotin in combination with bendamustine and rituximab (BR) has been approved in the U.S. and the E.U. for use in patients with relapsed or refractory DLBCL ineligible for transplant.  These approvals were based on a randomized study of patients treated with either polatuzumab vedotin plus BR or BR alone, where complete response was 40% in the polatuzumab vedotin + BR group versus 18% in the BR group.  The most common adverse events of this treatment were cytopenias and peripheral neuropathy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRl0dnj1Vhj6rJzI8owOhpDfW6udTcc2ebMTDMi9nCigLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38zntFOjtw%253D%253D&md5=ce98e553bd770ade31ef73bc672cb479</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1358%2Fdot.2020.56.4.3127026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2020.56.4.3127026%26sid%3Dliteratum%253Aachs%26aulast%3DAmaya%26aufirst%3DM.%2BL.%26aulast%3DJimeno%26aufirst%3DA.%26aulast%3DKamdar%26aufirst%3DM.%26atitle%3DPolatuzumab%2520Vedotin%2520to%2520Treat%2520Relapsed%2520or%2520Refractory%2520Diffuse%2520Large%2520B-Cell%2520Lymphoma%252C%2520in%2520Combination%2520with%2520Bendamustine%2520Plus%2520Rituximab%26jtitle%3DDrugs%2520Today%26date%3D2020%26volume%3D56%26spage%3D287%26epage%3D294%26doi%3D10.1358%2Fdot.2020.56.4.3127026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref183"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref183'); return false;" data-citation="" class="refNumLink">183</a></strong><div class="NLM_citation" id="cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doronina, S. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toki, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torgov, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendelsohn, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerveny, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chace, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeBlanc, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gearing, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bovee, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegall, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francisco, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wahl, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senter, P. D.</span></span> <span> </span><span class="NLM_article-title">Development of Potent Monoclonal Antibody Auristatin Conjugates for Cancer Therapy</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">778</span>– <span class="NLM_lpage">784</span>, <span class="refDoi"> DOI: 10.1038/nbt832</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1038%2Fnbt832" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=12778055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkvFertLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2003&pages=778-784&author=S.+O.+Doroninaauthor=B.+E.+Tokiauthor=M.+Y.+Torgovauthor=B.+A.+Mendelsohnauthor=C.+G.+Cervenyauthor=D.+F.+Chaceauthor=R.+L.+DeBlancauthor=R.+P.+Gearingauthor=T.+D.+Boveeauthor=C.+B.+Siegallauthor=J.+A.+Franciscoauthor=A.+F.+Wahlauthor=D.+L.+Meyerauthor=P.+D.+Senter&title=Development+of+Potent+Monoclonal+Antibody+Auristatin+Conjugates+for+Cancer+Therapy&doi=10.1038%2Fnbt832"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Development of potent monoclonal antibody auristatin conjugates for cancer therapy</span></div><div class="casAuthors">Doronina, Svetlana O.; Toki, Brian E.; Torgov, Michael Y.; Mendelsohn, Brian A.; Cerveny, Charles G.; Chace, Dana F.; DeBlanc, Ron L.; Gearing, R. Patrick; Bovee, Tim D.; Siegall, Clay B.; Francisco, Joseph A.; Wahl, Alan F.; Meyer, Damon L.; Senter, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">778-784</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We describe the in vitro and in vivo properties of monoclonal antibody (mAb)-drug conjugates consisting of the potent synthetic dolastatin 10 analogs auristatin E (AE) and monomethylauristatin E (MMAE), linked to the chimeric mAbs cBR96 (specific to Lewis Y on carcinomas) and cAC10 (specific to CD30 on hematol. malignancies).  The linkers used for conjugate formation included an acid-labile hydrazone and protease-sensitive dipeptides, leading to uniformly substituted conjugates that efficiently released active drug in the lysosomes of antigen-pos. (Ag+) tumor cells.  The peptide-linked mAb-valine-citrulline-MMAE and mAb-phenylalanine-lysine-MMAE conjugates were much more stable in buffers and plasma than the conjugates of mAb and the hydrazone of 5-benzoylvaleric acid-AE ester (AEVB).  As a result, the mAb-Val-Cit-MMAE conjugates exhibited greater in vitro specificity and lower in vivo toxicity than corresponding hydrazone conjugates.  In vivo studies demonstrated that the peptide-linked conjugates induced regressions and cures of established tumor xenografts with therapeutic indexes as high as 60-fold.  These conjugates illustrate the importance of linker technol., drug potency and conjugation methodol. in developing safe and efficacious mAb-drug conjugates for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro97SFKtdQ7rVg90H21EOLACvtfcHk0lii4NhM4REJig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkvFertLc%253D&md5=d77716ec93de5ac7473c18a597339086</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1038%2Fnbt832&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt832%26sid%3Dliteratum%253Aachs%26aulast%3DDoronina%26aufirst%3DS.%2BO.%26aulast%3DToki%26aufirst%3DB.%2BE.%26aulast%3DTorgov%26aufirst%3DM.%2BY.%26aulast%3DMendelsohn%26aufirst%3DB.%2BA.%26aulast%3DCerveny%26aufirst%3DC.%2BG.%26aulast%3DChace%26aufirst%3DD.%2BF.%26aulast%3DDeBlanc%26aufirst%3DR.%2BL.%26aulast%3DGearing%26aufirst%3DR.%2BP.%26aulast%3DBovee%26aufirst%3DT.%2BD.%26aulast%3DSiegall%26aufirst%3DC.%2BB.%26aulast%3DFrancisco%26aufirst%3DJ.%2BA.%26aulast%3DWahl%26aufirst%3DA.%2BF.%26aulast%3DMeyer%26aufirst%3DD.%2BL.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DDevelopment%2520of%2520Potent%2520Monoclonal%2520Antibody%2520Auristatin%2520Conjugates%2520for%2520Cancer%2520Therapy%26jtitle%3DNat.%2520Biotechnol.%26date%3D2003%26volume%3D21%26spage%3D778%26epage%3D784%26doi%3D10.1038%2Fnbt832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref184"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref184'); return false;" data-citation="" class="refNumLink">184</a></strong><div class="NLM_citation" id="cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dere, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuh, F. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozak, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bumbaca
Yadav, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nazzal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danilenko, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Go, M. A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polson, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prabhu, S.</span></span> <span> </span><span class="NLM_article-title">Evaluation and Use of an Anti-Cynomolgus Monkey CD79b Surrogate Antibody–Drug Conjugate to Enable Clinical Development of Polatuzumab Vedotin</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>176</i></span>,  <span class="NLM_fpage">3805</span>– <span class="NLM_lpage">3818</span>, <span class="refDoi"> DOI: 10.1111/bph.14784</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1111%2Fbph.14784" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31270798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1aqsLfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=176&publication_year=2019&pages=3805-3818&author=D.+Liauthor=D.+Leeauthor=R.+C.+Dereauthor=B.+Zhengauthor=S.-F.+Yuauthor=F.+K.+Fuhauthor=K.+R.+Kozakauthor=S.+Chungauthor=D.+Bumbaca%0AYadavauthor=D.+Nazzalauthor=D.+Danilenkoauthor=M.+A.+T.+Goauthor=M.+Williamsauthor=A.+G.+Polsonauthor=K.+A.+Poonauthor=S.+Prabhu&title=Evaluation+and+Use+of+an+Anti-Cynomolgus+Monkey+CD79b+Surrogate+Antibody%E2%80%93Drug+Conjugate+to+Enable+Clinical+Development+of+Polatuzumab+Vedotin&doi=10.1111%2Fbph.14784"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation and use of an anti-cynomolgus monkey CD79b surrogate antibody-drug conjugate to enable clinical development of polatuzumab vedotin</span></div><div class="casAuthors">Li, Dongwei; Lee, Donna; Dere, Randall C.; Zheng, Bing; Yu, Shang-Fan; Fuh, Franklin K.; Kozak, Katherine R.; Chung, Shan; Bumbaca Yadav, Daniela; Nazzal, Denise; Danilenko, Dimitry; Go, Mary Ann T.; Williams, Marna; Polson, Andrew G.; Poon, Kirsten Achilles; Prabhu, Saileta</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">176</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">3805-3818</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Polatuzumab vedotin is an antibody-drug conjugate (ADC) being developed for non-Hodgkin's lymphoma.  It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), an anti-mitotic agent.  Polatuzumab vedotin binds to human CD79b only.  Therefore, a surrogate ADC that binds to cynomolgus monkey CD79b was used to det. CD79b-mediated pharmacol. effects in the monkey and to enable first-in-human clin. trials.  Polatuzumab vedotin, the surrogate ADC, and the corresponding antibodies were evaluated in different assays in vitro and in animals.  In vitro assessments included binding to peripheral blood mononuclear cells from different species, binding to a human and monkey CD79b-expressing cell line, binding to human Fcγ receptors, and stability in plasma across species.  In vivo, ADCs were assessed for anti-tumor activity in mice, pharmacokinetics/pharmacodynamics in monkeys, and toxicity in rats and monkeys.  Polatuzumab vedotin and surrogate ADC bind with similar affinity to human and cynomolgus monkey B cells, resp.  Comparable in vitro plasma stability, in vivo anti-tumor activity, and mouse pharmacokinetics were also obsd. between the surrogate ADC and polatuzumab vedotin.  In monkeys, only the surrogate ADC showed B-cell depletion and B-cell-mediated drug disposition, but both ADCs showed similar MMAE-driven myelotoxicity, as expected.  The suitability of the surrogate ADC for evaluation of CD79b-dependent pharmacol. was demonstrated, and anti-tumor activity, pharmacokinetics/pharmacodynamics, and toxicity data with both ADCs supported the entry of polatuzumab vedotin into clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYvtxcRHld6bVg90H21EOLACvtfcHk0lii4NhM4REJig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1aqsLfE&md5=1e6be208a608aa546823232c509b0661</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1111%2Fbph.14784&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.14784%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DD.%26aulast%3DDere%26aufirst%3DR.%2BC.%26aulast%3DZheng%26aufirst%3DB.%26aulast%3DYu%26aufirst%3DS.-F.%26aulast%3DFuh%26aufirst%3DF.%2BK.%26aulast%3DKozak%26aufirst%3DK.%2BR.%26aulast%3DChung%26aufirst%3DS.%26aulast%3DBumbaca%2BYadav%26aufirst%3DD.%26aulast%3DNazzal%26aufirst%3DD.%26aulast%3DDanilenko%26aufirst%3DD.%26aulast%3DGo%26aufirst%3DM.%2BA.%2BT.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DPolson%26aufirst%3DA.%2BG.%26aulast%3DPoon%26aufirst%3DK.%2BA.%26aulast%3DPrabhu%26aufirst%3DS.%26atitle%3DEvaluation%2520and%2520Use%2520of%2520an%2520Anti-Cynomolgus%2520Monkey%2520CD79b%2520Surrogate%2520Antibody%25E2%2580%2593Drug%2520Conjugate%2520to%2520Enable%2520Clinical%2520Development%2520of%2520Polatuzumab%2520Vedotin%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2019%26volume%3D176%26spage%3D3805%26epage%3D3818%26doi%3D10.1111%2Fbph.14784" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref185"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref185'); return false;" data-citation="" class="refNumLink">185</a></strong><div class="NLM_citation" id="cit185a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Aikawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Togashi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwanaga, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishiya, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isoyama, T.</span></span> <span> </span><span class="NLM_article-title">Quizartinib, a Selective FLT3 Inhibitor, Maintains Antileukemic Activity in Preclinical Models of RAS-Mediated Midostaurin-Resistant Acute Myeloid Leukemia Cells</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">943</span>– <span class="NLM_lpage">955</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.27489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.18632%2Foncotarget.27489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=32215183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A280%3ADC%252BB383nslejtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=943-955&author=T.+Aikawaauthor=N.+Togashiauthor=K.+Iwanagaauthor=H.+Okadaauthor=Y.+Nishiyaauthor=S.+Inoueauthor=M.+J.+Levisauthor=T.+Isoyama&title=Quizartinib%2C+a+Selective+FLT3+Inhibitor%2C+Maintains+Antileukemic+Activity+in+Preclinical+Models+of+RAS-Mediated+Midostaurin-Resistant+Acute+Myeloid+Leukemia+Cells&doi=10.18632%2Foncotarget.27489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit185aR"><div class="casContent"><span class="casTitleNuber">185a</span><div class="casTitle"><span class="NLM_cas:atitle">Quizartinib, a selective FLT3 inhibitor, maintains antileukemic activity in preclinical models of RAS-mediated midostaurin-resistant acute myeloid leukemia cells</span></div><div class="casAuthors">Aikawa Tomoya; Togashi Noriko; Iwanaga Koichi; Okada Hiroyuki; Nishiya Yumi; Inoue Shinichi; Isoyama Takeshi; Levis Mark J</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">943-955</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">FLT3 internal tandem duplication (ITD) mutations are associated with poor prognosis in patients with acute myeloid leukemia (AML).  In this preclinical study, we characterized the binding affinity and selectivity of quizartinib, a small-molecule inhibitor of FLT3, and AC886, the active metabolite of quizartinib, compared with those of other FLT3 inhibitors.  Selectivity profiling against >400 kinases showed that quizartinib and AC886 were highly selective against FLT3.  Quizartinib and AC886 inhibited FLT3 signaling pathways in FLT3-ITD-mutated AML cells, leading to potent growth inhibition with IC50 values of <1 nM.  When quizartinib was administered to mice bearing FLT3-ITD mutated tumors, AC886 was rapidly detected and tumor regression was observed at doses of ≥1 mg/kg without severe body weight loss.  In addition, quizartinib inhibited the viability of midostaurin-resistant MOLM-14 cells and exerted potent antitumor activity in mouse xenograft models without severe body weight loss, while midostaurin and gilteritinib did not show significant antitumor effects.  This is the first detailed characterization of quizartinib and AC886 in comparison with other FLT3 inhibitors under the same experimental conditions.  Preclinical antileukemic activity in midostaurin-resistant FLT3-ITD-mutated AML cells suggests the potential value of quizartinib following midostaurin failure in patients with FLT3-ITD mutated AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS7wRn2iXI1_IvKgEt20y1XfW6udTcc2eZM7z_A5DsUVrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB383nslejtw%253D%253D&md5=9adcf7786ff2e64f56d2d964edb7cab5</span></div><a href="/servlet/linkout?suffix=cit185a&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.27489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.27489%26sid%3Dliteratum%253Aachs%26aulast%3DAikawa%26aufirst%3DT.%26aulast%3DTogashi%26aufirst%3DN.%26aulast%3DIwanaga%26aufirst%3DK.%26aulast%3DOkada%26aufirst%3DH.%26aulast%3DNishiya%26aufirst%3DY.%26aulast%3DInoue%26aufirst%3DS.%26aulast%3DLevis%26aufirst%3DM.%2BJ.%26aulast%3DIsoyama%26aufirst%3DT.%26atitle%3DQuizartinib%252C%2520a%2520Selective%2520FLT3%2520Inhibitor%252C%2520Maintains%2520Antileukemic%2520Activity%2520in%2520Preclinical%2520Models%2520of%2520RAS-Mediated%2520Midostaurin-Resistant%2520Acute%2520Myeloid%2520Leukemia%2520Cells%26jtitle%3DOncotarget%26date%3D2020%26volume%3D11%26spage%3D943%26epage%3D955%26doi%3D10.18632%2Foncotarget.27489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit185b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Naqvi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravandi, F.</span></span> <span> </span><span class="NLM_article-title">FLT3 Inhibitor Quizartinib (AC220)</span>. <i>Leuk. Lymphoma</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1866</span>– <span class="NLM_lpage">1876</span>, <span class="refDoi"> DOI: 10.1080/10428194.2019.1602263</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1080%2F10428194.2019.1602263" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=30997851" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnslOrsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2019&pages=1866-1876&author=K.+Naqviauthor=F.+Ravandi&title=FLT3+Inhibitor+Quizartinib+%28AC220%29&doi=10.1080%2F10428194.2019.1602263"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit185bR"><div class="casContent"><span class="casTitleNuber">185b</span><div class="casTitle"><span class="NLM_cas:atitle">FLT3 inhibitor quizartinib (AC220)</span></div><div class="casAuthors">Naqvi, Kiran; Ravandi, Farhad</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia & Lymphoma</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1866-1876</span>CODEN:
                <span class="NLM_cas:coden">LELYEA</span>;
        ISSN:<span class="NLM_cas:issn">1029-2403</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Acute myeloid leukemia (AML) is a heterogeneous disease and remains a therapeutic challenge.  Cytogenetics is a well-established prognostic factor.  Recent discovery of mol. mutations has gained momentum with some being potential therapeutic targets.  FLT3 mutation seen in approx. one third of the cytogenetically normal AML confers high risk of relapse and poor survival.  Quizartinib is the first drug developed specifically as a FLT3 inhibitor.  It has confirmed safety and efficacy in phase I and II clin. trials and has shown survival benefit over conventional chemotherapy in patients with FLT3 ITD mutated relapsed/refractory AML.  Despite such promise, disease relapses are still seen.  Besides the complex nature of AML itself, resistance mechanisms blunting the efficacy of quizartinib have been identified and are being investigated including TKD mutations, alternate signaling pathways and the bone marrow microenvironment.  Strategies using combination of quizartinib with other TKIs/agents like crenolinib, PIM kinase, and MEK inhibitors should be further explored.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXcUK188pPwbVg90H21EOLACvtfcHk0lgGVoEg5NQkuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnslOrsrg%253D&md5=c1f1aa313d92e49f45159e7cce9bbbdd</span></div><a href="/servlet/linkout?suffix=cit185b&amp;dbid=16384&amp;doi=10.1080%2F10428194.2019.1602263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10428194.2019.1602263%26sid%3Dliteratum%253Aachs%26aulast%3DNaqvi%26aufirst%3DK.%26aulast%3DRavandi%26aufirst%3DF.%26atitle%3DFLT3%2520Inhibitor%2520Quizartinib%2520%2528AC220%2529%26jtitle%3DLeuk.%2520Lymphoma%26date%3D2019%26volume%3D60%26spage%3D1866%26epage%3D1876%26doi%3D10.1080%2F10428194.2019.1602263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref186"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref186'); return false;" data-citation="" class="refNumLink">186</a></strong><div class="NLM_citation" id="cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprankle, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grotzfeld, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velasco, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunawardane, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cramer, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhagwat, S. S.</span></span> <span> </span><span class="NLM_article-title">Identification of N-(5-<i>tert</i>-Butyl-isoxazol-3-yl)-<i>N</i>-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo-[2,1-<i>b</i>][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a Uniquely Potent, Selective, and Efficacious Fms-Like Tyrosine Kinase-3 (FLT3) Inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">7808</span>– <span class="NLM_lpage">7816</span>, <span class="refDoi"> DOI: 10.1021/jm9007533</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9007533" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFCjt7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7808-7816&author=Q.+Chaoauthor=K.+G.+Sprankleauthor=R.+M.+Grotzfeldauthor=A.+G.+Laiauthor=T.+A.+Carterauthor=A.+M.+Velascoauthor=R.+N.+Gunawardaneauthor=M.+D.+Cramerauthor=M.+F.+Gardnerauthor=J.+Jamesauthor=P.+P.+Zarrinkarauthor=H.+K.+Patelauthor=S.+S.+Bhagwat&title=Identification+of+N-%285-tert-Butyl-isoxazol-3-yl%29-N-%7B4-%5B7-%282-morpholin-4-yl-ethoxy%29imidazo-%5B2%2C1-b%5D%5B1%2C3%5Dbenzothiazol-2-yl%5Dphenyl%7Durea+dihydrochloride+%28AC220%29%2C+a+Uniquely+Potent%2C+Selective%2C+and+Efficacious+Fms-Like+Tyrosine+Kinase-3+%28FLT3%29+Inhibitor&doi=10.1021%2Fjm9007533"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of N-(5-tert-Butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea Dihydrochloride (AC220), a Uniquely Potent, Selective, and Efficacious FMS-Like Tyrosine Kinase-3 (FLT3) Inhibitor</span></div><div class="casAuthors">Chao, Qi; Sprankle, Kelly G.; Grotzfeld, Robert M.; Lai, Andiliy G.; Carter, Todd A.; Velasco, Anne Marie; Gunawardane, Ruwanthi N.; Cramer, Merryl D.; Gardner, Michael F.; James, Joyce; Zarrinkar, Patrick P.; Patel, Hitesh K.; Bhagwat, Shripad S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7808-7816</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Treatment of AML patients with small mol. inhibitors of FLT3 kinase has been explored as a viable therapy.  However, these agents are found to be less than optimal for the treatment of AML because of lack of sufficient potency or suboptimal oral pharmacokinetics (PK) or lack of adequate tolerability at efficacious doses.  We have developed a series of extremely potent and highly selective FLT3 inhibitors with good oral PK properties.  The first series of compds. represented by 1 (AB530) was found to be a potent and selective FLT3 kinase inhibitor with good PK properties.  The aq. soly. and oral PK properties at higher doses in rodents were found to be less than optimal for clin. development.  A novel series of compds. were designed lacking the carboxamide group of 1 with an added water solubilizing group.  Compd. 7 (AC220) was identified from this series to be the most potent and selective FLT3 inhibitor with good pharmaceutical properties, excellent PK profile, and superior efficacy and tolerability in tumor xenograft models.  Compd. 7 has demonstrated a desirable safety and PK profile in humans and is currently in phase II clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAtNhT4frlQ7Vg90H21EOLACvtfcHk0lgGVoEg5NQkuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFCjt7zK&md5=1b64254428a51c637da0ff647ac8d567</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1021%2Fjm9007533&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9007533%26sid%3Dliteratum%253Aachs%26aulast%3DChao%26aufirst%3DQ.%26aulast%3DSprankle%26aufirst%3DK.%2BG.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DGunawardane%26aufirst%3DR.%2BN.%26aulast%3DCramer%26aufirst%3DM.%2BD.%26aulast%3DGardner%26aufirst%3DM.%2BF.%26aulast%3DJames%26aufirst%3DJ.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DBhagwat%26aufirst%3DS.%2BS.%26atitle%3DIdentification%2520of%2520N-%25285-tert-Butyl-isoxazol-3-yl%2529-N-%257B4-%255B7-%25282-morpholin-4-yl-ethoxy%2529imidazo-%255B2%252C1-b%255D%255B1%252C3%255Dbenzothiazol-2-yl%255Dphenyl%257Durea%2520dihydrochloride%2520%2528AC220%2529%252C%2520a%2520Uniquely%2520Potent%252C%2520Selective%252C%2520and%2520Efficacious%2520Fms-Like%2520Tyrosine%2520Kinase-3%2520%2528FLT3%2529%2520Inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7808%26epage%3D7816%26doi%3D10.1021%2Fjm9007533" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref187"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref187'); return false;" data-citation="" class="refNumLink">187</a></strong><div class="NLM_citation" id="cit187"><span><a href="https://www.genengnews.com/topics/translational-medicine/daiichi-sankyo-to-acquire-ambit-biosciences-for-up-to-410m/" class="extLink">https://www.genengnews.com/topics/translational-medicine/daiichi-sankyo-to-acquire-ambit-biosciences-for-up-to-410m/</a> (accessed 2020-12-18).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.genengnews.com%2Ftopics%2Ftranslational-medicine%2Fdaiichi-sankyo-to-acquire-ambit-biosciences-for-up-to-410m%2F+%28accessed+2020-12-18%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref188"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref188'); return false;" data-citation="" class="refNumLink">188</a></strong><div class="NLM_citation" id="cit188a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhagwat, S.</span>; <span class="NLM_string-name">Chao, Q.</span>; <span class="NLM_string-name">Grotzfeld, R. M.</span>; <span class="NLM_string-name">Patel, H. K.</span>; <span class="NLM_string-name">Sprankle, K. G.</span></span> <span> </span><span class="NLM_article-title">Imidazolothiazole Compounds for the Treatment of Disease</span>. <span class="NLM_patent">WO 2007109120 A1</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=S.+Bhagwat&author=Q.+Chao&author=R.+M.+Grotzfeld&author=H.+K.+Patel&author=K.+G.+Sprankle&title=Imidazolothiazole+Compounds+for+the+Treatment+of+Disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit188a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBhagwat%26aufirst%3DS.%26atitle%3DImidazolothiazole%2520Compounds%2520for%2520the%2520Treatment%2520of%2520Disease%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit188b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhagwat, S.</span>; <span class="NLM_string-name">Lai, W.</span>; <span class="NLM_string-name">Parent, S. D.</span>; <span class="NLM_string-name">Roe, M. J.</span>; <span class="NLM_string-name">Schwartz, A.</span>; <span class="NLM_string-name">Smolenskaya, V. N.</span></span> <span> </span><span class="NLM_article-title">Solid Forms Comprising <i>N</i>-(5-<i>tert</i>-Butyl-isoxazol-3-yl)-<i>N</i>′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-<i>b</i>][1,3]benzothiazol-2-yl]phenyl}urea, Compositions Thereof, and Uses Therewith</span>. <span class="NLM_patent">WO 2009038757 A2</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=S.+Bhagwat&author=W.+Lai&author=S.+D.+Parent&author=M.+J.+Roe&author=A.+Schwartz&author=V.+N.+Smolenskaya&title=Solid+Forms+Comprising+N-%285-tert-Butyl-isoxazol-3-yl%29-N%E2%80%B2-%7B4-%5B7-%282-morpholin-4-yl-ethoxy%29imidazo%5B2%2C1-b%5D%5B1%2C3%5Dbenzothiazol-2-yl%5Dphenyl%7Durea%2C+Compositions+Thereof%2C+and+Uses+Therewith"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit188b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBhagwat%26aufirst%3DS.%26atitle%3DSolid%2520Forms%2520Comprising%2520N-%25285-tert-Butyl-isoxazol-3-yl%2529-N%25E2%2580%25B2-%257B4-%255B7-%25282-morpholin-4-yl-ethoxy%2529imidazo%255B2%252C1-b%255D%255B1%252C3%255Dbenzothiazol-2-yl%255Dphenyl%257Durea%252C%2520Compositions%2520Thereof%252C%2520and%2520Uses%2520Therewith%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref189"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref189'); return false;" data-citation="" class="refNumLink">189</a></strong><div class="NLM_citation" id="cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gross, T. D.</span>; <span class="NLM_string-name">Prasad, A. R.</span>; <span class="NLM_string-name">Citineni, J. R.</span></span> <span> </span><span class="NLM_article-title">Process for the Preparation of Imidazo[2,1-<i>b</i>][1,3]benzothiazole Derivatives</span>. WO <span class="NLM_patent">2011056939 A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=T.+D.+Gross&author=A.+R.+Prasad&author=J.+R.+Citineni&title=Process+for+the+Preparation+of+Imidazo%5B2%2C1-b%5D%5B1%2C3%5Dbenzothiazole+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGross%26aufirst%3DT.%2BD.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%2520Imidazo%255B2%252C1-b%255D%255B1%252C3%255Dbenzothiazole%2520Derivatives%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref190"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref190'); return false;" data-citation="" class="refNumLink">190</a></strong><div class="NLM_citation" id="cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jans, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagstaff, K. M.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of Nuclear Transport</span>. <i>Curr. Opin. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">50</span>– <span class="NLM_lpage">60</span>, <span class="refDoi"> DOI: 10.1016/j.ceb.2019.01.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2Fj.ceb.2019.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=30826604" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXislKksrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2019&pages=50-60&author=D.+A.+Jansauthor=A.+J.+Martinauthor=K.+M.+Wagstaff&title=Inhibitors+of+Nuclear+Transport&doi=10.1016%2Fj.ceb.2019.01.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of nuclear transport</span></div><div class="casAuthors">Jans, David A.; Martin, Alexander J.; Wagstaff, Kylie M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Cell Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">50-60</span>CODEN:
                <span class="NLM_cas:coden">COCBE3</span>;
        ISSN:<span class="NLM_cas:issn">0955-0674</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Central to eukaryotic cell function, transport into and out of the nucleus is largely mediated by members of the Importin (IMP) superfamily of transporters of α- and β-types.  The first inhibitor of nuclear transport, leptomycin B (LMB), was shown to be a specific inhibitor of the IMPβ homolog Exportin 1 (EXP1) almost 20 years ago, but it has only been in the last five or so years that new inhibitors of nuclear export as well as import have been identified and characterised.  Of utility in biol. research, these inhibitors include those that target-specific EXPs/IMPs, with accompanying toxicity profiles, as well as agents that specifically target particular nuclear import cargoes.  Both types of inhibitors have begun to be tested in preclin./clin. studies, with particular focus on limiting various types of cancer or treating viral infection, and the most advanced agent targeting EXP1 (Selinexor) has progressed successfully through >40 clin. trials for a range of high-grade cancers and is approaching FDA approval for a no. of indications.  Selectively inhibiting the nucleocytoplasmic trafficking of specific proteins of interest remains a challenge, but progress in the area of the host-pathogen interface holds promise for the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYo9dIddFK5bVg90H21EOLACvtfcHk0lgE6A0u2_3yVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXislKksrg%253D&md5=c716540c78a6cdd8b0d5ab968415cfd4</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1016%2Fj.ceb.2019.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ceb.2019.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DJans%26aufirst%3DD.%2BA.%26aulast%3DMartin%26aufirst%3DA.%2BJ.%26aulast%3DWagstaff%26aufirst%3DK.%2BM.%26atitle%3DInhibitors%2520of%2520Nuclear%2520Transport%26jtitle%3DCurr.%2520Opin.%2520Cell%2520Biol.%26date%3D2019%26volume%3D58%26spage%3D50%26epage%3D60%26doi%3D10.1016%2Fj.ceb.2019.01.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref191"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref191'); return false;" data-citation="" class="refNumLink">191</a></strong><div class="NLM_citation" id="cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ben-Barouch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuruvilla, J.</span></span> <span> </span><span class="NLM_article-title">Selinexor (KTP-330) - a Selective Inhibitor of Nuclear Export (SINE): Anti-Tumor Activity in Diffuse Large B-Cell Lymphoma (DLBCL)</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1080/13543784.2020.1706087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1080%2F13543784.2020.1706087" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31847605" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVGlsb7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2020&pages=15-21&author=S.+Ben-Barouchauthor=J.+Kuruvilla&title=Selinexor+%28KTP-330%29+-+a+Selective+Inhibitor+of+Nuclear+Export+%28SINE%29%3A+Anti-Tumor+Activity+in+Diffuse+Large+B-Cell+Lymphoma+%28DLBCL%29&doi=10.1080%2F13543784.2020.1706087"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Selinexor (KTP-330) - a selective inhibitor of nuclear export (SINE): anti-tumor activity in diffuse large B-cell lymphoma (DLBCL)</span></div><div class="casAuthors">Ben-Barouch, Sharon; Kuruvilla, John</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-21</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Selinexor is a first-in-class, oral therapeutic that selectively inhibits nuclear export.  It has received fast track designation from the FDA for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) recently, and continues to be evaluated as a potential treatment for DLBCL.: This article reviews the available data from clin. trials regarding the efficacy of selinexor in DLBCL and highlights the key toxicity issues and how they may best be managed.  Ongoing and future studies in DLBCL are also discussed.: More translational studies are necessary to leverage the unique mechanism action and rationally inform the use of selinexor in combination strategies.  There are several different genetic subtypes of DLBCL, but it is not clear if these classifications will identify patients that may benefit from targeted therapies.  The broad potential mechanism of action of selinexor will require careful anal. to inform predictive or prognostic biomarkers.  Further evaluation of selinexor in combination with std. lymphoma regimens could identify deliverable promising regimens.  Future randomized trials are key for registration and to det. the optimal role for this first-in-class agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopMRVOtPthZrVg90H21EOLACvtfcHk0lgE6A0u2_3yVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVGlsb7P&md5=a633ee622b9103039a6a9e0cb3d478ba</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1080%2F13543784.2020.1706087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543784.2020.1706087%26sid%3Dliteratum%253Aachs%26aulast%3DBen-Barouch%26aufirst%3DS.%26aulast%3DKuruvilla%26aufirst%3DJ.%26atitle%3DSelinexor%2520%2528KTP-330%2529%2520-%2520a%2520Selective%2520Inhibitor%2520of%2520Nuclear%2520Export%2520%2528SINE%2529%253A%2520Anti-Tumor%2520Activity%2520in%2520Diffuse%2520Large%2520B-Cell%2520Lymphoma%2520%2528DLBCL%2529%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2020%26volume%3D29%26spage%3D15%26epage%3D21%26doi%3D10.1080%2F13543784.2020.1706087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref192"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref192'); return false;" data-citation="" class="refNumLink">192</a></strong><div class="NLM_citation" id="cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeSisto, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flannery, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pathak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mestnik, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philips, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bales, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashyap, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moroze, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkataraman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landesman, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vibhakar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, A. L.</span></span> <span> </span><span class="NLM_article-title">Exportin 1 Inhibition Induces Nerve Growth Factor Receptor Expression to Inhibit the NF-κB Pathway in Preclinical Models of Pediatric High-Grade Glioma</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">540</span>– <span class="NLM_lpage">551</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-18-1319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1158%2F1535-7163.MCT-18-1319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31594826" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnvFSktrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2020&pages=540-551&author=J.+A.+DeSistoauthor=P.+Flanneryauthor=R.+Lemmaauthor=A.+Pathakauthor=S.+Mestnikauthor=N.+Philipsauthor=N.+J.+Balesauthor=T.+Kashyapauthor=E.+Morozeauthor=S.+Venkataramanauthor=A.+L.+Kungauthor=B.+D.+Carterauthor=Y.+Landesmanauthor=R.+Vibhakarauthor=A.+L.+Green&title=Exportin+1+Inhibition+Induces+Nerve+Growth+Factor+Receptor+Expression+to+Inhibit+the+NF-%CE%BAB+Pathway+in+Preclinical+Models+of+Pediatric+High-Grade+Glioma&doi=10.1158%2F1535-7163.MCT-18-1319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Exportin 1 inhibition induces nerve growth factor receptor expression to inhibit the NF-κB pathway in preclinical models of pediatric high-grade glioma</span></div><div class="casAuthors">DeSisto, John A.; Flannery, Patrick; Lemma, Rakeb; Pathak, Amrita; Mestnik, Shelby; Philips, Natalie; Bales, Natalie J.; Kashyap, Trinayan; Moroze, Erin; Venkataraman, Sujatha; Kung, Andrew L.; Carter, Bruce D.; Landesman, Yosef; Vibhakar, Rajeev; Green, Adam L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">540-551</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">High-grade glioma (HGG) is the leading cause of cancer-related death among children.  Selinexor, an orally bioavailable, reversible inhibitor of the nuclear export protein, exportin 1, is in clin. trials for a range of cancers, including HGG.  It inhibits the NF-κB pathway and strongly induces the expression of nerve growth factor receptor (NGFR) in preclin. cancer models.  We hypothesized that selinexor inhibits NF-κB via upregulation of NGFR.  In HGG cells, sensitivity to selinexor correlated with increased induction of cell surface NGFR expression.  Knocking down NGFR in HGG cells increased proliferation, anchorage-independent growth, stemness markers, and levels of transcriptionally available nuclear NF-κB not bound to IκB-α, while decreasing apoptosis and sensitivity to selinexor.  Increasing IκB-α levels in NGFR knockdown cells restored sensitivity to selinexor.  Overexpression of NGFR using cDNA reduced levels of free nuclear NF-κB, decreased stemness markers, and increased markers of cellular differentiation.  In all HGG lines tested, selinexor decreased phosphorylation of NF-κB at serine 536 (a site assocd. with increased transcription of proliferative and inflammatory genes).  Because resistance to selinexor monotherapy occurred in our in vivo model, we screened selinexor with a panel of FDA-approved anticancer agents.  Bortezomib, a proteasome inhibitor that inhibits the NF-κB pathway through a different mechanism than selinexor, showed synergy with selinexor against HGG in vitro.  Our results help elucidate selinexor's mechanism of action and identify NGFR as a potential biomarker of its effect in HGG and in addn. suggest a combination therapy strategy for these challenging tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpM2nVjr0FgFLVg90H21EOLACvtfcHk0lgE6A0u2_3yVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnvFSktrc%253D&md5=9ac5293e322fb6d1cd8c9eca4a785de3</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-18-1319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-18-1319%26sid%3Dliteratum%253Aachs%26aulast%3DDeSisto%26aufirst%3DJ.%2BA.%26aulast%3DFlannery%26aufirst%3DP.%26aulast%3DLemma%26aufirst%3DR.%26aulast%3DPathak%26aufirst%3DA.%26aulast%3DMestnik%26aufirst%3DS.%26aulast%3DPhilips%26aufirst%3DN.%26aulast%3DBales%26aufirst%3DN.%2BJ.%26aulast%3DKashyap%26aufirst%3DT.%26aulast%3DMoroze%26aufirst%3DE.%26aulast%3DVenkataraman%26aufirst%3DS.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DCarter%26aufirst%3DB.%2BD.%26aulast%3DLandesman%26aufirst%3DY.%26aulast%3DVibhakar%26aufirst%3DR.%26aulast%3DGreen%26aufirst%3DA.%2BL.%26atitle%3DExportin%25201%2520Inhibition%2520Induces%2520Nerve%2520Growth%2520Factor%2520Receptor%2520Expression%2520to%2520Inhibit%2520the%2520NF-%25CE%25BAB%2520Pathway%2520in%2520Preclinical%2520Models%2520of%2520Pediatric%2520High-Grade%2520Glioma%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2020%26volume%3D19%26spage%3D540%26epage%3D551%26doi%3D10.1158%2F1535-7163.MCT-18-1319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref193"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref193'); return false;" data-citation="" class="refNumLink">193</a></strong><div class="NLM_citation" id="cit193a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouhaddou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obernier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Meara, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rezelj, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaney, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tummino, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huettenhain, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaake, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richards, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tutuncuoglu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foussard, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batra, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polacco, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braberg, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabius, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckhardt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soucheray, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cakir, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGregor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roesch, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallet, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mac Kain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miorin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naing, Z. Z. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirby, I. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melnyk, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chorba, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrio-Hernandez, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Memon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez-Armenta, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathy, C. J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perica, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilla, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganesan, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saltzberg, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rakesh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenthal, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calviello, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkataramanan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liboy-Lugo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wankowicz, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safari, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ugur, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koh, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savar, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, Q. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shengjuler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neal, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broadhurst, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klippsten, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharp, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wenzell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuzuoglu-Ozturk, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trenker, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavero, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiatt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathore, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noack, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroud, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frankel, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, O. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verba, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agard, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emerman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Zastrow, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verdin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashworth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">d’Enfert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukherjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malik, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimori, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ideker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craik, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floor, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraser, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sali, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggero, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taunton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kortemme, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beltrao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vignuzzi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Sastre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoichet, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krogan, N. J.</span></span> <span> </span><span class="NLM_article-title">A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug Repurposing</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>583</i></span>,  <span class="NLM_fpage">459</span>– <span class="NLM_lpage">468</span>, <span class="refDoi"> DOI: 10.1038/s41586-020-2286-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1038%2Fs41586-020-2286-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=32353859" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlCqtbrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=583&publication_year=2020&pages=459-468&author=D.+E.+Gordonauthor=G.+M.+Jangauthor=M.+Bouhaddouauthor=J.+Xuauthor=K.+Obernierauthor=K.+M.+Whiteauthor=M.+J.+O%E2%80%99Mearaauthor=V.+V.+Rezeljauthor=J.+Z.+Guoauthor=D.+L.+Swaneyauthor=T.+A.+Tumminoauthor=R.+Huettenhainauthor=R.+M.+Kaakeauthor=A.+L.+Richardsauthor=B.+Tutuncuogluauthor=H.+Foussardauthor=J.+Batraauthor=K.+Haasauthor=M.+Modakauthor=M.+Kimauthor=P.+Haasauthor=B.+J.+Polaccoauthor=H.+Brabergauthor=J.+M.+Fabiusauthor=M.+Eckhardtauthor=M.+Soucherayauthor=M.+J.+Bennettauthor=M.+Cakirauthor=M.+J.+McGregorauthor=Q.+Liauthor=B.+Meyerauthor=F.+Roeschauthor=T.+Valletauthor=A.+Mac+Kainauthor=L.+Miorinauthor=E.+Morenoauthor=Z.+Z.+C.+Naingauthor=Y.+Zhouauthor=S.+Pengauthor=Y.+Shiauthor=Z.+Zhangauthor=W.+Shenauthor=I.+T.+Kirbyauthor=J.+E.+Melnykauthor=J.+S.+Chorbaauthor=K.+Louauthor=S.+A.+Daiauthor=I.+Barrio-Hernandezauthor=D.+Memonauthor=C.+Hernandez-Armentaauthor=J.+Lyuauthor=C.+J.+P.+Mathyauthor=T.+Pericaauthor=K.+B.+Pillaauthor=S.+J.+Ganesanauthor=D.+J.+Saltzbergauthor=R.+Rakeshauthor=X.+Liuauthor=S.+B.+Rosenthalauthor=L.+Calvielloauthor=S.+Venkataramananauthor=J.+Liboy-Lugoauthor=Y.+Linauthor=X.-P.+Huangauthor=Y.+Liuauthor=S.+A.+Wankowiczauthor=M.+Bohnauthor=M.+Safariauthor=F.+S.+Ugurauthor=C.+Kohauthor=N.+S.+Savarauthor=Q.+D.+Tranauthor=D.+Shengjulerauthor=S.+J.+Fletcherauthor=M.+C.+O%E2%80%99Nealauthor=Y.+Caiauthor=J.+C.+J.+Changauthor=D.+J.+Broadhurstauthor=S.+Klippstenauthor=P.+P.+Sharpauthor=N.+A.+Wenzellauthor=D.+Kuzuoglu-Ozturkauthor=H.-Y.+Wangauthor=R.+Trenkerauthor=J.+M.+Youngauthor=D.+A.+Caveroauthor=J.+Hiattauthor=T.+L.+Rothauthor=U.+Rathoreauthor=A.+Subramanianauthor=J.+Noackauthor=M.+Hubertauthor=R.+M.+Stroudauthor=A.+D.+Frankelauthor=O.+S.+Rosenbergauthor=K.+A.+Verbaauthor=D.+A.+Agardauthor=M.+Ottauthor=M.+Emermanauthor=N.+Juraauthor=M.+von+Zastrowauthor=E.+Verdinauthor=A.+Ashworthauthor=O.+Schwartzauthor=C.+d%E2%80%99Enfertauthor=S.+Mukherjeeauthor=M.+Jacobsonauthor=H.+S.+Malikauthor=D.+G.+Fujimoriauthor=T.+Idekerauthor=C.+S.+Craikauthor=S.+N.+Floorauthor=J.+S.+Fraserauthor=J.+D.+Grossauthor=A.+Saliauthor=B.+L.+Rothauthor=D.+Ruggeroauthor=J.+Tauntonauthor=T.+Kortemmeauthor=P.+Beltraoauthor=M.+Vignuzziauthor=A.+Garc%C3%ADa-Sastreauthor=K.+M.+Shokatauthor=B.+K.+Shoichetauthor=N.+J.+Krogan&title=A+SARS-CoV-2+Protein+Interaction+Map+Reveals+Targets+for+Drug+Repurposing&doi=10.1038%2Fs41586-020-2286-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit193aR"><div class="casContent"><span class="casTitleNuber">193a</span><div class="casTitle"><span class="NLM_cas:atitle">A SARS-CoV-2 protein interaction map reveals targets for drug repurposing</span></div><div class="casAuthors">Gordon, David E.; Jang, Gwendolyn M.; Bouhaddou, Mehdi; Xu, Jiewei; Obernier, Kirsten; White, Kris M.; O'Meara, Matthew J.; Rezelj, Veronica V.; Guo, Jeffrey Z.; Swaney, Danielle L.; Tummino, Tia A.; Huttenhain, Ruth; Kaake, Robyn M.; Richards, Alicia L.; Tutuncuoglu, Beril; Foussard, Helene; Batra, Jyoti; Haas, Kelsey; Modak, Maya; Kim, Minkyu; Haas, Paige; Polacco, Benjamin J.; Braberg, Hannes; Fabius, Jacqueline M.; Eckhardt, Manon; Soucheray, Margaret; Bennett, Melanie J.; Cakir, Merve; McGregor, Michael J.; Li, Qiongyu; Meyer, Bjoern; Roesch, Ferdinand; Vallet, Thomas; Mac Kain, Alice; Miorin, Lisa; Moreno, Elena; Naing, Zun Zar Chi; Zhou, Yuan; Peng, Shiming; Shi, Ying; Zhang, Ziyang; Shen, Wenqi; Kirby, Ilsa T.; Melnyk, James E.; Chorba, John S.; Lou, Kevin; Dai, Shizhong A.; Barrio-Hernandez, Inigo; Memon, Danish; Hernandez-Armenta, Claudia; Lyu, Jiankun; Mathy, Christopher J. P.; Perica, Tina; Pilla, Kala Bharath; Ganesan, Sai J.; Saltzberg, Daniel J.; Rakesh, Ramachandran; Liu, Xi; Rosenthal, Sara B.; Calviello, Lorenzo; Venkataramanan, Srivats; Liboy-Lugo, Jose; Lin, Yizhu; Huang, Xi-Ping; Liu, YongFeng; Wankowicz, Stephanie A.; Bohn, Markus; Safari, Maliheh; Ugur, Fatima S.; Koh, Cassandra; Savar, Nastaran Sadat; Tran, Quang Dinh; Shengjuler, Djoshkun; Fletcher, Sabrina J.; O'Neal, Michael C.; Cai, Yiming; Chang, Jason C. J.; Broadhurst, David J.; Klippsten, Saker; Sharp, Phillip P.; Wenzell, Nicole A.; Kuzuoglu-Ozturk, Duygu; Wang, Hao-Yuan; Trenker, Raphael; Young, Janet M.; Cavero, Devin A.; Hiatt, Joseph; Roth, Theodore L.; Rathore, Ujjwal; Subramanian, Advait; Noack, Julia; Hubert, Mathieu; Stroud, Robert M.; Frankel, Alan D.; Rosenberg, Oren S.; Verba, Kliment A.; Agard, David A.; Ott, Melanie; Emerman, Michael; Jura, Natalia; von Zastrow, Mark; Verdin, Eric; Ashworth, Alan; Schwartz, Olivier; d'Enfert, Christophe; Mukherjee, Shaeri; Jacobson, Matt; Malik, Harmit S.; Fujimori, Danica G.; Ideker, Trey; Craik, Charles S.; Floor, Stephen N.; Fraser, James S.; Gross, John D.; Sali, Andrej; Roth, Bryan L.; Ruggero, Davide; Taunton, Jack; Kortemme, Tanja; Beltrao, Pedro; Vignuzzi, Marco; Garcia-Sastre, Adolfo; Shokat, Kevan M.; Shoichet, Brian K.; Krogan, Nevan J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">583</span>
        (<span class="NLM_cas:issue">7816</span>),
    <span class="NLM_cas:pages">459-468</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: A newly described coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is the causative agent of coronavirus disease 2019 (COVID-19), has infected over 2.3 million people, led to the death of more than 160,000 individuals and caused worldwide social and economic disruption1,2.  There are no antiviral drugs with proven clin. efficacy for the treatment of COVID-19, nor are there any vaccines that prevent infection with SARS-CoV-2, and efforts to develop drugs and vaccines are hampered by the limited knowledge of the mol. details of how SARS-CoV-2 infects cells.  Here we cloned, tagged and expressed 26 of the 29 SARS-CoV-2 proteins in human cells and identified the human proteins that phys. assocd. with each of the SARS-CoV-2 proteins using affinity-purifn. mass spectrometry, identifying 332 high-confidence protein-protein interactions between SARS-CoV-2 and human proteins.  Among these, we identify 66 druggable human proteins or host factors targeted by 69 compds. (of which, 29 drugs are approved by the US Food and Drug Administration, 12 are in clin. trials and 28 are preclin. compds.).  We screened a subset of these in multiple viral assays and found two sets of pharmacol. agents that displayed antiviral activity: inhibitors of mRNA translation and predicted regulators of the sigma-1 and sigma-2 receptors.  Further studies of these host-factor-targeting agents, including their combination with drugs that directly target viral enzymes, could lead to a therapeutic regimen to treat COVID-19.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDvJUIvi-Ws7Vg90H21EOLACvtfcHk0lg9PXnjBXz0iA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlCqtbrI&md5=ce8b172ae73aacd3b3d8bb64877f4435</span></div><a href="/servlet/linkout?suffix=cit193a&amp;dbid=16384&amp;doi=10.1038%2Fs41586-020-2286-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-020-2286-9%26sid%3Dliteratum%253Aachs%26aulast%3DGordon%26aufirst%3DD.%2BE.%26aulast%3DJang%26aufirst%3DG.%2BM.%26aulast%3DBouhaddou%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DObernier%26aufirst%3DK.%26aulast%3DWhite%26aufirst%3DK.%2BM.%26aulast%3DO%25E2%2580%2599Meara%26aufirst%3DM.%2BJ.%26aulast%3DRezelj%26aufirst%3DV.%2BV.%26aulast%3DGuo%26aufirst%3DJ.%2BZ.%26aulast%3DSwaney%26aufirst%3DD.%2BL.%26aulast%3DTummino%26aufirst%3DT.%2BA.%26aulast%3DHuettenhain%26aufirst%3DR.%26aulast%3DKaake%26aufirst%3DR.%2BM.%26aulast%3DRichards%26aufirst%3DA.%2BL.%26aulast%3DTutuncuoglu%26aufirst%3DB.%26aulast%3DFoussard%26aufirst%3DH.%26aulast%3DBatra%26aufirst%3DJ.%26aulast%3DHaas%26aufirst%3DK.%26aulast%3DModak%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DHaas%26aufirst%3DP.%26aulast%3DPolacco%26aufirst%3DB.%2BJ.%26aulast%3DBraberg%26aufirst%3DH.%26aulast%3DFabius%26aufirst%3DJ.%2BM.%26aulast%3DEckhardt%26aufirst%3DM.%26aulast%3DSoucheray%26aufirst%3DM.%26aulast%3DBennett%26aufirst%3DM.%2BJ.%26aulast%3DCakir%26aufirst%3DM.%26aulast%3DMcGregor%26aufirst%3DM.%2BJ.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DMeyer%26aufirst%3DB.%26aulast%3DRoesch%26aufirst%3DF.%26aulast%3DVallet%26aufirst%3DT.%26aulast%3DMac%2BKain%26aufirst%3DA.%26aulast%3DMiorin%26aufirst%3DL.%26aulast%3DMoreno%26aufirst%3DE.%26aulast%3DNaing%26aufirst%3DZ.%2BZ.%2BC.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DPeng%26aufirst%3DS.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DShen%26aufirst%3DW.%26aulast%3DKirby%26aufirst%3DI.%2BT.%26aulast%3DMelnyk%26aufirst%3DJ.%2BE.%26aulast%3DChorba%26aufirst%3DJ.%2BS.%26aulast%3DLou%26aufirst%3DK.%26aulast%3DDai%26aufirst%3DS.%2BA.%26aulast%3DBarrio-Hernandez%26aufirst%3DI.%26aulast%3DMemon%26aufirst%3DD.%26aulast%3DHernandez-Armenta%26aufirst%3DC.%26aulast%3DLyu%26aufirst%3DJ.%26aulast%3DMathy%26aufirst%3DC.%2BJ.%2BP.%26aulast%3DPerica%26aufirst%3DT.%26aulast%3DPilla%26aufirst%3DK.%2BB.%26aulast%3DGanesan%26aufirst%3DS.%2BJ.%26aulast%3DSaltzberg%26aufirst%3DD.%2BJ.%26aulast%3DRakesh%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DRosenthal%26aufirst%3DS.%2BB.%26aulast%3DCalviello%26aufirst%3DL.%26aulast%3DVenkataramanan%26aufirst%3DS.%26aulast%3DLiboy-Lugo%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DX.-P.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DWankowicz%26aufirst%3DS.%2BA.%26aulast%3DBohn%26aufirst%3DM.%26aulast%3DSafari%26aufirst%3DM.%26aulast%3DUgur%26aufirst%3DF.%2BS.%26aulast%3DKoh%26aufirst%3DC.%26aulast%3DSavar%26aufirst%3DN.%2BS.%26aulast%3DTran%26aufirst%3DQ.%2BD.%26aulast%3DShengjuler%26aufirst%3DD.%26aulast%3DFletcher%26aufirst%3DS.%2BJ.%26aulast%3DO%25E2%2580%2599Neal%26aufirst%3DM.%2BC.%26aulast%3DCai%26aufirst%3DY.%26aulast%3DChang%26aufirst%3DJ.%2BC.%2BJ.%26aulast%3DBroadhurst%26aufirst%3DD.%2BJ.%26aulast%3DKlippsten%26aufirst%3DS.%26aulast%3DSharp%26aufirst%3DP.%2BP.%26aulast%3DWenzell%26aufirst%3DN.%2BA.%26aulast%3DKuzuoglu-Ozturk%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DH.-Y.%26aulast%3DTrenker%26aufirst%3DR.%26aulast%3DYoung%26aufirst%3DJ.%2BM.%26aulast%3DCavero%26aufirst%3DD.%2BA.%26aulast%3DHiatt%26aufirst%3DJ.%26aulast%3DRoth%26aufirst%3DT.%2BL.%26aulast%3DRathore%26aufirst%3DU.%26aulast%3DSubramanian%26aufirst%3DA.%26aulast%3DNoack%26aufirst%3DJ.%26aulast%3DHubert%26aufirst%3DM.%26aulast%3DStroud%26aufirst%3DR.%2BM.%26aulast%3DFrankel%26aufirst%3DA.%2BD.%26aulast%3DRosenberg%26aufirst%3DO.%2BS.%26aulast%3DVerba%26aufirst%3DK.%2BA.%26aulast%3DAgard%26aufirst%3DD.%2BA.%26aulast%3DOtt%26aufirst%3DM.%26aulast%3DEmerman%26aufirst%3DM.%26aulast%3DJura%26aufirst%3DN.%26aulast%3Dvon%2BZastrow%26aufirst%3DM.%26aulast%3DVerdin%26aufirst%3DE.%26aulast%3DAshworth%26aufirst%3DA.%26aulast%3DSchwartz%26aufirst%3DO.%26aulast%3Dd%25E2%2580%2599Enfert%26aufirst%3DC.%26aulast%3DMukherjee%26aufirst%3DS.%26aulast%3DJacobson%26aufirst%3DM.%26aulast%3DMalik%26aufirst%3DH.%2BS.%26aulast%3DFujimori%26aufirst%3DD.%2BG.%26aulast%3DIdeker%26aufirst%3DT.%26aulast%3DCraik%26aufirst%3DC.%2BS.%26aulast%3DFloor%26aufirst%3DS.%2BN.%26aulast%3DFraser%26aufirst%3DJ.%2BS.%26aulast%3DGross%26aufirst%3DJ.%2BD.%26aulast%3DSali%26aufirst%3DA.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DRuggero%26aufirst%3DD.%26aulast%3DTaunton%26aufirst%3DJ.%26aulast%3DKortemme%26aufirst%3DT.%26aulast%3DBeltrao%26aufirst%3DP.%26aulast%3DVignuzzi%26aufirst%3DM.%26aulast%3DGarc%25C3%25ADa-Sastre%26aufirst%3DA.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26aulast%3DKrogan%26aufirst%3DN.%2BJ.%26atitle%3DA%2520SARS-CoV-2%2520Protein%2520Interaction%2520Map%2520Reveals%2520Targets%2520for%2520Drug%2520Repurposing%26jtitle%3DNature%26date%3D2020%26volume%3D583%26spage%3D459%26epage%3D468%26doi%3D10.1038%2Fs41586-020-2286-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit193b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Rubinstein, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinharter, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rini, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choueiri, T. K.</span></span> <span> </span><span class="NLM_article-title">The Covid-19 and Cancer Consortium: A Collaborative Effort to Understand the Effects of COVID-19 on Patients with Cancer</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">738</span>– <span class="NLM_lpage">741</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2020.04.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2Fj.ccell.2020.04.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=32454025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVSisLfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2020&pages=738-741&author=S.+M.+Rubinsteinauthor=J.+A.+Steinharterauthor=J.+Warnerauthor=B.+I.+Riniauthor=S.+Petersauthor=T.+K.+Choueiri&title=The+Covid-19+and+Cancer+Consortium%3A+A+Collaborative+Effort+to+Understand+the+Effects+of+COVID-19+on+Patients+with+Cancer&doi=10.1016%2Fj.ccell.2020.04.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit193bR"><div class="casContent"><span class="casTitleNuber">193b</span><div class="casTitle"><span class="NLM_cas:atitle">The COVID-19 and Cancer Consortium: A Collaborative Effort to Understand the Effects of COVID-19 on Patients with Cancer</span></div><div class="casAuthors">Rubinstein, Samuel M.; Steinharter, John A.; Warner, Jeremy; Rini, Brian I.; Peters, Solange; Choueiri, Toni K.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">738-741</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">National and international consortia will play a key role in understanding the effects of the coronavirus disease 2019 (COVID-19) pandemic on cancer patients.  The COVID-19 and Cancer Consortium (CCC19) aims to collect and analyze observational data at scale to inform clin. practice in real-time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDPOY3zWPid7Vg90H21EOLACvtfcHk0liOlPMwqIHIyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVSisLfP&md5=a5c6d0a8b0677aa529dd774ff4ae3745</span></div><a href="/servlet/linkout?suffix=cit193b&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2020.04.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2020.04.018%26sid%3Dliteratum%253Aachs%26aulast%3DRubinstein%26aufirst%3DS.%2BM.%26aulast%3DSteinharter%26aufirst%3DJ.%2BA.%26aulast%3DWarner%26aufirst%3DJ.%26aulast%3DRini%26aufirst%3DB.%2BI.%26aulast%3DPeters%26aufirst%3DS.%26aulast%3DChoueiri%26aufirst%3DT.%2BK.%26atitle%3DThe%2520Covid-19%2520and%2520Cancer%2520Consortium%253A%2520A%2520Collaborative%2520Effort%2520to%2520Understand%2520the%2520Effects%2520of%2520COVID-19%2520on%2520Patients%2520with%2520Cancer%26jtitle%3DCancer%2520Cell%26date%3D2020%26volume%3D37%26spage%3D738%26epage%3D741%26doi%3D10.1016%2Fj.ccell.2020.04.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref194"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref194'); return false;" data-citation="" class="refNumLink">194</a></strong><div class="NLM_citation" id="cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sandanayaka, V. P.</span>; <span class="NLM_string-name">Shacham, S.</span>; <span class="NLM_string-name">McCauley, D.</span>; <span class="NLM_string-name">Shechter, S.</span></span> <span> </span><span class="NLM_article-title">Preparation of Hydrazide Containing Nuclear Transport Modulators and Uses Thereof</span>. <span class="NLM_patent">WO 2013019548 A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=V.+P.+Sandanayaka&author=S.+Shacham&author=D.+McCauley&author=S.+Shechter&title=Preparation+of+Hydrazide+Containing+Nuclear+Transport+Modulators+and+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSandanayaka%26aufirst%3DV.%2BP.%26atitle%3DPreparation%2520of%2520Hydrazide%2520Containing%2520Nuclear%2520Transport%2520Modulators%2520and%2520Uses%2520Thereof%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref195"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref195'); return false;" data-citation="" class="refNumLink">195</a></strong><div class="NLM_citation" id="cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Austad, B. C.</span>; <span class="NLM_string-name">Roe, D. G.</span></span> <span> </span><span class="NLM_article-title">Polymorphs of Selinexor</span>. <span class="NLM_patent">WO 2016025904 A1</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=B.+C.+Austad&author=D.+G.+Roe&title=Polymorphs+of+Selinexor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAustad%26aufirst%3DB.%2BC.%26atitle%3DPolymorphs%2520of%2520Selinexor%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref196"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref196'); return false;" data-citation="" class="refNumLink">196</a></strong><div class="NLM_citation" id="cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keam, S. J.</span></span> <span> </span><span class="NLM_article-title">Trastuzumab Deruxtecan: First Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">501</span>– <span class="NLM_lpage">508</span>, <span class="refDoi"> DOI: 10.1007/s40265-020-01281-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs40265-020-01281-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=32144719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlslCqu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2020&pages=501-508&author=S.+J.+Keam&title=Trastuzumab+Deruxtecan%3A+First+Approval&doi=10.1007%2Fs40265-020-01281-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">Trastuzumab Deruxtecan: First Approval</span></div><div class="casAuthors">Keam, Susan J.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">501-508</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Abstr.: Trastuzumab deruxtecan (ENHERTU), a HER2-directed antibody and DNA topoisomerase I inhibitor conjugate, is being developed for the treatment of HER2-expressing solid tumors, including breast cancer, gastric cancer, colorectal cancer and non-small cell lung cancer by Daiichi Sankyo Company Ltd in collaboration with AstraZeneca.  Based primarily on the results of the phase 2 DESTINY-Breast01 trial, trastuzumab deruxtecan was recently approved in the USA under accelerated approval for the treatment of adult patients with unresectable or metastatic HER2-pos. breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.  This article summarizes the milestones in the development of trastuzumab deruxtecan leading to this first approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqo-GVK2i-3a7Vg90H21EOLACvtfcHk0liOlPMwqIHIyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlslCqu7s%253D&md5=66e522a0405a64ad234aa46d048f63b2</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1007%2Fs40265-020-01281-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-020-01281-4%26sid%3Dliteratum%253Aachs%26aulast%3DKeam%26aufirst%3DS.%2BJ.%26atitle%3DTrastuzumab%2520Deruxtecan%253A%2520First%2520Approval%26jtitle%3DDrugs%26date%3D2020%26volume%3D80%26spage%3D501%26epage%3D508%26doi%3D10.1007%2Fs40265-020-01281-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref197"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref197'); return false;" data-citation="" class="refNumLink">197</a></strong><div class="NLM_citation" id="cit197"><span><a href="https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-option-patients-her2-positive-breast-cancer-who-have-progressed-available" class="extLink">https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-option-patients-her2-positive-breast-cancer-who-have-progressed-available</a> (accessed 2020-12-18).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-approves-new-treatment-option-patients-her2-positive-breast-cancer-who-have-progressed-available+%28accessed+2020-12-18%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref198"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref198'); return false;" data-citation="" class="refNumLink">198</a></strong><div class="NLM_citation" id="cit198a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ogitani, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagihara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harada, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oitate, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arakawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atsumi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayakawa, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agatsuma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirai, T.</span></span> <span> </span><span class="NLM_article-title">DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">5097</span>– <span class="NLM_lpage">5108</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-15-2822</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref198/cit198a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1158%2F1078-0432.CCR-15-2822" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref198/cit198a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=27026201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref198/cit198a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslOhs77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=5097-5108&author=Y.+Ogitaniauthor=T.+Aidaauthor=K.+Hagiharaauthor=J.+Yamaguchiauthor=C.+Ishiiauthor=N.+Haradaauthor=M.+Somaauthor=H.+Okamotoauthor=M.+Oitateauthor=S.+Arakawaauthor=R.+Atsumiauthor=T.+Nakadaauthor=I.+Hayakawaauthor=Y.+Abeauthor=T.+Agatsumaauthor=T.+Hirai&title=DS-8201a%2C+A+Novel+HER2-Targeting+ADC+with+a+Novel+DNA+Topoisomerase+I+Inhibitor%2C+Demonstrates+a+Promising+Antitumor+Efficacy+with+Differentiation+from+T-DM1&doi=10.1158%2F1078-0432.CCR-15-2822"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit198aR"><div class="casContent"><span class="casTitleNuber">198a</span><div class="casTitle"><span class="NLM_cas:atitle">DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1</span></div><div class="casAuthors">Ogitani, Yusuke; Aida, Tetsuo; Hagihara, Katsunobu; Yamaguchi, Junko; Ishii, Chiaki; Harada, Naoya; Soma, Masako; Okamoto, Hiromi; Oitate, Masataka; Arakawa, Shingo; Hirai, Takehiro; Atsumi, Ryo; Nakada, Takashi; Hayakawa, Ichiro; Abe, Yuki; Agatsuma, Toshinori</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5097-5108</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">An anti-HER2 antibody-drug conjugate with a novel topoisomerase I inhibitor, DS-8201a, was generated as a new antitumor drug candidate, and its preclin. pharmacol. profile was assessed.  In vitro and in vivo pharmacol. activities of DS-8201a were evaluated and compared with T-DM1 in several HER2-pos. cell lines and patient-derived xenograft (PDX) models.  The mechanism of action for the efficacy was also evaluated.  Pharmacokinetics in cynomolgus monkeys and the safety profiles in rats and cynomolgus monkeys were assessed.  DS-8201a exhibited a HER2 expression-dependent cell growth-inhibitory activity and induced tumor regression with a single dosing at more than 1 mg/kg in a HER2-pos. gastric cancer NCI-N87 model.  Binding activity to HER2 and ADCC activity of DS-8201a were comparable with unconjugated anti-HER2 antibody.  DS-8201a also showed an inhibitory activity to Akt phosphorylation.  DS-8201a induced phosphorylation of Chk1 and Histone H2A.X, the markers of DNA damage.  Pharmacokinetics and safety profiles of DS-8201a were favorable and the highest non-severely toxic dose was 30 mg/kg in cynomolgus monkeys, supporting DS-8201a as being well tolerated in humans.  DS-8201a was effective in a T-DM1-insensitive PDX model with high HER2 expression.  DS-8201a, but not T-DM1, demonstrated antitumor efficacy against several breast cancer PDX models with low HER2 expression.  DS-8201a exhibited a potent antitumor activity in a broad selection of HER2-pos. models and favorable pharmacokinetics and safety profiles.  The results demonstrate that DS-8201a will be a valuable therapy with a great potential to respond to T-DM1-insensitive HER2-pos. cancers and low HER2-expressing cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCZitEmBAqAbVg90H21EOLACvtfcHk0ljRrToEmLAkOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslOhs77F&md5=3fc9a072b2ba05c80929713c843df3f5</span></div><a href="/servlet/linkout?suffix=cit198a&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-2822&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-2822%26sid%3Dliteratum%253Aachs%26aulast%3DOgitani%26aufirst%3DY.%26aulast%3DAida%26aufirst%3DT.%26aulast%3DHagihara%26aufirst%3DK.%26aulast%3DYamaguchi%26aufirst%3DJ.%26aulast%3DIshii%26aufirst%3DC.%26aulast%3DHarada%26aufirst%3DN.%26aulast%3DSoma%26aufirst%3DM.%26aulast%3DOkamoto%26aufirst%3DH.%26aulast%3DOitate%26aufirst%3DM.%26aulast%3DArakawa%26aufirst%3DS.%26aulast%3DAtsumi%26aufirst%3DR.%26aulast%3DNakada%26aufirst%3DT.%26aulast%3DHayakawa%26aufirst%3DI.%26aulast%3DAbe%26aufirst%3DY.%26aulast%3DAgatsuma%26aufirst%3DT.%26aulast%3DHirai%26aufirst%3DT.%26atitle%3DDS-8201a%252C%2520A%2520Novel%2520HER2-Targeting%2520ADC%2520with%2520a%2520Novel%2520DNA%2520Topoisomerase%2520I%2520Inhibitor%252C%2520Demonstrates%2520a%2520Promising%2520Antitumor%2520Efficacy%2520with%2520Differentiation%2520from%2520T-DM1%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2016%26volume%3D22%26spage%3D5097%26epage%3D5108%26doi%3D10.1158%2F1078-0432.CCR-15-2822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit198b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Nakada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naito, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashida, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morita, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyazaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasuya, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogitani, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honda, T.</span></span> <span> </span><span class="NLM_article-title">Novel Antibody Drug Conjugates Containing Exatecan Derivative-Based Cytotoxic Payloads</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1542</span>– <span class="NLM_lpage">1545</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.02.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref198/cit198b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2Fj.bmcl.2016.02.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref198/cit198b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=26898815" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref198/cit198b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC28XivVWktb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=1542-1545&author=T.+Nakadaauthor=T.+Masudaauthor=H.+Naitoauthor=M.+Yoshidaauthor=S.+Ashidaauthor=K.+Moritaauthor=H.+Miyazakiauthor=Y.+Kasuyaauthor=Y.+Ogitaniauthor=J.+Yamaguchiauthor=Y.+Abeauthor=T.+Honda&title=Novel+Antibody+Drug+Conjugates+Containing+Exatecan+Derivative-Based+Cytotoxic+Payloads&doi=10.1016%2Fj.bmcl.2016.02.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit198bR"><div class="casContent"><span class="casTitleNuber">198b</span><div class="casTitle"><span class="NLM_cas:atitle">Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads</span></div><div class="casAuthors">Nakada, Takashi; Masuda, Takeshi; Naito, Hiroyuki; Yoshida, Masao; Ashida, Shinji; Morita, Koji; Miyazaki, Hideki; Kasuya, Yuji; Ogitani, Yusuke; Yamaguchi, Junko; Abe, Yuki; Honda, Takeshi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1542-1545</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Trastuzumab conjugates consisting of exatecan derivs. were prepd. and their biol. activities and physicochem. properties were evaluated.  The ADCs showed strong efficacy and a low aggregation rate.  The exatecan derivs. were covalently connected via a peptidyl spacer (Gly-Gly-Phe-Gly), which is assumed to be stable in circulation, and were cleaved by lysosomal enzymes following ADC internalization into tumor tissue.  These anti-HER2 ADCs exhibited a high potency, specifically against HER2-pos. cancer cell lines in vitro.  The ADCs, bearing exatecan derivs. which have more than two methylene chains, exhibited superior cytotoxicity.  It was speculated that steric hindrance of the cleavable amide moiety could be involved in the drug release.  The adequate alkyl lengths of exatecan derivs. (13, 14, 15) were from two to four in terms of aggregation rate.  The ADC having a hydrophilic moiety showed good efficacy in a HER2-pos. and Trastuzumab-resistant breast carcinoma cell model in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorNLY5Zb5RLbVg90H21EOLACvtfcHk0ljRrToEmLAkOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XivVWktb4%253D&md5=9a3137c0339e82fe3bd6e4b2a0937a52</span></div><a href="/servlet/linkout?suffix=cit198b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.02.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.02.020%26sid%3Dliteratum%253Aachs%26aulast%3DNakada%26aufirst%3DT.%26aulast%3DMasuda%26aufirst%3DT.%26aulast%3DNaito%26aufirst%3DH.%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DAshida%26aufirst%3DS.%26aulast%3DMorita%26aufirst%3DK.%26aulast%3DMiyazaki%26aufirst%3DH.%26aulast%3DKasuya%26aufirst%3DY.%26aulast%3DOgitani%26aufirst%3DY.%26aulast%3DYamaguchi%26aufirst%3DJ.%26aulast%3DAbe%26aufirst%3DY.%26aulast%3DHonda%26aufirst%3DT.%26atitle%3DNovel%2520Antibody%2520Drug%2520Conjugates%2520Containing%2520Exatecan%2520Derivative-Based%2520Cytotoxic%2520Payloads%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D1542%26epage%3D1545%26doi%3D10.1016%2Fj.bmcl.2016.02.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref199"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref199'); return false;" data-citation="" class="refNumLink">199</a></strong><div class="NLM_citation" id="cit199"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, T.</span>; <span class="NLM_string-name">Naito, H.</span>; <span class="NLM_string-name">Nakada, T.</span>; <span class="NLM_string-name">Yoshida, M.</span>; <span class="NLM_string-name">Ashida, S.</span>; <span class="NLM_string-name">Miyazaki, H.</span>; <span class="NLM_string-name">Kasuya, Y.</span>; <span class="NLM_string-name">Morita, K.</span>; <span class="NLM_string-name">Abe, Y.</span>; <span class="NLM_string-name">Ogitani, Y.</span></span> <span> </span><span class="NLM_article-title">Preparation of Antibody–Drug Conjugates for Cancer Therapy</span>. <span class="NLM_patent">WO 2014057687 A1</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=T.+Masuda&author=H.+Naito&author=T.+Nakada&author=M.+Yoshida&author=S.+Ashida&author=H.+Miyazaki&author=Y.+Kasuya&author=K.+Morita&author=Y.+Abe&author=Y.+Ogitani&title=Preparation+of+Antibody%E2%80%93Drug+Conjugates+for+Cancer+Therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMasuda%26aufirst%3DT.%26atitle%3DPreparation%2520of%2520Antibody%25E2%2580%2593Drug%2520Conjugates%2520for%2520Cancer%2520Therapy%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref200"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref200'); return false;" data-citation="" class="refNumLink">200</a></strong><div class="NLM_citation" id="cit200a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiang, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hertzberg, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hecht, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L. F.</span></span> <span> </span><span class="NLM_article-title">Camptothecin Induces Protein-Linked DNA Breaks Via Mammalian DNA Topoisomerase I</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>260</i></span>,  <span class="NLM_fpage">14873</span>– <span class="NLM_lpage">14878</span>, <span class="refDoi"> DOI: 10.1016/S0021-9258(17)38654-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref200/cit200a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2FS0021-9258%2817%2938654-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref200/cit200a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=2997227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref200/cit200a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADyaL2MXlsFemt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=260&publication_year=1985&pages=14873-14878&author=Y.+H.+Hsiangauthor=R.+Hertzbergauthor=S.+Hechtauthor=L.+F.+Liu&title=Camptothecin+Induces+Protein-Linked+DNA+Breaks+Via+Mammalian+DNA+Topoisomerase+I&doi=10.1016%2FS0021-9258%2817%2938654-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit200aR"><div class="casContent"><span class="casTitleNuber">200a</span><div class="casTitle"><span class="NLM_cas:atitle">Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I</span></div><div class="casAuthors">Hsiang, Yaw Huei; Hertzberg, Robert; Hecht, Sidney; Liu, Leroy F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">260</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">14873-8</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">Camptothecin (I)  [7689-03-4], a cytotoxic drug, is a strong inhibitor of nucleic acid synthesis in mammalian cells and a potent inducer of strand breaks in chromosomal DNA.  Neither equil. dialysis nor unwinding measurement indicated any interaction between camptothecin and purified DNA.  However, I induces extensive single-strand DNA breaks in systems contg. purified mammalian DNA topoisomerase  [80449-01-0] I.  DNA breakage in vitro is immediate and reversible.  Analyses of camptothecin-induced DNA breaks show that topoisomerase I is covalently linked to the 3' end of the broken DNA.  In addn., I inhibits the catalytic activity of mammalian DNA topoisomerase I.  Apparently, I blocks the rejoining step of the breakage-reunion reaction of mammalian DNA topoisomerase I; this blockade results in the accumulation of a cleavable complex which resembles the transient intermediate proposed for eukaryotic DNA topoisomerase I.  The inhibition of nucleic acid synthesis and the induction of DNA strand breaks obsd. in vivo may be related to the formation of this drug-induced cleavable complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4OWZ16tDJsbVg90H21EOLACvtfcHk0lhg8kOvYn7fZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXlsFemt7c%253D&md5=d5811c51314199e69d2fad324720b1aa</span></div><a href="/servlet/linkout?suffix=cit200a&amp;dbid=16384&amp;doi=10.1016%2FS0021-9258%2817%2938654-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0021-9258%252817%252938654-4%26sid%3Dliteratum%253Aachs%26aulast%3DHsiang%26aufirst%3DY.%2BH.%26aulast%3DHertzberg%26aufirst%3DR.%26aulast%3DHecht%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DL.%2BF.%26atitle%3DCamptothecin%2520Induces%2520Protein-Linked%2520DNA%2520Breaks%2520Via%2520Mammalian%2520DNA%2520Topoisomerase%2520I%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1985%26volume%3D260%26spage%3D14873%26epage%3D14878%26doi%3D10.1016%2FS0021-9258%2817%2938654-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit200b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Nakada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugihara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jikoh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agatsuma, T.</span></span> <span> </span><span class="NLM_article-title">The Latest Research and Development into the Antibody–Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy</span>. <i>Chem. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">173</span>– <span class="NLM_lpage">185</span>, <span class="refDoi"> DOI: 10.1248/cpb.c18-00744</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref200/cit200b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1248%2Fcpb.c18-00744" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref200/cit200b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=30827997" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref200/cit200b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVejurjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2019&pages=173-185&author=T.+Nakadaauthor=K.+Sugiharaauthor=T.+Jikohauthor=Y.+Abeauthor=T.+Agatsuma&title=The+Latest+Research+and+Development+into+the+Antibody%E2%80%93Drug+Conjugate%2C+%5Bfam-%5D+Trastuzumab+Deruxtecan+%28DS-8201a%29%2C+for+HER2+Cancer+Therapy&doi=10.1248%2Fcpb.c18-00744"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit200bR"><div class="casContent"><span class="casTitleNuber">200b</span><div class="casTitle"><span class="NLM_cas:atitle">The latest research and development into the antibody-drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy</span></div><div class="casAuthors">Nakada, Takashi; Sugihara, Kiyoshi; Jikoh, Takahiro; Abe, Yuki; Agatsuma, Toshinori</div><div class="citationInfo"><span class="NLM_cas:title">Chemical & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">173-185</span>CODEN:
                <span class="NLM_cas:coden">CPBTAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-2363</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">A review.  A major limitation of traditional chemotherapy for cancer is dose-limiting toxicity, caused by the exposure of non-tumor cells to cytotoxic agents.  Use of mol. targeted drugs, such as specific kinase inhibitors and monoclonal antibodies, is a possible soln. to overcome this limitation and has achieved clin. success so far.  Use of an antibody-drug conjugate (ADC) is a rational strategy for improving efficacy and reducing systemic adverse events.  ADCs use antibodies selectively to deliver a potent cytotoxic agent to tumor cells, thus drastically improving the therapeutic index of chemotherapeutic agents.  Lessons learned from clin. failure of early ADCs during the 1980s to 90s have recently led to improvements in ADC technol., and resulted in the approval of four novel ADCs.  Nonetheless, further advances in ADC technol. are still required to streamline their clin. efficacy and reduce toxicity. [fam-] Trastuzumab deruxtecan (DS-8201a) is a next-generation ADC that satisfies these requirements based on currently available evidence.  DS-8201a has several innovative features; a highly potent novel payload with a high drug-to-antibody ratio, good homogeneity, a tumor-selective cleavable linker, stable linker-payload in circulation, and a short systemic half-life cytotoxic agent in vivo; the released cytotoxic payload could exert a bystander effect.  With respect to its preclin. profiles, DS-8201a could provide a valuable therapy with a great potential against HER2-expressing cancers in clin. settings.  In a phase I trial, DS-8201a showed acceptable safety profiles with potential therapeutic efficacy, with the wide therapeutic index.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEjmzqyRh1yrVg90H21EOLACvtfcHk0lhg8kOvYn7fZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVejurjJ&md5=ab7628fdc4af3c8e1d73e00553c9534e</span></div><a href="/servlet/linkout?suffix=cit200b&amp;dbid=16384&amp;doi=10.1248%2Fcpb.c18-00744&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fcpb.c18-00744%26sid%3Dliteratum%253Aachs%26aulast%3DNakada%26aufirst%3DT.%26aulast%3DSugihara%26aufirst%3DK.%26aulast%3DJikoh%26aufirst%3DT.%26aulast%3DAbe%26aufirst%3DY.%26aulast%3DAgatsuma%26aufirst%3DT.%26atitle%3DThe%2520Latest%2520Research%2520and%2520Development%2520into%2520the%2520Antibody%25E2%2580%2593Drug%2520Conjugate%252C%2520%255Bfam-%255D%2520Trastuzumab%2520Deruxtecan%2520%2528DS-8201a%2529%252C%2520for%2520HER2%2520Cancer%2520Therapy%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D2019%26volume%3D67%26spage%3D173%26epage%3D185%26doi%3D10.1248%2Fcpb.c18-00744" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref201"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref201'); return false;" data-citation="" class="refNumLink">201</a></strong><div class="NLM_citation" id="cit201"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Modi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saura, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsurutani, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sohn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denduluri, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aogi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokunaga, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurvitz, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahidi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yver, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krop, I.</span></span> <span> </span><span class="NLM_article-title">Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>382</i></span>,  <span class="NLM_fpage">610</span>– <span class="NLM_lpage">621</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1914510</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1056%2FNEJMoa1914510" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31825192" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjtlChur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=382&publication_year=2020&pages=610-621&author=S.+Modiauthor=C.+Sauraauthor=T.+Yamashitaauthor=Y.+H.+Parkauthor=S.+B.+Kimauthor=K.+Tamuraauthor=F.+Andreauthor=H.+Iwataauthor=Y.+Itoauthor=J.+Tsurutaniauthor=J.+Sohnauthor=N.+Denduluriauthor=C.+Perrinauthor=K.+Aogiauthor=E.+Tokunagaauthor=S.+A.+Imauthor=K.+S.+Leeauthor=S.+A.+Hurvitzauthor=J.+Cortesauthor=C.+Leeauthor=S.+Chenauthor=L.+Zhangauthor=J.+Shahidiauthor=A.+Yverauthor=I.+Krop&title=Trastuzumab+Deruxtecan+in+Previously+Treated+HER2-Positive+Breast+Cancer&doi=10.1056%2FNEJMoa1914510"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">Trastuzumab deruxtecan in previously treated HER2-positive breast cancer</span></div><div class="casAuthors">Modi, S.; Saura, C.; Yamashita, T.; Park, Y. H.; Kim, S.-B.; Tamura, K.; Andre, F.; Iwata, H.; Ito, Y.; Tsurutani, J.; Sohn, J.; Denduluri, N.; Perrin, C.; Aogi, K.; Tokunaga, E.; Im, S.-A.; Lee, K. S.; Hurvitz, S. A.; Cortes, J.; Lee, C.; Chen, S.; Zhang, L.; Shahidi, J.; Yver, A.; Krop, I.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">382</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">610-621</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">In this two-part, open-label, single-group, multicenter, phase 2 study, we evaluated trastuzumab deruxtecan in adults with pathol. documented HER2-pos. metastatic breast cancer who had received previous treatment with trastuzumab emtansine.  In the first part of the study, we evaluated three different doses of trastuzumab deruxtecan to establish a recommended dose; in the second part, we evaluated the efficacy and safety of the recommended dose.  Key secondary end points were the disease-control rate, clin.-benefit rate, duration of response and progression-free survival, and safety. results Overall, 184 patients who had undergone a median of six previous treatments received the recommended dose of trastuzumab deruxtecan (5.4 mg per kg of body wt.).  During the study, the most common adverse events of grade 3 or higher were a decreased neutrophil count (in 20.7% of the patients), anemia (in 8.7%), and nausea (in 7.6%).  On independent adjudication, the trial drug was assocd. with interstitial lung disease in 13.6% of the patients (grade 1 or 2, 10.9%; grade 3 or 4, 0.5%; and grade 5, 2.2%). conclusions Trastuzumab deruxtecan showed durable antitumor activity in a pretreated patient population with HER2-pos. metastatic breast cancer.  In addn. to nausea and myelosuppression, interstitial lung disease was obsd. in a subgroup of patients and requires attention to pulmonary symptoms and careful monitoring.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6Uc2NDB76h7Vg90H21EOLACvtfcHk0lhg8kOvYn7fZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjtlChur8%253D&md5=0b142802a47c4f50f0b2cdc82f22ce87</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1914510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1914510%26sid%3Dliteratum%253Aachs%26aulast%3DModi%26aufirst%3DS.%26aulast%3DSaura%26aufirst%3DC.%26aulast%3DYamashita%26aufirst%3DT.%26aulast%3DPark%26aufirst%3DY.%2BH.%26aulast%3DKim%26aufirst%3DS.%2BB.%26aulast%3DTamura%26aufirst%3DK.%26aulast%3DAndre%26aufirst%3DF.%26aulast%3DIwata%26aufirst%3DH.%26aulast%3DIto%26aufirst%3DY.%26aulast%3DTsurutani%26aufirst%3DJ.%26aulast%3DSohn%26aufirst%3DJ.%26aulast%3DDenduluri%26aufirst%3DN.%26aulast%3DPerrin%26aufirst%3DC.%26aulast%3DAogi%26aufirst%3DK.%26aulast%3DTokunaga%26aufirst%3DE.%26aulast%3DIm%26aufirst%3DS.%2BA.%26aulast%3DLee%26aufirst%3DK.%2BS.%26aulast%3DHurvitz%26aufirst%3DS.%2BA.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DShahidi%26aufirst%3DJ.%26aulast%3DYver%26aufirst%3DA.%26aulast%3DKrop%26aufirst%3DI.%26atitle%3DTrastuzumab%2520Deruxtecan%2520in%2520Previously%2520Treated%2520HER2-Positive%2520Breast%2520Cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2020%26volume%3D382%26spage%3D610%26epage%3D621%26doi%3D10.1056%2FNEJMoa1914510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref202"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref202'); return false;" data-citation="" class="refNumLink">202</a></strong><div class="NLM_citation" id="cit202"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nishi, Y.</span>; <span class="NLM_string-name">Sakanishi, K.</span>; <span class="NLM_string-name">Noguchi, S.</span>; <span class="NLM_string-name">Takeda, T.</span></span> <span> </span><span class="NLM_article-title">Novel Method for Producing Exatecan and Antibody–Drug Conjugates</span>. <span class="NLM_patent">WO 2019044946 A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=Y.+Nishi&author=K.+Sakanishi&author=S.+Noguchi&author=T.+Takeda&title=Novel+Method+for+Producing+Exatecan+and+Antibody%E2%80%93Drug+Conjugates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNishi%26aufirst%3DY.%26atitle%3DNovel%2520Method%2520for%2520Producing%2520Exatecan%2520and%2520Antibody%25E2%2580%2593Drug%2520Conjugates%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref203"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref203'); return false;" data-citation="" class="refNumLink">203</a></strong><div class="NLM_citation" id="cit203"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, T.</span>; <span class="NLM_string-name">Kouko, T.</span>; <span class="NLM_string-name">Noguchi, S.</span>; <span class="NLM_string-name">Yamane, Y.</span>; <span class="NLM_string-name">Kondo, F.</span>; <span class="NLM_string-name">Aoki, T.</span>; <span class="NLM_string-name">Takeda, T.</span>; <span class="NLM_string-name">Sakanishi, K.</span>; <span class="NLM_string-name">Sato, H.</span>; <span class="NLM_string-name">Ueda, T.</span>; <span class="NLM_string-name">Matuura, S.</span>; <span class="NLM_string-name">Kurahashi, K.</span>; <span class="NLM_string-name">Kitagawa, Y.</span>; <span class="NLM_string-name">Nakamura, T.</span></span> <span> </span><span class="NLM_article-title">Improved Production Method of Crystal of Drug-Linker Derivative for Production of Antibody–Drug Conjugate</span>. <span class="NLM_patent">WO 2019044947 A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=T.+Yamaguchi&author=T.+Kouko&author=S.+Noguchi&author=Y.+Yamane&author=F.+Kondo&author=T.+Aoki&author=T.+Takeda&author=K.+Sakanishi&author=H.+Sato&author=T.+Ueda&author=S.+Matuura&author=K.+Kurahashi&author=Y.+Kitagawa&author=T.+Nakamura&title=Improved+Production+Method+of+Crystal+of+Drug-Linker+Derivative+for+Production+of+Antibody%E2%80%93Drug+Conjugate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYamaguchi%26aufirst%3DT.%26atitle%3DImproved%2520Production%2520Method%2520of%2520Crystal%2520of%2520Drug-Linker%2520Derivative%2520for%2520Production%2520of%2520Antibody%25E2%2580%2593Drug%2520Conjugate%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref204"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref204'); return false;" data-citation="" class="refNumLink">204</a></strong><div class="NLM_citation" id="cit204"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Naito, H.</span>; <span class="NLM_string-name">Ogitani, Y.</span>; <span class="NLM_string-name">Masuda, T.</span>; <span class="NLM_string-name">Nakada, T.</span>; <span class="NLM_string-name">Yoshida, M.</span>; <span class="NLM_string-name">Ashida, S.</span>; <span class="NLM_string-name">Morita, K.</span>; <span class="NLM_string-name">Miyazaki, H.</span>; <span class="NLM_string-name">Kasuya, Y.</span>; <span class="NLM_string-name">Hayakawa, I.</span>; <span class="NLM_string-name">Abe, Y.</span></span> <span> </span><span class="NLM_article-title">Anti-Human HER2 Antibody Drug Conjugates with Excellent Safety and Therapeutic Antitumor Effect</span>. <span class="NLM_patent">WO 2015115091 A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=H.+Naito&author=Y.+Ogitani&author=T.+Masuda&author=T.+Nakada&author=M.+Yoshida&author=S.+Ashida&author=K.+Morita&author=H.+Miyazaki&author=Y.+Kasuya&author=I.+Hayakawa&author=Y.+Abe&title=Anti-Human+HER2+Antibody+Drug+Conjugates+with+Excellent+Safety+and+Therapeutic+Antitumor+Effect"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNaito%26aufirst%3DH.%26atitle%3DAnti-Human%2520HER2%2520Antibody%2520Drug%2520Conjugates%2520with%2520Excellent%2520Safety%2520and%2520Therapeutic%2520Antitumor%2520Effect%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref205"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref205'); return false;" data-citation="" class="refNumLink">205</a></strong><div class="NLM_citation" id="cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramarao, C.</span>; <span class="NLM_string-name">Rao, R.</span>; <span class="NLM_string-name">Nandipati, R. D.</span>; <span class="NLM_string-name">Chamle, V. A.</span>; <span class="NLM_string-name">Rao, A. V. R.</span></span> <span> </span><span class="NLM_article-title">Commercial Process for the Manufacture of (<i>S</i>)-Trione</span>. <span class="NLM_patent">IN 2010CH01460 A</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=C.+Ramarao&author=R.+Rao&author=R.+D.+Nandipati&author=V.+A.+Chamle&author=A.+V.+R.+Rao&title=Commercial+Process+for+the+Manufacture+of+%28S%29-Trione"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRamarao%26aufirst%3DC.%26atitle%3DCommercial%2520Process%2520for%2520the%2520Manufacture%2520of%2520%2528S%2529-Trione%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref206"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref206'); return false;" data-citation="" class="refNumLink">206</a></strong><div class="NLM_citation" id="cit206"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kamihara, S.</span>; <span class="NLM_string-name">Kanai, K.</span>; <span class="NLM_string-name">Noguchi, S.</span>; <span class="NLM_string-name">Terasawa, H.</span>; <span class="NLM_string-name">Kitaoka, H.</span></span> <span> </span><span class="NLM_article-title">Preparation of Camptothecin Derivative with Antitumor Activity</span>. <span class="NLM_patent">EP 737686 A1</span>, <span class="NLM_year">1996</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1996&author=S.+Kamihara&author=K.+Kanai&author=S.+Noguchi&author=H.+Terasawa&author=H.+Kitaoka&title=Preparation+of+Camptothecin+Derivative+with+Antitumor+Activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKamihara%26aufirst%3DS.%26atitle%3DPreparation%2520of%2520Camptothecin%2520Derivative%2520with%2520Antitumor%2520Activity%26date%3D1996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref207"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref207'); return false;" data-citation="" class="refNumLink">207</a></strong><div class="NLM_citation" id="cit207"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porco, J. A.,  Jr</span></span> <span> </span><span class="NLM_article-title">Modification of C-Terminal Peptides to Form Peptide Enamides: Synthesis of Chondriamides A and C</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">8215</span>– <span class="NLM_lpage">8221</span>, <span class="refDoi"> DOI: 10.1021/jo0158027</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo0158027" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnvVOiu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2001&pages=8215-8221&author=X.+Wangauthor=J.+A.+Porco&title=Modification+of+C-Terminal+Peptides+to+Form+Peptide+Enamides%3A+Synthesis+of+Chondriamides+A+and+C&doi=10.1021%2Fjo0158027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit207R"><div class="casContent"><span class="casTitleNuber">207</span><div class="casTitle"><span class="NLM_cas:atitle">Modification of C-Terminal Peptides to Form Peptide Enamides: Synthesis of Chondriamides A and C</span></div><div class="casAuthors">Wang, Xiang; Porco, John A., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8215-8221</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors describe the synthesis of peptide enamides based on tandem oxidative decarboxylation/elimination of C-terminal peptides.  Peptides contg. C-terminal tryptophans have been found to form Z-enamides with high selectivity, which has been exploited in the prepns. of cytotoxic indole-enamide natural products chondriamides A and C.  For example, H-Trp-OMe·HCl was acylated with trans-3-indoleacrylic acid in the presence of HOBt, EDC and DIEA in DMF at 0-25° to give N-acylated tryptophan I, which was tosylated and sapond. in that order to give free acid II.  For the oxidative decarboxylation and elimination step, II was treated with Pb(OAc)4, Cu(OAc)2 in pyridine/THF at 0-25° followed by treatment with LiClO4, DIEA in THF to give the enamide III in 63% yield with a 14:1 ratio of Z:E isomers.  Next, III was converted in two steps to chondriamide C and in three steps to chondriamide A, both obtained in >40% yields.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdRwa94VaIj7Vg90H21EOLACvtfcHk0ljIoMQ1c6jo8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnvVOiu78%253D&md5=2be279fc4ff2d88fa9f20554e91d9b35</span></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1021%2Fjo0158027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo0158027%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DPorco%26aufirst%3DJ.%2BA.%26atitle%3DModification%2520of%2520C-Terminal%2520Peptides%2520to%2520Form%2520Peptide%2520Enamides%253A%2520Synthesis%2520of%2520Chondriamides%2520A%2520and%2520C%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2001%26volume%3D66%26spage%3D8215%26epage%3D8221%26doi%3D10.1021%2Fjo0158027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref208"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref208'); return false;" data-citation="" class="refNumLink">208</a></strong><div class="NLM_citation" id="cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span>; <span class="NLM_string-name">Li, J.</span>; <span class="NLM_string-name">Zhuo, S.</span>; <span class="NLM_string-name">Wan, W.</span>; <span class="NLM_string-name">Yu, Y.</span>; <span class="NLM_string-name">Li, G.</span></span> <span> </span><span class="NLM_article-title">Antibody–Drug Conjugate Contains Antitumor Drugs with Two Different Action Mechanisms</span>. <span class="NLM_patent">CN 108853514 A</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=Y.+Zhu&author=J.+Li&author=S.+Zhuo&author=W.+Wan&author=Y.+Yu&author=G.+Li&title=Antibody%E2%80%93Drug+Conjugate+Contains+Antitumor+Drugs+with+Two+Different+Action+Mechanisms"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DY.%26atitle%3DAntibody%25E2%2580%2593Drug%2520Conjugate%2520Contains%2520Antitumor%2520Drugs%2520with%2520Two%2520Different%2520Action%2520Mechanisms%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref209"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref209'); return false;" data-citation="" class="refNumLink">209</a></strong><div class="NLM_citation" id="cit209a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Kamii, T.</span>; <span class="NLM_string-name">Nishimoto, N.</span></span> <span> </span><span class="NLM_article-title">Antibody–Drug Conjugate Formulation Containing Histidine Buffer and Its Lyophilization Method</span>. <span class="NLM_patent">WO 2019039483 A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=T.+Kamii&author=N.+Nishimoto&title=Antibody%E2%80%93Drug+Conjugate+Formulation+Containing+Histidine+Buffer+and+Its+Lyophilization+Method"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit209a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKamii%26aufirst%3DT.%26atitle%3DAntibody%25E2%2580%2593Drug%2520Conjugate%2520Formulation%2520Containing%2520Histidine%2520Buffer%2520and%2520Its%2520Lyophilization%2520Method%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit209b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, T.</span>; <span class="NLM_string-name">Sakuratani, K.</span></span> <span> </span><span class="NLM_article-title">Novel Linkers for Producing an Antibody–Drug Conjugate and Pharmaceutical Composition Using Thereof</span>. <span class="NLM_patent">WO 2020022363 A1</span>, <span class="NLM_year">2020</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=T.+Yamaguchi&author=K.+Sakuratani&title=Novel+Linkers+for+Producing+an+Antibody%E2%80%93Drug+Conjugate+and+Pharmaceutical+Composition+Using+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit209b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYamaguchi%26aufirst%3DT.%26atitle%3DNovel%2520Linkers%2520for%2520Producing%2520an%2520Antibody%25E2%2580%2593Drug%2520Conjugate%2520and%2520Pharmaceutical%2520Composition%2520Using%2520Thereof%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref210"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref210'); return false;" data-citation="" class="refNumLink">210</a></strong><div class="NLM_citation" id="cit210"><span><a href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-zanubrutinib-mantle-cell-lymphoma" class="extLink">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-zanubrutinib-mantle-cell-lymphoma</a> (accessed 2020-12-18).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fresources-information-approved-drugs%2Ffda-grants-accelerated-approval-zanubrutinib-mantle-cell-lymphoma+%28accessed+2020-12-18%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref211"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref211'); return false;" data-citation="" class="refNumLink">211</a></strong><div class="NLM_citation" id="cit211"><span><a href="http://www.globenewswire.com/news-release/2020/06/03/2042805/0/en/BeiGene-Announces-the-Approval-of-BRUKINSA-Zanubrutinib-in-China-for-Patients-with-Relapsed-Refractory-Chronic-Lymphocytic-Leukemia-or-Small-Lymphocytic-Lymphoma-and-Relapsed-Refra.html" class="extLink">http://www.globenewswire.com/news-release/2020/06/03/2042805/0/en/BeiGene-Announces-the-Approval-of-BRUKINSA-Zanubrutinib-in-China-for-Patients-with-Relapsed-Refractory-Chronic-Lymphocytic-Leukemia-or-Small-Lymphocytic-Lymphoma-and-Relapsed-Refra.html</a> (accessed 2020-12-18).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=http%3A%2F%2Fwww.globenewswire.com%2Fnews-release%2F2020%2F06%2F03%2F2042805%2F0%2Fen%2FBeiGene-Announces-the-Approval-of-BRUKINSA-Zanubrutinib-in-China-for-Patients-with-Relapsed-Refractory-Chronic-Lymphocytic-Leukemia-or-Small-Lymphocytic-Lymphoma-and-Relapsed-Refra.html+%28accessed+2020-12-18%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref212"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref212'); return false;" data-citation="" class="refNumLink">212</a></strong><div class="NLM_citation" id="cit212"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ou, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preston, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marbury, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novotny, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tawashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahasranaman, S.</span></span> <span> </span><span class="NLM_article-title">A Phase 1, Open-Label, Single-Dose Study of the Pharmacokinetics of Zanubrutinib in Subjects with Varying Degrees of Hepatic Impairment</span>. <i>Leuk. Lymphoma</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">1355</span>– <span class="NLM_lpage">1363</span>, <span class="refDoi"> DOI: 10.1080/10428194.2020.1719097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1080%2F10428194.2020.1719097" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=32031037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisFyjtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2020&pages=1355-1363&author=Y.+C.+Ouauthor=R.+A.+Prestonauthor=T.+C.+Marburyauthor=Z.+Tangauthor=W.+Novotnyauthor=M.+Tawashiauthor=T.+K.+Liauthor=S.+Sahasranaman&title=A+Phase+1%2C+Open-Label%2C+Single-Dose+Study+of+the+Pharmacokinetics+of+Zanubrutinib+in+Subjects+with+Varying+Degrees+of+Hepatic+Impairment&doi=10.1080%2F10428194.2020.1719097"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit212R"><div class="casContent"><span class="casTitleNuber">212</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 1, open-label, single-dose study of the pharmacokinetics of zanubrutinib in subjects with varying degrees of hepatic impairment</span></div><div class="casAuthors">Ou, Ying C.; Preston, Richard A.; Marbury, Thomas C.; Tang, Zhiyu; Novotny, William; Tawashi, Manal; Li, Ta-Kai; Sahasranaman, Srikumar</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia & Lymphoma</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1355-1363</span>CODEN:
                <span class="NLM_cas:coden">LELYEA</span>;
        ISSN:<span class="NLM_cas:issn">1029-2403</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">The pharmacokinetics and safety of single-dose zanubrutinib (80 mg) were assessed in subjects with mild, moderate, and severe hepatic impairment (n = 6 each, Child-Pugh class A, B, and C) relative to healthy controls (n = 11).  Zanubrutinib median Tmax was 1.25-2.25 h in all groups.  Compared to control group, mean zanubrutinib exposure (AUC0-inf) in the mild and moderate hepatic impairment groups was increased by 1.1- and 1.2-fold, which is within the range of PK variability for zanubrutinib.  The total and unbound AUC of zanubrutinib were 1.60- and 2.9-fold higher in subjects with severe hepatic impairment compared to healthy controls.  Terminal half-life was comparable between subjects with hepatic impairment and matched healthy controls.  Zanubrutinib was generally well-tolerated when administered as a single, 80-mg dose to subjects in this study.  Results of this study will be used, in conjunction with clin. safety and efficacy data, to develop dose recommendations for patients with hepatic impairment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrftoUnflCF1rVg90H21EOLACvtfcHk0li2K2eyblTQ-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisFyjtrk%253D&md5=45b2ad798ee07813d6f441305e3c2077</span></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=10.1080%2F10428194.2020.1719097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10428194.2020.1719097%26sid%3Dliteratum%253Aachs%26aulast%3DOu%26aufirst%3DY.%2BC.%26aulast%3DPreston%26aufirst%3DR.%2BA.%26aulast%3DMarbury%26aufirst%3DT.%2BC.%26aulast%3DTang%26aufirst%3DZ.%26aulast%3DNovotny%26aufirst%3DW.%26aulast%3DTawashi%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DT.%2BK.%26aulast%3DSahasranaman%26aufirst%3DS.%26atitle%3DA%2520Phase%25201%252C%2520Open-Label%252C%2520Single-Dose%2520Study%2520of%2520the%2520Pharmacokinetics%2520of%2520Zanubrutinib%2520in%2520Subjects%2520with%2520Varying%2520Degrees%2520of%2520Hepatic%2520Impairment%26jtitle%3DLeuk.%2520Lymphoma%26date%3D2020%26volume%3D61%26spage%3D1355%26epage%3D1363%26doi%3D10.1080%2F10428194.2020.1719097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref213"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref213'); return false;" data-citation="" class="refNumLink">213</a></strong><div class="NLM_citation" id="cit213"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elstrom, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novotny, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span> <span> </span><span class="NLM_article-title">Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton’s Tyrosine Kinase</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">4216</span>– <span class="NLM_lpage">4224</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-19-3703</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1158%2F1078-0432.CCR-19-3703" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=32461234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitF2ntbzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2020&pages=4216-4224&author=Y.+Songauthor=K.+S.+Zhouauthor=D.+Zouauthor=J.+Zhouauthor=J.+Huauthor=H.+Yangauthor=H.+Zhangauthor=J.+Jiauthor=W.+Xuauthor=J.+Jinauthor=F.+Lvauthor=R.+Fengauthor=S.+Gaoauthor=H.+Guoauthor=L.+Zhouauthor=R.+Elstromauthor=J.+Huangauthor=W.+Novotnyauthor=R.+Weiauthor=J.+Zhu&title=Treatment+of+Patients+with+Relapsed+or+Refractory+Mantle+Cell+Lymphoma+with+Zanubrutinib%2C+a+Selective+Inhibitor+of+Bruton%E2%80%99s+Tyrosine+Kinase&doi=10.1158%2F1078-0432.CCR-19-3703"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit213R"><div class="casContent"><span class="casTitleNuber">213</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of patients with relapsed or refractory mantle-cell lymphoma with zanubrutinib, a selective inhibitor of bruton's tyrosine kinase</span></div><div class="casAuthors">Song, Yuqin; Zhou, Keshu; Zou, Dehui; Zhou, Jianfeng; Hu, Jianda; Yang, Haiyan; Zhang, Huilai; Ji, Jie; Xu, Wei; Jin, Jie; Lv, Fangfang; Feng, Ru; Gao, Sujun; Guo, Haiyi; Zhou, Lei; Elstrom, Rebecca; Huang, Jane; Novotny, William; Wei, Rachel; Zhu, Jun</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4216-4224</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">We evaluated the efficacy and safety of zanubrutinib, an investigational selective Bruton's tyrosine kinase inhibitor.  Patients and Methods: Patients with relapsed/refractory MCL were enrolled in this ongoing phase II, single-arm, open-label study, and treated with oral zanubrutinib 160 mg twice daily.  The primary endpoint is overall response rate assessed by an independent review committee; secondary endpoints include duration of response, time to response, progression-free survival, and safety.  Eighty-six patients were enrolled after a median of 2 prior lines of therapy, received ≥1 dose of the study drug, and were evaluable for safety and efficacy.  After a median follow-up of 18.4 mo, 72 patients achieved an objective response, with 59 (68.6%) achieving a complete response.  Median DOR and PFS were 19.5 and 22.1 mo, resp.; 12-mo event-free ests. for DOR and PFS are 78% and 76%, resp.  Most common grade ≥3 adverse events were neutropenia and lung infection/pneumonia.  Three patients experienced major bleeding events, and there were no reports of atrial fibrillation.  Eight patients discontinued zanubrutinib for AEs.  These results demonstrate high and durable ORR and CR rates in patients with relapsed/refractory MCL.  Zanubrutinib was generally well tolerated; grade ≥3 BTK inhibitor-assocd. toxicities (hemorrhage, rash, hypertension, diarrhea, atrial fibrillation) were uncommon.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6RV6HcDWkfbVg90H21EOLACvtfcHk0lj-9dDeK1Yv1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitF2ntbzO&md5=e61a57ff68e27baaf1ba91a20bf5372a</span></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-19-3703&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-19-3703%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DK.%2BS.%26aulast%3DZou%26aufirst%3DD.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DJi%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DLv%26aufirst%3DF.%26aulast%3DFeng%26aufirst%3DR.%26aulast%3DGao%26aufirst%3DS.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DElstrom%26aufirst%3DR.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DNovotny%26aufirst%3DW.%26aulast%3DWei%26aufirst%3DR.%26aulast%3DZhu%26aufirst%3DJ.%26atitle%3DTreatment%2520of%2520Patients%2520with%2520Relapsed%2520or%2520Refractory%2520Mantle%2520Cell%2520Lymphoma%2520with%2520Zanubrutinib%252C%2520a%2520Selective%2520Inhibitor%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2020%26volume%3D26%26spage%3D4216%26epage%3D4224%26doi%3D10.1158%2F1078-0432.CCR-19-3703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref214"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref214'); return false;" data-citation="" class="refNumLink">214</a></strong><div class="NLM_citation" id="cit214a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">7923</span>– <span class="NLM_lpage">7940</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00687</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00687" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref214/cit214a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFSku7bP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=7923-7940&author=Y.+Guoauthor=Y.+Liuauthor=N.+Huauthor=D.+Yuauthor=C.+Zhouauthor=G.+Shiauthor=B.+Zhangauthor=M.+Weiauthor=J.+Liuauthor=L.+Luoauthor=Z.+Tangauthor=H.+Songauthor=Y.+Guoauthor=X.+Liuauthor=D.+Suauthor=S.+Zhangauthor=X.+Songauthor=X.+Zhouauthor=Y.+Hongauthor=S.+Chenauthor=Z.+Chengauthor=S.+Youngauthor=Q.+Weiauthor=H.+Wangauthor=Q.+Wangauthor=L.+Lvauthor=F.+Wangauthor=H.+Xuauthor=H.+Sunauthor=H.+Xingauthor=N.+Liauthor=W.+Zhangauthor=Z.+Wangauthor=G.+Liuauthor=Z.+Sunauthor=D.+Zhouauthor=W.+Liauthor=L.+Liuauthor=L.+Wangauthor=Z.+Wang&title=Discovery+of+Zanubrutinib+%28BGB-3111%29%2C+a+Novel%2C+Potent%2C+and+Selective+Covalent+Inhibitor+of+Bruton%E2%80%99s+Tyrosine+Kinase&doi=10.1021%2Facs.jmedchem.9b00687"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit214aR"><div class="casContent"><span class="casTitleNuber">214a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase</span></div><div class="casAuthors">Guo, Yunhang; Liu, Ye; Hu, Nan; Yu, Desheng; Zhou, Changyou; Shi, Gongyin; Zhang, Bo; Wei, Min; Liu, Junhua; Luo, Lusong; Tang, Zhiyu; Song, Huipeng; Guo, Yin; Liu, Xuesong; Su, Dan; Zhang, Shuo; Song, Xiaomin; Zhou, Xing; Hong, Yuan; Chen, Shuaishuai; Cheng, Zhenzhen; Young, Steve; Wei, Qiang; Wang, Haisheng; Wang, Qiuwen; Lv, Lei; Wang, Fan; Xu, Haipeng; Sun, Hanzi; Xing, Haimei; Li, Na; Zhang, Wei; Wang, Zhongbo; Liu, Guodong; Sun, Zhijian; Zhou, Dongping; Li, Wei; Liu, Libin; Wang, Lai; Wang, Zhiwei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7923-7940</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Aberrant activation of Bruton's tyrosine kinase (BTK) plays an important role in pathogenesis of B-cell lymphomas, suggesting that inhibition of BTK is useful in the treatment of hematol. malignancies.  The discovery of a more selective on-target covalent BTK inhibitor is of high value.  Herein, we disclose the discovery and preclin. characterization of a potent, selective, and irreversible BTK inhibitor as our clin. candidate by using in vitro potency, selectivity, pharmacokinetics (PK), and in vivo pharmacodynamic for prioritizing compds.  Compd. BGB-3111 (31a, Zanubrutinib) demonstrates (i) potent activity against BTK and excellent selectivity over other TEC, EGFR and Src family kinases, (ii) desirable ADME, excellent in vivo pharmacodynamic in mice and efficacy in OCI-LY10 xenograft models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgRMQ-gBKtdbVg90H21EOLACvtfcHk0lj-9dDeK1Yv1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFSku7bP&md5=5cdb551d296e60eb1e82b03b7a0384ee</span></div><a href="/servlet/linkout?suffix=cit214a&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00687%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DN.%26aulast%3DYu%26aufirst%3DD.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DShi%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DWei%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLuo%26aufirst%3DL.%26aulast%3DTang%26aufirst%3DZ.%26aulast%3DSong%26aufirst%3DH.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DSu%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DSong%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DHong%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DCheng%26aufirst%3DZ.%26aulast%3DYoung%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DLv%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DXing%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DSun%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DZ.%26atitle%3DDiscovery%2520of%2520Zanubrutinib%2520%2528BGB-3111%2529%252C%2520a%2520Novel%252C%2520Potent%252C%2520and%2520Selective%2520Covalent%2520Inhibitor%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D7923%26epage%3D7940%26doi%3D10.1021%2Facs.jmedchem.9b00687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit214b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span>; <span class="NLM_string-name">Guo, Y.</span>; <span class="NLM_string-name">Shi, G.</span></span> <span> </span><span class="NLM_article-title">Crystalline Form of (<i>S</i>)-7-(1-Acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide, Preparation, and Uses Thereof</span>. <span class="NLM_patent">WO 2018033853 A2</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=Z.+Wang&author=Y.+Guo&author=G.+Shi&title=Crystalline+Form+of+%28S%29-7-%281-Acryloylpiperidin-4-yl%29-2-%284-phenoxyphenyl%29-4%2C5%2C6%2C7-tetrahydropyrazolo%5B1%2C5-a%5Dpyrimidine-3-carboxamide%2C+Preparation%2C+and+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit214b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26atitle%3DCrystalline%2520Form%2520of%2520%2528S%2529-7-%25281-Acryloylpiperidin-4-yl%2529-2-%25284-phenoxyphenyl%2529-4%252C5%252C6%252C7-tetrahydropyrazolo%255B1%252C5-a%255Dpyrimidine-3-carboxamide%252C%2520Preparation%252C%2520and%2520Uses%2520Thereof%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit214c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span>; <span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">Fused Heterocyclic Compounds as Protein Kinase Inhibitors</span>. <span class="NLM_patent">WO 2014173289 A1</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=Y.+Guo&author=Z.+Wang&title=Fused+Heterocyclic+Compounds+as+Protein+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit214c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DY.%26atitle%3DFused%2520Heterocyclic%2520Compounds%2520as%2520Protein%2520Kinase%2520Inhibitors%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref215"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref215'); return false;" data-citation="" class="refNumLink">215</a></strong><div class="NLM_citation" id="cit215"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barra, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seca, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Della Corte, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giampaolino, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrero, S.</span></span> <span> </span><span class="NLM_article-title">Relugolix for the Treatment of Uterine Fibroids</span>. <i>Drugs Today</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">503</span>– <span class="NLM_lpage">512</span>, <span class="refDoi"> DOI: 10.1358/dot.2019.55.8.3020179</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1358%2Fdot.2019.55.8.3020179" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A280%3ADC%252BB3Mrisl2gtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2019&pages=503-512&author=F.+Barraauthor=M.+Secaauthor=L.+Della+Corteauthor=P.+Giampaolinoauthor=S.+Ferrero&title=Relugolix+for+the+Treatment+of+Uterine+Fibroids&doi=10.1358%2Fdot.2019.55.8.3020179"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit215R"><div class="casContent"><span class="casTitleNuber">215</span><div class="casTitle"><span class="NLM_cas:atitle">Relugolix for the treatment of uterine fibroids</span></div><div class="casAuthors">Barra F; Seca M; Ferrero S; Della Corte L; Giampaolino P</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of today (Barcelona, Spain : 1998)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">503-512</span>
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    </div><div class="casAbstract">Uterine leiomyomas represent the most common form of benign gynecological tumors affecting 20-40% of women during their life.  Several therapeutic options are available for treating these patients.  The use of medical treatment for myomas has largely grown in the last years, in particular for women who would refuse, postpone or are not candidates for surgery.  In the last years, the clinical investigation of gonadotropin-releasing hormone (GnRH) antagonists (GnRH-ants) has emerged.  This class of drugs exerts pure competitive antagonistic activity on the GnRH receptor at the pituitary gland, producing an immediate stop in the release of gonadotropins and sex steroids.  Relugolix is an orally active nonpeptide GnRH-ant, recently licensed for marketing in Japan for the treatment of symptoms related to uterine myomas.  Currently, several phase III clinical trials are ongoing to evaluate this molecule in this setting in the U.S. and Europe.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQpQKFSJnFw8RpyrDyM_m9cfW6udTcc2eb0WKF2wvliF7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3Mrisl2gtA%253D%253D&md5=b42693c2309b40a4b38e530508241dad</span></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=10.1358%2Fdot.2019.55.8.3020179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2019.55.8.3020179%26sid%3Dliteratum%253Aachs%26aulast%3DBarra%26aufirst%3DF.%26aulast%3DSeca%26aufirst%3DM.%26aulast%3DDella%2BCorte%26aufirst%3DL.%26aulast%3DGiampaolino%26aufirst%3DP.%26aulast%3DFerrero%26aufirst%3DS.%26atitle%3DRelugolix%2520for%2520the%2520Treatment%2520of%2520Uterine%2520Fibroids%26jtitle%3DDrugs%2520Today%26date%3D2019%26volume%3D55%26spage%3D503%26epage%3D512%26doi%3D10.1358%2Fdot.2019.55.8.3020179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref216"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref216'); return false;" data-citation="" class="refNumLink">216</a></strong><div class="NLM_citation" id="cit216a"><span><span class="NLM_label">(a) </span><a href="https://clinicaltrials.gov/ct2/show/NCT03085095" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03085095</a> (accessed 2020-09-15).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03085095+%28accessed+2020-09-15%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit216a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit216b"><span><span class="NLM_label">(b) </span><a href="https://clinicaltrials.gov/ct2/show/NCT03931915" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03931915</a> (accessed 2020-09-15).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03931915+%28accessed+2020-09-15%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit216b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref217"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref217'); return false;" data-citation="" class="refNumLink">217</a></strong><div class="NLM_citation" id="cit217"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cho, N.</span>; <span class="NLM_string-name">Imada, T.</span>; <span class="NLM_string-name">Hitaka, T.</span>; <span class="NLM_string-name">Miwa, K.</span>; <span class="NLM_string-name">Kusaka, M.</span>; <span class="NLM_string-name">Suzuki, N.</span></span> <span> </span><span class="NLM_article-title">Preparation of Thienopyrimidine Derivatives as Gonadotropin-Releasing Hormone Antagonists</span>. <span class="NLM_patent">WO 2004067535 A1</span>, <span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=N.+Cho&author=T.+Imada&author=T.+Hitaka&author=K.+Miwa&author=M.+Kusaka&author=N.+Suzuki&title=Preparation+of+Thienopyrimidine+Derivatives+as+Gonadotropin-Releasing+Hormone+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit217&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DN.%26atitle%3DPreparation%2520of%2520Thienopyrimidine%2520Derivatives%2520as%2520Gonadotropin-Releasing%2520Hormone%2520Antagonists%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref218"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref218'); return false;" data-citation="" class="refNumLink">218</a></strong><div class="NLM_citation" id="cit218"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miwa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hitaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshimatsu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakata, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furuya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamamura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitazaki, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of 1-{4-[1-(2,6-Difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-<i>d</i>]pyrimidin-6-yl]phenyl}-3-methoxyurea (TAK-385) as a Potent, Orally Active, Non-Peptide Antagonist of the Human Gonadotropin-Releasing Hormone Receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">4998</span>– <span class="NLM_lpage">5012</span>, <span class="refDoi"> DOI: 10.1021/jm200216q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200216q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnvFagsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4998-5012&author=K.+Miwaauthor=T.+Hitakaauthor=T.+Imadaauthor=S.+Sasakiauthor=M.+Yoshimatsuauthor=M.+Kusakaauthor=A.+Tanakaauthor=D.+Nakataauthor=S.+Furuyaauthor=S.+Endoauthor=K.+Hamamuraauthor=T.+Kitazaki&title=Discovery+of+1-%7B4-%5B1-%282%2C6-Difluorobenzyl%29-5-%5B%28dimethylamino%29methyl%5D-3-%286-methoxypyridazin-3-yl%29-2%2C4-dioxo-1%2C2%2C3%2C4-tetrahydrothieno%5B2%2C3-d%5Dpyrimidin-6-yl%5Dphenyl%7D-3-methoxyurea+%28TAK-385%29+as+a+Potent%2C+Orally+Active%2C+Non-Peptide+Antagonist+of+the+Human+Gonadotropin-Releasing+Hormone+Receptor&doi=10.1021%2Fjm200216q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit218R"><div class="casContent"><span class="casTitleNuber">218</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 1-{4-[1-(2,6-Difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl}-3-methoxyurea (TAK-385) as a Potent, Orally Active, Non-Peptide Antagonist of the Human Gonadotropin-Releasing Hormone Receptor</span></div><div class="casAuthors">Miwa, Kazuhiro; Hitaka, Takenori; Imada, Takashi; Sasaki, Satoshi; Yoshimatsu, Mie; Kusaka, Masami; Tanaka, Akira; Nakata, Daisuke; Furuya, Shuichi; Endo, Satoshi; Hamamura, Kazumasa; Kitazaki, Tomoyuki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4998-5012</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An orally active human gonadotropin-releasing hormone (GnRH) receptor antagonist, thieno[2,3-d]pyrimidine-2,4-dione deriv. I (sufugolix), was previously discovered.  To reduce the cytochrome P 450 (CYP) inhibitory activity and improve in vivo GnRH antagonistic activity, further optimization of this scaffold was carried out.  The synthetic efforts were focused on chem. modification at the 5 and 3 positions of the thieno[2,3-d]pyrimidine-2,4-dione ring based on computational modeling, which resulted in the discovery of 1-{4-[1-(2,6-difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl}-3-methoxyurea (II) as a highly potent and orally active GnRH antagonist.  Compd. II showed potent in vitro GnRH antagonistic activity in the presence of fetal bovine serum (FBS) without CYP inhibition.  Oral administration of II maintained the suppressive effect of the plasma LH levels in castrated cynomolgus monkeys at a 3 mg/kg dose for more than 24 h.  Compd. II is currently under clin. development with the code name of TAK-385.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrw-Ejv5bG8kbVg90H21EOLACvtfcHk0liXuKM2Ikuxjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnvFagsbY%253D&md5=1389cd91374bc908a561149de19b71b1</span></div><a href="/servlet/linkout?suffix=cit218&amp;dbid=16384&amp;doi=10.1021%2Fjm200216q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200216q%26sid%3Dliteratum%253Aachs%26aulast%3DMiwa%26aufirst%3DK.%26aulast%3DHitaka%26aufirst%3DT.%26aulast%3DImada%26aufirst%3DT.%26aulast%3DSasaki%26aufirst%3DS.%26aulast%3DYoshimatsu%26aufirst%3DM.%26aulast%3DKusaka%26aufirst%3DM.%26aulast%3DTanaka%26aufirst%3DA.%26aulast%3DNakata%26aufirst%3DD.%26aulast%3DFuruya%26aufirst%3DS.%26aulast%3DEndo%26aufirst%3DS.%26aulast%3DHamamura%26aufirst%3DK.%26aulast%3DKitazaki%26aufirst%3DT.%26atitle%3DDiscovery%2520of%25201-%257B4-%255B1-%25282%252C6-Difluorobenzyl%2529-5-%255B%2528dimethylamino%2529methyl%255D-3-%25286-methoxypyridazin-3-yl%2529-2%252C4-dioxo-1%252C2%252C3%252C4-tetrahydrothieno%255B2%252C3-d%255Dpyrimidin-6-yl%255Dphenyl%257D-3-methoxyurea%2520%2528TAK-385%2529%2520as%2520a%2520Potent%252C%2520Orally%2520Active%252C%2520Non-Peptide%2520Antagonist%2520of%2520the%2520Human%2520Gonadotropin-Releasing%2520Hormone%2520Receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4998%26epage%3D5012%26doi%3D10.1021%2Fjm200216q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref219"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref219'); return false;" data-citation="" class="refNumLink">219</a></strong><div class="NLM_citation" id="cit219"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furuya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujino, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Thieno[2,3-<i>d</i>]pyrimidine-2,4-dione Bearing a <i>p</i>-Methoxyureidophenyl Moiety at the 6-Position: A Highly Potent and Orally Bioavailable Non-Peptide Antagonist for the Human Luteinizing Hormone-Releasing Hormone Receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">113</span>– <span class="NLM_lpage">124</span>, <span class="refDoi"> DOI: 10.1021/jm020180i</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm020180i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BD38XovFygu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=113-124&author=S.+Sasakiauthor=N.+Choauthor=Y.+Naraauthor=M.+Haradaauthor=S.+Endoauthor=N.+Suzukiauthor=S.+Furuyaauthor=M.+Fujino&title=Discovery+of+a+Thieno%5B2%2C3-d%5Dpyrimidine-2%2C4-dione+Bearing+a+p-Methoxyureidophenyl+Moiety+at+the+6-Position%3A+A+Highly+Potent+and+Orally+Bioavailable+Non-Peptide+Antagonist+for+the+Human+Luteinizing+Hormone-Releasing+Hormone+Receptor&doi=10.1021%2Fjm020180i"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit219R"><div class="casContent"><span class="casTitleNuber">219</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Thieno[2,3-d]pyrimidine-2,4-dione Bearing a p-Methoxyureidophenyl Moiety at the 6-Position: A Highly Potent and Orally Bioavailable Non-Peptide Antagonist for the Human Luteinizing Hormone-Releasing Hormone Receptor</span></div><div class="casAuthors">Sasaki, Satoshi; Cho, Nobuo; Nara, Yoshi; Harada, Masataka; Endo, Satoshi; Suzuki, Nobuhiro; Furuya, Shuichi; Fujino, Masahiko</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">113-124</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We have previously disclosed the first potent and orally effective non-peptide antagonist for the human LH-releasing hormone (LHRH) receptor, a thieno[2,3-b]pyridin-4-one deriv., T-98475.  Extensive research on developing non-peptide LHRH antagonists has been carried out by employing a strategy of replacing the thienopyridin-4-one nucleus with other heterocyclic surrogates.  We describe herein the design and synthesis of a series of thieno[2,3-d]pyrimidine-2,4-dione derivs. contg. a biaryl moiety, which led to the discovery of a highly potent and orally active non-peptide LHRH antagonist, 5-(N-benzyl-N-methylaminomethyl)-1-(2,6-difluorobenzyl)-6-[4-(3-methoxyureido)phenyl]-3-phenylthieno[2,3-d]pyrimidine-2,4(1H,3H)-dione (I: TAK-013).  Compd. I showed high binding affinity and potent in vitro antagonistic activity for the human receptor with half-maximal inhibition concn. (IC50) values of 0.1 and 0.06 nM, resp.  Oral administration of I caused almost complete suppression of the plasma LH levels in castrated male cynomolgus monkeys at a 30 mg/kg dose with sufficient duration of action (more than 24 h).  The results demonstrated that the thienopyrimidine-2,4-dione core is an excellent surrogate for the thienopyridin-4-one and that thienopyrimidine-2,4-diones and thienopyridin-4-ones constitute a new class of potent and orally bioavailable LHRH receptor antagonists. Furthermore, mol. modeling studies indicate that the unique methoxyurea side chain of I preferentially forms an intramol. hydrogen bond between the aniline NH and the methoxy oxygen atom.  The hydrogen bond will shield the hydrogen bonding moieties from the solvent and reduce the desolvation energy cost.  It is therefore speculated that the intramol. hydrogen bond resulting from judicious incorporation of an oxygen atom into the terminal alkyl group of the urea may increase the apparent lipophilicity to allow increased membrane permeability and consequently to improve the oral absorption of I in monkeys.  On the basis of its profile, compd. I has been selected as a candidate for clin. trials and it is expected that it will provide a new class of potential therapeutic agents for the clin. treatment of a variety of sex-hormone-dependent diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmDf674AIEgbVg90H21EOLACvtfcHk0lhJtOowKND4Lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XovFygu70%253D&md5=bdfb9d73c0632d3ecc5bcd6043bf219b</span></div><a href="/servlet/linkout?suffix=cit219&amp;dbid=16384&amp;doi=10.1021%2Fjm020180i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020180i%26sid%3Dliteratum%253Aachs%26aulast%3DSasaki%26aufirst%3DS.%26aulast%3DCho%26aufirst%3DN.%26aulast%3DNara%26aufirst%3DY.%26aulast%3DHarada%26aufirst%3DM.%26aulast%3DEndo%26aufirst%3DS.%26aulast%3DSuzuki%26aufirst%3DN.%26aulast%3DFuruya%26aufirst%3DS.%26aulast%3DFujino%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520a%2520Thieno%255B2%252C3-d%255Dpyrimidine-2%252C4-dione%2520Bearing%2520a%2520p-Methoxyureidophenyl%2520Moiety%2520at%2520the%25206-Position%253A%2520A%2520Highly%2520Potent%2520and%2520Orally%2520Bioavailable%2520Non-Peptide%2520Antagonist%2520for%2520the%2520Human%2520Luteinizing%2520Hormone-Releasing%2520Hormone%2520Receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D113%26epage%3D124%26doi%3D10.1021%2Fjm020180i" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref220"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref220'); return false;" data-citation="" class="refNumLink">220</a></strong><div class="NLM_citation" id="cit220a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hoy, S. M.</span></span> <span> </span><span class="NLM_article-title">Elexacaftor/Ivacaftor/Tezacaftor: First Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">2001</span>– <span class="NLM_lpage">2007</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01233-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref220/cit220a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs40265-019-01233-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref220/cit220a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31784874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref220/cit220a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A280%3ADC%252BB3MfkvFaitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=2001-2007&author=S.+M.+Hoy&title=Elexacaftor%2FIvacaftor%2FTezacaftor%3A+First+Approval&doi=10.1007%2Fs40265-019-01233-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit220aR"><div class="casContent"><span class="casTitleNuber">220a</span><div class="casTitle"><span class="NLM_cas:atitle">Elexacaftor/Ivacaftor/Tezacaftor: First Approval</span></div><div class="casAuthors">Hoy Sheridan M</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2001-2007</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">A fixed-dose combination tablet of the cystic fibrosis transmembrane conductance regulator (CFTR) corrector tezacaftor and the CFTR potentiator ivacaftor with the next-generation CFTR corrector elexacaftor (hereafter referred to as elexacaftor/ivacaftor/tezacaftor) [Trikafta®] has been developed by Vertex Pharmaceuticals Inc. to treat patients with the most common cystic fibrosis mutation (F508del).  Its use has been associated with statistically significant and/or clinically meaningful improvements in lung function and respiratory-related quality of life compared with comparator regimens (placebo or ivacaftor/tezacaftor) in multinational phase II and III studies, and in October 2019 elexacaftor/ivacaftor/tezacaftor was approved by the US FDA for the treatment of cystic fibrosis in patients aged ≥ 12 years who have ≥ 1 F508del mutation in the CFTR gene.  A regulatory assessment for elexacaftor/ivacaftor/tezacaftor as a treatment for cystic fibrosis is underway in the EU.  This article summarizes the milestones in the development of elexacaftor/ivacaftor/tezacaftor leading to this first approval for the treatment of cystic fibrosis in patients aged ≥ 12 years who have ≥ 1 F508del mutation in the CFTR gene.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT2Dsf-znGt_RLDWw4HIq2sfW6udTcc2eYi9Tpw4TKwgLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MfkvFaitw%253D%253D&md5=4b00880ad8edb858bf89367264b4e9f7</span></div><a href="/servlet/linkout?suffix=cit220a&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01233-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01233-7%26sid%3Dliteratum%253Aachs%26aulast%3DHoy%26aufirst%3DS.%2BM.%26atitle%3DElexacaftor%252FIvacaftor%252FTezacaftor%253A%2520First%2520Approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D2001%26epage%3D2007%26doi%3D10.1007%2Fs40265-019-01233-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit220b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oermann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Resnick, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brady, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeNagel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guill, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoag, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newton, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willey-Courand, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naureckas, E. T.</span></span> <span> </span><span class="NLM_article-title">Cystic Fibrosis Foundation Pulmonary Guidelines. Use of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy in Patients with Cystic Fibrosis</span>. <i>Ann. Am. Thorac. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">271</span>– <span class="NLM_lpage">280</span>, <span class="refDoi"> DOI: 10.1513/AnnalsATS.201707-539OT</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref220/cit220b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1513%2FAnnalsATS.201707-539OT" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref220/cit220b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=29342367" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref220/cit220b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A280%3ADC%252BC1MvhsFKhsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=271-280&author=C.+L.+Renauthor=R.+L.+Morganauthor=C.+Oermannauthor=H.+E.+Resnickauthor=C.+Bradyauthor=A.+Campbellauthor=R.+DeNagelauthor=M.+Guillauthor=J.+Hoagauthor=A.+Liptonauthor=T.+Newtonauthor=S.+Petersauthor=D.+B.+Willey-Courandauthor=E.+T.+Naureckas&title=Cystic+Fibrosis+Foundation+Pulmonary+Guidelines.+Use+of+Cystic+Fibrosis+Transmembrane+Conductance+Regulator+Modulator+Therapy+in+Patients+with+Cystic+Fibrosis&doi=10.1513%2FAnnalsATS.201707-539OT"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit220bR"><div class="casContent"><span class="casTitleNuber">220b</span><div class="casTitle"><span class="NLM_cas:atitle">Cystic Fibrosis Foundation Pulmonary Guidelines. Use of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy in Patients with Cystic Fibrosis</span></div><div class="casAuthors">Ren Clement L; Morgan Rebecca L; Oermann Christopher; Resnick Helaine E; Brady Cynthia; Campbell Annette; DeNagel Richard; Guill Margaret; Hoag Jeffrey; Lipton Andrew; Newton Thomas; Peters Stacy; Willey-Courand Donna Beth; Naureckas Edward T</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the American Thoracic Society</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">271-280</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">RATIONALE:  Cystic fibrosis (CF) transmembrane conductance regulator (CFTR) modulators are a new class of medications targeting the underlying defect in CF.  Ivacaftor (IVA) and IVA combined with lumacaftor (LUM; IVA/LUM) have been approved by the U.S.  Food and Drug Administration (FDA) for use in patients with CF.  However, the FDA label for these medications encompasses patient groups that were not studied as part of the drug approval process.  CF clinicians, patients, and their families have recognized a need for recommendations to guide the use of these medications.  OBJECTIVE:  Develop evidence-based guidelines for CFTR modulator therapy in patients with CF.  METHODS:  A multidisciplinary committee of CF caregivers and patient representatives was assembled.  A methodologist, an epidemiologist, a medical librarian, and a biostatistician were recruited to assist with the literature search, evidence grading, and generation of recommendations.  The committee developed clinical questions using the Patient-Intervention-Comparison-Outcome format.  A systematic review was conducted to find relevant publications.  The evidence was then evaluated using the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach, and recommendations were made based on this analysis.  RESULTS:  For adults and children aged 6 years and older with CF due to gating mutations other than G551D or R117H, the guideline panel made a conditional recommendation for treatment with IVA.  For those with the R117H mutation, the guideline panel made a conditional recommendation for treatment with IVA for 1) adults aged 18 years or older, and 2) children aged 6-17 years with a forced expiratory volume in 1 second (FEV1) less than 90% predicted.  For those with the R117H mutation, the guideline panel made a conditional recommendation against treatment with IVA for 1) children aged 12-17 years with an FEV1 greater than 90% predicted, and 2) children less than 6 years of age.  Among those with two copies of F508del, the guideline panel made a strong recommendation for treatment with IVA/LUM for adults and children aged 12 years and older with an FEV1 less than 90% predicted; and made a conditional recommendation for treatment with IVA/LUM for 1) adults and children aged 12 years or older with an FEV1 greater than 90% predicted, and 2) children aged 6-11 years.  CONCLUSIONS:  Using the GRADE approach, we have made recommendations for the use of CFTR modulators in patients with CF.  These recommendations will be of help to CF clinicians, patients, and their families in guiding decisions regarding use of these medications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQvIaI3UZvtiO2mnZh2OgS0fW6udTcc2eboBGBQ7l2jo7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MvhsFKhsA%253D%253D&md5=28e86120150609327b22f90a76623f66</span></div><a href="/servlet/linkout?suffix=cit220b&amp;dbid=16384&amp;doi=10.1513%2FAnnalsATS.201707-539OT&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1513%252FAnnalsATS.201707-539OT%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DC.%2BL.%26aulast%3DMorgan%26aufirst%3DR.%2BL.%26aulast%3DOermann%26aufirst%3DC.%26aulast%3DResnick%26aufirst%3DH.%2BE.%26aulast%3DBrady%26aufirst%3DC.%26aulast%3DCampbell%26aufirst%3DA.%26aulast%3DDeNagel%26aufirst%3DR.%26aulast%3DGuill%26aufirst%3DM.%26aulast%3DHoag%26aufirst%3DJ.%26aulast%3DLipton%26aufirst%3DA.%26aulast%3DNewton%26aufirst%3DT.%26aulast%3DPeters%26aufirst%3DS.%26aulast%3DWilley-Courand%26aufirst%3DD.%2BB.%26aulast%3DNaureckas%26aufirst%3DE.%2BT.%26atitle%3DCystic%2520Fibrosis%2520Foundation%2520Pulmonary%2520Guidelines.%2520Use%2520of%2520Cystic%2520Fibrosis%2520Transmembrane%2520Conductance%2520Regulator%2520Modulator%2520Therapy%2520in%2520Patients%2520with%2520Cystic%2520Fibrosis%26jtitle%3DAnn.%2520Am.%2520Thorac.%2520Soc.%26date%3D2018%26volume%3D15%26spage%3D271%26epage%3D280%26doi%3D10.1513%2FAnnalsATS.201707-539OT" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit220c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Middleton, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mall, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drevinek, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lands, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKone, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polineni, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsey, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor-Cousar, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tullis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vermeulen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marigowda, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKee, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moskowitz, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savage, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waltz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xuan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowe, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, R.</span></span> <span> </span><span class="NLM_article-title">Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>381</i></span>,  <span class="NLM_fpage">1809</span>– <span class="NLM_lpage">1819</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1908639</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref220/cit220c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1056%2FNEJMoa1908639" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref220/cit220c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31697873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref220/cit220c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFejs7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=381&publication_year=2019&pages=1809-1819&author=P.+G.+Middletonauthor=M.+A.+Mallauthor=P.+Drevinekauthor=L.+C.+Landsauthor=E.+F.+McKoneauthor=D.+Polineniauthor=B.+W.+Ramseyauthor=J.+L.+Taylor-Cousarauthor=E.+Tullisauthor=F.+Vermeulenauthor=G.+Marigowdaauthor=C.+M.+McKeeauthor=S.+M.+Moskowitzauthor=N.+Nairauthor=J.+Savageauthor=C.+Simardauthor=S.+Tianauthor=D.+Waltzauthor=F.+Xuanauthor=S.+M.+Roweauthor=R.+Jain&title=Elexacaftor%E2%80%93Tezacaftor%E2%80%93Ivacaftor+for+Cystic+Fibrosis+with+a+Single+Phe508del+Allele&doi=10.1056%2FNEJMoa1908639"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit220cR"><div class="casContent"><span class="casTitleNuber">220c</span><div class="casTitle"><span class="NLM_cas:atitle">Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele</span></div><div class="casAuthors">Middleton, P. G.; Mall, M. A.; Drevinek, P.; Lands, L. C.; McKone, E. F.; Polineni, D.; Ramsey, B. W.; Taylor-Cousar, J. L.; Tullis, E.; Vermeulen, F.; Marigowda, G.; McKee, C. M.; Moskowitz, S. M.; Nair, N.; Savage, J.; Simard, C.; Tian, S.; Waltz, D.; Xuan, F.; Rowe, S. M.; Jain, R.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">381</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1809-1819</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Cystic fibrosis is caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) protein, and nearly 90% of patients have at least one copy of the Phe508del CFTR mutation.  In a phase 2 trial involving patients who were heterozygous for the Phe508del CFTR mutation and a minimal-function mutation (Phe508del-minimal function genotype), the next-generation CFTR corrector elexacaftor, in combination with tezacaftor and ivacaftor, improved Phe508del CFTR function and clin. outcomes.  Methods We conducted a phase 3, randomized, double-blind, placebo-controlled trial to confirm the efficacy and safety of elexacaftor-tezacaftor-ivacaftor in patients 12 years of age or older with cystic fibrosis with Phe508del-minimal function genotypes.  Patients were randomly assigned to receive elexacaftor-tezacaftor-ivacaftor or placebo for 24 wk.  The primary end point was abs. change from baseline in percentage of predicted forced expiratory vol. in 1 s (FEV1) at week 4.  Results A total of 403 patients underwent randomization and received at least one dose of active treatment or placebo.  Elexacaftor-tezacaftor-ivacaftor, relative to placebo, resulted in a percentage of predicted FEV1 that was 13.8 points higher at 4 wk and 14.3 points higher through 24 wk, a rate of pulmonary exacerbations that was 63% lower, a respiratory domain score on the Cystic Fibrosis Questionnaire-Revised (range, 0 to 100, with higher scores indicating a higher patient-reported quality of life with regard to respiratory symptoms; min. clin. important difference, 4 points) that was 20.2 points higher, and a sweat chloride concn. that was 41.8 mmol per L lower (P<0.001 for all comparisons).  Elexacaftor-tezacaftor-ivacaftor was generally safe and had an acceptable side-effect profile.  Most patients had adverse events that were mild or moderate.  Adverse events leading to discontinuation of the trial regimen occurred in 1% of the patients in the elexacaftor-tezacaftor-ivacaftor group.  Conclusions Elexacaftor-tezacaftor-ivacaftor was efficacious in patients with cystic fibrosis with Phe508del-minimal function genotypes, in whom previous CFTR modulator regimens were ineffective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCpB_nCizrq7Vg90H21EOLACvtfcHk0lgmhrHJ56BrIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFejs7vL&md5=ceacdc28020bb2a97ad32dd14a2aae95</span></div><a href="/servlet/linkout?suffix=cit220c&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1908639&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1908639%26sid%3Dliteratum%253Aachs%26aulast%3DMiddleton%26aufirst%3DP.%2BG.%26aulast%3DMall%26aufirst%3DM.%2BA.%26aulast%3DDrevinek%26aufirst%3DP.%26aulast%3DLands%26aufirst%3DL.%2BC.%26aulast%3DMcKone%26aufirst%3DE.%2BF.%26aulast%3DPolineni%26aufirst%3DD.%26aulast%3DRamsey%26aufirst%3DB.%2BW.%26aulast%3DTaylor-Cousar%26aufirst%3DJ.%2BL.%26aulast%3DTullis%26aufirst%3DE.%26aulast%3DVermeulen%26aufirst%3DF.%26aulast%3DMarigowda%26aufirst%3DG.%26aulast%3DMcKee%26aufirst%3DC.%2BM.%26aulast%3DMoskowitz%26aufirst%3DS.%2BM.%26aulast%3DNair%26aufirst%3DN.%26aulast%3DSavage%26aufirst%3DJ.%26aulast%3DSimard%26aufirst%3DC.%26aulast%3DTian%26aufirst%3DS.%26aulast%3DWaltz%26aufirst%3DD.%26aulast%3DXuan%26aufirst%3DF.%26aulast%3DRowe%26aufirst%3DS.%2BM.%26aulast%3DJain%26aufirst%3DR.%26atitle%3DElexacaftor%25E2%2580%2593Tezacaftor%25E2%2580%2593Ivacaftor%2520for%2520Cystic%2520Fibrosis%2520with%2520a%2520Single%2520Phe508del%2520Allele%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2019%26volume%3D381%26spage%3D1809%26epage%3D1819%26doi%3D10.1056%2FNEJMoa1908639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref221"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref221'); return false;" data-citation="" class="refNumLink">221</a></strong><div class="NLM_citation" id="cit221"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deeks, E. D.</span></span> <span> </span><span class="NLM_article-title">Lumacaftor/Ivacaftor: A Review in Cystic Fibrosis</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">1191</span>– <span class="NLM_lpage">1201</span>, <span class="refDoi"> DOI: 10.1007/s40265-016-0611-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs40265-016-0611-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=27394157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFOmu7bO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=1191-1201&author=E.+D.+Deeks&title=Lumacaftor%2FIvacaftor%3A+A+Review+in+Cystic+Fibrosis&doi=10.1007%2Fs40265-016-0611-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit221R"><div class="casContent"><span class="casTitleNuber">221</span><div class="casTitle"><span class="NLM_cas:atitle">Lumacaftor/Ivacaftor: A Review in Cystic Fibrosis</span></div><div class="casAuthors">Deeks, Emma D.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1191-1201</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Lumacaftor/ivacaftor (Orkambi) is a fixed-dose tablet contg. a corrector (lumacaftor) and potentiator (ivacaftor) of the cystic fibrosis transmembrane conductance regulator (CFTR) and is the first therapy approved to treat the underlying cause of cystic fibrosis in patients (aged ≥12 years) homozygous for the most common CFTR mutation, F508del.  Lumacaftor improves the processing of F508del CFTR and its transport to the cell surface, while ivacaftor increases the channel's open probability and transport of chloride.  In two 24-wk trials in the approved patient population (TRAFFIC and TRANSPORT), lumacaftor 400 mg plus ivacaftor 250 mg, administered every 12 h in combination with std. therapy, was assocd. with an ≈3 % statistically significant improvement in lung function relative to placebo (as measured by the percent predicted forced expiratory vol. in 1 s).  Lumacaftor plus ivacaftor did not significantly improve respiratory symptoms, although reduced pulmonary exacerbations to a clin. meaningful extent and, in one trial (TRANSPORT), significantly improved body mass index (BMI).  In an ongoing extension of these studies (PROGRESS), lumacaftor plus ivacaftor provided clin. benefit over a further 72 wk of treatment.  Lumacaftor plus ivacaftor had an acceptable tolerability profile, with the most common adverse events being respiratory or gastrointestinal in nature.  Thus, lumacaftor/ivacaftor expands the treatment options available for patients with cystic fibrosis homozygous for the F508del-CFTR mutation, although its precise place in clin. practice remains to be detd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpf0VxmHuTgI7Vg90H21EOLACvtfcHk0lgmhrHJ56BrIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFOmu7bO&md5=7be2b21495bde10b6ed5eb826e53613f</span></div><a href="/servlet/linkout?suffix=cit221&amp;dbid=16384&amp;doi=10.1007%2Fs40265-016-0611-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-016-0611-2%26sid%3Dliteratum%253Aachs%26aulast%3DDeeks%26aufirst%3DE.%2BD.%26atitle%3DLumacaftor%252FIvacaftor%253A%2520A%2520Review%2520in%2520Cystic%2520Fibrosis%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26spage%3D1191%26epage%3D1201%26doi%3D10.1007%2Fs40265-016-0611-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref222"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref222'); return false;" data-citation="" class="refNumLink">222</a></strong><div class="NLM_citation" id="cit222a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Gentzsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mall, M. A.</span></span> <span> </span><span class="NLM_article-title">Ion Channel Modulators in Cystic Fibrosis</span>. <i>Chest</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>154</i></span>,  <span class="NLM_fpage">383</span>– <span class="NLM_lpage">393</span>, <span class="refDoi"> DOI: 10.1016/j.chest.2018.04.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref222/cit222a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2Fj.chest.2018.04.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref222/cit222a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=29750923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref222/cit222a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A280%3ADC%252BC1Mfit1eqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2018&pages=383-393&author=M.+Gentzschauthor=M.+A.+Mall&title=Ion+Channel+Modulators+in+Cystic+Fibrosis&doi=10.1016%2Fj.chest.2018.04.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit222aR"><div class="casContent"><span class="casTitleNuber">222a</span><div class="casTitle"><span class="NLM_cas:atitle">Ion Channel Modulators in Cystic Fibrosis</span></div><div class="casAuthors">Gentzsch Martina; Mall Marcus A</div><div class="citationInfo"><span class="NLM_cas:title">Chest</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">383-393</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cystic fibrosis (CF) is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene and remains one of the most common life-shortening genetic diseases affecting the lung and other organs.  CFTR functions as a cyclic adenosine monophosphate-dependent anion channel that transports chloride and bicarbonate across epithelial surfaces, and disruption of these ion transport processes plays a central role in the pathogenesis of CF.  These findings provided the rationale for pharmacologic modulation of ion transport, either by targeting mutant CFTR or alternative ion channels that can compensate for CFTR dysfunction, as a promising therapeutic approach.  High-throughput screening has supported the development of CFTR modulator compounds.  CFTR correctors are designed to improve defective protein processing, trafficking, and cell surface expression, whereas potentiators increase the activity of mutant CFTR at the cell surface.  The approval of the first potentiator ivacaftor for the treatment of patients with specific CFTR mutations and, more recently, the corrector lumacaftor in combination with ivacaftor for patients homozygous for the common F508del mutation, were major breakthroughs on the path to causal therapies for all patients with CF.  The present review focuses on recent developments and remaining challenges of CFTR-directed therapies, as well as modulators of other ion channels such as alternative chloride channels and the epithelial sodium channel as additional targets in CF lung disease.  We further discuss how patient-derived precision medicine models may aid the translation of emerging next-generation ion channel modulators from the laboratory to the clinic and tailor their use for optimal therapeutic benefits in individual patients with CF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQAT7Rgd2Xw98SzjBFCN0BJfW6udTcc2ebchiB8LUhHT7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mfit1eqsw%253D%253D&md5=989ae3cd410621d14458af13ad6cf857</span></div><a href="/servlet/linkout?suffix=cit222a&amp;dbid=16384&amp;doi=10.1016%2Fj.chest.2018.04.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chest.2018.04.036%26sid%3Dliteratum%253Aachs%26aulast%3DGentzsch%26aufirst%3DM.%26aulast%3DMall%26aufirst%3DM.%2BA.%26atitle%3DIon%2520Channel%2520Modulators%2520in%2520Cystic%2520Fibrosis%26jtitle%3DChest%26date%3D2018%26volume%3D154%26spage%3D383%26epage%3D393%26doi%3D10.1016%2Fj.chest.2018.04.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit222b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Doull, I.</span></span> <span> </span><span class="NLM_article-title">Cystic Fibrosis 2019: Year in Review</span>. <i>Paediatr. Respir. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">95</span>– <span class="NLM_lpage">98</span>, <span class="refDoi"> DOI: 10.1016/j.prrv.2020.04.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref222/cit222b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2Fj.prrv.2020.04.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref222/cit222b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=32359945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref222/cit222b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A280%3ADC%252BB38vitFChtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2020&pages=95-98&author=I.+Doull&title=Cystic+Fibrosis+2019%3A+Year+in+Review&doi=10.1016%2Fj.prrv.2020.04.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit222bR"><div class="casContent"><span class="casTitleNuber">222b</span><div class="casTitle"><span class="NLM_cas:atitle">Cystic fibrosis 2019: Year in review</span></div><div class="casAuthors">Doull Iolo</div><div class="citationInfo"><span class="NLM_cas:title">Paediatric respiratory reviews</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">95-98</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The evidence base for modulator therapies in cystic fibrosis (CF) has continued to expand, and it is likely that up to 90% of people with CF could benefit.  Worldwide there are however marked inequalities of access to basic CF care and modulator therapies.  For infants and young children there is now an evidence base for inhaled hypertonic saline.  There is increasing evidence that structural lung disease in CF is not due purely to infection and that mucus retention and inflammation are also key, and further evidence of the value of azithromycin in those chronically infected with Pseudomonas aeruginosa.  Finally, exercise is good for you, but airway clearance is better for mucus clearance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR8kxIIBrn_dDEwO064Z95rfW6udTcc2ebchiB8LUhHT7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38vitFChtw%253D%253D&md5=658e8f2428826b49bad29f1b80bab472</span></div><a href="/servlet/linkout?suffix=cit222b&amp;dbid=16384&amp;doi=10.1016%2Fj.prrv.2020.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.prrv.2020.04.001%26sid%3Dliteratum%253Aachs%26aulast%3DDoull%26aufirst%3DI.%26atitle%3DCystic%2520Fibrosis%25202019%253A%2520Year%2520in%2520Review%26jtitle%3DPaediatr.%2520Respir.%2520Rev.%26date%3D2020%26volume%3D35%26spage%3D95%26epage%3D98%26doi%3D10.1016%2Fj.prrv.2020.04.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit222c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farzal, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniels, M. L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorp, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanation, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senior, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebert, C. S.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimple, A. J.</span></span> <span> </span><span class="NLM_article-title">Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A Review for the Otolaryngologist</span>. <i>Am. J. Rhinol. Allergy</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">573</span>– <span class="NLM_lpage">580</span>, <span class="refDoi"> DOI: 10.1177/1945892420912368</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref222/cit222c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1177%2F1945892420912368" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref222/cit222c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=32168995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref222/cit222c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A280%3ADC%252BB383jtFeisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2020&pages=573-580&author=S.+E.+Leeauthor=Z.+Farzalauthor=M.+L.+A.+Danielsauthor=B.+D.+Thorpauthor=A.+M.+Zanationauthor=B.+A.+Seniorauthor=C.+S.+Ebertauthor=A.+J.+Kimple&title=Cystic+Fibrosis+Transmembrane+Conductance+Regulator+Modulator+Therapy%3A+A+Review+for+the+Otolaryngologist&doi=10.1177%2F1945892420912368"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit222cR"><div class="casContent"><span class="casTitleNuber">222c</span><div class="casTitle"><span class="NLM_cas:atitle">Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A Review for the Otolaryngologist</span></div><div class="casAuthors">Lee Saangyoung E; Farzal Zainab; Thorp Brian D; Zanation Adam M; Senior Brent A; Ebert Charles S Jr; Kimple Adam J; Daniels M Leigh Anne</div><div class="citationInfo"><span class="NLM_cas:title">American journal of rhinology & allergy</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">573-580</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Cystic fibrosis (CF) is a genetic disease that may result in multiple systemic disorders and potentially fatal severe respiratory compromise.  However, the advent of CF transmembrane conductance regulator (CFTR) modulators has changed the management of CF for patients with select mutations.  Although clinical trials have highlighted increased pulmonary function and decreased exacerbations as a result of these novel therapies, their effect on the sinuses has not been well-described.  OBJECTIVE:  Our objective is to review the CFTR modulators to provide otolaryngologists, physicians who frequently care for patients with CF, a basic understanding of these drugs and their effects on chronic rhinosinusitis (CRS) in patients with CF.  METHODS:  The clinically approved and available CFTR modulators and specific indications for their use are reviewed.  Additionally, a systematic review of these therapies and effects on CRS in CF was performed.  RESULTS:  Four Food and Drug Administration approved CFTR modulators are available for patients with CF.  Current drugs are approved for gating, residual function, or F508del mutations.  Multiple reports describe CFTR modulators' increase in transepithelial ion transport in nasal epithelial cultures; however, clinical studies regarding effects of these modulators on sinonasal health are limited to 5 studies that present new data of the effects of CFTR modulators in CRS.  CONCLUSIONS:  CFTR modulators have changed management of CF.  Initial studies of these medications demonstrate promising results in CF; however, there is a paucity of literature describing the effect of CFTR modulators on CF-associated CRS, although initial results are encouraging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQFVkX2We16UAHqQV89nF-2fW6udTcc2ebchiB8LUhHT7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB383jtFeisA%253D%253D&md5=779e3c356350e02006fd8a605c74f3c4</span></div><a href="/servlet/linkout?suffix=cit222c&amp;dbid=16384&amp;doi=10.1177%2F1945892420912368&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1945892420912368%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DS.%2BE.%26aulast%3DFarzal%26aufirst%3DZ.%26aulast%3DDaniels%26aufirst%3DM.%2BL.%2BA.%26aulast%3DThorp%26aufirst%3DB.%2BD.%26aulast%3DZanation%26aufirst%3DA.%2BM.%26aulast%3DSenior%26aufirst%3DB.%2BA.%26aulast%3DEbert%26aufirst%3DC.%2BS.%26aulast%3DKimple%26aufirst%3DA.%2BJ.%26atitle%3DCystic%2520Fibrosis%2520Transmembrane%2520Conductance%2520Regulator%2520Modulator%2520Therapy%253A%2520A%2520Review%2520for%2520the%2520Otolaryngologist%26jtitle%3DAm.%2520J.%2520Rhinol.%2520Allergy%26date%3D2020%26volume%3D34%26spage%3D573%26epage%3D580%26doi%3D10.1177%2F1945892420912368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref223"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref223'); return false;" data-citation="" class="refNumLink">223</a></strong><div class="NLM_citation" id="cit223a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Abela, A. R.</span>; <span class="NLM_string-name">Alcacio, T.</span>; <span class="NLM_string-name">Anderson, C.</span>; <span class="NLM_string-name">Angell, P. T.</span>; <span class="NLM_string-name">Baek, M.</span>; <span class="NLM_string-name">Clemens, J. J.</span>; <span class="NLM_string-name">Cleveland, T.</span>; <span class="NLM_string-name">Ferris, L. A.</span>; <span class="NLM_string-name">Grootenhuis, P. D. J.</span>; <span class="NLM_string-name">Gross, R. S.</span>; <span class="NLM_string-name">Gulevich, A.</span>; <span class="NLM_string-name">Hadida Ruah, S. S.</span>; <span class="NLM_string-name">Hsia, C. K.-J.</span>; <span class="NLM_string-name">Hughes, R. M.</span>; <span class="NLM_string-name">Joshi, P. V.</span>; <span class="NLM_string-name">Kang, P.</span>; <span class="NLM_string-name">Keshavarz-Shokri, A.</span>; <span class="NLM_string-name">Khatuya, H.</span>; <span class="NLM_string-name">Krenitsky, P. J.</span>; <span class="NLM_string-name">McCartney, J.</span>; <span class="NLM_string-name">Miller, M. T.</span>; <span class="NLM_string-name">Paraselli, P.</span>; <span class="NLM_string-name">Pierre, F. J. D.</span>; <span class="NLM_string-name">Shi, Y.</span>; <span class="NLM_string-name">Shrestha, M.</span>; <span class="NLM_string-name">Siesel, D. A.</span>; <span class="NLM_string-name">Stavropoulos, K.</span>; <span class="NLM_string-name">Termin, A. P.</span>; <span class="NLM_string-name">Uy, J.</span>; <span class="NLM_string-name">Van Goor, F. F.</span>; <span class="NLM_string-name">Young, T. J.</span>; <span class="NLM_string-name">Zhou, J.</span></span> <span> </span><span class="NLM_article-title">Preparation of N-Heteroaroylsulfonamide Derivatives as Cystic Fibrosis Transmembrane Conductance Regulator Modulators for Treatment of Cystic Fibrosis</span>. <span class="NLM_patent">WO 2018107100 A1</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=A.+R.+Abela&author=T.+Alcacio&author=C.+Anderson&author=P.+T.+Angell&author=M.+Baek&author=J.+J.+Clemens&author=T.+Cleveland&author=L.+A.+Ferris&author=P.+D.+J.+Grootenhuis&author=R.+S.+Gross&author=A.+Gulevich&author=S.+S.+Hadida+Ruah&author=C.+K.-J.+Hsia&author=R.+M.+Hughes&author=P.+V.+Joshi&author=P.+Kang&author=A.+Keshavarz-Shokri&author=H.+Khatuya&author=P.+J.+Krenitsky&author=J.+McCartney&author=M.+T.+Miller&author=P.+Paraselli&author=F.+J.+D.+Pierre&author=Y.+Shi&author=M.+Shrestha&author=D.+A.+Siesel&author=K.+Stavropoulos&author=A.+P.+Termin&author=J.+Uy&author=F.+F.+Van+Goor&author=T.+J.+Young&author=J.+Zhou&title=Preparation+of+N-Heteroaroylsulfonamide+Derivatives+as+Cystic+Fibrosis+Transmembrane+Conductance+Regulator+Modulators+for+Treatment+of+Cystic+Fibrosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit223a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAbela%26aufirst%3DA.%2BR.%26atitle%3DPreparation%2520of%2520N-Heteroaroylsulfonamide%2520Derivatives%2520as%2520Cystic%2520Fibrosis%2520Transmembrane%2520Conductance%2520Regulator%2520Modulators%2520for%2520Treatment%2520of%2520Cystic%2520Fibrosis%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit223b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Angell, P. T.</span>; <span class="NLM_string-name">Harrison, C.</span>; <span class="NLM_string-name">Hughes, R. M.</span>; <span class="NLM_string-name">Lewandowski, B.</span>; <span class="NLM_string-name">Littler, B. J.</span>; <span class="NLM_string-name">Melillo, V.</span>; <span class="NLM_string-name">Nugent, W. A.</span>; <span class="NLM_string-name">Siesel, D. A.</span>; <span class="NLM_string-name">Smith, D.</span>; <span class="NLM_string-name">Studley, J.</span></span> <span> </span><span class="NLM_article-title">Processes for Making 6-Pyrazolo-2-pyrrolidinonicotinamides as Modulators of Cystic Fibrosis Transmembrane Conductance Regulator</span>. <span class="NLM_patent">WO 2019113476 A2</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=P.+T.+Angell&author=C.+Harrison&author=R.+M.+Hughes&author=B.+Lewandowski&author=B.+J.+Littler&author=V.+Melillo&author=W.+A.+Nugent&author=D.+A.+Siesel&author=D.+Smith&author=J.+Studley&title=Processes+for+Making+6-Pyrazolo-2-pyrrolidinonicotinamides+as+Modulators+of+Cystic+Fibrosis+Transmembrane+Conductance+Regulator"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit223b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAngell%26aufirst%3DP.%2BT.%26atitle%3DProcesses%2520for%2520Making%25206-Pyrazolo-2-pyrrolidinonicotinamides%2520as%2520Modulators%2520of%2520Cystic%2520Fibrosis%2520Transmembrane%2520Conductance%2520Regulator%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit223c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Haseltine, E. L.</span>; <span class="NLM_string-name">Moskowitz, S.</span>; <span class="NLM_string-name">Robertson, S.</span>; <span class="NLM_string-name">Waltz, D.</span></span> <span> </span><span class="NLM_article-title">Methods of Treatment for Cystic Fibrosis</span>. <span class="NLM_patent">WO 2019018395 A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=E.+L.+Haseltine&author=S.+Moskowitz&author=S.+Robertson&author=D.+Waltz&title=Methods+of+Treatment+for+Cystic+Fibrosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit223c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHaseltine%26aufirst%3DE.%2BL.%26atitle%3DMethods%2520of%2520Treatment%2520for%2520Cystic%2520Fibrosis%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit223d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Abela, A. R.</span>; <span class="NLM_string-name">Clemens, J. J.</span>; <span class="NLM_string-name">Grootenhuis, P. D. J.</span>; <span class="NLM_string-name">Hadida Ruah, S. S.</span>; <span class="NLM_string-name">Ishihara, Y.</span>; <span class="NLM_string-name">Khatuya, H.</span>; <span class="NLM_string-name">McCartney, J.</span>; <span class="NLM_string-name">Miller, M. T.</span>; <span class="NLM_string-name">Pierre, F. J. D.</span>; <span class="NLM_string-name">Tran, J. A.</span>; <span class="NLM_string-name">Zhou, J.</span></span> <span> </span><span class="NLM_article-title">Preparation of Pyrazolylsulfonyl Pyridinamides as Modulators of Cystic Fibrosis Transmembrane Conductance Regulator, and Pharmaceutical Compositions with Them</span>. <span class="NLM_patent">WO 2019200246 A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=A.+R.+Abela&author=J.+J.+Clemens&author=P.+D.+J.+Grootenhuis&author=S.+S.+Hadida+Ruah&author=Y.+Ishihara&author=H.+Khatuya&author=J.+McCartney&author=M.+T.+Miller&author=F.+J.+D.+Pierre&author=J.+A.+Tran&author=J.+Zhou&title=Preparation+of+Pyrazolylsulfonyl+Pyridinamides+as+Modulators+of+Cystic+Fibrosis+Transmembrane+Conductance+Regulator%2C+and+Pharmaceutical+Compositions+with+Them"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit223d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAbela%26aufirst%3DA.%2BR.%26atitle%3DPreparation%2520of%2520Pyrazolylsulfonyl%2520Pyridinamides%2520as%2520Modulators%2520of%2520Cystic%2520Fibrosis%2520Transmembrane%2520Conductance%2520Regulator%252C%2520and%2520Pharmaceutical%2520Compositions%2520with%2520Them%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref224"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref224'); return false;" data-citation="" class="refNumLink">224</a></strong><div class="NLM_citation" id="cit224"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, D. L.</span></span> <span> </span><span class="NLM_article-title">Patent Review of Synthetic Routes and Crystalline Forms of the CFTR-Modulator Drugs Ivacaftor, Lumacaftor, Tezacaftor, and Elexacaftor</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">2302</span>– <span class="NLM_lpage">2322</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.9b00326</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.9b00326" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVSks7zE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2019&pages=2302-2322&author=D.+L.+Hughes&title=Patent+Review+of+Synthetic+Routes+and+Crystalline+Forms+of+the+CFTR-Modulator+Drugs+Ivacaftor%2C+Lumacaftor%2C+Tezacaftor%2C+and+Elexacaftor&doi=10.1021%2Facs.oprd.9b00326"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit224R"><div class="casContent"><span class="casTitleNuber">224</span><div class="casTitle"><span class="NLM_cas:atitle">Patent Review of Synthetic Routes and Crystalline Forms of the CFTR-Modulator Drugs Ivacaftor, Lumacaftor, Tezacaftor, and Elexacaftor</span></div><div class="casAuthors">Hughes, David L.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2302-2322</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This review surveys synthetic routes and polymorphic forms of the three approved CFTR-modulators ivacaftor, lumacaftor, and tezacaftor and one Phase 3 development candidate, elexacaftor.  The patent literature was the source of information for synthetic routes and final forms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVcZY11vRm77Vg90H21EOLACvtfcHk0lhgV_8KdNLggg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVSks7zE&md5=f0cc8adf71401cb3aa7de566a51ddc71</span></div><a href="/servlet/linkout?suffix=cit224&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.9b00326&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.9b00326%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DD.%2BL.%26atitle%3DPatent%2520Review%2520of%2520Synthetic%2520Routes%2520and%2520Crystalline%2520Forms%2520of%2520the%2520CFTR-Modulator%2520Drugs%2520Ivacaftor%252C%2520Lumacaftor%252C%2520Tezacaftor%252C%2520and%2520Elexacaftor%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2019%26volume%3D23%26spage%3D2302%26epage%3D2322%26doi%3D10.1021%2Facs.oprd.9b00326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref225"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref225'); return false;" data-citation="" class="refNumLink">225</a></strong><div class="NLM_citation" id="cit225"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westfahl, J. C.</span></span> <span> </span><span class="NLM_article-title">Rearrangement of 2,2,6,6-Tetramethyl-4-piperidone in Phase-Transfer Catalyzed Reactions</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1980</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">1513</span>– <span class="NLM_lpage">1514</span>, <span class="refDoi"> DOI: 10.1021/jo01296a034</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo01296a034" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADyaL3cXhvFyhsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=1980&pages=1513-1514&author=J.+T.+Laiauthor=J.+C.+Westfahl&title=Rearrangement+of+2%2C2%2C6%2C6-Tetramethyl-4-piperidone+in+Phase-Transfer+Catalyzed+Reactions&doi=10.1021%2Fjo01296a034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit225R"><div class="casContent"><span class="casTitleNuber">225</span><div class="casTitle"><span class="NLM_cas:atitle">Rearrangement of 2,2,6,6-tetramethyl-4-piperidone in phase-transfer catalyzed reactions</span></div><div class="casAuthors">Lai, John T.; Westfahl, Jerry C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1980</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1513-14</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    </div><div class="casAbstract">When 2,2,6,6-tetramethyl-4-piperidone hydrate was treated with CHCl3 and 50% NaOH in the presence of a phase-transfer catalyst (e.g. PhCH2N+Et3Cl-), it rearranged to N-isopropenyl-3-methylene-5,5-dimethyl-2-pyrrolidinone(I) and 3-methylene-5,5-dimethyl-2-pyrrolidinone (II).  I was the major product.  II became predominant when an equal molar amt. of piperidine was added.  Trichloromethide, not dichlorocarbene, was the reactive intermediate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPpdVbo57aSLVg90H21EOLACvtfcHk0lgHyS2y-shJKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3cXhvFyhsbo%253D&md5=c2f654941bbd3305a6d63fd34a5d890c</span></div><a href="/servlet/linkout?suffix=cit225&amp;dbid=16384&amp;doi=10.1021%2Fjo01296a034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo01296a034%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DJ.%2BT.%26aulast%3DWestfahl%26aufirst%3DJ.%2BC.%26atitle%3DRearrangement%2520of%25202%252C2%252C6%252C6-Tetramethyl-4-piperidone%2520in%2520Phase-Transfer%2520Catalyzed%2520Reactions%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1980%26volume%3D45%26spage%3D1513%26epage%3D1514%26doi%3D10.1021%2Fjo01296a034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1a','cit1b','cit1c','cit1d','cit1e','cit1f','cit1g','cit1h','cit1i','cit1j','cit1k','cit1l','cit1m','cit1n','cit1o','cit1p','cit1q'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4a','cit4b'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7a','cit7b','cit7c'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13a','cit13b'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16a','cit16b'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19a','cit19b'],'ref20':['cit20'],'ref21':['cit21a','cit21b','cit21c'],'ref22':['cit22a','cit22b','cit22c','cit22d','cit22e'],'ref23':['cit23a','cit23b'],'ref24':['cit24a','cit24b','cit24c','cit24d','cit24e'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27a','cit27b','cit27c'],'ref28':['cit28a','cit28b','cit28c','cit28d','cit28e','cit28f','cit28g','cit28h'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31a','cit31b'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35a','cit35b'],'ref36':['cit36a','cit36b','cit36c'],'ref37':['cit37a','cit37b'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44a','cit44b'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47a','cit47b'],'ref48':['cit48'],'ref49':['cit49a','cit49b'],'ref50':['cit50a','cit50b'],'ref51':['cit51a','cit51b'],'ref52':['cit52a','cit52b','cit52c'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62a','cit62b'],'ref63':['cit63a','cit63b'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67a','cit67b'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74a','cit74b'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78a','cit78b','cit78c','cit78d'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82a','cit82b'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85a','cit85b'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94a','cit94b'],'ref95':['cit95'],'ref96':['cit96a','cit96b','cit96c','cit96d'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105a','cit105b'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109a','cit109b','cit109c'],'ref110':['cit110'],'ref111':['cit111a','cit111b'],'ref112':['cit112'],'ref113':['cit113a','cit113b','cit113c'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131a','cit131b','cit131c'],'ref132':['cit132a','cit132b'],'ref133':['cit133a','cit133b','cit133c'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140a','cit140b'],'ref141':['cit141'],'ref142':['cit142a','cit142b'],'ref143':['cit143a','cit143b','cit143c','cit143d'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147a','cit147b'],'ref148':['cit148'],'ref149':['cit149a','cit149b'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152a','cit152b','cit152c','cit152d','cit152e'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156a','cit156b'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175a','cit175b','cit175c','cit175d','cit175e','cit175f','cit175g'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178'],'ref179':['cit179'],'ref180':['cit180'],'ref181':['cit181'],'ref182':['cit182'],'ref183':['cit183'],'ref184':['cit184'],'ref185':['cit185a','cit185b'],'ref186':['cit186'],'ref187':['cit187'],'ref188':['cit188a','cit188b'],'ref189':['cit189'],'ref190':['cit190'],'ref191':['cit191'],'ref192':['cit192'],'ref193':['cit193a','cit193b'],'ref194':['cit194'],'ref195':['cit195'],'ref196':['cit196'],'ref197':['cit197'],'ref198':['cit198a','cit198b'],'ref199':['cit199'],'ref200':['cit200a','cit200b'],'ref201':['cit201'],'ref202':['cit202'],'ref203':['cit203'],'ref204':['cit204'],'ref205':['cit205'],'ref206':['cit206'],'ref207':['cit207'],'ref208':['cit208'],'ref209':['cit209a','cit209b'],'ref210':['cit210'],'ref211':['cit211'],'ref212':['cit212'],'ref213':['cit213'],'ref214':['cit214a','cit214b','cit214c'],'ref215':['cit215'],'ref216':['cit216a','cit216b'],'ref217':['cit217'],'ref218':['cit218'],'ref219':['cit219'],'ref220':['cit220a','cit220b','cit220c'],'ref221':['cit221'],'ref222':['cit222a','cit222b','cit222c'],'ref223':['cit223a','cit223b','cit223c','cit223d'],'ref224':['cit224'],'ref225':['cit225']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0067.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0067.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0002.jpeg" id="rightTab-GRAPHIC-d7e374-autogenerated" class="rightTab-fig internalNav" /></img><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0003.jpeg" id="rightTab-GRAPHIC-d7e375-autogenerated" class="rightTab-fig internalNav" /></img><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0004.jpeg" id="rightTab-GRAPHIC-d7e376-autogenerated" class="rightTab-fig internalNav" /></img><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0005.jpeg" id="rightTab-GRAPHIC-d7e377-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of the 40 NCEs approved in 2019.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0001.jpeg jm1c00208_0002.jpeg jm1c00208_0003.jpeg jm1c00208_0004.jpeg jm1c00208_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0009.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Cefiderocol Protected Catechol Fragment <b>7</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0010.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Cefiderocol (<b>I</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0011.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Lascufloxacin Fluoropyrrolidine Fragment <b>22</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0012.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Final Assembly of Lascufloxacin Hydrochloride (<b>II</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0013.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Lefamulin Cyclohexyl Fragment <b>34</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0070.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0070.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Lefamulin (<b>III</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0070.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0014.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of Pretomanid (<b>IV</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0015.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Preparation of Relebactam Piperidine <b>51</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0016.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Synthesis of Relebactam (<b>V</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch10" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0017.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Synthesis of Triclabendazole (<b>VI</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch11" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0018.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 11. Synthesis of Esaxerenone (<b>VII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch12" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0019.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 12. Synthesis of Voxelotor (<b>VIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch13" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0020.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 13. Synthesis of Brexanolone (<b>IX</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch14" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0021.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 14. Synthesis of Cenobamate (<b>X</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch15" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0022.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 15. Eli Lilly Synthesis of Lasmiditan (<b>XI</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch16" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0023.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 16. Synthesis of Lemborexant (<b>XII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch17" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Scheme 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0024.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 17. Synthesis of Lumateperone (<b>XIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch18" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Scheme 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0025.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 18. Synthesis of Mirogabalin Besylate (<b>XIV</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch19" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Scheme 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0026.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 19. Synthesis of Remimazolam Tosylate (<b>XV</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch20" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Scheme 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0027.jpeg" id="rightTab-gr23" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 20. Synthesis of Solriamfetol (<b>XVI</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch21" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Scheme 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0028.jpeg" id="rightTab-gr24" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 21. Synthesis of Ubrogepant Aminopiperidinone Fragment <b>140</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch22" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Scheme 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0029.jpeg" id="rightTab-gr25" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 22. Synthesis of Ubrogepant Pyrrolidinone <b>143</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch23" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Scheme 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0030.jpeg" id="rightTab-gr26" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 23. Synthesis of Ubrogepant Acid Fragment <b>153</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch24" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Scheme 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0031.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0031.jpeg" id="rightTab-gr27" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 24. Final Assembly of Ubrogepant (<b>XVII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch25" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Scheme 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0032.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0032.jpeg" id="rightTab-gr28" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 25. Synthesis of Benvitimod (<b>XVIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch25"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch26" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Scheme 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0033.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0033.jpeg" id="rightTab-gr29" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 26. Synthesis of Trifarotene (<b>XIX</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0033.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch26"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch27" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Scheme 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0034.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0034.jpeg" id="rightTab-gr30" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 27. Synthesis of Tenapanor Hydrochloride (<b>XX</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0034.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch27"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch28" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Scheme 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0035.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0035.jpeg" id="rightTab-gr31" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 28. Synthesis of Peficitinib Chloropyridine Derivative <b>181</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0035.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch28"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch29" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Scheme 29</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0036.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0036.jpeg" id="rightTab-gr32" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 29. Synthesis of Peficitinib Hydrobromide (<b>XXI</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0036.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch29"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch30" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Scheme 30</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0037.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0037.jpeg" id="rightTab-gr33" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 30. Synthesis of Upadacitinib Ethyl Carbamate <b>191</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0037.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch30"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch31" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Scheme 31</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0038.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0038.jpeg" id="rightTab-gr34" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 31. Synthesis of Upadacitinib (<b>XXII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0038.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch31"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch32" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Scheme 32</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0039.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0039.jpeg" id="rightTab-gr35" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 32. Synthesis of Remogliflozin Etabonate (<b>XXIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0039.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch32"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch33" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Scheme 33</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0040.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0040.jpeg" id="rightTab-gr36" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 33. Synthesis of Aryl Iodide Fragment <b>211</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0040.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch33"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch34" data-index="35" class="article__inlineFigure"><h2 class="fig-label">Scheme 34</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0041.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0041.jpeg" id="rightTab-gr37" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 34. Synthesis of Sotagliflozin (<b>XXIV</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0041.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch34"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch35" data-index="36" class="article__inlineFigure"><h2 class="fig-label">Scheme 35</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0042.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0042.jpeg" id="rightTab-gr38" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 35. Synthesis of Siponimod (<b>XXV</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0042.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch35"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch36" data-index="37" class="article__inlineFigure"><h2 class="fig-label">Scheme 36</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0043.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0043.jpeg" id="rightTab-gr39" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 36. Synthesis of Alpelisib (<b>XXVI</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0043.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch36"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="38" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0007.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Equilibrium of darolutamide (<b>XXVII</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch37" data-index="39" class="article__inlineFigure"><h2 class="fig-label">Scheme 37</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0044.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0044.jpeg" id="rightTab-gr40" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 37. Synthesis of Darolutamide (<b>XXVII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0044.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch37"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch38" data-index="40" class="article__inlineFigure"><h2 class="fig-label">Scheme 38</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0045.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0045.jpeg" id="rightTab-gr41" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 38. Synthesis of Enfortumab Vedotin (<b>XVIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0045.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch38"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch39" data-index="41" class="article__inlineFigure"><h2 class="fig-label">Scheme 39</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0046.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0046.jpeg" id="rightTab-gr42" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 39. Synthesis of Entrectinib Benzoic Acid Intermediate <b>258</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0046.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch39"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch40" data-index="42" class="article__inlineFigure"><h2 class="fig-label">Scheme 40</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0047.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0047.jpeg" id="rightTab-gr43" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 40. Synthesis of Entrectinib (<b>XXIX</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0047.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch40"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch41" data-index="43" class="article__inlineFigure"><h2 class="fig-label">Scheme 41</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0048.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0048.jpeg" id="rightTab-gr44" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 41. Synthesis of Erdafitinib (<b>XXX</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0048.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch41"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch42" data-index="44" class="article__inlineFigure"><h2 class="fig-label">Scheme 42</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0049.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0049.jpeg" id="rightTab-gr45" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 42. Synthesis of Fedratinib (<b>XXXI</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0049.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch42"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch43" data-index="45" class="article__inlineFigure"><h2 class="fig-label">Scheme 43</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0071.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0071.jpeg" id="rightTab-gr46" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 43. Synthesis of Fedratinib Aniline <b>274</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0071.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch43"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch44" data-index="46" class="article__inlineFigure"><h2 class="fig-label">Scheme 44</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0050.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0050.jpeg" id="rightTab-gr47" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 44. Synthesis of Flumatinib Mesylate (<b>XXXII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0050.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch44"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch45" data-index="47" class="article__inlineFigure"><h2 class="fig-label">Scheme 45</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0051.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0051.jpeg" id="rightTab-gr48" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 45. Synthesis of Flumatinib Amide <b>282</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0051.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch45"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch46" data-index="48" class="article__inlineFigure"><h2 class="fig-label">Scheme 46</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0052.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0052.jpeg" id="rightTab-gr49" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 46. Synthesis of Pexidartinib (<b>XXXIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0052.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch46"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch47" data-index="49" class="article__inlineFigure"><h2 class="fig-label">Scheme 47</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0053.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0053.jpeg" id="rightTab-gr50" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 47. Synthesis of Polatuzumab Vedotin (<b>XXXIV</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0053.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch47"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch48" data-index="50" class="article__inlineFigure"><h2 class="fig-label">Scheme 48</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0054.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0054.jpeg" id="rightTab-gr51" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 48. Synthesis of Quizartinib Dihydrochloride (<b>XXXV</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0054.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch48"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch49" data-index="51" class="article__inlineFigure"><h2 class="fig-label">Scheme 49</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0055.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0055.jpeg" id="rightTab-gr52" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 49. Synthesis of Selinexor (<b>XXXVI</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0055.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch49"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="52" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0008.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Approach to payload–linker assembly for trastuzumab deruxtecan (<b>XXXVII</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch50" data-index="53" class="article__inlineFigure"><h2 class="fig-label">Scheme 50</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0056.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0056.jpeg" id="rightTab-gr53" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 50. Synthesis of Exatecan Precursor <b>315</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0056.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch50"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch51" data-index="54" class="article__inlineFigure"><h2 class="fig-label">Scheme 51</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0057.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0057.jpeg" id="rightTab-gr54" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 51. Synthesis of Exatecan (<b>308</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0057.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch51"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch52" data-index="55" class="article__inlineFigure"><h2 class="fig-label">Scheme 52</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0058.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0058.jpeg" id="rightTab-gr55" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 52. Synthesis of Advanced Deruxtecan Linker Intermediate <b>325</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0058.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch52"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch53" data-index="56" class="article__inlineFigure"><h2 class="fig-label">Scheme 53</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0059.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0059.jpeg" id="rightTab-gr56" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 53. Synthesis of Deruxtecan (<b>307</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0059.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch53"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch54" data-index="57" class="article__inlineFigure"><h2 class="fig-label">Scheme 54</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0060.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0060.jpeg" id="rightTab-gr57" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 54. Conjugative Endgame for Trastuzumab Deruxtecan (<b>XXXVII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0060.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch54"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch55" data-index="58" class="article__inlineFigure"><h2 class="fig-label">Scheme 55</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0061.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0061.jpeg" id="rightTab-gr58" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 55. Synthesis of Zanubrutinib (<b>XXXVIII</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0061.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch55"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch56" data-index="59" class="article__inlineFigure"><h2 class="fig-label">Scheme 56</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0062.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0062.jpeg" id="rightTab-gr59" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 56. Synthesis of Zanubrutinib Vinylogous Amide <b>333</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0062.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch56"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch57" data-index="60" class="article__inlineFigure"><h2 class="fig-label">Scheme 57</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0063.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0063.jpeg" id="rightTab-gr60" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 57. Synthesis of Relugolix (<b>XXXIX</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0063.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch57"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch58" data-index="61" class="article__inlineFigure"><h2 class="fig-label">Scheme 58</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0064.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0064.jpeg" id="rightTab-gr61" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 58. Synthesis of Elexacaftor Pyrazole Fragment <b>354</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0064.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch58"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch59" data-index="62" class="article__inlineFigure"><h2 class="fig-label">Scheme 59</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0065.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0065.jpeg" id="rightTab-gr62" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 59. Preparation of Elexacaftor Pyrrolidine Salt <b>358</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0065.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch59"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch60" data-index="63" class="article__inlineFigure"><h2 class="fig-label">Scheme 60</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/medium/jm1c00208_0066.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0066.jpeg" id="rightTab-gr63" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 60. Synthesis of Elexacaftor (<b>XL</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00208/20210331/images/large/jm1c00208_0066.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00208&amp;id=sch60"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i132">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02245" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02245" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 225 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K. C.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2002 New Drugs</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">233</span>, <span class="refDoi"> DOI: 10.2174/1389557043487457</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.2174%2F1389557043487457" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=14965293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhvVWgu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=207-233&author=J.+Liauthor=K.+K.+C.+Liu&title=Synthetic+Approaches+to+the+2002+New+Drugs&doi=10.2174%2F1389557043487457"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2002 new drugs</span></div><div class="casAuthors">Li, Jin; Liu, Kevin K.-C.</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">207-233</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  In addn., these new chem. entities (NCEs) not only provide insights into mol. recognition, but also serve as drug-like leads for designing future new drugs.  Therefore, it is important to be acquainted with these new structures as well as their syntheses.  To these ends, this review covers the syntheses of 28 NCEs marketed in 2002.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGx8Y2c3smk7Vg90H21EOLACvtfcHk0lhnRgk4OaT6Gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhvVWgu7c%253D&md5=d93f443a242964b39e822ecb12ddacad</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.2174%2F1389557043487457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389557043487457%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DK.%2BK.%2BC.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202002%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2004%26volume%3D4%26spage%3D207%26epage%3D233%26doi%3D10.2174%2F1389557043487457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit1b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2004 New Drugs</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1133</span>– <span class="NLM_lpage">1144</span>, <span class="refDoi"> DOI: 10.2174/138955705774933329</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.2174%2F138955705774933329" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=16375759" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Gru77P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=1133-1144&author=J.+Liauthor=K.+K.+C.+Liuauthor=S.+Sakya&title=Synthetic+Approaches+to+the+2004+New+Drugs&doi=10.2174%2F138955705774933329"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2004 new drugs</span></div><div class="casAuthors">Li, Jin; Liu, Kevin K.-C.; Sakya, Subas</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1133-1144</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  In addn., these new chem. entities (NCEs) not only provide insights into mol. recognition, but also serve as leads for designing future drugs.  To this end, this review covers the syntheses of 12 NCEs marketed in 2004, such as azacitidine, duloxetine hydrochloride, etc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbXh0-pEnN47Vg90H21EOLACvtfcHk0lhnRgk4OaT6Gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Gru77P&md5=9593b6bfb38f08160e1b198f53b70a53</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.2174%2F138955705774933329&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955705774933329%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DK.%2BK.%2BC.%26aulast%3DSakya%26aufirst%3DS.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202004%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2005%26volume%3D5%26spage%3D1133%26epage%3D1144%26doi%3D10.2174%2F138955705774933329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit1c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2003 New Drugs</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1105</span>– <span class="NLM_lpage">1125</span>, <span class="refDoi"> DOI: 10.2174/1389557043402900</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.2174%2F1389557043402900" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=15579116" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVWitbfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=1105-1125&author=K.+K.-C.+Liuauthor=J.+Liauthor=S.+Sakya&title=Synthetic+Approaches+to+the+2003+New+Drugs&doi=10.2174%2F1389557043402900"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1cR"><div class="casContent"><span class="casTitleNuber">1c</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2003 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Li, Jin; Sakya, Subas</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1105-1125</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  In addn., these new chem. entities (NCEs) not only provide insights into mol. recognition, but also serve as drug-like leads for designing new future drugs.  To these ends, this review covers the syntheses of 23 NCEs marketed in 2003.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLauPqC1hEzbVg90H21EOLACvtfcHk0liD6xdmNnCFow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVWitbfO&md5=f3f6acd4fefd93ede895369105d1cefb</span></div><a href="/servlet/linkout?suffix=cit1c&amp;dbid=16384&amp;doi=10.2174%2F1389557043402900&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389557043402900%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DSakya%26aufirst%3DS.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202003%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2004%26volume%3D4%26spage%3D1105%26epage%3D1125%26doi%3D10.2174%2F1389557043402900" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit1d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K. C.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2005 New Drugs</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">429</span>– <span class="NLM_lpage">450</span>, <span class="refDoi"> DOI: 10.2174/138955707780363800</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.2174%2F138955707780363800" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=17430228" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BD2sXivV2hu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=429-450&author=S.+M.+Sakyaauthor=J.+Liauthor=K.+K.+C.+Liu&title=Synthetic+Approaches+to+the+2005+New+Drugs&doi=10.2174%2F138955707780363800"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1dR"><div class="casContent"><span class="casTitleNuber">1d</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2005 new drugs</span></div><div class="casAuthors">Sakya, Subas M.; Li, Jin; Liu, Kevin K.-C.</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">429-450</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  In addn., these new chem. entities (NCEs) not only provide insights into mol. recognition, but also serve as drug-like leads for designing future new drugs.  To these ends, this review covers the syntheses of 22 NCEs marketed in 2005.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpk_TvNK-ZG2LVg90H21EOLACvtfcHk0liD6xdmNnCFow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXivV2hu7g%253D&md5=cdbab18a11647fe6089fc6c6ded6ede9</span></div><a href="/servlet/linkout?suffix=cit1d&amp;dbid=16384&amp;doi=10.2174%2F138955707780363800&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955707780363800%26sid%3Dliteratum%253Aachs%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DK.%2BK.%2BC.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202005%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2007%26volume%3D7%26spage%3D429%26epage%3D450%26doi%3D10.2174%2F138955707780363800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit1e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2006 New Drugs</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1255</span>– <span class="NLM_lpage">1269</span>, <span class="refDoi"> DOI: 10.2174/138955707782795629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.2174%2F138955707782795629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=18220978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlKktr7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=1255-1269&author=K.+K.+C.+Liuauthor=S.+M.+Sakyaauthor=J.+Li&title=Synthetic+Approaches+to+the+2006+New+Drugs&doi=10.2174%2F138955707782795629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1eR"><div class="casContent"><span class="casTitleNuber">1e</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2006 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Sakya, Subas M.; Li, Jin</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1255-1269</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  In addn., these new chem. entities (NCEs) not only provide insights into mol. recognition, but also serve as drug-like leads for designing future new drugs.  To these ends, this review covers the syntheses of 16 NCEs marketed in 2006.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpX9HJKV9Z-pLVg90H21EOLACvtfcHk0ljwBJN0pk4QNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlKktr7K&md5=4d0a4be2d4e258c11f73792380a40078</span></div><a href="/servlet/linkout?suffix=cit1e&amp;dbid=16384&amp;doi=10.2174%2F138955707782795629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955707782795629%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.%2BC.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202006%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2007%26volume%3D7%26spage%3D1255%26epage%3D1269%26doi%3D10.2174%2F138955707782795629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit1f"><span><span class="NLM_label">(f) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2007 New Drugs</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1526</span>– <span class="NLM_lpage">1548</span>, <span class="refDoi"> DOI: 10.2174/138955708786786435</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.2174%2F138955708786786435" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1f&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=19075810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1f&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptFagtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=1526-1548&author=K.+K.+C.+Liuauthor=S.+M.+Sakyaauthor=C.+J.+O%E2%80%99Donnellauthor=J.+Li&title=Synthetic+Approaches+to+the+2007+New+Drugs&doi=10.2174%2F138955708786786435"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1fR"><div class="casContent"><span class="casTitleNuber">1f</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2007 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Sakya, Subas M.; O'Donnell, Christopher J.; Li, Jin</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1526-1548</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">This review covers the syntheses of 19 new chem. entities (NCEs) marketed in 2007.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  These NCEs provide insights into mol. recognition and also serve as leads for designing future new drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb2ujHwEzjb7Vg90H21EOLACvtfcHk0ljwBJN0pk4QNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptFagtw%253D%253D&md5=b2e378b89f153b6374a4aa375cf65fd7</span></div><a href="/servlet/linkout?suffix=cit1f&amp;dbid=16384&amp;doi=10.2174%2F138955708786786435&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955708786786435%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.%2BC.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202007%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2008%26volume%3D8%26spage%3D1526%26epage%3D1548%26doi%3D10.2174%2F138955708786786435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit1g"><span><span class="NLM_label">(g) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2008 New Drugs</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1655</span>– <span class="NLM_lpage">1675</span>, <span class="refDoi"> DOI: 10.2174/138955709791012201</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.2174%2F138955709791012201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1g&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=20088782" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1g&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmtVygtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=1655-1675&author=K.+K.-C.+Liuauthor=S.+M.+Sakyaauthor=C.+J.+O%E2%80%99Donnellauthor=J.+Li&title=Synthetic+Approaches+to+the+2008+New+Drugs&doi=10.2174%2F138955709791012201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1gR"><div class="casContent"><span class="casTitleNuber">1g</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2008 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Sakya, Subas M.; O'Donnell, Christopher J.; Li, Jin</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1655-1675</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  These new chem. entities (NCEs) provide insights into mol. recognition and also serve as leads for designing future new drugs.  This review covers the syntheses of 18 NCEs marketed in 2008.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozyNqyXXeUK7Vg90H21EOLACvtfcHk0ljwBJN0pk4QNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmtVygtL8%253D&md5=7c21b476dd957ab5b90c98502ee0ec2a</span></div><a href="/servlet/linkout?suffix=cit1g&amp;dbid=16384&amp;doi=10.2174%2F138955709791012201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955709791012201%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.-C.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202008%2520New%2520Drugs%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2009%26volume%3D9%26spage%3D1655%26epage%3D1675%26doi%3D10.2174%2F138955709791012201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit1h"><span><span class="NLM_label">(h) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2009 New Drugs</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1136</span>– <span class="NLM_lpage">1154</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2010.12.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1h&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2Fj.bmc.2010.12.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1h&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=21256756" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1h&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlKlu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=1136-1154&author=K.+K.+C.+Liuauthor=S.+M.+Sakyaauthor=C.+J.+O%E2%80%99Donnellauthor=A.+C.+Flickauthor=J.+Li&title=Synthetic+Approaches+to+the+2009+New+Drugs&doi=10.1016%2Fj.bmc.2010.12.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1hR"><div class="casContent"><span class="casTitleNuber">1h</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2009 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Sakya, Subas M.; O'Donnell, Christopher J.; Flick, Andrew C.; Li, Jin</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1136-1154</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each individual drug represents a privileged structure for its biol. target.  These new chem. entities (NCEs) provide insights into mol. recognition and also serve as leads for designing future new drugs.  This review covers the syntheses of 21 NCEs marketed in 2009.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhM07bPdVyP7Vg90H21EOLACvtfcHk0ljEJ8d2jMqgVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlKlu7Y%253D&md5=132426fbdd026496e573cb26110b559b</span></div><a href="/servlet/linkout?suffix=cit1h&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2010.12.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2010.12.038%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.%2BC.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202009%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2011%26volume%3D19%26spage%3D1136%26epage%3D1154%26doi%3D10.1016%2Fj.bmc.2010.12.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit1i"><span><span class="NLM_label">(i) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2010 New Drugs</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1155</span>– <span class="NLM_lpage">1174</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2011.12.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1i&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2Fj.bmc.2011.12.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1i&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=22261026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1i&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFSnsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=1155-1174&author=K.+K.+C.+Liuauthor=S.+M.+Sakyaauthor=C.+J.+O%E2%80%99Donnellauthor=A.+C.+Flickauthor=H.+X.+Ding&title=Synthetic+Approaches+to+the+2010+New+Drugs&doi=10.1016%2Fj.bmc.2011.12.049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1iR"><div class="casContent"><span class="casTitleNuber">1i</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2010 new drugs</span></div><div class="casAuthors">Liu, Kevin K.-C.; Sakya, Subas M.; O'Donnell, Christopher J.; Flick, Andrew C.; Ding, Hong X.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1155-1174</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each represents a privileged structure for its biol. target.  These new chem. entities (NCEs) provide insights into mol. recognition and also serve as leads for designing future new drugs.  This review covers the synthesis of 15 NCEs that were launched anywhere in the world in 2010.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpn4x86l05yfrVg90H21EOLACvtfcHk0ljEJ8d2jMqgVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFSnsLc%253D&md5=e4a5130168e87de1a00a090241a54412</span></div><a href="/servlet/linkout?suffix=cit1i&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2011.12.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2011.12.049%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DK.%2BK.%2BC.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DDing%26aufirst%3DH.%2BX.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202010%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26spage%3D1155%26epage%3D1174%26doi%3D10.1016%2Fj.bmc.2011.12.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit1j"><span><span class="NLM_label">(j) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2011 New Drugs</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2795</span>– <span class="NLM_lpage">2825</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2013.02.061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1j&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2Fj.bmc.2013.02.061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1j&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=23623674" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1j&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmsVCksbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=2795-2825&author=H.+X.+Dingauthor=K.+K.+C.+Liuauthor=S.+M.+Sakyaauthor=A.+C.+Flickauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+the+2011+New+Drugs&doi=10.1016%2Fj.bmc.2013.02.061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1jR"><div class="casContent"><span class="casTitleNuber">1j</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2011 new drugs</span></div><div class="casAuthors">Ding, Hong X.; Liu, Kevin K.-C.; Sakya, Subas M.; Flick, Andrew C.; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2795-2825</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs are introduced to the market every year and each represents a privileged structure for its biol. target.  These new chem. entities (NCEs) provide insights into mol. recognition and also serve as leads for designing future new drugs.  This review covers the synthesis of 26 NCEs that were launched in the world in 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4leMAGdR_wLVg90H21EOLACvtfcHk0ljEJ8d2jMqgVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmsVCksbs%253D&md5=07079afb3ea7459e73455de425e5d756</span></div><a href="/servlet/linkout?suffix=cit1j&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.02.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.02.061%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DLiu%26aufirst%3DK.%2BK.%2BC.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202011%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D2795%26epage%3D2825%26doi%3D10.1016%2Fj.bmc.2013.02.061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit1k"><span><span class="NLM_label">(k) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leverett, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyne, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakya, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2012 New Drugs</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">2005</span>– <span class="NLM_lpage">2032</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2014.02.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1k&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2Fj.bmc.2014.02.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1k&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=24629448" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1k&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkt1WhsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=2005-2032&author=H.+X.+Dingauthor=C.+A.+Leverettauthor=R.+E.+Kyneauthor=K.+K.+C.+Liuauthor=S.+M.+Sakyaauthor=A.+C.+Flickauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+the+2012+New+Drugs&doi=10.1016%2Fj.bmc.2014.02.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1kR"><div class="casContent"><span class="casTitleNuber">1k</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2012 new drugs</span></div><div class="casAuthors">Ding, Hong X.; Leverett, Carolyn A.; Kyne, Robert E.; Liu, Kevin K.-C.; Sakya, Subas M.; Flick, Andrew C.; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2005-2032</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs introduced to the market every year represent a privileged structure for a particular biol. target.  These new chem. entities (NCEs) provide insights into mol. recognition and also serve as leads for designing future new drugs.  This review covers the synthesis of twenty-six NCEs that were launched or approved worldwide in 2012 and two addnl. drugs which were launched at the end of 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5C7y-_vIFErVg90H21EOLACvtfcHk0lhDD3Ro8e9f4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkt1WhsL0%253D&md5=bb629a07ee4cfa5efe4f8b2ca0003410</span></div><a href="/servlet/linkout?suffix=cit1k&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.02.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.02.017%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DLeverett%26aufirst%3DC.%2BA.%26aulast%3DKyne%26aufirst%3DR.%2BE.%26aulast%3DLiu%26aufirst%3DK.%2BK.%2BC.%26aulast%3DSakya%26aufirst%3DS.%2BM.%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202012%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D2005%26epage%3D2032%26doi%3D10.1016%2Fj.bmc.2014.02.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit1l"><span><span class="NLM_label">(l) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leverett, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyne, R. E.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2013 New Drugs</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1895</span>– <span class="NLM_lpage">1922</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2015.02.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1l&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2Fj.bmc.2015.02.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1l&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=25797159" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1l&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC2MXktFKnt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=1895-1922&author=H.+X.+Dingauthor=C.+A.+Leverettauthor=R.+E.+Kyneauthor=K.+K.+C.+Liuauthor=S.+J.+Finkauthor=A.+C.+Flickauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+the+2013+New+Drugs&doi=10.1016%2Fj.bmc.2015.02.056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1lR"><div class="casContent"><span class="casTitleNuber">1l</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2013 new drugs</span></div><div class="casAuthors">Ding, Hong X.; Leverett, Carolyn A.; Kyne, Robert E., Jr.; Liu, Kevin K.-C.; Fink, Sarah J.; Flick, Andrew C.; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1895-1922</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs introduced to the market every year represent privileged structures for particular biol. targets.  These new chem. entities (NCEs) provide insight into mol. recognition and also serve as leads for designing future new drugs.  This annual review covers the synthesis of twenty-four NCEs that were approved for the first time in 2013 and two 2012 drugs which were not covered during the previous edition of this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr83u4l4iyn9LVg90H21EOLACvtfcHk0lhDD3Ro8e9f4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXktFKnt7k%253D&md5=b64a1ec20260b828d7f6de0e0a1319b0</span></div><a href="/servlet/linkout?suffix=cit1l&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.02.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.02.056%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DLeverett%26aufirst%3DC.%2BA.%26aulast%3DKyne%26aufirst%3DR.%2BE.%26aulast%3DLiu%26aufirst%3DK.%2BK.%2BC.%26aulast%3DFink%26aufirst%3DS.%2BJ.%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202013%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D1895%26epage%3D1922%26doi%3D10.1016%2Fj.bmc.2015.02.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit1m"><span><span class="NLM_label">(m) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leverett, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyne, R. E.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the 2014 New Drugs</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1937</span>– <span class="NLM_lpage">1980</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.03.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1m&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2Fj.bmc.2016.03.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1m&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=27020685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1m&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC28Xks1yktr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=1937-1980&author=A.+C.+Flickauthor=H.+X.+Dingauthor=C.+A.+Leverettauthor=R.+E.+Kyneauthor=K.+K.+C.+Liuauthor=S.+J.+Finkauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+the+2014+New+Drugs&doi=10.1016%2Fj.bmc.2016.03.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1mR"><div class="casContent"><span class="casTitleNuber">1m</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to the 2014 new drugs</span></div><div class="casAuthors">Flick, Andrew C.; Ding, Hong X.; Leverett, Carolyn A.; Kyne, Robert E., Jr.; Liu, Kevin K.-C.; Fink, Sarah J.; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1937-1980</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  New drugs introduced to the market every year represent privileged structures for particular biol. targets.  These new chem. entities (NCEs) provide insight into mol. recognition and also serve as leads for designing future new drugs.  This annual review covers the synthesis of thirty-seven NCEs that were approved for the first time in 2014 and one drug which was approved in 2013 and was not covered in a previous edition of this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlkq2WCDEAgbVg90H21EOLACvtfcHk0lhDD3Ro8e9f4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xks1yktr0%253D&md5=a5ce03081110edb2b616006c73d14650</span></div><a href="/servlet/linkout?suffix=cit1m&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.03.004%26sid%3Dliteratum%253Aachs%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DLeverett%26aufirst%3DC.%2BA.%26aulast%3DKyne%26aufirst%3DR.%2BE.%26aulast%3DLiu%26aufirst%3DK.%2BK.%2BC.%26aulast%3DFink%26aufirst%3DS.%2BJ.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%25202014%2520New%2520Drugs%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26spage%3D1937%26epage%3D1980%26doi%3D10.1016%2Fj.bmc.2016.03.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit1n"><span><span class="NLM_label">(n) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leverett, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kyne, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the New Drugs Approved During 2015</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">6480</span>– <span class="NLM_lpage">6515</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00010</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00010" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1n&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmt1amsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=6480-6515&author=A.+C.+Flickauthor=H.+X.+Dingauthor=C.+A.+Leverettauthor=R.+E.+Kyneauthor=K.+K.+C.+Liuauthor=S.+J.+Finkauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+the+New+Drugs+Approved+During+2015&doi=10.1021%2Facs.jmedchem.7b00010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1nR"><div class="casContent"><span class="casTitleNuber">1n</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic Approaches to the New Drugs Approved During 2015</span></div><div class="casAuthors">Flick, Andrew C.; Ding, Hong X.; Leverett, Carolyn A.; Kyne, Robert E.; Liu, Kevin K. -C.; Fink, Sarah J.; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6480-6515</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">New drugs introduced to the market every year represent privileged structures for particular biol. targets.  These new chem. entities (NCEs) provide insight into mol. recognition while serving as leads for designing future new drugs.  This annual review describes the most likely process-scale synthetic approaches to 29 new chem. entities (NCEs) that were approved for the first time in 2015.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5OCn9h-Lu07Vg90H21EOLACvtfcHk0liSkjR5AWUU0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmt1amsrw%253D&md5=b10c1f677c2f4a216b11a4c89e8b3683</span></div><a href="/servlet/linkout?suffix=cit1n&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00010%26sid%3Dliteratum%253Aachs%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DLeverett%26aufirst%3DC.%2BA.%26aulast%3DKyne%26aufirst%3DR.%2BE.%26aulast%3DLiu%26aufirst%3DK.%2BK.%2BC.%26aulast%3DFink%26aufirst%3DS.%2BJ.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%2520New%2520Drugs%2520Approved%2520During%25202015%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D6480%26epage%3D6515%26doi%3D10.1021%2Facs.jmedchem.7b00010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit1o"><span><span class="NLM_label">(o) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leverett, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to New Drugs Approved During 2016</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">7004</span>– <span class="NLM_lpage">7031</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00260</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00260" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1o&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntVCmsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=7004-7031&author=A.+C.+Flickauthor=H.+X.+Dingauthor=C.+A.+Leverettauthor=S.+J.+Finkauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+New+Drugs+Approved+During+2016&doi=10.1021%2Facs.jmedchem.8b00260"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1oR"><div class="casContent"><span class="casTitleNuber">1o</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic Approaches to New Drugs Approved During 2016</span></div><div class="casAuthors">Flick, Andrew C.; Ding, Hong X.; Leverett, Carolyn A.; Fink, Sarah J.; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7004-7031</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review discusses the published syntheses of the nineteen new chem. entities approved for the first time by a governing body anywhere in the world in 2016.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr16l1kfs1KlbVg90H21EOLACvtfcHk0liSkjR5AWUU0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntVCmsbc%253D&md5=183bbabe40dbfd7b7cfbcd94fd55f0d0</span></div><a href="/servlet/linkout?suffix=cit1o&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00260%26sid%3Dliteratum%253Aachs%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DLeverett%26aufirst%3DC.%2BA.%26aulast%3DFink%26aufirst%3DS.%2BJ.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520New%2520Drugs%2520Approved%2520During%25202016%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D7004%26epage%3D7031%26doi%3D10.1021%2Facs.jmedchem.8b00260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit1p"><span><span class="NLM_label">(p) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leverett, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McInturff, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helal, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to the New Drugs Approved During 2017</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">7340</span>– <span class="NLM_lpage">7382</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00196</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00196" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1p&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXms1Wqt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=7340-7382&author=A.+C.+Flickauthor=C.+A.+Leverettauthor=H.+X.+Dingauthor=E.+McInturffauthor=S.+J.+Finkauthor=C.+J.+Helalauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+the+New+Drugs+Approved+During+2017&doi=10.1021%2Facs.jmedchem.9b00196"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1pR"><div class="casContent"><span class="casTitleNuber">1p</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic Approaches to the New Drugs Approved During 2017</span></div><div class="casAuthors">Flick, Andrew C.; Leverett, Carolyn A.; Ding, Hong X.; McInturff, Emma; Fink, Sarah J.; Helal, Christopher J.; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7340-7382</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  New drugs introduced to the market every year represent privileged structures for particular biol. targets.  These new chem. entities (NCEs) provide insight into mol. recognition while serving as leads for designing future new drugs.  This annual review describes the most likely process-scale synthetic approaches to 31 new chem. entities approved for the first time globally in 2017.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozpSoktvArg7Vg90H21EOLACvtfcHk0liSkjR5AWUU0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXms1Wqt7g%253D&md5=83863eeaaadfcaab14c45e0ace932455</span></div><a href="/servlet/linkout?suffix=cit1p&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00196%26sid%3Dliteratum%253Aachs%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DLeverett%26aufirst%3DC.%2BA.%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DMcInturff%26aufirst%3DE.%26aulast%3DFink%26aufirst%3DS.%2BJ.%26aulast%3DHelal%26aufirst%3DC.%2BJ.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520the%2520New%2520Drugs%2520Approved%2520During%25202017%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D7340%26epage%3D7382%26doi%3D10.1021%2Facs.jmedchem.9b00196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit1q"><span><span class="NLM_label">(q) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Flick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leverett, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McInturff, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fink, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helal, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeForest, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morse, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahapatra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, C. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Approaches to New Drugs Approved During 2018</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">10652</span>– <span class="NLM_lpage">10704</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00345</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00345" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1q&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BB3cXot1WmsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=10652-10704&author=A.+C.+Flickauthor=C.+A.+Leverettauthor=H.+X.+Dingauthor=E.+McInturffauthor=S.+J.+Finkauthor=C.+J.+Helalauthor=J.+C.+DeForestauthor=P.+D.+Morseauthor=S.+Mahapatraauthor=C.+J.+O%E2%80%99Donnell&title=Synthetic+Approaches+to+New+Drugs+Approved+During+2018&doi=10.1021%2Facs.jmedchem.0c00345"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1qR"><div class="casContent"><span class="casTitleNuber">1q</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic Approaches to New Drugs Approved during 2018</span></div><div class="casAuthors">Flick, Andrew C.; Leverett, Carolyn A.; Ding, Hong X.; McInturff, Emma; Fink, Sarah J.; Helal, Christopher J.; DeForest, Jacob C.; Morse, Peter D.; Mahapatra, Subham; O'Donnell, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">10652-10704</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This annual review described the most likely process-scale synthetic approaches to thirty-nine new chem. entities approved for the first time globally in 2018.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp81HH6nQfU5bVg90H21EOLACvtfcHk0lg8pbHnokuP8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXot1WmsrY%253D&md5=9abe3e119215f96408e4a3448b36ce96</span></div><a href="/servlet/linkout?suffix=cit1q&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00345%26sid%3Dliteratum%253Aachs%26aulast%3DFlick%26aufirst%3DA.%2BC.%26aulast%3DLeverett%26aufirst%3DC.%2BA.%26aulast%3DDing%26aufirst%3DH.%2BX.%26aulast%3DMcInturff%26aufirst%3DE.%26aulast%3DFink%26aufirst%3DS.%2BJ.%26aulast%3DHelal%26aufirst%3DC.%2BJ.%26aulast%3DDeForest%26aufirst%3DJ.%2BC.%26aulast%3DMorse%26aufirst%3DP.%2BD.%26aulast%3DMahapatra%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26atitle%3DSynthetic%2520Approaches%2520to%2520New%2520Drugs%2520Approved%2520During%25202018%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D10652%26epage%3D10704%26doi%3D10.1021%2Facs.jmedchem.0c00345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="note"><p class="first last">For a more detailed description of the medicinal chemistry strategy and preclinical and clinical pharmacology of these drugs, see:</p></div><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Agard, N. J.</span>; <span class="NLM_string-name">Dragovich, P. S.</span>; <span class="NLM_string-name">Beal, A. M.</span>; <span class="NLM_string-name">Bolger, C. A.</span>; <span class="NLM_string-name">Kahn, S. A.</span>; <span class="NLM_string-name">Hubbard, B.</span>; <span class="NLM_string-name">Lipovšec, D.</span></span> <span> </span><span class="NLM_article-title">To Market, To Market—2019: Macromolecular Therapeutics</span>. In  <i>2020 Medicinal Chemistry Reviews</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronson, J. J.</span></span>, Ed.; <span class="NLM_publisher-name">Division of Medicinal Chemistry, American Chemical Society</span>: <span class="NLM_publisher-loc">Washington, DC</span>, <span class="NLM_year">2020</span>; Vol.  <span class="NLM_volume">55</span>, Chapter 28.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.29200%2Facsmedchemrev-v55.ch28" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=N.+J.+Agard&author=P.+S.+Dragovich&author=A.+M.+Beal&author=C.+A.+Bolger&author=S.+A.+Kahn&author=B.+Hubbard&author=D.+Lipov%C5%A1ecauthor=J.+J.+Bronson&title=2020+Medicinal+Chemistry+Reviews"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.29200%2Facsmedchemrev-v55.ch28&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.29200%252Facsmedchemrev-v55.ch28%26sid%3Dliteratum%253Aachs%26aulast%3DAgard%26aufirst%3DN.%2BJ.%26atitle%3DTo%2520Market%252C%2520To%2520Market%25E2%2580%25942019%253A%2520Macromolecular%2520Therapeutics%26btitle%3D2020%2520Medicinal%2520Chemistry%2520Reviews%26aulast%3DBronson%26aufirst%3DJ.%2BJ.%26pub%3DDivision%2520of%2520Medicinal%2520Chemistry%252C%2520American%2520Chemical%2520Society%26date%3D2020%26volume%3D55" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.-M.</span></span> <span> </span><span class="NLM_article-title">New Drug Approvals for 2019: Synthesis and Clinical Applications</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>205</i></span>,  <span class="NLM_fpage">112667</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112667</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2Fj.ejmech.2020.112667" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=32911308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslyjtr3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=205&publication_year=2020&pages=112667&author=S.+Yuanauthor=B.+Yuauthor=H.-M.+Liu&title=New+Drug+Approvals+for+2019%3A+Synthesis+and+Clinical+Applications&doi=10.1016%2Fj.ejmech.2020.112667"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">New drug approvals for 2019: Synthesis and clinical applications</span></div><div class="casAuthors">Yuan, Shuo; Yu, Bin; Liu, Hong-Min</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">205</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112667</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">48 new drugs including 38 chem. entities (33 new chem. entities, 3 new diagnostic agents, and 2 payloads of antibody drug conjugates) and 10 biologics were approved by the U.  S. Food and Drug Administration (FDA) during 2019.  These marketed new drugs represent privileged structures and novel action of mechanism, and thus can be served as leads to discover new drugs with the similar biol. targets and improved therapeutic efficacy.  This review aims to provide an overview regarding the synthetic approaches of 33 new chem. entities approved by the FDA in 2019 and their clin. applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5SG-B5Zmuf7Vg90H21EOLACvtfcHk0lg8pbHnokuP8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslyjtr3N&md5=4cd45aa9a308b65500be483d394d7a96</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112667&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112667%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DH.-M.%26atitle%3DNew%2520Drug%2520Approvals%2520for%25202019%253A%2520Synthesis%2520and%2520Clinical%2520Applications%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D205%26spage%3D112667%26doi%3D10.1016%2Fj.ejmech.2020.112667" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Zhanel, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golden, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zelenitsky, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiebe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adam, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Idowu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domalaon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweizer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhanel, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagace-Wiens, P. R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walkty, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noreddin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, J. P.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlowsky, J. A.</span></span> <span> </span><span class="NLM_article-title">Cefiderocol: A Siderophore Cephalosporin with Activity against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">271</span>– <span class="NLM_lpage">289</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-1055-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs40265-019-1055-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=30712199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFyjtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=271-289&author=G.+G.+Zhanelauthor=A.+R.+Goldenauthor=S.+Zelenitskyauthor=K.+Wiebeauthor=C.+K.+Lawrenceauthor=H.+J.+Adamauthor=T.+Idowuauthor=R.+Domalaonauthor=F.+Schweizerauthor=M.+A.+Zhanelauthor=P.+R.+S.+Lagace-Wiensauthor=A.+J.+Walktyauthor=A.+Noreddinauthor=J.+P.+Lynchauthor=J.+A.+Karlowsky&title=Cefiderocol%3A+A+Siderophore+Cephalosporin+with+Activity+against+Carbapenem-Resistant+and+Multidrug-Resistant+Gram-Negative+Bacilli&doi=10.1007%2Fs40265-019-1055-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli</span></div><div class="casAuthors">Zhanel, George G.; Golden, Alyssa R.; Zelenitsky, Sheryl; Wiebe, Karyn; Lawrence, Courtney K.; Adam, Heather J.; Idowu, Temilolu; Domalaon, Ronald; Schweizer, Frank; Zhanel, Michael A.; Lagace-Wiens, Philippe R. S.; Walkty, Andrew J.; Noreddin, Ayman; Lynch III, Joseph P.; Karlowsky, James A.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">271-289</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Cefiderocol is an injectable siderophore cephalosporin discovered and being developed by Shionogi & Co., Ltd., Japan.  As with other β-lactam antibiotics, the principal antibacterial/bactericidal activity of cefiderocol occurs by inhibition of Gram-neg. bacterial cell wall synthesis by binding to penicillin binding proteins; however, it is unique in that it enters the bacterial periplasmic space as a result of its siderophore-like property and has enhanced stability to β-lactamases.  The chem. structure of cefiderocol is similar to both ceftazidime and cefepime, which are third- and fourth-generation cephalosporins, resp., but with high stability to a variety of β-lactamases, including AmpC and extended-spectrum β-lactamases (ESBLs).  Cefiderocol has a pyrrolidinium group in the side chain at position 3 like cefepime and a carboxypropanoxyimino group in the side chain at position 7 of the cephem nucleus like ceftazidime.  The major difference in the chem. structures of cefiderocol, ceftazidime and cefepime is the presence of a catechol group on the side chain at position 3.  Together with the high stability to β-lactamases, including ESBLs, AmpC and carbapenemases, the microbiol. activity of cefiderocol against aerobic Gram-neg. bacilli is equal to or superior to that of ceftazidime-avibactam and meropenem, and it is active against a variety of Ambler class A, B, C and D β-lactamases.  Cefiderocol is also more potent than both ceftazidime-avibactam and meropenem vs. Acinetobacter baumannii, including meropenem non-susceptible and multidrug-resistant (MDR) isolates.  Cefiderocol's activity against meropenem-non-susceptible and Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriales is comparable or superior to ceftazidime-avibactam.  Cefiderocol is also more potent than both ceftazidime-avibactam and meropenem against all resistance phenotypes of Pseudomonas aeruginosa and against Stenotrophomonas maltophilia.  The current dosing regimen being used in phase III studies is 2 g administered i.v. every 8 h (q8 h) using a 3-h infusion.  The pharmacokinetics of cefiderocol are best described by a three-compartment linear model.  The mean plasma half-life (t1/2) was ∼ 2.3 h, protein binding is 58%, and total drug clearance ranged from 4.6-6.0 L/h for both single- and multi-dose infusions and was primarily renally excreted unchanged (61-71%).  Cefiderocol is primarily renally excreted unchanged and clearance correlates with creatinine clearance.  Dosage adjustment is thus required for both augmented renal clearance and in patients with moderate to severe renal impairment.  In vitro and in vivo pharmacodynamic studies have reported that as with other cephalosporins the pharmacodynamic index that best predicts clin. outcome is the percentage of time that free drug concns. exceed the min. inhibitory concn. (%fT > MIC).  In vivo efficacy of cefiderocol has been studied in a variety of humanized drug exposure murine and rat models of infection utilizing a variety of MDR and extremely drug resistant strains.  Cefiderocol has performed similarly to or has been superior to comparator agents, including ceftazidime and cefepime.  A phase II prospective, multicenter, double-blind, randomized clin. trial assessed the safety and efficacy of cefiderocol 2000 mg q8 h vs. imipenem/cilastatin 1000 mg q8 h, both administered i.v. for 7-14 days over 1 h, in the treatment of complicated urinary tract infection (cUTI, including pyelonephritis) or acute uncomplicated pyelonephritis in hospitalized adults.  A total of 452 patients were initially enrolled in the study, with 303 in the cefiderocol arm and 149 in the imipenem/cilastatin arm.  The primary outcome measure was a composite of clin. cure and microbiol. eradication at the test-of-cure (TOC) visit, i.e., 7 days after the end of treatment in the microbiol. intent-to-treat (MITT) population.  Secondary outcome measures included microbiol. response per pathogen and per patient at early assessment (EA), end of treatment (EOT), TOC, and follow-up (FUP); clin. response per pathogen and per patient at EA, EOT, TOC, and FUP; plasma, urine and concns. of cefiderocol; and the no. of participants with adverse events.  The composite of clin. and microbiol. response rates was 72.6% (183/252) for cefiderocol and 54.6% (65/119) for imipenem/cilastatin in the MITT population.  Clin. response rates per patient at the TOC visit were 89.7% (226/252) for cefiderocol and 87.4% (104/119) for imipenem/cilastatin in the MITT population.  Microbiol. eradication rates were 73.0% (184/252) for cefiderocol and 56.3% (67/119) for imipenem/cilastatin in the MITT population.  Addnl., two phase III clin. trials are currently being conducted by Shionogi & Co., Ltd., Japan.  The two trials are evaluating the efficacy of cefiderocol in the treatment of serious infections in adult patients caused by carbapenem-resistant Gram-neg. pathogens and evaluating the efficacy of cefiderocol in the treatment of adults with hospital-acquired bacterial pneumonia, ventilator-assocd. pneumonia or healthcare-assocd. pneumonia caused by Gram-neg. pathogens.  Cefiderocol appears to be well tolerated (minor reported adverse effects were gastrointestinal and phlebitis related), with a side effect profile that is comparable to other cephalosporin antimicrobials.  Cefiderocol appears to be well positioned to help address the increasing no. of infections caused by carbapenem-resistant and MDR Gram-neg. bacilli, including ESBL- and carbapenemase-producing strains (including metallo-β-lactamase producers).  A distinguishing feature of cefiderocol is its activity against resistant P. aeruginosa, A. baumannii, S. maltophilia and Burkholderia cepacia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj__AYoJTP8rVg90H21EOLACvtfcHk0lg8pbHnokuP8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFyjtLo%253D&md5=47bef7c5e2c7231f9a38e5e524efd0b2</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-1055-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-1055-2%26sid%3Dliteratum%253Aachs%26aulast%3DZhanel%26aufirst%3DG.%2BG.%26aulast%3DGolden%26aufirst%3DA.%2BR.%26aulast%3DZelenitsky%26aufirst%3DS.%26aulast%3DWiebe%26aufirst%3DK.%26aulast%3DLawrence%26aufirst%3DC.%2BK.%26aulast%3DAdam%26aufirst%3DH.%2BJ.%26aulast%3DIdowu%26aufirst%3DT.%26aulast%3DDomalaon%26aufirst%3DR.%26aulast%3DSchweizer%26aufirst%3DF.%26aulast%3DZhanel%26aufirst%3DM.%2BA.%26aulast%3DLagace-Wiens%26aufirst%3DP.%2BR.%2BS.%26aulast%3DWalkty%26aufirst%3DA.%2BJ.%26aulast%3DNoreddin%26aufirst%3DA.%26aulast%3DLynch%26aufirst%3DJ.%2BP.%26aulast%3DKarlowsky%26aufirst%3DJ.%2BA.%26atitle%3DCefiderocol%253A%2520A%2520Siderophore%2520Cephalosporin%2520with%2520Activity%2520against%2520Carbapenem-Resistant%2520and%2520Multidrug-Resistant%2520Gram-Negative%2520Bacilli%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D271%26epage%3D289%26doi%3D10.1007%2Fs40265-019-1055-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit4b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamawaki, K.</span></span> <span> </span><span class="NLM_article-title">Cefiderocol: Discovery, Chemistry, and in Vivo Profiles of a Novel Siderophore Cephalosporin</span>. <i>Clin. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">S538</span>– <span class="NLM_lpage">S543</span>, <span class="refDoi"> DOI: 10.1093/cid/ciz826</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1093%2Fcid%2Fciz826" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31724047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnsVKqt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2019&pages=S538-S543&author=T.+Satoauthor=K.+Yamawaki&title=Cefiderocol%3A+Discovery%2C+Chemistry%2C+and+in+Vivo+Profiles+of+a+Novel+Siderophore+Cephalosporin&doi=10.1093%2Fcid%2Fciz826"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4b</span><div class="casTitle"><span class="NLM_cas:atitle">Cefiderocol: discovery, chemistry, and in vivo profiles of a novel siderophore cephalosporin</span></div><div class="casAuthors">Sato, Takafumi; Yamawaki, Kenji</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Infectious Diseases</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">Suppl._7</span>),
    <span class="NLM_cas:pages">S538-S543</span>CODEN:
                <span class="NLM_cas:coden">CIDIEL</span>;
        ISSN:<span class="NLM_cas:issn">1537-6591</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The emergence of antimicrobial resistance is a significant public health issue worldwide, particularly for healthcare-assocd. infections caused by carbapenem-resistant gram-neg. pathogens.  Cefiderocol is a novel siderophore cephalosporin targeting gram-neg. bacteria, including strains with carbapenem resistance.  The structural characteristics of cefiderocol show similarity to both ceftazidime and cefepime, which enable cefiderocol to withstand hydrolysis by β-lactamases.  The unique chem. component is the addn. of a catechol moiety on the C-3 side chain, which chelates iron and mimics naturally occurring siderophore mols.  Following the chelation of iron, cefiderocol is actively transported across the outer membrane of the bacterial cell to the periplasmic space via specialized iron transporter channels.  Furthermore, cefiderocol has demonstrated structural stability against hydrolysis by both serine- and metallo-β-lactamases, including clin. relevant carbapenemases such as Klebsiella pneumoniae carbapenemase, oxacillin carbapenemase-48, and New Delhi metallo-β-lactamase.  Cefiderocol has demonstrated promising in vitro antibacterial and bactericidal activity, which correlates with its in vivo efficacy in several animal models.  This article reviews the discovery and chem. of cefiderocol, as well as some of the key microbiol. and in vivo findings on cefiderocol from recently conducted investigations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyXYWehTmFjbVg90H21EOLACvtfcHk0litIveqSCCuzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnsVKqt7g%253D&md5=2088f7219b245b209f0ebc0b59151eae</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1093%2Fcid%2Fciz826&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcid%252Fciz826%26sid%3Dliteratum%253Aachs%26aulast%3DSato%26aufirst%3DT.%26aulast%3DYamawaki%26aufirst%3DK.%26atitle%3DCefiderocol%253A%2520Discovery%252C%2520Chemistry%252C%2520and%2520in%2520Vivo%2520Profiles%2520of%2520a%2520Novel%2520Siderophore%2520Cephalosporin%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2019%26volume%3D69%26spage%3DS538%26epage%3DS543%26doi%3D10.1093%2Fcid%2Fciz826" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><a href="https://www.fda.gov/news-events/press-announcements/fda-approves-new-antibacterial-drug-treat-complicated-urinary-tract-infections-part-ongoing-efforts" class="extLink">https://www.fda.gov/news-events/press-announcements/fda-approves-new-antibacterial-drug-treat-complicated-urinary-tract-infections-part-ongoing-efforts</a> (accessed 2020-12-18).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-approves-new-antibacterial-drug-treat-complicated-urinary-tract-infections-part-ongoing-efforts+%28accessed+2020-12-18%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aoki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshizawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamawaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hisakawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasegawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusano, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugimoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishitani, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuji, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishikawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamano, Y.</span></span> <span> </span><span class="NLM_article-title">Cefiderocol (S-649266), A New Siderophore Cephalosporin Exhibiting Potent Activities against Pseudomonas Aeruginosa and Other Gram-Negative Pathogens Including Multi-Drug Resistant Bacteria: Structure Activity Relationship</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>155</i></span>,  <span class="NLM_fpage">847</span>– <span class="NLM_lpage">868</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.06.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2Fj.ejmech.2018.06.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=29960205" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1aktLzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=2018&pages=847-868&author=T.+Aokiauthor=H.+Yoshizawaauthor=K.+Yamawakiauthor=K.+Yokooauthor=J.+Satoauthor=S.+Hisakawaauthor=Y.+Hasegawaauthor=H.+Kusanoauthor=M.+Sanoauthor=H.+Sugimotoauthor=Y.+Nishitaniauthor=T.+Satoauthor=M.+Tsujiauthor=R.+Nakamuraauthor=T.+Nishikawaauthor=Y.+Yamano&title=Cefiderocol+%28S-649266%29%2C+A+New+Siderophore+Cephalosporin+Exhibiting+Potent+Activities+against+Pseudomonas+Aeruginosa+and+Other+Gram-Negative+Pathogens+Including+Multi-Drug+Resistant+Bacteria%3A+Structure+Activity+Relationship&doi=10.1016%2Fj.ejmech.2018.06.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship</span></div><div class="casAuthors">Aoki, Toshiaki; Yoshizawa, Hidenori; Yamawaki, Kenji; Yokoo, Katsuki; Sato, Jun; Hisakawa, Shinya; Hasegawa, Yasushi; Kusano, Hiroki; Sano, Masayuki; Sugimoto, Hideki; Nishitani, Yasuhiro; Sato, Takafumi; Tsuji, Masakatsu; Nakamura, Rio; Nishikawa, Toru; Yamano, Yoshinori</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">155</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">847-868</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The structure-activity relationship (SAR) for a novel series of catechol conjugated siderophore cephalosporins is described with their in vitro activities against multi-drug resistant Gram-neg. pathogens including Pseudomonas aeruginosa, Acinetobacter baumannii, Stenotrophomonas maltophilia and Enterobacteriaceae.  Cefiderocol (3) was one of the best mols. which displayed well-balanced and potent activities against multi-drug resistant Gram-neg. pathogens including carbapenem resistant bacteria among the prepd. compds. with the modified C-7 side chain and the modified C-3 side chain.  Cefiderocol (3) is a highly promising parenteral cephalosporin for the treatment of multi-drug resistant Gram-neg. infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZtNQuAziKHbVg90H21EOLACvtfcHk0litIveqSCCuzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1aktLzL&md5=8dbb57fbf55c68d788ffba60f4b5b597</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.06.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.06.014%26sid%3Dliteratum%253Aachs%26aulast%3DAoki%26aufirst%3DT.%26aulast%3DYoshizawa%26aufirst%3DH.%26aulast%3DYamawaki%26aufirst%3DK.%26aulast%3DYokoo%26aufirst%3DK.%26aulast%3DSato%26aufirst%3DJ.%26aulast%3DHisakawa%26aufirst%3DS.%26aulast%3DHasegawa%26aufirst%3DY.%26aulast%3DKusano%26aufirst%3DH.%26aulast%3DSano%26aufirst%3DM.%26aulast%3DSugimoto%26aufirst%3DH.%26aulast%3DNishitani%26aufirst%3DY.%26aulast%3DSato%26aufirst%3DT.%26aulast%3DTsuji%26aufirst%3DM.%26aulast%3DNakamura%26aufirst%3DR.%26aulast%3DNishikawa%26aufirst%3DT.%26aulast%3DYamano%26aufirst%3DY.%26atitle%3DCefiderocol%2520%2528S-649266%2529%252C%2520A%2520New%2520Siderophore%2520Cephalosporin%2520Exhibiting%2520Potent%2520Activities%2520against%2520Pseudomonas%2520Aeruginosa%2520and%2520Other%2520Gram-Negative%2520Pathogens%2520Including%2520Multi-Drug%2520Resistant%2520Bacteria%253A%2520Structure%2520Activity%2520Relationship%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D155%26spage%3D847%26epage%3D868%26doi%3D10.1016%2Fj.ejmech.2018.06.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsubara, F.</span>; <span class="NLM_string-name">Kurita, T.</span>; <span class="NLM_string-name">Nagamatsu, D.</span></span> <span> </span><span class="NLM_article-title">Salt of Cephalosporin Derivative, Crystalline Solid Form of Same and Method for Producing Same</span>. <span class="NLM_patent">WO 2016035845 A1</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=F.+Matsubara&author=T.+Kurita&author=D.+Nagamatsu&title=Salt+of+Cephalosporin+Derivative%2C+Crystalline+Solid+Form+of+Same+and+Method+for+Producing+Same"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMatsubara%26aufirst%3DF.%26atitle%3DSalt%2520of%2520Cephalosporin%2520Derivative%252C%2520Crystalline%2520Solid%2520Form%2520of%2520Same%2520and%2520Method%2520for%2520Producing%2520Same%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Fukuda, M.</span>; <span class="NLM_string-name">Watanabe, T.</span>; <span class="NLM_string-name">Kurita, T.</span>; <span class="NLM_string-name">Yokota, Y.</span>; <span class="NLM_string-name">Takeo, M.</span>; <span class="NLM_string-name">Noguchi, K.</span></span> <span> </span><span class="NLM_article-title">Preparation of Intermediate of Cephalosporin Derivatives</span>. <span class="NLM_patent">WO 2016035847 A1</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=M.+Fukuda&author=T.+Watanabe&author=T.+Kurita&author=Y.+Yokota&author=M.+Takeo&author=K.+Noguchi&title=Preparation+of+Intermediate+of+Cephalosporin+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFukuda%26aufirst%3DM.%26atitle%3DPreparation%2520of%2520Intermediate%2520of%2520Cephalosporin%2520Derivatives%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Kawasaki, H.</span>; <span class="NLM_string-name">Kojima, N.</span>; <span class="NLM_string-name">Fujihira, A.</span>; <span class="NLM_string-name">Takahashi, K.</span>; <span class="NLM_string-name">Matsubara, F.</span>; <span class="NLM_string-name">Matsuoka, N.</span></span> <span> </span><span class="NLM_article-title">Pharmaceutical Preparation Comprising Cephalosporin Having Catechol Groups with Improved Stability, and Manufacture Thereof</span>. <span class="NLM_patent">WO 2016035846 A1</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=H.+Kawasaki&author=N.+Kojima&author=A.+Fujihira&author=K.+Takahashi&author=F.+Matsubara&author=N.+Matsuoka&title=Pharmaceutical+Preparation+Comprising+Cephalosporin+Having+Catechol+Groups+with+Improved+Stability%2C+and+Manufacture+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKawasaki%26aufirst%3DH.%26atitle%3DPharmaceutical%2520Preparation%2520Comprising%2520Cephalosporin%2520Having%2520Catechol%2520Groups%2520with%2520Improved%2520Stability%252C%2520and%2520Manufacture%2520Thereof%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><a href="https://www.kegg.jp/dbget-bin/www_bget?dr:D11013" class="extLink">https://www.kegg.jp/dbget-bin/www_bget?dr:D11013</a> (accessed 2020-12-18).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.kegg.jp%2Fdbget-bin%2Fwww_bget%3Fdr%3AD11013+%28accessed+2020-12-18%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kishii, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takei, M.</span></span> <span> </span><span class="NLM_article-title">In Vitro Activities and Spectrum of the Novel Fluoroquinolone Lascufloxacin (KRP-AM1977)</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">e00120-17</span>, <span class="refDoi"> DOI: 10.1128/AAC.00120-17</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1128%2FAAC.00120-17" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=28320717" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2017&pages=e00120-17&author=R.+Kishiiauthor=Y.+Yamaguchiauthor=M.+Takei&title=In+Vitro+Activities+and+Spectrum+of+the+Novel+Fluoroquinolone+Lascufloxacin+%28KRP-AM1977%29&doi=10.1128%2FAAC.00120-17"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1128%2FAAC.00120-17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00120-17%26sid%3Dliteratum%253Aachs%26aulast%3DKishii%26aufirst%3DR.%26aulast%3DYamaguchi%26aufirst%3DY.%26aulast%3DTakei%26aufirst%3DM.%26atitle%3DIn%2520Vitro%2520Activities%2520and%2520Spectrum%2520of%2520the%2520Novel%2520Fluoroquinolone%2520Lascufloxacin%2520%2528KRP-AM1977%2529%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2017%26volume%3D61%26spage%3De00120-17%26doi%3D10.1128%2FAAC.00120-17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamagishi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsukawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suematsu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikamo, H.</span></span> <span> </span><span class="NLM_article-title">In vitro Activity of Lascufloxacin, a Novel Fluoroquinolone Antibacterial Agent, against Various Clinical Isolates of Anaerobes and <i>Streptococcus Anginosus</i> Group</span>. <i>Anaerobe</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">61</span>– <span class="NLM_lpage">64</span>, <span class="refDoi"> DOI: 10.1016/j.anaerobe.2018.08.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2Fj.anaerobe.2018.08.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=30114441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFequr3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2018&pages=61-64&author=Y.+Yamagishiauthor=Y.+Matsukawaauthor=H.+Suematsuauthor=H.+Mikamo&title=In+vitro+Activity+of+Lascufloxacin%2C+a+Novel+Fluoroquinolone+Antibacterial+Agent%2C+against+Various+Clinical+Isolates+of+Anaerobes+and+Streptococcus+Anginosus+Group&doi=10.1016%2Fj.anaerobe.2018.08.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro activity of lascufloxacin, a novel fluoroquinolone antibacterial agent, against various clinical isolates of anaerobes and Streptococcus anginosus group</span></div><div class="casAuthors">Yamagishi, Yuka; Matsukawa, Yoko; Suematsu, Hiroyuki; Mikamo, Hiroshige</div><div class="citationInfo"><span class="NLM_cas:title">Anaerobe</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">61-64</span>CODEN:
                <span class="NLM_cas:coden">ANAEF8</span>;
        ISSN:<span class="NLM_cas:issn">1075-9964</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The in vitro activities of lascufloxacin were evaluated by comparison with seven ref. compds. using 412 clin. isolates of anaerobes and Streptococcus anginosus group.  Lascufloxacin showed potent and broad antibacterial activities greater than those of existing quinolones against the clin. isolates used in this study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsjc-PBP_vRrVg90H21EOLACvtfcHk0likgM6FViAXYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFequr3O&md5=2393853dd981dfd38baaec4fe4b77604</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.anaerobe.2018.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.anaerobe.2018.08.002%26sid%3Dliteratum%253Aachs%26aulast%3DYamagishi%26aufirst%3DY.%26aulast%3DMatsukawa%26aufirst%3DY.%26aulast%3DSuematsu%26aufirst%3DH.%26aulast%3DMikamo%26aufirst%3DH.%26atitle%3DIn%2520vitro%2520Activity%2520of%2520Lascufloxacin%252C%2520a%2520Novel%2520Fluoroquinolone%2520Antibacterial%2520Agent%252C%2520against%2520Various%2520Clinical%2520Isolates%2520of%2520Anaerobes%2520and%2520Streptococcus%2520Anginosus%2520Group%26jtitle%3DAnaerobe%26date%3D2018%26volume%3D54%26spage%3D61%26epage%3D64%26doi%3D10.1016%2Fj.anaerobe.2018.08.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gotoh, T.</span>; <span class="NLM_string-name">Araya, I.</span></span> <span> </span><span class="NLM_article-title">Process for Production of 3,4-Disubstituted Pyrrolidine Derivative and Intermediate for the Production</span>. <span class="NLM_patent">EP 1992613 A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=T.+Gotoh&author=I.+Araya&title=Process+for+Production+of+3%2C4-Disubstituted+Pyrrolidine+Derivative+and+Intermediate+for+the+Production"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGotoh%26aufirst%3DT.%26atitle%3DProcess%2520for%2520Production%2520of%25203%252C4-Disubstituted%2520Pyrrolidine%2520Derivative%2520and%2520Intermediate%2520for%2520the%2520Production%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Uchida, H.</span>; <span class="NLM_string-name">Hanada, M.</span></span> <span> </span><span class="NLM_article-title">Solid Pharmaceutical Composition</span>. <span class="NLM_patent">US 20160067185 A1</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=H.+Uchida&author=M.+Hanada&title=Solid+Pharmaceutical+Composition"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DUchida%26aufirst%3DH.%26atitle%3DSolid%2520Pharmaceutical%2520Composition%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Guruswamy, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arul, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaitanya, M. V. S. R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darsi, S. S. P. K.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis and Antimicrobial Evaluation of Novel Tricyclic Benzoxazine Fluoroquinolones under Conventional and Microwave Methods</span>. <i>J. Heterocycl. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">532</span>– <span class="NLM_lpage">538</span>, <span class="refDoi"> DOI: 10.1002/jhet.2093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1002%2Fjhet.2093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC2MXltFSltLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2015&pages=532-538&author=B.+Guruswamyauthor=R.+Arulauthor=M.+V.+S.+R.+K.+Chaitanyaauthor=S.+S.+P.+K.+Darsi&title=Design%2C+Synthesis+and+Antimicrobial+Evaluation+of+Novel+Tricyclic+Benzoxazine+Fluoroquinolones+under+Conventional+and+Microwave+Methods&doi=10.1002%2Fjhet.2093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis and Antimicrobial Evaluation of Novel Tricyclic Benzoxazine Fluoroquinolones under Conventional and Microwave Methods</span></div><div class="casAuthors">Guruswamy, B.; Arul, R.; Chaitanya, M. V. S. R. K.; Darsi, S. S. Praveen Kumar</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Heterocyclic Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">532-538</span>CODEN:
                <span class="NLM_cas:coden">JHTCAD</span>;
        ISSN:<span class="NLM_cas:issn">1943-5193</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The synthesis of novel fluoroquinolones bearing 2-(piperidin-4-yl)-1H-benzo[d]imidazole I (R = Et, CH2CH2OEt, benzyl, etc.) was described.  Alternatively, synthesis of these products was also demonstrated using microwave irradn. technique.  The antimicrobial activity of newly synthesized compds. was evaluated against no. of microorganisms and the activity is compared with highly active levofloxacin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZo8c7SPxzu7Vg90H21EOLACvtfcHk0likgM6FViAXYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXltFSltLw%253D&md5=c8281e70883aa5d95fcc7c7d811b2fdb</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1002%2Fjhet.2093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjhet.2093%26sid%3Dliteratum%253Aachs%26aulast%3DGuruswamy%26aufirst%3DB.%26aulast%3DArul%26aufirst%3DR.%26aulast%3DChaitanya%26aufirst%3DM.%2BV.%2BS.%2BR.%2BK.%26aulast%3DDarsi%26aufirst%3DS.%2BS.%2BP.%2BK.%26atitle%3DDesign%252C%2520Synthesis%2520and%2520Antimicrobial%2520Evaluation%2520of%2520Novel%2520Tricyclic%2520Benzoxazine%2520Fluoroquinolones%2520under%2520Conventional%2520and%2520Microwave%2520Methods%26jtitle%3DJ.%2520Heterocycl.%2520Chem.%26date%3D2015%26volume%3D52%26spage%3D532%26epage%3D538%26doi%3D10.1002%2Fjhet.2093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Takagi, N.</span>; <span class="NLM_string-name">Fubasami, H.</span>; <span class="NLM_string-name">Matsukubo, H.</span></span> <span> </span><span class="NLM_article-title">(6,7-Substituted-8-alkoxy-1-cyclopropyl-1,4-dihydro-4-oxo-3-quinolinecarboxylic Acid O3,O4)bis(acyloxy-O)borates and the Salts Thereof, and Methods for Their Manufacture</span>. <span class="NLM_patent">EP 464823 A1</span>, <span class="NLM_year">1992</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1992&author=N.+Takagi&author=H.+Fubasami&author=H.+Matsukubo&title=%286%2C7-Substituted-8-alkoxy-1-cyclopropyl-1%2C4-dihydro-4-oxo-3-quinolinecarboxylic+Acid+O3%2CO4%29bis%28acyloxy-O%29borates+and+the+Salts+Thereof%2C+and+Methods+for+Their+Manufacture"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTakagi%26aufirst%3DN.%26atitle%3D%25286%252C7-Substituted-8-alkoxy-1-cyclopropyl-1%252C4-dihydro-4-oxo-3-quinolinecarboxylic%2520Acid%2520O3%252CO4%2529bis%2528acyloxy-O%2529borates%2520and%2520the%2520Salts%2520Thereof%252C%2520and%2520Methods%2520for%2520Their%2520Manufacture%26date%3D1992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, K. L.</span></span> <span> </span><span class="NLM_article-title">Leave It to Lefamulin: A Pleuromutilin Treatment Option in Community-Acquired Bacterial Pneumonia</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">1867</span>– <span class="NLM_lpage">1876</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01219-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs40265-019-01219-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31705486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFemtb7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=1867-1876&author=Y.+R.+Leeauthor=K.+L.+Jacobs&title=Leave+It+to+Lefamulin%3A+A+Pleuromutilin+Treatment+Option+in+Community-Acquired+Bacterial+Pneumonia&doi=10.1007%2Fs40265-019-01219-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Leave it to Lefamulin: A Pleuromutilin Treatment Option in Community-Acquired Bacterial Pneumonia</span></div><div class="casAuthors">Lee, Young Ran; Jacobs, Katy Louise</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1867-1876</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Lefamulin (BC-3781) is the first systemic pleuromutilin antibiotic found to be safe and effective in the treatment of community-acquired bacterial pneumonia (CABP) in humans.  This novel antibiotic was developed to combat the increasing incidence of bacterial resistance to current therapies.  As the first semisynthetic pleuromutilin for systemic use in humans, lefamulin has demonstrated efficacy against the most common bacteria responsible for CABP, including strains exhibiting resistance to macrolides, fluoroquinolones, tetracyclines, vancomycin, and beta-lactams.  In vitro studies have demonstrated efficacy against Staphylococcus aureus, beta-hemolytic and viridans group streptococci, coagulase-neg. staphylococci, Enterococcus faecium, Streptococcus pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, Chlamydophila pneumoniae, Legionella pneumophilia, and Moraxella catarrhalis at MIC values lower than those of currently available therapies.  Two phase III trials (LEAP-1 and LEAP-2) have demonstrated similar findings, meeting non-inferiority criteria for CABP with a minimal side-effect profile.  Pharmacokinetic and pharmacodynamic evaluations have shown sufficient drug levels in plasma, s.c. adipose tissue, skeletal muscle, and epithelial lining fluid, warranting further investigation for other clin. uses.  Lefamulin was approved by the United States Food and Drug Administration (FDA) on 19 August 2019 for the treatment of CABP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHUgKKAfSTYrVg90H21EOLACvtfcHk0lhL8ZJx_DtaqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFemtb7O&md5=6f7dccf9ec6e4b657b587bf7d92183a5</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01219-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01219-5%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DY.%2BR.%26aulast%3DJacobs%26aufirst%3DK.%2BL.%26atitle%3DLeave%2520It%2520to%2520Lefamulin%253A%2520A%2520Pleuromutilin%2520Treatment%2520Option%2520in%2520Community-Acquired%2520Bacterial%2520Pneumonia%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D1867%26epage%3D1876%26doi%3D10.1007%2Fs40265-019-01219-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Veve, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, J. L.</span></span> <span> </span><span class="NLM_article-title">Lefamulin: Review of a Promising Novel Pleuromutilin Antibiotic</span>. <i>Pharmacotherapy</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">935</span>– <span class="NLM_lpage">946</span>, <span class="refDoi"> DOI: 10.1002/phar.2166</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1002%2Fphar.2166" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=30019769" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs12is7zE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2018&pages=935-946&author=M.+P.+Veveauthor=J.+L.+Wagner&title=Lefamulin%3A+Review+of+a+Promising+Novel+Pleuromutilin+Antibiotic&doi=10.1002%2Fphar.2166"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Lefamulin: Review of a Promising Novel Pleuromutilin Antibiotic</span></div><div class="casAuthors">Veve, Michael P.; Wagner, Jamie L.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacotherapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">935-946</span>CODEN:
                <span class="NLM_cas:coden">PHPYDQ</span>;
        ISSN:<span class="NLM_cas:issn">1875-9114</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The emergence and spread of antimicrobial resistance have led to a global public health emergency requiring development of new antimicrobial classes.  Lefamulin (formally BC-3781) is a novel pleuromutilin antibiotic currently undergoing Food and Drug Administration review for community-acquired bacterial pneumonia (CABP) as i.v. (IV) and oral (PO) formulations.  Although pleuromutilin antibiotics were first developed in the 1950s, lefamulin is the first to be used for systemic treatment of bacterial infections in humans.  Lefamulin exhibits a unique mechanism of action through inhibition of protein synthesis by binding to the peptidyl transferase center of the 50S bacterial ribosome, thus preventing the binding of tRNA for peptide transfer.  Lefamulin displays activity against gram-pos. and atypical organisms assocd. with CABP (i.e., Streptococcus pneumoniae,Haemophilus influenzae, Mycoplasma pneumoniae,Legionella pneumophila, and Chlamydophila pneumoniae), with an expanded gram-pos. spectrum including Staphylococcus aureus (i.e., methicillin-resistant, vancomycin-intermediate, and heterogeneous strains) and vancomycin-resistant Enterococcus faecium.  Lefamulin was also shown to retain activity against multidrug-resistant Neisseria gonorrhoeae and Mycoplasma genitalium.  Lefamulin exhibits time-dependent killing, and the pharmacodynamic target best assocd. with antibacterial activity is fAUC0-24/MIC (min. inhibitory concn. [MIC]).  Preclin. and phase II trials indicate that lefamulin concs. in lung tissue are well tolerated at an IV dose of 150 mg twice/day over 1 h or a PO dose of 600 mg twice/day, and preliminary phase III data suggest similar efficacy when compared with moxifloxacin with or without linezolid in CABP.  Documented resistance and cross-resistance with other gram-pos. antibacterials remains low.  Addnl. published in vitro, in vivo, and preclin. trial data suggest further exploration of lefamulin in various infectious disease states (e.g., acute bacterial skin and skin structure infections, and sexually transmitted infections).  This review discusses the pertinent bacterial spectrum of activity, preclin. and ongoing clin. data, and potential roles in therapy for lefamulin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrai5MjdMSCqLVg90H21EOLACvtfcHk0lhL8ZJx_DtaqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs12is7zE&md5=1d12eb7df78105bde865e23af4e9c636</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1002%2Fphar.2166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fphar.2166%26sid%3Dliteratum%253Aachs%26aulast%3DVeve%26aufirst%3DM.%2BP.%26aulast%3DWagner%26aufirst%3DJ.%2BL.%26atitle%3DLefamulin%253A%2520Review%2520of%2520a%2520Promising%2520Novel%2520Pleuromutilin%2520Antibiotic%26jtitle%3DPharmacotherapy%26date%3D2018%26volume%3D38%26spage%3D935%26epage%3D946%26doi%3D10.1002%2Fphar.2166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Falco, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almirante, B.</span></span> <span> </span><span class="NLM_article-title">An Overview of Lefamulin for the Treatment of Community Acquired Bacterial Pneumonia</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">629</span>– <span class="NLM_lpage">636</span>, <span class="refDoi"> DOI: 10.1080/14656566.2020.1714592</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1080%2F14656566.2020.1714592" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31958020" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1Kjuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2020&pages=629-636&author=V.+Falcoauthor=J.+Burgosauthor=B.+Almirante&title=An+Overview+of+Lefamulin+for+the+Treatment+of+Community+Acquired+Bacterial+Pneumonia&doi=10.1080%2F14656566.2020.1714592"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16aR"><div class="casContent"><span class="casTitleNuber">16a</span><div class="casTitle"><span class="NLM_cas:atitle">An overview of lefamulin for the treatment of community acquired bacterial pneumonia</span></div><div class="casAuthors">Falco, Vicenc; Burgos, Joaquin; Almirante, Benito</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">629-636</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  : Lefamulin is a novel antibiotic that belongs to the pleuromutilin class with excellent activity against all microorganisms, including atypical pathogens, that cause community-acquired pneumonia (CAP).: This article reviews the spectrum of activity, the main pharmacokinetic and pharmacodynamic characteristics of lefamulin as well as its clin. efficacy and safety in the treatment of CAP in adult patients.: The clin. efficacy of lefamulin in patients with non severe CAP has been demonstrated in 2 randomized clin. trials.  Precisely one of the limitations of the phase 3 trials is that the proportion of severe CAP cases is very low.  Its particular mechanism of action, affecting ribosomal protein synthesis, provides a low probability of cross-resistance to other commonly used antibiotics in CAP.  These findings, together with the antimicrobial activity of lefamulin, its pharmacokinetic parameters and safety profile make it a good alternative for outpatient treatment of CAP.  In patients hospitalized with CAP, lefamulin can be used as a potential oral step-down agent after an i.v. regimen with beta-lactams, or as a therapeutic alternative in patients with β-lactam allergies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHwxGEKPDywbVg90H21EOLACvtfcHk0lhL8ZJx_DtaqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1Kjuro%253D&md5=12538028d3ecebd5f0b14e720ec47690</span></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=10.1080%2F14656566.2020.1714592&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14656566.2020.1714592%26sid%3Dliteratum%253Aachs%26aulast%3DFalco%26aufirst%3DV.%26aulast%3DBurgos%26aufirst%3DJ.%26aulast%3DAlmirante%26aufirst%3DB.%26atitle%3DAn%2520Overview%2520of%2520Lefamulin%2520for%2520the%2520Treatment%2520of%2520Community%2520Acquired%2520Bacterial%2520Pneumonia%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2020%26volume%3D21%26spage%3D629%26epage%3D636%26doi%3D10.1080%2F14656566.2020.1714592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit16b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">File, T. M.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saviski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelone, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seltzer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paukner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wicha, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talbot, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasink, L. B.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety of Intravenous-to-Oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-Acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation against Pneumonia (LEAP 1) Trial</span>. <i>Clin. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">1856</span>– <span class="NLM_lpage">1867</span>, <span class="refDoi"> DOI: 10.1093/cid/ciz090</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1093%2Fcid%2Fciz090" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=30722059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnsVKlurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2019&pages=1856-1867&author=T.+M.+Fileauthor=L.+Goldbergauthor=A.+Dasauthor=C.+Sweeneyauthor=J.+Saviskiauthor=S.+P.+Geloneauthor=E.+Seltzerauthor=S.+Pauknerauthor=W.+W.+Wichaauthor=G.+H.+Talbotauthor=L.+B.+Gasink&title=Efficacy+and+Safety+of+Intravenous-to-Oral+Lefamulin%2C+a+Pleuromutilin+Antibiotic%2C+for+the+Treatment+of+Community-Acquired+Bacterial+Pneumonia%3A+The+Phase+III+Lefamulin+Evaluation+against+Pneumonia+%28LEAP+1%29+Trial&doi=10.1093%2Fcid%2Fciz090"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16bR"><div class="casContent"><span class="casTitleNuber">16b</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of intravenous-to-oral lefamulin, a pleuromutilin antibiotic, for the treatment of community-acquired bacterial pneumonia: the phase III lefamulin evaluation against pneumonia (LEAP 1) trial</span></div><div class="casAuthors">File, Thomas M., Jr.; Goldberg, Lisa; Das, Anita; Sweeney, Carolyn; Saviski, John; Gelone, Steven P.; Seltzer, Elyse; Paukner, Susanne; Wicha, Wolfgang W.; Talbot, George H.; Gasink, Leanne B.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Infectious Diseases</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1856-1867</span>CODEN:
                <span class="NLM_cas:coden">CIDIEL</span>;
        ISSN:<span class="NLM_cas:issn">1537-6591</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background.  Lefamulin, a pleuromutilin antibiotic, is active against pathogens commonly causing community-acquired bacterial pneumonia (CABP).  The Lefamulin Evaluation Against Pneumonia (LEAP 1) study was a global noninferiority trial to evaluate the efficacy and safety of lefamulin for the treatment of CABP.  In this double-blind study, adults with CABP of Pneumonia Outcomes Research Team risk class ≥III were randomized 1:1 to receive lefamulin at 150 mg i.v. (IV) every 12 h or moxifloxacin at 400 mg IV every 24 h.  After 6 doses, patients could be switched to an oral study drug if prespecified improvement criteria were met.  If methicillin-resistant Staphylococcus aureus was suspected, either linezolid or placebo was added to moxifloxacin or lefamulin, resp.  The US Food and Drug Administration primary endpoint was an early clin. response (ECR) 96 ± 24 h after the first dose of the study drug in the intent-to-treat (ITT) population (noninferiority margin, 12.5%).  The European Medicines Agency co-primary endpoints were an investigator assessment of clin. response (IACR) 5-10 days after the last dose of the study drug in the modified ITT (mITT) and clin. evaluable (CE) populations (noninferiority margin, 10%).  There were 551 patients randomized (n = 276 lefamulin; n = 275 moxifloxacin).  Lefamulin was noninferior to moxifloxacin for ECR (87.3% vs 90.2%, resp.; difference -2.9%, 95% confidence interval [CI] g -8.5 to 2.8) and IACR (mITT, 81.7% vs 84.2%, resp.; difference -2.6%, 95% CI -8.9 to 3.9; CE, 86.9% vs 89.4%, resp.; difference -2.5%, 95% CI -8.4 to 3.4).  Rates of study drug discontinuation due to treatment-emergent adverse events were 2.9% for lefamulin and 4.4% for moxifloxacin.  Conclusions.  Lefamulin was noninferior to moxifloxacin for the primary efficacy endpoints and was generally safe and well tolerated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAygfQ2PIOZLVg90H21EOLACvtfcHk0lgFllppVv9GIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnsVKlurY%253D&md5=8f51288366ed79a4a793c07e66076187</span></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=10.1093%2Fcid%2Fciz090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcid%252Fciz090%26sid%3Dliteratum%253Aachs%26aulast%3DFile%26aufirst%3DT.%2BM.%26aulast%3DGoldberg%26aufirst%3DL.%26aulast%3DDas%26aufirst%3DA.%26aulast%3DSweeney%26aufirst%3DC.%26aulast%3DSaviski%26aufirst%3DJ.%26aulast%3DGelone%26aufirst%3DS.%2BP.%26aulast%3DSeltzer%26aufirst%3DE.%26aulast%3DPaukner%26aufirst%3DS.%26aulast%3DWicha%26aufirst%3DW.%2BW.%26aulast%3DTalbot%26aufirst%3DG.%2BH.%26aulast%3DGasink%26aufirst%3DL.%2BB.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Intravenous-to-Oral%2520Lefamulin%252C%2520a%2520Pleuromutilin%2520Antibiotic%252C%2520for%2520the%2520Treatment%2520of%2520Community-Acquired%2520Bacterial%2520Pneumonia%253A%2520The%2520Phase%2520III%2520Lefamulin%2520Evaluation%2520against%2520Pneumonia%2520%2528LEAP%25201%2529%2520Trial%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2019%26volume%3D69%26spage%3D1856%26epage%3D1867%26doi%3D10.1093%2Fcid%2Fciz090" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Riedl, R.</span>; <span class="NLM_string-name">Heilmayer, W.</span>; <span class="NLM_string-name">Spence, L.</span></span> <span> </span><span class="NLM_article-title">Process for the Preparation of Pleuromutilins</span>. <span class="NLM_patent">US 9120727 B2</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=R.+Riedl&author=W.+Heilmayer&author=L.+Spence&title=Process+for+the+Preparation+of+Pleuromutilins"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRiedl%26aufirst%3DR.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%2520Pleuromutilins%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heilmayer, W.</span>; <span class="NLM_string-name">Spence, L.</span>; <span class="NLM_string-name">Hinsmann, P.</span></span> <span> </span><span class="NLM_article-title">Purification of Pleuromutilin</span>. <span class="NLM_patent">WO 2018146264 A1</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=W.+Heilmayer&author=L.+Spence&author=P.+Hinsmann&title=Purification+of+Pleuromutilin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHeilmayer%26aufirst%3DW.%26atitle%3DPurification%2520of%2520Pleuromutilin%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Keam, S. J.</span></span> <span> </span><span class="NLM_article-title">Pretomanid: First Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">1797</span>– <span class="NLM_lpage">1803</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01207-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs40265-019-01207-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31583606" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A280%3ADC%252BB3MnkvF2gsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=1797-1803&author=S.+J.+Keam&title=Pretomanid%3A+First+Approval&doi=10.1007%2Fs40265-019-01207-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19aR"><div class="casContent"><span class="casTitleNuber">19a</span><div class="casTitle"><span class="NLM_cas:atitle">Pretomanid: First Approval</span></div><div class="casAuthors">Keam Susan J</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1797-1803</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Pretomanid, an oral nitroimidazooxazine antimycobacterial agent administered as part of the BPaL (bedaquiline, pretomanid and linezolid) and BPaMZ (bedaquiline, pretomanid, moxifloxacin and pyrazinamide) regimens, has been developed by the Global Alliance for TB Drug Development (TB Alliance) under license from Novartis, for the treatment for tuberculosis (TB).  TB Alliance has licensed Mylan to manufacture and commercialize pretomanid for use as part of the BPaMZ and BPaL regimens.  The license is non-exclusive in low- and middle-income countries and exclusive in high-income markets.  Pretomanid, as part of the BPaL regimen, was recently approved in the USA under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) pathway for the treatment of adults with pulmonary extensively drug-resistant (XDR) or treatment-intolerant or non-responsive multidrug-resistant (MDR) TB.  Pretomanid is also under regulatory review in the EU.  This article summarizes the milestones in the development of pretomanid leading to this first regulatory approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ32shufXmAyUNoizSOkG_FfW6udTcc2eYXI3C9A87rJ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MnkvF2gsA%253D%253D&md5=5c28b82e658d5ce4aa0f1187cf2e7736</span></div><a href="/servlet/linkout?suffix=cit19a&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01207-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01207-9%26sid%3Dliteratum%253Aachs%26aulast%3DKeam%26aufirst%3DS.%2BJ.%26atitle%3DPretomanid%253A%2520First%2520Approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D1797%26epage%3D1803%26doi%3D10.1007%2Fs40265-019-01207-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit19b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Stover, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warrener, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">VanDevanter, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherman, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arain, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langhorne, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Towell, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMurray, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreiswirth, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, W. R.</span></span> <span> </span><span class="NLM_article-title">A Small-Molecule Nitroimidazopyran Drug Candidate for the Treatment of Tuberculosis</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>405</i></span>,  <span class="NLM_fpage">962</span>– <span class="NLM_lpage">966</span>, <span class="refDoi"> DOI: 10.1038/35016103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1038%2F35016103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10879539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BD3cXks1Wksb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=405&publication_year=2000&pages=962-966&author=C.+K.+Stoverauthor=P.+Warrenerauthor=D.+R.+VanDevanterauthor=D.+R.+Shermanauthor=T.+M.+Arainauthor=M.+H.+Langhorneauthor=S.+W.+Andersonauthor=J.+A.+Towellauthor=Y.+Yuanauthor=D.+N.+McMurrayauthor=B.+N.+Kreiswirthauthor=C.+E.+Barryauthor=W.+R.+Baker&title=A+Small-Molecule+Nitroimidazopyran+Drug+Candidate+for+the+Treatment+of+Tuberculosis&doi=10.1038%2F35016103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19bR"><div class="casContent"><span class="casTitleNuber">19b</span><div class="casTitle"><span class="NLM_cas:atitle">A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis</span></div><div class="casAuthors">Stover, C. Kendall; Warrener, Paul; VanDevanter, Donald R.; Sherman, David R.; Arain, Taraq M.; Langhorne, Michael H.; Anderson, Scott W.; Towell, J. Andrew; Yuan, Ying; McMurray, David N.; Krelswirth, Barry N.; Barry, Clifton E.; Baker, William R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">405</span>
        (<span class="NLM_cas:issue">6789</span>),
    <span class="NLM_cas:pages">962-966</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Mycobacterium tuberculosis, which causes tuberculosis, is the greatest single infectious cause of mortality worldwide, killing roughly; two million people annually.  Ests. indicate that one-third of the world population is infected with latent M. tuberculosis.  The synergy between tuberculosis and the AIDS epidemic, and the surge of multidrug-resistant clin. isolates of M. tuberculosis have reaffirmed tuberculosis as a primary public health threat.  However, new antitubercular drugs with new mechanisms of action have not been developed in over thirty years.  Here we report a series of compds. contg. a nitroimidazopyran nucleus that possess antitubercular activity.  After activation by a mechanism dependent on M. tuberculosis F420 cofactor, nitroimidazopyrans inhibited the synthesis of protein and cell wall lipid.  In contrast to current antitubercular drugs, nitroimidazopyrans exhibited bactericidal activity against both replicating and static M. tuberculosis.  Lead compd. PA-824 showed potent bactericidal activity against multidrug-resistant M. tuberculosis and promising oral activity in animal infection models.  We conclude that nitroimidazopyrans offer the practical qualities of a small mol. with the potential for the treatment of tuberculosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrw41eD4TtVwbVg90H21EOLACvtfcHk0lgFllppVv9GIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXks1Wksb0%253D&md5=f5f6e2935928da72e328bddd4995515f</span></div><a href="/servlet/linkout?suffix=cit19b&amp;dbid=16384&amp;doi=10.1038%2F35016103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35016103%26sid%3Dliteratum%253Aachs%26aulast%3DStover%26aufirst%3DC.%2BK.%26aulast%3DWarrener%26aufirst%3DP.%26aulast%3DVanDevanter%26aufirst%3DD.%2BR.%26aulast%3DSherman%26aufirst%3DD.%2BR.%26aulast%3DArain%26aufirst%3DT.%2BM.%26aulast%3DLanghorne%26aufirst%3DM.%2BH.%26aulast%3DAnderson%26aufirst%3DS.%2BW.%26aulast%3DTowell%26aufirst%3DJ.%2BA.%26aulast%3DYuan%26aufirst%3DY.%26aulast%3DMcMurray%26aufirst%3DD.%2BN.%26aulast%3DKreiswirth%26aufirst%3DB.%2BN.%26aulast%3DBarry%26aufirst%3DC.%2BE.%26aulast%3DBaker%26aufirst%3DW.%2BR.%26atitle%3DA%2520Small-Molecule%2520Nitroimidazopyran%2520Drug%2520Candidate%2520for%2520the%2520Treatment%2520of%2520Tuberculosis%26jtitle%3DNature%26date%3D2000%26volume%3D405%26spage%3D962%26epage%3D966%26doi%3D10.1038%2F35016103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><a href="https://www.tballiance.org/why-new-tb-drugs/global-pandemic" class="extLink">https://www.tballiance.org/why-new-tb-drugs/global-pandemic</a> (accessed 2021-01-14).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.tballiance.org%2Fwhy-new-tb-drugs%2Fglobal-pandemic+%28accessed+2021-01-14%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Manjunatha, U. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boshoff, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowd, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albert, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norton, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniels, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. E.,  3rd</span></span> <span> </span><span class="NLM_article-title">Identification of a Nitroimidazo-Oxazine-Specific Protein Involved in PA-824 Resistance in Mycobacterium Tuberculosis</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">431</span>– <span class="NLM_lpage">436</span>, <span class="refDoi"> DOI: 10.1073/pnas.0508392103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1073%2Fpnas.0508392103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=16387854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BD28XpsVSltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=431-436&author=U.+H.+Manjunathaauthor=H.+Boshoffauthor=C.+S.+Dowdauthor=L.+Zhangauthor=T.+J.+Albertauthor=J.+E.+Nortonauthor=L.+Danielsauthor=T.+Dickauthor=S.+S.+Pangauthor=C.+E.+Barry&title=Identification+of+a+Nitroimidazo-Oxazine-Specific+Protein+Involved+in+PA-824+Resistance+in+Mycobacterium+Tuberculosis&doi=10.1073%2Fpnas.0508392103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21aR"><div class="casContent"><span class="casTitleNuber">21a</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis</span></div><div class="casAuthors">Manjunatha, Ujjini H.; Boshoff, Helena; Dowd, Cynthia S.; Zhang, Liang; Albert, Thomas J.; Norton, Jason E.; Daniels, Lacy; Dick, Thomas; Pang, Siew Siew; Barry, Clifton E., III</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">431-436</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">PA-824 is a promising new compd. for the treatment of tuberculosis that is currently undergoing human trials.  Like its progenitors metronidazole and CGI-17341, PA-824 is a prodrug of the nitroimidazole class, requiring bioreductive activation of an arom. nitro group to exert an antitubercular effect.  The authors have confirmed that resistance to PA-824 (a nitroimidazo-oxazine) and CGI-17341 (a nitroimidazo-oxazole) is most commonly mediated by loss of a specific glucose-6-phosphate dehydrogenase (FGD1) or its deazaflavin cofactor F420, which together provide electrons for the reductive activation of this class of mols.  Although FGD1 and F420 are necessary for sensitivity to these compds., they are not sufficient and require addnl. accessory proteins that directly interact with the nitroimidazole.  To understand more proximal events in the reductive activation of PA-824, the authors examd. mutants that were wild-type for both FGD1 and F420 and found that, although these mutants had acquired high-level resistance to PA-824 (and another nitroimidazo-oxazine), they retained sensitivity to CGI-17341 (and a related nitroimidazo-oxazole).  Microarray-based comparative genome sequencing of these mutants identified lesions in Rv3547, a conserved hypothetical protein with no known function.  Complementation with intact Rv3547 fully restored sensitivity to nitroimidazo-oxazines and restored the ability of Mtb to metabolize PA-824.  These results suggest that the sensitivity of Mtb to PA-824 and related compds. is mediated by a protein that is highly specific for subtle structural variations in these bicyclic nitroimidazoles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX0bL9yx6FB7Vg90H21EOLACvtfcHk0ljQHhVLOEISaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpsVSltQ%253D%253D&md5=66a247925f28a6d254c75a543bb52e74</span></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0508392103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0508392103%26sid%3Dliteratum%253Aachs%26aulast%3DManjunatha%26aufirst%3DU.%2BH.%26aulast%3DBoshoff%26aufirst%3DH.%26aulast%3DDowd%26aufirst%3DC.%2BS.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DAlbert%26aufirst%3DT.%2BJ.%26aulast%3DNorton%26aufirst%3DJ.%2BE.%26aulast%3DDaniels%26aufirst%3DL.%26aulast%3DDick%26aufirst%3DT.%26aulast%3DPang%26aufirst%3DS.%2BS.%26aulast%3DBarry%26aufirst%3DC.%2BE.%26atitle%3DIdentification%2520of%2520a%2520Nitroimidazo-Oxazine-Specific%2520Protein%2520Involved%2520in%2520PA-824%2520Resistance%2520in%2520Mycobacterium%2520Tuberculosis%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2006%26volume%3D103%26spage%3D431%26epage%3D436%26doi%3D10.1073%2Fpnas.0508392103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit21b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manjunatha, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boshoff, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ha, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niyomrattanakit, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ledwidge, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowd, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, I. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiricek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. E.,  3rd</span></span> <span> </span><span class="NLM_article-title">PA-824 Kills Nonreplicating Mycobacterium Tuberculosis by Intracellular No Release</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>322</i></span>,  <span class="NLM_fpage">1392</span>– <span class="NLM_lpage">1395</span>, <span class="refDoi"> DOI: 10.1126/science.1164571</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1126%2Fscience.1164571" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=19039139" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVagt7jN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=322&publication_year=2008&pages=1392-1395&author=R.+Singhauthor=U.+Manjunathaauthor=H.+I.+Boshoffauthor=Y.+H.+Haauthor=P.+Niyomrattanakitauthor=R.+Ledwidgeauthor=C.+S.+Dowdauthor=I.+Y.+Leeauthor=P.+Kimauthor=L.+Zhangauthor=S.+Kangauthor=T.+H.+Kellerauthor=J.+Jiricekauthor=C.+E.+Barry&title=PA-824+Kills+Nonreplicating+Mycobacterium+Tuberculosis+by+Intracellular+No+Release&doi=10.1126%2Fscience.1164571"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21bR"><div class="casContent"><span class="casTitleNuber">21b</span><div class="casTitle"><span class="NLM_cas:atitle">PA-824 Kills Nonreplicating Mycobacterium tuberculosis by Intracellular NO Release</span></div><div class="casAuthors">Singh, Ramandeep; Manjunatha, Ujjini; Boshoff, Helena I. M.; Ha, Young Hwan; Niyomrattanakit, Pornwaratt; Ledwidge, Richard; Dowd, Cynthia S.; Lee, Ill Young; Kim, Pilho; Zhang, Liang; Kang, Sunhee; Keller, Thomas H.; Jiricek, Jan; Barry, Clifton E., III</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">322</span>
        (<span class="NLM_cas:issue">5906</span>),
    <span class="NLM_cas:pages">1392-1395</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Bicyclic nitroimidazoles, including PA-824, are exciting candidates for the treatment of tuberculosis.  These prodrugs require intracellular activation for their biol. function.  We found that Rv3547 is a deazaflavin-dependent nitroreductase (Ddn) that converts PA-824 into three primary metabolites; the major one is the corresponding des-nitroimidazole (des-nitro).  When derivs. of PA-824 were used, the amt. of des-nitro metabolite formed was highly correlated with anaerobic killing of Mycobacterium tuberculosis (Mtb).  Des-nitro metabolite formation generated reactive nitrogen species, including nitric oxide (NO), which are the major effectors of the anaerobic activity of these compds.  Furthermore, NO scavengers protected the bacilli from the lethal effects of the drug.  Thus, these compds. may act as intracellular NO donors and could augment a killing mechanism intrinsic to the innate immune system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdOQ6XyUn59bVg90H21EOLACvtfcHk0ljQHhVLOEISaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVagt7jN&md5=5d7d8715b5565938b3ffd9fd35a723da</span></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=10.1126%2Fscience.1164571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1164571%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DManjunatha%26aufirst%3DU.%26aulast%3DBoshoff%26aufirst%3DH.%2BI.%26aulast%3DHa%26aufirst%3DY.%2BH.%26aulast%3DNiyomrattanakit%26aufirst%3DP.%26aulast%3DLedwidge%26aufirst%3DR.%26aulast%3DDowd%26aufirst%3DC.%2BS.%26aulast%3DLee%26aufirst%3DI.%2BY.%26aulast%3DKim%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DKang%26aufirst%3DS.%26aulast%3DKeller%26aufirst%3DT.%2BH.%26aulast%3DJiricek%26aufirst%3DJ.%26aulast%3DBarry%26aufirst%3DC.%2BE.%26atitle%3DPA-824%2520Kills%2520Nonreplicating%2520Mycobacterium%2520Tuberculosis%2520by%2520Intracellular%2520No%2520Release%26jtitle%3DScience%26date%3D2008%26volume%3D322%26spage%3D1392%26epage%3D1395%26doi%3D10.1126%2Fscience.1164571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit21c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Manjunatha, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boshoff, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, C. E.</span></span> <span> </span><span class="NLM_article-title">The Mechanism of Action of PA-824: Novel Insights from Transcriptional Profiling</span>. <i>Commun. Integr. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">215</span>– <span class="NLM_lpage">218</span>, <span class="refDoi"> DOI: 10.4161/cib.2.3.7926</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.4161%2Fcib.2.3.7926" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=19641733" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1yru7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2009&pages=215-218&author=U.+Manjunathaauthor=H.+I.+Boshoffauthor=C.+E.+Barry&title=The+Mechanism+of+Action+of+PA-824%3A+Novel+Insights+from+Transcriptional+Profiling&doi=10.4161%2Fcib.2.3.7926"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21cR"><div class="casContent"><span class="casTitleNuber">21c</span><div class="casTitle"><span class="NLM_cas:atitle">The mechanism of action of PA-824: novel insights from transcriptional profiling</span></div><div class="casAuthors">Manjunatha, Ujjini; Boshoff, Helena I. M.; Barry, Clifton E., III</div><div class="citationInfo"><span class="NLM_cas:title">Communicative & Integrative Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">215-218</span>CODEN:
                <span class="NLM_cas:coden">CIBOBQ</span>;
        ISSN:<span class="NLM_cas:issn">1942-0889</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">The bicyclic nitroimidazole PA-824 is a pro-drug with a very complex mechanism of action active against both replicating and hypoxic, non-replicating Mycobacterium tuberculosis.  Microarray anal. of the mode of action of PA-824 showed a puzzling mixed effect both on genes responsive to both cell wall inhibition (like isoniazid) and respiratory poisoning (like cyanide).  The aerobic killing mechanism of this drug appears to involve inhibition of cell wall mycolic acid biosynthesis through an as yet unknown mol. mechanism.  However, the structure-activity relationships governing aerobic activity do not parallel the relationships detg. anaerobic activity.  Based on the metabolite profiling of PA-824 and various derivs. by Ddn-mediated activation, we have shown that PA-824 acts directly as an NO donor.  This respiratory poisoning through nitric oxide release seemed to be a crucial element of anaerobic activity by PA-824.  The effect of PA-824 on the respiratory complex under hypoxic non-replicating conditions was also manifested in a rapid drop in intracellular ATP levels, again similar to that obsd. by cyanide treatment.  Thus, transcriptional profiling provided valuable clues to elucidating the mol. mechanism of mycobacterial killing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRIjCfr9dB9bVg90H21EOLACvtfcHk0li28WOH0GLFqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1yru7bF&md5=b7b25a9c2c9b39ff446571c9a2d6d297</span></div><a href="/servlet/linkout?suffix=cit21c&amp;dbid=16384&amp;doi=10.4161%2Fcib.2.3.7926&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcib.2.3.7926%26sid%3Dliteratum%253Aachs%26aulast%3DManjunatha%26aufirst%3DU.%26aulast%3DBoshoff%26aufirst%3DH.%2BI.%26aulast%3DBarry%26aufirst%3DC.%2BE.%26atitle%3DThe%2520Mechanism%2520of%2520Action%2520of%2520PA-824%253A%2520Novel%2520Insights%2520from%2520Transcriptional%2520Profiling%26jtitle%3DCommun.%2520Integr.%2520Biol.%26date%3D2009%26volume%3D2%26spage%3D215%26epage%3D218%26doi%3D10.4161%2Fcib.2.3.7926" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Marsini, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reider, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorensen, E. J.</span></span> <span> </span><span class="NLM_article-title">A Concise and Convergent Synthesis of PA-824</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">7479</span>– <span class="NLM_lpage">7482</span>, <span class="refDoi"> DOI: 10.1021/jo1015807</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo1015807" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1GqsbrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2010&pages=7479-7482&author=M.+A.+Marsiniauthor=P.+J.+Reiderauthor=E.+J.+Sorensen&title=A+Concise+and+Convergent+Synthesis+of+PA-824&doi=10.1021%2Fjo1015807"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22aR"><div class="casContent"><span class="casTitleNuber">22a</span><div class="casTitle"><span class="NLM_cas:atitle">A concise and convergent synthesis of PA-824</span></div><div class="casAuthors">Marsini, Maurice A.; Reider, Paul J.; Sorensen, Erik J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7479-7482</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An efficient four-step synthesis of PA-824 (I), a promising antituberculosis drug candidate, has been developed.  This concise approach offers significant improvements over the synthetic route currently used for large-scale prodn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0pd6Qc_jnNLVg90H21EOLACvtfcHk0li28WOH0GLFqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1GqsbrE&md5=6d2dba5d47e3efb9743efecd36e77cb3</span></div><a href="/servlet/linkout?suffix=cit22a&amp;dbid=16384&amp;doi=10.1021%2Fjo1015807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo1015807%26sid%3Dliteratum%253Aachs%26aulast%3DMarsini%26aufirst%3DM.%2BA.%26aulast%3DReider%26aufirst%3DP.%2BJ.%26aulast%3DSorensen%26aufirst%3DE.%2BJ.%26atitle%3DA%2520Concise%2520and%2520Convergent%2520Synthesis%2520of%2520PA-824%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2010%26volume%3D75%26spage%3D7479%26epage%3D7482%26doi%3D10.1021%2Fjo1015807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit22b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutherland, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kmentova, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franzblau, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denny, W. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Structure-Activity Studies of Biphenyl Analogues of the Tuberculosis Drug (6<i>S</i>)-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5<i>H</i>-imidazo[2,1-<i>b</i>][1,3]oxazine (PA-824)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">282</span>– <span class="NLM_lpage">294</span>, <span class="refDoi"> DOI: 10.1021/jm901207n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901207n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVKhs7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=282-294&author=B.+D.+Palmerauthor=A.+M.+Thompsonauthor=H.+S.+Sutherlandauthor=A.+Blaserauthor=I.+Kmentovaauthor=S.+G.+Franzblauauthor=B.+Wanauthor=Y.+Wangauthor=Z.+Maauthor=W.+A.+Denny&title=Synthesis+and+Structure-Activity+Studies+of+Biphenyl+Analogues+of+the+Tuberculosis+Drug+%286S%29-2-Nitro-6-%7B%5B4-%28trifluoromethoxy%29benzyl%5Doxy%7D-6%2C7-dihydro-5H-imidazo%5B2%2C1-b%5D%5B1%2C3%5Doxazine+%28PA-824%29&doi=10.1021%2Fjm901207n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22bR"><div class="casContent"><span class="casTitleNuber">22b</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and structure-activity studies of biphenyl analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)</span></div><div class="casAuthors">Palmer, Brian D.; Thompson, Andrew M.; Sutherland, Hamish S.; Blaser, Adrian; Kmentova, Iveta; Franzblau, Scott G.; Wan, Baojie; Wang, Yuehong; Ma, Zhenkun; Denny, William A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">282-294</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of biphenyl analogs of the new tuberculosis drug PA-824 e. g. , I was prepd., primarily by coupling the known (6S)-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-6-ol with iodobenzyl halides, followed by Suzuki coupling of these iodides with appropriate arylboronic acids or by assembly of the complete biaryl side chain prior to coupling with the above alc.  Antitubercular activity was detd. under both replicating (MABA) and nonreplicating (LORA) conditions.  Para-Linked biaryls were the most active, followed by meta-linked and then ortho-linked analogs.  A more detailed study of a larger group of para-linked analogs showed a significant correlation between potency (MABA) and both lipophilicity (CLOGP) and the electron-withdrawing properties of terminal ring substituents (.sum.σ).  Selected compds. were evaluated for their efficacy in a mouse model of acute Mycobacterium tuberculosis infection.  In vivo activity correlated well with the stability of compds. to microsomal metab.  Three compds. bearing combinations of lipophilic, electron-withdrawing groups achieved >200-fold higher efficacies than the parent drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5IcLLHAUDWbVg90H21EOLACvtfcHk0li28WOH0GLFqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVKhs7rL&md5=1ff5a8bd11f095f428898ec13f884259</span></div><a href="/servlet/linkout?suffix=cit22b&amp;dbid=16384&amp;doi=10.1021%2Fjm901207n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901207n%26sid%3Dliteratum%253Aachs%26aulast%3DPalmer%26aufirst%3DB.%2BD.%26aulast%3DThompson%26aufirst%3DA.%2BM.%26aulast%3DSutherland%26aufirst%3DH.%2BS.%26aulast%3DBlaser%26aufirst%3DA.%26aulast%3DKmentova%26aufirst%3DI.%26aulast%3DFranzblau%26aufirst%3DS.%2BG.%26aulast%3DWan%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DZ.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26atitle%3DSynthesis%2520and%2520Structure-Activity%2520Studies%2520of%2520Biphenyl%2520Analogues%2520of%2520the%2520Tuberculosis%2520Drug%2520%25286S%2529-2-Nitro-6-%257B%255B4-%2528trifluoromethoxy%2529benzyl%255Doxy%257D-6%252C7-dihydro-5H-imidazo%255B2%252C1-b%255D%255B1%252C3%255Doxazine%2520%2528PA-824%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D282%26epage%3D294%26doi%3D10.1021%2Fjm901207n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit22c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Strassfeld, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wickens, Z. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picazo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobsen, E. N.</span></span> <span> </span><span class="NLM_article-title">Highly Enantioselective, Hydrogen-Bond-Donor Catalyzed Additions to Oxetanes</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>142</i></span>,  <span class="NLM_fpage">9175</span>– <span class="NLM_lpage">9180</span>, <span class="refDoi"> DOI: 10.1021/jacs.0c03991</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.0c03991" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BB3cXosVKqsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2020&pages=9175-9180&author=D.+A.+Strassfeldauthor=Z.+K.+Wickensauthor=E.+Picazoauthor=E.+N.+Jacobsen&title=Highly+Enantioselective%2C+Hydrogen-Bond-Donor+Catalyzed+Additions+to+Oxetanes&doi=10.1021%2Fjacs.0c03991"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22cR"><div class="casContent"><span class="casTitleNuber">22c</span><div class="casTitle"><span class="NLM_cas:atitle">Highly Enantioselective, Hydrogen-Bond-Donor Catalyzed Additions to Oxetanes</span></div><div class="casAuthors">Strassfeld, Daniel A.; Wickens, Zachary K.; Picazo, Elias; Jacobsen, Eric N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">9175-9180</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A precisely designed chiral squaramide deriv. is shown to promote the highly enantioselective addn. of trimethylsilyl bromide (TMSBr) to a broad variety of 3-substituted and 3,3-disubstituted oxetanes.  The reaction provides direct and general access to synthetically valuable 1,3-bromohydrin building blocks from easily accessed achiral precursors.  The products are readily elaborated both by nucleophilic substitution and through transition-metal-catalyzed cross-coupling reactions.  The enantioselective catalytic oxetane ring opening was employed as part of a three-step, gram-scale synthesis of pretomanid, a recently approved medication for the treatment of multidrug-resistant tuberculosis.  Heavy-atom kinetic isotope effect (KIE) studies are consistent with enantiodetermining delivery of bromide from the H-bond-donor (HBD) catalyst to the activated oxetane.  While the nucleophilicity of the bromide ion is expected to be attenuated by assocn. to the HBD, overall rate acceleration is achieved by enhancement of Lewis acidity of the TMSBr reagent through anion abstraction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoU1lCPb-jtirVg90H21EOLACvtfcHk0lhch30ekLsUwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXosVKqsbY%253D&md5=ccc51be70e5455ce0da0a75a6eb2c871</span></div><a href="/servlet/linkout?suffix=cit22c&amp;dbid=16384&amp;doi=10.1021%2Fjacs.0c03991&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.0c03991%26sid%3Dliteratum%253Aachs%26aulast%3DStrassfeld%26aufirst%3DD.%2BA.%26aulast%3DWickens%26aufirst%3DZ.%2BK.%26aulast%3DPicazo%26aufirst%3DE.%26aulast%3DJacobsen%26aufirst%3DE.%2BN.%26atitle%3DHighly%2520Enantioselective%252C%2520Hydrogen-Bond-Donor%2520Catalyzed%2520Additions%2520to%2520Oxetanes%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2020%26volume%3D142%26spage%3D9175%26epage%3D9180%26doi%3D10.1021%2Fjacs.0c03991" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit22d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinde, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franzblau, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denny, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, B. D.</span></span> <span> </span><span class="NLM_article-title">Synthesis, Reduction Potentials, and Antitubercular Activity of Ring A/B Analogues of the Bioreductive Drug (6<i>S</i>)-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5<i>H</i>-imidazo[2,1-<i>b</i>][1,3]oxazine (PA-824)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">637</span>– <span class="NLM_lpage">645</span>, <span class="refDoi"> DOI: 10.1021/jm801087e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801087e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFais7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=637-645&author=A.+M.+Thompsonauthor=A.+Blaserauthor=R.+F.+Andersonauthor=S.+S.+Shindeauthor=S.+G.+Franzblauauthor=Z.+Maauthor=W.+A.+Dennyauthor=B.+D.+Palmer&title=Synthesis%2C+Reduction+Potentials%2C+and+Antitubercular+Activity+of+Ring+A%2FB+Analogues+of+the+Bioreductive+Drug+%286S%29-2-Nitro-6-%7B%5B4-%28trifluoromethoxy%29benzyl%5Doxy%7D-6%2C7-dihydro-5H-imidazo%5B2%2C1-b%5D%5B1%2C3%5Doxazine+%28PA-824%29&doi=10.1021%2Fjm801087e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22dR"><div class="casContent"><span class="casTitleNuber">22d</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Reduction Potentials, and Antitubercular Activity of Ring A/B Analogues of the Bioreductive Drug (6S)-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)</span></div><div class="casAuthors">Thompson, Andrew M.; Blaser, Adrian; Anderson, Robert F.; Shinde, Sujata S.; Franzblau, Scott G.; Ma, Zhenkun; Denny, William A.; Palmer, Brian D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">637-645</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The nitroimidazooxazine I (PA-824) is a new class of bioreductive drug for tuberculosis.  A series of related bicyclic nitroheterocycles was synthesized, designed to have a wide range of one-electron redn. potentials E(1) (from -570 to -338 mV, compared with -534 mV for I).  The obsd. E(1) values closely correlated with the σm values of the heteroatom at the 4/8-position of the adjacent six-membered ring.  Although the compds. spanned a range of E(1) values around that of I, only the nitroimidazothiazines showed significant antitubercular activity (at a similar level of potency), suggesting that E(1) is not the main driver of efficacy.  Furthermore, there was a correlation between activity and the formation of imidazole ring-reduced products at the two-electron level, pointing to the potential importance of this redn. pathway, which is detd. by the nature of the substituent at the 2-position of the 4-nitroimidazole ring.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoalNzH_DuAirVg90H21EOLACvtfcHk0lhch30ekLsUwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFais7%252FK&md5=a9fe7edce4c538f14ddec49942a1e9a0</span></div><a href="/servlet/linkout?suffix=cit22d&amp;dbid=16384&amp;doi=10.1021%2Fjm801087e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801087e%26sid%3Dliteratum%253Aachs%26aulast%3DThompson%26aufirst%3DA.%2BM.%26aulast%3DBlaser%26aufirst%3DA.%26aulast%3DAnderson%26aufirst%3DR.%2BF.%26aulast%3DShinde%26aufirst%3DS.%2BS.%26aulast%3DFranzblau%26aufirst%3DS.%2BG.%26aulast%3DMa%26aufirst%3DZ.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DPalmer%26aufirst%3DB.%2BD.%26atitle%3DSynthesis%252C%2520Reduction%2520Potentials%252C%2520and%2520Antitubercular%2520Activity%2520of%2520Ring%2520A%252FB%2520Analogues%2520of%2520the%2520Bioreductive%2520Drug%2520%25286S%2529-2-Nitro-6-%257B%255B4-%2528trifluoromethoxy%2529benzyl%255Doxy%257D-6%252C7-dihydro-5H-imidazo%255B2%252C1-b%255D%255B1%252C3%255Doxazine%2520%2528PA-824%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D637%26epage%3D645%26doi%3D10.1021%2Fjm801087e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit22e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Orita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miwa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uehara, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otera, J.</span></span> <span> </span><span class="NLM_article-title">Integration of Solventless Reaction in a Multi-Step Process: Application to an Efficient Synthesis of PA-824</span>. <i>Adv. Synth. Catal.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>349</i></span>,  <span class="NLM_fpage">2136</span>– <span class="NLM_lpage">2144</span>, <span class="refDoi"> DOI: 10.1002/adsc.200700119</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1002%2Fadsc.200700119" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFCnt7bO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=349&publication_year=2007&pages=2136-2144&author=A.+Oritaauthor=K.+Miwaauthor=G.+Ueharaauthor=J.+Otera&title=Integration+of+Solventless+Reaction+in+a+Multi-Step+Process%3A+Application+to+an+Efficient+Synthesis+of+PA-824&doi=10.1002%2Fadsc.200700119"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22eR"><div class="casContent"><span class="casTitleNuber">22e</span><div class="casTitle"><span class="NLM_cas:atitle">Integration of solventless reaction in a multi-step process: application to an efficient synthesis of PA-824</span></div><div class="casAuthors">Orita, Akihiro; Miwa, Kai; Uehara, Genta; Otera, Junzo</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Synthesis & Catalysis</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">349</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2136-2144</span>CODEN:
                <span class="NLM_cas:coden">ASCAF7</span>;
        ISSN:<span class="NLM_cas:issn">1615-4150</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">In order to improve redundant synthetic processes, the integration of a solventless reaction has proved to be useful for gaining high reaction mass efficiency (RME) as well as reducing the amt. of solvents.  This concept was applied to synthesis of PA-824, a potential antituberculosis drug.  Thus, the solventless ring-opening reaction of glycidyl silyl ether with 2,4-dinitroimidazole was connected to succeeding soln. reactions.  The ring-opening of glycidol followed by selective silylation of the primary hydroxy group under solventless conditions was also feasible.  As a consequence, the overall yield of the target compd. was nearly tripled, and thus the RME values were increased more than 2.5 times while the amt. of necessary solvents was decreased to less than 1/3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcpf25EF_EW7Vg90H21EOLACvtfcHk0lhch30ekLsUwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFCnt7bO&md5=869a7057a842e377f50972650e8a4802</span></div><a href="/servlet/linkout?suffix=cit22e&amp;dbid=16384&amp;doi=10.1002%2Fadsc.200700119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fadsc.200700119%26sid%3Dliteratum%253Aachs%26aulast%3DOrita%26aufirst%3DA.%26aulast%3DMiwa%26aufirst%3DK.%26aulast%3DUehara%26aufirst%3DG.%26aulast%3DOtera%26aufirst%3DJ.%26atitle%3DIntegration%2520of%2520Solventless%2520Reaction%2520in%2520a%2520Multi-Step%2520Process%253A%2520Application%2520to%2520an%2520Efficient%2520Synthesis%2520of%2520PA-824%26jtitle%3DAdv.%2520Synth.%2520Catal.%26date%3D2007%26volume%3D349%26spage%3D2136%26epage%3D2144%26doi%3D10.1002%2Fadsc.200700119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Baker, W. R.</span>; <span class="NLM_string-name">Cai, S.</span>; <span class="NLM_string-name">Keeler, E. L.</span></span> <span> </span><span class="NLM_article-title">Preparation of Bicyclic Nitroimidazole Antibacterial Compounds</span>. <span class="NLM_patent">WO 9701562 A1</span>, <span class="NLM_year">1997</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1997&author=W.+R.+Baker&author=S.+Cai&author=E.+L.+Keeler&title=Preparation+of+Bicyclic+Nitroimidazole+Antibacterial+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBaker%26aufirst%3DW.%2BR.%26atitle%3DPreparation%2520of%2520Bicyclic%2520Nitroimidazole%2520Antibacterial%2520Compounds%26date%3D1997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit23b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Baker, W. R.</span>; <span class="NLM_string-name">Cai, S.</span>; <span class="NLM_string-name">Keeler, E. L.</span></span> <span> </span><span class="NLM_article-title">Nitro-[2,1-<i>b</i>]imidazopyran Compounds and Antibacterial Uses Thereof</span>. <span class="NLM_patent">US 6087358 A</span>, <span class="NLM_year">2000</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2000&author=W.+R.+Baker&author=S.+Cai&author=E.+L.+Keeler&title=Nitro-%5B2%2C1-b%5Dimidazopyran+Compounds+and+Antibacterial+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBaker%26aufirst%3DW.%2BR.%26atitle%3DNitro-%255B2%252C1-b%255Dimidazopyran%2520Compounds%2520and%2520Antibacterial%2520Uses%2520Thereof%26date%3D2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Miao, D.</span>; <span class="NLM_string-name">Hu, Q.</span>; <span class="NLM_string-name">Li, Y.</span>; <span class="NLM_string-name">Yu, Z.</span>; <span class="NLM_string-name">Wang, H.</span>; <span class="NLM_string-name">Zhu, X.</span></span> <span> </span><span class="NLM_article-title">Synthesis Method of PA-824 (Pretomanid) for Treating Tuberculosis</span>. <span class="NLM_patent">CN 107915747 A</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=D.+Miao&author=Q.+Hu&author=Y.+Li&author=Z.+Yu&author=H.+Wang&author=X.+Zhu&title=Synthesis+Method+of+PA-824+%28Pretomanid%29+for+Treating+Tuberculosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMiao%26aufirst%3DD.%26atitle%3DSynthesis%2520Method%2520of%2520PA-824%2520%2528Pretomanid%2529%2520for%2520Treating%2520Tuberculosis%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit24b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Miao, D.</span>; <span class="NLM_string-name">Hu, Q.</span>; <span class="NLM_string-name">Zhang, X.</span>; <span class="NLM_string-name">Zhao, L.</span>; <span class="NLM_string-name">Cao, Y.</span>; <span class="NLM_string-name">Wang, H.</span></span> <span> </span><span class="NLM_article-title">Crystal Form of PA-824 and Preparation Method, and Its Application for Treating Tuberculosis (TB)</span>. <span class="NLM_patent">CN 106565744 A</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=D.+Miao&author=Q.+Hu&author=X.+Zhang&author=L.+Zhao&author=Y.+Cao&author=H.+Wang&title=Crystal+Form+of+PA-824+and+Preparation+Method%2C+and+Its+Application+for+Treating+Tuberculosis+%28TB%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMiao%26aufirst%3DD.%26atitle%3DCrystal%2520Form%2520of%2520PA-824%2520and%2520Preparation%2520Method%252C%2520and%2520Its%2520Application%2520for%2520Treating%2520Tuberculosis%2520%2528TB%2529%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit24c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.</span></span> <span> </span><span class="NLM_article-title">Synthesis Research of PA-824 as Antituberculosis Candidate</span>. <i>Huagong Shikan</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">51</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtV2rsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2010&pages=32-51&author=T.+Wangauthor=H.+Zhangauthor=H.+Fan&title=Synthesis+Research+of+PA-824+as+Antituberculosis+Candidate"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24cR"><div class="casContent"><span class="casTitleNuber">24c</span><div class="casTitle"><span class="NLM_cas:atitle">Microwave-assisted extraction method of Cuphea hookeriana Walp pigment</span></div><div class="casAuthors">Sun, Qianhong; Wang, Ying; Zhang, Lei; Wang, Binyu</div><div class="citationInfo"><span class="NLM_cas:title">Huagong Shikan</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">32-35</span>CODEN:
                <span class="NLM_cas:coden">HUSHFT</span>;
        ISSN:<span class="NLM_cas:issn">1002-154X</span>.
    
            (<span class="NLM_cas:orgname">Huagong Shikan Zazhishe</span>)
        </div><div class="casAbstract">The aim of this paper is to construct a microwave-assisted extn. method for extg. pigment of Cuphea hookeriana Walp.  Process parameters for different extn. process conditions were optimized.  The correlation of parameters to the extn. yield followed a order: liq. materials>power>ethanol concn.>microwave processing time.  The optimal technique was obtained as follows: solvent 80% of acidic aq. alc., microwave power 800 W, the solid/liq. proportion 1g:30mL, extg. time 60s.  Compared with traditional methods, the microwave extn. method has advantages of high efficiency, quick extn. rate and lower energy consumption, and it has a bright prospects for application in pigment extn. of plant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUhJM_AnDOkrVg90H21EOLACvtfcHk0lgPbAk3FWpiBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtV2rsw%253D%253D&md5=a8c9d249c0bb259eec0b063a6ce4cd38</span></div><a href="/servlet/linkout?suffix=cit24c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DFan%26aufirst%3DH.%26atitle%3DSynthesis%2520Research%2520of%2520PA-824%2520as%2520Antituberculosis%2520Candidate%26jtitle%3DHuagong%2520Shikan%26date%3D2010%26volume%3D24%26spage%3D32%26epage%3D51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit24d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, M.</span>; <span class="NLM_string-name">Yang, C.</span>; <span class="NLM_string-name">Li, L.</span>; <span class="NLM_string-name">Liu, E.</span>; <span class="NLM_string-name">Li, L.</span>; <span class="NLM_string-name">Zhan, H.</span>; <span class="NLM_string-name">Fan, W.</span>; <span class="NLM_string-name">Tian, J.</span>; <span class="NLM_string-name">Sang, D.</span>; <span class="NLM_string-name">Mao, X.</span></span> <span> </span><span class="NLM_article-title">A Method for Synthesizing Antituberculosis Drug Candidate PA-824</span>. <span class="NLM_patent">CN 106632393 A</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=M.+Yao&author=C.+Yang&author=L.+Li&author=E.+Liu&author=L.+Li&author=H.+Zhan&author=W.+Fan&author=J.+Tian&author=D.+Sang&author=X.+Mao&title=A+Method+for+Synthesizing+Antituberculosis+Drug+Candidate+PA-824"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DM.%26atitle%3DA%2520Method%2520for%2520Synthesizing%2520Antituberculosis%2520Drug%2520Candidate%2520PA-824%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit24e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, X.</span>; <span class="NLM_string-name">Miao, X.</span>; <span class="NLM_string-name">Guo, M.</span>; <span class="NLM_string-name">Gong, P.</span>; <span class="NLM_string-name">Jiang, N.</span>; <span class="NLM_string-name">Chen, G.</span></span> <span> </span><span class="NLM_article-title">Preparation Method of Nitroimidazolopyran Compound, and Its Application in Treating Tuberculosis</span>. <span class="NLM_patent">CN 110483549 A</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=X.+Zhai&author=X.+Miao&author=M.+Guo&author=P.+Gong&author=N.+Jiang&author=G.+Chen&title=Preparation+Method+of+Nitroimidazolopyran+Compound%2C+and+Its+Application+in+Treating+Tuberculosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZhai%26aufirst%3DX.%26atitle%3DPreparation%2520Method%2520of%2520Nitroimidazolopyran%2520Compound%252C%2520and%2520Its%2520Application%2520in%2520Treating%2520Tuberculosis%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, B. P.</span>; <span class="NLM_string-name">Reddy, K. R.</span>; <span class="NLM_string-name">Reddy, A. V. N.</span>; <span class="NLM_string-name">Krishna, B. V.</span></span> <span> </span><span class="NLM_article-title">An Improved Process for Preparing Pretomanid</span>. <span class="NLM_patent">IN 201641030408 A</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=B.+P.+Reddy&author=K.+R.+Reddy&author=A.+V.+N.+Reddy&author=B.+V.+Krishna&title=An+Improved+Process+for+Preparing+Pretomanid"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DReddy%26aufirst%3DB.%2BP.%26atitle%3DAn%2520Improved%2520Process%2520for%2520Preparing%2520Pretomanid%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rybak, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claeys, K. C.</span></span> <span> </span><span class="NLM_article-title">Imipenem-Cilastatin-Relebactam: A Novel B-Lactam-B-Lactamase Inhibitor Combination for the Treatment of Multidrug-Resistant Gram-Negative Infections</span>. <i>Pharmacotherapy</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">343</span>– <span class="NLM_lpage">356</span>, <span class="refDoi"> DOI: 10.1002/phar.2378</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1002%2Fphar.2378" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=32060929" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BB3cXntFSmt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2020&pages=343-356&author=J.+R.+Smithauthor=J.+M.+Rybakauthor=K.+C.+Claeys&title=Imipenem-Cilastatin-Relebactam%3A+A+Novel+B-Lactam-B-Lactamase+Inhibitor+Combination+for+the+Treatment+of+Multidrug-Resistant+Gram-Negative+Infections&doi=10.1002%2Fphar.2378"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Imipenem-Cilastatin-Relebactam: A Novel β-Lactam-β-Lactamase Inhibitor Combination for the Treatment of Multidrug-Resistant Gram-Negative Infections</span></div><div class="casAuthors">Smith, Jordan R.; Rybak, Jeffrey M.; Claeys, Kimberly C.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacotherapy</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">343-356</span>CODEN:
                <span class="NLM_cas:coden">PHPYDQ</span>;
        ISSN:<span class="NLM_cas:issn">1875-9114</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Imipenem-cilastatin-relebactam (IMI-REL) is a novel β-lactam-β-lactamase inhibitor combination recently approved for the treatment of complicated urinary tract infections (cUTIs) and complicated intraabdominal infections (cIAIs).  Relebactam is a β-lactamase inhibitor with the ability to inhibit a broad spectrum of β-lactamases such as class A and class C β-lactamases, including carbapenemases.  The addn. of relebactam to imipenem restores imipenem activity against several imipenem-resistant bacteria, including Enterobacteriaceae and Pseudomonas aeruginosa.  Clin. data demonstrate that IMI-REL is well tolerated and effective in the treatment of cUTIs and cIAIs due to imipenem-resistant bacteria.  In a phase III trial comparing IMI-REL with imipenem plus colistin, favorable clin. response was achieved in 71% and 70% of patients, resp.  Available clin. and pharmacokinetic data support the approved dosage of a 30-min infusion of imipenem 500 mg-cilastatin 500 mg-relebactam 250 mg every 6 h, along with dosage adjustments based on renal function.  In this review, we describe the chem., mechanism of action, spectrum of activity, pharmacokinetics and pharmacodynamics, and clin. efficacy, and safety and tolerability of this new agent.  The approval of IMI-REL represents another important step in the ongoing fight against multidrug-resistant gram-neg. pathogens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGph2Rjs531UWbVg90H21EOLACvtfcHk0lgPbAk3FWpiBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXntFSmt7s%253D&md5=6e670b780d6b80a00075df2de6ae4d9b</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1002%2Fphar.2378&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fphar.2378%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DJ.%2BR.%26aulast%3DRybak%26aufirst%3DJ.%2BM.%26aulast%3DClaeys%26aufirst%3DK.%2BC.%26atitle%3DImipenem-Cilastatin-Relebactam%253A%2520A%2520Novel%2520B-Lactam-B-Lactamase%2520Inhibitor%2520Combination%2520for%2520the%2520Treatment%2520of%2520Multidrug-Resistant%2520Gram-Negative%2520Infections%26jtitle%3DPharmacotherapy%26date%3D2020%26volume%3D40%26spage%3D343%26epage%3D356%26doi%3D10.1002%2Fphar.2378" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Bhagunde, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Racine, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizk, M. L.</span></span> <span> </span><span class="NLM_article-title">A Translational Pharmacokinetic/Pharmacodynamic Model to Characterize Bacterial Kill in the Presence of Imipenem-Relebactam</span>. <i>Int. J. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">55</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1016/j.ijid.2019.08.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2Fj.ijid.2019.08.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31479762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVOmtr%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2019&pages=55-61&author=P.+Bhagundeauthor=Z.+Zhangauthor=F.+Racineauthor=D.+Carrauthor=J.+Wuauthor=K.+Youngauthor=M.+L.+Rizk&title=A+Translational+Pharmacokinetic%2FPharmacodynamic+Model+to+Characterize+Bacterial+Kill+in+the+Presence+of+Imipenem-Relebactam&doi=10.1016%2Fj.ijid.2019.08.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27aR"><div class="casContent"><span class="casTitleNuber">27a</span><div class="casTitle"><span class="NLM_cas:atitle">A translational pharmacokinetic/pharmacodynamic model to characterize bacterial kill in the presence of imipenem-relebactam</span></div><div class="casAuthors">Bhagunde, Pratik; Zhang, Zufei; Racine, Fred; Carr, Donna; Wu, Jin; Young, Katherine; Rizk, Matthew L.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Infectious Diseases</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">55-61</span>CODEN:
                <span class="NLM_cas:coden">IJIDF3</span>;
        ISSN:<span class="NLM_cas:issn">1201-9712</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Relebactam is a small mol. β-lactamase inhibitor under clin. investigation for use as a fixed-dose combination with imipenem/cilastatin.  Here we present a translational pharmacokinetic/pharmacodynamic math. model to support optimal dose selection of relebactam.  Data derived from in vitro checkerboard and hollow fiber infection studies of imipenem-resistant strains of Pseudomonas aeruginosa were incorporated into the model.  The model integrates the effect of relebactam concn. on imipenem susceptibility in a semi-mechanistic manner using the checkerboard data and characterizes the bacterial time-kill profiles from the hollow fiber infection model data.  Simulations demonstrated that the ratio of the area under the concn.-time curve for free drug to the min. inhibitory concn. (fAUC/MIC) was the pharmacokinetic driver for relebactam, with a target fAUC/MIC = 7.5 assocd. with 2-log kill.  At a clin. dose of 250 mg relebactam, greater than 2-log redns. in bacterial load are projected for imipenem-resistant strains with an imipenem/relebactam MIC ≤ 4μg/mL.  The study confirms that the pharmacokinetic/pharmacodynamic driver for relebactam is fAUC/MIC, that an fAUC/MIC ratio of 7.5 is assocd. with 2-log kill in vitro, and that a 250 mg clin. dose of relebactam achieves this target value when delivered in combination with imipenem/cilastatin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbxW9s5LhnNbVg90H21EOLACvtfcHk0lhjCWm-e2SNdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVOmtr%252FP&md5=6652628dd0f67ca153408a9b338ac6ff</span></div><a href="/servlet/linkout?suffix=cit27a&amp;dbid=16384&amp;doi=10.1016%2Fj.ijid.2019.08.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijid.2019.08.026%26sid%3Dliteratum%253Aachs%26aulast%3DBhagunde%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DRacine%26aufirst%3DF.%26aulast%3DCarr%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DYoung%26aufirst%3DK.%26aulast%3DRizk%26aufirst%3DM.%2BL.%26atitle%3DA%2520Translational%2520Pharmacokinetic%252FPharmacodynamic%2520Model%2520to%2520Characterize%2520Bacterial%2520Kill%2520in%2520the%2520Presence%2520of%2520Imipenem-Relebactam%26jtitle%3DInt.%2520J.%2520Infect.%2520Dis.%26date%3D2019%26volume%3D89%26spage%3D55%26epage%3D61%26doi%3D10.1016%2Fj.ijid.2019.08.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit27b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kaushik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ammerman, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martins, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreiswirth, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamichhane, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parrish, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuermberger, E. L.</span></span> <span> </span><span class="NLM_article-title"><i>In vitro</i> Activity of the New β-Lactamase Inhibitors Relebactam and Vaborbactam in Combination with β-Lactams against Mycobacterium Abscessus Complex Clinical Isolates</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">e02623-18</span>, <span class="refDoi"> DOI: 10.1128/AAC.02623-18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1128%2FAAC.02623-18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=30642943" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2019&pages=e02623-18&author=A.+Kaushikauthor=N.+C.+Ammermanauthor=J.+Leeauthor=O.+Martinsauthor=B.+N.+Kreiswirthauthor=G.+Lamichhaneauthor=N.+M.+Parrishauthor=E.+L.+Nuermberger&title=In+vitro+Activity+of+the+New+%CE%B2-Lactamase+Inhibitors+Relebactam+and+Vaborbactam+in+Combination+with+%CE%B2-Lactams+against+Mycobacterium+Abscessus+Complex+Clinical+Isolates&doi=10.1128%2FAAC.02623-18"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27b&amp;dbid=16384&amp;doi=10.1128%2FAAC.02623-18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.02623-18%26sid%3Dliteratum%253Aachs%26aulast%3DKaushik%26aufirst%3DA.%26aulast%3DAmmerman%26aufirst%3DN.%2BC.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DMartins%26aufirst%3DO.%26aulast%3DKreiswirth%26aufirst%3DB.%2BN.%26aulast%3DLamichhane%26aufirst%3DG.%26aulast%3DParrish%26aufirst%3DN.%2BM.%26aulast%3DNuermberger%26aufirst%3DE.%2BL.%26atitle%3DIn%2520vitro%2520Activity%2520of%2520the%2520New%2520%25CE%25B2-Lactamase%2520Inhibitors%2520Relebactam%2520and%2520Vaborbactam%2520in%2520Combination%2520with%2520%25CE%25B2-Lactams%2520against%2520Mycobacterium%2520Abscessus%2520Complex%2520Clinical%2520Isolates%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2019%26volume%3D63%26spage%3De02623-18%26doi%3D10.1128%2FAAC.02623-18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit27c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, M. W.</span></span> <span> </span><span class="NLM_article-title">Clinical Pharmacokinetics and Pharmacodynamics of Imipenem-Cilastatin/Relebactam Combination Therapy</span>. <i>Clin. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">567</span>– <span class="NLM_lpage">573</span>, <span class="refDoi"> DOI: 10.1007/s40262-020-00865-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs40262-020-00865-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=32009210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BB3cXls1ynurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2020&pages=567-573&author=M.+W.+McCarthy&title=Clinical+Pharmacokinetics+and+Pharmacodynamics+of+Imipenem-Cilastatin%2FRelebactam+Combination+Therapy&doi=10.1007%2Fs40262-020-00865-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27cR"><div class="casContent"><span class="casTitleNuber">27c</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical Pharmacokinetics and Pharmacodynamics of Imipenem-Cilastatin/Relebactam Combination Therapy</span></div><div class="casAuthors">McCarthy, Matthew W.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">567-573</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Abstr.: On 16 July, 2019, the US Food and Drug Administration approved imipenem-cilastatin/relebactam (Recarbrio) for the treatment of adults with complicated urinary tract infections and complicated intra-abdominal infections.  This decision was based on substantial clin. and pre-clin. data, including rigorous pharmacokinetic and pharmacodynamic work, and is an important step forward in the management of these debilitating conditions.  This article provides an overview of the body of research assocd. with imipenem-cilastatin/relebactam, beginning with an examn. of the fundamental underpinnings of the pharmacokinetic/pharmacodynamic index.  This is followed by the pharmacokinetic/pharmacodynamic work that led to the approval of this novel drug combination, including data derived from checkerboard and hollow fiber infection studies, as well as large, multi-center, phase III clin. trials known as RESTORE-IMI 1 and RESTORE-IMI 2.  The article also explores how this important new antibiotic may be used to treat other infections in the years to come, including hospital-acquired bacterial pneumonia and ventilator-assocd. pneumonia attributed to imipenem-non-susceptible pathogens and certain atypical mycobacterial infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqx8mmN0IZvKrVg90H21EOLACvtfcHk0lhjCWm-e2SNdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXls1ynurg%253D&md5=03311683cc74d3be2dc4dc4d2538fb55</span></div><a href="/servlet/linkout?suffix=cit27c&amp;dbid=16384&amp;doi=10.1007%2Fs40262-020-00865-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40262-020-00865-3%26sid%3Dliteratum%253Aachs%26aulast%3DMcCarthy%26aufirst%3DM.%2BW.%26atitle%3DClinical%2520Pharmacokinetics%2520and%2520Pharmacodynamics%2520of%2520Imipenem-Cilastatin%252FRelebactam%2520Combination%2520Therapy%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2020%26volume%3D59%26spage%3D567%26epage%3D573%26doi%3D10.1007%2Fs40262-020-00865-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Blizzard, T. A.</span>; <span class="NLM_string-name">Chen, H.</span>; <span class="NLM_string-name">Gude, C.</span>; <span class="NLM_string-name">Hermes, J. D.</span>; <span class="NLM_string-name">Imbriglio, J. E.</span>; <span class="NLM_string-name">Kim, S.</span>; <span class="NLM_string-name">Wu, J. Y.</span>; <span class="NLM_string-name">Ha, S.</span>; <span class="NLM_string-name">Mortko, C. J.</span>; <span class="NLM_string-name">Mangion, I.</span>; <span class="NLM_string-name">Rivera, N.</span>; <span class="NLM_string-name">Ruck, R. T.</span>; <span class="NLM_string-name">Shevlin, M.</span></span> <span> </span><span class="NLM_article-title">Preparation of Sulfooxydiazabicyclooctanecarboxamide Derivatives and Analogues for Use as β-Lactamase Inhibitors</span>. <span class="NLM_patent">WO 2009091856 A2</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=T.+A.+Blizzard&author=H.+Chen&author=C.+Gude&author=J.+D.+Hermes&author=J.+E.+Imbriglio&author=S.+Kim&author=J.+Y.+Wu&author=S.+Ha&author=C.+J.+Mortko&author=I.+Mangion&author=N.+Rivera&author=R.+T.+Ruck&author=M.+Shevlin&title=Preparation+of+Sulfooxydiazabicyclooctanecarboxamide+Derivatives+and+Analogues+for+Use+as+%CE%B2-Lactamase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBlizzard%26aufirst%3DT.%2BA.%26atitle%3DPreparation%2520of%2520Sulfooxydiazabicyclooctanecarboxamide%2520Derivatives%2520and%2520Analogues%2520for%2520Use%2520as%2520%25CE%25B2-Lactamase%2520Inhibitors%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit28b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, J. Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shevlin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gudipati, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, Y.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, F.</span></span> <span> </span><span class="NLM_article-title">Diastereoselective FeCl3·6H2O/NaBH4 Reduction of Oxime Ether for the Synthesis of β-Lactamase Inhibitor Relebactam</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">994</span>– <span class="NLM_lpage">1000</span>, <span class="refDoi"> DOI: 10.1021/acs.joc.9b02948</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.joc.9b02948" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVWqsLbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2020&pages=994-1000&author=J.+Y.+L.+Chungauthor=D.+Mengauthor=M.+Shevlinauthor=V.+Gudipatiauthor=Q.+Chenauthor=Y.+Liuauthor=Y.-H.+Lamauthor=A.+Dumasauthor=J.+Scottauthor=Q.+Tuauthor=F.+Xu&title=Diastereoselective+FeCl3%C2%B76H2O%2FNaBH4+Reduction+of+Oxime+Ether+for+the+Synthesis+of+%CE%B2-Lactamase+Inhibitor+Relebactam&doi=10.1021%2Facs.joc.9b02948"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28bR"><div class="casContent"><span class="casTitleNuber">28b</span><div class="casTitle"><span class="NLM_cas:atitle">Diastereoselective FeCl3·6H2O/NaBH4 Reduction of Oxime Ether for the Synthesis of β-Lactamase Inhibitor Relebactam</span></div><div class="casAuthors">Chung, John Y. L.; Meng, Dongfang; Shevlin, Michael; Gudipati, Venugopal; Chen, Qinghao; Liu, Yizhou; Lam, Yu-hong; Dumas, Aaron; Scott, Jeremy; Tu, Qiang; Xu, Feng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">994-1000</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Relebactam, a potent β-lactamase inhibitor, in combination with Primaxin is an FDA-approved (Recarbrio) treatment for serious and antibiotic-resistant bacterial infections.  An efficient synthesis of key chiral piperidine intermediate I suitable for large-scale prepn. of relebactam is described.  The key steps include a unique highly diastereoselective FeCl3·6H2O/NaBH4 redn. of a chiral oxime ether and chemoselective amidation of the resulting unprotected pipecolic acid.  NMR studies and d. functional theory calcns. were carried out on the substrate-Fe(III) complexes, which shed light on diastereoselective redn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokHfs8PHiCoLVg90H21EOLACvtfcHk0liu0sQGKrYSIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVWqsLbJ&md5=2974d820ed9f3a93879c057494cf25e9</span></div><a href="/servlet/linkout?suffix=cit28b&amp;dbid=16384&amp;doi=10.1021%2Facs.joc.9b02948&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.joc.9b02948%26sid%3Dliteratum%253Aachs%26aulast%3DChung%26aufirst%3DJ.%2BY.%2BL.%26aulast%3DMeng%26aufirst%3DD.%26aulast%3DShevlin%26aufirst%3DM.%26aulast%3DGudipati%26aufirst%3DV.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLam%26aufirst%3DY.-H.%26aulast%3DDumas%26aufirst%3DA.%26aulast%3DScott%26aufirst%3DJ.%26aulast%3DTu%26aufirst%3DQ.%26aulast%3DXu%26aufirst%3DF.%26atitle%3DDiastereoselective%2520FeCl3%25C2%25B76H2O%252FNaBH4%2520Reduction%2520of%2520Oxime%2520Ether%2520for%2520the%2520Synthesis%2520of%2520%25CE%25B2-Lactamase%2520Inhibitor%2520Relebactam%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2020%26volume%3D85%26spage%3D994%26epage%3D1000%26doi%3D10.1021%2Facs.joc.9b02948" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit28c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, E. M.</span>; <span class="NLM_string-name">Freund, J.</span>; <span class="NLM_string-name">Gallop, M. A.</span>; <span class="NLM_string-name">Duncton, M. A. J.</span></span> <span> </span><span class="NLM_article-title">β-Lactamase Inhibitors and Uses Thereof</span>. <span class="NLM_patent">WO 2018208557 A1</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=E.+M.+Gordon&author=J.+Freund&author=M.+A.+Gallop&author=M.+A.+J.+Duncton&title=%CE%B2-Lactamase+Inhibitors+and+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGordon%26aufirst%3DE.%2BM.%26atitle%3D%25CE%25B2-Lactamase%2520Inhibitors%2520and%2520Uses%2520Thereof%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit28d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasuda, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reamer, R. A.</span></span> <span> </span><span class="NLM_article-title">N-Boc Deprotection and Isolation Method for Water-Soluble Zwitterionic Compounds</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">11792</span>– <span class="NLM_lpage">11796</span>, <span class="refDoi"> DOI: 10.1021/jo502319z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo502319z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVyjtLfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2014&pages=11792-11796&author=Z.+Liuauthor=N.+Yasudaauthor=M.+Simeoneauthor=R.+A.+Reamer&title=N-Boc+Deprotection+and+Isolation+Method+for+Water-Soluble+Zwitterionic+Compounds&doi=10.1021%2Fjo502319z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28dR"><div class="casContent"><span class="casTitleNuber">28d</span><div class="casTitle"><span class="NLM_cas:atitle">N-Boc Deprotection and Isolation Method for Water-Soluble Zwitterionic Compounds</span></div><div class="casAuthors">Liu, Zhijian; Yasuda, Nobuyoshi; Simeone, Michael; Reamer, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">11792-11796</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A highly efficient TMSI-mediated deprotection and direct isolation method to obtain zwitterionic compds. from the corresponding N-Boc derivs. has been developed.  This method has been demonstrated in the final deprotection/isolation of the β-lactamase inhibitor MK-7655 as a part of its manufg. process.  Further application of this process toward other zwitterionic compds., such as dipeptides and tripeptides, has been successfully developed.  Furthermore, a catalytic version of this transformation has been demonstrated in the presence of BSA or BSTFA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqk_bYF7atVrVg90H21EOLACvtfcHk0liu0sQGKrYSIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVyjtLfP&md5=9b486f313ca22a0cbca5a7be880b0c17</span></div><a href="/servlet/linkout?suffix=cit28d&amp;dbid=16384&amp;doi=10.1021%2Fjo502319z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo502319z%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DYasuda%26aufirst%3DN.%26aulast%3DSimeone%26aufirst%3DM.%26aulast%3DReamer%26aufirst%3DR.%2BA.%26atitle%3DN-Boc%2520Deprotection%2520and%2520Isolation%2520Method%2520for%2520Water-Soluble%2520Zwitterionic%2520Compounds%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2014%26volume%3D79%26spage%3D11792%26epage%3D11796%26doi%3D10.1021%2Fjo502319z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit28e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Mangion, I. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruck, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huffman, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shevlin, M.</span></span> <span> </span><span class="NLM_article-title">A Concise Synthesis of a β-Lactamase Inhibitor</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">5480</span>– <span class="NLM_lpage">5483</span>, <span class="refDoi"> DOI: 10.1021/ol202195n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol202195n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFOqu7%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=5480-5483&author=I.+K.+Mangionauthor=R.+T.+Ruckauthor=N.+Riveraauthor=M.+A.+Huffmanauthor=M.+Shevlin&title=A+Concise+Synthesis+of+a+%CE%B2-Lactamase+Inhibitor&doi=10.1021%2Fol202195n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28eR"><div class="casContent"><span class="casTitleNuber">28e</span><div class="casTitle"><span class="NLM_cas:atitle">A concise synthesis of a β-lactamase inhibitor</span></div><div class="casAuthors">Mangion, Ian K.; Ruck, Rebecca T.; Rivera, Nelo; Huffman, Mark A.; Shevlin, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5480-5483</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">MK-7655 (I) is a β-lactamase inhibitor in clin. trials as a combination therapy for the treatment of bacterial infection resistant to β-lactam antibiotics.  Its unusual structural challenges have inspired a rapid synthesis featuring an iridium-catalyzed N-H insertion and a series of late stage transformations designed around the reactivity of the labile bicyclo[3.2.1]urea at the core of the target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOWYLM3Irur7Vg90H21EOLACvtfcHk0liu0sQGKrYSIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFOqu7%252FF&md5=65c566fa7bb43e063c0e1dce89759c20</span></div><a href="/servlet/linkout?suffix=cit28e&amp;dbid=16384&amp;doi=10.1021%2Fol202195n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol202195n%26sid%3Dliteratum%253Aachs%26aulast%3DMangion%26aufirst%3DI.%2BK.%26aulast%3DRuck%26aufirst%3DR.%2BT.%26aulast%3DRivera%26aufirst%3DN.%26aulast%3DHuffman%26aufirst%3DM.%2BA.%26aulast%3DShevlin%26aufirst%3DM.%26atitle%3DA%2520Concise%2520Synthesis%2520of%2520a%2520%25CE%25B2-Lactamase%2520Inhibitor%26jtitle%3DOrg.%2520Lett.%26date%3D2011%26volume%3D13%26spage%3D5480%26epage%3D5483%26doi%3D10.1021%2Fol202195n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit28f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, S. P.</span>; <span class="NLM_string-name">Limanto, J.</span>; <span class="NLM_string-name">Zhong, Y.-L.</span>; <span class="NLM_string-name">Yasuda, N.</span>; <span class="NLM_string-name">Liu, Z.</span></span> <span> </span><span class="NLM_article-title">Preparation of <i>tert</i>-Butyl 4-((1<i>R</i>,2<i>S</i>,5<i>R</i>)-6-(Benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamido)piperidine-1-carboxylate</span>. <span class="NLM_patent">WO 2014200786 A1</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=S.+P.+Miller&author=J.+Limanto&author=Y.-L.+Zhong&author=N.+Yasuda&author=Z.+Liu&title=Preparation+of+tert-Butyl+4-%28%281R%2C2S%2C5R%29-6-%28Benzyloxy%29-7-oxo-1%2C6-diazabicyclo%5B3.2.1%5Doctane-2-carboxamido%29piperidine-1-carboxylate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28f&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DS.%2BP.%26atitle%3DPreparation%2520of%2520tert-Butyl%25204-%2528%25281R%252C2S%252C5R%2529-6-%2528Benzyloxy%2529-7-oxo-1%252C6-diazabicyclo%255B3.2.1%255Doctane-2-carboxamido%2529piperidine-1-carboxylate%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit28g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Pawar, S. S.</span>; <span class="NLM_string-name">Dond, B. D.</span>; <span class="NLM_string-name">Bhavsar, S.</span>; <span class="NLM_string-name">Jadhav, A. S.</span>; <span class="NLM_string-name">Ahirrao, V. K.</span>; <span class="NLM_string-name">Patil, K. R.</span>; <span class="NLM_string-name">Yeole, R. D.</span>; <span class="NLM_string-name">Deshpande, P. K.</span>; <span class="NLM_string-name">Patel, M. V.</span></span> <span> </span><span class="NLM_article-title">Process for O-Sulfonation of 1,6-Diazabicyclo[3.2.1]octane Compounds</span>. <span class="NLM_patent">WO 2018234962 A</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=S.+S.+Pawar&author=B.+D.+Dond&author=S.+Bhavsar&author=A.+S.+Jadhav&author=V.+K.+Ahirrao&author=K.+R.+Patil&author=R.+D.+Yeole&author=P.+K.+Deshpande&author=M.+V.+Patel&title=Process+for+O-Sulfonation+of+1%2C6-Diazabicyclo%5B3.2.1%5Doctane+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28g&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPawar%26aufirst%3DS.%2BS.%26atitle%3DProcess%2520for%2520O-Sulfonation%2520of%25201%252C6-Diazabicyclo%255B3.2.1%255Doctane%2520Compounds%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit28h"><span><span class="NLM_label">(h) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Wankhede, K. S.</span>; <span class="NLM_string-name">Surwase, M. M.</span>; <span class="NLM_string-name">Bhawsar, S.</span>; <span class="NLM_string-name">Deshpande, P. K.</span>; <span class="NLM_string-name">Yeole, R. D.</span>; <span class="NLM_string-name">Patel, M. V.</span></span> <span> </span><span class="NLM_article-title">Process for Preparation of (2<i>S</i>,5<i>R</i>)-Sulfuric Acid Mono-{[(4-aminopiperidin-4-yl)carbonyl]-7-oxo-1,6-diazabicyclo[3.2.1]-oct-6-yl}ester</span> <span class="NLM_patent">WO 2015033191 A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=K.+S.+Wankhede&author=M.+M.+Surwase&author=S.+Bhawsar&author=P.+K.+Deshpande&author=R.+D.+Yeole&author=M.+V.+Patel&title=Process+for+Preparation+of+%282S%2C5R%29-Sulfuric+Acid+Mono-%7B%5B%284-aminopiperidin-4-yl%29carbonyl%5D-7-oxo-1%2C6-diazabicyclo%5B3.2.1%5D-oct-6-yl%7Dester"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28h&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWankhede%26aufirst%3DK.%2BS.%26atitle%3DProcess%2520for%2520Preparation%2520of%2520%25282S%252C5R%2529-Sulfuric%2520Acid%2520Mono-%257B%255B%25284-aminopiperidin-4-yl%2529carbonyl%255D-7-oxo-1%252C6-diazabicyclo%255B3.2.1%255D-oct-6-yl%257Dester%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf" class="extLink">https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208711s000lbl.pdf</a> (accessed 2020-09-18).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2019%2F208711s000lbl.pdf+%28accessed+2020-09-18%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><a href="https://www.who.int/foodborne_trematode_infections/fascioliasis/en/" class="extLink">https://www.who.int/foodborne_trematode_infections/fascioliasis/en/</a> (accessed 2020-09-15).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.who.int%2Ffoodborne_trematode_infections%2Ffascioliasis%2Fen%2F+%28accessed+2020-09-15%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Gallay, J.-J.</span>; <span class="NLM_string-name">Kuhne, M.</span>; <span class="NLM_string-name">Meyer, A.</span>; <span class="NLM_string-name">Rechsteiner, O.</span>; <span class="NLM_string-name">Schellenbaum, M.</span></span> <span> </span><span class="NLM_article-title">2-Alkylthio-2-Alkylsulphinyl- and 2-Alkylsulfonyl-6-Phenylbenzimidazoles as Antihelmintic Agents</span>. <span class="NLM_patent">US 4197307 A</span>, <span class="NLM_year">1980</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1980&author=J.-J.+Gallay&author=M.+Kuhne&author=A.+Meyer&author=O.+Rechsteiner&author=M.+Schellenbaum&title=2-Alkylthio-2-Alkylsulphinyl-+and+2-Alkylsulfonyl-6-Phenylbenzimidazoles+as+Antihelmintic+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGallay%26aufirst%3DJ.-J.%26atitle%3D2-Alkylthio-2-Alkylsulphinyl-%2520and%25202-Alkylsulfonyl-6-Phenylbenzimidazoles%2520as%2520Antihelmintic%2520Agents%26date%3D1980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit31b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span>; <span class="NLM_string-name">Zhou, Q.</span></span> <span> </span><span class="NLM_article-title">Method for Preparing Triclabendazole</span>. <span class="NLM_patent">CN 101555231 A</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=X.+Li&author=Q.+Zhou&title=Method+for+Preparing+Triclabendazole"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26atitle%3DMethod%2520for%2520Preparing%2520Triclabendazole%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rane, R. A.</span>; <span class="NLM_string-name">Verma, S.</span>; <span class="NLM_string-name">Arulmoli, T.</span></span> <span> </span><span class="NLM_article-title">Process for Preparation of Triclabendazole</span>. <span class="NLM_patent">US 20130303781 A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=R.+A.+Rane&author=S.+Verma&author=T.+Arulmoli&title=Process+for+Preparation+of+Triclabendazole"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRane%26aufirst%3DR.%2BA.%26atitle%3DProcess%2520for%2520Preparation%2520of%2520Triclabendazole%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duggan, S.</span></span> <span> </span><span class="NLM_article-title">Esaxerenone: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">477</span>– <span class="NLM_lpage">481</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01073-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs40265-019-01073-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=30806972" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFyitLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=477-481&author=S.+Duggan&title=Esaxerenone%3A+First+Global+Approval&doi=10.1007%2Fs40265-019-01073-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Esaxerenone: First Global Approval</span></div><div class="casAuthors">Duggan, Sean</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">477-481</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Esaxerenone (MINNEBRO)-a novel oral, non-steroidal, selective mineralocorticoid receptor blocker-is being developed by Daiichi Sankyo for the treatment of hypertension and diabetic nephropathies.  In Jan. 2019, based on pos. results from a phase III trial conducted in Japan in patients with essential hypertension, esaxerenone received marketing approval in Japan for the treatment of hypertension.  This article summarizes the milestones in the development of esaxerenone leading to this first global approval for the treatment of hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2L1-zk-v857Vg90H21EOLACvtfcHk0liqxK4cXjWNoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFyitLk%253D&md5=5cc6a7b8dbdd3a58eaf1e3ceb2a15937</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01073-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01073-5%26sid%3Dliteratum%253Aachs%26aulast%3DDuggan%26aufirst%3DS.%26atitle%3DEsaxerenone%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D477%26epage%3D481%26doi%3D10.1007%2Fs40265-019-01073-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kolkhof, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bärfacker, L.</span></span> <span> </span><span class="NLM_article-title">Mineralocorticoid Receptor Antagonists: 60 Years of Research and Development</span>. <i>J. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>234</i></span>,  <span class="NLM_fpage">T125</span>– <span class="NLM_lpage">T140</span>, <span class="refDoi"> DOI: 10.1530/JOE-16-0600</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1530%2FJOE-16-0600" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=28634268" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1cXovVeisrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=234&publication_year=2017&pages=T125-T140&author=P.+Kolkhofauthor=L.+B%C3%A4rfacker&title=Mineralocorticoid+Receptor+Antagonists%3A+60+Years+of+Research+and+Development&doi=10.1530%2FJOE-16-0600"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Mineralocorticoid receptor antagonists: 60 years of research and development</span></div><div class="casAuthors">Kolkhof, Peter; Baerfacker, Lars</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Endocrinology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">234</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">T125-T140</span>CODEN:
                <span class="NLM_cas:coden">JOENAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-0795</span>.
    
            (<span class="NLM_cas:orgname">BioScientifica Ltd.</span>)
        </div><div class="casAbstract">A review.  The cDNA of the mineralocorticoid receptor (MR) was cloned 30 years ago, in 1987.  At that time, spirolactone, the first generation of synthetic steroid-based MR antagonists (MRAs), which was identified in preclin. in vivo models, had already been in clin. use for 30 years.  Subsequent decades of research and development by Searle & Co., Ciba-Geigy, Roussel Uclaf and Schering AG toward identifying a second generation of much more specific steroidal MRAs were all based on the initial 17-spirolactone construct.  The salient example is eplerenone, first described in 1987, coincidentally with the cloning of MR cDNA.  Its launch on the market in 2003 paralleled intensive drug discovery programs for a new generation of non-steroidal MRAs.  Now, 30 years after the cDNA cloning of MR and 60 years of clin. use of steroidal MRAs, novel non-steroidal MRAs such as apararenone, esaxerenone and finerenone are in late-stage clin. trials in patients with heart failure, chronic kidney disease (CKD), hypertension and liver disease.  Finerenone has already been studied in over 2000 patients with heart failure plus chronic kidney disease and/or diabetes, and in patients with diabetic kidney disease, in five phase II clin. trials.  Here, we reflect on the history of the various generations of MRAs and review characteristics of the most important steroidal and non-steroidal MRAs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQHEittdmQ4LVg90H21EOLACvtfcHk0liqxK4cXjWNoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXovVeisrg%253D&md5=e046bcbc7630871c4b62c8c754762d8c</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1530%2FJOE-16-0600&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1530%252FJOE-16-0600%26sid%3Dliteratum%253Aachs%26aulast%3DKolkhof%26aufirst%3DP.%26aulast%3DB%25C3%25A4rfacker%26aufirst%3DL.%26atitle%3DMineralocorticoid%2520Receptor%2520Antagonists%253A%252060%2520Years%2520of%2520Research%2520and%2520Development%26jtitle%3DJ.%2520Endocrinol.%26date%3D2017%26volume%3D234%26spage%3DT125%26epage%3DT140%26doi%3D10.1530%2FJOE-16-0600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Arai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Homma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morikawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ubukata, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuruoka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizuno, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sada, T.</span></span> <span> </span><span class="NLM_article-title">Pharmacological Profile of CS-3150, a Novel, Highly Potent and Selective Non-Steroidal Mineralocorticoid Receptor Antagonist</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>761</i></span>,  <span class="NLM_fpage">226</span>– <span class="NLM_lpage">234</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2015.06.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2Fj.ejphar.2015.06.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=26073023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtV2iur%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=761&publication_year=2015&pages=226-234&author=K.+Araiauthor=T.+Hommaauthor=Y.+Morikawaauthor=N.+Ubukataauthor=H.+Tsuruokaauthor=K.+Aokiauthor=H.+Ishikawaauthor=M.+Mizunoauthor=T.+Sada&title=Pharmacological+Profile+of+CS-3150%2C+a+Novel%2C+Highly+Potent+and+Selective+Non-Steroidal+Mineralocorticoid+Receptor+Antagonist&doi=10.1016%2Fj.ejphar.2015.06.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35aR"><div class="casContent"><span class="casTitleNuber">35a</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist</span></div><div class="casAuthors">Arai, Kiyoshi; Homma, Tsuyoshi; Morikawa, Yuka; Ubukata, Naoko; Tsuruoka, Hiyoyuki; Aoki, Kazumasa; Ishikawa, Hirokazu; Mizuno, Makoto; Sada, Toshio</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">761</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">226-234</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The present study was designed to characterize the pharmacol. profile of CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist.  In the radioligand-binding assay, CS-3150 inhibited 3H-aldosterone binding to mineralocorticoid receptor with an IC50 value of 9.4 nM, and its potency was superior to that of spironolactone and eplerenone, whose IC50s were 36 and 713 nM, resp.  CS-3150 also showed at least 1000-fold higher selectivity for mineralocorticoid receptor over other steroid hormone receptors, glucocorticoid receptor, androgen receptor and progesterone receptor.  In the reporter gene assay, CS-3150 inhibited aldosterone-induced transcriptional activation of human mineralocorticoid receptor with an IC50 value of 3.7 nM, and its potency was superior to that of spironolactone and eplerenone, whose IC50s were 66 and 970 nM, resp.  CS-3150 had no agonistic effect on mineralocorticoid receptor and did not show any antagonistic or agonistic effect on glucocorticoid receptor, androgen receptor and progesterone receptor even at the high concn. of 5 μM.  In adrenalectomized rats, single oral administration of CS-3150 suppressed aldosterone-induced decrease in urinary Na+/K+ ratio, an index of in vivo mineralocorticoid receptor activation, and this suppressive effect was more potent and longer-lasting than that of spironolactone and eplerenone.  Chronic treatment with CS-3150 inhibited blood pressure elevation induced by deoxycorticosterone acetate (DOCA)/salt-loading to rats, and this antihypertensive effect was more potent than that of spironolactone and eplerenone.  These findings indicate that CS-3150 is a selective and highly potent mineralocorticoid receptor antagonist with long-lasting oral activity.  This agent could be useful for the treatment of hypertension, cardiovascular and renal disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrD6nBWXLrrQLVg90H21EOLACvtfcHk0lj_0VKYc3voqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtV2iur%252FK&md5=89919d8637cc9cc23d1915e987b086d5</span></div><a href="/servlet/linkout?suffix=cit35a&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2015.06.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2015.06.015%26sid%3Dliteratum%253Aachs%26aulast%3DArai%26aufirst%3DK.%26aulast%3DHomma%26aufirst%3DT.%26aulast%3DMorikawa%26aufirst%3DY.%26aulast%3DUbukata%26aufirst%3DN.%26aulast%3DTsuruoka%26aufirst%3DH.%26aulast%3DAoki%26aufirst%3DK.%26aulast%3DIshikawa%26aufirst%3DH.%26aulast%3DMizuno%26aufirst%3DM.%26aulast%3DSada%26aufirst%3DT.%26atitle%3DPharmacological%2520Profile%2520of%2520CS-3150%252C%2520a%2520Novel%252C%2520Highly%2520Potent%2520and%2520Selective%2520Non-Steroidal%2520Mineralocorticoid%2520Receptor%2520Antagonist%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2015%26volume%3D761%26spage%3D226%26epage%3D234%26doi%3D10.1016%2Fj.ejphar.2015.06.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit35b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itoh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rakugi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshimura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamakawa, S.</span></span> <span> </span><span class="NLM_article-title">Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients with Essential Hypertension (ESAX-HTN Study)</span>. <i>Hypertension</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">58</span>, <span class="refDoi"> DOI: 10.1161/HYPERTENSIONAHA.119.13569</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1161%2FHYPERTENSIONAHA.119.13569" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31786983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlKiurzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2020&pages=51-58&author=S.+Itoauthor=H.+Itohauthor=H.+Rakugiauthor=Y.+Okudaauthor=M.+Yoshimuraauthor=S.+Yamakawa&title=Double-Blind+Randomized+Phase+3+Study+Comparing+Esaxerenone+%28CS-3150%29+and+Eplerenone+in+Patients+with+Essential+Hypertension+%28ESAX-HTN+Study%29&doi=10.1161%2FHYPERTENSIONAHA.119.13569"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35bR"><div class="casContent"><span class="casTitleNuber">35b</span><div class="casTitle"><span class="NLM_cas:atitle">Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study)</span></div><div class="casAuthors">Ito, Sadayoshi; Itoh, Hiroshi; Rakugi, Hiromi; Okuda, Yasuyuki; Yoshimura, Motonobu; Yamakawa, Satoru</div><div class="citationInfo"><span class="NLM_cas:title">Hypertension</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">51-58</span>CODEN:
                <span class="NLM_cas:coden">HPRTDN</span>;
        ISSN:<span class="NLM_cas:issn">0194-911X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Mineralocorticoid receptors (MRs) are implicated in the pathol. of hypertension.  MR blockers are recommended for the treatment of salt-sensitive or resistant hypertension.  This phase 3 multicenter, randomized, double-blind study compared the efficacy and safety of esaxerenone, a new selective nonsteroidal MR blocker, at 2.5 and 5 mg/day and eplerenone 50 mg/day in Japanese patients with essential hypertension.  After a 4-wk washout period, 1001 eligible adults with hypertension were randomized evenly to esaxerenone 2.5 or 5 mg/day or eplerenone 50 mg/day treatments, taken orally once daily for 12 wk.  Primary end points were changes in sitting systolic or diastolic blood pressure (BP) from baseline at the end of treatment.  Esaxerenone 2.5 mg/day was noninferior to eplerenone for redns. in sitting and 24-h BP.  Redns. in BP with esaxerenone 5 mg/day were significantly greater than those with esaxerenone 2.5 mg/day.  Changes in diurnal BP showed persistent 24-h antihypertensive effects in all treatment groups.  The proportions of patients achieving target sitting BP (<140/90 mm Hg) were 31.5%, 41.2%, and 27.5% with esaxerenone 2.5 and 5 mg/day and eplerenone 50 mg/day, resp.  Incidences of adverse events (all mild or moderate) were similar across treatment groups.  These results indicate that esaxerenone is an effective and well-tolerated MR blocker in Japanese patients with essential hypertension, with BP-lowering activity at least equiv. to eplerenone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwMdV4JvQNhrVg90H21EOLACvtfcHk0lj_0VKYc3voqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlKiurzE&md5=5b931b85f7068e10ca7eb093a25c8585</span></div><a href="/servlet/linkout?suffix=cit35b&amp;dbid=16384&amp;doi=10.1161%2FHYPERTENSIONAHA.119.13569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FHYPERTENSIONAHA.119.13569%26sid%3Dliteratum%253Aachs%26aulast%3DIto%26aufirst%3DS.%26aulast%3DItoh%26aufirst%3DH.%26aulast%3DRakugi%26aufirst%3DH.%26aulast%3DOkuda%26aufirst%3DY.%26aulast%3DYoshimura%26aufirst%3DM.%26aulast%3DYamakawa%26aufirst%3DS.%26atitle%3DDouble-Blind%2520Randomized%2520Phase%25203%2520Study%2520Comparing%2520Esaxerenone%2520%2528CS-3150%2529%2520and%2520Eplerenone%2520in%2520Patients%2520with%2520Essential%2520Hypertension%2520%2528ESAX-HTN%2520Study%2529%26jtitle%3DHypertension%26date%3D2020%26volume%3D75%26spage%3D51%26epage%3D58%26doi%3D10.1161%2FHYPERTENSIONAHA.119.13569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, M.</span>; <span class="NLM_string-name">Nagasawa, H.</span>; <span class="NLM_string-name">Sato, N.</span></span> <span> </span><span class="NLM_article-title">Method for Producing Pyrrole Derivative, and Intermediate Thereof</span>. <span class="NLM_patent">WO 2015030010</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=M.+Watanabe&author=H.+Nagasawa&author=N.+Sato&title=Method+for+Producing+Pyrrole+Derivative%2C+and+Intermediate+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWatanabe%26aufirst%3DM.%26atitle%3DMethod%2520for%2520Producing%2520Pyrrole%2520Derivative%252C%2520and%2520Intermediate%2520Thereof%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit36b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, M.</span>; <span class="NLM_string-name">Okachi, T.</span>; <span class="NLM_string-name">Kawahara, M.</span>; <span class="NLM_string-name">Nagasawa, H.</span>; <span class="NLM_string-name">Sato, N.</span>; <span class="NLM_string-name">Takita, T.</span>; <span class="NLM_string-name">Hasegawa, G.</span></span> <span> </span><span class="NLM_article-title">Pyrrole Derivative Crystal and Method for Manufacturing Same</span>. <span class="NLM_patent">WO 2014168103</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=M.+Watanabe&author=T.+Okachi&author=M.+Kawahara&author=H.+Nagasawa&author=N.+Sato&author=T.+Takita&author=G.+Hasegawa&title=Pyrrole+Derivative+Crystal+and+Method+for+Manufacturing+Same"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWatanabe%26aufirst%3DM.%26atitle%3DPyrrole%2520Derivative%2520Crystal%2520and%2520Method%2520for%2520Manufacturing%2520Same%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit36c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, M.</span>; <span class="NLM_string-name">Okachi, T.</span>; <span class="NLM_string-name">Kawahara, M.</span>; <span class="NLM_string-name">Nagasawa, H.</span>; <span class="NLM_string-name">Sato, N.</span>; <span class="NLM_string-name">Takita, T.</span>; <span class="NLM_string-name">Hasegawa, G.</span></span> <span> </span><span class="NLM_article-title">Crystal of Pyrrole Derivative and Method for Producing the Same</span>. <span class="NLM_patent">US 20160096803</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=M.+Watanabe&author=T.+Okachi&author=M.+Kawahara&author=H.+Nagasawa&author=N.+Sato&author=T.+Takita&author=G.+Hasegawa&title=Crystal+of+Pyrrole+Derivative+and+Method+for+Producing+the+Same"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWatanabe%26aufirst%3DM.%26atitle%3DCrystal%2520of%2520Pyrrole%2520Derivative%2520and%2520Method%2520for%2520Producing%2520the%2520Same%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, H. A.</span></span> <span> </span><span class="NLM_article-title">Voxelotor: First Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">209</span>– <span class="NLM_lpage">215</span>, <span class="refDoi"> DOI: 10.1007/s40265-020-01262-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs40265-020-01262-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=32020554" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A280%3ADC%252BB38%252FotlKmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2020&pages=209-215&author=H.+A.+Blair&title=Voxelotor%3A+First+Approval&doi=10.1007%2Fs40265-020-01262-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37aR"><div class="casContent"><span class="casTitleNuber">37a</span><div class="casTitle"><span class="NLM_cas:atitle">Voxelotor: First Approval</span></div><div class="casAuthors">Blair Hannah A</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">209-215</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Voxelotor (Oxbryta®) is a haemoglobin S polymerization inhibitor that has been developed for the treatment of sickle cell disease.  In November 2019, voxelotor received its first global approval in the USA for the treatment of sickle cell disease in adults and paediatric patients aged ≥ 12 years.  The drug was granted accelerated approval based on the results of the phase III HOPE trial.  Phase III clinical development of voxelotor for sickle cell disease is ongoing worldwide.  Voxelotor also has Orphan Drug designation and Priority Medicine status in Europe for the treatment of sickle cell disease.  This article summarizes the milestones in the development of voxelotor leading to this first approval as a disease-modifying agent for sickle cell disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTbpElibNSrFHwOGIfWJ7-GfW6udTcc2ebzH7Sdo_Mx_rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38%252FotlKmuw%253D%253D&md5=3c3d29ad328a435555bdd0fc54f24494</span></div><a href="/servlet/linkout?suffix=cit37a&amp;dbid=16384&amp;doi=10.1007%2Fs40265-020-01262-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-020-01262-7%26sid%3Dliteratum%253Aachs%26aulast%3DBlair%26aufirst%3DH.%2BA.%26atitle%3DVoxelotor%253A%2520First%2520Approval%26jtitle%3DDrugs%26date%3D2020%26volume%3D80%26spage%3D209%26epage%3D215%26doi%3D10.1007%2Fs40265-020-01262-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit37b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Metcalf, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dufu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva-Garcia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Partridge, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patskovska, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patskovsky, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almo, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gwaltney, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchaleelaha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulvannan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oksenberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span> <span> </span><span class="NLM_article-title">Discovery of GBT440, an Orally Bioavailable R-State Stabilizer of Sickle Cell Hemoglobin</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">321</span>– <span class="NLM_lpage">326</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00491</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00491" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFWqur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=321-326&author=B.+Metcalfauthor=C.+Chuangauthor=K.+Dufuauthor=M.+P.+Patelauthor=A.+Silva-Garciaauthor=C.+Johnsonauthor=Q.+Luauthor=J.+R.+Partridgeauthor=L.+Patskovskaauthor=Y.+Patskovskyauthor=S.+C.+Almoauthor=M.+P.+Jacobsonauthor=L.+Huaauthor=Q.+Xuauthor=S.+L.+Gwaltneyauthor=C.+Yeeauthor=J.+Harrisauthor=B.+P.+Morganauthor=J.+Jamesauthor=D.+Xuauthor=A.+Hutchaleelahaauthor=K.+Paulvannanauthor=D.+Oksenbergauthor=Z.+Li&title=Discovery+of+GBT440%2C+an+Orally+Bioavailable+R-State+Stabilizer+of+Sickle+Cell+Hemoglobin&doi=10.1021%2Facsmedchemlett.6b00491"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37bR"><div class="casContent"><span class="casTitleNuber">37b</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of GBT440, an Orally Bioavailable R-State Stabilizer of Sickle Cell Hemoglobin</span></div><div class="casAuthors">Metcalf, Brian; Chuang, Chihyuan; Dufu, Kobina; Patel, Mira P.; Silva-Garcia, Abel; Johnson, Carl; Lu, Qing; Partridge, James R.; Patskovska, Larysa; Patskovsky, Yury; Almo, Steven C.; Jacobson, Matthew P.; Hua, Lan; Xu, Qing; Gwaltney, Stephen L.; Yee, Calvin; Harris, Jason; Morgan, Bradley P.; James, Joyce; Xu, Donghong; Hutchaleelaha, Athiwat; Paulvannan, Kumar; Oksenberg, Donna; Li, Zhe</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">321-326</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors report the discovery of a new potent allosteric effector of sickle cell Hb, GBT440 I, that increases the affinity of Hb for oxygen and consequently inhibits its polymn. when subjected to hypoxic conditions.  Unlike earlier allosteric activators that bind covalently to Hb in a 2:1 stoichiometry, I binds with a 1:1 stoichiometry.  Compd. I is orally bioavailable and partitions highly and favorably into the red blood cell with a RBC/plasma ratio of ∼150.  This partitioning onto the target protein is anticipated to allow therapeutic concns. to be achieved in the red blood cell at low plasma concns.  I is in Phase 2 clin. trials for the treatment of sickle cell disease (NCT02285088).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6HR9j4wMylbVg90H21EOLACvtfcHk0lhPWSWw50GYPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFWqur0%253D&md5=63766931fdf731c68fd284cf86cc77d0</span></div><a href="/servlet/linkout?suffix=cit37b&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00491%26sid%3Dliteratum%253Aachs%26aulast%3DMetcalf%26aufirst%3DB.%26aulast%3DChuang%26aufirst%3DC.%26aulast%3DDufu%26aufirst%3DK.%26aulast%3DPatel%26aufirst%3DM.%2BP.%26aulast%3DSilva-Garcia%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DC.%26aulast%3DLu%26aufirst%3DQ.%26aulast%3DPartridge%26aufirst%3DJ.%2BR.%26aulast%3DPatskovska%26aufirst%3DL.%26aulast%3DPatskovsky%26aufirst%3DY.%26aulast%3DAlmo%26aufirst%3DS.%2BC.%26aulast%3DJacobson%26aufirst%3DM.%2BP.%26aulast%3DHua%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DGwaltney%26aufirst%3DS.%2BL.%26aulast%3DYee%26aufirst%3DC.%26aulast%3DHarris%26aufirst%3DJ.%26aulast%3DMorgan%26aufirst%3DB.%2BP.%26aulast%3DJames%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DD.%26aulast%3DHutchaleelaha%26aufirst%3DA.%26aulast%3DPaulvannan%26aufirst%3DK.%26aulast%3DOksenberg%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DZ.%26atitle%3DDiscovery%2520of%2520GBT440%252C%2520an%2520Orally%2520Bioavailable%2520R-State%2520Stabilizer%2520of%2520Sickle%2520Cell%2520Hemoglobin%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D321%26epage%3D326%26doi%3D10.1021%2Facsmedchemlett.6b00491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kato, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piel, F. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaston, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohene-Frempong, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnamurti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panepinto, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weatherall, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vichinsky, E. P.</span></span> <span> </span><span class="NLM_article-title">Sickle Cell Disease</span>. <i>Nat. Rev. Dis. Primers</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">18010</span>, <span class="refDoi"> DOI: 10.1038/nrdp.2018.10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1038%2Fnrdp.2018.10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=29542687" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A280%3ADC%252BC1MnhsVOnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2018&pages=18010&author=G.+J.+Katoauthor=F.+B.+Pielauthor=C.+D.+Reidauthor=M.+H.+Gastonauthor=K.+Ohene-Frempongauthor=L.+Krishnamurtiauthor=W.+R.+Smithauthor=J.+A.+Panepintoauthor=D.+J.+Weatherallauthor=F.+F.+Costaauthor=E.+P.+Vichinsky&title=Sickle+Cell+Disease&doi=10.1038%2Fnrdp.2018.10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Sickle cell disease</span></div><div class="casAuthors">Kato Gregory J; Piel Frederic B; Reid Clarice D; Gaston Marilyn H; Ohene-Frempong Kwaku; Krishnamurti Lakshmanan; Smith Wally R; Panepinto Julie A; Weatherall David J; Costa Fernando F; Vichinsky Elliott P</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Disease primers</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">18010</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Sickle cell disease (SCD) is a group of inherited disorders caused by mutations in HBB, which encodes haemoglobin subunit β.  The incidence is estimated to be between 300,000 and 400,000 neonates globally each year, the majority in sub-Saharan Africa.  Haemoglobin molecules that include mutant sickle β-globin subunits can polymerize; erythrocytes that contain mostly haemoglobin polymers assume a sickled form and are prone to haemolysis.  Other pathophysiological mechanisms that contribute to the SCD phenotype are vaso-occlusion and activation of the immune system.  SCD is characterized by a remarkable phenotypic complexity.  Common acute complications are acute pain events, acute chest syndrome and stroke; chronic complications (including chronic kidney disease) can damage all organs.  Hydroxycarbamide, blood transfusions and haematopoietic stem cell transplantation can reduce the severity of the disease.  Early diagnosis is crucial to improve survival, and universal newborn screening programmes have been implemented in some countries but are challenging in low-income, high-burden settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRfr1rFc0-x0Rjv2lLSLOxFfW6udTcc2ebzH7Sdo_Mx_rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MnhsVOnsg%253D%253D&md5=983b343f1afd547e34a7836b06320373</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fnrdp.2018.10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrdp.2018.10%26sid%3Dliteratum%253Aachs%26aulast%3DKato%26aufirst%3DG.%2BJ.%26aulast%3DPiel%26aufirst%3DF.%2BB.%26aulast%3DReid%26aufirst%3DC.%2BD.%26aulast%3DGaston%26aufirst%3DM.%2BH.%26aulast%3DOhene-Frempong%26aufirst%3DK.%26aulast%3DKrishnamurti%26aufirst%3DL.%26aulast%3DSmith%26aufirst%3DW.%2BR.%26aulast%3DPanepinto%26aufirst%3DJ.%2BA.%26aulast%3DWeatherall%26aufirst%3DD.%2BJ.%26aulast%3DCosta%26aufirst%3DF.%2BF.%26aulast%3DVichinsky%26aufirst%3DE.%2BP.%26atitle%3DSickle%2520Cell%2520Disease%26jtitle%3DNat.%2520Rev.%2520Dis.%2520Primers%26date%3D2018%26volume%3D4%26spage%3D18010%26doi%3D10.1038%2Fnrdp.2018.10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eaton, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofrichter, J.</span></span> <span> </span><span class="NLM_article-title">Sickle Cell Hemoglobin Polymerization</span>. <i>Adv. Protein Chem.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">279</span>, <span class="refDoi"> DOI: 10.1016/S0065-3233(08)60287-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2FS0065-3233%2808%2960287-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=2195851" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADyaK3MXktVGqtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1990&pages=63-279&author=W.+A.+Eatonauthor=J.+Hofrichter&title=Sickle+Cell+Hemoglobin+Polymerization&doi=10.1016%2FS0065-3233%2808%2960287-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Sickle cell hemoglobin polymerization</span></div><div class="casAuthors">Eaton, William A.; Hofrichter, James</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Protein Chemistry</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">63-279</span>CODEN:
                <span class="NLM_cas:coden">APCHA2</span>;
        ISSN:<span class="NLM_cas:issn">0065-3233</span>.
    </div><div class="casAbstract">A review with ∼300 refs. discussing the structure and thermodn., kinetics, and rheol. of HbS polymer in relation to the pathophysiol. and therapy of sickle cell anemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRiXAF3c3PS7Vg90H21EOLACvtfcHk0lhfULoNM2fbEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXktVGqtLs%253D&md5=4bf3caa0d638422cabe899c8f71162d6</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2FS0065-3233%2808%2960287-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0065-3233%252808%252960287-9%26sid%3Dliteratum%253Aachs%26aulast%3DEaton%26aufirst%3DW.%2BA.%26aulast%3DHofrichter%26aufirst%3DJ.%26atitle%3DSickle%2520Cell%2520Hemoglobin%2520Polymerization%26jtitle%3DAdv.%2520Protein%2520Chem.%26date%3D1990%26volume%3D40%26spage%3D63%26epage%3D279%26doi%3D10.1016%2FS0065-3233%2808%2960287-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oksenberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dufu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva-Garcia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchaleelaha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patskovska, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patskovsky, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almo, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metcalf, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Archer, D. R.</span></span> <span> </span><span class="NLM_article-title">GBT440 Increases Haemoglobin Oxygen Affinity, Reduces Sickling and Prolongs RBC Half-Life in a Murine Model of Sickle Cell Disease</span>. <i>Br. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>175</i></span>,  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">153</span>, <span class="refDoi"> DOI: 10.1111/bjh.14214</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1111%2Fbjh.14214" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=27378309" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFCkurfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2016&pages=141-153&author=D.+Oksenbergauthor=K.+Dufuauthor=M.+P.+Patelauthor=C.+Chuangauthor=Z.+Liauthor=Q.+Xuauthor=A.+Silva-Garciaauthor=C.+Zhouauthor=A.+Hutchaleelahaauthor=L.+Patskovskaauthor=Y.+Patskovskyauthor=S.+C.+Almoauthor=U.+Sinhaauthor=B.+W.+Metcalfauthor=D.+R.+Archer&title=GBT440+Increases+Haemoglobin+Oxygen+Affinity%2C+Reduces+Sickling+and+Prolongs+RBC+Half-Life+in+a+Murine+Model+of+Sickle+Cell+Disease&doi=10.1111%2Fbjh.14214"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease</span></div><div class="casAuthors">Oksenberg, Donna; Dufu, Kobina; Patel, Mira P.; Chuang, Chihyuan; Li, Zhe; Xu, Qing; Silva-Garcia, Abel; Zhou, Chengjing; Hutchaleelaha, Athiwat; Patskovska, Larysa; Patskovsky, Yury; Almo, Steven C.; Sinha, Uma; Metcalf, Brian W.; Archer, David R.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">141-153</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : A major driver of the pathophysiol. of sickle cell disease (SCD) is polymn. of deoxygenated Hb S (HbS), which leads to sickling and destruction of red blood cells (RBCs) and end-organ damage.  Pharmacol. increasing the proportion of oxygenated HbS in RBCs may inhibit polymn., prevent sickling and provide long term disease modification.  We report that GBT440, a small mol. which binds to the N-terminal α chain of Hb, increases HbS affinity for oxygen, delays in vitro HbS polymn. and prevents sickling of RBCs.  Moreover, in a murine model of SCD, GBT440 extends the half-life of RBCs, reduces reticulocyte counts and prevents ex vivoRBC sickling.  Importantly, oral dosing of GBT440 in animals demonstrates suitability for once daily dosing in humans and a highly selective partitioning into RBCs, which is a key therapeutic safety attribute.  Thus, GBT440 has the potential for clin. use as a disease-modifying agent in sickle cell patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9twqbw0I4ELVg90H21EOLACvtfcHk0lhfULoNM2fbEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFCkurfP&md5=07276e0b19eac3cb2baef00c872c9197</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1111%2Fbjh.14214&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjh.14214%26sid%3Dliteratum%253Aachs%26aulast%3DOksenberg%26aufirst%3DD.%26aulast%3DDufu%26aufirst%3DK.%26aulast%3DPatel%26aufirst%3DM.%2BP.%26aulast%3DChuang%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DSilva-Garcia%26aufirst%3DA.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DHutchaleelaha%26aufirst%3DA.%26aulast%3DPatskovska%26aufirst%3DL.%26aulast%3DPatskovsky%26aufirst%3DY.%26aulast%3DAlmo%26aufirst%3DS.%2BC.%26aulast%3DSinha%26aufirst%3DU.%26aulast%3DMetcalf%26aufirst%3DB.%2BW.%26aulast%3DArcher%26aufirst%3DD.%2BR.%26atitle%3DGBT440%2520Increases%2520Haemoglobin%2520Oxygen%2520Affinity%252C%2520Reduces%2520Sickling%2520and%2520Prolongs%2520RBC%2520Half-Life%2520in%2520a%2520Murine%2520Model%2520of%2520Sickle%2520Cell%2520Disease%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2016%26volume%3D175%26spage%3D141%26epage%3D153%26doi%3D10.1111%2Fbjh.14214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span>; <span class="NLM_string-name">Guz, N.</span>; <span class="NLM_string-name">Shao, Y.</span>; <span class="NLM_string-name">Cocuz, J.</span>; <span class="NLM_string-name">Frieser, M.</span>; <span class="NLM_string-name">Yiannikouros, G. P.</span>; <span class="NLM_string-name">Liao, L.</span></span> <span> </span><span class="NLM_article-title">Process for Synthesizing 2-Hydroxy-6-((2-(1-isopropyl-1<i>H</i>-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde</span>. <span class="NLM_patent">WO 2017197083</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=Z.+Li&author=N.+Guz&author=Y.+Shao&author=J.+Cocuz&author=M.+Frieser&author=G.+P.+Yiannikouros&author=L.+Liao&title=Process+for+Synthesizing+2-Hydroxy-6-%28%282-%281-isopropyl-1H-pyrazol-5-yl%29-pyridin-3-yl%29methoxy%29benzaldehyde"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DZ.%26atitle%3DProcess%2520for%2520Synthesizing%25202-Hydroxy-6-%2528%25282-%25281-isopropyl-1H-pyrazol-5-yl%2529-pyridin-3-yl%2529methoxy%2529benzaldehyde%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><a href="https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-post-partum-depression#::̃text=The%20U.S.%20Food%20and%20Drug,the%20FDA%20specifically%20for%20PPD" class="extLink">https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-post-partum-depression#::̃text=The%20U.S.%20Food%20and%20Drug,the%20FDA%20specifically%20for%20PPD</a> (accessed Sept 18, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-approves-first-treatment-post-partum-depression%23%3A%3A%CC%83text%3DThe%2520U.S.%2520Food%2520and%2520Drug%2Cthe%2520FDA%2520specifically%2520for%2520PPD+%28accessed+Sept+18%2C+2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kanes, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colquhoun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunduz-Bruce, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schacterle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doherty, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paul, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raines, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epperson, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deligiannidis, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riesenberg, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubinow, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meltzer-Brody, S.</span></span> <span> </span><span class="NLM_article-title">Brexanolone (SAGE-547 Injection) in Post-Partum Depression: A Randomised Controlled Trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>390</i></span>,  <span class="NLM_fpage">480</span>– <span class="NLM_lpage">489</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(17)31264-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2FS0140-6736%2817%2931264-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=28619476" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVWrtLfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=390&publication_year=2017&pages=480-489&author=S.+Kanesauthor=H.+Colquhounauthor=H.+Gunduz-Bruceauthor=R.+Arnoldauthor=A.+Schacterleauthor=J.+Dohertyauthor=E.+Hoffmannauthor=J.+Jonasauthor=S.+Paulauthor=S.+Rainesauthor=C.+N.+Eppersonauthor=K.+M.+Deligiannidisauthor=R.+Riesenbergauthor=D.+Rubinowauthor=S.+Meltzer-Brody&title=Brexanolone+%28SAGE-547+Injection%29+in+Post-Partum+Depression%3A+A+Randomised+Controlled+Trial&doi=10.1016%2FS0140-6736%2817%2931264-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Brexanolone (SAGE-547 injection) in post-partum depression: a randomized controlled trial</span></div><div class="casAuthors">Kanes, Stephen; Colquhoun, Helen; Gunduz-Bruce, Handan; Raines, Shane; Arnold, Ryan; Schacterle, Amy; Doherty, James; Epperson, C. Neill; Deligiannidis, Kristina M.; Riesenberg, Robert; Hoffmann, Ethan; Rubinow, David; Jonas, Jeffrey; Paul, Steven; Meltzer-Brody, Samantha</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">390</span>
        (<span class="NLM_cas:issue">10093</span>),
    <span class="NLM_cas:pages">480-489</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Post-partum depression is a serious mood disorder in women that might be triggered by peripartum fluctuations in reproductive hormones.  This phase 2 study investigated brexanolone (USAN; formerly SAGE-547 injection), an i.v. formulation of allopregnanolone, a pos. allosteric modulator of γ-aminobutyric acid (GABAA) receptors, for the treatment of post-partum depression.  For this double-blind, randomized, placebo-controlled trial, we enrolled self-referred or physician-referred female inpatients (≤6 mo post partum) with severe post-partum depression (Hamilton Rating Scale for Depression [HAM-D] total score ≥26) in four hospitals in the USA.  Eligible women were randomly assigned (1:1), via a computer-generated randomization program, to receive either a single, continuous i.v. dose of brexanolone or placebo for 60 h.  Patients and investigators were masked to treatment assignments.  The primary efficacy endpoint was the change from baseline in the 17-item HAM-D total score at 60 h, assessed in all randomized patients who started infusion of study drug or placebo and who had a completed baseline HAM-D assessment and at least one post-baseline HAM-D assessment.  Patients were followed up until day 30.  This trial is registered with ClinicalTrials.gov, no. NCT02614547.  This trial was done between Dec 15, 2015 (first enrollment), and May 19, 2016 (final visit of the last enrolled patient). 21 women were randomly assigned to the brexanolone (n=10) and placebo (n=11) groups.  At 60 h, mean redn. in HAM-D total score from baseline was 21·0 points (SE 2·9) in the brexanolone group compared with 8·8 points (SE 2·8) in the placebo group (difference -12·2, 95% CI -20·77 to -3·67; p=0·0075; effect size 1·2).  No deaths, serious adverse events, or discontinuations because of adverse events were reported in either group.  Four of ten patients in the brexanolone group had adverse events compared with eight of 11 in the placebo group.  The most frequently reported adverse events in the brexanolone group were dizziness (two patients in the brexanolone group vs three patients in the placebo group) and somnolence (two vs none).  Moderate treatment-emergent adverse events were reported in two patients in the brexanolone group (sinus tachycardia, n=1; somnolence, n=1) and in two patients in the placebo group (infusion site pain, n=1; tension headache, n=1); one patient in the placebo group had a severe treatment-emergent adverse event (insomnia).  In women with severe post-partum depression, infusion of brexanolone resulted in a significant and clin. meaningful redn. in HAM-D total score, compared with placebo.  Our results support the rationale for targeting synaptic and extrasynaptic GABAA receptors in the development of therapies for patients with post-partum depression.  A pivotal clin. program for the investigation of brexanolone in patients with post-partum depression is in progress.Sage Therapeutics, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrD2zxS90OOibVg90H21EOLACvtfcHk0lhnlle2WBKxbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVWrtLfO&md5=26d790135111213994d47e3e887f8908</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2817%2931264-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252817%252931264-3%26sid%3Dliteratum%253Aachs%26aulast%3DKanes%26aufirst%3DS.%26aulast%3DColquhoun%26aufirst%3DH.%26aulast%3DGunduz-Bruce%26aufirst%3DH.%26aulast%3DArnold%26aufirst%3DR.%26aulast%3DSchacterle%26aufirst%3DA.%26aulast%3DDoherty%26aufirst%3DJ.%26aulast%3DHoffmann%26aufirst%3DE.%26aulast%3DJonas%26aufirst%3DJ.%26aulast%3DPaul%26aufirst%3DS.%26aulast%3DRaines%26aufirst%3DS.%26aulast%3DEpperson%26aufirst%3DC.%2BN.%26aulast%3DDeligiannidis%26aufirst%3DK.%2BM.%26aulast%3DRiesenberg%26aufirst%3DR.%26aulast%3DRubinow%26aufirst%3DD.%26aulast%3DMeltzer-Brody%26aufirst%3DS.%26atitle%3DBrexanolone%2520%2528SAGE-547%2520Injection%2529%2520in%2520Post-Partum%2520Depression%253A%2520A%2520Randomised%2520Controlled%2520Trial%26jtitle%3DLancet%26date%3D2017%26volume%3D390%26spage%3D480%26epage%3D489%26doi%3D10.1016%2FS0140-6736%2817%2931264-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Meltzer-Brody, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colquhoun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riesenberg, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epperson, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deligiannidis, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubinow, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sankoh, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clemson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schacterle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanes, S.</span></span> <span> </span><span class="NLM_article-title">Brexanolone Injection in Post-Partum Depression: Two Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trials</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>392</i></span>,  <span class="NLM_fpage">1058</span>– <span class="NLM_lpage">1070</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(18)31551-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2FS0140-6736%2818%2931551-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=30177236" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1eit7fO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=392&publication_year=2018&pages=1058-1070&author=S.+Meltzer-Brodyauthor=H.+Colquhounauthor=R.+Riesenbergauthor=C.+N.+Eppersonauthor=K.+M.+Deligiannidisauthor=D.+R.+Rubinowauthor=H.+Liauthor=A.+J.+Sankohauthor=C.+Clemsonauthor=A.+Schacterleauthor=J.+Jonasauthor=S.+Kanes&title=Brexanolone+Injection+in+Post-Partum+Depression%3A+Two+Multicentre%2C+Double-Blind%2C+Randomised%2C+Placebo-Controlled%2C+Phase+3+Trials&doi=10.1016%2FS0140-6736%2818%2931551-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44aR"><div class="casContent"><span class="casTitleNuber">44a</span><div class="casTitle"><span class="NLM_cas:atitle">Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials</span></div><div class="casAuthors">Meltzer-Brody, Samantha; Colquhoun, Helen; Riesenberg, Robert; Epperson, C. Neill; Deligiannidis, Kristina M.; Rubinow, David R.; Li, Haihong; Sankoh, Abdul J.; Clemson, Christine; Schacterle, Amy; Jonas, Jeffrey; Kanes, Stephen</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">392</span>
        (<span class="NLM_cas:issue">10152</span>),
    <span class="NLM_cas:pages">1058-1070</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">We assessed brexanolone injection, a pos. allosteric modulator of GABAA receptors, for the treatment of moderate to severe post-partum depression.  We screened 375 women simultaneously across both studies, of whom 138 were randomly assigned to receive either BRX90, BRX60, or placebo in study 1, and 108 were randomly assigned to receive BRX90 or placebo in study 2.  In study 1, at 60 h, the LS mean redn. in HAM-D total score from baseline was 19·5 points in the BRX60 group and 17·7 points in the BRX90 group compared with 14·0 points in the placebo group.  In study 2, at 60 h, the LS mean redn. in HAM-D total score from baseline was 14·6 points in the BRX90 group.  In study 1, 19 patients in the BRX60 group and 22 patients in the BRX90 group had adverse events.  In study 2, 25 patients in the BRX90 group had adverse events.  The most common treatment-emergent AE were headache, dizziness, and somnolence.  In study 1, 1 patient had suicidal ideation and intentional overdose attempt during follow-up.  In study 2, 1 patient had altered state of consciousness and syncope.  Administration of brexanolone injection for post-partum depression resulted in significant and clin. meaningful redns. in HAM-D total score at 60 h compared with placebo, with rapid onset of action and durable treatment response during the study period.  Brexanolone injection is a novel therapeutic drug for post-partum depression that has the potential to improve treatment options for women with this disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpj--PbsOaXZbVg90H21EOLACvtfcHk0lhnlle2WBKxbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1eit7fO&md5=5072e7aff1bec96fa11f63b7cb41deea</span></div><a href="/servlet/linkout?suffix=cit44a&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2818%2931551-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252818%252931551-4%26sid%3Dliteratum%253Aachs%26aulast%3DMeltzer-Brody%26aufirst%3DS.%26aulast%3DColquhoun%26aufirst%3DH.%26aulast%3DRiesenberg%26aufirst%3DR.%26aulast%3DEpperson%26aufirst%3DC.%2BN.%26aulast%3DDeligiannidis%26aufirst%3DK.%2BM.%26aulast%3DRubinow%26aufirst%3DD.%2BR.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DSankoh%26aufirst%3DA.%2BJ.%26aulast%3DClemson%26aufirst%3DC.%26aulast%3DSchacterle%26aufirst%3DA.%26aulast%3DJonas%26aufirst%3DJ.%26aulast%3DKanes%26aufirst%3DS.%26atitle%3DBrexanolone%2520Injection%2520in%2520Post-Partum%2520Depression%253A%2520Two%2520Multicentre%252C%2520Double-Blind%252C%2520Randomised%252C%2520Placebo-Controlled%252C%2520Phase%25203%2520Trials%26jtitle%3DLancet%26date%3D2018%26volume%3D392%26spage%3D1058%26epage%3D1070%26doi%3D10.1016%2FS0140-6736%2818%2931551-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit44b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez Botella, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salituro, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beresis, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanco, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belfort, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loya, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ackley, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Althaus, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossman, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doherty, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robichaud, A. J.</span></span> <span> </span><span class="NLM_article-title">Neuroactive Steroids. 2. 3α-Hydroxy-3β-methyl-21-(4-cyano-1H-pyrazol-1′-yl)-19-nor-5β-pregnan-20-one (SAGE-217): A Clinical Next Generation Neuroactive Steroid Positive Allosteric Modulator of the (γ-Aminobutyric Acid)A Receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">7810</span>– <span class="NLM_lpage">7819</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00846</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00846" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A280%3ADC%252BC1cfitFSgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=7810-7819&author=G.+Martinez+Botellaauthor=F.+G.+Salituroauthor=B.+L.+Harrisonauthor=R.+T.+Beresisauthor=Z.+Baiauthor=M.-J.+Blancoauthor=G.+M.+Belfortauthor=J.+Daiauthor=C.+M.+Loyaauthor=M.+A.+Ackleyauthor=A.+L.+Althausauthor=S.+J.+Grossmanauthor=E.+Hoffmannauthor=J.+J.+Dohertyauthor=A.+J.+Robichaud&title=Neuroactive+Steroids.+2.+3%CE%B1-Hydroxy-3%CE%B2-methyl-21-%284-cyano-1H-pyrazol-1%E2%80%B2-yl%29-19-nor-5%CE%B2-pregnan-20-one+%28SAGE-217%29%3A+A+Clinical+Next+Generation+Neuroactive+Steroid+Positive+Allosteric+Modulator+of+the+%28%CE%B3-Aminobutyric+Acid%29A+Receptor&doi=10.1021%2Facs.jmedchem.7b00846"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44bR"><div class="casContent"><span class="casTitleNuber">44b</span><div class="casTitle"><span class="NLM_cas:atitle">Neuroactive Steroids. 2. 3α-Hydroxy-3β-methyl-21-(4-cyano-1H-pyrazol-1'-yl)-19-nor-5β-pregnan-20-one (SAGE-217): A Clinical Next Generation Neuroactive Steroid Positive Allosteric Modulator of the (γ-Aminobutyric Acid)A Receptor</span></div><div class="casAuthors">Martinez Botella Gabriel; Salituro Francesco G; Harrison Boyd L; Blanco Maria-Jesus; Belfort Gabriel M; Dai Jing; Loya Carlos M; Ackley Michael A; Althaus Alison L; Grossman Scott J; Hoffmann Ethan; Doherty James J; Robichaud Albert J; Beresis Richard T; Bai Zhu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7810-7819</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Certain classes of neuroactive steroids (NASs) are positive allosteric modulators (PAM) of synaptic and extrasynaptic GABAA receptors.  Herein, we report new SAR insights in a series of 5β-nor-19-pregnan-20-one analogues bearing substituted pyrazoles and triazoles at C-21, culminating in the discovery of 3α-hydroxy-3β-methyl-21-(4-cyano-1H-pyrazol-1'-yl)-19-nor-5β-pregnan-20-one (SAGE-217, 3), a potent GABAA receptor modulator at both synaptic and extrasynaptic receptor subtypes, with excellent oral DMPK properties.  Compound 3 has completed a phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial and is currently being studied in parallel phase 2 clinical trials for the treatment of postpartum depression (PPD), major depressive disorder (MDD), and essential tremor (ET).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTiySZLUBmmmoUSrryheKE6fW6udTcc2eYgsvMeWnGp-bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cfitFSgsg%253D%253D&md5=d9cb22ed2087152aa0e67d0906faa583</span></div><a href="/servlet/linkout?suffix=cit44b&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00846&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00846%26sid%3Dliteratum%253Aachs%26aulast%3DMartinez%2BBotella%26aufirst%3DG.%26aulast%3DSalituro%26aufirst%3DF.%2BG.%26aulast%3DHarrison%26aufirst%3DB.%2BL.%26aulast%3DBeresis%26aufirst%3DR.%2BT.%26aulast%3DBai%26aufirst%3DZ.%26aulast%3DBlanco%26aufirst%3DM.-J.%26aulast%3DBelfort%26aufirst%3DG.%2BM.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DLoya%26aufirst%3DC.%2BM.%26aulast%3DAckley%26aufirst%3DM.%2BA.%26aulast%3DAlthaus%26aufirst%3DA.%2BL.%26aulast%3DGrossman%26aufirst%3DS.%2BJ.%26aulast%3DHoffmann%26aufirst%3DE.%26aulast%3DDoherty%26aufirst%3DJ.%2BJ.%26aulast%3DRobichaud%26aufirst%3DA.%2BJ.%26atitle%3DNeuroactive%2520Steroids.%25202.%25203%25CE%25B1-Hydroxy-3%25CE%25B2-methyl-21-%25284-cyano-1H-pyrazol-1%25E2%2580%25B2-yl%2529-19-nor-5%25CE%25B2-pregnan-20-one%2520%2528SAGE-217%2529%253A%2520A%2520Clinical%2520Next%2520Generation%2520Neuroactive%2520Steroid%2520Positive%2520Allosteric%2520Modulator%2520of%2520the%2520%2528%25CE%25B3-Aminobutyric%2520Acid%2529A%2520Receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D7810%26epage%3D7819%26doi%3D10.1021%2Facs.jmedchem.7b00846" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Torregrossa, E.</span>; <span class="NLM_string-name">Brusasca, M.</span>; <span class="NLM_string-name">Manfrotto, C.</span></span> <span> </span><span class="NLM_article-title">Process for the Preparation of Allopregnanolone</span>. <span class="NLM_patent">US 20200087341 A1</span>, <span class="NLM_year">2020</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=E.+Torregrossa&author=M.+Brusasca&author=C.+Manfrotto&title=Process+for+the+Preparation+of+Allopregnanolone"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTorregrossa%26aufirst%3DE.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%2520Allopregnanolone%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">MacNevin, C.</span>; <span class="NLM_string-name">Stein, D. G.</span>; <span class="NLM_string-name">Liotta, D. C.</span>; <span class="NLM_string-name">Sayeed, I.</span>; <span class="NLM_string-name">Guthrie, D. B.</span>; <span class="NLM_string-name">Lockwood, M. A.</span>; <span class="NLM_string-name">Natchus, M. G.</span></span> <span> </span><span class="NLM_article-title">Preparation of Steroid Analogues for Neuroprotection</span>. <span class="NLM_patent">WO 2009108804 A2</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=C.+MacNevin&author=D.+G.+Stein&author=D.+C.+Liotta&author=I.+Sayeed&author=D.+B.+Guthrie&author=M.+A.+Lockwood&author=M.+G.+Natchus&title=Preparation+of+Steroid+Analogues+for+Neuroprotection"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMacNevin%26aufirst%3DC.%26atitle%3DPreparation%2520of%2520Steroid%2520Analogues%2520for%2520Neuroprotection%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Purdy, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrow, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blinn, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paul, S. M.</span></span> <span> </span><span class="NLM_article-title">Synthesis, Metabolism, and Pharmacological Activity of 3α-Hydroxy Steroids Which Potentiate GABA-Receptor-Mediated Chloride Ion Uptake in Rat Cerebral Cortical Synaptoneurosomes</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">1572</span>– <span class="NLM_lpage">1581</span>, <span class="refDoi"> DOI: 10.1021/jm00168a008</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00168a008" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADyaK3cXitlGltb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=1990&pages=1572-1581&author=R.+H.+Purdyauthor=A.+L.+Morrowauthor=J.+R.+Blinnauthor=S.+M.+Paul&title=Synthesis%2C+Metabolism%2C+and+Pharmacological+Activity+of+3%CE%B1-Hydroxy+Steroids+Which+Potentiate+GABA-Receptor-Mediated+Chloride+Ion+Uptake+in+Rat+Cerebral+Cortical+Synaptoneurosomes&doi=10.1021%2Fjm00168a008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47aR"><div class="casContent"><span class="casTitleNuber">47a</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, metabolism, and pharmacological activity of 3α-hydroxy steroids which potentiate GABA-receptor-mediated chloride ion uptake in rat cerebral cortical synaptoneurosomes</span></div><div class="casAuthors">Purdy, Robert H.; Morrow, A. Leslie; Blinn, James R.; Paul, Steven M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1572-81</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">A series of natural and synthetic 3α-hydroxy steroids were tested for their ability to potentiate GABA-receptor-mediated Cl- uptake into cerebral cortical synaptoneurosomes.  The naturally occurring metabolites 3α-hydroxy-5α-pregnan-20-one (I) and 3α,21-dihydroxy-5α-pregnan-20-one (II) were the most active in augmenting GABAA-receptor-mediated Cl- uptake.  Pharmacol. activity was reduced in the 5β-pregnane isomers and by some, but not all, modifications of the side chain.  The ability of these steroids to potentiate muscimol-stimulated Cl- uptake is lost by acetylation at C-3, introduction of unsatn. at C-9(11), inversion to the 3β-hydroxy isomer, or inversion of configuration at C-17.  A facile procedure is reported for the synthesis of unlabeled and tritium-labeled I and II.  The 9α,11α,12α-3H-labeled derivs. of I and II were used to identify the distribution and metabolic products of these active steroids.  Uptake of the more hydrophobic [3H]-I into brain was significantly greater than that of [3H]-II.  The principal 3H-labeled metabolites recovered from brain were the 3-oxo derivs., which are both inactive on GABA receptor-mediated Cl- flux.  Mol. modeling of the active steroids based on quant. structure-activity relationships provides evidence to support the stereospecificity of the binding interactions and suggests that there may be more than one type of steroid binding site assocd. with the GABAA-receptor-mediated Cl- ionophore.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopDFFJx0W6_LVg90H21EOLACvtfcHk0ljrcP-Opo4_-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXitlGltb4%253D&md5=702b2efda65742a8959dfd0328ef12c6</span></div><a href="/servlet/linkout?suffix=cit47a&amp;dbid=16384&amp;doi=10.1021%2Fjm00168a008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00168a008%26sid%3Dliteratum%253Aachs%26aulast%3DPurdy%26aufirst%3DR.%2BH.%26aulast%3DMorrow%26aufirst%3DA.%2BL.%26aulast%3DBlinn%26aufirst%3DJ.%2BR.%26aulast%3DPaul%26aufirst%3DS.%2BM.%26atitle%3DSynthesis%252C%2520Metabolism%252C%2520and%2520Pharmacological%2520Activity%2520of%25203%25CE%25B1-Hydroxy%2520Steroids%2520Which%2520Potentiate%2520GABA-Receptor-Mediated%2520Chloride%2520Ion%2520Uptake%2520in%2520Rat%2520Cerebral%2520Cortical%2520Synaptoneurosomes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1990%26volume%3D33%26spage%3D1572%26epage%3D1581%26doi%3D10.1021%2Fjm00168a008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit47b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kapras, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stastna, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chodounska, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pouzar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kristofikova, Z.</span></span> <span> </span><span class="NLM_article-title">Preparation of Steroid Sulfamates and Their Interaction with GABA<sub>A</sub> Receptor</span>. <i>Collect. Czech. Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">643</span>– <span class="NLM_lpage">650</span>, <span class="refDoi"> DOI: 10.1135/cccc2008187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1135%2Fcccc2008187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkvVSht7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2009&pages=643-650&author=V.+Kaprasauthor=E.+Stastnaauthor=H.+Chodounskaauthor=V.+Pouzarauthor=Z.+Kristofikova&title=Preparation+of+Steroid+Sulfamates+and+Their+Interaction+with+GABAA+Receptor&doi=10.1135%2Fcccc2008187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47bR"><div class="casContent"><span class="casTitleNuber">47b</span><div class="casTitle"><span class="NLM_cas:atitle">Preparation of steroid sulfamates and their interaction with GABAA receptor</span></div><div class="casAuthors">Kapras, Vojtech; Stastna, Eva; Chodounska, Hana; Pouzar, Vladimir; Kristofikova, Zdena</div><div class="citationInfo"><span class="NLM_cas:title">Collection of Czechoslovak Chemical Communications</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">643-650</span>CODEN:
                <span class="NLM_cas:coden">CCCCAK</span>;
        ISSN:<span class="NLM_cas:issn">0010-0765</span>.
    
            (<span class="NLM_cas:orgname">Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic</span>)
        </div><div class="casAbstract">Sulfamoyl chloride was used for the prepn. of 3α-sulfamate and 3β-sulfamate derivs. of steroids.  The target compds. thus prepd. included 20-oxo-5α-pregnan-3α-yl sulfamate, 20-oxo-5α-pregnan-3β-yl sulfamate, 20-oxo-5β-pregnan-3α-yl sulfamate and 20-oxo-5β-pregnan-3β-yl sulfamate from the corresponding 3α- and 3β-alcs.  Sulfur trioxide-pyridine complex was employed for the prepn. of 20-oxo-5α-pregnan-3α-yl pyridinium sulfate.  Specific steroid binding properties were detected by the decrease of the specific [35S]-tert-butylbicyclo[2.2.2]phosphorothionate binding after application of the tested compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEkSF-5-n6K7Vg90H21EOLACvtfcHk0ljrcP-Opo4_-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkvVSht7Y%253D&md5=19f95028012ef528015536ae0469e896</span></div><a href="/servlet/linkout?suffix=cit47b&amp;dbid=16384&amp;doi=10.1135%2Fcccc2008187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1135%252Fcccc2008187%26sid%3Dliteratum%253Aachs%26aulast%3DKapras%26aufirst%3DV.%26aulast%3DStastna%26aufirst%3DE.%26aulast%3DChodounska%26aufirst%3DH.%26aulast%3DPouzar%26aufirst%3DV.%26aulast%3DKristofikova%26aufirst%3DZ.%26atitle%3DPreparation%2520of%2520Steroid%2520Sulfamates%2520and%2520Their%2520Interaction%2520with%2520GABAA%2520Receptor%26jtitle%3DCollect.%2520Czech.%2520Chem.%2520Commun.%26date%3D2009%26volume%3D74%26spage%3D643%26epage%3D650%26doi%3D10.1135%2Fcccc2008187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><a href="https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-adults-partial-onset-seizures" class="extLink">https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-adults-partial-onset-seizures</a> (accessed 2020-09-15).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-approves-new-treatment-adults-partial-onset-seizures+%28accessed+2020-09-15%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Dougherty, M. L.</span></span> <span> </span><span class="NLM_article-title">Epilepsy Essentials: Cenobamate</span>. <i>Pract. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>, (<span class="NLM_issue">November/December</span>),  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">30</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&pages=29-30&issue=November%2FDecember&author=M.+L.+Dougherty&title=Epilepsy+Essentials%3A+Cenobamate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDougherty%26aufirst%3DM.%2BL.%26atitle%3DEpilepsy%2520Essentials%253A%2520Cenobamate%26jtitle%3DPract.%2520Neurol.%26date%3D2019%26issue%3DNovember%252FDecember%26spage%3D29%26epage%3D30" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit49b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, I.-S.</span></span> <span> </span><span class="NLM_article-title">Effects of Cenobamate (YKP3089), a Newly Developed Anti-Epileptic Drug, on Voltage-Gated Sodium Channels in Rat Hippocampal CA3 Neurons</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>855</i></span>,  <span class="NLM_fpage">175</span>– <span class="NLM_lpage">182</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2019.05.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2Fj.ejphar.2019.05.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31063770" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpsVajs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=855&publication_year=2019&pages=175-182&author=M.+Nakamuraauthor=J.-H.+Choauthor=H.+Shinauthor=I.-S.+Jang&title=Effects+of+Cenobamate+%28YKP3089%29%2C+a+Newly+Developed+Anti-Epileptic+Drug%2C+on+Voltage-Gated+Sodium+Channels+in+Rat+Hippocampal+CA3+Neurons&doi=10.1016%2Fj.ejphar.2019.05.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49bR"><div class="casContent"><span class="casTitleNuber">49b</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of cenobamate (YKP3089), a newly developed anti-epileptic drug, on voltage-gated sodium channels in rat hippocampal CA3 neurons</span></div><div class="casAuthors">Nakamura, Michiko; Cho, Jin-Hwa; Shin, Hyewon; Jang, Il-Sung</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">855</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">175-182</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">New, more effective pharmacol. treatments for epilepsy are needed, as a substantial portion of patients (>30%) are refractory to currently available anti-epileptic drugs.  Cenobamate (YKP3089) is an investigational anti-epileptic drug in clin. development.  Two completed adequate and well-controlled studies demonstrated a significant redn. in focal seizures with cenobamate in patients with epilepsy.  In this study, we characterized the effects of cenobamate on voltage-gated Na+ channels in acutely isolated rat hippocampal CA3 neurons using a whole-cell patch-clamp technique.  While cenobamate had little effect on the peak component of transient Na+ current (INaT) induced by brief depolarizing step pulses, it potently inhibited the non-inactivating persistent component of INa (INaP).  In addn., cenobamate potently inhibited the current by slow voltage-ramp stimuli.  Cenobamate significantly shifted the steady-state fast inactivation relationship toward a hyperpolarizing range, indicating that cenobamate binds to voltage-gated Na+ channels at the inactivated state with a higher affinity.  Cenobamate also accelerated the development of inactivation and retarded recovery from inactivation of voltage-gated Na+ channels.  In current clamp expts., cenobamate hyperpolarized membrane potentials in a concn.-dependent manner, and these effects were mediated by inhibiting the INaP.  Cenobamate also increased the threshold for generation of action potentials, and decreased the no. of action potentials elicited by depolarizing current injection.  Given that the INaP plays a pivotal role in the repetitive and/or burst generation of action potentials, the cenobamate-mediated preferential blockade of INaP might contribute to anti-epileptic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVK5NrddBugrVg90H21EOLACvtfcHk0ljrcP-Opo4_-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpsVajs70%253D&md5=ca9e3a5135f82c479661e7d9bcb25295</span></div><a href="/servlet/linkout?suffix=cit49b&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2019.05.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2019.05.007%26sid%3Dliteratum%253Aachs%26aulast%3DNakamura%26aufirst%3DM.%26aulast%3DCho%26aufirst%3DJ.-H.%26aulast%3DShin%26aufirst%3DH.%26aulast%3DJang%26aufirst%3DI.-S.%26atitle%3DEffects%2520of%2520Cenobamate%2520%2528YKP3089%2529%252C%2520a%2520Newly%2520Developed%2520Anti-Epileptic%2520Drug%252C%2520on%2520Voltage-Gated%2520Sodium%2520Channels%2520in%2520Rat%2520Hippocampal%2520CA3%2520Neurons%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2019%26volume%3D855%26spage%3D175%26epage%3D182%26doi%3D10.1016%2Fj.ejphar.2019.05.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, I.-S.</span></span> <span> </span><span class="NLM_article-title">Mechanism of Action of Cenobamate: Preferential Inhibition of the Persistent Sodium Current (P5.278)</span>. <i>Neurology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>90</i></span> (<span class="NLM_issue">15 Suppl.</span>),  <span class="NLM_fpage">P5.278</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2018&pages=P5.278&issue=15+Suppl.&author=M.+Nakamuraauthor=H.+Shinauthor=I.-S.+Jang&title=Mechanism+of+Action+of+Cenobamate%3A+Preferential+Inhibition+of+the+Persistent+Sodium+Current+%28P5.278%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNakamura%26aufirst%3DM.%26aulast%3DShin%26aufirst%3DH.%26aulast%3DJang%26aufirst%3DI.-S.%26atitle%3DMechanism%2520of%2520Action%2520of%2520Cenobamate%253A%2520Preferential%2520Inhibition%2520of%2520the%2520Persistent%2520Sodium%2520Current%2520%2528P5.278%2529%26jtitle%3DNeurology%26date%3D2018%26volume%3D90%26issue%3D15%2520Suppl%26spage%3DP5.278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit50b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Bialer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johannessen, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perucca, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, H. S.</span></span> <span> </span><span class="NLM_article-title">Progress Report on New Antiepileptic Drugs: A Summary of the Twelfth Eilat Conference (EILAT XII)</span>. <i>Epilepsy Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">141</span>, <span class="refDoi"> DOI: 10.1016/j.eplepsyres.2015.01.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2Fj.eplepsyres.2015.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=25769377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A280%3ADC%252BC2MjptFOhug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2015&pages=85-141&author=M.+Bialerauthor=S.+I.+Johannessenauthor=R.+H.+Levyauthor=E.+Peruccaauthor=T.+Tomsonauthor=H.+S.+White&title=Progress+Report+on+New+Antiepileptic+Drugs%3A+A+Summary+of+the+Twelfth+Eilat+Conference+%28EILAT+XII%29&doi=10.1016%2Fj.eplepsyres.2015.01.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50bR"><div class="casContent"><span class="casTitleNuber">50b</span><div class="casTitle"><span class="NLM_cas:atitle">Progress report on new antiepileptic drugs: A summary of the Twelfth Eilat Conference (EILAT XII)</span></div><div class="casAuthors">Bialer Meir; Johannessen Svein I; Levy Rene H; Perucca Emilio; Tomson Torbjorn; White H Steve</div><div class="citationInfo"><span class="NLM_cas:title">Epilepsy research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">85-141</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The Twelfth Eilat Conference on New Antiepileptic Drugs (AEDs) - EILAT XII, took place in Madrid, Spain from August 31st to September 3rd 2014.  About 130 basic scientists, clinical pharmacologists and neurologists from 22 countries attended the conference, whose main themes included "Conquering pharmacoresistant epilepsy", "Innovative emergency treatments", "Progress report on second-generation treatment" and "New methods and formulations".  Consistent with previous formats of this conference, a large part of the program was devoted to a review of AEDs in development, as well as updates on AEDs introduced since 2004.  Like the EILAT X and EILAT XI reports, the current article focuses on the preclinical and clinical pharmacology of AEDs that are currently in development.  These include adenosine-releasing silk, allopregnanolone (SAGE-547), AMP-X-0079, brivaracetam, bumetanide, cannabidiol, cannabidivarin, 2-deoxy-glucose, everolimus, ganaxolone, huperzine A, imepitoin, minocycline, NAX 801-2, pitolisant, PRX 0023, SAGE-217, valnoctamide and its homologue sec-butyl-propylacetamide (SPD), and VLB-01.  Since the previous Eilat conference, perampanel has been introduced into the market and twelve novel potential epilepsy treatments are presented for the first time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSxQNGd8mA3bUodMGTatQ7LfW6udTcc2eZMoBLuy-xzfLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MjptFOhug%253D%253D&md5=52293a4db7a5eb4e017b1c6f6b986950</span></div><a href="/servlet/linkout?suffix=cit50b&amp;dbid=16384&amp;doi=10.1016%2Fj.eplepsyres.2015.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.eplepsyres.2015.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DBialer%26aufirst%3DM.%26aulast%3DJohannessen%26aufirst%3DS.%2BI.%26aulast%3DLevy%26aufirst%3DR.%2BH.%26aulast%3DPerucca%26aufirst%3DE.%26aulast%3DTomson%26aufirst%3DT.%26aulast%3DWhite%26aufirst%3DH.%2BS.%26atitle%3DProgress%2520Report%2520on%2520New%2520Antiepileptic%2520Drugs%253A%2520A%2520Summary%2520of%2520the%2520Twelfth%2520Eilat%2520Conference%2520%2528EILAT%2520XII%2529%26jtitle%3DEpilepsy%2520Res.%26date%3D2015%26volume%3D111%26spage%3D85%26epage%3D141%26doi%3D10.1016%2Fj.eplepsyres.2015.01.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Krauss, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milanov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milovanovic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinhoff, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamin, M.</span></span> <span> </span><span class="NLM_article-title">Safety and Efficacy of Adjunctive Cenobamate (YKP3089) in Patients with Uncontrolled Focal Seizures: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Dose-Response Trial</span>. <i>Lancet Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">38</span>– <span class="NLM_lpage">48</span>, <span class="refDoi"> DOI: 10.1016/S1474-4422(19)30399-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2FS1474-4422%2819%2930399-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31734103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFKitbfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2020&pages=38-48&author=G.+L.+Kraussauthor=P.+Kleinauthor=C.+Brandtauthor=S.+K.+Leeauthor=I.+Milanovauthor=M.+Milovanovicauthor=B.+J.+Steinhoffauthor=M.+Kamin&title=Safety+and+Efficacy+of+Adjunctive+Cenobamate+%28YKP3089%29+in+Patients+with+Uncontrolled+Focal+Seizures%3A+A+Multicentre%2C+Double-Blind%2C+Randomised%2C+Placebo-Controlled%2C+Dose-Response+Trial&doi=10.1016%2FS1474-4422%2819%2930399-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51aR"><div class="casContent"><span class="casTitleNuber">51a</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial</span></div><div class="casAuthors">Krauss, Gregory L.; Klein, Pavel; Brandt, Christian; Lee, Sang Kun; Milanov, Ivan; Milovanovic, Maja; Steinhoff, Bernhard J.; Kamin, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Neurology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">38-48</span>CODEN:
                <span class="NLM_cas:coden">LNAEAM</span>;
        ISSN:<span class="NLM_cas:issn">1474-4422</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">We aimed to evaluate the safety, efficacy, and tolerability of adjunctive cenobamate in patients with uncontrolled focal-onset epilepsy.  Median percentage changes in seizure frequency were -24·0% (IQR -45·0 to -7·0%) for the placebo group compared with -35·5% (-62·5 to -15·0%; p=0·0071) for the 100 mg dose group, -55·0% (-73·0 to -23·0%; p<0·0001) for the 200 mg dose group, and -55·0% (-85·0 to -28·0%; p<0·0001) for the 400 mg dose group.  Responder rates during the maintenance phase were 25% (26 of 102 patients) for the placebo group compared with 40% (41 of 102; odds ratio 1·97, 95% CI 1·08-3·56; p=0·0365) for the 100 mg dose group, 56% (55 of 98; 3·74, 2·06-6·80; p<0·0001) for the 200 mg dose group, and 64% (61 of 95; 5·24, 2·84-9·67; p<0·0001) for the 400 mg dose group.  Treatment-emergent adverse events occurred in 76 (70%) of 108 patients in the placebo group, 70 (65%) of 108 in the 100 mg group, 84 (76%) of 110 in the 200 mg group, and 100 (90%) of 111 in the 400 mg group.  Treatment-emergent adverse events led to discontinuation in five (5%) patients in the placebo group, 11 (10%) in the 100 mg dose group, 15 (14%) in the 200 mg dose group, and 22 (20%) in the 400 mg dose group.  Adjunctive cenobamate reduced focal (partial)-onset seizure frequency, in a dose-related fashion.  Treatment-emergent adverse events were most frequent in the highest dose group.  Cenobamate appears to effective treatment option in patients with uncontrolled focal seizures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXjn-4gvNxabVg90H21EOLACvtfcHk0lgp9ItINI5BNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFKitbfF&md5=cb2451d4f97c64948f4fe9bfe55d1e0a</span></div><a href="/servlet/linkout?suffix=cit51a&amp;dbid=16384&amp;doi=10.1016%2FS1474-4422%2819%2930399-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1474-4422%252819%252930399-0%26sid%3Dliteratum%253Aachs%26aulast%3DKrauss%26aufirst%3DG.%2BL.%26aulast%3DKlein%26aufirst%3DP.%26aulast%3DBrandt%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DS.%2BK.%26aulast%3DMilanov%26aufirst%3DI.%26aulast%3DMilovanovic%26aufirst%3DM.%26aulast%3DSteinhoff%26aufirst%3DB.%2BJ.%26aulast%3DKamin%26aufirst%3DM.%26atitle%3DSafety%2520and%2520Efficacy%2520of%2520Adjunctive%2520Cenobamate%2520%2528YKP3089%2529%2520in%2520Patients%2520with%2520Uncontrolled%2520Focal%2520Seizures%253A%2520A%2520Multicentre%252C%2520Double-Blind%252C%2520Randomised%252C%2520Placebo-Controlled%252C%2520Dose-Response%2520Trial%26jtitle%3DLancet%2520Neurol.%26date%3D2020%26volume%3D19%26spage%3D38%26epage%3D48%26doi%3D10.1016%2FS1474-4422%2819%2930399-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit51b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">French, J. A.</span></span> <span> </span><span class="NLM_article-title">Cenobamate for Focal Seizures—A Game Changer?</span>. <i>Nat. Rev. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">134</span>, <span class="refDoi"> DOI: 10.1038/s41582-019-0309-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1038%2Fs41582-019-0309-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31915370" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlsVCmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2020&pages=133-134&author=J.+A.+French&title=Cenobamate+for+Focal+Seizures%E2%80%94A+Game+Changer%3F&doi=10.1038%2Fs41582-019-0309-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51bR"><div class="casContent"><span class="casTitleNuber">51b</span><div class="casTitle"><span class="NLM_cas:atitle">Cenobamate for focal seizures - a game changer?</span></div><div class="casAuthors">French, Jacqueline A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neurology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">133-134</span>CODEN:
                <span class="NLM_cas:coden">NRNACP</span>;
        ISSN:<span class="NLM_cas:issn">1759-4758</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">In the first published efficacy study of cenobamate for treatment-resistant focal seizures, high doses produced high seizure-free rates, suggesting cenobamate can outperform existing options.  A risk of serious rash and low tolerability at higher doses means further safety studies and clin. experience are needed to det. its clin. value.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsAAE9bcAkjrVg90H21EOLACvtfcHk0lgp9ItINI5BNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlsVCmuw%253D%253D&md5=2796aefd91a86ecf269bb7cda3f43add</span></div><a href="/servlet/linkout?suffix=cit51b&amp;dbid=16384&amp;doi=10.1038%2Fs41582-019-0309-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41582-019-0309-7%26sid%3Dliteratum%253Aachs%26aulast%3DFrench%26aufirst%3DJ.%2BA.%26atitle%3DCenobamate%2520for%2520Focal%2520Seizures%25E2%2580%2594A%2520Game%2520Changer%253F%26jtitle%3DNat.%2520Rev.%2520Neurol.%26date%3D2020%26volume%3D16%26spage%3D133%26epage%3D134%26doi%3D10.1038%2Fs41582-019-0309-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y.-M.</span>; <span class="NLM_string-name">Kim, C.-G.</span>; <span class="NLM_string-name">Kang, Y.-S.</span>; <span class="NLM_string-name">Yi, H.-J.</span>; <span class="NLM_string-name">Lee, H.-S.</span>; <span class="NLM_string-name">Ku, B.-C.</span>; <span class="NLM_string-name">Lee, E.-H.</span>; <span class="NLM_string-name">Im, D.-J.</span>; <span class="NLM_string-name">Shin, Y.-J.</span></span> <span> </span><span class="NLM_article-title">Preparation of Triazoles and Tetrazoles Containing Carbamoyl Group as Anticonvulsants</span>. <span class="NLM_patent">WO 2006112685 A1</span>, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=Y.-M.+Choi&author=C.-G.+Kim&author=Y.-S.+Kang&author=H.-J.+Yi&author=H.-S.+Lee&author=B.-C.+Ku&author=E.-H.+Lee&author=D.-J.+Im&author=Y.-J.+Shin&title=Preparation+of+Triazoles+and+Tetrazoles+Containing+Carbamoyl+Group+as+Anticonvulsants"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DY.-M.%26atitle%3DPreparation%2520of%2520Triazoles%2520and%2520Tetrazoles%2520Containing%2520Carbamoyl%2520Group%2520as%2520Anticonvulsants%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit52b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S. C.</span>; <span class="NLM_string-name">Uhm, M. Y.</span>; <span class="NLM_string-name">Lee, D. W.</span>; <span class="NLM_string-name">Kim, H. H.</span>; <span class="NLM_string-name">Lee, D. H.</span>; <span class="NLM_string-name">Lee, H. S.</span></span> <span> </span><span class="NLM_article-title">Process for Preparation of Carbamic Acid (<i>R</i>)-1-Aryl-2-tetrazolyl-ethyl Esters</span>. <span class="NLM_patent">WO 2011046380 A2</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=S.+C.+Lim&author=M.+Y.+Uhm&author=D.+W.+Lee&author=H.+H.+Kim&author=D.+H.+Lee&author=H.+S.+Lee&title=Process+for+Preparation+of+Carbamic+Acid+%28R%29-1-Aryl-2-tetrazolyl-ethyl+Esters"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DS.%2BC.%26atitle%3DProcess%2520for%2520Preparation%2520of%2520Carbamic%2520Acid%2520%2528R%2529-1-Aryl-2-tetrazolyl-ethyl%2520Esters%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit52c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S. C.</span>; <span class="NLM_string-name">Uhm, M. Y.</span>; <span class="NLM_string-name">Cho, N. R.</span>; <span class="NLM_string-name">Lee, D. W.</span>; <span class="NLM_string-name">Lee, J. Y.</span>; <span class="NLM_string-name">Kim, H. H.</span>; <span class="NLM_string-name">Lee, D. H.</span></span> <span> </span><span class="NLM_article-title">Preparation of Carbamic Acid (<i>R</i>)-1-Aryl-2-tetrazolyl-ethyl Esters</span>. <span class="NLM_patent">US 20100323410 A1</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=S.+C.+Lim&author=M.+Y.+Uhm&author=N.+R.+Cho&author=D.+W.+Lee&author=J.+Y.+Lee&author=H.+H.+Kim&author=D.+H.+Lee&title=Preparation+of+Carbamic+Acid+%28R%29-1-Aryl-2-tetrazolyl-ethyl+Esters"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DS.%2BC.%26atitle%3DPreparation%2520of%2520Carbamic%2520Acid%2520%2528R%2529-1-Aryl-2-tetrazolyl-ethyl%2520Esters%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Magano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunetz, J. R.</span></span> <span> </span><span class="NLM_article-title">Large-Scale Carbonyl Reductions in the Pharmaceutical Industry</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1156</span>– <span class="NLM_lpage">1184</span>, <span class="refDoi"> DOI: 10.1021/op2003826</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op2003826" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC38XitF2ntb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2012&pages=1156-1184&author=J.+Maganoauthor=J.+R.+Dunetz&title=Large-Scale+Carbonyl+Reductions+in+the+Pharmaceutical+Industry&doi=10.1021%2Fop2003826"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Large-Scale Carbonyl Reductions in the Pharmaceutical Industry</span></div><div class="casAuthors">Magano, Javier; Dunetz, Joshua R.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1156-1184</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Herein we present a review on methods for carbonyl redns. on large scale (≥100 mmol) applied to the synthesis of drug candidates in the pharmaceutical industry.  We discuss the most common and reliable methods for the redn. of aldehydes, ketones, carboxylic acids, esters, amides, imides, and acid chlorides.  Representative examples illustrate detailed reaction and workup conditions and highlight the advantages and limitations of each reducing agent with special emphasis on safety, cost, and amenability to scale-up.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxMDFgyL6o4bVg90H21EOLACvtfcHk0ljHNTd9pK8FDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitF2ntb4%253D&md5=3eeacc054ae4dd0dfeb3422237418573</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Fop2003826&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop2003826%26sid%3Dliteratum%253Aachs%26aulast%3DMagano%26aufirst%3DJ.%26aulast%3DDunetz%26aufirst%3DJ.%2BR.%26atitle%3DLarge-Scale%2520Carbonyl%2520Reductions%2520in%2520the%2520Pharmaceutical%2520Industry%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2012%26volume%3D16%26spage%3D1156%26epage%3D1184%26doi%3D10.1021%2Fop2003826" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, Y. N.</span></span> <span> </span><span class="NLM_article-title">Lasmiditan: First Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">1989</span>– <span class="NLM_lpage">1996</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01225-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs40265-019-01225-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31749059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A280%3ADC%252BB3MfhtlGgtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=1989-1996&author=Y.+N.+Lamb&title=Lasmiditan%3A+First+Approval&doi=10.1007%2Fs40265-019-01225-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Lasmiditan: First Approval</span></div><div class="casAuthors">Lamb Yvette N</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1989-1996</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Lasmiditan (REYVOW®; Eli Lilly and Company) is an orally available serotonin (5-HT)1F receptor agonist.  In October 2019, the US FDA approved lasmiditan 50 mg and 100 mg tablets for the acute treatment of migraine with or without aura in adults.  Approval was based on positive results from two pivotal phase III trials, in which lasmiditan significantly improved the proportions of patients achieving freedom from headache pain and freedom from the most bothersome symptom (photophobia, phonophobia or nausea), relative to placebo, when used to treat a migraine with moderate to severe pain.  Lasmiditan is not for use in the preventive treatment of migraine.  This article summarizes the milestones in the development of lasmiditan leading to its first approval for the acute treatment of migraine in adults.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQrg8vE0Fvv8VvAgqb2vdc5fW6udTcc2eboYvUWLZL8Ubntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MfhtlGgtg%253D%253D&md5=54ba4498e8b1a3f567f0e56b56e04322</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01225-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01225-7%26sid%3Dliteratum%253Aachs%26aulast%3DLamb%26aufirst%3DY.%2BN.%26atitle%3DLasmiditan%253A%2520First%2520Approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D1989%26epage%3D1996%26doi%3D10.1007%2Fs40265-019-01225-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><a href="https://investor.lilly.com/news-releases/news-release-details/lilly-completes-acquisition-colucid-pharmaceuticals" class="extLink">https://investor.lilly.com/news-releases/news-release-details/lilly-completes-acquisition-colucid-pharmaceuticals</a> (accessed 2020-12-18).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Finvestor.lilly.com%2Fnews-releases%2Fnews-release-details%2Flilly-completes-acquisition-colucid-pharmaceuticals+%28accessed+2020-12-18%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><a href="https://uspl.lilly.com/reyvow/reyvow.html#pi" class="extLink">https://uspl.lilly.com/reyvow/reyvow.html#pi</a> (accessed 2020-09-17).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fuspl.lilly.com%2Freyvow%2Freyvow.html%23pi+%28accessed+2020-09-17%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Loo, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ailani, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baygani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hundemer, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Port, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krege, J. H.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety of Lasmiditan in Patients Using Concomitant Migraine Preventive Medications: Findings from SAMURAI and SPARTAN, Two Randomized Phase 3 Trials</span>. <i>J. Headache Pain</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">84</span>, <span class="refDoi"> DOI: 10.1186/s10194-019-1032-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1186%2Fs10194-019-1032-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31340760" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A280%3ADC%252BB3MvgvVaitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=84&author=L.+S.+Looauthor=J.+Ailaniauthor=J.+Schimauthor=S.+Bayganiauthor=H.+P.+Hundemerauthor=M.+Portauthor=J.+H.+Krege&title=Efficacy+and+Safety+of+Lasmiditan+in+Patients+Using+Concomitant+Migraine+Preventive+Medications%3A+Findings+from+SAMURAI+and+SPARTAN%2C+Two+Randomized+Phase+3+Trials&doi=10.1186%2Fs10194-019-1032-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials</span></div><div class="casAuthors">Loo Li Shen; Baygani Simin; Port Martha; Krege John H; Ailani Jessica; Schim Jack; Hundemer Hans-Peter</div><div class="citationInfo"><span class="NLM_cas:title">The journal of headache and pain</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">84</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  To study the efficacy and safety of lasmiditan for acute treatment of migraine in patients using migraine preventive medications.  BACKGROUND:  While lasmiditan has been proven to be an effective acute treatment for migraine, its effectiveness has not been examined when used concurrently with migraine preventives.  METHODS:  SAMURAI and SPARTAN were similarly designed, double-blind, phase 3, placebo-controlled studies of patients 18 years or older with 3 to 8 migraine attacks per month.  Patients were randomized to treat a migraine attack with oral lasmiditan 50 mg (SPARTAN only), 100 mg, 200 mg, or placebo.  Migraine preventives were allowed as long as doses were stable for 3 months prior to screening and were unchanged during the study.  Preventive medications with established or probable efficacy, as recommended by the American Academy of Neurology, the American Headache Society, and the European Headache Federation, plus botulinum toxin type A and candesartan, were included.  Within the subgroups of patients using and not using preventive therapies, lasmiditan and placebo groups were analyzed for the outcome of pain-free at 2 h and other efficacy outcomes.  The subgroups of patients using and not using preventive therapies were compared and interaction p-values were calculated for safety and efficacy outcomes.  RESULTS:  In these trials, 698 of 3981 patients (17.5%) used migraine preventive treatments.  Among patients using preventives, all lasmiditan doses resulted in significantly more patients being pain-free at 2 h, compared to placebo (p < 0.05).  Primary efficacy outcome (pain-free at 2 h), key secondary outcome (most bothersome symptom-free at 2 h) and all other efficacy outcomes were not significantly different between patients using or not using migraine preventives (all interaction p-values ≥0.1).  Rates of adverse events were similar for patients using and not using preventive medications.  CONCLUSIONS:  Lasmiditan was more effective than placebo for the acute treatment of migraine in patients concurrently using migraine preventive medications.  Lasmiditan efficacy and safety measures were similar for patients using and not using preventive medications.  TRIAL REGISTRATION:  SAMURAI (NCT02439320) and SPARTAN (NCT02605174).  Registered 18 March 2015.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTAZ7GLHZKdm-WhZTslLrfffW6udTcc2eboYvUWLZL8Ubntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MvgvVaitA%253D%253D&md5=5501acda0fff8f2009e4eea1ce69f0d3</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1186%2Fs10194-019-1032-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs10194-019-1032-x%26sid%3Dliteratum%253Aachs%26aulast%3DLoo%26aufirst%3DL.%2BS.%26aulast%3DAilani%26aufirst%3DJ.%26aulast%3DSchim%26aufirst%3DJ.%26aulast%3DBaygani%26aufirst%3DS.%26aulast%3DHundemer%26aufirst%3DH.%2BP.%26aulast%3DPort%26aufirst%3DM.%26aulast%3DKrege%26aufirst%3DJ.%2BH.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Lasmiditan%2520in%2520Patients%2520Using%2520Concomitant%2520Migraine%2520Preventive%2520Medications%253A%2520Findings%2520from%2520SAMURAI%2520and%2520SPARTAN%252C%2520Two%2520Randomized%2520Phase%25203%2520Trials%26jtitle%3DJ.%2520Headache%2520Pain%26date%3D2019%26volume%3D20%26spage%3D84%26doi%3D10.1186%2Fs10194-019-1032-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, M. P.</span>; <span class="NLM_string-name">Kohlman, D. T.</span>; <span class="NLM_string-name">Liang, S. X.</span>; <span class="NLM_string-name">Mancuso, V.</span>; <span class="NLM_string-name">Victor, F.</span>; <span class="NLM_string-name">Xu, Y.-C.</span>; <span class="NLM_string-name">Ying, B.-P.</span>; <span class="NLM_string-name">Zacherl, D. P.</span>; <span class="NLM_string-name">Zhang, D.</span></span> <span> </span><span class="NLM_article-title">Pyridinoylpiperidines as 5-HT1F Agonists</span>. <span class="NLM_patent">WO 2003084949 A1</span>, <span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=M.+P.+Cohen&author=D.+T.+Kohlman&author=S.+X.+Liang&author=V.+Mancuso&author=F.+Victor&author=Y.-C.+Xu&author=B.-P.+Ying&author=D.+P.+Zacherl&author=D.+Zhang&title=Pyridinoylpiperidines+as+5-HT1F+Agonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DM.%2BP.%26atitle%3DPyridinoylpiperidines%2520as%25205-HT1F%2520Agonists%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deore, D.</span>; <span class="NLM_string-name">Bhirud, S. B.</span>; <span class="NLM_string-name">Chand, P.</span>; <span class="NLM_string-name">Naik, S.</span>; <span class="NLM_string-name">Badgujar, S.</span>; <span class="NLM_string-name">Baviskar, D.</span></span> <span> </span><span class="NLM_article-title">Process for Preparation of Lasmiditan</span>. <span class="NLM_patent">WO 2020095171 A1</span>, <span class="NLM_year">2020</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=D.+Deore&author=S.+B.+Bhirud&author=P.+Chand&author=S.+Naik&author=S.+Badgujar&author=D.+Baviskar&title=Process+for+Preparation+of+Lasmiditan"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDeore%26aufirst%3DD.%26atitle%3DProcess%2520for%2520Preparation%2520of%2520Lasmiditan%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, L. J.</span></span> <span> </span><span class="NLM_article-title">Lemborexant: First Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">425</span>– <span class="NLM_lpage">432</span>, <span class="refDoi"> DOI: 10.1007/s40265-020-01276-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs40265-020-01276-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=32096020" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlslCltro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2020&pages=425-432&author=L.+J.+Scott&title=Lemborexant%3A+First+Approval&doi=10.1007%2Fs40265-020-01276-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Lemborexant: First Approval</span></div><div class="casAuthors">Scott, Lesley J.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">425-432</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Abstr.: Lemborexant (DAYVIGO) is an orally administered, dual orexin receptor (OXR) antagonist that exhibits reversible competitive antagonism at OXR1 and OXR2 (> affinity at OXR2) that was discovered and developed by Eisai Inc. for the treatment of adult patients with insomnia.  In Dec. 2019, lemborexant received its first approval (with final interim scheduling) in the USA for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.  In Jan. 2020, lemborexant also received approval in Japan for the treatment of insomnia.  It is also being investigated for the treatment of irregular sleep-wake rhythm disorder (ISWRD) assocd. with mild to moderate Alzheimer's disease.  This article summarizes the milestones in the development of lemborexant leading to its first global approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9xrf3D4Hk4rVg90H21EOLACvtfcHk0liPvcnxKwvqbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlslCltro%253D&md5=3d7e881e7ca2d223682081871963761c</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1007%2Fs40265-020-01276-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-020-01276-1%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DL.%2BJ.%26atitle%3DLemborexant%253A%2520First%2520Approval%26jtitle%3DDrugs%26date%3D2020%26volume%3D80%26spage%3D425%26epage%3D432%26doi%3D10.1007%2Fs40265-020-01276-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roth, T.</span></span> <span> </span><span class="NLM_article-title">Insomnia: Definition, Prevalence, Etiology, and Consequences</span>. <i>J. Clin. Sleep Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>3</i></span> (<span class="NLM_issue">5 Suppl.</span>),  <span class="NLM_fpage">S7</span>– <span class="NLM_lpage">S10</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.5664%2Fjcsm.26929" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=17824495" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2007&pages=S7-S10&issue=5+Suppl.&author=T.+Roth&title=Insomnia%3A+Definition%2C+Prevalence%2C+Etiology%2C+and+Consequences"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.5664%2Fjcsm.26929&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5664%252Fjcsm.26929%26sid%3Dliteratum%253Aachs%26aulast%3DRoth%26aufirst%3DT.%26atitle%3DInsomnia%253A%2520Definition%252C%2520Prevalence%252C%2520Etiology%252C%2520and%2520Consequences%26jtitle%3DJ.%2520Clin.%2520Sleep%2520Med.%26date%3D2007%26volume%3D3%26issue%3D5%2520Suppl%26spage%3DS7%26epage%3DS10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Morin, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drake, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harvey, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystal, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manber, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riemann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiegelhalder, K.</span></span> <span> </span><span class="NLM_article-title">Insomnia Disorder</span>. <i>Nat. Rev. Dis. Primers</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">15026</span>, <span class="refDoi"> DOI: 10.1038/nrdp.2015.26</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1038%2Fnrdp.2015.26" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=27189779" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A280%3ADC%252BC2s%252Fgs1aqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2015&pages=15026&author=C.+M.+Morinauthor=C.+L.+Drakeauthor=A.+G.+Harveyauthor=A.+D.+Krystalauthor=R.+Manberauthor=D.+Riemannauthor=K.+Spiegelhalder&title=Insomnia+Disorder&doi=10.1038%2Fnrdp.2015.26"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62aR"><div class="casContent"><span class="casTitleNuber">62a</span><div class="casTitle"><span class="NLM_cas:atitle">Insomnia disorder</span></div><div class="casAuthors">Morin Charles M; Drake Christopher L; Harvey Allison G; Krystal Andrew D; Manber Rachel; Riemann Dieter; Spiegelhalder Kai</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Disease primers</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">15026</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Insomnia disorder affects a large proportion of the population on a situational, recurrent or chronic basis and is among the most common complaints in medical practice.  The disorder is predominantly characterized by dissatisfaction with sleep duration or quality and difficulties initiating or maintaining sleep, along with substantial distress and impairments of daytime functioning.  It can present as the chief complaint or, more often, co-occurs with other medical or psychiatric disorders, such as pain and depression.  Persistent insomnia has been linked with adverse long-term health outcomes, including diminished quality of life and physical and psychological morbidity.  Despite its high prevalence and burden, the aetiology and pathophysiology of insomnia is poorly understood.  In the past decade, important changes in classification and diagnostic paradigms have instigated a move from a purely symptom-based conceptualization to the recognition of insomnia as a disorder in its own right.  These changes have been paralleled by key advances in therapy, with generic pharmacological and psychological interventions being increasingly replaced by approaches that have sleep-specific and insomnia-specific therapeutic targets.  Psychological and pharmacological therapies effectively reduce the time it takes to fall asleep and the time spent awake after sleep onset, and produce a modest increase in total sleep time; these are outcomes that correlate with improvements in daytime functioning.  Despite this progress, several challenges remain, including the need to improve our knowledge of the mechanisms that underlie insomnia and to develop more cost-effective, efficient and accessible therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQcrna7Vp9c5HRxY89Cm6SyfW6udTcc2eY6CcOBtGIwXLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s%252Fgs1aqug%253D%253D&md5=3bae6793183afcb0c89f4b11ffca776f</span></div><a href="/servlet/linkout?suffix=cit62a&amp;dbid=16384&amp;doi=10.1038%2Fnrdp.2015.26&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrdp.2015.26%26sid%3Dliteratum%253Aachs%26aulast%3DMorin%26aufirst%3DC.%2BM.%26aulast%3DDrake%26aufirst%3DC.%2BL.%26aulast%3DHarvey%26aufirst%3DA.%2BG.%26aulast%3DKrystal%26aufirst%3DA.%2BD.%26aulast%3DManber%26aufirst%3DR.%26aulast%3DRiemann%26aufirst%3DD.%26aulast%3DSpiegelhalder%26aufirst%3DK.%26atitle%3DInsomnia%2520Disorder%26jtitle%3DNat.%2520Rev.%2520Dis.%2520Primers%26date%3D2015%26volume%3D1%26spage%3D15026%26doi%3D10.1038%2Fnrdp.2015.26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit62b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Abad, V. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guilleminault, C.</span></span> <span> </span><span class="NLM_article-title">Insomnia in Elderly Patients: Recommendations for Pharmacological Management</span>. <i>Drugs Aging</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">791</span>– <span class="NLM_lpage">817</span>, <span class="refDoi"> DOI: 10.1007/s40266-018-0569-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs40266-018-0569-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=30058034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVShtb%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2018&pages=791-817&author=V.+C.+Abadauthor=C.+Guilleminault&title=Insomnia+in+Elderly+Patients%3A+Recommendations+for+Pharmacological+Management&doi=10.1007%2Fs40266-018-0569-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62bR"><div class="casContent"><span class="casTitleNuber">62b</span><div class="casTitle"><span class="NLM_cas:atitle">Insomnia in Elderly Patients: Recommendations for Pharmacological Management</span></div><div class="casAuthors">Abad, Vivien C.; Guilleminault, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Drugs & Aging</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">791-817</span>CODEN:
                <span class="NLM_cas:coden">DRAGE6</span>;
        ISSN:<span class="NLM_cas:issn">1170-229X</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Chronic insomnia affects 57% of the elderly in the United States, with impairment of quality of life, function, and health.  Chronic insomnia burdens society with billions of dollars in direct and indirect costs of care.  The main modalities in the treatment of insomnia in the elderly are psychol./behavioral therapies, pharmacol. treatment, or a combination of both.  Various specialty societies view psychol./behavioral therapies as the initial treatment intervention.  Pharmacotherapy plays an adjunctive role when insomnia symptoms persist or when patients are unable to pursue cognitive behavioral therapies.  Current drugs for insomnia fall into different classes: orexin agonists, histamine receptor antagonists, non-benzodiazepine gamma aminobutyric acid receptor agonists, and benzodiazepines.  This review focuses on Food and Drug Administration (FDA)-approved drugs for insomnia, including suvorexant, low-dose doxepin, Z-drugs (eszopiclone, zolpidem, zaleplon), benzodiazepines (triazolam, temazepam), and ramelteon.  We review the indications, dosing, efficacy, benefits, and harms of these drugs in the elderly, and discuss data on drugs that are commonly used off-label to treat insomnia, and those that are in clin. development.  The choice of a hypnotic agent in the elderly is symptom-based.  Ramelteon or short-acting Z-drugs can treat sleep-onset insomnia.  Suvorexant or low-dose doxepin can improve sleep maintenance.  Eszopiclone or zolpidem extended release can be utilized for both sleep onset and sleep maintenance.  Low-dose zolpidem sublingual tablets or zaleplon can alleviate middle-of-the-night awakenings.  Benzodiazepines should not be used routinely.  Trazodone, a commonly used off-label drug for insomnia, improves sleep quality and sleep continuity but carries significant risks.  Tiagabine, sometimes used off-label for insomnia, is not effective and should not be utilized.  Non-FDA-approved hypnotic agents that are commonly used include melatonin, diphenhydramine, tryptophan, and valerian, despite limited data on benefits and harms.  Melatonin slightly improves sleep onset and sleep duration, but product quality and efficacy may vary.  Tryptophan decreases sleep onset in adults, but data in the elderly are not available.  Valerian is relatively safe but has equivocal benefits on sleep quality.  Phase II studies of dual orexin receptor antagonists (almorexant, lemborexant, and filorexant) have shown some improvement in sleep maintenance and sleep continuity.  Piromelatine may improve sleep maintenance.  Histamine receptor inverse agonists (APD-125, eplivanserin, and LY2624803) improve slow-wave sleep but, for various reasons, the drug companies withdrew their products.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoL09It5208Y7Vg90H21EOLACvtfcHk0liPvcnxKwvqbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVShtb%252FL&md5=609f59e3556523ff8c81a02aee785664</span></div><a href="/servlet/linkout?suffix=cit62b&amp;dbid=16384&amp;doi=10.1007%2Fs40266-018-0569-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40266-018-0569-8%26sid%3Dliteratum%253Aachs%26aulast%3DAbad%26aufirst%3DV.%2BC.%26aulast%3DGuilleminault%26aufirst%3DC.%26atitle%3DInsomnia%2520in%2520Elderly%2520Patients%253A%2520Recommendations%2520for%2520Pharmacological%2520Management%26jtitle%3DDrugs%2520Aging%26date%3D2018%26volume%3D35%26spage%3D791%26epage%3D817%26doi%3D10.1007%2Fs40266-018-0569-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Scammell, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winrow, C. J.</span></span> <span> </span><span class="NLM_article-title">Orexin Receptors: Pharmacology and Therapeutic Opportunities</span>. <i>Annu. Rev. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">243</span>– <span class="NLM_lpage">66</span>, <span class="refDoi"> DOI: 10.1146/annurev-pharmtox-010510-100528</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1146%2Fannurev-pharmtox-010510-100528" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=21034217" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisFOju74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2011&pages=243-66&author=T.+E.+Scammellauthor=C.+J.+Winrow&title=Orexin+Receptors%3A+Pharmacology+and+Therapeutic+Opportunities&doi=10.1146%2Fannurev-pharmtox-010510-100528"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63aR"><div class="casContent"><span class="casTitleNuber">63a</span><div class="casTitle"><span class="NLM_cas:atitle">Orexin receptors: pharmacology and therapeutic opportunities</span></div><div class="casAuthors">Scammell, Thoams E.; Winrow, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">243-266</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Orexin-A and -B (also known as hypocretin-1 and -2) are neuropeptides produced in the lateral hypothalamus that promote many aspects of arousal through the OX1 and OX2 receptors.  In fact, they are necessary for normal wakefulness, as loss of the orexin-producing neurons causes narcolepsy in humans and rodents.  This has generated considerable interest in developing small-mol. orexin receptor antagonists as a novel therapy for the treatment of insomnia.  Orexin antagonists, esp. those that block OX2 or both OX1 and OX2 receptors, clearly promote sleep in animals, and clin. results are encouraging: Several compds. are in Phase III trials.  As the orexin system mainly promotes arousal, these new compds. will likely improve insomnia without incurring many of the side effects encountered with current medications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5EYJ1Vu6n0bVg90H21EOLACvtfcHk0lijf4WnjVABmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisFOju74%253D&md5=2fe03aa1eda09d266ab0d93426740f60</span></div><a href="/servlet/linkout?suffix=cit63a&amp;dbid=16384&amp;doi=10.1146%2Fannurev-pharmtox-010510-100528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-pharmtox-010510-100528%26sid%3Dliteratum%253Aachs%26aulast%3DScammell%26aufirst%3DT.%2BE.%26aulast%3DWinrow%26aufirst%3DC.%2BJ.%26atitle%3DOrexin%2520Receptors%253A%2520Pharmacology%2520and%2520Therapeutic%2520Opportunities%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2011%26volume%3D51%26spage%3D243%26epage%3D66%26doi%3D10.1146%2Fannurev-pharmtox-010510-100528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit63b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Grandner, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perlis, M. L.</span></span> <span> </span><span class="NLM_article-title">Pharmacotherapy for Insomnia Disorder in Older Adults</span>. <i>JAMA Netw. Open</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>2</i></span>, <span class="NLM_elocation-id">e1918214</span> <span class="refDoi"> DOI: 10.1001/jamanetworkopen.2019.18214</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1001%2Fjamanetworkopen.2019.18214" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31880788" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2019&author=M.+A.+Grandnerauthor=M.+L.+Perlis&title=Pharmacotherapy+for+Insomnia+Disorder+in+Older+Adults&doi=10.1001%2Fjamanetworkopen.2019.18214"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63b&amp;dbid=16384&amp;doi=10.1001%2Fjamanetworkopen.2019.18214&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamanetworkopen.2019.18214%26sid%3Dliteratum%253Aachs%26aulast%3DGrandner%26aufirst%3DM.%2BA.%26aulast%3DPerlis%26aufirst%3DM.%2BL.%26atitle%3DPharmacotherapy%2520for%2520Insomnia%2520Disorder%2520in%2520Older%2520Adults%26jtitle%3DJAMA%2520Netw.%2520Open%26date%3D2019%26volume%3D2%26doi%3D10.1001%2Fjamanetworkopen.2019.18214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span> <span> </span><span class="NLM_article-title">The Orexin/Receptor System: Molecular Mechanism and Therapeutic Potential for Neurological Diseases</span>. <i>Front. Mol. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">220</span>, <span class="refDoi"> DOI: 10.3389/fnmol.2018.00220</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.3389%2Ffnmol.2018.00220" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=30002617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFGmt7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=220&author=C.+Wangauthor=Q.+Wangauthor=B.+Jiauthor=Y.+Panauthor=C.+Xuauthor=B.+Chengauthor=B.+Baiauthor=J.+Chen&title=The+Orexin%2FReceptor+System%3A+Molecular+Mechanism+and+Therapeutic+Potential+for+Neurological+Diseases&doi=10.3389%2Ffnmol.2018.00220"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">The orexin/receptor system: molecular mechanism and therapeutic potential for neurological diseases</span></div><div class="casAuthors">Wang, Chunmei; Wang, Qinqin; Ji, Bingyuan; Pan, Yanyou; Xu, Chao; Cheng, Baohua; Bai, Bo; Chen, Jing</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Molecular Neuroscience</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">220/1-220/16</span>CODEN:
                <span class="NLM_cas:coden">FMNRAJ</span>;
        ISSN:<span class="NLM_cas:issn">1662-5099</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Orexins, also known as hypocretins, are two neuropeptides secreted from orexin-contg. neurons, mainly in the lateral hypothalamus (LH).  Orexins orchestrate their effects by binding and activating two G-protein-coupled receptors (GPCRs), orexin receptor type 1 (OX1R) and type 2 (OX2R).  Orexin/receptor pathways play vital regulatory roles in many physiol. processes, esp. feeding behavior, sleep-wake rhythm, reward and addiction and energy balance.  Furthermore several reports showed that orexin/receptor pathways are involved in pathol. processes of neurol. diseases such as narcolepsy, depression, ischemic stroke, drug addiction and Alzheimer's disease (AD).  This review article summarizes the expression patterns, physiol. functions and potential mol. mechanisms of the orexin/receptor system in neurol. diseases, providing an overall framework for considering these pathways from the standpoints of basic research and clin. treatment of neurol. diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGre2X2KfcbVS7Vg90H21EOLACvtfcHk0lijf4WnjVABmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFGmt7fK&md5=d6e7659df8c3ac08fa58cd7958a449b3</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.3389%2Ffnmol.2018.00220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnmol.2018.00220%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DJi%26aufirst%3DB.%26aulast%3DPan%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DC.%26aulast%3DCheng%26aufirst%3DB.%26aulast%3DBai%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DJ.%26atitle%3DThe%2520Orexin%252FReceptor%2520System%253A%2520Molecular%2520Mechanism%2520and%2520Therapeutic%2520Potential%2520for%2520Neurological%2520Diseases%26jtitle%3DFront.%2520Mol.%2520Neurosci.%26date%3D2018%26volume%3D11%26spage%3D220%26doi%3D10.3389%2Ffnmol.2018.00220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naoe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terauchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozaki, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doko, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takemura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorimachi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beuckmann, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yonaga, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of (1<i>R</i>,2<i>S</i>)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-<i>N</i>-(5-fluoropyridin-2-yl)cyclopropanecarboxamide (E2006): A Potent and Efficacious Oral Orexin Receptor Antagonist</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">4648</span>– <span class="NLM_lpage">4664</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00217</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00217" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotVSntbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4648-4664&author=Y.+Yoshidaauthor=Y.+Naoeauthor=T.+Terauchiauthor=F.+Ozakiauthor=T.+Dokoauthor=A.+Takemuraauthor=T.+Tanakaauthor=K.+Sorimachiauthor=C.+T.+Beuckmannauthor=M.+Suzukiauthor=T.+Uenoauthor=S.+Ozakiauthor=M.+Yonaga&title=Discovery+of+%281R%2C2S%29-2-%7B%5B%282%2C4-Dimethylpyrimidin-5-yl%29oxy%5Dmethyl%7D-2-%283-fluorophenyl%29-N-%285-fluoropyridin-2-yl%29cyclopropanecarboxamide+%28E2006%29%3A+A+Potent+and+Efficacious+Oral+Orexin+Receptor+Antagonist&doi=10.1021%2Facs.jmedchem.5b00217"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (1R,2S)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide (E2006): A Potent and Efficacious Oral Orexin Receptor Antagonist</span></div><div class="casAuthors">Yoshida, Yu; Naoe, Yoshimitsu; Terauchi, Taro; Ozaki, Fumihiro; Doko, Takashi; Takemura, Ayumi; Tanaka, Toshiaki; Sorimachi, Keiichi; Beuckmann, Carsten T.; Suzuki, Michiyuki; Ueno, Takashi; Ozaki, Shunsuke; Yonaga, Masahiro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4648-4664</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The orexin/hypocretin receptors are a family of G protein-coupled receptors and consist of orexin-1 (OX1) and orexin-2 (OX2) receptor subtypes.  Orexin receptors are expressed throughout the central nervous system and are involved in the regulation of the sleep/wake cycle.  Because modulation of these receptors constitutes a promising target for novel treatments of disorders assocd. with the control of sleep and wakefulness, such as insomnia, the development of orexin receptor antagonists has emerged as an important focus in drug discovery research.  Here, we report the design, synthesis, characterization, and structure-activity relationships (SARs) of novel orexin receptor antagonists.  Various modifications made to the core structure of a previously developed compd. (-)-5 (I), the lead mol., resulted in compds. with improved chem. and pharmacol. profiles.  The investigation afforded a potential therapeutic agent, (1R,2S)-2-{[(2,4-dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide (E2006, II), an orally active, potent orexin antagonist.  The efficacy was demonstrated in mice in an in vivo study by using sleep parameter measurements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzsPb-jXQr4bVg90H21EOLACvtfcHk0lijf4WnjVABmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotVSntbk%253D&md5=939b30c00a05039e911484ef1f6800ad</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00217&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00217%26sid%3Dliteratum%253Aachs%26aulast%3DYoshida%26aufirst%3DY.%26aulast%3DNaoe%26aufirst%3DY.%26aulast%3DTerauchi%26aufirst%3DT.%26aulast%3DOzaki%26aufirst%3DF.%26aulast%3DDoko%26aufirst%3DT.%26aulast%3DTakemura%26aufirst%3DA.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DSorimachi%26aufirst%3DK.%26aulast%3DBeuckmann%26aufirst%3DC.%2BT.%26aulast%3DSuzuki%26aufirst%3DM.%26aulast%3DUeno%26aufirst%3DT.%26aulast%3DOzaki%26aufirst%3DS.%26aulast%3DYonaga%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520%25281R%252C2S%2529-2-%257B%255B%25282%252C4-Dimethylpyrimidin-5-yl%2529oxy%255Dmethyl%257D-2-%25283-fluorophenyl%2529-N-%25285-fluoropyridin-2-yl%2529cyclopropanecarboxamide%2520%2528E2006%2529%253A%2520A%2520Potent%2520and%2520Efficacious%2520Oral%2520Orexin%2520Receptor%2520Antagonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4648%26epage%3D4664%26doi%3D10.1021%2Facs.jmedchem.5b00217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moniz, G. A.</span>; <span class="NLM_string-name">Wilcoxen, A. Z.</span>; <span class="NLM_string-name">Benayoud, F.</span>; <span class="NLM_string-name">Lee, J.</span>; <span class="NLM_string-name">Zhang, H.</span>; <span class="NLM_string-name">Terauchi, T.</span>; <span class="NLM_string-name">Takemura, A.</span>; <span class="NLM_string-name">Yoshida, Y.</span>; <span class="NLM_string-name">Tanaka, T.</span>; <span class="NLM_string-name">Sorimachi, K.</span>; <span class="NLM_string-name">Naoe, Y.</span>; <span class="NLM_string-name">Kazuta, Y.</span></span> <span> </span><span class="NLM_article-title">Methods and Compounds Useful in the Synthesis of Orexin-2 Receptor Antagonists</span>. <span class="NLM_patent">WO 2013123240 A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=G.+A.+Moniz&author=A.+Z.+Wilcoxen&author=F.+Benayoud&author=J.+Lee&author=H.+Zhang&author=T.+Terauchi&author=A.+Takemura&author=Y.+Yoshida&author=T.+Tanaka&author=K.+Sorimachi&author=Y.+Naoe&author=Y.+Kazuta&title=Methods+and+Compounds+Useful+in+the+Synthesis+of+Orexin-2+Receptor+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMoniz%26aufirst%3DG.%2BA.%26atitle%3DMethods%2520and%2520Compounds%2520Useful%2520in%2520the%2520Synthesis%2520of%2520Orexin-2%2520Receptor%2520Antagonists%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Wennogle, L. P.</span>; <span class="NLM_string-name">Li, P.</span></span> <span> </span><span class="NLM_article-title">Organic Compounds, Substituted Fluorinated Heterocycle Fused Gamma-Carbolines for Use in Treatment of Diseases Involving 5-HT2A Receptor, Serotonin Transporter, and/or Pathways Involving Dopamine Receptor Signaling</span>. <span class="NLM_patent">WO 2017165755 A1</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=L.+P.+Wennogle&author=P.+Li&title=Organic+Compounds%2C+Substituted+Fluorinated+Heterocycle+Fused+Gamma-Carbolines+for+Use+in+Treatment+of+Diseases+Involving+5-HT2A+Receptor%2C+Serotonin+Transporter%2C+and%2For+Pathways+Involving+Dopamine+Receptor+Signaling"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWennogle%26aufirst%3DL.%2BP.%26atitle%3DOrganic%2520Compounds%252C%2520Substituted%2520Fluorinated%2520Heterocycle%2520Fused%2520Gamma-Carbolines%2520for%2520Use%2520in%2520Treatment%2520of%2520Diseases%2520Involving%25205-HT2A%2520Receptor%252C%2520Serotonin%2520Transporter%252C%2520and%252For%2520Pathways%2520Involving%2520Dopamine%2520Receptor%2520Signaling%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit67b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, G.</span>; <span class="NLM_string-name">Davis, R.</span>; <span class="NLM_string-name">Wennogle, L. P.</span></span> <span> </span><span class="NLM_article-title">Novel Methods for Acute Treatment of Depression and/or Anxiety</span>. <span class="NLM_patent">WO 2019178484 A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=G.+Snyder&author=R.+Davis&author=L.+P.+Wennogle&title=Novel+Methods+for+Acute+Treatment+of+Depression+and%2For+Anxiety"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSnyder%26aufirst%3DG.%26atitle%3DNovel%2520Methods%2520for%2520Acute%2520Treatment%2520of%2520Depression%2520and%252For%2520Anxiety%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blair, H. A.</span></span> <span> </span><span class="NLM_article-title">Lumateperone: First Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">417</span>– <span class="NLM_lpage">423</span>, <span class="refDoi"> DOI: 10.1007/s40265-020-01271-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs40265-020-01271-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=32060882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A280%3ADC%252BB387itl2iuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2020&pages=417-423&author=H.+A.+Blair&title=Lumateperone%3A+First+Approval&doi=10.1007%2Fs40265-020-01271-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Lumateperone: First Approval</span></div><div class="casAuthors">Blair Hannah A</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">417-423</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Lumateperone (Caplyta(®)) is a novel, orally available agent developed by Intra-Cellular Therapies (under a license from Bristol-Myers Squibb) for the treatment of schizophrenia and other neuropsychiatric and neurological disorders.  Lumateperone is a first-in-class selective and simultaneous modulator of serotonin, dopamine and glutamate.  In December 2019, lumateperone received its first global approval in the USA for the treatment of schizophrenia in adults.  The drug is also under clinical development for bipolar depression, behavioural disorders associated with dementia and Alzheimer's disease, sleep maintenance insomnia and major depressive disorders.  This article summarizes the milestones in the development of lumateperone leading to this first approval for the treatment of schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSA-ZQG6zODSPEeosoOnpOLfW6udTcc2eY34Z3pLKr9r7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB387itl2iuw%253D%253D&md5=26b1f35c1ec74f78be3b37b984f5bffa</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1007%2Fs40265-020-01271-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-020-01271-6%26sid%3Dliteratum%253Aachs%26aulast%3DBlair%26aufirst%3DH.%2BA.%26atitle%3DLumateperone%253A%2520First%2520Approval%26jtitle%3DDrugs%26date%3D2020%26volume%3D80%26spage%3D417%26epage%3D423%26doi%3D10.1007%2Fs40265-020-01271-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davis, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correll, C. U.</span></span> <span> </span><span class="NLM_article-title">ITI-007 in the Treatment of Schizophrenia: From Novel Pharmacology to Clinical Outcomes</span>. <i>Expert Rev. Neurother.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">601</span>– <span class="NLM_lpage">614</span>, <span class="refDoi"> DOI: 10.1080/14737175.2016.1174577</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1080%2F14737175.2016.1174577" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=27042868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC28XmslOjsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=601-614&author=R.+E.+Davisauthor=C.+U.+Correll&title=ITI-007+in+the+Treatment+of+Schizophrenia%3A+From+Novel+Pharmacology+to+Clinical+Outcomes&doi=10.1080%2F14737175.2016.1174577"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes</span></div><div class="casAuthors">Davis, Robert E.; Correll, Christoph U.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Neurotherapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">601-614</span>CODEN:
                <span class="NLM_cas:coden">ERNXAR</span>;
        ISSN:<span class="NLM_cas:issn">1473-7175</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">ITI-007 is an investigational drug being developed for schizophrenia and other neuropsychiatric/neurodegenerative diseases.  ITI-007 has a unique pharmacol. profile, combining potent 5-HT2a receptor antagonism with cell-type-specific dopamine and glutamate receptor modulation, plus serotonin reuptake inhibition.  At dopamine-D2 receptors, ITI-007 acts as a post-synaptic antagonist and pre-synaptic partial agonist.  Addnl., ITI-007 stimulates phosphorylation of glutamatergic NMDA-NR2B receptors, downstream of dopamine-D1 receptor intracellular signaling.  Based on a large, placebo and risperidone controlled, Phase-II trial, ITI-007 60 mg was shown to be effective in reducing symptoms in patients with acutely exacerbated schizophrenia.  The antipsychotic efficacy of ITI-007 60 mg in this patient population was confirmed in a recently completed Phase III study.  ITI-007 was assocd. with minimal safety risk compared to risperidone (Phase II study) or placebo (both studies) for neuromotor disturbances, prolactin changes, wt. gain and metabolic abnormalities.  A second 6-wk, placebo and risperidone-controlled Phase-III trial in acutely exacerbated schizophrenia is ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVCRMQthqMa7Vg90H21EOLACvtfcHk0ljZOKo06DypsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmslOjsrs%253D&md5=8781454405edda6e05bb7d384606ddc0</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1080%2F14737175.2016.1174577&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14737175.2016.1174577%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DR.%2BE.%26aulast%3DCorrell%26aufirst%3DC.%2BU.%26atitle%3DITI-007%2520in%2520the%2520Treatment%2520of%2520Schizophrenia%253A%2520From%2520Novel%2520Pharmacology%2520to%2520Clinical%2520Outcomes%26jtitle%3DExpert%2520Rev.%2520Neurother.%26date%3D2016%26volume%3D16%26spage%3D601%26epage%3D614%26doi%3D10.1080%2F14737175.2016.1174577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ellison, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dufresne, R. L.</span></span> <span> </span><span class="NLM_article-title">A Review of the Clinical Utility of Serum Clozapine and Norclozapine Levels</span>. <i>Ment. Health Clin.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">68</span>– <span class="NLM_lpage">73</span>, <span class="refDoi"> DOI: 10.9740/mhc.2015.03.068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.9740%2Fmhc.2015.03.068" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=68-73&author=J.+C.+Ellisonauthor=R.+L.+Dufresne&title=A+Review+of+the+Clinical+Utility+of+Serum+Clozapine+and+Norclozapine+Levels&doi=10.9740%2Fmhc.2015.03.068"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.9740%2Fmhc.2015.03.068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.9740%252Fmhc.2015.03.068%26sid%3Dliteratum%253Aachs%26aulast%3DEllison%26aufirst%3DJ.%2BC.%26aulast%3DDufresne%26aufirst%3DR.%2BL.%26atitle%3DA%2520Review%2520of%2520the%2520Clinical%2520Utility%2520of%2520Serum%2520Clozapine%2520and%2520Norclozapine%2520Levels%26jtitle%3DMent.%2520Health%2520Clin.%26date%3D2015%26volume%3D5%26spage%3D68%26epage%3D73%26doi%3D10.9740%2Fmhc.2015.03.068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buckley, P. F.</span></span> <span> </span><span class="NLM_article-title">Olanzapine: A Critical Review of Recent Literature</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">2077</span>– <span class="NLM_lpage">2089</span>, <span class="refDoi"> DOI: 10.1517/14656566.6.12.2077</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1517%2F14656566.6.12.2077" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=16197360" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFCjsbjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=2077-2089&author=P.+F.+Buckley&title=Olanzapine%3A+A+Critical+Review+of+Recent+Literature&doi=10.1517%2F14656566.6.12.2077"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Olanzapine: a critical review of recent literature</span></div><div class="casAuthors">Buckley, Peter F.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2077-2089</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">The purpose of this review is to critically review the current literature on olanzapine with an emphasis on emergent themes and key findings in the use of this agent for the treatment of mood disorders and schizophrenia.  New information continues to emerge on the impact of olanzapine on schizo-phrenia and on aspects of the course of mood disorders.  There are also continued efforts to understand, predict and manage the side-effect risk with olanzapine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquFaBBxEa2sbVg90H21EOLACvtfcHk0lgHKSC-TeWUUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFCjsbjL&md5=7a8d254ff01b11854b8af9e93acb80a5</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1517%2F14656566.6.12.2077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.6.12.2077%26sid%3Dliteratum%253Aachs%26aulast%3DBuckley%26aufirst%3DP.%2BF.%26atitle%3DOlanzapine%253A%2520A%2520Critical%2520Review%2520of%2520Recent%2520Literature%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2005%26volume%3D6%26spage%3D2077%26epage%3D2089%26doi%3D10.1517%2F14656566.6.12.2077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robichaud, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomesch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beard, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrick, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanover, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mates, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wennogle, L. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Tetracyclic Quinoxaline Derivative as a Potent and Orally Active Multifunctional Drug Candidate for the Treatment of Neuropsychiatric and Neurological Disorders</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">2670</span>– <span class="NLM_lpage">2682</span>, <span class="refDoi"> DOI: 10.1021/jm401958n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401958n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC2cXivFOhu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=2670-2682&author=P.+Liauthor=Q.+Zhangauthor=A.+J.+Robichaudauthor=T.+Leeauthor=J.+Tomeschauthor=W.+Yaoauthor=J.+D.+Beardauthor=G.+L.+Snyderauthor=H.+Zhuauthor=Y.+Pengauthor=J.+P.+Hendrickauthor=K.+E.+Vanoverauthor=R.+E.+Davisauthor=S.+Matesauthor=L.+P.+Wennogle&title=Discovery+of+a+Tetracyclic+Quinoxaline+Derivative+as+a+Potent+and+Orally+Active+Multifunctional+Drug+Candidate+for+the+Treatment+of+Neuropsychiatric+and+Neurological+Disorders&doi=10.1021%2Fjm401958n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Tetracyclic Quinoxaline Derivative as a Potent and Orally Active Multifunctional Drug Candidate for the Treatment of Neuropsychiatric and Neurological Disorders</span></div><div class="casAuthors">Li, Peng; Zhang, Qiang; Robichaud, Albert J.; Lee, Taekyu; Tomesch, John; Yao, Wei; Beard, J. David; Snyder, Gretchen L.; Zhu, Hongwen; Peng, Youyi; Hendrick, Joseph P.; Vanover, Kimberly E.; Davis, Robert E.; Mates, Sharon; Wennogle, Lawrence P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2670-2682</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report the synthesis and structure-activity relationships of a class of tetracyclic butyrophenones that exhibit potent binding affinities to serotonin 5-HT2A and dopamine D2 receptors.  This work has led to the discovery of 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluorophenyl)-butan-1-one 4-methylbenzenesulfonate (ITI-007, I.TsOH), which is a potent 5-HT2A antagonist, postsynaptic D2 antagonist, and inhibitor of serotonin transporter.  This multifunctional drug candidate is orally bioavailable and exhibits good antipsychotic efficacy in vivo.  Currently, this investigational new drug is under clin. development for the treatment of neuropsychiatric and neurol. disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozLklhmBkFo7Vg90H21EOLACvtfcHk0lgHKSC-TeWUUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXivFOhu7o%253D&md5=318c9a3df9d79a2ac593c40015021015</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1021%2Fjm401958n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401958n%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DRobichaud%26aufirst%3DA.%2BJ.%26aulast%3DLee%26aufirst%3DT.%26aulast%3DTomesch%26aufirst%3DJ.%26aulast%3DYao%26aufirst%3DW.%26aulast%3DBeard%26aufirst%3DJ.%2BD.%26aulast%3DSnyder%26aufirst%3DG.%2BL.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DPeng%26aufirst%3DY.%26aulast%3DHendrick%26aufirst%3DJ.%2BP.%26aulast%3DVanover%26aufirst%3DK.%2BE.%26aulast%3DDavis%26aufirst%3DR.%2BE.%26aulast%3DMates%26aufirst%3DS.%26aulast%3DWennogle%26aufirst%3DL.%2BP.%26atitle%3DDiscovery%2520of%2520a%2520Tetracyclic%2520Quinoxaline%2520Derivative%2520as%2520a%2520Potent%2520and%2520Orally%2520Active%2520Multifunctional%2520Drug%2520Candidate%2520for%2520the%2520Treatment%2520of%2520Neuropsychiatric%2520and%2520Neurological%2520Disorders%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D2670%26epage%3D2682%26doi%3D10.1021%2Fjm401958n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, B.</span></span> <span> </span><span class="NLM_article-title">The Fischer Indole Synthesis</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1963</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">373</span>– <span class="NLM_lpage">401</span>, <span class="refDoi"> DOI: 10.1021/cr60224a003</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr60224a003" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=1963&pages=373-401&author=B.+Robinson&title=The+Fischer+Indole+Synthesis&doi=10.1021%2Fcr60224a003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1021%2Fcr60224a003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr60224a003%26sid%3Dliteratum%253Aachs%26aulast%3DRobinson%26aufirst%3DB.%26atitle%3DThe%2520Fischer%2520Indole%2520Synthesis%26jtitle%3DChem.%2520Rev.%26date%3D1963%26volume%3D63%26spage%3D373%26epage%3D401%26doi%3D10.1021%2Fcr60224a003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartwig, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driver, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernández-Rivas, C.</span></span> <span> </span><span class="NLM_article-title">Palladium-Catalyzed C-N(sp<sup>2</sup>) Bond Formation: N-Arylation of Aromatic and Unsaturated Nitrogen and the Reductive Elimination Chemistry of Palladium Azolyl and Methyleneamido Complexes</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">827</span>– <span class="NLM_lpage">828</span>, <span class="refDoi"> DOI: 10.1021/ja973524g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja973524g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref74/cit74a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADyaK1cXmvFWmtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=1998&pages=827-828&author=G.+Mannauthor=J.+F.+Hartwigauthor=M.+S.+Driverauthor=C.+Fern%C3%A1ndez-Rivas&title=Palladium-Catalyzed+C-N%28sp2%29+Bond+Formation%3A+N-Arylation+of+Aromatic+and+Unsaturated+Nitrogen+and+the+Reductive+Elimination+Chemistry+of+Palladium+Azolyl+and+Methyleneamido+Complexes&doi=10.1021%2Fja973524g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74aR"><div class="casContent"><span class="casTitleNuber">74a</span><div class="casTitle"><span class="NLM_cas:atitle">Palladium-Catalyzed C-N(sp2) Bond Formation: N-Arylation of Aromatic and Unsaturated Nitrogen and the Reductive Elimination Chemistry of Palladium Azolyl and Methyleneamido Complexes</span></div><div class="casAuthors">Mann, Grace; Hartwig, John F.; Driver, ftref Michael S.; Fernandez-Rivas, Carolina</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">827-828</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Studies on palladium-catalyzed arylation of unsatd. or arom. nitrogen centers, along with direct observation of the key C-N bond-forming reductive elimination of N-aryl pyrrole and N-aryl imines are reported.  Reaction of aryl halides with pyrrole, indole, carbazole, or benzophenone imine, in the presence of a base and a catalytic amt. of Pd(OAc)2 and DPPF gave N-aryl azoles and N-aryl imines in high yields.  N-aryl azoles are biol. important and N-aryl imines serve as protected anilines.  These new C-N bond-forming reactions are suitable for electron poor or electron rich aryl halides.  The step in the catalytic cycle that forms the C-N bond is likely to be a reductive elimination.  C-N bond-forming reductive eliminations involving unsatd. or arom. nitrogens have not been obsd. previously, but are important for understanding how the relative C-N reductive elimination rates relate to the well-known C-C bond-forming reductive eliminations involving alkyl, aryl, and vinyl groups.  Reductive eliminations to form N-aryl azoles were slow, but occurred in high yields with DPPF as the ligand on palladium.  Yields were lower for analogous PPh3 complexes.  In contrast to the elimination of N-aryl azoles, reductive eliminations to form N-aryl imines from palladium methyleneamido complexes were fast and were more akin to C-N reductive eliminations of arylamines or C-C reductive elimination of styrenes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq8P9QzvuwS7Vg90H21EOLACvtfcHk0lgHKSC-TeWUUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmvFWmtQ%253D%253D&md5=1bbea02bae760fbc209e03ff279475c7</span></div><a href="/servlet/linkout?suffix=cit74a&amp;dbid=16384&amp;doi=10.1021%2Fja973524g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja973524g%26sid%3Dliteratum%253Aachs%26aulast%3DMann%26aufirst%3DG.%26aulast%3DHartwig%26aufirst%3DJ.%2BF.%26aulast%3DDriver%26aufirst%3DM.%2BS.%26aulast%3DFern%25C3%25A1ndez-Rivas%26aufirst%3DC.%26atitle%3DPalladium-Catalyzed%2520C-N%2528sp2%2529%2520Bond%2520Formation%253A%2520N-Arylation%2520of%2520Aromatic%2520and%2520Unsaturated%2520Nitrogen%2520and%2520the%2520Reductive%2520Elimination%2520Chemistry%2520of%2520Palladium%2520Azolyl%2520and%2520Methyleneamido%2520Complexes%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1998%26volume%3D120%26spage%3D827%26epage%3D828%26doi%3D10.1021%2Fja973524g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit74b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wolfe, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Åhman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadighi, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchwald, S. L.</span></span> <span> </span><span class="NLM_article-title">An Ammonia Equivalent for the Palladium-Catalyzed Amination of Aryl Halides and Triflates</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">6367</span>– <span class="NLM_lpage">6370</span>, <span class="refDoi"> DOI: 10.1016/S0040-4039(97)01465-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2FS0040-4039%2897%2901465-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADyaK2sXlvFGns7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1997&pages=6367-6370&author=J.+P.+Wolfeauthor=J.+%C3%85hmanauthor=J.+P.+Sadighiauthor=R.+A.+Singerauthor=S.+L.+Buchwald&title=An+Ammonia+Equivalent+for+the+Palladium-Catalyzed+Amination+of+Aryl+Halides+and+Triflates&doi=10.1016%2FS0040-4039%2897%2901465-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74bR"><div class="casContent"><span class="casTitleNuber">74b</span><div class="casTitle"><span class="NLM_cas:atitle">An ammonia equivalent for the palladium-catalyzed amination of aryl halides and triflates</span></div><div class="casAuthors">Wolfe, John P.; Ahman, Jens; Sadighi, Joseph P.; Singer, Robert A.; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">6367-6370</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Com. available benzophenone imine serves as a convenient NH3 equiv. in the Pd-catalyzed amination of aryl halides and triflates.  The benzophenone imine adducts can be cleaved directly to the corresponding primary anilines by catalytic hydrogenation or treatment with hydroxylamine hydrochloride or a catalytic amt. of HCl in wet THF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXMgy_yfX_ubVg90H21EOLACvtfcHk0li3Q7JxaCRo_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXlvFGns7k%253D&md5=a460a4291911fcf3da1c7f6f61a1c38b</span></div><a href="/servlet/linkout?suffix=cit74b&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2897%2901465-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252897%252901465-2%26sid%3Dliteratum%253Aachs%26aulast%3DWolfe%26aufirst%3DJ.%2BP.%26aulast%3D%25C3%2585hman%26aufirst%3DJ.%26aulast%3DSadighi%26aufirst%3DJ.%2BP.%26aulast%3DSinger%26aufirst%3DR.%2BA.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DAn%2520Ammonia%2520Equivalent%2520for%2520the%2520Palladium-Catalyzed%2520Amination%2520of%2520Aryl%2520Halides%2520and%2520Triflates%26jtitle%3DTetrahedron%2520Lett.%26date%3D1997%26volume%3D38%26spage%3D6367%26epage%3D6370%26doi%3D10.1016%2FS0040-4039%2897%2901465-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chincholkar, M.</span></span> <span> </span><span class="NLM_article-title">Analgesic Mechanisms of Gabapentinoids and Effects in Experimental Pain Models: A Narrative Review</span>. <i>Br. J. Anaesth.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">1315</span>– <span class="NLM_lpage">1334</span>, <span class="refDoi"> DOI: 10.1016/j.bja.2018.02.066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2Fj.bja.2018.02.066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=29793598" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXkvVCrsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2018&pages=1315-1334&author=M.+Chincholkar&title=Analgesic+Mechanisms+of+Gabapentinoids+and+Effects+in+Experimental+Pain+Models%3A+A+Narrative+Review&doi=10.1016%2Fj.bja.2018.02.066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Analgesic mechanisms of gabapentinoids and effects in experimental pain models: a narrative review</span></div><div class="casAuthors">Chincholkar, M.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Anaesthesia</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1315-1334</span>CODEN:
                <span class="NLM_cas:coden">BJANAD</span>;
        ISSN:<span class="NLM_cas:issn">1471-6771</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The focus of perioperative pain management should be to attempt to minimise the nociceptive input and reduce the risk of transition to central sensitization.  Gabapentinoids are being increasingly used as adjuncts for management of perioperative pain.  Although gabapentinoids are classed as calcium channel blockers, their mechanisms of action are poorly understood.  The analgesic effect in neuropathic pain is well evidenced but the role in postoperative pain is less certain.  Medline and EMBASE database searches were conducted to identify studies relating to mechanisms of action and effects in exptl. animal models of inflammatory and postoperative pain and human models of exptl. pain.  The effects of gabapentinoids may be attributed to depression of dorsal horn sensitivity through a multitude of mechanisms.  They inhibit calcium mediated neurotransmitter release through effects on α2δ-1 subunits.  They inhibit forward trafficking of α2δ-1 from the dorsal root ganglion, their recycling from endosomal compartments, thrombospondin mediated processes and stimulate glutamate uptake by excitatory amino acid transporters.  Mechanisms not directly related to neurotransmitter release at dorsal horn include inhibition of descending serotonergic facilitation, stimulation of descending inhibition, anti-inflammatory actions, and influence on the affective component of pain.  Gabapentinoids are effective analgesics in most animal models of inflammation and postoperative pain but effects in human models are variable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcjsuFSpt4K7Vg90H21EOLACvtfcHk0li3Q7JxaCRo_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXkvVCrsg%253D%253D&md5=a7f36db7a18eb0a7d0701d773a1562de</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2Fj.bja.2018.02.066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bja.2018.02.066%26sid%3Dliteratum%253Aachs%26aulast%3DChincholkar%26aufirst%3DM.%26atitle%3DAnalgesic%2520Mechanisms%2520of%2520Gabapentinoids%2520and%2520Effects%2520in%2520Experimental%2520Pain%2520Models%253A%2520A%2520Narrative%2520Review%26jtitle%3DBr.%2520J.%2520Anaesth.%26date%3D2018%26volume%3D120%26spage%3D1315%26epage%3D1334%26doi%3D10.1016%2Fj.bja.2018.02.066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deeks, E. D.</span></span> <span> </span><span class="NLM_article-title">Mirogabalin: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">463</span>– <span class="NLM_lpage">468</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01070-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs40265-019-01070-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=30778848" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnvFyitrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=463-468&author=E.+D.+Deeks&title=Mirogabalin%3A+First+Global+Approval&doi=10.1007%2Fs40265-019-01070-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Mirogabalin: First Global Approval</span></div><div class="casAuthors">Deeks, Emma D.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">463-468</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Mirogabalin besylate (hereafter mirogabalin) [Tarlige] is an orally administered gabapentinoid developed by Daiichi Sankyo for the treatment of peripheral neuropathic pain (PNP), including diabetic PNP and post-herpetic neuralgia.  The drug binds to and modulates the α2δ-1 subunit of the voltage-gated calcium channels widely found in the nervous system in areas that mediate pain transmission and processing.  Mirogabalin has a unique binding profile and long duration of action.  The drug is approved in Japan for the treatment of PNP and is in clin. development for this indication elsewhere in Asia.  Clin. development of the drug for fibromyalgia pain was discontinued in the USA and EU after the primary endpoint was not met in phase 3 trials.  No recent reports of development have been identified for PNP in the USA or India or for fibromyalgia pain in Australia, India, New Zealand, Russia, Argentina, Belarus, Chile, Colombia, Israel, Mexico, Switzerland, Canada, Serbia or South Africa.  This article summarizes the milestones in the development of mirogabalin leading to this first approval for PNP.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoA8cUiDvLmPbVg90H21EOLACvtfcHk0li3Q7JxaCRo_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnvFyitrg%253D&md5=9a9b9f14f0190da528f3bc9b8cf277a7</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01070-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01070-8%26sid%3Dliteratum%253Aachs%26aulast%3DDeeks%26aufirst%3DE.%2BD.%26atitle%3DMirogabalin%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D463%26epage%3D468%26doi%3D10.1007%2Fs40265-019-01070-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Domon, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arakawa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuda, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitano, Y.</span></span> <span> </span><span class="NLM_article-title">Binding Characteristics and Analgesic Effects of Mirogabalin, a Novel Ligand for the α2δ Subunit of Voltage-Gated Calcium Channels</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>365</i></span>,  <span class="NLM_fpage">573</span>– <span class="NLM_lpage">582</span>, <span class="refDoi"> DOI: 10.1124/jpet.117.247551</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1124%2Fjpet.117.247551" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=29563324" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVCntbrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=365&publication_year=2018&pages=573-582&author=Y.+Domonauthor=N.+Arakawaauthor=T.+Inoueauthor=F.+Matsudaauthor=M.+Takahashiauthor=N.+Yamamuraauthor=K.+Kaiauthor=Y.+Kitano&title=Binding+Characteristics+and+Analgesic+Effects+of+Mirogabalin%2C+a+Novel+Ligand+for+the+%CE%B12%CE%B4+Subunit+of+Voltage-Gated+Calcium+Channels&doi=10.1124%2Fjpet.117.247551"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Binding characteristics and analgesic effects of mirogabalin, a novel ligand for the a2d subunit of voltage-gated calcium channels</span></div><div class="casAuthors">Domon, Yuki; Arakawa, Naohisa; Inoue, Tatsuya; Matsuda, Fumihiko; Takahashi, Makoto; Yamamura, Naotoshi; Kai, Kiyonori; Kitano, Yutaka</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">365</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">573-582</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">In the present study, we investigated the in vitro binding characteristics and in vivo analgesic effects of mirogabalin compared with those of pregabalin, a std. a2d ligand.  Mirogabalin showed potent and selective binding affinities for the a2d subunits, while having no effects on 186 off-target proteins.  Similar to pregabalin, mirogabalin did not show clear subtype selectivity (a2d-1 vs. a2d-2) or species differences (human vs. rat).  However, in contrast to pregabalin, mirogabalin showed greater binding affinities for human a2d-1, human a2d-2, rat a2d-1, and rat a2d-2 subunits; further, it had a slower dissocn. rate for the a2d-1 subunit than the a2d-2 subunit.  In safety pharmacol. evaluations, mirogabalin and pregabalin inhibited rota-rod performance and locomotor activity in rats; however, the safety indexes of mirogabalin were superior to those of pregabalin.  In conclusion, mirogabalin shows potent and selective binding affinities for the human and rat a2d subunits, and slower dissocn. rates for the a2d-1 subunit than the a2d-2 subunit.  It shows potent and long-lasting analgesic effects in rat models of neuropathic pain, and wider safety margins for side effects of the central nervous system.  These properties of mirogabalin can be assocd. with its unique binding characteristics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHpJ0JBnhkh7Vg90H21EOLACvtfcHk0liAEPvHuDkS_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVCntbrP&md5=e0c0b3f89de15327211551395f4db648</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1124%2Fjpet.117.247551&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.117.247551%26sid%3Dliteratum%253Aachs%26aulast%3DDomon%26aufirst%3DY.%26aulast%3DArakawa%26aufirst%3DN.%26aulast%3DInoue%26aufirst%3DT.%26aulast%3DMatsuda%26aufirst%3DF.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DYamamura%26aufirst%3DN.%26aulast%3DKai%26aufirst%3DK.%26aulast%3DKitano%26aufirst%3DY.%26atitle%3DBinding%2520Characteristics%2520and%2520Analgesic%2520Effects%2520of%2520Mirogabalin%252C%2520a%2520Novel%2520Ligand%2520for%2520the%2520%25CE%25B12%25CE%25B4%2520Subunit%2520of%2520Voltage-Gated%2520Calcium%2520Channels%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2018%26volume%3D365%26spage%3D573%26epage%3D582%26doi%3D10.1124%2Fjpet.117.247551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, K.</span>; <span class="NLM_string-name">Kawamura, A.</span>; <span class="NLM_string-name">Arakawa, N.</span>; <span class="NLM_string-name">Domon, Y.</span></span> <span> </span><span class="NLM_article-title">Preparation of Bicyclic γ-Amino Acid Derivatives as Potential-Dependent Calcium Channel A2δ Subunit Ligands</span>. <span class="NLM_patent">WO 2009041453 A1</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=K.+Shimada&author=A.+Kawamura&author=N.+Arakawa&author=Y.+Domon&title=Preparation+of+Bicyclic+%CE%B3-Amino+Acid+Derivatives+as+Potential-Dependent+Calcium+Channel+A2%CE%B4+Subunit+Ligands"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DShimada%26aufirst%3DK.%26atitle%3DPreparation%2520of%2520Bicyclic%2520%25CE%25B3-Amino%2520Acid%2520Derivatives%2520as%2520Potential-Dependent%2520Calcium%2520Channel%2520A2%25CE%25B4%2520Subunit%2520Ligands%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit78b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, Y.</span>; <span class="NLM_string-name">Ukai, K.</span>; <span class="NLM_string-name">Kitawaki, T.</span>; <span class="NLM_string-name">Nakajima, T.</span>; <span class="NLM_string-name">Kitagawa, Y.</span>; <span class="NLM_string-name">Furuya, Y.</span>; <span class="NLM_string-name">Imai, M.</span>; <span class="NLM_string-name">Numagami, E.</span>; <span class="NLM_string-name">Wakayama, M.</span>; <span class="NLM_string-name">Saito, A.</span></span> <span> </span><span class="NLM_article-title">Preparation of High-Purity Optically Active Bicyclic γ-Amino Acid Derivative</span>. <span class="NLM_patent">WO 2015005298 A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=Y.+Nakamura&author=K.+Ukai&author=T.+Kitawaki&author=T.+Nakajima&author=Y.+Kitagawa&author=Y.+Furuya&author=M.+Imai&author=E.+Numagami&author=M.+Wakayama&author=A.+Saito&title=Preparation+of+High-Purity+Optically+Active+Bicyclic+%CE%B3-Amino+Acid+Derivative"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNakamura%26aufirst%3DY.%26atitle%3DPreparation%2520of%2520High-Purity%2520Optically%2520Active%2520Bicyclic%2520%25CE%25B3-Amino%2520Acid%2520Derivative%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit78c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, Y.</span>; <span class="NLM_string-name">Kimura, K.</span></span> <span> </span><span class="NLM_article-title">Method for the Preparation of Bicyclic Compound Via Iminium Salt</span>. <span class="NLM_patent">WO 2012169474 A1</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=Y.+Nakamura&author=K.+Kimura&title=Method+for+the+Preparation+of+Bicyclic+Compound+Via+Iminium+Salt"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNakamura%26aufirst%3DY.%26atitle%3DMethod%2520for%2520the%2520Preparation%2520of%2520Bicyclic%2520Compound%2520Via%2520Iminium%2520Salt%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit78d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, Y.</span>; <span class="NLM_string-name">Furuya, Y.</span>; <span class="NLM_string-name">Shimada, K.</span>; <span class="NLM_string-name">Onishi, Y.</span></span> <span> </span><span class="NLM_article-title">Optical Resolution of Bicyclic Compound Using Enzyme</span>. <span class="NLM_patent">WO 2013154066 A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=Y.+Nakamura&author=Y.+Furuya&author=K.+Shimada&author=Y.+Onishi&title=Optical+Resolution+of+Bicyclic+Compound+Using+Enzyme"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNakamura%26aufirst%3DY.%26atitle%3DOptical%2520Resolution%2520of%2520Bicyclic%2520Compound%2520Using%2520Enzyme%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martín
Castro, A. M.</span></span> <span> </span><span class="NLM_article-title">Claisen Rearrangement over the Past Nine Decades</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">2939</span>– <span class="NLM_lpage">3002</span>, <span class="refDoi"> DOI: 10.1021/cr020703u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr020703u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A280%3ADC%252BD2c3os1GjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2004&pages=2939-3002&author=A.+M.+Mart%C3%ADn%0ACastro&title=Claisen+Rearrangement+over+the+Past+Nine+Decades&doi=10.1021%2Fcr020703u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Claisen rearrangement over the past nine decades</span></div><div class="casAuthors">Martin Castro Ana M</div><div class="citationInfo"><span class="NLM_cas:title">Chemical reviews</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2939-3002</span>
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQd_KT9-T-OQ4xhnOQkIHOxfW6udTcc2eZLnzfCuj15qLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c3os1GjsQ%253D%253D&md5=ca5ca8c432c74dcc346d1f7447a39f31</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1021%2Fcr020703u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr020703u%26sid%3Dliteratum%253Aachs%26aulast%3DMart%25C3%25ADn%2BCastro%26aufirst%3DA.%2BM.%26atitle%3DClaisen%2520Rearrangement%2520over%2520the%2520Past%2520Nine%2520Decades%26jtitle%3DChem.%2520Rev.%26date%3D2004%26volume%3D104%26spage%3D2939%26epage%3D3002%26doi%3D10.1021%2Fcr020703u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, G.</span></span> <span> </span><span class="NLM_article-title">The Knoevenagel Condensation</span>. <i>In Organic Reactions</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_fpage">204</span>– <span class="NLM_lpage">599</span>, <span class="refDoi"> DOI: 10.1002/0471264180.or015.02</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1002%2F0471264180.or015.02" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&pages=204-599&author=G.+Jones&title=The+Knoevenagel+Condensation&doi=10.1002%2F0471264180.or015.02"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1002%2F0471264180.or015.02&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F0471264180.or015.02%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DG.%26atitle%3DThe%2520Knoevenagel%2520Condensation%26jtitle%3DIn%2520Organic%2520Reactions%26date%3D2011%26spage%3D204%26epage%3D599%26doi%3D10.1002%2F0471264180.or015.02" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Snider, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allentoff, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, Y. S.</span></span> <span> </span><span class="NLM_article-title">Type III Intramolecular [2 + 2] Cycloadditions of Vinylketenes</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">5320</span>– <span class="NLM_lpage">5328</span>, <span class="refDoi"> DOI: 10.1021/jo00257a022</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo00257a022" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADyaL1cXlvV2rtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1988&pages=5320-5328&author=B.+B.+Sniderauthor=A.+J.+Allentoffauthor=Y.+S.+Kulkarni&title=Type+III+Intramolecular+%5B2+%2B+2%5D+Cycloadditions+of+Vinylketenes&doi=10.1021%2Fjo00257a022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Type III intramolecular [2 + 2] cycloadditions of vinylketenes</span></div><div class="casAuthors">Snider, Barry B.; Allentoff, Alban J.; Kulkarni, Yashwant S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5320-8</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    </div><div class="casAbstract">Treatment of trans-α,β-unsatd. acid chlorides with Et3N in C6H6 at reflux gives a ca. 1:1 mixt. of cis- and trans-α,β-unsatd. ketenes in excellent yield.  If there is a second double bond in the side chain, the cis isomer undergoes a type III intramol. cycloaddn. to produce a bicyclo[3.2.0]hept-3-en-6-one and/or a bicyclo[3.1.1]hept-2-en-6-one in 30-50% yield from the acid chloride.  The effect of substituents on the stereochem. and regiochem. of the cycloaddn. is described.  Thus, intramol. cycloaddn reaction of (E)-6-methyl-2,6-heptadienoic acid gave 43% 1-methylbicyclo[3.2.0]hept-3-en-6-one.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrm6-p6p4Yl57Vg90H21EOLACvtfcHk0lgNxAwx5e9UIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXlvV2rtb0%253D&md5=38766f3170999fc74f2df7e220f20afa</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1021%2Fjo00257a022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00257a022%26sid%3Dliteratum%253Aachs%26aulast%3DSnider%26aufirst%3DB.%2BB.%26aulast%3DAllentoff%26aufirst%3DA.%2BJ.%26aulast%3DKulkarni%26aufirst%3DY.%2BS.%26atitle%3DType%2520III%2520Intramolecular%2520%255B2%2520%252B%25202%255D%2520Cycloadditions%2520of%2520Vinylketenes%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1988%26volume%3D53%26spage%3D5320%26epage%3D5328%26doi%3D10.1021%2Fjo00257a022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDowell, T. S.</span></span> <span> </span><span class="NLM_article-title">Remimazolam, a Short-Acting GABA(A) Receptor Agonist for Intravenous Sedation and/or Anesthesia in Day-Case Surgical and Non-Surgical Procedures</span>. <i>IDrugs</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">929</span>– <span class="NLM_lpage">937</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=21154153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvVeltb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2010&pages=929-937&author=W.+K.+Rogersauthor=T.+S.+McDowell&title=Remimazolam%2C+a+Short-Acting+GABA%28A%29+Receptor+Agonist+for+Intravenous+Sedation+and%2For+Anesthesia+in+Day-Case+Surgical+and+Non-Surgical+Procedures"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82aR"><div class="casContent"><span class="casTitleNuber">82a</span><div class="casTitle"><span class="NLM_cas:atitle">Remimazolam, a short-acting GABAA receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures</span></div><div class="casAuthors">Rogers, William Kirke; McDowell, Thomas S.</div><div class="citationInfo"><span class="NLM_cas:title">IDrugs</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">929-937</span>CODEN:
                <span class="NLM_cas:coden">IDRUFN</span>;
        ISSN:<span class="NLM_cas:issn">2040-3410</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Remimazolam (CNS-7056) is a short-acting GABAA receptor agonist, under development by PAION, in collaboration with Japanese licensee Ono Pharmaceutical, as an i.v. sedative agent for potential use in day-case procedures, and the induction and maintenance of anesthesia.  A member of the benzodiazapene class of drugs, the structure of remimazolam was modified to produce a drug that displays organ-independent metab.  The incorporation of a carboxylic ester moiety into the benzodiazapene core of remimazolam renders it susceptible to non-specific tissue esterases and it is rapidly metabolized into its pharmacol. inactive metabolite CNS-7054.  Preclin. studies in sheep demonstrated that remimazolam produced a more rapid onset of action, and a shorter duration of action, compared with midazolam.  In a phase IIa clin. trial evaluating remimazolam as a procedural sedative for upper gastrointestinal endoscopy in patients, the time to recovery from sedation was shorter and more consistent with remimazolam, relative to midazolam.  Because of its organ-independent metab. and rapid and predictable onset and recovery, remimazolam appears to have potential advantages over other currently available short-acting sedatives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrU4KS2bq2azrVg90H21EOLACvtfcHk0lgNxAwx5e9UIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvVeltb4%253D&md5=d5b3fd32ceb0dceb0794bb12da622978</span></div><a href="/servlet/linkout?suffix=cit82a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRogers%26aufirst%3DW.%2BK.%26aulast%3DMcDowell%26aufirst%3DT.%2BS.%26atitle%3DRemimazolam%252C%2520a%2520Short-Acting%2520GABA%2528A%2529%2520Receptor%2520Agonist%2520for%2520Intravenous%2520Sedation%2520and%252For%2520Anesthesia%2520in%2520Day-Case%2520Surgical%2520and%2520Non-Surgical%2520Procedures%26jtitle%3DIDrugs%26date%3D2010%26volume%3D13%26spage%3D929%26epage%3D937" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit82b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Saari, T. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uusi-Oukari, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahonen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olkkola, K. T.</span></span> <span> </span><span class="NLM_article-title">Enhancement of GABAergic Activity: Neuropharmacological Effects of Benzodiazepines and Therapeutic Use in Anesthesiology</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">243</span>– <span class="NLM_lpage">267</span>, <span class="refDoi"> DOI: 10.1124/pr.110.002717</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1124%2Fpr.110.002717" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=21245208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjslGis7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2011&pages=243-267&author=T.+I.+Saariauthor=M.+Uusi-Oukariauthor=J.+Ahonenauthor=K.+T.+Olkkola&title=Enhancement+of+GABAergic+Activity%3A+Neuropharmacological+Effects+of+Benzodiazepines+and+Therapeutic+Use+in+Anesthesiology&doi=10.1124%2Fpr.110.002717"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82bR"><div class="casContent"><span class="casTitleNuber">82b</span><div class="casTitle"><span class="NLM_cas:atitle">Enhancement of GABAergic activity: neuropharmacological effects of benzodiazepines and therapeutic use in anesthesiology</span></div><div class="casAuthors">Saari, Teijo I.; Uusi-Oukari, Mikko; Ahonen, Jouni; Olkkola, Klaus T.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">243-267</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  GABA is the major inhibitory neurotransmitter in the central nervous system (CNS).  The type A GABA receptor (GABAAR) system is the primary pharmacol. target for many drugs used in clin. anesthesia.  The α1, β2, and γ2 subunit-contg. GABAARs located in the various parts of CNS are thought to be involved in versatile effects caused by inhaled anesthetics and classic benzodiazepines (BZD), both of which are widely used in clin. anesthesiol.  During the past decade, the emergence of tonic inhibitory conductance in extrasynaptic GABAARs has coincided with evidence showing that these receptors are highly sensitive to the sedatives and hypnotics used in anesthesia.  Anesthetic enhancement of tonic GABAergic inhibition seems to be preferentially increased in regions shown to be important in controlling memory, awareness, and sleep.  This review focuses on the physiol. of the GABAARs and the pharmacol. properties of clin. used BZDs.  Although classic BZDs are widely used in anesthesiol. practice, there is a const. need for new drugs with more favorable pharmacokinetic and pharmacodynamic effects and fewer side effects.  New hypnotics are currently developed, and promising results for one of these, the GABAAR agonist remimazolam, have recently been published.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkr0H2ObeOh7Vg90H21EOLACvtfcHk0lgNxAwx5e9UIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjslGis7s%253D&md5=226f9e78eac12ce20ec0c6f41a667785</span></div><a href="/servlet/linkout?suffix=cit82b&amp;dbid=16384&amp;doi=10.1124%2Fpr.110.002717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.110.002717%26sid%3Dliteratum%253Aachs%26aulast%3DSaari%26aufirst%3DT.%2BI.%26aulast%3DUusi-Oukari%26aufirst%3DM.%26aulast%3DAhonen%26aufirst%3DJ.%26aulast%3DOlkkola%26aufirst%3DK.%2BT.%26atitle%3DEnhancement%2520of%2520GABAergic%2520Activity%253A%2520Neuropharmacological%2520Effects%2520of%2520Benzodiazepines%2520and%2520Therapeutic%2520Use%2520in%2520Anesthesiology%26jtitle%3DPharmacol.%2520Rev.%26date%3D2011%26volume%3D63%26spage%3D243%26epage%3D267%26doi%3D10.1124%2Fpr.110.002717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rex, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhandari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desta, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMicco, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaeffer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Etzkorn, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barish, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pruitt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cash, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quirk, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiongco, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernstein, D.</span></span> <span> </span><span class="NLM_article-title">A Phase III Study Evaluating the Efficacy and Safety of Remimazolam (CNS 7056) Compared with Placebo and Midazolam in Patients Undergoing Colonoscopy</span>. <i>Gastrointest. Endosc.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">427</span>– <span class="NLM_lpage">437</span>, <span class="refDoi"> DOI: 10.1016/j.gie.2018.04.2351</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2Fj.gie.2018.04.2351" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=29723512" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A280%3ADC%252BC1MjpsFSiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2018&pages=427-437&author=D.+K.+Rexauthor=R.+Bhandariauthor=T.+Destaauthor=M.+P.+DeMiccoauthor=C.+Schaefferauthor=K.+Etzkornauthor=C.+F.+Barishauthor=R.+Pruittauthor=B.+D.+Cashauthor=D.+Quirkauthor=F.+Tiongcoauthor=S.+Sullivanauthor=D.+Bernstein&title=A+Phase+III+Study+Evaluating+the+Efficacy+and+Safety+of+Remimazolam+%28CNS+7056%29+Compared+with+Placebo+and+Midazolam+in+Patients+Undergoing+Colonoscopy&doi=10.1016%2Fj.gie.2018.04.2351"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">A phase III study evaluating the efficacy and safety of remimazolam (CNS 7056) compared with placebo and midazolam in patients undergoing colonoscopy</span></div><div class="casAuthors">Rex Douglas K; Bhandari Raj; Desta Taddese; DeMicco Michael P; Schaeffer Cynthia; Etzkorn Kyle; Barish Charles F; Pruitt Ronald; Cash Brooks D; Quirk Daniel; Tiongco Felix; Sullivan Shelby; Bernstein David</div><div class="citationInfo"><span class="NLM_cas:title">Gastrointestinal endoscopy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">427-437.e6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND AND AIMS:  Remimazolam is an ultrashort-acting benzodiazepine.  METHODS:  We performed a randomized double-blind comparison of remimazolam to placebo for outpatient colonoscopy.  This study design was a requirement of the U.S.  Food and Drug Administration.  An additional group was randomized to open-label midazolam administered according to its package insert instructions (the randomization ratio for remimazolam:placebo:midazolam was 30:6:10).  Study medications were administered under the supervision of the endoscopist, without any involvement of an anesthesia specialist.  Patients were given 50 to 75 μg of fentanyl before receiving study medications.  Patients who failed to achieve adequate sedation in any arm were rescued with midazolam dosed at the investigator's discretion.  The primary endpoint was a composite that required 3 criteria be met: completion of the colonoscopy, no need for rescue medication, and ≤5 doses of remimazolam or placebo in any 15-minute interval (≤3 doses of midazolam in any 12-minute interval in the open-label midazolam arm).  RESULTS:  There were 461 randomized patients in 12 U.S. sites.  The primary endpoint was met for remimazolam, placebo, and midazolam in 91.3%, 1.7%, and 25.2% of patients, respectively (P < .0001 for remimazolam vs placebo).  Patients administered remimazolam received less fentanyl, had faster recovery of neuropsychiatric function, were ready for discharge earlier, and felt back to normal sooner than patients with both placebo and midazolam.  Hypotension was less frequent with remimazolam, and hypoxia occurred in 1% of patients with remimazolam or midazolam.  There were no treatment-emergent serious adverse events.  CONCLUSION:  Remimazolam can be administered safely under the supervision of endoscopists for outpatient colonoscopy, and it allows faster recovery of neuropsychiatric function compared with placebo (midazolam rescue) and midazolam. (Clinical trial registration number: NCT02290873.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSFZEybBPieYXwOGIfWJ7-GfW6udTcc2eaAo3YH49L2kLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MjpsFSiuw%253D%253D&md5=49006518b16bd1a25863950791c5fbcf</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2Fj.gie.2018.04.2351&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.gie.2018.04.2351%26sid%3Dliteratum%253Aachs%26aulast%3DRex%26aufirst%3DD.%2BK.%26aulast%3DBhandari%26aufirst%3DR.%26aulast%3DDesta%26aufirst%3DT.%26aulast%3DDeMicco%26aufirst%3DM.%2BP.%26aulast%3DSchaeffer%26aufirst%3DC.%26aulast%3DEtzkorn%26aufirst%3DK.%26aulast%3DBarish%26aufirst%3DC.%2BF.%26aulast%3DPruitt%26aufirst%3DR.%26aulast%3DCash%26aufirst%3DB.%2BD.%26aulast%3DQuirk%26aufirst%3DD.%26aulast%3DTiongco%26aufirst%3DF.%26aulast%3DSullivan%26aufirst%3DS.%26aulast%3DBernstein%26aufirst%3DD.%26atitle%3DA%2520Phase%2520III%2520Study%2520Evaluating%2520the%2520Efficacy%2520and%2520Safety%2520of%2520Remimazolam%2520%2528CNS%25207056%2529%2520Compared%2520with%2520Placebo%2520and%2520Midazolam%2520in%2520Patients%2520Undergoing%2520Colonoscopy%26jtitle%3DGastrointest.%2520Endosc.%26date%3D2018%26volume%3D88%26spage%3D427%26epage%3D437%26doi%3D10.1016%2Fj.gie.2018.04.2351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><a href="https://www.paion.com/fileadmin/user_upload/Annual_financial_report_2019.pdf" class="extLink">https://www.paion.com/fileadmin/user_upload/Annual_financial_report_2019.pdf</a> (accessed March 24, 2021)<a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__m.en-2Dcphi.cn_news_show-2D60667.html&amp;d=DwMGaQ&amp;c=UE1eNsedaKncO0Yl_u8bfw&amp;r=MKA0UqpxRyImwzO_tEhpkCczC9cjy5h9oz_Ouk5Cc5s&amp;m=-4LALaCF2r5FJfAZhrY6lNCusszVReTqiDE0k0hDI6k&amp;s=zNgbs2gPWpvdaZZ8tj_wxZnPfKORLU7i7OJ6Pq3axXY&amp;e=" class="extLink">https://urldefense.proofpoint.com/v2/url?u=https-3A__m.en-2Dcphi.cn_news_show-2D60667.html&d=DwMGaQ&c=UE1eNsedaKncO0Yl_u8bfw&r=MKA0UqpxRyImwzO_tEhpkCczC9cjy5h9oz_Ouk5Cc5s&m=-4LALaCF2r5FJfAZhrY6lNCusszVReTqiDE0k0hDI6k&s=zNgbs2gPWpvdaZZ8tj_wxZnPfKORLU7i7OJ6Pq3axXY&e=</a> (accessed 2021-01-12).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.paion.com%2Ffileadmin%2Fuser_upload%2FAnnual_financial_report_2019.pdf+%28accessed+March+24%2C+2021%29https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__m.en-2Dcphi.cn_news_show-2D60667.html%26d%3DDwMGaQ%26c%3DUE1eNsedaKncO0Yl_u8bfw%26r%3DMKA0UqpxRyImwzO_tEhpkCczC9cjy5h9oz_Ouk5Cc5s%26m%3D-4LALaCF2r5FJfAZhrY6lNCusszVReTqiDE0k0hDI6k%26s%3DzNgbs2gPWpvdaZZ8tj_wxZnPfKORLU7i7OJ6Pq3axXY%26e%3D+%28accessed+2021-01-12%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, P. L.</span>; <span class="NLM_string-name">Jung, D. K.</span>; <span class="NLM_string-name">Kaldor, I.</span>; <span class="NLM_string-name">Pacofsky, G. J.</span>; <span class="NLM_string-name">Stafford, J. A.</span>; <span class="NLM_string-name">Tidwell, J. H.</span></span> <span> </span><span class="NLM_article-title">Short-Acting Benzodiazepines</span>. <span class="NLM_patent">WO 0069836 A1</span>, <span class="NLM_year">2000</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2000&author=P.+L.+Feldman&author=D.+K.+Jung&author=I.+Kaldor&author=G.+J.+Pacofsky&author=J.+A.+Stafford&author=J.+H.+Tidwell&title=Short-Acting+Benzodiazepines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFeldman%26aufirst%3DP.%2BL.%26atitle%3DShort-Acting%2520Benzodiazepines%26date%3D2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit85b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, P.</span>; <span class="NLM_string-name">Wu, G.</span>; <span class="NLM_string-name">Gao, X.</span>; <span class="NLM_string-name">Zhang, Q.</span>; <span class="NLM_string-name">Chen, Y.</span></span> <span> </span><span class="NLM_article-title">Benzodiazepine Derivatives Tosylate Salts, Their Polymorphic Forms, Preparation Methods and Uses Thereof</span>. <span class="NLM_patent">WO 2013029431 A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=P.+Sun&author=G.+Wu&author=X.+Gao&author=Q.+Zhang&author=Y.+Chen&title=Benzodiazepine+Derivatives+Tosylate+Salts%2C+Their+Polymorphic+Forms%2C+Preparation+Methods+and+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DP.%26atitle%3DBenzodiazepine%2520Derivatives%2520Tosylate%2520Salts%252C%2520Their%2520Polymorphic%2520Forms%252C%2520Preparation%2520Methods%2520and%2520Uses%2520Thereof%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span>; <span class="NLM_string-name">Gao, X.</span>; <span class="NLM_string-name">Bian, L.</span></span> <span> </span><span class="NLM_article-title">A Kind of Preparation Method of Benzodiazepine * Derivatives</span>. <span class="NLM_patent">CN 108264499 A</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=H.+Xu&author=X.+Gao&author=L.+Bian&title=A+Kind+of+Preparation+Method+of+Benzodiazepine+*+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DH.%26atitle%3DA%2520Kind%2520of%2520Preparation%2520Method%2520of%2520Benzodiazepine%2520%252A%2520Derivatives%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noriaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishino, S.</span></span> <span> </span><span class="NLM_article-title">Advances in Pharmaceutical Treatment Options for Narcolepsy</span>. <i>Expert Opin. Orphan Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">597</span>– <span class="NLM_lpage">610</span>, <span class="refDoi"> DOI: 10.1080/21678707.2018.1521267</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1080%2F21678707.2018.1521267" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslOksrfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2018&pages=597-610&author=T.+Takahashiauthor=S.+Noriakiauthor=M.+Matsumuraauthor=C.+Liauthor=K.+Takahashiauthor=S.+Nishino&title=Advances+in+Pharmaceutical+Treatment+Options+for+Narcolepsy&doi=10.1080%2F21678707.2018.1521267"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in pharmaceutical treatment options for narcolepsy</span></div><div class="casAuthors">Takahashi, Tatsunori; Noriaki, Sakai; Matsumura, Mari; Li, Chenyu; Takahashi, Kayo; Nishino, Seiji</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Orphan Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">597-610</span>CODEN:
                <span class="NLM_cas:coden">EOODAJ</span>;
        ISSN:<span class="NLM_cas:issn">2167-8707</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: Narcolepsy is a syndrome characterized by excessive daytime sleepiness (EDS), cataplexy, and other abnormal manifestations of rapid eye movement sleep phenomena.  Since hypocretin deficiency is presumed to be the main pathophysiol. of narcoleptic symptoms, hypocretin replacement therapy would be promising; small mol. hypocretin receptor agonists and intranasal administration of hypocretin peptides are recognized as potential pharmaceutical treatments.  Pitolisant, a histaminergic inverse agonist, recently became available in European countries for the treatment of EDS.  Addnl., other emerging treatments such as immunotherapies, TRH analogs, and solriamfetol have been under investigation.: The pathophysiol. of narcolepsy is summarized, along with the current and emerging pharmaceutical treatments for narcolepsy.: Hypocretin replacement therapy might be the most straightforward and effective treatment to address both cataplexy and EDS.  Although small mol. synthetic hypocretin receptor agonists and intranasal hypocretin administration have been developed, for hypocretin receptor agonists, only preliminary data are available, and the efficacy data for intranasal delivery in human subjects are also lacking.  Recently, the U.  S. FDA has accepted the New Drug Application of solriamfetol for excessive sleepiness.  It is likely that other emerging treatments will also become available in the clin. setting in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcT2IROEHRdLVg90H21EOLACvtfcHk0lhevx7_4g5mIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslOksrfF&md5=0a49a2f5d9dad8cd06333a35e60ed3ee</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1080%2F21678707.2018.1521267&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F21678707.2018.1521267%26sid%3Dliteratum%253Aachs%26aulast%3DTakahashi%26aufirst%3DT.%26aulast%3DNoriaki%26aufirst%3DS.%26aulast%3DMatsumura%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DTakahashi%26aufirst%3DK.%26aulast%3DNishino%26aufirst%3DS.%26atitle%3DAdvances%2520in%2520Pharmaceutical%2520Treatment%2520Options%2520for%2520Narcolepsy%26jtitle%3DExpert%2520Opin.%2520Orphan%2520Drugs%26date%3D2018%26volume%3D6%26spage%3D597%26epage%3D610%26doi%3D10.1080%2F21678707.2018.1521267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, J.</span></span> <span> </span><span class="NLM_article-title">Solriamfetol for the Treatment of Excessive Daytime Sleepiness Associated with Narcolepsy</span>. <i>Expert Rev. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">723</span>– <span class="NLM_lpage">728</span>, <span class="refDoi"> DOI: 10.1080/17512433.2019.1632705</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1080%2F17512433.2019.1632705" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31215815" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtF2ntL%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2019&pages=723-728&author=J.+Yangauthor=J.+Gao&title=Solriamfetol+for+the+Treatment+of+Excessive+Daytime+Sleepiness+Associated+with+Narcolepsy&doi=10.1080%2F17512433.2019.1632705"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Solriamfetol for the treatment of excessive daytime sleepiness associated with narcolepsy</span></div><div class="casAuthors">Yang, Junyi; Gao, Junfa</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">723-728</span>CODEN:
                <span class="NLM_cas:coden">ERCPAG</span>;
        ISSN:<span class="NLM_cas:issn">1751-2433</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Narcolepsy is a chronic disabling condition, excessive daytime somnolence is the main symptoms of it.  There is currently no cure for narcolepsy, and hence there is a great need for new treatment options.  Solriamfetol is a new selective dopamine and norepinephrine reuptake inhibitor with robust wake-promoting effects.  The purpose of this paper is to review solriamfetol.: The chem. property, mechanism of action, pharmacokinetics, clin. efficacy, and safety of solriamfetol are introduced in this paper.: Solriamfetol can bind to dopamine and norepinephrine transporters and inhibit reuptake of dopamine and norepinephrine.  Clin. trials showed that solriamfetol could significantly improve the ability to stay awake and subjective symptoms of excessive sleepiness in adults with narcolepsy.  Solriamfetol was well tolerated.  Very common adverse reactions were headache, nausea, decreased appetite, insomnia, and anxiety.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrd4WAi6hUSZrVg90H21EOLACvtfcHk0lhevx7_4g5mIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtF2ntL%252FM&md5=ec3732b4ecedaa5eb02bc79b552ebc2c</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1080%2F17512433.2019.1632705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17512433.2019.1632705%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DJ.%26atitle%3DSolriamfetol%2520for%2520the%2520Treatment%2520of%2520Excessive%2520Daytime%2520Sleepiness%2520Associated%2520with%2520Narcolepsy%26jtitle%3DExpert%2520Rev.%2520Clin.%2520Pharmacol.%26date%3D2019%26volume%3D12%26spage%3D723%26epage%3D728%26doi%3D10.1080%2F17512433.2019.1632705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abad, V. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guilleminault, C.</span></span> <span> </span><span class="NLM_article-title">Solriamfetol for the Treatment of Daytime Sleepiness in Obstructive Sleep Apnea</span>. <i>Expert Rev. Respir. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1007</span>– <span class="NLM_lpage">1019</span>, <span class="refDoi"> DOI: 10.1080/17476348.2018.1541742</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1080%2F17476348.2018.1541742" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=30365900" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVyhsb3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2018&pages=1007-1019&author=V.+C.+Abadauthor=C.+Guilleminault&title=Solriamfetol+for+the+Treatment+of+Daytime+Sleepiness+in+Obstructive+Sleep+Apnea&doi=10.1080%2F17476348.2018.1541742"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Solriamfetol for the treatment of daytime sleepiness in obstructive sleep apnea</span></div><div class="casAuthors">Abad, Vivien C.; Guilleminault, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Respiratory Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1007-1019</span>CODEN:
                <span class="NLM_cas:coden">ERRMBF</span>;
        ISSN:<span class="NLM_cas:issn">1747-6348</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  : Obstructive sleep apnea (OSA) is highly prevalent and constitutes a major health hazard.  Current pharmacotherapy is ineffective in correcting sleep-disordered breathing and is used adjunctively to address residual sleepiness.  A new drug, solriamfetol, a selective norepinephrine-dopamine reuptake inhibitor, is the first drug of its class that is being considered by the US Food and Drug Administration (FDA) to treat excessive sleepiness in OSA and narcolepsy patients.: This review covers drug chem., pharmacodynamics, pharmacokinetics, and metab. of solriamfetol.  Results of three Phase 3 trials, Treatment of OSA and Narcolepsy Excessive Sleepiness (TONES 3, 4, 5), relevant to OSA patients are summarized.  Published abstrs./articles and a 2017 Jazz Investor Presentation provided data.  Databases searched included PubMed, Google Scholar, Lexi-Comp, Scopus, Science, and Ovid.: Solriamfetol shows promise as adjunctive therapy in OSA.  It is well tolerated and effective in reducing sleepiness and is an alternative to modafinil or armodafinil.  Unlike stimulants like methylphenidate or dextroamphetamine, it does not have cardiac effects, rebound hypersomnia, or withdrawal effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXNDKKRG2fPbVg90H21EOLACvtfcHk0ljgjJdULx-pzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVyhsb3F&md5=0c4026642ed1eecc0ea64d013e19e5ca</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1080%2F17476348.2018.1541742&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17476348.2018.1541742%26sid%3Dliteratum%253Aachs%26aulast%3DAbad%26aufirst%3DV.%2BC.%26aulast%3DGuilleminault%26aufirst%3DC.%26atitle%3DSolriamfetol%2520for%2520the%2520Treatment%2520of%2520Daytime%2520Sleepiness%2520in%2520Obstructive%2520Sleep%2520Apnea%26jtitle%3DExpert%2520Rev.%2520Respir.%2520Med.%26date%3D2018%26volume%3D12%26spage%3D1007%26epage%3D1019%26doi%3D10.1080%2F17476348.2018.1541742" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y. M.</span>; <span class="NLM_string-name">Byun, J. K.</span></span> <span> </span><span class="NLM_article-title">Preparation of <i>O</i>-(Carbamoyl)Phenylalaninol Antidepressants</span>. <span class="NLM_patent">WO 9607637 A1</span>, <span class="NLM_year">1996</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1996&author=Y.+M.+Choi&author=J.+K.+Byun&title=Preparation+of+O-%28Carbamoyl%29Phenylalaninol+Antidepressants"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DY.%2BM.%26atitle%3DPreparation%2520of%2520O-%2528Carbamoyl%2529Phenylalaninol%2520Antidepressants%26date%3D1996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhirud, S. B.</span>; <span class="NLM_string-name">Naik, S.</span>; <span class="NLM_string-name">Mishra, S. K.</span>; <span class="NLM_string-name">Kawthekar, R. B.</span>; <span class="NLM_string-name">Patekar, D. S.</span>; <span class="NLM_string-name">Patil, N.</span></span> <span> </span><span class="NLM_article-title">Process for the Preparation of Solriamfetol and Its Salts, Particularly Its Dibenzoyl-<span class="smallcaps smallerCapital">d</span>-Tartrate and Di-<i>p</i>-Toluoyl-<span class="smallcaps smallerCapital">d</span>-Tartrate Used as Precursors for Solriamfetol Hydrochloride</span>. <span class="NLM_patent">WO 2020035769 A1</span>, <span class="NLM_year">2020</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=S.+B.+Bhirud&author=S.+Naik&author=S.+K.+Mishra&author=R.+B.+Kawthekar&author=D.+S.+Patekar&author=N.+Patil&title=Process+for+the+Preparation+of+Solriamfetol+and+Its+Salts%2C+Particularly+Its+Dibenzoyl-d-Tartrate+and+Di-p-Toluoyl-d-Tartrate+Used+as+Precursors+for+Solriamfetol+Hydrochloride"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBhirud%26aufirst%3DS.%2BB.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%2520Solriamfetol%2520and%2520Its%2520Salts%252C%2520Particularly%2520Its%2520Dibenzoyl-d-Tartrate%2520and%2520Di-p-Toluoyl-d-Tartrate%2520Used%2520as%2520Precursors%2520for%2520Solriamfetol%2520Hydrochloride%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, L. J.</span></span> <span> </span><span class="NLM_article-title">Ubrogepant: First Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">323</span>– <span class="NLM_lpage">328</span>, <span class="refDoi"> DOI: 10.1007/s40265-020-01264-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs40265-020-01264-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=32020557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A280%3ADC%252BB38%252FotlKlsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2020&pages=323-328&author=L.+J.+Scott&title=Ubrogepant%3A+First+Approval&doi=10.1007%2Fs40265-020-01264-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Ubrogepant: First Approval</span></div><div class="casAuthors">Scott Lesley J</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">323-328</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Ubrogepant (Ubrelvy®) is an orally administered, small molecule, highly-selective, calcitonin gene-related peptide (CGRP) antagonist that was developed by Allergan under license to Merck & Co. as an acute treatment for migraine.  In December 2019, ubrogepant received its first global approval in the USA for the acute treatment of migraine (± aura) in adults.  This article summarizes the milestones in the development of ubrogepant leading to its first global approval for the acute treatment of migraine (± aura) in adults.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTbpElibNSrFMvLc4ARHEmzfW6udTcc2ebuVkfAff9Ye7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38%252FotlKlsA%253D%253D&md5=dee277e0c6d6835ea105dbb4024f8a92</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1007%2Fs40265-020-01264-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-020-01264-5%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DL.%2BJ.%26atitle%3DUbrogepant%253A%2520First%2520Approval%26jtitle%3DDrugs%26date%3D2020%26volume%3D80%26spage%3D323%26epage%3D328%26doi%3D10.1007%2Fs40265-020-01264-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">Safety and Efficacy of Ubrogepant for the Acute Treatment of Episodic Migraine: A Meta-Analysis of Randomized Clinical Trials</span>. <i>CNS Drugs</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">463</span>– <span class="NLM_lpage">471</span>, <span class="refDoi"> DOI: 10.1007/s40263-020-00715-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs40263-020-00715-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=32193827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlvFOmtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2020&pages=463-471&author=Y.+Yangauthor=M.+Chenauthor=Y.+Sunauthor=B.+Gaoauthor=Z.+Chenauthor=Z.+Wang&title=Safety+and+Efficacy+of+Ubrogepant+for+the+Acute+Treatment+of+Episodic+Migraine%3A+A+Meta-Analysis+of+Randomized+Clinical+Trials&doi=10.1007%2Fs40263-020-00715-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and Efficacy of Ubrogepant for the Acute Treatment of Episodic Migraine: A Meta-Analysis of Randomized Clinical Trials</span></div><div class="casAuthors">Yang, Yanbo; Chen, Mingjia; Sun, Yue; Gao, Bixi; Chen, Zhouqing; Wang, Zhong</div><div class="citationInfo"><span class="NLM_cas:title">CNS Drugs</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">463-471</span>CODEN:
                <span class="NLM_cas:coden">CNDREF</span>;
        ISSN:<span class="NLM_cas:issn">1172-7047</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Abstr.: Background: Ubrogepant is a small mol. calcitonin gene-related peptide receptor antagonist that is used for the acute treatment of migraine.  Objective: The aim was to conduct a meta-anal. to systematically evaluate the efficacy and safety of ubrogepant for the treatment of episodic migraine compared with placebo in the adult population.  Methods: We systematically searched PubMed, EMBASE, and the Cochrane Library Central Register of Controlled Trials for relevant randomized clin. trials, from the earliest available date to Nov. 10, 2019, to evaluate the efficacy and safety of short-term ubrogepant use.  Inclusion criteria were (1) randomized clin. trial; (2) enrolled adult participants diagnosed with episodic migraine; (3) compared ubrogepant with placebo at doses that were evaluated in phase III clin. trials; (4) enrolled more than 100 patients in each group; and (5) provided any information on primary or secondary outcomes.  Trials were excluded if their participants were diagnosed with chronic migraine.  Results: A total of three multicenter, randomized clin. trials with 3326 patients were included.  Ubrogepant use was assocd. with a significantly higher percentage of patients with pain freedom (ubrogepant 20.8%; placebo 12.6%; relative risk [RR] 1.65, 95% confidence interval [CI] 1.38-1.98) and absence of the most bothersome migraine-assocd. symptoms (ubrogepant 37.3%; placebo 27.6%; RR 1.35, 95% CI 1.20-1.53) at 2 h post-dose compared with placebo.  Ubrogepant increased the rate of absence of migraine-assocd. symptoms at 2 h post-dose compared with placebo (photophobia: RR 1.30 [95% CI 1.18-1.44], I2 = 49%; phonophobia: RR 1.20 [95% CI 1.11-1.29]; nausea: RR 1.07 [95% CI 1.02-1.13]), and patients were more likely to function normally at 2 h post-dose compared with placebo (RR 1.30 [95% CI 1.16-1.45]).  No significant difference was found for treatment-related adverse events within 48 h or 30 days for ubrogepant compared with placebo (48 h: RR 1.07 [95% CI 0.85-1.35]; 30 days: RR 1.03 [95% CI 0.79-1.34]).  Subgroup anal. demonstrated that compared to placebo, ubrogepant led to greater rates of freedom from pain at 2 h with 25-mg, 50-mg, and 100-mg doses and absence of the most bothersome symptoms with 50-mg and 100-mg doses.  Conclusions: The use of ubrogepant as an acute treatment of episodic migraine in adults led to a greater percentage of freedom from pain and absence of the most bothersome symptoms at 2 h post-dose.  Short-term use of ubrogepant was not related to an increased risk for adverse events.  Further studies are needed to evaluate efficacy and safety for long-term use and in specific subgroups of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLwAEfqfxC0bVg90H21EOLACvtfcHk0ljgjJdULx-pzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlvFOmtLc%253D&md5=717a479cce7f32fc41d95616dd0b1e6d</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1007%2Fs40263-020-00715-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40263-020-00715-7%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DGao%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DZ.%26atitle%3DSafety%2520and%2520Efficacy%2520of%2520Ubrogepant%2520for%2520the%2520Acute%2520Treatment%2520of%2520Episodic%2520Migraine%253A%2520A%2520Meta-Analysis%2520of%2520Randomized%2520Clinical%2520Trials%26jtitle%3DCNS%2520Drugs%26date%3D2020%26volume%3D34%26spage%3D463%26epage%3D471%26doi%3D10.1007%2Fs40263-020-00715-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Dodick, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipton, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ailani, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finnegan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trugman, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szegedi, A.</span></span> <span> </span><span class="NLM_article-title">Ubrogepant for the Treatment of Migraine</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>381</i></span>,  <span class="NLM_fpage">2230</span>– <span class="NLM_lpage">2241</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1813049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1056%2FNEJMoa1813049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31800988" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVylsL3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=381&publication_year=2019&pages=2230-2241&author=D.+W.+Dodickauthor=R.+B.+Liptonauthor=J.+Ailaniauthor=K.+Luauthor=M.+Finneganauthor=J.+M.+Trugmanauthor=A.+Szegedi&title=Ubrogepant+for+the+Treatment+of+Migraine&doi=10.1056%2FNEJMoa1813049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94aR"><div class="casContent"><span class="casTitleNuber">94a</span><div class="casTitle"><span class="NLM_cas:atitle">Ubrogepant for the treatment of migraine</span></div><div class="casAuthors">Dodick, David W.; Lipton, Richard B.; Ailani, Jessica; Lu, Kaifeng; Finnegan, Michelle; Trugman, Joel M.; Szegedi, Armin</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">381</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2230-2241</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Ubrogepant is an oral, small-mol. calcitonin gene-related peptide receptor antagonist for acute migraine treatment. methods We conducted a randomized trial to evaluate the efficacy, safety, and side-effect profile of ubrogepant.  We assigned adults with migraine, with or without aura, in a 1:1:1 ratio to receive an initial dose of placebo, ubrogepant at a dose of 50 mg, or ubrogepant at a dose of 100 mg for treatment of a single migraine attack, with the option to take a second dose.  The coprimary efficacy end points were freedom from pain at 2 h after the initial dose and absence of the most bothersome migraine-assocd. symptom at 2 h.  Secondary end points included pain relief (at 2 h), sustained pain relief (from 2 to 24 h), sustained freedom from pain (from 2 to 24 h), and absence of symptoms assocd. with migraine (photophobia, phonophobia, and nausea) at 2 h. results A total of 1672 participants were enrolled; 559 were assigned to receive placebo, 556 to receive 50 mg of ubrogepant, and 557 to receive 100 mg of ubrogepant.  The percentage of participants who had freedom from pain at 2 h was 11.8% in the placebo group, 19.2% in the 50-mg ubrogepant group (P = 0.002, adjusted for multiplicity, for the comparison with placebo), and 21.2% in the 100-mg ubrogepant group (P<0.001).  The percentage of participants who had freedom from the most bothersome symptom at 2 h was 27.8% in the placebo group, 38.6% in the 50-mg ubrogepant group (P = 0.002), and 37.7% in the 100-mg ubrogepant group (P = 0.002).  Adverse events within 48 h after the initial or optional second dose were reported in 12.8% of participants in the placebo group, in 9.4% in the 50-mg ubrogepant group, and in 16.3% in the 100-mg ubrogepant group.  The most common adverse events were nausea, somnolence, and dry mouth (reported in 0.4 to 4.1%); these events were more frequent in the 100-mg ubrogepant group (reported in 2.1 to 4.1%).  Serious adverse events reported within 30 days in the ubrogepant groups included appendicitis, spontaneous abortion, pericardial effusion, and seizure; none of the events occurred within 48 h after the dose. conclusions A higher percentage of participants who received ubrogepant than of those who received placebo had freedom from pain and absence of the most bothersome symptom at 2 h after the dose.  The most commonly reported adverse events were nausea, somnolence, and dry mouth.  Further trials are needed to det. the durability and safety of ubrogepant for acute migraine treatment and to compare it with other drugs for migraine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozl_vTLCa_ALVg90H21EOLACvtfcHk0ligyrlDKuTlbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVylsL3K&md5=3ac0c00c8b4d6216e24fb20ec4ce75dc</span></div><a href="/servlet/linkout?suffix=cit94a&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1813049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1813049%26sid%3Dliteratum%253Aachs%26aulast%3DDodick%26aufirst%3DD.%2BW.%26aulast%3DLipton%26aufirst%3DR.%2BB.%26aulast%3DAilani%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DK.%26aulast%3DFinnegan%26aufirst%3DM.%26aulast%3DTrugman%26aufirst%3DJ.%2BM.%26aulast%3DSzegedi%26aufirst%3DA.%26atitle%3DUbrogepant%2520for%2520the%2520Treatment%2520of%2520Migraine%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2019%26volume%3D381%26spage%3D2230%26epage%3D2241%26doi%3D10.1056%2FNEJMoa1813049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit94b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraley, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgey, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regan, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danziger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michener, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hostetler, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerjee, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvatore, C.</span></span> <span> </span><span class="NLM_article-title">Characterization of Ubrogepant: A Potent and Selective Antagonist of the Human Calcitonin Gene-Related Peptide Receptor</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>373</i></span>,  <span class="NLM_fpage">160</span>– <span class="NLM_lpage">166</span>, <span class="refDoi"> DOI: 10.1124/jpet.119.261065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1124%2Fjpet.119.261065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BB3cXovV2rsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2020&pages=160-166&author=E.+Mooreauthor=M.+E.+Fraleyauthor=I.+M.+Bellauthor=C.+S.+Burgeyauthor=R.+B.+Whiteauthor=C.-C.+Liauthor=C.+P.+Reganauthor=A.+Danzigerauthor=M.+S.+Michenerauthor=E.+Hostetlerauthor=P.+Banerjeeauthor=C.+Salvatore&title=Characterization+of+Ubrogepant%3A+A+Potent+and+Selective+Antagonist+of+the+Human+Calcitonin+Gene-Related+Peptide+Receptor&doi=10.1124%2Fjpet.119.261065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94bR"><div class="casContent"><span class="casTitleNuber">94b</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of ubrogepant: a potent and selective antagonist of the human calcitonin gene-related peptide receptor</span></div><div class="casAuthors">Moore, Eric; Fraley, Mark E.; Bell, Ian M.; Burgey, Christopher S.; White, Rebecca B.; Li, Chi-Chung; Regan, Christopher P.; Danziger, Andrew; Michener, Maria Stranieri; Hostetler, Eric; Banerjee, Pradeep; Salvatore, Christopher</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">160-166</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A growing body of evidence has implicated the calcitonin gene-related peptide (CGRP) receptors in migraine pathophysiol.  With the approval of monoclonal antibodies targeting CGRP or the CGRP receptor, the inhibition of CGRP-mediated signaling emerged as a promising approach for preventive treatments of migraine in adults.  Recently, small-mol. anti-CGRP treatments have shown efficacy for treating migraine.  The current studies aimed to characterize the pharmacol. properties of ubrogepant, an orally bioavailable CGRP receptor antagonist for the acute treatment of migraine.  In a series of ligand-binding assays, ubrogepant exhibited a high binding affinity for native (Ki = 0.067 nM) and cloned human (Ki = 0.070 nM) and rhesus CGRP receptors (Ki = 0.079 nM), with relatively lower affinities for CGRP receptors from rat, mouse, rabbit, and dog.  In functional assays, ubrogepant potently blocked human a-CGRP2-stimulated cAMP response (IC50 of 0.08 nM) and exhibited highly selective antagonist activity for the CGRP receptor compared with other members of the human calcitonin receptor family.  Results demonstrated that ubrogepant produced concn.-dependent inhibition of CIDV with a mean EC50 of 3.2 and 2.6 nM in rhesus monkeys and humans, resp.  Brain penetration studies with ubrogepant in monkeys showed a cerebrospinal fluid:plasma ratio of 0.03 and low CGRP receptor occupancy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCwthjgvD5tLVg90H21EOLACvtfcHk0ligyrlDKuTlbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXovV2rsLw%253D&md5=1a6ac185d26ebae7e5c0c16f34bf2c3c</span></div><a href="/servlet/linkout?suffix=cit94b&amp;dbid=16384&amp;doi=10.1124%2Fjpet.119.261065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.119.261065%26sid%3Dliteratum%253Aachs%26aulast%3DMoore%26aufirst%3DE.%26aulast%3DFraley%26aufirst%3DM.%2BE.%26aulast%3DBell%26aufirst%3DI.%2BM.%26aulast%3DBurgey%26aufirst%3DC.%2BS.%26aulast%3DWhite%26aufirst%3DR.%2BB.%26aulast%3DLi%26aufirst%3DC.-C.%26aulast%3DRegan%26aufirst%3DC.%2BP.%26aulast%3DDanziger%26aufirst%3DA.%26aulast%3DMichener%26aufirst%3DM.%2BS.%26aulast%3DHostetler%26aufirst%3DE.%26aulast%3DBanerjee%26aufirst%3DP.%26aulast%3DSalvatore%26aufirst%3DC.%26atitle%3DCharacterization%2520of%2520Ubrogepant%253A%2520A%2520Potent%2520and%2520Selective%2520Antagonist%2520of%2520the%2520Human%2520Calcitonin%2520Gene-Related%2520Peptide%2520Receptor%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2020%26volume%3D373%26spage%3D160%26epage%3D166%26doi%3D10.1124%2Fjpet.119.261065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holland, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goadsby, P. J.</span></span> <span> </span><span class="NLM_article-title">Targeted CGRP Small Molecule Antagonists for Acute Migraine Therapy</span>. <i>Neurotherapeutics</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">304</span>– <span class="NLM_lpage">312</span>, <span class="refDoi"> DOI: 10.1007/s13311-018-0617-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs13311-018-0617-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=29556965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltFWltLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=304-312&author=P.+R.+Hollandauthor=P.+J.+Goadsby&title=Targeted+CGRP+Small+Molecule+Antagonists+for+Acute+Migraine+Therapy&doi=10.1007%2Fs13311-018-0617-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted CGRP Small Molecule Antagonists for Acute Migraine Therapy</span></div><div class="casAuthors">Holland, Philip R.; Goadsby, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Neurotherapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">304-312</span>CODEN:
                <span class="NLM_cas:coden">NEURNV</span>;
        ISSN:<span class="NLM_cas:issn">1878-7479</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Migraine is a highly prevalent, severe, and disabling neurol. condition with a significant unmet need for effective acute therapies.  Patients (∼50%) are dissatisfied with their currently available therapies.  Calcitonin gene-related peptide (CGRP) has emerged as a key neuropeptide involved in the pathophysiol. of migraines.  As reviewed in this manuscript, a no. of small mol. antagonists of the CGRP receptor have been developed for migraine therapy.  Incredibly, the majority of the clin. trials conducted have proven pos., demonstrating the importance of this signalling pathway in migraine.  Unfortunately, a no. of these mols. raised liver toxicity concerns when used daily for as little as 7 days resulting in their discontinuation.  Despite the clear safety concerns, clin. trial data suggests that their intermittent use remains a viable and safe alternative, with 2 mols. remaining in clin. development (ubrogepant and rimegepant).  Further, these proofs of principle studies identifying CGRP as a viable clin. target have led to the development of several CGRP or CGRP receptor-targeted monoclonal antibodies that continue to show good clin. efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohm5utSthexrVg90H21EOLACvtfcHk0ligyrlDKuTlbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltFWltLs%253D&md5=3ea00aa7553e9134c86509b02ecb5d58</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1007%2Fs13311-018-0617-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13311-018-0617-4%26sid%3Dliteratum%253Aachs%26aulast%3DHolland%26aufirst%3DP.%2BR.%26aulast%3DGoadsby%26aufirst%3DP.%2BJ.%26atitle%3DTargeted%2520CGRP%2520Small%2520Molecule%2520Antagonists%2520for%2520Acute%2520Migraine%2520Therapy%26jtitle%3DNeurotherapeutics%26date%3D2018%26volume%3D15%26spage%3D304%26epage%3D312%26doi%3D10.1007%2Fs13311-018-0617-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Bell, I. M.</span>; <span class="NLM_string-name">Fraley, M. E.</span>; <span class="NLM_string-name">Gallicchio, S. N.</span>; <span class="NLM_string-name">Ginnetti, A.</span>; <span class="NLM_string-name">Mitchell, H. J.</span>; <span class="NLM_string-name">Paone, D. V.</span>; <span class="NLM_string-name">Staas, D. D.</span>; <span class="NLM_string-name">Wang, C.</span>; <span class="NLM_string-name">Zartman, C. B.</span>; <span class="NLM_string-name">Stevenson, H. E.</span></span> <span> </span><span class="NLM_article-title">Preparation of Piperidinonylcarboxamideazaindane Derivatives for Use as CGRP Receptor Antagonists</span>. <span class="NLM_patent">WO 2012064910 A1</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=I.+M.+Bell&author=M.+E.+Fraley&author=S.+N.+Gallicchio&author=A.+Ginnetti&author=H.+J.+Mitchell&author=D.+V.+Paone&author=D.+D.+Staas&author=C.+Wang&author=C.+B.+Zartman&author=H.+E.+Stevenson&title=Preparation+of+Piperidinonylcarboxamideazaindane+Derivatives+for+Use+as+CGRP+Receptor+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBell%26aufirst%3DI.%2BM.%26atitle%3DPreparation%2520of%2520Piperidinonylcarboxamideazaindane%2520Derivatives%2520for%2520Use%2520as%2520CGRP%2520Receptor%2520Antagonists%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit96b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Belyk, K. M.</span>; <span class="NLM_string-name">Cleator, E.</span>; <span class="NLM_string-name">Kuo, S.-C.</span>; <span class="NLM_string-name">Maligres, P. E.</span>; <span class="NLM_string-name">Xiang, B.</span>; <span class="NLM_string-name">Yasuda, N.</span>; <span class="NLM_string-name">Yin, J.</span></span> <span> </span><span class="NLM_article-title">Process for Preparing Pyrrolo[2,3-<i>b</i>]Pyridine Derivatives as CGRP Receptor Antagonists</span>. <span class="NLM_patent">WO2013138418 A2</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=K.+M.+Belyk&author=E.+Cleator&author=S.-C.+Kuo&author=P.+E.+Maligres&author=B.+Xiang&author=N.+Yasuda&author=J.+Yin&title=Process+for+Preparing+Pyrrolo%5B2%2C3-b%5DPyridine+Derivatives+as+CGRP+Receptor+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBelyk%26aufirst%3DK.%2BM.%26atitle%3DProcess%2520for%2520Preparing%2520Pyrrolo%255B2%252C3-b%255DPyridine%2520Derivatives%2520as%2520CGRP%2520Receptor%2520Antagonists%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit96c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span>; <span class="NLM_string-name">Molinaro, C.</span>; <span class="NLM_string-name">Wuelfing, W. P.</span>; <span class="NLM_string-name">Yasuda, N.</span>; <span class="NLM_string-name">Yin, J.</span>; <span class="NLM_string-name">Zhong, Y.-L.</span>; <span class="NLM_string-name">Lynch, J.</span>; <span class="NLM_string-name">Andreani, T.</span></span> <span> </span><span class="NLM_article-title">Process for Preparing Spirolactams as CGRP Receptor Antagonists</span>. <span class="NLM_patent">WO2013169348 A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=F.+Chen&author=C.+Molinaro&author=W.+P.+Wuelfing&author=N.+Yasuda&author=J.+Yin&author=Y.-L.+Zhong&author=J.+Lynch&author=T.+Andreani&title=Process+for+Preparing+Spirolactams+as+CGRP+Receptor+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DF.%26atitle%3DProcess%2520for%2520Preparing%2520Spirolactams%2520as%2520CGRP%2520Receptor%2520Antagonists%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit96d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span>; <span class="NLM_string-name">Molinaro, C.</span>; <span class="NLM_string-name">Wuelfing, W. P.</span>; <span class="NLM_string-name">Yasuda, N.</span>; <span class="NLM_string-name">Yin, J.</span>; <span class="NLM_string-name">Zhong, Y.-L.</span>; <span class="NLM_string-name">Lynch, J.</span>; <span class="NLM_string-name">Andreani, T.</span></span> <span> </span><span class="NLM_article-title">Process for Making CGRP Receptor Antagonists</span>. <span class="NLM_patent">US 9174989 B2</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=F.+Chen&author=C.+Molinaro&author=W.+P.+Wuelfing&author=N.+Yasuda&author=J.+Yin&author=Y.-L.+Zhong&author=J.+Lynch&author=T.+Andreani&title=Process+for+Making+CGRP+Receptor+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DF.%26atitle%3DProcess%2520for%2520Making%2520CGRP%2520Receptor%2520Antagonists%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joyce, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brachmann, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glazer, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lango, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwär, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bode, H. B.</span></span> <span> </span><span class="NLM_article-title">Bacterial Biosynthesis of a Multipotent Stilbene</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">1942</span>– <span class="NLM_lpage">1945</span>, <span class="refDoi"> DOI: 10.1002/anie.200705148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1002%2Fanie.200705148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjtFGns7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2008&pages=1942-1945&author=S.+A.+Joyceauthor=A.+O.+Brachmannauthor=I.+Glazerauthor=L.+Langoauthor=G.+Schw%C3%A4rauthor=D.+J.+Clarkeauthor=H.+B.+Bode&title=Bacterial+Biosynthesis+of+a+Multipotent+Stilbene&doi=10.1002%2Fanie.200705148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Bacterial biosynthesis of a multipotent stilbene</span></div><div class="casAuthors">Joyce, Susan A.; Brachmann, Alexander O.; Glazer, Itamar; Lango, Lea; Schwaer, Gertrud; Clarke, David J.; Bode, Helge B.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1942-1945</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The biosynthesis of the only nonplant stilbene (I) by Photorhabdus has been solved by identification of all the genes involved in its biosynthesis and by feeding expts.  I is derived from the condensation of two β-ketoacyl thioesters and is required for the normal development of Heterorhabditis nematodes, the natural host of Photorhabdus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7rDKVf76R1bVg90H21EOLACvtfcHk0ljnuO7WKdWR_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjtFGns7Y%253D&md5=e522231c97fd095cf533196cc2f85a85</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1002%2Fanie.200705148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200705148%26sid%3Dliteratum%253Aachs%26aulast%3DJoyce%26aufirst%3DS.%2BA.%26aulast%3DBrachmann%26aufirst%3DA.%2BO.%26aulast%3DGlazer%26aufirst%3DI.%26aulast%3DLango%26aufirst%3DL.%26aulast%3DSchw%25C3%25A4r%26aufirst%3DG.%26aulast%3DClarke%26aufirst%3DD.%2BJ.%26aulast%3DBode%26aufirst%3DH.%2BB.%26atitle%3DBacterial%2520Biosynthesis%2520of%2520a%2520Multipotent%2520Stilbene%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2008%26volume%3D47%26spage%3D1942%26epage%3D1945%26doi%3D10.1002%2Fanie.200705148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Furue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto-Hachiya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuji, G.</span></span> <span> </span><span class="NLM_article-title">Aryl Hydrocarbon Receptor in Atopic Dermatitis and Psoriasis</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">5424</span>, <span class="refDoi"> DOI: 10.3390/ijms20215424</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.3390%2Fijms20215424" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BB3cXptFSisbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=5424&author=M.+Furueauthor=A.+Hashimoto-Hachiyaauthor=G.+Tsuji&title=Aryl+Hydrocarbon+Receptor+in+Atopic+Dermatitis+and+Psoriasis&doi=10.3390%2Fijms20215424"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Aryl hydrocarbon receptor in atopic dermatitis and psoriasis</span></div><div class="casAuthors">Furue, Masutaka; Hashimoto-Hachiya, Akiko; Tsuji, Gaku</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5424</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  The aryl hydrocarbon receptor (AHR)/AHR-nuclear translocator (ARNT) system is a sensitive sensor for small mol., xenobiotic chems. of exogenous and endogenous origin, including dioxins, phytochems., microbial bioproducts, and tryptophan photoproducts.  AHR/ARNT are abundantly expressed in the skin.  Once activated, the AHR/ARNT axis strengthens skin barrier functions and accelerates epidermal terminal differentiation by upregulating filaggrin expression.  In addn., AHR activation induces oxidative stress.  However, some AHR ligands simultaneously activate the nuclear factor-erythroid 2-related factor-2 (NRF2) transcription factor, which is a master switch of antioxidative enzymes that neutralizes oxidative stress.  The immunoregulatory system governing T-helper 17/22 (Th17/22) and T regulatory cells (Treg) is also regulated by the AHR system.  Notably, AHR agonists, such as tapinarof, are currently used as therapeutic agents in psoriasis and atopic dermatitis.  In this review, we summarize recent topics on AHR related to atopic dermatitis and psoriasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFGUR1M-E3XrVg90H21EOLACvtfcHk0ljnuO7WKdWR_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXptFSisbg%253D&md5=86eae79a17386d7bb00630feaa97415c</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.3390%2Fijms20215424&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20215424%26sid%3Dliteratum%253Aachs%26aulast%3DFurue%26aufirst%3DM.%26aulast%3DHashimoto-Hachiya%26aufirst%3DA.%26aulast%3DTsuji%26aufirst%3DG.%26atitle%3DAryl%2520Hydrocarbon%2520Receptor%2520in%2520Atopic%2520Dermatitis%2520and%2520Psoriasis%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26spage%3D5424%26doi%3D10.3390%2Fijms20215424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zang, Y.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, D.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Z.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, W.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Y.</span></span> <span> </span><span class="NLM_article-title">Use of a Dose-Response Model to Guide Future Clinical Trial of Benvitimod Cream to Treat Mild and Moderate Psoriasis</span>. <i>Int. J. Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">95</span>, <span class="refDoi"> DOI: 10.5414/CP202486</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.5414%2FCP202486" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=26709597" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC28XmvV2gtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2016&pages=87-95&author=Y.-N.+Zangauthor=D.-L.+Jiangauthor=L.+Caiauthor=X.+Chenauthor=Q.+Wangauthor=Z.-W.+Xieauthor=Y.+Liuauthor=C.-Y.+Zhangauthor=S.+Jingauthor=G.-H.+Chenauthor=J.-Z.+Zhangauthor=L.+Xuauthor=W.-Y.+Fengauthor=L.-B.+Zhaoauthor=Y.+Fang&title=Use+of+a+Dose-Response+Model+to+Guide+Future+Clinical+Trial+of+Benvitimod+Cream+to+Treat+Mild+and+Moderate+Psoriasis&doi=10.5414%2FCP202486"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Use of a dose-response model to guide future clinical trials of benvitimod cream to treat mild and moderate psoriasis</span></div><div class="casAuthors">Zang, Yan-Nan; Jiang, Dao-Li; Cai, Lin; Chen, Xin; Wang, Qian; Xie, Zhen-Wei; Liu, Yang; Zhang, Chun-Yan; Jing, Shan; Chen, Gen-Hui; Zhang, Jian-Zhong; Xu, Ling; Feng, Wan-Yu; Zhao, Li-Bo; Fang, Yi</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Clinical Pharmacology and Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">87-95</span>CODEN:
                <span class="NLM_cas:coden">ICTHEK</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Dustri-Verlag Dr. Karl Feistle</span>)
        </div><div class="casAbstract">Objective: To investigate the time-dose-response relationship of benvitimod cream after topical administration in patients with mild and moderate psoriasis vulgaris for dosage regimen exploring.  Methods: 36 patients with mild and moderate psoriasis vulgaris were randomly assigned to receive 0.5%, 1.0%, 1.5%, and 0% (placebo) benvitimod cream of 30 g/1.7 m2 twice daily for 6 wk.  The primary efficacy outcome was the proportion of patients achieving more than 75% change of the psoriasis area and severity index (PASI 75) from baseline.  A longitudinal Emax model was established using the NONMEM method, and then applied to try to find an appropriate dose for following trials.  Results: In the final time-dose-response model, the primary outcome at week 6 of PASI 75 of the 0.5%, 1.0%, and 1.5% benvitimod cream was 31%, 63%, and 75%, resp., demonstrating that the 1.0% benvitimod cream was an appropriate dose for the next trial.  The time parameters of ET50 and ET90 were 15 and 69 days for 1.0% benvitimod cream, indicating that the max. efficacy of PASI change rate was obtained at approx. week 10.  The accuracy of PASI change rate by extrapolation prediction was limited at week 10, so the treatment period should be longer in future trials.  Conclusions: The established dose-response model could well describe the relationship between PASI change rate and doses of benvitimod cream in patients with mild and moderate psoriasis vulgaris.  This modeling approach may help choose 1.0% benvitimod cream twice daily as a dosage regimen in following clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqkSagXwYp8bVg90H21EOLACvtfcHk0lj3EMG70HfifQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmvV2gtLY%253D&md5=5ed5633b5e741e183c219533fa2d6635</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.5414%2FCP202486&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5414%252FCP202486%26sid%3Dliteratum%253Aachs%26aulast%3DZang%26aufirst%3DY.-N.%26aulast%3DJiang%26aufirst%3DD.-L.%26aulast%3DCai%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DXie%26aufirst%3DZ.-W.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DC.-Y.%26aulast%3DJing%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DG.-H.%26aulast%3DZhang%26aufirst%3DJ.-Z.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DFeng%26aufirst%3DW.-Y.%26aulast%3DZhao%26aufirst%3DL.-B.%26aulast%3DFang%26aufirst%3DY.%26atitle%3DUse%2520of%2520a%2520Dose-Response%2520Model%2520to%2520Guide%2520Future%2520Clinical%2520Trial%2520of%2520Benvitimod%2520Cream%2520to%2520Treat%2520Mild%2520and%2520Moderate%2520Psoriasis%26jtitle%3DInt.%2520J.%2520Clin.%2520Pharmacol.%2520Ther.%26date%3D2016%26volume%3D54%26spage%3D87%26epage%3D95%26doi%3D10.5414%2FCP202486" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span> <span> </span><span class="NLM_article-title">Industrialized Production Process of New Medicament Benvitimod for Treating Psoriasis</span>. <span class="NLM_patent">CN 103172497 A</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=B.+Li&title=Industrialized+Production+Process+of+New+Medicament+Benvitimod+for+Treating+Psoriasis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DB.%26atitle%3DIndustrialized%2520Production%2520Process%2520of%2520New%2520Medicament%2520Benvitimod%2520for%2520Treating%2520Psoriasis%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf" class="extLink">https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf</a> (accessed 2020-09-17).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2019%2F211527s000lbl.pdf+%28accessed+2020-09-17%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, L. J.</span></span> <span> </span><span class="NLM_article-title">Trifarotene: First Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">1905</span>– <span class="NLM_lpage">1909</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01218-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs40265-019-01218-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31713811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFCjtrfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=1905-1909&author=L.+J.+Scott&title=Trifarotene%3A+First+Approval&doi=10.1007%2Fs40265-019-01218-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Trifarotene: First Approval</span></div><div class="casAuthors">Scott, Lesley J.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1905-1909</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Topical trifarotene (Aklief) is a first-in-class, fourth-generation retinoid [selective retinoic acid receptor (RAR)-γ agonist] being developed by Galderma Research and Development LLC for the treatment of acne vulgaris.  In Oct. 2019 trifarotene received its first global approval in the USA for the topical treatment of acne vulgaris in patients 9 years of age and older.  This article summarizes the milestones in the development of trifarotene leading to its first global approval for acne vulgaris.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpE9jRMJrjPS7Vg90H21EOLACvtfcHk0lj3EMG70HfifQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFCjtrfM&md5=9c811e694067c8bfe303e1d27d0b6d40</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01218-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01218-6%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DL.%2BJ.%26atitle%3DTrifarotene%253A%2520First%2520Approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D1905%26epage%3D1909%26doi%3D10.1007%2Fs40265-019-01218-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiboutot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popp, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gooderham, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynde, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Rosso, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blume-Peytavi, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weglovska, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parish, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witkowska, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez Colon, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alió Saenz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graeber, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein Gold, L.</span></span> <span> </span><span class="NLM_article-title">Randomized Phase 3 Evaluation of Trifarotene 50 μg/g Cream Treatment of Moderate Facial and Truncal Acne</span>. <i>J. Am. Acad. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">1691</span>– <span class="NLM_lpage">1699</span>, <span class="refDoi"> DOI: 10.1016/j.jaad.2019.02.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2Fj.jaad.2019.02.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=30802558" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVWqtbfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2019&pages=1691-1699&author=J.+Tanauthor=D.+Thiboutotauthor=G.+Poppauthor=M.+Gooderhamauthor=C.+Lyndeauthor=J.+Del+Rossoauthor=J.+Weissauthor=U.+Blume-Peytaviauthor=J.+Weglovskaauthor=S.+Johnsonauthor=L.+Parishauthor=D.+Witkowskaauthor=N.+Sanchez+Colonauthor=A.+Ali%C3%B3+Saenzauthor=F.+Ahmadauthor=M.+Graeberauthor=L.+Stein+Gold&title=Randomized+Phase+3+Evaluation+of+Trifarotene+50+%CE%BCg%2Fg+Cream+Treatment+of+Moderate+Facial+and+Truncal+Acne&doi=10.1016%2Fj.jaad.2019.02.044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized phase 3 evaluation of trifarotene 50μg/g cream treatment of moderate facial and truncal acne</span></div><div class="casAuthors">Tan, Jerry; Thiboutot, Diane; Popp, Georg; Gooderham, Melinda; Lynde, Charles; Del Rosso, James; Weiss, Jonathan; Blume-Peytavi, Ulrike; Weglovska, Jolanta; Johnson, Sandra; Parish, Lawrence; Witkowska, Dagmara; Sanchez Colon, Nestor; Alio Saenz, Alessandra; Ahmad, Faiz; Graeber, Michael; Stein Gold, Linda</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Academy of Dermatology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1691-1699</span>CODEN:
                <span class="NLM_cas:coden">JAADDB</span>;
        ISSN:<span class="NLM_cas:issn">0190-9622</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Acne vulgaris often affects the face, shoulders, chest, and back, but treatment of nonfacial acne has not been rigorously studied.  Assess the safety and efficacy of trifarotene 50μg/g cream, a novel topical retinoid, in moderate facial and truncal acne.  Two phase III double-blind, randomized, vehicle-controlled, 12-wk studies of once-daily trifarotene cream vs. vehicle in subjects aged 9 years or older.  The primary end points were rate of success on the face, as detd. by the Investigator's Global Assessment (clear or almost clear and ≥2-grade improvement), and abs. change from baseline in inflammatory and noninflammatory counts from baseline to week 12.  The secondary end points were rate of success on the trunk (clear or almost clear and ≥2-grade improvement) and abs. change in truncal inflammatory and noninflammatory counts from baseline to week 12.  Safety was assessed through adverse events, local tolerability, vital signs, and routine lab. testing results.  In both studies, at week 12 the facial success rates according to the Investigator's Global Assessment and truncal Physician's Global Assessment and change in inflammatory and noninflammatory lesion counts (both abs. and percentage) were all highly significant in favor of trifarotene when compared with the vehicle.  Adjunctive topical or systemic treatments were not studied.  These studies demonstrate that trifarotene appears to be safe, effective, and well tolerated in treatment of both facial and truncal acne.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1FR_eONWv6LVg90H21EOLACvtfcHk0lj3EMG70HfifQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVWqtbfL&md5=9e524bd5f9089c957704ac5e9fcb70ac</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1016%2Fj.jaad.2019.02.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaad.2019.02.044%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DThiboutot%26aufirst%3DD.%26aulast%3DPopp%26aufirst%3DG.%26aulast%3DGooderham%26aufirst%3DM.%26aulast%3DLynde%26aufirst%3DC.%26aulast%3DDel%2BRosso%26aufirst%3DJ.%26aulast%3DWeiss%26aufirst%3DJ.%26aulast%3DBlume-Peytavi%26aufirst%3DU.%26aulast%3DWeglovska%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DS.%26aulast%3DParish%26aufirst%3DL.%26aulast%3DWitkowska%26aufirst%3DD.%26aulast%3DSanchez%2BColon%26aufirst%3DN.%26aulast%3DAli%25C3%25B3%2BSaenz%26aufirst%3DA.%26aulast%3DAhmad%26aufirst%3DF.%26aulast%3DGraeber%26aufirst%3DM.%26aulast%3DStein%2BGold%26aufirst%3DL.%26atitle%3DRandomized%2520Phase%25203%2520Evaluation%2520of%2520Trifarotene%252050%2520%25CE%25BCg%252Fg%2520Cream%2520Treatment%2520of%2520Moderate%2520Facial%2520and%2520Truncal%2520Acne%26jtitle%3DJ.%2520Am.%2520Acad.%2520Dermatol.%26date%3D2019%26volume%3D80%26spage%3D1691%26epage%3D1699%26doi%3D10.1016%2Fj.jaad.2019.02.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Biadatti, T.</span>; <span class="NLM_string-name">Dumais, L.</span>; <span class="NLM_string-name">Soulet, C.</span>; <span class="NLM_string-name">Talano, S.</span>; <span class="NLM_string-name">Daver, S.</span></span> <span> </span><span class="NLM_article-title">Novel Ligands That Modulate RAR Receptors, and Use Thereof in Human Medicine and in Cosmetics</span>. <span class="NLM_patent">WO 2006066978 A1</span>, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=T.+Biadatti&author=L.+Dumais&author=C.+Soulet&author=S.+Talano&author=S.+Daver&title=Novel+Ligands+That+Modulate+RAR+Receptors%2C+and+Use+Thereof+in+Human+Medicine+and+in+Cosmetics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBiadatti%26aufirst%3DT.%26atitle%3DNovel%2520Ligands%2520That%2520Modulate%2520RAR%2520Receptors%252C%2520and%2520Use%2520Thereof%2520in%2520Human%2520Medicine%2520and%2520in%2520Cosmetics%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Zielińska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasilewski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fichna, J.</span></span> <span> </span><span class="NLM_article-title">Tenapanor Hydrochloride for the Treatment of Constipation-Predominant Irritable Bowel Syndrome</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1093</span>– <span class="NLM_lpage">1099</span>, <span class="refDoi"> DOI: 10.1517/13543784.2015.1054480</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1517%2F13543784.2015.1054480" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=26065434" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFCksb3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2015&pages=1093-1099&author=M.+Zieli%C5%84skaauthor=A.+Wasilewskiauthor=J.+Fichna&title=Tenapanor+Hydrochloride+for+the+Treatment+of+Constipation-Predominant+Irritable+Bowel+Syndrome&doi=10.1517%2F13543784.2015.1054480"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105aR"><div class="casContent"><span class="casTitleNuber">105a</span><div class="casTitle"><span class="NLM_cas:atitle">Tenapanor hydrochloride for the treatment of constipation-predominant irritable bowel syndrome</span></div><div class="casAuthors">Zielinska, Marta; Wasilewski, Andrzej; Fichna, Jakub</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1093-1099</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Introduction: Constipation-predominant irritable bowel syndrome (IBS-C) is a common functional gastrointestinal (GI) disorder characterized by recurrent abdominal pain and prolonged GI transit.  The pathogenesis of IBS-C has still not been established; therefore, drugs currently in use in IBS-C act mainly symptomatically, whereas novel pharmacol. targets are urgently needed.  Tenapanor is a potent inhibitor of Na+/H+ exchanger 3 [NHE3], localized in the apical membrane of intestinal epithelial cells.  NHE3 participates in the uptake of sodium ions and water from the intestinal lumen.  Areas covered: In this review, the authors discuss pharmacodynamics and pharmacokinetics of tenapanor, focusing on animal models and in vitro studies.  They also summarize clin. trials on tenapanor's safety and efficacy in view of its potential role in IBS-C therapy.  Expert opinion: Tenapanor possesses an excellent preclin. safety profile and, as of now, there are no serious concerns about its side effects.  The non-systemic action of tenapanor constitutes a significant advantage, as it minimizes possible adverse effects or drug-drug interactions.  However, Phase III clin. trials are still needed to confirm results obtained in earlier phases and optimize the dose-response for tenapanor, whereas limiting diarrhea, its major adverse effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR0UxJixVSu7Vg90H21EOLACvtfcHk0ljs4aQQwzXrxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFCksb3P&md5=8dc37d7e06076fd906964ff774f48fea</span></div><a href="/servlet/linkout?suffix=cit105a&amp;dbid=16384&amp;doi=10.1517%2F13543784.2015.1054480&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2015.1054480%26sid%3Dliteratum%253Aachs%26aulast%3DZieli%25C5%2584ska%26aufirst%3DM.%26aulast%3DWasilewski%26aufirst%3DA.%26aulast%3DFichna%26aufirst%3DJ.%26atitle%3DTenapanor%2520Hydrochloride%2520for%2520the%2520Treatment%2520of%2520Constipation-Predominant%2520Irritable%2520Bowel%2520Syndrome%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2015%26volume%3D24%26spage%3D1093%26epage%3D1099%26doi%3D10.1517%2F13543784.2015.1054480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit105b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span> <span> </span><span class="NLM_article-title">Tenapanor: First Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">1897</span>– <span class="NLM_lpage">1903</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01215-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs40265-019-01215-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31677150" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFemsLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=1897-1903&author=A.+Markham&title=Tenapanor%3A+First+Approval&doi=10.1007%2Fs40265-019-01215-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105bR"><div class="casContent"><span class="casTitleNuber">105b</span><div class="casTitle"><span class="NLM_cas:atitle">Tenapanor: First Approval</span></div><div class="casAuthors">Markham, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1897-1903</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">The selective sodium hydrogen exchanger 3 (NHE3) inhibitor tenapanor is being developed by Ardelyx Inc. for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) [under the tradename IBSRELA] and for hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis or with end stage renal disease (ESRD).  Based on pos. results from the phase III T3MPO trial program, tenapanor was recently approved in the USA for the treatment of IBS-C in adults.  This article summarises the milestones in the development of tenapanor leading to this first approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpE-doTb0dW1bVg90H21EOLACvtfcHk0ljs4aQQwzXrxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFemsLjP&md5=7d27d0d461b6b153e15097e54d9a67fa</span></div><a href="/servlet/linkout?suffix=cit105b&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01215-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01215-9%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26atitle%3DTenapanor%253A%2520First%2520Approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D1897%26epage%3D1903%26doi%3D10.1007%2Fs40265-019-01215-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leadbetter, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carreras, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koo-McCoy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohler, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labonte, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenbaum, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navre, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charmot, D.</span></span> <span> </span><span class="NLM_article-title">RDX5791, a First-in-Class Minimally Systemic NHE3 Inhibitor in Clinical Development for CIC and IBS-C, Increases Intestinal Sodium Leading to Enhanced Intestinal Fluid Volume and Transit</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>140</i></span>,  <span class="NLM_fpage">S-99</span>, <span class="refDoi"> DOI: 10.1016/S0016-5085(11)60405-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2FS0016-5085%2811%2960405-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2011&pages=S-99&author=A.+G.+Spencerauthor=J.+W.+Jacobsauthor=M.+R.+Leadbetterauthor=C.+W.+Carrerasauthor=X.+Duauthor=N.+Bellauthor=S.+Koo-McCoyauthor=J.+N.+Kohlerauthor=E.+Labonteauthor=D.+P.+Rosenbaumauthor=M.+Navreauthor=D.+Charmot&title=RDX5791%2C+a+First-in-Class+Minimally+Systemic+NHE3+Inhibitor+in+Clinical+Development+for+CIC+and+IBS-C%2C+Increases+Intestinal+Sodium+Leading+to+Enhanced+Intestinal+Fluid+Volume+and+Transit&doi=10.1016%2FS0016-5085%2811%2960405-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1016%2FS0016-5085%2811%2960405-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0016-5085%252811%252960405-8%26sid%3Dliteratum%253Aachs%26aulast%3DSpencer%26aufirst%3DA.%2BG.%26aulast%3DJacobs%26aufirst%3DJ.%2BW.%26aulast%3DLeadbetter%26aufirst%3DM.%2BR.%26aulast%3DCarreras%26aufirst%3DC.%2BW.%26aulast%3DDu%26aufirst%3DX.%26aulast%3DBell%26aufirst%3DN.%26aulast%3DKoo-McCoy%26aufirst%3DS.%26aulast%3DKohler%26aufirst%3DJ.%2BN.%26aulast%3DLabonte%26aufirst%3DE.%26aulast%3DRosenbaum%26aufirst%3DD.%2BP.%26aulast%3DNavre%26aufirst%3DM.%26aulast%3DCharmot%26aufirst%3DD.%26atitle%3DRDX5791%252C%2520a%2520First-in-Class%2520Minimally%2520Systemic%2520NHE3%2520Inhibitor%2520in%2520Clinical%2520Development%2520for%2520CIC%2520and%2520IBS-C%252C%2520Increases%2520Intestinal%2520Sodium%2520Leading%2520to%2520Enhanced%2520Intestinal%2520Fluid%2520Volume%2520and%2520Transit%26jtitle%3DGastroenterology%26date%3D2011%26volume%3D140%26spage%3DS-99%26doi%3D10.1016%2FS0016-5085%2811%2960405-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211801s000lbl.pdf" class="extLink">https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211801s000lbl.pdf</a> (accessed 2020-09-18).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2019%2F211801s000lbl.pdf+%28accessed+2020-09-18%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Charmot, D.</span></span> <span> </span><span class="NLM_article-title">Non-Systemic Drugs: A Critical Review</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1434</span>– <span class="NLM_lpage">1445</span>, <span class="refDoi"> DOI: 10.2174/138161212799504858</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.2174%2F138161212799504858" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=22300258" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvVKku7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=1434-1445&author=D.+Charmot&title=Non-Systemic+Drugs%3A+A+Critical+Review&doi=10.2174%2F138161212799504858"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Non-systemic drugs: a critical review</span></div><div class="casAuthors">Charmot, Dominique</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1434-1445</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Non-systemic drugs act within the intestinal lumen without reaching the systemic circulation.  The first generation included polymeric resins that sequester phosphate ions, potassium ions, or bile acids for the treatment of electrolyte imbalances or hypercholesteremia.  The field has evolved towards non-absorbable small mols. or peptides targeting luminal enzymes or transporters for the treatment of mineral metab. disorders, diabetes, gastrointestinal (GI) disorders, and enteric infections.  From a drug design and development perspective, non-systemic agents offer novel opportunities to address unmet medical needs while minimizing toxicity risks, but also present new challenges, including developing a better understanding and control of non-transcellular leakage pathways into the systemic circulation.  The pharmacokinetic-pharmacodynamic relationship of drugs acting in the GI tract can be complex due to the variability of intestinal transit, interaction with chyme, and the complex environment of the surface epithelia.  We review the main classes of nonabsorbable agents at various stages of development, and their therapeutic potential and limitations.  The rapid progress in the identification of intestinal receptors and transporters, their functional characterization and role in metabolic and inflammatory disorders, will undoubtedly renew interest in the development of novel, safe, non-systemic therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKdEQRhLF7irVg90H21EOLACvtfcHk0ljNQFMpKRqB2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvVKku7g%253D&md5=7a391aa741bb1a4bba9516b0f39acee1</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.2174%2F138161212799504858&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161212799504858%26sid%3Dliteratum%253Aachs%26aulast%3DCharmot%26aufirst%3DD.%26atitle%3DNon-Systemic%2520Drugs%253A%2520A%2520Critical%2520Review%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2012%26volume%3D18%26spage%3D1434%26epage%3D1445%26doi%3D10.2174%2F138161212799504858" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Charmot, D.</span>; <span class="NLM_string-name">Jacobs, J. W.</span>; <span class="NLM_string-name">Leadbetter, M. R.</span>; <span class="NLM_string-name">Navre, M.</span>; <span class="NLM_string-name">Carreras, C.</span>; <span class="NLM_string-name">Bell, N.</span></span> <span> </span><span class="NLM_article-title">Preparation of Isoquinolines and Related Compounds as Inhibitors of NHE-Mediated Antiport Useful in the Treatment of Disorders Associated with Fluid Retention or Salt Overload and Gastrointestinal Tract Disorders</span>. <span class="NLM_patent">WO 2010078449 A2</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=D.+Charmot&author=J.+W.+Jacobs&author=M.+R.+Leadbetter&author=M.+Navre&author=C.+Carreras&author=N.+Bell&title=Preparation+of+Isoquinolines+and+Related+Compounds+as+Inhibitors+of+NHE-Mediated+Antiport+Useful+in+the+Treatment+of+Disorders+Associated+with+Fluid+Retention+or+Salt+Overload+and+Gastrointestinal+Tract+Disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCharmot%26aufirst%3DD.%26atitle%3DPreparation%2520of%2520Isoquinolines%2520and%2520Related%2520Compounds%2520as%2520Inhibitors%2520of%2520NHE-Mediated%2520Antiport%2520Useful%2520in%2520the%2520Treatment%2520of%2520Disorders%2520Associated%2520with%2520Fluid%2520Retention%2520or%2520Salt%2520Overload%2520and%2520Gastrointestinal%2520Tract%2520Disorders%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit109b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Bell, N.</span>; <span class="NLM_string-name">Carreras, C.</span>; <span class="NLM_string-name">Charmot, D.</span>; <span class="NLM_string-name">Chen, T.</span>; <span class="NLM_string-name">Leadbetter, M.</span>; <span class="NLM_string-name">Jacobs, J.</span>; <span class="NLM_string-name">Lewis, J.</span></span> <span> </span><span class="NLM_article-title">Compounds and Methods for Inhibiting NHE-Mediated Antiport in the Treatment of Disorders Associated with Fluid Retention or Salt Overload and Gastrointestinal Tract Disorders</span>. <span class="NLM_patent">WO 2010078449</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=N.+Bell&author=C.+Carreras&author=D.+Charmot&author=T.+Chen&author=M.+Leadbetter&author=J.+Jacobs&author=J.+Lewis&title=Compounds+and+Methods+for+Inhibiting+NHE-Mediated+Antiport+in+the+Treatment+of+Disorders+Associated+with+Fluid+Retention+or+Salt+Overload+and+Gastrointestinal+Tract+Disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBell%26aufirst%3DN.%26atitle%3DCompounds%2520and%2520Methods%2520for%2520Inhibiting%2520NHE-Mediated%2520Antiport%2520in%2520the%2520Treatment%2520of%2520Disorders%2520Associated%2520with%2520Fluid%2520Retention%2520or%2520Salt%2520Overload%2520and%2520Gastrointestinal%2520Tract%2520Disorders%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit109c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Luthra, P. K.</span>; <span class="NLM_string-name">Ahmad, S.</span>; <span class="NLM_string-name">Das, D.</span>; <span class="NLM_string-name">Singh, S.</span>; <span class="NLM_string-name">Singh, A.</span></span> <span> </span><span class="NLM_article-title">Processes for the Preparation of Tenapanor, Its Crystalline Dihydrochloride Form and Intermediates Thereof</span>. <span class="NLM_patent">WO 2020051014 A1</span>, <span class="NLM_year">2020</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=P.+K.+Luthra&author=S.+Ahmad&author=D.+Das&author=S.+Singh&author=A.+Singh&title=Processes+for+the+Preparation+of+Tenapanor%2C+Its+Crystalline+Dihydrochloride+Form+and+Intermediates+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLuthra%26aufirst%3DP.%2BK.%26atitle%3DProcesses%2520for%2520the%2520Preparation%2520of%2520Tenapanor%252C%2520Its%2520Crystalline%2520Dihydrochloride%2520Form%2520and%2520Intermediates%2520Thereof%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keam, S. J.</span></span> <span> </span><span class="NLM_article-title">Peficitinib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">887</span>– <span class="NLM_lpage">891</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01131-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs40265-019-01131-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31093950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFWmtLzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=887-891&author=A.+Markhamauthor=S.+J.+Keam&title=Peficitinib%3A+First+Global+Approval&doi=10.1007%2Fs40265-019-01131-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Peficitinib: First Global Approval</span></div><div class="casAuthors">Markham, Anthony; Keam, Susan J.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">887-891</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Peficitinib [Smyraf (Astellas Pharma)] is a Janus kinase (JAK)1, JAK2, JAK3 and tyrosine kinase (Tyk)2 (pan-JAK) inhibitor recently approved in Japan for the treatment of rheumatoid arthritis.  Inhibition of JAK suppresses the activation of cytokine signalling pathways involved in inflammation and joint destruction in rheumatoid arthritis.  Peficitinib has been shown to significantly improve ACR20 and other measures of disease severity and to reduce the mean modified total Sharp score change from baseline in clin. trials.  This article summarizes the milestones in the development of peficitinib leading to this first approval as a treatment for rheumatoid arthritis in patients who have an inadequate response to conventional therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0H33aqSsFn7Vg90H21EOLACvtfcHk0ljNQFMpKRqB2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFWmtLzI&md5=eb2d2061829fc515854130050139871c</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01131-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01131-y%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26aulast%3DKeam%26aufirst%3DS.%2BJ.%26atitle%3DPeficitinib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D887%26epage%3D891%26doi%3D10.1007%2Fs40265-019-01131-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawakami, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwasaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, J. C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rokuda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izutsu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ushijima, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaneko, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akazawa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiomi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, E.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety of Peficitinib (ASP015K) in Patients with Rheumatoid Arthritis and an Inadequate Response to Conventional DMARDs: A Randomised, Double-Blind, Placebo-Controlled Phase III Trial (RAJ3)</span>. <i>Ann. Rheum. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">1320</span>– <span class="NLM_lpage">1332</span>, <span class="refDoi"> DOI: 10.1136/annrheumdis-2019-215163</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1136%2Fannrheumdis-2019-215163" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31350270" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BB3cXktVSqu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2019&pages=1320-1332&author=Y.+Tanakaauthor=T.+Takeuchiauthor=S.+Tanakaauthor=A.+Kawakamiauthor=M.+Iwasakiauthor=Y.+W.+Songauthor=Y.-H.+Chenauthor=J.+C.-C.+Weiauthor=S.-H.+Leeauthor=M.+Rokudaauthor=H.+Izutsuauthor=S.+Ushijimaauthor=Y.+Kanekoauthor=R.+Akazawaauthor=T.+Shiomiauthor=E.+Yamada&title=Efficacy+and+Safety+of+Peficitinib+%28ASP015K%29+in+Patients+with+Rheumatoid+Arthritis+and+an+Inadequate+Response+to+Conventional+DMARDs%3A+A+Randomised%2C+Double-Blind%2C+Placebo-Controlled+Phase+III+Trial+%28RAJ3%29&doi=10.1136%2Fannrheumdis-2019-215163"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111aR"><div class="casContent"><span class="casTitleNuber">111a</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3)</span></div><div class="casAuthors">Tanaka, Yoshiya; Takeuchi, Tsutomu; Tanaka, Sakae; Kawakami, Atsushi; Iwasaki, Manabu; Song, Yeong Wook; Chen, Yi-Hsing; Wei, James Cheng-Chung; Lee, Sang-Heon; Rokuda, Mitsuhiro; Izutsu, Hiroyuki; Ushijima, Satoshi; Kaneko, Yuichiro; Akazawa, Rio; Shiomi, Teruaki; Yamada, Emi</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the Rheumatic Diseases</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1320-1332</span>CODEN:
                <span class="NLM_cas:coden">ARDIAO</span>;
        ISSN:<span class="NLM_cas:issn">0003-4967</span>.
    
            (<span class="NLM_cas:orgname">BMJ</span>)
        </div><div class="casAbstract">Objectives To investigate the efficacy and safety of peficitinib, an oral Janus kinase inhibitor, in patients with rheumatoid arthritis (RA).  Methods In this double-blind phase III study, patients with RA and an inadequate response to prior diseasemodifying anti-rheumatic drugs (DMARDs) were randomised to peficitinib 100 mg once daily, peficitinib 150 mg once daily, placebo or open-label etanercept for 52 wk' treatment; placebo-treated patients were switched at week 12 to peficitinib 100 or 150 mg once daily.  The primary endpoint was American College of Rheumatol. (ACR)20 response at week 12/ early termination (ET).  Secondary endpoints (assessed throughout) included ACR20, ACR50 and ACR70 response, changes from baseline in disease activity scores (DAS)28 and ACR core parameters, adverse events (AEs) and changes in clin. or lab. measurements.  Results In total, 507 patients received treatment.  ACR20 response rates at week 12/ET were significantly higher in the peficitinib 100 mg (57.7%) and 150 mg (74.5%) groups vs. placebo (30.7%) (p<0.001).  ACR50/70 response rates were also higher for both peficitinib doses vs. placebo.  Improvements in ACR response were maintained until week 52.  Changes from baseline in DAS28-C-reactive protein/ erythrocyte sedimentation rate and the ACR core set were significantly greater for both peficitinib doses vs. placebo at week 12/ET (p<0.001).  AE incidence was similar across treatment arms.  Incidence of serious infection and herpes zoster-related disease was higher with peficitinib vs. placebo, but with no clear dosedependent increase.  Conclusions In patients with RA and inadequate response to DMARDs, peficitinib 100 mg once daily or 150 mg once daily was efficacious in reducing RA symptoms and was well tolerated compared with placebo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDAebqPwKbebVg90H21EOLACvtfcHk0lhQqNZ38EEDBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXktVSqu7k%253D&md5=c4ccdebb71ae698e654b57fee74c0ce5</span></div><a href="/servlet/linkout?suffix=cit111a&amp;dbid=16384&amp;doi=10.1136%2Fannrheumdis-2019-215163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fannrheumdis-2019-215163%26sid%3Dliteratum%253Aachs%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DTakeuchi%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DS.%26aulast%3DKawakami%26aufirst%3DA.%26aulast%3DIwasaki%26aufirst%3DM.%26aulast%3DSong%26aufirst%3DY.%2BW.%26aulast%3DChen%26aufirst%3DY.-H.%26aulast%3DWei%26aufirst%3DJ.%2BC.-C.%26aulast%3DLee%26aufirst%3DS.-H.%26aulast%3DRokuda%26aufirst%3DM.%26aulast%3DIzutsu%26aufirst%3DH.%26aulast%3DUshijima%26aufirst%3DS.%26aulast%3DKaneko%26aufirst%3DY.%26aulast%3DAkazawa%26aufirst%3DR.%26aulast%3DShiomi%26aufirst%3DT.%26aulast%3DYamada%26aufirst%3DE.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Peficitinib%2520%2528ASP015K%2529%2520in%2520Patients%2520with%2520Rheumatoid%2520Arthritis%2520and%2520an%2520Inadequate%2520Response%2520to%2520Conventional%2520DMARDs%253A%2520A%2520Randomised%252C%2520Double-Blind%252C%2520Placebo-Controlled%2520Phase%2520III%2520Trial%2520%2528RAJ3%2529%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2019%26volume%3D78%26spage%3D1320%26epage%3D1332%26doi%3D10.1136%2Fannrheumdis-2019-215163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit111b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawakami, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwasaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katayama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rokuda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izutsu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ushijima, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaneko, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiomi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Der Heijde, D.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety of Peficitinib (ASP015K) in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III Randomised, Double-Blind, Placebo-Controlled Trial (RAJ4) in Japan</span>. <i>Ann. Rheum. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">1305</span>– <span class="NLM_lpage">1319</span>, <span class="refDoi"> DOI: 10.1136/annrheumdis-2019-215164</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1136%2Fannrheumdis-2019-215164" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31350269" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BB3cXktVSqu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2019&pages=1305-1319&author=T.+Takeuchiauthor=Y.+Tanakaauthor=S.+Tanakaauthor=A.+Kawakamiauthor=M.+Iwasakiauthor=K.+Katayamaauthor=M.+Rokudaauthor=H.+Izutsuauthor=S.+Ushijimaauthor=Y.+Kanekoauthor=T.+Shiomiauthor=E.+Yamadaauthor=D.+Van+Der+Heijde&title=Efficacy+and+Safety+of+Peficitinib+%28ASP015K%29+in+Patients+with+Rheumatoid+Arthritis+and+an+Inadequate+Response+to+Methotrexate%3A+Results+of+a+Phase+III+Randomised%2C+Double-Blind%2C+Placebo-Controlled+Trial+%28RAJ4%29+in+Japan&doi=10.1136%2Fannrheumdis-2019-215164"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111bR"><div class="casContent"><span class="casTitleNuber">111b</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomized, double-blind, placebo-controlled trial (RAJ4) in Japan</span></div><div class="casAuthors">Takeuchi, Tsutomu; Tanaka, Yoshiya; Tanaka, Sakae; Kawakami, Atsushi; Iwasaki, Manabu; Katayama, Kou; Rokuda, Mitsuhiro; Izutsu, Hiroyuki; Ushijima, Satoshi; Kaneko, Yuichiro; Shiomi, Teruaki; Yamada, Emi; Van Der Heijde, Desiree</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the Rheumatic Diseases</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1305-1319</span>CODEN:
                <span class="NLM_cas:coden">ARDIAO</span>;
        ISSN:<span class="NLM_cas:issn">0003-4967</span>.
    
            (<span class="NLM_cas:orgname">BMJ</span>)
        </div><div class="casAbstract">To evaluate the efficacy and safety of the oral Janus kinase (JAK) inhibitor peficitinib vs. placebo in Japanese patients with rheumatoid arthritis (RA).  In this multicentre, double-blind, parallel group, placebo-controlled phase III study, patients with RA and inadequate response to methotrexate (MTX) were randomized 1:1:1 to placebo, peficitinib 100 mg once daily or peficitinib 150 mg once daily with MTX for 52 wk.  Based on baseline randomization, at week 12, non-responders receiving placebo were switched to peficitinib until the end of treatment; the remaining patients were switched to peficitinib at week 28.  Primary efficacy variables were American College of Rheumatol. (ACR)20 response rate at week 12/early termination (ET) and change from baseline in van der Heijde-modified total Sharp score (mTSS) at week 28/ET.  The 519 patients were randomized and treated.  Significantly more (p<0.001) peficitinib (58.6%, 100 mg; 64.4%, 150 mg) than placebo (21.8%) recipients achieved ACR20 response at week 12/ ET.  Significantly lower (p<0.001) mean changes from baseline in mTSS at week 28/ET occurred in peficitinib (1.62, 100 mg; 1.03, 150 mg) than placebo (3.37) recipients.  Peficitinib was assocd. with haematol. and biochem. parameter changes, and increased incidence of serious infections and herpes zoster-related disease.  One death from suicide occurred in a patient in the placebo group after switching to peficitinib 100 mg.  In Japanese patients with RA and inadequate response to MTX, peficitinib demonstrated significant superiority vs. placebo in reducing RA symptoms and suppressing joint destruction.  Peficitinib had an acceptable safety and tolerability profile, with no new safety signals compared with other JAK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomsauLdMHNw7Vg90H21EOLACvtfcHk0lhQqNZ38EEDBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXktVSqu7Y%253D&md5=1e3d6da357f25c0cb2be7220f4d77ba5</span></div><a href="/servlet/linkout?suffix=cit111b&amp;dbid=16384&amp;doi=10.1136%2Fannrheumdis-2019-215164&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fannrheumdis-2019-215164%26sid%3Dliteratum%253Aachs%26aulast%3DTakeuchi%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DTanaka%26aufirst%3DS.%26aulast%3DKawakami%26aufirst%3DA.%26aulast%3DIwasaki%26aufirst%3DM.%26aulast%3DKatayama%26aufirst%3DK.%26aulast%3DRokuda%26aufirst%3DM.%26aulast%3DIzutsu%26aufirst%3DH.%26aulast%3DUshijima%26aufirst%3DS.%26aulast%3DKaneko%26aufirst%3DY.%26aulast%3DShiomi%26aufirst%3DT.%26aulast%3DYamada%26aufirst%3DE.%26aulast%3DVan%2BDer%2BHeijde%26aufirst%3DD.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Peficitinib%2520%2528ASP015K%2529%2520in%2520Patients%2520with%2520Rheumatoid%2520Arthritis%2520and%2520an%2520Inadequate%2520Response%2520to%2520Methotrexate%253A%2520Results%2520of%2520a%2520Phase%2520III%2520Randomised%252C%2520Double-Blind%252C%2520Placebo-Controlled%2520Trial%2520%2528RAJ4%2529%2520in%2520Japan%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2019%26volume%3D78%26spage%3D1305%26epage%3D1319%26doi%3D10.1136%2Fannrheumdis-2019-215164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, G. G.</span></span> <span> </span><span class="NLM_article-title">Comparative Efficacy and Safety of Peficitinib 25, 50, 100, and 150 mg in Patients with Active Rheumatoid Arthritis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials</span>. <i>Clin. Drug Invest.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">72</span>, <span class="refDoi"> DOI: 10.1007/s40261-019-00863-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs40261-019-00863-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31602572" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFCkt7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2020&pages=65-72&author=Y.+H.+Leeauthor=G.+G.+Song&title=Comparative+Efficacy+and+Safety+of+Peficitinib+25%2C+50%2C+100%2C+and+150+mg+in+Patients+with+Active+Rheumatoid+Arthritis%3A+A+Bayesian+Network+Meta-Analysis+of+Randomized+Controlled+Trials&doi=10.1007%2Fs40261-019-00863-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative Efficacy and Safety of Peficitinib 25, 50, 100, and 150 mg in Patients with Active Rheumatoid Arthritis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials</span></div><div class="casAuthors">Lee, Young Ho; Song, Gwan Gyu</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Drug Investigation</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">65-72</span>CODEN:
                <span class="NLM_cas:coden">CDINFR</span>;
        ISSN:<span class="NLM_cas:issn">1173-2563</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Background and Objective: Peficitinib, a JAK3-selective inhibitor that blocks the signal transduction and then suppresses immune responses, has been developed for the treatment of patients with moderate to severe active rheumatoid arthritis (RA).  We assessed the relative efficacy and safety of once-daily administration of peficitinib (a JAK3-selective inhibitor) 25 mg, 50 mg, 100 mg, and 150 mg in patients with active RA.  Methods: A Bayesian network meta-anal. was conducted to combine direct and indirect evidence from eligible randomized controlled trials (RCTs).  The literature search was performed up to May 2019 using MEDLINE, Embase, and the Cochrane Controlled Trials Register.  Results: Three RCTs involving 948 patients met the inclusion criteria.  There were ten pairwise comparisons, including five direct comparisons and five interventions.  The American College of Rheumatol. 20% (ACR20) response rate was significantly higher in the peficitinib 150-mg group than in the placebo group (odds ratio (OR): 3.61; 95% credible interval (CrI): 2.35-5.57).  Similarly, the ACR20 response rate was significantly higher in the peficitinib 100-mg group than in the placebo group (OR: 2.33, 95% CrI: 1.51-3.56).  The peficitinib 50-mg group had a significantly higher ACR20 response rate than the placebo group.  However, the ACR20 response rate was not significantly higher in the peficitinib 25-mg group than in the placebo group.  The ranking probability based on the surface under the cumulative ranking curve (SUCRA) indicated that peficitinib 150 mg was likely to achieve the best ACR20 response rate (SUCRA = 0.995), followed by peficitinib 100 mg (SUCRA = 0.696), peficitinib 50 mg (SUCRA = 0.558), peficitinib 25 mg (SUCRA = 0.153), and placebo (SUCRA = 0.098).  The ACR50 and ACR70 response rates showed a similar distribution pattern to the ACR20 response rate.  The difference in the no. of patients with adverse events (AEs) among the intervention groups was not statistically significant.  Conclusions: Peficitinib 50, 100, and 150 mg once daily was effective in treating active RA, without causing a significant risk for AEs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozk8cPRSzjSrVg90H21EOLACvtfcHk0lhQqNZ38EEDBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFCkt7bK&md5=44afac47286da7a1a8c31313ab7f3151</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1007%2Fs40261-019-00863-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40261-019-00863-9%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DY.%2BH.%26aulast%3DSong%26aufirst%3DG.%2BG.%26atitle%3DComparative%2520Efficacy%2520and%2520Safety%2520of%2520Peficitinib%252025%252C%252050%252C%2520100%252C%2520and%2520150%2520mg%2520in%2520Patients%2520with%2520Active%2520Rheumatoid%2520Arthritis%253A%2520A%2520Bayesian%2520Network%2520Meta-Analysis%2520of%2520Randomized%2520Controlled%2520Trials%26jtitle%3DClin.%2520Drug%2520Invest.%26date%3D2020%26volume%3D40%26spage%3D65%26epage%3D72%26doi%3D10.1007%2Fs40261-019-00863-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, T.</span>; <span class="NLM_string-name">Tanaka, A.</span>; <span class="NLM_string-name">Nakai, K.</span>; <span class="NLM_string-name">Sasaki, H.</span>; <span class="NLM_string-name">Takahashi, F.</span>; <span class="NLM_string-name">Shirakami, S.</span>; <span class="NLM_string-name">Hatanaka, K.</span>; <span class="NLM_string-name">Nakajima, Y.</span>; <span class="NLM_string-name">Mukoyoshi, K.</span>; <span class="NLM_string-name">Hamaguchi, H.</span>; <span class="NLM_string-name">Kunikawa, S.</span>; <span class="NLM_string-name">Higashi, Y.</span></span> <span> </span><span class="NLM_article-title">Preparation of Heterocyclic Compounds as Janus Kinase 3 Inhibitors</span>. <span class="NLM_patent">WO 2007077949 A1</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=T.+Inoue&author=A.+Tanaka&author=K.+Nakai&author=H.+Sasaki&author=F.+Takahashi&author=S.+Shirakami&author=K.+Hatanaka&author=Y.+Nakajima&author=K.+Mukoyoshi&author=H.+Hamaguchi&author=S.+Kunikawa&author=Y.+Higashi&title=Preparation+of+Heterocyclic+Compounds+as+Janus+Kinase+3+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit113a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DInoue%26aufirst%3DT.%26atitle%3DPreparation%2520of%2520Heterocyclic%2520Compounds%2520as%2520Janus%2520Kinase%25203%2520Inhibitors%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit113b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Nakajima, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tojo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatanaka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirakami, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukoyoshi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamaguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moritomo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, T.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Evaluation of 1<i>H</i>-Pyrrolo[2,3-<i>b</i>]Pyridine Derivatives as Novel Immunomodulators Targeting Janus Kinase 3</span>. <i>Chem. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">341</span>– <span class="NLM_lpage">353</span>, <span class="refDoi"> DOI: 10.1248/cpb.c15-00036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1248%2Fcpb.c15-00036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=25786493" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlCns7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2015&pages=341-353&author=Y.+Nakajimaauthor=T.+Tojoauthor=M.+Moritaauthor=K.+Hatanakaauthor=S.+Shirakamiauthor=A.+Tanakaauthor=H.+Sasakiauthor=K.+Nakaiauthor=K.+Mukoyoshiauthor=H.+Hamaguchiauthor=F.+Takahashiauthor=A.+Moritomoauthor=Y.+Higashiauthor=T.+Inoue&title=Synthesis+and+Evaluation+of+1H-Pyrrolo%5B2%2C3-b%5DPyridine+Derivatives+as+Novel+Immunomodulators+Targeting+Janus+Kinase+3&doi=10.1248%2Fcpb.c15-00036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113bR"><div class="casContent"><span class="casTitleNuber">113b</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of 1H-pyrrolo[2,3-b]pyridine derivatives as novel immunomodulators targeting Janus kinase 3</span></div><div class="casAuthors">Nakajima, Yutaka; Tojo, Takashi; Morita, Masataka; Hatanaka, Keiko; Shirakami, Shohei; Tanaka, Akira; Sasaki, Hiroshi; Nakai, Kazuo; Mukoyoshi, Koichiro; Hamaguchi, Hisao; Takahashi, Fumie; Moritomo, Ayako; Higashi, Yasuyuki; Inoue, Takayuki</div><div class="citationInfo"><span class="NLM_cas:title">Chemical & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">341-353</span>CODEN:
                <span class="NLM_cas:coden">CPBTAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-2363</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">A series of 1H-pyrrolo[2,3-b]pyridine derivs. I [R = H, Me, c-Hex, Ph; R1 = NHCH(CH2CH3)2, piperidin-1-yl, ((1S,2R)-2-methylcyclohexyl)aminyl, cyclohexylaminyl, etc.] as novel immunomodulators targeting JAK3 for use in treating immune diseases such as organ transplantation has been described.  In the chem. modification of N-cyclohexyl-N-methyl-1H-pyrrolo[2,3-b]pyridin-4-amine, the introduction of a carbamoyl group to the C5-position and substitution of a cyclohexylamino group at the C4-position of the 1H-pyrrolo[2,3-b]pyridine ring led to a large increase in JAK3 inhibitory activity.  Compd. I [R = H, R1 = ((1S,2R)-2-methylcyclohexyl)aminyl] was identified as a potent, moderately selective JAK3 inhibitor, and the immunomodulating effect of I [R = H, R1 = ((1S,2R)-2-methylcyclohexyl)aminyl] on interleukin-2-stimulated T cell proliferation was shown.  Docking calcns. and WaterMap anal. of the 1H-pyrrolo[2,3-b]pyridine-5-carboxamide derivs. I were conducted to confirm the substituent effects on JAK3 inhibitory activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqu2gjDw0D-L7Vg90H21EOLACvtfcHk0lhLi5XBo50i6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlCns7rF&md5=63a1e935c4507ce9e679c94eaed58b3c</span></div><a href="/servlet/linkout?suffix=cit113b&amp;dbid=16384&amp;doi=10.1248%2Fcpb.c15-00036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fcpb.c15-00036%26sid%3Dliteratum%253Aachs%26aulast%3DNakajima%26aufirst%3DY.%26aulast%3DTojo%26aufirst%3DT.%26aulast%3DMorita%26aufirst%3DM.%26aulast%3DHatanaka%26aufirst%3DK.%26aulast%3DShirakami%26aufirst%3DS.%26aulast%3DTanaka%26aufirst%3DA.%26aulast%3DSasaki%26aufirst%3DH.%26aulast%3DNakai%26aufirst%3DK.%26aulast%3DMukoyoshi%26aufirst%3DK.%26aulast%3DHamaguchi%26aufirst%3DH.%26aulast%3DTakahashi%26aufirst%3DF.%26aulast%3DMoritomo%26aufirst%3DA.%26aulast%3DHigashi%26aufirst%3DY.%26aulast%3DInoue%26aufirst%3DT.%26atitle%3DSynthesis%2520and%2520Evaluation%2520of%25201H-Pyrrolo%255B2%252C3-b%255DPyridine%2520Derivatives%2520as%2520Novel%2520Immunomodulators%2520Targeting%2520Janus%2520Kinase%25203%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D2015%26volume%3D63%26spage%3D341%26epage%3D353%26doi%3D10.1248%2Fcpb.c15-00036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit113c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hamaguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amano, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moritomo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirakami, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakajima, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, T.</span></span> <span> </span><span class="NLM_article-title">Discovery and Structural Characterization of Peficitinib (ASP015K) as a Novel and Potent JAK Inhibitor</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">4971</span>– <span class="NLM_lpage">4983</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2018.08.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2Fj.bmc.2018.08.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=30145050" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFyktrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=4971-4983&author=H.+Hamaguchiauthor=Y.+Amanoauthor=A.+Moritomoauthor=S.+Shirakamiauthor=Y.+Nakajimaauthor=K.+Nakaiauthor=N.+Nomuraauthor=M.+Itoauthor=Y.+Higashiauthor=T.+Inoue&title=Discovery+and+Structural+Characterization+of+Peficitinib+%28ASP015K%29+as+a+Novel+and+Potent+JAK+Inhibitor&doi=10.1016%2Fj.bmc.2018.08.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113cR"><div class="casContent"><span class="casTitleNuber">113c</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and structural characterization of peficitinib (ASP015K) as a novel and potent JAK inhibitor</span></div><div class="casAuthors">Hamaguchi, Hisao; Amano, Yasushi; Moritomo, Ayako; Shirakami, Shohei; Nakajima, Yutaka; Nakai, Kazuo; Nomura, Naoko; Ito, Misato; Higashi, Yasuyuki; Inoue, Takayuki</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4971-4983</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Janus kinases (JAKs) are considered promising targets for the treatment of autoimmune diseases including rheumatoid arthritis (RA) due to their important role in multiple cytokine receptor signaling pathways.  Recently, several JAK inhibitors have been developed for the treatment of RA.  Here, the authors describe the identification of the novel orally bioavailable JAK inhibitor 18, peficitinib (also known as ASP015K), which showed moderate selectivity for JAK3 over JAK1, JAK2, and TYK2 in enzyme assays.  Chem. modification at the C4-position of lead compd. 5 led to a large increase in JAK inhibitory activity and metabolic stability in liver microsomes.  Furthermore, the authors detd. the crystal structures of JAK1, JAK2, JAK3, and TYK2 in a complex with peficitinib, and revealed that the 1H-pyrrolo[2,3-b]pyridine-5-carboxamide scaffold of peficitinib forms triple hydrogen bonds with the hinge region.  Interestingly, the binding modes of peficitinib in the ATP-binding pockets differed among JAK1, JAK2, JAK3, and TYK2.  WaterMap anal. of the crystal structures suggests that unfavorable water mols. are the likely reason for the difference in orientation of the 1H-pyrrolo[2,3-b]pyridine-5-carboxamide scaffold to the hinge region among JAKs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXmtQr-zPJgbVg90H21EOLACvtfcHk0lhLi5XBo50i6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFyktrnO&md5=ee50230760e7ab2300f9ccb6a42f62a8</span></div><a href="/servlet/linkout?suffix=cit113c&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2018.08.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2018.08.005%26sid%3Dliteratum%253Aachs%26aulast%3DHamaguchi%26aufirst%3DH.%26aulast%3DAmano%26aufirst%3DY.%26aulast%3DMoritomo%26aufirst%3DA.%26aulast%3DShirakami%26aufirst%3DS.%26aulast%3DNakajima%26aufirst%3DY.%26aulast%3DNakai%26aufirst%3DK.%26aulast%3DNomura%26aufirst%3DN.%26aulast%3DIto%26aufirst%3DM.%26aulast%3DHigashi%26aufirst%3DY.%26aulast%3DInoue%26aufirst%3DT.%26atitle%3DDiscovery%2520and%2520Structural%2520Characterization%2520of%2520Peficitinib%2520%2528ASP015K%2529%2520as%2520a%2520Novel%2520and%2520Potent%2520JAK%2520Inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26spage%3D4971%26epage%3D4983%26doi%3D10.1016%2Fj.bmc.2018.08.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bryan, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajapaksa, N. S.</span></span> <span> </span><span class="NLM_article-title">Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">9030</span>– <span class="NLM_lpage">9058</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00667</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00667" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVOmsLzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9030-9058&author=M.+C.+Bryanauthor=N.+S.+Rajapaksa&title=Kinase+Inhibitors+for+the+Treatment+of+Immunological+Disorders%3A+Recent+Advances&doi=10.1021%2Facs.jmedchem.8b00667"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances</span></div><div class="casAuthors">Bryan, Marian C.; Rajapaksa, Naomi S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">9030-9058</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Small mol. inhibitors targeting autoimmune and inflammatory processes have been an area of intense focus within academia and industry.  Much of this work has been aimed at key kinases operating as central nodes in inflammatory signaling pathways.  While this focus has led to over 30 FDA-approved small mol. kinase inhibitors, only one is currently approved for autoimmune and inflammatory diseases.  Despite this lack of success, there remains tremendous reason for excitement.  Our growing understanding of the biol. involved in the inflammatory response, the factors that lead to safer small mol. kinase inhibitors, and the availability of selective tool mols. for interrogating specific nodes and pathways are all pushing the field forward.  This article focuses on recent developments requiring novel approaches to create safe and effective small mol. kinase inhibitors and where further work is needed to realize the promise of small mol. kinase inhibitors for patient benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVucOE4LCJALVg90H21EOLACvtfcHk0lgQdScaGk2SiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVOmsLzI&md5=aff62adff54c9152d2b2156b05d67400</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00667&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00667%26sid%3Dliteratum%253Aachs%26aulast%3DBryan%26aufirst%3DM.%2BC.%26aulast%3DRajapaksa%26aufirst%3DN.%2BS.%26atitle%3DKinase%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520Immunological%2520Disorders%253A%2520Recent%2520Advances%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D9030%26epage%3D9058%26doi%3D10.1021%2Facs.jmedchem.8b00667" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duggan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keam, S. J.</span></span> <span> </span><span class="NLM_article-title">Upadacitinib: First Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">1819</span>– <span class="NLM_lpage">1828</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01211-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs40265-019-01211-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31642025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A280%3ADC%252BB3MjgvVSrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=1819-1828&author=S.+Dugganauthor=S.+J.+Keam&title=Upadacitinib%3A+First+Approval&doi=10.1007%2Fs40265-019-01211-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Upadacitinib: First Approval</span></div><div class="casAuthors">Duggan Sean; Keam Susan J</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1819-1828</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Upadacitinib (Rinvoq®), an orally-administered Janus kinase 1 (JAK-1) inhibitor, is being developed by AbbVie for the treatment of rheumatoid arthritis.  In August 2019, based on positive results from multinational phase III trials conducted in patients with rheumatoid arthritis, upadacitinib received marketing approval in the USA for the treatment of moderately to severely active rheumatoid arthritis and an inadequate response or intolerance to methotrexate.  This article summarizes the milestones in the development of upadacitinib leading to this first approval for the treatment of rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRfxtr5CsQWZxWfpMXQLRstfW6udTcc2eYd-wPser7e6Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MjgvVSrtg%253D%253D&md5=3ef93907bbec16e744d0fb2b6dae65e0</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01211-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01211-z%26sid%3Dliteratum%253Aachs%26aulast%3DDuggan%26aufirst%3DS.%26aulast%3DKeam%26aufirst%3DS.%2BJ.%26atitle%3DUpadacitinib%253A%2520First%2520Approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D1819%26epage%3D1828%26doi%3D10.1007%2Fs40265-019-01211-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matteson, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murad, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vassallo, R.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety of Tofacitinib, Baricitinib, and Upadacitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis</span>. <i>Mayo Clin. Proc.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">P1404</span>– <span class="NLM_lpage">P1419</span>, <span class="refDoi"> DOI: 10.1016/j.mayocp.2020.01.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2Fj.mayocp.2020.01.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=32499126" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BB3cXksVyhur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2020&pages=P1404-P1419&author=F.+Wangauthor=L.+Sunauthor=S.+Wangauthor=J.+M.+Davisauthor=E.+L.+Mattesonauthor=M.+H.+Muradauthor=F.+Luoauthor=R.+Vassallo&title=Efficacy+and+Safety+of+Tofacitinib%2C+Baricitinib%2C+and+Upadacitinib+for+Rheumatoid+Arthritis%3A+A+Systematic+Review+and+Meta-Analysis&doi=10.1016%2Fj.mayocp.2020.01.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and Safety of Tofacitinib, Baricitinib, and Upadacitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis</span></div><div class="casAuthors">Wang, Faping; Sun, Ling; Wang, Shaohua; Davis, John M., III; Matteson, Eric L.; Murad, M. Hassan; Luo, Fengming; Vassallo, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Mayo Clinic Proceedings</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1404-1419</span>CODEN:
                <span class="NLM_cas:coden">MACPAJ</span>;
        ISSN:<span class="NLM_cas:issn">0025-6196</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Meta-Anal.  To assess the efficacy and safety profiles of different dosing regimens of tofacitinib, baricitinib, and upadacitinib, novel selective oral Janus activated kinase inhibitors, in rheumatoid arthritis (RA).Randomized controlled trials of tofacitinib (5 and 10 mg twice daily) baricitinib (2 and 4 mg daily), and upadacitinib (15 and 30 mg daily) in RA were identified from MEDLINE, EMBASE, and Cochrane databases through Dec. 11, 2019.  Random-effects models were used to est. pooled mean differences and relative risks (RRs).  American College of Rheumatol. 20%, Health Assessment Questionnaire-Disability Index, adverse events, risk for infection, venous thromboembolic events, and malignancy were calcd.Twenty trials with an overall low risk of bias involving 8982 patients were identified.  Tofacitinib, baricitinib, and upadacitinib improved RA control as detd. by American College of Rheumatol. 20% (RR, 2.03; 95% CI, 1.87 to 2.20) and Health Assessment Questionnaire-Disability Index scores (mean differences, -0.31; 95% CI, -0.34 to -0.28) compared with placebo.  Data for venous thromboembolic events were not available for tofacitinib or baricitinib, but there was no increase in risk with upadacitinib (15 mg daily: RR, 2.34; 95% CI, 0.34 to 15.92).Tofacitinib, baricitinib, and upadacitinib significantly improve RA control.  Head-to-head Janus activated kinase inhibitor clin. trials are needed to further inform decision making.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPUHOp3UYN_7Vg90H21EOLACvtfcHk0lgQdScaGk2SiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXksVyhur4%253D&md5=6c9a72b336492abe2fb16e80384b3a66</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1016%2Fj.mayocp.2020.01.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mayocp.2020.01.039%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DF.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DDavis%26aufirst%3DJ.%2BM.%26aulast%3DMatteson%26aufirst%3DE.%2BL.%26aulast%3DMurad%26aufirst%3DM.%2BH.%26aulast%3DLuo%26aufirst%3DF.%26aulast%3DVassallo%26aufirst%3DR.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Tofacitinib%252C%2520Baricitinib%252C%2520and%2520Upadacitinib%2520for%2520Rheumatoid%2520Arthritis%253A%2520A%2520Systematic%2520Review%2520and%2520Meta-Analysis%26jtitle%3DMayo%2520Clin.%2520Proc.%26date%3D2020%26volume%3D95%26spage%3DP1404%26epage%3DP1419%26doi%3D10.1016%2Fj.mayocp.2020.01.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211675s000lbl.pdf" class="extLink">https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211675s000lbl.pdf</a> (accessed 2020-09-15).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2019%2F211675s000lbl.pdf+%28accessed+2020-09-15%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parmentier, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graff, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argiriadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camp, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padley, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyland, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosebraugh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wishart, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, A. J.</span></span> <span> </span><span class="NLM_article-title">In Vitro and in Vivo Characterization of the JAK1 Selectivity of Upadacitinib (ABT-494)</span>. <i>BMC Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">23</span>, <span class="refDoi"> DOI: 10.1186/s41927-018-0031-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1186%2Fs41927-018-0031-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=30886973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A280%3ADC%252BB3cbls1ymuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2018&pages=23&author=J.+M.+Parmentierauthor=J.+Vossauthor=C.+Graffauthor=A.+Schwartzauthor=M.+Argiriadiauthor=M.+Friedmanauthor=H.+S.+Campauthor=R.+J.+Padleyauthor=J.+S.+Georgeauthor=D.+Hylandauthor=M.+Rosebraughauthor=N.+Wishartauthor=L.+Olsonauthor=A.+J.+Long&title=In+Vitro+and+in+Vivo+Characterization+of+the+JAK1+Selectivity+of+Upadacitinib+%28ABT-494%29&doi=10.1186%2Fs41927-018-0031-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)</span></div><div class="casAuthors">Parmentier Julie M; Voss Jeff; Graff Candace; Schwartz Annette; Argiriadi Maria; Friedman Michael; George Jonathan S; Hyland Deborah; Wishart Neil; Olson Lisa; Long Andrew J; Camp Heidi S; Padley Robert J; Rosebraugh Matthew</div><div class="citationInfo"><span class="NLM_cas:title">BMC rheumatology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">23</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Background:  Anti-cytokine therapies such as adalimumab, tocilizumab, and the small molecule JAK inhibitor tofacitinib have proven that cytokines and their subsequent downstream signaling processes are important in the pathogenesis of rheumatoid arthritis.  Tofacitinib, a pan-JAK inhibitor, is the first approved JAK inhibitor for the treatment of RA and has been shown to be effective in managing disease.  However, in phase 2 dose-ranging studies tofacitinib was associated with dose-limiting tolerability and safety issues such as anemia.  Upadacitinib (ABT-494) is a selective JAK1 inhibitor that was engineered to address the hypothesis that greater JAK1 selectivity over other JAK family members will translate into a more favorable benefit:risk profile.  Upadacitinib selectively targets JAK1 dependent disease drivers such as IL-6 and IFNγ, while reducing effects on reticulocytes and natural killer (NK) cells, which potentially contributed to the tolerability issues of tofacitinib.  Methods:  Structure-based hypotheses were used to design the JAK1 selective inhibitor upadacitinib.  JAK family selectivity was defined with in vitro assays including biochemical assessments, engineered cell lines, and cytokine stimulation.  In vivo selectivity was defined by the efficacy of upadacitinib and tofacitinib in a rat adjuvant induced arthritis model, activity on reticulocyte deployment, and effect on circulating NK cells.  The translation of the preclinical JAK1 selectivity was assessed in healthy volunteers using ex vivo stimulation with JAK-dependent cytokines.  Results:  Here, we show the structural basis for the JAK1 selectivity of upadacitinib, along with the in vitro JAK family selectivity profile and subsequent in vivo physiological consequences.  Upadacitinib is ~ 60 fold selective for JAK1 over JAK2, and > 100 fold selective over JAK3 in cellular assays.  While both upadacitinib and tofacitinib demonstrated efficacy in a rat model of arthritis, the increased selectivity of upadacitinib for JAK1 resulted in a reduced effect on reticulocyte deployment and NK cell depletion relative to efficacy.  Ex vivo pharmacodynamic data obtained from Phase I healthy volunteers confirmed the JAK1 selectivity of upadactinib in a clinical setting.  Conclusions:  The data presented here highlight the JAK1 selectivity of upadacinitinib and supports its use as an effective therapy for the treatment of RA with the potential for an improved benefit:risk profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRTVFFxllNWaxfKb6ELK8t0fW6udTcc2eYG4wmzSphTSLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cbls1ymuw%253D%253D&md5=5ca2dcb18a98362567d2193e858cc800</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1186%2Fs41927-018-0031-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs41927-018-0031-x%26sid%3Dliteratum%253Aachs%26aulast%3DParmentier%26aufirst%3DJ.%2BM.%26aulast%3DVoss%26aufirst%3DJ.%26aulast%3DGraff%26aufirst%3DC.%26aulast%3DSchwartz%26aufirst%3DA.%26aulast%3DArgiriadi%26aufirst%3DM.%26aulast%3DFriedman%26aufirst%3DM.%26aulast%3DCamp%26aufirst%3DH.%2BS.%26aulast%3DPadley%26aufirst%3DR.%2BJ.%26aulast%3DGeorge%26aufirst%3DJ.%2BS.%26aulast%3DHyland%26aufirst%3DD.%26aulast%3DRosebraugh%26aufirst%3DM.%26aulast%3DWishart%26aufirst%3DN.%26aulast%3DOlson%26aufirst%3DL.%26aulast%3DLong%26aufirst%3DA.%2BJ.%26atitle%3DIn%2520Vitro%2520and%2520in%2520Vivo%2520Characterization%2520of%2520the%2520JAK1%2520Selectivity%2520of%2520Upadacitinib%2520%2528ABT-494%2529%26jtitle%3DBMC%2520Rheumatol.%26date%3D2018%26volume%3D2%26spage%3D23%26doi%3D10.1186%2Fs41927-018-0031-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Allian, A.</span>; <span class="NLM_string-name">Jayanth, J.</span>; <span class="NLM_string-name">Mohamed, M.-E.</span>; <span class="NLM_string-name">Mulhern, M.</span>; <span class="NLM_string-name">Nordstroem, L. F.</span>; <span class="NLM_string-name">Othman, A.</span>; <span class="NLM_string-name">Rozema, M.</span>; <span class="NLM_string-name">Bhagavatula, L.</span>; <span class="NLM_string-name">Marroum, P. J.</span>; <span class="NLM_string-name">Mayer, P. T.</span></span> <span> </span><span class="NLM_article-title">Processes for the preparation of (3<i>S</i>,4<i>R</i>)-3-ethyl-4-(3<i>H</i>-imidazo[1,2-<i>a</i>]pyrrolo[2,3-<i>e</i>]-pyrazin-8-yl)-<i>N</i>-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof</span>. <span class="NLM_patent">WO 2017066775 A1</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=A.+Allian&author=J.+Jayanth&author=M.-E.+Mohamed&author=M.+Mulhern&author=L.+F.+Nordstroem&author=A.+Othman&author=M.+Rozema&author=L.+Bhagavatula&author=P.+J.+Marroum&author=P.+T.+Mayer&title=Processes+for+the+preparation+of+%283S%2C4R%29-3-ethyl-4-%283H-imidazo%5B1%2C2-a%5Dpyrrolo%5B2%2C3-e%5D-pyrazin-8-yl%29-N-%282%2C2%2C2-trifluoroethyl%29pyrrolidine-1-carboxamide+and+solid+state+forms+thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAllian%26aufirst%3DA.%26atitle%3DProcesses%2520for%2520the%2520preparation%2520of%2520%25283S%252C4R%2529-3-ethyl-4-%25283H-imidazo%255B1%252C2-a%255Dpyrrolo%255B2%252C3-e%255D-pyrazin-8-yl%2529-N-%25282%252C2%252C2-trifluoroethyl%2529pyrrolidine-1-carboxamide%2520and%2520solid%2520state%2520forms%2520thereof%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Larock, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yum, E. K.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Indoles Via Palladium-Catalyzed Heteroannulation of Internal Alkynes</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">6689</span>– <span class="NLM_lpage">6690</span>, <span class="refDoi"> DOI: 10.1021/ja00017a059</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja00017a059" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADyaK3MXkvFajsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=1991&pages=6689-6690&author=R.+C.+Larockauthor=E.+K.+Yum&title=Synthesis+of+Indoles+Via+Palladium-Catalyzed+Heteroannulation+of+Internal+Alkynes&doi=10.1021%2Fja00017a059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of indoles via palladium-catalyzed heteroannulation of internal alkynes</span></div><div class="casAuthors">Larock, Richard C.; Yum, Eul Kgun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6689-90</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">2,3-Disubstituted indoles are formed in high yields by the Pd-catalyzed annulation of internal alkynes by o-IC6H4NH2 and its derivs.  The reaction is highly regioselective and tolerates alkynes bearing aryl, alc. and silyl groups, as well as C:C bonds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJ_hHxDmTHKLVg90H21EOLACvtfcHk0lindgOPSQpR6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXkvFajsrs%253D&md5=498dd4febb8eba7e5903cd02b9258a16</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1021%2Fja00017a059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00017a059%26sid%3Dliteratum%253Aachs%26aulast%3DLarock%26aufirst%3DR.%2BC.%26aulast%3DYum%26aufirst%3DE.%2BK.%26atitle%3DSynthesis%2520of%2520Indoles%2520Via%2520Palladium-Catalyzed%2520Heteroannulation%2520of%2520Internal%2520Alkynes%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1991%26volume%3D113%26spage%3D6689%26epage%3D6690%26doi%3D10.1021%2Fja00017a059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van Epps, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiamengo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edmunds, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ericsson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frank, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goedken, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotecki, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morytko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shekhar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skinner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wishart, N.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Tricyclic Cores for Kinase Inhibition</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">693</span>– <span class="NLM_lpage">698</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.11.108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2Fj.bmcl.2012.11.108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=23265875" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVyiurbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=693-698&author=S.+Van+Eppsauthor=B.+Fiamengoauthor=J.+Edmundsauthor=A.+Ericssonauthor=K.+Frankauthor=M.+Friedmanauthor=D.+Georgeauthor=J.+Georgeauthor=E.+Goedkenauthor=B.+Koteckiauthor=G.+Martinezauthor=P.+Mertaauthor=M.+Morytkoauthor=S.+Shekharauthor=B.+Skinnerauthor=K.+Stewartauthor=J.+Vossauthor=G.+Wallaceauthor=L.+Wangauthor=L.+Wangauthor=N.+Wishart&title=Design+and+Synthesis+of+Tricyclic+Cores+for+Kinase+Inhibition&doi=10.1016%2Fj.bmcl.2012.11.108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of tricyclic cores for kinase inhibition</span></div><div class="casAuthors">Van Epps, Stacy; Fiamengo, Bryan; Edmunds, Jeremy; Ericsson, Anna; Frank, Kristine; Friedman, Michael; George, Dawn; George, Jonathan; Goedken, Eric; Kotecki, Brian; Martinez, Gloria; Merta, Philip; Morytko, Michael; Shekhar, Shashank; Skinner, Barbara; Stewart, Kent; Voss, Jeffrey; Wallace, Grier; Wang, Lu; Wishart, Neil</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">693-698</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Interest in therapeutic kinase inhibitors continues to grow beyond success in oncol.  To date, ATP-mimetic kinase inhibitors have focused primarily on monocyclic and bicyclic heterocyclic cores.  We sought to expand on the repertoire of potential cores for kinase inhibition by exploring tricyclic variants of classical bicyclic hinge binding motifs such as pyrrolopyridine and pyrrolopyrazine.  Herein we describe the syntheses of eight alternative tricyclic cores as well as in vitro screening results for representative kinases of potential therapeutic interest.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpw43t_VvXMbbVg90H21EOLACvtfcHk0lindgOPSQpR6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVyiurbJ&md5=59cb993b841a73569309f0fca703b4c4</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.11.108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.11.108%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BEpps%26aufirst%3DS.%26aulast%3DFiamengo%26aufirst%3DB.%26aulast%3DEdmunds%26aufirst%3DJ.%26aulast%3DEricsson%26aufirst%3DA.%26aulast%3DFrank%26aufirst%3DK.%26aulast%3DFriedman%26aufirst%3DM.%26aulast%3DGeorge%26aufirst%3DD.%26aulast%3DGeorge%26aufirst%3DJ.%26aulast%3DGoedken%26aufirst%3DE.%26aulast%3DKotecki%26aufirst%3DB.%26aulast%3DMartinez%26aufirst%3DG.%26aulast%3DMerta%26aufirst%3DP.%26aulast%3DMorytko%26aufirst%3DM.%26aulast%3DShekhar%26aufirst%3DS.%26aulast%3DSkinner%26aufirst%3DB.%26aulast%3DStewart%26aufirst%3DK.%26aulast%3DVoss%26aufirst%3DJ.%26aulast%3DWallace%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWishart%26aufirst%3DN.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Tricyclic%2520Cores%2520for%2520Kinase%2520Inhibition%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D693%26epage%3D698%26doi%3D10.1016%2Fj.bmcl.2012.11.108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schaefer, J. P.</span>; <span class="NLM_string-name">Bloomfield, J. J.</span></span> <span> </span><span class="NLM_article-title">The Dieckmann Condensation (Including the Thorpe-Ziegler Condensation)</span>. In  <i>Organic Reactions</i>; <span class="NLM_publisher-name">John Wiley & Sons</span>: <span class="NLM_publisher-loc">Somerset, NJ</span>, <span class="NLM_year">2011</span>; pp  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">203</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1002%2F0471264180.or015.01" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&pages=1-203&author=J.+P.+Schaefer&author=J.+J.+Bloomfield&title=Organic+Reactions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1002%2F0471264180.or015.01&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F0471264180.or015.01%26sid%3Dliteratum%253Aachs%26aulast%3DSchaefer%26aufirst%3DJ.%2BP.%26atitle%3DThe%2520Dieckmann%2520Condensation%2520%2528Including%2520the%2520Thorpe-Ziegler%2520Condensation%2529%26btitle%3DOrganic%2520Reactions%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%26date%3D2011%26spage%3D1%26epage%3D203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tellers, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McWilliams, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphrey, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Journet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMichele, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinksmon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKeown, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tillyer, R. D.</span></span> <span> </span><span class="NLM_article-title">On the Mechanism of an Asymmetric α,β-Unsaturated Carboxylic Acid Hydrogenation: Application to the Synthesis of a PGD2 Receptor Antagonist</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">17063</span>– <span class="NLM_lpage">17073</span>, <span class="refDoi"> DOI: 10.1021/ja0623358</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja0623358" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht12ls7nF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2006&pages=17063-17073&author=D.+M.+Tellersauthor=J.+C.+McWilliamsauthor=G.+Humphreyauthor=M.+Journetauthor=L.+DiMicheleauthor=J.+Hinksmonauthor=A.+E.+McKeownauthor=T.+Rosnerauthor=Y.+Sunauthor=R.+D.+Tillyer&title=On+the+Mechanism+of+an+Asymmetric+%CE%B1%2C%CE%B2-Unsaturated+Carboxylic+Acid+Hydrogenation%3A+Application+to+the+Synthesis+of+a+PGD2+Receptor+Antagonist&doi=10.1021%2Fja0623358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">On the Mechanism of an Asymmetric α,β-Unsaturated Carboxylic Acid Hydrogenation: Application to the Synthesis of a PGD2 Receptor Antagonist</span></div><div class="casAuthors">Tellers, David M.; McWilliams, J. Christopher; Humphrey, Guy; Journet, Michel; DiMichele, Lisa; Hinksmon, Joseph; McKeown, Arlene E.; Rosner, Thorsten; Sun, Yongkui; Tillyer, Richard D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">17063-17073</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Ruthenium complexes employing axially chiral ligands were found to be effective asym. hydrogenation catalysts for the redn. of α,β-unsatd. ene acid I to give II, a prostaglandin D2 (PGD2) receptor antagonist.  With [(S-BINAP)Ru(p-cymene)Cl2]2 (III, S-BINAP = (S)-(+)-2,2'-bis(diphenylphospino)-1,1'-binaphthyl), it was discovered that low hydrogen pressures (<30 psi) were essential to achieve high enantioselectivities (92% ee).  A detailed mechanistic study was undertaken to elucidate this pressure dependence.  It was detd. that compd. I is in a ruthenium-catalyzed equil. with endocyclic isomer IV and in photochem. equil. with the Z isomer.  Each isomer could be hydrogenated to give II, albeit with different rates and enantioselectivities.  Hydrogenation of IV with III was found to give II in high enantiomeric excess, regardless of pressure and at a rate substantially faster than that of hydrogenation of I and its Z-isomer.  In contrast, isomers I and the Z-isomer exhibited pressure-dependent enantioselectivities, with higher enantiomeric excesses obtained at lower pressures.  A rationale for this pressure dependence is described.  Deuterium labeling studies with IV and tiglic acid were used to elucidate the mechanism of hydride insertion and product release from ruthenium.  Under neutral conditions, protonolysis was the major pathway for metal-carbon cleavage, while under basic conditions, hydrogenolysis of the metal-carbon bond was predominant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoK672H_nH_e7Vg90H21EOLACvtfcHk0ljIGRw3Z2lFeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht12ls7nF&md5=772b115c9de846aa8b33bebe0c70d6da</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1021%2Fja0623358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja0623358%26sid%3Dliteratum%253Aachs%26aulast%3DTellers%26aufirst%3DD.%2BM.%26aulast%3DMcWilliams%26aufirst%3DJ.%2BC.%26aulast%3DHumphrey%26aufirst%3DG.%26aulast%3DJournet%26aufirst%3DM.%26aulast%3DDiMichele%26aufirst%3DL.%26aulast%3DHinksmon%26aufirst%3DJ.%26aulast%3DMcKeown%26aufirst%3DA.%2BE.%26aulast%3DRosner%26aufirst%3DT.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DTillyer%26aufirst%3DR.%2BD.%26atitle%3DOn%2520the%2520Mechanism%2520of%2520an%2520Asymmetric%2520%25CE%25B1%252C%25CE%25B2-Unsaturated%2520Carboxylic%2520Acid%2520Hydrogenation%253A%2520Application%2520to%2520the%2520Synthesis%2520of%2520a%2520PGD2%2520Receptor%2520Antagonist%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2006%26volume%3D128%26spage%3D17063%26epage%3D17073%26doi%3D10.1021%2Fja0623358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Corey, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaykovsky, M.</span></span> <span> </span><span class="NLM_article-title">Dimethylsulfoxonium Methylide</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1962</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">867</span>– <span class="NLM_lpage">868</span>, <span class="refDoi"> DOI: 10.1021/ja00864a040</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja00864a040" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADyaF38XktVelt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=1962&pages=867-868&author=E.+J.+Coreyauthor=M.+Chaykovsky&title=Dimethylsulfoxonium+Methylide&doi=10.1021%2Fja00864a040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Dimethylsulfoxonium methylide</span></div><div class="casAuthors">Corey, E. J.; Chaykovsky, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1962</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">867-8</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">Solns. of the title compd., Me2S(O)CH2 (I), were prepd. by adding 1 equiv. of powd. NaH to Me3SOCl in Me2SO at room temp.  I reacts with Ph2CO, BzH, 4-phenylcyclohexanone, and cycloheptanone to produce the corresponding methylene epoxide in 90, 56, 72, and 71% yield, resp.  PhCH2COPh and 4-cholestenone are not attacked by I.  PhCH:CHBz and I react to form 95% 2-phenyl-2-benzoylcyclopropane.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKJ5faQzZazLVg90H21EOLACvtfcHk0ljIGRw3Z2lFeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF38XktVelt7w%253D&md5=a0a1b8481c8c59335084926338965f50</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1021%2Fja00864a040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00864a040%26sid%3Dliteratum%253Aachs%26aulast%3DCorey%26aufirst%3DE.%2BJ.%26aulast%3DChaykovsky%26aufirst%3DM.%26atitle%3DDimethylsulfoxonium%2520Methylide%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1962%26volume%3D84%26spage%3D867%26epage%3D868%26doi%3D10.1021%2Fja00864a040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span> <span> </span><span class="NLM_article-title">Remogliflozin Etabonate: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">1157</span>– <span class="NLM_lpage">1161</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01150-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs40265-019-01150-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31201711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFyisrjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=1157-1161&author=A.+Markham&title=Remogliflozin+Etabonate%3A+First+Global+Approval&doi=10.1007%2Fs40265-019-01150-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Remogliflozin Etabonate: First Global Approval</span></div><div class="casAuthors">Markham, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1157-1161</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Remogliflozin, a selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor, which is to be administered as remogliflozin etabonate (Remo, Remozen), the prodrug for remogliflozin, recently received its first approval as a treatment for type 2 diabetes mellitus (T2DM) in India.  This article summarizes the milestones in the development of remogliflozin etabonate leading to this first approval for T2DM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0u5UfapE0prVg90H21EOLACvtfcHk0ljIGRw3Z2lFeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFyisrjP&md5=d599b50ff2c1d3131e7d3dbbc2ce663f</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01150-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01150-9%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26atitle%3DRemogliflozin%2520Etabonate%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D1157%26epage%3D1161%26doi%3D10.1007%2Fs40265-019-01150-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mikhail, N.</span></span> <span> </span><span class="NLM_article-title">Remogliflozin Etabonate: A Novel SGLT2 Inhibitor for Treatment of Diabetes Mellitus</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1381</span>– <span class="NLM_lpage">1387</span>, <span class="refDoi"> DOI: 10.1517/13543784.2015.1061501</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1517%2F13543784.2015.1061501" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=26288025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslWgsrrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2015&pages=1381-1387&author=N.+Mikhail&title=Remogliflozin+Etabonate%3A+A+Novel+SGLT2+Inhibitor+for+Treatment+of+Diabetes+Mellitus&doi=10.1517%2F13543784.2015.1061501"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Remogliflozin etabonate: a novel SGLT2 inhibitor for treatment of diabetes mellitus</span></div><div class="casAuthors">Mikhail, Nasser</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1381-1387</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Inhibitors of sodium-glucose co-transporter type 2 (SGLT2) represent a new class of anti-hyperglycemic agents with a unique mechanism of action.  These drugs lower blood glucose by increasing urinary glucose excretion.  Remogliflozin etabonate (RE) is a prodrug of remogliflozin, an SGLT2 inhibitor under development.  The following article reviews all of the clin. studies published regarding metab., drug interaction, safety and efficacy of RE in healthy subjects, patients with type 1 and type 2 diabetes.  Available data suggest low potential for RE to interact with other drugs affecting the P 450 system.  Compared with placebo, RE reduces Hb A1c (HbA1c) levels by an av. of 0.5 - 1.0% after 12 wk of therapy in drug-naive patients with type 2 diabetes.  Because of its relatively short half-life, RE may be slightly more effective when used twice daily than once daily.  One preliminary study also showed that RE decreased plasma glucose levels in type 1 diabetes.  Advantages of RE include modest wt. loss of ∼ 2 kg, low risk of hypoglycemia, and a trend toward decrease in blood pressure.  The commonest adverse effects of RE are genital mycotic infections, urinary tract infections, and dizziness.  However, further studies are needed to establish its long-term safety and efficacy, and to det. whether it has specific advantages over currently approved SGLT2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXbRYZ1I__ILVg90H21EOLACvtfcHk0lij_fvVi3Nnfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslWgsrrJ&md5=f32c67db6d483a6328b1828fc35d0c7b</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1517%2F13543784.2015.1061501&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2015.1061501%26sid%3Dliteratum%253Aachs%26aulast%3DMikhail%26aufirst%3DN.%26atitle%3DRemogliflozin%2520Etabonate%253A%2520A%2520Novel%2520SGLT2%2520Inhibitor%2520for%2520Treatment%2520of%2520Diabetes%2520Mellitus%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2015%26volume%3D24%26spage%3D1381%26epage%3D1387%26doi%3D10.1517%2F13543784.2015.1061501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dash, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babu, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivas, N. R.</span></span> <span> </span><span class="NLM_article-title">Comparative Pharmacokinetics of Three SGLT-2 Inhibitors Sergliflozin, Remogliflozin and Ertugliflozin: An Overview</span>. <i>Xenobiotica</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">1015</span>– <span class="NLM_lpage">1026</span>, <span class="refDoi"> DOI: 10.1080/00498254.2016.1247219</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1080%2F00498254.2016.1247219" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=27718782" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslGqsL3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2017&pages=1015-1026&author=R.+P.+Dashauthor=R.+J.+Babuauthor=N.+R.+Srinivas&title=Comparative+Pharmacokinetics+of+Three+SGLT-2+Inhibitors+Sergliflozin%2C+Remogliflozin+and+Ertugliflozin%3A+An+Overview&doi=10.1080%2F00498254.2016.1247219"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative pharmacokinetics of three SGLT-2 inhibitors sergliflozin, remogliflozin and ertugliflozin: an overview</span></div><div class="casAuthors">Dash, Ranjeet Prasad; Babu, R. Jayachandra; Srinivas, Nuggehally R.</div><div class="citationInfo"><span class="NLM_cas:title">Xenobiotica</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1015-1026</span>CODEN:
                <span class="NLM_cas:coden">XENOBH</span>;
        ISSN:<span class="NLM_cas:issn">0049-8254</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">1. Several sodium-glucose cotransporter-2 (SGLT-2) inhibitors are in clin. use for the management of type 2 diabetes.  The objectives of the current review were: (a) to provide a comparative pharmacokinetics including absorption, distribution, metab. and excretory (ADME) profiles of three SGLT-2 inhibitors namely: sergliflozin, remogliflozin and ertugliflozin; (b) to provide some perspectives on possible developmental issues.2.  Based on the half-life (t1/2) values obsd. in humans, the rank order of the three SGLT-2 inhibitors was ertugliflozin (16 h) > remogliflozin (2-4 h) > sergliflozin (1-1.5 h).  Therefore, while once a day dosing of ertugliflozin is possible, the other two drugs need to be dosed more frequently.  Perhaps, the short t1/2 of sergliflozin may have contributed for its discontinuation.3.  Although there was paucity of published data on the metab., transporter related and excretory aspects for sergliflozin, the other two drugs provided a differentiating profile.  However, the compiled data suggested that there may be a minimal or no risk of pharmacokinetic drug interaction issues assocd. with any of the reviewed drugs.4.  Because of the crowded development pipeline and approved SGLT-2 inhibitors, the safety and efficacy of sergliflozin, remogliflozin and ertugliflozin appear to be a key from differentiation perspective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxS-KdVFfEk7Vg90H21EOLACvtfcHk0lij_fvVi3Nnfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslGqsL3M&md5=5e2b9d9c4505757ebf79ab6328982091</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1080%2F00498254.2016.1247219&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00498254.2016.1247219%26sid%3Dliteratum%253Aachs%26aulast%3DDash%26aufirst%3DR.%2BP.%26aulast%3DBabu%26aufirst%3DR.%2BJ.%26aulast%3DSrinivas%26aufirst%3DN.%2BR.%26atitle%3DComparative%2520Pharmacokinetics%2520of%2520Three%2520SGLT-2%2520Inhibitors%2520Sergliflozin%252C%2520Remogliflozin%2520and%2520Ertugliflozin%253A%2520An%2520Overview%26jtitle%3DXenobiotica%26date%3D2017%26volume%3D47%26spage%3D1015%26epage%3D1026%26doi%3D10.1080%2F00498254.2016.1247219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sigafoos, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowers, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castellino, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Culp, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reese, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphreys, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussey, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor Semmes, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobbins, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polli, J. W.</span></span> <span> </span><span class="NLM_article-title">Assessment of the Drug Interaction Risk for Remogliflozin Etabonate, a Sodium-Dependent Glucose Cotransporter-2 Inhibitor: Evidence from <i>in Vitro</i>, Human Mass Balance, and Ketoconazole Interaction Studies</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">2090</span>– <span class="NLM_lpage">2101</span>, <span class="refDoi"> DOI: 10.1124/dmd.112.047258</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1124%2Fdmd.112.047258" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=22851617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFKkt73L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=2090-2101&author=J.+F.+Sigafoosauthor=G.+D.+Bowersauthor=S.+Castellinoauthor=A.+G.+Culpauthor=D.+S.+Wagnerauthor=M.+J.+Reeseauthor=J.+E.+Humphreysauthor=E.+K.+Husseyauthor=R.+L.+O%E2%80%99Connor+Semmesauthor=A.+Kapurauthor=W.+Taoauthor=R.+L.+Dobbinsauthor=J.+W.+Polli&title=Assessment+of+the+Drug+Interaction+Risk+for+Remogliflozin+Etabonate%2C+a+Sodium-Dependent+Glucose+Cotransporter-2+Inhibitor%3A+Evidence+from+in+Vitro%2C+Human+Mass+Balance%2C+and+Ketoconazole+Interaction+Studies&doi=10.1124%2Fdmd.112.047258"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Assessment of the drug interaction risk for remogliflozin etabonate, a sodium-dependent glucose cotransporter-2 inhibitor: evidence from in vitro, human mass balance, and ketoconazole interaction studies</span></div><div class="casAuthors">Sigafoos, James F.; Bowers, Gary D.; Castellino, Stephen; Culp, Amanda G.; Wagner, David S.; Reese, Melinda J.; Humphreys, Joan E.; Hussey, Elizabeth K.; Semmes, Robin L. O'Connor; Kapur, Anita; Tao, Wenli; Dobbins, Robert L.; Polli, Joseph W.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2090-2101</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Remogliflozin etabonate is the ester prodrug of remogliflozin, a selective sodium-dependent glucose cotransporter-2 inhibitor.  This work investigated the absorption, metab., and excretion of [14C]remogliflozin etabonate in humans, as well as the influence of P-glycoprotein (Pgp) and cytochrome P 450 (P 450) enzymes on the disposition of remogliflozin etabonate and its metabolites to understand the risks for drug interactions.  After a single oral 402 ± 1.0 mg (106 ± 0.3 μCi) dose, [14C]remogliflozin etabonate is rapidly absorbed and extensively metabolized.  The area under the concn.-time curve from 0 to infinity [AUC(0-∞)] of plasma radioactivity was approx. 14-fold higher than the sum of the AUC(0-∞) of remogliflozin etabonate, remogliflozin, and 5-methyl-4-({4-[(1-methylethyl)oxy]phenyl}methyl)-1H-pyrazol-3-yl-β-D-glucopyranoside (GSK279782), a pharmacol. active N-dealkylated metabolite.  Elimination half-lives of total radioactivity, remogliflozin etabonate, and remogliflozin were 6.57, 0.39, and 1.57 h, resp.  Products of remogliflozin etabonate metab. are eliminated primarily via renal excretion, with 92.8% of the dose recovered in the urine.  Three glucuronide metabolites made up the majority of the radioactivity in plasma and represent 67.1% of the dose in urine, with 5-methyl-1-(1-methylethyl)-4-({4-[(1-methylethyl)oxy]phenyl}methyl)-1H-pyrazol-3-yl-β-D-glucopyranosiduronic acid (GSK1997711) representing 47.8% of the dose.  In vitro studies demonstrated that remogliflozin etabonate and remogliflozin are Pgp substrates, and that CYP3A4 can form GSK279782 directly from remogliflozin.  A ketoconazole clin. drug interaction study, along with the human mass balance findings, confirmed that CYP3A4 contributes less than 50% to remogliflozin metab., demonstrating that other enzyme pathways (e.g., P450s, UDP-glucuronosyltransferases, and glucosidases) make significant contributions to the drug's clearance.  Overall, these studies support a low clin. drug interaction risk for remogliflozin etabonate due to the availability of multiple biotransformation pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoCS5ji1GnebVg90H21EOLACvtfcHk0lij_fvVi3Nnfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFKkt73L&md5=e416fe362dec69d516bc6dee55988d92</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1124%2Fdmd.112.047258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.112.047258%26sid%3Dliteratum%253Aachs%26aulast%3DSigafoos%26aufirst%3DJ.%2BF.%26aulast%3DBowers%26aufirst%3DG.%2BD.%26aulast%3DCastellino%26aufirst%3DS.%26aulast%3DCulp%26aufirst%3DA.%2BG.%26aulast%3DWagner%26aufirst%3DD.%2BS.%26aulast%3DReese%26aufirst%3DM.%2BJ.%26aulast%3DHumphreys%26aufirst%3DJ.%2BE.%26aulast%3DHussey%26aufirst%3DE.%2BK.%26aulast%3DO%25E2%2580%2599Connor%2BSemmes%26aufirst%3DR.%2BL.%26aulast%3DKapur%26aufirst%3DA.%26aulast%3DTao%26aufirst%3DW.%26aulast%3DDobbins%26aufirst%3DR.%2BL.%26aulast%3DPolli%26aufirst%3DJ.%2BW.%26atitle%3DAssessment%2520of%2520the%2520Drug%2520Interaction%2520Risk%2520for%2520Remogliflozin%2520Etabonate%252C%2520a%2520Sodium-Dependent%2520Glucose%2520Cotransporter-2%2520Inhibitor%253A%2520Evidence%2520from%2520in%2520Vitro%252C%2520Human%2520Mass%2520Balance%252C%2520and%2520Ketoconazole%2520Interaction%2520Studies%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2012%26volume%3D40%26spage%3D2090%26epage%3D2101%26doi%3D10.1124%2Fdmd.112.047258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dharmalingam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aravind, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thacker, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paramesh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chawla, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asirvatham, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goyal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shembalkar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balamurugan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadam, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alva, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kodgule, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tandon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaidyanathan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pendse, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaikwad, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katare, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suryawanshi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barkate, H.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">587</span>– <span class="NLM_lpage">600</span>, <span class="refDoi"> DOI: 10.1007/s40265-020-01285-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs40265-020-01285-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=32162274" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlslGjurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2020&pages=587-600&author=M.+Dharmalingamauthor=S.+R.+Aravindauthor=H.+Thackerauthor=S.+Parameshauthor=B.+Mohanauthor=M.+Chawlaauthor=A.+Asirvathamauthor=R.+Goyalauthor=J.+Shembalkarauthor=R.+Balamuruganauthor=P.+Kadamauthor=H.+Alvaauthor=R.+Kodguleauthor=M.+Tandonauthor=S.+Vaidyanathanauthor=A.+Pendseauthor=R.+Gaikwadauthor=S.+Katareauthor=S.+Suryawanshiauthor=H.+Barkate&title=Efficacy+and+Safety+of+Remogliflozin+Etabonate%2C+a+New+Sodium+Glucose+Co-Transporter-2+Inhibitor%2C+in+Patients+with+Type+2+Diabetes+Mellitus%3A+A+24-Week%2C+Randomized%2C+Double-Blind%2C+Active-Controlled+Trial&doi=10.1007%2Fs40265-020-01285-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial</span></div><div class="casAuthors">Dharmalingam, Mala; Aravind, S. R.; Thacker, Hemant; Paramesh, S.; Mohan, Brij; Chawla, Manoj; Asirvatham, Arthur; Goyal, Ramesh; Shembalkar, Jayashri; Balamurugan, R.; Kadam, Pradnya; Alva, Hansraj; Kodgule, Rahul; Tandon, Monika; Vaidyanathan, Sivakumar; Pendse, Amol; Gaikwad, Rajesh; Katare, Sagar; Suryawanshi, Sachin; Barkate, Hanmant</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">587-600</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Abstr.: Background: Metformin is the first-line treatment for type 2 diabetes mellitus (T2DM), but many patients either cannot tolerate it or cannot achieve glycemic control with metformin alone, so treatment with other glucose-lowering agents in combination with metformin is frequently required.  Remogliflozin etabonate, a novel agent, is an orally bioavailable prodrug of remogliflozin, which is a potent and selective sodium-glucose co-transporter-2 inhibitor.  Objective: Our objective was to evaluate the efficacy and safety of remogliflozin etabonate compared with dapagliflozin in subjects with T2DM in whom a stable dose of metformin as monotherapy was providing inadequate glycemic control.  Methods: A 24-wk randomized, double-blind, double-dummy, active-controlled, three-arm, parallel-group, multicenter, phase III study was conducted in India.  Patients aged ≥ 18 and ≤ 65 years diagnosed with T2DM, receiving metformin ≥ 1500 mg/day, and with glycated Hb (HbA1c) levels ≥ 7 to ≤ 10% at screening were randomized into three groups.  Every patient received metformin ≥ 1500 mg and either remogliflozin etabonate 100 mg twice daily (BID) (group 1, n = 225) or remogliflozin etabonate 250 mg BID (group 2, n = 241) or dapagliflozin 10 mg once daily (QD) in the morning and placebo QD in the evening (group 3, n = 146).  The patients were followed-up at weeks 1 and 4 and at 4-wk intervals thereafter until week 24.  The endpoints included mean change in HbA1c (primary endpoint, noninferiority margin = 0.35), fasting plasma glucose (FPG), postprandial plasma glucose (PPG), bodyweight, blood pressure, and fasting lipids.  Treatment-emergent adverse events (TEAEs), safety lab. values, ECG, and vital signs were evaluated.  Results: Of 612 randomized patients, 167 (group 1), 175 (group 2), and 103 (group 3) patients with comparable baseline characteristics completed the study.  Mean change ± std. error (SE) in HbA1c from baseline to week 24 was - 0.72 ± 0.09, - 0.77 ± 0.09, and - 0.58 ± 0.12% in groups 1, 2, and 3, resp.  The difference in mean HbA1c of group 1 vs. group 3 (- 0.14%, 90% confidence interval [CI] - 0.38 to 0.10) and group 2 vs. group 3 (- 0.19%; 90% CI - 0.42 to 0.05) was noninferior to that in group 3 (p < 0.001).  No significant difference was found between group 1 or group 2 and group 3 in change in FPG, PPG, and bodyweight.  The overall incidence of TEAEs was comparable across study groups (group 1 = 32.6%, group 2 = 34.4%, group 3 = 29.5%), including adverse events (AEs) of special interest (hypoglycemic events, urinary tract infection, genital fungal infection).  Most TEAEs were mild to moderate in intensity, and no severe AEs were reported.  Conclusion: This study demonstrated the noninferiority of remogliflozin etabonate 100 and 250 mg compared with dapagliflozin, from the first anal. of an initial 612 patients.  Remogliflozin etabonate therefore may be considered an effective and well-tolerated alternative treatment option for glycemic control in T2DM.  Trial Registration: CTRI/2017/07/009121.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoer0K7fLdXvrVg90H21EOLACvtfcHk0liNyjYewaeTEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlslGjurs%253D&md5=f95767947ac543a6155c276375a583fa</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1007%2Fs40265-020-01285-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-020-01285-0%26sid%3Dliteratum%253Aachs%26aulast%3DDharmalingam%26aufirst%3DM.%26aulast%3DAravind%26aufirst%3DS.%2BR.%26aulast%3DThacker%26aufirst%3DH.%26aulast%3DParamesh%26aufirst%3DS.%26aulast%3DMohan%26aufirst%3DB.%26aulast%3DChawla%26aufirst%3DM.%26aulast%3DAsirvatham%26aufirst%3DA.%26aulast%3DGoyal%26aufirst%3DR.%26aulast%3DShembalkar%26aufirst%3DJ.%26aulast%3DBalamurugan%26aufirst%3DR.%26aulast%3DKadam%26aufirst%3DP.%26aulast%3DAlva%26aufirst%3DH.%26aulast%3DKodgule%26aufirst%3DR.%26aulast%3DTandon%26aufirst%3DM.%26aulast%3DVaidyanathan%26aufirst%3DS.%26aulast%3DPendse%26aufirst%3DA.%26aulast%3DGaikwad%26aufirst%3DR.%26aulast%3DKatare%26aufirst%3DS.%26aulast%3DSuryawanshi%26aufirst%3DS.%26aulast%3DBarkate%26aufirst%3DH.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Remogliflozin%2520Etabonate%252C%2520a%2520New%2520Sodium%2520Glucose%2520Co-Transporter-2%2520Inhibitor%252C%2520in%2520Patients%2520with%2520Type%25202%2520Diabetes%2520Mellitus%253A%2520A%252024-Week%252C%2520Randomized%252C%2520Double-Blind%252C%2520Active-Controlled%2520Trial%26jtitle%3DDrugs%26date%3D2020%26volume%3D80%26spage%3D587%26epage%3D600%26doi%3D10.1007%2Fs40265-020-01285-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Swamy, V.</span>; <span class="NLM_string-name">Bhirud, S. B.</span>; <span class="NLM_string-name">Nair, R.</span>; <span class="NLM_string-name">Khemnar, E.</span>; <span class="NLM_string-name">Kadam, S.</span>; <span class="NLM_string-name">Thorat, J.</span></span> <span> </span><span class="NLM_article-title">An Improved Process for the Preparation Remogliflozin Etabonate or Pharmaceutically Acceptable Salt, Solvate, Hydrate Thereof</span>. <span class="NLM_patent">WO 2019193572</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=V.+Swamy&author=S.+B.+Bhirud&author=R.+Nair&author=E.+Khemnar&author=S.+Kadam&author=J.+Thorat&title=An+Improved+Process+for+the+Preparation+Remogliflozin+Etabonate+or+Pharmaceutically+Acceptable+Salt%2C+Solvate%2C+Hydrate+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSwamy%26aufirst%3DV.%26atitle%3DAn%2520Improved%2520Process%2520for%2520the%2520Preparation%2520Remogliflozin%2520Etabonate%2520or%2520Pharmaceutically%2520Acceptable%2520Salt%252C%2520Solvate%252C%2520Hydrate%2520Thereof%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, D. E.</span>; <span class="NLM_string-name">McClure, M. S.</span>; <span class="NLM_string-name">Powers, J. D.</span>; <span class="NLM_string-name">Crawford, C. F.</span>; <span class="NLM_string-name">Berry, M. B.</span></span> <span> </span><span class="NLM_article-title">Process for the Preparation of Glucopyranosyloxypyrazoles</span>. <span class="NLM_patent">WO 2010127067</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=D.+E.+Patterson&author=M.+S.+McClure&author=J.+D.+Powers&author=C.+F.+Crawford&author=M.+B.+Berry&title=Process+for+the+Preparation+of+Glucopyranosyloxypyrazoles"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPatterson%26aufirst%3DD.%2BE.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%2520Glucopyranosyloxypyrazoles%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit131b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, D. E.</span>; <span class="NLM_string-name">McClure, M. S.</span>; <span class="NLM_string-name">Powers, J. D.</span>; <span class="NLM_string-name">Crawford, C. F.</span>; <span class="NLM_string-name">Berry, M. B.</span></span> <span> </span><span class="NLM_article-title">Chemical Process</span>. <span class="NLM_patent">US 20120053330</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=D.+E.+Patterson&author=M.+S.+McClure&author=J.+D.+Powers&author=C.+F.+Crawford&author=M.+B.+Berry&title=Chemical+Process"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPatterson%26aufirst%3DD.%2BE.%26atitle%3DChemical%2520Process%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit131c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">McClure, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caine, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crump, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glover, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kedia, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, J.</span></span> <span> </span><span class="NLM_article-title">Highly Selective Primary Alkoxycarboxylation and Esterification of Unprotected Pyranose Derivatives Mediated by Scandium(III) Triflate Catalysis</span>. <i>Eur. J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2012</i></span>,  <span class="NLM_fpage">3561</span>– <span class="NLM_lpage">3565</span>, <span class="refDoi"> DOI: 10.1002/ejoc.201200261</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1002%2Fejoc.201200261" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC38Xms1eru7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2012&publication_year=2012&pages=3561-3565&author=M.+S.+McClureauthor=M.+B.+Berryauthor=D.+Caineauthor=C.+Crawfordauthor=B.+C.+Crumpauthor=B.+N.+Gloverauthor=S.+B.+Kediaauthor=A.+Millarauthor=M.+B.+Mitchellauthor=C.+J.+Nicholsauthor=D.+E.+Pattersonauthor=J.+Powers&title=Highly+Selective+Primary+Alkoxycarboxylation+and+Esterification+of+Unprotected+Pyranose+Derivatives+Mediated+by+Scandium%28III%29+Triflate+Catalysis&doi=10.1002%2Fejoc.201200261"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131cR"><div class="casContent"><span class="casTitleNuber">131c</span><div class="casTitle"><span class="NLM_cas:atitle">Highly Selective Primary Alkoxycarboxylation and Esterification of Unprotected Pyranose Derivatives Mediated by Scandium(III) Triflate Catalysis</span></div><div class="casAuthors">McClure, Michael S.; Berry, Malcolm B.; Caine, Darren; Crawford, Claire; Crump, Brian C.; Glover, Bobby N.; Kedia, Sandeep B.; Millar, Alan; Mitchell, Mark B.; Nichols, Christopher J.; Patterson, Daniel E.; Powers, Jeremiah</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2012</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">3561-3565, S3561/1-S3561/35</span>CODEN:
                <span class="NLM_cas:coden">EJOCFK</span>;
        ISSN:<span class="NLM_cas:issn">1099-0690</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A highly scandium(III) triflate-catalyzed regioselective alkoxycarboxylation and acylation of primary alcs. of pyranose derivs., e.g. I (R = H) gave the corresponding glycosides, e.g. I [R = C(O)OEt] in good yields, is described.  The reaction is high yielding and proceeds under mild conditions with 0.15-1 mol-% Sc(OTf)3 used in combination with anhydrides or pyro-carbonates at 40-50 °C.  Selectivities obsd. for alkoxycarboxylation of unprotected pyranose derivs. are > 95 %, and this constitutes a significant advantage over existing methods.  Mechanistic implications, including the role of steric demand and metal-heteroatom coordination are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVrN6YUmN2YLVg90H21EOLACvtfcHk0liNyjYewaeTEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xms1eru7c%253D&md5=31a64de6d81599581699e9ef2759b5e7</span></div><a href="/servlet/linkout?suffix=cit131c&amp;dbid=16384&amp;doi=10.1002%2Fejoc.201200261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejoc.201200261%26sid%3Dliteratum%253Aachs%26aulast%3DMcClure%26aufirst%3DM.%2BS.%26aulast%3DBerry%26aufirst%3DM.%2BB.%26aulast%3DCaine%26aufirst%3DD.%26aulast%3DCrawford%26aufirst%3DC.%26aulast%3DCrump%26aufirst%3DB.%2BC.%26aulast%3DGlover%26aufirst%3DB.%2BN.%26aulast%3DKedia%26aufirst%3DS.%2BB.%26aulast%3DMillar%26aufirst%3DA.%26aulast%3DMitchell%26aufirst%3DM.%2BB.%26aulast%3DNichols%26aufirst%3DC.%2BJ.%26aulast%3DPatterson%26aufirst%3DD.%2BE.%26aulast%3DPowers%26aufirst%3DJ.%26atitle%3DHighly%2520Selective%2520Primary%2520Alkoxycarboxylation%2520and%2520Esterification%2520of%2520Unprotected%2520Pyranose%2520Derivatives%2520Mediated%2520by%2520Scandium%2528III%2529%2520Triflate%2520Catalysis%26jtitle%3DEur.%2520J.%2520Org.%2520Chem.%26date%3D2012%26volume%3D2012%26spage%3D3561%26epage%3D3565%26doi%3D10.1002%2Fejoc.201200261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Deeks, E. D.</span></span> <span> </span><span class="NLM_article-title">Sotagliflozin: A Review in Type 1 Diabetes</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">1977</span>– <span class="NLM_lpage">1987</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01230-w</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs40265-019-01230-w" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31761990" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A280%3ADC%252BB3Mfis1elsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=1977-1987&author=E.+D.+Deeks&title=Sotagliflozin%3A+A+Review+in+Type+1+Diabetes&doi=10.1007%2Fs40265-019-01230-w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132aR"><div class="casContent"><span class="casTitleNuber">132a</span><div class="casTitle"><span class="NLM_cas:atitle">Sotagliflozin: A Review in Type 1 Diabetes</span></div><div class="casAuthors">Deeks Emma D</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1977-1987</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Sotagliflozin (Zynquista®) is the first dual inhibitor of sodium-glucose co-transporter-1 and -2 (SGLT1 and 2).  In the phase 3, inTANDEM 1-3 trials, adjunctive use of oral sotagliflozin (200 mg or 400 mg once daily) improved glycaemic control and reduced bodyweight and insulin requirements relative to placebo over 24 weeks of treatment in adults whose type 1 diabetes (T1D) was inadequately controlled by insulin therapy.  Similar benefits were seen with the drug in patients who were overweight/obese [i.e. body mass index (BMI) ≥ 27 kg/m(2)] in inTANDEM 1 and 2 (pooled).  The benefits of sotagliflozin were largely maintained over 52 weeks of treatment.  Overall, use of sotagliflozin in this setting is generally well tolerated and reduces, or at least does not increase, the likelihood of hypoglycaemia; however, as with other SGLT inhibitors, sotagliflozin carries a risk of diabetic ketoacidosis (DKA).  On the basis of its risk/benefit profile, sotagliflozin is indicated in the EU as an adjunct to insulin in adults with T1D with a BMI ≥ 27 kg/m(2) who have failed to achieve adequate glycaemic control despite optimal insulin therapy, thus expanding the currently limited adjunctive oral treatment options available for use in this population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT73gPAhxy4lK2q3xNe7a7QfW6udTcc2ea-OqaECfVMk7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3Mfis1elsA%253D%253D&md5=df376424720fa574b7c5f8c21e210fba</span></div><a href="/servlet/linkout?suffix=cit132a&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01230-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01230-w%26sid%3Dliteratum%253Aachs%26aulast%3DDeeks%26aufirst%3DE.%2BD.%26atitle%3DSotagliflozin%253A%2520A%2520Review%2520in%2520Type%25201%2520Diabetes%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D1977%26epage%3D1987%26doi%3D10.1007%2Fs40265-019-01230-w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit132b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Nuffer, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trujillo, J. M.</span></span> <span> </span><span class="NLM_article-title">A Review of Sotagliflozin for Use in Type 1 Diabetes</span>. <i>Ther. Adv. Endocrinol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1177/2042018819890527</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1177%2F2042018819890527" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1-12&author=W.+Nufferauthor=B.+Williamsauthor=J.+M.+Trujillo&title=A+Review+of+Sotagliflozin+for+Use+in+Type+1+Diabetes&doi=10.1177%2F2042018819890527"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit132b&amp;dbid=16384&amp;doi=10.1177%2F2042018819890527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F2042018819890527%26sid%3Dliteratum%253Aachs%26aulast%3DNuffer%26aufirst%3DW.%26aulast%3DWilliams%26aufirst%3DB.%26aulast%3DTrujillo%26aufirst%3DJ.%2BM.%26atitle%3DA%2520Review%2520of%2520Sotagliflozin%2520for%2520Use%2520in%2520Type%25201%2520Diabetes%26jtitle%3DTher.%2520Adv.%2520Endocrinol.%2520Metab.%26date%3D2019%26volume%3D10%26spage%3D1%26epage%3D12%26doi%3D10.1177%2F2042018819890527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Rendell, M. S.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety of Sotagliflozin in Treating Diabetes Type 1</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">307</span>– <span class="NLM_lpage">315</span>, <span class="refDoi"> DOI: 10.1080/14656566.2017.1414801</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1080%2F14656566.2017.1414801" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=29212386" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlOnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=307-315&author=M.+S.+Rendell&title=Efficacy+and+Safety+of+Sotagliflozin+in+Treating+Diabetes+Type+1&doi=10.1080%2F14656566.2017.1414801"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133aR"><div class="casContent"><span class="casTitleNuber">133a</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of sotagliflozin in treating diabetes type 1</span></div><div class="casAuthors">Rendell, Marc S.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">307-315</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Introduction: Sotagliflozin is the first dual SGLT1/SGLT2 inhibitor developed for use in diabetes.  Sotagliflozin blocks SGLT2 in the kidneys and SGLT1 in the intestines resulting in reduced early phase glucose absorption and increased blood levels of GLP-1 and PYY.  Urinary glucose excretion is lower than with other agents as a result of decreased glucose absorption.  The primary development effort to date has been in Type 1 diabetes.  Areas covered: The published information on sotagliflozin is reviewed, along with the recent results of several pivotal Type 1 diabetes trials.  Expert opinion: Sotagliflozin treatment lowers HbA1c and reduces glucose variability, with a trend to less hypoglycemic events.  In the Type 1 trials, sotagliflozin treated individuals experienced DKA at a higher rate than placebo treated patients.  An addnl. safety issue arises from the as yet unknown potential risks in women of child bearing potential in whom DKA is of utmost concern.  The sotagliflozin development program has now been extended to trials in Type 2 diabetes, and long term studies will be needed to assess the benefits and risks of the agent in comparison to other currently marketed SGLT2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZ8NVz2zZpYrVg90H21EOLACvtfcHk0lgItPTnS8K18A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlOnsw%253D%253D&md5=ca54a2b039a79b31639e8f28a8762fe7</span></div><a href="/servlet/linkout?suffix=cit133a&amp;dbid=16384&amp;doi=10.1080%2F14656566.2017.1414801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14656566.2017.1414801%26sid%3Dliteratum%253Aachs%26aulast%3DRendell%26aufirst%3DM.%2BS.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520Sotagliflozin%2520in%2520Treating%2520Diabetes%2520Type%25201%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2018%26volume%3D19%26spage%3D307%26epage%3D315%26doi%3D10.1080%2F14656566.2017.1414801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit133b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Cefalo, C. M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cinti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moffa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Impronta, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorice, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mezza, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pontecorvi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giaccari, A.</span></span> <span> </span><span class="NLM_article-title">Sotagliflozin, the First Dual SGLT Inhibitor: Current Outlook and Perspectives</span>. <i>Cardiovasc. Diabetol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">20</span>, <span class="refDoi"> DOI: 10.1186/s12933-019-0828-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1186%2Fs12933-019-0828-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=30819210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A280%3ADC%252BB3cfovFGqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=20&author=C.+M.+A.+Cefaloauthor=F.+Cintiauthor=S.+Moffaauthor=F.+Improntaauthor=G.+P.+Soriceauthor=T.+Mezzaauthor=A.+Pontecorviauthor=A.+Giaccari&title=Sotagliflozin%2C+the+First+Dual+SGLT+Inhibitor%3A+Current+Outlook+and+Perspectives&doi=10.1186%2Fs12933-019-0828-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133bR"><div class="casContent"><span class="casTitleNuber">133b</span><div class="casTitle"><span class="NLM_cas:atitle">Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives</span></div><div class="casAuthors">Cefalo Chiara Maria Assunta; Cinti Francesca; Moffa Simona; Impronta Flavia; Sorice Gian Pio; Mezza Teresa; Pontecorvi Alfredo; Giaccari Andrea; Cefalo Chiara Maria Assunta; Cinti Francesca; Moffa Simona; Impronta Flavia; Sorice Gian Pio; Mezza Teresa; Pontecorvi Alfredo; Giaccari Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular diabetology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">20</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Sotagliflozin is a dual sodium-glucose co-transporter-2 and 1 (SGLT2/1) inhibitor for the treatment of both type 1 (T1D) and type 2 diabetes (T2D).  Sotagliflozin inhibits renal sodium-glucose co-transporter 2 (determining significant excretion of glucose in the urine, in the same way as other, already available SGLT-2 selective inhibitors) and intestinal SGLT-1, delaying glucose absorption and therefore reducing post prandial glucose.  Well-designed clinical trials, have shown that sotagliflozin (as monotherapy or add-on therapy to other anti-hyperglycemic agents) improves glycated hemoglobin in adults with T2D, with beneficial effects on bodyweight and blood pressure.  Similar results have been obtained in adults with T1D treated with either continuous subcutaneous insulin infusion or multiple daily insulin injections, even after insulin optimization.  A still ongoing phase 3 study is currently evaluating the effect of sotagliflozin on cardiovascular outcomes (ClinicalTrials.gov NCT03315143).  In this review we illustrate the advantages and disadvantages of dual SGLT 2/1 inhibition, in order to better characterize and investigate its mechanisms of action and potentialities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT0aUujJc8o0dK0qsdY6Nc1fW6udTcc2ea-OqaECfVMk7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cfovFGqsA%253D%253D&md5=1ab51883200e473784a2ef9a79287ed7</span></div><a href="/servlet/linkout?suffix=cit133b&amp;dbid=16384&amp;doi=10.1186%2Fs12933-019-0828-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12933-019-0828-y%26sid%3Dliteratum%253Aachs%26aulast%3DCefalo%26aufirst%3DC.%2BM.%2BA.%26aulast%3DCinti%26aufirst%3DF.%26aulast%3DMoffa%26aufirst%3DS.%26aulast%3DImpronta%26aufirst%3DF.%26aulast%3DSorice%26aufirst%3DG.%2BP.%26aulast%3DMezza%26aufirst%3DT.%26aulast%3DPontecorvi%26aufirst%3DA.%26aulast%3DGiaccari%26aufirst%3DA.%26atitle%3DSotagliflozin%252C%2520the%2520First%2520Dual%2520SGLT%2520Inhibitor%253A%2520Current%2520Outlook%2520and%2520Perspectives%26jtitle%3DCardiovasc.%2520Diabetol.%26date%3D2019%26volume%3D18%26spage%3D20%26doi%3D10.1186%2Fs12933-019-0828-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit133c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Rendell, M. S.</span></span> <span> </span><span class="NLM_article-title">The Journey from Gene Knockout to Clinical Medicine: Telotristat and Sotagliflozin</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">817</span>– <span class="NLM_lpage">824</span>, <span class="refDoi"> DOI: 10.2147/DDDT.S144556</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.2147%2FDDDT.S144556" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=30880915" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlCgt7nL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2019&pages=817-824&author=M.+S.+Rendell&title=The+Journey+from+Gene+Knockout+to+Clinical+Medicine%3A+Telotristat+and+Sotagliflozin&doi=10.2147%2FDDDT.S144556"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133cR"><div class="casContent"><span class="casTitleNuber">133c</span><div class="casTitle"><span class="NLM_cas:atitle">The journey from gene knockout to clinical medicine: telotristat and sotagliflozin</span></div><div class="casAuthors">Rendell, Marc S.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">817-824</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Gene knockout has been a powerful technique to evaluate the physiol. role of selected gene products.  Lexicon pioneered high-throughput gene knockout technol. and went further in designing agents to inhibit products of gene expression.  Two agents have entered late-stage development.  Telotristat is an inhibitor of tryptophan hydroxylase (TPH), preventing the prodn. of serotonin.  Although this agent blocks the two isoforms of TPH, it does not cross the blood-brain barrier, thus avoiding central neurol. manifestations.  It inhibits the peripheral prodn. of serotonin, and in particular prevents serotonin action in the intestines, resulting in decreased peristaltic action.  Lexicon successfully developed telotristat to treat carcinoid syndrome not responding adequately to somatostatin inhibitors.  Sotagliflozin development proceeded from the observation that dual inhibition of SGLT2 in the kidneys and SGLT1 in the intestines resulted in increased renal glucose excretion, reduced early-phase glucose absorption, as well as increased blood levels of GLP-1 and PYY.  Initial development efforts focused on type 1 diabetes and have shown reduced postprandial glucose levels, less tendency to hypoglycemia, and lower HbA1c.  Several other SGLT2 inhibitors have been assocd. with increased frequency of diabetic ketoacidosis (DKA).  In the type 1 trials, sotagliflozin-treated individuals experienced DKA at a higher rate than placebo-treated patients.  The sotagliflozin development program has now been extended to trials on type 2 diabetes.  Long-term clin. trials will det. the benefits and risks of the agent in comparison to other currently marketed SGLT2 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-Fc7sxo4CkLVg90H21EOLACvtfcHk0lie8dk24OLCbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlCgt7nL&md5=1dd88aa094e8a816c7617a07dd2ae21e</span></div><a href="/servlet/linkout?suffix=cit133c&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S144556&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S144556%26sid%3Dliteratum%253Aachs%26aulast%3DRendell%26aufirst%3DM.%2BS.%26atitle%3DThe%2520Journey%2520from%2520Gene%2520Knockout%2520to%2520Clinical%2520Medicine%253A%2520Telotristat%2520and%2520Sotagliflozin%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2019%26volume%3D13%26spage%3D817%26epage%3D824%26doi%3D10.2147%2FDDDT.S144556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iimura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bednarz, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Q.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, N.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span> <span> </span><span class="NLM_article-title">Process Development of Sotagliflozin, a Dual Inhibitor of Sodium-Glucose Cotransporter-1/2 for the Treatment of Diabetes</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">2689</span>– <span class="NLM_lpage">2701</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.0c00359</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.0c00359" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFyqsrnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2020&pages=2689-2701&author=M.+M.+Zhaoauthor=H.+Zhangauthor=S.+Iimuraauthor=M.+S.+Bednarzauthor=Q.-L.+Songauthor=N.-K.+Limauthor=J.+Yanauthor=W.+Wuauthor=K.+Daiauthor=X.+Guauthor=Y.+Wang&title=Process+Development+of+Sotagliflozin%2C+a+Dual+Inhibitor+of+Sodium-Glucose+Cotransporter-1%2F2+for+the+Treatment+of+Diabetes&doi=10.1021%2Facs.oprd.0c00359"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Process Development of Sotagliflozin, a Dual Inhibitor of Sodium-Glucose Cotransporter-1/2 for the Treatment of Diabetes</span></div><div class="casAuthors">Zhao, Matthew M.; Zhang, Haiming; Iimura, Shinya; Bednarz, Mark S.; Song, Qiu-Ling; Lim, Ngiap-Kie; Yan, Jie; Wu, Wenxue; Dai, Kuangchu; Gu, Xiaodong; Wang, Youchu</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2689-2701</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The development of an efficient manufg. process for sotagliflozin (LX4211), a dual inhibitor of sodium-glucose cotransporter-1/2 (SGLT-1/2) for the treatment of diabetes, is described.  Sotagliflozin features five contiguous chiral centers on the carbohydrate core flanked by a thioether group and a biaryl moiety.  Three chiral centers are obtained from the starting material L-xylose, while the other two were established (or modified) via three highly stereoselective transformations: Luche redn. (dr: 97/3), dynamic kinetic resoln. of anomeric hemiacetal (dr: 95/5), and Lewis acid-promoted thiolation (dr: 1000/1).  Global deprotection of the resulting penultimate intermediate with catalytic sodium methoxide followed by recrystn. furnishes sotagliflozin.  The longest linear sequence consists of 10 steps from L-xylose with an overall yield of 40%.  This process has been performed on multi-hundred kilogram batches to satisfy the drug substance development demands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomlSCt_ZR7BbVg90H21EOLACvtfcHk0lie8dk24OLCbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFyqsrnP&md5=691f8d1beca1ce2f0069c6830baa0a0a</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.0c00359&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.0c00359%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DM.%2BM.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DIimura%26aufirst%3DS.%26aulast%3DBednarz%26aufirst%3DM.%2BS.%26aulast%3DSong%26aufirst%3DQ.-L.%26aulast%3DLim%26aufirst%3DN.-K.%26aulast%3DYan%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DDai%26aufirst%3DK.%26aulast%3DGu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DY.%26atitle%3DProcess%2520Development%2520of%2520Sotagliflozin%252C%2520a%2520Dual%2520Inhibitor%2520of%2520Sodium-Glucose%2520Cotransporter-1%252F2%2520for%2520the%2520Treatment%2520of%2520Diabetes%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2020%26volume%3D24%26spage%3D2689%26epage%3D2701%26doi%3D10.1021%2Facs.oprd.0c00359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Paul, S. M.</span>; <span class="NLM_string-name">Perlberg, A.</span>; <span class="NLM_string-name">Zhao, M. M.</span></span> <span> </span><span class="NLM_article-title">Preparation of Solid Forms of (2<i>S</i>,3<i>R</i>,4<i>R</i>,5<i>S</i>,6<i>R</i>)-2-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2<i>H</i>-pyran-3,4,5-triol for Use in Treating Disorders Related to the Inhibition of Sodium Glucose Co-Transporter 2</span>. <span class="NLM_patent">WO 2010009197 A1</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=S.+M.+De+Paul&author=A.+Perlberg&author=M.+M.+Zhao&title=Preparation+of+Solid+Forms+of+%282S%2C3R%2C4R%2C5S%2C6R%29-2-%284-Chloro-3-%284-ethoxybenzyl%29phenyl%29-6-%28methylthio%29tetrahydro-2H-pyran-3%2C4%2C5-triol+for+Use+in+Treating+Disorders+Related+to+the+Inhibition+of+Sodium+Glucose+Co-Transporter+2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BPaul%26aufirst%3DS.%2BM.%26atitle%3DPreparation%2520of%2520Solid%2520Forms%2520of%2520%25282S%252C3R%252C4R%252C5S%252C6R%2529-2-%25284-Chloro-3-%25284-ethoxybenzyl%2529phenyl%2529-6-%2528methylthio%2529tetrahydro-2H-pyran-3%252C4%252C5-triol%2520for%2520Use%2520in%2520Treating%2520Disorders%2520Related%2520to%2520the%2520Inhibition%2520of%2520Sodium%2520Glucose%2520Co-Transporter%25202%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><a href="https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-mayzent-siponimod-first-oral-drug-treat-secondary-progressive-ms-active-disease" class="extLink">https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-mayzent-siponimod-first-oral-drug-treat-secondary-progressive-ms-active-disease</a> (accessed 2020-09-15).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.novartis.com%2Fnews%2Fmedia-releases%2Fnovartis-receives-fda-approval-mayzent-siponimod-first-oral-drug-treat-secondary-progressive-ms-active-disease+%28accessed+2020-09-15%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209884s000lbl.pdf" class="extLink">https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209884s000lbl.pdf</a> (accessed 2021-01-14).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2019%2F209884s000lbl.pdf+%28accessed+2021-01-14%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuntland, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefebvre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinterding, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">End, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heining, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruns, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuesslein-Hildesheim, B.</span></span> <span> </span><span class="NLM_article-title">Discovery of BAF312 (Siponimod), a Potent and Selective S1P Receptor Modulator</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">333</span>– <span class="NLM_lpage">337</span>, <span class="refDoi"> DOI: 10.1021/ml300396r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300396r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktVynug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=333-337&author=S.+Panauthor=N.+S.+Grayauthor=W.+Gaoauthor=Y.+Miauthor=Y.+Fanauthor=X.+Wangauthor=T.+Tuntlandauthor=J.+Cheauthor=S.+Lefebvreauthor=Y.+Chenauthor=A.+Chuauthor=K.+Hinterdingauthor=A.+Gardinauthor=P.+Endauthor=P.+Heiningauthor=C.+Brunsauthor=N.+G.+Cookeauthor=B.+Nuesslein-Hildesheim&title=Discovery+of+BAF312+%28Siponimod%29%2C+a+Potent+and+Selective+S1P+Receptor+Modulator&doi=10.1021%2Fml300396r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of BAF312 (Siponimod), a Potent and Selective S1P Receptor Modulator</span></div><div class="casAuthors">Pan, Shifeng; Gray, Nathanael S.; Gao, Wenqi; Mi, Yuan; Fan, Yi; Wang, Xing; Tuntland, Tove; Che, Jianwei; Lefebvre, Sophie; Chen, Yu; Chu, Alan; Hinterding, Klaus; Gardin, Anne; End, Peter; Heining, Peter; Bruns, Christian; Cooke, Nigel G.; Nuesslein-Hildesheim, Barbara</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">333-337</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of alkoxyimino derivs. as S1P1 agonists were discovered through de novo design using FTY720 as the chem. starting point.  Extensive structure-activity relationship studies led to the discovery of (E)-1-(4-(1-(((4-cyclohexyl-3-(trifluoromethyl)benzyl)oxy)imino)ethyl)-2-ethylbenzyl)azetidine-3-carboxylic acid (I, BAF312, Siponimod), which has recently completed phase 2 clin. trials in patients with relapsing-remitting multiple sclerosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoV0CukK1Qn3bVg90H21EOLACvtfcHk0lie8dk24OLCbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktVynug%253D%253D&md5=a410b8b34f28380a51b3ffb63ae23161</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1021%2Fml300396r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300396r%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DS.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DGao%26aufirst%3DW.%26aulast%3DMi%26aufirst%3DY.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DChe%26aufirst%3DJ.%26aulast%3DLefebvre%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DChu%26aufirst%3DA.%26aulast%3DHinterding%26aufirst%3DK.%26aulast%3DGardin%26aufirst%3DA.%26aulast%3DEnd%26aufirst%3DP.%26aulast%3DHeining%26aufirst%3DP.%26aulast%3DBruns%26aufirst%3DC.%26aulast%3DCooke%26aufirst%3DN.%2BG.%26aulast%3DNuesslein-Hildesheim%26aufirst%3DB.%26atitle%3DDiscovery%2520of%2520BAF312%2520%2528Siponimod%2529%252C%2520a%2520Potent%2520and%2520Selective%2520S1P%2520Receptor%2520Modulator%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D333%26epage%3D337%26doi%3D10.1021%2Fml300396r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gallou, F.</span>; <span class="NLM_string-name">Sedelmeier, J. M.</span>; <span class="NLM_string-name">Vogel, C.</span></span> <span> </span><span class="NLM_article-title">Process for Preparing <i>N</i>-(4-Cyclohexyl-3-Trifluoromethyl-Benzyloxy)-Acetimidic Acid Ethyl Ester</span>. <span class="NLM_patent">WO 2013113915 A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=F.+Gallou&author=J.+M.+Sedelmeier&author=C.+Vogel&title=Process+for+Preparing+N-%284-Cyclohexyl-3-Trifluoromethyl-Benzyloxy%29-Acetimidic+Acid+Ethyl+Ester"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGallou%26aufirst%3DF.%26atitle%3DProcess%2520for%2520Preparing%2520N-%25284-Cyclohexyl-3-Trifluoromethyl-Benzyloxy%2529-Acetimidic%2520Acid%2520Ethyl%2520Ester%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Juric, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabernero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janku, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burris, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schellens, J. H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middleton, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berlin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gil-Martin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rugo, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seggewiss-Bernhardt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bootle, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demanse, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenstein, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coughlin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quadt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span> <span> </span><span class="NLM_article-title">Phosphatidylinositol 3-Kinase A-Selective Inhibition with Alpelisib (BYL719) in Pik3ca-Altered Solid Tumors: Results from the First-in-Human Study</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">1291</span>– <span class="NLM_lpage">1299</span>, <span class="refDoi"> DOI: 10.1200/JCO.2017.72.7107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1200%2FJCO.2017.72.7107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=29401002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlynurbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2018&pages=1291-1299&author=D.+Juricauthor=J.+Rodonauthor=J.+Taberneroauthor=F.+Jankuauthor=H.+A.+Burrisauthor=J.+H.+M.+Schellensauthor=M.+R.+Middletonauthor=J.+Berlinauthor=M.+Schulerauthor=M.+Gil-Martinauthor=H.+S.+Rugoauthor=R.+Seggewiss-Bernhardtauthor=A.+Huangauthor=D.+Bootleauthor=D.+Demanseauthor=L.+Blumensteinauthor=C.+Coughlinauthor=C.+Quadtauthor=J.+Baselga&title=Phosphatidylinositol+3-Kinase+A-Selective+Inhibition+with+Alpelisib+%28BYL719%29+in+Pik3ca-Altered+Solid+Tumors%3A+Results+from+the+First-in-Human+Study&doi=10.1200%2FJCO.2017.72.7107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140aR"><div class="casContent"><span class="casTitleNuber">140a</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphatidylinositol 3-Kinase α-selective inhibition with alpelisib (BYL719) in PIK3CA-altered solid tumors: results from the first-in-human study</span></div><div class="casAuthors">Juric, Dejan; Rodon, Jordi; Tabernero, Josep; Janku, Filip; Burris, Howard A.; Schellens, Jan H. M.; Middleton, Mark R.; Berlin, Jordan; Schuler, Martin; Gil-Martin, Marta; Rugo, Hope S.; Seggewiss-Bernhardt, Ruth; Huang, Alan; Bootle, Douglas; Demanse, David; Blumenstein, Lars; Coughlin, Christina; Quadt, Cornelia; Baselga, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1291-1299</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose We report the first-in-human phase Ia study to our knowledge (ClinicalTrials.gov identifier: NCT01219699) identifying the max. tolerated dose and assessing safety and preliminary efficacy of single-agent alpelisib (BYL719), an oral phosphatidylinositol 3-kinase α (PI3Kα)-selective inhibitor.  Patients and Methods In the dose-escalation phase, patients with PIK3CA-altered advanced solid tumors received once-daily or twice-daily oral alpelisib on a continuous schedule.  In the dose-expansion phase, patients with PIK3CA-altered solid tumors and PIK3CA-wild-type, estrogen receptor-pos./human epidermal growth factor receptor 2-neg. breast cancer received alpelisib 400 mg once daily.  Results One hundred thirty-four patients received treatment.  Alpelisib max. tolerated doses were established as 400mg once daily and 150mg twice daily.  Nine patients (13.2%) in the dose-escalation phase had dose-limiting toxicities of hyperglycemia (n = 6), nausea (n = 2), and both hyperglycemia and hypophosphatemia (n = 1).  Frequent all-grade, treatment-related adverse events included hyperglycemia (51.5%), nausea (50.0%), decreased appetite (41.8%), diarrhea (40.3%), and vomiting (31.3%).  Alpelisib was rapidly absorbed; half-life was 7.6 h at 400 mg once daily with minimal accumulation.  Objective tumor responses were obsd. at doses ≥ 270 mg once daily; overall response ratewas 6.0% (n = 8; one patient with endometrial cancer had a complete response, and seven patients with cervical, breast, endometrial, colon, and rectal cancers had partial responses).  Stable disease was achieved in 70 (52.2%) patients and was maintained . 24 wk in 13 (9.7%) patients; disease control rate (complete and partial responses and stable disease) was 58.2%.  In patients with estrogen receptor-pos./human epidermal growth factor receptor 2-neg. breast cancer, median progression-free survival was 5.5 mo.  Frequently mutated genes (≥ 10% tumors) included TP53 (51.3%), APC (23.7%), KRAS (22.4%), ARID1A (13.2%), and FBXW7 (10.5%).  Conclusion Alpelisib demonstrated a tolerable safety profile and encouraging preliminary activity in patients with PIK3CA-altered solid tumors, supporting the rationale for selective PI3Kα inhibition in combination with other agents for the treatment of PIK3CA-mutant tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGps0P3SQLaDT7Vg90H21EOLACvtfcHk0lgDAhqLvKmueA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlynurbO&md5=e95593fa4359b0ae552c92f909387f5b</span></div><a href="/servlet/linkout?suffix=cit140a&amp;dbid=16384&amp;doi=10.1200%2FJCO.2017.72.7107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2017.72.7107%26sid%3Dliteratum%253Aachs%26aulast%3DJuric%26aufirst%3DD.%26aulast%3DRodon%26aufirst%3DJ.%26aulast%3DTabernero%26aufirst%3DJ.%26aulast%3DJanku%26aufirst%3DF.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%2BM.%26aulast%3DMiddleton%26aufirst%3DM.%2BR.%26aulast%3DBerlin%26aufirst%3DJ.%26aulast%3DSchuler%26aufirst%3DM.%26aulast%3DGil-Martin%26aufirst%3DM.%26aulast%3DRugo%26aufirst%3DH.%2BS.%26aulast%3DSeggewiss-Bernhardt%26aufirst%3DR.%26aulast%3DHuang%26aufirst%3DA.%26aulast%3DBootle%26aufirst%3DD.%26aulast%3DDemanse%26aufirst%3DD.%26aulast%3DBlumenstein%26aufirst%3DL.%26aulast%3DCoughlin%26aufirst%3DC.%26aulast%3DQuadt%26aufirst%3DC.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DPhosphatidylinositol%25203-Kinase%2520A-Selective%2520Inhibition%2520with%2520Alpelisib%2520%2528BYL719%2529%2520in%2520Pik3ca-Altered%2520Solid%2520Tumors%253A%2520Results%2520from%2520the%2520First-in-Human%2520Study%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D36%26spage%3D1291%26epage%3D1299%26doi%3D10.1200%2FJCO.2017.72.7107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit140b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span> <span> </span><span class="NLM_article-title">Alpelisib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">1249</span>– <span class="NLM_lpage">1253</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01161-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs40265-019-01161-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31256368" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlCiur%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=1249-1253&author=A.+Markham&title=Alpelisib%3A+First+Global+Approval&doi=10.1007%2Fs40265-019-01161-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140bR"><div class="casContent"><span class="casTitleNuber">140b</span><div class="casTitle"><span class="NLM_cas:atitle">Alpelisib: First Global Approval</span></div><div class="casAuthors">Markham, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1249-1253</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Alpelisib (Piqray)-an orally available phosphatidylinositol 3-kinase (PI3K) inhibitor with specific activity against PI3K alpha (PI3Kα)-is being developed by Novartis for the treatment of breast cancer.  Alpelisib has demonstrated efficacy in combination with fulvestrant as treatment for hormone receptor (HR)-pos., human epidermal growth factor receptor-2 (HER2)-neg. breast cancer in patients with a PIK3CA mutation and was recently approved for this indication in the USA.  This article summarizes the milestones in the development of alpelisib leading to this first approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqX1sEhr0QGHrVg90H21EOLACvtfcHk0lgDAhqLvKmueA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlCiur%252FN&md5=4d9e9d1e3742a9bce160ca2c7987ce6c</span></div><a href="/servlet/linkout?suffix=cit140b&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01161-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01161-6%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26atitle%3DAlpelisib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D1249%26epage%3D1253%26doi%3D10.1007%2Fs40265-019-01161-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><a href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-alpelisib-metastatic-breast-cancer" class="extLink">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-alpelisib-metastatic-breast-cancer</a> (accessed 2020-06-02).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fresources-information-approved-drugs%2Ffda-approves-alpelisib-metastatic-breast-cancer+%28accessed+2020-06-02%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Koboldt, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulton, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLellan, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalicki-Veizer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMichael, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulton, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dooling, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mardis, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ally, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasundaram, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butterfield, Y. S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlsen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuah, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, H.-J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coope, R. J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhalla, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirst, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirst, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holt, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mungall, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pleasance, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon Robertson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schein, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shafiei, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sipahimalani, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slobodan, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoll, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiessen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varhol, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wye, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birol, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marra, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherniack, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saksena, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onofrio, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pho, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schumacher, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gentry, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crenshaw, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ardlie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beroukhim, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winckler, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Getz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabriel, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kucherlapati, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoadley, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Todd Auman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turman, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Topal, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, H.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva, G. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iglesia, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Usary, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Booker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulabani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bodenheimer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoyle, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simons, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soloway, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mose, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jefferys, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neil Hayes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perou, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malik, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahurkar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisenberger, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Triche, T.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bootwalla, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maglinte, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berman, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Den Berg, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baylin, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laird, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creighton, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donehower, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Getz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voet, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saksena, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gehlenborg, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiCara, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yingchun Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivachenko, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stojanov, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nazaire, M.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorvaldsdottir, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesirov, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreisberg, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernard, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bressler, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erkkila, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorsson, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shmulevich, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciriello, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinhold, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerami, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arman Aksoy, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antipin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reva, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladanyi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sander, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anur, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spellman, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhaak, R. R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akbani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broom, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casasent, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakefield, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unruh, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baggerly, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coombes, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstein, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haussler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benz, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benz, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szeto, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paull, E. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sokolov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thusberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mooney, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellrott, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grifford, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilks, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craft, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meerzaman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gastier-Foster, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramirez, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pyatt, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zmuda, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frick, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtenberg, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brookens, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerken, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harper, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leraas, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wise, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabler, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAllister, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barr, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart-Kothari, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarvin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandusky, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacocca, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabeno, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czerwinski, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrelli, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolzhansky, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abramov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voronina, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potapova, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suchorska, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murawa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kycler, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibbs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spychała, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murawa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brzeziński, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Łaźniak, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teresiak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leporowska, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogusz-Czerniewicz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malicki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackiewicz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiznerowicz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Le, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohl, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viet Tien, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorp, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Bang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sussman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duc Phu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hajek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phi Hung, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viet The Phuong, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quyet Thang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaki Khan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penny, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallery, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curley, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shelton, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yena, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingle, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Couch, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lingle, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maria
Gonzalez-Angulo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyer, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, X.</span></span> <span> </span><span class="NLM_article-title">Comprehensive Molecular Portraits of Human Breast Tumours</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>490</i></span>,  <span class="NLM_fpage">61</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.1038/nature11412</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1038%2Fnature11412" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=23000897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlyltrvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=490&publication_year=2012&pages=61-70&author=D.+C.+Koboldtauthor=R.+S.+Fultonauthor=M.+D.+McLellanauthor=H.+Schmidtauthor=J.+Kalicki-Veizerauthor=J.+F.+McMichaelauthor=L.+L.+Fultonauthor=D.+J.+Doolingauthor=L.+Dingauthor=E.+R.+Mardisauthor=R.+K.+Wilsonauthor=A.+Allyauthor=M.+Balasundaramauthor=Y.+S.+N.+Butterfieldauthor=R.+Carlsenauthor=C.+Carterauthor=A.+Chuauthor=E.+Chuahauthor=H.-J.+E.+Chunauthor=R.+J.+N.+Coopeauthor=N.+Dhallaauthor=R.+Guinauthor=C.+Hirstauthor=M.+Hirstauthor=R.+A.+Holtauthor=D.+Leeauthor=H.+I.+Liauthor=M.+Mayoauthor=R.+A.+Mooreauthor=A.+J.+Mungallauthor=E.+Pleasanceauthor=A.+Gordon+Robertsonauthor=J.+E.+Scheinauthor=A.+Shafieiauthor=P.+Sipahimalaniauthor=J.+R.+Slobodanauthor=D.+Stollauthor=A.+Tamauthor=N.+Thiessenauthor=R.+J.+Varholauthor=N.+Wyeauthor=T.+Zengauthor=Y.+Zhaoauthor=I.+Birolauthor=S.+J.+M.+Jonesauthor=M.+A.+Marraauthor=A.+D.+Cherniackauthor=G.+Saksenaauthor=R.+C.+Onofrioauthor=N.+H.+Phoauthor=S.+L.+Carterauthor=S.+E.+Schumacherauthor=B.+Tabakauthor=B.+Hernandezauthor=J.+Gentryauthor=H.+Nguyenauthor=A.+Crenshawauthor=K.+Ardlieauthor=R.+Beroukhimauthor=W.+Wincklerauthor=G.+Getzauthor=S.+B.+Gabrielauthor=M.+Meyersonauthor=L.+Chinauthor=P.+J.+Parkauthor=R.+Kucherlapatiauthor=K.+A.+Hoadleyauthor=J.+Todd+Aumanauthor=C.+Fanauthor=Y.+J.+Turmanauthor=Y.+Shiauthor=L.+Liauthor=M.+D.+Topalauthor=X.+Heauthor=H.-H.+Chaoauthor=A.+Pratauthor=G.+O.+Silvaauthor=M.+D.+Iglesiaauthor=W.+Zhaoauthor=J.+Usaryauthor=J.+S.+Bergauthor=M.+Adamsauthor=J.+Bookerauthor=J.+Wuauthor=A.+Gulabaniauthor=T.+Bodenheimerauthor=A.+P.+Hoyleauthor=J.+V.+Simonsauthor=M.+G.+Solowayauthor=L.+E.+Moseauthor=S.+R.+Jefferysauthor=S.+Baluauthor=J.+S.+Parkerauthor=D.+Neil+Hayesauthor=C.+M.+Perouauthor=S.+Malikauthor=S.+Mahurkarauthor=H.+Shenauthor=D.+J.+Weisenbergerauthor=T.+Tricheauthor=P.+H.+Laiauthor=M.+S.+Bootwallaauthor=D.+T.+Maglinteauthor=B.+P.+Bermanauthor=D.+J.+Van+Den+Bergauthor=S.+B.+Baylinauthor=P.+W.+Lairdauthor=C.+J.+Creightonauthor=L.+A.+Donehowerauthor=G.+Getzauthor=M.+Nobleauthor=D.+Voetauthor=G.+Saksenaauthor=N.+Gehlenborgauthor=D.+DiCaraauthor=J.+Zhangauthor=H.+Zhangauthor=C.-J.+Wuauthor=S.+Yingchun+Liuauthor=M.+S.+Lawrenceauthor=L.+Zouauthor=A.+Sivachenkoauthor=P.+Linauthor=P.+Stojanovauthor=R.+Jingauthor=J.+Choauthor=R.+Sinhaauthor=R.+W.+Parkauthor=M.-D.+Nazaireauthor=J.+Robinsonauthor=H.+Thorvaldsdottirauthor=J.+Mesirovauthor=P.+J.+Parkauthor=L.+Chinauthor=S.+Reynoldsauthor=R.+B.+Kreisbergauthor=B.+Bernardauthor=R.+Bresslerauthor=T.+Erkkilaauthor=J.+Linauthor=V.+Thorssonauthor=W.+Zhangauthor=I.+Shmulevichauthor=G.+Cirielloauthor=N.+Weinholdauthor=N.+Schultzauthor=J.+Gaoauthor=E.+Ceramiauthor=B.+Grossauthor=A.+Jacobsenauthor=R.+Sinhaauthor=B.+Arman+Aksoyauthor=Y.+Antipinauthor=B.+Revaauthor=R.+Shenauthor=B.+S.+Taylorauthor=M.+Ladanyiauthor=C.+Sanderauthor=P.+Anurauthor=P.+T.+Spellmanauthor=Y.+Luauthor=W.+Liuauthor=R.+R.+G.+Verhaakauthor=G.+B.+Millsauthor=R.+Akbaniauthor=N.+Zhangauthor=B.+M.+Broomauthor=T.+D.+Casasentauthor=C.+Wakefieldauthor=A.+K.+Unruhauthor=K.+Baggerlyauthor=K.+Coombesauthor=J.+N.+Weinsteinauthor=D.+Hausslerauthor=C.+C.+Benzauthor=J.+M.+Stuartauthor=S.+C.+Benzauthor=J.+Zhuauthor=C.+C.+Szetoauthor=G.+K.+Scottauthor=C.+Yauauthor=E.+O.+Paullauthor=D.+Carlinauthor=C.+Wongauthor=A.+Sokolovauthor=J.+Thusbergauthor=S.+Mooneyauthor=S.+Ngauthor=T.+C.+Goldsteinauthor=K.+Ellrottauthor=M.+Griffordauthor=C.+Wilksauthor=S.+Maauthor=B.+Craftauthor=C.+Yanauthor=Y.+Huauthor=D.+Meerzamanauthor=J.+M.+Gastier-Fosterauthor=J.+Bowenauthor=N.+C.+Ramirezauthor=A.+D.+Blackauthor=R.+E.+Pyattauthor=P.+Whiteauthor=E.+J.+Zmudaauthor=J.+Frickauthor=T.+M.+Lichtenbergauthor=R.+Brookensauthor=M.+M.+Georgeauthor=M.+A.+Gerkenauthor=H.+A.+Harperauthor=K.+M.+Leraasauthor=L.+J.+Wiseauthor=T.+R.+Tablerauthor=C.+McAllisterauthor=T.+Barrauthor=M.+Hart-Kothariauthor=K.+Tarvinauthor=C.+Sallerauthor=G.+Sanduskyauthor=C.+Mitchellauthor=M.+V.+Iacoccaauthor=J.+Brownauthor=B.+Rabenoauthor=C.+Czerwinskiauthor=N.+Petrelliauthor=O.+Dolzhanskyauthor=M.+Abramovauthor=O.+Voroninaauthor=O.+Potapovaauthor=J.+R.+Marksauthor=W.+M.+Suchorskaauthor=D.+Murawaauthor=W.+Kyclerauthor=M.+Ibbsauthor=K.+Korskiauthor=A.+Spycha%C5%82aauthor=P.+Murawaauthor=J.+J.+Brzezi%C5%84skiauthor=H.+Perzauthor=R.+%C5%81a%C5%BAniakauthor=M.+Teresiakauthor=H.+Tatkaauthor=E.+Leporowskaauthor=M.+Bogusz-Czerniewiczauthor=J.+Malickiauthor=A.+Mackiewiczauthor=M.+Wiznerowiczauthor=X.+Van+Leauthor=B.+Kohlauthor=N.+Viet+Tienauthor=R.+Thorpauthor=N.+Van+Bangauthor=H.+Sussmanauthor=B.+Duc+Phuauthor=R.+Hajekauthor=N.+Phi+Hungauthor=T.+Viet+The+Phuongauthor=H.+Quyet+Thangauthor=K.+Zaki+Khanauthor=R.+Pennyauthor=D.+Malleryauthor=E.+Curleyauthor=C.+Sheltonauthor=P.+Yenaauthor=J.+N.+Ingleauthor=F.+J.+Couchauthor=W.+L.+Lingleauthor=T.+A.+Kingauthor=A.+Maria%0AGonzalez-Anguloauthor=G.+B.+Millsauthor=M.+D.+Dyerauthor=S.+Liuauthor=X.+Meng&title=Comprehensive+Molecular+Portraits+of+Human+Breast+Tumours&doi=10.1038%2Fnature11412"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142aR"><div class="casContent"><span class="casTitleNuber">142a</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive molecular portraits of human breast tumors</span></div><div class="casAuthors">Koboldt, Daniel C.; Fulton, Robert S.; McLellan, Michael D.; Schmidt, Heather; Kalicki-Veizer, Joelle; McMichael, Joshua F.; Fulton, Lucinda L.; Dooling, David J.; Ding, Li; Mardis, Elaine R.; Wilson, Richard K.; Ally, Adrian; Balasundaram, Miruna; Butterfield, Yaron S. N.; Carlsen, Rebecca; Carter, Candace; Chu, Andy; Chuah, Eric; Chun, Hye-Jung E.; Coope, Robin J. N.; Dhalla, Noreen; Guin, Ranabir; Hirst, Carrie; Hirst, Martin; Holt, Robert A.; Lee, Darlene; Li, Haiyan I.; Mayo, Michael; Moore, Richard A.; Mungall, Andrew J.; Pleasance, Erin; Gordon Robertson, A.; Schein, Jacqueline E.; Shafiei, Arash; Sipahimalani, Payal; Slobodan, Jared R.; Stoll, Dominik; Tam, Angela; Thiessen, Nina; Varhol, Richard J.; Wye, Natasja; Zeng, Thomas; Zhao, Yongjun; Birol, Inanc; Jones, Steven J. M.; Marra, Marco A.; Cherniack, Andrew D.; Saksena, Gordon; Onofrio, Robert C.; Pho, Nam H.; Carter, Scott L.; Schumacher, Steven E.; Tabak, Barbara; Hernandez, Bryan; Gentry, Jeff; Nguyen, Huy; Crenshaw, Andrew; Ardlie, Kristin; Beroukhim, Rameen; Winckler, Wendy; Getz, Gad; Gabriel, Stacey B.; Meyerson, Matthew; Chin, Lynda; Park, Peter J.; Kucherlapati, Raju; Hoadley, Katherine A.; Todd Auman, J.; Fan, Cheng; Turman, Yidi J.; Shi, Yan; Li, Ling; Topal, Michael D.; He, Xiaping; Chao, Hann-Hsiang; Prat, Aleix; Silva, Grace O.; Iglesia, Michael D.; Zhao, Wei; Usary, Jerry; Berg, Jonathan S.; Adams, Michael; Brooker, Jessica; Wu, Junyuan; Gulabani, Anisha; Bodenheimer, Tom; Hoyle, Alan P.; Simons, Janae V.; Soloway, Matthew G.; Mose, Lisle E.; Jefferys, Stuart R.; Balu, Saianand; Parker, Joel S.; Hayes, D. Neil; Perou, Charles M.; Malik, Simeen; Mahurkar, Swapna; Shen, Hui; Weisenberger, Daniel J.; Triche, Timothy, Jr.; Lai, Phillip H.; Bootwalla, Moiz S.; Maglinte, Dennis T.; Berman, Benjamin P.; Van Den Berg, David J.; Baylin, Stephen B.; Laird, Peter W.; Creighton, Chad J.; Donehower, Lawrence A.; Getz, Gad; Noble, Michael; Voet, Doug; Saksena, Gordon; Gehlenborg, Nils; DiCara, Daniel; Zhang, Juinhua; Zhang, Hailei; Wu, Chang-Jiun; Liu, Spring Yingchun; Lawrence, Michael S.; Zou, Lihua; Sivachenko, Andrey; Lin, Pei; Stojanov, Petar; Jing, Rui; Cho, Juok; Sinha, Raktim; Park, Richard W.; Nazaire, Marc-Danie; Robinson, Jim; Thorvaldsdottir, Helga; Mesirov, Jill; Park, Peter J.; Chin, Lynda; Reynolds, Sheila; Kreisberg, Richard B.; Bernard, Brady; Bressler, Ryan; Erkkila, Timo; Lin, Jake; Thorsson, Vesteinn; Zhang, Wei; Shmulevich, Ilya; Ciriello, Giovanni; Weinhold, Nils; Schultz, Nikolaus; Gao, Jianjiong; Cerami, Ethan; Gross, Benjamin; Jacobsen, Anders; Sinha, Rileen; Arman Aksoy, B.; Antipin, Yevgeniy; Reva, Boris; Shen, Ronglai; Taylor, Barry S.; Ladanyi, Marc; Sander, Chris; Anur, Pavana; Spellman, Paul T.; Lu, Yiling; Liu, Wenbin; Verhaak, Roel R. G.; Mills, Gordon B.; Akbani, Rehan; Zhang, Nianxiang; Broom, Bradley M.; Casasent, Tod D.; Wakefield, Chris; Unruh, Anna K.; Baggerly, Keith; Coombes, Kevin; Weinstein, John N.; Haussler, David; Benz, Christopher C.; Stuart, Joshua M.; Benz, Stephen C.; Zhu, Jingchun; Szeto, Christopher C.; Scott, Gary K.; Yau, Christina; Paull, Evan O.; Carlin, Daniel; Wong, Christopher; Sokolov, Artem; Thusberg, Janita; Mooney, Sean; Ng, Sam; Goldstein, Theodore C.; Ellrott, Kyle; Grifford, Mia; Wilks, Christopher; Ma, Singer; Craft, Brian; Yan, Chunhua; Hu, Ying; Meerzaman, Daoud; Gastier-Foster, Julie M.; Bowen, Jay; Ramirez, Nilsa C.; Black, Aaron D.; White, Peter; Zmuda, Erik J.; Frick, Jessica; Lichtenberg, Tara M.; Brookens, Robin; George, Myra M.; Gerken, Mark A.; Harper, Hollie A.; Leraas, Kristen M.; Wise, Lisa J.; Tabler, Teresa R.; McAllister, Cynthia; Barr, Thomas; Hart-Kothari, Melissa; Tarvin, Katie; Saller, Charles; Sandusky, George; Mitchell, Colleen; Iacocca, Mary V.; Brown, Jennifer; Rabeno, Brenda; Czerwinski, Christine; Petrelli, Nicholas; Dolzhansky, Oleg; Abramov, Mikhail; Voronina, Olga; Potapova, Olga; Marks, Jeffrey R.; Suchorska, Wiktoria M.; Murawa, Dawid; Kycler, Witold; Ibbs, Matthew; Korski, Konstanty; Spychala, Arkadiusz; Murawa, Pawel; Brzezinski, Jacek J.; Perz, Hanna; Lazniak, Radoslaw; Teresiak, Marek; Tatka, Honorata; Leporowska, Ewa; Bogusz-Czerniewicz, Marta; Malicki, Julian; Mackiewicz, Andrzej; Wiznerowicz, Maciej; Le, Xuan Van; Kohl, Bernard; Nguyen, Viet Tien; Thorp, Richard; Nguyen, Van Bang; Sussman, Howard; Phu, Bui Duc; Hajek, Richard; Nguyen, Phi Hung; Phuong, Tran Viet The; Thang, Huynh Quyet; Khan, Khurram Zaki; Penny, Robert; Mallery, David; Curley, Erin; Shelton, Candace; Yena, Peggy; Ingle, James N.; Couch, Fergus J.; Lingle, Wilma L.; King, Tari A.; Gonzalez-Angulo, Ana Maria; Mills, Gordon B.; Dyer, Mary D.; Liu, Shuying; Meng, Xiaolong; Patangan, Modesto; Waldman, Frederic; Stoeppler, Hubert; Rathmell, W. Kimryn; Thorne, Leigh; Huang, Mei; Boice, Lori; Hill, Ashley; Morrison, Carl; Gaudioso, Carmelo; Bshara, Wiam; Daily, Kelly; Egea, Sophie C.; Pegram, Mark D.; Gomez-Fernandez, Carmen; Dhir, Rajiv; Bhargava, Rohit; Brufsky, Adam; Shriver, Craig D.; Hooke, Jeffrey A.; Leigh Campbell, Jamie; Mural, Richard J.; Hu, Hai; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">490</span>
        (<span class="NLM_cas:issue">7418</span>),
    <span class="NLM_cas:pages">61-70</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We analyzed primary breast cancers by genomic DNA copy no. arrays, DNA methylation, exome sequencing, mRNA arrays, microRNA sequencing and reverse-phase protein arrays.  Our ability to integrate information across platforms provided key insights into previously defined gene expression subtypes and demonstrated the existence of four main breast cancer classes when combining data from five platforms, each of which shows significant mol. heterogeneity.  Somatic mutations in only three genes (TP53, PIK3CA and GATA3) occurred at >10% incidence across all breast cancers; however, there were numerous subtype-assocd. and novel gene mutations including the enrichment of specific mutations in GATA3, PIK3CA and MAP3K1 with the luminal A subtype.  We identified two novel protein-expression-defined subgroups, possibly produced by stromal/microenvironmental elements, and integrated analyses identified specific signaling pathways dominant in each mol. subtype including a HER2/phosphorylated HER2/EGFR/phosphorylated EGFR signature within the HER2-enriched expression subtype.  Comparison of basal-like breast tumors with high-grade serous ovarian tumors showed many mol. commonalities, indicating a related etiol. and similar therapeutic opportunities.  The biol. finding of the four main breast cancer subtypes caused by different subsets of genetic and epigenetic abnormalities raises the hypothesis that much of the clin. observable plasticity and heterogeneity occurs within, and not across, these major biol. subtypes of breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo931CeJ0ZZBrVg90H21EOLACvtfcHk0lhdIFmneKqw3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlyltrvN&md5=0836d0dd2c87f61c82fc0c5f33859407</span></div><a href="/servlet/linkout?suffix=cit142a&amp;dbid=16384&amp;doi=10.1038%2Fnature11412&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11412%26sid%3Dliteratum%253Aachs%26aulast%3DKoboldt%26aufirst%3DD.%2BC.%26aulast%3DFulton%26aufirst%3DR.%2BS.%26aulast%3DMcLellan%26aufirst%3DM.%2BD.%26aulast%3DSchmidt%26aufirst%3DH.%26aulast%3DKalicki-Veizer%26aufirst%3DJ.%26aulast%3DMcMichael%26aufirst%3DJ.%2BF.%26aulast%3DFulton%26aufirst%3DL.%2BL.%26aulast%3DDooling%26aufirst%3DD.%2BJ.%26aulast%3DDing%26aufirst%3DL.%26aulast%3DMardis%26aufirst%3DE.%2BR.%26aulast%3DWilson%26aufirst%3DR.%2BK.%26aulast%3DAlly%26aufirst%3DA.%26aulast%3DBalasundaram%26aufirst%3DM.%26aulast%3DButterfield%26aufirst%3DY.%2BS.%2BN.%26aulast%3DCarlsen%26aufirst%3DR.%26aulast%3DCarter%26aufirst%3DC.%26aulast%3DChu%26aufirst%3DA.%26aulast%3DChuah%26aufirst%3DE.%26aulast%3DChun%26aufirst%3DH.-J.%2BE.%26aulast%3DCoope%26aufirst%3DR.%2BJ.%2BN.%26aulast%3DDhalla%26aufirst%3DN.%26aulast%3DGuin%26aufirst%3DR.%26aulast%3DHirst%26aufirst%3DC.%26aulast%3DHirst%26aufirst%3DM.%26aulast%3DHolt%26aufirst%3DR.%2BA.%26aulast%3DLee%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DH.%2BI.%26aulast%3DMayo%26aufirst%3DM.%26aulast%3DMoore%26aufirst%3DR.%2BA.%26aulast%3DMungall%26aufirst%3DA.%2BJ.%26aulast%3DPleasance%26aufirst%3DE.%26aulast%3DGordon%2BRobertson%26aufirst%3DA.%26aulast%3DSchein%26aufirst%3DJ.%2BE.%26aulast%3DShafiei%26aufirst%3DA.%26aulast%3DSipahimalani%26aufirst%3DP.%26aulast%3DSlobodan%26aufirst%3DJ.%2BR.%26aulast%3DStoll%26aufirst%3DD.%26aulast%3DTam%26aufirst%3DA.%26aulast%3DThiessen%26aufirst%3DN.%26aulast%3DVarhol%26aufirst%3DR.%2BJ.%26aulast%3DWye%26aufirst%3DN.%26aulast%3DZeng%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DBirol%26aufirst%3DI.%26aulast%3DJones%26aufirst%3DS.%2BJ.%2BM.%26aulast%3DMarra%26aufirst%3DM.%2BA.%26aulast%3DCherniack%26aufirst%3DA.%2BD.%26aulast%3DSaksena%26aufirst%3DG.%26aulast%3DOnofrio%26aufirst%3DR.%2BC.%26aulast%3DPho%26aufirst%3DN.%2BH.%26aulast%3DCarter%26aufirst%3DS.%2BL.%26aulast%3DSchumacher%26aufirst%3DS.%2BE.%26aulast%3DTabak%26aufirst%3DB.%26aulast%3DHernandez%26aufirst%3DB.%26aulast%3DGentry%26aufirst%3DJ.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DCrenshaw%26aufirst%3DA.%26aulast%3DArdlie%26aufirst%3DK.%26aulast%3DBeroukhim%26aufirst%3DR.%26aulast%3DWinckler%26aufirst%3DW.%26aulast%3DGetz%26aufirst%3DG.%26aulast%3DGabriel%26aufirst%3DS.%2BB.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DChin%26aufirst%3DL.%26aulast%3DPark%26aufirst%3DP.%2BJ.%26aulast%3DKucherlapati%26aufirst%3DR.%26aulast%3DHoadley%26aufirst%3DK.%2BA.%26aulast%3DTodd%2BAuman%26aufirst%3DJ.%26aulast%3DFan%26aufirst%3DC.%26aulast%3DTurman%26aufirst%3DY.%2BJ.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DTopal%26aufirst%3DM.%2BD.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DChao%26aufirst%3DH.-H.%26aulast%3DPrat%26aufirst%3DA.%26aulast%3DSilva%26aufirst%3DG.%2BO.%26aulast%3DIglesia%26aufirst%3DM.%2BD.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DUsary%26aufirst%3DJ.%26aulast%3DBerg%26aufirst%3DJ.%2BS.%26aulast%3DAdams%26aufirst%3DM.%26aulast%3DBooker%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DGulabani%26aufirst%3DA.%26aulast%3DBodenheimer%26aufirst%3DT.%26aulast%3DHoyle%26aufirst%3DA.%2BP.%26aulast%3DSimons%26aufirst%3DJ.%2BV.%26aulast%3DSoloway%26aufirst%3DM.%2BG.%26aulast%3DMose%26aufirst%3DL.%2BE.%26aulast%3DJefferys%26aufirst%3DS.%2BR.%26aulast%3DBalu%26aufirst%3DS.%26aulast%3DParker%26aufirst%3DJ.%2BS.%26aulast%3DNeil%2BHayes%26aufirst%3DD.%26aulast%3DPerou%26aufirst%3DC.%2BM.%26aulast%3DMalik%26aufirst%3DS.%26aulast%3DMahurkar%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DWeisenberger%26aufirst%3DD.%2BJ.%26aulast%3DTriche%26aufirst%3DT.%26aulast%3DLai%26aufirst%3DP.%2BH.%26aulast%3DBootwalla%26aufirst%3DM.%2BS.%26aulast%3DMaglinte%26aufirst%3DD.%2BT.%26aulast%3DBerman%26aufirst%3DB.%2BP.%26aulast%3DVan%2BDen%2BBerg%26aufirst%3DD.%2BJ.%26aulast%3DBaylin%26aufirst%3DS.%2BB.%26aulast%3DLaird%26aufirst%3DP.%2BW.%26aulast%3DCreighton%26aufirst%3DC.%2BJ.%26aulast%3DDonehower%26aufirst%3DL.%2BA.%26aulast%3DGetz%26aufirst%3DG.%26aulast%3DNoble%26aufirst%3DM.%26aulast%3DVoet%26aufirst%3DD.%26aulast%3DSaksena%26aufirst%3DG.%26aulast%3DGehlenborg%26aufirst%3DN.%26aulast%3DDiCara%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DC.-J.%26aulast%3DYingchun%2BLiu%26aufirst%3DS.%26aulast%3DLawrence%26aufirst%3DM.%2BS.%26aulast%3DZou%26aufirst%3DL.%26aulast%3DSivachenko%26aufirst%3DA.%26aulast%3DLin%26aufirst%3DP.%26aulast%3DStojanov%26aufirst%3DP.%26aulast%3DJing%26aufirst%3DR.%26aulast%3DCho%26aufirst%3DJ.%26aulast%3DSinha%26aufirst%3DR.%26aulast%3DPark%26aufirst%3DR.%2BW.%26aulast%3DNazaire%26aufirst%3DM.-D.%26aulast%3DRobinson%26aufirst%3DJ.%26aulast%3DThorvaldsdottir%26aufirst%3DH.%26aulast%3DMesirov%26aufirst%3DJ.%26aulast%3DPark%26aufirst%3DP.%2BJ.%26aulast%3DChin%26aufirst%3DL.%26aulast%3DReynolds%26aufirst%3DS.%26aulast%3DKreisberg%26aufirst%3DR.%2BB.%26aulast%3DBernard%26aufirst%3DB.%26aulast%3DBressler%26aufirst%3DR.%26aulast%3DErkkila%26aufirst%3DT.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DThorsson%26aufirst%3DV.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DShmulevich%26aufirst%3DI.%26aulast%3DCiriello%26aufirst%3DG.%26aulast%3DWeinhold%26aufirst%3DN.%26aulast%3DSchultz%26aufirst%3DN.%26aulast%3DGao%26aufirst%3DJ.%26aulast%3DCerami%26aufirst%3DE.%26aulast%3DGross%26aufirst%3DB.%26aulast%3DJacobsen%26aufirst%3DA.%26aulast%3DSinha%26aufirst%3DR.%26aulast%3DArman%2BAksoy%26aufirst%3DB.%26aulast%3DAntipin%26aufirst%3DY.%26aulast%3DReva%26aufirst%3DB.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DTaylor%26aufirst%3DB.%2BS.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DSander%26aufirst%3DC.%26aulast%3DAnur%26aufirst%3DP.%26aulast%3DSpellman%26aufirst%3DP.%2BT.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DVerhaak%26aufirst%3DR.%2BR.%2BG.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DAkbani%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DBroom%26aufirst%3DB.%2BM.%26aulast%3DCasasent%26aufirst%3DT.%2BD.%26aulast%3DWakefield%26aufirst%3DC.%26aulast%3DUnruh%26aufirst%3DA.%2BK.%26aulast%3DBaggerly%26aufirst%3DK.%26aulast%3DCoombes%26aufirst%3DK.%26aulast%3DWeinstein%26aufirst%3DJ.%2BN.%26aulast%3DHaussler%26aufirst%3DD.%26aulast%3DBenz%26aufirst%3DC.%2BC.%26aulast%3DStuart%26aufirst%3DJ.%2BM.%26aulast%3DBenz%26aufirst%3DS.%2BC.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DSzeto%26aufirst%3DC.%2BC.%26aulast%3DScott%26aufirst%3DG.%2BK.%26aulast%3DYau%26aufirst%3DC.%26aulast%3DPaull%26aufirst%3DE.%2BO.%26aulast%3DCarlin%26aufirst%3DD.%26aulast%3DWong%26aufirst%3DC.%26aulast%3DSokolov%26aufirst%3DA.%26aulast%3DThusberg%26aufirst%3DJ.%26aulast%3DMooney%26aufirst%3DS.%26aulast%3DNg%26aufirst%3DS.%26aulast%3DGoldstein%26aufirst%3DT.%2BC.%26aulast%3DEllrott%26aufirst%3DK.%26aulast%3DGrifford%26aufirst%3DM.%26aulast%3DWilks%26aufirst%3DC.%26aulast%3DMa%26aufirst%3DS.%26aulast%3DCraft%26aufirst%3DB.%26aulast%3DYan%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DMeerzaman%26aufirst%3DD.%26aulast%3DGastier-Foster%26aufirst%3DJ.%2BM.%26aulast%3DBowen%26aufirst%3DJ.%26aulast%3DRamirez%26aufirst%3DN.%2BC.%26aulast%3DBlack%26aufirst%3DA.%2BD.%26aulast%3DPyatt%26aufirst%3DR.%2BE.%26aulast%3DWhite%26aufirst%3DP.%26aulast%3DZmuda%26aufirst%3DE.%2BJ.%26aulast%3DFrick%26aufirst%3DJ.%26aulast%3DLichtenberg%26aufirst%3DT.%2BM.%26aulast%3DBrookens%26aufirst%3DR.%26aulast%3DGeorge%26aufirst%3DM.%2BM.%26aulast%3DGerken%26aufirst%3DM.%2BA.%26aulast%3DHarper%26aufirst%3DH.%2BA.%26aulast%3DLeraas%26aufirst%3DK.%2BM.%26aulast%3DWise%26aufirst%3DL.%2BJ.%26aulast%3DTabler%26aufirst%3DT.%2BR.%26aulast%3DMcAllister%26aufirst%3DC.%26aulast%3DBarr%26aufirst%3DT.%26aulast%3DHart-Kothari%26aufirst%3DM.%26aulast%3DTarvin%26aufirst%3DK.%26aulast%3DSaller%26aufirst%3DC.%26aulast%3DSandusky%26aufirst%3DG.%26aulast%3DMitchell%26aufirst%3DC.%26aulast%3DIacocca%26aufirst%3DM.%2BV.%26aulast%3DBrown%26aufirst%3DJ.%26aulast%3DRabeno%26aufirst%3DB.%26aulast%3DCzerwinski%26aufirst%3DC.%26aulast%3DPetrelli%26aufirst%3DN.%26aulast%3DDolzhansky%26aufirst%3DO.%26aulast%3DAbramov%26aufirst%3DM.%26aulast%3DVoronina%26aufirst%3DO.%26aulast%3DPotapova%26aufirst%3DO.%26aulast%3DMarks%26aufirst%3DJ.%2BR.%26aulast%3DSuchorska%26aufirst%3DW.%2BM.%26aulast%3DMurawa%26aufirst%3DD.%26aulast%3DKycler%26aufirst%3DW.%26aulast%3DIbbs%26aufirst%3DM.%26aulast%3DKorski%26aufirst%3DK.%26aulast%3DSpycha%25C5%2582a%26aufirst%3DA.%26aulast%3DMurawa%26aufirst%3DP.%26aulast%3DBrzezi%25C5%2584ski%26aufirst%3DJ.%2BJ.%26aulast%3DPerz%26aufirst%3DH.%26aulast%3D%25C5%2581a%25C5%25BAniak%26aufirst%3DR.%26aulast%3DTeresiak%26aufirst%3DM.%26aulast%3DTatka%26aufirst%3DH.%26aulast%3DLeporowska%26aufirst%3DE.%26aulast%3DBogusz-Czerniewicz%26aufirst%3DM.%26aulast%3DMalicki%26aufirst%3DJ.%26aulast%3DMackiewicz%26aufirst%3DA.%26aulast%3DWiznerowicz%26aufirst%3DM.%26aulast%3DVan%2BLe%26aufirst%3DX.%26aulast%3DKohl%26aufirst%3DB.%26aulast%3DViet%2BTien%26aufirst%3DN.%26aulast%3DThorp%26aufirst%3DR.%26aulast%3DVan%2BBang%26aufirst%3DN.%26aulast%3DSussman%26aufirst%3DH.%26aulast%3DDuc%2BPhu%26aufirst%3DB.%26aulast%3DHajek%26aufirst%3DR.%26aulast%3DPhi%2BHung%26aufirst%3DN.%26aulast%3DViet%2BThe%2BPhuong%26aufirst%3DT.%26aulast%3DQuyet%2BThang%26aufirst%3DH.%26aulast%3DZaki%2BKhan%26aufirst%3DK.%26aulast%3DPenny%26aufirst%3DR.%26aulast%3DMallery%26aufirst%3DD.%26aulast%3DCurley%26aufirst%3DE.%26aulast%3DShelton%26aufirst%3DC.%26aulast%3DYena%26aufirst%3DP.%26aulast%3DIngle%26aufirst%3DJ.%2BN.%26aulast%3DCouch%26aufirst%3DF.%2BJ.%26aulast%3DLingle%26aufirst%3DW.%2BL.%26aulast%3DKing%26aufirst%3DT.%2BA.%26aulast%3DMaria%2BGonzalez-Angulo%26aufirst%3DA.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DDyer%26aufirst%3DM.%2BD.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DMeng%26aufirst%3DX.%26atitle%3DComprehensive%2520Molecular%2520Portraits%2520of%2520Human%2520Breast%2520Tumours%26jtitle%3DNature%26date%3D2012%26volume%3D490%26spage%3D61%26epage%3D70%26doi%3D10.1038%2Fnature11412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit142b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sabine, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crozier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brookes, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drake, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piper, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Velde, C. J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasenburg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kieback, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markopoulos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dirix, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seynaeve, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rea, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartlett, J. M. S.</span></span> <span> </span><span class="NLM_article-title">Mutational Analysis of PI3K/AKT Signaling Pathway in Tamoxifen Exemestane Adjuvant Multinational Pathology Study</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">2951</span>– <span class="NLM_lpage">2958</span>, <span class="refDoi"> DOI: 10.1200/JCO.2013.53.8272</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1200%2FJCO.2013.53.8272" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=25071141" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVClt7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=2951-2958&author=V.+S.+Sabineauthor=C.+Crozierauthor=C.+L.+Brookesauthor=C.+Drakeauthor=T.+Piperauthor=C.+J.+H.+van+de+Veldeauthor=A.+Hasenburgauthor=D.+G.+Kiebackauthor=C.+Markopoulosauthor=L.+Dirixauthor=C.+Seynaeveauthor=D.+W.+Reaauthor=J.+M.+S.+Bartlett&title=Mutational+Analysis+of+PI3K%2FAKT+Signaling+Pathway+in+Tamoxifen+Exemestane+Adjuvant+Multinational+Pathology+Study&doi=10.1200%2FJCO.2013.53.8272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142bR"><div class="casContent"><span class="casTitleNuber">142b</span><div class="casTitle"><span class="NLM_cas:atitle">Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study</span></div><div class="casAuthors">Sabine, Vicky S.; Crozier, Cheryl; Brookes, Cassandra L.; Drake, Camilla; Piper, Tammy; van de Velde, Cornelis J. H.; Hasenburg, Annette; Kieback, Dirk G.; Markopoulos, Christos; Dirix, Luc; Seynaeve, Caroline; Rea, Daniel W.; Bartlett, John M. S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">2951-2958</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Deregulation of key PI3K/AKT pathway genes may contribute to endocrine resistance in breast cancer (BC).  PIK3CA is the most frequently mutated gene in luminal BC (∼ 35%); however, the effect of mutations in helical vs. kinase domains remains controversial.  We hypothesize that improved outcomes occur in patients with estrogen receptor-pos. (ER pos.) BC receiving endocrine therapy and possessing PIK3CA mutations.  Materials and Methods: DNA was extd. from 4,540 formalin-fixed paraffin-embedded BC samples from the Exemestane Vs. Tamoxifen-Exemestane pathol. study.  Mutational analyses were performed for 25 mutations (PIK3CA×10, AKT1×1, KRAS×5, HRAS×3, NRAS×2 and BRAF×4).  Results: PIK3CA mutations were frequent (39.8%), whereas RAS/RAF mutations were rare (< 1%).  In univariable analyses PIK3CA mutations were assocd. with significantly improved 5-yr distant relapse-free survival (DRFS; HR, 0.76; 95% CI, 0.63 to 0.91; P = .003).  However, a multivariable anal. correcting for known clin. and biol. prognostic factors failed to demonstrate that PIK3CA mutation status is an independent prognostic marker for DRFS (HR, 0.92; 95% CI, 0.75 to 1.12; P = .4012).  PIK3CA mutations were more frequent in low-risk luminal BCs (eg, grade 1 node v 3, node-neg. v -pos.), confounding the relationship between mutations and outcome.  Conclusion PIK3CA mutations are present in approx. 40% of luminal BCs but are not an independent predictor of outcome in the context of endocrine therapy, whereas RAS/RAF mutations are rare in luminal BC.  A complex relationship between low-risk cancers and PIK3CA mutations was identified.  Although the PI3K/AKT pathway remains a viable therapeutic target as the result of a high mutation frequency, PIK3CA mutations do not seem to affect residual risk following treatment with endocrine therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopC9qdV5seeLVg90H21EOLACvtfcHk0lidwEkhNN638Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVClt7%252FI&md5=37cab79073c6cc4df51807e53f456c81</span></div><a href="/servlet/linkout?suffix=cit142b&amp;dbid=16384&amp;doi=10.1200%2FJCO.2013.53.8272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2013.53.8272%26sid%3Dliteratum%253Aachs%26aulast%3DSabine%26aufirst%3DV.%2BS.%26aulast%3DCrozier%26aufirst%3DC.%26aulast%3DBrookes%26aufirst%3DC.%2BL.%26aulast%3DDrake%26aufirst%3DC.%26aulast%3DPiper%26aufirst%3DT.%26aulast%3Dvan%2Bde%2BVelde%26aufirst%3DC.%2BJ.%2BH.%26aulast%3DHasenburg%26aufirst%3DA.%26aulast%3DKieback%26aufirst%3DD.%2BG.%26aulast%3DMarkopoulos%26aufirst%3DC.%26aulast%3DDirix%26aufirst%3DL.%26aulast%3DSeynaeve%26aufirst%3DC.%26aulast%3DRea%26aufirst%3DD.%2BW.%26aulast%3DBartlett%26aufirst%3DJ.%2BM.%2BS.%26atitle%3DMutational%2520Analysis%2520of%2520PI3K%252FAKT%2520Signaling%2520Pathway%2520in%2520Tamoxifen%2520Exemestane%2520Adjuvant%2520Multinational%2520Pathology%2520Study%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D32%26spage%3D2951%26epage%3D2958%26doi%3D10.1200%2FJCO.2013.53.8272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Furet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guagnano, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairhurst, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imbach-Weese, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruce, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritsch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blasco, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aichholz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caravatti, G.</span></span> <span> </span><span class="NLM_article-title">Discovery of NVP-BYL719 a Potent and Selective Phosphatidylinositol-3 Kinase Alpha Inhibitor Selected for Clinical Evaluation</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3741</span>– <span class="NLM_lpage">3748</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.05.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2Fj.bmcl.2013.05.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=23726034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC3sXosFaisrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=3741-3748&author=P.+Furetauthor=V.+Guagnanoauthor=R.+A.+Fairhurstauthor=P.+Imbach-Weeseauthor=I.+Bruceauthor=M.+Knappauthor=C.+Fritschauthor=F.+Blascoauthor=J.+Blanzauthor=R.+Aichholzauthor=J.+Hamonauthor=D.+Fabbroauthor=G.+Caravatti&title=Discovery+of+NVP-BYL719+a+Potent+and+Selective+Phosphatidylinositol-3+Kinase+Alpha+Inhibitor+Selected+for+Clinical+Evaluation&doi=10.1016%2Fj.bmcl.2013.05.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143aR"><div class="casContent"><span class="casTitleNuber">143a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation</span></div><div class="casAuthors">Furet, Pascal; Guagnano, Vito; Fairhurst, Robin A.; Imbach-Weese, Patricia; Bruce, Ian; Knapp, Mark; Fritsch, Christine; Blasco, Francesca; Blanz, Joachim; Aichholz, Reiner; Hamon, Jacques; Fabbro, Doriano; Caravatti, Giorgio</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3741-3748</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Phosphatidylinositol-3-kinase α (PI3Kα) is a therapeutic target of high interest in anticancer drug research.  On the basis of a binding model rationalizing the high selectivity and potency of a particular series of 2-aminothiazole compds. in inhibiting PI3Kα, a medicinal chem. program has led to the discovery of the clin. candidate NVP-BYL719 I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraN93Vwrfb4bVg90H21EOLACvtfcHk0lidwEkhNN638Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXosFaisrY%253D&md5=a0d2d69e01e7a82a5fed04114105925e</span></div><a href="/servlet/linkout?suffix=cit143a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.05.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.05.007%26sid%3Dliteratum%253Aachs%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DGuagnano%26aufirst%3DV.%26aulast%3DFairhurst%26aufirst%3DR.%2BA.%26aulast%3DImbach-Weese%26aufirst%3DP.%26aulast%3DBruce%26aufirst%3DI.%26aulast%3DKnapp%26aufirst%3DM.%26aulast%3DFritsch%26aufirst%3DC.%26aulast%3DBlasco%26aufirst%3DF.%26aulast%3DBlanz%26aufirst%3DJ.%26aulast%3DAichholz%26aufirst%3DR.%26aulast%3DHamon%26aufirst%3DJ.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DCaravatti%26aufirst%3DG.%26atitle%3DDiscovery%2520of%2520NVP-BYL719%2520a%2520Potent%2520and%2520Selective%2520Phosphatidylinositol-3%2520Kinase%2520Alpha%2520Inhibitor%2520Selected%2520for%2520Clinical%2520Evaluation%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D3741%26epage%3D3748%26doi%3D10.1016%2Fj.bmcl.2013.05.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit143b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Gallou, I. S.</span>; <span class="NLM_string-name">Gauer, C.</span>; <span class="NLM_string-name">Stowasser, F.</span></span> <span> </span><span class="NLM_article-title">Preparation of Crystalline Form of (<i>S</i>)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-(4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)pyridin-4-yl]thiazol-2-yl)Amide and Its Use as PI3K Inhibitor</span>. <span class="NLM_patent">WO 2012016970 A1</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=I.+S.+Gallou&author=C.+Gauer&author=F.+Stowasser&title=Preparation+of+Crystalline+Form+of+%28S%29-Pyrrolidine-1%2C2-dicarboxylic+acid+2-amide+1-%284-methyl-5-%5B2-%282%2C2%2C2-trifluoro-1%2C1-dimethylethyl%29pyridin-4-yl%5Dthiazol-2-yl%29Amide+and+Its+Use+as+PI3K+Inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit143b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGallou%26aufirst%3DI.%2BS.%26atitle%3DPreparation%2520of%2520Crystalline%2520Form%2520of%2520%2528S%2529-Pyrrolidine-1%252C2-dicarboxylic%2520acid%25202-amide%25201-%25284-methyl-5-%255B2-%25282%252C2%252C2-trifluoro-1%252C1-dimethylethyl%2529pyridin-4-yl%255Dthiazol-2-yl%2529Amide%2520and%2520Its%2520Use%2520as%2520PI3K%2520Inhibitor%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit143c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Caponigro, G.</span>; <span class="NLM_string-name">Horn-Spirohn, T.</span>; <span class="NLM_string-name">Lehar, J.</span></span> <span> </span><span class="NLM_article-title">Pharmaceutical Combination Comprising the PI3K Inhibitor Alpelisib and the B-Raf Inhibitor Dabrafenib; the Use of Such Combination in the Treatment or Prevention of Cancer</span>. <span class="NLM_patent">WO 2017037573 A1</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=G.+Caponigro&author=T.+Horn-Spirohn&author=J.+Lehar&title=Pharmaceutical+Combination+Comprising+the+PI3K+Inhibitor+Alpelisib+and+the+B-Raf+Inhibitor+Dabrafenib%3B+the+Use+of+Such+Combination+in+the+Treatment+or+Prevention+of+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit143c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCaponigro%26aufirst%3DG.%26atitle%3DPharmaceutical%2520Combination%2520Comprising%2520the%2520PI3K%2520Inhibitor%2520Alpelisib%2520and%2520the%2520B-Raf%2520Inhibitor%2520Dabrafenib%253B%2520the%2520Use%2520of%2520Such%2520Combination%2520in%2520the%2520Treatment%2520or%2520Prevention%2520of%2520Cancer%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit143d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, R.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuo, Z.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y.-P.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, Antitumor Activity and Theoretical Calculation of Novel PI3Ka Inhibitors</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">103737</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2020.103737</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2Fj.bioorg.2020.103737" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=32193031" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlt1eltL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2020&pages=103737&author=R.-Y.+Jinauthor=T.+Tangauthor=S.+Zhouauthor=X.+Longauthor=H.+Guoauthor=J.+Zhouauthor=H.+Yanauthor=Z.+Liauthor=Z.-Y.+Zuoauthor=H.-L.+Xieauthor=Y.-P.+Tang&title=Design%2C+Synthesis%2C+Antitumor+Activity+and+Theoretical+Calculation+of+Novel+PI3Ka+Inhibitors&doi=10.1016%2Fj.bioorg.2020.103737"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143dR"><div class="casContent"><span class="casTitleNuber">143d</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, antitumor activity and theoretical calculation of novel PI3Ka inhibitors</span></div><div class="casAuthors">Jin, Ru-Yi; Tang, Tian; Zhou, Sha; Long, Xu; Guo, Hui; Zhou, Jing; Yan, Hao; Li, Zhi; Zuo, Zheng-Yu; Xie, Hong-Lei; Tang, Yu-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">103737</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">PI3Kα has been identified as an ideal target to treat with PIK3CA gene mutation disease, including drugs such as Alpelisib and Copanlisib.  Five purine analogs and four thiazole analogs were designed and synthesized.  Their enzymic activity against PI3Ka/β/γ/δ were tested, resp.  All compds. showed excellent selectivity in modulating PI3Ka activity, and parts of the compds. showed good inhibition.  Meanwhile, Autodock 4.2 was used to explore the binding mode of I (X = CH2), the most potent compd., with the target protein.  In addn., DFT was used to calc. the HOMO-LUMO maps of the compds. I (X = CH2, O)and pos. control.  This paper will provide some useful information for further drug design of PI3Kα inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpV3yML-gA7ZrVg90H21EOLACvtfcHk0lhR2k4swC2yHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlt1eltL0%253D&md5=a37c7739138ee57a14c6a91688e3821e</span></div><a href="/servlet/linkout?suffix=cit143d&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2020.103737&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2020.103737%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DR.-Y.%26aulast%3DTang%26aufirst%3DT.%26aulast%3DZhou%26aufirst%3DS.%26aulast%3DLong%26aufirst%3DX.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DYan%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DZuo%26aufirst%3DZ.-Y.%26aulast%3DXie%26aufirst%3DH.-L.%26aulast%3DTang%26aufirst%3DY.-P.%26atitle%3DDesign%252C%2520Synthesis%252C%2520Antitumor%2520Activity%2520and%2520Theoretical%2520Calculation%2520of%2520Novel%2520PI3Ka%2520Inhibitors%26jtitle%3DBioorg.%2520Chem.%26date%3D2020%26volume%3D98%26spage%3D103737%26doi%3D10.1016%2Fj.bioorg.2020.103737" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Erb, B.</span>; <span class="NLM_string-name">Gallou, I. S.</span>; <span class="NLM_string-name">Kleinbeck, F. K.</span></span> <span> </span><span class="NLM_article-title">Process for the Preparation of <i>N</i>1-(Pyridinylthiazolyl)pyrrolidine-1,2-dicarboxamide Derivatives</span>. <span class="NLM_patent">WO 2012117071 A1</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=B.+Erb&author=I.+S.+Gallou&author=F.+K.+Kleinbeck&title=Process+for+the+Preparation+of+N1-%28Pyridinylthiazolyl%29pyrrolidine-1%2C2-dicarboxamide+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DErb%26aufirst%3DB.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%2520N1-%2528Pyridinylthiazolyl%2529pyrrolidine-1%252C2-dicarboxamide%2520Derivatives%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duggan, S.</span></span> <span> </span><span class="NLM_article-title">Darolutamide: First Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">1813</span>– <span class="NLM_lpage">1818</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01212-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs40265-019-01212-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31605368" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFGmsLzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=1813-1818&author=A.+Markhamauthor=S.+Duggan&title=Darolutamide%3A+First+Approval&doi=10.1007%2Fs40265-019-01212-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Darolutamide: First Approval</span></div><div class="casAuthors">Markham, Anthony; Duggan, Sean</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1813-1818</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Darolutamide (NUBEQA) is a structurally distinct non-steroidal androgen receptor antagonist being developed by Orion and Bayer as a treatment for prostate cancer.  Based on pos. results in the phase III ARAMIS trial, darolutamide was recently approved in the USA for the treatment of men with non-metastatic castration-resistant prostate cancer.  This article summarizes the milestones in the development of darolutamide leading to this first approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-yVESrmxlELVg90H21EOLACvtfcHk0lhR2k4swC2yHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFGmsLzE&md5=1d5a9ca159a713d87f87ee4945e03c62</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01212-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01212-y%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26aulast%3DDuggan%26aufirst%3DS.%26atitle%3DDarolutamide%253A%2520First%2520Approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D1813%26epage%3D1818%26doi%3D10.1007%2Fs40265-019-01212-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gelmann, E. P.</span></span> <span> </span><span class="NLM_article-title">Molecular Biology of the Androgen Receptor</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">3001</span>– <span class="NLM_lpage">3015</span>, <span class="refDoi"> DOI: 10.1200/JCO.2002.10.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1200%2FJCO.2002.10.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=12089231" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BD38Xlslyrt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2002&pages=3001-3015&author=E.+P.+Gelmann&title=Molecular+Biology+of+the+Androgen+Receptor&doi=10.1200%2FJCO.2002.10.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular biology of the androgen receptor</span></div><div class="casAuthors">Gelmann, Edward P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3001-3015</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Androgen receptor (AR) is a member of the steroid hormone receptor family of mols.  AR primarily is responsible for mediating the physiol. effects of androgens by binding to specific DNA sequences that influence transcription of androgen-responsive genes.  The three-dimensional structure of the AR ligand-binding domain has shown it is similar to other steroid hormone receptors and that ligand binding alters the protein conformation to allow binding of coactivator mols. that amplify the hormone signal and mediate transcriptional initiation.  However, AR also undergoes intramol. interactions that regulate its interactions with coactivators and influence its activity.  A large no. of naturally occurring mutations of the human AR gene have provided important information about AR mol. structure and intermol. interactions.  AR is also a crit. mediator of prostate cancer promotion, conferring growth signals to prostate cancer cells throughout the natural history of the disease.  Late-stage prostate cancer, unresponsive to hormonal deprivation, sustains AR signaling through a diverse array of mol. strategies.  Variations in the AR gene may also confer genetic predisposition to prostate cancer development and severity.  Further understanding of AR action and new strategies to interfere with AR signaling hold promise for improving prostate cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGow1FLAt0Xj67Vg90H21EOLACvtfcHk0lhR2k4swC2yHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xlslyrt7c%253D&md5=9bb664012a4ef9cdc841e56abddb5231</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1200%2FJCO.2002.10.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2002.10.018%26sid%3Dliteratum%253Aachs%26aulast%3DGelmann%26aufirst%3DE.%2BP.%26atitle%3DMolecular%2520Biology%2520of%2520the%2520Androgen%2520Receptor%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2002%26volume%3D20%26spage%3D3001%26epage%3D3015%26doi%3D10.1200%2FJCO.2002.10.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Taplin, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balk, S. P.</span></span> <span> </span><span class="NLM_article-title">Androgen Receptor: A Key Molecule in the Progression of Prostate Cancer to Hormone Independence</span>. <i>J. Cell. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">483</span>– <span class="NLM_lpage">190</span>, <span class="refDoi"> DOI: 10.1002/jcb.10653</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1002%2Fjcb.10653" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=14755679" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsVWjsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2004&pages=483-190&author=M.+E.+Taplinauthor=S.+P.+Balk&title=Androgen+Receptor%3A+A+Key+Molecule+in+the+Progression+of+Prostate+Cancer+to+Hormone+Independence&doi=10.1002%2Fjcb.10653"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147aR"><div class="casContent"><span class="casTitleNuber">147a</span><div class="casTitle"><span class="NLM_cas:atitle">Androgen receptor: A key molecule in the progression of prostate cancer to hormone independence</span></div><div class="casAuthors">Taplin, Mary-Ellen; Balk, Steven P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Biochemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">483-490</span>CODEN:
                <span class="NLM_cas:coden">JCEBD5</span>;
        ISSN:<span class="NLM_cas:issn">0730-2312</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">A review.  Despite earlier detection and recent advances in surgery and radiation, prostate cancer is second only to lung cancer in male cancer deaths in the United States.  Hormone therapy in the form of medical or surgical castration remains the mainstay of systemic treatment in prostate cancer.  Over the last 15 yr with the clin. use of prostate specific antigen (PSA), there has been a shift to using hormone therapy earlier in the disease course and for longer duration.  Despite initial favorable response to hormone therapy, over a period of time these tumors will develop androgen-independence that results in death.  The androgen receptor (AR) is central to the initiation and growth of prostate cancer and to its response to hormone therapy.  Analyses have shown that AR continues to be expressed in androgen-independent tumors and AR signaling remains intact as demonstrated by the expression of the AR regulated gene, PSA.  Androgen-independent prostate cancers have demonstrated a variety of AR alterations that are either not found in hormone naive tumors or found at lower frequency.  These changes include AR amplification, AR point mutation, and changes in expression of AR co-regulatory proteins.  These AR changes result in a "super AR" that can respond to lower concns. of androgens or to a wider variety of agonistic ligands.  There is also mounting evidence that AR can be activated in a ligand independent fashion by compds. such as growth factors or cytokines working independently or in combination.  These growth factors working through receptor tyrosine kinase pathways may promote AR activation and growth in low androgen environments.  The clin. significance of these AR alterations in the development and progression of androgen-independent prostate cancer remains to be detd.  Understanding the changes in AR signaling in the evolution of androgen-independent prostate cancer will be key to the development of more effective hormone therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcsjFuYf-yBrVg90H21EOLACvtfcHk0lgg3VmQmV7-Kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsVWjsrc%253D&md5=2a61b4f669124bf5aba64a6b724dd7d4</span></div><a href="/servlet/linkout?suffix=cit147a&amp;dbid=16384&amp;doi=10.1002%2Fjcb.10653&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcb.10653%26sid%3Dliteratum%253Aachs%26aulast%3DTaplin%26aufirst%3DM.%2BE.%26aulast%3DBalk%26aufirst%3DS.%2BP.%26atitle%3DAndrogen%2520Receptor%253A%2520A%2520Key%2520Molecule%2520in%2520the%2520Progression%2520of%2520Prostate%2520Cancer%2520to%2520Hormone%2520Independence%26jtitle%3DJ.%2520Cell.%2520Biochem.%26date%3D2004%26volume%3D91%26spage%3D483%26epage%3D190%26doi%3D10.1002%2Fjcb.10653" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit147b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Heinlein, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span> <span> </span><span class="NLM_article-title">Androgen Receptor in Prostate Cancer</span>. <i>Endocr. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">276</span>– <span class="NLM_lpage">308</span>, <span class="refDoi"> DOI: 10.1210/er.2002-0032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1210%2Fer.2002-0032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=15082523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktFSqtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2004&pages=276-308&author=C.+A.+Heinleinauthor=C.+Chang&title=Androgen+Receptor+in+Prostate+Cancer&doi=10.1210%2Fer.2002-0032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147bR"><div class="casContent"><span class="casTitleNuber">147b</span><div class="casTitle"><span class="NLM_cas:atitle">Androgen receptor in prostate cancer</span></div><div class="casAuthors">Heinlein, Cynthia A.; Chang, Chawnshang</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine Reviews</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">276-308</span>CODEN:
                <span class="NLM_cas:coden">ERVIDP</span>;
        ISSN:<span class="NLM_cas:issn">0163-769X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">A review.  The normal development and maintenance of the prostate is dependent on androgen acting through the androgen receptor (AR).  AR remains important in the development and progression of prostate cancer.  AR expression is maintained throughout prostate cancer progression, and the majority of androgen-independent or hormone refractory prostate cancers express AR.  Mutation of AR, esp. mutations that result in a relaxation of AR ligand specificity, may contribute to the progression of prostate cancer and the failure of endocrine therapy by allowing AR transcriptional activation in response to antiandrogens or other endogenous hormones.  Similarly, alterations in the relative expression of AR coregulators have been found to occur with prostate cancer progression and may contribute to differences in AR ligand specificity or transcriptional activity.  Prostate cancer progression is also assocd. with increased growth factor prodn. and an altered response to growth factors by prostate cancer cells.  The kinase signal transduction cascades initiated by mitogenic growth factors modulate the transcriptional activity of AR and the interaction between AR and AR coactivators.  The inhibition of AR activity through mechanisms in addn. to androgen ablation, such as modulation of signal transduction pathways, may delay prostate cancer progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohu1DBHGGcpLVg90H21EOLACvtfcHk0lgg3VmQmV7-Kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktFSqtLY%253D&md5=26055b1c7af99c71c9c9f6143b97a5ef</span></div><a href="/servlet/linkout?suffix=cit147b&amp;dbid=16384&amp;doi=10.1210%2Fer.2002-0032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fer.2002-0032%26sid%3Dliteratum%253Aachs%26aulast%3DHeinlein%26aufirst%3DC.%2BA.%26aulast%3DChang%26aufirst%3DC.%26atitle%3DAndrogen%2520Receptor%2520in%2520Prostate%2520Cancer%26jtitle%3DEndocr.%2520Rev.%26date%3D2004%26volume%3D25%26spage%3D276%26epage%3D308%26doi%3D10.1210%2Fer.2002-0032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moilanen, A.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riikonen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oksala, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravanti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aho, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wohlfahrt, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nykänen, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Törmäkangas, O. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palvimo, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kallio, P. J.</span></span> <span> </span><span class="NLM_article-title">Discovery of ODM-201, a New-Generation Androgen Receptor Inhibitor Targeting Resistance Mechanisms to Androgen Signaling-Directed Prostate Cancer Therapies</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">12007</span>, <span class="refDoi"> DOI: 10.1038/srep12007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1038%2Fsrep12007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=26137992" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A280%3ADC%252BC28%252Fgs1Grtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=12007&author=A.-M.+Moilanenauthor=R.+Riikonenauthor=R.+Oksalaauthor=L.+Ravantiauthor=E.+Ahoauthor=G.+Wohlfahrtauthor=P.+S.+Nyk%C3%A4nenauthor=O.+P.+T%C3%B6rm%C3%A4kangasauthor=J.+J.+Palvimoauthor=P.+J.+Kallio&title=Discovery+of+ODM-201%2C+a+New-Generation+Androgen+Receptor+Inhibitor+Targeting+Resistance+Mechanisms+to+Androgen+Signaling-Directed+Prostate+Cancer+Therapies&doi=10.1038%2Fsrep12007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies</span></div><div class="casAuthors">Moilanen Anu-Maarit; Riikonen Reetta; Oksala Riikka; Ravanti Laura; Aho Eija; Wohlfahrt Gerd; Nykanen Pirjo S; Tormakangas Olli P; Kallio Pekka J; Palvimo Jorma J</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">12007</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Activation of androgen receptor (AR) is crucial for prostate cancer growth.  Remarkably, also castration-resistant prostate cancer (CRPC) is dependent on functional AR, and several mechanisms have been proposed to explain the addiction.  Known causes of CRPC include gene amplification and overexpression as well as point mutations of AR.  We report here the pharmacological profile of ODM-201, a novel AR inhibitor that showed significant antitumor activity and a favorable safety profile in phase 1/2 studies in men with CRPC.  ODM-201 is a full and high-affinity AR antagonist that, similar to second-generation antiandrogens enzalutamide and ARN-509, inhibits testosterone-induced nuclear translocation of AR.  Importantly, ODM-201 also blocks the activity of the tested mutant ARs arising in response to antiandrogen therapies, including the F876L mutation that confers resistance to enzalutamide and ARN-509.  In addition, ODM-201 reduces the growth of AR-overexpressing VCaP prostate cancer cells both in vitro and in a castration-resistant VCaP xenograft model.  In contrast to other antiandrogens, ODM-201 shows negligible brain penetrance and does not increase serum testosterone levels in mice.  In conclusion, ODM-201 is a potent AR inhibitor that overcomes resistance to AR-targeted therapies by antagonizing both overexpressed and mutated ARs.  ODM-201 is currently in a phase 3 trial in CRPC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRGSs0XLGfdrZHZzFRCXxVKfW6udTcc2eYWdt_ViO4N47ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252Fgs1Grtg%253D%253D&md5=b7dddd064bec0bf7c3b828028820cdc9</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1038%2Fsrep12007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep12007%26sid%3Dliteratum%253Aachs%26aulast%3DMoilanen%26aufirst%3DA.-M.%26aulast%3DRiikonen%26aufirst%3DR.%26aulast%3DOksala%26aufirst%3DR.%26aulast%3DRavanti%26aufirst%3DL.%26aulast%3DAho%26aufirst%3DE.%26aulast%3DWohlfahrt%26aufirst%3DG.%26aulast%3DNyk%25C3%25A4nen%26aufirst%3DP.%2BS.%26aulast%3DT%25C3%25B6rm%25C3%25A4kangas%26aufirst%3DO.%2BP.%26aulast%3DPalvimo%26aufirst%3DJ.%2BJ.%26aulast%3DKallio%26aufirst%3DP.%2BJ.%26atitle%3DDiscovery%2520of%2520ODM-201%252C%2520a%2520New-Generation%2520Androgen%2520Receptor%2520Inhibitor%2520Targeting%2520Resistance%2520Mechanisms%2520to%2520Androgen%2520Signaling-Directed%2520Prostate%2520Cancer%2520Therapies%26jtitle%3DSci.%2520Rep.%26date%3D2015%26volume%3D5%26spage%3D12007%26doi%3D10.1038%2Fsrep12007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Laitinen, I.</span>; <span class="NLM_string-name">Karjalainen, O.</span></span> <span> </span><span class="NLM_article-title">Process for the Preparation of Androgen Receptor Antagonists and Intermediates Thereof</span>. <span class="NLM_patent">WO 2016162604</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=I.+Laitinen&author=O.+Karjalainen&title=Process+for+the+Preparation+of+Androgen+Receptor+Antagonists+and+Intermediates+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit149a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLaitinen%26aufirst%3DI.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%2520Androgen%2520Receptor%2520Antagonists%2520and%2520Intermediates%2520Thereof%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit149b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, D. L.</span></span> <span> </span><span class="NLM_article-title">Review of Synthetic Routes and Crystalline Forms of the Antiandrogen Oncology Drugs Enzalutamide, Apalutamide, and Darolutamide</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">347</span>– <span class="NLM_lpage">362</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.0c00005</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.0c00005" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref149/cit149b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjtl2ku7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2020&pages=347-362&author=D.+L.+Hughes&title=Review+of+Synthetic+Routes+and+Crystalline+Forms+of+the+Antiandrogen+Oncology+Drugs+Enzalutamide%2C+Apalutamide%2C+and+Darolutamide&doi=10.1021%2Facs.oprd.0c00005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149bR"><div class="casContent"><span class="casTitleNuber">149b</span><div class="casTitle"><span class="NLM_cas:atitle">Review of Synthetic Routes and Crystalline Forms of the Anti-Androgen Oncology Drugs Enzalutamide, Apalutamide, and Darolutamide</span></div><div class="casAuthors">Hughes, David L.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">347-362</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This article reviewed the synthetic routes and final cryst. forms of recently approved anti-androgen drugs enzalutamide, apalutamide, and darolutamide, used for treatment of prostate cancer.  The patent literature was the primary source of information.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJxg3gDFfY3bVg90H21EOLACvtfcHk0liehw03Nn_h_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjtl2ku7k%253D&md5=4e5ef1b009701200500f5ea16744b1fa</span></div><a href="/servlet/linkout?suffix=cit149b&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.0c00005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.0c00005%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DD.%2BL.%26atitle%3DReview%2520of%2520Synthetic%2520Routes%2520and%2520Crystalline%2520Forms%2520of%2520the%2520Antiandrogen%2520Oncology%2520Drugs%2520Enzalutamide%252C%2520Apalutamide%252C%2520and%2520Darolutamide%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2020%26volume%3D24%26spage%3D347%26epage%3D362%26doi%3D10.1021%2Facs.oprd.0c00005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanna, K. S.</span></span> <span> </span><span class="NLM_article-title">Enfortumab Vedotin to Treat Urothelial Carcinoma</span>. <i>Drugs Today</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">335</span>, <span class="refDoi"> DOI: 10.1358/dot.2020.56.5.3127027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1358%2Fdot.2020.56.5.3127027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A280%3ADC%252BB38vmvVahtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2020&pages=329-335&author=K.+S.+Hanna&title=Enfortumab+Vedotin+to+Treat+Urothelial+Carcinoma&doi=10.1358%2Fdot.2020.56.5.3127027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Enfortumab vedotin to treat urothelial carcinoma</span></div><div class="casAuthors">Hanna K S</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of today (Barcelona, Spain : 1998)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">329-335</span>
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    </div><div class="casAbstract">The antibody-drug conjugate enfortumab vedotin is a fully humanized monoclonal antibody targeting Nectin-4 linked to a microtubule-disrupting agent, monomethyl auristatin E, via a protease-cleavable maleimidocaproyl valine-citrulline linker.  In this article, we provide a comprehensive review of the preclinical and clinical activity of enfortumab vedotin, which has been recently approved in the U.S. for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who have previously received a programmed cell death protein 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) inhibitor as well as platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting.  Enfortumab vedotin is the first antibody-drug conjugate approved for patients with urothelial carcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQJU-wjw_aULU2yPDyEFiigfW6udTcc2eZ5Xu1SaSiEELntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38vmvVahtQ%253D%253D&md5=cf5fecfaae37104c4a9218f741b0117f</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1358%2Fdot.2020.56.5.3127027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2020.56.5.3127027%26sid%3Dliteratum%253Aachs%26aulast%3DHanna%26aufirst%3DK.%2BS.%26atitle%3DEnfortumab%2520Vedotin%2520to%2520Treat%2520Urothelial%2520Carcinoma%26jtitle%3DDrugs%2520Today%26date%3D2020%26volume%3D56%26spage%3D329%26epage%3D335%26doi%3D10.1358%2Fdot.2020.56.5.3127027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Satpayev, D.</span>; <span class="NLM_string-name">Morrison, R. K.</span>; <span class="NLM_string-name">Morrison, K. J. M.</span>; <span class="NLM_string-name">Gudas, J.</span>; <span class="NLM_string-name">Jakobovits, A.</span>; <span class="NLM_string-name">Torgov, M.</span>; <span class="NLM_string-name">An, Z.</span></span> <span> </span><span class="NLM_article-title">Antibody–Drug Conjugates That Bind to 191P4D12 Proteins and Their Use in Treatment of Cancer</span>. <span class="NLM_patent">US 20120078028 A1</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=D.+Satpayev&author=R.+K.+Morrison&author=K.+J.+M.+Morrison&author=J.+Gudas&author=A.+Jakobovits&author=M.+Torgov&author=Z.+An&title=Antibody%E2%80%93Drug+Conjugates+That+Bind+to+191P4D12+Proteins+and+Their+Use+in+Treatment+of+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSatpayev%26aufirst%3DD.%26atitle%3DAntibody%25E2%2580%2593Drug%2520Conjugates%2520That%2520Bind%2520to%2520191P4D12%2520Proteins%2520and%2520Their%2520Use%2520in%2520Treatment%2520of%2520Cancer%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Salama, Z. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keam, S. J.</span></span> <span> </span><span class="NLM_article-title">Entrectinib: First Global Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">1477</span>– <span class="NLM_lpage">1483</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01177-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs40265-019-01177-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31372957" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A280%3ADC%252BB3MvktVemsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=1477-1483&author=Z.+T.+Al-Salamaauthor=S.+J.+Keam&title=Entrectinib%3A+First+Global+Approval&doi=10.1007%2Fs40265-019-01177-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152aR"><div class="casContent"><span class="casTitleNuber">152a</span><div class="casTitle"><span class="NLM_cas:atitle">Entrectinib: First Global Approval</span></div><div class="casAuthors">Al-Salama Zaina T; Keam Susan J</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1477-1483</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Entrectinib (Rozlytrek(®)) is an oral selective inhibitor of the tyrosine kinases tropomyosin receptor kinases (Trk)A/B/C [encoded by the genes neurotrophic tyrosine receptor kinase (NTRK) 1, 2 and 3, respectively], c-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK) with central nervous system (CNS) activity developed by Roche for the treatment of various solid tumours harbouring NTRK1/2/3 or ROS1 gene fusions.  In June 2019, entrectinib received its first global approval in Japan, for the treatment of adult and paediatric patients with NTRK fusion-positive, advanced or recurrent solid tumours and is under regulatory review for the treatment of adult patients with ROS1-positive non-small cell lung cancer (NSCLC).  Entrectinib is also under regulatory review in the USA (PDUFA date 18 August 2019) and EU [Priority Medicines (PRIME) designation] for NTRK-positive solid tumours and ROS1-positive NSCLC.  This article summarizes the milestones in the development of entrectinib leading to this first global approval for solid tumours in Japan.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRqIyGZmvQlpEkUaC_kzhvyfW6udTcc2eZ5Xu1SaSiEELntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MvktVemsg%253D%253D&md5=750c86d20c43273cf07f505988ac8dbd</span></div><a href="/servlet/linkout?suffix=cit152a&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01177-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01177-y%26sid%3Dliteratum%253Aachs%26aulast%3DAl-Salama%26aufirst%3DZ.%2BT.%26aulast%3DKeam%26aufirst%3DS.%2BJ.%26atitle%3DEntrectinib%253A%2520First%2520Global%2520Approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D1477%26epage%3D1483%26doi%3D10.1007%2Fs40265-019-01177-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit152b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wehrmann, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golden, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naraparaju, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croucher, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacFarland, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolla, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cam, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornby, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodeur, G. M.</span></span> <span> </span><span class="NLM_article-title">Entrectinib Is a Potent Inhibitor of TRK-Driven Neuroblastomas in a Xenograft Mouse Model</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>372</i></span>,  <span class="NLM_fpage">179</span>– <span class="NLM_lpage">186</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2016.01.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2Fj.canlet.2016.01.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=26797418" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtF2nsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2016&pages=179-186&author=R.+Iyerauthor=L.+Wehrmannauthor=R.+L.+Goldenauthor=K.+Naraparajuauthor=J.+L.+Croucherauthor=S.+P.+MacFarlandauthor=P.+Guanauthor=V.+Kollaauthor=G.+Weiauthor=N.+Camauthor=G.+Liauthor=Z.+Hornbyauthor=G.+M.+Brodeur&title=Entrectinib+Is+a+Potent+Inhibitor+of+TRK-Driven+Neuroblastomas+in+a+Xenograft+Mouse+Model&doi=10.1016%2Fj.canlet.2016.01.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152bR"><div class="casContent"><span class="casTitleNuber">152b</span><div class="casTitle"><span class="NLM_cas:atitle">Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model</span></div><div class="casAuthors">Iyer, Radhika; Wehrmann, Lea; Golden, Rebecca L.; Naraparaju, Koumudi; Croucher, Jamie L.; MacFarland, Suzanne P.; Guan, Peng; Kolla, Venkatadri; Wei, Ge; Cam, Nicholas; Li, Gang; Hornby, Zachary; Brodeur, Garrett M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">179-186</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Neuroblastoma (NB) is one of the most common and deadly childhood solid tumors.  These tumors are characterized by clin. heterogeneity, from spontaneous regression to relentless progression, and the Trk family of neurotrophin receptors plays an important role in this heterogeneous behavior.  We wanted to det. if entrectinib (RXDX-101, Ignyta, Inc.), an oral Pan-Trk, Alk and Ros1 inhibitor, was effective in our NB model.  In vitro effects of entrectinib, either as a single agent or in combination with the chemotherapeutic agents Irinotecan (Irino) and Temozolomide (TMZ), were studied on an SH-SY5Y cell line stably transfected with TrkB.  In vivo growth inhibition activity was studied in NB xenografts, again as a single agent or in combination with Irino-TMZ.  Entrectinib significantly inhibited the growth of TrkB-expressing NB cells in vitro, and it significantly enhanced the growth inhibition of Irino-TMZ when used in combination.  Single agent therapy resulted in significant tumor growth inhibition in animals treated with entrectinib compared to control animals [p < 0.0001 for event-free survival (EFS)].  Addn. of entrectinib to Irino-TMZ also significantly improved the EFS of animals compared to vehicle or Irino-TMZ treated animals [p < 0.0001 for combination vs. control, p = 0.0012 for combination vs. Irino-TMZ].  We show that entrectinib inhibits growth of TrkB expressing NB cells in vitro and in vivo, and that it enhances the efficacy of conventional chemotherapy in in vivo models.  Our data suggest that entrectinib is a potent Trk inhibitor and should be tested in clin. trials for NBs and other Trk-expressing tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbMHXOlRcgw7Vg90H21EOLACvtfcHk0liehw03Nn_h_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtF2nsrs%253D&md5=61009162e126baedb2eb91d37c305fe9</span></div><a href="/servlet/linkout?suffix=cit152b&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2016.01.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2016.01.018%26sid%3Dliteratum%253Aachs%26aulast%3DIyer%26aufirst%3DR.%26aulast%3DWehrmann%26aufirst%3DL.%26aulast%3DGolden%26aufirst%3DR.%2BL.%26aulast%3DNaraparaju%26aufirst%3DK.%26aulast%3DCroucher%26aufirst%3DJ.%2BL.%26aulast%3DMacFarland%26aufirst%3DS.%2BP.%26aulast%3DGuan%26aufirst%3DP.%26aulast%3DKolla%26aufirst%3DV.%26aulast%3DWei%26aufirst%3DG.%26aulast%3DCam%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DHornby%26aufirst%3DZ.%26aulast%3DBrodeur%26aufirst%3DG.%2BM.%26atitle%3DEntrectinib%2520Is%2520a%2520Potent%2520Inhibitor%2520of%2520TRK-Driven%2520Neuroblastomas%2520in%2520a%2520Xenograft%2520Mouse%2520Model%26jtitle%3DCancer%2520Lett.%26date%3D2016%26volume%3D372%26spage%3D179%26epage%3D186%26doi%3D10.1016%2Fj.canlet.2016.01.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit152c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ricciuti, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brambilla, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baglivo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matocci, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiari, R.</span></span> <span> </span><span class="NLM_article-title">Targeting NTRK Fusion in Non-Small Cell Lung Cancer: Rationale and Clinical Evidence</span>. <i>Med. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">105</span>, <span class="refDoi"> DOI: 10.1007/s12032-017-0967-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs12032-017-0967-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=28444624" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A280%3ADC%252BC1crhtlartw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2017&pages=105&author=B.+Ricciutiauthor=M.+Brambillaauthor=G.+Metroauthor=S.+Baglivoauthor=R.+Matocciauthor=M.+Pirroauthor=R.+Chiari&title=Targeting+NTRK+Fusion+in+Non-Small+Cell+Lung+Cancer%3A+Rationale+and+Clinical+Evidence&doi=10.1007%2Fs12032-017-0967-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152cR"><div class="casContent"><span class="casTitleNuber">152c</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence</span></div><div class="casAuthors">Ricciuti Biagio; Brambilla Marta; Metro Giulio; Baglivo Sara; Matocci Roberta; Chiari Rita; Pirro Matteo</div><div class="citationInfo"><span class="NLM_cas:title">Medical oncology (Northwood, London, England)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">105</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">In the era of personalized medicine, the identification of targetable genetic alterations represented a major step forward in anticancer therapy.  NTRK rearrangements represent the molecular driver of a subset of solid tumors, including 3% of non-small-cell lung cancers (NSCLCs).  Preliminary data indicate that molecularly selected NSCLC patients harboring NTRK fusions derive an unprecedented clinical benefit from Trk-directed targeted therapies.  The aim of this review is to describe the molecular biology of NTRK signaling pathway and to summarize the preclinical data on novel Trk inhibitors, touching upon the clinical development of these inhibitors for the treatment of advanced NSCLC, which have already shown encouraging anticancer activity and acceptable safety profile in early phase I clinical trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQTnwSnq62_edHxxy173TfNfW6udTcc2eZOvaztXKTa3rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1crhtlartw%253D%253D&md5=5bda2359279c7a766d92663ce761b50f</span></div><a href="/servlet/linkout?suffix=cit152c&amp;dbid=16384&amp;doi=10.1007%2Fs12032-017-0967-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12032-017-0967-5%26sid%3Dliteratum%253Aachs%26aulast%3DRicciuti%26aufirst%3DB.%26aulast%3DBrambilla%26aufirst%3DM.%26aulast%3DMetro%26aufirst%3DG.%26aulast%3DBaglivo%26aufirst%3DS.%26aulast%3DMatocci%26aufirst%3DR.%26aulast%3DPirro%26aufirst%3DM.%26aulast%3DChiari%26aufirst%3DR.%26atitle%3DTargeting%2520NTRK%2520Fusion%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%253A%2520Rationale%2520and%2520Clinical%2520Evidence%26jtitle%3DMed.%2520Oncol.%26date%3D2017%26volume%3D34%26spage%3D105%26doi%3D10.1007%2Fs12032-017-0967-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit152d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Menichincheri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ardini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnaghi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avanzi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banfi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bossi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buffa, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canevari, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ceriani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colombo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donati, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fasolini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felder, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiorelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiorentini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isacchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgia, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchionni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nesi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orrenius, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panzeri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesenti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusconi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saccardo, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanotti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orsini, P.</span></span> <span> </span><span class="NLM_article-title">Discovery of Entrectinib: A New 3-Aminoindazole as a Potent Anaplastic Lymphoma Kinase (ALK), C-Ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) Inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">3392</span>– <span class="NLM_lpage">3408</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00064</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00064" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref152/cit152d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC28Xks1eitL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=3392-3408&author=M.+Menichincheriauthor=E.+Ardiniauthor=P.+Magnaghiauthor=N.+Avanziauthor=P.+Banfiauthor=R.+Bossiauthor=L.+Buffaauthor=G.+Canevariauthor=L.+Cerianiauthor=M.+Colomboauthor=L.+Cortiauthor=D.+Donatiauthor=M.+Fasoliniauthor=E.+Felderauthor=C.+Fiorelliauthor=F.+Fiorentiniauthor=A.+Galvaniauthor=A.+Isacchiauthor=A.+L.+Borgiaauthor=C.+Marchionniauthor=M.+Nesiauthor=C.+Orreniusauthor=A.+Panzeriauthor=E.+Pesentiauthor=L.+Rusconiauthor=M.+B.+Saccardoauthor=E.+Vanottiauthor=E.+Perroneauthor=P.+Orsini&title=Discovery+of+Entrectinib%3A+A+New+3-Aminoindazole+as+a+Potent+Anaplastic+Lymphoma+Kinase+%28ALK%29%2C+C-Ros+Oncogene+1+Kinase+%28ROS1%29%2C+and+Pan-Tropomyosin+Receptor+Kinases+%28Pan-TRKs%29+Inhibitor&doi=10.1021%2Facs.jmedchem.6b00064"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152dR"><div class="casContent"><span class="casTitleNuber">152d</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor</span></div><div class="casAuthors">Menichincheri, Maria; Ardini, Elena; Magnaghi, Paola; Avanzi, Nilla; Banfi, Patrizia; Bossi, Roberto; Buffa, Laura; Canevari, Giulia; Ceriani, Lucio; Colombo, Maristella; Corti, Luca; Donati, Daniele; Fasolini, Marina; Felder, Eduard; Fiorelli, Claudio; Fiorentini, Francesco; Galvani, Arturo; Isacchi, Antonella; Borgia, Andrea Lombardi; Marchionni, Chiara; Nesi, Marcella; Orrenius, Christian; Panzeri, Achille; Pesenti, Enrico; Rusconi, Luisa; Saccardo, Maria Beatrice; Vanotti, Ermes; Perrone, Ettore; Orsini, Paolo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3392-3408</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase responsible for the development of different tumor types.  Despite the remarkable clin. activity of crizotinib (Xalkori), the first ALK inhibitor approved in 2011, the emergence of resistance mutations and of brain metastases frequently causes relapse in patients.  Within the ALK drug discovery program, the authors identified compd. I, a novel 3-aminoindazole active on ALK in biochem. and in cellular assays.  Its optimization led to compd. II (entrectinib), a potent orally available ALK inhibitor active on ALK-dependent cell lines, efficiently penetrant the blood-brain barrier (BBB) in different animal species and highly efficacious in in vivo xenograft models.  Moreover, entrectinib resulted to be strictly potent on the closely related tyrosine kinases ROS1 and TRKs recently found constitutively activated in several tumor types.  Entrectinib is currently undergoing phase I/II clin. trial for the treatment of patients affected by ALK-, ROS1-, and TRK-pos. tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpU_xyLC5-GabVg90H21EOLACvtfcHk0liR6llGsQD0Dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xks1eitL8%253D&md5=140217fba2ac81d71600f7344f2d8a3e</span></div><a href="/servlet/linkout?suffix=cit152d&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00064%26sid%3Dliteratum%253Aachs%26aulast%3DMenichincheri%26aufirst%3DM.%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DMagnaghi%26aufirst%3DP.%26aulast%3DAvanzi%26aufirst%3DN.%26aulast%3DBanfi%26aufirst%3DP.%26aulast%3DBossi%26aufirst%3DR.%26aulast%3DBuffa%26aufirst%3DL.%26aulast%3DCanevari%26aufirst%3DG.%26aulast%3DCeriani%26aufirst%3DL.%26aulast%3DColombo%26aufirst%3DM.%26aulast%3DCorti%26aufirst%3DL.%26aulast%3DDonati%26aufirst%3DD.%26aulast%3DFasolini%26aufirst%3DM.%26aulast%3DFelder%26aufirst%3DE.%26aulast%3DFiorelli%26aufirst%3DC.%26aulast%3DFiorentini%26aufirst%3DF.%26aulast%3DGalvani%26aufirst%3DA.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DBorgia%26aufirst%3DA.%2BL.%26aulast%3DMarchionni%26aufirst%3DC.%26aulast%3DNesi%26aufirst%3DM.%26aulast%3DOrrenius%26aufirst%3DC.%26aulast%3DPanzeri%26aufirst%3DA.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DRusconi%26aufirst%3DL.%26aulast%3DSaccardo%26aufirst%3DM.%2BB.%26aulast%3DVanotti%26aufirst%3DE.%26aulast%3DPerrone%26aufirst%3DE.%26aulast%3DOrsini%26aufirst%3DP.%26atitle%3DDiscovery%2520of%2520Entrectinib%253A%2520A%2520New%25203-Aminoindazole%2520as%2520a%2520Potent%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%252C%2520C-Ros%2520Oncogene%25201%2520Kinase%2520%2528ROS1%2529%252C%2520and%2520Pan-Tropomyosin%2520Receptor%2520Kinases%2520%2528Pan-TRKs%2529%2520Inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D3392%26epage%3D3408%26doi%3D10.1021%2Facs.jmedchem.6b00064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit152e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Rolfo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giovannetti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gil-Bazo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Passiglia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giallombardo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peeters, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raez, L.</span></span> <span> </span><span class="NLM_article-title">Entrectinib: A Potent New TRK, ROS1, and ALK Inhibitor</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1493</span>– <span class="NLM_lpage">1500</span>, <span class="refDoi"> DOI: 10.1517/13543784.2015.1096344</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1517%2F13543784.2015.1096344" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=26457764" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslGiurfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2015&pages=1493-1500&author=C.+Rolfoauthor=R.+Ruizauthor=E.+Giovannettiauthor=I.+Gil-Bazoauthor=A.+Russoauthor=F.+Passigliaauthor=M.+Giallombardoauthor=M.+Peetersauthor=L.+Raez&title=Entrectinib%3A+A+Potent+New+TRK%2C+ROS1%2C+and+ALK+Inhibitor&doi=10.1517%2F13543784.2015.1096344"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152eR"><div class="casContent"><span class="casTitleNuber">152e</span><div class="casTitle"><span class="NLM_cas:atitle">Entrectinib: a potent new TRK, ROS1, and ALK inhibitor</span></div><div class="casAuthors">Rolfo, Christian; Ruiz, Rossana; Giovannetti, Elisa; Gil-Bazo, Ignacio; Russo, Antonio; Passiglia, Francesco; Giallombardo, Marco; Peeters, Marc; Raez, Luis</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1493-1500</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Entrectinib: Receptor tyrosine kinases (RTKs) and their signaling pathways, control normal cellular processes; however, their deregulation play important roles in malignant transformation.  In advanced non-small cell lung cancer (NSCLC), the recognition of oncogenic activation of specific RTKs, has led to the development of molecularly targeted agents that only benefit roughly 20% of patients.  Entrectinib is a pan-TRK, ROS1 and ALK inhibitor that has shown potent anti-neoplastic activity and tolerability in various neoplastic conditions, particularly NSCLC.  This review outlines the pharmacokinetics, pharmacodynamics, mechanism of action, safety, tolerability, pre-clin. studies and clin. trials of entrectinib, a promising novel agent for the treatment of advanced solid tumors with mol. alterations of Trk-A, B and C, ROS1 or ALK.: Among the several exptl. drugs under clin. development, entrectinib is emerging as an innovative and promising targeted agent.  The encouraging antitumor activity reported in the Phase 1 studies, together with the acceptable toxicity profile, suggest that entrectinib, thanks to its peculiar mechanism of action, could play an important role in the treatment-strategies of multiple TRK-A, B, C, ROS1, and ALK- dependent solid tumors, including NSCLC and colorectal cancer.  That being said, further evidence for its clin. use is still needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1dnNvbW7UarVg90H21EOLACvtfcHk0ljDJoQIQ3OPRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslGiurfN&md5=0affa310c3da8996f49cc1b7b931fa68</span></div><a href="/servlet/linkout?suffix=cit152e&amp;dbid=16384&amp;doi=10.1517%2F13543784.2015.1096344&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2015.1096344%26sid%3Dliteratum%253Aachs%26aulast%3DRolfo%26aufirst%3DC.%26aulast%3DRuiz%26aufirst%3DR.%26aulast%3DGiovannetti%26aufirst%3DE.%26aulast%3DGil-Bazo%26aufirst%3DI.%26aulast%3DRusso%26aufirst%3DA.%26aulast%3DPassiglia%26aufirst%3DF.%26aulast%3DGiallombardo%26aufirst%3DM.%26aulast%3DPeeters%26aufirst%3DM.%26aulast%3DRaez%26aufirst%3DL.%26atitle%3DEntrectinib%253A%2520A%2520Potent%2520New%2520TRK%252C%2520ROS1%252C%2520and%2520ALK%2520Inhibitor%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2015%26volume%3D24%26spage%3D1493%26epage%3D1500%26doi%3D10.1517%2F13543784.2015.1096344" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><a href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc" class="extLink">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc</a> (accessed 2020-12-18).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fresources-information-approved-drugs%2Ffda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc+%28accessed+2020-12-18%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><a href="https://cancerdiscovery.aacrjournals.org/content/9/10/OF2" class="extLink">https://cancerdiscovery.aacrjournals.org/content/9/10/OF2</a> (accessed 2020-06-11).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fcancerdiscovery.aacrjournals.org%2Fcontent%2F9%2F10%2FOF2+%28accessed+2020-06-11%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drilon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siena, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dziadziuszko, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlesi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krebs, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Braud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolfo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karapetis, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arkenau, H.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chae, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otterson, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murakami, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, D. S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prenen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riehl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow-Maneval, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmons, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doebele, R. C.</span></span> <span> </span><span class="NLM_article-title">Entrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer: Integrated Analysis of Three Phase 1–2 Trials</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">261</span>– <span class="NLM_lpage">270</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(19)30690-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2FS1470-2045%2819%2930690-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31838015" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlyht7nM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2020&pages=261-270&author=A.+Drilonauthor=S.+Sienaauthor=R.+Dziadziuszkoauthor=F.+Barlesiauthor=M.+G.+Krebsauthor=A.+T.+Shawauthor=F.+de+Braudauthor=C.+Rolfoauthor=M.-J.+Ahnauthor=J.+Wolfauthor=T.+Setoauthor=B.+C.+Choauthor=M.+R.+Patelauthor=C.-H.+Chiuauthor=T.+Johnauthor=K.+Gotoauthor=C.+S.+Karapetisauthor=H.-T.+Arkenauauthor=S.-W.+Kimauthor=Y.+Oheauthor=Y.-C.+Liauthor=Y.+K.+Chaeauthor=C.+H.+Chungauthor=G.+A.+Ottersonauthor=H.+Murakamiauthor=C.-C.+Linauthor=D.+S.+W.+Tanauthor=H.+Prenenauthor=T.+Riehlauthor=E.+Chow-Manevalauthor=B.+Simmonsauthor=N.+Cuiauthor=A.+Johnsonauthor=S.+Engauthor=T.+R.+Wilsonauthor=R.+C.+Doebele&title=Entrectinib+in+ROS1+Fusion-Positive+Non-Small-Cell+Lung+Cancer%3A+Integrated+Analysis+of+Three+Phase+1%E2%80%932+Trials&doi=10.1016%2FS1470-2045%2819%2930690-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials</span></div><div class="casAuthors">Drilon, Alexander; Siena, Salvatore; Dziadziuszko, Rafal; Barlesi, Fabrice; Krebs, Matthew G.; Shaw, Alice T.; de Braud, Filippo; Rolfo, Christian; Ahn, Myung-Ju; Wolf, Jurgen; Seto, Takashi; Cho, Byoung Chul; Patel, Manish R.; Chiu, Chao-Hua; John, Thomas; Goto, Koichi; Karapetis, Christos S.; Arkenau, Hendrick-Tobias; Kim, Sang-We; Ohe, Yuichiro; Li, Yu-Chung; Chae, Young K.; Chung, Christine H.; Otterson, Gregory A.; Murakami, Haruyasu; Lin, Chia-Chi; Tan, Daniel S. W.; Prenen, Hans; Riehl, Todd; Chow-Maneval, Edna; Simmons, Brian; Cui, Na; Johnson, Ann; Eng, Susan; Wilson, Timothy R.; Doebele, Robert C.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">261-270</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Recurrent gene fusions, such as ROS1 fusions, are oncogenic drivers of various cancers, including non-small-cell lung cancer (NSCLC).  Up to 36% of patients with ROS1 fusion-pos. NSCLC have brain metastases at the diagnosis of advanced disease.  Entrectinib is a ROS1 inhibitor that has been designed to effectively penetrate and remain in the CNS.  We explored the use of entrectinib in patients with locally advanced or metastatic ROS1 fusion-pos. NSCLC.  We did an integrated anal. of three ongoing phase 1 or 2 trials of entrectinib (ALKA-372-001, STARTRK-1, and STARTRK-2).  The efficacy-evaluable population included adult patients (aged ≥18 years) with locally advanced or metastatic ROS1 fusion-pos. NSCLC who received entrectinib at a dose of at least 600 mg orally once per day, with at least 12 mo' follow-up.  All patients had an Eastern Cooperative Oncol. Group performance status of 0-2, and previous cancer treatment (except for ROS1 inhibitors) was allowed.  The primary endpoints were the proportion of patients with an objective response (complete or partial response according to Response Evaluation Criteria in Solid Tumors version 1.1) and duration of response, and were evaluated by blinded independent central review.  The safety-evaluable population for the safety anal. included all patients with ROS1 fusion-pos. NSCLC in the three trials who received at least one dose of entrectinib (irresp. of dose or duration of follow-up).  These ongoing studies are registered with ClinicalTrials.gov, NCT02097810 (STARTRK-1) and NCT02568267 (STARTRK-2), and EudraCT, 2012-000148-88 (ALKA-372-001).  Patients were enrolled in ALKA-372-001 from Oct 26, 2012, to March 27, 2018; in STARTRK-1 from Aug 7, 2014, to May 10, 2018; and in STARTRK-2 from Nov 19, 2015 (enrolment is ongoing).  At the data cutoff date for this anal. (May 31, 2018), 41 (77%; 95% CI 64-88) of 53 patients in the efficacy-evaluable population had an objective response.  Median follow-up was 15·5 monhts (IQR 13·4-20·2).  Median duration of response was 24·6 mo (95% CI 11·4-34·8).  In the safety-evaluable population, 79 (59%) of 134 patients had grade 1 or 2 treatment-related adverse events. 46 (34%) of 134 patients had grade 3 or 4 treatment-related adverse events, with the most common being wt. increase (ten [8%]) and neutropenia (five [4%]). 15 (11%) patients had serious treatment-related adverse events, the most common of which were nervous system disorders (four [3%]) and cardiac disorders (three [2%]).  No treatment-related deaths occurred.  Entrectinib is active with durable disease control in patients with ROS1 fusion-pos. NSCLC, and is well tolerated with a manageable safety profile, making it amenable to long-term dosing in these patients.  These data highlight the need to routinely test for ROS1 fusions to broaden therapeutic options for patients with ROS1 fusion-pos. NSCLC.Ignyta/F Hoffmann-La Roche.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWfS5hEFDF4rVg90H21EOLACvtfcHk0ljDJoQIQ3OPRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlyht7nM&md5=8c451f65061d0ad0ac6bd8f6730ab51c</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2819%2930690-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252819%252930690-4%26sid%3Dliteratum%253Aachs%26aulast%3DDrilon%26aufirst%3DA.%26aulast%3DSiena%26aufirst%3DS.%26aulast%3DDziadziuszko%26aufirst%3DR.%26aulast%3DBarlesi%26aufirst%3DF.%26aulast%3DKrebs%26aufirst%3DM.%2BG.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3Dde%2BBraud%26aufirst%3DF.%26aulast%3DRolfo%26aufirst%3DC.%26aulast%3DAhn%26aufirst%3DM.-J.%26aulast%3DWolf%26aufirst%3DJ.%26aulast%3DSeto%26aufirst%3DT.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DPatel%26aufirst%3DM.%2BR.%26aulast%3DChiu%26aufirst%3DC.-H.%26aulast%3DJohn%26aufirst%3DT.%26aulast%3DGoto%26aufirst%3DK.%26aulast%3DKarapetis%26aufirst%3DC.%2BS.%26aulast%3DArkenau%26aufirst%3DH.-T.%26aulast%3DKim%26aufirst%3DS.-W.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DY.-C.%26aulast%3DChae%26aufirst%3DY.%2BK.%26aulast%3DChung%26aufirst%3DC.%2BH.%26aulast%3DOtterson%26aufirst%3DG.%2BA.%26aulast%3DMurakami%26aufirst%3DH.%26aulast%3DLin%26aufirst%3DC.-C.%26aulast%3DTan%26aufirst%3DD.%2BS.%2BW.%26aulast%3DPrenen%26aufirst%3DH.%26aulast%3DRiehl%26aufirst%3DT.%26aulast%3DChow-Maneval%26aufirst%3DE.%26aulast%3DSimmons%26aufirst%3DB.%26aulast%3DCui%26aufirst%3DN.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DEng%26aufirst%3DS.%26aulast%3DWilson%26aufirst%3DT.%2BR.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26atitle%3DEntrectinib%2520in%2520ROS1%2520Fusion-Positive%2520Non-Small-Cell%2520Lung%2520Cancer%253A%2520Integrated%2520Analysis%2520of%2520Three%2520Phase%25201%25E2%2580%25932%2520Trials%26jtitle%3DLancet%2520Oncol.%26date%3D2020%26volume%3D21%26spage%3D261%26epage%3D270%26doi%3D10.1016%2FS1470-2045%2819%2930690-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Lombardi Borgia, A.</span>; <span class="NLM_string-name">Menichincheri, M.</span>; <span class="NLM_string-name">Orsini, P.</span>; <span class="NLM_string-name">Panzeri, A.</span>; <span class="NLM_string-name">Perrone, E.</span>; <span class="NLM_string-name">Vanotti, E.</span>; <span class="NLM_string-name">Nesi, M.</span>; <span class="NLM_string-name">Marchionni, C.</span></span> <span> </span><span class="NLM_article-title">Preparation of Substituted Indazole Derivatives for Use as Kinase Inhibitors</span>. <span class="NLM_patent">WO 2009013126 A1</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=A.+Lombardi+Borgia&author=M.+Menichincheri&author=P.+Orsini&author=A.+Panzeri&author=E.+Perrone&author=E.+Vanotti&author=M.+Nesi&author=C.+Marchionni&title=Preparation+of+Substituted+Indazole+Derivatives+for+Use+as+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit156a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLombardi%2BBorgia%26aufirst%3DA.%26atitle%3DPreparation%2520of%2520Substituted%2520Indazole%2520Derivatives%2520for%2520Use%2520as%2520Kinase%2520Inhibitors%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit156b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Menichincheri, M.</span>; <span class="NLM_string-name">Bertrand, J. A.</span>; <span class="NLM_string-name">Marchionni, C.</span>; <span class="NLM_string-name">Nesi, M.</span>; <span class="NLM_string-name">Orsini, P.</span>; <span class="NLM_string-name">Panzeri, A.</span></span> <span> </span><span class="NLM_article-title">Preparation of Substituted Indazole Derivatives Active as Kinase Inhibitors for Treating Cancer, Cell Proliferative Disorders, and Other Diseases</span>. <span class="NLM_patent">WO 2010069966 A1</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=M.+Menichincheri&author=J.+A.+Bertrand&author=C.+Marchionni&author=M.+Nesi&author=P.+Orsini&author=A.+Panzeri&title=Preparation+of+Substituted+Indazole+Derivatives+Active+as+Kinase+Inhibitors+for+Treating+Cancer%2C+Cell+Proliferative+Disorders%2C+and+Other+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit156b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMenichincheri%26aufirst%3DM.%26atitle%3DPreparation%2520of%2520Substituted%2520Indazole%2520Derivatives%2520Active%2520as%2520Kinase%2520Inhibitors%2520for%2520Treating%2520Cancer%252C%2520Cell%2520Proliferative%2520Disorders%252C%2520and%2520Other%2520Diseases%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barbugian, N. A.</span>; <span class="NLM_string-name">Forino, R.</span>; <span class="NLM_string-name">Fumagalli, T.</span>; <span class="NLM_string-name">Orsini, P.</span></span> <span> </span><span class="NLM_article-title">Process for the Preparation of <i>N</i>-[5-(3,5-Difluorobenzyl)-1<i>H</i>-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(tetrahydropyran-4-ylamino)-benzamide</span>. <span class="NLM_patent">WO 2013174876 A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=N.+A.+Barbugian&author=R.+Forino&author=T.+Fumagalli&author=P.+Orsini&title=Process+for+the+Preparation+of+N-%5B5-%283%2C5-Difluorobenzyl%29-1H-indazol-3-yl%5D-4-%284-methylpiperazin-1-yl%29-2-%28tetrahydropyran-4-ylamino%29-benzamide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBarbugian%26aufirst%3DN.%2BA.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%2520N-%255B5-%25283%252C5-Difluorobenzyl%2529-1H-indazol-3-yl%255D-4-%25284-methylpiperazin-1-yl%2529-2-%2528tetrahydropyran-4-ylamino%2529-benzamide%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murray, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newell, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angibaud, P.</span></span> <span> </span><span class="NLM_article-title">A Successful Collaboration between Academia, Biotech and Pharma Led to Discovery of Erdafitinib, a Selective FGFR Inhibitor Recently Approved by the FDA</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1509</span>– <span class="NLM_lpage">1511</span>, <span class="refDoi"> DOI: 10.1039/C9MD90044F</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1039%2FC9MD90044F" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1Oms73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1509-1511&author=C.+W.+Murrayauthor=D.+R.+Newellauthor=P.+Angibaud&title=A+Successful+Collaboration+between+Academia%2C+Biotech+and+Pharma+Led+to+Discovery+of+Erdafitinib%2C+a+Selective+FGFR+Inhibitor+Recently+Approved+by+the+FDA&doi=10.1039%2FC9MD90044F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">A successful collaboration between academia, biotech and pharma led to discovery of erdafitinib, a selective FGFR inhibitor recently approved by the FDA</span></div><div class="casAuthors">Murray, Christopher W.; Newell, David R.; Angibaud, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1509-1511</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPXodFayPaObVg90H21EOLACvtfcHk0lgROg9SjaaxrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1Oms73P&md5=dab27c44172ffb251ad03a53ffa2176b</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1039%2FC9MD90044F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC9MD90044F%26sid%3Dliteratum%253Aachs%26aulast%3DMurray%26aufirst%3DC.%2BW.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DAngibaud%26aufirst%3DP.%26atitle%3DA%2520Successful%2520Collaboration%2520between%2520Academia%252C%2520Biotech%2520and%2520Pharma%2520Led%2520to%2520Discovery%2520of%2520Erdafitinib%252C%2520a%2520Selective%2520FGFR%2520Inhibitor%2520Recently%2520Approved%2520by%2520the%2520FDA%26jtitle%3DMedChemComm%26date%3D2019%26volume%3D10%26spage%3D1509%26epage%3D1511%26doi%3D10.1039%2FC9MD90044F" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><a href="http://www.janssen.com/balversa-erdafitinib-receives-us-fda-approval-treatment-patients-locally-advanced-or-metastatic" class="extLink">www.janssen.com/balversa-erdafitinib-receives-us-fda-approval-treatment-patients-locally-advanced-or-metastatic</a> (accessed 2020-12-18).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=www.janssen.com%2Fbalversa-erdafitinib-receives-us-fda-approval-treatment-patients-locally-advanced-or-metastatic+%28accessed+2020-12-18%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><a href="https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-metastatic-bladder-cancer" class="extLink">https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-metastatic-bladder-cancer</a> (accessed 2020-12-18).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-approves-first-targeted-therapy-metastatic-bladder-cancer+%28accessed+2020-12-18%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><a href="https://seer.cancer.gov/statfacts/html/urinb.html" class="extLink">https://seer.cancer.gov/statfacts/html/urinb.html</a> (accessed 2020-09-15).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fseer.cancer.gov%2Fstatfacts%2Fhtml%2Furinb.html+%28accessed+2020-09-15%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212018s000lbl.pdf" class="extLink">https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212018s000lbl.pdf</a> (accessed 2021-01-14).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2019%2F212018s000lbl.pdf+%28accessed+2021-01-14%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perera, T. P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jovcheva, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mevellec, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vialard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Lange, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhulst, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulussen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van De Ven, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freyne, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squires, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saxty, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilissen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newell, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Platero, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karkera, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angibaud, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laquerre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenzi, M. V.</span></span> <span> </span><span class="NLM_article-title">Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1010</span>– <span class="NLM_lpage">1020</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-16-0589</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1158%2F1535-7163.MCT-16-0589" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=28341788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpt1Sht7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=1010-1020&author=T.+P.+S.+Pereraauthor=E.+Jovchevaauthor=L.+Mevellecauthor=J.+Vialardauthor=D.+De+Langeauthor=T.+Verhulstauthor=C.+Paulussenauthor=K.+Van+De+Venauthor=P.+Kingauthor=E.+Freyneauthor=D.+C.+Reesauthor=M.+Squiresauthor=G.+Saxtyauthor=M.+Pageauthor=C.+W.+Murrayauthor=R.+Gilissenauthor=G.+Wardauthor=N.+T.+Thompsonauthor=D.+R.+Newellauthor=N.+Chengauthor=L.+Xieauthor=J.+Yangauthor=S.+J.+Plateroauthor=J.+D.+Karkeraauthor=C.+Moyauthor=P.+Angibaudauthor=S.+Laquerreauthor=M.+V.+Lorenzi&title=Discovery+and+Pharmacological+Characterization+of+JNJ-42756493+%28Erdafitinib%29%2C+a+Functionally+Selective+Small-Molecule+FGFR+Family+Inhibitor&doi=10.1158%2F1535-7163.MCT-16-0589"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor</span></div><div class="casAuthors">Perera, Timothy P. S.; Jovcheva, Eleonora; Mevellec, Laurence; Vialard, Jorge; De Lange, Desiree; Verhulst, Tinne; Paulussen, Caroline; Van De Ven, Kelly; King, Peter; Freyne, Eddy; Rees, David C.; Squires, Matthew; Saxty, Gordon; Page, Martin; Murray, Christopher W.; Gilissen, Ron; Ward, George; Thompson, Neil T.; Newell, David R.; Cheng, Na; Xie, Liang; Yang, Jennifer; Platero, Suso J.; Karkera, Jayaprakash D.; Moy, Christopher; Angibaud, Patrick; Laquerre, Sylvie; Lorenzi, Matthew V.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1010-1020</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Fibroblast growth factor (FGF) signaling plays crit. roles in key biol. processes ranging from embryogenesis to wound healing and has strong links to several hallmarks of cancer.  Genetic alterations in FGF receptor (FGFR) family members are assocd. with increased tumor growth, metastasis, angiogenesis, and decreased survival.  JNJ-42756493, erdafitinib, is an orally active small mol. with potent tyrosine kinase inhibitory activity against all four FGFR family members and selectivity vs. other highly related kinases.  JNJ-42756493 shows rapid uptake into the lysosomal compartment of cells in culture, which is assocd. with prolonged inhibition of FGFR signaling, possibly due to sustained release of the inhibitor.  In xenografts from human tumor cell lines or patient-derived tumor tissue with activating FGFR alterations, JNJ-42756493 administration results in potent and dose-dependent antitumor activity accompanied by pharmacodynamic modulation of phospho-FGFR and phospho-ERK in tumors.  The results of the current study provide a strong rationale for the clin. investigation of JNJ-42756493 in patients with tumors harboring FGFR pathway alterations.  Mol Cancer Ther; 16(6); 1010-20. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhJZ2AgFcI6LVg90H21EOLACvtfcHk0lgROg9SjaaxrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpt1Sht7g%253D&md5=2cae21f09ad519925ab2a3c760284b02</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0589%26sid%3Dliteratum%253Aachs%26aulast%3DPerera%26aufirst%3DT.%2BP.%2BS.%26aulast%3DJovcheva%26aufirst%3DE.%26aulast%3DMevellec%26aufirst%3DL.%26aulast%3DVialard%26aufirst%3DJ.%26aulast%3DDe%2BLange%26aufirst%3DD.%26aulast%3DVerhulst%26aufirst%3DT.%26aulast%3DPaulussen%26aufirst%3DC.%26aulast%3DVan%2BDe%2BVen%26aufirst%3DK.%26aulast%3DKing%26aufirst%3DP.%26aulast%3DFreyne%26aufirst%3DE.%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DSquires%26aufirst%3DM.%26aulast%3DSaxty%26aufirst%3DG.%26aulast%3DPage%26aufirst%3DM.%26aulast%3DMurray%26aufirst%3DC.%2BW.%26aulast%3DGilissen%26aufirst%3DR.%26aulast%3DWard%26aufirst%3DG.%26aulast%3DThompson%26aufirst%3DN.%2BT.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DCheng%26aufirst%3DN.%26aulast%3DXie%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DPlatero%26aufirst%3DS.%2BJ.%26aulast%3DKarkera%26aufirst%3DJ.%2BD.%26aulast%3DMoy%26aufirst%3DC.%26aulast%3DAngibaud%26aufirst%3DP.%26aulast%3DLaquerre%26aufirst%3DS.%26aulast%3DLorenzi%26aufirst%3DM.%2BV.%26atitle%3DDiscovery%2520and%2520Pharmacological%2520Characterization%2520of%2520JNJ-42756493%2520%2528Erdafitinib%2529%252C%2520a%2520Functionally%2520Selective%2520Small-Molecule%2520FGFR%2520Family%2520Inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2017%26volume%3D16%26spage%3D1010%26epage%3D1020%26doi%3D10.1158%2F1535-7163.MCT-16-0589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saxty, G. M. C. W.</span>; <span class="NLM_string-name">Berdini, V.</span>; <span class="NLM_string-name">Besong, G. E.</span>; <span class="NLM_string-name">Hamlett, C. C. F.</span>; <span class="NLM_string-name">Johnson, C. N.</span>; <span class="NLM_string-name">Woodhead, S. J.</span>; <span class="NLM_string-name">Reader, M.</span>; <span class="NLM_string-name">Rees, D. C.</span>; <span class="NLM_string-name">Mevellec, L. A.</span>; <span class="NLM_string-name">Angibaud, P. R.</span>; <span class="NLM_string-name">Freyne, E. J. E.</span>; <span class="NLM_string-name">Govaerts, T. C. H.</span>; <span class="NLM_string-name">Weerts, J. E. E.</span>; <span class="NLM_string-name">Perera, T. P. S.</span>; <span class="NLM_string-name">Gilissen, R. A. H. J.</span>; <span class="NLM_string-name">Wroblowski, B.</span>; <span class="NLM_string-name">Lacrampe, J. F. A.</span>; <span class="NLM_string-name">Papanikos, A.</span>; <span class="NLM_string-name">Querolle, O. A. G.</span>; <span class="NLM_string-name">Pasquier, E. T. J.</span>; <span class="NLM_string-name">Pilatte, I. N. C.</span>; <span class="NLM_string-name">Bonnet, P. G. A.</span>; <span class="NLM_string-name">Embrechts, W. C. J.</span>; <span class="NLM_string-name">Akkari, R.</span>; <span class="NLM_string-name">Meerpoel, L.</span></span> <span> </span><span class="NLM_article-title">Pyrazolyl Quinazoline Kinase Inhibitors</span>. <span class="NLM_patent">WO 2011135376 A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=G.+M.+C.+W.+Saxty&author=V.+Berdini&author=G.+E.+Besong&author=C.+C.+F.+Hamlett&author=C.+N.+Johnson&author=S.+J.+Woodhead&author=M.+Reader&author=D.+C.+Rees&author=L.+A.+Mevellec&author=P.+R.+Angibaud&author=E.+J.+E.+Freyne&author=T.+C.+H.+Govaerts&author=J.+E.+E.+Weerts&author=T.+P.+S.+Perera&author=R.+A.+H.+J.+Gilissen&author=B.+Wroblowski&author=J.+F.+A.+Lacrampe&author=A.+Papanikos&author=O.+A.+G.+Querolle&author=E.+T.+J.+Pasquier&author=I.+N.+C.+Pilatte&author=P.+G.+A.+Bonnet&author=W.+C.+J.+Embrechts&author=R.+Akkari&author=L.+Meerpoel&title=Pyrazolyl+Quinazoline+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSaxty%26aufirst%3DG.%2BM.%2BC.%2BW.%26atitle%3DPyrazolyl%2520Quinazoline%2520Kinase%2520Inhibitors%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ragheb, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLornan, D. P.</span></span> <span> </span><span class="NLM_article-title">Current and Future Role of Fedratinib in the Treatment of Myelofibrosis</span>. <i>Future Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">175</span>– <span class="NLM_lpage">186</span>, <span class="refDoi"> DOI: 10.2217/fon-2019-0612</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.2217%2Ffon-2019-0612" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31971457" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitlGmt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2020&pages=175-186&author=M.+Raghebauthor=C.+N.+Harrisonauthor=D.+P.+McLornan&title=Current+and+Future+Role+of+Fedratinib+in+the+Treatment+of+Myelofibrosis&doi=10.2217%2Ffon-2019-0612"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Current and future role of fedratinib in the treatment of myelofibrosis</span></div><div class="casAuthors">Ragheb, Monica; Harrison, Claire N.; McLornan, Donal P.</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">175-186</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1744-8301</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Fedratinib (INREBIC [fedratinib] capsules, Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation), is a potent JAK2 inhibitor that has been approved for use in myelofibrosis, both as a first-line agent and also in second line following ruxolitinib (Novartis Pharmaceuticals, Basel, Switzerland) failure or intolerance.  Within this article, we will review relevant preclin. and early/late clin. trial data concerning the use of fedratinib to treat myeloproliferative neoplasms.  Moreover, we will review in detail the assumed safety issues that led to temporary cessation of all programs with the agent in 2013 which subsequently re-entered the clin. arena in 2017.  We will discuss how physicians may safely transition a patient across from ruxolitinib to fedratinib following intolerance or lack of efficacy.  At last, we will discuss potential future applications of this agent within the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpj3DAteR97M7Vg90H21EOLACvtfcHk0lhTVN27J6U4EA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitlGmt7k%253D&md5=0b0e682e3318cefd59a964c332b3aba8</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.2217%2Ffon-2019-0612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon-2019-0612%26sid%3Dliteratum%253Aachs%26aulast%3DRagheb%26aufirst%3DM.%26aulast%3DHarrison%26aufirst%3DC.%2BN.%26aulast%3DMcLornan%26aufirst%3DD.%2BP.%26atitle%3DCurrent%2520and%2520Future%2520Role%2520of%2520Fedratinib%2520in%2520the%2520Treatment%2520of%2520Myelofibrosis%26jtitle%3DFuture%2520Oncol.%26date%3D2020%26volume%3D16%26spage%3D175%26epage%3D186%26doi%3D10.2217%2Ffon-2019-0612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bose, P.</span></span> <span> </span><span class="NLM_article-title">Advances in Potential Treatment Options for Myeloproliferative Neoplasm Associated Myelofibrosis</span>. <i>Expert Opin. Orphan Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">415</span>– <span class="NLM_lpage">425</span>, <span class="refDoi"> DOI: 10.1080/21678707.2019.1664900</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1080%2F21678707.2019.1664900" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=33094033" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVemsLbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2019&pages=415-425&author=P.+Bose&title=Advances+in+Potential+Treatment+Options+for+Myeloproliferative+Neoplasm+Associated+Myelofibrosis&doi=10.1080%2F21678707.2019.1664900"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in potential treatment options for myeloproliferative neoplasm associated myelofibrosis</span></div><div class="casAuthors">Bose, Prithviraj</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Orphan Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">415-425</span>CODEN:
                <span class="NLM_cas:coden">EOODAJ</span>;
        ISSN:<span class="NLM_cas:issn">2167-8707</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  : The Janus kinase (JAK)1/2 inhibitor ruxolitinib provides rapid, sustained and often dramatic benefits to patients with myelofibrosis, inducing spleen shrinkage and ameliorating symptoms, and improves survival.  However, the drug has little effect on the underlying bone marrow fibrosis or on mutant allele burden, and clin. resistance eventually develops.  Furthermore, ruxolitinib-induced cytopenias can be challenging in everyday practice.: The developmental therapeutics landscape in MF is discussed.  This includes potential partners for ruxolitinib being developed with an aim to improve cytopenias, or to enhance its disease-modifying effects.  The development of other JAK inhibitors with efficacy post-ruxolitinib or other unique attributes is being pursued in earnest.  Agents with novel mechanisms of action are being studied in patients whose disease responds sub-optimally to, is refractory to or progresses after ruxolitinib.: The JAK inhibitors fedratinib, pacritinib and momelotinib are clearly active, and it is expected that one or more of these will become licensed in the future.  The activin receptor ligand traps are promising as treatments for anemia.  Imetelstat has shown interesting activity post-ruxolitinib, and azactidine may be a useful partner for ruxolitinib in some patients.  Appropriately, multiple pre-clin. and clin. leads are being pursued in this difficult therapeutic area.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnB43vheV7dLVg90H21EOLACvtfcHk0lhTVN27J6U4EA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVemsLbN&md5=80653a777dd5eeca110d8b8463656fe9</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1080%2F21678707.2019.1664900&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F21678707.2019.1664900%26sid%3Dliteratum%253Aachs%26aulast%3DBose%26aufirst%3DP.%26atitle%3DAdvances%2520in%2520Potential%2520Treatment%2520Options%2520for%2520Myeloproliferative%2520Neoplasm%2520Associated%2520Myelofibrosis%26jtitle%3DExpert%2520Opin.%2520Orphan%2520Drugs%26date%3D2019%26volume%3D7%26spage%3D415%26epage%3D425%26doi%3D10.1080%2F21678707.2019.1664900" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diamond, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rupar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behshad, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardiner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wynn, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeleswaram, S.</span></span> <span> </span><span class="NLM_article-title">The Janus Kinase 2 Inhibitor Fedratinib Inhibits Thiamine Uptake: A Putative Mechanism for the Onset of Wernicke’s Encephalopathy</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">1656</span>– <span class="NLM_lpage">1662</span>, <span class="refDoi"> DOI: 10.1124/dmd.114.058883</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1124%2Fdmd.114.058883" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=25063672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1yqurzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2014&pages=1656-1662&author=Q.+Zhangauthor=Y.+Zhangauthor=S.+Diamondauthor=J.+Boerauthor=J.+J.+Harrisauthor=Y.+Liauthor=M.+Ruparauthor=E.+Behshadauthor=C.+Gardinerauthor=P.+Collierauthor=P.+Liuauthor=T.+Burnauthor=R.+Wynnauthor=G.+Hollisauthor=S.+Yeleswaram&title=The+Janus+Kinase+2+Inhibitor+Fedratinib+Inhibits+Thiamine+Uptake%3A+A+Putative+Mechanism+for+the+Onset+of+Wernicke%E2%80%99s+Encephalopathy&doi=10.1124%2Fdmd.114.058883"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">The janus kinase 2 inhibitor fedratinib inhibits thiamine uptake: a putative mechanism for the onset of Wernicke's encephalopathy</span></div><div class="casAuthors">Zhang, Qiang; Zhang, Yan; Diamond, Sharon; Boer, Jason; Harris, Jennifer J.; Li, Yu; Rupar, Mark; Behshad, Elham; Gardiner, Christine; Collier, Paul; Liu, Phillip; Burn, Timothy; Wynn, Richard; Hollis, Gregory; Yeleswaram, Swamy</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1656-1662, 7 pp.</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The clin. development of fedratinib, a Janus kinase (JAK2) inhibitor, was terminated after reports of Wernicke's encephalopathy in myelofibrosis patients.  Since Wernicke's encephalopathy is induced by thiamine deficiency, investigations were conducted to probe possible mechanisms through which fedratinib may lead to a thiamine-deficient state.  In vitro studies indicate that fedratinib potently inhibits the carrier-mediated uptake and transcellular flux of thiamine in Caco-2 cells, suggesting that oral absorption of dietary thiamine is significantly compromised by fedratinib dosing.  Transport studies with recombinant human thiamine transporters identified the individual human thiamine transporter (hTHTR2) that is inhibited by fedratinib.  Inhibition of thiamine uptake appears unique to fedratinib and is not shared by marketed JAK inhibitors, and this observation is consistent with the known structure-activity relationship for the binding of thiamine to its transporters.  The results from these studies provide a mol. basis for the development of Wernicke's encephalopathy upon fedratinib treatment and highlight the need to evaluate interactions of investigational drugs with nutrient transporters in addn. to classic xenobiotic transporters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3h6hu-138srVg90H21EOLACvtfcHk0lhTVN27J6U4EA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1yqurzJ&md5=0e840cc3953ddcdf2f0864450f6f5c6e</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1124%2Fdmd.114.058883&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.114.058883%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DDiamond%26aufirst%3DS.%26aulast%3DBoer%26aufirst%3DJ.%26aulast%3DHarris%26aufirst%3DJ.%2BJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DRupar%26aufirst%3DM.%26aulast%3DBehshad%26aufirst%3DE.%26aulast%3DGardiner%26aufirst%3DC.%26aulast%3DCollier%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DBurn%26aufirst%3DT.%26aulast%3DWynn%26aufirst%3DR.%26aulast%3DHollis%26aufirst%3DG.%26aulast%3DYeleswaram%26aufirst%3DS.%26atitle%3DThe%2520Janus%2520Kinase%25202%2520Inhibitor%2520Fedratinib%2520Inhibits%2520Thiamine%2520Uptake%253A%2520A%2520Putative%2520Mechanism%2520for%2520the%2520Onset%2520of%2520Wernicke%25E2%2580%2599s%2520Encephalopathy%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2014%26volume%3D42%26spage%3D1656%26epage%3D1662%26doi%3D10.1124%2Fdmd.114.058883" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><a href="https://www.fda.gov/news-events/press-announcements/fda-approves-treatment-patients-rare-bone-marrow-disorder" class="extLink">https://www.fda.gov/news-events/press-announcements/fda-approves-treatment-patients-rare-bone-marrow-disorder</a> (accessed 2020-12-18).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-approves-treatment-patients-rare-bone-marrow-disorder+%28accessed+2020-12-18%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blair, H. A.</span></span> <span> </span><span class="NLM_article-title">Fedratinib: First Approval for Treating Myelofibrosis</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">1719</span>– <span class="NLM_lpage">1725</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01205-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs40265-019-01205-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31571162" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVOlu7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=1719-1725&author=H.+A.+Blair&title=Fedratinib%3A+First+Approval+for+Treating+Myelofibrosis&doi=10.1007%2Fs40265-019-01205-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Fedratinib: First approval for treating myelofibrosis</span></div><div class="casAuthors">Blair, Hannah A.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1719-1725</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Fedratinib (INREBIC) is a JAK2-selective inhibitor that has been developed as an oral treatment for myelofibrosis.  In August 2019, fedratinib received its first global approval in the USA for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.  Phase III clin. development for myelofibrosis is ongoing worldwide.  This article summarizes the milestones in the development of fedratinib leading to this first approval for myelofibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0phtMTwbye7Vg90H21EOLACvtfcHk0lip8SlNfgpsCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVOlu7rP&md5=36fa843febf45050d5dd2d1044b715c8</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01205-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01205-x%26sid%3Dliteratum%253Aachs%26aulast%3DBlair%26aufirst%3DH.%2BA.%26atitle%3DFedratinib%253A%2520First%2520Approval%2520for%2520Treating%2520Myelofibrosis%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D1719%26epage%3D1725%26doi%3D10.1007%2Fs40265-019-01205-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Noronha, G.</span>; <span class="NLM_string-name">Mak, C. C.</span>; <span class="NLM_string-name">Cao, J.</span>; <span class="NLM_string-name">Renick, J.</span>; <span class="NLM_string-name">McPherson, A.</span>; <span class="NLM_string-name">Zeng, B.</span>; <span class="NLM_string-name">Pathak, V. P.</span>; <span class="NLM_string-name">Lohse, D. L.</span>; <span class="NLM_string-name">Hood, J. D.</span>; <span class="NLM_string-name">Soll, R. M.</span></span> <span> </span><span class="NLM_article-title">Preparation of Pyrimidine Derivatives as JAK Kinases Inhibitors</span>. <span class="NLM_patent">US 20110212077 A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=G.+Noronha&author=C.+C.+Mak&author=J.+Cao&author=J.+Renick&author=A.+McPherson&author=B.+Zeng&author=V.+P.+Pathak&author=D.+L.+Lohse&author=J.+D.+Hood&author=R.+M.+Soll&title=Preparation+of+Pyrimidine+Derivatives+as+JAK+Kinases+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNoronha%26aufirst%3DG.%26atitle%3DPreparation%2520of%2520Pyrimidine%2520Derivatives%2520as%2520JAK%2520Kinases%2520Inhibitors%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tefferi, A.</span></span> <span> </span><span class="NLM_article-title"><i>N</i>-<i>tert</i>-Butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino]benzenesulfonamide for Treating Myelofibrosis</span>. <span class="NLM_patent">WO 2012060847 A1</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=A.+Tefferi&title=N-tert-Butyl-3-%5B%285-methyl-2-%7B%5B4-%282-pyrrolidin-1-ylethoxy%29phenyl%5Damino%7Dpyrimidin-4-yl%29amino%5Dbenzenesulfonamide+for+Treating+Myelofibrosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DTefferi%26aufirst%3DA.%26atitle%3DN-tert-Butyl-3-%255B%25285-methyl-2-%257B%255B4-%25282-pyrrolidin-1-ylethoxy%2529phenyl%255Damino%257Dpyrimidin-4-yl%2529amino%255Dbenzenesulfonamide%2520for%2520Treating%2520Myelofibrosis%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span>; <span class="NLM_string-name">Li, H.</span></span> <span> </span><span class="NLM_article-title">Preparation of Diphenyl Aminopyrimidine Compounds as JAK2 Kinase Inhibitors</span>. <span class="NLM_patent">CN 109232440 A</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=Y.+Wang&author=H.+Li&title=Preparation+of+Diphenyl+Aminopyrimidine+Compounds+as+JAK2+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26atitle%3DPreparation%2520of%2520Diphenyl%2520Aminopyrimidine%2520Compounds%2520as%2520JAK2%2520Kinase%2520Inhibitors%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><a href="http://www.nmpa.gov.cn/WS04/CL2056/371524.html" class="extLink">http://www.nmpa.gov.cn/WS04/CL2056/371524.html</a> (accessed 2021-01-14).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=http%3A%2F%2Fwww.nmpa.gov.cn%2FWS04%2FCL2056%2F371524.html+%28accessed+2021-01-14%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span> <span> </span><span class="NLM_article-title">Frontline Flumatinib Versus Imatinib in Patients with Chronic Myeloid Leukemia in Chronic Phase: Results from the China Randomized Phase III Study</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">7004</span>, <span class="refDoi"> DOI: 10.1200/JCO.2019.37.15_suppl.7004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1200%2FJCO.2019.37.15_suppl.7004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2019&pages=7004&author=Z.+Liauthor=L.+Mengauthor=Y.+Zhangauthor=H.+Zhuauthor=J.+Cuiauthor=A.+Sunauthor=Y.+Huauthor=J.+Jinauthor=H.+Jiangauthor=X.+Zhangauthor=Y.+Liauthor=Q.+Liuauthor=L.+Liuauthor=W.+Zhangauthor=J.+Guauthor=J.-H.+Qiaoauthor=B.+Liuauthor=F.+Zhangauthor=Y.+Guoauthor=J.+Wang&title=Frontline+Flumatinib+Versus+Imatinib+in+Patients+with+Chronic+Myeloid+Leukemia+in+Chronic+Phase%3A+Results+from+the+China+Randomized+Phase+III+Study&doi=10.1200%2FJCO.2019.37.15_suppl.7004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1200%2FJCO.2019.37.15_suppl.7004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2019.37.15_suppl.7004%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DMeng%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DSun%26aufirst%3DA.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DGu%26aufirst%3DJ.%26aulast%3DQiao%26aufirst%3DJ.-H.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26atitle%3DFrontline%2520Flumatinib%2520Versus%2520Imatinib%2520in%2520Patients%2520with%2520Chronic%2520Myeloid%2520Leukemia%2520in%2520Chronic%2520Phase%253A%2520Results%2520from%2520the%2520China%2520Randomized%2520Phase%2520III%2520Study%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2019%26volume%3D37%26spage%3D7004%26doi%3D10.1200%2FJCO.2019.37.15_suppl.7004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, P.</span>; <span class="NLM_string-name">Lv, A.</span>; <span class="NLM_string-name">Yang, B.</span>; <span class="NLM_string-name">Hu, C.</span>; <span class="NLM_string-name">Wang, W.</span></span> <span> </span><span class="NLM_article-title">Aminopyrimidine Compounds and Their Salts, Process for Preparation and Pharmaceutical Use Thereof</span>. <span class="NLM_patent">WO 2006069525 A1</span>, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=P.+Sun&author=A.+Lv&author=B.+Yang&author=C.+Hu&author=W.+Wang&title=Aminopyrimidine+Compounds+and+Their+Salts%2C+Process+for+Preparation+and+Pharmaceutical+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit175a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DP.%26atitle%3DAminopyrimidine%2520Compounds%2520and%2520Their%2520Salts%252C%2520Process%2520for%2520Preparation%2520and%2520Pharmaceutical%2520Use%2520Thereof%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit175b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Q.</span>; <span class="NLM_string-name">Du, Z.</span>; <span class="NLM_string-name">Kang, X.</span></span> <span> </span><span class="NLM_article-title">Method for Preparing Flumatinib Mesylate</span>. <span class="NLM_patent">CN 102796079 A</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=Q.+Zhu&author=Z.+Du&author=X.+Kang&title=Method+for+Preparing+Flumatinib+Mesylate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit175b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DQ.%26atitle%3DMethod%2520for%2520Preparing%2520Flumatinib%2520Mesylate%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit175c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J.</span>; <span class="NLM_string-name">Chen, Y.</span>; <span class="NLM_string-name">Yang, W.</span>; <span class="NLM_string-name">Jin, A.</span></span> <span> </span><span class="NLM_article-title">Method for Refining Flumatinib</span>. <span class="NLM_patent">CN 105777714 A</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=J.+Cui&author=Y.+Chen&author=W.+Yang&author=A.+Jin&title=Method+for+Refining+Flumatinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit175c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%26atitle%3DMethod%2520for%2520Refining%2520Flumatinib%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit175d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, L.</span>; <span class="NLM_string-name">Jin, A.</span></span> <span> </span><span class="NLM_article-title">Synthesizing Method of Flumatinib</span>. <span class="NLM_patent">CN 105884746 A</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=L.+Jin&author=A.+Jin&title=Synthesizing+Method+of+Flumatinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit175d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DL.%26atitle%3DSynthesizing%2520Method%2520of%2520Flumatinib%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit175e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Lv, H.</span>; <span class="NLM_string-name">Wu, D.</span>; <span class="NLM_string-name">Jiang, C.</span>; <span class="NLM_string-name">Zhang, Y.</span>; <span class="NLM_string-name">Cao, J.</span></span> <span> </span><span class="NLM_article-title">Flumatinib Mesylate Intermediate Purification Method</span>. <span class="NLM_patent">CN 107652269 A</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=H.+Lv&author=D.+Wu&author=C.+Jiang&author=Y.+Zhang&author=J.+Cao&title=Flumatinib+Mesylate+Intermediate+Purification+Method"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit175e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLv%26aufirst%3DH.%26atitle%3DFlumatinib%2520Mesylate%2520Intermediate%2520Purification%2520Method%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit175f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span>; <span class="NLM_string-name">Liu, L.</span>; <span class="NLM_string-name">Wu, D.</span>; <span class="NLM_string-name">Sun, Y.</span>; <span class="NLM_string-name">Cao, J.</span></span> <span> </span><span class="NLM_article-title">Synthetic Method of Intermediate of Flumatinib Mesylate</span>. <span class="NLM_patent">CN 107663151 A</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=M.+Chen&author=L.+Liu&author=D.+Wu&author=Y.+Sun&author=J.+Cao&title=Synthetic+Method+of+Intermediate+of+Flumatinib+Mesylate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit175f&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DM.%26atitle%3DSynthetic%2520Method%2520of%2520Intermediate%2520of%2520Flumatinib%2520Mesylate%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit175g"><span><span class="NLM_label">(g) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gou, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis, Crystal Structure, and Spectral Characterization of Flumatinib Mesylate</span>. <i>Synth. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">2564</span>– <span class="NLM_lpage">2570</span>, <span class="refDoi"> DOI: 10.1080/00397910903289248</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1080%2F00397910903289248" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175g&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpslOju7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2010&pages=2564-2570&author=G.+Xuauthor=H.+Shenauthor=T.+Tongauthor=A.+Luauthor=S.+Gou&title=Synthesis%2C+Crystal+Structure%2C+and+Spectral+Characterization+of+Flumatinib+Mesylate&doi=10.1080%2F00397910903289248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit175gR"><div class="casContent"><span class="casTitleNuber">175g</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Crystal Structure, and Spectral Characterization of Flumatinib Mesylate</span></div><div class="casAuthors">Xu, Gang; Shen, Hong; Tong, Taifeng; Lu, Aifeng; Gou, Shaohua</div><div class="citationInfo"><span class="NLM_cas:title">Synthetic Communications</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2564-2570</span>CODEN:
                <span class="NLM_cas:coden">SYNCAV</span>;
        ISSN:<span class="NLM_cas:issn">0039-7911</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">Flumatinib mesylate (I), a 3-substituted picolinamide deriv. structurally similar to imatinib mesylate, was prepd.  The compd. was characterized by IR, UV, NMR, and electrospray ionization-mass spectra together with x-ray crystal structure anal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1olx-bKQ3MrVg90H21EOLACvtfcHk0lhKErOJztRO7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpslOju7Y%253D&md5=4203b742f57f7743000f437c0f408d43</span></div><a href="/servlet/linkout?suffix=cit175g&amp;dbid=16384&amp;doi=10.1080%2F00397910903289248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F00397910903289248%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DG.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DTong%26aufirst%3DT.%26aulast%3DLu%26aufirst%3DA.%26aulast%3DGou%26aufirst%3DS.%26atitle%3DSynthesis%252C%2520Crystal%2520Structure%252C%2520and%2520Spectral%2520Characterization%2520of%2520Flumatinib%2520Mesylate%26jtitle%3DSynth.%2520Commun.%26date%3D2010%26volume%3D40%26spage%3D2564%26epage%3D2570%26doi%3D10.1080%2F00397910903289248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span>; <span class="NLM_string-name">Zhao, J.</span>; <span class="NLM_string-name">Ji, H.</span>; <span class="NLM_string-name">Zong, S.</span></span> <span> </span><span class="NLM_article-title">The Preparation Method of Flumatinib</span>. <span class="NLM_patent">CN 111072636 A</span>, <span class="NLM_year">2020</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=G.+Chen&author=J.+Zhao&author=H.+Ji&author=S.+Zong&title=The+Preparation+Method+of+Flumatinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DG.%26atitle%3DThe%2520Preparation%2520Method%2520of%2520Flumatinib%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tap, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelderblom, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmerini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blay, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcindor, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganjoo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Broto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterfy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Healey, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van de Sande, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelhorn, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuster, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yver, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong-Starksen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stacchiotti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, A. J.</span></span> <span> </span><span class="NLM_article-title">Pexidartinib Versus Placebo for Advanced Tenosynovial Giant Cell Tumour (Enliven): A Randomised Phase 3 Trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>394</i></span>,  <span class="NLM_fpage">478</span>– <span class="NLM_lpage">487</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(19)30764-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2FS0140-6736%2819%2930764-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31229240" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1Wqt7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=394&publication_year=2019&pages=478-487&author=W.+D.+Tapauthor=H.+Gelderblomauthor=E.+Palmeriniauthor=J.+Desaiauthor=S.+Bauerauthor=J.+Y.+Blayauthor=T.+Alcindorauthor=K.+Ganjooauthor=J.+Martin-Brotoauthor=C.+W.+Ryanauthor=D.+M.+Thomasauthor=C.+Peterfyauthor=J.+H.+Healeyauthor=M.+van+de+Sandeauthor=H.+L.+Gelhornauthor=D.+E.+Shusterauthor=Q.+Wangauthor=A.+Yverauthor=H.+H.+Hsuauthor=P.+S.+Linauthor=S.+Tong-Starksenauthor=S.+Stacchiottiauthor=A.+J.+Wagner&title=Pexidartinib+Versus+Placebo+for+Advanced+Tenosynovial+Giant+Cell+Tumour+%28Enliven%29%3A+A+Randomised+Phase+3+Trial&doi=10.1016%2FS0140-6736%2819%2930764-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial</span></div><div class="casAuthors">Tap, William D.; Gelderblom, Hans; Palmerini, Emanuela; Desai, Jayesh; Bauer, Sebastian; Blay, Jean-Yves; Alcindor, Thierry; Ganjoo, Kristen; Martin-Broto, Javier; Ryan, Christopher W.; Thomas, David M.; Peterfy, Charles; Healey, John H.; van de Sande, Michiel; Gelhorn, Heather L.; Shuster, Dale E.; Wang, Qiang; Yver, Antoine; Hsu, Henry H.; Lin, Paul S.; Tong-Starksen, Sandra; Stacchiotti, Silvia; Wagner, Andrew J.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">394</span>
        (<span class="NLM_cas:issue">10197</span>),
    <span class="NLM_cas:pages">478-487</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">We aimed to evaluate pexidartinib, a CSF1 receptor inhibitor, in patients with TGCT to provide them with a viable systemic treatment option, esp. in cases that are not amenable to surgical resection.  This phase 3 randomised trial had two parts.  Part one was a double-blind study in which patients with symptomatic, advanced TGCT for whom surgery was not recommended were randomly assigned via an integrated web response system (1:1) to the pexidartinib or placebo group.  Individuals in the pexidartinib group received a loading dose of 1000 mg pexidartinib per day orally (400 mg morning; 600 mg evening) for the first 2 wk, followed by 800 mg per day (400 mg twice a day) for 22 wk.  Safety was analyzed in all patients who received at least one dose of the study drug.  The proportion of patients who achieved overall response was higher for pexidartinib than placebo at week 25 by RECIST (24 [39%] of 61 vs none of 59; abs. difference 39% [95% CI 27-53]; p<0.0001).  Hair color changes (67%), fatigue (54%), aspartate aminotransferase increase (39%), nausea (38%), alanine aminotransferase increase (28%), and dysgeusia (25%) were the most frequent pexidartinib-assocd. adverse events. Three patients given pexidartinib had aminotransferase elevations three or more times the upper limit of normal with total bilirubin and alk. phosphatase two or more times the upper limit of normal indicative of mixed or cholestatic hepatotoxicity, one lasting 7 mo and confirmed by biopsy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2mP33487nP7Vg90H21EOLACvtfcHk0lhKErOJztRO7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1Wqt7jI&md5=0f59ec1b2387ce7d238c28cc9d727aa5</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2819%2930764-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252819%252930764-0%26sid%3Dliteratum%253Aachs%26aulast%3DTap%26aufirst%3DW.%2BD.%26aulast%3DGelderblom%26aufirst%3DH.%26aulast%3DPalmerini%26aufirst%3DE.%26aulast%3DDesai%26aufirst%3DJ.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DBlay%26aufirst%3DJ.%2BY.%26aulast%3DAlcindor%26aufirst%3DT.%26aulast%3DGanjoo%26aufirst%3DK.%26aulast%3DMartin-Broto%26aufirst%3DJ.%26aulast%3DRyan%26aufirst%3DC.%2BW.%26aulast%3DThomas%26aufirst%3DD.%2BM.%26aulast%3DPeterfy%26aufirst%3DC.%26aulast%3DHealey%26aufirst%3DJ.%2BH.%26aulast%3Dvan%2Bde%2BSande%26aufirst%3DM.%26aulast%3DGelhorn%26aufirst%3DH.%2BL.%26aulast%3DShuster%26aufirst%3DD.%2BE.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DYver%26aufirst%3DA.%26aulast%3DHsu%26aufirst%3DH.%2BH.%26aulast%3DLin%26aufirst%3DP.%2BS.%26aulast%3DTong-Starksen%26aufirst%3DS.%26aulast%3DStacchiotti%26aufirst%3DS.%26aulast%3DWagner%26aufirst%3DA.%2BJ.%26atitle%3DPexidartinib%2520Versus%2520Placebo%2520for%2520Advanced%2520Tenosynovial%2520Giant%2520Cell%2520Tumour%2520%2528Enliven%2529%253A%2520A%2520Randomised%2520Phase%25203%2520Trial%26jtitle%3DLancet%26date%3D2019%26volume%3D394%26spage%3D478%26epage%3D487%26doi%3D10.1016%2FS0140-6736%2819%2930764-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211810s000lbl.pdf" class="extLink">https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211810s000lbl.pdf</a> (accessed 2021-01-14).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2019%2F211810s000lbl.pdf+%28accessed+2021-01-14%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref179"><div class="reference"><strong class="refLabel"><a href="#ref179" class="rightTabRefNumLink">179</a></strong><div class="NLM_citation" id="rightTab-cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, Y. N.</span></span> <span> </span><span class="NLM_article-title">Pexidartinib: First Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">1805</span>– <span class="NLM_lpage">1812</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01210-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs40265-019-01210-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31602563" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFCkt7bI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=1805-1812&author=Y.+N.+Lamb&title=Pexidartinib%3A+First+Approval&doi=10.1007%2Fs40265-019-01210-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Pexidartinib: First Approval</span></div><div class="casAuthors">Lamb, Yvette N.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1805-1812</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Pexidartinib (TURALIO) is an orally administered small mol. tyrosine kinase inhibitor with selective activity against the colony-stimulating factor 1 (CSF1) receptor, KIT proto-oncogene receptor tyrosine kinase (KIT) and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation (FLT3-ITD).  In August 2019, the US FDA approved pexidartinib capsules for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) assocd. with severe morbidity or functional limitations and not amenable to improvement with surgery.  This approval was based on pos. results from the phase III ENLIVEN trial.  Pexidartinib is being investigated in various malignancies as monotherapy or combination therapy.  This article summarizes the milestones in the development of pexidartinib leading to its first approval for TGCT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozyYjPD6iP87Vg90H21EOLACvtfcHk0ljXUG9fJ8C8IA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFCkt7bI&md5=749eeadc87c3d34db97ee6aaa7837cac</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01210-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01210-0%26sid%3Dliteratum%253Aachs%26aulast%3DLamb%26aufirst%3DY.%2BN.%26atitle%3DPexidartinib%253A%2520First%2520Approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D1805%26epage%3D1812%26doi%3D10.1007%2Fs40265-019-01210-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref180"><div class="reference"><strong class="refLabel"><a href="#ref180" class="rightTabRefNumLink">180</a></strong><div class="NLM_citation" id="rightTab-cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spangenberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohsfield, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crapser, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phan, N. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Severson, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burton, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spevak, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habets, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rymar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walters, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nespi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broome, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, B. L.</span></span> <span> </span><span class="NLM_article-title">Sustained Microglial Depletion with CSF1R Inhibitor Impairs Parenchymal Plaque Development in an Alzheimer’s Disease Model</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">3758</span>, <span class="refDoi"> DOI: 10.1038/s41467-019-11674-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1038%2Fs41467-019-11674-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31434879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A280%3ADC%252BB3MrgtFOruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=3758&author=E.+Spangenbergauthor=L.+A.+Hohsfieldauthor=J.+Crapserauthor=N.+Y.+Phanauthor=K.+N.+Greenauthor=P.+L.+Seversonauthor=J.+Zhangauthor=E.+A.+Burtonauthor=Y.+Zhangauthor=W.+Spevakauthor=J.+Linauthor=G.+Habetsauthor=A.+Rymarauthor=G.+Tsangauthor=J.+Waltersauthor=M.+Nespiauthor=P.+Singhauthor=S.+Broomeauthor=P.+Ibrahimauthor=C.+Zhangauthor=G.+Bollagauthor=B.+L.+West&title=Sustained+Microglial+Depletion+with+CSF1R+Inhibitor+Impairs+Parenchymal+Plaque+Development+in+an+Alzheimer%E2%80%99s+Disease+Model&doi=10.1038%2Fs41467-019-11674-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer's disease model</span></div><div class="casAuthors">Spangenberg Elizabeth; Hohsfield Lindsay A; Crapser Joshua; Phan Nicole Y; Green Kim N; Severson Paul L; Zhang Jiazhong; Burton Elizabeth A; Zhang Ying; Spevak Wayne; Lin Jack; Habets Gaston; Rymar Andrey; Tsang Garson; Walters Jason; Nespi Marika; Singh Parmveer; Broome Stephanie; Ibrahim Prabha; Zhang Chao; Bollag Gideon; West Brian L</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3758</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Many risk genes for the development of Alzheimer's disease (AD) are exclusively or highly expressed in myeloid cells.  Microglia are dependent on colony-stimulating factor 1 receptor (CSF1R) signaling for their survival.  We designed and synthesized a highly selective brain-penetrant CSF1R inhibitor (PLX5622) allowing for extended and specific microglial elimination, preceding and during pathology development.  We find that in the 5xFAD mouse model of AD, plaques fail to form in the parenchymal space following microglial depletion, except in areas containing surviving microglia.  Instead, Aβ deposits in cortical blood vessels reminiscent of cerebral amyloid angiopathy.  Altered gene expression in the 5xFAD hippocampus is also reversed by the absence of microglia.  Transcriptional analyses of the residual plaque-forming microglia show they exhibit a disease-associated microglia profile.  Collectively, we describe the structure, formulation, and efficacy of PLX5622, which allows for sustained microglial depletion and identify roles of microglia in initiating plaque pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSZsPEWZPmRRMNIRw0GKUoEfW6udTcc2eYGuIQwywBvqbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MrgtFOruw%253D%253D&md5=ec6089949cf49ffec6faefe983cb3beb</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1038%2Fs41467-019-11674-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-019-11674-z%26sid%3Dliteratum%253Aachs%26aulast%3DSpangenberg%26aufirst%3DE.%26aulast%3DHohsfield%26aufirst%3DL.%2BA.%26aulast%3DCrapser%26aufirst%3DJ.%26aulast%3DPhan%26aufirst%3DN.%2BY.%26aulast%3DGreen%26aufirst%3DK.%2BN.%26aulast%3DSeverson%26aufirst%3DP.%2BL.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DBurton%26aufirst%3DE.%2BA.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DSpevak%26aufirst%3DW.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DHabets%26aufirst%3DG.%26aulast%3DRymar%26aufirst%3DA.%26aulast%3DTsang%26aufirst%3DG.%26aulast%3DWalters%26aufirst%3DJ.%26aulast%3DNespi%26aufirst%3DM.%26aulast%3DSingh%26aufirst%3DP.%26aulast%3DBroome%26aufirst%3DS.%26aulast%3DIbrahim%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DWest%26aufirst%3DB.%2BL.%26atitle%3DSustained%2520Microglial%2520Depletion%2520with%2520CSF1R%2520Inhibitor%2520Impairs%2520Parenchymal%2520Plaque%2520Development%2520in%2520an%2520Alzheimer%25E2%2580%2599s%2520Disease%2520Model%26jtitle%3DNat.%2520Commun.%26date%3D2019%26volume%3D10%26spage%3D3758%26doi%3D10.1038%2Fs41467-019-11674-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref181"><div class="reference"><strong class="refLabel"><a href="#ref181" class="rightTabRefNumLink">181</a></strong><div class="NLM_citation" id="rightTab-cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, P. N. J. M.</span>; <span class="NLM_string-name">Matsuura, S.</span></span>; <span> </span><span class="NLM_article-title">Synthesis of 1<i>H</i>-Pyrrolo[2,3-<i>b</i>]pyridin Derivatives That Modulate Kinases</span>. <span class="NLM_patent">WO 2016179412 A1</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=P.+N.+J.+M.+Ibrahim&author=S.+Matsuura&title=Synthesis+of+1H-Pyrrolo%5B2%2C3-b%5Dpyridin+Derivatives+That+Modulate+Kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%2BJ.%2BM.%26atitle%3DSynthesis%2520of%25201H-Pyrrolo%255B2%252C3-b%255Dpyridin%2520Derivatives%2520That%2520Modulate%2520Kinases%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref182"><div class="reference"><strong class="refLabel"><a href="#ref182" class="rightTabRefNumLink">182</a></strong><div class="NLM_citation" id="rightTab-cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Amaya, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimeno, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamdar, M.</span></span> <span> </span><span class="NLM_article-title">Polatuzumab Vedotin to Treat Relapsed or Refractory Diffuse Large B-Cell Lymphoma, in Combination with Bendamustine Plus Rituximab</span>. <i>Drugs Today</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">287</span>– <span class="NLM_lpage">294</span>, <span class="refDoi"> DOI: 10.1358/dot.2020.56.4.3127026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1358%2Fdot.2020.56.4.3127026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A280%3ADC%252BB38zntFOjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2020&pages=287-294&author=M.+L.+Amayaauthor=A.+Jimenoauthor=M.+Kamdar&title=Polatuzumab+Vedotin+to+Treat+Relapsed+or+Refractory+Diffuse+Large+B-Cell+Lymphoma%2C+in+Combination+with+Bendamustine+Plus+Rituximab&doi=10.1358%2Fdot.2020.56.4.3127026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximab</span></div><div class="casAuthors">Amaya M L; Jimeno A; Kamdar M</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of today (Barcelona, Spain : 1998)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">287-294</span>
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    </div><div class="casAbstract">Diffuse large B-cell lymphoma (DLBCL) is the most common non Hodgkin lymphoma (NHL) in adults, and it accounts for about 30% of adult NHL cases.  Newly diagnosed patients are treated with rituximab in combination with anthracycline-containing chemotherapy, but a significant number of patients relapse after initial treatment.  New strategies for relapsed lymphomas are in development among which antibody-drug conjugates (ADCs) are currently in clinical trials.  Polatuzumab vedotin is a novel ADC which binds to the commonly expressed B-cell antigen CD79b, and it delivers monomethyl auristatin E, a small molecule with anti-tubulin activity.  Polatuzumab vedotin in combination with bendamustine and rituximab (BR) has been approved in the U.S. and the E.U. for use in patients with relapsed or refractory DLBCL ineligible for transplant.  These approvals were based on a randomized study of patients treated with either polatuzumab vedotin plus BR or BR alone, where complete response was 40% in the polatuzumab vedotin + BR group versus 18% in the BR group.  The most common adverse events of this treatment were cytopenias and peripheral neuropathy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRl0dnj1Vhj6rJzI8owOhpDfW6udTcc2ebesYz7l-26crntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38zntFOjtw%253D%253D&md5=ce98e553bd770ade31ef73bc672cb479</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1358%2Fdot.2020.56.4.3127026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2020.56.4.3127026%26sid%3Dliteratum%253Aachs%26aulast%3DAmaya%26aufirst%3DM.%2BL.%26aulast%3DJimeno%26aufirst%3DA.%26aulast%3DKamdar%26aufirst%3DM.%26atitle%3DPolatuzumab%2520Vedotin%2520to%2520Treat%2520Relapsed%2520or%2520Refractory%2520Diffuse%2520Large%2520B-Cell%2520Lymphoma%252C%2520in%2520Combination%2520with%2520Bendamustine%2520Plus%2520Rituximab%26jtitle%3DDrugs%2520Today%26date%3D2020%26volume%3D56%26spage%3D287%26epage%3D294%26doi%3D10.1358%2Fdot.2020.56.4.3127026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref183"><div class="reference"><strong class="refLabel"><a href="#ref183" class="rightTabRefNumLink">183</a></strong><div class="NLM_citation" id="rightTab-cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doronina, S. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toki, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torgov, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendelsohn, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerveny, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chace, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeBlanc, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gearing, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bovee, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegall, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francisco, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wahl, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senter, P. D.</span></span> <span> </span><span class="NLM_article-title">Development of Potent Monoclonal Antibody Auristatin Conjugates for Cancer Therapy</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">778</span>– <span class="NLM_lpage">784</span>, <span class="refDoi"> DOI: 10.1038/nbt832</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1038%2Fnbt832" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=12778055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkvFertLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2003&pages=778-784&author=S.+O.+Doroninaauthor=B.+E.+Tokiauthor=M.+Y.+Torgovauthor=B.+A.+Mendelsohnauthor=C.+G.+Cervenyauthor=D.+F.+Chaceauthor=R.+L.+DeBlancauthor=R.+P.+Gearingauthor=T.+D.+Boveeauthor=C.+B.+Siegallauthor=J.+A.+Franciscoauthor=A.+F.+Wahlauthor=D.+L.+Meyerauthor=P.+D.+Senter&title=Development+of+Potent+Monoclonal+Antibody+Auristatin+Conjugates+for+Cancer+Therapy&doi=10.1038%2Fnbt832"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Development of potent monoclonal antibody auristatin conjugates for cancer therapy</span></div><div class="casAuthors">Doronina, Svetlana O.; Toki, Brian E.; Torgov, Michael Y.; Mendelsohn, Brian A.; Cerveny, Charles G.; Chace, Dana F.; DeBlanc, Ron L.; Gearing, R. Patrick; Bovee, Tim D.; Siegall, Clay B.; Francisco, Joseph A.; Wahl, Alan F.; Meyer, Damon L.; Senter, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">778-784</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We describe the in vitro and in vivo properties of monoclonal antibody (mAb)-drug conjugates consisting of the potent synthetic dolastatin 10 analogs auristatin E (AE) and monomethylauristatin E (MMAE), linked to the chimeric mAbs cBR96 (specific to Lewis Y on carcinomas) and cAC10 (specific to CD30 on hematol. malignancies).  The linkers used for conjugate formation included an acid-labile hydrazone and protease-sensitive dipeptides, leading to uniformly substituted conjugates that efficiently released active drug in the lysosomes of antigen-pos. (Ag+) tumor cells.  The peptide-linked mAb-valine-citrulline-MMAE and mAb-phenylalanine-lysine-MMAE conjugates were much more stable in buffers and plasma than the conjugates of mAb and the hydrazone of 5-benzoylvaleric acid-AE ester (AEVB).  As a result, the mAb-Val-Cit-MMAE conjugates exhibited greater in vitro specificity and lower in vivo toxicity than corresponding hydrazone conjugates.  In vivo studies demonstrated that the peptide-linked conjugates induced regressions and cures of established tumor xenografts with therapeutic indexes as high as 60-fold.  These conjugates illustrate the importance of linker technol., drug potency and conjugation methodol. in developing safe and efficacious mAb-drug conjugates for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro97SFKtdQ7rVg90H21EOLACvtfcHk0licvEyYrVkbKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkvFertLc%253D&md5=d77716ec93de5ac7473c18a597339086</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1038%2Fnbt832&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt832%26sid%3Dliteratum%253Aachs%26aulast%3DDoronina%26aufirst%3DS.%2BO.%26aulast%3DToki%26aufirst%3DB.%2BE.%26aulast%3DTorgov%26aufirst%3DM.%2BY.%26aulast%3DMendelsohn%26aufirst%3DB.%2BA.%26aulast%3DCerveny%26aufirst%3DC.%2BG.%26aulast%3DChace%26aufirst%3DD.%2BF.%26aulast%3DDeBlanc%26aufirst%3DR.%2BL.%26aulast%3DGearing%26aufirst%3DR.%2BP.%26aulast%3DBovee%26aufirst%3DT.%2BD.%26aulast%3DSiegall%26aufirst%3DC.%2BB.%26aulast%3DFrancisco%26aufirst%3DJ.%2BA.%26aulast%3DWahl%26aufirst%3DA.%2BF.%26aulast%3DMeyer%26aufirst%3DD.%2BL.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DDevelopment%2520of%2520Potent%2520Monoclonal%2520Antibody%2520Auristatin%2520Conjugates%2520for%2520Cancer%2520Therapy%26jtitle%3DNat.%2520Biotechnol.%26date%3D2003%26volume%3D21%26spage%3D778%26epage%3D784%26doi%3D10.1038%2Fnbt832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref184"><div class="reference"><strong class="refLabel"><a href="#ref184" class="rightTabRefNumLink">184</a></strong><div class="NLM_citation" id="rightTab-cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dere, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuh, F. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozak, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bumbaca
Yadav, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nazzal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danilenko, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Go, M. A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polson, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prabhu, S.</span></span> <span> </span><span class="NLM_article-title">Evaluation and Use of an Anti-Cynomolgus Monkey CD79b Surrogate Antibody–Drug Conjugate to Enable Clinical Development of Polatuzumab Vedotin</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>176</i></span>,  <span class="NLM_fpage">3805</span>– <span class="NLM_lpage">3818</span>, <span class="refDoi"> DOI: 10.1111/bph.14784</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1111%2Fbph.14784" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31270798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1aqsLfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=176&publication_year=2019&pages=3805-3818&author=D.+Liauthor=D.+Leeauthor=R.+C.+Dereauthor=B.+Zhengauthor=S.-F.+Yuauthor=F.+K.+Fuhauthor=K.+R.+Kozakauthor=S.+Chungauthor=D.+Bumbaca%0AYadavauthor=D.+Nazzalauthor=D.+Danilenkoauthor=M.+A.+T.+Goauthor=M.+Williamsauthor=A.+G.+Polsonauthor=K.+A.+Poonauthor=S.+Prabhu&title=Evaluation+and+Use+of+an+Anti-Cynomolgus+Monkey+CD79b+Surrogate+Antibody%E2%80%93Drug+Conjugate+to+Enable+Clinical+Development+of+Polatuzumab+Vedotin&doi=10.1111%2Fbph.14784"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation and use of an anti-cynomolgus monkey CD79b surrogate antibody-drug conjugate to enable clinical development of polatuzumab vedotin</span></div><div class="casAuthors">Li, Dongwei; Lee, Donna; Dere, Randall C.; Zheng, Bing; Yu, Shang-Fan; Fuh, Franklin K.; Kozak, Katherine R.; Chung, Shan; Bumbaca Yadav, Daniela; Nazzal, Denise; Danilenko, Dimitry; Go, Mary Ann T.; Williams, Marna; Polson, Andrew G.; Poon, Kirsten Achilles; Prabhu, Saileta</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">176</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">3805-3818</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Polatuzumab vedotin is an antibody-drug conjugate (ADC) being developed for non-Hodgkin's lymphoma.  It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), an anti-mitotic agent.  Polatuzumab vedotin binds to human CD79b only.  Therefore, a surrogate ADC that binds to cynomolgus monkey CD79b was used to det. CD79b-mediated pharmacol. effects in the monkey and to enable first-in-human clin. trials.  Polatuzumab vedotin, the surrogate ADC, and the corresponding antibodies were evaluated in different assays in vitro and in animals.  In vitro assessments included binding to peripheral blood mononuclear cells from different species, binding to a human and monkey CD79b-expressing cell line, binding to human Fcγ receptors, and stability in plasma across species.  In vivo, ADCs were assessed for anti-tumor activity in mice, pharmacokinetics/pharmacodynamics in monkeys, and toxicity in rats and monkeys.  Polatuzumab vedotin and surrogate ADC bind with similar affinity to human and cynomolgus monkey B cells, resp.  Comparable in vitro plasma stability, in vivo anti-tumor activity, and mouse pharmacokinetics were also obsd. between the surrogate ADC and polatuzumab vedotin.  In monkeys, only the surrogate ADC showed B-cell depletion and B-cell-mediated drug disposition, but both ADCs showed similar MMAE-driven myelotoxicity, as expected.  The suitability of the surrogate ADC for evaluation of CD79b-dependent pharmacol. was demonstrated, and anti-tumor activity, pharmacokinetics/pharmacodynamics, and toxicity data with both ADCs supported the entry of polatuzumab vedotin into clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYvtxcRHld6bVg90H21EOLACvtfcHk0licvEyYrVkbKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1aqsLfE&md5=1e6be208a608aa546823232c509b0661</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1111%2Fbph.14784&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.14784%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DD.%26aulast%3DDere%26aufirst%3DR.%2BC.%26aulast%3DZheng%26aufirst%3DB.%26aulast%3DYu%26aufirst%3DS.-F.%26aulast%3DFuh%26aufirst%3DF.%2BK.%26aulast%3DKozak%26aufirst%3DK.%2BR.%26aulast%3DChung%26aufirst%3DS.%26aulast%3DBumbaca%2BYadav%26aufirst%3DD.%26aulast%3DNazzal%26aufirst%3DD.%26aulast%3DDanilenko%26aufirst%3DD.%26aulast%3DGo%26aufirst%3DM.%2BA.%2BT.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DPolson%26aufirst%3DA.%2BG.%26aulast%3DPoon%26aufirst%3DK.%2BA.%26aulast%3DPrabhu%26aufirst%3DS.%26atitle%3DEvaluation%2520and%2520Use%2520of%2520an%2520Anti-Cynomolgus%2520Monkey%2520CD79b%2520Surrogate%2520Antibody%25E2%2580%2593Drug%2520Conjugate%2520to%2520Enable%2520Clinical%2520Development%2520of%2520Polatuzumab%2520Vedotin%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2019%26volume%3D176%26spage%3D3805%26epage%3D3818%26doi%3D10.1111%2Fbph.14784" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref185"><div class="reference"><strong class="refLabel"><a href="#ref185" class="rightTabRefNumLink">185</a></strong><div class="NLM_citation" id="rightTab-cit185a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Aikawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Togashi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwanaga, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishiya, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levis, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isoyama, T.</span></span> <span> </span><span class="NLM_article-title">Quizartinib, a Selective FLT3 Inhibitor, Maintains Antileukemic Activity in Preclinical Models of RAS-Mediated Midostaurin-Resistant Acute Myeloid Leukemia Cells</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">943</span>– <span class="NLM_lpage">955</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.27489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.18632%2Foncotarget.27489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=32215183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A280%3ADC%252BB383nslejtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=943-955&author=T.+Aikawaauthor=N.+Togashiauthor=K.+Iwanagaauthor=H.+Okadaauthor=Y.+Nishiyaauthor=S.+Inoueauthor=M.+J.+Levisauthor=T.+Isoyama&title=Quizartinib%2C+a+Selective+FLT3+Inhibitor%2C+Maintains+Antileukemic+Activity+in+Preclinical+Models+of+RAS-Mediated+Midostaurin-Resistant+Acute+Myeloid+Leukemia+Cells&doi=10.18632%2Foncotarget.27489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit185aR"><div class="casContent"><span class="casTitleNuber">185a</span><div class="casTitle"><span class="NLM_cas:atitle">Quizartinib, a selective FLT3 inhibitor, maintains antileukemic activity in preclinical models of RAS-mediated midostaurin-resistant acute myeloid leukemia cells</span></div><div class="casAuthors">Aikawa Tomoya; Togashi Noriko; Iwanaga Koichi; Okada Hiroyuki; Nishiya Yumi; Inoue Shinichi; Isoyama Takeshi; Levis Mark J</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">943-955</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">FLT3 internal tandem duplication (ITD) mutations are associated with poor prognosis in patients with acute myeloid leukemia (AML).  In this preclinical study, we characterized the binding affinity and selectivity of quizartinib, a small-molecule inhibitor of FLT3, and AC886, the active metabolite of quizartinib, compared with those of other FLT3 inhibitors.  Selectivity profiling against >400 kinases showed that quizartinib and AC886 were highly selective against FLT3.  Quizartinib and AC886 inhibited FLT3 signaling pathways in FLT3-ITD-mutated AML cells, leading to potent growth inhibition with IC50 values of <1 nM.  When quizartinib was administered to mice bearing FLT3-ITD mutated tumors, AC886 was rapidly detected and tumor regression was observed at doses of ≥1 mg/kg without severe body weight loss.  In addition, quizartinib inhibited the viability of midostaurin-resistant MOLM-14 cells and exerted potent antitumor activity in mouse xenograft models without severe body weight loss, while midostaurin and gilteritinib did not show significant antitumor effects.  This is the first detailed characterization of quizartinib and AC886 in comparison with other FLT3 inhibitors under the same experimental conditions.  Preclinical antileukemic activity in midostaurin-resistant FLT3-ITD-mutated AML cells suggests the potential value of quizartinib following midostaurin failure in patients with FLT3-ITD mutated AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS7wRn2iXI1_IvKgEt20y1XfW6udTcc2eY-ak0FcQA2nrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB383nslejtw%253D%253D&md5=9adcf7786ff2e64f56d2d964edb7cab5</span></div><a href="/servlet/linkout?suffix=cit185a&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.27489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.27489%26sid%3Dliteratum%253Aachs%26aulast%3DAikawa%26aufirst%3DT.%26aulast%3DTogashi%26aufirst%3DN.%26aulast%3DIwanaga%26aufirst%3DK.%26aulast%3DOkada%26aufirst%3DH.%26aulast%3DNishiya%26aufirst%3DY.%26aulast%3DInoue%26aufirst%3DS.%26aulast%3DLevis%26aufirst%3DM.%2BJ.%26aulast%3DIsoyama%26aufirst%3DT.%26atitle%3DQuizartinib%252C%2520a%2520Selective%2520FLT3%2520Inhibitor%252C%2520Maintains%2520Antileukemic%2520Activity%2520in%2520Preclinical%2520Models%2520of%2520RAS-Mediated%2520Midostaurin-Resistant%2520Acute%2520Myeloid%2520Leukemia%2520Cells%26jtitle%3DOncotarget%26date%3D2020%26volume%3D11%26spage%3D943%26epage%3D955%26doi%3D10.18632%2Foncotarget.27489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit185b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Naqvi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravandi, F.</span></span> <span> </span><span class="NLM_article-title">FLT3 Inhibitor Quizartinib (AC220)</span>. <i>Leuk. Lymphoma</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1866</span>– <span class="NLM_lpage">1876</span>, <span class="refDoi"> DOI: 10.1080/10428194.2019.1602263</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1080%2F10428194.2019.1602263" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=30997851" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnslOrsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2019&pages=1866-1876&author=K.+Naqviauthor=F.+Ravandi&title=FLT3+Inhibitor+Quizartinib+%28AC220%29&doi=10.1080%2F10428194.2019.1602263"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit185bR"><div class="casContent"><span class="casTitleNuber">185b</span><div class="casTitle"><span class="NLM_cas:atitle">FLT3 inhibitor quizartinib (AC220)</span></div><div class="casAuthors">Naqvi, Kiran; Ravandi, Farhad</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia & Lymphoma</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1866-1876</span>CODEN:
                <span class="NLM_cas:coden">LELYEA</span>;
        ISSN:<span class="NLM_cas:issn">1029-2403</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Acute myeloid leukemia (AML) is a heterogeneous disease and remains a therapeutic challenge.  Cytogenetics is a well-established prognostic factor.  Recent discovery of mol. mutations has gained momentum with some being potential therapeutic targets.  FLT3 mutation seen in approx. one third of the cytogenetically normal AML confers high risk of relapse and poor survival.  Quizartinib is the first drug developed specifically as a FLT3 inhibitor.  It has confirmed safety and efficacy in phase I and II clin. trials and has shown survival benefit over conventional chemotherapy in patients with FLT3 ITD mutated relapsed/refractory AML.  Despite such promise, disease relapses are still seen.  Besides the complex nature of AML itself, resistance mechanisms blunting the efficacy of quizartinib have been identified and are being investigated including TKD mutations, alternate signaling pathways and the bone marrow microenvironment.  Strategies using combination of quizartinib with other TKIs/agents like crenolinib, PIM kinase, and MEK inhibitors should be further explored.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXcUK188pPwbVg90H21EOLACvtfcHk0ljVNkIviZ6EzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnslOrsrg%253D&md5=c1f1aa313d92e49f45159e7cce9bbbdd</span></div><a href="/servlet/linkout?suffix=cit185b&amp;dbid=16384&amp;doi=10.1080%2F10428194.2019.1602263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10428194.2019.1602263%26sid%3Dliteratum%253Aachs%26aulast%3DNaqvi%26aufirst%3DK.%26aulast%3DRavandi%26aufirst%3DF.%26atitle%3DFLT3%2520Inhibitor%2520Quizartinib%2520%2528AC220%2529%26jtitle%3DLeuk.%2520Lymphoma%26date%3D2019%26volume%3D60%26spage%3D1866%26epage%3D1876%26doi%3D10.1080%2F10428194.2019.1602263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref186"><div class="reference"><strong class="refLabel"><a href="#ref186" class="rightTabRefNumLink">186</a></strong><div class="NLM_citation" id="rightTab-cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprankle, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grotzfeld, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velasco, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunawardane, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cramer, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhagwat, S. S.</span></span> <span> </span><span class="NLM_article-title">Identification of N-(5-<i>tert</i>-Butyl-isoxazol-3-yl)-<i>N</i>-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo-[2,1-<i>b</i>][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a Uniquely Potent, Selective, and Efficacious Fms-Like Tyrosine Kinase-3 (FLT3) Inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">7808</span>– <span class="NLM_lpage">7816</span>, <span class="refDoi"> DOI: 10.1021/jm9007533</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9007533" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFCjt7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7808-7816&author=Q.+Chaoauthor=K.+G.+Sprankleauthor=R.+M.+Grotzfeldauthor=A.+G.+Laiauthor=T.+A.+Carterauthor=A.+M.+Velascoauthor=R.+N.+Gunawardaneauthor=M.+D.+Cramerauthor=M.+F.+Gardnerauthor=J.+Jamesauthor=P.+P.+Zarrinkarauthor=H.+K.+Patelauthor=S.+S.+Bhagwat&title=Identification+of+N-%285-tert-Butyl-isoxazol-3-yl%29-N-%7B4-%5B7-%282-morpholin-4-yl-ethoxy%29imidazo-%5B2%2C1-b%5D%5B1%2C3%5Dbenzothiazol-2-yl%5Dphenyl%7Durea+dihydrochloride+%28AC220%29%2C+a+Uniquely+Potent%2C+Selective%2C+and+Efficacious+Fms-Like+Tyrosine+Kinase-3+%28FLT3%29+Inhibitor&doi=10.1021%2Fjm9007533"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of N-(5-tert-Butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea Dihydrochloride (AC220), a Uniquely Potent, Selective, and Efficacious FMS-Like Tyrosine Kinase-3 (FLT3) Inhibitor</span></div><div class="casAuthors">Chao, Qi; Sprankle, Kelly G.; Grotzfeld, Robert M.; Lai, Andiliy G.; Carter, Todd A.; Velasco, Anne Marie; Gunawardane, Ruwanthi N.; Cramer, Merryl D.; Gardner, Michael F.; James, Joyce; Zarrinkar, Patrick P.; Patel, Hitesh K.; Bhagwat, Shripad S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7808-7816</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Treatment of AML patients with small mol. inhibitors of FLT3 kinase has been explored as a viable therapy.  However, these agents are found to be less than optimal for the treatment of AML because of lack of sufficient potency or suboptimal oral pharmacokinetics (PK) or lack of adequate tolerability at efficacious doses.  We have developed a series of extremely potent and highly selective FLT3 inhibitors with good oral PK properties.  The first series of compds. represented by 1 (AB530) was found to be a potent and selective FLT3 kinase inhibitor with good PK properties.  The aq. soly. and oral PK properties at higher doses in rodents were found to be less than optimal for clin. development.  A novel series of compds. were designed lacking the carboxamide group of 1 with an added water solubilizing group.  Compd. 7 (AC220) was identified from this series to be the most potent and selective FLT3 inhibitor with good pharmaceutical properties, excellent PK profile, and superior efficacy and tolerability in tumor xenograft models.  Compd. 7 has demonstrated a desirable safety and PK profile in humans and is currently in phase II clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAtNhT4frlQ7Vg90H21EOLACvtfcHk0ljVNkIviZ6EzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFCjt7zK&md5=1b64254428a51c637da0ff647ac8d567</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1021%2Fjm9007533&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9007533%26sid%3Dliteratum%253Aachs%26aulast%3DChao%26aufirst%3DQ.%26aulast%3DSprankle%26aufirst%3DK.%2BG.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DGunawardane%26aufirst%3DR.%2BN.%26aulast%3DCramer%26aufirst%3DM.%2BD.%26aulast%3DGardner%26aufirst%3DM.%2BF.%26aulast%3DJames%26aufirst%3DJ.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DBhagwat%26aufirst%3DS.%2BS.%26atitle%3DIdentification%2520of%2520N-%25285-tert-Butyl-isoxazol-3-yl%2529-N-%257B4-%255B7-%25282-morpholin-4-yl-ethoxy%2529imidazo-%255B2%252C1-b%255D%255B1%252C3%255Dbenzothiazol-2-yl%255Dphenyl%257Durea%2520dihydrochloride%2520%2528AC220%2529%252C%2520a%2520Uniquely%2520Potent%252C%2520Selective%252C%2520and%2520Efficacious%2520Fms-Like%2520Tyrosine%2520Kinase-3%2520%2528FLT3%2529%2520Inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7808%26epage%3D7816%26doi%3D10.1021%2Fjm9007533" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref187"><div class="reference"><strong class="refLabel"><a href="#ref187" class="rightTabRefNumLink">187</a></strong><div class="NLM_citation" id="rightTab-cit187"><span><a href="https://www.genengnews.com/topics/translational-medicine/daiichi-sankyo-to-acquire-ambit-biosciences-for-up-to-410m/" class="extLink">https://www.genengnews.com/topics/translational-medicine/daiichi-sankyo-to-acquire-ambit-biosciences-for-up-to-410m/</a> (accessed 2020-12-18).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.genengnews.com%2Ftopics%2Ftranslational-medicine%2Fdaiichi-sankyo-to-acquire-ambit-biosciences-for-up-to-410m%2F+%28accessed+2020-12-18%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref188"><div class="reference"><strong class="refLabel"><a href="#ref188" class="rightTabRefNumLink">188</a></strong><div class="NLM_citation" id="rightTab-cit188a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhagwat, S.</span>; <span class="NLM_string-name">Chao, Q.</span>; <span class="NLM_string-name">Grotzfeld, R. M.</span>; <span class="NLM_string-name">Patel, H. K.</span>; <span class="NLM_string-name">Sprankle, K. G.</span></span> <span> </span><span class="NLM_article-title">Imidazolothiazole Compounds for the Treatment of Disease</span>. <span class="NLM_patent">WO 2007109120 A1</span>, <span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=S.+Bhagwat&author=Q.+Chao&author=R.+M.+Grotzfeld&author=H.+K.+Patel&author=K.+G.+Sprankle&title=Imidazolothiazole+Compounds+for+the+Treatment+of+Disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit188a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBhagwat%26aufirst%3DS.%26atitle%3DImidazolothiazole%2520Compounds%2520for%2520the%2520Treatment%2520of%2520Disease%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit188b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhagwat, S.</span>; <span class="NLM_string-name">Lai, W.</span>; <span class="NLM_string-name">Parent, S. D.</span>; <span class="NLM_string-name">Roe, M. J.</span>; <span class="NLM_string-name">Schwartz, A.</span>; <span class="NLM_string-name">Smolenskaya, V. N.</span></span> <span> </span><span class="NLM_article-title">Solid Forms Comprising <i>N</i>-(5-<i>tert</i>-Butyl-isoxazol-3-yl)-<i>N</i>′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-<i>b</i>][1,3]benzothiazol-2-yl]phenyl}urea, Compositions Thereof, and Uses Therewith</span>. <span class="NLM_patent">WO 2009038757 A2</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=S.+Bhagwat&author=W.+Lai&author=S.+D.+Parent&author=M.+J.+Roe&author=A.+Schwartz&author=V.+N.+Smolenskaya&title=Solid+Forms+Comprising+N-%285-tert-Butyl-isoxazol-3-yl%29-N%E2%80%B2-%7B4-%5B7-%282-morpholin-4-yl-ethoxy%29imidazo%5B2%2C1-b%5D%5B1%2C3%5Dbenzothiazol-2-yl%5Dphenyl%7Durea%2C+Compositions+Thereof%2C+and+Uses+Therewith"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit188b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBhagwat%26aufirst%3DS.%26atitle%3DSolid%2520Forms%2520Comprising%2520N-%25285-tert-Butyl-isoxazol-3-yl%2529-N%25E2%2580%25B2-%257B4-%255B7-%25282-morpholin-4-yl-ethoxy%2529imidazo%255B2%252C1-b%255D%255B1%252C3%255Dbenzothiazol-2-yl%255Dphenyl%257Durea%252C%2520Compositions%2520Thereof%252C%2520and%2520Uses%2520Therewith%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref189"><div class="reference"><strong class="refLabel"><a href="#ref189" class="rightTabRefNumLink">189</a></strong><div class="NLM_citation" id="rightTab-cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gross, T. D.</span>; <span class="NLM_string-name">Prasad, A. R.</span>; <span class="NLM_string-name">Citineni, J. R.</span></span> <span> </span><span class="NLM_article-title">Process for the Preparation of Imidazo[2,1-<i>b</i>][1,3]benzothiazole Derivatives</span>. WO <span class="NLM_patent">2011056939 A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=T.+D.+Gross&author=A.+R.+Prasad&author=J.+R.+Citineni&title=Process+for+the+Preparation+of+Imidazo%5B2%2C1-b%5D%5B1%2C3%5Dbenzothiazole+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGross%26aufirst%3DT.%2BD.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%2520Imidazo%255B2%252C1-b%255D%255B1%252C3%255Dbenzothiazole%2520Derivatives%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref190"><div class="reference"><strong class="refLabel"><a href="#ref190" class="rightTabRefNumLink">190</a></strong><div class="NLM_citation" id="rightTab-cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jans, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagstaff, K. M.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of Nuclear Transport</span>. <i>Curr. Opin. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">50</span>– <span class="NLM_lpage">60</span>, <span class="refDoi"> DOI: 10.1016/j.ceb.2019.01.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2Fj.ceb.2019.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=30826604" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXislKksrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2019&pages=50-60&author=D.+A.+Jansauthor=A.+J.+Martinauthor=K.+M.+Wagstaff&title=Inhibitors+of+Nuclear+Transport&doi=10.1016%2Fj.ceb.2019.01.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of nuclear transport</span></div><div class="casAuthors">Jans, David A.; Martin, Alexander J.; Wagstaff, Kylie M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Cell Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">50-60</span>CODEN:
                <span class="NLM_cas:coden">COCBE3</span>;
        ISSN:<span class="NLM_cas:issn">0955-0674</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Central to eukaryotic cell function, transport into and out of the nucleus is largely mediated by members of the Importin (IMP) superfamily of transporters of α- and β-types.  The first inhibitor of nuclear transport, leptomycin B (LMB), was shown to be a specific inhibitor of the IMPβ homolog Exportin 1 (EXP1) almost 20 years ago, but it has only been in the last five or so years that new inhibitors of nuclear export as well as import have been identified and characterised.  Of utility in biol. research, these inhibitors include those that target-specific EXPs/IMPs, with accompanying toxicity profiles, as well as agents that specifically target particular nuclear import cargoes.  Both types of inhibitors have begun to be tested in preclin./clin. studies, with particular focus on limiting various types of cancer or treating viral infection, and the most advanced agent targeting EXP1 (Selinexor) has progressed successfully through >40 clin. trials for a range of high-grade cancers and is approaching FDA approval for a no. of indications.  Selectively inhibiting the nucleocytoplasmic trafficking of specific proteins of interest remains a challenge, but progress in the area of the host-pathogen interface holds promise for the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYo9dIddFK5bVg90H21EOLACvtfcHk0lj7EInfq1yEoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXislKksrg%253D&md5=c716540c78a6cdd8b0d5ab968415cfd4</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1016%2Fj.ceb.2019.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ceb.2019.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DJans%26aufirst%3DD.%2BA.%26aulast%3DMartin%26aufirst%3DA.%2BJ.%26aulast%3DWagstaff%26aufirst%3DK.%2BM.%26atitle%3DInhibitors%2520of%2520Nuclear%2520Transport%26jtitle%3DCurr.%2520Opin.%2520Cell%2520Biol.%26date%3D2019%26volume%3D58%26spage%3D50%26epage%3D60%26doi%3D10.1016%2Fj.ceb.2019.01.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref191"><div class="reference"><strong class="refLabel"><a href="#ref191" class="rightTabRefNumLink">191</a></strong><div class="NLM_citation" id="rightTab-cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ben-Barouch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuruvilla, J.</span></span> <span> </span><span class="NLM_article-title">Selinexor (KTP-330) - a Selective Inhibitor of Nuclear Export (SINE): Anti-Tumor Activity in Diffuse Large B-Cell Lymphoma (DLBCL)</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1080/13543784.2020.1706087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1080%2F13543784.2020.1706087" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31847605" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVGlsb7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2020&pages=15-21&author=S.+Ben-Barouchauthor=J.+Kuruvilla&title=Selinexor+%28KTP-330%29+-+a+Selective+Inhibitor+of+Nuclear+Export+%28SINE%29%3A+Anti-Tumor+Activity+in+Diffuse+Large+B-Cell+Lymphoma+%28DLBCL%29&doi=10.1080%2F13543784.2020.1706087"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Selinexor (KTP-330) - a selective inhibitor of nuclear export (SINE): anti-tumor activity in diffuse large B-cell lymphoma (DLBCL)</span></div><div class="casAuthors">Ben-Barouch, Sharon; Kuruvilla, John</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-21</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Selinexor is a first-in-class, oral therapeutic that selectively inhibits nuclear export.  It has received fast track designation from the FDA for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) recently, and continues to be evaluated as a potential treatment for DLBCL.: This article reviews the available data from clin. trials regarding the efficacy of selinexor in DLBCL and highlights the key toxicity issues and how they may best be managed.  Ongoing and future studies in DLBCL are also discussed.: More translational studies are necessary to leverage the unique mechanism action and rationally inform the use of selinexor in combination strategies.  There are several different genetic subtypes of DLBCL, but it is not clear if these classifications will identify patients that may benefit from targeted therapies.  The broad potential mechanism of action of selinexor will require careful anal. to inform predictive or prognostic biomarkers.  Further evaluation of selinexor in combination with std. lymphoma regimens could identify deliverable promising regimens.  Future randomized trials are key for registration and to det. the optimal role for this first-in-class agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopMRVOtPthZrVg90H21EOLACvtfcHk0lj7EInfq1yEoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVGlsb7P&md5=a633ee622b9103039a6a9e0cb3d478ba</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1080%2F13543784.2020.1706087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543784.2020.1706087%26sid%3Dliteratum%253Aachs%26aulast%3DBen-Barouch%26aufirst%3DS.%26aulast%3DKuruvilla%26aufirst%3DJ.%26atitle%3DSelinexor%2520%2528KTP-330%2529%2520-%2520a%2520Selective%2520Inhibitor%2520of%2520Nuclear%2520Export%2520%2528SINE%2529%253A%2520Anti-Tumor%2520Activity%2520in%2520Diffuse%2520Large%2520B-Cell%2520Lymphoma%2520%2528DLBCL%2529%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2020%26volume%3D29%26spage%3D15%26epage%3D21%26doi%3D10.1080%2F13543784.2020.1706087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref192"><div class="reference"><strong class="refLabel"><a href="#ref192" class="rightTabRefNumLink">192</a></strong><div class="NLM_citation" id="rightTab-cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeSisto, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flannery, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pathak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mestnik, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philips, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bales, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashyap, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moroze, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkataraman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landesman, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vibhakar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, A. L.</span></span> <span> </span><span class="NLM_article-title">Exportin 1 Inhibition Induces Nerve Growth Factor Receptor Expression to Inhibit the NF-κB Pathway in Preclinical Models of Pediatric High-Grade Glioma</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">540</span>– <span class="NLM_lpage">551</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-18-1319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1158%2F1535-7163.MCT-18-1319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31594826" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnvFSktrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2020&pages=540-551&author=J.+A.+DeSistoauthor=P.+Flanneryauthor=R.+Lemmaauthor=A.+Pathakauthor=S.+Mestnikauthor=N.+Philipsauthor=N.+J.+Balesauthor=T.+Kashyapauthor=E.+Morozeauthor=S.+Venkataramanauthor=A.+L.+Kungauthor=B.+D.+Carterauthor=Y.+Landesmanauthor=R.+Vibhakarauthor=A.+L.+Green&title=Exportin+1+Inhibition+Induces+Nerve+Growth+Factor+Receptor+Expression+to+Inhibit+the+NF-%CE%BAB+Pathway+in+Preclinical+Models+of+Pediatric+High-Grade+Glioma&doi=10.1158%2F1535-7163.MCT-18-1319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Exportin 1 inhibition induces nerve growth factor receptor expression to inhibit the NF-κB pathway in preclinical models of pediatric high-grade glioma</span></div><div class="casAuthors">DeSisto, John A.; Flannery, Patrick; Lemma, Rakeb; Pathak, Amrita; Mestnik, Shelby; Philips, Natalie; Bales, Natalie J.; Kashyap, Trinayan; Moroze, Erin; Venkataraman, Sujatha; Kung, Andrew L.; Carter, Bruce D.; Landesman, Yosef; Vibhakar, Rajeev; Green, Adam L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">540-551</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">High-grade glioma (HGG) is the leading cause of cancer-related death among children.  Selinexor, an orally bioavailable, reversible inhibitor of the nuclear export protein, exportin 1, is in clin. trials for a range of cancers, including HGG.  It inhibits the NF-κB pathway and strongly induces the expression of nerve growth factor receptor (NGFR) in preclin. cancer models.  We hypothesized that selinexor inhibits NF-κB via upregulation of NGFR.  In HGG cells, sensitivity to selinexor correlated with increased induction of cell surface NGFR expression.  Knocking down NGFR in HGG cells increased proliferation, anchorage-independent growth, stemness markers, and levels of transcriptionally available nuclear NF-κB not bound to IκB-α, while decreasing apoptosis and sensitivity to selinexor.  Increasing IκB-α levels in NGFR knockdown cells restored sensitivity to selinexor.  Overexpression of NGFR using cDNA reduced levels of free nuclear NF-κB, decreased stemness markers, and increased markers of cellular differentiation.  In all HGG lines tested, selinexor decreased phosphorylation of NF-κB at serine 536 (a site assocd. with increased transcription of proliferative and inflammatory genes).  Because resistance to selinexor monotherapy occurred in our in vivo model, we screened selinexor with a panel of FDA-approved anticancer agents.  Bortezomib, a proteasome inhibitor that inhibits the NF-κB pathway through a different mechanism than selinexor, showed synergy with selinexor against HGG in vitro.  Our results help elucidate selinexor's mechanism of action and identify NGFR as a potential biomarker of its effect in HGG and in addn. suggest a combination therapy strategy for these challenging tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpM2nVjr0FgFLVg90H21EOLACvtfcHk0lhi0o77ZeOVYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnvFSktrc%253D&md5=9ac5293e322fb6d1cd8c9eca4a785de3</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-18-1319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-18-1319%26sid%3Dliteratum%253Aachs%26aulast%3DDeSisto%26aufirst%3DJ.%2BA.%26aulast%3DFlannery%26aufirst%3DP.%26aulast%3DLemma%26aufirst%3DR.%26aulast%3DPathak%26aufirst%3DA.%26aulast%3DMestnik%26aufirst%3DS.%26aulast%3DPhilips%26aufirst%3DN.%26aulast%3DBales%26aufirst%3DN.%2BJ.%26aulast%3DKashyap%26aufirst%3DT.%26aulast%3DMoroze%26aufirst%3DE.%26aulast%3DVenkataraman%26aufirst%3DS.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DCarter%26aufirst%3DB.%2BD.%26aulast%3DLandesman%26aufirst%3DY.%26aulast%3DVibhakar%26aufirst%3DR.%26aulast%3DGreen%26aufirst%3DA.%2BL.%26atitle%3DExportin%25201%2520Inhibition%2520Induces%2520Nerve%2520Growth%2520Factor%2520Receptor%2520Expression%2520to%2520Inhibit%2520the%2520NF-%25CE%25BAB%2520Pathway%2520in%2520Preclinical%2520Models%2520of%2520Pediatric%2520High-Grade%2520Glioma%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2020%26volume%3D19%26spage%3D540%26epage%3D551%26doi%3D10.1158%2F1535-7163.MCT-18-1319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref193"><div class="reference"><strong class="refLabel"><a href="#ref193" class="rightTabRefNumLink">193</a></strong><div class="NLM_citation" id="rightTab-cit193a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouhaddou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obernier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Meara, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rezelj, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaney, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tummino, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huettenhain, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaake, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richards, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tutuncuoglu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foussard, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batra, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polacco, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braberg, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabius, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckhardt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soucheray, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cakir, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGregor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roesch, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallet, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mac Kain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miorin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naing, Z. Z. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirby, I. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melnyk, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chorba, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrio-Hernandez, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Memon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez-Armenta, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathy, C. J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perica, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilla, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganesan, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saltzberg, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rakesh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenthal, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calviello, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkataramanan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liboy-Lugo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wankowicz, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safari, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ugur, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koh, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savar, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, Q. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shengjuler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neal, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broadhurst, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klippsten, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharp, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wenzell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuzuoglu-Ozturk, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trenker, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavero, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiatt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathore, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noack, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroud, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frankel, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, O. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verba, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agard, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emerman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Zastrow, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verdin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashworth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">d’Enfert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukherjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malik, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimori, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ideker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craik, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floor, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraser, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sali, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggero, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taunton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kortemme, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beltrao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vignuzzi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Sastre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoichet, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krogan, N. J.</span></span> <span> </span><span class="NLM_article-title">A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug Repurposing</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>583</i></span>,  <span class="NLM_fpage">459</span>– <span class="NLM_lpage">468</span>, <span class="refDoi"> DOI: 10.1038/s41586-020-2286-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1038%2Fs41586-020-2286-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=32353859" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlCqtbrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=583&publication_year=2020&pages=459-468&author=D.+E.+Gordonauthor=G.+M.+Jangauthor=M.+Bouhaddouauthor=J.+Xuauthor=K.+Obernierauthor=K.+M.+Whiteauthor=M.+J.+O%E2%80%99Mearaauthor=V.+V.+Rezeljauthor=J.+Z.+Guoauthor=D.+L.+Swaneyauthor=T.+A.+Tumminoauthor=R.+Huettenhainauthor=R.+M.+Kaakeauthor=A.+L.+Richardsauthor=B.+Tutuncuogluauthor=H.+Foussardauthor=J.+Batraauthor=K.+Haasauthor=M.+Modakauthor=M.+Kimauthor=P.+Haasauthor=B.+J.+Polaccoauthor=H.+Brabergauthor=J.+M.+Fabiusauthor=M.+Eckhardtauthor=M.+Soucherayauthor=M.+J.+Bennettauthor=M.+Cakirauthor=M.+J.+McGregorauthor=Q.+Liauthor=B.+Meyerauthor=F.+Roeschauthor=T.+Valletauthor=A.+Mac+Kainauthor=L.+Miorinauthor=E.+Morenoauthor=Z.+Z.+C.+Naingauthor=Y.+Zhouauthor=S.+Pengauthor=Y.+Shiauthor=Z.+Zhangauthor=W.+Shenauthor=I.+T.+Kirbyauthor=J.+E.+Melnykauthor=J.+S.+Chorbaauthor=K.+Louauthor=S.+A.+Daiauthor=I.+Barrio-Hernandezauthor=D.+Memonauthor=C.+Hernandez-Armentaauthor=J.+Lyuauthor=C.+J.+P.+Mathyauthor=T.+Pericaauthor=K.+B.+Pillaauthor=S.+J.+Ganesanauthor=D.+J.+Saltzbergauthor=R.+Rakeshauthor=X.+Liuauthor=S.+B.+Rosenthalauthor=L.+Calvielloauthor=S.+Venkataramananauthor=J.+Liboy-Lugoauthor=Y.+Linauthor=X.-P.+Huangauthor=Y.+Liuauthor=S.+A.+Wankowiczauthor=M.+Bohnauthor=M.+Safariauthor=F.+S.+Ugurauthor=C.+Kohauthor=N.+S.+Savarauthor=Q.+D.+Tranauthor=D.+Shengjulerauthor=S.+J.+Fletcherauthor=M.+C.+O%E2%80%99Nealauthor=Y.+Caiauthor=J.+C.+J.+Changauthor=D.+J.+Broadhurstauthor=S.+Klippstenauthor=P.+P.+Sharpauthor=N.+A.+Wenzellauthor=D.+Kuzuoglu-Ozturkauthor=H.-Y.+Wangauthor=R.+Trenkerauthor=J.+M.+Youngauthor=D.+A.+Caveroauthor=J.+Hiattauthor=T.+L.+Rothauthor=U.+Rathoreauthor=A.+Subramanianauthor=J.+Noackauthor=M.+Hubertauthor=R.+M.+Stroudauthor=A.+D.+Frankelauthor=O.+S.+Rosenbergauthor=K.+A.+Verbaauthor=D.+A.+Agardauthor=M.+Ottauthor=M.+Emermanauthor=N.+Juraauthor=M.+von+Zastrowauthor=E.+Verdinauthor=A.+Ashworthauthor=O.+Schwartzauthor=C.+d%E2%80%99Enfertauthor=S.+Mukherjeeauthor=M.+Jacobsonauthor=H.+S.+Malikauthor=D.+G.+Fujimoriauthor=T.+Idekerauthor=C.+S.+Craikauthor=S.+N.+Floorauthor=J.+S.+Fraserauthor=J.+D.+Grossauthor=A.+Saliauthor=B.+L.+Rothauthor=D.+Ruggeroauthor=J.+Tauntonauthor=T.+Kortemmeauthor=P.+Beltraoauthor=M.+Vignuzziauthor=A.+Garc%C3%ADa-Sastreauthor=K.+M.+Shokatauthor=B.+K.+Shoichetauthor=N.+J.+Krogan&title=A+SARS-CoV-2+Protein+Interaction+Map+Reveals+Targets+for+Drug+Repurposing&doi=10.1038%2Fs41586-020-2286-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit193aR"><div class="casContent"><span class="casTitleNuber">193a</span><div class="casTitle"><span class="NLM_cas:atitle">A SARS-CoV-2 protein interaction map reveals targets for drug repurposing</span></div><div class="casAuthors">Gordon, David E.; Jang, Gwendolyn M.; Bouhaddou, Mehdi; Xu, Jiewei; Obernier, Kirsten; White, Kris M.; O'Meara, Matthew J.; Rezelj, Veronica V.; Guo, Jeffrey Z.; Swaney, Danielle L.; Tummino, Tia A.; Huttenhain, Ruth; Kaake, Robyn M.; Richards, Alicia L.; Tutuncuoglu, Beril; Foussard, Helene; Batra, Jyoti; Haas, Kelsey; Modak, Maya; Kim, Minkyu; Haas, Paige; Polacco, Benjamin J.; Braberg, Hannes; Fabius, Jacqueline M.; Eckhardt, Manon; Soucheray, Margaret; Bennett, Melanie J.; Cakir, Merve; McGregor, Michael J.; Li, Qiongyu; Meyer, Bjoern; Roesch, Ferdinand; Vallet, Thomas; Mac Kain, Alice; Miorin, Lisa; Moreno, Elena; Naing, Zun Zar Chi; Zhou, Yuan; Peng, Shiming; Shi, Ying; Zhang, Ziyang; Shen, Wenqi; Kirby, Ilsa T.; Melnyk, James E.; Chorba, John S.; Lou, Kevin; Dai, Shizhong A.; Barrio-Hernandez, Inigo; Memon, Danish; Hernandez-Armenta, Claudia; Lyu, Jiankun; Mathy, Christopher J. P.; Perica, Tina; Pilla, Kala Bharath; Ganesan, Sai J.; Saltzberg, Daniel J.; Rakesh, Ramachandran; Liu, Xi; Rosenthal, Sara B.; Calviello, Lorenzo; Venkataramanan, Srivats; Liboy-Lugo, Jose; Lin, Yizhu; Huang, Xi-Ping; Liu, YongFeng; Wankowicz, Stephanie A.; Bohn, Markus; Safari, Maliheh; Ugur, Fatima S.; Koh, Cassandra; Savar, Nastaran Sadat; Tran, Quang Dinh; Shengjuler, Djoshkun; Fletcher, Sabrina J.; O'Neal, Michael C.; Cai, Yiming; Chang, Jason C. J.; Broadhurst, David J.; Klippsten, Saker; Sharp, Phillip P.; Wenzell, Nicole A.; Kuzuoglu-Ozturk, Duygu; Wang, Hao-Yuan; Trenker, Raphael; Young, Janet M.; Cavero, Devin A.; Hiatt, Joseph; Roth, Theodore L.; Rathore, Ujjwal; Subramanian, Advait; Noack, Julia; Hubert, Mathieu; Stroud, Robert M.; Frankel, Alan D.; Rosenberg, Oren S.; Verba, Kliment A.; Agard, David A.; Ott, Melanie; Emerman, Michael; Jura, Natalia; von Zastrow, Mark; Verdin, Eric; Ashworth, Alan; Schwartz, Olivier; d'Enfert, Christophe; Mukherjee, Shaeri; Jacobson, Matt; Malik, Harmit S.; Fujimori, Danica G.; Ideker, Trey; Craik, Charles S.; Floor, Stephen N.; Fraser, James S.; Gross, John D.; Sali, Andrej; Roth, Bryan L.; Ruggero, Davide; Taunton, Jack; Kortemme, Tanja; Beltrao, Pedro; Vignuzzi, Marco; Garcia-Sastre, Adolfo; Shokat, Kevan M.; Shoichet, Brian K.; Krogan, Nevan J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">583</span>
        (<span class="NLM_cas:issue">7816</span>),
    <span class="NLM_cas:pages">459-468</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: A newly described coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is the causative agent of coronavirus disease 2019 (COVID-19), has infected over 2.3 million people, led to the death of more than 160,000 individuals and caused worldwide social and economic disruption1,2.  There are no antiviral drugs with proven clin. efficacy for the treatment of COVID-19, nor are there any vaccines that prevent infection with SARS-CoV-2, and efforts to develop drugs and vaccines are hampered by the limited knowledge of the mol. details of how SARS-CoV-2 infects cells.  Here we cloned, tagged and expressed 26 of the 29 SARS-CoV-2 proteins in human cells and identified the human proteins that phys. assocd. with each of the SARS-CoV-2 proteins using affinity-purifn. mass spectrometry, identifying 332 high-confidence protein-protein interactions between SARS-CoV-2 and human proteins.  Among these, we identify 66 druggable human proteins or host factors targeted by 69 compds. (of which, 29 drugs are approved by the US Food and Drug Administration, 12 are in clin. trials and 28 are preclin. compds.).  We screened a subset of these in multiple viral assays and found two sets of pharmacol. agents that displayed antiviral activity: inhibitors of mRNA translation and predicted regulators of the sigma-1 and sigma-2 receptors.  Further studies of these host-factor-targeting agents, including their combination with drugs that directly target viral enzymes, could lead to a therapeutic regimen to treat COVID-19.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDvJUIvi-Ws7Vg90H21EOLACvtfcHk0lhi0o77ZeOVYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlCqtbrI&md5=ce8b172ae73aacd3b3d8bb64877f4435</span></div><a href="/servlet/linkout?suffix=cit193a&amp;dbid=16384&amp;doi=10.1038%2Fs41586-020-2286-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-020-2286-9%26sid%3Dliteratum%253Aachs%26aulast%3DGordon%26aufirst%3DD.%2BE.%26aulast%3DJang%26aufirst%3DG.%2BM.%26aulast%3DBouhaddou%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DObernier%26aufirst%3DK.%26aulast%3DWhite%26aufirst%3DK.%2BM.%26aulast%3DO%25E2%2580%2599Meara%26aufirst%3DM.%2BJ.%26aulast%3DRezelj%26aufirst%3DV.%2BV.%26aulast%3DGuo%26aufirst%3DJ.%2BZ.%26aulast%3DSwaney%26aufirst%3DD.%2BL.%26aulast%3DTummino%26aufirst%3DT.%2BA.%26aulast%3DHuettenhain%26aufirst%3DR.%26aulast%3DKaake%26aufirst%3DR.%2BM.%26aulast%3DRichards%26aufirst%3DA.%2BL.%26aulast%3DTutuncuoglu%26aufirst%3DB.%26aulast%3DFoussard%26aufirst%3DH.%26aulast%3DBatra%26aufirst%3DJ.%26aulast%3DHaas%26aufirst%3DK.%26aulast%3DModak%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DHaas%26aufirst%3DP.%26aulast%3DPolacco%26aufirst%3DB.%2BJ.%26aulast%3DBraberg%26aufirst%3DH.%26aulast%3DFabius%26aufirst%3DJ.%2BM.%26aulast%3DEckhardt%26aufirst%3DM.%26aulast%3DSoucheray%26aufirst%3DM.%26aulast%3DBennett%26aufirst%3DM.%2BJ.%26aulast%3DCakir%26aufirst%3DM.%26aulast%3DMcGregor%26aufirst%3DM.%2BJ.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DMeyer%26aufirst%3DB.%26aulast%3DRoesch%26aufirst%3DF.%26aulast%3DVallet%26aufirst%3DT.%26aulast%3DMac%2BKain%26aufirst%3DA.%26aulast%3DMiorin%26aufirst%3DL.%26aulast%3DMoreno%26aufirst%3DE.%26aulast%3DNaing%26aufirst%3DZ.%2BZ.%2BC.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DPeng%26aufirst%3DS.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DShen%26aufirst%3DW.%26aulast%3DKirby%26aufirst%3DI.%2BT.%26aulast%3DMelnyk%26aufirst%3DJ.%2BE.%26aulast%3DChorba%26aufirst%3DJ.%2BS.%26aulast%3DLou%26aufirst%3DK.%26aulast%3DDai%26aufirst%3DS.%2BA.%26aulast%3DBarrio-Hernandez%26aufirst%3DI.%26aulast%3DMemon%26aufirst%3DD.%26aulast%3DHernandez-Armenta%26aufirst%3DC.%26aulast%3DLyu%26aufirst%3DJ.%26aulast%3DMathy%26aufirst%3DC.%2BJ.%2BP.%26aulast%3DPerica%26aufirst%3DT.%26aulast%3DPilla%26aufirst%3DK.%2BB.%26aulast%3DGanesan%26aufirst%3DS.%2BJ.%26aulast%3DSaltzberg%26aufirst%3DD.%2BJ.%26aulast%3DRakesh%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DRosenthal%26aufirst%3DS.%2BB.%26aulast%3DCalviello%26aufirst%3DL.%26aulast%3DVenkataramanan%26aufirst%3DS.%26aulast%3DLiboy-Lugo%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DX.-P.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DWankowicz%26aufirst%3DS.%2BA.%26aulast%3DBohn%26aufirst%3DM.%26aulast%3DSafari%26aufirst%3DM.%26aulast%3DUgur%26aufirst%3DF.%2BS.%26aulast%3DKoh%26aufirst%3DC.%26aulast%3DSavar%26aufirst%3DN.%2BS.%26aulast%3DTran%26aufirst%3DQ.%2BD.%26aulast%3DShengjuler%26aufirst%3DD.%26aulast%3DFletcher%26aufirst%3DS.%2BJ.%26aulast%3DO%25E2%2580%2599Neal%26aufirst%3DM.%2BC.%26aulast%3DCai%26aufirst%3DY.%26aulast%3DChang%26aufirst%3DJ.%2BC.%2BJ.%26aulast%3DBroadhurst%26aufirst%3DD.%2BJ.%26aulast%3DKlippsten%26aufirst%3DS.%26aulast%3DSharp%26aufirst%3DP.%2BP.%26aulast%3DWenzell%26aufirst%3DN.%2BA.%26aulast%3DKuzuoglu-Ozturk%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DH.-Y.%26aulast%3DTrenker%26aufirst%3DR.%26aulast%3DYoung%26aufirst%3DJ.%2BM.%26aulast%3DCavero%26aufirst%3DD.%2BA.%26aulast%3DHiatt%26aufirst%3DJ.%26aulast%3DRoth%26aufirst%3DT.%2BL.%26aulast%3DRathore%26aufirst%3DU.%26aulast%3DSubramanian%26aufirst%3DA.%26aulast%3DNoack%26aufirst%3DJ.%26aulast%3DHubert%26aufirst%3DM.%26aulast%3DStroud%26aufirst%3DR.%2BM.%26aulast%3DFrankel%26aufirst%3DA.%2BD.%26aulast%3DRosenberg%26aufirst%3DO.%2BS.%26aulast%3DVerba%26aufirst%3DK.%2BA.%26aulast%3DAgard%26aufirst%3DD.%2BA.%26aulast%3DOtt%26aufirst%3DM.%26aulast%3DEmerman%26aufirst%3DM.%26aulast%3DJura%26aufirst%3DN.%26aulast%3Dvon%2BZastrow%26aufirst%3DM.%26aulast%3DVerdin%26aufirst%3DE.%26aulast%3DAshworth%26aufirst%3DA.%26aulast%3DSchwartz%26aufirst%3DO.%26aulast%3Dd%25E2%2580%2599Enfert%26aufirst%3DC.%26aulast%3DMukherjee%26aufirst%3DS.%26aulast%3DJacobson%26aufirst%3DM.%26aulast%3DMalik%26aufirst%3DH.%2BS.%26aulast%3DFujimori%26aufirst%3DD.%2BG.%26aulast%3DIdeker%26aufirst%3DT.%26aulast%3DCraik%26aufirst%3DC.%2BS.%26aulast%3DFloor%26aufirst%3DS.%2BN.%26aulast%3DFraser%26aufirst%3DJ.%2BS.%26aulast%3DGross%26aufirst%3DJ.%2BD.%26aulast%3DSali%26aufirst%3DA.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DRuggero%26aufirst%3DD.%26aulast%3DTaunton%26aufirst%3DJ.%26aulast%3DKortemme%26aufirst%3DT.%26aulast%3DBeltrao%26aufirst%3DP.%26aulast%3DVignuzzi%26aufirst%3DM.%26aulast%3DGarc%25C3%25ADa-Sastre%26aufirst%3DA.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26aulast%3DKrogan%26aufirst%3DN.%2BJ.%26atitle%3DA%2520SARS-CoV-2%2520Protein%2520Interaction%2520Map%2520Reveals%2520Targets%2520for%2520Drug%2520Repurposing%26jtitle%3DNature%26date%3D2020%26volume%3D583%26spage%3D459%26epage%3D468%26doi%3D10.1038%2Fs41586-020-2286-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit193b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Rubinstein, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinharter, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rini, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choueiri, T. K.</span></span> <span> </span><span class="NLM_article-title">The Covid-19 and Cancer Consortium: A Collaborative Effort to Understand the Effects of COVID-19 on Patients with Cancer</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">738</span>– <span class="NLM_lpage">741</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2020.04.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2Fj.ccell.2020.04.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=32454025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVSisLfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2020&pages=738-741&author=S.+M.+Rubinsteinauthor=J.+A.+Steinharterauthor=J.+Warnerauthor=B.+I.+Riniauthor=S.+Petersauthor=T.+K.+Choueiri&title=The+Covid-19+and+Cancer+Consortium%3A+A+Collaborative+Effort+to+Understand+the+Effects+of+COVID-19+on+Patients+with+Cancer&doi=10.1016%2Fj.ccell.2020.04.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit193bR"><div class="casContent"><span class="casTitleNuber">193b</span><div class="casTitle"><span class="NLM_cas:atitle">The COVID-19 and Cancer Consortium: A Collaborative Effort to Understand the Effects of COVID-19 on Patients with Cancer</span></div><div class="casAuthors">Rubinstein, Samuel M.; Steinharter, John A.; Warner, Jeremy; Rini, Brian I.; Peters, Solange; Choueiri, Toni K.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">738-741</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">National and international consortia will play a key role in understanding the effects of the coronavirus disease 2019 (COVID-19) pandemic on cancer patients.  The COVID-19 and Cancer Consortium (CCC19) aims to collect and analyze observational data at scale to inform clin. practice in real-time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDPOY3zWPid7Vg90H21EOLACvtfcHk0lgJeMGOz-_PUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVSisLfP&md5=a5c6d0a8b0677aa529dd774ff4ae3745</span></div><a href="/servlet/linkout?suffix=cit193b&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2020.04.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2020.04.018%26sid%3Dliteratum%253Aachs%26aulast%3DRubinstein%26aufirst%3DS.%2BM.%26aulast%3DSteinharter%26aufirst%3DJ.%2BA.%26aulast%3DWarner%26aufirst%3DJ.%26aulast%3DRini%26aufirst%3DB.%2BI.%26aulast%3DPeters%26aufirst%3DS.%26aulast%3DChoueiri%26aufirst%3DT.%2BK.%26atitle%3DThe%2520Covid-19%2520and%2520Cancer%2520Consortium%253A%2520A%2520Collaborative%2520Effort%2520to%2520Understand%2520the%2520Effects%2520of%2520COVID-19%2520on%2520Patients%2520with%2520Cancer%26jtitle%3DCancer%2520Cell%26date%3D2020%26volume%3D37%26spage%3D738%26epage%3D741%26doi%3D10.1016%2Fj.ccell.2020.04.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref194"><div class="reference"><strong class="refLabel"><a href="#ref194" class="rightTabRefNumLink">194</a></strong><div class="NLM_citation" id="rightTab-cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sandanayaka, V. P.</span>; <span class="NLM_string-name">Shacham, S.</span>; <span class="NLM_string-name">McCauley, D.</span>; <span class="NLM_string-name">Shechter, S.</span></span> <span> </span><span class="NLM_article-title">Preparation of Hydrazide Containing Nuclear Transport Modulators and Uses Thereof</span>. <span class="NLM_patent">WO 2013019548 A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=V.+P.+Sandanayaka&author=S.+Shacham&author=D.+McCauley&author=S.+Shechter&title=Preparation+of+Hydrazide+Containing+Nuclear+Transport+Modulators+and+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSandanayaka%26aufirst%3DV.%2BP.%26atitle%3DPreparation%2520of%2520Hydrazide%2520Containing%2520Nuclear%2520Transport%2520Modulators%2520and%2520Uses%2520Thereof%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref195"><div class="reference"><strong class="refLabel"><a href="#ref195" class="rightTabRefNumLink">195</a></strong><div class="NLM_citation" id="rightTab-cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Austad, B. C.</span>; <span class="NLM_string-name">Roe, D. G.</span></span> <span> </span><span class="NLM_article-title">Polymorphs of Selinexor</span>. <span class="NLM_patent">WO 2016025904 A1</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=B.+C.+Austad&author=D.+G.+Roe&title=Polymorphs+of+Selinexor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAustad%26aufirst%3DB.%2BC.%26atitle%3DPolymorphs%2520of%2520Selinexor%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref196"><div class="reference"><strong class="refLabel"><a href="#ref196" class="rightTabRefNumLink">196</a></strong><div class="NLM_citation" id="rightTab-cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keam, S. J.</span></span> <span> </span><span class="NLM_article-title">Trastuzumab Deruxtecan: First Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">501</span>– <span class="NLM_lpage">508</span>, <span class="refDoi"> DOI: 10.1007/s40265-020-01281-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs40265-020-01281-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=32144719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlslCqu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2020&pages=501-508&author=S.+J.+Keam&title=Trastuzumab+Deruxtecan%3A+First+Approval&doi=10.1007%2Fs40265-020-01281-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">Trastuzumab Deruxtecan: First Approval</span></div><div class="casAuthors">Keam, Susan J.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">501-508</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Abstr.: Trastuzumab deruxtecan (ENHERTU), a HER2-directed antibody and DNA topoisomerase I inhibitor conjugate, is being developed for the treatment of HER2-expressing solid tumors, including breast cancer, gastric cancer, colorectal cancer and non-small cell lung cancer by Daiichi Sankyo Company Ltd in collaboration with AstraZeneca.  Based primarily on the results of the phase 2 DESTINY-Breast01 trial, trastuzumab deruxtecan was recently approved in the USA under accelerated approval for the treatment of adult patients with unresectable or metastatic HER2-pos. breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.  This article summarizes the milestones in the development of trastuzumab deruxtecan leading to this first approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqo-GVK2i-3a7Vg90H21EOLACvtfcHk0lgJeMGOz-_PUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlslCqu7s%253D&md5=66e522a0405a64ad234aa46d048f63b2</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1007%2Fs40265-020-01281-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-020-01281-4%26sid%3Dliteratum%253Aachs%26aulast%3DKeam%26aufirst%3DS.%2BJ.%26atitle%3DTrastuzumab%2520Deruxtecan%253A%2520First%2520Approval%26jtitle%3DDrugs%26date%3D2020%26volume%3D80%26spage%3D501%26epage%3D508%26doi%3D10.1007%2Fs40265-020-01281-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref197"><div class="reference"><strong class="refLabel"><a href="#ref197" class="rightTabRefNumLink">197</a></strong><div class="NLM_citation" id="rightTab-cit197"><span><a href="https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-option-patients-her2-positive-breast-cancer-who-have-progressed-available" class="extLink">https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-option-patients-her2-positive-breast-cancer-who-have-progressed-available</a> (accessed 2020-12-18).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-approves-new-treatment-option-patients-her2-positive-breast-cancer-who-have-progressed-available+%28accessed+2020-12-18%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref198"><div class="reference"><strong class="refLabel"><a href="#ref198" class="rightTabRefNumLink">198</a></strong><div class="NLM_citation" id="rightTab-cit198a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ogitani, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagihara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harada, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oitate, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arakawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atsumi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayakawa, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agatsuma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirai, T.</span></span> <span> </span><span class="NLM_article-title">DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">5097</span>– <span class="NLM_lpage">5108</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-15-2822</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref198/cit198a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1158%2F1078-0432.CCR-15-2822" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref198/cit198a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=27026201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref198/cit198a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslOhs77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=5097-5108&author=Y.+Ogitaniauthor=T.+Aidaauthor=K.+Hagiharaauthor=J.+Yamaguchiauthor=C.+Ishiiauthor=N.+Haradaauthor=M.+Somaauthor=H.+Okamotoauthor=M.+Oitateauthor=S.+Arakawaauthor=R.+Atsumiauthor=T.+Nakadaauthor=I.+Hayakawaauthor=Y.+Abeauthor=T.+Agatsumaauthor=T.+Hirai&title=DS-8201a%2C+A+Novel+HER2-Targeting+ADC+with+a+Novel+DNA+Topoisomerase+I+Inhibitor%2C+Demonstrates+a+Promising+Antitumor+Efficacy+with+Differentiation+from+T-DM1&doi=10.1158%2F1078-0432.CCR-15-2822"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit198aR"><div class="casContent"><span class="casTitleNuber">198a</span><div class="casTitle"><span class="NLM_cas:atitle">DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1</span></div><div class="casAuthors">Ogitani, Yusuke; Aida, Tetsuo; Hagihara, Katsunobu; Yamaguchi, Junko; Ishii, Chiaki; Harada, Naoya; Soma, Masako; Okamoto, Hiromi; Oitate, Masataka; Arakawa, Shingo; Hirai, Takehiro; Atsumi, Ryo; Nakada, Takashi; Hayakawa, Ichiro; Abe, Yuki; Agatsuma, Toshinori</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5097-5108</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">An anti-HER2 antibody-drug conjugate with a novel topoisomerase I inhibitor, DS-8201a, was generated as a new antitumor drug candidate, and its preclin. pharmacol. profile was assessed.  In vitro and in vivo pharmacol. activities of DS-8201a were evaluated and compared with T-DM1 in several HER2-pos. cell lines and patient-derived xenograft (PDX) models.  The mechanism of action for the efficacy was also evaluated.  Pharmacokinetics in cynomolgus monkeys and the safety profiles in rats and cynomolgus monkeys were assessed.  DS-8201a exhibited a HER2 expression-dependent cell growth-inhibitory activity and induced tumor regression with a single dosing at more than 1 mg/kg in a HER2-pos. gastric cancer NCI-N87 model.  Binding activity to HER2 and ADCC activity of DS-8201a were comparable with unconjugated anti-HER2 antibody.  DS-8201a also showed an inhibitory activity to Akt phosphorylation.  DS-8201a induced phosphorylation of Chk1 and Histone H2A.X, the markers of DNA damage.  Pharmacokinetics and safety profiles of DS-8201a were favorable and the highest non-severely toxic dose was 30 mg/kg in cynomolgus monkeys, supporting DS-8201a as being well tolerated in humans.  DS-8201a was effective in a T-DM1-insensitive PDX model with high HER2 expression.  DS-8201a, but not T-DM1, demonstrated antitumor efficacy against several breast cancer PDX models with low HER2 expression.  DS-8201a exhibited a potent antitumor activity in a broad selection of HER2-pos. models and favorable pharmacokinetics and safety profiles.  The results demonstrate that DS-8201a will be a valuable therapy with a great potential to respond to T-DM1-insensitive HER2-pos. cancers and low HER2-expressing cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCZitEmBAqAbVg90H21EOLACvtfcHk0lhs45ZsVhJeDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslOhs77F&md5=3fc9a072b2ba05c80929713c843df3f5</span></div><a href="/servlet/linkout?suffix=cit198a&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-2822&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-2822%26sid%3Dliteratum%253Aachs%26aulast%3DOgitani%26aufirst%3DY.%26aulast%3DAida%26aufirst%3DT.%26aulast%3DHagihara%26aufirst%3DK.%26aulast%3DYamaguchi%26aufirst%3DJ.%26aulast%3DIshii%26aufirst%3DC.%26aulast%3DHarada%26aufirst%3DN.%26aulast%3DSoma%26aufirst%3DM.%26aulast%3DOkamoto%26aufirst%3DH.%26aulast%3DOitate%26aufirst%3DM.%26aulast%3DArakawa%26aufirst%3DS.%26aulast%3DAtsumi%26aufirst%3DR.%26aulast%3DNakada%26aufirst%3DT.%26aulast%3DHayakawa%26aufirst%3DI.%26aulast%3DAbe%26aufirst%3DY.%26aulast%3DAgatsuma%26aufirst%3DT.%26aulast%3DHirai%26aufirst%3DT.%26atitle%3DDS-8201a%252C%2520A%2520Novel%2520HER2-Targeting%2520ADC%2520with%2520a%2520Novel%2520DNA%2520Topoisomerase%2520I%2520Inhibitor%252C%2520Demonstrates%2520a%2520Promising%2520Antitumor%2520Efficacy%2520with%2520Differentiation%2520from%2520T-DM1%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2016%26volume%3D22%26spage%3D5097%26epage%3D5108%26doi%3D10.1158%2F1078-0432.CCR-15-2822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit198b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Nakada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naito, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashida, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morita, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyazaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasuya, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogitani, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honda, T.</span></span> <span> </span><span class="NLM_article-title">Novel Antibody Drug Conjugates Containing Exatecan Derivative-Based Cytotoxic Payloads</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1542</span>– <span class="NLM_lpage">1545</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.02.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref198/cit198b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2Fj.bmcl.2016.02.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref198/cit198b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=26898815" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref198/cit198b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC28XivVWktb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=1542-1545&author=T.+Nakadaauthor=T.+Masudaauthor=H.+Naitoauthor=M.+Yoshidaauthor=S.+Ashidaauthor=K.+Moritaauthor=H.+Miyazakiauthor=Y.+Kasuyaauthor=Y.+Ogitaniauthor=J.+Yamaguchiauthor=Y.+Abeauthor=T.+Honda&title=Novel+Antibody+Drug+Conjugates+Containing+Exatecan+Derivative-Based+Cytotoxic+Payloads&doi=10.1016%2Fj.bmcl.2016.02.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit198bR"><div class="casContent"><span class="casTitleNuber">198b</span><div class="casTitle"><span class="NLM_cas:atitle">Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads</span></div><div class="casAuthors">Nakada, Takashi; Masuda, Takeshi; Naito, Hiroyuki; Yoshida, Masao; Ashida, Shinji; Morita, Koji; Miyazaki, Hideki; Kasuya, Yuji; Ogitani, Yusuke; Yamaguchi, Junko; Abe, Yuki; Honda, Takeshi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1542-1545</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Trastuzumab conjugates consisting of exatecan derivs. were prepd. and their biol. activities and physicochem. properties were evaluated.  The ADCs showed strong efficacy and a low aggregation rate.  The exatecan derivs. were covalently connected via a peptidyl spacer (Gly-Gly-Phe-Gly), which is assumed to be stable in circulation, and were cleaved by lysosomal enzymes following ADC internalization into tumor tissue.  These anti-HER2 ADCs exhibited a high potency, specifically against HER2-pos. cancer cell lines in vitro.  The ADCs, bearing exatecan derivs. which have more than two methylene chains, exhibited superior cytotoxicity.  It was speculated that steric hindrance of the cleavable amide moiety could be involved in the drug release.  The adequate alkyl lengths of exatecan derivs. (13, 14, 15) were from two to four in terms of aggregation rate.  The ADC having a hydrophilic moiety showed good efficacy in a HER2-pos. and Trastuzumab-resistant breast carcinoma cell model in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorNLY5Zb5RLbVg90H21EOLACvtfcHk0lhs45ZsVhJeDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XivVWktb4%253D&md5=9a3137c0339e82fe3bd6e4b2a0937a52</span></div><a href="/servlet/linkout?suffix=cit198b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.02.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.02.020%26sid%3Dliteratum%253Aachs%26aulast%3DNakada%26aufirst%3DT.%26aulast%3DMasuda%26aufirst%3DT.%26aulast%3DNaito%26aufirst%3DH.%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DAshida%26aufirst%3DS.%26aulast%3DMorita%26aufirst%3DK.%26aulast%3DMiyazaki%26aufirst%3DH.%26aulast%3DKasuya%26aufirst%3DY.%26aulast%3DOgitani%26aufirst%3DY.%26aulast%3DYamaguchi%26aufirst%3DJ.%26aulast%3DAbe%26aufirst%3DY.%26aulast%3DHonda%26aufirst%3DT.%26atitle%3DNovel%2520Antibody%2520Drug%2520Conjugates%2520Containing%2520Exatecan%2520Derivative-Based%2520Cytotoxic%2520Payloads%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D1542%26epage%3D1545%26doi%3D10.1016%2Fj.bmcl.2016.02.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref199"><div class="reference"><strong class="refLabel"><a href="#ref199" class="rightTabRefNumLink">199</a></strong><div class="NLM_citation" id="rightTab-cit199"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, T.</span>; <span class="NLM_string-name">Naito, H.</span>; <span class="NLM_string-name">Nakada, T.</span>; <span class="NLM_string-name">Yoshida, M.</span>; <span class="NLM_string-name">Ashida, S.</span>; <span class="NLM_string-name">Miyazaki, H.</span>; <span class="NLM_string-name">Kasuya, Y.</span>; <span class="NLM_string-name">Morita, K.</span>; <span class="NLM_string-name">Abe, Y.</span>; <span class="NLM_string-name">Ogitani, Y.</span></span> <span> </span><span class="NLM_article-title">Preparation of Antibody–Drug Conjugates for Cancer Therapy</span>. <span class="NLM_patent">WO 2014057687 A1</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=T.+Masuda&author=H.+Naito&author=T.+Nakada&author=M.+Yoshida&author=S.+Ashida&author=H.+Miyazaki&author=Y.+Kasuya&author=K.+Morita&author=Y.+Abe&author=Y.+Ogitani&title=Preparation+of+Antibody%E2%80%93Drug+Conjugates+for+Cancer+Therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMasuda%26aufirst%3DT.%26atitle%3DPreparation%2520of%2520Antibody%25E2%2580%2593Drug%2520Conjugates%2520for%2520Cancer%2520Therapy%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref200"><div class="reference"><strong class="refLabel"><a href="#ref200" class="rightTabRefNumLink">200</a></strong><div class="NLM_citation" id="rightTab-cit200a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiang, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hertzberg, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hecht, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L. F.</span></span> <span> </span><span class="NLM_article-title">Camptothecin Induces Protein-Linked DNA Breaks Via Mammalian DNA Topoisomerase I</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>260</i></span>,  <span class="NLM_fpage">14873</span>– <span class="NLM_lpage">14878</span>, <span class="refDoi"> DOI: 10.1016/S0021-9258(17)38654-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref200/cit200a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2FS0021-9258%2817%2938654-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref200/cit200a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=2997227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref200/cit200a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADyaL2MXlsFemt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=260&publication_year=1985&pages=14873-14878&author=Y.+H.+Hsiangauthor=R.+Hertzbergauthor=S.+Hechtauthor=L.+F.+Liu&title=Camptothecin+Induces+Protein-Linked+DNA+Breaks+Via+Mammalian+DNA+Topoisomerase+I&doi=10.1016%2FS0021-9258%2817%2938654-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit200aR"><div class="casContent"><span class="casTitleNuber">200a</span><div class="casTitle"><span class="NLM_cas:atitle">Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I</span></div><div class="casAuthors">Hsiang, Yaw Huei; Hertzberg, Robert; Hecht, Sidney; Liu, Leroy F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">260</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">14873-8</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">Camptothecin (I)  [7689-03-4], a cytotoxic drug, is a strong inhibitor of nucleic acid synthesis in mammalian cells and a potent inducer of strand breaks in chromosomal DNA.  Neither equil. dialysis nor unwinding measurement indicated any interaction between camptothecin and purified DNA.  However, I induces extensive single-strand DNA breaks in systems contg. purified mammalian DNA topoisomerase  [80449-01-0] I.  DNA breakage in vitro is immediate and reversible.  Analyses of camptothecin-induced DNA breaks show that topoisomerase I is covalently linked to the 3' end of the broken DNA.  In addn., I inhibits the catalytic activity of mammalian DNA topoisomerase I.  Apparently, I blocks the rejoining step of the breakage-reunion reaction of mammalian DNA topoisomerase I; this blockade results in the accumulation of a cleavable complex which resembles the transient intermediate proposed for eukaryotic DNA topoisomerase I.  The inhibition of nucleic acid synthesis and the induction of DNA strand breaks obsd. in vivo may be related to the formation of this drug-induced cleavable complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4OWZ16tDJsbVg90H21EOLACvtfcHk0ljM5ZAzaD8iKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXlsFemt7c%253D&md5=d5811c51314199e69d2fad324720b1aa</span></div><a href="/servlet/linkout?suffix=cit200a&amp;dbid=16384&amp;doi=10.1016%2FS0021-9258%2817%2938654-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0021-9258%252817%252938654-4%26sid%3Dliteratum%253Aachs%26aulast%3DHsiang%26aufirst%3DY.%2BH.%26aulast%3DHertzberg%26aufirst%3DR.%26aulast%3DHecht%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DL.%2BF.%26atitle%3DCamptothecin%2520Induces%2520Protein-Linked%2520DNA%2520Breaks%2520Via%2520Mammalian%2520DNA%2520Topoisomerase%2520I%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1985%26volume%3D260%26spage%3D14873%26epage%3D14878%26doi%3D10.1016%2FS0021-9258%2817%2938654-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit200b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Nakada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugihara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jikoh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agatsuma, T.</span></span> <span> </span><span class="NLM_article-title">The Latest Research and Development into the Antibody–Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy</span>. <i>Chem. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">173</span>– <span class="NLM_lpage">185</span>, <span class="refDoi"> DOI: 10.1248/cpb.c18-00744</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref200/cit200b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1248%2Fcpb.c18-00744" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref200/cit200b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=30827997" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref200/cit200b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVejurjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2019&pages=173-185&author=T.+Nakadaauthor=K.+Sugiharaauthor=T.+Jikohauthor=Y.+Abeauthor=T.+Agatsuma&title=The+Latest+Research+and+Development+into+the+Antibody%E2%80%93Drug+Conjugate%2C+%5Bfam-%5D+Trastuzumab+Deruxtecan+%28DS-8201a%29%2C+for+HER2+Cancer+Therapy&doi=10.1248%2Fcpb.c18-00744"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit200bR"><div class="casContent"><span class="casTitleNuber">200b</span><div class="casTitle"><span class="NLM_cas:atitle">The latest research and development into the antibody-drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy</span></div><div class="casAuthors">Nakada, Takashi; Sugihara, Kiyoshi; Jikoh, Takahiro; Abe, Yuki; Agatsuma, Toshinori</div><div class="citationInfo"><span class="NLM_cas:title">Chemical & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">173-185</span>CODEN:
                <span class="NLM_cas:coden">CPBTAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-2363</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">A review.  A major limitation of traditional chemotherapy for cancer is dose-limiting toxicity, caused by the exposure of non-tumor cells to cytotoxic agents.  Use of mol. targeted drugs, such as specific kinase inhibitors and monoclonal antibodies, is a possible soln. to overcome this limitation and has achieved clin. success so far.  Use of an antibody-drug conjugate (ADC) is a rational strategy for improving efficacy and reducing systemic adverse events.  ADCs use antibodies selectively to deliver a potent cytotoxic agent to tumor cells, thus drastically improving the therapeutic index of chemotherapeutic agents.  Lessons learned from clin. failure of early ADCs during the 1980s to 90s have recently led to improvements in ADC technol., and resulted in the approval of four novel ADCs.  Nonetheless, further advances in ADC technol. are still required to streamline their clin. efficacy and reduce toxicity. [fam-] Trastuzumab deruxtecan (DS-8201a) is a next-generation ADC that satisfies these requirements based on currently available evidence.  DS-8201a has several innovative features; a highly potent novel payload with a high drug-to-antibody ratio, good homogeneity, a tumor-selective cleavable linker, stable linker-payload in circulation, and a short systemic half-life cytotoxic agent in vivo; the released cytotoxic payload could exert a bystander effect.  With respect to its preclin. profiles, DS-8201a could provide a valuable therapy with a great potential against HER2-expressing cancers in clin. settings.  In a phase I trial, DS-8201a showed acceptable safety profiles with potential therapeutic efficacy, with the wide therapeutic index.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEjmzqyRh1yrVg90H21EOLACvtfcHk0ljM5ZAzaD8iKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVejurjJ&md5=ab7628fdc4af3c8e1d73e00553c9534e</span></div><a href="/servlet/linkout?suffix=cit200b&amp;dbid=16384&amp;doi=10.1248%2Fcpb.c18-00744&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fcpb.c18-00744%26sid%3Dliteratum%253Aachs%26aulast%3DNakada%26aufirst%3DT.%26aulast%3DSugihara%26aufirst%3DK.%26aulast%3DJikoh%26aufirst%3DT.%26aulast%3DAbe%26aufirst%3DY.%26aulast%3DAgatsuma%26aufirst%3DT.%26atitle%3DThe%2520Latest%2520Research%2520and%2520Development%2520into%2520the%2520Antibody%25E2%2580%2593Drug%2520Conjugate%252C%2520%255Bfam-%255D%2520Trastuzumab%2520Deruxtecan%2520%2528DS-8201a%2529%252C%2520for%2520HER2%2520Cancer%2520Therapy%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D2019%26volume%3D67%26spage%3D173%26epage%3D185%26doi%3D10.1248%2Fcpb.c18-00744" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref201"><div class="reference"><strong class="refLabel"><a href="#ref201" class="rightTabRefNumLink">201</a></strong><div class="NLM_citation" id="rightTab-cit201"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Modi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saura, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsurutani, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sohn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denduluri, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aogi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokunaga, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurvitz, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahidi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yver, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krop, I.</span></span> <span> </span><span class="NLM_article-title">Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>382</i></span>,  <span class="NLM_fpage">610</span>– <span class="NLM_lpage">621</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1914510</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1056%2FNEJMoa1914510" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31825192" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjtlChur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=382&publication_year=2020&pages=610-621&author=S.+Modiauthor=C.+Sauraauthor=T.+Yamashitaauthor=Y.+H.+Parkauthor=S.+B.+Kimauthor=K.+Tamuraauthor=F.+Andreauthor=H.+Iwataauthor=Y.+Itoauthor=J.+Tsurutaniauthor=J.+Sohnauthor=N.+Denduluriauthor=C.+Perrinauthor=K.+Aogiauthor=E.+Tokunagaauthor=S.+A.+Imauthor=K.+S.+Leeauthor=S.+A.+Hurvitzauthor=J.+Cortesauthor=C.+Leeauthor=S.+Chenauthor=L.+Zhangauthor=J.+Shahidiauthor=A.+Yverauthor=I.+Krop&title=Trastuzumab+Deruxtecan+in+Previously+Treated+HER2-Positive+Breast+Cancer&doi=10.1056%2FNEJMoa1914510"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">Trastuzumab deruxtecan in previously treated HER2-positive breast cancer</span></div><div class="casAuthors">Modi, S.; Saura, C.; Yamashita, T.; Park, Y. H.; Kim, S.-B.; Tamura, K.; Andre, F.; Iwata, H.; Ito, Y.; Tsurutani, J.; Sohn, J.; Denduluri, N.; Perrin, C.; Aogi, K.; Tokunaga, E.; Im, S.-A.; Lee, K. S.; Hurvitz, S. A.; Cortes, J.; Lee, C.; Chen, S.; Zhang, L.; Shahidi, J.; Yver, A.; Krop, I.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">382</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">610-621</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">In this two-part, open-label, single-group, multicenter, phase 2 study, we evaluated trastuzumab deruxtecan in adults with pathol. documented HER2-pos. metastatic breast cancer who had received previous treatment with trastuzumab emtansine.  In the first part of the study, we evaluated three different doses of trastuzumab deruxtecan to establish a recommended dose; in the second part, we evaluated the efficacy and safety of the recommended dose.  Key secondary end points were the disease-control rate, clin.-benefit rate, duration of response and progression-free survival, and safety. results Overall, 184 patients who had undergone a median of six previous treatments received the recommended dose of trastuzumab deruxtecan (5.4 mg per kg of body wt.).  During the study, the most common adverse events of grade 3 or higher were a decreased neutrophil count (in 20.7% of the patients), anemia (in 8.7%), and nausea (in 7.6%).  On independent adjudication, the trial drug was assocd. with interstitial lung disease in 13.6% of the patients (grade 1 or 2, 10.9%; grade 3 or 4, 0.5%; and grade 5, 2.2%). conclusions Trastuzumab deruxtecan showed durable antitumor activity in a pretreated patient population with HER2-pos. metastatic breast cancer.  In addn. to nausea and myelosuppression, interstitial lung disease was obsd. in a subgroup of patients and requires attention to pulmonary symptoms and careful monitoring.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6Uc2NDB76h7Vg90H21EOLACvtfcHk0ljM5ZAzaD8iKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjtlChur8%253D&md5=0b142802a47c4f50f0b2cdc82f22ce87</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1914510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1914510%26sid%3Dliteratum%253Aachs%26aulast%3DModi%26aufirst%3DS.%26aulast%3DSaura%26aufirst%3DC.%26aulast%3DYamashita%26aufirst%3DT.%26aulast%3DPark%26aufirst%3DY.%2BH.%26aulast%3DKim%26aufirst%3DS.%2BB.%26aulast%3DTamura%26aufirst%3DK.%26aulast%3DAndre%26aufirst%3DF.%26aulast%3DIwata%26aufirst%3DH.%26aulast%3DIto%26aufirst%3DY.%26aulast%3DTsurutani%26aufirst%3DJ.%26aulast%3DSohn%26aufirst%3DJ.%26aulast%3DDenduluri%26aufirst%3DN.%26aulast%3DPerrin%26aufirst%3DC.%26aulast%3DAogi%26aufirst%3DK.%26aulast%3DTokunaga%26aufirst%3DE.%26aulast%3DIm%26aufirst%3DS.%2BA.%26aulast%3DLee%26aufirst%3DK.%2BS.%26aulast%3DHurvitz%26aufirst%3DS.%2BA.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DShahidi%26aufirst%3DJ.%26aulast%3DYver%26aufirst%3DA.%26aulast%3DKrop%26aufirst%3DI.%26atitle%3DTrastuzumab%2520Deruxtecan%2520in%2520Previously%2520Treated%2520HER2-Positive%2520Breast%2520Cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2020%26volume%3D382%26spage%3D610%26epage%3D621%26doi%3D10.1056%2FNEJMoa1914510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref202"><div class="reference"><strong class="refLabel"><a href="#ref202" class="rightTabRefNumLink">202</a></strong><div class="NLM_citation" id="rightTab-cit202"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nishi, Y.</span>; <span class="NLM_string-name">Sakanishi, K.</span>; <span class="NLM_string-name">Noguchi, S.</span>; <span class="NLM_string-name">Takeda, T.</span></span> <span> </span><span class="NLM_article-title">Novel Method for Producing Exatecan and Antibody–Drug Conjugates</span>. <span class="NLM_patent">WO 2019044946 A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=Y.+Nishi&author=K.+Sakanishi&author=S.+Noguchi&author=T.+Takeda&title=Novel+Method+for+Producing+Exatecan+and+Antibody%E2%80%93Drug+Conjugates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNishi%26aufirst%3DY.%26atitle%3DNovel%2520Method%2520for%2520Producing%2520Exatecan%2520and%2520Antibody%25E2%2580%2593Drug%2520Conjugates%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref203"><div class="reference"><strong class="refLabel"><a href="#ref203" class="rightTabRefNumLink">203</a></strong><div class="NLM_citation" id="rightTab-cit203"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, T.</span>; <span class="NLM_string-name">Kouko, T.</span>; <span class="NLM_string-name">Noguchi, S.</span>; <span class="NLM_string-name">Yamane, Y.</span>; <span class="NLM_string-name">Kondo, F.</span>; <span class="NLM_string-name">Aoki, T.</span>; <span class="NLM_string-name">Takeda, T.</span>; <span class="NLM_string-name">Sakanishi, K.</span>; <span class="NLM_string-name">Sato, H.</span>; <span class="NLM_string-name">Ueda, T.</span>; <span class="NLM_string-name">Matuura, S.</span>; <span class="NLM_string-name">Kurahashi, K.</span>; <span class="NLM_string-name">Kitagawa, Y.</span>; <span class="NLM_string-name">Nakamura, T.</span></span> <span> </span><span class="NLM_article-title">Improved Production Method of Crystal of Drug-Linker Derivative for Production of Antibody–Drug Conjugate</span>. <span class="NLM_patent">WO 2019044947 A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=T.+Yamaguchi&author=T.+Kouko&author=S.+Noguchi&author=Y.+Yamane&author=F.+Kondo&author=T.+Aoki&author=T.+Takeda&author=K.+Sakanishi&author=H.+Sato&author=T.+Ueda&author=S.+Matuura&author=K.+Kurahashi&author=Y.+Kitagawa&author=T.+Nakamura&title=Improved+Production+Method+of+Crystal+of+Drug-Linker+Derivative+for+Production+of+Antibody%E2%80%93Drug+Conjugate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYamaguchi%26aufirst%3DT.%26atitle%3DImproved%2520Production%2520Method%2520of%2520Crystal%2520of%2520Drug-Linker%2520Derivative%2520for%2520Production%2520of%2520Antibody%25E2%2580%2593Drug%2520Conjugate%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref204"><div class="reference"><strong class="refLabel"><a href="#ref204" class="rightTabRefNumLink">204</a></strong><div class="NLM_citation" id="rightTab-cit204"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Naito, H.</span>; <span class="NLM_string-name">Ogitani, Y.</span>; <span class="NLM_string-name">Masuda, T.</span>; <span class="NLM_string-name">Nakada, T.</span>; <span class="NLM_string-name">Yoshida, M.</span>; <span class="NLM_string-name">Ashida, S.</span>; <span class="NLM_string-name">Morita, K.</span>; <span class="NLM_string-name">Miyazaki, H.</span>; <span class="NLM_string-name">Kasuya, Y.</span>; <span class="NLM_string-name">Hayakawa, I.</span>; <span class="NLM_string-name">Abe, Y.</span></span> <span> </span><span class="NLM_article-title">Anti-Human HER2 Antibody Drug Conjugates with Excellent Safety and Therapeutic Antitumor Effect</span>. <span class="NLM_patent">WO 2015115091 A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=H.+Naito&author=Y.+Ogitani&author=T.+Masuda&author=T.+Nakada&author=M.+Yoshida&author=S.+Ashida&author=K.+Morita&author=H.+Miyazaki&author=Y.+Kasuya&author=I.+Hayakawa&author=Y.+Abe&title=Anti-Human+HER2+Antibody+Drug+Conjugates+with+Excellent+Safety+and+Therapeutic+Antitumor+Effect"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNaito%26aufirst%3DH.%26atitle%3DAnti-Human%2520HER2%2520Antibody%2520Drug%2520Conjugates%2520with%2520Excellent%2520Safety%2520and%2520Therapeutic%2520Antitumor%2520Effect%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref205"><div class="reference"><strong class="refLabel"><a href="#ref205" class="rightTabRefNumLink">205</a></strong><div class="NLM_citation" id="rightTab-cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramarao, C.</span>; <span class="NLM_string-name">Rao, R.</span>; <span class="NLM_string-name">Nandipati, R. D.</span>; <span class="NLM_string-name">Chamle, V. A.</span>; <span class="NLM_string-name">Rao, A. V. R.</span></span> <span> </span><span class="NLM_article-title">Commercial Process for the Manufacture of (<i>S</i>)-Trione</span>. <span class="NLM_patent">IN 2010CH01460 A</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=C.+Ramarao&author=R.+Rao&author=R.+D.+Nandipati&author=V.+A.+Chamle&author=A.+V.+R.+Rao&title=Commercial+Process+for+the+Manufacture+of+%28S%29-Trione"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRamarao%26aufirst%3DC.%26atitle%3DCommercial%2520Process%2520for%2520the%2520Manufacture%2520of%2520%2528S%2529-Trione%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref206"><div class="reference"><strong class="refLabel"><a href="#ref206" class="rightTabRefNumLink">206</a></strong><div class="NLM_citation" id="rightTab-cit206"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kamihara, S.</span>; <span class="NLM_string-name">Kanai, K.</span>; <span class="NLM_string-name">Noguchi, S.</span>; <span class="NLM_string-name">Terasawa, H.</span>; <span class="NLM_string-name">Kitaoka, H.</span></span> <span> </span><span class="NLM_article-title">Preparation of Camptothecin Derivative with Antitumor Activity</span>. <span class="NLM_patent">EP 737686 A1</span>, <span class="NLM_year">1996</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1996&author=S.+Kamihara&author=K.+Kanai&author=S.+Noguchi&author=H.+Terasawa&author=H.+Kitaoka&title=Preparation+of+Camptothecin+Derivative+with+Antitumor+Activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKamihara%26aufirst%3DS.%26atitle%3DPreparation%2520of%2520Camptothecin%2520Derivative%2520with%2520Antitumor%2520Activity%26date%3D1996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref207"><div class="reference"><strong class="refLabel"><a href="#ref207" class="rightTabRefNumLink">207</a></strong><div class="NLM_citation" id="rightTab-cit207"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porco, J. A.,  Jr</span></span> <span> </span><span class="NLM_article-title">Modification of C-Terminal Peptides to Form Peptide Enamides: Synthesis of Chondriamides A and C</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">8215</span>– <span class="NLM_lpage">8221</span>, <span class="refDoi"> DOI: 10.1021/jo0158027</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo0158027" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnvVOiu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2001&pages=8215-8221&author=X.+Wangauthor=J.+A.+Porco&title=Modification+of+C-Terminal+Peptides+to+Form+Peptide+Enamides%3A+Synthesis+of+Chondriamides+A+and+C&doi=10.1021%2Fjo0158027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit207R"><div class="casContent"><span class="casTitleNuber">207</span><div class="casTitle"><span class="NLM_cas:atitle">Modification of C-Terminal Peptides to Form Peptide Enamides: Synthesis of Chondriamides A and C</span></div><div class="casAuthors">Wang, Xiang; Porco, John A., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8215-8221</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors describe the synthesis of peptide enamides based on tandem oxidative decarboxylation/elimination of C-terminal peptides.  Peptides contg. C-terminal tryptophans have been found to form Z-enamides with high selectivity, which has been exploited in the prepns. of cytotoxic indole-enamide natural products chondriamides A and C.  For example, H-Trp-OMe·HCl was acylated with trans-3-indoleacrylic acid in the presence of HOBt, EDC and DIEA in DMF at 0-25° to give N-acylated tryptophan I, which was tosylated and sapond. in that order to give free acid II.  For the oxidative decarboxylation and elimination step, II was treated with Pb(OAc)4, Cu(OAc)2 in pyridine/THF at 0-25° followed by treatment with LiClO4, DIEA in THF to give the enamide III in 63% yield with a 14:1 ratio of Z:E isomers.  Next, III was converted in two steps to chondriamide C and in three steps to chondriamide A, both obtained in >40% yields.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdRwa94VaIj7Vg90H21EOLACvtfcHk0lhS07cLvyt2LQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnvVOiu78%253D&md5=2be279fc4ff2d88fa9f20554e91d9b35</span></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1021%2Fjo0158027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo0158027%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DPorco%26aufirst%3DJ.%2BA.%26atitle%3DModification%2520of%2520C-Terminal%2520Peptides%2520to%2520Form%2520Peptide%2520Enamides%253A%2520Synthesis%2520of%2520Chondriamides%2520A%2520and%2520C%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2001%26volume%3D66%26spage%3D8215%26epage%3D8221%26doi%3D10.1021%2Fjo0158027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref208"><div class="reference"><strong class="refLabel"><a href="#ref208" class="rightTabRefNumLink">208</a></strong><div class="NLM_citation" id="rightTab-cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span>; <span class="NLM_string-name">Li, J.</span>; <span class="NLM_string-name">Zhuo, S.</span>; <span class="NLM_string-name">Wan, W.</span>; <span class="NLM_string-name">Yu, Y.</span>; <span class="NLM_string-name">Li, G.</span></span> <span> </span><span class="NLM_article-title">Antibody–Drug Conjugate Contains Antitumor Drugs with Two Different Action Mechanisms</span>. <span class="NLM_patent">CN 108853514 A</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=Y.+Zhu&author=J.+Li&author=S.+Zhuo&author=W.+Wan&author=Y.+Yu&author=G.+Li&title=Antibody%E2%80%93Drug+Conjugate+Contains+Antitumor+Drugs+with+Two+Different+Action+Mechanisms"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DY.%26atitle%3DAntibody%25E2%2580%2593Drug%2520Conjugate%2520Contains%2520Antitumor%2520Drugs%2520with%2520Two%2520Different%2520Action%2520Mechanisms%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref209"><div class="reference"><strong class="refLabel"><a href="#ref209" class="rightTabRefNumLink">209</a></strong><div class="NLM_citation" id="rightTab-cit209a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Kamii, T.</span>; <span class="NLM_string-name">Nishimoto, N.</span></span> <span> </span><span class="NLM_article-title">Antibody–Drug Conjugate Formulation Containing Histidine Buffer and Its Lyophilization Method</span>. <span class="NLM_patent">WO 2019039483 A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=T.+Kamii&author=N.+Nishimoto&title=Antibody%E2%80%93Drug+Conjugate+Formulation+Containing+Histidine+Buffer+and+Its+Lyophilization+Method"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit209a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKamii%26aufirst%3DT.%26atitle%3DAntibody%25E2%2580%2593Drug%2520Conjugate%2520Formulation%2520Containing%2520Histidine%2520Buffer%2520and%2520Its%2520Lyophilization%2520Method%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit209b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, T.</span>; <span class="NLM_string-name">Sakuratani, K.</span></span> <span> </span><span class="NLM_article-title">Novel Linkers for Producing an Antibody–Drug Conjugate and Pharmaceutical Composition Using Thereof</span>. <span class="NLM_patent">WO 2020022363 A1</span>, <span class="NLM_year">2020</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=T.+Yamaguchi&author=K.+Sakuratani&title=Novel+Linkers+for+Producing+an+Antibody%E2%80%93Drug+Conjugate+and+Pharmaceutical+Composition+Using+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit209b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYamaguchi%26aufirst%3DT.%26atitle%3DNovel%2520Linkers%2520for%2520Producing%2520an%2520Antibody%25E2%2580%2593Drug%2520Conjugate%2520and%2520Pharmaceutical%2520Composition%2520Using%2520Thereof%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref210"><div class="reference"><strong class="refLabel"><a href="#ref210" class="rightTabRefNumLink">210</a></strong><div class="NLM_citation" id="rightTab-cit210"><span><a href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-zanubrutinib-mantle-cell-lymphoma" class="extLink">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-zanubrutinib-mantle-cell-lymphoma</a> (accessed 2020-12-18).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fresources-information-approved-drugs%2Ffda-grants-accelerated-approval-zanubrutinib-mantle-cell-lymphoma+%28accessed+2020-12-18%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref211"><div class="reference"><strong class="refLabel"><a href="#ref211" class="rightTabRefNumLink">211</a></strong><div class="NLM_citation" id="rightTab-cit211"><span><a href="http://www.globenewswire.com/news-release/2020/06/03/2042805/0/en/BeiGene-Announces-the-Approval-of-BRUKINSA-Zanubrutinib-in-China-for-Patients-with-Relapsed-Refractory-Chronic-Lymphocytic-Leukemia-or-Small-Lymphocytic-Lymphoma-and-Relapsed-Refra.html" class="extLink">http://www.globenewswire.com/news-release/2020/06/03/2042805/0/en/BeiGene-Announces-the-Approval-of-BRUKINSA-Zanubrutinib-in-China-for-Patients-with-Relapsed-Refractory-Chronic-Lymphocytic-Leukemia-or-Small-Lymphocytic-Lymphoma-and-Relapsed-Refra.html</a> (accessed 2020-12-18).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=http%3A%2F%2Fwww.globenewswire.com%2Fnews-release%2F2020%2F06%2F03%2F2042805%2F0%2Fen%2FBeiGene-Announces-the-Approval-of-BRUKINSA-Zanubrutinib-in-China-for-Patients-with-Relapsed-Refractory-Chronic-Lymphocytic-Leukemia-or-Small-Lymphocytic-Lymphoma-and-Relapsed-Refra.html+%28accessed+2020-12-18%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref212"><div class="reference"><strong class="refLabel"><a href="#ref212" class="rightTabRefNumLink">212</a></strong><div class="NLM_citation" id="rightTab-cit212"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ou, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preston, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marbury, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novotny, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tawashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahasranaman, S.</span></span> <span> </span><span class="NLM_article-title">A Phase 1, Open-Label, Single-Dose Study of the Pharmacokinetics of Zanubrutinib in Subjects with Varying Degrees of Hepatic Impairment</span>. <i>Leuk. Lymphoma</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">1355</span>– <span class="NLM_lpage">1363</span>, <span class="refDoi"> DOI: 10.1080/10428194.2020.1719097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1080%2F10428194.2020.1719097" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=32031037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisFyjtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2020&pages=1355-1363&author=Y.+C.+Ouauthor=R.+A.+Prestonauthor=T.+C.+Marburyauthor=Z.+Tangauthor=W.+Novotnyauthor=M.+Tawashiauthor=T.+K.+Liauthor=S.+Sahasranaman&title=A+Phase+1%2C+Open-Label%2C+Single-Dose+Study+of+the+Pharmacokinetics+of+Zanubrutinib+in+Subjects+with+Varying+Degrees+of+Hepatic+Impairment&doi=10.1080%2F10428194.2020.1719097"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit212R"><div class="casContent"><span class="casTitleNuber">212</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 1, open-label, single-dose study of the pharmacokinetics of zanubrutinib in subjects with varying degrees of hepatic impairment</span></div><div class="casAuthors">Ou, Ying C.; Preston, Richard A.; Marbury, Thomas C.; Tang, Zhiyu; Novotny, William; Tawashi, Manal; Li, Ta-Kai; Sahasranaman, Srikumar</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia & Lymphoma</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1355-1363</span>CODEN:
                <span class="NLM_cas:coden">LELYEA</span>;
        ISSN:<span class="NLM_cas:issn">1029-2403</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">The pharmacokinetics and safety of single-dose zanubrutinib (80 mg) were assessed in subjects with mild, moderate, and severe hepatic impairment (n = 6 each, Child-Pugh class A, B, and C) relative to healthy controls (n = 11).  Zanubrutinib median Tmax was 1.25-2.25 h in all groups.  Compared to control group, mean zanubrutinib exposure (AUC0-inf) in the mild and moderate hepatic impairment groups was increased by 1.1- and 1.2-fold, which is within the range of PK variability for zanubrutinib.  The total and unbound AUC of zanubrutinib were 1.60- and 2.9-fold higher in subjects with severe hepatic impairment compared to healthy controls.  Terminal half-life was comparable between subjects with hepatic impairment and matched healthy controls.  Zanubrutinib was generally well-tolerated when administered as a single, 80-mg dose to subjects in this study.  Results of this study will be used, in conjunction with clin. safety and efficacy data, to develop dose recommendations for patients with hepatic impairment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrftoUnflCF1rVg90H21EOLACvtfcHk0ljDN4I1tN76vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisFyjtrk%253D&md5=45b2ad798ee07813d6f441305e3c2077</span></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=10.1080%2F10428194.2020.1719097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F10428194.2020.1719097%26sid%3Dliteratum%253Aachs%26aulast%3DOu%26aufirst%3DY.%2BC.%26aulast%3DPreston%26aufirst%3DR.%2BA.%26aulast%3DMarbury%26aufirst%3DT.%2BC.%26aulast%3DTang%26aufirst%3DZ.%26aulast%3DNovotny%26aufirst%3DW.%26aulast%3DTawashi%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DT.%2BK.%26aulast%3DSahasranaman%26aufirst%3DS.%26atitle%3DA%2520Phase%25201%252C%2520Open-Label%252C%2520Single-Dose%2520Study%2520of%2520the%2520Pharmacokinetics%2520of%2520Zanubrutinib%2520in%2520Subjects%2520with%2520Varying%2520Degrees%2520of%2520Hepatic%2520Impairment%26jtitle%3DLeuk.%2520Lymphoma%26date%3D2020%26volume%3D61%26spage%3D1355%26epage%3D1363%26doi%3D10.1080%2F10428194.2020.1719097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref213"><div class="reference"><strong class="refLabel"><a href="#ref213" class="rightTabRefNumLink">213</a></strong><div class="NLM_citation" id="rightTab-cit213"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elstrom, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novotny, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span> <span> </span><span class="NLM_article-title">Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton’s Tyrosine Kinase</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">4216</span>– <span class="NLM_lpage">4224</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-19-3703</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1158%2F1078-0432.CCR-19-3703" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=32461234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitF2ntbzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2020&pages=4216-4224&author=Y.+Songauthor=K.+S.+Zhouauthor=D.+Zouauthor=J.+Zhouauthor=J.+Huauthor=H.+Yangauthor=H.+Zhangauthor=J.+Jiauthor=W.+Xuauthor=J.+Jinauthor=F.+Lvauthor=R.+Fengauthor=S.+Gaoauthor=H.+Guoauthor=L.+Zhouauthor=R.+Elstromauthor=J.+Huangauthor=W.+Novotnyauthor=R.+Weiauthor=J.+Zhu&title=Treatment+of+Patients+with+Relapsed+or+Refractory+Mantle+Cell+Lymphoma+with+Zanubrutinib%2C+a+Selective+Inhibitor+of+Bruton%E2%80%99s+Tyrosine+Kinase&doi=10.1158%2F1078-0432.CCR-19-3703"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit213R"><div class="casContent"><span class="casTitleNuber">213</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of patients with relapsed or refractory mantle-cell lymphoma with zanubrutinib, a selective inhibitor of bruton's tyrosine kinase</span></div><div class="casAuthors">Song, Yuqin; Zhou, Keshu; Zou, Dehui; Zhou, Jianfeng; Hu, Jianda; Yang, Haiyan; Zhang, Huilai; Ji, Jie; Xu, Wei; Jin, Jie; Lv, Fangfang; Feng, Ru; Gao, Sujun; Guo, Haiyi; Zhou, Lei; Elstrom, Rebecca; Huang, Jane; Novotny, William; Wei, Rachel; Zhu, Jun</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4216-4224</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">We evaluated the efficacy and safety of zanubrutinib, an investigational selective Bruton's tyrosine kinase inhibitor.  Patients and Methods: Patients with relapsed/refractory MCL were enrolled in this ongoing phase II, single-arm, open-label study, and treated with oral zanubrutinib 160 mg twice daily.  The primary endpoint is overall response rate assessed by an independent review committee; secondary endpoints include duration of response, time to response, progression-free survival, and safety.  Eighty-six patients were enrolled after a median of 2 prior lines of therapy, received ≥1 dose of the study drug, and were evaluable for safety and efficacy.  After a median follow-up of 18.4 mo, 72 patients achieved an objective response, with 59 (68.6%) achieving a complete response.  Median DOR and PFS were 19.5 and 22.1 mo, resp.; 12-mo event-free ests. for DOR and PFS are 78% and 76%, resp.  Most common grade ≥3 adverse events were neutropenia and lung infection/pneumonia.  Three patients experienced major bleeding events, and there were no reports of atrial fibrillation.  Eight patients discontinued zanubrutinib for AEs.  These results demonstrate high and durable ORR and CR rates in patients with relapsed/refractory MCL.  Zanubrutinib was generally well tolerated; grade ≥3 BTK inhibitor-assocd. toxicities (hemorrhage, rash, hypertension, diarrhea, atrial fibrillation) were uncommon.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6RV6HcDWkfbVg90H21EOLACvtfcHk0ljDN4I1tN76vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitF2ntbzO&md5=e61a57ff68e27baaf1ba91a20bf5372a</span></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-19-3703&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-19-3703%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DK.%2BS.%26aulast%3DZou%26aufirst%3DD.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DJi%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DLv%26aufirst%3DF.%26aulast%3DFeng%26aufirst%3DR.%26aulast%3DGao%26aufirst%3DS.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DElstrom%26aufirst%3DR.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DNovotny%26aufirst%3DW.%26aulast%3DWei%26aufirst%3DR.%26aulast%3DZhu%26aufirst%3DJ.%26atitle%3DTreatment%2520of%2520Patients%2520with%2520Relapsed%2520or%2520Refractory%2520Mantle%2520Cell%2520Lymphoma%2520with%2520Zanubrutinib%252C%2520a%2520Selective%2520Inhibitor%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2020%26volume%3D26%26spage%3D4216%26epage%3D4224%26doi%3D10.1158%2F1078-0432.CCR-19-3703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref214"><div class="reference"><strong class="refLabel"><a href="#ref214" class="rightTabRefNumLink">214</a></strong><div class="NLM_citation" id="rightTab-cit214a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">7923</span>– <span class="NLM_lpage">7940</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00687</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00687" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref214/cit214a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFSku7bP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=7923-7940&author=Y.+Guoauthor=Y.+Liuauthor=N.+Huauthor=D.+Yuauthor=C.+Zhouauthor=G.+Shiauthor=B.+Zhangauthor=M.+Weiauthor=J.+Liuauthor=L.+Luoauthor=Z.+Tangauthor=H.+Songauthor=Y.+Guoauthor=X.+Liuauthor=D.+Suauthor=S.+Zhangauthor=X.+Songauthor=X.+Zhouauthor=Y.+Hongauthor=S.+Chenauthor=Z.+Chengauthor=S.+Youngauthor=Q.+Weiauthor=H.+Wangauthor=Q.+Wangauthor=L.+Lvauthor=F.+Wangauthor=H.+Xuauthor=H.+Sunauthor=H.+Xingauthor=N.+Liauthor=W.+Zhangauthor=Z.+Wangauthor=G.+Liuauthor=Z.+Sunauthor=D.+Zhouauthor=W.+Liauthor=L.+Liuauthor=L.+Wangauthor=Z.+Wang&title=Discovery+of+Zanubrutinib+%28BGB-3111%29%2C+a+Novel%2C+Potent%2C+and+Selective+Covalent+Inhibitor+of+Bruton%E2%80%99s+Tyrosine+Kinase&doi=10.1021%2Facs.jmedchem.9b00687"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit214aR"><div class="casContent"><span class="casTitleNuber">214a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase</span></div><div class="casAuthors">Guo, Yunhang; Liu, Ye; Hu, Nan; Yu, Desheng; Zhou, Changyou; Shi, Gongyin; Zhang, Bo; Wei, Min; Liu, Junhua; Luo, Lusong; Tang, Zhiyu; Song, Huipeng; Guo, Yin; Liu, Xuesong; Su, Dan; Zhang, Shuo; Song, Xiaomin; Zhou, Xing; Hong, Yuan; Chen, Shuaishuai; Cheng, Zhenzhen; Young, Steve; Wei, Qiang; Wang, Haisheng; Wang, Qiuwen; Lv, Lei; Wang, Fan; Xu, Haipeng; Sun, Hanzi; Xing, Haimei; Li, Na; Zhang, Wei; Wang, Zhongbo; Liu, Guodong; Sun, Zhijian; Zhou, Dongping; Li, Wei; Liu, Libin; Wang, Lai; Wang, Zhiwei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7923-7940</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Aberrant activation of Bruton's tyrosine kinase (BTK) plays an important role in pathogenesis of B-cell lymphomas, suggesting that inhibition of BTK is useful in the treatment of hematol. malignancies.  The discovery of a more selective on-target covalent BTK inhibitor is of high value.  Herein, we disclose the discovery and preclin. characterization of a potent, selective, and irreversible BTK inhibitor as our clin. candidate by using in vitro potency, selectivity, pharmacokinetics (PK), and in vivo pharmacodynamic for prioritizing compds.  Compd. BGB-3111 (31a, Zanubrutinib) demonstrates (i) potent activity against BTK and excellent selectivity over other TEC, EGFR and Src family kinases, (ii) desirable ADME, excellent in vivo pharmacodynamic in mice and efficacy in OCI-LY10 xenograft models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgRMQ-gBKtdbVg90H21EOLACvtfcHk0ljDN4I1tN76vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFSku7bP&md5=5cdb551d296e60eb1e82b03b7a0384ee</span></div><a href="/servlet/linkout?suffix=cit214a&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00687%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DN.%26aulast%3DYu%26aufirst%3DD.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DShi%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DWei%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLuo%26aufirst%3DL.%26aulast%3DTang%26aufirst%3DZ.%26aulast%3DSong%26aufirst%3DH.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DSu%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DSong%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DHong%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DCheng%26aufirst%3DZ.%26aulast%3DYoung%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DLv%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DXing%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DSun%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DZ.%26atitle%3DDiscovery%2520of%2520Zanubrutinib%2520%2528BGB-3111%2529%252C%2520a%2520Novel%252C%2520Potent%252C%2520and%2520Selective%2520Covalent%2520Inhibitor%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D7923%26epage%3D7940%26doi%3D10.1021%2Facs.jmedchem.9b00687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit214b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span>; <span class="NLM_string-name">Guo, Y.</span>; <span class="NLM_string-name">Shi, G.</span></span> <span> </span><span class="NLM_article-title">Crystalline Form of (<i>S</i>)-7-(1-Acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-<i>a</i>]pyrimidine-3-carboxamide, Preparation, and Uses Thereof</span>. <span class="NLM_patent">WO 2018033853 A2</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=Z.+Wang&author=Y.+Guo&author=G.+Shi&title=Crystalline+Form+of+%28S%29-7-%281-Acryloylpiperidin-4-yl%29-2-%284-phenoxyphenyl%29-4%2C5%2C6%2C7-tetrahydropyrazolo%5B1%2C5-a%5Dpyrimidine-3-carboxamide%2C+Preparation%2C+and+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit214b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26atitle%3DCrystalline%2520Form%2520of%2520%2528S%2529-7-%25281-Acryloylpiperidin-4-yl%2529-2-%25284-phenoxyphenyl%2529-4%252C5%252C6%252C7-tetrahydropyrazolo%255B1%252C5-a%255Dpyrimidine-3-carboxamide%252C%2520Preparation%252C%2520and%2520Uses%2520Thereof%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit214c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span>; <span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">Fused Heterocyclic Compounds as Protein Kinase Inhibitors</span>. <span class="NLM_patent">WO 2014173289 A1</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=Y.+Guo&author=Z.+Wang&title=Fused+Heterocyclic+Compounds+as+Protein+Kinase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit214c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DY.%26atitle%3DFused%2520Heterocyclic%2520Compounds%2520as%2520Protein%2520Kinase%2520Inhibitors%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref215"><div class="reference"><strong class="refLabel"><a href="#ref215" class="rightTabRefNumLink">215</a></strong><div class="NLM_citation" id="rightTab-cit215"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barra, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seca, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Della Corte, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giampaolino, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrero, S.</span></span> <span> </span><span class="NLM_article-title">Relugolix for the Treatment of Uterine Fibroids</span>. <i>Drugs Today</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">503</span>– <span class="NLM_lpage">512</span>, <span class="refDoi"> DOI: 10.1358/dot.2019.55.8.3020179</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1358%2Fdot.2019.55.8.3020179" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A280%3ADC%252BB3Mrisl2gtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2019&pages=503-512&author=F.+Barraauthor=M.+Secaauthor=L.+Della+Corteauthor=P.+Giampaolinoauthor=S.+Ferrero&title=Relugolix+for+the+Treatment+of+Uterine+Fibroids&doi=10.1358%2Fdot.2019.55.8.3020179"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit215R"><div class="casContent"><span class="casTitleNuber">215</span><div class="casTitle"><span class="NLM_cas:atitle">Relugolix for the treatment of uterine fibroids</span></div><div class="casAuthors">Barra F; Seca M; Ferrero S; Della Corte L; Giampaolino P</div><div class="citationInfo"><span class="NLM_cas:title">Drugs of today (Barcelona, Spain : 1998)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">503-512</span>
        ISSN:<span class="NLM_cas:issn">1699-3993</span>.
    </div><div class="casAbstract">Uterine leiomyomas represent the most common form of benign gynecological tumors affecting 20-40% of women during their life.  Several therapeutic options are available for treating these patients.  The use of medical treatment for myomas has largely grown in the last years, in particular for women who would refuse, postpone or are not candidates for surgery.  In the last years, the clinical investigation of gonadotropin-releasing hormone (GnRH) antagonists (GnRH-ants) has emerged.  This class of drugs exerts pure competitive antagonistic activity on the GnRH receptor at the pituitary gland, producing an immediate stop in the release of gonadotropins and sex steroids.  Relugolix is an orally active nonpeptide GnRH-ant, recently licensed for marketing in Japan for the treatment of symptoms related to uterine myomas.  Currently, several phase III clinical trials are ongoing to evaluate this molecule in this setting in the U.S. and Europe.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQpQKFSJnFw8RpyrDyM_m9cfW6udTcc2ebGhcpj3I7g07ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3Mrisl2gtA%253D%253D&md5=b42693c2309b40a4b38e530508241dad</span></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=10.1358%2Fdot.2019.55.8.3020179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdot.2019.55.8.3020179%26sid%3Dliteratum%253Aachs%26aulast%3DBarra%26aufirst%3DF.%26aulast%3DSeca%26aufirst%3DM.%26aulast%3DDella%2BCorte%26aufirst%3DL.%26aulast%3DGiampaolino%26aufirst%3DP.%26aulast%3DFerrero%26aufirst%3DS.%26atitle%3DRelugolix%2520for%2520the%2520Treatment%2520of%2520Uterine%2520Fibroids%26jtitle%3DDrugs%2520Today%26date%3D2019%26volume%3D55%26spage%3D503%26epage%3D512%26doi%3D10.1358%2Fdot.2019.55.8.3020179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref216"><div class="reference"><strong class="refLabel"><a href="#ref216" class="rightTabRefNumLink">216</a></strong><div class="NLM_citation" id="rightTab-cit216a"><span><span class="NLM_label">(a) </span><a href="https://clinicaltrials.gov/ct2/show/NCT03085095" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03085095</a> (accessed 2020-09-15).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03085095+%28accessed+2020-09-15%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit216a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit216b"><span><span class="NLM_label">(b) </span><a href="https://clinicaltrials.gov/ct2/show/NCT03931915" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03931915</a> (accessed 2020-09-15).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03931915+%28accessed+2020-09-15%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit216b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref217"><div class="reference"><strong class="refLabel"><a href="#ref217" class="rightTabRefNumLink">217</a></strong><div class="NLM_citation" id="rightTab-cit217"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cho, N.</span>; <span class="NLM_string-name">Imada, T.</span>; <span class="NLM_string-name">Hitaka, T.</span>; <span class="NLM_string-name">Miwa, K.</span>; <span class="NLM_string-name">Kusaka, M.</span>; <span class="NLM_string-name">Suzuki, N.</span></span> <span> </span><span class="NLM_article-title">Preparation of Thienopyrimidine Derivatives as Gonadotropin-Releasing Hormone Antagonists</span>. <span class="NLM_patent">WO 2004067535 A1</span>, <span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=N.+Cho&author=T.+Imada&author=T.+Hitaka&author=K.+Miwa&author=M.+Kusaka&author=N.+Suzuki&title=Preparation+of+Thienopyrimidine+Derivatives+as+Gonadotropin-Releasing+Hormone+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit217&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DN.%26atitle%3DPreparation%2520of%2520Thienopyrimidine%2520Derivatives%2520as%2520Gonadotropin-Releasing%2520Hormone%2520Antagonists%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref218"><div class="reference"><strong class="refLabel"><a href="#ref218" class="rightTabRefNumLink">218</a></strong><div class="NLM_citation" id="rightTab-cit218"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miwa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hitaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshimatsu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakata, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furuya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamamura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitazaki, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of 1-{4-[1-(2,6-Difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-<i>d</i>]pyrimidin-6-yl]phenyl}-3-methoxyurea (TAK-385) as a Potent, Orally Active, Non-Peptide Antagonist of the Human Gonadotropin-Releasing Hormone Receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">4998</span>– <span class="NLM_lpage">5012</span>, <span class="refDoi"> DOI: 10.1021/jm200216q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200216q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnvFagsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4998-5012&author=K.+Miwaauthor=T.+Hitakaauthor=T.+Imadaauthor=S.+Sasakiauthor=M.+Yoshimatsuauthor=M.+Kusakaauthor=A.+Tanakaauthor=D.+Nakataauthor=S.+Furuyaauthor=S.+Endoauthor=K.+Hamamuraauthor=T.+Kitazaki&title=Discovery+of+1-%7B4-%5B1-%282%2C6-Difluorobenzyl%29-5-%5B%28dimethylamino%29methyl%5D-3-%286-methoxypyridazin-3-yl%29-2%2C4-dioxo-1%2C2%2C3%2C4-tetrahydrothieno%5B2%2C3-d%5Dpyrimidin-6-yl%5Dphenyl%7D-3-methoxyurea+%28TAK-385%29+as+a+Potent%2C+Orally+Active%2C+Non-Peptide+Antagonist+of+the+Human+Gonadotropin-Releasing+Hormone+Receptor&doi=10.1021%2Fjm200216q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit218R"><div class="casContent"><span class="casTitleNuber">218</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 1-{4-[1-(2,6-Difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl}-3-methoxyurea (TAK-385) as a Potent, Orally Active, Non-Peptide Antagonist of the Human Gonadotropin-Releasing Hormone Receptor</span></div><div class="casAuthors">Miwa, Kazuhiro; Hitaka, Takenori; Imada, Takashi; Sasaki, Satoshi; Yoshimatsu, Mie; Kusaka, Masami; Tanaka, Akira; Nakata, Daisuke; Furuya, Shuichi; Endo, Satoshi; Hamamura, Kazumasa; Kitazaki, Tomoyuki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4998-5012</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An orally active human gonadotropin-releasing hormone (GnRH) receptor antagonist, thieno[2,3-d]pyrimidine-2,4-dione deriv. I (sufugolix), was previously discovered.  To reduce the cytochrome P 450 (CYP) inhibitory activity and improve in vivo GnRH antagonistic activity, further optimization of this scaffold was carried out.  The synthetic efforts were focused on chem. modification at the 5 and 3 positions of the thieno[2,3-d]pyrimidine-2,4-dione ring based on computational modeling, which resulted in the discovery of 1-{4-[1-(2,6-difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl}-3-methoxyurea (II) as a highly potent and orally active GnRH antagonist.  Compd. II showed potent in vitro GnRH antagonistic activity in the presence of fetal bovine serum (FBS) without CYP inhibition.  Oral administration of II maintained the suppressive effect of the plasma LH levels in castrated cynomolgus monkeys at a 3 mg/kg dose for more than 24 h.  Compd. II is currently under clin. development with the code name of TAK-385.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrw-Ejv5bG8kbVg90H21EOLACvtfcHk0lhguxMdoRygWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnvFagsbY%253D&md5=1389cd91374bc908a561149de19b71b1</span></div><a href="/servlet/linkout?suffix=cit218&amp;dbid=16384&amp;doi=10.1021%2Fjm200216q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200216q%26sid%3Dliteratum%253Aachs%26aulast%3DMiwa%26aufirst%3DK.%26aulast%3DHitaka%26aufirst%3DT.%26aulast%3DImada%26aufirst%3DT.%26aulast%3DSasaki%26aufirst%3DS.%26aulast%3DYoshimatsu%26aufirst%3DM.%26aulast%3DKusaka%26aufirst%3DM.%26aulast%3DTanaka%26aufirst%3DA.%26aulast%3DNakata%26aufirst%3DD.%26aulast%3DFuruya%26aufirst%3DS.%26aulast%3DEndo%26aufirst%3DS.%26aulast%3DHamamura%26aufirst%3DK.%26aulast%3DKitazaki%26aufirst%3DT.%26atitle%3DDiscovery%2520of%25201-%257B4-%255B1-%25282%252C6-Difluorobenzyl%2529-5-%255B%2528dimethylamino%2529methyl%255D-3-%25286-methoxypyridazin-3-yl%2529-2%252C4-dioxo-1%252C2%252C3%252C4-tetrahydrothieno%255B2%252C3-d%255Dpyrimidin-6-yl%255Dphenyl%257D-3-methoxyurea%2520%2528TAK-385%2529%2520as%2520a%2520Potent%252C%2520Orally%2520Active%252C%2520Non-Peptide%2520Antagonist%2520of%2520the%2520Human%2520Gonadotropin-Releasing%2520Hormone%2520Receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4998%26epage%3D5012%26doi%3D10.1021%2Fjm200216q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref219"><div class="reference"><strong class="refLabel"><a href="#ref219" class="rightTabRefNumLink">219</a></strong><div class="NLM_citation" id="rightTab-cit219"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furuya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujino, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Thieno[2,3-<i>d</i>]pyrimidine-2,4-dione Bearing a <i>p</i>-Methoxyureidophenyl Moiety at the 6-Position: A Highly Potent and Orally Bioavailable Non-Peptide Antagonist for the Human Luteinizing Hormone-Releasing Hormone Receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">113</span>– <span class="NLM_lpage">124</span>, <span class="refDoi"> DOI: 10.1021/jm020180i</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm020180i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BD38XovFygu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=113-124&author=S.+Sasakiauthor=N.+Choauthor=Y.+Naraauthor=M.+Haradaauthor=S.+Endoauthor=N.+Suzukiauthor=S.+Furuyaauthor=M.+Fujino&title=Discovery+of+a+Thieno%5B2%2C3-d%5Dpyrimidine-2%2C4-dione+Bearing+a+p-Methoxyureidophenyl+Moiety+at+the+6-Position%3A+A+Highly+Potent+and+Orally+Bioavailable+Non-Peptide+Antagonist+for+the+Human+Luteinizing+Hormone-Releasing+Hormone+Receptor&doi=10.1021%2Fjm020180i"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit219R"><div class="casContent"><span class="casTitleNuber">219</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Thieno[2,3-d]pyrimidine-2,4-dione Bearing a p-Methoxyureidophenyl Moiety at the 6-Position: A Highly Potent and Orally Bioavailable Non-Peptide Antagonist for the Human Luteinizing Hormone-Releasing Hormone Receptor</span></div><div class="casAuthors">Sasaki, Satoshi; Cho, Nobuo; Nara, Yoshi; Harada, Masataka; Endo, Satoshi; Suzuki, Nobuhiro; Furuya, Shuichi; Fujino, Masahiko</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">113-124</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We have previously disclosed the first potent and orally effective non-peptide antagonist for the human LH-releasing hormone (LHRH) receptor, a thieno[2,3-b]pyridin-4-one deriv., T-98475.  Extensive research on developing non-peptide LHRH antagonists has been carried out by employing a strategy of replacing the thienopyridin-4-one nucleus with other heterocyclic surrogates.  We describe herein the design and synthesis of a series of thieno[2,3-d]pyrimidine-2,4-dione derivs. contg. a biaryl moiety, which led to the discovery of a highly potent and orally active non-peptide LHRH antagonist, 5-(N-benzyl-N-methylaminomethyl)-1-(2,6-difluorobenzyl)-6-[4-(3-methoxyureido)phenyl]-3-phenylthieno[2,3-d]pyrimidine-2,4(1H,3H)-dione (I: TAK-013).  Compd. I showed high binding affinity and potent in vitro antagonistic activity for the human receptor with half-maximal inhibition concn. (IC50) values of 0.1 and 0.06 nM, resp.  Oral administration of I caused almost complete suppression of the plasma LH levels in castrated male cynomolgus monkeys at a 30 mg/kg dose with sufficient duration of action (more than 24 h).  The results demonstrated that the thienopyrimidine-2,4-dione core is an excellent surrogate for the thienopyridin-4-one and that thienopyrimidine-2,4-diones and thienopyridin-4-ones constitute a new class of potent and orally bioavailable LHRH receptor antagonists. Furthermore, mol. modeling studies indicate that the unique methoxyurea side chain of I preferentially forms an intramol. hydrogen bond between the aniline NH and the methoxy oxygen atom.  The hydrogen bond will shield the hydrogen bonding moieties from the solvent and reduce the desolvation energy cost.  It is therefore speculated that the intramol. hydrogen bond resulting from judicious incorporation of an oxygen atom into the terminal alkyl group of the urea may increase the apparent lipophilicity to allow increased membrane permeability and consequently to improve the oral absorption of I in monkeys.  On the basis of its profile, compd. I has been selected as a candidate for clin. trials and it is expected that it will provide a new class of potential therapeutic agents for the clin. treatment of a variety of sex-hormone-dependent diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmDf674AIEgbVg90H21EOLACvtfcHk0lhguxMdoRygWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XovFygu70%253D&md5=bdfb9d73c0632d3ecc5bcd6043bf219b</span></div><a href="/servlet/linkout?suffix=cit219&amp;dbid=16384&amp;doi=10.1021%2Fjm020180i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020180i%26sid%3Dliteratum%253Aachs%26aulast%3DSasaki%26aufirst%3DS.%26aulast%3DCho%26aufirst%3DN.%26aulast%3DNara%26aufirst%3DY.%26aulast%3DHarada%26aufirst%3DM.%26aulast%3DEndo%26aufirst%3DS.%26aulast%3DSuzuki%26aufirst%3DN.%26aulast%3DFuruya%26aufirst%3DS.%26aulast%3DFujino%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520a%2520Thieno%255B2%252C3-d%255Dpyrimidine-2%252C4-dione%2520Bearing%2520a%2520p-Methoxyureidophenyl%2520Moiety%2520at%2520the%25206-Position%253A%2520A%2520Highly%2520Potent%2520and%2520Orally%2520Bioavailable%2520Non-Peptide%2520Antagonist%2520for%2520the%2520Human%2520Luteinizing%2520Hormone-Releasing%2520Hormone%2520Receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D113%26epage%3D124%26doi%3D10.1021%2Fjm020180i" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref220"><div class="reference"><strong class="refLabel"><a href="#ref220" class="rightTabRefNumLink">220</a></strong><div class="NLM_citation" id="rightTab-cit220a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hoy, S. M.</span></span> <span> </span><span class="NLM_article-title">Elexacaftor/Ivacaftor/Tezacaftor: First Approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">2001</span>– <span class="NLM_lpage">2007</span>, <span class="refDoi"> DOI: 10.1007/s40265-019-01233-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref220/cit220a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs40265-019-01233-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref220/cit220a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31784874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref220/cit220a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A280%3ADC%252BB3MfkvFaitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=2001-2007&author=S.+M.+Hoy&title=Elexacaftor%2FIvacaftor%2FTezacaftor%3A+First+Approval&doi=10.1007%2Fs40265-019-01233-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit220aR"><div class="casContent"><span class="casTitleNuber">220a</span><div class="casTitle"><span class="NLM_cas:atitle">Elexacaftor/Ivacaftor/Tezacaftor: First Approval</span></div><div class="casAuthors">Hoy Sheridan M</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2001-2007</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">A fixed-dose combination tablet of the cystic fibrosis transmembrane conductance regulator (CFTR) corrector tezacaftor and the CFTR potentiator ivacaftor with the next-generation CFTR corrector elexacaftor (hereafter referred to as elexacaftor/ivacaftor/tezacaftor) [Trikafta®] has been developed by Vertex Pharmaceuticals Inc. to treat patients with the most common cystic fibrosis mutation (F508del).  Its use has been associated with statistically significant and/or clinically meaningful improvements in lung function and respiratory-related quality of life compared with comparator regimens (placebo or ivacaftor/tezacaftor) in multinational phase II and III studies, and in October 2019 elexacaftor/ivacaftor/tezacaftor was approved by the US FDA for the treatment of cystic fibrosis in patients aged ≥ 12 years who have ≥ 1 F508del mutation in the CFTR gene.  A regulatory assessment for elexacaftor/ivacaftor/tezacaftor as a treatment for cystic fibrosis is underway in the EU.  This article summarizes the milestones in the development of elexacaftor/ivacaftor/tezacaftor leading to this first approval for the treatment of cystic fibrosis in patients aged ≥ 12 years who have ≥ 1 F508del mutation in the CFTR gene.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT2Dsf-znGt_RLDWw4HIq2sfW6udTcc2eYgJHs0ehDcFbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MfkvFaitw%253D%253D&md5=4b00880ad8edb858bf89367264b4e9f7</span></div><a href="/servlet/linkout?suffix=cit220a&amp;dbid=16384&amp;doi=10.1007%2Fs40265-019-01233-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-019-01233-7%26sid%3Dliteratum%253Aachs%26aulast%3DHoy%26aufirst%3DS.%2BM.%26atitle%3DElexacaftor%252FIvacaftor%252FTezacaftor%253A%2520First%2520Approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D2001%26epage%3D2007%26doi%3D10.1007%2Fs40265-019-01233-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit220b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oermann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Resnick, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brady, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeNagel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guill, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoag, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newton, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willey-Courand, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naureckas, E. T.</span></span> <span> </span><span class="NLM_article-title">Cystic Fibrosis Foundation Pulmonary Guidelines. Use of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy in Patients with Cystic Fibrosis</span>. <i>Ann. Am. Thorac. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">271</span>– <span class="NLM_lpage">280</span>, <span class="refDoi"> DOI: 10.1513/AnnalsATS.201707-539OT</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref220/cit220b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1513%2FAnnalsATS.201707-539OT" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref220/cit220b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=29342367" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref220/cit220b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A280%3ADC%252BC1MvhsFKhsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=271-280&author=C.+L.+Renauthor=R.+L.+Morganauthor=C.+Oermannauthor=H.+E.+Resnickauthor=C.+Bradyauthor=A.+Campbellauthor=R.+DeNagelauthor=M.+Guillauthor=J.+Hoagauthor=A.+Liptonauthor=T.+Newtonauthor=S.+Petersauthor=D.+B.+Willey-Courandauthor=E.+T.+Naureckas&title=Cystic+Fibrosis+Foundation+Pulmonary+Guidelines.+Use+of+Cystic+Fibrosis+Transmembrane+Conductance+Regulator+Modulator+Therapy+in+Patients+with+Cystic+Fibrosis&doi=10.1513%2FAnnalsATS.201707-539OT"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit220bR"><div class="casContent"><span class="casTitleNuber">220b</span><div class="casTitle"><span class="NLM_cas:atitle">Cystic Fibrosis Foundation Pulmonary Guidelines. Use of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy in Patients with Cystic Fibrosis</span></div><div class="casAuthors">Ren Clement L; Morgan Rebecca L; Oermann Christopher; Resnick Helaine E; Brady Cynthia; Campbell Annette; DeNagel Richard; Guill Margaret; Hoag Jeffrey; Lipton Andrew; Newton Thomas; Peters Stacy; Willey-Courand Donna Beth; Naureckas Edward T</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the American Thoracic Society</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">271-280</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">RATIONALE:  Cystic fibrosis (CF) transmembrane conductance regulator (CFTR) modulators are a new class of medications targeting the underlying defect in CF.  Ivacaftor (IVA) and IVA combined with lumacaftor (LUM; IVA/LUM) have been approved by the U.S.  Food and Drug Administration (FDA) for use in patients with CF.  However, the FDA label for these medications encompasses patient groups that were not studied as part of the drug approval process.  CF clinicians, patients, and their families have recognized a need for recommendations to guide the use of these medications.  OBJECTIVE:  Develop evidence-based guidelines for CFTR modulator therapy in patients with CF.  METHODS:  A multidisciplinary committee of CF caregivers and patient representatives was assembled.  A methodologist, an epidemiologist, a medical librarian, and a biostatistician were recruited to assist with the literature search, evidence grading, and generation of recommendations.  The committee developed clinical questions using the Patient-Intervention-Comparison-Outcome format.  A systematic review was conducted to find relevant publications.  The evidence was then evaluated using the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach, and recommendations were made based on this analysis.  RESULTS:  For adults and children aged 6 years and older with CF due to gating mutations other than G551D or R117H, the guideline panel made a conditional recommendation for treatment with IVA.  For those with the R117H mutation, the guideline panel made a conditional recommendation for treatment with IVA for 1) adults aged 18 years or older, and 2) children aged 6-17 years with a forced expiratory volume in 1 second (FEV1) less than 90% predicted.  For those with the R117H mutation, the guideline panel made a conditional recommendation against treatment with IVA for 1) children aged 12-17 years with an FEV1 greater than 90% predicted, and 2) children less than 6 years of age.  Among those with two copies of F508del, the guideline panel made a strong recommendation for treatment with IVA/LUM for adults and children aged 12 years and older with an FEV1 less than 90% predicted; and made a conditional recommendation for treatment with IVA/LUM for 1) adults and children aged 12 years or older with an FEV1 greater than 90% predicted, and 2) children aged 6-11 years.  CONCLUSIONS:  Using the GRADE approach, we have made recommendations for the use of CFTR modulators in patients with CF.  These recommendations will be of help to CF clinicians, patients, and their families in guiding decisions regarding use of these medications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQvIaI3UZvtiO2mnZh2OgS0fW6udTcc2eZ-yYVdW2INS7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MvhsFKhsA%253D%253D&md5=28e86120150609327b22f90a76623f66</span></div><a href="/servlet/linkout?suffix=cit220b&amp;dbid=16384&amp;doi=10.1513%2FAnnalsATS.201707-539OT&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1513%252FAnnalsATS.201707-539OT%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DC.%2BL.%26aulast%3DMorgan%26aufirst%3DR.%2BL.%26aulast%3DOermann%26aufirst%3DC.%26aulast%3DResnick%26aufirst%3DH.%2BE.%26aulast%3DBrady%26aufirst%3DC.%26aulast%3DCampbell%26aufirst%3DA.%26aulast%3DDeNagel%26aufirst%3DR.%26aulast%3DGuill%26aufirst%3DM.%26aulast%3DHoag%26aufirst%3DJ.%26aulast%3DLipton%26aufirst%3DA.%26aulast%3DNewton%26aufirst%3DT.%26aulast%3DPeters%26aufirst%3DS.%26aulast%3DWilley-Courand%26aufirst%3DD.%2BB.%26aulast%3DNaureckas%26aufirst%3DE.%2BT.%26atitle%3DCystic%2520Fibrosis%2520Foundation%2520Pulmonary%2520Guidelines.%2520Use%2520of%2520Cystic%2520Fibrosis%2520Transmembrane%2520Conductance%2520Regulator%2520Modulator%2520Therapy%2520in%2520Patients%2520with%2520Cystic%2520Fibrosis%26jtitle%3DAnn.%2520Am.%2520Thorac.%2520Soc.%26date%3D2018%26volume%3D15%26spage%3D271%26epage%3D280%26doi%3D10.1513%2FAnnalsATS.201707-539OT" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit220c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Middleton, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mall, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drevinek, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lands, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKone, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polineni, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramsey, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor-Cousar, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tullis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vermeulen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marigowda, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKee, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moskowitz, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savage, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waltz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xuan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowe, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, R.</span></span> <span> </span><span class="NLM_article-title">Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>381</i></span>,  <span class="NLM_fpage">1809</span>– <span class="NLM_lpage">1819</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1908639</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref220/cit220c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1056%2FNEJMoa1908639" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref220/cit220c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=31697873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref220/cit220c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFejs7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=381&publication_year=2019&pages=1809-1819&author=P.+G.+Middletonauthor=M.+A.+Mallauthor=P.+Drevinekauthor=L.+C.+Landsauthor=E.+F.+McKoneauthor=D.+Polineniauthor=B.+W.+Ramseyauthor=J.+L.+Taylor-Cousarauthor=E.+Tullisauthor=F.+Vermeulenauthor=G.+Marigowdaauthor=C.+M.+McKeeauthor=S.+M.+Moskowitzauthor=N.+Nairauthor=J.+Savageauthor=C.+Simardauthor=S.+Tianauthor=D.+Waltzauthor=F.+Xuanauthor=S.+M.+Roweauthor=R.+Jain&title=Elexacaftor%E2%80%93Tezacaftor%E2%80%93Ivacaftor+for+Cystic+Fibrosis+with+a+Single+Phe508del+Allele&doi=10.1056%2FNEJMoa1908639"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit220cR"><div class="casContent"><span class="casTitleNuber">220c</span><div class="casTitle"><span class="NLM_cas:atitle">Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele</span></div><div class="casAuthors">Middleton, P. G.; Mall, M. A.; Drevinek, P.; Lands, L. C.; McKone, E. F.; Polineni, D.; Ramsey, B. W.; Taylor-Cousar, J. L.; Tullis, E.; Vermeulen, F.; Marigowda, G.; McKee, C. M.; Moskowitz, S. M.; Nair, N.; Savage, J.; Simard, C.; Tian, S.; Waltz, D.; Xuan, F.; Rowe, S. M.; Jain, R.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">381</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1809-1819</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Cystic fibrosis is caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) protein, and nearly 90% of patients have at least one copy of the Phe508del CFTR mutation.  In a phase 2 trial involving patients who were heterozygous for the Phe508del CFTR mutation and a minimal-function mutation (Phe508del-minimal function genotype), the next-generation CFTR corrector elexacaftor, in combination with tezacaftor and ivacaftor, improved Phe508del CFTR function and clin. outcomes.  Methods We conducted a phase 3, randomized, double-blind, placebo-controlled trial to confirm the efficacy and safety of elexacaftor-tezacaftor-ivacaftor in patients 12 years of age or older with cystic fibrosis with Phe508del-minimal function genotypes.  Patients were randomly assigned to receive elexacaftor-tezacaftor-ivacaftor or placebo for 24 wk.  The primary end point was abs. change from baseline in percentage of predicted forced expiratory vol. in 1 s (FEV1) at week 4.  Results A total of 403 patients underwent randomization and received at least one dose of active treatment or placebo.  Elexacaftor-tezacaftor-ivacaftor, relative to placebo, resulted in a percentage of predicted FEV1 that was 13.8 points higher at 4 wk and 14.3 points higher through 24 wk, a rate of pulmonary exacerbations that was 63% lower, a respiratory domain score on the Cystic Fibrosis Questionnaire-Revised (range, 0 to 100, with higher scores indicating a higher patient-reported quality of life with regard to respiratory symptoms; min. clin. important difference, 4 points) that was 20.2 points higher, and a sweat chloride concn. that was 41.8 mmol per L lower (P<0.001 for all comparisons).  Elexacaftor-tezacaftor-ivacaftor was generally safe and had an acceptable side-effect profile.  Most patients had adverse events that were mild or moderate.  Adverse events leading to discontinuation of the trial regimen occurred in 1% of the patients in the elexacaftor-tezacaftor-ivacaftor group.  Conclusions Elexacaftor-tezacaftor-ivacaftor was efficacious in patients with cystic fibrosis with Phe508del-minimal function genotypes, in whom previous CFTR modulator regimens were ineffective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCpB_nCizrq7Vg90H21EOLACvtfcHk0lgvEPgPWooz4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFejs7vL&md5=ceacdc28020bb2a97ad32dd14a2aae95</span></div><a href="/servlet/linkout?suffix=cit220c&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1908639&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1908639%26sid%3Dliteratum%253Aachs%26aulast%3DMiddleton%26aufirst%3DP.%2BG.%26aulast%3DMall%26aufirst%3DM.%2BA.%26aulast%3DDrevinek%26aufirst%3DP.%26aulast%3DLands%26aufirst%3DL.%2BC.%26aulast%3DMcKone%26aufirst%3DE.%2BF.%26aulast%3DPolineni%26aufirst%3DD.%26aulast%3DRamsey%26aufirst%3DB.%2BW.%26aulast%3DTaylor-Cousar%26aufirst%3DJ.%2BL.%26aulast%3DTullis%26aufirst%3DE.%26aulast%3DVermeulen%26aufirst%3DF.%26aulast%3DMarigowda%26aufirst%3DG.%26aulast%3DMcKee%26aufirst%3DC.%2BM.%26aulast%3DMoskowitz%26aufirst%3DS.%2BM.%26aulast%3DNair%26aufirst%3DN.%26aulast%3DSavage%26aufirst%3DJ.%26aulast%3DSimard%26aufirst%3DC.%26aulast%3DTian%26aufirst%3DS.%26aulast%3DWaltz%26aufirst%3DD.%26aulast%3DXuan%26aufirst%3DF.%26aulast%3DRowe%26aufirst%3DS.%2BM.%26aulast%3DJain%26aufirst%3DR.%26atitle%3DElexacaftor%25E2%2580%2593Tezacaftor%25E2%2580%2593Ivacaftor%2520for%2520Cystic%2520Fibrosis%2520with%2520a%2520Single%2520Phe508del%2520Allele%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2019%26volume%3D381%26spage%3D1809%26epage%3D1819%26doi%3D10.1056%2FNEJMoa1908639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref221"><div class="reference"><strong class="refLabel"><a href="#ref221" class="rightTabRefNumLink">221</a></strong><div class="NLM_citation" id="rightTab-cit221"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deeks, E. D.</span></span> <span> </span><span class="NLM_article-title">Lumacaftor/Ivacaftor: A Review in Cystic Fibrosis</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">1191</span>– <span class="NLM_lpage">1201</span>, <span class="refDoi"> DOI: 10.1007/s40265-016-0611-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1007%2Fs40265-016-0611-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=27394157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFOmu7bO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=1191-1201&author=E.+D.+Deeks&title=Lumacaftor%2FIvacaftor%3A+A+Review+in+Cystic+Fibrosis&doi=10.1007%2Fs40265-016-0611-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit221R"><div class="casContent"><span class="casTitleNuber">221</span><div class="casTitle"><span class="NLM_cas:atitle">Lumacaftor/Ivacaftor: A Review in Cystic Fibrosis</span></div><div class="casAuthors">Deeks, Emma D.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1191-1201</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Lumacaftor/ivacaftor (Orkambi) is a fixed-dose tablet contg. a corrector (lumacaftor) and potentiator (ivacaftor) of the cystic fibrosis transmembrane conductance regulator (CFTR) and is the first therapy approved to treat the underlying cause of cystic fibrosis in patients (aged ≥12 years) homozygous for the most common CFTR mutation, F508del.  Lumacaftor improves the processing of F508del CFTR and its transport to the cell surface, while ivacaftor increases the channel's open probability and transport of chloride.  In two 24-wk trials in the approved patient population (TRAFFIC and TRANSPORT), lumacaftor 400 mg plus ivacaftor 250 mg, administered every 12 h in combination with std. therapy, was assocd. with an ≈3 % statistically significant improvement in lung function relative to placebo (as measured by the percent predicted forced expiratory vol. in 1 s).  Lumacaftor plus ivacaftor did not significantly improve respiratory symptoms, although reduced pulmonary exacerbations to a clin. meaningful extent and, in one trial (TRANSPORT), significantly improved body mass index (BMI).  In an ongoing extension of these studies (PROGRESS), lumacaftor plus ivacaftor provided clin. benefit over a further 72 wk of treatment.  Lumacaftor plus ivacaftor had an acceptable tolerability profile, with the most common adverse events being respiratory or gastrointestinal in nature.  Thus, lumacaftor/ivacaftor expands the treatment options available for patients with cystic fibrosis homozygous for the F508del-CFTR mutation, although its precise place in clin. practice remains to be detd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpf0VxmHuTgI7Vg90H21EOLACvtfcHk0lgvEPgPWooz4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFOmu7bO&md5=7be2b21495bde10b6ed5eb826e53613f</span></div><a href="/servlet/linkout?suffix=cit221&amp;dbid=16384&amp;doi=10.1007%2Fs40265-016-0611-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-016-0611-2%26sid%3Dliteratum%253Aachs%26aulast%3DDeeks%26aufirst%3DE.%2BD.%26atitle%3DLumacaftor%252FIvacaftor%253A%2520A%2520Review%2520in%2520Cystic%2520Fibrosis%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26spage%3D1191%26epage%3D1201%26doi%3D10.1007%2Fs40265-016-0611-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref222"><div class="reference"><strong class="refLabel"><a href="#ref222" class="rightTabRefNumLink">222</a></strong><div class="NLM_citation" id="rightTab-cit222a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Gentzsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mall, M. A.</span></span> <span> </span><span class="NLM_article-title">Ion Channel Modulators in Cystic Fibrosis</span>. <i>Chest</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>154</i></span>,  <span class="NLM_fpage">383</span>– <span class="NLM_lpage">393</span>, <span class="refDoi"> DOI: 10.1016/j.chest.2018.04.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref222/cit222a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2Fj.chest.2018.04.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref222/cit222a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=29750923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref222/cit222a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A280%3ADC%252BC1Mfit1eqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2018&pages=383-393&author=M.+Gentzschauthor=M.+A.+Mall&title=Ion+Channel+Modulators+in+Cystic+Fibrosis&doi=10.1016%2Fj.chest.2018.04.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit222aR"><div class="casContent"><span class="casTitleNuber">222a</span><div class="casTitle"><span class="NLM_cas:atitle">Ion Channel Modulators in Cystic Fibrosis</span></div><div class="casAuthors">Gentzsch Martina; Mall Marcus A</div><div class="citationInfo"><span class="NLM_cas:title">Chest</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">383-393</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cystic fibrosis (CF) is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene and remains one of the most common life-shortening genetic diseases affecting the lung and other organs.  CFTR functions as a cyclic adenosine monophosphate-dependent anion channel that transports chloride and bicarbonate across epithelial surfaces, and disruption of these ion transport processes plays a central role in the pathogenesis of CF.  These findings provided the rationale for pharmacologic modulation of ion transport, either by targeting mutant CFTR or alternative ion channels that can compensate for CFTR dysfunction, as a promising therapeutic approach.  High-throughput screening has supported the development of CFTR modulator compounds.  CFTR correctors are designed to improve defective protein processing, trafficking, and cell surface expression, whereas potentiators increase the activity of mutant CFTR at the cell surface.  The approval of the first potentiator ivacaftor for the treatment of patients with specific CFTR mutations and, more recently, the corrector lumacaftor in combination with ivacaftor for patients homozygous for the common F508del mutation, were major breakthroughs on the path to causal therapies for all patients with CF.  The present review focuses on recent developments and remaining challenges of CFTR-directed therapies, as well as modulators of other ion channels such as alternative chloride channels and the epithelial sodium channel as additional targets in CF lung disease.  We further discuss how patient-derived precision medicine models may aid the translation of emerging next-generation ion channel modulators from the laboratory to the clinic and tailor their use for optimal therapeutic benefits in individual patients with CF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQAT7Rgd2Xw98SzjBFCN0BJfW6udTcc2ebgWljh24Pzj7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1Mfit1eqsw%253D%253D&md5=989ae3cd410621d14458af13ad6cf857</span></div><a href="/servlet/linkout?suffix=cit222a&amp;dbid=16384&amp;doi=10.1016%2Fj.chest.2018.04.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chest.2018.04.036%26sid%3Dliteratum%253Aachs%26aulast%3DGentzsch%26aufirst%3DM.%26aulast%3DMall%26aufirst%3DM.%2BA.%26atitle%3DIon%2520Channel%2520Modulators%2520in%2520Cystic%2520Fibrosis%26jtitle%3DChest%26date%3D2018%26volume%3D154%26spage%3D383%26epage%3D393%26doi%3D10.1016%2Fj.chest.2018.04.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit222b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Doull, I.</span></span> <span> </span><span class="NLM_article-title">Cystic Fibrosis 2019: Year in Review</span>. <i>Paediatr. Respir. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">95</span>– <span class="NLM_lpage">98</span>, <span class="refDoi"> DOI: 10.1016/j.prrv.2020.04.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref222/cit222b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1016%2Fj.prrv.2020.04.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref222/cit222b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=32359945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref222/cit222b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A280%3ADC%252BB38vitFChtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2020&pages=95-98&author=I.+Doull&title=Cystic+Fibrosis+2019%3A+Year+in+Review&doi=10.1016%2Fj.prrv.2020.04.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit222bR"><div class="casContent"><span class="casTitleNuber">222b</span><div class="casTitle"><span class="NLM_cas:atitle">Cystic fibrosis 2019: Year in review</span></div><div class="casAuthors">Doull Iolo</div><div class="citationInfo"><span class="NLM_cas:title">Paediatric respiratory reviews</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">95-98</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The evidence base for modulator therapies in cystic fibrosis (CF) has continued to expand, and it is likely that up to 90% of people with CF could benefit.  Worldwide there are however marked inequalities of access to basic CF care and modulator therapies.  For infants and young children there is now an evidence base for inhaled hypertonic saline.  There is increasing evidence that structural lung disease in CF is not due purely to infection and that mucus retention and inflammation are also key, and further evidence of the value of azithromycin in those chronically infected with Pseudomonas aeruginosa.  Finally, exercise is good for you, but airway clearance is better for mucus clearance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR8kxIIBrn_dDEwO064Z95rfW6udTcc2ebgWljh24Pzj7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38vitFChtw%253D%253D&md5=658e8f2428826b49bad29f1b80bab472</span></div><a href="/servlet/linkout?suffix=cit222b&amp;dbid=16384&amp;doi=10.1016%2Fj.prrv.2020.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.prrv.2020.04.001%26sid%3Dliteratum%253Aachs%26aulast%3DDoull%26aufirst%3DI.%26atitle%3DCystic%2520Fibrosis%25202019%253A%2520Year%2520in%2520Review%26jtitle%3DPaediatr.%2520Respir.%2520Rev.%26date%3D2020%26volume%3D35%26spage%3D95%26epage%3D98%26doi%3D10.1016%2Fj.prrv.2020.04.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit222c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farzal, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniels, M. L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorp, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanation, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senior, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebert, C. S.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimple, A. J.</span></span> <span> </span><span class="NLM_article-title">Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A Review for the Otolaryngologist</span>. <i>Am. J. Rhinol. Allergy</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">573</span>– <span class="NLM_lpage">580</span>, <span class="refDoi"> DOI: 10.1177/1945892420912368</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref222/cit222c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=10.1177%2F1945892420912368" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref222/cit222c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=32168995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref222/cit222c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A280%3ADC%252BB383jtFeisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2020&pages=573-580&author=S.+E.+Leeauthor=Z.+Farzalauthor=M.+L.+A.+Danielsauthor=B.+D.+Thorpauthor=A.+M.+Zanationauthor=B.+A.+Seniorauthor=C.+S.+Ebertauthor=A.+J.+Kimple&title=Cystic+Fibrosis+Transmembrane+Conductance+Regulator+Modulator+Therapy%3A+A+Review+for+the+Otolaryngologist&doi=10.1177%2F1945892420912368"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit222cR"><div class="casContent"><span class="casTitleNuber">222c</span><div class="casTitle"><span class="NLM_cas:atitle">Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A Review for the Otolaryngologist</span></div><div class="casAuthors">Lee Saangyoung E; Farzal Zainab; Thorp Brian D; Zanation Adam M; Senior Brent A; Ebert Charles S Jr; Kimple Adam J; Daniels M Leigh Anne</div><div class="citationInfo"><span class="NLM_cas:title">American journal of rhinology & allergy</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">573-580</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Cystic fibrosis (CF) is a genetic disease that may result in multiple systemic disorders and potentially fatal severe respiratory compromise.  However, the advent of CF transmembrane conductance regulator (CFTR) modulators has changed the management of CF for patients with select mutations.  Although clinical trials have highlighted increased pulmonary function and decreased exacerbations as a result of these novel therapies, their effect on the sinuses has not been well-described.  OBJECTIVE:  Our objective is to review the CFTR modulators to provide otolaryngologists, physicians who frequently care for patients with CF, a basic understanding of these drugs and their effects on chronic rhinosinusitis (CRS) in patients with CF.  METHODS:  The clinically approved and available CFTR modulators and specific indications for their use are reviewed.  Additionally, a systematic review of these therapies and effects on CRS in CF was performed.  RESULTS:  Four Food and Drug Administration approved CFTR modulators are available for patients with CF.  Current drugs are approved for gating, residual function, or F508del mutations.  Multiple reports describe CFTR modulators' increase in transepithelial ion transport in nasal epithelial cultures; however, clinical studies regarding effects of these modulators on sinonasal health are limited to 5 studies that present new data of the effects of CFTR modulators in CRS.  CONCLUSIONS:  CFTR modulators have changed management of CF.  Initial studies of these medications demonstrate promising results in CF; however, there is a paucity of literature describing the effect of CFTR modulators on CF-associated CRS, although initial results are encouraging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQFVkX2We16UAHqQV89nF-2fW6udTcc2ebgWljh24Pzj7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB383jtFeisA%253D%253D&md5=779e3c356350e02006fd8a605c74f3c4</span></div><a href="/servlet/linkout?suffix=cit222c&amp;dbid=16384&amp;doi=10.1177%2F1945892420912368&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1945892420912368%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DS.%2BE.%26aulast%3DFarzal%26aufirst%3DZ.%26aulast%3DDaniels%26aufirst%3DM.%2BL.%2BA.%26aulast%3DThorp%26aufirst%3DB.%2BD.%26aulast%3DZanation%26aufirst%3DA.%2BM.%26aulast%3DSenior%26aufirst%3DB.%2BA.%26aulast%3DEbert%26aufirst%3DC.%2BS.%26aulast%3DKimple%26aufirst%3DA.%2BJ.%26atitle%3DCystic%2520Fibrosis%2520Transmembrane%2520Conductance%2520Regulator%2520Modulator%2520Therapy%253A%2520A%2520Review%2520for%2520the%2520Otolaryngologist%26jtitle%3DAm.%2520J.%2520Rhinol.%2520Allergy%26date%3D2020%26volume%3D34%26spage%3D573%26epage%3D580%26doi%3D10.1177%2F1945892420912368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref223"><div class="reference"><strong class="refLabel"><a href="#ref223" class="rightTabRefNumLink">223</a></strong><div class="NLM_citation" id="rightTab-cit223a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Abela, A. R.</span>; <span class="NLM_string-name">Alcacio, T.</span>; <span class="NLM_string-name">Anderson, C.</span>; <span class="NLM_string-name">Angell, P. T.</span>; <span class="NLM_string-name">Baek, M.</span>; <span class="NLM_string-name">Clemens, J. J.</span>; <span class="NLM_string-name">Cleveland, T.</span>; <span class="NLM_string-name">Ferris, L. A.</span>; <span class="NLM_string-name">Grootenhuis, P. D. J.</span>; <span class="NLM_string-name">Gross, R. S.</span>; <span class="NLM_string-name">Gulevich, A.</span>; <span class="NLM_string-name">Hadida Ruah, S. S.</span>; <span class="NLM_string-name">Hsia, C. K.-J.</span>; <span class="NLM_string-name">Hughes, R. M.</span>; <span class="NLM_string-name">Joshi, P. V.</span>; <span class="NLM_string-name">Kang, P.</span>; <span class="NLM_string-name">Keshavarz-Shokri, A.</span>; <span class="NLM_string-name">Khatuya, H.</span>; <span class="NLM_string-name">Krenitsky, P. J.</span>; <span class="NLM_string-name">McCartney, J.</span>; <span class="NLM_string-name">Miller, M. T.</span>; <span class="NLM_string-name">Paraselli, P.</span>; <span class="NLM_string-name">Pierre, F. J. D.</span>; <span class="NLM_string-name">Shi, Y.</span>; <span class="NLM_string-name">Shrestha, M.</span>; <span class="NLM_string-name">Siesel, D. A.</span>; <span class="NLM_string-name">Stavropoulos, K.</span>; <span class="NLM_string-name">Termin, A. P.</span>; <span class="NLM_string-name">Uy, J.</span>; <span class="NLM_string-name">Van Goor, F. F.</span>; <span class="NLM_string-name">Young, T. J.</span>; <span class="NLM_string-name">Zhou, J.</span></span> <span> </span><span class="NLM_article-title">Preparation of N-Heteroaroylsulfonamide Derivatives as Cystic Fibrosis Transmembrane Conductance Regulator Modulators for Treatment of Cystic Fibrosis</span>. <span class="NLM_patent">WO 2018107100 A1</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=A.+R.+Abela&author=T.+Alcacio&author=C.+Anderson&author=P.+T.+Angell&author=M.+Baek&author=J.+J.+Clemens&author=T.+Cleveland&author=L.+A.+Ferris&author=P.+D.+J.+Grootenhuis&author=R.+S.+Gross&author=A.+Gulevich&author=S.+S.+Hadida+Ruah&author=C.+K.-J.+Hsia&author=R.+M.+Hughes&author=P.+V.+Joshi&author=P.+Kang&author=A.+Keshavarz-Shokri&author=H.+Khatuya&author=P.+J.+Krenitsky&author=J.+McCartney&author=M.+T.+Miller&author=P.+Paraselli&author=F.+J.+D.+Pierre&author=Y.+Shi&author=M.+Shrestha&author=D.+A.+Siesel&author=K.+Stavropoulos&author=A.+P.+Termin&author=J.+Uy&author=F.+F.+Van+Goor&author=T.+J.+Young&author=J.+Zhou&title=Preparation+of+N-Heteroaroylsulfonamide+Derivatives+as+Cystic+Fibrosis+Transmembrane+Conductance+Regulator+Modulators+for+Treatment+of+Cystic+Fibrosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit223a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAbela%26aufirst%3DA.%2BR.%26atitle%3DPreparation%2520of%2520N-Heteroaroylsulfonamide%2520Derivatives%2520as%2520Cystic%2520Fibrosis%2520Transmembrane%2520Conductance%2520Regulator%2520Modulators%2520for%2520Treatment%2520of%2520Cystic%2520Fibrosis%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit223b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Angell, P. T.</span>; <span class="NLM_string-name">Harrison, C.</span>; <span class="NLM_string-name">Hughes, R. M.</span>; <span class="NLM_string-name">Lewandowski, B.</span>; <span class="NLM_string-name">Littler, B. J.</span>; <span class="NLM_string-name">Melillo, V.</span>; <span class="NLM_string-name">Nugent, W. A.</span>; <span class="NLM_string-name">Siesel, D. A.</span>; <span class="NLM_string-name">Smith, D.</span>; <span class="NLM_string-name">Studley, J.</span></span> <span> </span><span class="NLM_article-title">Processes for Making 6-Pyrazolo-2-pyrrolidinonicotinamides as Modulators of Cystic Fibrosis Transmembrane Conductance Regulator</span>. <span class="NLM_patent">WO 2019113476 A2</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=P.+T.+Angell&author=C.+Harrison&author=R.+M.+Hughes&author=B.+Lewandowski&author=B.+J.+Littler&author=V.+Melillo&author=W.+A.+Nugent&author=D.+A.+Siesel&author=D.+Smith&author=J.+Studley&title=Processes+for+Making+6-Pyrazolo-2-pyrrolidinonicotinamides+as+Modulators+of+Cystic+Fibrosis+Transmembrane+Conductance+Regulator"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit223b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAngell%26aufirst%3DP.%2BT.%26atitle%3DProcesses%2520for%2520Making%25206-Pyrazolo-2-pyrrolidinonicotinamides%2520as%2520Modulators%2520of%2520Cystic%2520Fibrosis%2520Transmembrane%2520Conductance%2520Regulator%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit223c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Haseltine, E. L.</span>; <span class="NLM_string-name">Moskowitz, S.</span>; <span class="NLM_string-name">Robertson, S.</span>; <span class="NLM_string-name">Waltz, D.</span></span> <span> </span><span class="NLM_article-title">Methods of Treatment for Cystic Fibrosis</span>. <span class="NLM_patent">WO 2019018395 A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=E.+L.+Haseltine&author=S.+Moskowitz&author=S.+Robertson&author=D.+Waltz&title=Methods+of+Treatment+for+Cystic+Fibrosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit223c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHaseltine%26aufirst%3DE.%2BL.%26atitle%3DMethods%2520of%2520Treatment%2520for%2520Cystic%2520Fibrosis%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit223d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Abela, A. R.</span>; <span class="NLM_string-name">Clemens, J. J.</span>; <span class="NLM_string-name">Grootenhuis, P. D. J.</span>; <span class="NLM_string-name">Hadida Ruah, S. S.</span>; <span class="NLM_string-name">Ishihara, Y.</span>; <span class="NLM_string-name">Khatuya, H.</span>; <span class="NLM_string-name">McCartney, J.</span>; <span class="NLM_string-name">Miller, M. T.</span>; <span class="NLM_string-name">Pierre, F. J. D.</span>; <span class="NLM_string-name">Tran, J. A.</span>; <span class="NLM_string-name">Zhou, J.</span></span> <span> </span><span class="NLM_article-title">Preparation of Pyrazolylsulfonyl Pyridinamides as Modulators of Cystic Fibrosis Transmembrane Conductance Regulator, and Pharmaceutical Compositions with Them</span>. <span class="NLM_patent">WO 2019200246 A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=A.+R.+Abela&author=J.+J.+Clemens&author=P.+D.+J.+Grootenhuis&author=S.+S.+Hadida+Ruah&author=Y.+Ishihara&author=H.+Khatuya&author=J.+McCartney&author=M.+T.+Miller&author=F.+J.+D.+Pierre&author=J.+A.+Tran&author=J.+Zhou&title=Preparation+of+Pyrazolylsulfonyl+Pyridinamides+as+Modulators+of+Cystic+Fibrosis+Transmembrane+Conductance+Regulator%2C+and+Pharmaceutical+Compositions+with+Them"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit223d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAbela%26aufirst%3DA.%2BR.%26atitle%3DPreparation%2520of%2520Pyrazolylsulfonyl%2520Pyridinamides%2520as%2520Modulators%2520of%2520Cystic%2520Fibrosis%2520Transmembrane%2520Conductance%2520Regulator%252C%2520and%2520Pharmaceutical%2520Compositions%2520with%2520Them%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref224"><div class="reference"><strong class="refLabel"><a href="#ref224" class="rightTabRefNumLink">224</a></strong><div class="NLM_citation" id="rightTab-cit224"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, D. L.</span></span> <span> </span><span class="NLM_article-title">Patent Review of Synthetic Routes and Crystalline Forms of the CFTR-Modulator Drugs Ivacaftor, Lumacaftor, Tezacaftor, and Elexacaftor</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">2302</span>– <span class="NLM_lpage">2322</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.9b00326</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.9b00326" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVSks7zE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2019&pages=2302-2322&author=D.+L.+Hughes&title=Patent+Review+of+Synthetic+Routes+and+Crystalline+Forms+of+the+CFTR-Modulator+Drugs+Ivacaftor%2C+Lumacaftor%2C+Tezacaftor%2C+and+Elexacaftor&doi=10.1021%2Facs.oprd.9b00326"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit224R"><div class="casContent"><span class="casTitleNuber">224</span><div class="casTitle"><span class="NLM_cas:atitle">Patent Review of Synthetic Routes and Crystalline Forms of the CFTR-Modulator Drugs Ivacaftor, Lumacaftor, Tezacaftor, and Elexacaftor</span></div><div class="casAuthors">Hughes, David L.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2302-2322</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This review surveys synthetic routes and polymorphic forms of the three approved CFTR-modulators ivacaftor, lumacaftor, and tezacaftor and one Phase 3 development candidate, elexacaftor.  The patent literature was the source of information for synthetic routes and final forms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVcZY11vRm77Vg90H21EOLACvtfcHk0liC9d2dLeZV8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVSks7zE&md5=f0cc8adf71401cb3aa7de566a51ddc71</span></div><a href="/servlet/linkout?suffix=cit224&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.9b00326&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.9b00326%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DD.%2BL.%26atitle%3DPatent%2520Review%2520of%2520Synthetic%2520Routes%2520and%2520Crystalline%2520Forms%2520of%2520the%2520CFTR-Modulator%2520Drugs%2520Ivacaftor%252C%2520Lumacaftor%252C%2520Tezacaftor%252C%2520and%2520Elexacaftor%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2019%26volume%3D23%26spage%3D2302%26epage%3D2322%26doi%3D10.1021%2Facs.oprd.9b00326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref225"><div class="reference"><strong class="refLabel"><a href="#ref225" class="rightTabRefNumLink">225</a></strong><div class="NLM_citation" id="rightTab-cit225"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westfahl, J. C.</span></span> <span> </span><span class="NLM_article-title">Rearrangement of 2,2,6,6-Tetramethyl-4-piperidone in Phase-Transfer Catalyzed Reactions</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1980</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">1513</span>– <span class="NLM_lpage">1514</span>, <span class="refDoi"> DOI: 10.1021/jo01296a034</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo01296a034" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;key=1%3ACAS%3A528%3ADyaL3cXhvFyhsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=1980&pages=1513-1514&author=J.+T.+Laiauthor=J.+C.+Westfahl&title=Rearrangement+of+2%2C2%2C6%2C6-Tetramethyl-4-piperidone+in+Phase-Transfer+Catalyzed+Reactions&doi=10.1021%2Fjo01296a034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit225R"><div class="casContent"><span class="casTitleNuber">225</span><div class="casTitle"><span class="NLM_cas:atitle">Rearrangement of 2,2,6,6-tetramethyl-4-piperidone in phase-transfer catalyzed reactions</span></div><div class="casAuthors">Lai, John T.; Westfahl, Jerry C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1980</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1513-14</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    </div><div class="casAbstract">When 2,2,6,6-tetramethyl-4-piperidone hydrate was treated with CHCl3 and 50% NaOH in the presence of a phase-transfer catalyst (e.g. PhCH2N+Et3Cl-), it rearranged to N-isopropenyl-3-methylene-5,5-dimethyl-2-pyrrolidinone(I) and 3-methylene-5,5-dimethyl-2-pyrrolidinone (II).  I was the major product.  II became predominant when an equal molar amt. of piperidine was added.  Trichloromethide, not dichlorocarbene, was the reactive intermediate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPpdVbo57aSLVg90H21EOLACvtfcHk0liC9d2dLeZV8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3cXhvFyhsbo%253D&md5=c2f654941bbd3305a6d63fd34a5d890c</span></div><a href="/servlet/linkout?suffix=cit225&amp;dbid=16384&amp;doi=10.1021%2Fjo01296a034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo01296a034%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DJ.%2BT.%26aulast%3DWestfahl%26aufirst%3DJ.%2BC.%26atitle%3DRearrangement%2520of%25202%252C2%252C6%252C6-Tetramethyl-4-piperidone%2520in%2520Phase-Transfer%2520Catalyzed%2520Reactions%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1980%26volume%3D45%26spage%3D1513%26epage%3D1514%26doi%3D10.1021%2Fjo01296a034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.1c00208&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-7%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.1c00208%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.1c00208" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                9MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-b425991822a79ada59b3.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-fb88834b824b41b135ad.js"></script>

<script type="text/javascript" src="/wro/ke1q~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66797ee918af1985","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
